
<html lang="en"     class="pb-page"  data-request-id="be2ea147-3f8c-4899-b537-bdd9e6e1aeaf"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;article:article:10.1021/acs.jmedchem.9b02075;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2020.63.issue-17;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Molecule Property Analyses of Active Compounds for Mycobacterium tuberculosis" /></meta><meta name="dc.Creator" content="Vadim  Makarov" /></meta><meta name="dc.Creator" content="Elena  Salina" /></meta><meta name="dc.Creator" content="Robert C.  Reynolds" /></meta><meta name="dc.Creator" content="Phyo Phyo  Kyaw Zin" /></meta><meta name="dc.Creator" content="Sean  Ekins" /></meta><meta name="dc.Description" content="Tuberculosis (TB) continues to claim the lives of around 1.7 million people per year. Most concerning are the reports of multidrug drug resistance. Paradoxically, this global health pandemic is dem..." /></meta><meta name="Description" content="Tuberculosis (TB) continues to claim the lives of around 1.7 million people per year. Most concerning are the reports of multidrug drug resistance. Paradoxically, this global health pandemic is dem..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 7, 2020" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b02075" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b02075" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b02075" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b02075" /></link>
        
    
    

<title>Molecule Property Analyses of Active Compounds for Mycobacterium tuberculosis | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b02075" /></meta><meta property="og:title" content="Molecule Property Analyses of Active Compounds for Mycobacterium tuberculosis" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/large/jm9b02075_0006.jpeg" /></meta><meta property="og:description" content="Tuberculosis (TB) continues to claim the lives of around 1.7 million people per year. Most concerning are the reports of multidrug drug resistance. Paradoxically, this global health pandemic is demanding new therapies when resources and interest are waning. However, continued tuberculosis drug discovery is critical to address the global health need and burgeoning multidrug resistance. Many diverse classes of antitubercular compounds have been identified with activity in vitro and in vivo. Our analyses of over 100 active leads are representative of thousands of active compounds generated over the past decade, suggests that they come from few chemical classes or natural product sources. We are therefore repeatedly identifying compounds that are similar to those that preceded them. Our molecule-centered cheminformatics analyses point to the need to dramatically increase the diversity of chemical libraries tested and get outside of the historic Mtb property space if we are to generate novel improved antitubercular leads." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b02075"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b02075">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b02075&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b02075&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b02075&amp;href=/doi/10.1021/acs.jmedchem.9b02075" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 17</span><span class="cit-fg-pageRange">, 8917-8955</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/17" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b02021" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.9b02092" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Molecule Property Analyses of Active Compounds for <i>Mycobacterium tuberculosis</i></span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Vadim Makarov</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Vadim Makarov</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">FRC Fundamentals of Biotechnology, Russian Academy of Science, Moscow 119071, Russia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Vadim++Makarov">Vadim Makarov</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Elena Salina</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Elena Salina</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">FRC Fundamentals of Biotechnology, Russian Academy of Science, Moscow 119071, Russia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Elena++Salina">Elena Salina</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Robert C. Reynolds</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Robert C. Reynolds</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicine, Division of Hematology and Oncology, University of Alabama at Birmingham, NP 2540 J, 1720 Second Avenue South, Birmingham, Alabama 35294-3300, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Robert+C.++Reynolds">Robert C. Reynolds</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Phyo Phyo Kyaw Zin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Phyo Phyo Kyaw Zin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry, North Carolina State University, Raleigh, North Carolina 27695, United States</div><div class="loa-info-affiliations-info">Bioinformatics Research Center, North Carolina State University, Raleigh, North Carolina 27695, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Phyo+Phyo++Kyaw+Zin">Phyo Phyo Kyaw Zin</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Sean Ekins</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sean Ekins</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Collaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510 Raleigh, North Carolina 27606, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: +1 215-687-1320. Email: <a href="/cdn-cgi/l/email-protection#8efdebefe0ceede1e2e2efece1fceffae7e1e0fdfee6effce3efa0ede1e3"><span class="__cf_email__" data-cfemail="641701050a24070b080805060b1605100d0b0a17140c051609054a070b09">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sean++Ekins">Sean Ekins</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath5">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5691-5790" title="Orcid link">http://orcid.org/0000-0002-5691-5790</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b02075&amp;href=/doi/10.1021%2Facs.jmedchem.9b02075" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 17</span><span class="cit-pageRange">, 8917–8955</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 7, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>13 December 2019</li><li><span class="item_label"><b>Published</b> online</span>7 April 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 10 September 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b02075" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b02075</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8917%26pageCount%3D39%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DVadim%2BMakarov%252C%2BElena%2BSalina%252C%2BRobert%2BC.%2BReynolds%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D17%26contentID%3Dacs.jmedchem.9b02075%26title%3DMolecule%2BProperty%2BAnalyses%2Bof%2BActive%2BCompounds%2Bfor%2BMycobacterium%2Btuberculosis%26numPages%3D39%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8955%26publicationDate%3DSeptember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b02075"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1396</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">6</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b02075" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Molecule Property Analyses of Active Compounds for Mycobacterium tuberculosis&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Vadim&quot;,&quot;last_name&quot;:&quot;Makarov&quot;},{&quot;first_name&quot;:&quot;Elena&quot;,&quot;last_name&quot;:&quot;Salina&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;C. Reynolds&quot;},{&quot;first_name&quot;:&quot;Phyo&quot;,&quot;last_name&quot;:&quot;Phyo Kyaw Zin&quot;},{&quot;first_name&quot;:&quot;Sean&quot;,&quot;last_name&quot;:&quot;Ekins&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;07&quot;,&quot;issue&quot;:&quot;17&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;8917-8955&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b02075&quot;},&quot;abstract&quot;:&quot;Tuberculosis (TB) continues to claim the lives of around 1.7 million people per year. Most concerning are the reports of multidrug drug resistance. Paradoxically, this global health pandemic is demanding new therapies when resources and interest are waning. However, continued tuberculosis drug discovery is critical to address the global health need and burgeoning multidrug resistance. Many diverse classes of antitubercular compounds have been identified with activity in vitro and in vivo. Our analyses of over 100 active leads are representative of thousands of active compounds generated over the past decade, suggests that they come from few chemical classes or natural product sources. We are therefore repeatedly identifying compounds that are similar to those that preceded them. Our molecule-centered cheminformatics analyses point to the need to dramatically increase the diversity of chemical libraries tested and get outside of the historic Mtb property space if we are to generate novel improved antitubercula&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b02075&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b02075" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b02075&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b02075" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b02075&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b02075" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b02075&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b02075&amp;href=/doi/10.1021/acs.jmedchem.9b02075" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b02075" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b02075" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (10 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b02075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b02075%26sid%3Dliteratum%253Aachs%26pmid%3D32259446%26genre%3Darticle%26aulast%3DMakarov%26date%3D2020%26atitle%3DMolecule%2BProperty%2BAnalyses%2Bof%2BActive%2BCompounds%2Bfor%2BMycobacterium%2Btuberculosis%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D17%26spage%3D8917%26epage%3D8955%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291430" title="Infectious diseases">Infectious diseases</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=291352" title="Screening assays">Screening assays</a>,</li><li><a href="/action/doSearch?ConceptID=292202" title="Drug discovery">Drug discovery</a>,</li><li><a href="/action/doSearch?ConceptID=291754" title="Molecules">Molecules</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/17" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/jmcmar.2020.63.issue-17/20200910/jmcmar.2020.63.issue-17.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/medium/jm9b02075_0006.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/large/jm9b02075_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02075&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Tuberculosis (TB) continues to claim the lives of around 1.7 million people per year. Most concerning are the reports of multidrug drug resistance. Paradoxically, this global health pandemic is demanding new therapies when resources and interest are waning. However, continued tuberculosis drug discovery is critical to address the global health need and burgeoning multidrug resistance. Many diverse classes of antitubercular compounds have been identified with activity in vitro and in vivo. Our analyses of over 100 active leads are representative of thousands of active compounds generated over the past decade, suggests that they come from few chemical classes or natural product sources. We are therefore repeatedly identifying compounds that are similar to those that preceded them. Our molecule-centered cheminformatics analyses point to the need to dramatically increase the diversity of chemical libraries tested and get outside of the historic <i>Mtb</i> property space if we are to generate novel improved antitubercular leads.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52515" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52515" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">It is widely known that <i>Mycobacterium tuberculosis</i> (<i>Mtb</i>) infection is causative of tuberculosis (TB), and claims the lives of around 1.7 million people with 10.4 million infections reported per year.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Hence TB continues to be the focus of many international efforts to develop new therapeutics to address resistance to the available first- and second-line drugs.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Because of increasing TB morbidity in developed countries in the late 1990s and the global expansion of drug-resistant strains, a high priority has since been given to the development of new TB drugs by the World Health Organization, Bill and Melinda Gates Foundation, National Institutes of Health as well as other international institutions and funds. While the widely used TB drugs were developed in the late 1950s–1960s (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, compounds <b>1</b>–<b>4</b>), it is only recently that the first new drugs (bedaquiline, delamanid, and pretomanid) came on the market in over 40 years<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5,6)</a> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, compounds <b>5</b>–<b>7</b>); these latter molecules are currently not widely used because of their cost (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) and their use is limited to multidrug resistant <i>Mtb</i> (MDR-TB).<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7,8)</a> Interestingly, these three molecules also have the highest hydrophobicity (ALogP) out of the seven approved TB drugs and no hydrogen bond donors which is unusual (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.9b02075/suppl_file/jm9b02075_si_001.pdf" class="ext-link">Table S1</a>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. First Line and Recently Approved Antituberculars<a onclick="showRef(event, 'ref9 ref10 ref11 ref12 ref13 ref14 ref15 ref16 ref17 ref18 ref19 ref20 ref21 ref22 ref23 ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11 ref12 ref13 ref14 ref15 ref16 ref17 ref18 ref19 ref20 ref21 ref22 ref23 ref24 ref25">(9−25)</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/medium/jm9b02075_0009.gif" alt="" id="GRAPHIC-d7e331-autogenerated" /></img><div></div></div><div class="NLM_p">The appearance and increasing number of <i>Mtb</i> strains with multiple drug resistance (i.e, MDR is defined as resistance to at least rifampicin (RPN) and isoniazid (INH)) and extensive drug resistance (i.e., XDR means MDR and additional resistance to at least one fluoroquinolone and one injectable second-line drug) represent a potential serious public health crisis. These intractable TB strains are associated with low cure rate and high mortality<a onclick="showRef(event, 'ref3 ref26'); return false;" href="javascript:void(0);" class="ref ref3 ref26">(3,26)</a> as well as significant added treatment costs. Even more concerning, totally drug-resistant strains (TDR-TB) have been reported in clinical practice.<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27,28)</a></div><div class="NLM_p">Widespread <i>latent</i> tuberculosis<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> and the low potency of current TB drugs against <i>latent disease</i> represent one more weakness with current TB therapy.<a onclick="showRef(event, 'ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref30 ref31">(30,31)</a> According to the WHO, <i>Mtb</i> now exists as latent disease in approximately one-quarter of the global population. Latent infection remains asymptomatic for a long time. Over a lifetime, it becomes active in about 5% of infected persons,<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> and reactivation is associated with a weakened immune system (including pediatric and geriatric cases) and in patients with compromised immune status, such as individuals undergoing immunosuppressive therapy or infected with HIV. HIV-positive patients carrying latent tuberculosis also have a several-fold higher risk of developing active tuberculosis (8–10% annually). Therefore, although millions of cases of reactivated tuberculosis are reported worldwide, reliable methods of timely diagnosis and treatment of latent TB have not been developed. Thus, latent TB and reactivation risk represent a significant health issue. There is no doubt that the development of advanced TB drugs will play a key role in the reduction of morbidity and mortality levels required for achievement of WHO’s global international goals.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> This state of affairs and the general importance of this issue were also emphasized during a recent WHO Ministerial Conference held in Russia,<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> where TB represents a major healthcare challenge.</div><div class="NLM_p">There are several other difficulties involved with <i>Mtb</i> drug discovery, namely the bacteria is slow growing, a BSL3 laboratory is required to work with the bacteria and studies are complicated by the need to assess MIC and intracellular killing in infected macrophages.<a onclick="showRef(event, 'ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref34 ref35">(34,35)</a> Ultimately, in vivo assessment is also slow because of the length of infections required as well as the need for acute and chronic animal models. Subsequently, the pipeline for antituberculars, which is mostly driven by the TB Alliance, is by any standards very thin with approximately a dozen new tuberculosis drugs undergoing phase 1–3 clinical studies currently as summarized by the working group on new TB drugs (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/medium/jm9b02075_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/large/jm9b02075_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Current TB drug pipeline.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> * denotes new chemical class. Molecules in phase 3 have all been FDA (bedaquiline and pretomanid) or EU (delamanid) approved but are also components of ongoing trials. Image courtesy of Dr. Barbara Laughon (NIAID) <a href="http://www.newtbdrugs.org" class="extLink">www.newtbdrugs.org</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/large/jm9b02075_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02075&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Some of these drugs are expected to become viable products. In particular, six compounds to combat MDR-TB are being investigated within the framework of phase II and III clinical trials. Bedaquiline (<b>5</b>, Sirturo, Janssen Therapeutics, Titusville, NJ, USA), delamanid (<b>6</b>, Deltyba, Otsuka Pharmaceuticals, Tokyo, Japan), and pretomanid (<b>7</b>, TB Alliance, USA) have been approved for MDR-TB, respectively, and are still undergoing additional clinical trials as combinations with other drugs. Repurposing of the known drugs clofazimine and levofloxacin are in phase II and III trials as tuberculosis therapy.<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36,37)</a><i>Mtb</i> strains resistant to some of these molecules have been already reported,<a onclick="showRef(event, 'ref38 ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref38 ref39 ref40">(38−40)</a> which suggests the limited time window with a new drug before losing sensitivity in the field. This issue also points to the continued urgent need for rapid development of the most advanced TB drugs and continual feeding of the research pipeline. For all the decades and billions of dollars spent on tuberculosis drug discovery, this begs the question: why is there not more to show for it? Let us begin by looking at the two of the most recent drugs to be approved for <i>Mtb</i>.</div><div id="sec1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Nitroimidazoles as “New” Drugs for Mtb</h3><div class="NLM_p">Initially, nitroimidazoles were produced as bicyclic nitroimidazofuran derivatives developed for cancer chemotherapy as radiosensitizers.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Once they were identified in 1989 to be potent against actively growing nonfissile tuberculosis, interest in this class of compounds took off and this work has been extensively reviewed.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Delamanid (OPC-67683 <b>6</b>) and pretomanid (PA-824 (<b>7</b>)) are examples of this class of compounds (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>), and there is continued interest in developing additional compounds in this series.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> This class of compounds is therefore far from new, dating back 30 years. When you compare the two compounds, it is apparent that they are very similar in terms of activity against drug sensitive and resistant <i>Mtb</i>.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Comparison of Delamanid and Pretomanid</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">delamanid <b>6</b></th><th class="colsep0 rowsep0" align="center">pretomanid <b>7</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MIC (μg/mL)</td><td class="colsep0 rowsep0" align="left">0.012 μg/mL<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a></td><td class="colsep0 rowsep0" align="left">(MIC<sub>90</sub>) of 0.039 μg/mL<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">drug resistant clinical isolates MIC (μg/mL)</td><td class="colsep0 rowsep0" align="left">∼0.01 μg/mL<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a></td><td class="colsep0 rowsep0" align="left">0.031–0.531 μg/mL<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">compound class</td><td class="colsep0 rowsep0" align="left">nitrodihydroimidazooxazole</td><td class="colsep0 rowsep0" align="left">nitroimidazopyran</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mechanism</td><td class="colsep0 rowsep0" align="left">Nonmutagenic. Delamanid inhibited the synthesis of methoxy- and ketomycolic acid.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a></td><td class="colsep0 rowsep0" align="left">Protein synthesis and lipid synthesis are substantially inhibited. Pretomanid is activated by a process that requires the unique deazaflavin F420 and depends on electron transport. Active against latent TB.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human dosing</td><td class="colsep0 rowsep0" align="left">Delamanid was well tolerated in initial studies.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Delamanid was associated with an increase in sputum-culture conversion at 2 months among patients with multidrug-resistant tuberculosis.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> It was also shown to improve outcomes and survival in MDR TB.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a></td><td class="colsep0 rowsep0" align="left">Maximum plasma levels in 4–5 h, steady state after 5–6 days daily dosing, elimination half-life 16–20 h,<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> causes creatinine to rise by inhibiting renal tubular creatinine secretion,<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> bactericidal from 200 to 1200 mg daily over 14 days,<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> a dose of 100–200 mg appears safe and effective,<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> pretomanid–moxifloxacin–pyrazinamide is potentially suitable for drug sensitive and MDR TB,<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> pretomanid does not inhibit CYP3A4 in a clinically relevant manner,<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> increase in exposure with high fat meal,<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> combination with bedaquiline and pyrazinamide indicates a new treatment approach,<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> moxifloxacin, pretomanid and pyrazinamide was safe and well tolerated and showed superior efficacy.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a></td></tr></tbody></table></div></div><div class="NLM_p last">Compound <b>6</b> is a nitroimidazoxazole that was developed<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> for the treatment of MDR-TB. Compound <b>6</b> was developed from a smaller nitroimidazole,<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> and <b>6</b> inhibits biosynthesis of methoxy-mycolic and keto-mycolic acids (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>), which are essential components of the TB mycobacterial cellular wall. It is notable that both <b>6</b> and <b>7</b> require metabolic activation by deazaflavin-dependent nitroreductase (Ddn) to provide antitubercular activity.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> Compound <b>6</b>-resistant cells were characterized by Rv3547 (<i>ddn</i>), showing the gene encoding Ddn mutations and lacking the ability to provide metabolic activation of this compound.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a><i>Mtb</i> produces the inactive desnitro-imidazoxazole as the major metabolite of <b>6</b>. We can infer that Rv3547 reduces the delamanid nitro group, forming an intermediate between the <b>6</b> prodrug and the inactive terminal metabolite (i.e., desnitro-imidazoxazole).<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Compound <b>6</b> has potent antitubercular activity including against drug-resistant strains, and no cross resistance has been reported with any current tuberculosis drug.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> Compound <b>7</b> is a bicyclic nitroimidazole, nitroimidazooxazine, or nitroimidazopyran derivative. Studies have shown both bactericidal and sterilizing effects on drug-resistant, drug-susceptible <i>Mtb</i> strains and resting mycobacterial cells.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> In vitro studies using <i>Mtb</i> clinical multidrug resistant isolates and in vivo studies using mouse and guinea pig models demonstrated antitubercular activity.<a onclick="showRef(event, 'ref44 ref62'); return false;" href="javascript:void(0);" class="ref ref44 ref62">(44,62)</a> According to mouse preclinical studies, threshold toxicity is more than 1000 mg/kg after single oral administration.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Compound <b>7</b> does not demonstrate cross resistance with conventional tuberculosis drugs.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Compound <b>7</b> is transformed into three major metabolites, causing a release of nitric oxide (NO, a natural antibiotic released by macrophages<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a>). Similar to isoniazid, <b>7</b> inhibits cell wall growth by affecting the biosynthesis of mycolic acids under aerobic conditions. Under anaerobic conditions, it causes a cyanide-like action, such that pretomanid acts as a respiratory poison leading to NO production and respiratory inhibition in <i>Mtb</i> by binding to the heme/cytochrome iron orbital that normally binds oxygen and acts like cyanide would.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> NO is produced by imidazole ring two-electron reduction rather than extraction from the nitro group.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Compound <b>7</b>’s effect on the mycobacterial respiratory chain is manifested at lower ATP intracellular levels.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> According to a recent study, intracellular accumulation of methyl glyoxal (i.e., a toxic metabolite) may be another <b>7</b>-induced mechanism of mycobacterial killing.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> Curiously, <b>7</b> also “imitates” the natural immune response of the host organism such that only penetration into <i>Mtb</i> can induce NO production.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> If we are to greatly improve upon these compounds and leverage the same approach of NO production, we would need to address the high frequency of resistance and overcome drug resistance seen in the clinic.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a></div></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">Analysis of Active Antitubercular Compounds</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13666" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13666" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In recent years, there has been an abundance of reviews written on the topic of tuberculosis drug discovery as well as advances in treatment regimens and newer approaches to therapy. While we do not intend to cover the same ground, it is worth noting that most of these prior publications tend to focus on the underlying biology and targets used.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> They also hone in on a relatively small number of targets such as InhA, DNA gyrase, RNA polymerase combined with a few newer common targets like MmpL3, DprE1, CTP synthetase, and QcrB.<a onclick="showRef(event, 'ref68 ref69'); return false;" href="javascript:void(0);" class="ref ref68 ref69">(68,69)</a> Others have described emerging targets with some of the hits from high throughput screens that appear structurally similar across different groups.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> A recent review<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> covered more current research but makes no attempt to organize the compounds by structure class. Other reviews have also covered a larger period of time but without a distinction of any kind of bioactivity threshold.<a onclick="showRef(event, 'ref72 ref73'); return false;" href="javascript:void(0);" class="ref ref72 ref73">(72,73)</a> While such reviews have tackled why TB drug discovery is so challenging, they focused heavily on the TB Alliance pipeline with little if any discussion of the chemistry.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> More recent reviews have provided small selections of lead compounds for TB grouped by pathways targeted, while also commenting on the difficulty in developing fast acting drugs.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> In contrast to these many reports, the objective of the current review is to provide a new perspective on the design and development of TB drugs. Perhaps importantly, none of these prior reviews has attempted to analyze or understand recent antitubercular chemistry in the context of the large numbers of active compounds described over the past few decades.We will therefore focus our attention on issues with these compounds and specifically the gains made in the development of these molecules (including against drug-resistant strains and MDR-TB). To dramatically limit the number of compounds addressed over the past decade, we will focus on those affecting drug-susceptible or drug-resistant <i>Mtb</i> strains <i>that have demonstrated predominantly minimum inhibitory concentrations (MICs) < 10 μM, low toxicity and in many cases have shown promising in vivo efficacy</i>. While we have also assessed those publications that have taken a target-based approach and identified potent molecules, in many cases they do not have an acceptable MIC. For example, a fragment-based screening approach took a weak 4-phenyl-1<i>H</i>-imidazole compound hit for inosine-5′-monophosphate dehydrogenase (IMPDH) and improved it to IC<sub>50</sub> of 0.27 μM but did not show inhibition of bacterial growth up to 50 μM.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> This molecule therefore does not fit our selection criteria.</div><div class="NLM_p">Most of the compounds assessed are from relatively recent years, with a few older compounds for comparison. Many of the scaffolds described have significant liabilities in selectivity or drug disposition/toxicity, which we will highlight. While several of the papers highlighted have been published in this journal, we are not limiting our scope to this alone. It is also unlikely that we have captured every TB drug discovery paper to all readers’ satisfaction, but our intent is to provide a sampling, a “taste of TB drug discovery” if you will, and then place them in the bigger context. We have therefore divided the 118 molecules into separate tables (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Tables <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">12</a>). The selection of what are the actual cores of these molecules may vary by the differing perspectives of readers. We will demonstrate how the fruitful search for these new highly active antituberculosis compounds performed by many groups globally has led to some chemical diversification of antitubercular drugs, but we question whether it is enough. Our goal is to structurally categorize the most promising leads rather than focus on biology, allowing an analysis from a molecular property perspective, which is fundamentally different compared with any of the preceding reviews. Thus, we can attempt to more clearly understand the chemical as well as mechanistic diversity of these potential innovative drugs that have been identified to date.</div><div class="NLM_p">Our combined decades of experience in drug discovery applied to tuberculosis spans several areas such as high throughput screening (HTS) of hundreds of thousands of compounds,<a onclick="showRef(event, 'ref77 ref78 ref79'); return false;" href="javascript:void(0);" class="ref ref77 ref78 ref79">(77−79)</a> medicinal chemistry that has led to two compounds currently in clinical trials for TB,<a onclick="showRef(event, 'ref80 ref81'); return false;" href="javascript:void(0);" class="ref ref80 ref81">(80,81)</a> and machine learning computational approaches to categorize and identify new antitubercular leads as well as developing a structural understanding of crucial features for antituberculosis activity.<a onclick="showRef(event, 'ref82 ref83 ref84'); return false;" href="javascript:void(0);" class="ref ref82 ref83 ref84">(82−84)</a> Therefore, we will focus on some of these key areas to highlight molecules of interest. Writing this Perspective from our different unique viewpoints has indicated that there is scope for more diversity in chemistry and approaches to attack <i>Mtb</i>.</div><div class="NLM_p">It is apparent from the recent antitubercular leads that there is a very limited palate of chemical classes. Some of the structural classes shown in this Perspective represent common chemistries that have been applied elsewhere for anti-infectives or other types of therapeutics. For example, we have included pyrrole, indole-2-carboxamide, pyrazole[1,5-<i>a</i>]pyridine-3 carboxamide, pyrazolepyridone, imidazole[1,2-<i>a</i>]pyridine and oxazolidinone (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>), ethylenediamine and dipiperidine, hydrazone (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>), indole, 1,3,4-oxadiazole, 1,3,4-thiadiazole, oxadiazole, tetrazole-5-thiol, thiazole, benzothiazole, thiadiazole (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>), riminophenazine, pyridinone, phthalimide, quinoline, 4-aminoquinolone (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>), formamidopyrimidine, pyrimidine, diarylpyrazole, tetrahydropyrazolopyrimidine, pyrimidine-azaindole, indole (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>), quinazolinone, oxadiazole-pyranopyridine, chromeno[3,2-<i>c</i>]pyridine, methylcoumarin, triazoloquinolone, and benzothiazinone (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>), dispiropyrrolothiazole, spiro-pyrrolothiazoles, octylberberine, capuramycins, caprazamycins, spectinomycins, and galactose linked nitroimidazoles (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>), isooxazoline, oxazole, benzo[<i>d</i>]oxazole, and triazole (<a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">Table <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">10</a></a>), benzimidazole, indazole, phthalazine, nitrofuran, and 3-aracylphthalide and oxoborol (<a class="ref showTableEvent internalNav" data-ID="tbl11" href="#tbl11">Table <a class="ref showTableEvent internalNav" data-ID="tbl11" href="#tbl11">11</a></a>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Pyrrole, Indole-2-carboxamide, Pyrazole[1,5-<i>a</i>]pyridine-3 carboxamide, Pyrazolepyridone, Imidazole[1,2-<i>a</i>]pyridine, and Oxazolidinone Chemical Classes<a class="ref internalNav" href="#tbl3-fn1" aria-label="a">a</a><a onclick="showRef(event, 'ref40 ref81 ref107 ref108 ref109 ref110 ref111 ref112 ref113 ref114 ref115 ref116 ref117 ref118 ref119 ref120 ref121 ref122 ref123 ref124 ref125 ref126 ref127 ref128 ref129'); return false;" href="javascript:void(0);" class="ref ref40 ref81 ref107 ref108 ref109 ref110 ref111 ref112 ref113 ref114 ref115 ref116 ref117 ref118 ref119 ref120 ref121 ref122 ref123 ref124 ref125 ref126 ref127 ref128 ref129">(40,81,107−129)</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/medium/jm9b02075_0018.gif" alt="" id="GRAPHIC-d7e878-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/medium/jm9b02075_0019.gif" alt="" id="GRAPHIC-d7e879-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl3-fn1"><div class="footnote" id="tbl3-fn1"><sup><sup>a</sup></sup><p class="last">MmpL3 = mycobacterial membrane protein Large 3, DprE1 = decaprenylphosphoryl-β-<span class="smallcaps smallerCapital">d</span>-ribose oxidase. PAINS were calculated as described by Lagorce et al.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> Compound assay promiscuity was also predicted with BadApple.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a></p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Ethylenediamine, Dipiperidine, and Hydrazone Chemical Classes<a class="ref internalNav" href="#tbl4-fn1" aria-label="a">a</a><a onclick="showRef(event, 'ref130 ref131 ref132 ref133 ref134 ref135 ref136 ref137 ref138 ref139 ref140 ref141'); return false;" href="javascript:void(0);" class="ref ref130 ref131 ref132 ref133 ref134 ref135 ref136 ref137 ref138 ref139 ref140 ref141">(130−141)</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/medium/jm9b02075_0020.gif" alt="" id="GRAPHIC-d7e914-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl4-fn1"><div class="footnote" id="tbl4-fn1"><sup><sup>a</sup></sup><p class="last">MmpL3 = mycobacterial membrane protein Large 3. Compound assay promiscuity was also predicted with BadApple.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a></p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Indole, 1,3,4-Oxadiazole, 1,3,4-Thiadiazole, Oxadiazole, Tetrazole-5-thiol, Thiazole, Benzothiazole, and Thiadiazole Chemical Classes<a class="ref internalNav" href="#tbl5-fn1" aria-label="a">a</a><a onclick="showRef(event, 'ref142 ref143 ref144 ref145 ref146 ref147 ref148 ref149 ref150 ref151 ref152 ref153 ref154'); return false;" href="javascript:void(0);" class="ref ref142 ref143 ref144 ref145 ref146 ref147 ref148 ref149 ref150 ref151 ref152 ref153 ref154">(142−154)</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/medium/jm9b02075_0021.gif" alt="" id="GRAPHIC-d7e945-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/medium/jm9b02075_0022.gif" alt="" id="GRAPHIC-d7e946-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl5-fn1"><div class="footnote" id="tbl5-fn1"><sup><sup>a</sup></sup><p class="last">PanC = pantothenate synthetase, PrrB and PrrA are a two-component regulatory system, DprE1 = decaprenylphosphoryl-β-<span class="smallcaps smallerCapital">d</span>-ribose oxidase. PAINS were calculated as described by Lagorce et al.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> Compound assay promiscuity was also predicted with BadApple.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a></p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Riminophenazine, Pyridinone, Phthalimide, Quinoline, and 4-Aminoquinolone Chemical Classes<a class="ref internalNav" href="#tbl6-fn1" aria-label="a">a</a><a onclick="showRef(event, 'ref155 ref156 ref157 ref158 ref159 ref160 ref161 ref162 ref163'); return false;" href="javascript:void(0);" class="ref ref155 ref156 ref157 ref158 ref159 ref160 ref161 ref162 ref163">(155−163)</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/medium/jm9b02075_0023.gif" alt="" id="GRAPHIC-d7e977-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/medium/jm9b02075_0024.gif" alt="" id="GRAPHIC-d7e978-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl6-fn1"><div class="footnote" id="tbl6-fn1"><sup><sup>a</sup></sup><p class="last">QcrB = the b subunit of cytochrome bcc complex, DprE1 = decaprenylphosphoryl-β-<span class="smallcaps smallerCapital">d</span>-ribose oxidase. PAINS were calculated as described by Lagorce et al.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> Compound assay promiscuity was also predicted with BadApple.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a></p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Formamidopyrimidine, Pyrimidine, Diarylpyrazole, Tetrahydropyrazolopyrimidine, Pyrimidine-Azaindole, and Indole Chemical Classes<a class="ref internalNav" href="#tbl7-fn1" aria-label="a">a</a><a onclick="showRef(event, 'ref164 ref165 ref166 ref167 ref168 ref169 ref170 ref171 ref172 ref173 ref174'); return false;" href="javascript:void(0);" class="ref ref164 ref165 ref166 ref167 ref168 ref169 ref170 ref171 ref172 ref173 ref174">(164−174)</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/medium/jm9b02075_0025.gif" alt="" id="GRAPHIC-d7e1012-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/medium/jm9b02075_0026.gif" alt="" id="GRAPHIC-d7e1013-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl7-fn1"><div class="footnote" id="tbl7-fn1"><sup><sup>a</sup></sup><p class="last">DprE1 = decaprenylphosphoryl-β-<span class="smallcaps smallerCapital">d</span>-ribose oxidase. Compound assay promiscuity was also predicted with BadApple.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a></p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Quinazolinone, Oxadiazole-Pyranopyridine, Chromeno[3,2-<i>c</i>]pyridine, Methylcoumarin, Triazoloquinolone, and Benzothiazinone Chemical Classes<a class="ref internalNav" href="#tbl8-fn1" aria-label="a">a</a><a onclick="showRef(event, 'ref81 ref175 ref176 ref177 ref178 ref179 ref180 ref181 ref182 ref183 ref184'); return false;" href="javascript:void(0);" class="ref ref81 ref175 ref176 ref177 ref178 ref179 ref180 ref181 ref182 ref183 ref184">(81,175−184)</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/medium/jm9b02075_0027.gif" alt="" id="GRAPHIC-d7e1049-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/medium/jm9b02075_0028.gif" alt="" id="GRAPHIC-d7e1050-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl8-fn1"><div class="footnote" id="tbl8-fn1"><sup><sup>a</sup></sup><p class="last">AHAS = acetohydroxyacid synthases, DprE1 = decaprenylphosphoryl-β-<span class="smallcaps smallerCapital">d</span>-ribose oxidase. Compound assay promiscuity was also predicted with BadApple.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a></p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Dispiropyrrolothiazole, Spiro-pyrrolothiazoles, Octylberberine, Capuramycins, Caprazamycins, Spectinomycins, Galactose Linked Nitroimidazoles Chemical Classes<a class="ref internalNav" href="#tbl9-fn1" aria-label="a">a</a><a onclick="showRef(event, 'ref185 ref186 ref187 ref188 ref189 ref190 ref191 ref192 ref193 ref194 ref195 ref196 ref197 ref198 ref199 ref200 ref201 ref202 ref203 ref204 ref205'); return false;" href="javascript:void(0);" class="ref ref185 ref186 ref187 ref188 ref189 ref190 ref191 ref192 ref193 ref194 ref195 ref196 ref197 ref198 ref199 ref200 ref201 ref202 ref203 ref204 ref205">(185−205)</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/medium/jm9b02075_0029.gif" alt="" id="GRAPHIC-d7e1093-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/medium/jm9b02075_0030.gif" alt="" id="GRAPHIC-d7e1094-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl9-fn1"><div class="footnote" id="tbl9-fn1"><sup><sup>a</sup></sup><p class="last">MraY = phospho-MurNAc-pentapeptide translocase, WecA = phosphoglycosyltransferase, InhA= enoyl-ACP reductase. Compound assay promiscuity was also predicted with BadApple.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a></p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl10"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 10. Oxadiazole, Isooxazoline, Oxazole, Benzo[<i>d</i>]oxazole, and Triazole Chemical Classes<a class="ref internalNav" href="#tbl10-fn1" aria-label="a">a</a><a onclick="showRef(event, 'ref206 ref207 ref208 ref209 ref210 ref211 ref212 ref213'); return false;" href="javascript:void(0);" class="ref ref206 ref207 ref208 ref209 ref210 ref211 ref212 ref213">(206−213)</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/medium/jm9b02075_0010.gif" alt="" id="GRAPHIC-d7e1122-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/medium/jm9b02075_0011.gif" alt="" id="GRAPHIC-d7e1123-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl10-fn1"><div class="footnote" id="tbl10-fn1"><sup><sup>a</sup></sup><p class="last">InhA = enoyl-ACP reductase. PAINS were calculated as described by Lagorce et al.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> Compound assay promiscuity was also predicted with BadApple.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a></p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl11"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 11. Benzimidazole, Indazole, Phthalazine, Nitrofuran, 3-Aracylphthalide, and Oxoborol Chemical Classes<a class="ref internalNav" href="#tbl11-fn1" aria-label="a">a</a><a onclick="showRef(event, 'ref124 ref214 ref215 ref216 ref217 ref218 ref219 ref220 ref221 ref222 ref223 ref224'); return false;" href="javascript:void(0);" class="ref ref124 ref214 ref215 ref216 ref217 ref218 ref219 ref220 ref221 ref222 ref223 ref224">(124,214−224)</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/medium/jm9b02075_0012.gif" alt="" id="GRAPHIC-d7e1156-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/medium/jm9b02075_0013.gif" alt="" id="GRAPHIC-d7e1157-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl11-fn1"><div class="footnote" id="tbl11-fn1"><sup><sup>a</sup></sup><p class="last">FtsZ = filamenting temperature-sensitive mutant Z, KasA = β-ketoacyl ACP synthase I, LeuRS = leucyl-tRNA synthetase. PAINS were calculated as described by Lagorce et al.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> Compound assay promiscuity was also predicted with BadApple.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a></p></div></div><div></div></div><div class="NLM_p">In terms of multiple structural classes inhibiting specific targets, this outcome is clearly revealed for pyroles, indole-2-carboxamide (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>), ethylenediamine (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>), which have been shown to inhibit MmpL3, pyrazolepyridone (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>), benzothiazole (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>), 4-aminoquinlone (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>), pyrimidine-azaindole, indole (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>), and benzothiazinone (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>), which inhibit DprE1. While several other structural classes have evidence on their targets, such information is typically absent (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl11" href="#tbl11">11</a>, compounds <b>8</b>–<b>125</b>).</div><div class="NLM_p">As examples using this Perspective, we will specifically highlight some relatively recent publications or those that take different approaches to identify lead compounds (<a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">Table <a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">12</a></a>). For instance, a study described the triazine antitubercular <b>104</b>,<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> which was initially discovered using a machine learning model.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> This compound was recently found to be activated by F<sub>420</sub>H<sub>2</sub> and one or more nitroreductases in addition to Ddn. Formation of NO<sup>•</sup> and a <i>des</i>-nitro metabolite were identified.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> An analogue <b>105</b> was generated in an attempt to improve the in vivo pharmacokinetics (PK). Both <b>104</b> and <b>105</b> achieved their activity via release of intrabacterial NO<sup>•</sup> along with inhibition of InhA.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> The thiophenecarboxamide <b>106</b> was found to be activated by EthA and then inhibited PyrG, identifying the importance of metabolic activation.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> A computational pharmacophore identified quinoxoline di-<i>N</i>-oxides and a lead optimization program produced several compounds such as <b>107</b>.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> An additional study used a Bayesian model to identify compounds, one of which <b>108</b> was pyrazolo[1,5-<i>a</i>]pyrimidine,<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> a class of compounds that had also been identified by several others through a concurrent high throughput screening program. A third compound identified in a separate Bayesian model screen was an imidazole <b>109</b>, which demonstrated reasonable in vitro activity. These computationally derived hits are vastly outnumbered by those discovered by other approaches such as HTS.</div><div class="NLM_table-wrap" id="tbl12"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 12. More Recent Lead Compounds of Different Structural Classes<a class="ref internalNav" href="#tbl12-fn1" aria-label="a">a</a><a onclick="showRef(event, 'ref66 ref85 ref86 ref87 ref88 ref89 ref91 ref92 ref93 ref95 ref96 ref97 ref98 ref99 ref100 ref101 ref102 ref103 ref104 ref225'); return false;" href="javascript:void(0);" class="ref ref66 ref85 ref86 ref87 ref88 ref89 ref91 ref92 ref93 ref95 ref96 ref97 ref98 ref99 ref100 ref101 ref102 ref103 ref104 ref225">(66,85−89,91−93,95−104,225)</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/medium/jm9b02075_0014.gif" alt="" id="GRAPHIC-d7e1315-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/medium/jm9b02075_0015.gif" alt="" id="GRAPHIC-d7e1316-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/medium/jm9b02075_0016.gif" alt="" id="GRAPHIC-d7e1317-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/medium/jm9b02075_0017.gif" alt="" id="GRAPHIC-d7e1318-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl12-fn1"><div class="footnote" id="tbl12-fn1"><sup><sup>a</sup></sup><p class="last">Ddn = deazaflavin-dependent nitroreductase, InhA = enoyl-ACP reductase, PyrG = CTP synthetase, QcrB = the b subunit of cytochrome bcc complex, IMPDH = inosine-5′-monophosphate dehydrogenase, DprE1 = decaprenylphosphoryl-β-<span class="smallcaps smallerCapital">d</span>-ribose oxidase, Pks13 = polyketide synthase 13, Mmpl3 = mycobacterial membrane protein Large 3, Mptpb = protein tyrosine phosphatase B. PAINS were calculated as described by Lagorce et al.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> Compound assay promiscuity was also predicted with BadApple.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a></p></div></div><div></div></div><div class="NLM_p">For example, Song et al. have reported the structure–activity relationship (SAR) of about 30 new analogues of an earlier thymidine-based hit against the <i>Mtb</i> thymidylate kinase (TMPK), ostensibly using ligand efficiency (LE) metrics.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> LE ranged from 0.18–0.29 for all compounds. Compound <b>110</b> emerged as the lead active, giving an IC<sub>50</sub> of 0.95 μM versus <i>Mtb</i> TMPK and activity against whole cell <i>Mtb</i> H37Rv (MIC = 7.8–15.6 μM). Screening against <i>Mtb</i> H37Rv in the presence of verapamil, an efflux pump inhibitor, modestly improved activity (MIC with verapamil (40 μg/mL) = 3.9–7.8 μM), suggesting that efflux may play a role in the differential activity against <i>Mtb</i> TMPK and the whole cell MIC. A crystal structure of the lead compound with <i>Mtb</i> TMPK was also reported.</div><div class="NLM_p">A series of indolyl azaspiroketal Mannich bases has been reported to show selective membrane permeabilization of <i>Mtb</i> membranes.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> The lead agent <b>111</b> gave an MIC<sub>90</sub> versus <i>Mtb</i> BCG of 0.8 μM and an IC<sub>50</sub> against VERO cells of 29 μM for a modest selectivity index (SI) of 36 (SI commonly presented as IC<sub>50</sub> VERO/MIC<sub>90</sub><i>Mtb</i>). Not surprisingly, the compound has a relatively high log <i>P</i> by medicinal chemistry standards (5.12) and demonstrates 50% hemolysis of human red blood cells at 64 μM. The lead demonstrated acceptable PK in mice and gave a modest reduction in CFU counts in the lungs (−0.75 log<sub>10</sub>) and spleens (−0.84 log<sub>10</sub>) of <i>Mtb</i> H37Rv infected mice when dosed at 100 mg/kg daily over 4 weeks (6 days per week, total of 24 doses).</div><div class="NLM_p">Whole cell aerobic <i>Mtb</i> screening of the corporate Lilly screening deck produced a submicromolar active in the morpholino-thiophene class.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> Further assessment validated the active hit, leading to structure–activity relationship (SAR) optimization and advanced screening. The minimal pharmacophore was the morpholino-thiophene and produced a new lead compound <b>112</b> with an MIC of 0.24 μM against <i>Mtb</i> H37Rv, VERO cell toxicity of 37 μM, and a resulting selectivity index (SI = VERO IC<sub>50</sub>/<i>Mtb</i> MIC) of 154. Microsomal stability was improved over the initial hit, but intrinsic clearance in mice using mouse liver microsomes remained significant at 8 mL/min/g liver. Activity in a murine intratracheal infection model at 100 mg/kg for 4 days led to a modest reduction of CFU in the lung of 0.8 log compared to 2.8 log for moxifloxacin. Initial mechanism of action (MOA) studies suggested that QcrB, a subunit of the menaquinol cytochrome <i>c</i> oxidoreductase and part of the <i>Mtb</i> bc1-aa3-type cytochrome <i>c</i> oxidase complex, was a potential target.</div><div class="NLM_p"><i>Mtb</i> IMPDH has been the target of numerous drug discovery programs. Hedstrom et al. have pursued the SAR of the benzoxazole scaffold to produce a new lead inhibitor <b>113</b>.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> This compound had showed potent inhibition of <i>Mtb</i> IMPDH (<i>K</i><sub>i,app</sub> = 18 nM) and good activity versus <i>Mtb</i> H37Rv (MIC = 1.0 μM). Additionally, the compound is active against conditional and knockdown strains, easing current concerns that guanine salvage can protect <i>Mtb</i> bacilli in the host. The compound showed reasonable pharmacokinetics in mice, but there are issues with mouse microsomal stability and high serum binding, suggesting that optimization of the class for targeting <i>Mtb</i> in vivo will be required.</div><div class="NLM_p">The group of Spain et al. recently reported continuing studies developing the SAR of bis-substituted cyclams as antimycobacterial agents.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> One compound in the series <b>114</b> demonstrated modest activity against <i>Mtb</i> H37Rv (6.25 μg/mL) and showed improved thermodynamic solubility as the ZnCl<sub>2</sub> salt relative to other metal salt forms. The compound showed approximately a 3-fold reduction in <i>Mycobacterium marinum</i> fluorescence/infection in the zebrafish embryo model using tdTomato-fluorescent <i>M. marinum</i> at a dose of 10 μM, refreshed every second day of infection. It remains unclear how effective the molecule is as the metal salt or whether it is just a delivery mechanism for Zn<sup>2+</sup>, a metal known to have antibacterial activity. Beyond the issue of stability of the metal salt to gut pH, these are relatively large (MW = 967.31 amu), charged species which might impact oral bioavailability and utility as drugs.</div><div class="NLM_p">Several substituted phenyl-aminothiazoles were reported through the TAACF screens in 2009 as potent and relatively selective inhibitors versus <i>M. tuberculosis</i>. Other groups have explored the SAR of this class since that time, but no definitive target(s) have emerged. Azzali et al. recently published over 30 analogues designed to further develop SAR of the class leading to compound <b>115</b>.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> This lead had similar activity to highly related structures reported out of the TAACF screens, and the reported compound showed MIC<sub>90</sub> values against several strains of <i>Mtb</i> in the range of 0.060–0.125 μg/mL, with retention of activity against several established drug resistant <i>Mtb</i> strains. Furthermore, <b>115</b> was relatively selective for <i>Mtb</i> versus a mammalian cell line, HMDM, (IC<sub>50</sub> = 53 μg/mL), verifying earlier toxicity reports for the class by the TAACF (VERO cells). The paper also includes metabolism (<i>T</i><sub>1/2</sub> and intrinsic clearance) from human liver microsomes (<i>T</i><sub>1/2</sub> = 16.1 ± 0.2 min and CL′<sub>int</sub> = 38.8 mL/min/kg) and information relating to efflux in drug resistant <i>Mtb</i> strains, suggesting that the compound is metabolically stable and apparently is not susceptible to drug efflux pumps. The paper does not address concerns regarding chelating ability of the class. This group has also described a similar compound that is antitubercular and inhibits efflux activity.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a></div><div class="NLM_p">Wilson et al. report the SAR development of an HTS hit from the Biofocus DPI Softfocus Library that is in the 6-dialkylaminopyrimidine carboxamide class.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> A lead compound <b>116</b> was identified from some 50 analogues that demonstrated high activity against <i>Mtb</i> H37Rv (MIC<sub>99</sub> = 1.3 μM) and comparable activity against several clinical strains. The compound has a relatively high cLogP (5.0) and was tested in various assays for PK and demonstrated moderate uptake, stability, and showed low clearance via intravenous administration despite poor microsomal stability, most likely resulting from extensive tissue distribution as indicated by a high volume of distribution (<i>V</i><sub>d</sub> = 21.8 L/kg). Early MOA studies using an affinity anchored analogue and sepharose beads in a chemoproteomic approach suggested two potential novel targets of unknown function, BCG_3193 (Rv3169) and BCG_3827 (Rv3768).</div><div class="NLM_p">A SAR was recently reported for approximately 20 heterocyclic <i>N</i>-oxides, leading to advanced screening of a novel hybrid of INH and a benzo-oxadiazole-<i>N</i>-oxide, (<i>E</i>)-6-((2-isonicotinoylhydrazono)methyl)benzo[<i>c</i>][1,2,5]-oxadiazole 1-oxide.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> Compound <b>117</b> shows good antitubercular activity against actively growing <i>Mtb</i> H37Rv (MIC<sub>90</sub> = 1.1 μM) and dormant (hypoxic) <i>Mtb</i> H37Rv (MIC<sub>90</sub> = 6.6 μM), including a small number of drug resistant strains (e.g., INH-R MIC<sub>90</sub> = 8.6 μM, RMP-R MIC<sub>90</sub> = 3.8 μM, BDQ-R MIC<sub>90</sub> = 1.2 μM). While the agent was relatively nontoxic against MRC-5 cells with IC<sub>50</sub> of 519.2 μM, it showed some toxicity versus HepG2 (IC<sub>50</sub> = 16.0 μM). The active lead was further evaluated for mutagenicity using the micronucleus test in peripheral mouse blood reticulocytes, and there was no indication of genotoxicity up to a single dose of 500 mg/kg after 30 h. Compound <b>117</b> was bactericidal in culture against <i>Mtb</i> H37Rv infection in the J774A.1, a macrophage cell line, at 23.86 μg/mL (4× MIC), 5.84 μg/mL (MIC), and 1.46 μg/mL (MIC/4), essentially sterilizing the culture at all doses. Extensive absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties including liver toxicity were determined for the lead, resulting in screening in vivo against <i>Mtb</i> Erdman in an acute murine model of tuberculosis. Compound <b>117</b> also showed complete sterilization in the lungs of female BALB/c mice at 200 mg/kg given daily for 5–7 days over a three-week period.</div><div class="NLM_p">Interest in the target DprE1 has led to a HTS screening campaign at GSK and the discovery of a novel hit in the hydantoin class <b>118</b>.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> In a recent report by Rogacki et al., the activity of the initial hit and an extensive SAR program are described.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> The initial hit <b>118</b> showed potent inhibition of DprE1 (pIC<sub>50</sub> = 7.0), good activity against <i>Mtb</i> H37Rv (8.3 μM) using the resazurin reduction assay with fluorescent readout, no toxicity to HepG2 cells up to 100 μM, and good kinetic aqueous solubility (202 μM) relative to the MIC. A relatively thorough SAR exploration of the scaffold resulting in over 100 analogues gave only modest improvements in activity and other medicinal chemistry parameters. Mechanistically, the compound is a reversible inhibitor of DprE1. The authors concluded that the compound class has few or no major liabilities, is generally characterized by good metabolic stability, has no appreciable cytotoxicity, and possesses a physicochemical profile acceptable for further development. Further optimization was reported as underway including in vivo experiments in a respiratory rodent model of <i>Mtb</i>.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a></div><div class="NLM_p">Two recent publications present the discovery and further natural product-inspired SAR optimization of the coumestan scaffold. The first publication reports nearly 50 analogues resulting in the lead <b>119</b>, demonstrating significant activity against <i>Mtb</i> H37Rv in the MABA assay (MIC<sub>90</sub> = 0.125–0.25 μg/mL).<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> The compound showed relatively significant toxicity to VERO cells (IC<sub>50</sub> = 4 μg/mL.), yielding a modest selectivity index (SI) (IC<sub>50</sub>/MIC<sub>90</sub>) = 16–32. Interestingly, four other human derived cell lines [MRC-5 and HFL1 (human lung fibroblast cells), QSG-7701 (human liver cell), and HEK-293 (human embryonic kidney cell)] showed no toxicity up to 50 μg/mL. The lead was further evaluated in the serum inhibition titration (SIT) assay by dosing BALB/c mice at 100 mg/kg via oral gavage and collecting serum at 30, 60, and 120 min. After processing the serum, the 30 min cohort gave good inhibition of <i>Mtb</i> H37Rv in the in vitro MABA assay, suggesting that the lead is orally available and that metabolism likely intervenes past the 30 min time point. Selection of resistant <i>Mtb</i> mutants and sequencing identified polyketide synthase 13 as a putative target. In a second paper,<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> Zhang et al. continued optimization of the scaffold, identifying <b>120</b> as a second-generation lead that shows improved activity (MIC<sub>90</sub> = 0.0039 μg/mL) against <i>Mtb</i> H37Rv and MIC<sub>90</sub>s in the range of 0.0039–0.0156 μg/mL against several drug resistant strains.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> Compound <b>120</b> also demonstrated toxicity against VERO cells (IC<sub>50</sub> = 4 μg/mL) but had significantly reduced toxicity against the four human-derived cell lines discussed previously. Compound <b>120</b> gave a good half-life (<i>T</i><sub>1/2</sub> = 120.1 min) in human liver microsomes and showed 8-fold higher activity than INH in the SIT assay dosed at 100 mg/kg with serum taken at 30 min.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a></div><div class="NLM_p">Clofazimine (CFZ) <b>34</b> is a highly active antitubercular agent, although the drug suffers from liabilities including high lipophilicity and fat solubility causing discoloration of fatty tissues in the patient. Zhang et al. describe optimization of the CFZ riminophenazine scaffold with the goal of reducing lipohilicity to manage these drug liabilities.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> Several CFZ analogues gave comparable or better activity as compared to CFZ with significantly reduced lipophilicity (ClogP). Six compounds with potent activity against <i>M. tuberculosis</i> in vitro, low acute toxicity in mice, and excellent PK profiles were further screened in an acute mouse model of MDR-TB infection. All compounds were highly efficacious, yielding 3–5 logs of CFU reduction in the lungs after 20 days in comparison to untreated control animals.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> Two compounds exhibited equal or better in vivo efficacy against MDR-TB compared to CFZ with the potential for reduced coloration in fatty tissues, and these analogues are being further evaluated for advanced development. For comparison, <b>121</b> gave an MIC of 0.016 μg/mL (CFZ 0.12 μg/mL), VERO cell toxicity of >64 μg/mL (CFZ 68.6 μg/mL), and a measured log <i>P</i> of 3.74 (CFZ 5.34).<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a></div><div class="NLM_p">Screening of the GSK compound library yielded a novel spirocyclic hit that was further optimized in a recent SAR program and made available through their open source program.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> This effort yielded an improved compound <b>122</b> with potent antitubercular activity (<i>Mtb</i> H37Rv MIC<sub>90</sub> = 0.06 μM). Cell health for the SAR set was measured in HepG2 cells and is reported as a triple-readout (membrane permeability, mitochondrial potential, and nuclear morphology) phenotypic assay measuring changes in cell structure as a preliminary consequence of cytotoxic injury. The assay used automated imaging to measure IC<sub>50</sub> values for the effect of compounds on human liver-derived, HepG2 cells (48 h incubation) as a surrogate of hepatotoxicity. For high doses (>100 mg/kg/day), numbers <80 μM raise alarms for hepatotoxicity. Compound <b>122</b> gave results 12.6, 10.7, and 11.0 μM, respectively. Compound <b>122</b> also had high lipophilicity and poor solubility as well as activity in the hERG assay, leading to cardiotoxicity concerns. PK results for <b>122</b> showed acceptable bioavailability with lower intrinsic clearance, a longer half-life, and oral AUC values suitable for progression into efficacy studies relative to other analogues. Compound <b>122</b> was further assayed in an acute murine model of <i>Mtb</i>– female CB57BL/6J mice infected with <i>Mtb</i> H37Rv intratracheally at ∼10<sup>5</sup> CFU. In a quick assay where the compound was administered for 8 days, the ED99 to give a 2-log reduction in lung CFU was reported to be 11.6 mg/kg. At a 50 mg/kg dosing regimen, <b>122</b> gave a cidal response and a 4.2 log reduction in CFU in the lungs compared to untreated controls.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> Further analoguing showed modest effects on some of the liabilities but confirmed potential cardiotoxicity and tolerability issues leading to sidelining of this compound series. <i>Mtb</i> MmpL3 was proposed as a possible target either directly or through a related perturbation in the transmembrane proton gradient.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a></div><div class="NLM_p"><i>Mtb</i> cytochrome P450 CYP121A1 is essential for bacterial viability, and a recent paper by Taban et al. describes a small SAR study of three series of biarylpyrazole imidazoles and triazoles including antitubercular and <i>Mtb</i> CYP121A1 inhibition data.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> About 20 compounds were reported in the three series, with MIC values ranging from 6.25 to >100 μg/mL. The −CH<sub>2</sub>-imidazole series was the most active in terms of <i>K</i><sub>D</sub> for CYP121A1 and inhibition of <i>Mtb</i> H7Rv in the resazurin microtiter assay. For example, <b>123</b> gave a <i>K</i><sub>D</sub> of 13.6 μM against CYP121A1 and a MIC of 6.25 μg/mL.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> In general, the MIC was found to correlate with calculated log <i>P</i> values. It is not clear regarding whether log <i>P</i> or log <i>D</i> is more relevant as the imidazole moiety is protonatable at physiological pH. Furthermore, there was no discussion relating to effects on human CYP enzymes or selectivity versus mammalian cells (e.g., VERO, HepG2 etc.). Co-crystal structures are reported for certain analogues with CYP121A1.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a></div><div class="NLM_p">Oh et al. have reported a novel hydroxypyrimidinone hit <b>124</b> from the chemical library of the St. Jude Children’s Research Hospital that appears to target decaprenylphosphoryl-β-<span class="smallcaps smallerCapital">d</span>-ribose 2-oxidase (DprE1, Rv3790).<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> The compound shows good activity against <i>Mtb</i> H37Rv in two media, 7H9/ADC (MIC 4.7 μM) and GAST (MIC 0.4 μM), and no toxicity to HepG2 cells up to 100 μM. The hit was bactericidal to actively replicating <i>Mtb</i> in vitro, with a 1–2 log reduction in CFU units observed over 7 days with weak dose dependence over a wide range of concentrations.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> Compound <b>124</b> did not show bactericidal activity against anaerobic, nonreplicating <i>Mtb</i> cells generated in the Wayne hypoxic <i>Mtb</i> model. PK profiling of <b>124</b> in C57BL/6 mice administered an oral suspension at a single dose of 10 mg/kg indicated poor absorption and in vivo efficacy against <i>Mtb</i> was not undertaken. Ex vivo activity against <i>Mtb</i> H37Rv in J774 murine macrophages gave apparent bactericidal activity. Nearly 20 analogues of the initial hit were reported with very little improvement in activity results. Furthermore, <b>124</b> is considerably less active than other reported DprE1 inhibitors that are progressing toward clinical use.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a></div><div class="NLM_p last">A structure-based program targeting <i>Mycobacterium tuberculosis</i> protein-tyrosine-phosphatase B (MptpB) was recently reported by Vickers et al. that resulted in a lead compound <b>125</b> (IC<sub>50</sub> Mptpb = 2.98 μM).<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> Certain analogues showed high selectivity for the mycobacterial phosphatase relative to human counterparts and low toxicity up to 150 μM in the mouse J774 macrophage cell line. Compound <b>125</b> showed reasonable kinetic solubility (200 μM) and acceptable results in the PAMPA screen (78.1 nM/s), suggesting the potential for good cell penetration. Compound <b>125</b> also showed improved pharmacological properties relative to other analogues with reasonable orally bioavailability and a good PK profile. Because the target is only essential in vivo, it is not surprising that it has a very modest impact on the growth of H37Rv in vitro. However, at both 20 and 100 μM, the compound significantly impacts bacterial burden in the human THP-1 macrophage model against both MDR strain (Beijing-W) and the drug-susceptible <i>M. tuberculosis</i> H37Rv strains.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> Furthermore, the compound at the low dose of 5 μM demonstrates compatibility in combination with rifampin and isoniazid (0.1 μg/mL for INH and 0.3 μg/mL for RIF), reducing bacterial burden by 93% in BCG infected J774 mouse macrophages. In vivo profiling of <b>125</b> in guinea pigs showed high exposure (<i>C</i><sub>max</sub> 112 μg/mL, AUC 230 μg·h/mL), long half-life (<i>t</i><sub>1/2</sub> 5 h), good oral availability, and appropriate tissue distribution in guinea pigs under either parental or oral dosing. Compound <b>125</b> was further tested for efficacy as monotherapy in the acute and chronic guinea pig models of TB (female Hartley Duncan). In the acute infection, animals were infected with approximately 96 CFU and, after 24 h, orally dosed once daily at 100 mg/kg for 4 weeks. Treatment resulted in a 0.9 log reduction of bacterial burden in the lungs relative to vehicle.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> For the chronic infection, guinea pigs were infected with ca. 63 CFU, and <b>125</b> was orally administered daily at 100 mg/kg for 4 weeks starting at 28 days post infection. In this model, treatment with <b>125</b> resulted in at least 1 log reduction in bacterial burden in lungs and spleens.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Molecular Diversity of Recent Compounds for TB</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20121" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20121" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Interestingly, only a relatively small number (17) of the 118 molecules in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Tables <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">12</a> (representing 14%) are pan assay interference compounds (PAINS) as assessed using the FAF-3 online software.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> However, more compounds (62) are flagged with the BadApple software (representing 52% in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Tables <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">12</a>), which attempts to identify compounds with assay promiscuity.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> There is generally good agreement with these two approaches. Previous comparisons of TB in vitro and in vivo data sets have determined the mean of molecular descriptors/properties across actives and inactives.<a onclick="showRef(event, 'ref226 ref227'); return false;" href="javascript:void(0);" class="ref ref226 ref227">(226,227)</a> We have determined eight simple molecular properties for the molecules in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.9b02075/suppl_file/jm9b02075_si_001.pdf" class="ext-link">Table S1</a>) and <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Tables <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">12</a> (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.9b02075/suppl_file/jm9b02075_si_001.pdf" class="ext-link">Table S2</a>). These data are remarkably similar to our previous analyses, suggesting a mean molecular weight of 390.96 and ALogP for 2.84 for approved TB drugs and mean molecular weight 399.57 and ALogP of 3.66 for TB leads, which are comparable to in vivo actives described earlier with a mean molecular weight of 411 and ALogP of 3.11.<a onclick="showRef(event, 'ref226'); return false;" href="javascript:void(0);" class="ref ref226">(226)</a> These may represent property ranges to target for TB activity. A more extensive cheminformatics analysis is now described in order to assess the chemical property space coverage of these <i>Mtb</i> leads.</div><div class="NLM_p">To assess the molecular diversity of the compounds active against <i>Mtb</i> described in this Perspective, we have generated a principal component analysis (PCA) plot based on eight 2D descriptors, which included molecular weight, topological polar surface area, number of aromatic rings, number of hydrogen bond acceptors, number of hydrogen bond donors, number of rotatable bonds, ring count, and MolLogP. All these descriptor calculations were generated with manual python scripts using RDKit,<a onclick="showRef(event, 'ref228'); return false;" href="javascript:void(0);" class="ref ref228">(228)</a> Pandas,<a onclick="showRef(event, 'ref229'); return false;" href="javascript:void(0);" class="ref ref229">(229)</a> NumPy<a onclick="showRef(event, 'ref230'); return false;" href="javascript:void(0);" class="ref ref230">(230)</a> libraries, and Jupyter Notebook.<a onclick="showRef(event, 'ref231'); return false;" href="javascript:void(0);" class="ref ref231">(231)</a> Before conducting PCA, the explicit descriptors were imputed “NAN” and ensured there were no missing values, and scaled from zero to one for each feature using MinMaxScaler from scikit-learn.<a onclick="showRef(event, 'ref232'); return false;" href="javascript:void(0);" class="ref ref232">(232)</a> We then conducted PCA using three sets of descriptors on (1) <i>Mtb</i> approved drugs (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) and 118 <i>Mtb</i> leads (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Tables <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">12</a>), (2) 7762 active compounds (MIC < 10 μM) from a set of 18 886 compounds with <i>Mtb</i> data<a onclick="showRef(event, 'ref233'); return false;" href="javascript:void(0);" class="ref ref233">(233)</a> (<i>Mtb</i> actives) and 118 <i>Mtb</i> leads data sets, and (3) <i>Mtb</i> actives, 118 <i>Mtb</i> compound data set, approved drugs, and Microsource spectrum data sets. The PCA figures were generated using Matplotlib<a onclick="showRef(event, 'ref234'); return false;" href="javascript:void(0);" class="ref ref234">(234)</a> library and Jupyter Notebook.</div><div class="NLM_p">PCA analysis of <i>Mtb</i> approved drugs (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) and 118 <i>Mtb</i> leads (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Tables <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">12</a>) indicates coverage of the same property space (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A). When visualized using the chemical network visualization, this may represent a more useful approach to grouping the molecules than the <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Tables <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">12</a>. We have summarized several “outlier” molecules away from the main cluster shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A. These molecules are also shown in Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.9b02075/suppl_file/jm9b02075_si_001.pdf" class="ext-link">Tables S2 and S3</a>. What is apparent is that many of these “natural product like” such as <b>66</b>, <b>67</b>, <b>69</b>, <b>70</b>, <b>71</b>, or very large <b>114</b> with generally low ALogP (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.9b02075/suppl_file/jm9b02075_si_001.pdf" class="ext-link">Table S2</a>). Many of these molecules cluster together (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B). Several of outliers are very lipophilic <b>19</b>, <b>41</b>, <b>84</b>, <b>85</b>, and <b>94</b>. Interestingly, the high ALogP outliers are to the left and the low ALogP molecules are to the right. As one would expect similar molecules group together such as <b>1</b> and <b>2</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/medium/jm9b02075_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/large/jm9b02075_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Data visualization of <i>Mtb</i> approved drugs and <i>Mtb</i> lead compounds in this review. (A) The PCA generated with eight descriptors showed that <i>Mtb</i> approved drugs are overlapped with the 118 <i>Mtb</i> leads data set, with the three components of PCA representing 82.8% of the variance (<i>x</i> = 41.7%, <i>y</i> = 28.5%, <i>z</i> = 12.6%). Molecule numbers represent those outside the main cluster with structures shown (see also Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.9b02075/suppl_file/jm9b02075_si_001.pdf" class="ext-link">Table S3</a>). (B) Chemical network visualization containing compounds from <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> (green) and <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Tables <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">12</a> (red). This was generated using the same eight descriptors, with unsupervised hierarchical clustering using the Euclidean distance method, Wards linkage. Numbering corresponds to molecules in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>–<a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">12</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/large/jm9b02075_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02075&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We have compared these TB lead molecules to a recently curated set of 7762 active compounds (MIC < 10 μM) from a set of 18 886 compounds with <i>Mtb</i> data<a onclick="showRef(event, 'ref233'); return false;" href="javascript:void(0);" class="ref ref233">(233)</a> (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). The only TB lead that appears separate from the main cluster of TB Actives is <b>114</b>, which is a bis-substituted cyclam (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.9b02075/suppl_file/jm9b02075_si_001.pdf" class="ext-link">Table S2 and S3</a>) with a high molecular weight and low ALogP. This analysis shows that the compounds in this review are representative of the chemical property space of the thousands of <i>Mtb</i> “active” compounds published by many laboratories to date and when compared to approved drugs (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> and <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). Digging deeper into the outlier molecules as described herein suggests that the extremes of ALogP and molecular weight (and perhaps other simple descriptors) need to be further explored in detail, as most of the TB leads seem to be in the “sweet spot” of mean molecule properties that we have seen covered over the years with our various analyses.<a onclick="showRef(event, 'ref226 ref227'); return false;" href="javascript:void(0);" class="ref ref226 ref227">(226,227)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/medium/jm9b02075_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/large/jm9b02075_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Principal component analysis of compounds in this review (blue) alongside a curated set of <i>Mtb</i> actives<a onclick="showRef(event, 'ref228'); return false;" href="javascript:void(0);" class="ref ref228">(228)</a> (red, MIC < 10 μM threshold). The PCA generated with eight descriptors showed that <i>Mtb</i> actives are overlapped with the 118 <i>Mtb</i> compound data set, with the three components of PCA representing 85.78% of the variance (<i>x</i> = 55.82%, <i>y</i> = 18.65%, <i>z</i> = 11.31%). Lead molecule <b>114</b> is clearly outside of the main cluster of TB actives (for structure, see Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.9b02075/suppl_file/jm9b02075_si_001.pdf" class="ext-link">Table S3</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/large/jm9b02075_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02075&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/medium/jm9b02075_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/large/jm9b02075_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Principal component analysis of 118 lead compounds in this review (blue) alongside a curated set of <i>Mtb</i> actives<a onclick="showRef(event, 'ref228'); return false;" href="javascript:void(0);" class="ref ref228">(228)</a> (red, MIC < 10 μM threshold), approved drugs (green), and Microsource spectrum (yellow), and we then generated a PCA fitted with eight descriptors of the merged frame including all four data sets. The three components explained a variation of 89.57% (<i>x</i> = 52.89%, <i>y</i> = 24.39%, <i>z</i> = 12.29%). A majority of the four data sets were found overlapped in the same PCA space.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/large/jm9b02075_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02075&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">While we can attempt to classify the lead compounds structurally, we can also organize them by each property (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). This type of circular dendrogram approach while showing a relatively close proximity in log <i>P</i> property space alone clearly indicates very few low log <i>P</i> molecules among these <i>Mtb</i> leads, for example structurally similar natural products or analogues <b>66</b> and <b>67</b>, <b>69</b>, and <b>70</b>. This would suggest the need to further explore natural product or natural product derivative property space. These various molecule visualization methods are far more realistic in grouping the molecules than by classes based on structure types.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/medium/jm9b02075_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/large/jm9b02075_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Circular dendrogram obtained from the hierarchical clustering of the 118 lead compounds for <i>Mtb</i> using eight descriptors, Ward linkage, and Euclidian distance. Compound nodes and names are colored according to their MolLogP.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/large/jm9b02075_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02075&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Machine Learning for TB Drug Discovery</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17836" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17836" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Alternative approaches to identify new leads for TB can learn from past data. We and others<a onclick="showRef(event, 'ref235'); return false;" href="javascript:void(0);" class="ref ref235">(235)</a> have published widely using the naïve Bayesian approach for tuberculosis drug discovery.<a onclick="showRef(event, 'ref227 ref236'); return false;" href="javascript:void(0);" class="ref ref227 ref236">(227,236)</a> Models that combined bioactivity and cytotoxicity data were used to rank compounds such as the GSK antimalarial data set.<a onclick="showRef(event, 'ref237'); return false;" href="javascript:void(0);" class="ref ref237">(237)</a> From the top 46 molecules, seven were chosen and five had MIC ≤ 2 μg/mL, the most active <b>104</b> being 0.0625 μg/mL.<a onclick="showRef(event, 'ref238'); return false;" href="javascript:void(0);" class="ref ref238">(238)</a> A second example used two different <i>Mtb</i> whole cell models to score three vendor libraries from which 550 compounds were tested and 124 actives identified.<a onclick="showRef(event, 'ref239'); return false;" href="javascript:void(0);" class="ref ref239">(239)</a> A third example filtered a library of >150 000 molecules and tested 48 compounds, of which 11 were active,<a onclick="showRef(event, 'ref225'); return false;" href="javascript:void(0);" class="ref ref225">(225)</a> including <b>109</b>. The models achieved screening hit rates of 15–71% for suggested compounds, far higher than the 0.6–1.5% typical for random library HTS screening.<a onclick="showRef(event, 'ref85 ref239 ref240'); return false;" href="javascript:void(0);" class="ref ref85 ref239 ref240">(85,239,240)</a> Fusion of three dual activity models gave an excellent ROC value, with a fourth external data set from the same laboratory.<a onclick="showRef(event, 'ref241'); return false;" href="javascript:void(0);" class="ref ref241">(241)</a> These models have also been used individually with a test set of 1924 molecules, for which cytotoxicity was determined in three cell lines, and enrichments of 11.8-fold were observed in the best case.<a onclick="showRef(event, 'ref242'); return false;" href="javascript:void(0);" class="ref ref242">(242)</a> Fusing single point data (bioactivity only) with dual activity data ultimately led to models with 345 011 molecules in them, but these were no more predictive that the smaller dual activity data sets when tested with external data.<a onclick="showRef(event, 'ref243'); return false;" href="javascript:void(0);" class="ref ref243">(243)</a> We have also used Bayesian and additional machine learning approaches to model data from the mouse <i>Mtb</i> efficacy model that have been published over the last 70 years. Models were initially constructed with 773 compounds and used to predict 11 molecules from the literature (eight were correctly predicted).<a onclick="showRef(event, 'ref244'); return false;" href="javascript:void(0);" class="ref ref244">(244)</a> More recently, these models have been updated and used with a test set of 60 molecules. The best <i>Mtb</i> in vivo models in this case now possess 5-fold ROC values >0.7, sensitivity >80%, and concordance >60%. These results indicated Bayesian models using literature in vivo <i>Mtb</i> data generated by different laboratories in many different mouse models can be predictive and also be used alongside other models to select antitubercular compounds with in vivo efficacy.<a onclick="showRef(event, 'ref245'); return false;" href="javascript:void(0);" class="ref ref245">(245)</a> We have also recently curated the <i>Mtb</i> data and developed newer machine learning models with 18 886 molecules (with activity cut offs of 10 μM, 1 μM, and 100 nM).<a onclick="showRef(event, 'ref233'); return false;" href="javascript:void(0);" class="ref ref233">(233)</a> These data sets were used to evaluate many different machine learning methods (including deep learning and support vector machines) and were assessed with additional molecules published in 2017. The 100 nM cutoff model was tested with an evaluation set (<i>n</i> = 153 compounds) and showed comparable statistics to those seen with 5-fold cross validation (accuracy = 0.83, precision = 0.27, recall = 1.00, specificity = 0.81, kappa = 0.36, and MCC = 0.47). Bayesian machine learning models constructed with literature <i>Mtb</i> data generated by different laboratories generally were equivalent to or outperformed deep neural networks with external test sets.<a onclick="showRef(event, 'ref233'); return false;" href="javascript:void(0);" class="ref ref233">(233)</a> There are also individual efforts that have developed large numbers of promising leads such as the HTS of two million compounds that resulted in the GSK set of 177 lead compounds.<a onclick="showRef(event, 'ref246'); return false;" href="javascript:void(0);" class="ref ref246">(246)</a> We have previously shown that our Bayesian models identified some of these compounds before they were even published when they were a subset of an antimalarial library (described earlier<a onclick="showRef(event, 'ref237'); return false;" href="javascript:void(0);" class="ref ref237">(237)</a>), providing an excellent example of prospective prediction.<a onclick="showRef(event, 'ref247'); return false;" href="javascript:void(0);" class="ref ref247">(247)</a> This raises the larger question of whether these models are able to identify the GSK leads because the models generated with large numbers of compounds from the SRI/TAACF screens were of a broad diversity that they essentially cover <i>Mtb</i> property space. Alternatively, may we be interpolating from these compounds that the GSK library just sample close analogues of the SRI/TAACF library? On the basis of analysis of the literature, it is clear from this work that we are quite adept at rediscovering compounds from the past, finding close analogues or structural scaffolds from years previously. Finding truly novel original molecules that are active against <i>Mtb</i> (and for that matter any bacteria) from machine learning models is a challenge we need to explore further in future because it is still a work in progress.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65281" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65281" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The recent development of tuberculosis research and development programs has been fruitful in terms of generating thousands of preclinical leads. Over the past decade alone, TB drug discovery has advanced with the screening of large drug-like and pharmaceutical company libraries starting with the TAACF in 2009 screening over 300 000 compounds.<a onclick="showRef(event, 'ref77 ref78 ref79'); return false;" href="javascript:void(0);" class="ref ref77 ref78 ref79">(77−79)</a> Several companies such as Novartis and GSK have screened even more compounds in the many millions.<a onclick="showRef(event, 'ref172 ref246'); return false;" href="javascript:void(0);" class="ref ref172 ref246">(172,246)</a> The GSK library phenotypic screens alone covered two million molecules.<a onclick="showRef(event, 'ref246'); return false;" href="javascript:void(0);" class="ref ref246">(246)</a> It is likely that in total well over five million compounds have been tested against <i>Mtb</i> by academia and big pharmaceutical companies. These chemical libraries likely have some overlap, but nevertheless many chemical classes have been examined and more unique lead compounds were discovered in this way. Therefore, there is now a very low chance of finding new compounds, and we will have to switch to looking for compounds against known targets or explore other sources of molecules. It may also be a challenge to come up with designs of new compounds which can address drug resistance. An alternative approach is the design and development of compounds which do not kill bacteria but instead block their virulence.<a onclick="showRef(event, 'ref248 ref249'); return false;" href="javascript:void(0);" class="ref ref248 ref249">(248,249)</a> These compounds likely will not have an MIC in in vitro testing but will have in vivo activity. This points to further testing of compounds in in vivo animal models, which is certainly expensive, or optimizing combinations of drugs using other biochemical approaches. These alternative approaches will also have issues in how one goes after them and the need for expensive downstream animal/combination studies.</div><div class="NLM_p">It should be noted that academics and industry are not always truly using and acknowledging available public resources such as the earlier NIH screens but are oftentimes rediscovering known actives and only poorly improving on them. That includes the data on their toxicity, the drug-like properties of the scaffolds, and general oral availability of these <i>Mtb</i> active molecules. Our earlier efforts with the Collaborative Drug Discovery database to make these <i>Mtb</i> data and machine learning models available represent some of the earliest attempts to help other research programs learn from this accumulated data and support open source drug discovery.<a onclick="showRef(event, 'ref83 ref84'); return false;" href="javascript:void(0);" class="ref ref83 ref84">(83,84)</a><i>Mtb</i> drug discovery needs a truly field-wide effort to succeed (it takes a village rather than isolated academics), and more needs to be done faster even still with all the issues of cost, compliance, drug resistance. and many thousands of people still dying annually. The Global Alliance’s recent advances (their approval of pretomanid and general ownership of the TB pipeline) are worthy of highlighting, especially as it has likely involved a massive investment in collaborative drug discovery and development. The GSK Open Source efforts (at a fraction of the Global Alliance’s budget) are also notable and should be lauded for their making hit and lead compounds accessible to the public as well as highlighting true modern pharmaceutical drug discovery research, particularly paradigms for advancement of compounds for in vivo and preclinical toxicity and pharmacokinetics assessment. Unfortunately, these many efforts have not yet led to new drugs and most of these resulting publications (some of which are included herein) represent molecules that did not perform well when they reached in vivo. One of our observations that derived from the efforts at collating leads for this publication was that many papers still appear on the same poor, toxic insoluble scaffolds without all the necessary minimal information to truly evaluate candidates (i.e., solubility, toxicity in mammalian cells, etc.) that are now standards in antibacterial drug discovery. Still, the increasing academic and industry collaborations has tended to at least anecdotally improve the drug-likeness of the compounds that resulted. Unfortunately, our cheminformatics analysis suggests that still, the recent lead compounds occupy the same property space as known drugs (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) as well as the larger set of TB in vitro or in vivo actives (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> and <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). There are, however, several “natural product like” or large molecules <b>66</b>, <b>67</b>, <b>69</b>, <b>70</b>, <b>71</b>, and <b>114</b>, or others <b>19</b>, <b>41</b>, <b>84</b>, <b>85</b>, and <b>94</b> that are at the extremes of the ALogP scale (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.9b02075/suppl_file/jm9b02075_si_001.pdf" class="ext-link">Table S2</a>) compared to the majority of the TB leads (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A), and they stand out from the rest. It may be worth exploring these outlier areas of property space further. Some of the TB lead molecules also appear to contain PAINS<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> and/or structural features that represent increased compound assay promiscuity.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> These molecules may need to be avoided or deprioritized. It is likely that limited structural diversity within screening libraries is also limiting the target diversity covered, which might explain why we see so many compounds for the promiscuous targets such as Mmpl3 and DprE1. Alternatively, and a common perception, it is possible that <i>Mtb</i> drug discovery has unique challenges due to the cellular barriers and druggability of targets requiring extremely small molecules or larger lipophilic compounds to access and bind targets within the cell. While there are many issues with <i>Mtb</i> drug discovery still to be answered from the chemistry/target perspective, the question of why lipophilic sulfur-containing compounds are hits in many <i>Mtb</i> screens is also intriguing. Is this just a case of metabolic activation or is there something else involved?</div><div class="NLM_p">In this Perspective, we have reviewed many different classes of compounds representing respectable coverage of <i>Mtb</i> chemical property space that might suggest reasonable target diversity and a promising foundation for the development of new drugs that will address burgeoning <i>Mtb</i> drug resistance in the clinic. This abundance of preclinical leads, many of which are active in mice and/or active versus MDR strains of <i>Mtb</i> provides some hope, although the current clinical trial pipeline remains limited (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Other reviews have suggested there is a need for novel targets.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> While the current perspective certainly confirms this finding, it is notable that there are also many compounds where the MOAs are unknown, and it is possible that unique and new targets may be hiding in plain sight. Perhaps a more critical observation is the generally limited variety of structural classes utilized and the general homogeneity of chemistry space. These current successes in generating new leads for <i>Mtb</i> have been driven primarily by funding from NIH/NIAID and BMGF as well as to some extent EU funding and, to a lesser extent, investments from pharmaceutical companies.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> While results from these programs are promising, there is still a dire need to develop more new leads in the hope that some of them will advance to the clinic for TB. More commitment to developing shorter treatment regimens are dependent on strong synergistic interactions between drugs, and more screens for synergy are also needed. However, rarely does a compound with in vitro synergy translate to in vivo synergy,<a onclick="showRef(event, 'ref250'); return false;" href="javascript:void(0);" class="ref ref250">(250)</a> more often than not the differences in ADME and PK properties of the two or more combined drugs will result in antagonism or no benefit.<a onclick="showRef(event, 'ref250'); return false;" href="javascript:void(0);" class="ref ref250">(250)</a> Additionally, efforts to identify compounds affecting latent TB are of crucial importance to better target an essentially untreated population of bacilli in both actively diseased as well as latently infected patients.<a onclick="showRef(event, 'ref251'); return false;" href="javascript:void(0);" class="ref ref251">(251)</a> Certainly, the compatibility of new TB agents and antiretroviral drugs to treat HIV-infected TB patients is another key issue that has to be addressed.<a onclick="showRef(event, 'ref252 ref253'); return false;" href="javascript:void(0);" class="ref ref252 ref253">(252,253)</a> The complexity of developing treatments for TB has led to the exploration of various chemical cores described herein that are outside traditional classes of antibacterials or antituberculars as shown in some of the nearly 118 lead compounds selected (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Tables <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">12</a>). Furthermore, many perfectly good drugs are available that could be revisited for delivery via different routes. For example, a recent review has summarized prospects for using inhaled drug delivery to reinvigorate TB treatment.<a onclick="showRef(event, 'ref254'); return false;" href="javascript:void(0);" class="ref ref254">(254)</a> In this vein, there are a large number of published examples of leads that possess poor PK and efficacy when dosed orally (including those described in this review), and this set might serve as an excellent reservoir of new drugs using an alternative delivery route such as inhalation. After decades of relatively modest outcomes in <i>Mtb</i> drug discovery and development, we think it is time for a “breath of fresh air” in this area.</div><div class="NLM_p last">While there have been some moderate successes in the field over the past decade, as researchers we are having to run faster just to stay in place. Clearly, the investments to date have underdelivered, but perhaps our expectations may be set unrealistically high. For example: should we move beyond relying on oral drug delivery, and do we always need to know the target for a new hit or lead? Hundreds of high-quality papers over the past decade that delve into the detailed mechanistic underpinnings of molecules for <i>Mtb</i> have not delivered more than a small fraction that are viable clinical candidates. How can we shift from having generations of TB scientists producing the same types of closely related molecules? We hope that this goes some way toward recognizing the need for fresh perspectives on <i>Mtb</i> drug discovery in order to answer some of these questions and lead us to another golden era in antibacterial drug discovery. The current pipeline is dominated by one organization, the TB Alliance. Maybe it is time for them and the community in general to rethink expectations of <i>Mtb</i> preclinical candidates and how we could perform drug discovery differently. We have presented evidence for how we can learn from the published <i>Mtb</i> data on lead compounds using computational models such as machine learning and cheminformatics analyses which may help us to explore new structural classes and property space. These types of approaches have been under-utilized in <i>Mtb</i> drug discovery, likely due to a lack of funding and also acceptance, this may change with the many recent articles on machine learning. It is abundantly clear there is still a bias toward small molecules when there may be very large natural products (e.g., macrolactones etc.) that could have promising antitubercular activity. We certainly have not explored all of these large molecules to date. It is well overdue to do this and, as importantly, we need to better learn from the molecules and data that have accumulated over the years. It is not in our best interests to ignore the collective preceding chemistry for antituberculars, but we do need to shift to new areas of chemistry because we are continuously covering the same ground. This Perspective represents our latest efforts in nearly a decade of analysis of small molecules for <i>Mtb</i> in order to provide fresh insights to improve our productivity and likelihood of success in future.</div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20"><a href="/doi/suppl/10.1021/acs.jmedchem.9b02075" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13260" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13260" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.9b02075?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b02075</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Molecular properties <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Tables <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">12</a> compounds; bold highlights represent molecules that appear as outliers on <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> or <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>; outlier molecules from <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> and <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b02075/suppl_file/jm9b02075_si_001.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b02075/suppl_file/jm9b02075_si_001.pdf">jm9b02075_si_001.pdf (103.95 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b02075" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72040" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72040" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sean Ekins</span> - <span class="hlFld-Affiliation affiliation">Collaborations
Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510 Raleigh, North Carolina 27606, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5691-5790" title="Orcid link">http://orcid.org/0000-0002-5691-5790</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#b6c5d3d7d8f6d5d9dadad7d4d9c4d7c2dfd9d8c5c6ded7c4dbd798d5d9db"><span class="__cf_email__" data-cfemail="a3d0c6c2cde3c0cccfcfc2c1ccd1c2d7cacccdd0d3cbc2d1cec28dc0ccce">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vadim Makarov</span> - <span class="hlFld-Affiliation affiliation">FRC
Fundamentals of Biotechnology, Russian Academy
of Science, Moscow 119071, Russia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elena Salina</span> - <span class="hlFld-Affiliation affiliation">FRC
Fundamentals of Biotechnology, Russian Academy
of Science, Moscow 119071, Russia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert C. Reynolds</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicine, Division of Hematology and Oncology, University of Alabama at Birmingham, NP 2540 J, 1720 Second Avenue South, Birmingham, Alabama 35294-3300, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Phyo Phyo Kyaw Zin</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry, North Carolina State University, Raleigh, North Carolina 27695, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Bioinformatics
Research Center, North Carolina State University, Raleigh, North Carolina 27695, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): S.E. is the CEO and owner of Collaborations Pharmaceuticals, Inc.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45052" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45052" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Vadim Makarov</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02075&amp;id=BIO-d7e2567-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Vadim Makarov</b> is the Chief of Lab in the Department of Stresses of Microorganisms, A.N. Bach Institute of Biochemistry, Moscow, Russian Federation. He is an expert in medicinal chemistry and rational drug design with special interest in developing antimicrobial and antiviral agents. His recent work in drug development has focused on antituberculosis drugs, and as result of his efforts in cooperation with several European scientific groups (NM4TB; LSHP-CT-2005-018923), a new class of synthetic organic compounds having high antituberculosis activity in vivo and in vitro was discovered (1,3-benzothiazinones). Two compounds from this group are under in-depth clinical investigation, with PBTZ169 being the lead candidate. Dr. Makarov’s team makes extensive use of advanced methods of medicinal chemistry, rational drug design, and study of metabolic transformations.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Elena Salina</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02075&amp;id=BIO-d7e2572-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Elena Salina</b> received a M.Sc. degree from the Mendeleev University of Chemical Technology of Russia in 2002. Then she began graduate studies at the Bach Institute of Biochemistry of the Russian Academy of Sciences, where she received a Ph.D. in Biochemistry under the direction of Professor A. Kaprelyants in 2006. She conducted postdoctoral studies at the same Institute working on <i>M. tuberculosis</i> persistence and modelling mycobacterial dormancy. Later, she worked in the field of finding new drugs for latent tuberculosis at the Federal Research Center of Biotechnology of the Russian Academy of Sciences, where she is currently a Senior Scientist. Dr. Elena G. Salina’s research interests concern the discovery of new drugs for the treatment of latent tuberculosis infection and multitargeted nonselective inhibition.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Robert C. Reynolds</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02075&amp;id=BIO-d7e2580-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Robert C. Reynolds</b> received a B.Sc. in Chemistry from the University of Virginia in 1977 and a Ph.D. from Duke University in 1985, while a student at Duke University under Dr. Barbara Shaw in Chemistry and Dr. David Sedwick in the Department of Medicine. After a postdoctoral fellowship at NIEHS in the Research Triangle Park with Dr. Robert London in the area of probe development for in vivo NMR metabolism, Dr. Reynolds began a 25-year career in drug design and synthesis at Southern Research Institute in Birmingham, Alabama, reaching the position of Director of Drug Discovery Technology. His major areas of emphasis were new target and drug discovery against cancer and infectious diseases, particularly tuberculosis. In 2012, Dr. Reynolds joined the University of Alabama at Birmingham.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Phyo Phyo Kyaw Zin</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02075&amp;id=BIO-d7e2585-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Phyo Phyo Kyaw Zin</b> received her B.A. in Chemistry and Computer Science from Berea College. She is now a Ph.D. candidate in the Fourches lab at North Carolina State University and a recipient of the AAUW International Doctoral Fellowship and Olive Ruth Russell Scholarships. Her research areas involve molecular informatics, computer-aided drug design, development of cheminformatics approaches/software to generate virtual chemical libraries, analysis and visualization of big chemical databases, and implementation of AI-powered (ML such as DLNN) cheminformatics methods to build QSAR models.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Sean Ekins</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02075&amp;id=BIO-d7e2590-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Sean Ekins</b> graduated from the University of Aberdeen, receiving his M.Sc., Ph.D., and D.Sc. in Clinical Pharmacology. He was a postdoctoral fellow at Lilly Research Laboratories then worked as a senior scientist at Pfizer and Lilly Research Laboratories, Associate Director of Computational Drug Discovery at Concurrent Pharmaceuticals, Inc., Vice President of Computational Biology at GeneGo, then worked for a number of companies, as CSO at Collaborative Drug Discovery and is currently CEO and Founder at Collaborations Pharmaceuticals, Inc. He is an Entrepreneur-in-residence at the Eshelman School of Pharmacy, UNC Chapel Hill. Sean has coauthored >300 peer reviewed scientific papers, book chapters and patents as well as edited/coedited five books. He has worked for over a decade on tuberculosis drug discovery using machine learning.</p></figure></div><div class="ack" id="ACK-d7e2563-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45701" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45701" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We kindly acknowledge NIH NINDS: 1R01NS102164-01, RFBR 17-54-30007, SC RF AAAA-A19-119010590004-2, and NIAID R41AI13456. E.S. is grateful to the State Contract of the Russian Federation for financial support. S.E. kindly acknowledges Dr. Miriam Braunstein (UNC—Chapel Hill), Dr. Anthony Hickey (RTI), Dr. Joel Freundlich (Rutgers University), Dr. Ana Puhl (Collaborations Pharmaceuticals, Inc.), and Dr. Thomas Lane (Collaborations Pharmaceuticals, Inc.) for collaborations on tuberculosis and Dr. Barbara Laughon (NIAID) for permission to use the TB pipeline figure. S.E. kindly thanks BIOVIA for providing Discovery Studio.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ADMET</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism, excretion and toxicity</p></td></tr><tr><td class="NLM_term">AHAS</td><td class="NLM_def"><p class="first last">acetohydroxyacid synthases</p></td></tr><tr><td class="NLM_term">Ddn</td><td class="NLM_def"><p class="first last">deazaflavin-dependent nitroreductase</p></td></tr><tr><td class="NLM_term">DprE1</td><td class="NLM_def"><p class="first last">decaprenylphosphoryl-β-<span class="smallcaps smallerCapital">d</span>-ribose oxidase</p></td></tr><tr><td class="NLM_term">FtsZ</td><td class="NLM_def"><p class="first last">filamenting temperature-sensitive mutant Z</p></td></tr><tr><td class="NLM_term">GSK</td><td class="NLM_def"><p class="first last">GlaxoSmithKline</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human ether-a-gogo-related gene</p></td></tr><tr><td class="NLM_term">HIV</td><td class="NLM_def"><p class="first last">human immunodeficiency virus</p></td></tr><tr><td class="NLM_term">HTS</td><td class="NLM_def"><p class="first last">high throughput screening</p></td></tr><tr><td class="NLM_term">IMPDH</td><td class="NLM_def"><p class="first last">inosine-5′-monophosphate dehydrogenase</p></td></tr><tr><td class="NLM_term">InhA</td><td class="NLM_def"><p class="first last">enoyl-ACP reductase</p></td></tr><tr><td class="NLM_term">KasA</td><td class="NLM_def"><p class="first last">β-ketoacyl ACP synthase I</p></td></tr><tr><td class="NLM_term">LeuRS</td><td class="NLM_def"><p class="first last">leucyl-tRNA synthetase</p></td></tr><tr><td class="NLM_term">LE</td><td class="NLM_def"><p class="first last">ligand efficiency</p></td></tr><tr><td class="NLM_term">MDR</td><td class="NLM_def"><p class="first last">multidrug resistant</p></td></tr><tr><td class="NLM_term">MmpL3</td><td class="NLM_def"><p class="first last">mycobacterial membrane protein Large 3</p></td></tr><tr><td class="NLM_term">MOA</td><td class="NLM_def"><p class="first last">mechanism of action</p></td></tr><tr><td class="NLM_term">Mptpb</td><td class="NLM_def"><p class="first last">protein tyrosine phosphatase</p></td></tr><tr><td class="NLM_term">MraY</td><td class="NLM_def"><p class="first last">phospho-MurNAc-pentapeptide translocase</p></td></tr><tr><td class="NLM_term"><i>Mtb</i></td><td class="NLM_def"><p class="first last"><i>Mycobacterium tuberculosis</i></p></td></tr><tr><td class="NLM_term">NIAID</td><td class="NLM_def"><p class="first last">National Institute of Allergy and Infectious Diseases</p></td></tr><tr><td class="NLM_term">NO</td><td class="NLM_def"><p class="first last">nitric oxide</p></td></tr><tr><td class="NLM_term">PAINS</td><td class="NLM_def"><p class="first last">pan assay Interference compounds</p></td></tr><tr><td class="NLM_term">PanC</td><td class="NLM_def"><p class="first last">pantothenate synthetase</p></td></tr><tr><td class="NLM_term">PCA</td><td class="NLM_def"><p class="first last">principal component analysis</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">Pks13</td><td class="NLM_def"><p class="first last">polyketide synthase 13</p></td></tr><tr><td class="NLM_term">PyrG</td><td class="NLM_def"><p class="first last">CTP synthetase</p></td></tr><tr><td class="NLM_term">QcrB</td><td class="NLM_def"><p class="first last">The b subunit of cytochrome bcc complex</p></td></tr><tr><td class="NLM_term">ROC</td><td class="NLM_def"><p class="first last">receiver operator characteristic</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SI</td><td class="NLM_def"><p class="first last">selectivity index</p></td></tr><tr><td class="NLM_term">SRI/TAACF</td><td class="NLM_def"><p class="first last">Southern Research International/Tuberculosis Antimicrobial Acquisition and Coordinating Facility</p></td></tr><tr><td class="NLM_term">TB</td><td class="NLM_def"><p class="first last">tuberculosis</p></td></tr><tr><td class="NLM_term">TDR</td><td class="NLM_def"><p class="first last">totally drug resistant</p></td></tr><tr><td class="NLM_term">WecA</td><td class="NLM_def"><p class="first last">phosphoglycosyltransferase</p></td></tr><tr><td class="NLM_term">WHO</td><td class="NLM_def"><p class="first last">World Health Organization</p></td></tr><tr><td class="NLM_term">XDR</td><td class="NLM_def"><p class="first last">extensively drug resistant</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i28">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66328" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66328" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 254 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span> <i>Accelerating Discovery</i>; <span class="NLM_publisher-name">The Working Group
for New TB Drugs</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">2016</span>; <a href="http://www.newtbdrugs.org" class="extLink">www.newtbdrugs.org</a> (accessed 2020-03-03).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Accelerating+Discovery%3B+The+Working+Group%0Afor+New+TB+Drugs%3A+New+York%2C+2016%3B+www.newtbdrugs.org+%28accessed+2020-03-03%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26jtitle%3DAccelerating%2520Discovery%26pub%3DThe%2520Working%2520Group%250Afor%2520New%2520TB%2520Drugs%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Low, M.</span></span> <i>The Tuberculosis Treatment Pipeline: A Breakthrough Year For The Treatment Of XDR-TB</i>; <span class="NLM_publisher-name">Treatment Action Group</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">2017</span>;<a href="https://www.treatmentactiongroup.org/resources/pipeline-report/2017-pipeline-report/the-tuberculosis-treatment-pipeline-a-breakthrough-year-for-the-treatment-of-xdr-tb/" class="extLink">https://www.treatmentactiongroup.org/resources/pipeline-report/2017-pipeline-report/the-tuberculosis-treatment-pipeline-a-breakthrough-year-for-the-treatment-of-xdr-tb/</a> (accessed 2020-03-03).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=M.+Low&title=The+Tuberculosis+Treatment+Pipeline%3A+A+Breakthrough+Year+For+The+Treatment+Of+XDR-TB"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3DLow%26aufirst%3DM.%26jtitle%3DThe%2520Tuberculosis%2520Treatment%2520Pipeline%253A%2520A%2520Breakthrough%2520Year%2520For%2520The%2520Treatment%2520Of%2520XDR-TB%26pub%3DTreatment%2520Action%2520Group%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span> <i>Global Tuberculosis Report
2019</i>; <span class="NLM_publisher-name">World Health
Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2019</span>; <a href="https://www.who.int/tb/publications/global_report/en/" class="extLink">https://www.who.int/tb/publications/global_report/en/</a> (accessed 2020-03-03).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Global+Tuberculosis+Report%0A2019%3B+World+Health%0AOrganization%3A+Geneva%2C+2019%3B+https%3A%2F%2Fwww.who.int%2Ftb%2Fpublications%2Fglobal_report%2Fen%2F+%28accessed+2020-03-03%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26jtitle%3DGlobal%2520Tuberculosis%2520Report%250A2019%26pub%3DWorld%2520Health%250AOrganization%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jakab, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acosta, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kluge, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dara, M.</span></span> <span> </span><span class="NLM_article-title">Consolidated action plan to prevent and combat multidrug- and extensively drug-resistant tuberculosis in the WHO european region 2011–2015: Cost-effectiveness analysis</span>. <i>Tuberculosis (Oxford, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">S212</span>– <span class="NLM_lpage">S216</span>, <span class="refDoi"> DOI: 10.1016/j.tube.2015.02.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.tube.2015.02.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=25829287" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2015&pages=S212-S216&author=Z.+Jakabauthor=C.+D.+Acostaauthor=H.+H.+Klugeauthor=M.+Dara&title=Consolidated+action+plan+to+prevent+and+combat+multidrug-+and+extensively+drug-resistant+tuberculosis+in+the+WHO+european+region+2011%E2%80%932015%3A+Cost-effectiveness+analysis&doi=10.1016%2Fj.tube.2015.02.027"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.tube.2015.02.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tube.2015.02.027%26sid%3Dliteratum%253Aachs%26aulast%3DJakab%26aufirst%3DZ.%26aulast%3DAcosta%26aufirst%3DC.%2BD.%26aulast%3DKluge%26aufirst%3DH.%2BH.%26aulast%3DDara%26aufirst%3DM.%26atitle%3DConsolidated%2520action%2520plan%2520to%2520prevent%2520and%2520combat%2520multidrug-%2520and%2520extensively%2520drug-resistant%2520tuberculosis%2520in%2520the%2520WHO%2520european%2520region%25202011%25E2%2580%25932015%253A%2520Cost-effectiveness%2520analysis%26jtitle%3DTuberculosis%2520%2528Oxford%252C%2520U.%2520K.%2529%26date%3D2015%26volume%3D95%26spage%3DS212%26epage%3DS216%26doi%3D10.1016%2Fj.tube.2015.02.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mikusova, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span> <span> </span><span class="NLM_article-title">Learning from the past for tb drug discovery in the future</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">534</span>– <span class="NLM_lpage">545</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2016.09.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.drudis.2016.09.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=27717850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A280%3ADC%252BC2svnsVWmtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=534-545&author=K.+Mikusovaauthor=S.+Ekins&title=Learning+from+the+past+for+tb+drug+discovery+in+the+future&doi=10.1016%2Fj.drudis.2016.09.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Learning from the past for TB drug discovery in the future</span></div><div class="casAuthors">Mikusova Katarina; Ekins Sean</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">534-545</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Tuberculosis drug discovery has shifted in recent years from a primarily target-based approach to one that uses phenotypic high-throughput screens.  As examples of this, through our EU-funded FP7 collaborations, New Medicines for Tuberculosis was target-based and our more-recent More Medicines for Tuberculosis project predominantly used phenotypic screening.  From these projects we have examples of success (DprE1) and failure (PimA) going from drug to target and from target to drug, respectively.  It is clear that we still have much to learn about the drug targets and the complex effects of the drugs on Mycobacterium tuberculosis.  We propose a more integrated approach that learns from earlier drug discovery efforts that could help to move drug discovery forward.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTiiBeAayc7NTToTC3aBaesfW6udTcc2eZBGNRLAIXby7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svnsVWmtA%253D%253D&md5=8f169df66fbdee538f899b2619bba19e</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2016.09.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2016.09.025%26sid%3Dliteratum%253Aachs%26aulast%3DMikusova%26aufirst%3DK.%26aulast%3DEkins%26aufirst%3DS.%26atitle%3DLearning%2520from%2520the%2520past%2520for%2520tb%2520drug%2520discovery%2520in%2520the%2520future%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2017%26volume%3D22%26spage%3D534%26epage%3D545%26doi%3D10.1016%2Fj.drudis.2016.09.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S. T.</span></span> <span> </span><span class="NLM_article-title">Tuberculosis drug discovery needs public-private consortia</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">477</span>– <span class="NLM_lpage">478</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2016.09.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.drudis.2016.09.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=27717851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A280%3ADC%252BC2svnsVWmtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=477-478&author=S.+T.+Cole&title=Tuberculosis+drug+discovery+needs+public-private+consortia&doi=10.1016%2Fj.drudis.2016.09.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Tuberculosis drug discovery needs public-private consortia</span></div><div class="casAuthors">Cole Stewart T</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">477-478</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTiiBeAayc7NSsZ1x6zOs0vfW6udTcc2eZBGNRLAIXby7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svnsVWmtQ%253D%253D&md5=c4c07dfadbe8e89b8cbfaf6e1fa2b6f3</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2016.09.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2016.09.026%26sid%3Dliteratum%253Aachs%26aulast%3DCole%26aufirst%3DS.%2BT.%26atitle%3DTuberculosis%2520drug%2520discovery%2520needs%2520public-private%2520consortia%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2017%26volume%3D22%26spage%3D477%26epage%3D478%26doi%3D10.1016%2Fj.drudis.2016.09.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conradie, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diacon, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngubane, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howell, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everitt, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crook, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendel, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egizi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreira, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timm, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHugh, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wills, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bateson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Niekerk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olugbosi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spigelman, M.</span></span> <span> </span><span class="NLM_article-title">Treatment of highly drug-resistant pulmonary tuberculosis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>382</i></span>,  <span class="NLM_fpage">893</span>– <span class="NLM_lpage">902</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1901814</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1056%2FNEJMoa1901814" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=32130813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkvVKrsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=382&publication_year=2020&pages=893-902&author=F.+Conradieauthor=A.+H.+Diaconauthor=N.+Ngubaneauthor=P.+Howellauthor=D.+Everittauthor=A.+M.+Crookauthor=C.+M.+Mendelauthor=E.+Egiziauthor=J.+Moreiraauthor=J.+Timmauthor=T.+D.+McHughauthor=G.+H.+Willsauthor=A.+Batesonauthor=R.+Huntauthor=C.+Van+Niekerkauthor=M.+Liauthor=M.+Olugbosiauthor=M.+Spigelman&title=Treatment+of+highly+drug-resistant+pulmonary+tuberculosis&doi=10.1056%2FNEJMoa1901814"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of highly drug-resistant pulmonary tuberculosis</span></div><div class="casAuthors">Conradie, Francesca; Diacon, Andreas H.; Ngubane, Nosipho; Howell, Pauline; Everitt, Daniel; Crook, Angela M.; Mendel, Carl M.; Egizi, Erica; Moreira, Joanna; Timm, Juliano; McHugh, Timothy D.; Wills, Genevieve H.; Bateson, Anna; Hunt, Robert; Van Niekerk, Christo; Li, Mengchun; Olugbosi, Morounfolu; Spigelman, Melvin</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">382</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">893-902</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Patients with highly drug-resistant forms of tuberculosis have limited treatment options and historically have had poor outcomes. methods In an open-label, single-group study in which follow-up is ongoing at three South African sites, we investigated treatment with three oral drugs - bedaquiline, pretomanid, and linezolid - that have bactericidal activity against tuberculosis and to which there is little preexisting resistance.  We evaluated the safety and efficacy of the drug combination for 26 wk in patients with extensively drug-resistant tuberculosis and patients with multidrug-resistant tuberculosis that was not responsive to treatment or for which a second-line regimen had been discontinued because of side effects.  The primary end point was the incidence of an unfavorable outcome, defined as treatment failure (bacteriol. or clin.) or relapse during follow-up, which continued until 6 mo after the end of treatment.  Patients were classified as having a favorable outcome at 6 mo if they had resoln. of clin. disease, a neg. culture status, and had not already been classified as having had an unfavorable outcome.  Other efficacy end points and safety were also evaluated. results A total of 109 patients were enrolled in the study and were included in the evaluation of efficacy and safety end points.  At 6 mo after the end of treatment in the intention-to-treat anal., 11 patients (10%) had an unfavorable outcome and 98 patients (90%; 95% confidence interval, 83 to 95) had a favorable outcome.  The 11 unfavorable outcomes were 7 deaths (6 during treatment and 1 from an unknown cause during follow-up), 1 withdrawal of consent during treatment, 2 relapses during follow-up, and 1 loss to follow-up.  The expected linezolid toxic effects of peripheral neuropathy (occurring in 81% of patients) and myelosuppression (48%), although common, were manageable, often leading to dose redns. or interruptions in treatment with linezolid. conclusions The combination of bedaquiline, pretomanid, and linezolid led to a favorable outcome at 6 mo after the end of therapy in a high percentage of patients with highly drug-resistant forms of tuberculosis; some assocd. toxic effects were obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoagq93PXO5qrVg90H21EOLACvtfcHk0lgzLGFfOF-ckA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkvVKrsb0%253D&md5=e7210ad01d84d5c99708cdd124a29145</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1901814&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1901814%26sid%3Dliteratum%253Aachs%26aulast%3DConradie%26aufirst%3DF.%26aulast%3DDiacon%26aufirst%3DA.%2BH.%26aulast%3DNgubane%26aufirst%3DN.%26aulast%3DHowell%26aufirst%3DP.%26aulast%3DEveritt%26aufirst%3DD.%26aulast%3DCrook%26aufirst%3DA.%2BM.%26aulast%3DMendel%26aufirst%3DC.%2BM.%26aulast%3DEgizi%26aufirst%3DE.%26aulast%3DMoreira%26aufirst%3DJ.%26aulast%3DTimm%26aufirst%3DJ.%26aulast%3DMcHugh%26aufirst%3DT.%2BD.%26aulast%3DWills%26aufirst%3DG.%2BH.%26aulast%3DBateson%26aufirst%3DA.%26aulast%3DHunt%26aufirst%3DR.%26aulast%3DVan%2BNiekerk%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DOlugbosi%26aufirst%3DM.%26aulast%3DSpigelman%26aufirst%3DM.%26atitle%3DTreatment%2520of%2520highly%2520drug-resistant%2520pulmonary%2520tuberculosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2020%26volume%3D382%26spage%3D893%26epage%3D902%26doi%3D10.1056%2FNEJMoa1901814" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thwaites, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nahid, P.</span></span> <span> </span><span class="NLM_article-title">Triumph and tragedy of 21st century tuberculosis drug development</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>382</i></span>,  <span class="NLM_fpage">959</span>– <span class="NLM_lpage">960</span>, <span class="refDoi"> DOI: 10.1056/NEJMe2000860</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1056%2FNEJMe2000860" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=32130819" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A280%3ADC%252BB387ptlajuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=382&publication_year=2020&pages=959-960&author=G.+Thwaitesauthor=P.+Nahid&title=Triumph+and+tragedy+of+21st+century+tuberculosis+drug+development&doi=10.1056%2FNEJMe2000860"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Triumph and Tragedy of 21st Century Tuberculosis Drug Development</span></div><div class="casAuthors">Thwaites Guy; Nahid Payam</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">382</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">959-960</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTkHxyU3n4vkQpJitSxOdIlfW6udTcc2eYtTqPXMrsJYrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB387ptlajuw%253D%253D&md5=1742bbff59536529629c904aa6c56887</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2FNEJMe2000860&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMe2000860%26sid%3Dliteratum%253Aachs%26aulast%3DThwaites%26aufirst%3DG.%26aulast%3DNahid%26aufirst%3DP.%26atitle%3DTriumph%2520and%2520tragedy%2520of%252021st%2520century%2520tuberculosis%2520drug%2520development%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2020%26volume%3D382%26spage%3D959%26epage%3D960%26doi%3D10.1056%2FNEJMe2000860" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vilcheze, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, W. R.,  Jr.</span></span> <span> </span><span class="NLM_article-title">The mechanism of isoniazid killing: Clarity through the scope of genetics</span>. <i>Annu. Rev. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">35</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1146/annurev.micro.61.111606.122346</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1146%2Fannurev.micro.61.111606.122346" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=18035606" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlartrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2007&pages=35-50&author=C.+Vilchezeauthor=W.+R.+Jacobs&title=The+mechanism+of+isoniazid+killing%3A+Clarity+through+the+scope+of+genetics&doi=10.1146%2Fannurev.micro.61.111606.122346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The mechanism of isoniazid killing: clarity through the scope of genetics</span></div><div class="casAuthors">Vilcheze, Catherine; Jacobs, William R., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Microbiology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">35-50</span>CODEN:
                <span class="NLM_cas:coden">ARMIAZ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4227</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Isoniazid (INH) is one of the most efficient drugs for the treatment of Mycobacterium tuberculosis infections.  Despite its rather simple chem. structure, the mechanism by which INH kills M. tuberculosis is complex.  A full understanding of the mechanisms of action of INH required the development of genetic tools in M. tuberculosis.  Herein, we discuss the different hypotheses that have been used to describe INH action against M. tuberculosis over the past 50 years in terms of the pregenetic and genetic era.  We also review the different mechanisms of INH resistance and propose what we think is the means by which INH kills M. tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdq3WkgwRRL7Vg90H21EOLACvtfcHk0lgzLGFfOF-ckA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlartrbI&md5=c4857e9173ad388225afbec9688585d7</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1146%2Fannurev.micro.61.111606.122346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.micro.61.111606.122346%26sid%3Dliteratum%253Aachs%26aulast%3DVilcheze%26aufirst%3DC.%26aulast%3DJacobs%26aufirst%3DW.%2BR.%26atitle%3DThe%2520mechanism%2520of%2520isoniazid%2520killing%253A%2520Clarity%2520through%2520the%2520scope%2520of%2520genetics%26jtitle%3DAnnu.%2520Rev.%2520Microbiol.%26date%3D2007%26volume%3D61%26spage%3D35%26epage%3D50%26doi%3D10.1146%2Fannurev.micro.61.111606.122346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scorpio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">662</span>– <span class="NLM_lpage">667</span>, <span class="refDoi"> DOI: 10.1038/nm0696-662</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1038%2Fnm0696-662" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=8640557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADyaK28XjsVSjtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1996&pages=662-667&author=A.+Scorpioauthor=Y.+Zhang&title=Mutations+in+pncA%2C+a+gene+encoding+pyrazinamidase%2Fnicotinamidase%2C+cause+resistance+to+the+antituberculous+drug+pyrazinamide+in+tubercle+bacillus&doi=10.1038%2Fnm0696-662"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus</span></div><div class="casAuthors">Scorpio, Angelo; Zhang, Ying</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">662-667</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Co.</span>)
        </div><div class="casAbstract">Naturally pyrazinamide (PZA)-resistant Mycobacterium bovis and acquired PZA-resistant M. tuberculosis strains lose pyrazinamidase (PZase).  To investigate the mol. mechanism of PZA resistance, we have cloned the gene (pncA) encoding M. tuberculosis PZase.  Mutations in pncA were identified in both types of PZA-resistant strains, and transformation of these strains with a functional pncA gene restored PZase activity and PZA susceptibility.  These findings, besides providing the basis for understanding how PZA works, should have implications for rapid detection of PZA-resistant clin. isolates of M. tuberculosis and also for rapid differentiation of M. bovis from M. tuberculosis strains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVdd4sFkh_b7Vg90H21EOLACvtfcHk0liyaW4mBExMrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XjsVSjtbo%253D&md5=8b494b8294bc17e131105a8736fb5a3e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnm0696-662&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm0696-662%26sid%3Dliteratum%253Aachs%26aulast%3DScorpio%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DMutations%2520in%2520pncA%252C%2520a%2520gene%2520encoding%2520pyrazinamidase%252Fnicotinamidase%252C%2520cause%2520resistance%2520to%2520the%2520antituberculous%2520drug%2520pyrazinamide%2520in%2520tubercle%2520bacillus%26jtitle%3DNat.%2520Med.%26date%3D1996%26volume%3D2%26spage%3D662%26epage%3D667%26doi%3D10.1038%2Fnm0696-662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heifets, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flory, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindholm-Levy, P. J.</span></span> <span> </span><span class="NLM_article-title">Does pyrazinoic acid as an active moiety of pyrazinamide have specific activity against mycobacterium tuberculosis?</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">1252</span>– <span class="NLM_lpage">1254</span>, <span class="refDoi"> DOI: 10.1128/AAC.33.8.1252</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.33.8.1252" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=2508544" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADyaL1MXlslSqt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1989&pages=1252-1254&author=L.+B.+Heifetsauthor=M.+A.+Floryauthor=P.+J.+Lindholm-Levy&title=Does+pyrazinoic+acid+as+an+active+moiety+of+pyrazinamide+have+specific+activity+against+mycobacterium+tuberculosis%3F&doi=10.1128%2FAAC.33.8.1252"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Does pyrazinoic acid as an active moiety of pyrazinamide have specific activity against Mycobacterium tuberculosis?</span></div><div class="casAuthors">Heifets, Leonid B.; Flory, Marcella A.; Lindholm-Levy, Pamela J.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1252-4</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    </div><div class="casAbstract">The commonly accepted hypothesis explaining the mechanism of action of pyrazinamide (PZA) is based on the assumption that PZA-susceptible M. tuberculosis strains produce pyrazinamidase, which hydrolyzes PZA to the antibacterial moiety pyrazinoic acid (POA).  It is not clear whether POA has specific antimicrobial activity or whether the inhibition of growth caused by POA is due to its ability to lower the pH of the environment below the limits of tolerance of M. tuberculosis growth.  It was confirmed in this study that POA, depending on the concn., lowered the pH of 7H12 broth (pH 6.0) to values from 5.8 at 120.0 μg/mL to 4.6 at 960.0 μg/mL.  Therefore, the inhibitory effects of different concns. of POA were examd. in broth in which the final pH was adjusted to 5.6 by adding appropriate amts. of H3PO4 or K2HPO4.  Under these conditions, a clear concn.-response correlation was found, proving that POA does have specific antimicrobial activity.  The MIC of POA at pH 5.6 was 240-480 μg/mL, 8-16-fold higher than the MIC of PZA under the same conditions and much higher than the concns. achievable in humans.  This suggests that the action of POA in an acid environment is a combined effect of its specific activity and its ability to lower the pH below the limits of tolerance of the target organism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8rLsiPiAcarVg90H21EOLACvtfcHk0liyaW4mBExMrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXlslSqt7g%253D&md5=8afd8fd6e18033e254d29e107b9b109b</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1128%2FAAC.33.8.1252&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.33.8.1252%26sid%3Dliteratum%253Aachs%26aulast%3DHeifets%26aufirst%3DL.%2BB.%26aulast%3DFlory%26aufirst%3DM.%2BA.%26aulast%3DLindholm-Levy%26aufirst%3DP.%2BJ.%26atitle%3DDoes%2520pyrazinoic%2520acid%2520as%2520an%2520active%2520moiety%2520of%2520pyrazinamide%2520have%2520specific%2520activity%2520against%2520mycobacterium%2520tuberculosis%253F%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1989%26volume%3D33%26spage%3D1252%26epage%3D1254%26doi%3D10.1128%2FAAC.33.8.1252" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Botha, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirgel, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkin, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Wal, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donald, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchison, D. A.</span></span> <span> </span><span class="NLM_article-title">Early bactericidal activity of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosis</span>. <i>S Afr. Med. J.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">158</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=8619142" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A280%3ADyaK287nvFGmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=1996&pages=155-158&author=F.+J.+Bothaauthor=F.+A.+Sirgelauthor=D.+P.+Parkinauthor=B.+W.+van+de+Walauthor=P.+R.+Donaldauthor=D.+A.+Mitchison&title=Early+bactericidal+activity+of+ethambutol%2C+pyrazinamide+and+the+fixed+combination+of+isoniazid%2C+rifampicin+and+pyrazinamide+%28Rifater%29+in+patients+with+pulmonary+tuberculosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Early bactericidal activity of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosis</span></div><div class="casAuthors">Botha F J; Sirgel F A; Parkin D P; van de Wal B W; Donald P R; Mitchison D A</div><div class="citationInfo"><span class="NLM_cas:title">South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">155-8</span>
        ISSN:<span class="NLM_cas:issn">0256-9574</span>.
    </div><div class="casAbstract">The early bactericidal activity (EBA) of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater: Mer National) was evaluated in patients with pulmonary tuberculosis who were sputum-positive on microscopy for acid-fast bacilli.  Twenty-eight patients (mean age 33 years and weight 51 kg on average; range 40-59 kg) were studied.  The fall in viable counts of Mycobacterium tuberculosis in sputum collections during the 2 days following the start of treatment was estimated from counts of colony-forming units (CFUs) of M. tuberculosis per ml of sputum cultured on selective 7H10 agar medium.  The EBA for ethambutol determined in 9 patients was 0.245 +/- 0.046, log10 CFU/ml sputum/day, that for pyrazinamide was 0.003 +/- 0.014 log10 CFU/ml sputum/day and that for Rifater 0.558 +/- 0.054 log10 CFU/ml sputum/day.  The results obtained are similar to those reported in a previous study of the first 2 days of treatment, but in smaller numbers of patients, and confirm the moderate EBA of ethambutol while pyrazinamide is again shown to have very little EBA.  Rifater has a marked EBA which may be due mainly to the action of isoniazid.  This methodology may be valuable in the rapid evaluation of the bactericidal activity of new antituberculosis agents and the comparison of different dose sizes of agents of the same class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTJ0XHzfjbvacve_zCu79I8fW6udTcc2eYcbth7pi53Erntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK287nvFGmsw%253D%253D&md5=dcd8bcb0199ab8a1e98dddcfad447894</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBotha%26aufirst%3DF.%2BJ.%26aulast%3DSirgel%26aufirst%3DF.%2BA.%26aulast%3DParkin%26aufirst%3DD.%2BP.%26aulast%3Dvan%2Bde%2BWal%26aufirst%3DB.%2BW.%26aulast%3DDonald%26aufirst%3DP.%2BR.%26aulast%3DMitchison%26aufirst%3DD.%2BA.%26atitle%3DEarly%2520bactericidal%2520activity%2520of%2520ethambutol%252C%2520pyrazinamide%2520and%2520the%2520fixed%2520combination%2520of%2520isoniazid%252C%2520rifampicin%2520and%2520pyrazinamide%2520%2528Rifater%2529%2520in%2520patients%2520with%2520pulmonary%2520tuberculosis%26jtitle%3DS%2520Afr.%2520Med.%2520J.%26date%3D1996%26volume%3D86%26spage%3D155%26epage%3D158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nusrath
Unissa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanna, L. E.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanisms of action, resistance, detection to the first-line anti tuberculosis drugs: Rifampicin and pyrazinamide in the post whole genome sequencing era</span>. <i>Tuberculosis (Oxford, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">96</span>– <span class="NLM_lpage">107</span>, <span class="refDoi"> DOI: 10.1016/j.tube.2017.04.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.tube.2017.04.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=28610794" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnsV2ltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2017&pages=96-107&author=A.+Nusrath%0AUnissaauthor=L.+E.+Hanna&title=Molecular+mechanisms+of+action%2C+resistance%2C+detection+to+the+first-line+anti+tuberculosis+drugs%3A+Rifampicin+and+pyrazinamide+in+the+post+whole+genome+sequencing+era&doi=10.1016%2Fj.tube.2017.04.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms of action, resistance, detection to the first-line anti tuberculosis drugs: Rifampicin and pyrazinamide in the post whole genome sequencing era</span></div><div class="casAuthors">Nusrath Unissa, Ameeruddin; Hanna, Luke Elizabeth</div><div class="citationInfo"><span class="NLM_cas:title">Tuberculosis (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">96-107</span>CODEN:
                <span class="NLM_cas:coden">TUBECU</span>;
        ISSN:<span class="NLM_cas:issn">1472-9792</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Recent studies in addn. to studies based on whole genome sequencing (WGS) of clin. isolates of Mycobacterium tuberculosis (MTB) from diverse geog. regions have provided useful insights into the mechanisms of drug resistance.  Of importance, are some of the findings pertaining to mechanisms of resistance to two of the first-line anti-tuberculosis (TB) drugs, namely, rifampicin (RIF) and pyrazinamide (PZA).  For example, the implication of mutations in rpoA and rpoC genes that act as compensatory mutations for those in the rpoB gene with respect to RIF resistance is noteworthy.  Similarly, in the case of PZA resistance, the role of rpsA and panD genes has recently been noted.  This highlights the evolving knowledge of resistance to these drugs.  The present article provides a detailed account of the mol. mechanisms of resistance against two sterilizing first line anti-TB drugs (RIF and PZA) as well as an overview of sequence-based methods for detection of resistance to the drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFC90MranjGrVg90H21EOLACvtfcHk0liEiLaJmBZRCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnsV2ltro%253D&md5=199d1cb67c061ade94bf1377781f3ed6</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.tube.2017.04.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tube.2017.04.008%26sid%3Dliteratum%253Aachs%26aulast%3DNusrath%2BUnissa%26aufirst%3DA.%26aulast%3DHanna%26aufirst%3DL.%2BE.%26atitle%3DMolecular%2520mechanisms%2520of%2520action%252C%2520resistance%252C%2520detection%2520to%2520the%2520first-line%2520anti%2520tuberculosis%2520drugs%253A%2520Rifampicin%2520and%2520pyrazinamide%2520in%2520the%2520post%2520whole%2520genome%2520sequencing%2520era%26jtitle%3DTuberculosis%2520%2528Oxford%252C%2520U.%2520K.%2529%26date%3D2017%26volume%3D105%26spage%3D96%26epage%3D107%26doi%3D10.1016%2Fj.tube.2017.04.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhasselt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillemont, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gohlmann, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neefs, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Gestel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timmerman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Chaffoy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huitric, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cambau, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truffot-Pernot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lounis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarlier, V.</span></span> <span> </span><span class="NLM_article-title">A diarylquinoline drug active on the ATP synthase of mycobacterium tuberculosis</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>307</i></span>,  <span class="NLM_fpage">223</span>– <span class="NLM_lpage">227</span>, <span class="refDoi"> DOI: 10.1126/science.1106753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1126%2Fscience.1106753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=15591164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD2MXisVKkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=307&publication_year=2005&pages=223-227&author=K.+Andriesauthor=P.+Verhasseltauthor=J.+Guillemontauthor=H.+W.+Gohlmannauthor=J.+M.+Neefsauthor=H.+Winklerauthor=J.+Van+Gestelauthor=P.+Timmermanauthor=M.+Zhuauthor=E.+Leeauthor=P.+Williamsauthor=D.+de+Chaffoyauthor=E.+Huitricauthor=S.+Hoffnerauthor=E.+Cambauauthor=C.+Truffot-Pernotauthor=N.+Lounisauthor=V.+Jarlier&title=A+diarylquinoline+drug+active+on+the+ATP+synthase+of+mycobacterium+tuberculosis&doi=10.1126%2Fscience.1106753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis</span></div><div class="casAuthors">Andries, Koen; Verhasselt, Peter; Guillemont, Jerome; Goehlmann, Hinrich W. H.; Neefs, Jean-Marc; Winkler, Hans; Van Gestel, Jef; Timmerman, Philip; Zhu, Min; Lee, Ennis; Williams, Peter; de Chaffoy, Didier; Huitric, Emma; Hoffner, Sven; Cambau, Emmanuelle; Truffot-Pernot, Chantal; Lounis, Nacer; Jarlier, Vincent</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">307</span>
        (<span class="NLM_cas:issue">5707</span>),
    <span class="NLM_cas:pages">223-227</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The incidence of tuberculosis has been increasing substantially on a worldwide basis over the past decade, but no tuberculosis-specific drugs have been discovered in 40 years.  We identified a diarylquinoline, R207910, that potently inhibits both drug-sensitive and drug-resistant Mycobacterium tuberculosis in vitro (min. inhibitory concn. 0.06 μg/mL).  In mice, R207910 exceeded the bactericidal activities of isoniazid and rifampin by at least 1 log unit.  Substitution of drugs included in the World Health Organization's first-line tuberculosis treatment regimen (rifampin, isoniazid, and pyrazinamide) with R207910 accelerated bactericidal activity, leading to complete culture conversion after 2 mo of treatment in some combinations.  A single dose of R207910 inhibited mycobacterial growth for 1 wk.  Plasma levels assocd. with efficacy in mice were well tolerated in healthy human volunteers.  Mutants selected in vitro suggest that the drug targets the proton pump of ATP (ATP) synthase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9LY7RSAIXUrVg90H21EOLACvtfcHk0liEiLaJmBZRCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXisVKkug%253D%253D&md5=099b643f173bb77e70cf1aa6e9871ffe</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1126%2Fscience.1106753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1106753%26sid%3Dliteratum%253Aachs%26aulast%3DAndries%26aufirst%3DK.%26aulast%3DVerhasselt%26aufirst%3DP.%26aulast%3DGuillemont%26aufirst%3DJ.%26aulast%3DGohlmann%26aufirst%3DH.%2BW.%26aulast%3DNeefs%26aufirst%3DJ.%2BM.%26aulast%3DWinkler%26aufirst%3DH.%26aulast%3DVan%2BGestel%26aufirst%3DJ.%26aulast%3DTimmerman%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DE.%26aulast%3DWilliams%26aufirst%3DP.%26aulast%3Dde%2BChaffoy%26aufirst%3DD.%26aulast%3DHuitric%26aufirst%3DE.%26aulast%3DHoffner%26aufirst%3DS.%26aulast%3DCambau%26aufirst%3DE.%26aulast%3DTruffot-Pernot%26aufirst%3DC.%26aulast%3DLounis%26aufirst%3DN.%26aulast%3DJarlier%26aufirst%3DV.%26atitle%3DA%2520diarylquinoline%2520drug%2520active%2520on%2520the%2520ATP%2520synthase%2520of%2520mycobacterium%2520tuberculosis%26jtitle%3DScience%26date%3D2005%26volume%3D307%26spage%3D223%26epage%3D227%26doi%3D10.1126%2Fscience.1106753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diacon, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pym, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grobusch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patientia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rustomjee, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page-Shipp, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pistorius, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krause, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogoshi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Churchyard, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palomino, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Marez, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Heeswijk, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lounis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyvisch, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verbeeck, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parys, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Beule, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mc Neeley, D. F.</span></span> <span> </span><span class="NLM_article-title">The diarylquinoline TMC207 for multidrug-resistant tuberculosis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>360</i></span>,  <span class="NLM_fpage">2397</span>– <span class="NLM_lpage">2405</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa0808427</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1056%2FNEJMoa0808427" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=19494215" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntVKqsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=360&publication_year=2009&pages=2397-2405&author=A.+H.+Diaconauthor=A.+Pymauthor=M.+Grobuschauthor=R.+Patientiaauthor=R.+Rustomjeeauthor=L.+Page-Shippauthor=C.+Pistoriusauthor=R.+Krauseauthor=M.+Bogoshiauthor=G.+Churchyardauthor=A.+Venterauthor=J.+Allenauthor=J.+C.+Palominoauthor=T.+De+Marezauthor=R.+P.+van+Heeswijkauthor=N.+Lounisauthor=P.+Meyvischauthor=J.+Verbeeckauthor=W.+Parysauthor=K.+de+Beuleauthor=K.+Andriesauthor=D.+F.+Mc+Neeley&title=The+diarylquinoline+TMC207+for+multidrug-resistant+tuberculosis&doi=10.1056%2FNEJMoa0808427"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The diarylquinoline TMC207 for multidrug-resistant tuberculosis</span></div><div class="casAuthors">Diacon, Andreas H.; Pym, Alexander; Grobusch, Martin; Patientia, Ramonde; Rustomjee, Roxana; Page-Shipp, Liesl; Pistorius, Christoffel; Krause, Rene; Bogoshi, Mampedi; Churchyard, Gavin; Venter, Amour; Allen, Jenny; Palomino, Juan Carlos; De Marez, Tine; van Heeswijk, Rolf P. G.; Lounis, Nacer; Meyvisch, Paul; Verbeeck, Johan; Parys, Wim; de Beule, Karel; Andries, Koen; McNeeley, David F.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">360</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2397-2405</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND; The diarylquinoline TMC207 offers a new mechanism of antituberculosis action by inhibiting mycobacterial ATP synthase.  TMC207 potently inhibits drug-sensitive and drug-resistant Mycobacterium tuberculosis in vitro and shows bactericidal activity in patients who have drug-susceptible pulmonary tuberculosis.  METHODS: In the first stage of a two-stage, phase 2, randomized, controlled trial, we randomly assigned 47 patients who had newly diagnosed multidrug-resistant pulmonary tuberculosis to receive either TMC207 (400 mg daily for 2 wk, followed by 200 mg three times a week for 6 wk) (23 patients) or placebo (24 patients) in combination with a std. five-drug, second-line antituberculosis regimen.  The primary efficacy end point was the conversion of sputum cultures, in liq. broth, from pos. to neg.  RESULTS: The addn. of TMC207 to std. therapy for multidrug-resistant tuberculosis reduced the time to conversion to a neg. sputum culture, as compared with placebo (hazard ratio, 11.8; 95% confidence interval, 2.3 to 61.3; P = 0.003 by Cox regression anal.) and increased the proportion of patients with conversion of sputum culture (48% vs. 9%).  The mean log10 count of colony-forming units in the sputum declined more rapidly in the TMC207 group than in the placebo group.  No significant differences in av. plasma TMC207 concns. were noted between patients with and those without culture conversion.  Most adverse events were mild to moderate, and only nausea occurred significantly more frequently among patients in the TMC207 group than among patients in the placebo group (26% vs. 4%, P = 0.04).  CONCLUSIONS: The clin. activity of TMC207 validates ATP synthase as a viable target for the treatment of tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra39rie2VZP7Vg90H21EOLACvtfcHk0liIKNn2Hk4wVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntVKqsrs%253D&md5=76bdbf7f0263a168e58532addaf90a0a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0808427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0808427%26sid%3Dliteratum%253Aachs%26aulast%3DDiacon%26aufirst%3DA.%2BH.%26aulast%3DPym%26aufirst%3DA.%26aulast%3DGrobusch%26aufirst%3DM.%26aulast%3DPatientia%26aufirst%3DR.%26aulast%3DRustomjee%26aufirst%3DR.%26aulast%3DPage-Shipp%26aufirst%3DL.%26aulast%3DPistorius%26aufirst%3DC.%26aulast%3DKrause%26aufirst%3DR.%26aulast%3DBogoshi%26aufirst%3DM.%26aulast%3DChurchyard%26aufirst%3DG.%26aulast%3DVenter%26aufirst%3DA.%26aulast%3DAllen%26aufirst%3DJ.%26aulast%3DPalomino%26aufirst%3DJ.%2BC.%26aulast%3DDe%2BMarez%26aufirst%3DT.%26aulast%3Dvan%2BHeeswijk%26aufirst%3DR.%2BP.%26aulast%3DLounis%26aufirst%3DN.%26aulast%3DMeyvisch%26aufirst%3DP.%26aulast%3DVerbeeck%26aufirst%3DJ.%26aulast%3DParys%26aufirst%3DW.%26aulast%3Dde%2BBeule%26aufirst%3DK.%26aulast%3DAndries%26aufirst%3DK.%26aulast%3DMc%2BNeeley%26aufirst%3DD.%2BF.%26atitle%3DThe%2520diarylquinoline%2520TMC207%2520for%2520multidrug-resistant%2520tuberculosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D360%26spage%3D2397%26epage%3D2405%26doi%3D10.1056%2FNEJMoa0808427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dendouga, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vergauwen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molenberghs, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vranckx, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willebrords, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ristic, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lill, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorange, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillemont, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bald, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span> <span> </span><span class="NLM_article-title">Diarylquinolines target subunit c of mycobacterial ATP synthase</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">324</span>, <span class="refDoi"> DOI: 10.1038/nchembio884</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1038%2Fnchembio884" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=17496888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltlOjurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=323-324&author=A.+Koulauthor=N.+Dendougaauthor=K.+Vergauwenauthor=B.+Molenberghsauthor=L.+Vranckxauthor=R.+Willebrordsauthor=Z.+Risticauthor=H.+Lillauthor=I.+Dorangeauthor=J.+Guillemontauthor=D.+Baldauthor=K.+Andries&title=Diarylquinolines+target+subunit+c+of+mycobacterial+ATP+synthase&doi=10.1038%2Fnchembio884"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Diarylquinolines target subunit c of mycobacterial ATP synthase</span></div><div class="casAuthors">Koul, Anil; Dendouga, Najoua; Vergauwen, Karen; Molenberghs, Brenda; Vranckx, Luc; Willebrords, Rudy; Ristic, Zorica; Lill, Holger; Dorange, Ismet; Guillemont, Jerome; Bald, Dirk; Andries, Koen</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">323-324</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The diarylquinoline R207910 (TMC207) is a promising candidate in clin. development for the treatment of tuberculosis.  Though R207910-resistant mycobacteria bear mutations in ATP synthase, the compd.'s precise target is not known.  Here we establish by genetic, biochem. and binding assays that the oligomeric subunit c (AtpE) of ATP synthase is the target of R207910.  Thus targeting energy metab. is a new, promising approach for antibacterial drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoo57k1zZdTLVg90H21EOLACvtfcHk0liIKNn2Hk4wVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltlOjurc%253D&md5=f9ba04042bef448f5910cea0e89715f0</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fnchembio884&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio884%26sid%3Dliteratum%253Aachs%26aulast%3DKoul%26aufirst%3DA.%26aulast%3DDendouga%26aufirst%3DN.%26aulast%3DVergauwen%26aufirst%3DK.%26aulast%3DMolenberghs%26aufirst%3DB.%26aulast%3DVranckx%26aufirst%3DL.%26aulast%3DWillebrords%26aufirst%3DR.%26aulast%3DRistic%26aufirst%3DZ.%26aulast%3DLill%26aufirst%3DH.%26aulast%3DDorange%26aufirst%3DI.%26aulast%3DGuillemont%26aufirst%3DJ.%26aulast%3DBald%26aufirst%3DD.%26aulast%3DAndries%26aufirst%3DK.%26atitle%3DDiarylquinolines%2520target%2520subunit%2520c%2520of%2520mycobacterial%2520ATP%2520synthase%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2007%26volume%3D3%26spage%3D323%26epage%3D324%26doi%3D10.1038%2Fnchembio884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vranckx, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dendouga, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balemans, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van den
Wyngaert, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vergauwen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Göhlmann, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willebrords, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poncelet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillemont, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bald, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span> <span> </span><span class="NLM_article-title">Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">25273</span>– <span class="NLM_lpage">25280</span>, <span class="refDoi"> DOI: 10.1074/jbc.M803899200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1074%2Fjbc.M803899200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=18625705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVyisLrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=25273-25280&author=A.+Koulauthor=L.+Vranckxauthor=N.+Dendougaauthor=W.+Balemansauthor=I.+Van+den%0AWyngaertauthor=K.+Vergauwenauthor=H.+W.+G%C3%B6hlmannauthor=R.+Willebrordsauthor=A.+Ponceletauthor=J.+Guillemontauthor=D.+Baldauthor=K.+Andries&title=Diarylquinolines+are+bactericidal+for+dormant+mycobacteria+as+a+result+of+disturbed+ATP+homeostasis&doi=10.1074%2Fjbc.M803899200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Diarylquinolines Are Bactericidal for Dormant Mycobacteria as a Result of Disturbed ATP Homeostasis</span></div><div class="casAuthors">Koul, Anil; Vranckx, Luc; Dendouga, Najoua; Balemans, Wendy; Van den Wyngaert, Ilse; Vergauwen, Karen; Goehlmann, Hinrich W. H.; Willebrords, Rudy; Poncelet, Alain; Guillemont, Jerome; Bald, Dirk; Andries, Koen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">25273-25280</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">An estd. one-third of the world population is latently infected with Mycobacterium tuberculosis.  These nonreplicating, dormant bacilli are tolerant to conventional antituberculosis drugs, such as isoniazid.  We recently identified diarylquinoline R207910 (also called TMC207) as an inhibitor of ATP synthase with a remarkable activity against replicating mycobacteria.  In the present study, we show that R207910 kills dormant bacilli as effectively as aerobically grown bacilli with the same target specificity.  Despite a transcriptional down-regulation of the ATP synthase operon and significantly lower cellular ATP levels, we show that dormant mycobacteria do possess residual ATP synthase enzymic activity.  This activity is blocked by nanomolar concns. of R207910, thereby further reducing ATP levels and causing a pronounced bactericidal effect.  We conclude that this residual ATP synthase activity is indispensable for the survival of dormant mycobacteria, making it a promising drug target to tackle dormant infections.  The unique dual bactericidal activity of diarylquinolines on dormant as well as replicating bacterial subpopulations distinguishes them entirely from the current anti-tuberculosis drugs and underlines the potential of R207910 to shorten tuberculosis treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRevC8Pav5B7Vg90H21EOLACvtfcHk0lgY0VHEoX38AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVyisLrP&md5=a7aab9f2cfbab62e204f7a91e78f32ec</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M803899200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M803899200%26sid%3Dliteratum%253Aachs%26aulast%3DKoul%26aufirst%3DA.%26aulast%3DVranckx%26aufirst%3DL.%26aulast%3DDendouga%26aufirst%3DN.%26aulast%3DBalemans%26aufirst%3DW.%26aulast%3DVan%2Bden%2BWyngaert%26aufirst%3DI.%26aulast%3DVergauwen%26aufirst%3DK.%26aulast%3DG%25C3%25B6hlmann%26aufirst%3DH.%2BW.%26aulast%3DWillebrords%26aufirst%3DR.%26aulast%3DPoncelet%26aufirst%3DA.%26aulast%3DGuillemont%26aufirst%3DJ.%26aulast%3DBald%26aufirst%3DD.%26aulast%3DAndries%26aufirst%3DK.%26atitle%3DDiarylquinolines%2520are%2520bactericidal%2520for%2520dormant%2520mycobacteria%2520as%2520a%2520result%2520of%2520disturbed%2520ATP%2520homeostasis%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26spage%3D25273%26epage%3D25280%26doi%3D10.1074%2Fjbc.M803899200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haagsma, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdillahi-Ibrahim, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krab, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vergauwen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillemont, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lill, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bald, D.</span></span> <span> </span><span class="NLM_article-title">Selectivity of TMC207 towards mycobacterial atp synthase compared with that towards the eukaryotic homologue</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">1290</span>– <span class="NLM_lpage">1292</span>, <span class="refDoi"> DOI: 10.1128/AAC.01393-08</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.01393-08" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=19075053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivF2ksbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2009&pages=1290-1292&author=A.+C.+Haagsmaauthor=R.+Abdillahi-Ibrahimauthor=M.+J.+Wagnerauthor=K.+Krabauthor=K.+Vergauwenauthor=J.+Guillemontauthor=K.+Andriesauthor=H.+Lillauthor=A.+Koulauthor=D.+Bald&title=Selectivity+of+TMC207+towards+mycobacterial+atp+synthase+compared+with+that+towards+the+eukaryotic+homologue&doi=10.1128%2FAAC.01393-08"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue</span></div><div class="casAuthors">Haagsma, Anna C.; Abdillahi-Ibrahim, Rooda; Wagner, Marijke J.; Krab, Klaas; Vergauwen, Karen; Guillemont, Jerome; Andries, Koen; Lill, Holger; Koul, Anil; Bald, Dirk</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1290-1292</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The diarylquinoline TMC207 kills Mycobacterium tuberculosis by specifically inhibiting ATP synthase.  We show here that human mitochondrial ATP synthase (50% inhibitory concn. [IC50] of >200 μM) displayed more than 20,000-fold lower sensitivity for TMC207 compared to that of mycobacterial ATP synthase (IC50 of 10 nM).  Also, oxygen consumption in mouse liver and bovine heart mitochondria showed very low sensitivity for TMC207.  These results suggest that TMC207 may not elicit ATP synthesis-related toxicity in mammalian cells.  ATP synthase, although highly conserved between prokaryotes and eukaryotes, may still qualify as an attractive antibiotic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQm0byrOhERLVg90H21EOLACvtfcHk0lgY0VHEoX38AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivF2ksbs%253D&md5=531b56f5d74d1bb6d0f217b209cdd4be</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1128%2FAAC.01393-08&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01393-08%26sid%3Dliteratum%253Aachs%26aulast%3DHaagsma%26aufirst%3DA.%2BC.%26aulast%3DAbdillahi-Ibrahim%26aufirst%3DR.%26aulast%3DWagner%26aufirst%3DM.%2BJ.%26aulast%3DKrab%26aufirst%3DK.%26aulast%3DVergauwen%26aufirst%3DK.%26aulast%3DGuillemont%26aufirst%3DJ.%26aulast%3DAndries%26aufirst%3DK.%26aulast%3DLill%26aufirst%3DH.%26aulast%3DKoul%26aufirst%3DA.%26aulast%3DBald%26aufirst%3DD.%26atitle%3DSelectivity%2520of%2520TMC207%2520towards%2520mycobacterial%2520atp%2520synthase%2520compared%2520with%2520that%2520towards%2520the%2520eukaryotic%2520homologue%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2009%26volume%3D53%26spage%3D1290%26epage%3D1292%26doi%3D10.1128%2FAAC.01393-08" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Jonge, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koymans, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillemont, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span> <span> </span><span class="NLM_article-title">A computational model of the inhibition of mycobacterium tuberculosis ATPase by a new drug candidate r207910</span>. <i>Proteins: Struct., Funct., Genet.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">971</span>– <span class="NLM_lpage">980</span>, <span class="refDoi"> DOI: 10.1002/prot.21376</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1002%2Fprot.21376" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=17387738" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlsFSjsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=971-980&author=M.+R.+de%0AJongeauthor=L.+H.+Koymansauthor=J.+E.+Guillemontauthor=A.+Koulauthor=K.+Andries&title=A+computational+model+of+the+inhibition+of+mycobacterium+tuberculosis+ATPase+by+a+new+drug+candidate+r207910&doi=10.1002%2Fprot.21376"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910</span></div><div class="casAuthors">de Jonge, Marc R.; Koymans, Luc H. M.; Guillemont, Jerome E. G.; Koul, Anil; Andries, Koen</div><div class="citationInfo"><span class="NLM_cas:title">Proteins: Structure, Function, and Bioinformatics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">971-980</span>CODEN:
                <span class="NLM_cas:coden">PSFBAF</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Diarylquinolines (DARQs) are a new class of potent inhibitors of the ATPase of Mycobacterium tuberculosis.  We have created a homol. model of a binding site for this class of compds. located on the contact area of the a-subunit (gene atpB) and c-subunits (gene atpE) of Mycobacterium tuberculosis ATPase.  The binding pocket that was identified from the anal. of the homol. model is formed by 4 helixes of three c-subunits and 2 helixes of the a-subunit.  The lead compd. of the DARQ series, R207910, was docked into the pocket using a simulated annealing, multiple conformer, docking algorithm.  Different stereoisomers were treated sep.  The best docking pose for each stereoisomer was optimized by mol. dynamics simulation on the 5300 atoms of the binding region and ligand.  The interaction energies in the computed complexes enable us to rank the different stereoisomers in order of interaction strength with the ATPase binding pockets.  We propose that the activity of R207910 against Mycobacterium tuberculosis is based on interference of the compd. with the escapement geometry of the proton transfer chain.  Upon binding the compd. mimicks the conserved Arg-186 residue of the a-subunit and interacts in its place with the conserved acidic residue Glu-61 of the c-subunit.  This mode of action is corroborated by the good agreement between the computed interaction energies and the obsd. pattern of stereo-specificity in the model of the binding region.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroZmmKsrCXZ7Vg90H21EOLACvtfcHk0lgY0VHEoX38AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlsFSjsr8%253D&md5=7cfb48ec3eab0070e90cf8a0c1c6037e</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fprot.21376&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprot.21376%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BJonge%26aufirst%3DM.%2BR.%26aulast%3DKoymans%26aufirst%3DL.%2BH.%26aulast%3DGuillemont%26aufirst%3DJ.%2BE.%26aulast%3DKoul%26aufirst%3DA.%26aulast%3DAndries%26aufirst%3DK.%26atitle%3DA%2520computational%2520model%2520of%2520the%2520inhibition%2520of%2520mycobacterium%2520tuberculosis%2520ATPase%2520by%2520a%2520new%2520drug%2520candidate%2520r207910%26jtitle%3DProteins%253A%2520Struct.%252C%2520Funct.%252C%2520Genet.%26date%3D2007%26volume%3D67%26spage%3D971%26epage%3D980%26doi%3D10.1002%2Fprot.21376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smyej, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jonghe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Looszova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mannens, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhaeghe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thijssen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starckx, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lampo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouan, M. C.</span></span> <span> </span><span class="NLM_article-title">Dose- and time-dependency of the toxicity and pharmacokinetic profiles of bedaquiline and its n-desmethyl metabolite in dogs</span>. <i>Toxicol. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">663</span>– <span class="NLM_lpage">675</span>, <span class="refDoi"> DOI: 10.1177/0192623317723085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1177%2F0192623317723085" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=28789609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC1cXks1Cltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2017&pages=663-675&author=I.+Smyejauthor=S.+De+Jongheauthor=A.+Looszovaauthor=G.+Mannensauthor=T.+Verhaegheauthor=S.+Thijssenauthor=S.+Starckxauthor=A.+Lampoauthor=M.+C.+Rouan&title=Dose-+and+time-dependency+of+the+toxicity+and+pharmacokinetic+profiles+of+bedaquiline+and+its+n-desmethyl+metabolite+in+dogs&doi=10.1177%2F0192623317723085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Dose- and time-dependency of the toxicity and pharmacokinetic profiles of bedaquiline and its n-desmethyl metabolite in dogs</span></div><div class="casAuthors">Smyej, Ilham; De Jonghe, Sandra; Looszova, Adriana; Mannens, Geert; Verhaeghe, Tom; Thijssen, Sandy; Starckx, Sofie; Lampo, Ann; Rouan, Marie-Claude</div><div class="citationInfo"><span class="NLM_cas:title">Toxicologic Pathology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">663-675</span>CODEN:
                <span class="NLM_cas:coden">TOPADD</span>;
        ISSN:<span class="NLM_cas:issn">0192-6233</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Bedaquiline (BDQ) is an antibiotic to treat pulmonary multidrug-resistant tuberculosis (MDR-TB).  Studies up to 39 wk were conducted orally in dogs to assess the toxicity and pharmacokinetics of BDQ and its N-desmethyl metabolite (D-BDQ).  Phospholipidosis (PLD) seen in the monocytic phagocytic system was considered an adaptive change.  Skeletal muscle, heart, stomach, liver, and pancreas toxicities with D-BDQ as the main contributor were assocd. with a less-than-dose-proportional increase in plasma exposure and an overproportional tissue uptake of BDQ and D-BDQ at high-dose levels.  Tissue concns. of BDQ and D-BDQ slowly decreased after lowering the dose, contributing to the recovery of the pathol. findings.  Treatment was better tolerated at mid-dose levels, characterized by a dose-proportional increase in plasma and tissue exposures.  Treatment at a low dose, reaching exposures approximating therapeutic exposures, was without adverse effects and not assocd. with PLD.  There was no evidence of delayed toxicities after treatment cessation.  Intermittent dosing was better tolerated at high doses.  Since MDR-TB patients are dosed within the linear plasma exposure range and plasma levels of BDQ and D-BDQ are similar or lower than in dogs, PLD and adverse findings related to tissue accumulation that occurred at high doses in dogs are unlikely to occur in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGol3098AxhKMbVg90H21EOLACvtfcHk0li12NOQqEd0JA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXks1Cltw%253D%253D&md5=b69d2fad7b039dcf223463da324a9ce8</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1177%2F0192623317723085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0192623317723085%26sid%3Dliteratum%253Aachs%26aulast%3DSmyej%26aufirst%3DI.%26aulast%3DDe%2BJonghe%26aufirst%3DS.%26aulast%3DLooszova%26aufirst%3DA.%26aulast%3DMannens%26aufirst%3DG.%26aulast%3DVerhaeghe%26aufirst%3DT.%26aulast%3DThijssen%26aufirst%3DS.%26aulast%3DStarckx%26aufirst%3DS.%26aulast%3DLampo%26aufirst%3DA.%26aulast%3DRouan%26aufirst%3DM.%2BC.%26atitle%3DDose-%2520and%2520time-dependency%2520of%2520the%2520toxicity%2520and%2520pharmacokinetic%2520profiles%2520of%2520bedaquiline%2520and%2520its%2520n-desmethyl%2520metabolite%2520in%2520dogs%26jtitle%3DToxicol.%2520Pathol.%26date%3D2017%26volume%3D45%26spage%3D663%26epage%3D675%26doi%3D10.1177%2F0192623317723085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tong, A. S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherland, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, S. K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillemont, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motte, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van den Broeck, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franzblau, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upton, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denny, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conole, D.</span></span> <span> </span><span class="NLM_article-title">6-cyano analogues of bedaquiline as less lipophilic and potentially safer diarylquinolines for tuberculosis</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1019</span>– <span class="NLM_lpage">1024</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00196</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00196" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFCis7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1019-1024&author=A.+S.+T.+Tongauthor=P.+J.+Choiauthor=A.+Blaserauthor=H.+S.+Sutherlandauthor=S.+K.+Y.+Tsangauthor=J.+Guillemontauthor=M.+Motteauthor=C.+B.+Cooperauthor=K.+Andriesauthor=W.+Van+den+Broeckauthor=S.+G.+Franzblauauthor=A.+M.+Uptonauthor=W.+A.+Dennyauthor=B.+D.+Palmerauthor=D.+Conole&title=6-cyano+analogues+of+bedaquiline+as+less+lipophilic+and+potentially+safer+diarylquinolines+for+tuberculosis&doi=10.1021%2Facsmedchemlett.7b00196"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">6-Cyano Analogues of Bedaquiline as Less Lipophilic and Potentially Safer Diarylquinolines for Tuberculosis</span></div><div class="casAuthors">Tong, Amy S. T.; Choi, Peter J.; Blaser, Adrian; Sutherland, Hamish S.; Tsang, Sophia K. Y.; Guillemont, Jerome; Motte, Magali; Cooper, Christopher B.; Andries, Koen; Van den Broeck, Walter; Franzblau, Scott G.; Upton, Anna M.; Denny, William A.; Palmer, Brian D.; Conole, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1019-1024</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bedaquiline (1) is a new drug for tuberculosis and the first of the diarylquinoline class.  It demonstrates excellent efficacy against TB but induces phospholipidosis at high doses, has a long terminal elimination half-life (due to its high lipophilicity), and exhibits potent hERG channel inhibition, resulting in clin. QTc interval prolongation.  A no. of structural ring A analogs of bedaquiline have been prepd. and evaluated for their anti-M.tb activity (MIC90), with a view to their possible application as less lipophilic second generation compds.  It was previously obsd. that a range of 6-substituted analogs of 1 demonstrated a pos. correlation between potency (MIC90) toward M.tb and drug lipophilicity.  Contrary to this trend, we discovered, by virtue of a clogP/M.tb score, that a 6-cyano (CN) substituent provides a substantial redn. in lipophilicity with only modest effects on MIC values, suggesting this substituent as a useful tool in the search for effective and safer analogs of 1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh633c0HlHiLVg90H21EOLACvtfcHk0li12NOQqEd0JA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFCis7vN&md5=f7314475257a0b3a8bfe89cc0095b0ea</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00196%26sid%3Dliteratum%253Aachs%26aulast%3DTong%26aufirst%3DA.%2BS.%2BT.%26aulast%3DChoi%26aufirst%3DP.%2BJ.%26aulast%3DBlaser%26aufirst%3DA.%26aulast%3DSutherland%26aufirst%3DH.%2BS.%26aulast%3DTsang%26aufirst%3DS.%2BK.%2BY.%26aulast%3DGuillemont%26aufirst%3DJ.%26aulast%3DMotte%26aufirst%3DM.%26aulast%3DCooper%26aufirst%3DC.%2BB.%26aulast%3DAndries%26aufirst%3DK.%26aulast%3DVan%2Bden%2BBroeck%26aufirst%3DW.%26aulast%3DFranzblau%26aufirst%3DS.%2BG.%26aulast%3DUpton%26aufirst%3DA.%2BM.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DPalmer%26aufirst%3DB.%2BD.%26aulast%3DConole%26aufirst%3DD.%26atitle%3D6-cyano%2520analogues%2520of%2520bedaquiline%2520as%2520less%2520lipophilic%2520and%2520potentially%2520safer%2520diarylquinolines%2520for%2520tuberculosis%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D1019%26epage%3D1024%26doi%3D10.1021%2Facsmedchemlett.7b00196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guglielmetti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Du, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jachym, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caumes, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veziris, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metivier, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrejak, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brossier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chadelat, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dautzenberg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarlier, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raskine, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivoire, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veziris, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appere, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assouline, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borie, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boukari, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caseris, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caumes, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douadi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumoulin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duval, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faucher, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallien, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Grusse, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meynard, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naccache, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philippe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richaud, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saad, H.</span></span> <span> </span><span class="NLM_article-title">Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: Interim analysis of a french cohort</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">188</span>– <span class="NLM_lpage">194</span>, <span class="refDoi"> DOI: 10.1093/cid/ciu786</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1093%2Fcid%2Fciu786" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=25320286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFWlsb%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2015&pages=188-194&author=L.+Guglielmettiauthor=D.+Le+Duauthor=M.+Jachymauthor=B.+Henryauthor=D.+Martinauthor=E.+Caumesauthor=N.+Vezirisauthor=N.+Metivierauthor=J.+Robertauthor=C.+Andrejakauthor=C.+Bernardauthor=F.+Brossierauthor=K.+Chadelatauthor=B.+Dautzenbergauthor=V.+Jarlierauthor=L.+Raskineauthor=B.+Rivoireauthor=N.+Vezirisauthor=C.+Appereauthor=P.+Assoulineauthor=R.+Borieauthor=L.+Boukariauthor=M.+Caserisauthor=E.+Caumesauthor=Y.+Douadiauthor=J.+Dumoulinauthor=C.+Duvalauthor=J.+F.+Faucherauthor=S.+Gallienauthor=C.+Godetauthor=J.+Le+Grusseauthor=A.+Lopesauthor=J.+L.+Meynardauthor=J.+M.+Naccacheauthor=B.+Philippeauthor=C.+Richaudauthor=H.+Saad&title=Compassionate+use+of+bedaquiline+for+the+treatment+of+multidrug-resistant+and+extensively+drug-resistant+tuberculosis%3A+Interim+analysis+of+a+french+cohort&doi=10.1093%2Fcid%2Fciu786"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a french cohort</span></div><div class="casAuthors">Guglielmetti, Lorenzo; Le Du, Damien; Jachym, Mathilde; Henry, Benoit; Martin, Diane; Caumes, Eric; Veziris, Nicolas; Metivier, Nathalie; Robert, Jerome</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Infectious Diseases</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">188-194</span>CODEN:
                <span class="NLM_cas:coden">CIDIEL</span>;
        ISSN:<span class="NLM_cas:issn">1058-4838</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background.  Bedaquiline is a new antibiotic that was approved for the treatment of multidrug-resistant (MDR) tuberculosis.  We aimed to evaluate the short-term microbiol. efficacy and the tolerability profile of bedaquiline.  Methods.  We performed a retrospective cohort study among patients with MDR tuberculosis receiving bedaquiline for compassionate use between Jan. 2010 and July 2013 and evaluated at 6 mo of bedaquiline treatment.  Results.  A total of 35 patients with MDR tuberculosis were included in the study.  Nineteen (54%) had extensively drug-resistant (XDR) tuberculosis, and 14 (40%) had isolates resistant to fluoroquinolones (Fqs) or second-line injectables.  Bedaquiline was assocd. with a median of 4 (range, 2-5) other drugs, including linezolid in 33 (94%) cases.  At 6 mo of bedaquiline treatment, culture conversion was achieved in 28 of 29 (97%) cases with culture-pos. pulmonary tuberculosis at bedaquiline initiation.  Median time to culture conversion was 85 days (range, 8-235 days).  Variables independently assocd. with culture conversion were treatment with a Fq (P = .01), absence of lung cavities (P < .001), and absence of hepatitis C virus infection (P = .001).  A total of 7 patients (20%) experienced a ≥60-ms increase in QT interval, leading to bedaquiline discontinuation in 2 (6%) cases.  Severe liver enzyme elevation occurred in 2 patients (6%).  During the study period, 1 death (3%) occurred and was reported as unrelated to tuberculosis or antituberculosis treatment.  Conclusions.  The use of bedaquiline combined with other active drugs has the potential to achieve high culture conversion rates in complicated MDR and XDR tuberculosis cases, with a reassuring safety profile at 6 mo of treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqO-sBVN1eNCrVg90H21EOLACvtfcHk0lgOggR_YDlQyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFWlsb%252FM&md5=a058d6dae325811594f9090c064b07dd</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1093%2Fcid%2Fciu786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcid%252Fciu786%26sid%3Dliteratum%253Aachs%26aulast%3DGuglielmetti%26aufirst%3DL.%26aulast%3DLe%2BDu%26aufirst%3DD.%26aulast%3DJachym%26aufirst%3DM.%26aulast%3DHenry%26aufirst%3DB.%26aulast%3DMartin%26aufirst%3DD.%26aulast%3DCaumes%26aufirst%3DE.%26aulast%3DVeziris%26aufirst%3DN.%26aulast%3DMetivier%26aufirst%3DN.%26aulast%3DRobert%26aufirst%3DJ.%26aulast%3DAndrejak%26aufirst%3DC.%26aulast%3DBernard%26aufirst%3DC.%26aulast%3DBrossier%26aufirst%3DF.%26aulast%3DChadelat%26aufirst%3DK.%26aulast%3DDautzenberg%26aufirst%3DB.%26aulast%3DJarlier%26aufirst%3DV.%26aulast%3DRaskine%26aufirst%3DL.%26aulast%3DRivoire%26aufirst%3DB.%26aulast%3DVeziris%26aufirst%3DN.%26aulast%3DAppere%26aufirst%3DC.%26aulast%3DAssouline%26aufirst%3DP.%26aulast%3DBorie%26aufirst%3DR.%26aulast%3DBoukari%26aufirst%3DL.%26aulast%3DCaseris%26aufirst%3DM.%26aulast%3DCaumes%26aufirst%3DE.%26aulast%3DDouadi%26aufirst%3DY.%26aulast%3DDumoulin%26aufirst%3DJ.%26aulast%3DDuval%26aufirst%3DC.%26aulast%3DFaucher%26aufirst%3DJ.%2BF.%26aulast%3DGallien%26aufirst%3DS.%26aulast%3DGodet%26aufirst%3DC.%26aulast%3DLe%2BGrusse%26aufirst%3DJ.%26aulast%3DLopes%26aufirst%3DA.%26aulast%3DMeynard%26aufirst%3DJ.%2BL.%26aulast%3DNaccache%26aufirst%3DJ.%2BM.%26aulast%3DPhilippe%26aufirst%3DB.%26aulast%3DRichaud%26aufirst%3DC.%26aulast%3DSaad%26aufirst%3DH.%26atitle%3DCompassionate%2520use%2520of%2520bedaquiline%2520for%2520the%2520treatment%2520of%2520multidrug-resistant%2520and%2520extensively%2520drug-resistant%2520tuberculosis%253A%2520Interim%2520analysis%2520of%2520a%2520french%2520cohort%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2015%26volume%3D60%26spage%3D188%26epage%3D194%26doi%3D10.1093%2Fcid%2Fciu786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Esposito, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianchini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasi, F.</span></span> <span> </span><span class="NLM_article-title">Bedaquiline and delamanid in tuberculosis</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">2319</span>– <span class="NLM_lpage">2330</span>, <span class="refDoi"> DOI: 10.1517/14656566.2015.1080240</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1517%2F14656566.2015.1080240" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=26293803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A280%3ADC%252BC287kvVCqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=2319-2330&author=S.+Espositoauthor=S.+Bianchiniauthor=F.+Blasi&title=Bedaquiline+and+delamanid+in+tuberculosis&doi=10.1517%2F14656566.2015.1080240"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Bedaquiline and delamanid in tuberculosis</span></div><div class="casAuthors">Esposito Susanna; Bianchini Sonia; Blasi Francesco</div><div class="citationInfo"><span class="NLM_cas:title">Expert opinion on pharmacotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2319-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  In recent years, a pressing need to develop new, effective and safe drugs against tuberculosis (TB) has continued.  Poor adherence to a long therapeutic regimen against TB, intermittent drug use, errors in medical prescriptions, low quality of old TB drugs and ineffective TB control have led to the emergence of resistant TB.  AREAS COVERED:  Two new drugs have gained importance and seem promising against resistant TB: bedaquiline and delamanid.  This review summarizes the main characteristics of these two drugs and their role in TB management.  EXPERT OPINION:  Bedaquiline and delamanid appear to be promising new anti-TB drugs.  Due to a mechanism of action that is different from that of other available drugs, their efficacy has appeared optimal in cases of adults with resistant pulmonary TB.  Although their pharmacokinetic and pharmacodynamic profiles seem optimal, potential cardiologic side effects such as QT-interval prolongation have been associated with their use.  However, specific studies performed in the pediatric population are needed to confirm these results.  This seems particularly important considering the long duration of TB treatment required for resistant TB as well as the potential interactions with other drugs included in anti-TB regimens or administered for an underlying comorbidity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQx4lkJjTc-RUNoizSOkG_FfW6udTcc2eaGD0nbo7TTYLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287kvVCqsA%253D%253D&md5=b0eed12fa6bc0ebfaf1b54e392faa662</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1517%2F14656566.2015.1080240&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2015.1080240%26sid%3Dliteratum%253Aachs%26aulast%3DEsposito%26aufirst%3DS.%26aulast%3DBianchini%26aufirst%3DS.%26aulast%3DBlasi%26aufirst%3DF.%26atitle%3DBedaquiline%2520and%2520delamanid%2520in%2520tuberculosis%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2015%26volume%3D16%26spage%3D2319%26epage%3D2330%26doi%3D10.1517%2F14656566.2015.1080240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stover, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warrener, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VanDevanter, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arain, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langhorne, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towell, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMurray, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreiswirth, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, W. R.</span></span> <span> </span><span class="NLM_article-title">A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>405</i></span>,  <span class="NLM_fpage">962</span>– <span class="NLM_lpage">966</span>, <span class="refDoi"> DOI: 10.1038/35016103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1038%2F35016103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10879539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD3cXks1Wksb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=405&publication_year=2000&pages=962-966&author=C.+K.+Stoverauthor=P.+Warrenerauthor=D.+R.+VanDevanterauthor=D.+R.+Shermanauthor=T.+M.+Arainauthor=M.+H.+Langhorneauthor=S.+W.+Andersonauthor=J.+A.+Towellauthor=Y.+Yuanauthor=D.+N.+McMurrayauthor=B.+N.+Kreiswirthauthor=C.+E.+Barryauthor=W.+R.+Baker&title=A+small-molecule+nitroimidazopyran+drug+candidate+for+the+treatment+of+tuberculosis&doi=10.1038%2F35016103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis</span></div><div class="casAuthors">Stover, C. Kendall; Warrener, Paul; VanDevanter, Donald R.; Sherman, David R.; Arain, Taraq M.; Langhorne, Michael H.; Anderson, Scott W.; Towell, J. Andrew; Yuan, Ying; McMurray, David N.; Krelswirth, Barry N.; Barry, Clifton E.; Baker, William R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">405</span>
        (<span class="NLM_cas:issue">6789</span>),
    <span class="NLM_cas:pages">962-966</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Mycobacterium tuberculosis, which causes tuberculosis, is the greatest single infectious cause of mortality worldwide, killing roughly; two million people annually.  Ests. indicate that one-third of the world population is infected with latent M. tuberculosis.  The synergy between tuberculosis and the AIDS epidemic, and the surge of multidrug-resistant clin. isolates of M. tuberculosis have reaffirmed tuberculosis as a primary public health threat.  However, new antitubercular drugs with new mechanisms of action have not been developed in over thirty years.  Here we report a series of compds. contg. a nitroimidazopyran nucleus that possess antitubercular activity.  After activation by a mechanism dependent on M. tuberculosis F420 cofactor, nitroimidazopyrans inhibited the synthesis of protein and cell wall lipid.  In contrast to current antitubercular drugs, nitroimidazopyrans exhibited bactericidal activity against both replicating and static M. tuberculosis.  Lead compd. PA-824 showed potent bactericidal activity against multidrug-resistant M. tuberculosis and promising oral activity in animal infection models.  We conclude that nitroimidazopyrans offer the practical qualities of a small mol. with the potential for the treatment of tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrw41eD4TtVwbVg90H21EOLACvtfcHk0ljfmN965XcW9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXks1Wksb0%253D&md5=f5f6e2935928da72e328bddd4995515f</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2F35016103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35016103%26sid%3Dliteratum%253Aachs%26aulast%3DStover%26aufirst%3DC.%2BK.%26aulast%3DWarrener%26aufirst%3DP.%26aulast%3DVanDevanter%26aufirst%3DD.%2BR.%26aulast%3DSherman%26aufirst%3DD.%2BR.%26aulast%3DArain%26aufirst%3DT.%2BM.%26aulast%3DLanghorne%26aufirst%3DM.%2BH.%26aulast%3DAnderson%26aufirst%3DS.%2BW.%26aulast%3DTowell%26aufirst%3DJ.%2BA.%26aulast%3DYuan%26aufirst%3DY.%26aulast%3DMcMurray%26aufirst%3DD.%2BN.%26aulast%3DKreiswirth%26aufirst%3DB.%2BN.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26aulast%3DBaker%26aufirst%3DW.%2BR.%26atitle%3DA%2520small-molecule%2520nitroimidazopyran%2520drug%2520candidate%2520for%2520the%2520treatment%2520of%2520tuberculosis%26jtitle%3DNature%26date%3D2000%26volume%3D405%26spage%3D962%26epage%3D966%26doi%3D10.1038%2F35016103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span> <i>FDA
Approves New Treatment for Highly Drug-Resistant Forms of Tuberculosis</i>; <span class="NLM_publisher-name">TB Alliance</span>: <span class="NLM_publisher-loc">New
York</span>, <span class="NLM_year">2019</span>; <a href="https://www.tballiance.org/news/fda-approves-new-treatment-highly-drug-resistant-forms-tuberculosis" class="extLink">https://www.tballiance.org/news/fda-approves-new-treatment-highly-drug-resistant-forms-tuberculosis</a> (accessed Mar 3, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+FDA%0AApproves+New+Treatment+for+Highly+Drug-Resistant+Forms+of+Tuberculosis%3B+TB+Alliance%3A+New%0AYork%2C+2019%3B+https%3A%2F%2Fwww.tballiance.org%2Fnews%2Ffda-approves-new-treatment-highly-drug-resistant-forms-tuberculosis+%28accessed+Mar+3%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26jtitle%3DFDA%250AApproves%2520New%2520Treatment%2520for%2520Highly%2520Drug-Resistant%2520Forms%2520of%2520Tuberculosis%26pub%3DTB%2520Alliance%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zumla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nahid, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S. T.</span></span> <span> </span><span class="NLM_article-title">Advances in the development of new tuberculosis drugs and treatment regimens</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">388</span>– <span class="NLM_lpage">404</span>, <span class="refDoi"> DOI: 10.1038/nrd4001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1038%2Fnrd4001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=23629506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3sXms1Kmsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=388-404&author=A.+Zumlaauthor=P.+Nahidauthor=S.+T.+Cole&title=Advances+in+the+development+of+new+tuberculosis+drugs+and+treatment+regimens&doi=10.1038%2Fnrd4001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in the development of new tuberculosis drugs and treatment regimens</span></div><div class="casAuthors">Zumla, Alimuddin; Nahid, Payam; Cole, Stewart T.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">388-404</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the introduction 40 years ago of the inexpensive and effective four-drug (isoniazid, rifampicin, pyrazinamide and ethambutol) treatment regimen, tuberculosis (TB) continues to cause considerable morbidity and mortality worldwide.  For the first time since the 1960s, new and novel drugs and regimens for all forms of TB are emerging.  Such regimens are likely to utilize both repurposed drugs and new chem. entities, and several of these regimens are now progressing through clin. trials.  This article covers current concepts and recent advances in TB drug discovery and development, including an update of ongoing TB treatment trials, newer clin. trial designs, TB biomarkers and adjunct host-directed therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrs_a1A-oQwcrVg90H21EOLACvtfcHk0ljfmN965XcW9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXms1Kmsrk%253D&md5=fbf12f867a19ffff4d7fb74a98699682</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnrd4001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4001%26sid%3Dliteratum%253Aachs%26aulast%3DZumla%26aufirst%3DA.%26aulast%3DNahid%26aufirst%3DP.%26aulast%3DCole%26aufirst%3DS.%2BT.%26atitle%3DAdvances%2520in%2520the%2520development%2520of%2520new%2520tuberculosis%2520drugs%2520and%2520treatment%2520regimens%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D388%26epage%3D404%26doi%3D10.1038%2Fnrd4001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klopper, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gey van Pittius, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streicher, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirgel, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chabula-Nxiweni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoosain, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coetzee, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David van Helden, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Victor, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trollip, A. P.</span></span> <span> </span><span class="NLM_article-title">Emergence and spread of extensively and totally drug-resistant tuberculosis, South Africa</span>. <i>Emerging Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">449</span>– <span class="NLM_lpage">455</span>, <span class="refDoi"> DOI: 10.3201/eid1903.120246</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.3201%2Feid1903.120246" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=23622714" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A280%3ADC%252BC3srptFWmtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=449-455&author=M.+Klopperauthor=R.+M.+Warrenauthor=C.+Hayesauthor=N.+C.+Gey+van+Pittiusauthor=E.+M.+Streicherauthor=B.+M%C3%BCllerauthor=F.+A.+Sirgelauthor=M.+Chabula-Nxiweniauthor=E.+Hoosainauthor=G.+Coetzeeauthor=P.+David+van+Heldenauthor=T.+C.+Victorauthor=A.+P.+Trollip&title=Emergence+and+spread+of+extensively+and+totally+drug-resistant+tuberculosis%2C+South+Africa&doi=10.3201%2Feid1903.120246"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Emergence and spread of extensively and totally drug-resistant tuberculosis, South Africa</span></div><div class="casAuthors">Klopper Marisa; Warren Robin Mark; Hayes Cindy; Gey van Pittius Nicolaas Claudius; Streicher Elizabeth Maria; Muller Borna; Sirgel Frederick Adriaan; Chabula-Nxiweni Mamisa; Hoosain Ebrahim; Coetzee Gerrit; David van Helden Paul; Victor Thomas Calldo; Trollip Andre Phillip</div><div class="citationInfo"><span class="NLM_cas:title">Emerging infectious diseases</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">449-55</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Factors driving the increase in drug-resistant tuberculosis (TB) in the Eastern Cape Province, South Africa, are not understood.  A convenience sample of 309 drug-susceptible and 342 multidrug-resistant (MDR) TB isolates, collected July 2008-July 2009, were characterized by spoligotyping, DNA fingerprinting, insertion site mapping, and targeted DNA sequencing.  Analysis of molecular-based data showed diverse genetic backgrounds among drug-sensitive and MDR TB sensu stricto isolates in contrast to restricted genetic backgrounds among pre-extensively drug-resistant (pre-XDR) TB and XDR TB isolates.  Second-line drug resistance was significantly associated with the atypical Beijing genotype.  DNA fingerprinting and sequencing demonstrated that the pre-XDR and XDR atypical Beijing isolates evolved from a common progenitor; 85% and 92%, respectively, were clustered, indicating transmission.  Ninety-three percent of atypical XDR Beijing isolates had mutations that confer resistance to 10 anti-TB drugs, and some isolates also were resistant to para-aminosalicylic acid.  These findings suggest the emergence of totally drug-resistant TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQqLENfnM1xFLesJRIHUP1ofW6udTcc2eauVAR1a2wJKbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3srptFWmtA%253D%253D&md5=92a85b3511db35661a99506c53ba5655</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.3201%2Feid1903.120246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3201%252Feid1903.120246%26sid%3Dliteratum%253Aachs%26aulast%3DKlopper%26aufirst%3DM.%26aulast%3DWarren%26aufirst%3DR.%2BM.%26aulast%3DHayes%26aufirst%3DC.%26aulast%3DGey%2Bvan%2BPittius%26aufirst%3DN.%2BC.%26aulast%3DStreicher%26aufirst%3DE.%2BM.%26aulast%3DM%25C3%25BCller%26aufirst%3DB.%26aulast%3DSirgel%26aufirst%3DF.%2BA.%26aulast%3DChabula-Nxiweni%26aufirst%3DM.%26aulast%3DHoosain%26aufirst%3DE.%26aulast%3DCoetzee%26aufirst%3DG.%26aulast%3DDavid%2Bvan%2BHelden%26aufirst%3DP.%26aulast%3DVictor%26aufirst%3DT.%2BC.%26aulast%3DTrollip%26aufirst%3DA.%2BP.%26atitle%3DEmergence%2520and%2520spread%2520of%2520extensively%2520and%2520totally%2520drug-resistant%2520tuberculosis%252C%2520South%2520Africa%26jtitle%3DEmerging%2520Infect.%2520Dis.%26date%3D2013%26volume%3D19%26spage%3D449%26epage%3D455%26doi%3D10.3201%2Feid1903.120246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Slomski, A.</span></span> <span> </span><span class="NLM_article-title">South Africa warns of emergence of ″totally″ drug-resistant tuberculosis</span>. <i>JAMA</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>309</i></span>,  <span class="NLM_fpage">1097</span>– <span class="NLM_lpage">1098</span>, <span class="refDoi"> DOI: 10.1001/jama.2013.1802</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1001%2Fjama.2013.1802" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=23512035" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltlOrtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=309&publication_year=2013&pages=1097-1098&author=A.+Slomski&title=South+Africa+warns+of+emergence+of+%E2%80%B3totally%E2%80%B3+drug-resistant+tuberculosis&doi=10.1001%2Fjama.2013.1802"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">South Africa warns of emergence of "totally' drug-resistant tuberculosis</span></div><div class="casAuthors">Slomski, Anita</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">309</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1097-1098</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">0098-7484</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyHpNQHGBVBLVg90H21EOLACvtfcHk0lhAKf74Q0A41A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltlOrtrk%253D&md5=5519cd62d449bfd52e9ac0c2f385bf35</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1001%2Fjama.2013.1802&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2013.1802%26sid%3Dliteratum%253Aachs%26aulast%3DSlomski%26aufirst%3DA.%26atitle%3DSouth%2520Africa%2520warns%2520of%2520emergence%2520of%2520%25E2%2580%25B3totally%25E2%2580%25B3%2520drug-resistant%2520tuberculosis%26jtitle%3DJAMA%26date%3D2013%26volume%3D309%26spage%3D1097%26epage%3D1098%26doi%3D10.1001%2Fjama.2013.1802" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span> <i>Latent Tuberculosis
Infection; Updated and Consolidated Guidelines
for Programmatic Management</i>; <span class="NLM_publisher-name">World Health
Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2018</span>; <a href="http://apps.who.int/iris/bitstream/10665/260233/1/9789241550239-eng.pdf" class="extLink">apps.who.int/iris/bitstream/10665/260233/1/9789241550239-eng.pdf</a> (accessed 2020-03-03).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Latent+Tuberculosis%0AInfection%3B+Updated+and+Consolidated+Guidelines%0Afor+Programmatic+Management%3B+World+Health%0AOrganization%3A+Geneva%2C+2018%3B+apps.who.int%2Firis%2Fbitstream%2F10665%2F260233%2F1%2F9789241550239-eng.pdf+%28accessed+2020-03-03%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26jtitle%3DLatent%2520Tuberculosis%250AInfection%253B%2520Updated%2520and%2520Consolidated%2520Guidelines%250Afor%2520Programmatic%2520Management%26pub%3DWorld%2520Health%250AOrganization%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yew, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barer, M. R.</span></span> <span> </span><span class="NLM_article-title">Targeting persisters for tuberculosis control</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">2223</span>– <span class="NLM_lpage">2230</span>, <span class="refDoi"> DOI: 10.1128/AAC.06288-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.06288-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=22391538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsVKktbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=2223-2230&author=Y.+Zhangauthor=W.+W.+Yewauthor=M.+R.+Barer&title=Targeting+persisters+for+tuberculosis+control&doi=10.1128%2FAAC.06288-11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting persisters for tuberculosis control</span></div><div class="casAuthors">Zhang, Ying; Yew, Wing Wai; Barer, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2223-2230</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">A review.  Mycobacterial persisters, the survivors from antibiotic exposure, necessitate the lengthy treatment of tuberculosis (TB) and pose a significant challenge for our control of the disease.  We suggest that persisters in TB are heterogeneous in nature and comprise various proportions of the population depending on the circumstances; the mechanisms of their formation are complex and may be related to those required for persistence in chronic infection.  Results from recent studies implicate multiple pathways for persister formation, including energy prodn., the stringent response, global regulators, the trans-translation pathway, proteasomal protein degrdn., toxin-antitoxin modules, and transporter or efflux mechanisms.  A combination of specifically persister-targeted approaches, such as catching them when active and susceptible either by stimulating them to "wake up" or by intermittent drug dosing, the development of new drugs, the use of appropriate drug combinations, and combined chemotherapy and immunotherapy, may be needed for more effective elimination of persisters and better treatment of TB.  Variations in levels of persister formation and in host genetics can play a role in the outcome of clin. treatment, and thus, these may entail personalized treatment regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9GlERNHgMUrVg90H21EOLACvtfcHk0lhAKf74Q0A41A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsVKktbc%253D&md5=5711a4cb75fab28f2781c27349b6ae7d</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1128%2FAAC.06288-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.06288-11%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DYew%26aufirst%3DW.%2BW.%26aulast%3DBarer%26aufirst%3DM.%2BR.%26atitle%3DTargeting%2520persisters%2520for%2520tuberculosis%2520control%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D2223%26epage%3D2230%26doi%3D10.1128%2FAAC.06288-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iacobino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piccaro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannoni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustazzolu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fattorini, L.</span></span> <span> </span><span class="NLM_article-title">Fighting tuberculosis by drugs targeting nonreplicating mycobacterium tuberculosis bacilli</span>. <i>Int. J. Mycobacteriol</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.4103/ijmy.ijmy_85_17</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.4103%2Fijmy.ijmy_85_17" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=28776518" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A280%3ADC%252BC1cfksVaitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2017&pages=213-221&author=A.+Iacobinoauthor=G.+Piccaroauthor=F.+Giannoniauthor=A.+Mustazzoluauthor=L.+Fattorini&title=Fighting+tuberculosis+by+drugs+targeting+nonreplicating+mycobacterium+tuberculosis+bacilli&doi=10.4103%2Fijmy.ijmy_85_17"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Fighting tuberculosis by drugs targeting nonreplicating Mycobacterium tuberculosis bacilli</span></div><div class="casAuthors">Iacobino Angelo; Giannoni Federico; Mustazzolu Alessandro; Fattorini Lanfranco; Piccaro Giovanni</div><div class="citationInfo"><span class="NLM_cas:title">International journal of mycobacteriology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">213-221</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Current tuberculosis (TB) treatment requires 6 months of combination therapy with isoniazid (INH), rifampin (RIF), pyrazinamide (PZA), and ethambutol for active TB and 9 months of INH or 3 months of rifapentine (RFP) + INH for latent TB.  The lungs of patients with active and latent TB contain heterogeneous mixtures of cellular and caseous granulomas harboring Mycobacterium tuberculosis bacilli ranging from actively replicating (AR) to nonreplicating (NR), phenotypically drug-resistant stages.  Several in vitro models to obtain NR cells were reported, including exposure to hypoxia, nutrient starvation, acid + nitric oxide, and stationary phase.  Overall, these models showed that RIF, RFP, PA-824 (PA), metronidazole (MZ), bedaquiline (BQ), and fluoroquinolones were the most active drugs against NR M. tuberculosis.  In hypoxia at pH 5.8, some combinations killed AR plus NR cells, as shown by lack of regrowth in liquid media, whereas in hypoxia at pH 7.3 (the pH of the caseum), only RIF and RFP efficiently killed NR bacilli while several other drugs showed little effect.  In conventional mouse models, combinations containing RFP, BQ, PA, PZA, moxifloxacin, sutezolid, linezolid, and clofazimine sterilized animals in ≤2 months, as shown by lack of viable bacilli in lung homogenates after 3 months without therapy.  Drugs were less effective in C3HeB/FeJ mice forming caseous granulomas.  Overall, in vitro observations and in vivo studies suggest that the search for new TB drugs could be addressed to low lipophilic molecules (e.g., new rpoB inhibitors with clogP < 3) killing NR M. tuberculosis in hypoxia at neutral pH and reaching high rates of unbound drug in the caseum.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS463w1DslAViM8MEzWGjS9fW6udTcc2eY1at7ISznCHbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cfksVaitg%253D%253D&md5=4f58e1e755973f7fb52c90b1fa13840f</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.4103%2Fijmy.ijmy_85_17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252Fijmy.ijmy_85_17%26sid%3Dliteratum%253Aachs%26aulast%3DIacobino%26aufirst%3DA.%26aulast%3DPiccaro%26aufirst%3DG.%26aulast%3DGiannoni%26aufirst%3DF.%26aulast%3DMustazzolu%26aufirst%3DA.%26aulast%3DFattorini%26aufirst%3DL.%26atitle%3DFighting%2520tuberculosis%2520by%2520drugs%2520targeting%2520nonreplicating%2520mycobacterium%2520tuberculosis%2520bacilli%26jtitle%3DInt.%2520J.%2520Mycobacteriol%26date%3D2017%26volume%3D6%26spage%3D213%26epage%3D221%26doi%3D10.4103%2Fijmy.ijmy_85_17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span> <i>Global Tuberculosis
Report 2017</i>; <span class="NLM_publisher-name">World Health
Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2017</span>; <a href="https://www.who.int/tb/publications/global_report/gtbr2017_main_text.pdf" class="extLink">https://www.who.int/tb/publications/global_report/gtbr2017_main_text.pdf</a> (accessed 2020-03-03).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Global+Tuberculosis%0AReport+2017%3B+World+Health%0AOrganization%3A+Geneva%2C+2017%3B+https%3A%2F%2Fwww.who.int%2Ftb%2Fpublications%2Fglobal_report%2Fgtbr2017_main_text.pdf+%28accessed+2020-03-03%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26jtitle%3DGlobal%2520Tuberculosis%250AReport%25202017%26pub%3DWorld%2520Health%250AOrganization%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span> <i>Global Ministerial Conference
On Ending TB In The Sustainable Development
Era</i>; <span class="NLM_publisher-name">World Health Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2017</span>; <a href="http://www.who.int/mediacentre/events/2017/ministerial-conference-tb/en/" class="extLink">http://www.who.int/mediacentre/events/2017/ministerial-conference-tb/en/</a> (accessed Mar 3, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Global+Ministerial+Conference%0AOn+Ending+TB+In+The+Sustainable+Development%0AEra%3B+World+Health+Organization%3A+Geneva%2C+2017%3B+http%3A%2F%2Fwww.who.int%2Fmediacentre%2Fevents%2F2017%2Fministerial-conference-tb%2Fen%2F+%28accessed+Mar+3%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26jtitle%3DGlobal%2520Ministerial%2520Conference%250AOn%2520Ending%2520TB%2520In%2520The%2520Sustainable%2520Development%250AEra%26pub%3DWorld%2520Health%2520Organization%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dooley, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nahid, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoelscher, M.</span></span> <span> </span><span class="NLM_article-title">Challenges in the clinical assessment of novel tuberculosis drugs</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">116</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1016/j.addr.2016.01.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.addr.2016.01.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=26827911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFSksbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2016&pages=116-122&author=K.+E.+Dooleyauthor=P.+P.+Phillipsauthor=P.+Nahidauthor=M.+Hoelscher&title=Challenges+in+the+clinical+assessment+of+novel+tuberculosis+drugs&doi=10.1016%2Fj.addr.2016.01.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Challenges in the clinical assessment of novel tuberculosis drugs</span></div><div class="casAuthors">Dooley, Kelly E.; Phillips, Patrick P. J.; Nahid, Payam; Hoelscher, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">116-122</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">To tackle the global TB epidemic effectively, novel treatment strategies are critically needed to shorten the duration of TB therapy and treat drug-resistant TB.  Drug development for TB, stymied for decades, has enjoyed a renaissance over the past several years.  However, the development of new TB regimens is hindered by the limitations in our understanding and use of preclin. models; the paucity of accurate, early surrogate markers of cure, and challenges in untangling the individual contributions of drugs to multidrug regimens in a complex, multi-compartment disease.  Lack of profit motive, advocacy, and imagination has contributed mightily to the dearth of drugs we have on the shelf to treat this ancient disease.  Areas that will speed the development of new regimens for TB include novel murine and in vitro pharmacodynamics models, clin. endpoints that are not culture-based, innovative clin. trial designs, and an infusion of much-needed funding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryOQVd0wsQeLVg90H21EOLACvtfcHk0lhH9QoQX54PdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFSksbo%253D&md5=8e0c6922ed115b64df7723c386556e87</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2016.01.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2016.01.014%26sid%3Dliteratum%253Aachs%26aulast%3DDooley%26aufirst%3DK.%2BE.%26aulast%3DPhillips%26aufirst%3DP.%2BP.%26aulast%3DNahid%26aufirst%3DP.%26aulast%3DHoelscher%26aufirst%3DM.%26atitle%3DChallenges%2520in%2520the%2520clinical%2520assessment%2520of%2520novel%2520tuberculosis%2520drugs%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2016%26volume%3D102%26spage%3D116%26epage%3D122%26doi%3D10.1016%2Fj.addr.2016.01.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manjunatha, U. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. W.</span></span> <span> </span><span class="NLM_article-title">Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">5087</span>– <span class="NLM_lpage">5097</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2014.12.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmc.2014.12.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=25577708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltVamtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=5087-5097&author=U.+H.+Manjunathaauthor=P.+W.+Smith&title=Perspective%3A+Challenges+and+opportunities+in+TB+drug+discovery+from+phenotypic+screening&doi=10.1016%2Fj.bmc.2014.12.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening</span></div><div class="casAuthors">Manjunatha, Ujjini H.; Smith, Paul W.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5087-5097</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Tuberculosis poses a major global health problem and multi-drug resistant strains are increasingly prevalent.  Hence there is an urgent need to discover new TB drugs.  Cell based phenotypic screening represents a powerful approach to identify anti-mycobacterial compds. and elucidate novel targets.  Three high throughput phenotypic screens were performed at NITD against mycobacterium.  Hits were identified and chem. series selected for optimization.  This produced compds. with good in vitro anti-mycobacterial activity and pharmacokinetic properties.  Some compds. displayed oral activity in mouse efficacy models of TB.  Herein, the authors review the TB discovery efforts at NITD and share experiences in optimization of phenotypic hits, describing challenges encountered and lessons learned.  The authors also offer perspectives to facilitate future selection and advancement of phenotypic hits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGbroyRLtEcrVg90H21EOLACvtfcHk0ljsJj9V9ovztg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltVamtg%253D%253D&md5=8d03c078275a58fa6629eaa9f36a5073</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.12.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.12.031%26sid%3Dliteratum%253Aachs%26aulast%3DManjunatha%26aufirst%3DU.%2BH.%26aulast%3DSmith%26aufirst%3DP.%2BW.%26atitle%3DPerspective%253A%2520Challenges%2520and%2520opportunities%2520in%2520TB%2520drug%2520discovery%2520from%2520phenotypic%2520screening%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D5087%26epage%3D5097%26doi%3D10.1016%2Fj.bmc.2014.12.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behr, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowdy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dheda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Divangahi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehme, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginsberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaminathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spigelman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getahun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menzies, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raviglione, M.</span></span> <span> </span><span class="NLM_article-title">Tuberculosis</span>. <i>Nat. Rev. Dis. Primers</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">16076</span>, <span class="refDoi"> DOI: 10.1038/nrdp.2016.76</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1038%2Fnrdp.2016.76" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=27784885" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A280%3ADC%252BC2sngtVCgsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2016&pages=16076&author=M.+Paiauthor=M.+A.+Behrauthor=D.+Dowdyauthor=K.+Dhedaauthor=M.+Divangahiauthor=C.+C.+Boehmeauthor=A.+Ginsbergauthor=S.+Swaminathanauthor=M.+Spigelmanauthor=H.+Getahunauthor=D.+Menziesauthor=M.+Raviglione&title=Tuberculosis&doi=10.1038%2Fnrdp.2016.76"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Tuberculosis</span></div><div class="casAuthors">Pai Madhukar; Behr Marcel A; Divangahi Maziar; Menzies Dick; Pai Madhukar; Dowdy David; Dheda Keertan; Boehme Catharina C; Ginsberg Ann; Swaminathan Soumya; Spigelman Melvin; Getahun Haileyesus; Raviglione Mario</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Disease primers</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">16076</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Tuberculosis (TB) is an airborne infectious disease caused by organisms of the Mycobacterium tuberculosis complex.  Although primarily a pulmonary pathogen, M. tuberculosis can cause disease in almost any part of the body.  Infection with M. tuberculosis can evolve from containment in the host, in which the bacteria are isolated within granulomas (latent TB infection), to a contagious state, in which the patient will show symptoms that can include cough, fever, night sweats and weight loss.  Only active pulmonary TB is contagious.  In many low-income and middle-income countries, TB continues to be a major cause of morbidity and mortality, and drug-resistant TB is a major concern in many settings.  Although several new TB diagnostics have been developed, including rapid molecular tests, there is a need for simpler point-of-care tests.  Treatment usually requires a prolonged course of multiple antimicrobials, stimulating efforts to develop shorter drug regimens.  Although the Bacillus Calmette-Guerin (BCG) vaccine is used worldwide, mainly to prevent life-threatening TB in infants and young children, it has been ineffective in controlling the global TB epidemic.  Thus, efforts are underway to develop newer vaccines with improved efficacy.  New tools as well as improved programme implementation and financing are necessary to end the global TB epidemic by 2035.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRkhlsQg_ocTUPI-fCgwosgfW6udTcc2eY9OUxLowkX2bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sngtVCgsw%253D%253D&md5=b2170e953514895635d3d13d8deefa24</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fnrdp.2016.76&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrdp.2016.76%26sid%3Dliteratum%253Aachs%26aulast%3DPai%26aufirst%3DM.%26aulast%3DBehr%26aufirst%3DM.%2BA.%26aulast%3DDowdy%26aufirst%3DD.%26aulast%3DDheda%26aufirst%3DK.%26aulast%3DDivangahi%26aufirst%3DM.%26aulast%3DBoehme%26aufirst%3DC.%2BC.%26aulast%3DGinsberg%26aufirst%3DA.%26aulast%3DSwaminathan%26aufirst%3DS.%26aulast%3DSpigelman%26aufirst%3DM.%26aulast%3DGetahun%26aufirst%3DH.%26aulast%3DMenzies%26aufirst%3DD.%26aulast%3DRaviglione%26aufirst%3DM.%26atitle%3DTuberculosis%26jtitle%3DNat.%2520Rev.%2520Dis.%2520Primers%26date%3D2016%26volume%3D2%26spage%3D16076%26doi%3D10.1038%2Fnrdp.2016.76" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wallis, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeurer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mwaba, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakaya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rustomjee, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Migliori, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Churchyard, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaminathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoelscher, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zumla, A.</span></span> <span> </span><span class="NLM_article-title">Tuberculosis--advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">e34</span>– <span class="NLM_lpage">46</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(16)00070-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2FS1473-3099%2816%2900070-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=27036358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28Xksl2htbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=e34-46&author=R.+S.+Wallisauthor=M.+Maeurerauthor=P.+Mwabaauthor=J.+Chakayaauthor=R.+Rustomjeeauthor=G.+B.+Miglioriauthor=B.+Maraisauthor=M.+Schitoauthor=G.+Churchyardauthor=S.+Swaminathanauthor=M.+Hoelscherauthor=A.+Zumla&title=Tuberculosis%2D%2Dadvances+in+development+of+new+drugs%2C+treatment+regimens%2C+host-directed+therapies%2C+and+biomarkers&doi=10.1016%2FS1473-3099%2816%2900070-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Tuberculosis-advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers</span></div><div class="casAuthors">Wallis, Robert S.; Maeurer, Markus; Mwaba, Peter; Chakaya, Jeremiah; Rustomjee, Roxana; Migliori, Giovanni Battista; Marais, Ben; Schito, Marco; Churchyard, Gavin; Swaminathan, Soumya; Hoelscher, Michael; Zumla, Alimuddin</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e34-e46</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Tuberculosis is the leading infectious cause of death worldwide, with 9·6 million cases and 1·5 million deaths reported in 2014.  WHO ests. 480 000 cases of these were multidrug resistant (MDR).  Less than half of patients who entered into treatment for MDR tuberculosis successfully completed that treatment, mainly due to high mortality and loss to follow-up.  These in turn illustrate weaknesses in current treatment regimens and national tuberculosis programs, coupled with operational treatment challenges.  In this Review we provide an update on recent developments in the tuberculosis drug-development pipeline (including new and repurposed antimicrobials and host-directed drugs) as they are applied to new regimens to shorten and improve outcomes of tuberculosis treatment.  Several new or repurposed antimicrobial drugs are in advanced trial stages for MDR tuberculosis, and two new antimicrobial drug candidates are in early-stage trials.  Several trials to reduce the duration of therapy in MDR and drug-susceptible tuberculosis are ongoing.  A wide range of candidate host-directed therapies are being developed to accelerate eradication of infection, prevent new drug resistance, and prevent permanent lung injury.  As these drugs have been approved for other clin. indications, they are now ready for repurposing for tuberculosis in phase 2 clin. trials.  We assess risks assocd. with evaluation of new treatment regimens, and highlight opportunities to advance tuberculosis research generally through regulatory innovation in MDR tuberculosis.  Progress in tuberculosis-specific biomarkers (including culture conversion, PET and CT imaging, and gene expression profiles) can support this innovation.  Several global initiatives now provide unique opportunities to tackle the tuberculosis epidemic through collaborative partnerships between high-income countries and middle-income and low-income countries for clin. trials training and research, allowing funders to coordinate several national and regional programs for greatest overall effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqW7RYOzuq_erVg90H21EOLACvtfcHk0ljsJj9V9ovztg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xksl2htbk%253D&md5=601317865b3b3f4581e5b30c7a923c7f</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2816%2900070-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252816%252900070-0%26sid%3Dliteratum%253Aachs%26aulast%3DWallis%26aufirst%3DR.%2BS.%26aulast%3DMaeurer%26aufirst%3DM.%26aulast%3DMwaba%26aufirst%3DP.%26aulast%3DChakaya%26aufirst%3DJ.%26aulast%3DRustomjee%26aufirst%3DR.%26aulast%3DMigliori%26aufirst%3DG.%2BB.%26aulast%3DMarais%26aufirst%3DB.%26aulast%3DSchito%26aufirst%3DM.%26aulast%3DChurchyard%26aufirst%3DG.%26aulast%3DSwaminathan%26aufirst%3DS.%26aulast%3DHoelscher%26aufirst%3DM.%26aulast%3DZumla%26aufirst%3DA.%26atitle%3DTuberculosis--advances%2520in%2520development%2520of%2520new%2520drugs%252C%2520treatment%2520regimens%252C%2520host-directed%2520therapies%252C%2520and%2520biomarkers%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2016%26volume%3D16%26spage%3De34%26epage%3D46%26doi%3D10.1016%2FS1473-3099%2816%2900070-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bloemberg, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stucki, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trauner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borrell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latshang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coscolla, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hömke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulthess, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagneux, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Böttger, E. C.</span></span> <span> </span><span class="NLM_article-title">Acquired resistance to bedaquiline and delamanid in therapy for tuberculosis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>373</i></span>,  <span class="NLM_fpage">1986</span>– <span class="NLM_lpage">1988</span>, <span class="refDoi"> DOI: 10.1056/NEJMc1505196</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1056%2FNEJMc1505196" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=26559594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A280%3ADC%252BC28vhsFShsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=1986-1988&author=G.+V.+Bloembergauthor=P.+M.+Kellerauthor=D.+Stuckiauthor=A.+Traunerauthor=S.+Borrellauthor=T.+Latshangauthor=M.+Coscollaauthor=T.+Rotheauthor=R.+H%C3%B6mkeauthor=C.+Ritterauthor=J.+Feldmannauthor=B.+Schulthessauthor=S.+Gagneuxauthor=E.+C.+B%C3%B6ttger&title=Acquired+resistance+to+bedaquiline+and+delamanid+in+therapy+for+tuberculosis&doi=10.1056%2FNEJMc1505196"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis</span></div><div class="casAuthors">Bloemberg Guido V; Keller Peter M; Stucki David; Stuckia David; Trauner Andrej; Borrell Sonia; Latshang Tsogyal; Coscolla Mireia; Rothe Thomas; Homke Rico; Ritter Claudia; Feldmann Julia; Schulthess Bettina; Gagneux Sebastien; Bottger Erik C</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1986-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Treatment of multidrug-resistant Mycobacterium tuberculosis is a challenge.  This letter describes the emergence of resistance to new therapies, bedaquiline and delamanid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTLIDv4u6-jfsuCWE5mhx1RfW6udTcc2eamPAE3Yg6xRLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28vhsFShsQ%253D%253D&md5=24a5c9caaa21e592d780445e59bda863</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1056%2FNEJMc1505196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMc1505196%26sid%3Dliteratum%253Aachs%26aulast%3DBloemberg%26aufirst%3DG.%2BV.%26aulast%3DKeller%26aufirst%3DP.%2BM.%26aulast%3DStucki%26aufirst%3DD.%26aulast%3DTrauner%26aufirst%3DA.%26aulast%3DBorrell%26aufirst%3DS.%26aulast%3DLatshang%26aufirst%3DT.%26aulast%3DCoscolla%26aufirst%3DM.%26aulast%3DRothe%26aufirst%3DT.%26aulast%3DH%25C3%25B6mke%26aufirst%3DR.%26aulast%3DRitter%26aufirst%3DC.%26aulast%3DFeldmann%26aufirst%3DJ.%26aulast%3DSchulthess%26aufirst%3DB.%26aulast%3DGagneux%26aufirst%3DS.%26aulast%3DB%25C3%25B6ttger%26aufirst%3DE.%2BC.%26atitle%3DAcquired%2520resistance%2520to%2520bedaquiline%2520and%2520delamanid%2520in%2520therapy%2520for%2520tuberculosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26spage%3D1986%26epage%3D1988%26doi%3D10.1056%2FNEJMc1505196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Segala, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sougakoff, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nevejans-Chauffour, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarlier, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrella, S.</span></span> <span> </span><span class="NLM_article-title">New mutations in the mycobacterial atp synthase: New insights into the binding of the diarylquinoline TMC207 to the atp synthase c-ring structure</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">2326</span>– <span class="NLM_lpage">2334</span>, <span class="refDoi"> DOI: 10.1128/AAC.06154-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.06154-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=22354303" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsVKku7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=2326-2334&author=E.+Segalaauthor=W.+Sougakoffauthor=A.+Nevejans-Chauffourauthor=V.+Jarlierauthor=S.+Petrella&title=New+mutations+in+the+mycobacterial+atp+synthase%3A+New+insights+into+the+binding+of+the+diarylquinoline+TMC207+to+the+atp+synthase+c-ring+structure&doi=10.1128%2FAAC.06154-11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">New mutations in the mycobacterial ATP synthase: new insights into the binding of the diarylquinoline TMC207 to the ATP synthase C-ring structure</span></div><div class="casAuthors">Segala, Elena; Sougakoff, Wladimir; Nevejans-Chauffour, Aurelie; Jarlier, Vincent; Petrella, Stephanie</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2326-2334</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">TMC207 is a new antituberculous drug belonging to the diarylquinoline class which very efficiently inhibits the ATP synthase of mycobacteria such as Mycobacterium tuberculosis, one of the most important pathogens in the world.  In order to map the amino acid residues involved in the binding of the drug, we have selected in vitro TMC207-resistant mutants from M. tuberculosis and diverse atypical mycobacteria.  Six distinct mutations, Asp28→Gly, Asp28→Ala, Leu59→Val, Glu61→Asp, Ala63→Pro, and Ile66→Met, have been identified in the subunit c forming a C ring in the ATP synthase.  They were studied by evaluating the levels of resistance that they confer in the selected clones and by using an isogenic complementation system in Mycobacterium smegmatis.  The rates of increase of TMC207 MIC values (8- to 133-fold) were interpreted by constructing by homol. modeling a structure of the mycobacterial C ring which was used for docking simulations with TMC207.  Our results suggest that the residues found to be mutated in the resistant clones, together with a tyrosine specifically conserved at position 64 in mycobacteria, define a cleft located between two adjacent c subunits in the C ring.  This cleft, which encompasses the proton-binding site (Glu61), is well fitted to bind TMC207 at the level of the bromoquinoline moiety, with the drug being anchored by several ionic, hydrogen, and halogen bonds with residues Glu61, Tyr64, and Asp28, resp.  These data shed light on the mol. interactions allowing TMC207 to bind specifically and efficiently at the level of the proton-binding site of the mycobacterial C ring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQYj2k1m5D_7Vg90H21EOLACvtfcHk0ljPNTnB6WGcug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsVKku7o%253D&md5=0496b56930586279c2896a3ba375535f</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1128%2FAAC.06154-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.06154-11%26sid%3Dliteratum%253Aachs%26aulast%3DSegala%26aufirst%3DE.%26aulast%3DSougakoff%26aufirst%3DW.%26aulast%3DNevejans-Chauffour%26aufirst%3DA.%26aulast%3DJarlier%26aufirst%3DV.%26aulast%3DPetrella%26aufirst%3DS.%26atitle%3DNew%2520mutations%2520in%2520the%2520mycobacterial%2520atp%2520synthase%253A%2520New%2520insights%2520into%2520the%2520binding%2520of%2520the%2520diarylquinoline%2520TMC207%2520to%2520the%2520atp%2520synthase%2520c-ring%2520structure%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D2326%26epage%3D2334%26doi%3D10.1128%2FAAC.06154-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yew, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Mycobacterium tuberculosis mutations associated with reduced susceptibility to linezolid</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2542</span>– <span class="NLM_lpage">2544</span>, <span class="refDoi"> DOI: 10.1128/AAC.02941-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.02941-15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=26810645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1egtrvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2016&pages=2542-2544&author=S.+Zhangauthor=J.+Chenauthor=P.+Cuiauthor=W.+Shiauthor=X.+Shiauthor=H.+Niuauthor=D.+Chanauthor=W.+W.+Yewauthor=W.+Zhangauthor=Y.+Zhang&title=Mycobacterium+tuberculosis+mutations+associated+with+reduced+susceptibility+to+linezolid&doi=10.1128%2FAAC.02941-15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Mycobacterium tuberculosis mutations associated with reduced susceptibility to linezolid</span></div><div class="casAuthors">Zhang, Shuo; Chen, Jiazhen; Cui, Peng; Shi, Wanliang; Shi, Xiaohong; Niu, Hongxia; Chan, Denise; Yew, Wing Wai; Zhang, Wenhong; Zhang, Ying</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2542-2544</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Linezolid (LZD) has become increasingly important for the treatment of multidrug-resistant tuberculosis (MDR-TB), but its mechanisms of resistance are not well characterized.  We isolated 32 mutants of Mycobacterium tuberculosis with reduced susceptibility to LZD, which was accounted for by rrl and rplC mutations in almost equal proportions, causing lower and higher MICs, resp.  Our findings provide useful information for the rapid detection of LZD resistance for improved treatment of MDR-TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNlEoDGkb4t7Vg90H21EOLACvtfcHk0ljPNTnB6WGcug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1egtrvI&md5=c9c5155d3af6086adb2d915a7a15f993</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1128%2FAAC.02941-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02941-15%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DCui%26aufirst%3DP.%26aulast%3DShi%26aufirst%3DW.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DNiu%26aufirst%3DH.%26aulast%3DChan%26aufirst%3DD.%26aulast%3DYew%26aufirst%3DW.%2BW.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DMycobacterium%2520tuberculosis%2520mutations%2520associated%2520with%2520reduced%2520susceptibility%2520to%2520linezolid%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2016%26volume%3D60%26spage%3D2542%26epage%3D2544%26doi%3D10.1128%2FAAC.02941-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mukherjee, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boshoff, H.</span></span> <span> </span><span class="NLM_article-title">Nitroimidazoles for the treatment of TB: Past, present and future</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1427</span>– <span class="NLM_lpage">1454</span>, <span class="refDoi"> DOI: 10.4155/fmc.11.90</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.4155%2Ffmc.11.90" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=21879846" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFSktr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=1427-1454&author=T.+Mukherjeeauthor=H.+Boshoff&title=Nitroimidazoles+for+the+treatment+of+TB%3A+Past%2C+present+and+future&doi=10.4155%2Ffmc.11.90"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Nitroimidazoles for the treatment of TB: past, present and future</span></div><div class="casAuthors">Mukherjee, Tathagata; Boshoff, Helena</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1427-1454</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Tuberculosis remains a leading cause of death resulting from an infectious agent, and the spread of multi- and extensively drug-resistant strains of Mycobacterium tuberculosis poses a threat to management of global health.  New drugs that effectively shorten the duration of treatment and are active against drug-resistant strains of this pathogen are urgently required to develop effective chemotherapies to combat this disease.  Two nitroimidazoles, PA-824 and OPC-67683, are currently in Phase II clin. trials for the treatment of TB and the outcome of these may det. the future directions of drug development for anti-tubercular nitroimidazoles.  In this review we summarize the development of these nitroimidazoles and alternative analogs in these series that may offer attractive alternatives to PA-824 and OPC-67683 for further development in the drug-discovery pipeline.  Lastly, the potential pitfalls in the development of nitroimidazoles as drugs for TB are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8GQsibDorcLVg90H21EOLACvtfcHk0lh2GAza3esjXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFSktr%252FN&md5=44739c4906d7b9e1ffeaa76f65acb16c</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.4155%2Ffmc.11.90&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.11.90%26sid%3Dliteratum%253Aachs%26aulast%3DMukherjee%26aufirst%3DT.%26aulast%3DBoshoff%26aufirst%3DH.%26atitle%3DNitroimidazoles%2520for%2520the%2520treatment%2520of%2520TB%253A%2520Past%252C%2520present%2520and%2520future%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2011%26volume%3D3%26spage%3D1427%26epage%3D1454%26doi%3D10.4155%2Ffmc.11.90" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherland, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kmentova, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franzblau, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denny, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A. M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure-activity relationships for extended side chain analogues of the antitubercular drug (6s)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5h-imidazo[2,1-b][1, 3]oxazine (pa-824)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">3036</span>– <span class="NLM_lpage">3059</span>, <span class="refDoi"> DOI: 10.1021/jm501608q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501608q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksVOrtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3036-3059&author=B.+D.+Palmerauthor=H.+S.+Sutherlandauthor=A.+Blaserauthor=I.+Kmentovaauthor=S.+G.+Franzblauauthor=B.+Wanauthor=Y.+Wangauthor=Z.+Maauthor=W.+A.+Dennyauthor=A.+M.+Thompson&title=Synthesis+and+structure-activity+relationships+for+extended+side+chain+analogues+of+the+antitubercular+drug+%286s%29-2-nitro-6-%7B%5B4-%28trifluoromethoxy%29benzyl%5Doxy%7D-6%2C7-dihydro-5h-imidazo%5B2%2C1-b%5D%5B1%2C+3%5Doxazine+%28pa-824%29&doi=10.1021%2Fjm501608q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Structure-Activity Relationships for Extended Side Chain Analogues of the Antitubercular Drug (6S)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)</span></div><div class="casAuthors">Palmer, Brian D.; Sutherland, Hamish S.; Blaser, Adrian; Kmentova, Iveta; Franzblau, Scott G.; Wan, Baojie; Wang, Yuehong; Ma, Zhenkun; Denny, William A.; Thompson, Andrew M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3036-3059</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel extended side chain nitroimidazooxazine analogs featuring diverse linker groups between two aryl rings, e.g., I, were studied as a potential strategy to improve soly. and oral activity against chronic infection by Mycobacterium tuberculosis.  Both lipophilic and highly polar functionalities (e.g., carboxamide, alkylamine, piperazine, piperidine, but not sulfonamide) were well tolerated in vitro, and the hydrophilic linkers provided some soly. improvements, particularly in combination with pyridine rings.  Most of the 18 compds. further assessed showed high microsomal stabilities, although in the acute infection mouse model, just one stilbene (6-fold) and two pyridine-contg. acetylene derivs. (5-fold and >933-fold) gave in vivo efficacies notably superior to the clin. stage compd. pretomanid (PA-824).  The most efficacious analog, I, also displayed outstanding in vivo activity in the stringent chronic model (up to 24-fold better than the drug delamanid and 4-fold greater than our previous best phenylpyridine candidate), with favorable pharmacokinetics, including good oral bioavailability in the rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRBPDGOUW_AbVg90H21EOLACvtfcHk0lh2GAza3esjXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksVOrtrY%253D&md5=2ce7144ac56b5ec156d83a09d4d6af90</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fjm501608q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501608q%26sid%3Dliteratum%253Aachs%26aulast%3DPalmer%26aufirst%3DB.%2BD.%26aulast%3DSutherland%26aufirst%3DH.%2BS.%26aulast%3DBlaser%26aufirst%3DA.%26aulast%3DKmentova%26aufirst%3DI.%26aulast%3DFranzblau%26aufirst%3DS.%2BG.%26aulast%3DWan%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DZ.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DThompson%26aufirst%3DA.%2BM.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationships%2520for%2520extended%2520side%2520chain%2520analogues%2520of%2520the%2520antitubercular%2520drug%2520%25286s%2529-2-nitro-6-%257B%255B4-%2528trifluoromethoxy%2529benzyl%255Doxy%257D-6%252C7-dihydro-5h-imidazo%255B2%252C1-b%255D%255B1%252C%25203%255Doxazine%2520%2528pa-824%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D3036%26epage%3D3059%26doi%3D10.1021%2Fjm501608q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stinson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurepina, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujiwara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawasaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timm, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shashkina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreiswirth, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geiter, L.</span></span> <span> </span><span class="NLM_article-title">MIC of delamanid (OPC-67683) against mycobacterium tuberculosis clinical isolates and a proposed critical concentration</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">3316</span>– <span class="NLM_lpage">3322</span>, <span class="refDoi"> DOI: 10.1128/AAC.03014-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.03014-15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=26976868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1entrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2016&pages=3316-3322&author=K.+Stinsonauthor=N.+Kurepinaauthor=A.+Venterauthor=M.+Fujiwaraauthor=M.+Kawasakiauthor=J.+Timmauthor=E.+Shashkinaauthor=B.+N.+Kreiswirthauthor=Y.+Liuauthor=M.+Matsumotoauthor=L.+Geiter&title=MIC+of+delamanid+%28OPC-67683%29+against+mycobacterium+tuberculosis+clinical+isolates+and+a+proposed+critical+concentration&doi=10.1128%2FAAC.03014-15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">MIC of delamanid (OPC-67683) against Mycobacterium tuberculosis clinical isolates and a proposed critical concentration</span></div><div class="casAuthors">Stinson, Kelly; Kurepina, Natalia; Venter, Amour; Fujiwara, Mamoru; Kawasaki, Masanori; Timm, Juliano; Shashkina, Elena; Kreiswirth, Barry N.; Liu, Yongge; Matsumoto, Makoto; Geiter, Lawrence</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3316-3322</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The increasing global burden of multidrug-resistant tuberculosis (MDR-TB) requires reliable drug susceptibility testing that accurately characterizes susceptibility and resistance of pathogenic bacteria to effectively treat patients with this deadly disease.  Delamanid is an anti-TB agent first approved in the European Union in 2014 for the treatment of pulmonary MDR-TB in adults.  Using the agar proportion method, delamanid MIC was detd. for 460 isolates: 316 from patients enrolled in a phase 2 global clin. trial, 76 from two phase 2 early bactericidal activity trials conducted in South Africa, and 68 isolates obtained outside clin. trials (45 from Japanese patients and 23 from South African patients).  With the exception of two isolates, MICs ranged from 0.001 to 0.05 μg/mL, resulting in an MIC50 of 0.004 μg/mL and an MIC90 of 0.012 μg/mL.  Various degrees of resistance to other anti-TB drugs did not affect the distribution of MICs, nor did origin of isolates from regions/countries other than South Africa.  A crit. concn./breakpoint of 0.2 μg/mL can be used to define susceptible and resistant isolates based on the distribution of MICs and available pharmacokinetic data.  Thus, clin. isolates from delamanid-naive patients with tuberculosis have a very low MIC for delamanid and baseline resistance is rare, demonstrating the potential potency of delamanid and supporting its use in an optimized background treatment regimen for MDR-TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGot2O44cdNSm7Vg90H21EOLACvtfcHk0lh2GAza3esjXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1entrrL&md5=9a69303ff8d63f8aa0e73c8dd5f068cb</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1128%2FAAC.03014-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.03014-15%26sid%3Dliteratum%253Aachs%26aulast%3DStinson%26aufirst%3DK.%26aulast%3DKurepina%26aufirst%3DN.%26aulast%3DVenter%26aufirst%3DA.%26aulast%3DFujiwara%26aufirst%3DM.%26aulast%3DKawasaki%26aufirst%3DM.%26aulast%3DTimm%26aufirst%3DJ.%26aulast%3DShashkina%26aufirst%3DE.%26aulast%3DKreiswirth%26aufirst%3DB.%2BN.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DMatsumoto%26aufirst%3DM.%26aulast%3DGeiter%26aufirst%3DL.%26atitle%3DMIC%2520of%2520delamanid%2520%2528OPC-67683%2529%2520against%2520mycobacterium%2520tuberculosis%2520clinical%2520isolates%2520and%2520a%2520proposed%2520critical%2520concentration%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2016%26volume%3D60%26spage%3D3316%26epage%3D3322%26doi%3D10.1128%2FAAC.03014-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lenaerts, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruppo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marietta, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driscoll, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tompkins, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, I. M.</span></span> <span> </span><span class="NLM_article-title">Preclinical testing of the nitroimidazopyran PA-824 for activity against mycobacterium tuberculosis in a series of in vitro and in vivo models</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">2294</span>– <span class="NLM_lpage">2301</span>, <span class="refDoi"> DOI: 10.1128/AAC.49.6.2294-2301.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.49.6.2294-2301.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=15917524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkvFCgsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2005&pages=2294-2301&author=A.+J.+Lenaertsauthor=V.+Gruppoauthor=K.+S.+Mariettaauthor=C.+M.+Johnsonauthor=D.+K.+Driscollauthor=N.+M.+Tompkinsauthor=J.+D.+Roseauthor=R.+C.+Reynoldsauthor=I.+M.+Orme&title=Preclinical+testing+of+the+nitroimidazopyran+PA-824+for+activity+against+mycobacterium+tuberculosis+in+a+series+of+in+vitro+and+in+vivo+models&doi=10.1128%2FAAC.49.6.2294-2301.2005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models</span></div><div class="casAuthors">Lenaerts, Anne J.; Gruppo, Veronica; Marietta, Karen S.; Johnson, Christine M.; Driscoll, Diane K.; Tompkins, Nicholas M.; Rose, Jerry D.; Reynolds, Robert C.; Orme, Ian M.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2294-2301</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">This study extends earlier reports regarding the in vitro and in vivo efficacies of the nitroimidazopyran PA-824 against M. tuberculosis.  PA-824 was tested in vitro against a broad panel of multidrug-resistant clin. isolates and was found to be highly active against all isolates (MIC <1 μg/mL).  The activity of PA-824 against M. tuberculosis was also assessed grown under conditions of O2 depletion.  PA-824 showed significant activity at 2, 10, and 50 μg/mL, similar to that of metronidazole, in a dose-dependent manner.  In a short-course mouse infection model, the efficacy of PA-824 at 50, 100, and 300 mg/kg of body wt. formulated in methylcellulose or cyclodextrin/lecithin after 9 oral treatments was compared with those of isoniazid, rifampin, and moxifloxacin.  PA-824 at 100 mg/kg in cyclodextrin/lecithin was as active as moxifloxacin at 100 mg/kg and isoniazid at 25 mg/kg and was slightly more active than rifampin at 20 mg/kg.  Long-term treatment with PA-824 at 100 mg/kg in cyclodextrin/lecithin reduced the bacterial load below 500 CFU in the lungs and spleen.  No significant differences in activity between PA-824 and the other single drug treatments tested (isoniazid at 25 mg/kg, rifampin at 10 mg/kg, gatifloxacin at 100 mg/kg, and moxifloxacin at 100 mg/kg) could be obsd.  In summary, its good activity in in vivo models, as well as its activity against multidrug-resistant M. tuberculosis and against M. tuberculosis isolates in a potentially latent state, makes PA-824 an attractive drug candidate for the therapy of tuberculosis.  These data indicate that there is significant potential for effective oral delivery of PA-824 for the treatment of tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm0IFHIxA0KrVg90H21EOLACvtfcHk0lgZ-czcEFjw1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkvFCgsrw%253D&md5=69ac4231bc1270bee6203ee69e955e26</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1128%2FAAC.49.6.2294-2301.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.49.6.2294-2301.2005%26sid%3Dliteratum%253Aachs%26aulast%3DLenaerts%26aufirst%3DA.%2BJ.%26aulast%3DGruppo%26aufirst%3DV.%26aulast%3DMarietta%26aufirst%3DK.%2BS.%26aulast%3DJohnson%26aufirst%3DC.%2BM.%26aulast%3DDriscoll%26aufirst%3DD.%2BK.%26aulast%3DTompkins%26aufirst%3DN.%2BM.%26aulast%3DRose%26aufirst%3DJ.%2BD.%26aulast%3DReynolds%26aufirst%3DR.%2BC.%26aulast%3DOrme%26aufirst%3DI.%2BM.%26atitle%3DPreclinical%2520testing%2520of%2520the%2520nitroimidazopyran%2520PA-824%2520for%2520activity%2520against%2520mycobacterium%2520tuberculosis%2520in%2520a%2520series%2520of%2520in%2520vitro%2520and%2520in%2520vivo%2520models%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2005%26volume%3D49%26spage%3D2294%26epage%3D2301%26doi%3D10.1128%2FAAC.49.6.2294-2301.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashizume, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomishige, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawasaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsubouchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimokawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komatsu, M.</span></span> <span> </span><span class="NLM_article-title">OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice</span>. <i>PLoS Med.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">e466</span>, <span class="refDoi"> DOI: 10.1371/journal.pmed.0030466</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1371%2Fjournal.pmed.0030466" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=17132069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A280%3ADC%252BD28npsFKgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2006&pages=e466&author=M.+Matsumotoauthor=H.+Hashizumeauthor=T.+Tomishigeauthor=M.+Kawasakiauthor=H.+Tsubouchiauthor=H.+Sasakiauthor=Y.+Shimokawaauthor=M.+Komatsu&title=OPC-67683%2C+a+nitro-dihydro-imidazooxazole+derivative+with+promising+action+against+tuberculosis+in+vitro+and+in+mice&doi=10.1371%2Fjournal.pmed.0030466"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice</span></div><div class="casAuthors">Matsumoto Makoto; Hashizume Hiroyuki; Tomishige Tatsuo; Kawasaki Masanori; Tsubouchi Hidetsugu; Sasaki Hirofumi; Shimokawa Yoshihiko; Komatsu Makoto</div><div class="citationInfo"><span class="NLM_cas:title">PLoS medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e466</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Tuberculosis (TB) is still a leading cause of death worldwide.  Almost a third of the world's population is infected with TB bacilli, and each year approximately 8 million people develop active TB and 2 million die as a result.  Today's TB treatment, which dates back to the 1970s, is long and burdensome, requiring at least 6 mo of multidrug chemotherapy.  The situation is further compounded by the emergence of multidrug-resistant TB (MDR-TB) and by the infection's lethal synergy with HIV/AIDS.  Global health and philanthropic organizations are now pleading for new drug interventions that can address these unmet needs in TB treatment.  METHODS AND FINDINGS:  Here we report OPC-67683, a nitro-dihydro-imidazooxazole derivative that was screened to help combat the unmet needs in TB treatment.  The compound is a mycolic acid biosynthesis inhibitor found to be free of mutagenicity and to possess highly potent activity against TB, including MDR-TB, as shown by its exceptionally low minimum inhibitory concentration (MIC) range of 0.006-0.024 microg/ml in vitro and highly effective therapeutic activity at low doses in vivo.  Additionally, the results of the post-antibiotic effect of OPC-67683 on intracellular Mycobacterium tuberculosis showed the agent to be highly and dose-dependently active also against intracellular M. tuberculosis H37Rv after a 4-h pulsed exposure, and this activity at a concentration of 0.1 microg/ml was similar to that of the first-line drug rifampicin (RFP) at a concentration of 3 microg/ml.  The combination of OPC-67683 with RFP and pyrazinamide (PZA) exhibited a remarkably quicker eradication (by at least 2 mo) of viable TB bacilli in the lung in comparison with the standard regimen consisting of RFP, isoniazid (INH), ethambutol (EB), and PZA.  Furthermore, OPC-67683 was not affected by nor did it affect the activity of liver microsome enzymes, suggesting the possibility for OPC-67683 to be used in combination with drugs, including anti-retrovirals, that induce or are metabolized by cytochrome P450 enzymes.  CONCLUSIONS:  We concluded that based on these properties OPC-67683 has the potential to be used as a TB drug to help combat the unmet needs in TB treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRSF0z_BNLNYeRS7coPn-RtfW6udTcc2eaSj3VIwN8vdLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28npsFKgug%253D%253D&md5=8a80560cc653b1c76ff4d47430317d18</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pmed.0030466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pmed.0030466%26sid%3Dliteratum%253Aachs%26aulast%3DMatsumoto%26aufirst%3DM.%26aulast%3DHashizume%26aufirst%3DH.%26aulast%3DTomishige%26aufirst%3DT.%26aulast%3DKawasaki%26aufirst%3DM.%26aulast%3DTsubouchi%26aufirst%3DH.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DShimokawa%26aufirst%3DY.%26aulast%3DKomatsu%26aufirst%3DM.%26atitle%3DOPC-67683%252C%2520a%2520nitro-dihydro-imidazooxazole%2520derivative%2520with%2520promising%2520action%2520against%2520tuberculosis%2520in%2520vitro%2520and%2520in%2520mice%26jtitle%3DPLoS%2520Med.%26date%3D2006%26volume%3D3%26spage%3De466%26doi%3D10.1371%2Fjournal.pmed.0030466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diacon, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanekom, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narunsky, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hittel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geiter, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paccaly, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donald, P. R.</span></span> <span> </span><span class="NLM_article-title">Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients</span>. <i>Int. J. Tuberc Lung Dis</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">949</span>– <span class="NLM_lpage">954</span>, <span class="refDoi"> DOI: 10.5588/ijtld.10.0616</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.5588%2Fijtld.10.0616" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=21682970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A280%3ADC%252BC3Mnhs1KisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2011&pages=949-954&author=A.+H.+Diaconauthor=R.+Dawsonauthor=M.+Hanekomauthor=K.+Narunskyauthor=A.+Venterauthor=N.+Hittelauthor=L.+J.+Geiterauthor=C.+D.+Wellsauthor=A.+J.+Paccalyauthor=P.+R.+Donald&title=Early+bactericidal+activity+of+delamanid+%28OPC-67683%29+in+smear-positive+pulmonary+tuberculosis+patients&doi=10.5588%2Fijtld.10.0616"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients</span></div><div class="casAuthors">Diacon A H; Dawson R; Hanekom M; Narunsky K; Venter A; Hittel N; Geiter L J; Wells C D; Paccaly A J; Donald P R</div><div class="citationInfo"><span class="NLM_cas:title">The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">949-54</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Delamanid (OPC-67683) is a novel mycolic acid biosynthesis inhibitor active against Mycobacterium tuberculosis at a low minimum inhibitory concentration.  METHODS:  Forty-eight patients with smear-positive tuberculosis (63% male; 54.7 ± 9.9 kg; 30.7 ± 10.8 years) were randomly assigned to receive delamanid 100, 200, 300 or 400 mg daily for 14 days.  Colony forming units (cfu) of M. tuberculosis were counted on agar plates from overnight sputum collections to calculate early bactericidal activity (EBA), defined as fall in log(10) cfu/ml sputum/day.  RESULTS:  The EBA of delamanid was monophasic and not significantly different between dosages; however, more patients receiving 200 mg (70%) and 300 mg (80%) experienced a response of ≥0.9 log(10) cfu/ml sputum decline over 14 days than those receiving 100 mg (45%) and 400 mg (27%).  The average EBA of all dosages combined (0.040 ± 0.056 log(10) cfu/ml sputum/day) was significant from day 2 onward.  Delamanid exposure was less than dosage-proportional, reaching a plateau at 300 mg, likely due to dose-limited absorption.  Moderate but significant correlation was found between C(max) and EBA, indicating exposure dependence.  Delamanid was well tolerated without significant toxicity.  CONCLUSIONS:  Delamanid at all dosages was safe, well tolerated and demonstrated significant exposure-dependent EBA over 14 days, supporting further investigation of its pharmacokinetics and anti-tuberculosis activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRTDc03ThD2G0h5eUSa2oe_fW6udTcc2eYdbEuPV01nJbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3Mnhs1KisQ%253D%253D&md5=63848ed5b6c4f8c5f089a0e257efc02b</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.5588%2Fijtld.10.0616&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5588%252Fijtld.10.0616%26sid%3Dliteratum%253Aachs%26aulast%3DDiacon%26aufirst%3DA.%2BH.%26aulast%3DDawson%26aufirst%3DR.%26aulast%3DHanekom%26aufirst%3DM.%26aulast%3DNarunsky%26aufirst%3DK.%26aulast%3DVenter%26aufirst%3DA.%26aulast%3DHittel%26aufirst%3DN.%26aulast%3DGeiter%26aufirst%3DL.%2BJ.%26aulast%3DWells%26aufirst%3DC.%2BD.%26aulast%3DPaccaly%26aufirst%3DA.%2BJ.%26aulast%3DDonald%26aufirst%3DP.%2BR.%26atitle%3DEarly%2520bactericidal%2520activity%2520of%2520delamanid%2520%2528OPC-67683%2529%2520in%2520smear-positive%2520pulmonary%2520tuberculosis%2520patients%26jtitle%3DInt.%2520J.%2520Tuberc%2520Lung%2520Dis%26date%3D2011%26volume%3D15%26spage%3D949%26epage%3D954%26doi%3D10.5588%2Fijtld.10.0616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gler, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skripconoka, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Garavito, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabrera-Rivero, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vargas-Vasquez, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shim, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, G. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danilovits, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogata, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurve, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tupasi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koh, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seaworth, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geiter, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C. D.</span></span> <span> </span><span class="NLM_article-title">Delamanid for multidrug-resistant pulmonary tuberculosis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>366</i></span>,  <span class="NLM_fpage">2151</span>– <span class="NLM_lpage">2160</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1112433</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1056%2FNEJMoa1112433" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=22670901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38XovVSisr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=2151-2160&author=M.+T.+Glerauthor=V.+Skripconokaauthor=E.+Sanchez-Garavitoauthor=H.+Xiaoauthor=J.+L.+Cabrera-Riveroauthor=D.+E.+Vargas-Vasquezauthor=M.+Gaoauthor=M.+Awadauthor=S.+K.+Parkauthor=T.+S.+Shimauthor=G.+Y.+Suhauthor=M.+Danilovitsauthor=H.+Ogataauthor=A.+Kurveauthor=J.+Changauthor=K.+Suzukiauthor=T.+Tupasiauthor=W.+J.+Kohauthor=B.+Seaworthauthor=L.+J.+Geiterauthor=C.+D.+Wells&title=Delamanid+for+multidrug-resistant+pulmonary+tuberculosis&doi=10.1056%2FNEJMoa1112433"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Delamanid for multidrug-resistant pulmonary tuberculosis</span></div><div class="casAuthors">Gler, Maria Tarcela; Skripconoka, Vija; Sanchez-Garavito, Epifanio; Xiao, Heping; Cabrera-Rivero, Jose L.; Vargas-Vasquez, Dante E.; Gao, Mengqiu; Awad, Mohamed; Park, Seung-Kyu; Shim, Tae Sun; Suh, Gee Young; Danilovits, Manfred; Ogata, Hideo; Kurve, Anu; Chang, Joon; Suzuki, Katsuhiro; Tupasi, Thelma; Koh, Won-Jung; Seaworth, Barbara; Geiter, Lawrence J.; Wells, Charles D.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2151-2160</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Delamanid (OPC-67683), a nitro-dihydro-imidazooxazole deriv., is a new antituberculosis medication that inhibits mycolic acid synthesis and has shown potent in vitro and in vivo activity against drug-resistant strains of Mycobacterium tuberculosis.  In this randomized, placebo-controlled, multinational clin. trial, we assigned 481 patients (nearly all of whom were neg. for the human immunodeficiency virus) with pulmonary multidrug-resistant tuberculosis to receive delamanid, at a dose of 100 mg twice daily (161 patients) or 200 mg twice daily (160 patients), or placebo (160 patients) for 2 mo in combination with a background drug regimen developed according to World Health Organization guidelines.  Sputum cultures were as- sessed weekly with the use of both liq. broth and solid medium; sputum-culture conversion was defined as a series of 5 or more consecutive cultures that were neg. for growth of M. tuberculosis.  The primary efficacy end point was the proportion of patients with sputum-culture conversion in liq. broth medium at 2 mo.  Among patients who received a background drug regimen plus 100 mg of delamanid twice daily, 45.40/% had sputum-culture conversion in liq. broth at 2 mo, as compared with 29.6% of patients who received a background drug regimen plus placebo (P = 0.008).  Likewise, as compared with the placebo group, the group that received the background drug regimen plus 200 mg of delamanid twice daily had a higher proportion of patients with sputum-culture conversion (41.9%, P = 0.04).  The findings were similar with assessment of sputum-culture conversion in solid medium.  Most adverse events were mild to moderate in severity and were evenly distributed across groups.  Although no clin. events due to QT prolongation on electrocardiog. were obsd., QT prolongation was reported significantly more frequently in the groups that received delamanid.  Delamanid was assocd. with an increase in sputum-culture conversion at 2 mo among patients with multidrug-resistant tuberculosis.  This finding suggests that delamanid could enhance treatment options for multidrug-resistant tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaZFfjOeFeQ7Vg90H21EOLACvtfcHk0lgEqt8AF4UZLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovVSisr4%253D&md5=5a2edf0b004340d589d1bf047430f9bb</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1112433&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1112433%26sid%3Dliteratum%253Aachs%26aulast%3DGler%26aufirst%3DM.%2BT.%26aulast%3DSkripconoka%26aufirst%3DV.%26aulast%3DSanchez-Garavito%26aufirst%3DE.%26aulast%3DXiao%26aufirst%3DH.%26aulast%3DCabrera-Rivero%26aufirst%3DJ.%2BL.%26aulast%3DVargas-Vasquez%26aufirst%3DD.%2BE.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DAwad%26aufirst%3DM.%26aulast%3DPark%26aufirst%3DS.%2BK.%26aulast%3DShim%26aufirst%3DT.%2BS.%26aulast%3DSuh%26aufirst%3DG.%2BY.%26aulast%3DDanilovits%26aufirst%3DM.%26aulast%3DOgata%26aufirst%3DH.%26aulast%3DKurve%26aufirst%3DA.%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DSuzuki%26aufirst%3DK.%26aulast%3DTupasi%26aufirst%3DT.%26aulast%3DKoh%26aufirst%3DW.%2BJ.%26aulast%3DSeaworth%26aufirst%3DB.%26aulast%3DGeiter%26aufirst%3DL.%2BJ.%26aulast%3DWells%26aufirst%3DC.%2BD.%26atitle%3DDelamanid%2520for%2520multidrug-resistant%2520pulmonary%2520tuberculosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26spage%3D2151%26epage%3D2160%26doi%3D10.1056%2FNEJMoa1112433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skripconoka, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danilovits, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pehme, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skenders, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kummik, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirule, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leimane, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurve, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levina, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geiter, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manissero, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C. D.</span></span> <span> </span><span class="NLM_article-title">Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">1393</span>– <span class="NLM_lpage">1400</span>, <span class="refDoi"> DOI: 10.1183/09031936.00125812</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1183%2F09031936.00125812" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=23018916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A280%3ADC%252BC3s%252Fgsl2ltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2013&pages=1393-1400&author=V.+Skripconokaauthor=M.+Danilovitsauthor=L.+Pehmeauthor=T.+Tomsonauthor=G.+Skendersauthor=T.+Kummikauthor=A.+Ciruleauthor=V.+Leimaneauthor=A.+Kurveauthor=K.+Levinaauthor=L.+J.+Geiterauthor=D.+Manisseroauthor=C.+D.+Wells&title=Delamanid+improves+outcomes+and+reduces+mortality+in+multidrug-resistant+tuberculosis&doi=10.1183%2F09031936.00125812"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis</span></div><div class="casAuthors">Skripconoka Vija; Danilovits Manfred; Pehme Lea; Tomson Tarmo; Skenders Girts; Kummik Tiina; Cirule Andra; Leimane Vaira; Kurve Anu; Levina Klavdia; Geiter Lawrence J; Manissero Davide; Wells Charles D</div><div class="citationInfo"><span class="NLM_cas:title">The European respiratory journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1393-400</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Multidrug-resistant and extensively drug-resistant tuberculosis (TB) are associated with worse treatment outcomes for patients, including higher mortality, than for drug-sensitive tuberculosis.  Delamanid (OPC-67683) is a novel anti-TB medication with demonstrated activity against multidrug-resistant disease.  Patients who participated in the previously reported randomised, placebo-controlled trial of delamanid and the subsequent open-label extension trial were eligible to participate in a 24-month observational study designed to capture treatment outcomes.  Treatment outcomes, as assessed by clinicians and defined by the World Health Organization, were categorised as favourable and unfavourable.  Delamanid treatment groups were combined for analysis, based on their duration of treatment.  In total, for 421 (87.5%) out of 481 patients from the original randomised controlled trial, consent was granted for follow-up assessments.  Favourable outcomes were observed in 143 (74.5%) out of 192 patients who received delamanid for ≥6 months, compared to 126 (55%) out of 229 patients who received delamanid for ≤2 months.  Mortality was reduced to 1.0% among those receiving long-term delamanid versus short-term/no delamanid (8.3%; p<0.001).  Treatment benefit was also seen among patients with extensively drug-resistant TB.  This analysis suggests that treatment with delamanid for 6 months in combination with an optimised background regimen can improve outcomes and reduce mortality among patients with both multidrug-resistant and extensively drug-resistant TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ2JcitGJjjkMNIRw0GKUoEfW6udTcc2eYdbEuPV01nJbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s%252Fgsl2ltw%253D%253D&md5=63c616aef7dfd5858d274fe1a74ab290</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1183%2F09031936.00125812&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00125812%26sid%3Dliteratum%253Aachs%26aulast%3DSkripconoka%26aufirst%3DV.%26aulast%3DDanilovits%26aufirst%3DM.%26aulast%3DPehme%26aufirst%3DL.%26aulast%3DTomson%26aufirst%3DT.%26aulast%3DSkenders%26aufirst%3DG.%26aulast%3DKummik%26aufirst%3DT.%26aulast%3DCirule%26aufirst%3DA.%26aulast%3DLeimane%26aufirst%3DV.%26aulast%3DKurve%26aufirst%3DA.%26aulast%3DLevina%26aufirst%3DK.%26aulast%3DGeiter%26aufirst%3DL.%2BJ.%26aulast%3DManissero%26aufirst%3DD.%26aulast%3DWells%26aufirst%3DC.%2BD.%26atitle%3DDelamanid%2520improves%2520outcomes%2520and%2520reduces%2520mortality%2520in%2520multidrug-resistant%2520tuberculosis%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2013%26volume%3D41%26spage%3D1393%26epage%3D1400%26doi%3D10.1183%2F09031936.00125812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ginsberg, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurenzi, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouse, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitney, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spigelman, M. K.</span></span> <span> </span><span class="NLM_article-title">Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">3720</span>– <span class="NLM_lpage">3725</span>, <span class="refDoi"> DOI: 10.1128/AAC.00106-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.00106-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=19528280" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFCjsr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2009&pages=3720-3725&author=A.+M.+Ginsbergauthor=M.+W.+Laurenziauthor=D.+J.+Rouseauthor=K.+D.+Whitneyauthor=M.+K.+Spigelman&title=Safety%2C+tolerability%2C+and+pharmacokinetics+of+PA-824+in+healthy+subjects&doi=10.1128%2FAAC.00106-09"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects</span></div><div class="casAuthors">Ginsberg, Ann M.; Laurenzi, Martino W.; Rouse, Doris J.; Whitney, Karl D.; Spigelman, Melvin K.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3720-3725</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">PA-824 is a novel antibacterial agent that has shown in vitro activity against both drug-sensitive and drug-resistant Mycobacterium tuberculosis.  The compd.'s MIC is between 0.015 and 0.25 μg/mL for drug-sensitive strains and between 0.03 and 0.53 μg/mL for drug-resistant strains.  In addn., it is active against nonreplicating anaerobic Mycobacterium tuberculosis.  The safety, tolerability, and pharmacokinetics of PA-824 were evaluated in two escalating-dose clin. studies, one a single-dose study and the other a multiple-dose study (up to 7 days of daily dosing).  In 58 healthy subjects dosed with PA-824 in these studies, the drug candidate was well tolerated, with no significant or serious adverse events.  In both studies, following oral administration PA-824 reached maximal plasma levels in 4 to 5 h independently of the dose.  Maximal blood levels averaged approx. 3 μg/mL (1,500-mg dose) in the single-dose study and 3.8 μg/mL (600-mg dose) in the multiple-dose study.  Steady state was achieved after 5 to 6 days of daily dosing, with an accumulation ratio of approx. 2.  The elimination half-life averaged 16 to 20 h.  Overall, PA-824 was well tolerated following oral doses once daily for up to 7 days, and pharmacokinetic parameters were consistent with a once-a-day regimen.  The results of these studies, combined with the demonstrated activity of PA-824 against drug-sensitive and multidrug-resistant Mycobacterium tuberculosis, support the investigation of this novel compd. for the treatment of tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqOz72SCeRarVg90H21EOLACvtfcHk0lj11JXUYobICw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFCjsr7E&md5=b1a66b6df94526f21a3873747ad54487</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1128%2FAAC.00106-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00106-09%26sid%3Dliteratum%253Aachs%26aulast%3DGinsberg%26aufirst%3DA.%2BM.%26aulast%3DLaurenzi%26aufirst%3DM.%2BW.%26aulast%3DRouse%26aufirst%3DD.%2BJ.%26aulast%3DWhitney%26aufirst%3DK.%2BD.%26aulast%3DSpigelman%26aufirst%3DM.%2BK.%26atitle%3DSafety%252C%2520tolerability%252C%2520and%2520pharmacokinetics%2520of%2520PA-824%2520in%2520healthy%2520subjects%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2009%26volume%3D53%26spage%3D3720%26epage%3D3725%26doi%3D10.1128%2FAAC.00106-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ginsberg, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurenzi, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouse, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitney, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spigelman, M. K.</span></span> <span> </span><span class="NLM_article-title">Assessment of the effects of the nitroimidazo-oxazine PA-824 on renal function in healthy subjects</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">3726</span>– <span class="NLM_lpage">3733</span>, <span class="refDoi"> DOI: 10.1128/AAC.00112-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.00112-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=19528286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFCjsr7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2009&pages=3726-3733&author=A.+M.+Ginsbergauthor=M.+W.+Laurenziauthor=D.+J.+Rouseauthor=K.+D.+Whitneyauthor=M.+K.+Spigelman&title=Assessment+of+the+effects+of+the+nitroimidazo-oxazine+PA-824+on+renal+function+in+healthy+subjects&doi=10.1128%2FAAC.00112-09"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Assessment of the effects of the nitroimidazo-oxazine PA-824 on renal function in healthy subjects</span></div><div class="casAuthors">Ginsberg, Ann M.; Laurenzi, Martino W.; Rouse, Doris J.; Whitney, Karl D.; Spigelman, Mel K.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3726-3733</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The mechanism underlying a dose-dependent, reversible increase in serum creatinine (SC) caused by the administration of PA-824, a novel nitroimidazo-oxazine, was evaluated in 47 healthy male and female volunteers.  Subjects were administered either 800 or 1,000 mg PA-824 or matching placebo once daily for 8 days.  The following renal function parameters were detd. before and during dosing and after a 7-day washout: SC, glomerular filtration rate (GFR; measured as the iohexol clearance), effective renal plasma flow (ERPF; measured as the para-amino hippurate clearance), filtration fraction (FF), creatinine clearance (CrCl), extraglomerular creatinine excretion (EGCE; defined as CrCl minus GFR), blood urea nitrogen (BUN), and uric acid (UA) levels.  Eight days' administration of 800 or 1,000 mg PA-824 was assocd. with increased SC and a trend toward decreased CrCl and EGCE.  SC, CrCl, and EGCE values returned to normal/baseline within 1 wk's washout.  GFR, ERPF, FF, BUN, and UA values were similar across groups during treatment and washout.  The reversible increase in SC obsd. in this and earlier trials of PA-824, thus, did not appear to be the result of a pathol. effect on renal function (as measured by GFR, ERPF, FF, BUN, or UA).  Pharmacokinetic analyses confirmed that PA-824 exposures were similar to those in previous healthy-volunteer clin. studies.  That EGCE declined maximally when drug levels were highest suggests that PA-824 causes creatinine levels to rise by inhibiting renal tubular creatinine secretion.  Such an effect, considered clin. benign, has been described for several marketed drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGps3TtHUhGEmbVg90H21EOLACvtfcHk0lj11JXUYobICw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFCjsr7F&md5=810576f2b77f1ffe8e9235eee612fcac</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1128%2FAAC.00112-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00112-09%26sid%3Dliteratum%253Aachs%26aulast%3DGinsberg%26aufirst%3DA.%2BM.%26aulast%3DLaurenzi%26aufirst%3DM.%2BW.%26aulast%3DRouse%26aufirst%3DD.%2BJ.%26aulast%3DWhitney%26aufirst%3DK.%2BD.%26aulast%3DSpigelman%26aufirst%3DM.%2BK.%26atitle%3DAssessment%2520of%2520the%2520effects%2520of%2520the%2520nitroimidazo-oxazine%2520PA-824%2520on%2520renal%2520function%2520in%2520healthy%2520subjects%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2009%26volume%3D53%26spage%3D3726%26epage%3D3733%26doi%3D10.1128%2FAAC.00112-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diacon, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanekom, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narunsky, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maritz, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donald, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Niekerk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitney, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouse, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurenzi, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginsberg, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spigelman, M. K.</span></span> <span> </span><span class="NLM_article-title">Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">3402</span>– <span class="NLM_lpage">3407</span>, <span class="refDoi"> DOI: 10.1128/AAC.01354-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.01354-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=20498324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVOmsL%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2010&pages=3402-3407&author=A.+H.+Diaconauthor=R.+Dawsonauthor=M.+Hanekomauthor=K.+Narunskyauthor=S.+J.+Maritzauthor=A.+Venterauthor=P.+R.+Donaldauthor=C.+van+Niekerkauthor=K.+Whitneyauthor=D.+J.+Rouseauthor=M.+W.+Laurenziauthor=A.+M.+Ginsbergauthor=M.+K.+Spigelman&title=Early+bactericidal+activity+and+pharmacokinetics+of+PA-824+in+smear-positive+tuberculosis+patients&doi=10.1128%2FAAC.01354-09"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients</span></div><div class="casAuthors">Diacon, Andreas H.; Dawson, Rodney; Hanekom, Madeleine; Narunsky, Kim; Maritz, Stefan J.; Venter, Amour; Donald, Peter R.; van Niekerk, Christo; Whitney, Karl; Rouse, Doris J.; Laurenzi, Martino W.; Ginsberg, Ann M.; Spigelman, Melvin K.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3402-3407</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">PA-824 is a novel nitroimidazo-oxazine being evaluated for its potential to improve tuberculosis (TB) therapy.  This randomized study evaluated safety, tolerability, pharmacokinetics, and extended early bactericidal activity of PA-824 in drug-sensitive, sputum smear-pos., adult pulmonary tuberculosis patients.  Fifteen patients per cohort received 1 of 4 doses of oral PA-824: 200, 600, 1,000, or 1,200 mg per day for 14 days.  Eight subjects received once daily std. antituberculosis treatment as pos. control.  The primary efficacy endpoint was the mean rate of change in log CFU of Mycobacterium tuberculosis in sputum incubated on agar plates from serial overnight sputum collections, expressed as log10 CFU/day/mL (± std. deviation [SD]).  The drug demonstrated increases that were dose linear but less than dose proportional in serum concns. in doses from 200 to 1,000 mg daily.  Dosing of 1,200 mg gave no addnl. exposure compared to 1,000 mg daily.  The mean daily CFU fall under std. treatment was 0.148 (±0.055), consistent with that found in previous studies.  The mean daily fall under PA-824 was 0.098 (±0.072) and was equiv. for all four dosages.  PA-824 appeared safe and well tolerated; the incidence of adverse events potentially related to PA-824 appeared dose related.  We conclude that PA-824 demonstrated bactericidal activity over the dose range of 200 to 1,200 mg daily over 14 days.  Because max. efficacy was unexpectedly achieved at the lowest dosage tested, the activity of lower dosages should now be explored.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBHw5siQAbFbVg90H21EOLACvtfcHk0lj11JXUYobICw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVOmsL%252FM&md5=63a362b7dccb7ad7b5a7177ab81aecc6</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1128%2FAAC.01354-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01354-09%26sid%3Dliteratum%253Aachs%26aulast%3DDiacon%26aufirst%3DA.%2BH.%26aulast%3DDawson%26aufirst%3DR.%26aulast%3DHanekom%26aufirst%3DM.%26aulast%3DNarunsky%26aufirst%3DK.%26aulast%3DMaritz%26aufirst%3DS.%2BJ.%26aulast%3DVenter%26aufirst%3DA.%26aulast%3DDonald%26aufirst%3DP.%2BR.%26aulast%3Dvan%2BNiekerk%26aufirst%3DC.%26aulast%3DWhitney%26aufirst%3DK.%26aulast%3DRouse%26aufirst%3DD.%2BJ.%26aulast%3DLaurenzi%26aufirst%3DM.%2BW.%26aulast%3DGinsberg%26aufirst%3DA.%2BM.%26aulast%3DSpigelman%26aufirst%3DM.%2BK.%26atitle%3DEarly%2520bactericidal%2520activity%2520and%2520pharmacokinetics%2520of%2520PA-824%2520in%2520smear-positive%2520tuberculosis%2520patients%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2010%26volume%3D54%26spage%3D3402%26epage%3D3407%26doi%3D10.1128%2FAAC.01354-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diacon, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">du Bois, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narunsky, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donald, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Niekerk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erondu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginsberg, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spigelman, M. K.</span></span> <span> </span><span class="NLM_article-title">Phase ii dose-ranging trial of the early bactericidal activity of PA-824</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">3027</span>– <span class="NLM_lpage">3031</span>, <span class="refDoi"> DOI: 10.1128/AAC.06125-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.06125-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=22430968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38XnslWrtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=3027-3031&author=A.+H.+Diaconauthor=R.+Dawsonauthor=J.+du+Boisauthor=K.+Narunskyauthor=A.+Venterauthor=P.+R.+Donaldauthor=C.+van+Niekerkauthor=N.+Eronduauthor=A.+M.+Ginsbergauthor=P.+Beckerauthor=M.+K.+Spigelman&title=Phase+ii+dose-ranging+trial+of+the+early+bactericidal+activity+of+PA-824&doi=10.1128%2FAAC.06125-11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II dose-ranging trial of the early bactericidal activity of PA-824</span></div><div class="casAuthors">Diacon, Andreas H.; Dawson, Rodney; du Bois, Jeannine; Narunsky, Kim; Venter, Amour; Donald, Peter R.; van Niekerk, Christo; Erondu, Ngozi; Ginsberg, Ann M.; Becker, Piet; Spigelman, Melvin K.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3027-3031</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">PA-824 is a novel nitroimidazo-oxazine under evaluation as an antituberculosis agent.  A dose-ranging randomized study was conducted to evaluate the safety, tolerability, pharmacokinetics, and early bactericidal activity of PA-824 in drug-sensitive, sputum smear-pos. adult pulmonary-tuberculosis patients to find the lowest dose giving optimal bactericidal activity (EBA).  Fifteen patients per cohort received oral PA-824 in doses of 50 mg, 100 mg, 150 mg, or 200 mg per kg body wt. per day for 14 days.  Eight subjects received once-daily std. antituberculosis treatment with isoniazid, rifampin, pyrazinamide, and ethambutol (HRZE) as a pos. control.  The primary efficacy endpoint was the mean rate of decline in log CFU of Mycobacterium tuberculosis in sputum incubated on agar plates from serial overnight sputum collections, expressed as log10 CFU/day/mL sputum (± std. deviation).  The mean 14-day EBA of HRZE was consistent with previous studies (0.177 ± 0.042), and that of PA-824 at 50 mg, 100 mg, 150 mg, and 200 mg was 0.063 ± 0.058, 0.091 ± 0.073, 0.078 ± 0.074, and 0.112 ± 0.070, resp.  Although the study was not powered for testing the difference between arms, there was a trend toward significance, indicating a lower EBA at the 50-mg dose.  Serum PA-824 levels were approx. dose proportional with respect to the area under the time-concn. curve.  All doses were safe and well tolerated with no dose-limiting adverse events or clin. significant QTc changes.  A dose of 100 mg to 200 mg PA-824 daily appears to be safe and efficacious and will be further evaluated as a component of novel antituberculosis regimens for drug-sensitive and drug-resistant tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVNhRHi7F0urVg90H21EOLACvtfcHk0lg00oMBf0aP7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnslWrtrk%253D&md5=5ab64eb6bc8d02e4e7b1bb6d9d112920</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1128%2FAAC.06125-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.06125-11%26sid%3Dliteratum%253Aachs%26aulast%3DDiacon%26aufirst%3DA.%2BH.%26aulast%3DDawson%26aufirst%3DR.%26aulast%3Ddu%2BBois%26aufirst%3DJ.%26aulast%3DNarunsky%26aufirst%3DK.%26aulast%3DVenter%26aufirst%3DA.%26aulast%3DDonald%26aufirst%3DP.%2BR.%26aulast%3Dvan%2BNiekerk%26aufirst%3DC.%26aulast%3DErondu%26aufirst%3DN.%26aulast%3DGinsberg%26aufirst%3DA.%2BM.%26aulast%3DBecker%26aufirst%3DP.%26aulast%3DSpigelman%26aufirst%3DM.%2BK.%26atitle%3DPhase%2520ii%2520dose-ranging%2520trial%2520of%2520the%2520early%2520bactericidal%2520activity%2520of%2520PA-824%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D3027%26epage%3D3031%26doi%3D10.1128%2FAAC.06125-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diacon, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Groote-Bidlingmaier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symons, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donald, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Niekerk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everitt, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendel, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spigelman, M. K.</span></span> <span> </span><span class="NLM_article-title">14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: A randomised trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>380</i></span>,  <span class="NLM_fpage">986</span>– <span class="NLM_lpage">993</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(12)61080-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2FS0140-6736%2812%2961080-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=22828481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVykt7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2012&pages=986-993&author=A.+H.+Diaconauthor=R.+Dawsonauthor=F.+von+Groote-Bidlingmaierauthor=G.+Symonsauthor=A.+Venterauthor=P.+R.+Donaldauthor=C.+van+Niekerkauthor=D.+Everittauthor=H.+Winterauthor=P.+Beckerauthor=C.+M.+Mendelauthor=M.+K.+Spigelman&title=14-day+bactericidal+activity+of+PA-824%2C+bedaquiline%2C+pyrazinamide%2C+and+moxifloxacin+combinations%3A+A+randomised+trial&doi=10.1016%2FS0140-6736%2812%2961080-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial</span></div><div class="casAuthors">Diacon, Andreas H.; Dawson, Rodney; von Groote-Bidlingmaier, Florian; Symons, Gregory; Venter, Amour; Donald, Peter R.; van Niekerk, Christo; Everitt, Daniel; Winter, Helen; Becker, Piet; Mendel, Carl M.; Spigelman, Melvin K.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">380</span>
        (<span class="NLM_cas:issue">9846</span>),
    <span class="NLM_cas:pages">986-993</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">New drugs, but also shorter, better-tolerated regimens are needed to tackle the high global burden of tuberculosis complicated by drug resistance and retroviral disease.  We investigated new multiple-agent combinations over the first 14 days of treatment to assess their suitability for future development.In this prospective, randomised, early bactericidal activity (EBA) study, treatment-naive, drug-susceptible patients with uncomplicated pulmonary tuberculosis were admitted to hospitals in Cape Town, South Africa, between Oct 7, 2010, and Aug 19, 2011.  Patients were randomised centrally by computer-generated randomisation sequence to receive bedaquiline, bedaquiline-pyrazinamide, PA-824-pyrazinamide, bedaquiline-PA-824, PA-824-moxifloxacin-pyrazinamide, or unmasked std. antituberculosis treatment as pos. control.  The primary outcome was the 14-day EBA assessed in a central lab. from the daily fall in colony forming units (CFU) of M tuberculosis per mL of sputum in daily overnight sputum collections.  Bilinear regression curves were fitted for each group sep. and groups compared with ANOVA for ranks, followed by pair-wise comparisons adjusted for multiplicity.  Clin. staff were partially masked but lab. personnel were fully masked.  This study is registered, NCT01215851.The mean 14-day EBA of PA-824-moxifloxacin-pyrazinamide (n=13; 0·233 [SD 0·128]) was significantly higher than that of bedaquiline (14; 0·061 [0·068]), bedaquiline-pyrazinamide (15; 0·131 [0·102]), bedaquiline-PA-824 (14; 0·114 [0·050]), but not PA-824-pyrazinamide (14; 0·154 [0·040]), and comparable with that of std. treatment (ten; 0·140 [0·094]).  Treatments were well tolerated and appeared safe.  One patient on PA-824-moxifloxacin-pyrazinamide was withdrawn because of cor. QT interval changes exceeding criteria prespecified in the protocol.PA-824-moxifloxacin-pyrazinamide is potentially suitable for treating drug-sensitive and multidrug-resistant tuberculosis.  Multiagent EBA studies can contribute to reducing the time needed to develop new antituberculosis regimens.The Global Alliance for TB Drug Development (TB Alliance).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq84xfW4g0r6LVg90H21EOLACvtfcHk0lg00oMBf0aP7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVykt7bM&md5=4b387bb7346fff813e692518e073619c</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2812%2961080-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252812%252961080-0%26sid%3Dliteratum%253Aachs%26aulast%3DDiacon%26aufirst%3DA.%2BH.%26aulast%3DDawson%26aufirst%3DR.%26aulast%3Dvon%2BGroote-Bidlingmaier%26aufirst%3DF.%26aulast%3DSymons%26aufirst%3DG.%26aulast%3DVenter%26aufirst%3DA.%26aulast%3DDonald%26aufirst%3DP.%2BR.%26aulast%3Dvan%2BNiekerk%26aufirst%3DC.%26aulast%3DEveritt%26aufirst%3DD.%26aulast%3DWinter%26aufirst%3DH.%26aulast%3DBecker%26aufirst%3DP.%26aulast%3DMendel%26aufirst%3DC.%2BM.%26aulast%3DSpigelman%26aufirst%3DM.%2BK.%26atitle%3D14-day%2520bactericidal%2520activity%2520of%2520PA-824%252C%2520bedaquiline%252C%2520pyrazinamide%252C%2520and%2520moxifloxacin%2520combinations%253A%2520A%2520randomised%2520trial%26jtitle%3DLancet%26date%3D2012%26volume%3D380%26spage%3D986%26epage%3D993%26doi%3D10.1016%2FS0140-6736%2812%2961080-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winter, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egizi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erondu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginsberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouse, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Severynse-Stevens, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everitt, D.</span></span> <span> </span><span class="NLM_article-title">Evaluation of pharmacokinetic interaction between PA-824 and midazolam in healthy adult subjects</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3699</span>– <span class="NLM_lpage">3703</span>, <span class="refDoi"> DOI: 10.1128/AAC.02632-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.02632-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=23689718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Wgtb3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2013&pages=3699-3703&author=H.+Winterauthor=E.+Egiziauthor=N.+Eronduauthor=A.+Ginsbergauthor=D.+J.+Rouseauthor=D.+Severynse-Stevensauthor=E.+Pauliauthor=D.+Everitt&title=Evaluation+of+pharmacokinetic+interaction+between+PA-824+and+midazolam+in+healthy+adult+subjects&doi=10.1128%2FAAC.02632-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of pharmacokinetic interaction between PA-824 and midazolam in healthy adult subjects</span></div><div class="casAuthors">Winter, Helen; Egizi, Erica; Erondu, Ngozi; Ginsberg, Ann; Rouse, Doris J.; Severynse-Stevens, Diana; Pauli, Elliott; Everitt, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3699-3703</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">This study assessed the safety, tolerability, and pharmacokinetic interaction between PA-824, a novel antitubercular nitroimidazo-oxazine, and midazolam, a CYP3A4 substrate, in 14 healthy adult male and female subjects.  The study followed up on observations in vitro that PA-824 caused weak and time-dependent inhibition of CYP3A4.  Subjects received a single oral dose of midazolam (2 mg), followed by a 2-day washout.  After the washout, all subjects received PA-824 (400 mg) once daily for 14 consecutive days.  On day 14, all subjects received the final PA-824 dose coadministered with a 2-mg oral dose of midazolam.  The pharmacokinetic endpoints AUC0-t, AUC0-∞, and Cmax for midazolam and 1-hydroxy midazolam were compared between midazolam administered alone vs. midazolam coadministered with PA-824.  Statistical anal. demonstrated that the mean midazolam values of Cmax, AUC0-t, and AUC0-∞ parameters were reduced by ca. 16, 15, and 15%, resp., when PA-824 was coadministered with midazolam.  The total exposure (AUC) of 1-hydroxy midazolam was 13 to 14% greater when coadministered with PA-824 compared to midazolam administered alone.  The Cmax of 1-hydroxy midazolam was similar between treatments.  Based on these results, PA-824 does not inhibit or induce CYP3A4 to a clin. meaningful extent and is not likely to markedly affect the pharmacokinetics of CYP3A4 metabolized drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYL4vjAgGRCrVg90H21EOLACvtfcHk0liFS5AC2Isfgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Wgtb3L&md5=596e43ace93fca069a3d53ac661ab352</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1128%2FAAC.02632-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02632-12%26sid%3Dliteratum%253Aachs%26aulast%3DWinter%26aufirst%3DH.%26aulast%3DEgizi%26aufirst%3DE.%26aulast%3DErondu%26aufirst%3DN.%26aulast%3DGinsberg%26aufirst%3DA.%26aulast%3DRouse%26aufirst%3DD.%2BJ.%26aulast%3DSeverynse-Stevens%26aufirst%3DD.%26aulast%3DPauli%26aufirst%3DE.%26aulast%3DEveritt%26aufirst%3DD.%26atitle%3DEvaluation%2520of%2520pharmacokinetic%2520interaction%2520between%2520PA-824%2520and%2520midazolam%2520in%2520healthy%2520adult%2520subjects%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2013%26volume%3D57%26spage%3D3699%26epage%3D3703%26doi%3D10.1128%2FAAC.02632-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winter, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginsberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egizi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erondu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitney, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everitt, D.</span></span> <span> </span><span class="NLM_article-title">Effect of a high-calorie, high-fat meal on the bioavailability and pharmacokinetics of PA-824 in healthy adult subjects</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5516</span>– <span class="NLM_lpage">5520</span>, <span class="refDoi"> DOI: 10.1128/AAC.00798-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.00798-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=23979737" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1KjtrfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2013&pages=5516-5520&author=H.+Winterauthor=A.+Ginsbergauthor=E.+Egiziauthor=N.+Eronduauthor=K.+Whitneyauthor=E.+Pauliauthor=D.+Everitt&title=Effect+of+a+high-calorie%2C+high-fat+meal+on+the+bioavailability+and+pharmacokinetics+of+PA-824+in+healthy+adult+subjects&doi=10.1128%2FAAC.00798-13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of a high-calorie, high-fat meal on the bioavailability and pharmacokinetics of PA-824 in healthy adult subjects</span></div><div class="casAuthors">Winter, Helen; Ginsberg, Ann; Egizi, Erica; Erondu, Ngozi; Whitney, Karl; Pauli, Elliott; Everitt, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5516-5520</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">PA-824 is a novel nitroimidazo-oxazine being developed as an antituberculosis agent.  Two randomized studies evaluated the pharmacokinetics and safety of a single oral dose of PA-824 administered to healthy adult subjects 30 min after a high-calorie, high-fat meal (fed state) vs. after a min. 10-h fast (fasted state).  A total of 48 subjects were dosed in the two studies in a randomized crossover design with PA-824 at dose levels of 50, 200, or 1,000 mg in the fed state or fasted state.  After the administration of PA-824, the geometric mean ratios of Cmax and AUC0-∞ revealed an increase in exposure with the addn. of a high-caloric, high-fat meal compared to the fasted state by 140 and 145% at 50 mg, 176 and 188% at 200 mg, and 450 and 473% at 50, 200, and 1,000 mg, resp.  The median Tmax in the fed state was 4 h for the 50-mg dose and 5 h for the 200- and 1,000-mg doses.  In the fasted state, the median Tmax was 4 h for the 50- and 200-mg doses and 6.5 h for the 1,000-mg dose.  All doses were well tolerated, and no serious adverse events occurred in either study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhzWCvarM6ELVg90H21EOLACvtfcHk0liFS5AC2Isfgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1KjtrfI&md5=4c5a3b058505d5609c814b430f4d0a8c</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1128%2FAAC.00798-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00798-13%26sid%3Dliteratum%253Aachs%26aulast%3DWinter%26aufirst%3DH.%26aulast%3DGinsberg%26aufirst%3DA.%26aulast%3DEgizi%26aufirst%3DE.%26aulast%3DErondu%26aufirst%3DN.%26aulast%3DWhitney%26aufirst%3DK.%26aulast%3DPauli%26aufirst%3DE.%26aulast%3DEveritt%26aufirst%3DD.%26atitle%3DEffect%2520of%2520a%2520high-calorie%252C%2520high-fat%2520meal%2520on%2520the%2520bioavailability%2520and%2520pharmacokinetics%2520of%2520PA-824%2520in%2520healthy%2520adult%2520subjects%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2013%26volume%3D57%26spage%3D5516%26epage%3D5520%26doi%3D10.1128%2FAAC.00798-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diacon, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Groote-Bidlingmaier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symons, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donald, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Niekerk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everitt, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchings, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schall, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendel, C. M.</span></span> <span> </span><span class="NLM_article-title">Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>191</i></span>,  <span class="NLM_fpage">943</span>– <span class="NLM_lpage">953</span>, <span class="refDoi"> DOI: 10.1164/rccm.201410-1801OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1164%2Frccm.201410-1801OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=25622149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFOktLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2015&pages=943-953&author=A.+H.+Diaconauthor=R.+Dawsonauthor=F.+von+Groote-Bidlingmaierauthor=G.+Symonsauthor=A.+Venterauthor=P.+R.+Donaldauthor=C.+van+Niekerkauthor=D.+Everittauthor=J.+Hutchingsauthor=D.+A.+Burgerauthor=R.+Schallauthor=C.+M.+Mendel&title=Bactericidal+activity+of+pyrazinamide+and+clofazimine+alone+and+in+combinations+with+pretomanid+and+bedaquiline&doi=10.1164%2Frccm.201410-1801OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline</span></div><div class="casAuthors">Diacon, Andreas H.; Dawson, Rodney; von Groote-Bidlingmaier, Florian; Symons, Gregory; Venter, Amour; Donald, Peter R.; van Niekerk, Christo; Everitt, Daniel; Hutchings, Jane; Burger, Divan A.; Schall, Robert; Mendel, Carl M.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">943-953</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Rationale: New regimens to shorten tuberculosis treatment and manage patients with drug- resistan t tuberculosis who are infected with HIV are urgently needed.  Exptl. and clin. evidence suggests that the new drugs bedaquiline (B) and pretomanid (Pa), combined with an existing drug, pyTazinaraide (Z), and a repurposed drug, clolazirnine (C), may assist treatment shortening of drug-susceptible and drug-resistant tuberculosis.  Objectives: To evaluate the 14-day bactericidal activity ofC and Z in monotherapy and in combinations with Pa and B.  Methods: Groups of 15 treatment-naive, sputum smear-pos. patients with pulmonary tuberculosis were randomized to receive combinations of B with Z-C, Pa-Z, Pa-Z-C, a nd Pa-C, or C or Z alone, or std. combination treatment for 14 days.  The primary endpoint was the mean daily fait in log10 Mycobacterium tuberculosis CPU per mL sputum estd. by joint nonlinear mixed-effects Bayesian regression modeling.  Measurements and Main Results: Estd. activities were 0.167 (95% confidence interval [CI], 0.075-0.257) for B-Pa-Z, 0.151 (95% CI, 0.071-0.232) for std. treatment, 0.124 (95% CI, 0.035-0.214) for B-Z-C, 0.115 (95% CI, 0.039-0.189) for B-Pa-Z-C, and 0.076 (95% CI, 0.005-0.145) for B-Pa-C.  Z alone had modest activity (0.036; 95% CI, -0.026 to 0.099).  C had no activity alone (-0.017; 95% CI, -0.085 to 0.053) or in combinations.  Treatments were well tolerated and safe.  Conclusions: B-Pa-Z, including two novel agents without resistance in prevalent M. tuberculosis strains, is a potential new tuberculosis treatment regimen.  C had no measurable activity in the first 14 days of treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzeaBbihJunrVg90H21EOLACvtfcHk0liFS5AC2Isfgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFOktLk%253D&md5=92e0ef0ffb5904edb462cbd0b15755b6</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1164%2Frccm.201410-1801OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201410-1801OC%26sid%3Dliteratum%253Aachs%26aulast%3DDiacon%26aufirst%3DA.%2BH.%26aulast%3DDawson%26aufirst%3DR.%26aulast%3Dvon%2BGroote-Bidlingmaier%26aufirst%3DF.%26aulast%3DSymons%26aufirst%3DG.%26aulast%3DVenter%26aufirst%3DA.%26aulast%3DDonald%26aufirst%3DP.%2BR.%26aulast%3Dvan%2BNiekerk%26aufirst%3DC.%26aulast%3DEveritt%26aufirst%3DD.%26aulast%3DHutchings%26aufirst%3DJ.%26aulast%3DBurger%26aufirst%3DD.%2BA.%26aulast%3DSchall%26aufirst%3DR.%26aulast%3DMendel%26aufirst%3DC.%2BM.%26atitle%3DBactericidal%2520activity%2520of%2520pyrazinamide%2520and%2520clofazimine%2520alone%2520and%2520in%2520combinations%2520with%2520pretomanid%2520and%2520bedaquiline%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2015%26volume%3D191%26spage%3D943%26epage%3D953%26doi%3D10.1164%2Frccm.201410-1801OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diacon, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everitt, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Niekerk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donald, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schall, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spigelman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conradie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenach, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ive, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page-Shipp, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Variava, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reither, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ntinginya, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pym, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Groote-Bidlingmaier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendel, C. M.</span></span> <span> </span><span class="NLM_article-title">Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: A phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>385</i></span>,  <span class="NLM_fpage">1738</span>– <span class="NLM_lpage">1747</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(14)62002-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2FS0140-6736%2814%2962002-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=25795076" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvVWgs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=385&publication_year=2015&pages=1738-1747&author=R.+Dawsonauthor=A.+H.+Diaconauthor=D.+Everittauthor=C.+van+Niekerkauthor=P.+R.+Donaldauthor=D.+A.+Burgerauthor=R.+Schallauthor=M.+Spigelmanauthor=A.+Conradieauthor=K.+Eisenachauthor=A.+Venterauthor=P.+Iveauthor=L.+Page-Shippauthor=E.+Variavaauthor=K.+Reitherauthor=N.+E.+Ntinginyaauthor=A.+Pymauthor=F.+von+Groote-Bidlingmaierauthor=C.+M.+Mendel&title=Efficiency+and+safety+of+the+combination+of+moxifloxacin%2C+pretomanid+%28PA-824%29%2C+and+pyrazinamide+during+the+first+8+weeks+of+antituberculosis+treatment%3A+A+phase+2b%2C+open-label%2C+partly+randomised+trial+in+patients+with+drug-susceptible+or+drug-resistant+pulmonary+tuberculosis&doi=10.1016%2FS0140-6736%2814%2962002-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis</span></div><div class="casAuthors">Dawson, Rodney; Diacon, Andreas H.; Everitt, Daniel; van Niekerk, Christo; Donald, Peter R.; Burger, Divan A.; Schall, Robert; Spigelman, Melvin; Conradie, Almari; Eisenach, Kathleen; Venter, Amour; Ive, Prudence; Page-Shipp, Liesl; Variava, Ebrahim; Reither, Klaus; Ntinginya, Nyanda E.; Pym, Alexander; von Groote-Bidlingmaier, Florian; Mendel, Carl M.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">385</span>
        (<span class="NLM_cas:issue">9979</span>),
    <span class="NLM_cas:pages">1738-1747</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">New antituberculosis regimens are urgently needed to shorten tuberculosis treatment.  Following on from favorable assessment in a 2 wk study, we investigated a novel regimen for efficacy and safety in drug-susceptible and multidrug-resistant (MDR) tuberculosis during the first 8 wk of treatment.  We did this phase 2b study of bactericidal activity-defined as the decrease in colony forming units (CFUs) of Mycobacterium tuberculosis in the sputum of patients with microscopy smear-pos. pulmonary tuberculosis-at eight sites in South Africa and Tanzania.  We enrolled treatment-naive patients with drug-susceptible, pulmonary tuberculosis, who were randomly assigned by computer-generated sequences to receive either 8 wk of moxifloxacin, 100 mg pretomanid (formerly known as PA-824), and pyrazinamide (MPa100Z regimen); moxifloxacin, 200 mg pretomanid, and pyrazinamide (MPa200Z regimen); or the current std. care for drug-susceptible pulmonary tuberculosis, isoniazid, rifampicin, PZA, and ethambutol (HRZE regimen).  A group of patients with MDR tuberculosis received MPa200Z (DRMPa200Z group).  The primary outcome was bactericidal activity measured by the mean daily rate of redn. in M tuberculosis CFUs per mL overnight sputum collected once a week, with joint Bayesian non-linear mixed-effects regression modeling.  We also assessed safety and tolerability by monitoring adverse events.  This study is registered with ClinicalTrials.gov, no. NCT01498419.  Between March 24, 2012, and July 26, 2013 we enrolled 207 patients and randomly assigned them to treatment groups; we assigned 60 patients to the MPa100Z regimen, 62 to the MPa200Z regimen, and 59 to the HRZE regimen.  We non-randomly assigned 26 patients with drug-resistant tuberculosis to the DRMPa200Z regimen.  In patients with drug-susceptible tuberculosis, the bactericidal activity of MPa200Z (n=54) on days 0-56 (0·155, 95% Bayesian credibility interval 0·133-0·178) was significantly greater than for HRZE (n=54, 0·112, 0·093-0·131).  DRMPa200Z (n=9) had bactericidal activity of 0·117 (0·070-0·174).  The bactericidal activity on days 7-14 was strongly assocd. with bactericidal activity on days 7-56.  Frequencies of adverse events were similar to std. treatment in all groups.  The most common adverse event was hyperuricemia in 59 (29%) patients (17 [28%] patients in MPa100Z group, 17 [27%] patients in MPa200Z group, 17 [29%] patients. in HRZE group, and 8 [31%] patients in DRMPa200Z group).  Other common adverse events were nausea in (14 [23%] patients in MPa100Z group, 8 [13%] patients in MPa200Z group, 7 [12%] patients in HRZE group, and 8 [31%] patients in DRMPa200Z group) and vomiting (7 [12%] patients in MPa100Z group, 7 [11%] patients in MPa200Z group, 7 [12%] patients in HRZE group, and 4 [15%] patients in DRMPa200Z group).  No on-treatment ECG occurrences of cor. QT interval more than 500 ms (an indicator of potential of ventricular tachyarrhythmia) were reported.  No phenotypic resistance developed to any of the drugs in the regimen.  The combination of moxifloxacin, pretomanid, and pyrazinamide, was safe, well tolerated, and showed superior bactericidal activity in drug-susceptible tuberculosis during 8 wk of treatment.  Results were consistent between drug-susceptible and MDR tuberculosis.  This new regimen is ready to enter phase 3 trials in patients with drug-susceptible tuberculosis and MDR-tuberculosis, with the goal of shortening and simplifying treatment.  Global Alliance for TB Drug Development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIrFs7Z3Zt97Vg90H21EOLACvtfcHk0lgfsjjdnCN-wA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvVWgs7g%253D&md5=5dc925f5677225aa3003069a3fb12c05</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2814%2962002-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252814%252962002-X%26sid%3Dliteratum%253Aachs%26aulast%3DDawson%26aufirst%3DR.%26aulast%3DDiacon%26aufirst%3DA.%2BH.%26aulast%3DEveritt%26aufirst%3DD.%26aulast%3Dvan%2BNiekerk%26aufirst%3DC.%26aulast%3DDonald%26aufirst%3DP.%2BR.%26aulast%3DBurger%26aufirst%3DD.%2BA.%26aulast%3DSchall%26aufirst%3DR.%26aulast%3DSpigelman%26aufirst%3DM.%26aulast%3DConradie%26aufirst%3DA.%26aulast%3DEisenach%26aufirst%3DK.%26aulast%3DVenter%26aufirst%3DA.%26aulast%3DIve%26aufirst%3DP.%26aulast%3DPage-Shipp%26aufirst%3DL.%26aulast%3DVariava%26aufirst%3DE.%26aulast%3DReither%26aufirst%3DK.%26aulast%3DNtinginya%26aufirst%3DN.%2BE.%26aulast%3DPym%26aufirst%3DA.%26aulast%3Dvon%2BGroote-Bidlingmaier%26aufirst%3DF.%26aulast%3DMendel%26aufirst%3DC.%2BM.%26atitle%3DEfficiency%2520and%2520safety%2520of%2520the%2520combination%2520of%2520moxifloxacin%252C%2520pretomanid%2520%2528PA-824%2529%252C%2520and%2520pyrazinamide%2520during%2520the%2520first%25208%2520weeks%2520of%2520antituberculosis%2520treatment%253A%2520A%2520phase%25202b%252C%2520open-label%252C%2520partly%2520randomised%2520trial%2520in%2520patients%2520with%2520drug-susceptible%2520or%2520drug-resistant%2520pulmonary%2520tuberculosis%26jtitle%3DLancet%26date%3D2015%26volume%3D385%26spage%3D1738%26epage%3D1747%26doi%3D10.1016%2FS0140-6736%2814%2962002-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ashtekar, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa-Perira, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagrajan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vishvanathan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatt, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rittel, W.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo activities of the nitroimidazole CGI 17341 against mycobacterium tuberculosis</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">183</span>– <span class="NLM_lpage">186</span>, <span class="refDoi"> DOI: 10.1128/AAC.37.2.183</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.37.2.183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=8452346" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADyaK3sXitV2hu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1993&pages=183-186&author=D.+R.+Ashtekarauthor=R.+Costa-Periraauthor=K.+Nagrajanauthor=N.+Vishvanathanauthor=A.+D.+Bhattauthor=W.+Rittel&title=In+vitro+and+in+vivo+activities+of+the+nitroimidazole+CGI+17341+against+mycobacterium+tuberculosis&doi=10.1128%2FAAC.37.2.183"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis</span></div><div class="casAuthors">Ashtekar, Dilip R.; Costa-Perira, Rabi; Nagrajan, K.; Vishvanathan, N.; Bhatt, Arun D.; Rittel, Werner</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">183-6</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    </div><div class="casAbstract">CGI 17341 (2-ethyl-5-nitro-2,3-dihydro[2-1b]imidazooxazole, I)) is a novel orally active representative of the 5-nitroimidazole series of antimicrobial agents.  At concns. of 0.1-0.3 μg/mL, I inhibited the drug-susceptible and multidrug-resistant strains of M. tuberculosis.  I had no cross-resistance with isoniazid, rifampin, streptomycin, or ethambutol.  While the in vitro activity of I against M. tuberculosis was comparable to those of isoniazid and rifampin, it was superior to those of streptomycin, ciprofloxacin, norfloxacin, and oxazolidinone DuP 721.  The MIC of I was not affected when the pH of the medium was decreased from 6.8 to 5.6, while 4-6-fold increases in the MICs of ciprofloxacin and isoniazid were obsd.  In mice infected with M. tuberculosis, the 50% ED for I was 7.7 mg/kg body wt. (95% confidence limits, 3.5 and 10.27) when administered on days 11 and 12 postinfection.  I gave a dose-dependent and significant increase in the survival time.  I is a promising and novel antituberculosis compd. with potent in vitro and in vivo activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowsgP8VyIuv7Vg90H21EOLACvtfcHk0lgfsjjdnCN-wA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXitV2hu7k%253D&md5=b0867ca5ab8169a4dcf8940b1c69a11e</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1128%2FAAC.37.2.183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.37.2.183%26sid%3Dliteratum%253Aachs%26aulast%3DAshtekar%26aufirst%3DD.%2BR.%26aulast%3DCosta-Perira%26aufirst%3DR.%26aulast%3DNagrajan%26aufirst%3DK.%26aulast%3DVishvanathan%26aufirst%3DN.%26aulast%3DBhatt%26aufirst%3DA.%2BD.%26aulast%3DRittel%26aufirst%3DW.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520activities%2520of%2520the%2520nitroimidazole%2520CGI%252017341%2520against%2520mycobacterium%2520tuberculosis%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1993%26volume%3D37%26spage%3D183%26epage%3D186%26doi%3D10.1128%2FAAC.37.2.183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manjunatha, U. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boshoff, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowd, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albert, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norton, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.,  3rd.</span></span> <span> </span><span class="NLM_article-title">Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in mycobacterium tuberculosis</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">431</span>– <span class="NLM_lpage">436</span>, <span class="refDoi"> DOI: 10.1073/pnas.0508392103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1073%2Fpnas.0508392103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=16387854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD28XpsVSltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=431-436&author=U.+H.+Manjunathaauthor=H.+Boshoffauthor=C.+S.+Dowdauthor=L.+Zhangauthor=T.+J.+Albertauthor=J.+E.+Nortonauthor=L.+Danielsauthor=T.+Dickauthor=S.+S.+Pangauthor=C.+E.+Barry&title=Identification+of+a+nitroimidazo-oxazine-specific+protein+involved+in+PA-824+resistance+in+mycobacterium+tuberculosis&doi=10.1073%2Fpnas.0508392103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis</span></div><div class="casAuthors">Manjunatha, Ujjini H.; Boshoff, Helena; Dowd, Cynthia S.; Zhang, Liang; Albert, Thomas J.; Norton, Jason E.; Daniels, Lacy; Dick, Thomas; Pang, Siew Siew; Barry, Clifton E., III</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">431-436</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">PA-824 is a promising new compd. for the treatment of tuberculosis that is currently undergoing human trials.  Like its progenitors metronidazole and CGI-17341, PA-824 is a prodrug of the nitroimidazole class, requiring bioreductive activation of an arom. nitro group to exert an antitubercular effect.  The authors have confirmed that resistance to PA-824 (a nitroimidazo-oxazine) and CGI-17341 (a nitroimidazo-oxazole) is most commonly mediated by loss of a specific glucose-6-phosphate dehydrogenase (FGD1) or its deazaflavin cofactor F420, which together provide electrons for the reductive activation of this class of mols.  Although FGD1 and F420 are necessary for sensitivity to these compds., they are not sufficient and require addnl. accessory proteins that directly interact with the nitroimidazole.  To understand more proximal events in the reductive activation of PA-824, the authors examd. mutants that were wild-type for both FGD1 and F420 and found that, although these mutants had acquired high-level resistance to PA-824 (and another nitroimidazo-oxazine), they retained sensitivity to CGI-17341 (and a related nitroimidazo-oxazole).  Microarray-based comparative genome sequencing of these mutants identified lesions in Rv3547, a conserved hypothetical protein with no known function.  Complementation with intact Rv3547 fully restored sensitivity to nitroimidazo-oxazines and restored the ability of Mtb to metabolize PA-824.  These results suggest that the sensitivity of Mtb to PA-824 and related compds. is mediated by a protein that is highly specific for subtle structural variations in these bicyclic nitroimidazoles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX0bL9yx6FB7Vg90H21EOLACvtfcHk0lhhcOD5t7n6Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpsVSltQ%253D%253D&md5=66a247925f28a6d254c75a543bb52e74</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0508392103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0508392103%26sid%3Dliteratum%253Aachs%26aulast%3DManjunatha%26aufirst%3DU.%2BH.%26aulast%3DBoshoff%26aufirst%3DH.%26aulast%3DDowd%26aufirst%3DC.%2BS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DAlbert%26aufirst%3DT.%2BJ.%26aulast%3DNorton%26aufirst%3DJ.%2BE.%26aulast%3DDaniels%26aufirst%3DL.%26aulast%3DDick%26aufirst%3DT.%26aulast%3DPang%26aufirst%3DS.%2BS.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26atitle%3DIdentification%2520of%2520a%2520nitroimidazo-oxazine-specific%2520protein%2520involved%2520in%2520PA-824%2520resistance%2520in%2520mycobacterium%2520tuberculosis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26spage%3D431%26epage%3D436%26doi%3D10.1073%2Fpnas.0508392103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sha, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, H.</span></span> <span> </span><span class="NLM_article-title">Clinical benefit of delamanid (opc-67683) in the treatment of multidrug-resistant tuberculosis patients in china</span>. <i>Cell Biochem. Biophys.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">957</span>– <span class="NLM_lpage">963</span>, <span class="refDoi"> DOI: 10.1007/s12013-013-9589-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1007%2Fs12013-013-9589-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=23546935" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVKit7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2013&pages=957-963&author=Q.+Zhangauthor=Y.+Liuauthor=S.+Tangauthor=W.+Shaauthor=H.+Xiao&title=Clinical+benefit+of+delamanid+%28opc-67683%29+in+the+treatment+of+multidrug-resistant+tuberculosis+patients+in+china&doi=10.1007%2Fs12013-013-9589-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical Benefit of Delamanid (OPC-67683) in the Treatment of Multidrug-Resistant Tuberculosis Patients in China</span></div><div class="casAuthors">Zhang, Qing; Liu, Yidian; Tang, Shenjie; Sha, Wei; Xiao, Heping</div><div class="citationInfo"><span class="NLM_cas:title">Cell Biochemistry and Biophysics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">957-963</span>CODEN:
                <span class="NLM_cas:coden">CBBIFV</span>;
        ISSN:<span class="NLM_cas:issn">1085-9195</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The cure rates are much lower for multidrug-resistant (MDR) tuberculosis (TB) patients.  Delamanid (OPC-67683) has been evaluated in phase-II MDR-TB clin. trials.  Herein, we reviewed MDR-TB cases in which treatment regimens, with/without delamanid, were administered.  Thirty-eight patients were enrolled; 26 received delamanid-contg. regimens (treatment group) while 12 received placebo-contg. regimens (control group) for 56 days.  Data regarding clin./radio-microbiol. characteristics, drug tolerability, and treatment outcomes were collected.  We found that all patients had isolates resistant to a median of 5 (range 2-7) drugs; 24 (92.3 fx) patients in treatment group and 11 (91.7 fx) in control group had cavities.  Culture conversion was obtained in 32 pulmonary TB cases (median 74.5 days).  At data censure, 30/38 patients successfully completed therapy with documented neg. cultures for at least 18 mo before the end of treatment.  Two patients (5 consecutive neg. cultures) are still on treatment.  Six patients had poor outcome (3 failures/2 lost/1 death).  In 13 patients, adverse events were obsd. that included mental disorder, QT interval prolongation, and increased blood cortisol whereas only 3 patients stopped delamanid treatment because of adverse events.  It was, therefore, concluded that delamanid was well-tolerated, had low rates of discontinuation, and could be effective for treating MDR-TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDwcBx_s8v47Vg90H21EOLACvtfcHk0lhhcOD5t7n6Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVKit7fO&md5=06493fae373a1b1e53bffb57ce315243</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1007%2Fs12013-013-9589-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12013-013-9589-5%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DS.%26aulast%3DSha%26aufirst%3DW.%26aulast%3DXiao%26aufirst%3DH.%26atitle%3DClinical%2520benefit%2520of%2520delamanid%2520%2528opc-67683%2529%2520in%2520the%2520treatment%2520of%2520multidrug-resistant%2520tuberculosis%2520patients%2520in%2520china%26jtitle%3DCell%2520Biochem.%2520Biophys.%26date%3D2013%26volume%3D67%26spage%3D957%26epage%3D963%26doi%3D10.1007%2Fs12013-013-9589-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manjunatha, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boshoff, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niyomrattanakit, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ledwidge, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowd, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, I. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiricek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.</span></span> <span> </span><span class="NLM_article-title">PA-824 kills nonreplicating mycobacterium tuberculosis by intracellular no release</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>322</i></span>,  <span class="NLM_fpage">1392</span>– <span class="NLM_lpage">1395</span>, <span class="refDoi"> DOI: 10.1126/science.1164571</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1126%2Fscience.1164571" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=19039139" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVagt7jN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=322&publication_year=2008&pages=1392-1395&author=R.+Singhauthor=U.+Manjunathaauthor=H.+I.+Boshoffauthor=Y.+H.+Haauthor=P.+Niyomrattanakitauthor=R.+Ledwidgeauthor=C.+S.+Dowdauthor=I.+Y.+Leeauthor=P.+Kimauthor=L.+Zhangauthor=S.+Kangauthor=T.+H.+Kellerauthor=J.+Jiricekauthor=C.+E.+Barry&title=PA-824+kills+nonreplicating+mycobacterium+tuberculosis+by+intracellular+no+release&doi=10.1126%2Fscience.1164571"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO Release</span></div><div class="casAuthors">Singh, Ramandeep; Manjunatha, Ujjini; Boshoff, Helena I. M.; Ha, Young Hwan; Niyomrattanakit, Pornwaratt; Ledwidge, Richard; Dowd, Cynthia S.; Lee, Ill Young; Kim, Pilho; Zhang, Liang; Kang, Sunhee; Keller, Thomas H.; Jiricek, Jan; Barry, Clifton E., III</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">322</span>
        (<span class="NLM_cas:issue">5906</span>),
    <span class="NLM_cas:pages">1392-1395</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Bicyclic nitroimidazoles, including PA-824, are exciting candidates for the treatment of tuberculosis.  These prodrugs require intracellular activation for their biol. function.  We found that Rv3547 is a deazaflavin-dependent nitroreductase (Ddn) that converts PA-824 into three primary metabolites; the major one is the corresponding des-nitroimidazole (des-nitro).  When derivs. of PA-824 were used, the amt. of des-nitro metabolite formed was highly correlated with anaerobic killing of Mycobacterium tuberculosis (Mtb).  Des-nitro metabolite formation generated reactive nitrogen species, including nitric oxide (NO), which are the major effectors of the anaerobic activity of these compds.  Furthermore, NO scavengers protected the bacilli from the lethal effects of the drug.  Thus, these compds. may act as intracellular NO donors and could augment a killing mechanism intrinsic to the innate immune system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdOQ6XyUn59bVg90H21EOLACvtfcHk0lhhcOD5t7n6Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVagt7jN&md5=5d7d8715b5565938b3ffd9fd35a723da</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1126%2Fscience.1164571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1164571%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DManjunatha%26aufirst%3DU.%26aulast%3DBoshoff%26aufirst%3DH.%2BI.%26aulast%3DHa%26aufirst%3DY.%2BH.%26aulast%3DNiyomrattanakit%26aufirst%3DP.%26aulast%3DLedwidge%26aufirst%3DR.%26aulast%3DDowd%26aufirst%3DC.%2BS.%26aulast%3DLee%26aufirst%3DI.%2BY.%26aulast%3DKim%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DKang%26aufirst%3DS.%26aulast%3DKeller%26aufirst%3DT.%2BH.%26aulast%3DJiricek%26aufirst%3DJ.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26atitle%3DPA-824%2520kills%2520nonreplicating%2520mycobacterium%2520tuberculosis%2520by%2520intracellular%2520no%2520release%26jtitle%3DScience%26date%3D2008%26volume%3D322%26spage%3D1392%26epage%3D1395%26doi%3D10.1126%2Fscience.1164571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stover, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warrener, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VanDevanter, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arain, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langhorne, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towell, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMurray, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreiswirth, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, W. R.</span></span> <span> </span><span class="NLM_article-title">A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>405</i></span>,  <span class="NLM_fpage">962</span>– <span class="NLM_lpage">966</span>, <span class="refDoi"> DOI: 10.1038/35016103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1038%2F35016103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10879539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD3cXks1Wksb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=405&publication_year=2000&pages=962-966&author=C.+K.+Stoverauthor=P.+Warrenerauthor=D.+R.+VanDevanterauthor=D.+R.+Shermanauthor=T.+M.+Arainauthor=M.+H.+Langhorneauthor=S.+W.+Andersonauthor=J.+A.+Towellauthor=Y.+Yuanauthor=D.+N.+McMurrayauthor=B.+N.+Kreiswirthauthor=C.+E.+Barryauthor=W.+R.+Baker&title=A+small-molecule+nitroimidazopyran+drug+candidate+for+the+treatment+of+tuberculosis&doi=10.1038%2F35016103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis</span></div><div class="casAuthors">Stover, C. Kendall; Warrener, Paul; VanDevanter, Donald R.; Sherman, David R.; Arain, Taraq M.; Langhorne, Michael H.; Anderson, Scott W.; Towell, J. Andrew; Yuan, Ying; McMurray, David N.; Krelswirth, Barry N.; Barry, Clifton E.; Baker, William R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">405</span>
        (<span class="NLM_cas:issue">6789</span>),
    <span class="NLM_cas:pages">962-966</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Mycobacterium tuberculosis, which causes tuberculosis, is the greatest single infectious cause of mortality worldwide, killing roughly; two million people annually.  Ests. indicate that one-third of the world population is infected with latent M. tuberculosis.  The synergy between tuberculosis and the AIDS epidemic, and the surge of multidrug-resistant clin. isolates of M. tuberculosis have reaffirmed tuberculosis as a primary public health threat.  However, new antitubercular drugs with new mechanisms of action have not been developed in over thirty years.  Here we report a series of compds. contg. a nitroimidazopyran nucleus that possess antitubercular activity.  After activation by a mechanism dependent on M. tuberculosis F420 cofactor, nitroimidazopyrans inhibited the synthesis of protein and cell wall lipid.  In contrast to current antitubercular drugs, nitroimidazopyrans exhibited bactericidal activity against both replicating and static M. tuberculosis.  Lead compd. PA-824 showed potent bactericidal activity against multidrug-resistant M. tuberculosis and promising oral activity in animal infection models.  We conclude that nitroimidazopyrans offer the practical qualities of a small mol. with the potential for the treatment of tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrw41eD4TtVwbVg90H21EOLACvtfcHk0lhdOa8gLFsO2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXks1Wksb0%253D&md5=f5f6e2935928da72e328bddd4995515f</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1038%2F35016103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35016103%26sid%3Dliteratum%253Aachs%26aulast%3DStover%26aufirst%3DC.%2BK.%26aulast%3DWarrener%26aufirst%3DP.%26aulast%3DVanDevanter%26aufirst%3DD.%2BR.%26aulast%3DSherman%26aufirst%3DD.%2BR.%26aulast%3DArain%26aufirst%3DT.%2BM.%26aulast%3DLanghorne%26aufirst%3DM.%2BH.%26aulast%3DAnderson%26aufirst%3DS.%2BW.%26aulast%3DTowell%26aufirst%3DJ.%2BA.%26aulast%3DYuan%26aufirst%3DY.%26aulast%3DMcMurray%26aufirst%3DD.%2BN.%26aulast%3DKreiswirth%26aufirst%3DB.%2BN.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26aulast%3DBaker%26aufirst%3DW.%2BR.%26atitle%3DA%2520small-molecule%2520nitroimidazopyran%2520drug%2520candidate%2520for%2520the%2520treatment%2520of%2520tuberculosis%26jtitle%3DNature%26date%3D2000%26volume%3D405%26spage%3D962%26epage%3D966%26doi%3D10.1038%2F35016103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parikh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalwadi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aboti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, L.</span></span> <span> </span><span class="NLM_article-title">Inhaled microparticles of antitubercular antibiotic for in vitro and in vivo alveolar macrophage targeting and activation of phagocytosis</span>. <i>J. Antibiot.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">387</span>– <span class="NLM_lpage">394</span>, <span class="refDoi"> DOI: 10.1038/ja.2014.13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1038%2Fja.2014.13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=24569669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2cXos1artLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2014&pages=387-394&author=R.+Parikhauthor=S.+Dalwadiauthor=P.+Abotiauthor=L.+Patel&title=Inhaled+microparticles+of+antitubercular+antibiotic+for+in+vitro+and+in+vivo+alveolar+macrophage+targeting+and+activation+of+phagocytosis&doi=10.1038%2Fja.2014.13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Inhaled microparticles of antitubercular antibiotic for in vitro and in vivo alveolar macrophage targeting and activation of phagocytosis</span></div><div class="casAuthors">Parikh, Rajesh; Dalwadi, Sonali; Aboti, Pooja; Patel, Leena</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antibiotics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">387-394</span>CODEN:
                <span class="NLM_cas:coden">JANTAJ</span>;
        ISSN:<span class="NLM_cas:issn">0021-8820</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Tuberculosis (TB) is a chronic infectious disease with increasing incidence of drug resistance.  Oral treatment for TB and multidrug resistance-TB can have serious side effects.  The causative agent of TB, Mycobacterium tuberculosis, resides in alveolar macrophages (AMs).  Pulmonary administration of antitubercular (anti-TB) antibiotic can help in delivery of high concn. to AM.  The ability of AM to phagocytose can also be utilized to generate mycobactericidal nitric oxide (NO) to improve efficacy of anti-TB antibiotics.  The objective in this investigation was made to prep. isoniazid microparticles (IM) and polymeric microparticles of isoniazid (INH-PM) using poly-ε-caprolactone as polymer and to evaluate in vitro through cell culture techniques and in vivo through pulmonary administration of IM and INH-PM for uptake of isoniazid by AM.  The hepatotoxicity was detd. through serum glutamate oxaloacetate transferase (SGOT) and serum glutamate pyruvate transferase (SGPT) levels and histol. examn.  The results depicted that the significantly higher (P<0.05) concn. of isoniazid was found in AM with INH-PM in vitro and in vivo.  NO prodn. was also significantly higher but less than toxic level.  SGOT and SGPT levels, uptake of INH by liver and histol. examn. were indicative of no hepatotoxicity with INH-PM and IM.  Phagocytosis of IM and INH-PM leads to significantly higher drug level in AM as well as prodn. of significantly higher levels of NO without compromising the viability of cells.  The administration of IM and INH-PM as dry powder inhalation formulation may reduce the treatment time of TB and chances of drug-resistant TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq169CcUy19TbVg90H21EOLACvtfcHk0lhdOa8gLFsO2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXos1artLg%253D&md5=4ac9749042bbaa5f7dd484ed403a4c7a</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1038%2Fja.2014.13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fja.2014.13%26sid%3Dliteratum%253Aachs%26aulast%3DParikh%26aufirst%3DR.%26aulast%3DDalwadi%26aufirst%3DS.%26aulast%3DAboti%26aufirst%3DP.%26aulast%3DPatel%26aufirst%3DL.%26atitle%3DInhaled%2520microparticles%2520of%2520antitubercular%2520antibiotic%2520for%2520in%2520vitro%2520and%2520in%2520vivo%2520alveolar%2520macrophage%2520targeting%2520and%2520activation%2520of%2520phagocytosis%26jtitle%3DJ.%2520Antibiot.%26date%3D2014%26volume%3D67%26spage%3D387%26epage%3D394%26doi%3D10.1038%2Fja.2014.13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manjunatha, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boshoff, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.</span></span> <span> </span><span class="NLM_article-title">The mechanism of action of PA-824: Novel insights from transcriptional profiling</span>. <i>Commun. Integr. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">218</span>, <span class="refDoi"> DOI: 10.4161/cib.2.3.7926</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.4161%2Fcib.2.3.7926" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=19641733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1yru7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2009&pages=215-218&author=U.+Manjunathaauthor=H.+I.+Boshoffauthor=C.+E.+Barry&title=The+mechanism+of+action+of+PA-824%3A+Novel+insights+from+transcriptional+profiling&doi=10.4161%2Fcib.2.3.7926"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">The mechanism of action of PA-824: novel insights from transcriptional profiling</span></div><div class="casAuthors">Manjunatha, Ujjini; Boshoff, Helena I. M.; Barry, Clifton E., III</div><div class="citationInfo"><span class="NLM_cas:title">Communicative & Integrative Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">215-218</span>CODEN:
                <span class="NLM_cas:coden">CIBOBQ</span>;
        ISSN:<span class="NLM_cas:issn">1942-0889</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">The bicyclic nitroimidazole PA-824 is a pro-drug with a very complex mechanism of action active against both replicating and hypoxic, non-replicating Mycobacterium tuberculosis.  Microarray anal. of the mode of action of PA-824 showed a puzzling mixed effect both on genes responsive to both cell wall inhibition (like isoniazid) and respiratory poisoning (like cyanide).  The aerobic killing mechanism of this drug appears to involve inhibition of cell wall mycolic acid biosynthesis through an as yet unknown mol. mechanism.  However, the structure-activity relationships governing aerobic activity do not parallel the relationships detg. anaerobic activity.  Based on the metabolite profiling of PA-824 and various derivs. by Ddn-mediated activation, we have shown that PA-824 acts directly as an NO donor.  This respiratory poisoning through nitric oxide release seemed to be a crucial element of anaerobic activity by PA-824.  The effect of PA-824 on the respiratory complex under hypoxic non-replicating conditions was also manifested in a rapid drop in intracellular ATP levels, again similar to that obsd. by cyanide treatment.  Thus, transcriptional profiling provided valuable clues to elucidating the mol. mechanism of mycobacterial killing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRIjCfr9dB9bVg90H21EOLACvtfcHk0lhdOa8gLFsO2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1yru7bF&md5=b7b25a9c2c9b39ff446571c9a2d6d297</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.4161%2Fcib.2.3.7926&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcib.2.3.7926%26sid%3Dliteratum%253Aachs%26aulast%3DManjunatha%26aufirst%3DU.%26aulast%3DBoshoff%26aufirst%3DH.%2BI.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26atitle%3DThe%2520mechanism%2520of%2520action%2520of%2520PA-824%253A%2520Novel%2520insights%2520from%2520transcriptional%2520profiling%26jtitle%3DCommun.%2520Integr.%2520Biol.%26date%3D2009%26volume%3D2%26spage%3D215%26epage%3D218%26doi%3D10.4161%2Fcib.2.3.7926" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baptista, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fazakerley, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mur, L. A. J.</span></span> <span> </span><span class="NLM_article-title">Untargeted metabolomics reveals a new mode of action of pretomanid (PA-824)</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">5084</span>, <span class="refDoi"> DOI: 10.1038/s41598-018-23110-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1038%2Fs41598-018-23110-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=29572459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A280%3ADC%252BC1MnksVelsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=5084&author=R.+Baptistaauthor=D.+M.+Fazakerleyauthor=M.+Beckmannauthor=L.+Baillieauthor=L.+A.+J.+Mur&title=Untargeted+metabolomics+reveals+a+new+mode+of+action+of+pretomanid+%28PA-824%29&doi=10.1038%2Fs41598-018-23110-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Untargeted metabolomics reveals a new mode of action of pretomanid (PA-824)</span></div><div class="casAuthors">Baptista Rafael; Fazakerley David M; Beckmann Manfred; Mur Luis A J; Baillie Les</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5084</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Pretomanid is a promising anti-tubercular drug currently at clinical phase III, but its mechanisms of action are currently unclear.  This study aimed to: (i) reveal the metabolome of Mycobacterium smegmatis under pretomanid treatment; (ii) compare major sources of metabolite variation in bacteria treated with pretomanid treatment and other antibiotics; and (iii) to target metabolites responsible for the killing activity of pretomanid in mycobacteria.  Untargeted high-resolution metabolite profiling was carried out using flow infusion electrospray ion high resolution mass spectrometry (FIE-HRMS) to identify and quantify metabolites.  The identification of key metabolites was independently confirmed by gas-chromatography time-of flight mass spectrometry (GC-tofMS) in comparison to standards.  Pretomanid treatments generated a unique distinctive metabolite profile when compared to ampicillin, ethambutol, ethionamide, isoniazid, kanamycin, linezolid, rifampicin and streptomycin.  Metabolites which differed significantly only with pretomanid treatment were identified and mapped on to bacterial metabolic pathways.  This targeted the pentose phosphate pathway with significant accumulation seen with fructose-6-phosphate, ribose-5-phosphate and glyceraldehyde-3-phosphate.  These effects were linked to the accumulation of a toxic metabolite methylglyoxal.  This compound showed significant antimicrobial activity (MIC 0.65 mM) against M. smegmatis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSTqMwunm4ScKNc3HjJRoFAfW6udTcc2eaQDuzf_21-prntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MnksVelsg%253D%253D&md5=15e388e024002bd8c2212767f7573fff</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1038%2Fs41598-018-23110-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-018-23110-1%26sid%3Dliteratum%253Aachs%26aulast%3DBaptista%26aufirst%3DR.%26aulast%3DFazakerley%26aufirst%3DD.%2BM.%26aulast%3DBeckmann%26aufirst%3DM.%26aulast%3DBaillie%26aufirst%3DL.%26aulast%3DMur%26aufirst%3DL.%2BA.%2BJ.%26atitle%3DUntargeted%2520metabolomics%2520reveals%2520a%2520new%2520mode%2520of%2520action%2520of%2520pretomanid%2520%2528PA-824%2529%26jtitle%3DSci.%2520Rep.%26date%3D2018%26volume%3D8%26spage%3D5084%26doi%3D10.1038%2Fs41598-018-23110-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoyama, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jadhav, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stratton, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilotta, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singleton, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paget, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pottorf, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davila-Pagan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kandasamy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grady, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soteropoulos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dartois, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connell, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freundlich, J. S.</span></span> <span> </span><span class="NLM_article-title">Antitubercular triazines: Optimization and intrabacterial metabolism</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">172</span>– <span class="NLM_lpage">185</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2019.10.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.chembiol.2019.10.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=31711854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFegsr3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2020&pages=172-185&issue=2&author=X.+Wangauthor=D.+Inoyamaauthor=R.+Russoauthor=S.+G.+Liauthor=R.+Jadhavauthor=T.+P.+Strattonauthor=N.+Mittalauthor=J.+A.+Bilottaauthor=E.+Singletonauthor=T.+Kimauthor=S.+D.+Pagetauthor=R.+S.+Pottorfauthor=Y.+M.+Ahnauthor=A.+Davila-Paganauthor=S.+Kandasamyauthor=C.+Gradyauthor=S.+Hussainauthor=P.+Soteropoulosauthor=M.+D.+Zimmermanauthor=H.+P.+Hoauthor=S.+Parkauthor=V.+Dartoisauthor=S.+Ekinsauthor=N.+Connellauthor=P.+Kumarauthor=J.+S.+Freundlich&title=Antitubercular+triazines%3A+Optimization+and+intrabacterial+metabolism&doi=10.1016%2Fj.chembiol.2019.10.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Antitubercular Triazines: Optimization and Intrabacterial Metabolism</span></div><div class="casAuthors">Wang, Xin; Inoyama, Daigo; Russo, Riccardo; Li, Shao-Gang; Jadhav, Ravindra; Stratton, Thomas P.; Mittal, Nisha; Bilotta, Joseph A.; Singleton, Eric; Kim, Thomas; Paget, Steve D.; Pottorf, Richard S.; Ahn, Yong-Mo; Davila-Pagan, Alejandro; Kandasamy, Srinivasan; Grady, Courtney; Hussain, Seema; Soteropoulos, Patricia; Zimmerman, Matthew D.; Ho, Hsin Pin; Park, Steven; Dartois, Veronique; Ekins, Sean; Connell, Nancy; Kumar, Pradeep; Freundlich, Joel S.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">172-185.e11</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The triazine antitubercular JSF-2019 was of interest due to its in vitro efficacy and the nitro group shared with the clin. relevant delamanid and pretomanid.  JSF-2019 undergoes activation requiring F420H2 and one or more nitroreductases in addn. to Ddn.  An intrabacterial drug metab. (IBDM) platform was leveraged to demonstrate the system kinetics, evidencing formation of NO· and a des-nitro metabolite.  Structure-activity relationship studies focused on improving the soly. and mouse pharmacokinetic profile of JSF-2019 and culminated in JSF-2513, relying on the key introduction of a morpholine.  Mechanistic studies with JSF-2019, JSF-2513, and other triazines stressed the significance of achieving potent in vitro efficacy via release of intrabacterial NO· along with inhibition of InhA and, more generally, the FAS-II pathway.  This study highlights the importance of probing IBDM and its potential to clarify mechanism of action, which in this case is a combination of NO· release and InhA inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoFhvEW0PwI7Vg90H21EOLACvtfcHk0lgzKv_jqWJPjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFegsr3K&md5=e45fbb9c5c65a3bd3356df164508f921</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2019.10.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2019.10.010%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DInoyama%26aufirst%3DD.%26aulast%3DRusso%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DS.%2BG.%26aulast%3DJadhav%26aufirst%3DR.%26aulast%3DStratton%26aufirst%3DT.%2BP.%26aulast%3DMittal%26aufirst%3DN.%26aulast%3DBilotta%26aufirst%3DJ.%2BA.%26aulast%3DSingleton%26aufirst%3DE.%26aulast%3DKim%26aufirst%3DT.%26aulast%3DPaget%26aufirst%3DS.%2BD.%26aulast%3DPottorf%26aufirst%3DR.%2BS.%26aulast%3DAhn%26aufirst%3DY.%2BM.%26aulast%3DDavila-Pagan%26aufirst%3DA.%26aulast%3DKandasamy%26aufirst%3DS.%26aulast%3DGrady%26aufirst%3DC.%26aulast%3DHussain%26aufirst%3DS.%26aulast%3DSoteropoulos%26aufirst%3DP.%26aulast%3DZimmerman%26aufirst%3DM.%2BD.%26aulast%3DHo%26aufirst%3DH.%2BP.%26aulast%3DPark%26aufirst%3DS.%26aulast%3DDartois%26aufirst%3DV.%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DConnell%26aufirst%3DN.%26aulast%3DKumar%26aufirst%3DP.%26aulast%3DFreundlich%26aufirst%3DJ.%2BS.%26atitle%3DAntitubercular%2520triazines%253A%2520Optimization%2520and%2520intrabacterial%2520metabolism%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2020%26volume%3D27%26issue%3D2%26spage%3D172%26epage%3D185%26doi%3D10.1016%2Fj.chembiol.2019.10.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">e11.</p></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Swaminathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundaramurthi, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palaniappan, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, S.</span></span> <span> </span><span class="NLM_article-title">Recent developments in genomics, bioinformatics and drug discovery to combat emerging drug-resistant tuberculosis</span>. <i>Tuberculosis (Oxford, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">40</span>, <span class="refDoi"> DOI: 10.1016/j.tube.2016.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.tube.2016.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=27865394" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlGmtLjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2016&pages=31-40&author=S.+Swaminathanauthor=J.+C.+Sundaramurthiauthor=A.+N.+Palaniappanauthor=S.+Narayanan&title=Recent+developments+in+genomics%2C+bioinformatics+and+drug+discovery+to+combat+emerging+drug-resistant+tuberculosis&doi=10.1016%2Fj.tube.2016.08.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Recent developments in genomics, bioinformatics and drug discovery to combat emerging drug-resistant tuberculosis</span></div><div class="casAuthors">Swaminathan, Soumya; Sundaramurthi, Jagadish Chandrabose; Palaniappan, Alangudi Natarajan; Narayanan, Sujatha</div><div class="citationInfo"><span class="NLM_cas:title">Tuberculosis (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">31-40</span>CODEN:
                <span class="NLM_cas:coden">TUBECU</span>;
        ISSN:<span class="NLM_cas:issn">1472-9792</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Emergence of drug-resistant tuberculosis (DR-TB) is a big challenge in TB control.  The delay in diagnosis of DR-TB leads to its increased transmission, and therefore prevalence.  Recent developments in genomics have enabled whole genome sequencing (WGS) of Mycobacterium tuberculosis (M. tuberculosis) from 3-day-old liq. culture and directly from uncultured sputa, while new bioinformatics tools facilitate to det. DR mutations rapidly from the resulting sequences.  The present drug discovery and development pipeline is filled with candidate drugs which have shown efficacy against DR-TB.  Furthermore, some of the FDA-approved drugs are being evaluated for repurposing, and this approach appears promising as several drugs are reported to enhance efficacy of the std. TB drugs, reduce drug tolerance, or modulate the host immune response to control the growth of intracellular M. tuberculosis.  Recent developments in genomics and bioinformatics along with new drug discovery collectively have the potential to result in synergistic impact leading to the development of a rapid protocol to det. the drug resistance profile of the infecting strain so as to provide personalized medicine.  Hence, in this review, we discuss recent developments in WGS, bioinformatics and drug discovery to perceive how they would transform the management of tuberculosis in a timely manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm0xa2-N193rVg90H21EOLACvtfcHk0lgzKv_jqWJPjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlGmtLjI&md5=c4c84cc2fce629c326acd946331be4f8</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2Fj.tube.2016.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tube.2016.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DSwaminathan%26aufirst%3DS.%26aulast%3DSundaramurthi%26aufirst%3DJ.%2BC.%26aulast%3DPalaniappan%26aufirst%3DA.%2BN.%26aulast%3DNarayanan%26aufirst%3DS.%26atitle%3DRecent%2520developments%2520in%2520genomics%252C%2520bioinformatics%2520and%2520drug%2520discovery%2520to%2520combat%2520emerging%2520drug-resistant%2520tuberculosis%26jtitle%3DTuberculosis%2520%2528Oxford%252C%2520U.%2520K.%2529%26date%3D2016%26volume%3D101%26spage%3D31%26epage%3D40%26doi%3D10.1016%2Fj.tube.2016.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Campanico, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreira, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopes, F.</span></span> <span> </span><span class="NLM_article-title">Drug discovery in tuberculosis. New drug targets and antimycobacterial agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>150</i></span>,  <span class="NLM_fpage">525</span>– <span class="NLM_lpage">545</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.03.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.ejmech.2018.03.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=29549838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkslaitbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2018&pages=525-545&author=A.+Campanicoauthor=R.+Moreiraauthor=F.+Lopes&title=Drug+discovery+in+tuberculosis.+New+drug+targets+and+antimycobacterial+agents&doi=10.1016%2Fj.ejmech.2018.03.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Drug discovery in tuberculosis. New drug targets and antimycobacterial agents</span></div><div class="casAuthors">Campanico, Andre; Moreira, Rui; Lopes, Francisca</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">525-545</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Tuberculosis (TB) remains a major health problem worldwide.  The infectious agent, Mycobacterium tuberculosis, has a unique ability to survive within the host, alternating between active and latent disease states, and escaping the immune system defenses.  The extended duration of anti-TB regimens and the increasing prevalence of multidrug- (MDR) and extensively drug-resistant (XDR) M. tuberculosis strains have created an urgent need for new antibiotics active against drug-resistant organisms and that can shorten std. therapy.  However, despite success in identifying active compds. through phenotypic screens, the conversion of hits into novel chem. series and ultimately into clin. candidates is hampered by the poor efficacy in eliminating M. tuberculosis within different host compartments, including macrophages, as well as a lack of knowledge about the specific target(s) inhibited and/or upregulated.  The current status of anti-TB lead generation has much improved over the last decade, as exemplified by the recent approval of bedaquiline and delamanid to treat MDR-TB and XDR-TB.  This review provides a crit. anal. on the strategies used to progress hit compds. into viable lead candidates, and how emerging targets may play a role in TB drug discovery in the near future.  Four new relevant targets are addressed: the enoyl-acyl carrier protein reductase, InhA; the transmembrane transport protein large, MmpL3; the decaprenylphospho-beta-D-ribofuranose 2-oxidase, DprE1; and the ubiquinol-cytochrome C reductase, QcrB.  Validated hit compds. for each target are presented and explored, and the medicinal chem. strategies to expand SAR around novel chemotypes analyzed.  In addn., very recent emerging targets are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUk-MoGG4LfbVg90H21EOLACvtfcHk0li_urQDmtgUxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkslaitbc%253D&md5=57f1035f8081c62033438d9123ee0280</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.03.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.03.020%26sid%3Dliteratum%253Aachs%26aulast%3DCampanico%26aufirst%3DA.%26aulast%3DMoreira%26aufirst%3DR.%26aulast%3DLopes%26aufirst%3DF.%26atitle%3DDrug%2520discovery%2520in%2520tuberculosis.%2520New%2520drug%2520targets%2520and%2520antimycobacterial%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D150%26spage%3D525%26epage%3D545%26doi%3D10.1016%2Fj.ejmech.2018.03.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chiarelli, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esposito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orena, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasca, M. R.</span></span> <span> </span><span class="NLM_article-title">New and old hot drug targets in tuberculosis</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3813</span>– <span class="NLM_lpage">3846</span>, <span class="refDoi"> DOI: 10.2174/1389557516666160831164925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.2174%2F1389557516666160831164925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=27666933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVOhtbvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=3813-3846&author=L.+R.+Chiarelliauthor=G.+Moriauthor=M.+Espositoauthor=B.+S.+Orenaauthor=M.+R.+Pasca&title=New+and+old+hot+drug+targets+in+tuberculosis&doi=10.2174%2F1389557516666160831164925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">New and Old Hot Drug Targets in Tuberculosis</span></div><div class="casAuthors">Chiarelli, Laurent Roberto; Mori, Giorgia; Esposito, Marta; Orena, Beatrice Silvia; Pasca, Maria Rosalia</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">3813-3846</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Tuberculosis is an infectious disease caused by the bacillus Mycobacterium tuberculosis.  The World Health Organization publishes global tuberculosis reports annually in order to provide the latest information in the surveillance of drug resistance.  Given the alarming rise of resistance to antitubercular drugs worldwide, finding new cellular targets and developing new analogs or new compds. with greater potency against already known targets are both important aspects in fighting drug-sensitive and drug-resistant M. tuberculosis strains.  In this context, the introduction of the phenotypic screens as an efficient tool for the identification of active compds. for tuberculosis drug discovery has improved the possibility to find new effective targets.  With this review we describe the state of art of the currently well validated antitubercular drug targets as well as the advances in discovery of new ones.  The main targets will be discussed starting from the oldest such as the enoyl reductase InhA which is constantly repurposed with new inhibitors, through the well assessed targets like the gyrase, the ATP synthetase or the RNA polymerase, up to the hot promiscuous targets decaprenylphosphoryl-Dribose oxidase DprE1 and the mycolic acid transporter MmpL3, or the newly validated and promising targets like the CTP synthetase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvbtYX91i0i7Vg90H21EOLACvtfcHk0li_urQDmtgUxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVOhtbvL&md5=f00c5400343d8a9945e1b26039fd95f1</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.2174%2F1389557516666160831164925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389557516666160831164925%26sid%3Dliteratum%253Aachs%26aulast%3DChiarelli%26aufirst%3DL.%2BR.%26aulast%3DMori%26aufirst%3DG.%26aulast%3DEsposito%26aufirst%3DM.%26aulast%3DOrena%26aufirst%3DB.%2BS.%26aulast%3DPasca%26aufirst%3DM.%2BR.%26atitle%3DNew%2520and%2520old%2520hot%2520drug%2520targets%2520in%2520tuberculosis%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2016%26volume%3D23%26spage%3D3813%26epage%3D3846%26doi%3D10.2174%2F1389557516666160831164925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mdluli, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upton, A.</span></span> <span> </span><span class="NLM_article-title">The tuberculosis drug discovery and development pipeline and emerging drug targets</span>. <i>Cold Spring Harbor Perspect. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">a021154</span>, <span class="refDoi"> DOI: 10.1101/cshperspect.a021154</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1101%2Fcshperspect.a021154" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=25635061" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=a021154&author=K.+Mdluliauthor=T.+Kanekoauthor=A.+Upton&title=The+tuberculosis+drug+discovery+and+development+pipeline+and+emerging+drug+targets&doi=10.1101%2Fcshperspect.a021154"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a021154&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a021154%26sid%3Dliteratum%253Aachs%26aulast%3DMdluli%26aufirst%3DK.%26aulast%3DKaneko%26aufirst%3DT.%26aulast%3DUpton%26aufirst%3DA.%26atitle%3DThe%2520tuberculosis%2520drug%2520discovery%2520and%2520development%2520pipeline%2520and%2520emerging%2520drug%2520targets%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspect.%2520Med.%26date%3D2015%26volume%3D5%26spage%3Da021154%26doi%3D10.1101%2Fcshperspect.a021154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Man Chin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dos Santos, J. L.</span></span> <span> </span><span class="NLM_article-title">Advances in drug discovery of new antitubercular multidrug-resistant compounds</span>. <i>Pharmaceuticals</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">51</span>, <span class="refDoi"> DOI: 10.3390/ph10020051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.3390%2Fph10020051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVGgtL3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2017&pages=51&author=G.+Fernandesauthor=C.+Man+Chinauthor=J.+L.+Dos+Santos&title=Advances+in+drug+discovery+of+new+antitubercular+multidrug-resistant+compounds&doi=10.3390%2Fph10020051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in drug discovery of new antitubercular multidrug-resistant compounds</span></div><div class="casAuthors">Fernandes, Guilherme Felipe dos Santos; Chin, Chung Man; Dos, Jean Leandro Santo</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceuticals</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">51/1-51/17</span>CODEN:
                <span class="NLM_cas:coden">PHARH2</span>;
        ISSN:<span class="NLM_cas:issn">1424-8247</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Tuberculosis (TB), a disease caused mainly by the Mycobacterium tuberculosis (Mtb), is according to the World Health Organization (WHO) the infectious disease responsible for the highest no. of deaths worldwide.  The increased no. of multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) strains, and the ineffectiveness of the current treatment against latent tuberculosis are challenges to be overcome in the coming years.  The scenario of drug discovery becomes alarming when it is considered that the no. of new drugs does not increase proportionally to the emergence of drug resistance.  In this review, we will demonstrate the current advances in antitubercular drug discovery, focusing on the research of compds. with potent antituberculosis activity against MDR-TB strains.  Herein, active compds. against MDR-TB with min. inhibitory concns. (MICs) less than 11 μM and low toxicity published in the last 4 years in the databases PubMed, Web of Science and Scopus will be presented and discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr42opO3TGqlbVg90H21EOLACvtfcHk0lhuku_kVi2Ybw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVGgtL3F&md5=396d4e24b26faa44e68f661e6706b2e6</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.3390%2Fph10020051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fph10020051%26sid%3Dliteratum%253Aachs%26aulast%3DFernandes%26aufirst%3DG.%26aulast%3DMan%2BChin%26aufirst%3DC.%26aulast%3DDos%2BSantos%26aufirst%3DJ.%2BL.%26atitle%3DAdvances%2520in%2520drug%2520discovery%2520of%2520new%2520antitubercular%2520multidrug-resistant%2520compounds%26jtitle%3DPharmaceuticals%26date%3D2017%26volume%3D10%26spage%3D51%26doi%3D10.3390%2Fph10020051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, R.</span></span> <span> </span><span class="NLM_article-title">New structural classes of antituberculosis agents</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">684</span>– <span class="NLM_lpage">740</span>, <span class="refDoi"> DOI: 10.1002/med.21454</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1002%2Fmed.21454" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=28598559" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A280%3ADC%252BC1cnmslWltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2018&pages=684-740&author=V.+Kumarauthor=S.+Patelauthor=R.+Jain&title=New+structural+classes+of+antituberculosis+agents&doi=10.1002%2Fmed.21454"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">New structural classes of antituberculosis agents</span></div><div class="casAuthors">Kumar Vajinder; Patel Sanjay; Jain Rahul; Kumar Vajinder</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal research reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">684-740</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Tuberculosis (TB), one of the deadliest diseases is shattering the health and socioeconomic status of the society.  The emergence of multidrug resistant (MDR) and extremely drug resistant (XDR) strains has provided unprecedented lethal character to TB.  The development of MDR and XDR strains of TB results in more deaths, longer duration of therapy, and appearance of the disease in the immunocompromised patients.  Because of the development of rapid resistance by Mycobacterium tuberculosis, researchers are confronted with serious challenges in combating TB.  For instance, the need for potency and specificity in therapeutic agents approaching clinics, and the increasing demand of low toxicity due to long duration of treatment.  Recently, it is proposed that such challenges could be addressed by a shift from contemporary or known classes of drugs to new scaffold-containing or entirely new structural classes of drugs that possibly act on the previously unknown targets, resulting in possibly less instances of resistance development.  The exploitation of advances made in the biology of TB in the last and present decades have created opportunities to discover a large number of new structural classes that specifically targets TB by molecular mechanism of action(s) unknown earlier.  We have earlier reviewed new structural classes of anti-TB agents up to year 2005.  This review covers literature reports of the subsequent 10 years on the discovery of new structural classes of synthetic anti-TB agents.  Due to the availability of large number of research reports, we have divided new compounds in 38 structural classes, 368 structures, and 307 references.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSeCgKMDdtGrekdrW1FkXG-fW6udTcc2ebjjLV10Hdo7Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnmslWltg%253D%253D&md5=78d6b10f567bb66c82241ab993b160e4</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1002%2Fmed.21454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21454%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DJain%26aufirst%3DR.%26atitle%3DNew%2520structural%2520classes%2520of%2520antituberculosis%2520agents%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2018%26volume%3D38%26spage%3D684%26epage%3D740%26doi%3D10.1002%2Fmed.21454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">da
Silva, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campos, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribeiro, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Silva, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavan, F. R.</span></span> <span> </span><span class="NLM_article-title">New antimycobacterial agents in the pre-clinical phase or beyond: Recent advances in patent literature (2001–2016)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">269</span>– <span class="NLM_lpage">282</span>, <span class="refDoi"> DOI: 10.1080/13543776.2017.1253681</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1080%2F13543776.2017.1253681" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=27796146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVOjsLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=269-282&author=P.+B.+da%0ASilvaauthor=D.+L.+Camposauthor=C.+M.+Ribeiroauthor=I.+C.+da+Silvaauthor=F.+R.+Pavan&title=New+antimycobacterial+agents+in+the+pre-clinical+phase+or+beyond%3A+Recent+advances+in+patent+literature+%282001%E2%80%932016%29&doi=10.1080%2F13543776.2017.1253681"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">New antimycobacterial agents in the pre-clinical phase or beyond: recent advances in patent literature (2001-2016)</span></div><div class="casAuthors">da Silva, Patricia Bento; Campos, Debora Leite; Ribeiro, Camila Maringolo; da Silva, Isabel Cristiane; Pavan, Fernando Rogerio</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">269-282</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Introduction: Tuberculosis, an infectious disease, has caused more deaths worldwide than any other single infectious disease, killing more than 1.5 million people each year; equating to 4,100 deaths a day.  In the past 60 years, no new drugs have been added to the first line regimen, in spite of the fact that thousands of papers have been published on drugs against tuberculosis and hundreds of drugs have received patents as new potential products.  Thus, there is undoubtedly an urgent need for the deployment of new effective drugs against tuberculosis.  Areas covered: This review brings to the reader the opportunity to understand the chem. and biol. characteristics of all patented anti-tuberculosis drugs in North America, Europe, Japan, and Russia.  The 116 patents discussed here concern new mols. in the early or advanced phase of development in the last 16 years.  Expert opinion: Of all 116 patents, only one developed drug, bedaquiline, is used, and then, only in specific cases.  Another three drugs are in clin. studies.  However, many other compds., for which there are in vitro and in vivo studies, seem to fulfil the requisite criteria to be a new anti-tuberculosis agent.  However, why are they not in use.  Why were so many studies interrupted.  Why is there no more news for many of these drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1S72vxKotPLVg90H21EOLACvtfcHk0lhuku_kVi2Ybw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVOjsLjP&md5=b2360bfe2bcff758c005ef23c6905660</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1080%2F13543776.2017.1253681&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2017.1253681%26sid%3Dliteratum%253Aachs%26aulast%3Dda%2BSilva%26aufirst%3DP.%2BB.%26aulast%3DCampos%26aufirst%3DD.%2BL.%26aulast%3DRibeiro%26aufirst%3DC.%2BM.%26aulast%3Dda%2BSilva%26aufirst%3DI.%2BC.%26aulast%3DPavan%26aufirst%3DF.%2BR.%26atitle%3DNew%2520antimycobacterial%2520agents%2520in%2520the%2520pre-clinical%2520phase%2520or%2520beyond%253A%2520Recent%2520advances%2520in%2520patent%2520literature%2520%25282001%25E2%2580%25932016%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2017%26volume%3D27%26spage%3D269%26epage%3D282%26doi%3D10.1080%2F13543776.2017.1253681" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evangelopoulos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHugh, T. D.</span></span> <span> </span><span class="NLM_article-title">Improving the tuberculosis drug development pipeline</span>. <i>Chem. Biol. Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">951</span>– <span class="NLM_lpage">960</span>, <span class="refDoi"> DOI: 10.1111/cbdd.12549</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1111%2Fcbdd.12549" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=25772393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1CntL7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2015&pages=951-960&author=D.+Evangelopoulosauthor=T.+D.+McHugh&title=Improving+the+tuberculosis+drug+development+pipeline&doi=10.1111%2Fcbdd.12549"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Improving the Tuberculosis Drug Development Pipeline</span></div><div class="casAuthors">Evangelopoulos, Dimitrios; McHugh, Timothy D.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">951-960</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Mycobacterium tuberculosis is considered one of the most successful pathogens and multidrug-resistant tuberculosis, a disease that urgently requires new chem. entities to be developed for treatment.  There are currently several new mols. under clin. investigation in the tuberculosis (TB) drug development pipeline.  However, the complex lifestyle of M. tuberculosis within the host presents a barrier to the development of new drugs.  In this review, we highlight the reasons that make TB drug discovery and development challenging as well as providing solns., future directions and alternative approaches to new therapeutics for TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiYXL_L7EpMrVg90H21EOLACvtfcHk0ljKUgeX-_ILkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1CntL7L&md5=942bf372a15ce0c8d21f6b121552d892</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1111%2Fcbdd.12549&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcbdd.12549%26sid%3Dliteratum%253Aachs%26aulast%3DEvangelopoulos%26aufirst%3DD.%26aulast%3DMcHugh%26aufirst%3DT.%2BD.%26atitle%3DImproving%2520the%2520tuberculosis%2520drug%2520development%2520pipeline%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2015%26volume%3D86%26spage%3D951%26epage%3D960%26doi%3D10.1111%2Fcbdd.12549" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Libardo, M. D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boshoff, H. I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.,  III</span></span> <span> </span><span class="NLM_article-title">The present state of the tuberculosis drug development pipeline</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">81</span>– <span class="NLM_lpage">94</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2018.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.coph.2018.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=30144650" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2018&pages=81-94&author=M.+D.+J.+Libardoauthor=H.+I.+M.+Boshoffauthor=C.+E.+Barry&title=The+present+state+of+the+tuberculosis+drug+development+pipeline&doi=10.1016%2Fj.coph.2018.08.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2018.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2018.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DLibardo%26aufirst%3DM.%2BD.%2BJ.%26aulast%3DBoshoff%26aufirst%3DH.%2BI.%2BM.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26atitle%3DThe%2520present%2520state%2520of%2520the%2520tuberculosis%2520drug%2520development%2520pipeline%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2018%26volume%3D42%26spage%3D81%26epage%3D94%26doi%3D10.1016%2Fj.coph.2018.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trapero, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacitto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabbah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coyne, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizrahi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blundell, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ascher, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abell, C.</span></span> <span> </span><span class="NLM_article-title">Fragment-based approach to targeting inosine-5′-monophosphate dehydrogenase (IMPDH) from mycobacterium tuberculosis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2806</span>– <span class="NLM_lpage">2822</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01622</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01622" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltVGksb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2806-2822&author=A.+Traperoauthor=A.+Pacittoauthor=V.+Singhauthor=M.+Sabbahauthor=A.+G.+Coyneauthor=V.+Mizrahiauthor=T.+L.+Blundellauthor=D.+B.+Ascherauthor=C.+Abell&title=Fragment-based+approach+to+targeting+inosine-5%E2%80%B2-monophosphate+dehydrogenase+%28IMPDH%29+from+mycobacterium+tuberculosis&doi=10.1021%2Facs.jmedchem.7b01622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-Based Approach to Targeting Inosine-5'-monophosphate Dehydrogenase (IMPDH) from Mycobacterium tuberculosis</span></div><div class="casAuthors">Trapero, Ana; Pacitto, Angela; Singh, Vinayak; Sabbah, Mohamad; Coyne, Anthony G.; Mizrahi, Valerie; Blundell, Tom L.; Ascher, David B.; Abell, Chris</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2806-2822</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tuberculosis (TB) remains a major cause of mortality worldwide, and improved treatments are needed to combat emergence of drug resistance.  IMP dehydrogenase (IMPDH), a crucial enzyme required for de novo synthesis of guanine nucleotides, is an attractive TB drug target.  Herein, we describe the identification of potent IMPDH inhibitors using fragment-based screening and structure-based design techniques.  Screening of a fragment library for Mycobacterium thermoresistible (Mth) IMPDH ΔCBS inhibitors identified a low affinity phenylimidazole deriv.  X-ray crystallog. of the Mth IMPDH ΔCBS-IMP-inhibitor complex revealed that two mols. of the fragment were bound in the NAD binding pocket of IMPDH.  Linking the two mols. of the fragment afforded compds. with more than 1000-fold improvement in IMPDH affinity over the initial fragment hit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIloJxzRRl5bVg90H21EOLACvtfcHk0ljKUgeX-_ILkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltVGksb0%253D&md5=a0decf859d321144e41547dda2b38fbf</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01622%26sid%3Dliteratum%253Aachs%26aulast%3DTrapero%26aufirst%3DA.%26aulast%3DPacitto%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DV.%26aulast%3DSabbah%26aufirst%3DM.%26aulast%3DCoyne%26aufirst%3DA.%2BG.%26aulast%3DMizrahi%26aufirst%3DV.%26aulast%3DBlundell%26aufirst%3DT.%2BL.%26aulast%3DAscher%26aufirst%3DD.%2BB.%26aulast%3DAbell%26aufirst%3DC.%26atitle%3DFragment-based%2520approach%2520to%2520targeting%2520inosine-5%25E2%2580%25B2-monophosphate%2520dehydrogenase%2520%2528IMPDH%2529%2520from%2520mycobacterium%2520tuberculosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D2806%26epage%3D2822%26doi%3D10.1021%2Facs.jmedchem.7b01622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ananthan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faaleolea, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobrath, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwong, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laughon, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maddry, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasmussen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Secrist, J. A.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shindo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Showe, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosa, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suling, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, E. L.</span></span> <span> </span><span class="NLM_article-title">High-throughput screening for inhibitors of mycobacterium tuberculosis h37rv</span>. <i>Tuberculosis (Oxford, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">334</span>– <span class="NLM_lpage">353</span>, <span class="refDoi"> DOI: 10.1016/j.tube.2009.05.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.tube.2009.05.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=19758845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlaktbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2009&pages=334-353&author=S.+Ananthanauthor=E.+R.+Faaleoleaauthor=R.+C.+Goldmanauthor=J.+V.+Hobrathauthor=C.+D.+Kwongauthor=B.+E.+Laughonauthor=J.+A.+Maddryauthor=A.+Mehtaauthor=L.+Rasmussenauthor=R.+C.+Reynoldsauthor=J.+A.+Secristauthor=N.+Shindoauthor=D.+N.+Showeauthor=M.+I.+Sosaauthor=W.+J.+Sulingauthor=E.+L.+White&title=High-throughput+screening+for+inhibitors+of+mycobacterium+tuberculosis+h37rv&doi=10.1016%2Fj.tube.2009.05.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv</span></div><div class="casAuthors">Ananthan, Subramaniam; Faaleolea, Ellen R.; Goldman, Robert C.; Hobrath, Judith V.; Kwong, Cecil D.; Laughon, Barbara E.; Maddry, Joseph A.; Mehta, Alka; Rasmussen, Lynn; Reynolds, Robert C.; Secrist, John A., III; Shindo, Nice; Showe, Dustin N.; Sosa, Melinda I.; Suling, William J.; White, E. Lucile</div><div class="citationInfo"><span class="NLM_cas:title">Tuberculosis (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">334-353</span>CODEN:
                <span class="NLM_cas:coden">TUBECU</span>;
        ISSN:<span class="NLM_cas:issn">1472-9792</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">There is an urgent need for the discovery and development of new antitubercular agents that target new biochem. pathways and treat drug resistant forms of the disease.  One approach to addressing this need is through high-throughput screening of medicinally relevant libraries against the whole bacterium in order to discover a variety of new, active scaffolds that will stimulate new biol. research and drug discovery.  Through the Tuberculosis Antimicrobial Acquisition and Coordinating Facility (www.taacf.org), a large, medicinally relevant chem. library was screened against M. tuberculosis strain H37Rv.  The screening methods and a medicinal chem. anal. of the results are reported herein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqJYVfZDJLPrVg90H21EOLACvtfcHk0lgtIOdMjsoY-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlaktbs%253D&md5=709badc384ae51ed8c9d42e30d4e9653</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.tube.2009.05.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tube.2009.05.008%26sid%3Dliteratum%253Aachs%26aulast%3DAnanthan%26aufirst%3DS.%26aulast%3DFaaleolea%26aufirst%3DE.%2BR.%26aulast%3DGoldman%26aufirst%3DR.%2BC.%26aulast%3DHobrath%26aufirst%3DJ.%2BV.%26aulast%3DKwong%26aufirst%3DC.%2BD.%26aulast%3DLaughon%26aufirst%3DB.%2BE.%26aulast%3DMaddry%26aufirst%3DJ.%2BA.%26aulast%3DMehta%26aufirst%3DA.%26aulast%3DRasmussen%26aufirst%3DL.%26aulast%3DReynolds%26aufirst%3DR.%2BC.%26aulast%3DSecrist%26aufirst%3DJ.%2BA.%26aulast%3DShindo%26aufirst%3DN.%26aulast%3DShowe%26aufirst%3DD.%2BN.%26aulast%3DSosa%26aufirst%3DM.%2BI.%26aulast%3DSuling%26aufirst%3DW.%2BJ.%26aulast%3DWhite%26aufirst%3DE.%2BL.%26atitle%3DHigh-throughput%2520screening%2520for%2520inhibitors%2520of%2520mycobacterium%2520tuberculosis%2520h37rv%26jtitle%3DTuberculosis%2520%2528Oxford%252C%2520U.%2520K.%2529%26date%3D2009%26volume%3D89%26spage%3D334%26epage%3D353%26doi%3D10.1016%2Fj.tube.2009.05.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maddry, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ananthan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobrath, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwong, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maddox, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasmussen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Secrist, J. A.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosa, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span> <span> </span><span class="NLM_article-title">Antituberculosis activity of the molecular libraries screening center network library</span>. <i>Tuberculosis (Oxford, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">354</span>– <span class="NLM_lpage">363</span>, <span class="refDoi"> DOI: 10.1016/j.tube.2009.07.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.tube.2009.07.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=19783214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlaktbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2009&pages=354-363&author=J.+A.+Maddryauthor=S.+Ananthanauthor=R.+C.+Goldmanauthor=J.+V.+Hobrathauthor=C.+D.+Kwongauthor=C.+Maddoxauthor=L.+Rasmussenauthor=R.+C.+Reynoldsauthor=J.+A.+Secristauthor=M.+I.+Sosaauthor=E.+L.+Whiteauthor=W.+Zhang&title=Antituberculosis+activity+of+the+molecular+libraries+screening+center+network+library&doi=10.1016%2Fj.tube.2009.07.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Antituberculosis activity of the Molecular Libraries Screening Center Network library</span></div><div class="casAuthors">Maddry, Joseph A.; Ananthan, Subramaniam; Goldman, Robert C.; Hobrath, Judith V.; Kwong, Cecil D.; Maddox, Clinton; Rasmussen, Lynn; Reynolds, Robert C.; Secrist, John A., III; Sosa, Melinda I.; White, E. Lucile; Zhang, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Tuberculosis (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">354-363</span>CODEN:
                <span class="NLM_cas:coden">TUBECU</span>;
        ISSN:<span class="NLM_cas:issn">1472-9792</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">There is an urgent need for the discovery and development of new antitubercular agents that target novel biochem. pathways and treat drug-resistant forms of the disease.  One approach to addressing this need is through high-throughput screening of drug-like small mol. libraries against the whole bacterium in order to identify a variety of new, active scaffolds that will stimulate addnl. biol. research and drug discovery.  Through the Mol. Libraries Screening Center Network, the NIAID Tuberculosis Antimicrobial Acquisition and Coordinating Facility tested a 215,110-compd. library against Mycobacterium tuberculosis strain H37Rv.  A medicinal chem. survey of the results from the screening campaign is reported herein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH1oCyettJJLVg90H21EOLACvtfcHk0lgtIOdMjsoY-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlaktbY%253D&md5=2b8d1ea9ef392231534d6eb020771da9</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1016%2Fj.tube.2009.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tube.2009.07.006%26sid%3Dliteratum%253Aachs%26aulast%3DMaddry%26aufirst%3DJ.%2BA.%26aulast%3DAnanthan%26aufirst%3DS.%26aulast%3DGoldman%26aufirst%3DR.%2BC.%26aulast%3DHobrath%26aufirst%3DJ.%2BV.%26aulast%3DKwong%26aufirst%3DC.%2BD.%26aulast%3DMaddox%26aufirst%3DC.%26aulast%3DRasmussen%26aufirst%3DL.%26aulast%3DReynolds%26aufirst%3DR.%2BC.%26aulast%3DSecrist%26aufirst%3DJ.%2BA.%26aulast%3DSosa%26aufirst%3DM.%2BI.%26aulast%3DWhite%26aufirst%3DE.%2BL.%26aulast%3DZhang%26aufirst%3DW.%26atitle%3DAntituberculosis%2520activity%2520of%2520the%2520molecular%2520libraries%2520screening%2520center%2520network%2520library%26jtitle%3DTuberculosis%2520%2528Oxford%252C%2520U.%2520K.%2529%26date%3D2009%26volume%3D89%26spage%3D354%26epage%3D363%26doi%3D10.1016%2Fj.tube.2009.07.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ananthan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faaleolea, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobrath, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwong, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maddox, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasmussen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosa, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thammasuvimol, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Secrist, J. A.,  3rd.</span></span> <span> </span><span class="NLM_article-title">High throughput screening of a library based on kinase inhibitor scaffolds against mycobacterium tuberculosis h37rv</span>. <i>Tuberculosis (Oxford, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">72</span>– <span class="NLM_lpage">83</span>, <span class="refDoi"> DOI: 10.1016/j.tube.2011.05.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.tube.2011.05.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=21708485" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVCjur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2012&pages=72-83&author=R.+C.+Reynoldsauthor=S.+Ananthanauthor=E.+Faaleoleaauthor=J.+V.+Hobrathauthor=C.+D.+Kwongauthor=C.+Maddoxauthor=L.+Rasmussenauthor=M.+I.+Sosaauthor=E.+Thammasuvimolauthor=E.+L.+Whiteauthor=W.+Zhangauthor=J.+A.+Secrist&title=High+throughput+screening+of+a+library+based+on+kinase+inhibitor+scaffolds+against+mycobacterium+tuberculosis+h37rv&doi=10.1016%2Fj.tube.2011.05.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">High throughput screening of a library based on kinase inhibitor scaffolds against Mycobacterium tuberculosis H37Rv</span></div><div class="casAuthors">Reynolds, Robert C.; Ananthan, Subramaniam; Faaleolea, Ellen; Hobrath, Judith V.; Kwong, Cecil D.; Maddox, Clinton; Rasmussen, Lynn; Sosa, Melinda I.; Thammasuvimol, Elizabeth; White, E. Lucile; Zhang, Wei; Secrist, John A., III</div><div class="citationInfo"><span class="NLM_cas:title">Tuberculosis (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">72-83</span>CODEN:
                <span class="NLM_cas:coden">TUBECU</span>;
        ISSN:<span class="NLM_cas:issn">1472-9792</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Summary: Kinase targets are being pursued in a variety of diseases beyond cancer, including immune and metabolic as well as viral, parasitic, fungal and bacterial.  In particular, there is a relatively recent interest in kinase and ATP-binding targets in Mycobacterium tuberculosis in order to identify inhibitors and potential drugs for essential proteins that are not targeted by current drug regimens.  Herein, we report the high throughput screening results for a targeted library of approx. 26,000 compds. that was designed based on current kinase inhibitor scaffolds and known kinase binding sites.  The phenotypic data presented herein may form the basis for selecting scaffolds/compds. for further enzymic screens against specific kinase or other ATP-binding targets in Mycobacterium tuberculosis based on the apparent activity against the whole bacteria in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMT3SfbMPvRLVg90H21EOLACvtfcHk0lgtIOdMjsoY-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVCjur0%253D&md5=00aa700691dc03d427fd3d4851e605b7</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2Fj.tube.2011.05.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tube.2011.05.005%26sid%3Dliteratum%253Aachs%26aulast%3DReynolds%26aufirst%3DR.%2BC.%26aulast%3DAnanthan%26aufirst%3DS.%26aulast%3DFaaleolea%26aufirst%3DE.%26aulast%3DHobrath%26aufirst%3DJ.%2BV.%26aulast%3DKwong%26aufirst%3DC.%2BD.%26aulast%3DMaddox%26aufirst%3DC.%26aulast%3DRasmussen%26aufirst%3DL.%26aulast%3DSosa%26aufirst%3DM.%2BI.%26aulast%3DThammasuvimol%26aufirst%3DE.%26aulast%3DWhite%26aufirst%3DE.%2BL.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DSecrist%26aufirst%3DJ.%2BA.%26atitle%3DHigh%2520throughput%2520screening%2520of%2520a%2520library%2520based%2520on%2520kinase%2520inhibitor%2520scaffolds%2520against%2520mycobacterium%2520tuberculosis%2520h37rv%26jtitle%3DTuberculosis%2520%2528Oxford%252C%2520U.%2520K.%2529%26date%3D2012%26volume%3D92%26spage%3D72%26epage%3D83%26doi%3D10.1016%2Fj.tube.2011.05.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Makarov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lechartier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neres, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Sar, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raadsen, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartkoorn, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryabova, O. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decosterd, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widmer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buclin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bitter, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pojer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyson, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S. T.</span></span> <span> </span><span class="NLM_article-title">Towards a new combination therapy for tuberculosis with next generation benzothiazinones</span>. <i>EMBO Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">372</span>– <span class="NLM_lpage">383</span>, <span class="refDoi"> DOI: 10.1002/emmm.201303575</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1002%2Femmm.201303575" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=24500695" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjvVyjtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=372-383&author=V.+Makarovauthor=B.+Lechartierauthor=M.+Zhangauthor=J.+Neresauthor=A.+M.+van+der%0ASarauthor=S.+A.+Raadsenauthor=R.+C.+Hartkoornauthor=O.+B.+Ryabovaauthor=A.+Vocatauthor=L.+A.+Decosterdauthor=N.+Widmerauthor=T.+Buclinauthor=W.+Bitterauthor=K.+Andriesauthor=F.+Pojerauthor=P.+J.+Dysonauthor=S.+T.+Cole&title=Towards+a+new+combination+therapy+for+tuberculosis+with+next+generation+benzothiazinones&doi=10.1002%2Femmm.201303575"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Towards a new combination therapy for tuberculosis with next generation benzothiazinones</span></div><div class="casAuthors">Makarov, Vadim; Lechartier, Benoit; Zhang, Ming; Neres, Joao; van der Sar, Astrid M.; Raadsen, Susanne A.; Hartkoorn, Ruben C.; Ryabova, Olga B.; Vocat, Anthony; Decosterd, Laurent A.; Widmer, Nicolas; Buclin, Thierry; Bitter, Wilbert; Andries, Koen; Pojer, Florence; Dyson, Paul J.; Cole, Stewart T.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Molecular Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">372-383</span>CODEN:
                <span class="NLM_cas:coden">EMMMAM</span>;
        ISSN:<span class="NLM_cas:issn">1757-4684</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The benzothiazinone lead compd., BTZ043, kills Mycobacterium tuberculosis by inhibiting the essential flavo-enzyme DprE1, decaprenylphosphoryl-beta-D-ribose 2-epimerase.  Here, we synthesized a new series of piperazine-contg. benzothiazinones (PBTZ) and show that, like BTZ043, the preclin. candidate PBTZ169 binds covalently to DprE1.  The crystal structure of the DprE1-PBTZ169 complex reveals formation of a semimercaptal adduct with Cys387 in the active site and explains the irreversible inactivation of the enzyme.  Compared to BTZ043, PBTZ169 has improved potency, safety and efficacy in zebrafish and mouse models of tuberculosis (TB).  When combined with other TB drugs, PBTZ169 showed additive activity against M. tuberculosis in vitro except with bedaquiline (BDQ) where synergy was obsd.  A new regimen comprising PBTZ169, BDQ and pyrazinamide was found to be more efficacious than the std. three drug treatment in a murine model of chronic disease.  PBTZ169 is thus an attractive drug candidate to treat TB in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_BD_M46wCiLVg90H21EOLACvtfcHk0liE5DVMrsOYVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjvVyjtLw%253D&md5=5393e68ca6f35be17ae10a397b443907</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1002%2Femmm.201303575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Femmm.201303575%26sid%3Dliteratum%253Aachs%26aulast%3DMakarov%26aufirst%3DV.%26aulast%3DLechartier%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DNeres%26aufirst%3DJ.%26aulast%3Dvan%2Bder%2BSar%26aufirst%3DA.%2BM.%26aulast%3DRaadsen%26aufirst%3DS.%2BA.%26aulast%3DHartkoorn%26aufirst%3DR.%2BC.%26aulast%3DRyabova%26aufirst%3DO.%2BB.%26aulast%3DVocat%26aufirst%3DA.%26aulast%3DDecosterd%26aufirst%3DL.%2BA.%26aulast%3DWidmer%26aufirst%3DN.%26aulast%3DBuclin%26aufirst%3DT.%26aulast%3DBitter%26aufirst%3DW.%26aulast%3DAndries%26aufirst%3DK.%26aulast%3DPojer%26aufirst%3DF.%26aulast%3DDyson%26aufirst%3DP.%2BJ.%26aulast%3DCole%26aufirst%3DS.%2BT.%26atitle%3DTowards%2520a%2520new%2520combination%2520therapy%2520for%2520tuberculosis%2520with%2520next%2520generation%2520benzothiazinones%26jtitle%3DEMBO%2520Mol.%2520Med.%26date%3D2014%26volume%3D6%26spage%3D372%26epage%3D383%26doi%3D10.1002%2Femmm.201303575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Makarov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manina, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikusova, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mollmann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryabova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saint-Joanis, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasca, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buroni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucarelli, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rossi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belanova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bobovska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dianiskova, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kordulakova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sala, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fullam, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKinney, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christophe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waddell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butcher, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrethsen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenkrands, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brosch, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nandi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bharath, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaonkar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shandil, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balganesh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyagi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosset, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riccardi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S. T.</span></span> <span> </span><span class="NLM_article-title">Benzothiazinones kill mycobacterium tuberculosis by blocking arabinan synthesis</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>324</i></span>,  <span class="NLM_fpage">801</span>– <span class="NLM_lpage">804</span>, <span class="refDoi"> DOI: 10.1126/science.1171583</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1126%2Fscience.1171583" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=19299584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsVeksrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=324&publication_year=2009&pages=801-804&author=V.+Makarovauthor=G.+Maninaauthor=K.+Mikusovaauthor=U.+Mollmannauthor=O.+Ryabovaauthor=B.+Saint-Joanisauthor=N.+Dharauthor=M.+R.+Pascaauthor=S.+Buroniauthor=A.+P.+Lucarelliauthor=A.+Milanoauthor=E.+De+Rossiauthor=M.+Belanovaauthor=A.+Bobovskaauthor=P.+Dianiskovaauthor=J.+Kordulakovaauthor=C.+Salaauthor=E.+Fullamauthor=P.+Schneiderauthor=J.+D.+McKinneyauthor=P.+Brodinauthor=T.+Christopheauthor=S.+Waddellauthor=P.+Butcherauthor=J.+Albrethsenauthor=I.+Rosenkrandsauthor=R.+Broschauthor=V.+Nandiauthor=S.+Bharathauthor=S.+Gaonkarauthor=R.+K.+Shandilauthor=V.+Balasubramanianauthor=T.+Balganeshauthor=S.+Tyagiauthor=J.+Grossetauthor=G.+Riccardiauthor=S.+T.+Cole&title=Benzothiazinones+kill+mycobacterium+tuberculosis+by+blocking+arabinan+synthesis&doi=10.1126%2Fscience.1171583"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis</span></div><div class="casAuthors">Makarov, Vadim; Manina, Giulia; Mikusova, Katarina; Moellmann, Ute; Ryabova, Olga; Saint-Joanis, Brigitte; Dhar, Neeraj; Pasca, Maria Rosalia; Buroni, Silvia; Lucarelli, Anna Paola; Milano, Anna; De Rossi, Edda; Belanova, Martina; Bobovska, Adela; Dianiskova, Petronela; Kordulakova, Jana; Sala, Claudia; Fullam, Elizabeth; Schneider, Patricia; McKinney, John D.; Brodin, Priscille; Christophe, Thierry; Waddell, Simon; Butcher, Philip; Albrethsen, Jakob; Rosenkrands, Ida; Brosch, Roland; Nandi, Vrinda; Bharath, Sowmya; Gaonkar, Sheshagiri; Shandil, Radha K.; Balasubramanian, Venkataraman; Balganesh, Tanjore; Tyagi, Sandeep; Grosset, Jacques; Riccardi, Giovanna; Cole, Stewart T.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">324</span>
        (<span class="NLM_cas:issue">5928</span>),
    <span class="NLM_cas:pages">801-804</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">New drugs are required to counter the tuberculosis (TB) pandemic.  Here, we describe the synthesis and characterization of 1,3-benzothiazin-4-ones (BTZs), a new class of antimycobacterial agents that kill Mycobacterium tuberculosis in vitro, ex vivo, and in mouse models of TB.  Using genetics and biochem., we identified the enzyme decaprenylphosphoryl-β-D-ribose 2'-epimerase as a major BTZ target.  Inhibition of this enzymic activity abolishes the formation of decaprenylphosphoryl arabinose, a key precursor that is required for the synthesis of the cell-wall arabinans, thus provoking cell lysis and bacterial death.  The most advanced compd., BTZ043, is a candidate for inclusion in combination therapies for both drug-sensitive and extensively drug-resistant TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZiVvk0T_DOrVg90H21EOLACvtfcHk0liE5DVMrsOYVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsVeksrY%253D&md5=1d80f14ba88460ef5c8ea31793dbb592</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1126%2Fscience.1171583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1171583%26sid%3Dliteratum%253Aachs%26aulast%3DMakarov%26aufirst%3DV.%26aulast%3DManina%26aufirst%3DG.%26aulast%3DMikusova%26aufirst%3DK.%26aulast%3DMollmann%26aufirst%3DU.%26aulast%3DRyabova%26aufirst%3DO.%26aulast%3DSaint-Joanis%26aufirst%3DB.%26aulast%3DDhar%26aufirst%3DN.%26aulast%3DPasca%26aufirst%3DM.%2BR.%26aulast%3DBuroni%26aufirst%3DS.%26aulast%3DLucarelli%26aufirst%3DA.%2BP.%26aulast%3DMilano%26aufirst%3DA.%26aulast%3DDe%2BRossi%26aufirst%3DE.%26aulast%3DBelanova%26aufirst%3DM.%26aulast%3DBobovska%26aufirst%3DA.%26aulast%3DDianiskova%26aufirst%3DP.%26aulast%3DKordulakova%26aufirst%3DJ.%26aulast%3DSala%26aufirst%3DC.%26aulast%3DFullam%26aufirst%3DE.%26aulast%3DSchneider%26aufirst%3DP.%26aulast%3DMcKinney%26aufirst%3DJ.%2BD.%26aulast%3DBrodin%26aufirst%3DP.%26aulast%3DChristophe%26aufirst%3DT.%26aulast%3DWaddell%26aufirst%3DS.%26aulast%3DButcher%26aufirst%3DP.%26aulast%3DAlbrethsen%26aufirst%3DJ.%26aulast%3DRosenkrands%26aufirst%3DI.%26aulast%3DBrosch%26aufirst%3DR.%26aulast%3DNandi%26aufirst%3DV.%26aulast%3DBharath%26aufirst%3DS.%26aulast%3DGaonkar%26aufirst%3DS.%26aulast%3DShandil%26aufirst%3DR.%2BK.%26aulast%3DBalasubramanian%26aufirst%3DV.%26aulast%3DBalganesh%26aufirst%3DT.%26aulast%3DTyagi%26aufirst%3DS.%26aulast%3DGrosset%26aufirst%3DJ.%26aulast%3DRiccardi%26aufirst%3DG.%26aulast%3DCole%26aufirst%3DS.%2BT.%26atitle%3DBenzothiazinones%2520kill%2520mycobacterium%2520tuberculosis%2520by%2520blocking%2520arabinan%2520synthesis%26jtitle%3DScience%26date%3D2009%26volume%3D324%26spage%3D801%26epage%3D804%26doi%3D10.1126%2Fscience.1171583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freundlich, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talcott, C.</span></span> <span> </span><span class="NLM_article-title">Computational databases, pathway and cheminformatics tools for tuberculosis drug discovery</span>. <i>Trends Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">74</span>, <span class="refDoi"> DOI: 10.1016/j.tim.2010.10.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.tim.2010.10.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=21129975" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFyrtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=65-74&author=S.+Ekinsauthor=J.+S.+Freundlichauthor=I.+Choiauthor=M.+Sarkerauthor=C.+Talcott&title=Computational+databases%2C+pathway+and+cheminformatics+tools+for+tuberculosis+drug+discovery&doi=10.1016%2Fj.tim.2010.10.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Computational databases, pathway and cheminformatics tools for tuberculosis drug discovery</span></div><div class="casAuthors">Ekins, Sean; Freundlich, Joel S.; Choi, Inhee; Sarker, Malabika; Talcott, Carolyn</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Microbiology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">65-74</span>CODEN:
                <span class="NLM_cas:coden">TRMIEA</span>;
        ISSN:<span class="NLM_cas:issn">0966-842X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  We are witnessing the growing menace of both increasing cases of drug-sensitive and drug-resistant Mycobacterium tuberculosis strains and the challenge to produce the first new tuberculosis (TB) drug in well over 40 years.  The TB community, having invested in extensive high-throughput screening efforts, is faced with the question of how to optimally leverage these data to move from a hit to a lead to a clin. candidate and potentially, a new drug.  Complementing this approach, yet conducted on a much smaller scale, cheminformatic techniques have been leveraged and are examd. in this review.  We suggest that these computational approaches should be optimally integrated within a workflow with exptl. approaches to accelerate TB drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplSgfEUzeep7Vg90H21EOLACvtfcHk0liE5DVMrsOYVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFyrtrc%253D&md5=bc87f2b9ac1aced3dac949fda2acf5b9</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.tim.2010.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tim.2010.10.005%26sid%3Dliteratum%253Aachs%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DFreundlich%26aufirst%3DJ.%2BS.%26aulast%3DChoi%26aufirst%3DI.%26aulast%3DSarker%26aufirst%3DM.%26aulast%3DTalcott%26aufirst%3DC.%26atitle%3DComputational%2520databases%252C%2520pathway%2520and%2520cheminformatics%2520tools%2520for%2520tuberculosis%2520drug%2520discovery%26jtitle%3DTrends%2520Microbiol.%26date%3D2011%26volume%3D19%26spage%3D65%26epage%3D74%26doi%3D10.1016%2Fj.tim.2010.10.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipinski, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradford, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dole, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spektor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blondeau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goncharoff, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohman, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunin, B. A.</span></span> <span> </span><span class="NLM_article-title">Analysis and hit filtering of a very large library of compounds screened against mycobacterium tuberculosis</span>. <i>Mol. BioSyst.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">2316</span>– <span class="NLM_lpage">2324</span>, <span class="refDoi"> DOI: 10.1039/C0MB00104J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1039%2FC0MB00104J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=20835433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1KqtL7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=2316-2324&author=S.+Ekinsauthor=T.+Kanekoauthor=C.+A.+Lipinskiauthor=J.+Bradfordauthor=K.+Doleauthor=A.+Spektorauthor=K.+Gregoryauthor=D.+Blondeauauthor=S.+Ernstauthor=J.+Yangauthor=N.+Goncharoffauthor=M.+M.+Hohmanauthor=B.+A.+Bunin&title=Analysis+and+hit+filtering+of+a+very+large+library+of+compounds+screened+against+mycobacterium+tuberculosis&doi=10.1039%2FC0MB00104J"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis and hit filtering of a very large library of compounds screened against Mycobacterium tuberculosis</span></div><div class="casAuthors">Ekins, Sean; Kaneko, Takushi; Lipinski, Christopher A.; Bradford, Justin; Dole, Krishna; Spektor, Anna; Gregory, Kellan; Blondeau, David; Ernst, Sylvia; Yang, Jeremy; Goncharoff, Nicko; Hohman, Moses M.; Bunin, Barry A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular BioSystems</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2316-2324</span>CODEN:
                <span class="NLM_cas:coden">MBOIBW</span>;
        ISSN:<span class="NLM_cas:issn">1742-206X</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">There is an urgent need for new drugs against tuberculosis which annually claims 1.7-1.8 million lives.  One approach to identify potential leads is to screen in vitro small mols. against Mycobacterium tuberculosis (Mtb).  Until recently there was no central repository to collect information on compds. screened.  Consequently, it has been difficult to analyze mol. properties of compds. that inhibit the growth of Mtb in vitro.  We have collected data from publically available sources on over 300 000 small mols. deposited in the Collaborative Drug Discovery TB Database.  A cheminformatics anal. on these compds. indicates that inhibitors of the growth of Mtb have statistically higher mean logP, rule of 5 alerts, while also having lower HBD count, atom count and lower PSA (ChemAxon descriptors), compared to compds. that are classed as inactive.  Addnl., Bayesian models for selecting Mtb active compds. were evaluated with over 100 000 compds. and, they demonstrated 10 fold enrichment over random for the top ranked 600 compds.  This represents a promising approach for finding compds. active against Mtb in whole cells screened under the same in vitro conditions.  Various sets of Mtb hit mols. were also examd. by various filtering rules used widely in the pharmaceutical industry to identify compds. with potentially reactive moieties.  We found differences between the no. of compds. flagged by these rules in Mtb datasets, malaria hits, FDA approved drugs and antibiotics.  Combining these approaches may enable selection of compds. with increased probability of inhibition of whole cell Mtb activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSaytzWyG0H7Vg90H21EOLACvtfcHk0ljepvUHKRX55Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1KqtL7L&md5=66783a6e7ae22ad9b0022d94d6a77cea</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1039%2FC0MB00104J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC0MB00104J%26sid%3Dliteratum%253Aachs%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DKaneko%26aufirst%3DT.%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26aulast%3DBradford%26aufirst%3DJ.%26aulast%3DDole%26aufirst%3DK.%26aulast%3DSpektor%26aufirst%3DA.%26aulast%3DGregory%26aufirst%3DK.%26aulast%3DBlondeau%26aufirst%3DD.%26aulast%3DErnst%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DGoncharoff%26aufirst%3DN.%26aulast%3DHohman%26aufirst%3DM.%2BM.%26aulast%3DBunin%26aufirst%3DB.%2BA.%26atitle%3DAnalysis%2520and%2520hit%2520filtering%2520of%2520a%2520very%2520large%2520library%2520of%2520compounds%2520screened%2520against%2520mycobacterium%2520tuberculosis%26jtitle%3DMol.%2520BioSyst.%26date%3D2010%26volume%3D6%26spage%3D2316%26epage%3D2324%26doi%3D10.1039%2FC0MB00104J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradford, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dole, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spektor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blondeau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunin, B. A.</span></span> <span> </span><span class="NLM_article-title">A collaborative database and computational models for tuberculosis drug discovery</span>. <i>Mol. BioSyst.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">840</span>– <span class="NLM_lpage">851</span>, <span class="refDoi"> DOI: 10.1039/b917766c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1039%2Fb917766c" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=20567770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvVSrtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=840-851&author=S.+Ekinsauthor=J.+Bradfordauthor=K.+Doleauthor=A.+Spektorauthor=K.+Gregoryauthor=D.+Blondeauauthor=M.+Hohmanauthor=B.+A.+Bunin&title=A+collaborative+database+and+computational+models+for+tuberculosis+drug+discovery&doi=10.1039%2Fb917766c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">A collaborative database and computational models for tuberculosis drug discovery</span></div><div class="casAuthors">Ekins, Sean; Bradford, Justin; Dole, Krishna; Spektor, Anna; Gregory, Kellan; Blondeau, David; Hohman, Moses; Bunin, Barry A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular BioSystems</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">840-851</span>CODEN:
                <span class="NLM_cas:coden">MBOIBW</span>;
        ISSN:<span class="NLM_cas:issn">1742-206X</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The search for mols. with activity against Mycobacterium tuberculosis (Mtb) is employing many approaches in parallel including high throughput screening and computational methods.  We have developed a database (CDD TB) to capture public and private Mtb data while enabling data mining and collaborations with other researchers.  We have used the public data along with several cheminformatics approaches to produce models that describe active and inactive compds.  We have compared these datasets to those for known FDA approved drugs and between Mtb active and inactive compds.  The distribution of polar surface area and pKa of active compds. was found to be a statistically significant determinant of activity against Mtb.  Hydrophobicity was not always statistically significant. Bayesian classification models for 220463 mols. were generated and tested with external mols., and enabled the discrimination of active or inactive substructures from other datasets in the CDD TB.  Computational pharmacophores based on known Mtb drugs were able to map to and retrieve a small subset of some of the Mtb datasets, including a high percentage of Mtb actives.  The combination of the database, dataset anal., Bayesian and pharmacophore models provides new insights into mol. properties and features that are determinants of activity in whole cells.  This study provides novel insights into the key 1D mol. descriptors, 2D chem. substructures and 3D pharmacophores which can be used to mine the chem. space, prioritizing those mols. with a higher probability of activity against Mtb.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgfg8SbojRpLVg90H21EOLACvtfcHk0ljepvUHKRX55Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvVSrtrg%253D&md5=5bab2de79f0bb02dc9f3b24563776b16</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1039%2Fb917766c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb917766c%26sid%3Dliteratum%253Aachs%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DBradford%26aufirst%3DJ.%26aulast%3DDole%26aufirst%3DK.%26aulast%3DSpektor%26aufirst%3DA.%26aulast%3DGregory%26aufirst%3DK.%26aulast%3DBlondeau%26aufirst%3DD.%26aulast%3DHohman%26aufirst%3DM.%26aulast%3DBunin%26aufirst%3DB.%2BA.%26atitle%3DA%2520collaborative%2520database%2520and%2520computational%2520models%2520for%2520tuberculosis%2520drug%2520discovery%26jtitle%3DMol.%2520BioSyst.%26date%3D2010%26volume%3D6%26spage%3D840%26epage%3D851%26doi%3D10.1039%2Fb917766c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koo, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekonomidis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talaue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paget, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolhiser, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenaerts, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunin, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connell, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freundlich, J. S.</span></span> <span> </span><span class="NLM_article-title">Bayesian models leveraging bioactivity and cytotoxicity information for drug discovery</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">370</span>– <span class="NLM_lpage">378</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2013.01.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.chembiol.2013.01.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=23521795" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksFOgt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=370-378&author=S.+Ekinsauthor=R.+C.+Reynoldsauthor=H.+Kimauthor=M.+S.+Kooauthor=M.+Ekonomidisauthor=M.+Talaueauthor=S.+D.+Pagetauthor=L.+K.+Woolhiserauthor=A.+J.+Lenaertsauthor=B.+A.+Buninauthor=N.+Connellauthor=J.+S.+Freundlich&title=Bayesian+models+leveraging+bioactivity+and+cytotoxicity+information+for+drug+discovery&doi=10.1016%2Fj.chembiol.2013.01.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Bayesian Models Leveraging Bioactivity and Cytotoxicity Information for Drug Discovery</span></div><div class="casAuthors">Ekins, Sean; Reynolds, Robert C.; Kim, Hiyun; Koo, Mi-Sun; Ekonomidis, Marilyn; Talaue, Meliza; Paget, Steve D.; Woolhiser, Lisa K.; Lenaerts, Anne J.; Bunin, Barry A.; Connell, Nancy; Freundlich, Joel S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">370-378</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Identification of unique leads represents a significant challenge in drug discovery.  This hurdle is magnified in neglected diseases such as tuberculosis.  We have leveraged public high-throughput screening (HTS) data to exptl. validate a virtual screening approach employing Bayesian models built with bioactivity information (single-event model) as well as bioactivity and cytotoxicity information (dual-event model).  We virtually screened a com. library and exptl. confirmed actives with hit rates exceeding typical HTS results by one to two orders of magnitude.  This initial dual-event Bayesian model identified compds. with antitubercular whole-cell activity and low mammalian cell cytotoxicity from a published set of antimalarials.  The most potent hit exhibits the in vitro activity and in vitro/in vivo safety profile of a drug lead.  These Bayesian models offer significant economies in time and cost to drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHn7pP5TWKSbVg90H21EOLACvtfcHk0ljepvUHKRX55Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksFOgt7g%253D&md5=4b64d1c0fa67896b9d61c7f2fd606542</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2013.01.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2013.01.011%26sid%3Dliteratum%253Aachs%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DReynolds%26aufirst%3DR.%2BC.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DKoo%26aufirst%3DM.%2BS.%26aulast%3DEkonomidis%26aufirst%3DM.%26aulast%3DTalaue%26aufirst%3DM.%26aulast%3DPaget%26aufirst%3DS.%2BD.%26aulast%3DWoolhiser%26aufirst%3DL.%2BK.%26aulast%3DLenaerts%26aufirst%3DA.%2BJ.%26aulast%3DBunin%26aufirst%3DB.%2BA.%26aulast%3DConnell%26aufirst%3DN.%26aulast%3DFreundlich%26aufirst%3DJ.%2BS.%26atitle%3DBayesian%2520models%2520leveraging%2520bioactivity%2520and%2520cytotoxicity%2520information%2520for%2520drug%2520discovery%26jtitle%3DChem.%2520Biol.%26date%3D2013%26volume%3D20%26spage%3D370%26epage%3D378%26doi%3D10.1016%2Fj.chembiol.2013.01.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mori, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarelli, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esposito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makarov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellinzoni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartkoorn, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degiacomi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boldrin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jesus Lopes Ribeiro, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marino, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Centarova, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svetlikova, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasko, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazakova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lepioshkin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barilone, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fondi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baulard, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikusova, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alzari, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manganelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Carvalho, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riccardi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasca, M. R.</span></span> <span> </span><span class="NLM_article-title">Thiophenecarboxamide derivatives activated by etha kill mycobacterium tuberculosis by inhibiting the CTP synthetase PyrG</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">917</span>– <span class="NLM_lpage">927</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2015.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.chembiol.2015.05.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=26097035" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtV2it7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=917-927&author=G.+Moriauthor=L.+R.+Chiarelliauthor=M.+Espositoauthor=V.+Makarovauthor=M.+Bellinzoniauthor=R.+C.+Hartkoornauthor=G.+Degiacomiauthor=F.+Boldrinauthor=S.+Ekinsauthor=A.+L.+de+Jesus+Lopes+Ribeiroauthor=L.+B.+Marinoauthor=I.+Centarovaauthor=Z.+Svetlikovaauthor=J.+Blaskoauthor=E.+Kazakovaauthor=A.+Lepioshkinauthor=N.+Bariloneauthor=G.+Zanoniauthor=A.+Portaauthor=M.+Fondiauthor=R.+Faniauthor=A.+R.+Baulardauthor=K.+Mikusovaauthor=P.+M.+Alzariauthor=R.+Manganelliauthor=L.+P.+de+Carvalhoauthor=G.+Riccardiauthor=S.+T.+Coleauthor=M.+R.+Pasca&title=Thiophenecarboxamide+derivatives+activated+by+etha+kill+mycobacterium+tuberculosis+by+inhibiting+the+CTP+synthetase+PyrG&doi=10.1016%2Fj.chembiol.2015.05.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Thiophenecarboxamide Derivatives Activated by EthA Kill Mycobacterium tuberculosis by Inhibiting the CTP Synthetase PyrG</span></div><div class="casAuthors">Mori, Giorgia; Chiarelli, Laurent R.; Esposito, Marta; Makarov, Vadim; Bellinzoni, Marco; Hartkoorn, Ruben C.; Degiacomi, Giulia; Boldrin, Francesca; Ekins, Sean; Ribeiro, Ana Luisa de Jesus Lopes; Marino, Leonardo B.; Centarova, Ivana; Svetlikova, Zuzana; Blasko, Jaroslav; Kazakova, Elena; Lepioshkin, Alexander; Barilone, Nathalie; Zanoni, Giuseppe; Porta, Alessio; Fondi, Marco; Fani, Renato; Baulard, Alain R.; Mikusova, Katarina; Alzari, Pedro M.; Manganelli, Riccardo; de Carvalho, Luiz Pedro S.; Riccardi, Giovanna; Cole, Stewart T.; Pasca, Maria Rosalia</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">917-927</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">To combat the emergence of drug-resistant strains of Mycobacterium tuberculosis, new antitubercular agents and novel drug targets are needed.  Phenotypic screening of a library of 594 hit compds. uncovered two leads that were active against M. tuberculosis in its replicating, non-replicating, and intracellular states: compds. 7947882 (5-methyl-N-(4-nitrophenyl)thiophene-2-carboxamide) and 7904688 (3-phenyl-N-[(4-piperidin-1-ylphenyl)carbamothioyl]propanamide).  Mutants resistant to both compds. harbored mutations in ethA (rv3854c), the gene encoding the monooxygenase EthA, and/or in pyrG (rv1699) coding for the CTP synthetase, PyrG.  Biochem. studies demonstrated that EthA is responsible for the activation of the compds., and by mass spectrometry the authors identified the active metabolite of 7947882, which directly inhibits PyrG activity.  Metabolomic studies revealed that pharmacol. inhibition of PyrG strongly perturbs DNA and RNA biosynthesis, and other metabolic processes requiring nucleotides.  Finally, the crystal structure of PyrG was solved, paving the way for rational drug design with this newly validated drug target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFEer4apXX9LVg90H21EOLACvtfcHk0lh7VAFIeiqofw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtV2it7jJ&md5=7d03e0254f93e8504dc0b3f4248ea54c</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2015.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2015.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DMori%26aufirst%3DG.%26aulast%3DChiarelli%26aufirst%3DL.%2BR.%26aulast%3DEsposito%26aufirst%3DM.%26aulast%3DMakarov%26aufirst%3DV.%26aulast%3DBellinzoni%26aufirst%3DM.%26aulast%3DHartkoorn%26aufirst%3DR.%2BC.%26aulast%3DDegiacomi%26aufirst%3DG.%26aulast%3DBoldrin%26aufirst%3DF.%26aulast%3DEkins%26aufirst%3DS.%26aulast%3Dde%2BJesus%2BLopes%2BRibeiro%26aufirst%3DA.%2BL.%26aulast%3DMarino%26aufirst%3DL.%2BB.%26aulast%3DCentarova%26aufirst%3DI.%26aulast%3DSvetlikova%26aufirst%3DZ.%26aulast%3DBlasko%26aufirst%3DJ.%26aulast%3DKazakova%26aufirst%3DE.%26aulast%3DLepioshkin%26aufirst%3DA.%26aulast%3DBarilone%26aufirst%3DN.%26aulast%3DZanoni%26aufirst%3DG.%26aulast%3DPorta%26aufirst%3DA.%26aulast%3DFondi%26aufirst%3DM.%26aulast%3DFani%26aufirst%3DR.%26aulast%3DBaulard%26aufirst%3DA.%2BR.%26aulast%3DMikusova%26aufirst%3DK.%26aulast%3DAlzari%26aufirst%3DP.%2BM.%26aulast%3DManganelli%26aufirst%3DR.%26aulast%3Dde%2BCarvalho%26aufirst%3DL.%2BP.%26aulast%3DRiccardi%26aufirst%3DG.%26aulast%3DCole%26aufirst%3DS.%2BT.%26aulast%3DPasca%26aufirst%3DM.%2BR.%26atitle%3DThiophenecarboxamide%2520derivatives%2520activated%2520by%2520etha%2520kill%2520mycobacterium%2520tuberculosis%2520by%2520inhibiting%2520the%2520CTP%2520synthetase%2520PyrG%26jtitle%3DChem.%2520Biol.%26date%3D2015%26volume%3D22%26spage%3D917%26epage%3D927%26doi%3D10.1016%2Fj.chembiol.2015.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madrid, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stratton, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talcott, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourbon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Travers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yadav, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freundlich, J. S.</span></span> <span> </span><span class="NLM_article-title">Combining metabolite-based pharmacophores with bayesian machine learning models for mycobacterium tuberculosis drug discovery</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">e0141076</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0141076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1371%2Fjournal.pone.0141076" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=26517557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFGqu7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=e0141076&author=S.+Ekinsauthor=P.+B.+Madridauthor=M.+Sarkerauthor=S.+G.+Liauthor=N.+Mittalauthor=P.+Kumarauthor=X.+Wangauthor=T.+P.+Strattonauthor=M.+Zimmermanauthor=C.+Talcottauthor=P.+Bourbonauthor=M.+Traversauthor=M.+Yadavauthor=J.+S.+Freundlich&title=Combining+metabolite-based+pharmacophores+with+bayesian+machine+learning+models+for+mycobacterium+tuberculosis+drug+discovery&doi=10.1371%2Fjournal.pone.0141076"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Combining metabolite-based pharmacophores with Bayesian machine Learning Models for Mycobacterium tuberculosis drug discovery</span></div><div class="casAuthors">Ekins, Sean; Madrid, Peter B.; Sarker, Malabika; Li, Shao-Gang; Mittal, Nisha; Kumar, Pradeep; Wang, Xin; Stratton, Thomas P.; Zimmerman, Matthew; Talcott, Carolyn; Bourbon, Pauline; Travers, Mike; Yadav, Maneesh; Freundlich, Joel S.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e0141076/1-e0141076/20</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Integrated computational approaches for Mycobacterium tuberculosis (Mtb) are useful to identify new mols. that could lead to future tuberculosis (TB) drugs.  Our approach uses information derived from the TBCyc pathway and genome database, the Collaborative Drug Discovery TB database combined with 3D pharmacophores and dual event Bayesian models of whole-cell activity and lack of cytotoxicity.  We have prioritized a large no. of mols. that may act as mimics of substrates and metabolites in the TB metabolome.  We computationally searched over 200,000 com. mols. using 66 pharmacophores based on substrates and metabolites from Mtb and further filtering with Bayesian models.  We ultimately tested 110 compds. in vitro that resulted in two compds. of interest, BAS 04912643 and BAS 00623753 (MIC of 2.5 and 5 μg/mL, resp.).  These mols. were used as a starting point for hit-to-lead optimization.  The most promising class proved to be the quinoxaline di-N-oxides, evidenced by transcriptional profiling to induce mRNA level perturbations most closely resembling known protonophores.  One of these, SRI58 exhibited an MIC = 1.25 μg/mL vs. Mtband a CC50 in Vero cells of >40 μg/mL, while featuring fair Caco-2 A-B permeability (2.3 × 10-6 cm/s), kinetic soly. (125 μMat pH 7.4 in PBS) and mouse metabolic stability (63.6% remaining after 1 h incubation with mouse liver microsomes).  Despite demonstration of how a combined bioinformatics/cheminformatics approach afforded a small mol. with promising in vitro profiles, we found that SRI58 did not exhibit quantifiable blood levels in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1Q4DnXCIy_LVg90H21EOLACvtfcHk0lh7VAFIeiqofw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFGqu7vN&md5=d19ba65818e14fc9fb1305664a827340</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0141076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0141076%26sid%3Dliteratum%253Aachs%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DMadrid%26aufirst%3DP.%2BB.%26aulast%3DSarker%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DS.%2BG.%26aulast%3DMittal%26aufirst%3DN.%26aulast%3DKumar%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DStratton%26aufirst%3DT.%2BP.%26aulast%3DZimmerman%26aufirst%3DM.%26aulast%3DTalcott%26aufirst%3DC.%26aulast%3DBourbon%26aufirst%3DP.%26aulast%3DTravers%26aufirst%3DM.%26aulast%3DYadav%26aufirst%3DM.%26aulast%3DFreundlich%26aufirst%3DJ.%2BS.%26atitle%3DCombining%2520metabolite-based%2520pharmacophores%2520with%2520bayesian%2520machine%2520learning%2520models%2520for%2520mycobacterium%2520tuberculosis%2520drug%2520discovery%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26spage%3De0141076%26doi%3D10.1371%2Fjournal.pone.0141076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merceron, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gracia, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quintana, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Risseeuw, M. D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hulpia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ainsa, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munier-Lehmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savvides, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Calenbergh, S.</span></span> <span> </span><span class="NLM_article-title">Structure guided lead generation toward nonchiral m. Tuberculosis thymidylate kinase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2753</span>– <span class="NLM_lpage">2775</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01570</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01570" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjvFWnsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2753-2775&author=L.+Songauthor=R.+Merceronauthor=B.+Graciaauthor=A.+L.+Quintanaauthor=M.+D.+P.+Risseeuwauthor=F.+Hulpiaauthor=P.+Cosauthor=J.+A.+Ainsaauthor=H.+Munier-Lehmannauthor=S.+N.+Savvidesauthor=S.+Van+Calenbergh&title=Structure+guided+lead+generation+toward+nonchiral+m.+Tuberculosis+thymidylate+kinase+inhibitors&doi=10.1021%2Facs.jmedchem.7b01570"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Structure Guided Lead Generation toward Nonchiral M. tuberculosis Thymidylate Kinase Inhibitors</span></div><div class="casAuthors">Song, Lijun; Merceron, Romain; Gracia, Begona; Quintana, Ainhoa Lucia; Risseeuw, Martijn D. P.; Hulpia, Fabian; Cos, Paul; Ainsa, Jose A.; Munier-Lehmann, Helene; Savvides, Savvas N.; Van Calenbergh, Serge</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2753-2775</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In recent years, thymidylate kinase (TMPK), an enzyme indispensable for bacterial DNA biosynthesis, has been pursued for the development of new antibacterial agents including against Mycobacterium tuberculosis, the causative agent for the widespread infectious disease tuberculosis (TB).  In response to a growing need for more effective anti-TB drugs, the authors have built upon the authors' previous efforts toward the exploration of novel and potent Mycobacterium tuberculosis TMPK (MtTMPK) inhibitors, and reported here the design of a novel series of non-nucleoside inhibitors of MtTMPK.  The inhibitors display hitherto unexplored interactions in the active site of MtTMPK, offering new insights into structure-activity relationships.  To investigate the discrepancy between enzyme inhibitory activity and the whole-cell activity, expts. with efflux pump inhibitors and efflux pump knockout mutants were performed.  The min. inhibitory concns. of particular inhibitors increased significantly when detd. for the efflux pump mmr knockout mutant, which partly explains the obsd. dissonance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4USuGJ25TnbVg90H21EOLACvtfcHk0lj-ywQeD_CfxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjvFWnsr4%253D&md5=c4b195c0bb6969ad71abece65c82bd4a</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01570&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01570%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DL.%26aulast%3DMerceron%26aufirst%3DR.%26aulast%3DGracia%26aufirst%3DB.%26aulast%3DQuintana%26aufirst%3DA.%2BL.%26aulast%3DRisseeuw%26aufirst%3DM.%2BD.%2BP.%26aulast%3DHulpia%26aufirst%3DF.%26aulast%3DCos%26aufirst%3DP.%26aulast%3DAinsa%26aufirst%3DJ.%2BA.%26aulast%3DMunier-Lehmann%26aufirst%3DH.%26aulast%3DSavvides%26aufirst%3DS.%2BN.%26aulast%3DVan%2BCalenbergh%26aufirst%3DS.%26atitle%3DStructure%2520guided%2520lead%2520generation%2520toward%2520nonchiral%2520m.%2520Tuberculosis%2520thymidylate%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D2753%26epage%3D2775%26doi%3D10.1021%2Facs.jmedchem.7b01570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nyantakyi, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dartois, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gengenbacher, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Go, M. L.</span></span> <span> </span><span class="NLM_article-title">Indolyl azaspiroketal mannich bases are potent antimycobacterial agents with selective membrane permeabilizing effects and in vivo activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">5733</span>– <span class="NLM_lpage">5750</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00777</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00777" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFamtbrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5733-5750&author=S.+A.+Nyantakyiauthor=M.+Liauthor=P.+Gopalauthor=M.+Zimmermanauthor=V.+Dartoisauthor=M.+Gengenbacherauthor=T.+Dickauthor=M.+L.+Go&title=Indolyl+azaspiroketal+mannich+bases+are+potent+antimycobacterial+agents+with+selective+membrane+permeabilizing+effects+and+in+vivo+activity&doi=10.1021%2Facs.jmedchem.8b00777"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Indolyl Azaspiroketal Mannich Bases Are Potent Antimycobacterial Agents with Selective Membrane Permeabilizing Effects and in Vivo Activity</span></div><div class="casAuthors">Nyantakyi, Samuel Agyei; Li, Ming; Gopal, Pooja; Zimmerman, Matthew; Dartois, Veronique; Gengenbacher, Martin; Dick, Thomas; Go, Mei-Lin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5733-5750</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The inclusion of an azaspiroketal Mannich base in the membrane targeting antitubercular 6-methoxy-1-n-octyl-1H-indole scaffold resulted in analogs with improved selectivity and submicromolar activity against Mycobacterium tuberculosis H37Rv.  The potency enhancing properties of the spiro-ring fused motif was affirmed by SAR and validated in a mouse model of tuberculosis.  As expected for membrane inserting agents, the indolyl azaspiroketal Mannich bases perturbed phospholipid vesicles, permeabilized bacterial cells and induced the mycobacterial cell envelope stress reporter promoter piniBAC.  Surprisingly, their membrane disruptive effects did not appear to be assocd. with bacterial membrane depolarization.  This profile was not uniquely assocd. with azaspiroketal Mannich bases but was characteristic of indolyl Mannich bases as a class.  Whereas resistant mycobacteria could not be isolated for a less potent indolyl Mannich base, the more potent azaspiroketal analog displayed low spontaneous resistance mutation frequency of 10-8/CFU.  This may indicate involvement of an addnl. envelope-related target in its mechanism of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5WAc0tww1bLVg90H21EOLACvtfcHk0lj-ywQeD_CfxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFamtbrL&md5=625be13274f01452304295afed077bf6</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00777&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00777%26sid%3Dliteratum%253Aachs%26aulast%3DNyantakyi%26aufirst%3DS.%2BA.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DGopal%26aufirst%3DP.%26aulast%3DZimmerman%26aufirst%3DM.%26aulast%3DDartois%26aufirst%3DV.%26aulast%3DGengenbacher%26aufirst%3DM.%26aulast%3DDick%26aufirst%3DT.%26aulast%3DGo%26aufirst%3DM.%2BL.%26atitle%3DIndolyl%2520azaspiroketal%2520mannich%2520bases%2520are%2520potent%2520antimycobacterial%2520agents%2520with%2520selective%2520membrane%2520permeabilizing%2520effects%2520and%2520in%2520vivo%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D5733%26epage%3D5750%26doi%3D10.1021%2Facs.jmedchem.8b00777" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cleghorn, L. A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Odingo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wescott, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korkegian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masquelin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez Moure, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huggett, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epemolu, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuccotto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scullion, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shishikura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rullas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guijarro, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hipskind, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parish, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyatt, P. G.</span></span> <span> </span><span class="NLM_article-title">Identification of morpholino thiophenes as novel mycobacterium tuberculosis inhibitors, targeting QcrB</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">6592</span>– <span class="NLM_lpage">6608</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00172</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00172" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Snu7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6592-6608&author=L.+A.+T.+Cleghornauthor=P.+C.+Rayauthor=J.+Odingoauthor=A.+Kumarauthor=H.+Wescottauthor=A.+Korkegianauthor=T.+Masquelinauthor=A.+Lopez+Moureauthor=C.+Wilsonauthor=S.+Davisauthor=M.+Huggettauthor=P.+Turnerauthor=A.+Smithauthor=O.+Epemoluauthor=F.+Zuccottoauthor=J.+Rileyauthor=P.+Scullionauthor=Y.+Shishikuraauthor=L.+Fergusonauthor=J.+Rullasauthor=L.+Guijarroauthor=K.+D.+Readauthor=S.+R.+Greenauthor=P.+Hipskindauthor=T.+Parishauthor=P.+G.+Wyatt&title=Identification+of+morpholino+thiophenes+as+novel+mycobacterium+tuberculosis+inhibitors%2C+targeting+QcrB&doi=10.1021%2Facs.jmedchem.8b00172"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Morpholino Thiophenes as Novel Mycobacterium tuberculosis Inhibitors, Targeting QcrB</span></div><div class="casAuthors">Cleghorn, Laura A. T.; Ray, Peter C.; Odingo, Joshua; Kumar, Anuradha; Wescott, Heather; Korkegian, Aaron; Masquelin, Thierry; Lopez Moure, Abraham; Wilson, Caroline; Davis, Susan; Huggett, Margaret; Turner, Penelope; Smith, Alasdair; Epemolu, Ola; Zuccotto, Fabio; Riley, Jennifer; Scullion, Paul; Shishikura, Yoko; Ferguson, Liam; Rullas, Joaquin; Guijarro, Laura; Read, Kevin D.; Green, Simon R.; Hipskind, Phil; Parish, Tanya; Wyatt, Paul G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6592-6608</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">With the emergence of multidrug-resistant strains of Mycobacterium tuberculosis there is a pressing need for new oral drugs with novel mechanisms of action.  Herein, we describe the identification of a novel morpholino-thiophenes (MOT) series following phenotypic screening of the Eli Lilly corporate library against M. tuberculosis strain H37Rv.  The design, synthesis, and structure-activity relationships of a range of analogs around the confirmed actives are described.  Optimized leads with potent whole cell activity against H37Rv, no cytotoxicity flags, and in vivo efficacy in an acute murine model of infection are described.  Mode-of-action studies suggest that the novel scaffold targets QcrB, a subunit of the menaquinol cytochrome c oxidoreductase, part of the bc1-aa3-type cytochrome c oxidase complex that is responsible for driving oxygen-dependent respiration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnvp7vi-tDWrVg90H21EOLACvtfcHk0lj-ywQeD_CfxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Snu7vJ&md5=ded53f24ded8bce34881a03dc4034aa4</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00172&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00172%26sid%3Dliteratum%253Aachs%26aulast%3DCleghorn%26aufirst%3DL.%2BA.%2BT.%26aulast%3DRay%26aufirst%3DP.%2BC.%26aulast%3DOdingo%26aufirst%3DJ.%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DWescott%26aufirst%3DH.%26aulast%3DKorkegian%26aufirst%3DA.%26aulast%3DMasquelin%26aufirst%3DT.%26aulast%3DLopez%2BMoure%26aufirst%3DA.%26aulast%3DWilson%26aufirst%3DC.%26aulast%3DDavis%26aufirst%3DS.%26aulast%3DHuggett%26aufirst%3DM.%26aulast%3DTurner%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DEpemolu%26aufirst%3DO.%26aulast%3DZuccotto%26aufirst%3DF.%26aulast%3DRiley%26aufirst%3DJ.%26aulast%3DScullion%26aufirst%3DP.%26aulast%3DShishikura%26aufirst%3DY.%26aulast%3DFerguson%26aufirst%3DL.%26aulast%3DRullas%26aufirst%3DJ.%26aulast%3DGuijarro%26aufirst%3DL.%26aulast%3DRead%26aufirst%3DK.%2BD.%26aulast%3DGreen%26aufirst%3DS.%2BR.%26aulast%3DHipskind%26aufirst%3DP.%26aulast%3DParish%26aufirst%3DT.%26aulast%3DWyatt%26aufirst%3DP.%2BG.%26atitle%3DIdentification%2520of%2520morpholino%2520thiophenes%2520as%2520novel%2520mycobacterium%2520tuberculosis%2520inhibitors%252C%2520targeting%2520QcrB%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D6592%26epage%3D6608%26doi%3D10.1021%2Facs.jmedchem.8b00172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chacko, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boshoff, H. I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferraris, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gollapalli, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pepi, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joachimiak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizrahi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuny, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedstrom, L.</span></span> <span> </span><span class="NLM_article-title">Expanding benzoxazole-based inosine 5′-monophosphate dehydrogenase (IMPDH) inhibitor structure-activity as potential antituberculosis agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">4739</span>– <span class="NLM_lpage">4756</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01839</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01839" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpt12hsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4739-4756&author=S.+Chackoauthor=H.+I.+M.+Boshoffauthor=V.+Singhauthor=D.+M.+Ferrarisauthor=D.+R.+Gollapalliauthor=M.+Zhangauthor=A.+P.+Lawsonauthor=M.+J.+Pepiauthor=A.+Joachimiakauthor=M.+Rizziauthor=V.+Mizrahiauthor=G.+D.+Cunyauthor=L.+Hedstrom&title=Expanding+benzoxazole-based+inosine+5%E2%80%B2-monophosphate+dehydrogenase+%28IMPDH%29+inhibitor+structure-activity+as+potential+antituberculosis+agents&doi=10.1021%2Facs.jmedchem.7b01839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Expanding Benzoxazole-Based Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitor Structure-Activity As Potential Antituberculosis Agents</span></div><div class="casAuthors">Chacko, Shibin; Boshoff, Helena I. M.; Singh, Vinayak; Ferraris, Davide M.; Gollapalli, Deviprasad R.; Zhang, Minjia; Lawson, Ann P.; Pepi, Michael J.; Joachimiak, Andrzej; Rizzi, Menico; Mizrahi, Valerie; Cuny, Gregory D.; Hedstrom, Lizbeth</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4739-4756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">New drugs and mol. targets are urgently needed to address the emergence and spread of drug-resistant tuberculosis.  Mycobacterium tuberculosis (Mtb) IMP dehydrogenase 2 (MtbIMPDH2) is a promising yet controversial potential target.  The inhibition of MtbIMPDH2 blocks the biosynthesis of guanine nucleotides, but high concns. of guanine can potentially rescue the bacteria.  Herein we describe an expansion of the structure-activity relationship (SAR) for the benzoxazole series of MtbIMPDH2 inhibitors and demonstrate that min. inhibitory concns. (MIC) of ≤1 μM can be achieved.  The antibacterial activity of the most promising compd., 17b (Q151), is derived from the inhibition of MtbIMPDH2 as demonstrated by conditional knockdown and resistant strains.  Importantly, guanine does not change the MIC of 17b, alleviating the concern that guanine salvage can protect Mtb in vivo.  These findings suggest that MtbIMPDH2 is a vulnerable target for tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTo6ddjA2z7LVg90H21EOLACvtfcHk0lhsAoalNoUpLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpt12hsrg%253D&md5=525dca6fb8eadbb47fcb42814797ab1e</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01839%26sid%3Dliteratum%253Aachs%26aulast%3DChacko%26aufirst%3DS.%26aulast%3DBoshoff%26aufirst%3DH.%2BI.%2BM.%26aulast%3DSingh%26aufirst%3DV.%26aulast%3DFerraris%26aufirst%3DD.%2BM.%26aulast%3DGollapalli%26aufirst%3DD.%2BR.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DLawson%26aufirst%3DA.%2BP.%26aulast%3DPepi%26aufirst%3DM.%2BJ.%26aulast%3DJoachimiak%26aufirst%3DA.%26aulast%3DRizzi%26aufirst%3DM.%26aulast%3DMizrahi%26aufirst%3DV.%26aulast%3DCuny%26aufirst%3DG.%2BD.%26aulast%3DHedstrom%26aufirst%3DL.%26atitle%3DExpanding%2520benzoxazole-based%2520inosine%25205%25E2%2580%25B2-monophosphate%2520dehydrogenase%2520%2528IMPDH%2529%2520inhibitor%2520structure-activity%2520as%2520potential%2520antituberculosis%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D4739%26epage%3D4756%26doi%3D10.1021%2Facs.jmedchem.7b01839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spain, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagalingam, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batten, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hortle, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oehlers, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murage, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orford, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crisologo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Triccas, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutledge, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Todd, M. H.</span></span> <span> </span><span class="NLM_article-title">Antitubercular bis-substituted cyclam derivatives: Structure-activity relationships and in vivo studies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">3595</span>– <span class="NLM_lpage">3608</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01569</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01569" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltFOlsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=3595-3608&author=M.+Spainauthor=J.+K.+Wongauthor=G.+Nagalingamauthor=J.+M.+Battenauthor=E.+Hortleauthor=S.+H.+Oehlersauthor=X.+F.+Jiangauthor=H.+E.+Murageauthor=J.+T.+Orfordauthor=P.+Crisologoauthor=J.+A.+Triccasauthor=P.+J.+Rutledgeauthor=M.+H.+Todd&title=Antitubercular+bis-substituted+cyclam+derivatives%3A+Structure-activity+relationships+and+in+vivo+studies&doi=10.1021%2Facs.jmedchem.7b01569"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Antitubercular Bis-Substituted Cyclam Derivatives: Structure-Activity Relationships and in Vivo Studies</span></div><div class="casAuthors">Spain, Malcolm; Wong, Joseph K.-H.; Nagalingam, Gayathri; Batten, James M.; Hortle, Elinor; Oehlers, Stefan H.; Jiang, Xiao Fan; Murage, Hasini E.; Orford, Jack T.; Crisologo, Patrick; Triccas, James A.; Rutledge, Peter J.; Todd, Matthew H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3595-3608</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors recently reported the discovery of nontoxic cyclam-derived compds. that are active against drug-resistant Mycobacterium tuberculosis.  In this paper the authors report exploration of the structure-activity relationship for this class of compds., identifying several simpler compds. with comparable activity.  The most promising compd. identified, possessing significantly improved water soly., displayed high levels of bacterial clearance in an in vivo zebrafish embryo model, suggesting this compd. series has promise for in vivo treatment of tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpooUdSuTJfE7Vg90H21EOLACvtfcHk0lhsAoalNoUpLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltFOlsbk%253D&md5=2c717da9cf4db74818d3163da0f446bc</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01569%26sid%3Dliteratum%253Aachs%26aulast%3DSpain%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DJ.%2BK.%26aulast%3DNagalingam%26aufirst%3DG.%26aulast%3DBatten%26aufirst%3DJ.%2BM.%26aulast%3DHortle%26aufirst%3DE.%26aulast%3DOehlers%26aufirst%3DS.%2BH.%26aulast%3DJiang%26aufirst%3DX.%2BF.%26aulast%3DMurage%26aufirst%3DH.%2BE.%26aulast%3DOrford%26aufirst%3DJ.%2BT.%26aulast%3DCrisologo%26aufirst%3DP.%26aulast%3DTriccas%26aufirst%3DJ.%2BA.%26aulast%3DRutledge%26aufirst%3DP.%2BJ.%26aulast%3DTodd%26aufirst%3DM.%2BH.%26atitle%3DAntitubercular%2520bis-substituted%2520cyclam%2520derivatives%253A%2520Structure-activity%2520relationships%2520and%2520in%2520vivo%2520studies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D3595%26epage%3D3608%26doi%3D10.1021%2Facs.jmedchem.7b01569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Azzali, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machado, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaushik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacondio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flisi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabassi, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamichhane, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viveiros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costantino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieroni, M.</span></span> <span> </span><span class="NLM_article-title">Substituted n-phenyl-5-(2-(phenylamino)thiazol-4-yl)isoxazole-3-carboxamides are valuable antitubercular candidates that evade innate efflux machinery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">7108</span>– <span class="NLM_lpage">7122</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00793</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00793" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Cntb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=7108-7122&author=E.+Azzaliauthor=D.+Machadoauthor=A.+Kaushikauthor=F.+Vacondioauthor=S.+Flisiauthor=C.+S.+Cabassiauthor=G.+Lamichhaneauthor=M.+Viveirosauthor=G.+Costantinoauthor=M.+Pieroni&title=Substituted+n-phenyl-5-%282-%28phenylamino%29thiazol-4-yl%29isoxazole-3-carboxamides+are+valuable+antitubercular+candidates+that+evade+innate+efflux+machinery&doi=10.1021%2Facs.jmedchem.7b00793"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Substituted N-Phenyl-5-(2-(phenylamino)thiazol-4-yl)isoxazole-3-carboxamides Are Valuable Antitubercular Candidates that Evade Innate Efflux Machinery</span></div><div class="casAuthors">Azzali, Elisa; Machado, Diana; Kaushik, Amit; Vacondio, Federica; Flisi, Sara; Cabassi, Clotilde Silvia; Lamichhane, Gyanu; Viveiros, Miguel; Costantino, Gabriele; Pieroni, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7108-7122</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tuberculosis remains one of the deadliest infectious diseases in the world, and the increased no. of multidrug-resistant and extremely drug-resistant strains is a significant reason for concern.  This makes the discovery of novel antitubercular agents a cogent priority.  The authors have previously addressed this need by reporting a series of substituted 2-aminothiazoles capable to inhibit the growth of actively replicating, nonreplicating persistent, and resistant Mycobacterium tuberculosis strains.  Clues from the structure-activity relationships lining up the antitubercular activity were exploited for the rational design of improved analogs.  Two compds., namely N-phenyl-5-(2-(p-tolylamino)thiazol-4-yl)isoxazole-3-carboxamide I and N-(pyridin-2-yl)-5-(2-(p-tolylamino)thiazol-4-yl)isoxazole-3-carboxamide II,were found to show high inhibitory activity toward susceptible M. tuberculosis strains, with an MIC90 of 0.125-0.25 μg/mL (0.33-0.66 μM) and 0.06-0.125 μg/mL (0.16-0.32 μM), resp.  Moreover, they maintained good activity also toward resistant strains, and they were selective over other bacterial species and eukaryotic cells, metabolically stable, and apparently not susceptible to the action of efflux pumps.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyE_6sjwqBxLVg90H21EOLACvtfcHk0lhsAoalNoUpLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Cntb7M&md5=afde65c4b74ba9f180dc8c8834d551dd</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00793&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00793%26sid%3Dliteratum%253Aachs%26aulast%3DAzzali%26aufirst%3DE.%26aulast%3DMachado%26aufirst%3DD.%26aulast%3DKaushik%26aufirst%3DA.%26aulast%3DVacondio%26aufirst%3DF.%26aulast%3DFlisi%26aufirst%3DS.%26aulast%3DCabassi%26aufirst%3DC.%2BS.%26aulast%3DLamichhane%26aufirst%3DG.%26aulast%3DViveiros%26aufirst%3DM.%26aulast%3DCostantino%26aufirst%3DG.%26aulast%3DPieroni%26aufirst%3DM.%26atitle%3DSubstituted%2520n-phenyl-5-%25282-%2528phenylamino%2529thiazol-4-yl%2529isoxazole-3-carboxamides%2520are%2520valuable%2520antitubercular%2520candidates%2520that%2520evade%2520innate%2520efflux%2520machinery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D7108%26epage%3D7122%26doi%3D10.1021%2Facs.jmedchem.7b00793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Machado, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azzali, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Couto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costantino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieroni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viveiros, M.</span></span> <span> </span><span class="NLM_article-title">Adjuvant therapies against tuberculosis: Discovery of a 2-aminothiazole targeting mycobacterium tuberculosis energetics</span>. <i>Future Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1383</span>– <span class="NLM_lpage">1402</span>, <span class="refDoi"> DOI: 10.2217/fmb-2018-0110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.2217%2Ffmb-2018-0110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=30259757" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVKgtLfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=1383-1402&author=D.+Machadoauthor=E.+Azzaliauthor=I.+Coutoauthor=G.+Costantinoauthor=M.+Pieroniauthor=M.+Viveiros&title=Adjuvant+therapies+against+tuberculosis%3A+Discovery+of+a+2-aminothiazole+targeting+mycobacterium+tuberculosis+energetics&doi=10.2217%2Ffmb-2018-0110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Adjuvant therapies against tuberculosis: discovery of a 2-aminothiazole targeting Mycobacterium tuberculosis energetics</span></div><div class="casAuthors">Machado, Diana; Azzali, Elisa; Couto, Isabel; Costantino, Gabriele; Pieroni, Marco; Viveiros, Miguel</div><div class="citationInfo"><span class="NLM_cas:title">Future Microbiology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1383-1402</span>CODEN:
                <span class="NLM_cas:coden">FMUIAR</span>;
        ISSN:<span class="NLM_cas:issn">1746-0913</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">To evaluate the activity of the 2-aminothiazole UPAR-174 following an unexplored approach: targeting Mycobacterium tuberculosis with lipophilic compds. that present antituberculosis and efflux inhibitory activity.  Antituberculosis activity was assessed against replicating, nonreplicating and intracellular bacilli.  Its capacity to inhibit active efflux was detd.  ATP quantification and membrane potential anal. were performed.  Intracellular activity was studied on human-monocyte-derived macrophages.  UPAR-174 is an efflux inhibitor active against replicating, nonreplicating and intracellular M. tuberculosis.  It dissipates the membrane potential and causes ATP depletion.  Targeting M. tuberculosis with lipophilic efflux inhibitors, exploring their dual activity - dissipation of the proton motive force and efflux inhibition - represents an attractive strategy to fight against drug-resistant tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDq9jEhaFSELVg90H21EOLACvtfcHk0lj_F2mx2CJ-Wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVKgtLfF&md5=d14603271d909853723bfc199eaabd56</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.2217%2Ffmb-2018-0110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffmb-2018-0110%26sid%3Dliteratum%253Aachs%26aulast%3DMachado%26aufirst%3DD.%26aulast%3DAzzali%26aufirst%3DE.%26aulast%3DCouto%26aufirst%3DI.%26aulast%3DCostantino%26aufirst%3DG.%26aulast%3DPieroni%26aufirst%3DM.%26aulast%3DViveiros%26aufirst%3DM.%26atitle%3DAdjuvant%2520therapies%2520against%2520tuberculosis%253A%2520Discovery%2520of%2520a%25202-aminothiazole%2520targeting%2520mycobacterium%2520tuberculosis%2520energetics%26jtitle%3DFuture%2520Microbiol.%26date%3D2018%26volume%3D13%26spage%3D1383%26epage%3D1402%26doi%3D10.2217%2Ffmb-2018-0110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gessner, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moosa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seldon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizrahi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soares de
Melo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simelane, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nchinda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abay, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njoroge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunschwig, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boshoff, H. I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirgel, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Helden, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghidelli-Disse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pflaumer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boesche, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rebollo-Lopez, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urones, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selenski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafuente-Monasterio, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Axtman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lelievre, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Street, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghorpade, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chibale, K.</span></span> <span> </span><span class="NLM_article-title">Novel antitubercular 6-dialkylaminopyrimidine carboxamides from phenotypic whole-cell high throughput screening of a softfocus library: Structure-activity relationship and target identification studies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">10118</span>– <span class="NLM_lpage">10134</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01347</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01347" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVWqtbjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=10118-10134&author=C.+R.+Wilsonauthor=R.+K.+Gessnerauthor=A.+Moosaauthor=R.+Seldonauthor=D.+F.+Warnerauthor=V.+Mizrahiauthor=C.+Soares+de%0AMeloauthor=S.+B.+Simelaneauthor=A.+Nchindaauthor=E.+Abayauthor=D.+Taylorauthor=M.+Njorogeauthor=C.+Brunschwigauthor=N.+Lawrenceauthor=H.+I.+M.+Boshoffauthor=C.+E.+Barryauthor=F.+A.+Sirgelauthor=P.+van+Heldenauthor=C.+J.+Harrisauthor=R.+Gordonauthor=S.+Ghidelli-Disseauthor=H.+Pflaumerauthor=M.+Boescheauthor=G.+Drewesauthor=O.+Sanzauthor=G.+Santosauthor=M.+J.+Rebollo-Lopezauthor=B.+Uronesauthor=C.+Selenskiauthor=M.+J.+Lafuente-Monasterioauthor=M.+Axtmanauthor=J.+Lelievreauthor=L.+Ballellauthor=R.+Muellerauthor=L.+J.+Streetauthor=S.+R.+Ghorpadeauthor=K.+Chibale&title=Novel+antitubercular+6-dialkylaminopyrimidine+carboxamides+from+phenotypic+whole-cell+high+throughput+screening+of+a+softfocus+library%3A+Structure-activity+relationship+and+target+identification+studies&doi=10.1021%2Facs.jmedchem.7b01347"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Antitubercular 6-Dialkylaminopyrimidine Carboxamides from Phenotypic Whole-Cell High Throughput Screening of a SoftFocus Library: Structure-Activity Relationship and Target Identification Studies</span></div><div class="casAuthors">Wilson, Colin R.; Gessner, Richard K.; Moosa, Atica; Seldon, Ronnett; Warner, Digby F.; Mizrahi, Valerie; Soares de Melo, Candice; Simelane, Sandile B.; Nchinda, Aloysius; Abay, Efrem; Taylor, Dale; Njoroge, Mathew; Brunschwig, Christel; Lawrence, Nina; Boshoff, Helena I. M.; Barry, Clifton E.; Sirgel, Frederick A.; van Helden, Paul; Harris, C. John; Gordon, Richard; Ghidelli-Disse, Sonja; Pflaumer, Hannah; Boesche, Markus; Drewes, Gerard; Sanz, Olalla; Santos, Gracia; Rebollo-Lopez, Maria Jose; Urones, Beatriz; Selenski, Carolyn; Lafuente-Monasterio, Maria Jose; Axtman, Matthew; Lelievre, Joel; Ballell, Lluis; Mueller, Rudolf; Street, Leslie J.; Ghorpade, Sandeep R.; Chibale, Kelly</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10118-10134</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A BioFocus DPI SoftFocus library of ∼35,000 compds. was screened against Mycobacterium tuberculosis (Mtb) to identify novel hits with antitubercular activity.  The hits were evaluated in biol. triage assays to exclude compds. suggested to function via frequently encountered promiscuous mechanisms of action including inhibition of the QcrB subunit of the cytochrome bc1 complex, disruption of cell-wall homeostasis, and DNA damage.  Among the hits that passed this screening cascade, a 6-dialkylaminopyrimidine carboxamide series was prioritized for hit to lead optimization.  Compds. from this series were active against clin. Mtb strains, while no cross-resistance to conventional antituberculosis drugs was obsd.  This suggested a novel mechanism of action, which was confirmed by chemoproteomic anal. leading to the identification of BCG_3193 and BCG_3827 as putative targets of the series with unknown function.  Initial structure-activity relationship studies have resulted in compds. with moderate to potent antitubercular activity and improved physicochem. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdBt_xcb2SIbVg90H21EOLACvtfcHk0lj_F2mx2CJ-Wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVWqtbjL&md5=364c9cd37481ad64be7ea86ea0c042e3</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01347&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01347%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DC.%2BR.%26aulast%3DGessner%26aufirst%3DR.%2BK.%26aulast%3DMoosa%26aufirst%3DA.%26aulast%3DSeldon%26aufirst%3DR.%26aulast%3DWarner%26aufirst%3DD.%2BF.%26aulast%3DMizrahi%26aufirst%3DV.%26aulast%3DSoares%2Bde%2BMelo%26aufirst%3DC.%26aulast%3DSimelane%26aufirst%3DS.%2BB.%26aulast%3DNchinda%26aufirst%3DA.%26aulast%3DAbay%26aufirst%3DE.%26aulast%3DTaylor%26aufirst%3DD.%26aulast%3DNjoroge%26aufirst%3DM.%26aulast%3DBrunschwig%26aufirst%3DC.%26aulast%3DLawrence%26aufirst%3DN.%26aulast%3DBoshoff%26aufirst%3DH.%2BI.%2BM.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26aulast%3DSirgel%26aufirst%3DF.%2BA.%26aulast%3Dvan%2BHelden%26aufirst%3DP.%26aulast%3DHarris%26aufirst%3DC.%2BJ.%26aulast%3DGordon%26aufirst%3DR.%26aulast%3DGhidelli-Disse%26aufirst%3DS.%26aulast%3DPflaumer%26aufirst%3DH.%26aulast%3DBoesche%26aufirst%3DM.%26aulast%3DDrewes%26aufirst%3DG.%26aulast%3DSanz%26aufirst%3DO.%26aulast%3DSantos%26aufirst%3DG.%26aulast%3DRebollo-Lopez%26aufirst%3DM.%2BJ.%26aulast%3DUrones%26aufirst%3DB.%26aulast%3DSelenski%26aufirst%3DC.%26aulast%3DLafuente-Monasterio%26aufirst%3DM.%2BJ.%26aulast%3DAxtman%26aufirst%3DM.%26aulast%3DLelievre%26aufirst%3DJ.%26aulast%3DBallell%26aufirst%3DL.%26aulast%3DMueller%26aufirst%3DR.%26aulast%3DStreet%26aufirst%3DL.%2BJ.%26aulast%3DGhorpade%26aufirst%3DS.%2BR.%26aulast%3DChibale%26aufirst%3DK.%26atitle%3DNovel%2520antitubercular%25206-dialkylaminopyrimidine%2520carboxamides%2520from%2520phenotypic%2520whole-cell%2520high%2520throughput%2520screening%2520of%2520a%2520softfocus%2520library%253A%2520Structure-activity%2520relationship%2520and%2520target%2520identification%2520studies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D10118%26epage%3D10134%26doi%3D10.1021%2Facs.jmedchem.7b01347" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dos
Santos Fernandes, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Souza, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno-Viguri, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santivanez-Veliz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paucar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Silanes, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chegaev, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guglielmo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazzarato, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fruttero, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Man Chin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Silva, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chorilli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solcia, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribeiro, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, C. S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marino, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosquesi, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Carvalho, L. P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Souza Costa, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franzblau, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavan, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dos Santos, J. L.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and characterization of N-oxide-containing heterocycles with in vivo sterilizing antitubercular activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">8647</span>– <span class="NLM_lpage">8660</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01332</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01332" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFyrtbzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=8647-8660&author=G.+F.+Dos%0ASantos+Fernandesauthor=P.+C.+de+Souzaauthor=E.+Moreno-Viguriauthor=M.+Santivanez-Velizauthor=R.+Paucarauthor=S.+Perez-Silanesauthor=K.+Chegaevauthor=S.+Guglielmoauthor=L.+Lazzaratoauthor=R.+Frutteroauthor=C.+Man+Chinauthor=P.+B.+da+Silvaauthor=M.+Chorilliauthor=M.+C.+Solciaauthor=C.+M.+Ribeiroauthor=C.+S.+P.+Silvaauthor=L.+B.+Marinoauthor=P.+L.+Bosquesiauthor=D.+M.+Huntauthor=L.+P.+S.+de+Carvalhoauthor=C.+A.+de+Souza+Costaauthor=S.+H.+Choauthor=Y.+Wangauthor=S.+G.+Franzblauauthor=F.+R.+Pavanauthor=J.+L.+Dos+Santos&title=Design%2C+synthesis%2C+and+characterization+of+N-oxide-containing+heterocycles+with+in+vivo+sterilizing+antitubercular+activity&doi=10.1021%2Facs.jmedchem.7b01332"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Characterization of N-Oxide-Containing Heterocycles with in Vivo Sterilizing Antitubercular Activity</span></div><div class="casAuthors">dos Santos Fernandes, Guilherme Felipe; de Souza, Paula Carolina; Moreno-Viguri, Elsa; Santivanez-Veliz, Mery; Paucar, Rocio; Perez-Silanes, Silvia; Chegaev, Konstantin; Guglielmo, Stefano; Lazzarato, Loretta; Fruttero, Roberta; Man Chin, Chung; da Silva, Patricia Bento; Chorilli, Marlus; Solcia, Mariana Cristina; Ribeiro, Camila Maringolo; Silva, Caio Sander Paiva; Marino, Leonardo Biancolino; Bosquesi, Priscila Longhin; Hunt, Debbie M.; de Carvalho, Luiz Pedro S.; de Souza Costa, Carlos Alberto; Cho, Sang Hyun; Wang, Yuehong; Franzblau, Scott Gary; Pavan, Fernando Rogerio; dos Santos, Jean Leandro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8647-8660</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tuberculosis, caused by Mycobacterium tuberculosis (Mtb), is the infectious disease responsible for the highest no. of deaths worldwide.  Herein, 22 new N-oxide-contg. heterocyclic compds. were synthesized followed by in vitro and in vivo evaluation of their antitubercular potential against Mtb.  (E)-6-((2-Isonicotinoylhydrazono)methyl)benzo[c][1,2,5]oxadiazole 1-oxide (8) is the most promising compd., with MIC90 values of 1.10 and 6.62 μM against active and nonreplicating Mtb, resp.  Addnl., the authors carried out in vivo expts. to confirm the safety and efficacy of compd. 8; the compd. is orally bioavailable and highly effective, leading to a redn. of Mtb to undetectable levels in a mouse model of infection.  Microarray-based initial studies on the mechanism of action suggest that compd. 8 blocks translation.  Altogether, these results indicate that benzofuroxan deriv. 8 is a promising lead compd. for the development of a novel chem. class of antitubercular drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnVx2fk-STtrVg90H21EOLACvtfcHk0lgiuLSK0DReFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFyrtbzJ&md5=8a3cfe6b45fcb347a40123f8447c9a98</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01332%26sid%3Dliteratum%253Aachs%26aulast%3DDos%2BSantos%2BFernandes%26aufirst%3DG.%2BF.%26aulast%3Dde%2BSouza%26aufirst%3DP.%2BC.%26aulast%3DMoreno-Viguri%26aufirst%3DE.%26aulast%3DSantivanez-Veliz%26aufirst%3DM.%26aulast%3DPaucar%26aufirst%3DR.%26aulast%3DPerez-Silanes%26aufirst%3DS.%26aulast%3DChegaev%26aufirst%3DK.%26aulast%3DGuglielmo%26aufirst%3DS.%26aulast%3DLazzarato%26aufirst%3DL.%26aulast%3DFruttero%26aufirst%3DR.%26aulast%3DMan%2BChin%26aufirst%3DC.%26aulast%3Dda%2BSilva%26aufirst%3DP.%2BB.%26aulast%3DChorilli%26aufirst%3DM.%26aulast%3DSolcia%26aufirst%3DM.%2BC.%26aulast%3DRibeiro%26aufirst%3DC.%2BM.%26aulast%3DSilva%26aufirst%3DC.%2BS.%2BP.%26aulast%3DMarino%26aufirst%3DL.%2BB.%26aulast%3DBosquesi%26aufirst%3DP.%2BL.%26aulast%3DHunt%26aufirst%3DD.%2BM.%26aulast%3Dde%2BCarvalho%26aufirst%3DL.%2BP.%2BS.%26aulast%3Dde%2BSouza%2BCosta%26aufirst%3DC.%2BA.%26aulast%3DCho%26aufirst%3DS.%2BH.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DFranzblau%26aufirst%3DS.%2BG.%26aulast%3DPavan%26aufirst%3DF.%2BR.%26aulast%3DDos%2BSantos%26aufirst%3DJ.%2BL.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520characterization%2520of%2520N-oxide-containing%2520heterocycles%2520with%2520in%2520vivo%2520sterilizing%2520antitubercular%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D8647%26epage%3D8660%26doi%3D10.1021%2Facs.jmedchem.7b01332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rogacki, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitta, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balabon, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huss, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Roman, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argyrou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanco-Ruano, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cacho, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vande Velde, C. M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augustyns, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barros, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Veken, P.</span></span> <span> </span><span class="NLM_article-title">Identification and profiling of hydantoins-a novel class of potent antimycobacterial dpre1 inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">11221</span>– <span class="NLM_lpage">11249</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01356</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01356" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlylsLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=11221-11249&author=M.+K.+Rogackiauthor=E.+Pittaauthor=O.+Balabonauthor=S.+Hussauthor=E.+M.+Lopez-Romanauthor=A.+Argyrouauthor=D.+Blanco-Ruanoauthor=M.+Cachoauthor=C.+M.+L.+Vande+Veldeauthor=K.+Augustynsauthor=L.+Ballellauthor=D.+Barrosauthor=R.+H.+Batesauthor=F.+Cunninghamauthor=P.+Van+der+Veken&title=Identification+and+profiling+of+hydantoins-a+novel+class+of+potent+antimycobacterial+dpre1+inhibitors&doi=10.1021%2Facs.jmedchem.8b01356"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and Profiling of Hydantoins-A Novel Class of Potent Antimycobacterial DprE1 Inhibitors</span></div><div class="casAuthors">Rogacki, Maciej K.; Pitta, Eleni; Balabon, Olga; Huss, Sophie; Lopez-Roman, Eva Maria; Argyrou, Argyrides; Blanco-Ruano, Delia; Cacho, Monica; Vande Velde, Christophe M. L.; Augustyns, Koen; Ballell, Lluis; Barros, David; Bates, Robert H.; Cunningham, Fraser; Van der Veken, Pieter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">11221-11249</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tuberculosis is the leading cause of death worldwide from infectious diseases.  With the development of drug-resistant strains of Mycobacterium tuberculosis, there is an acute need for new medicines with novel modes of action.  Herein, we report the discovery and profiling of a novel hydantoin-based family of antimycobacterial inhibitors of the decaprenylphospho-β-D-ribofuranose 2-oxidase (DprE1).  In this study, we have prepd. a library of more than a 100 compds. and evaluated them for their biol. and physicochem. properties.  The series is characterized by high enzymic and whole-cell activity, low cytotoxicity, and a good overall physicochem. profile.  In addn., we show that the series acts via reversible inhibition of the DprE1 enzyme.  Overall, the novel compd. family forms an attractive base for progression to further stages of optimization and may provide a promising drug candidate in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMw2Vn8XKan7Vg90H21EOLACvtfcHk0lgiuLSK0DReFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlylsLzE&md5=647fdfe146a1802016d7e38a8543e522</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01356&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01356%26sid%3Dliteratum%253Aachs%26aulast%3DRogacki%26aufirst%3DM.%2BK.%26aulast%3DPitta%26aufirst%3DE.%26aulast%3DBalabon%26aufirst%3DO.%26aulast%3DHuss%26aufirst%3DS.%26aulast%3DLopez-Roman%26aufirst%3DE.%2BM.%26aulast%3DArgyrou%26aufirst%3DA.%26aulast%3DBlanco-Ruano%26aufirst%3DD.%26aulast%3DCacho%26aufirst%3DM.%26aulast%3DVande%2BVelde%26aufirst%3DC.%2BM.%2BL.%26aulast%3DAugustyns%26aufirst%3DK.%26aulast%3DBallell%26aufirst%3DL.%26aulast%3DBarros%26aufirst%3DD.%26aulast%3DBates%26aufirst%3DR.%2BH.%26aulast%3DCunningham%26aufirst%3DF.%26aulast%3DVan%2Bder%2BVeken%26aufirst%3DP.%26atitle%3DIdentification%2520and%2520profiling%2520of%2520hydantoins-a%2520novel%2520class%2520of%2520potent%2520antimycobacterial%2520dpre1%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D11221%26epage%3D11249%26doi%3D10.1021%2Facs.jmedchem.8b01356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manson, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Earl, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunosewoyo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishai, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L. F.</span></span> <span> </span><span class="NLM_article-title">Identification of novel coumestan derivatives as polyketide synthase 13 inhibitors against mycobacterium tuberculosis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">791</span>– <span class="NLM_lpage">803</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01319</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01319" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotVyqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=791-803&author=W.+Zhangauthor=S.+Lunauthor=S.+H.+Wangauthor=X.+W.+Jiangauthor=F.+Yangauthor=J.+Tangauthor=A.+L.+Mansonauthor=A.+M.+Earlauthor=H.+Gunosewoyoauthor=W.+R.+Bishaiauthor=L.+F.+Yu&title=Identification+of+novel+coumestan+derivatives+as+polyketide+synthase+13+inhibitors+against+mycobacterium+tuberculosis&doi=10.1021%2Facs.jmedchem.7b01319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis</span></div><div class="casAuthors">Zhang, Wei; Lun, Shichun; Wang, Shu-Huan; Jiang, Xing-Wu; Yang, Fan; Tang, Jie; Manson, Abigail L.; Earl, Ashlee M.; Gunosewoyo, Hendra; Bishai, William R.; Yu, Li-Fang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">791-803</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of the mycolic acid pathway has proven a viable strategy in antitubercular drug discovery.  The AccA3/AccD4/FadD32/Pks13 complex of Mycobacterium tuberculosis constitutes an essential biosynthetic mechanism for mycolic acids.  Small mols. targeting the thioesterase domain of Pks13 have been reported, including a benzofuran-based compd. whose X-ray cocrystal structure has been very recently solved.  Its initial inactivity in a serum inhibition titrn. (SIT) assay led us to further probe other structurally related benzofurans with the aim to improve their potency and bioavailability.  Herein, we report our preliminary structure-activity relationship studies around this scaffold, highlighting a natural product-inspired cyclization strategy to form coumestans that are shown to be active in SIT.  Whole genome deep sequencing of the coumestan-resistant mutants confirmed a single nucleotide polymorphism in the pks13 gene responsible for the resistance phenotype, demonstrating the druggability of this target for the development of new antitubercular agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1LJWIdOrTvLVg90H21EOLACvtfcHk0lgiuLSK0DReFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotVyqtw%253D%253D&md5=053f265d21ca7eff9f396c33907a1d75</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01319%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DLun%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DS.%2BH.%26aulast%3DJiang%26aufirst%3DX.%2BW.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DManson%26aufirst%3DA.%2BL.%26aulast%3DEarl%26aufirst%3DA.%2BM.%26aulast%3DGunosewoyo%26aufirst%3DH.%26aulast%3DBishai%26aufirst%3DW.%2BR.%26aulast%3DYu%26aufirst%3DL.%2BF.%26atitle%3DIdentification%2520of%2520novel%2520coumestan%2520derivatives%2520as%2520polyketide%2520synthase%252013%2520inhibitors%2520against%2520mycobacterium%2520tuberculosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D791%26epage%3D803%26doi%3D10.1021%2Facs.jmedchem.7b01319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunosewoyo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishai, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L. F.</span></span> <span> </span><span class="NLM_article-title">Identification of novel coumestan derivatives as polyketide synthase 13 inhibitors against mycobacterium tuberculosis. Part ii</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">3575</span>– <span class="NLM_lpage">3589</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00010</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00010" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC1MXltFeksL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=3575-3589&author=W.+Zhangauthor=S.+Lunauthor=L.+L.+Liuauthor=S.+Xiaoauthor=G.+Duanauthor=H.+Gunosewoyoauthor=F.+Yangauthor=J.+Tangauthor=W.+R.+Bishaiauthor=L.+F.+Yu&title=Identification+of+novel+coumestan+derivatives+as+polyketide+synthase+13+inhibitors+against+mycobacterium+tuberculosis.+Part+ii&doi=10.1021%2Facs.jmedchem.9b00010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of novel coumestan derivatives as polyketide synthase 13 inhibitors against Mycobacterium tuberculosis. part II</span></div><div class="casAuthors">Zhang, Wei; Lun, Shichun; Liu, Ling-Ling; Xiao, Shiqi; Duan, Guanfu; Gunosewoyo, Hendra; Yang, Fan; Tang, Jie; Bishai, William R.; Yu, Li-Fang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3575-3589</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Our group recently reported the identification of novel coumestan derivs. as Mycobacterium tuberculosis (Mtb) Pks13-thioesterase (TE) domain inhibitors, with mutations obsd. (D1644G and N1640K) in the generated coumestan-resistant Mtb colonies.  Herein, we report a further structure-activity relationships exploration exploiting the available Pks13-TE X-ray co-crystal structure that resulted in the discovery of extremely potent coumestan analogs 48(I) and 50(II).  These mols. possess excellent anti-tuberculosis activity against both the drug-susceptible (MIC = 0.0039 μg/mL) and drug-resistant Mtb strains (MIC = 0.0078 μg/mL).  Moreover, the excellent in vitro activity is translated to the in vivo mouse serum inhibitory titrn. assay, with administration of I at 100 mg/kg showing an 8-fold higher activity than that of isoniazid or TAM16 given at 10 or 100 mg/kg, resp.  Preliminary ADME-Tox data for the coumestans were promising and, coupled with the practicality of synthesis, warrant further in vivo efficacy assessments of the coumestan derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolhzlD7NMcz7Vg90H21EOLACvtfcHk0lgXdFCVWUn0FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXltFeksL0%253D&md5=30c5e50311e413573a0c861fc5c64cb3</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00010%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DLun%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DL.%2BL.%26aulast%3DXiao%26aufirst%3DS.%26aulast%3DDuan%26aufirst%3DG.%26aulast%3DGunosewoyo%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DBishai%26aufirst%3DW.%2BR.%26aulast%3DYu%26aufirst%3DL.%2BF.%26atitle%3DIdentification%2520of%2520novel%2520coumestan%2520derivatives%2520as%2520polyketide%2520synthase%252013%2520inhibitors%2520against%2520mycobacterium%2520tuberculosis.%2520Part%2520ii%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D3575%26epage%3D3589%26doi%3D10.1021%2Facs.jmedchem.9b00010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upton, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span> <span> </span><span class="NLM_article-title">Identification of less lipophilic riminophenazine derivatives for the treatment of drug-resistant tuberculosis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">8409</span>– <span class="NLM_lpage">8417</span>, <span class="refDoi"> DOI: 10.1021/jm300828h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300828h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1yrsbjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8409-8417&author=D.+Zhangauthor=Y.+Luauthor=K.+Liuauthor=B.+Liuauthor=J.+Wangauthor=G.+Zhangauthor=H.+Zhangauthor=Y.+Liuauthor=B.+Wangauthor=M.+Zhengauthor=L.+Fuauthor=Y.+Houauthor=N.+Gongauthor=Y.+Lvauthor=C.+Liauthor=C.+B.+Cooperauthor=A.+M.+Uptonauthor=D.+Yinauthor=Z.+Maauthor=H.+Huang&title=Identification+of+less+lipophilic+riminophenazine+derivatives+for+the+treatment+of+drug-resistant+tuberculosis&doi=10.1021%2Fjm300828h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Less Lipophilic Riminophenazine Derivatives for the Treatment of Drug-Resistant Tuberculosis</span></div><div class="casAuthors">Zhang, Dongfeng; Lu, Yu; Liu, Kai; Liu, Binna; Wang, Jingbin; Zhang, Gang; Zhang, Hao; Liu, Yang; Wang, Bin; Zheng, Meiqin; Fu, Lei; Hou, Yanyan; Gong, Ningbo; Lv, Yang; Li, Chun; Cooper, Christopher B.; Upton, Anna M.; Yin, Dali; Ma, Zhenkun; Huang, Haihong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8409-8417</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Clofazimine (CFZ), a member of the riminophenazine class, has been studied in clin. trials for the treatment of multidrug-resistant tuberculosis (MDR-TB).  CFZ has several side effects which can be attributed to its extremely high lipophilicity.  A series of novel riminophenazine analogs bearing a C-2 pyridyl substituent was designed and synthesized with the goal of maintaining potent activity against Mycobacterium tuberculosis (M. tuberculosis) while improving upon its safety profile by lowering the lipophilicity.  All compds. were evaluated for their in vitro activity and cytotoxicity.  The results demonstrated that many new compds. had potent activity against M. tuberculosis with MICs of less than 0.03 μg/mL and low cytotoxicity with IC50 values greater than 64 μg/mL.  Some compds. were tested for in vivo efficacy against MDR-TB in an exptl. mouse infection model.  Two compds. I [R = 2-OMe, 6-Me] demonstrated equiv. or better efficacy than CFZ in this model with significantly reduced skin discoloration potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFLZ4IRiNxTbVg90H21EOLACvtfcHk0lgXdFCVWUn0FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1yrsbjJ&md5=591d0b4655abf45726abfce56fb4b868</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1021%2Fjm300828h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300828h%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DFu%26aufirst%3DL.%26aulast%3DHou%26aufirst%3DY.%26aulast%3DGong%26aufirst%3DN.%26aulast%3DLv%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DCooper%26aufirst%3DC.%2BB.%26aulast%3DUpton%26aufirst%3DA.%2BM.%26aulast%3DYin%26aufirst%3DD.%26aulast%3DMa%26aufirst%3DZ.%26aulast%3DHuang%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520less%2520lipophilic%2520riminophenazine%2520derivatives%2520for%2520the%2520treatment%2520of%2520drug-resistant%2520tuberculosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8409%26epage%3D8417%26doi%3D10.1021%2Fjm300828h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guardia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baiget, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cacho, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortega-Guerra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nxumalo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khanye, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rullas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortega, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Herran, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraile-Gabaldon, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esquivias, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porras-De Francisco, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Encinas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivero, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miguel-Siles, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osende, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badiola, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutledge, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Todd, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remuinan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alemparte, C.</span></span> <span> </span><span class="NLM_article-title">Easy-to-synthesize spirocyclic compounds possess remarkable in vivo activity against mycobacterium tuberculosis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">11327</span>– <span class="NLM_lpage">11340</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01533</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01533" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1OqsLjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=11327-11340&author=A.+Guardiaauthor=J.+Baigetauthor=M.+Cachoauthor=A.+Perezauthor=M.+Ortega-Guerraauthor=W.+Nxumaloauthor=S.+D.+Khanyeauthor=J.+Rullasauthor=F.+Ortegaauthor=E.+Jimenezauthor=E.+Perez-Herranauthor=M.+T.+Fraile-Gabaldonauthor=J.+Esquiviasauthor=R.+Fernandezauthor=E.+Porras-De+Franciscoauthor=L.+Encinasauthor=M.+Alonsoauthor=I.+Giordanoauthor=C.+Riveroauthor=J.+Miguel-Silesauthor=J.+G.+Osendeauthor=K.+A.+Badiolaauthor=P.+J.+Rutledgeauthor=M.+H.+Toddauthor=M.+Remuinanauthor=C.+Alemparte&title=Easy-to-synthesize+spirocyclic+compounds+possess+remarkable+in+vivo+activity+against+mycobacterium+tuberculosis&doi=10.1021%2Facs.jmedchem.8b01533"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Easy-To-Synthesize Spirocyclic Compounds Possess Remarkable in Vivo Activity against Mycobacterium tuberculosis</span></div><div class="casAuthors">Guardia, Ana; Baiget, Jessica; Cacho, Monica; Perez, Arancha; Ortega-Guerra, Montserrat; Nxumalo, Winston; Khanye, Setshaba D.; Rullas, Joaquin; Ortega, Fatima; Jimenez, Elena; Perez-Herran, Esther; Fraile-Gabaldon, Maria Teresa; Esquivias, Jorge; Fernandez, Raquel; Porras-De Francisco, Esther; Encinas, Lourdes; Alonso, Marta; Giordano, Ilaria; Rivero, Cristina; Miguel-Siles, Juan; Osende, Javier G.; Badiola, Katrina A.; Rutledge, Peter J.; Todd, Matthew H.; Remuinan, Modesto; Alemparte, Carlos</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">11327-11340</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Society urgently needs new, effective medicines for the treatment of tuberculosis.  To kick-start the required hit-to-lead campaigns, the libraries of pharmaceutical companies have recently been evaluated for starting points.  The GlaxoSmithKline (GSK) library yielded many high-quality hits, and the assocd. data were placed in the public domain to stimulate engagement by the wider community.  One such series, the spiro compds., are described here.  The compds. were explored by a combination of traditional inhouse research and open source methods.  The series benefits from a particularly simple structure and a short assocd. synthetic chem. route.  Many members of the series displayed striking potency and low toxicity, and highly promising in vivo activity in a mouse model was confirmed with one of the analogs.  Ultimately the series was discontinued due to concerns over safety, but the assocd. data remain public domain, empowering others to resume the series if the perceived deficiencies can be overcome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmizcPsa-ok7Vg90H21EOLACvtfcHk0lgXdFCVWUn0FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1OqsLjJ&md5=ca3395ecd8dc725c5162f0965eee84db</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01533&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01533%26sid%3Dliteratum%253Aachs%26aulast%3DGuardia%26aufirst%3DA.%26aulast%3DBaiget%26aufirst%3DJ.%26aulast%3DCacho%26aufirst%3DM.%26aulast%3DPerez%26aufirst%3DA.%26aulast%3DOrtega-Guerra%26aufirst%3DM.%26aulast%3DNxumalo%26aufirst%3DW.%26aulast%3DKhanye%26aufirst%3DS.%2BD.%26aulast%3DRullas%26aufirst%3DJ.%26aulast%3DOrtega%26aufirst%3DF.%26aulast%3DJimenez%26aufirst%3DE.%26aulast%3DPerez-Herran%26aufirst%3DE.%26aulast%3DFraile-Gabaldon%26aufirst%3DM.%2BT.%26aulast%3DEsquivias%26aufirst%3DJ.%26aulast%3DFernandez%26aufirst%3DR.%26aulast%3DPorras-De%2BFrancisco%26aufirst%3DE.%26aulast%3DEncinas%26aufirst%3DL.%26aulast%3DAlonso%26aufirst%3DM.%26aulast%3DGiordano%26aufirst%3DI.%26aulast%3DRivero%26aufirst%3DC.%26aulast%3DMiguel-Siles%26aufirst%3DJ.%26aulast%3DOsende%26aufirst%3DJ.%2BG.%26aulast%3DBadiola%26aufirst%3DK.%2BA.%26aulast%3DRutledge%26aufirst%3DP.%2BJ.%26aulast%3DTodd%26aufirst%3DM.%2BH.%26aulast%3DRemuinan%26aufirst%3DM.%26aulast%3DAlemparte%26aufirst%3DC.%26atitle%3DEasy-to-synthesize%2520spirocyclic%2520compounds%2520possess%2520remarkable%2520in%2520vivo%2520activity%2520against%2520mycobacterium%2520tuberculosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D11327%26epage%3D11340%26doi%3D10.1021%2Facs.jmedchem.8b01533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taban, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elshihawy, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torun, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zucchini, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altuwairigi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngu, A. S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLean, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sood, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marino, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munro, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Carvalho, L. P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simons, C.</span></span> <span> </span><span class="NLM_article-title">Novel aryl substituted pyrazoles as small molecule inhibitors of cytochrome P450 CYP121a1: Synthesis and antimycobacterial evaluation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">10257</span>– <span class="NLM_lpage">10267</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01562</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01562" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvV2mtLzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=10257-10267&author=I.+M.+Tabanauthor=H.+Elshihawyauthor=B.+Torunauthor=B.+Zucchiniauthor=C.+J.+Williamsonauthor=D.+Altuwairigiauthor=A.+S.+T.+Nguauthor=K.+J.+McLeanauthor=C.+W.+Levyauthor=S.+Soodauthor=L.+B.+Marinoauthor=A.+W.+Munroauthor=L.+P.+S.+de+Carvalhoauthor=C.+Simons&title=Novel+aryl+substituted+pyrazoles+as+small+molecule+inhibitors+of+cytochrome+P450+CYP121a1%3A+Synthesis+and+antimycobacterial+evaluation&doi=10.1021%2Facs.jmedchem.7b01562"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Aryl Substituted Pyrazoles as Small Molecule Inhibitors of Cytochrome P450 CYP121A1: Synthesis and Antimycobacterial Evaluation</span></div><div class="casAuthors">Taban, Ismail M.; Elshihawy, Hosam E. A. E.; Torun, Beyza; Zucchini, Benedetta; Williamson, Clare J.; Altuwairigi, Dania; Ngu, Adeline S. T.; McLean, Kirsty J.; Levy, Colin W.; Sood, Sakshi; Marino, Leonardo B.; Munro, Andrew W.; de Carvalho, Luiz Pedro S.; Simons, Claire</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10257-10267</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Three series of biarylpyrazole, imidazole and triazoles are described, which vary in the linker between the biaryl pyrazole and imidazole/triazole group.  The imidazole and triazole series with the short -CH2- linker displayed promising antimycobacterial activity, with the imidazole-CH2- series showing low MIC values (6.25-25 μg/mL), which was also influenced by lipophilicity.  Extending the linker to -C(O)NH(CH2)2- resulted in a loss of antimycobacterial activity.  The binding affinity of the compds. with CYP121A1 was detd. by UV-visible optical titrns. with KD values of 2.63, 35.6, and 290 μM, resp., for the tightest binding compds. I, II, and III from their resp. series.  Both binding affinity assays and docking studies of the CYP121A1 inhibitors suggest type II indirect binding through interstitial water mols., with key binding residues Thr77, Val78, Val82, Val83, Met86, Ser237, Gln385, and Arg386, comparable with the binding interactions obsd. with fluconazole and the natural substrate dicyclotyrosine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNC8RyFfrTz7Vg90H21EOLACvtfcHk0liM2-P4z0d69w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvV2mtLzF&md5=10b15551ca37506e6034c6d582ade219</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01562&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01562%26sid%3Dliteratum%253Aachs%26aulast%3DTaban%26aufirst%3DI.%2BM.%26aulast%3DElshihawy%26aufirst%3DH.%26aulast%3DTorun%26aufirst%3DB.%26aulast%3DZucchini%26aufirst%3DB.%26aulast%3DWilliamson%26aufirst%3DC.%2BJ.%26aulast%3DAltuwairigi%26aufirst%3DD.%26aulast%3DNgu%26aufirst%3DA.%2BS.%2BT.%26aulast%3DMcLean%26aufirst%3DK.%2BJ.%26aulast%3DLevy%26aufirst%3DC.%2BW.%26aulast%3DSood%26aufirst%3DS.%26aulast%3DMarino%26aufirst%3DL.%2BB.%26aulast%3DMunro%26aufirst%3DA.%2BW.%26aulast%3Dde%2BCarvalho%26aufirst%3DL.%2BP.%2BS.%26aulast%3DSimons%26aufirst%3DC.%26atitle%3DNovel%2520aryl%2520substituted%2520pyrazoles%2520as%2520small%2520molecule%2520inhibitors%2520of%2520cytochrome%2520P450%2520CYP121a1%253A%2520Synthesis%2520and%2520antimycobacterial%2520evaluation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D10257%26epage%3D10267%26doi%3D10.1021%2Facs.jmedchem.7b01562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelhart, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallach, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnappinger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arora, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manikkam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gac, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murgolo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodwin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutphin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiner, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Via, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boshoff, H. I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.,  3rd.</span></span> <span> </span><span class="NLM_article-title">Discovery and structure-activity-relationship study of n-alkyl-5-hydroxypyrimidinone carboxamides as novel antitubercular agents targeting decaprenylphosphoryl-beta-d-ribose 2′-oxidase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">9952</span>– <span class="NLM_lpage">9965</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00883</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00883" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvV2rsrfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9952-9965&author=S.+Ohauthor=Y.+Parkauthor=C.+A.+Engelhartauthor=J.+B.+Wallachauthor=D.+Schnappingerauthor=K.+Aroraauthor=M.+Manikkamauthor=B.+Gacauthor=H.+Wangauthor=N.+Murgoloauthor=D.+B.+Olsenauthor=M.+Goodwinauthor=M.+Sutphinauthor=D.+M.+Weinerauthor=L.+E.+Viaauthor=H.+I.+M.+Boshoffauthor=C.+E.+Barry&title=Discovery+and+structure-activity-relationship+study+of+n-alkyl-5-hydroxypyrimidinone+carboxamides+as+novel+antitubercular+agents+targeting+decaprenylphosphoryl-beta-d-ribose+2%E2%80%B2-oxidase&doi=10.1021%2Facs.jmedchem.8b00883"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Structure-Activity-Relationship Study of N-Alkyl-5-hydroxypyrimidinone Carboxamides as Novel Antitubercular Agents Targeting Decaprenylphosphoryl-β-D-ribose 2'-Oxidase</span></div><div class="casAuthors">Oh, Sangmi; Park, Yumi; Engelhart, Curtis A.; Wallach, Joshua B.; Schnappinger, Dirk; Arora, Kriti; Manikkam, Michelle; Gac, Brian; Wang, Hongwu; Murgolo, Nicholas; Olsen, David B.; Goodwin, Michael; Sutphin, Michelle; Weiner, Danielle M.; Via, Laura E.; Boshoff, Helena I. M.; Barry, Clifton E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9952-9965</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Magnesium plays an important role in infection with Mycobacterium tuberculosis (Mtb) as a signal of the extracellular environment, as a cofactor for many enzymes, and as a structural element in important macromols.  Raltegravir, an antiretroviral drug that inhibits HIV-1 integrase is known to derive its potency from selective sequestration of active-site magnesium ions in addn. to binding to a hydrophobic pocket.  In order to det. if essential Mtb-related phosphoryl transfers could be disrupted in a similar manner, a directed screen of known mols. with integrase inhibitor-like pharmacophores (N-alkyl-5-hydroxypyrimidinone carboxamides) was performed.  Initial hits afforded compds. with low-micromolar potency against Mtb, acceptable cytotoxicity and PK characteristics, and robust SAR.  Elucidation of the target of these compds. revealed that they lacked magnesium dependence and instead disappointingly inhibited a known promiscuous target in Mtb, decaprenylphosphoryl-β-D-ribose 2'-oxidase (DprE1, Rv3790).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOxHRHtAf2rbVg90H21EOLACvtfcHk0liM2-P4z0d69w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvV2rsrfP&md5=5c8f50d73f857fcde7277ca80109fee9</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00883%26sid%3Dliteratum%253Aachs%26aulast%3DOh%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DY.%26aulast%3DEngelhart%26aufirst%3DC.%2BA.%26aulast%3DWallach%26aufirst%3DJ.%2BB.%26aulast%3DSchnappinger%26aufirst%3DD.%26aulast%3DArora%26aufirst%3DK.%26aulast%3DManikkam%26aufirst%3DM.%26aulast%3DGac%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DMurgolo%26aufirst%3DN.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DGoodwin%26aufirst%3DM.%26aulast%3DSutphin%26aufirst%3DM.%26aulast%3DWeiner%26aufirst%3DD.%2BM.%26aulast%3DVia%26aufirst%3DL.%2BE.%26aulast%3DBoshoff%26aufirst%3DH.%2BI.%2BM.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26atitle%3DDiscovery%2520and%2520structure-activity-relationship%2520study%2520of%2520n-alkyl-5-hydroxypyrimidinone%2520carboxamides%2520as%2520novel%2520antitubercular%2520agents%2520targeting%2520decaprenylphosphoryl-beta-d-ribose%25202%25E2%2580%25B2-oxidase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D9952%26epage%3D9965%26doi%3D10.1021%2Facs.jmedchem.8b00883" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vickers, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, A. P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakraborty, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurepina, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saville, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naranjo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pons, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnettger, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreiswith, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perlin, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavet, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabernero, L.</span></span> <span> </span><span class="NLM_article-title">Structure-based design of mptpb inhibitors that reduce multidrug-resistant mycobacterium tuberculosis survival and infection burden in vivo</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">8337</span>– <span class="NLM_lpage">8352</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00832</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00832" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1WitLfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=8337-8352&author=C.+F.+Vickersauthor=A.+P.+G.+Silvaauthor=A.+Chakrabortyauthor=P.+Fernandezauthor=N.+Kurepinaauthor=C.+Savilleauthor=Y.+Naranjoauthor=M.+Ponsauthor=L.+S.+Schnettgerauthor=M.+G.+Gutierrezauthor=S.+Parkauthor=B.+N.+Kreiswithauthor=D.+S.+Perlinauthor=E.+J.+Thomasauthor=J.+S.+Cavetauthor=L.+Tabernero&title=Structure-based+design+of+mptpb+inhibitors+that+reduce+multidrug-resistant+mycobacterium+tuberculosis+survival+and+infection+burden+in+vivo&doi=10.1021%2Facs.jmedchem.8b00832"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design of MptpB Inhibitors That Reduce Multidrug-Resistant Mycobacterium tuberculosis Survival and Infection Burden in Vivo</span></div><div class="casAuthors">Vickers, Clare F.; Silva, Ana P. G.; Chakraborty, Ajanta; Fernandez, Paulina; Kurepina, Natalia; Saville, Charis; Naranjo, Yandi; Pons, Miquel; Schnettger, Laura S.; Gutierrez, Maximiliano G.; Park, Steven; Kreiswith, Barry N.; Perlin, David S.; Thomas, Eric J.; Cavet, Jennifer S.; Tabernero, Lydia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8337-8352</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mycobacterium tuberculosis protein tyrosine-phosphatase B (MptpB) is a secreted virulence factor that subverts antimicrobial activity in the host.  The authors report the structure-based design of selective MptpB inhibitors that reduce survival of multidrug-resistant tuberculosis strains in macrophages and enhance killing efficacy by first-line antibiotics.  Monotherapy with an orally bioavailable MptpB inhibitor reduces infection burden in acute and chronic guinea pig models and improves the overall pathol.  The authors' findings provide a new paradigm for tuberculosis treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0GsTlmstuSLVg90H21EOLACvtfcHk0liM2-P4z0d69w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1WitLfP&md5=4c3614b7cf3955301131cbf33f734546</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00832&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00832%26sid%3Dliteratum%253Aachs%26aulast%3DVickers%26aufirst%3DC.%2BF.%26aulast%3DSilva%26aufirst%3DA.%2BP.%2BG.%26aulast%3DChakraborty%26aufirst%3DA.%26aulast%3DFernandez%26aufirst%3DP.%26aulast%3DKurepina%26aufirst%3DN.%26aulast%3DSaville%26aufirst%3DC.%26aulast%3DNaranjo%26aufirst%3DY.%26aulast%3DPons%26aufirst%3DM.%26aulast%3DSchnettger%26aufirst%3DL.%2BS.%26aulast%3DGutierrez%26aufirst%3DM.%2BG.%26aulast%3DPark%26aufirst%3DS.%26aulast%3DKreiswith%26aufirst%3DB.%2BN.%26aulast%3DPerlin%26aufirst%3DD.%2BS.%26aulast%3DThomas%26aufirst%3DE.%2BJ.%26aulast%3DCavet%26aufirst%3DJ.%2BS.%26aulast%3DTabernero%26aufirst%3DL.%26atitle%3DStructure-based%2520design%2520of%2520mptpb%2520inhibitors%2520that%2520reduce%2520multidrug-resistant%2520mycobacterium%2520tuberculosis%2520survival%2520and%2520infection%2520burden%2520in%2520vivo%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D8337%26epage%3D8352%26doi%3D10.1021%2Facs.jmedchem.8b00832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lagorce, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperandio, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miteva, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villoutreix, B. O.</span></span> <span> </span><span class="NLM_article-title">FAF-drugs3: A web server for compound property calculation and chemical library design</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">W200</span>– <span class="NLM_lpage">207</span>, <span class="refDoi"> DOI: 10.1093/nar/gkv353</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1093%2Fnar%2Fgkv353" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=25883137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVymtLfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=W200-207&author=D.+Lagorceauthor=O.+Sperandioauthor=J.+B.+Baellauthor=M.+A.+Mitevaauthor=B.+O.+Villoutreix&title=FAF-drugs3%3A+A+web+server+for+compound+property+calculation+and+chemical+library+design&doi=10.1093%2Fnar%2Fgkv353"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">FAF-Drugs3: a web server for compound property calculation and chemical library design</span></div><div class="casAuthors">Lagorce, David; Sperandio, Olivier; Baell, Jonathan B.; Miteva, Maria A.; Villoutreix, Bruno O.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">W1</span>),
    <span class="NLM_cas:pages">W200-W207</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Drug attrition late in preclin. or clin. development is a serious economic problem in the field of drug discovery.  These problems can be linked, in part, to the quality of the compd. collections used during the hit generation stage and to the selection of compds. undergoing optimization.  Here, we present FAF-Drugs3, a web server that can be used for drug discovery and chem. biol. projects to help in prepg. compd. libraries and to assist decision-making during the hit selection/lead optimization phase.  Since it was first described in 2006, FAF-Drugs has been significantly modified.  The tool now applies an enhanced structure curation procedure, can filter or analyze mols. with user-defined or eight predefined physicochem. filters as well as with several simple ADMET (absorption, distribution, metab., excretion and toxicity) rules.  In addn., compds. can be filtered using an updated list of 154 hand-curated structural alerts while Pan Assay Interference compds. (PAINS) and other, generally unwanted groups are also investigated.  FAF-Drugs3 offers access to user-friendly html result pages and the possibility to download all computed data.  The server requires as input an SDF file of the compds.; it is open to all users and can be accessed without registration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxYZ-hCUhlmrVg90H21EOLACvtfcHk0lhriqNVkYoolw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVymtLfM&md5=5cf8888c489b90f392117ab065986214</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkv353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkv353%26sid%3Dliteratum%253Aachs%26aulast%3DLagorce%26aufirst%3DD.%26aulast%3DSperandio%26aufirst%3DO.%26aulast%3DBaell%26aufirst%3DJ.%2BB.%26aulast%3DMiteva%26aufirst%3DM.%2BA.%26aulast%3DVilloutreix%26aufirst%3DB.%2BO.%26atitle%3DFAF-drugs3%253A%2520A%2520web%2520server%2520for%2520compound%2520property%2520calculation%2520and%2520chemical%2520library%2520design%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2015%26volume%3D43%26spage%3DW200%26epage%3D207%26doi%3D10.1093%2Fnar%2Fgkv353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ursu, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipinski, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sklar, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oprea, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bologa, C. G.</span></span> <span> </span><span class="NLM_article-title">Badapple: Promiscuity patterns from noisy evidence</span>. <i>J. Cheminf.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">29</span>, <span class="refDoi"> DOI: 10.1186/s13321-016-0137-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1186%2Fs13321-016-0137-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=29&author=J.+J.+Yangauthor=O.+Ursuauthor=C.+A.+Lipinskiauthor=L.+A.+Sklarauthor=T.+I.+Opreaauthor=C.+G.+Bologa&title=Badapple%3A+Promiscuity+patterns+from+noisy+evidence&doi=10.1186%2Fs13321-016-0137-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1186%2Fs13321-016-0137-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13321-016-0137-3%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.%2BJ.%26aulast%3DUrsu%26aufirst%3DO.%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26aulast%3DSklar%26aufirst%3DL.%2BA.%26aulast%3DOprea%26aufirst%3DT.%2BI.%26aulast%3DBologa%26aufirst%3DC.%2BG.%26atitle%3DBadapple%253A%2520Promiscuity%2520patterns%2520from%2520noisy%2520evidence%26jtitle%3DJ.%2520Cheminf.%26date%3D2016%26volume%3D8%26spage%3D29%26doi%3D10.1186%2Fs13321-016-0137-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deidda, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lampis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fioravanti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biava, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porretta, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanetti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pompei, R.</span></span> <span> </span><span class="NLM_article-title">Bactericidal activities of the pyrrole derivative BM212 against multidrug-resistant and intramacrophagic mycobacterium tuberculosis strains</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">3035</span>– <span class="NLM_lpage">3037</span>, <span class="refDoi"> DOI: 10.1128/AAC.42.11.3035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.42.11.3035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=9797251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADyaK1cXnt1ShtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1998&pages=3035-3037&author=D.+Deiddaauthor=G.+Lampisauthor=R.+Fioravantiauthor=M.+Biavaauthor=G.+C.+Porrettaauthor=S.+Zanettiauthor=R.+Pompei&title=Bactericidal+activities+of+the+pyrrole+derivative+BM212+against+multidrug-resistant+and+intramacrophagic+mycobacterium+tuberculosis+strains&doi=10.1128%2FAAC.42.11.3035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Bactericidal activities of the pyrrole derivative BM212 against multidrug-resistant and intramacrophagic Mycobacterium tuberculosis strains</span></div><div class="casAuthors">Deidda, Della; Lampis, Giorgio; Fioravanti, Rossella; Biava, Mariangela; Porretta, Giulio Cesare; Zanetti, Stefania; Pompei, Raffaello</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3035-3037</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The pyrrole deriv. BM212 (I) was shown to possess strong inhibitory activity against both Mycobacterium tuberculosis and some nontuberculosis mycobacteria.  I was inhibitory to drug-resistant mycobacteria and also exerted bactericidal activity against intracellular bacilli residing in the U937 human histiocytic lymphoma cell line.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8kBYE37EBcLVg90H21EOLACvtfcHk0lhriqNVkYoolw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnt1ShtLY%253D&md5=177ce62fe435889b34f4f90aea30dcec</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1128%2FAAC.42.11.3035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.42.11.3035%26sid%3Dliteratum%253Aachs%26aulast%3DDeidda%26aufirst%3DD.%26aulast%3DLampis%26aufirst%3DG.%26aulast%3DFioravanti%26aufirst%3DR.%26aulast%3DBiava%26aufirst%3DM.%26aulast%3DPorretta%26aufirst%3DG.%2BC.%26aulast%3DZanetti%26aufirst%3DS.%26aulast%3DPompei%26aufirst%3DR.%26atitle%3DBactericidal%2520activities%2520of%2520the%2520pyrrole%2520derivative%2520BM212%2520against%2520multidrug-resistant%2520and%2520intramacrophagic%2520mycobacterium%2520tuberculosis%2520strains%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1998%26volume%3D42%26spage%3D3035%26epage%3D3037%26doi%3D10.1128%2FAAC.42.11.3035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">La Rosa, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poce, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canseco, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buroni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasca, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biava, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raju, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porretta, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfonso, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battilocchio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javid, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorrentino, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ioerger, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacchettini, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Logu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rossi, E.</span></span> <span> </span><span class="NLM_article-title">Mmpl3 is the cellular target of the antitubercular pyrrole derivative BM212</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">324</span>– <span class="NLM_lpage">331</span>, <span class="refDoi"> DOI: 10.1128/AAC.05270-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.05270-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=22024828" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1Gqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=324-331&author=V.+La+Rosaauthor=G.+Poceauthor=J.+O.+Cansecoauthor=S.+Buroniauthor=M.+R.+Pascaauthor=M.+Biavaauthor=R.+M.+Rajuauthor=G.+C.+Porrettaauthor=S.+Alfonsoauthor=C.+Battilocchioauthor=B.+Javidauthor=F.+Sorrentinoauthor=T.+R.+Ioergerauthor=J.+C.+Sacchettiniauthor=F.+Manettiauthor=M.+Bottaauthor=A.+De+Loguauthor=E.+J.+Rubinauthor=E.+De+Rossi&title=Mmpl3+is+the+cellular+target+of+the+antitubercular+pyrrole+derivative+BM212&doi=10.1128%2FAAC.05270-11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212</span></div><div class="casAuthors">La Rosa, Valentina; Poce, Giovanna; Canseco, Julio Ortiz; Buroni, Silvia; Pasca, Maria Rosalia; Biava, Mariangela; Raju, Ravikiran M.; Porretta, Giulio Cesare; Alfonso, Salvatore; Battilocchio, Claudio; Javid, Babak; Sorrentino, Flavia; Ioerger, Thomas R.; Sacchettini, James C.; Manetti, Fabrizio; Botta, Maurizio; De Logu, Alessandro; Rubin, Eric J.; De Rossi, Edda</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">324-331</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The 1,5-diarylpyrrole deriv. BM212 was previously shown to be active against multidrug-resistant clin. isolates and Mycobacterium tuberculosis residing within macrophages as well as against Mycobacterium avium and other atypical mycobacteria.  To det. its mechanism of action, the cellular target was identified.  Spontaneous Mycobacterium smegmatis, Mycobacterium bovis BCG, and M. tuberculosis H37Rv mutants that were resistant to BM212 were isolated.  By the screening of genomic libraries and by whole-genome sequencing, it was found that all the characterized mutants showed mutations in the mmpL3 gene, allowing the conclusion that resistance to BM212 maps to the MmpL3 protein, a member of the MmpL (mycobacterial membrane protein, large) family.  Susceptibility was unaffected by the efflux pump inhibitors reserpine, carbonylcyanide m-chlorophenylhydrazone, and verapamil.  Uptake/efflux expts. with [14C]BM212 demonstrated that resistance is not driven by the efflux of BM212.  Together, these data strongly suggest that the MmpL3 protein is the cellular target of BM212.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBpqZddgKhTLVg90H21EOLACvtfcHk0lhz9LOPLUsYoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1Gqtw%253D%253D&md5=f73b43cff2112c31ae27878eeb740d76</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1128%2FAAC.05270-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.05270-11%26sid%3Dliteratum%253Aachs%26aulast%3DLa%2BRosa%26aufirst%3DV.%26aulast%3DPoce%26aufirst%3DG.%26aulast%3DCanseco%26aufirst%3DJ.%2BO.%26aulast%3DBuroni%26aufirst%3DS.%26aulast%3DPasca%26aufirst%3DM.%2BR.%26aulast%3DBiava%26aufirst%3DM.%26aulast%3DRaju%26aufirst%3DR.%2BM.%26aulast%3DPorretta%26aufirst%3DG.%2BC.%26aulast%3DAlfonso%26aufirst%3DS.%26aulast%3DBattilocchio%26aufirst%3DC.%26aulast%3DJavid%26aufirst%3DB.%26aulast%3DSorrentino%26aufirst%3DF.%26aulast%3DIoerger%26aufirst%3DT.%2BR.%26aulast%3DSacchettini%26aufirst%3DJ.%2BC.%26aulast%3DManetti%26aufirst%3DF.%26aulast%3DBotta%26aufirst%3DM.%26aulast%3DDe%2BLogu%26aufirst%3DA.%26aulast%3DRubin%26aufirst%3DE.%2BJ.%26aulast%3DDe%2BRossi%26aufirst%3DE.%26atitle%3DMmpl3%2520is%2520the%2520cellular%2520target%2520of%2520the%2520antitubercular%2520pyrrole%2520derivative%2520BM212%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D324%26epage%3D331%26doi%3D10.1128%2FAAC.05270-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhakta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scalacci, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dasugari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evangelopoulos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHugh, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortazavi, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Twist, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petricci, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castagnolo, D.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of 1-((1,5-bis(4-chlorophenyl)-2-methyl-1h-pyrrol-3-yl)methyl)-4-methylpiperazine (bm212) and n-adamantan-2-yl-n′-((e)-3,7-dimethylocta-2,6-dienyl)ethane-1,2-diamine (SQ109) pyrrole hybrid derivatives: Discovery of potent antitubercular agents effective against multidrug-resistant mycobacteria</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2780</span>– <span class="NLM_lpage">2793</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00031</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00031" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28XjtVCisr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2780-2793&author=S.+Bhaktaauthor=N.+Scalacciauthor=A.+Maitraauthor=A.+K.+Brownauthor=S.+Dasugariauthor=D.+Evangelopoulosauthor=T.+D.+McHughauthor=P.+N.+Mortazaviauthor=A.+Twistauthor=E.+Petricciauthor=F.+Manettiauthor=D.+Castagnolo&title=Design+and+synthesis+of+1-%28%281%2C5-bis%284-chlorophenyl%29-2-methyl-1h-pyrrol-3-yl%29methyl%29-4-methylpiperazine+%28bm212%29+and+n-adamantan-2-yl-n%E2%80%B2-%28%28e%29-3%2C7-dimethylocta-2%2C6-dienyl%29ethane-1%2C2-diamine+%28SQ109%29+pyrrole+hybrid+derivatives%3A+Discovery+of+potent+antitubercular+agents+effective+against+multidrug-resistant+mycobacteria&doi=10.1021%2Facs.jmedchem.6b00031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of 1-((1,5-Bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-yl)methyl)-4-methylpiperazine (BM212) and N-Adamantan-2-yl-N'-((E)-3,7-dimethylocta-2,6-dienyl)ethane-1,2-diamine (SQ109) Pyrrole Hybrid Derivatives: Discovery of Potent Antitubercular Agents Effective against Multidrug-Resistant Mycobacteria</span></div><div class="casAuthors">Bhakta, Sanjib; Scalacci, Nicolo; Maitra, Arundhati; Brown, Alistair K.; Dasugari, Saiprasad; Evangelopoulos, Dimitrios; McHugh, Timothy D.; Mortazavi, Parisa N.; Twist, Alexander; Petricci, Elena; Manetti, Fabrizio; Castagnolo, Daniele</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2780-2793</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel pyrroles have been designed, synthesized, and evaluated against mycobacterial strains.  The pyrroles have originally been designed as hybrids of the antitubercular drugs BM212 and SQ109, which showed common chem. features with very similar topol. distribution.  A perfect superposition of the structures of BM212 and SQ109 revealed by computational studies suggested the introduction of bulky substituents at the terminal portion of the pyrrole C3 side chain and the removal of the C5 aryl moiety.  Five compds. showed high activity toward Mycobacterium tuberculosis, while I and II were highly active also against multidrug-resistant clin. isolates.  Compd. II showed low eukaryotic cell toxicity, turning out to be an excellent lead candidate for preclin. trials.  In addn., four compds. showed potent inhibition (comparable to that of verapamil) toward the whole-cell drug efflux pump activity of mycobacteria, thus turning out to be promising multidrug-resistance-reversing agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiHSHN7HZypLVg90H21EOLACvtfcHk0lhz9LOPLUsYoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjtVCisr4%253D&md5=75b64a2124cf35b56ea26b402ca993a7</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00031%26sid%3Dliteratum%253Aachs%26aulast%3DBhakta%26aufirst%3DS.%26aulast%3DScalacci%26aufirst%3DN.%26aulast%3DMaitra%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DA.%2BK.%26aulast%3DDasugari%26aufirst%3DS.%26aulast%3DEvangelopoulos%26aufirst%3DD.%26aulast%3DMcHugh%26aufirst%3DT.%2BD.%26aulast%3DMortazavi%26aufirst%3DP.%2BN.%26aulast%3DTwist%26aufirst%3DA.%26aulast%3DPetricci%26aufirst%3DE.%26aulast%3DManetti%26aufirst%3DF.%26aulast%3DCastagnolo%26aufirst%3DD.%26atitle%3DDesign%2520and%2520synthesis%2520of%25201-%2528%25281%252C5-bis%25284-chlorophenyl%2529-2-methyl-1h-pyrrol-3-yl%2529methyl%2529-4-methylpiperazine%2520%2528bm212%2529%2520and%2520n-adamantan-2-yl-n%25E2%2580%25B2-%2528%2528e%2529-3%252C7-dimethylocta-2%252C6-dienyl%2529ethane-1%252C2-diamine%2520%2528SQ109%2529%2520pyrrole%2520hybrid%2520derivatives%253A%2520Discovery%2520of%2520potent%2520antitubercular%2520agents%2520effective%2520against%2520multidrug-resistant%2520mycobacteria%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D2780%26epage%3D2793%26doi%3D10.1021%2Facs.jmedchem.6b00031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group">Anon</span> <span> </span><span class="NLM_article-title">Ll-3858</span>. <i>Tuberculosis (Oxford, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">126</span>, <span class="refDoi"> DOI: 10.1016/S1472-9792(08)70015-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2FS1472-9792%2808%2970015-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=18486049" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2008&pages=126&author=Anon&title=Ll-3858&doi=10.1016%2FS1472-9792%2808%2970015-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1016%2FS1472-9792%2808%2970015-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1472-9792%252808%252970015-5%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DLl-3858%26jtitle%3DTuberculosis%2520%2528Oxford%252C%2520U.%2520K.%2529%26date%3D2008%26volume%3D88%26spage%3D126%26doi%3D10.1016%2FS1472-9792%2808%2970015-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cardona, P.-J.</span></span> <i>Understanding Tuberculosis: New Approaches to Fighting Against Drug Resistance</i>; <span class="NLM_publisher-name">IntechOpen</span>: <span class="NLM_publisher-loc">London</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.5772%2F2477" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=P.-J.+Cardona&title=Understanding+Tuberculosis%3A+New+Approaches+to+Fighting+Against+Drug+Resistance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.5772%2F2477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.5772%252F2477%26sid%3Dliteratum%253Aachs%26aulast%3DCardona%26aufirst%3DP.-J.%26btitle%3DUnderstanding%2520Tuberculosis%253A%2520New%2520Approaches%2520to%2520Fighting%2520Against%2520Drug%2520Resistance%26pub%3DIntechOpen%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stec, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onajole, O. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merenbloom, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vistoli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishai, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Indole-2-carboxamide-based MmpL3 inhibitors show exceptional antitubercular activity in an animal model of tuberculosis infection</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">6232</span>– <span class="NLM_lpage">6247</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00415</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00415" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsVCltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=6232-6247&author=J.+Stecauthor=O.+K.+Onajoleauthor=S.+Lunauthor=H.+Guoauthor=B.+Merenbloomauthor=G.+Vistoliauthor=W.+R.+Bishaiauthor=A.+P.+Kozikowski&title=Indole-2-carboxamide-based+MmpL3+inhibitors+show+exceptional+antitubercular+activity+in+an+animal+model+of+tuberculosis+infection&doi=10.1021%2Facs.jmedchem.6b00415"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Indole-2-carboxamide-based MmpL3 Inhibitors Show Exceptional Antitubercular Activity in an Animal Model of Tuberculosis Infection</span></div><div class="casAuthors">Stec, Jozef; Onajole, Oluseye K.; Lun, Shichun; Guo, Haidan; Merenbloom, Benjamin; Vistoli, Giulio; Bishai, William R.; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6232-6247</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Our team had previously identified certain indolecarboxamides that represented a new chem. scaffold that showed promising anti-TB activity at both an in vitro and in vivo level.  Based on mutational anal. using bacteria found resistant to one of these indolecarboxamides, we identified the trehalose monomycolate transporter MmpL3 as the likely target of these compds.  In the present work, we now further elaborate on the SAR of these compds., which has led in turn to the identification of a new analog, 4,6-difluoro-N-((1R,2R,3R,5S)-2,6,6-trimethylbicyclo[3.1.1]heptan-3-yl)-1H-indole-2-carboxamide (26), that shows excellent activity against drug-sensitive (MIC = 0.012 μM; SI ≥ 16000), multidrug-resistant (MDR), and extensively drug-resistant (XDR) Mycobacterium tuberculosis strains, has superior ADMET properties, and shows excellent activity in the TB aerosol lung infection model.  Compd. 26 is also shown to work in synergy with rifampin.  Because of these properties, we believe that indolecarboxamide 26 is a possible candidate for advancement to human clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg0h9TR-VL5rVg90H21EOLACvtfcHk0ljCy5Xkd0XDTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsVCltb8%253D&md5=f9e3d545a65f85deb3f97054dca77c1f</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00415%26sid%3Dliteratum%253Aachs%26aulast%3DStec%26aufirst%3DJ.%26aulast%3DOnajole%26aufirst%3DO.%2BK.%26aulast%3DLun%26aufirst%3DS.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DMerenbloom%26aufirst%3DB.%26aulast%3DVistoli%26aufirst%3DG.%26aulast%3DBishai%26aufirst%3DW.%2BR.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DIndole-2-carboxamide-based%2520MmpL3%2520inhibitors%2520show%2520exceptional%2520antitubercular%2520activity%2520in%2520an%2520animal%2520model%2520of%2520tuberculosis%2520infection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D6232%26epage%3D6247%26doi%3D10.1021%2Facs.jmedchem.6b00415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njire, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franzblauc, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of pyrazolo[1,5-a]pyridine-3-carboxamides as novel antitubercular agents</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">814</span>– <span class="NLM_lpage">818</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00176</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00176" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVansL3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=814-818&author=J.+Tangauthor=B.+Wangauthor=T.+Wuauthor=J.+Wanauthor=Z.+Tuauthor=M.+Njireauthor=B.+Wanauthor=S.+G.+Franzblaucauthor=T.+Zhangauthor=X.+Luauthor=K.+Ding&title=Design%2C+synthesis%2C+and+biological+evaluation+of+pyrazolo%5B1%2C5-a%5Dpyridine-3-carboxamides+as+novel+antitubercular+agents&doi=10.1021%2Facsmedchemlett.5b00176"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of Pyrazolo[1,5-a]pyridine-3-carboxamides as Novel Antitubercular Agents</span></div><div class="casAuthors">Tang, Jian; Wang, Bangxing; Wu, Tian; Wan, Junting; Tu, Zhengchao; Njire, Moses; Wan, Baojie; Franzblauc, Scott G.; Zhang, Tianyu; Lu, Xiaoyun; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">814-818</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pyrazolo[1,5-a]pyridine-3-carboxamides such as I (R = Me, MeO, H, Et, i-Pr, t-Bu, Cl, F3C) were prepd. as potential antituberculosis agents; their toxicities to Vero cells and their inhibition of drug-susceptible and drug-resistant Mycobacterium tuberculosis (Mtb) strains were detd.  The activities of selected compds. were detd. against a fluorescent reporter-contg. Mtb strain and against a drug-resistant Mtb strain in mice.  In particular, I (R = MeO) significantly reduced the bacterial burden in an autoluminescent H37Ra infected mouse model, suggesting it to be a potential lead compd. for future antitubercular drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQQpKb_Lf-TrVg90H21EOLACvtfcHk0ljCy5Xkd0XDTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVansL3O&md5=1064849b13a2674f43e162b503c3f851</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00176&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00176%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DWan%26aufirst%3DJ.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DNjire%26aufirst%3DM.%26aulast%3DWan%26aufirst%3DB.%26aulast%3DFranzblauc%26aufirst%3DS.%2BG.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520pyrazolo%255B1%252C5-a%255Dpyridine-3-carboxamides%2520as%2520novel%2520antitubercular%2520agents%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D814%26epage%3D818%26doi%3D10.1021%2Facsmedchemlett.5b00176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Panda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirude, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humnabadkar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagalapur, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guptha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahadevaswamy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambady, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegde, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudrapatna, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosagrahara, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sambandamurthy, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raichurkar, A.</span></span> <span> </span><span class="NLM_article-title">Discovery of pyrazolopyridones as a novel class of noncovalent DprE1 inhibitor with potent anti-mycobacterial activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4761</span>– <span class="NLM_lpage">4771</span>, <span class="refDoi"> DOI: 10.1021/jm5002937</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5002937" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnvVShtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4761-4771&author=M.+Pandaauthor=S.+Ramachandranauthor=V.+Ramachandranauthor=P.+S.+Shirudeauthor=V.+Humnabadkarauthor=K.+Nagalapurauthor=S.+Sharmaauthor=P.+Kaurauthor=S.+Gupthaauthor=A.+Narayanauthor=J.+Mahadevaswamyauthor=A.+Ambadyauthor=N.+Hegdeauthor=S.+S.+Rudrapatnaauthor=V.+P.+Hosagraharaauthor=V.+K.+Sambandamurthyauthor=A.+Raichurkar&title=Discovery+of+pyrazolopyridones+as+a+novel+class+of+noncovalent+DprE1+inhibitor+with+potent+anti-mycobacterial+activity&doi=10.1021%2Fjm5002937"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Pyrazolopyridones as a Novel Class of Noncovalent DprE1 Inhibitor with Potent Anti-Mycobacterial Activity</span></div><div class="casAuthors">Panda, Manoranjan; Ramachandran, Sreekanth; Ramachandran, Vasanthi; Shirude, Pravin S.; Humnabadkar, Vaishali; Nagalapur, Kavitha; Sharma, Sreevalli; Kaur, Parvinder; Guptha, Supreeth; Narayan, Ashwini; Mahadevaswamy, Jyothi; Ambady, Anisha; Hegde, Naina; Rudrapatna, Suresh S.; Hosagrahara, Vinayak P.; Sambandamurthy, Vasan K.; Raichurkar, Anandkumar</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4761-4771</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel pyrazolopyridone class of inhibitors was identified from whole cell screening against Mycobacterium tuberculosis (Mtb).  The series exhibits excellent bactericidality in vitro, resulting in a 4 log redn. in colony forming units following compd. exposure.  The significant modulation of min. inhibitory concn. (MIC) against a Mtb strain overexpressing the Rv3790 gene suggested the target of pyrazolopyridones to be decaprenylphosphoryl-β-D-ribose-2'-epimerase (DprE1).  Genetic mapping of resistance mutation coupled with potent enzyme inhibition activity confirmed the mol. target.  Detailed biochem. characterization revealed the series to be a noncovalent inhibitor of DprE1.  Docking studies at the active site suggest that the series can be further diversified to improve the physicochem. properties without compromising the antimycobacterial activity.  The pyrazolopyridone class of inhibitors offers an attractive non-nitro lead series targeting the essential and vulnerable DprE1 enzyme for the discovery of novel antimycobacterial agents to treat both drug susceptible and drug resistant strains of Mtb.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdYV8Pi2ynA7Vg90H21EOLACvtfcHk0ljCy5Xkd0XDTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnvVShtrw%253D&md5=dd3c1daf880d2f50d3187a0f9d1ab363</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1021%2Fjm5002937&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5002937%26sid%3Dliteratum%253Aachs%26aulast%3DPanda%26aufirst%3DM.%26aulast%3DRamachandran%26aufirst%3DS.%26aulast%3DRamachandran%26aufirst%3DV.%26aulast%3DShirude%26aufirst%3DP.%2BS.%26aulast%3DHumnabadkar%26aufirst%3DV.%26aulast%3DNagalapur%26aufirst%3DK.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DKaur%26aufirst%3DP.%26aulast%3DGuptha%26aufirst%3DS.%26aulast%3DNarayan%26aufirst%3DA.%26aulast%3DMahadevaswamy%26aufirst%3DJ.%26aulast%3DAmbady%26aufirst%3DA.%26aulast%3DHegde%26aufirst%3DN.%26aulast%3DRudrapatna%26aufirst%3DS.%2BS.%26aulast%3DHosagrahara%26aufirst%3DV.%2BP.%26aulast%3DSambandamurthy%26aufirst%3DV.%2BK.%26aulast%3DRaichurkar%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520pyrazolopyridones%2520as%2520a%2520novel%2520class%2520of%2520noncovalent%2520DprE1%2520inhibitor%2520with%2520potent%2520anti-mycobacterial%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4761%26epage%3D4771%26doi%3D10.1021%2Fjm5002937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Riccardi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasca, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarelli, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manina, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattevi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binda, C.</span></span> <span> </span><span class="NLM_article-title">The dpre1 enzyme, one of the most vulnerable targets of mycobacterium tuberculosis</span>. <i>Appl. Microbiol. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">8841</span>– <span class="NLM_lpage">8848</span>, <span class="refDoi"> DOI: 10.1007/s00253-013-5218-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1007%2Fs00253-013-5218-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=24037308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVCnurrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2013&pages=8841-8848&author=G.+Riccardiauthor=M.+R.+Pascaauthor=L.+R.+Chiarelliauthor=G.+Maninaauthor=A.+Matteviauthor=C.+Binda&title=The+dpre1+enzyme%2C+one+of+the+most+vulnerable+targets+of+mycobacterium+tuberculosis&doi=10.1007%2Fs00253-013-5218-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">The DprE1 enzyme, one of the most vulnerable targets of Mycobacterium tuberculosis</span></div><div class="casAuthors">Riccardi, Giovanna; Pasca, Maria Rosalia; Chiarelli, Laurent Roberto; Manina, Giulia; Mattevi, Andrea; Binda, Claudia</div><div class="citationInfo"><span class="NLM_cas:title">Applied Microbiology and Biotechnology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8841-8848</span>CODEN:
                <span class="NLM_cas:coden">AMBIDG</span>;
        ISSN:<span class="NLM_cas:issn">0175-7598</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  The re-emergence of tuberculosis (TB) in recent years led the World Health Organization (WHO) to launch the Stop TB Strategy program.  In addn. to repurposing existing drugs and exploring novel mol. combinations, an essential step to face the burden of TB will be to develop new drugs by identifying vulnerable bacterial targets.  Recent studies have focused on decaprenylphosphoryl-D-ribose oxidase (DprE1) of M. tuberculosis, an essential enzyme involved in cell wall metab., for which new promising mols. have proved efficacy as antitubercular agents.  Here, the authors summarize the state of the art concerning DprE1 in terms of structure, enzymic activity, and inhibitors.  This enzyme is emerging as one of the most vulnerable targets in M. tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA_XaR7fi41bVg90H21EOLACvtfcHk0liJD6q2abrXzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVCnurrO&md5=a04f5e574bdf2c42a68fb9af89d7bd4b</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1007%2Fs00253-013-5218-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00253-013-5218-x%26sid%3Dliteratum%253Aachs%26aulast%3DRiccardi%26aufirst%3DG.%26aulast%3DPasca%26aufirst%3DM.%2BR.%26aulast%3DChiarelli%26aufirst%3DL.%2BR.%26aulast%3DManina%26aufirst%3DG.%26aulast%3DMattevi%26aufirst%3DA.%26aulast%3DBinda%26aufirst%3DC.%26atitle%3DThe%2520dpre1%2520enzyme%252C%2520one%2520of%2520the%2520most%2520vulnerable%2520targets%2520of%2520mycobacterium%2520tuberculosis%26jtitle%3DAppl.%2520Microbiol.%2520Biotechnol.%26date%3D2013%26volume%3D97%26spage%3D8841%26epage%3D8848%26doi%3D10.1007%2Fs00253-013-5218-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brecik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Centárová, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukherjee, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolly, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huszár, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bobovská, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilacsková, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mokošová, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svetlíková, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Šarkan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neres, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korduláková, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikušová, K.</span></span> <span> </span><span class="NLM_article-title">DprE1 is a vulnerable tuberculosis drug target due to its cell wall localization</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1631</span>– <span class="NLM_lpage">1636</span>, <span class="refDoi"> DOI: 10.1021/acschembio.5b00237</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.5b00237" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntVWns70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1631-1636&author=M.+Brecikauthor=I.+Cent%C3%A1rov%C3%A1author=R.+Mukherjeeauthor=G.+S.+Kollyauthor=S.+Husz%C3%A1rauthor=A.+Bobovsk%C3%A1author=E.+Kilacskov%C3%A1author=V.+Moko%C5%A1ov%C3%A1author=Z.+Svetl%C3%ADkov%C3%A1author=M.+%C5%A0arkanauthor=J.+Neresauthor=J.+Kordul%C3%A1kov%C3%A1author=S.+T.+Coleauthor=K.+Miku%C5%A1ov%C3%A1&title=DprE1+is+a+vulnerable+tuberculosis+drug+target+due+to+its+cell+wall+localization&doi=10.1021%2Facschembio.5b00237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">DprE1 Is a Vulnerable Tuberculosis Drug Target Due to Its Cell Wall Localization</span></div><div class="casAuthors">Brecik, Miroslav; Centarova, Ivana; Mukherjee, Raju; Kolly, Gaelle S.; Huszar, Stanislav; Bobovska, Adela; Kilacskova, Emoke; Mokosova, Veronika; Svetlikova, Zuzana; Sarkan, Michal; Neres, Joao; Kordulakova, Jana; Cole, Stewart T.; Mikusova, Katarina</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1631-1636</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The flavo-enzyme DprE1 catalyzes a key epimerization step in the decaprenyl-phosphoryl D-arabinose (DPA) pathway, which is essential for mycobacterial cell wall biogenesis and targeted by several new tuberculosis drug candidates.  Here, using differential radiolabeling with DPA precursors and high-resoln. fluorescence microscopy, we disclose the unexpected extracytoplasmic localization of DprE1 and periplasmic synthesis of DPA.  Collectively, this explains the vulnerability of DprE1 and the remarkable potency of the best inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2tTdrWjQmBrVg90H21EOLACvtfcHk0liJD6q2abrXzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntVWns70%253D&md5=bc1317378445d84300aca1615ef8d058</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1021%2Facschembio.5b00237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.5b00237%26sid%3Dliteratum%253Aachs%26aulast%3DBrecik%26aufirst%3DM.%26aulast%3DCent%25C3%25A1rov%25C3%25A1%26aufirst%3DI.%26aulast%3DMukherjee%26aufirst%3DR.%26aulast%3DKolly%26aufirst%3DG.%2BS.%26aulast%3DHusz%25C3%25A1r%26aufirst%3DS.%26aulast%3DBobovsk%25C3%25A1%26aufirst%3DA.%26aulast%3DKilacskov%25C3%25A1%26aufirst%3DE.%26aulast%3DMoko%25C5%25A1ov%25C3%25A1%26aufirst%3DV.%26aulast%3DSvetl%25C3%25ADkov%25C3%25A1%26aufirst%3DZ.%26aulast%3D%25C5%25A0arkan%26aufirst%3DM.%26aulast%3DNeres%26aufirst%3DJ.%26aulast%3DKordul%25C3%25A1kov%25C3%25A1%26aufirst%3DJ.%26aulast%3DCole%26aufirst%3DS.%2BT.%26aulast%3DMiku%25C5%25A1ov%25C3%25A1%26aufirst%3DK.%26atitle%3DDprE1%2520is%2520a%2520vulnerable%2520tuberculosis%2520drug%2520target%2520due%2520to%2520its%2520cell%2520wall%2520localization%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2015%26volume%3D10%26spage%3D1631%26epage%3D1636%26doi%3D10.1021%2Facschembio.5b00237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, X.</span></span> <span> </span><span class="NLM_article-title">Identification of n-(2-phenoxyethyl)imidazo[1,2-a]pyridine-3- carboxamides as new antituberculosis agents</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1130</span>– <span class="NLM_lpage">1133</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00330</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00330" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1CmtbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=1130-1133&author=Z.+Wuauthor=Y.+Luauthor=L.+Liauthor=R.+Zhaoauthor=B.+Wangauthor=K.+Lvauthor=M.+Liuauthor=X.+You&title=Identification+of+n-%282-phenoxyethyl%29imidazo%5B1%2C2-a%5Dpyridine-3-+carboxamides+as+new+antituberculosis+agents&doi=10.1021%2Facsmedchemlett.6b00330"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of N-(2-Phenoxyethyl)imidazo[1,2-a]pyridine-3-carboxamides as New Antituberculosis Agents</span></div><div class="casAuthors">Wu, Zhaoyang; Lu, Yu; Li, Linhu; Zhao, Rui; Wang, Bin; Lv, Kai; Liu, Mingliang; You, Xuefu</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1130-1133</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of imidazo[1,2-a]pyridine carboxamides (IPAs) bearing an N-(2-phenoxyethyl) moiety was designed and synthesized as new antitubercular agents.  Seven 2,6-di-Me IPAs demonstrated excellent in vitro activity (MIC: 0.025-0.054 μg/mL) against the drug susceptive H37Rv strain and two clin. isolated multidrug-resistant Mycobacterium tuberculosis strains.  Compd. I displayed acceptable safety and pharmacokinetic properties, opening a new direction for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDiXPMdtzWD7Vg90H21EOLACvtfcHk0liJD6q2abrXzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1CmtbvI&md5=f4f5d7f14c67d86e515289cc03dd50bf</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00330%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DLv%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DYou%26aufirst%3DX.%26atitle%3DIdentification%2520of%2520n-%25282-phenoxyethyl%2529imidazo%255B1%252C2-a%255Dpyridine-3-%2520carboxamides%2520as%2520new%2520antituberculosis%2520agents%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D1130%26epage%3D1133%26doi%3D10.1021%2Facsmedchemlett.6b00330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Post-Martens, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denkin, S.</span></span> <span> </span><span class="NLM_article-title">New drug candidates and therapeutic targets for tuberculosis therapy</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">27</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(05)03626-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2FS1359-6446%2805%2903626-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=16478687" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD28XhsFygsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2006&pages=21-27&author=Y.+Zhangauthor=K.+Post-Martensauthor=S.+Denkin&title=New+drug+candidates+and+therapeutic+targets+for+tuberculosis+therapy&doi=10.1016%2FS1359-6446%2805%2903626-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">New drug candidates and therapeutic targets for tuberculosis therapy</span></div><div class="casAuthors">Zhang, Ying; Post-Martens, Katrin; Denkin, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1 & 2</span>),
    <span class="NLM_cas:pages">21-27</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Despite advances in chemotherapy and the BCG (Bacillus Calmette-Guerin) vaccine, tuberculosis remains a significant infectious disease.  Although it can be cured, the therapy takes at least 6-9 mo, and the laborious and lengthy treatment brings with it dangers of noncompliance, significant toxicity and drug resistance.  The increasing emergence of drug resistance and the problem of mycobacterial persistence highlight the need to develop novel TB drugs that are active against drug resistant bacteria but, more importantly, kill persistent bacteria and shorten the length of treatment.  Recent new and exciting developments in tuberculosis drug discovery show good promise of a possible revolution in the chemotherapy of tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfStEdhpVTDLVg90H21EOLACvtfcHk0lhuUfDpysSWxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhsFygsbc%253D&md5=0db52ffead572bcf52139af571749954</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2805%2903626-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252805%252903626-3%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DPost-Martens%26aufirst%3DK.%26aulast%3DDenkin%26aufirst%3DS.%26atitle%3DNew%2520drug%2520candidates%2520and%2520therapeutic%2520targets%2520for%2520tuberculosis%2520therapy%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2006%26volume%3D11%26spage%3D21%26epage%3D27%26doi%3D10.1016%2FS1359-6446%2805%2903626-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leach, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brickner, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noe, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, P. F.</span></span> <span> </span><span class="NLM_article-title">Linezolid, the first oxazolidinone antibacterial agent</span>. <i>Ann. N. Y. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>1222</i></span>,  <span class="NLM_fpage">49</span>– <span class="NLM_lpage">54</span>, <span class="refDoi"> DOI: 10.1111/j.1749-6632.2011.05962.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1111%2Fj.1749-6632.2011.05962.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=21434942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtVykurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1222&publication_year=2011&pages=49-54&author=K.+L.+Leachauthor=S.+J.+Bricknerauthor=M.+C.+Noeauthor=P.+F.+Miller&title=Linezolid%2C+the+first+oxazolidinone+antibacterial+agent&doi=10.1111%2Fj.1749-6632.2011.05962.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Linezolid, the first oxazolidinone antibacterial agent</span></div><div class="casAuthors">Leach, Karen L.; Brickner, Steven J.; Noe, Mark C.; Miller, Paul F.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the New York Academy of Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">1222</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">49-54</span>CODEN:
                <span class="NLM_cas:coden">ANYAA9</span>;
        ISSN:<span class="NLM_cas:issn">0077-8923</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Linezolid (Zyvox) is the first member of an entirely new class of antibiotics to reach the market in over 35 years; it was approved for use in 2000.  A member of the oxazolidinone class of antibiotics, linezolid is highly effective for the treatment of serious Gram-pos. infections and has activity that compares favorably with vancomycin for most clin. relevant pathogens.  Zyvox is approved for use against serious Gram-pos. infections, including those caused by Streptococcus pneumoniae, and the very challenging methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium organisms.  Zyvox inhibits bacterial protein synthesis by binding to 23S rRNA in the catalytic site of the 50S ribosome.  It can be administered both orally and i.v. and has good tissue distribution.  Recent results have demonstrated that oxazolidinone analogs related to linezolid are effective in treating pulmonary tuberculosis caused by resistant Mycobacterium tuberculosis in animal infection models and suggest addnl. new therapeutic applications for these antibiotics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwUe7BGP38ObVg90H21EOLACvtfcHk0lhuUfDpysSWxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtVykurs%253D&md5=986e1ad5613495d3344b26f03489e4ab</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1111%2Fj.1749-6632.2011.05962.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1749-6632.2011.05962.x%26sid%3Dliteratum%253Aachs%26aulast%3DLeach%26aufirst%3DK.%2BL.%26aulast%3DBrickner%26aufirst%3DS.%2BJ.%26aulast%3DNoe%26aufirst%3DM.%2BC.%26aulast%3DMiller%26aufirst%3DP.%2BF.%26atitle%3DLinezolid%252C%2520the%2520first%2520oxazolidinone%2520antibacterial%2520agent%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D2011%26volume%3D1222%26spage%3D49%26epage%3D54%26doi%3D10.1111%2Fj.1749-6632.2011.05962.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Falagas, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siempos, I. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vardakas, K. Z.</span></span> <span> </span><span class="NLM_article-title">Linezolid versus glycopeptide or beta-lactam for treatment of gram-positive bacterial infections: Meta-analysis of randomised controlled trials</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">53</span>– <span class="NLM_lpage">66</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(07)70312-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2FS1473-3099%2807%2970312-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=18156089" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhs1ejtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=53-66&author=M.+E.+Falagasauthor=I.+I.+Siemposauthor=K.+Z.+Vardakas&title=Linezolid+versus+glycopeptide+or+beta-lactam+for+treatment+of+gram-positive+bacterial+infections%3A+Meta-analysis+of+randomised+controlled+trials&doi=10.1016%2FS1473-3099%2807%2970312-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Linezolid versus glycopeptide or β-lactam for treatment of Gram-positive bacterial infections: a meta-analysis of randomised controlled trials</span></div><div class="casAuthors">Falagas, Matthew E.; Siempos, Ilias I.; Vardakas, Konstantinos Z.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">53-66</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Linezolid has been approved for the treatment of patients with infections caused by Gram-pos. cocci that are resistant to traditionally used antibiotics, including glycopeptides.  This oxazolidinone antibiotic has been reported to have excellent pharmacokinetics and effectiveness.  We did a meta-anal. of randomised controlled trials (RCTs) to clarify whether linezolid is superior to glycopeptides or β-lactams for the treatment of Gram-pos. infections.  12 RCTs, involving 6093 patients, were included.  Overall, with respect to treatment success, linezolid was more effective than glycopeptides or β-lactams (odds ratio [OR] 1.41 [95% CI 1.11-1.81]).  Mortality was similar between the groups (OR 0.97 [0.79-1.19]).  Linezolid was more effective than comparators in patients with skin and soft-tissue infections (OR 1.67 [1.31-2.12]) and bacteremia (OR 2.07 [1.13-3.78]).  However, there was no difference in treatment success for patients with pneumonia (OR 1.03 [0.75-1.42]).  Treatment with linezolid was not assocd. with more adverse effects in general (OR 1.40 [0.95-2.06]); however, thrombocytopenia was recorded more commonly in patients receiving linezolid (OR 11.72 [3.66-37.57]).  Although linezolid is more effective than its comparators for the empirical treatment of selected patients, several points, such as the use of less potent antistaphylococcal β-lactams, the same all-cause mortality, and the higher probability of thrombocytopenia, should be taken into account and may limit the use of linezolid to specific patient populations or infections that are difficult to treat with other antibiotics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8g49kzGy9GrVg90H21EOLACvtfcHk0lhuUfDpysSWxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhs1ejtb0%253D&md5=ccd6c273993bb91c9a50ea4b19064083</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2807%2970312-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252807%252970312-2%26sid%3Dliteratum%253Aachs%26aulast%3DFalagas%26aufirst%3DM.%2BE.%26aulast%3DSiempos%26aufirst%3DI.%2BI.%26aulast%3DVardakas%26aufirst%3DK.%2BZ.%26atitle%3DLinezolid%2520versus%2520glycopeptide%2520or%2520beta-lactam%2520for%2520treatment%2520of%2520gram-positive%2520bacterial%2520infections%253A%2520Meta-analysis%2520of%2520randomised%2520controlled%2520trials%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2008%26volume%3D8%26spage%3D53%26epage%3D66%26doi%3D10.1016%2FS1473-3099%2807%2970312-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Narita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuji, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, V. L.</span></span> <span> </span><span class="NLM_article-title">Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome</span>. <i>Pharmacotherapy</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1189</span>– <span class="NLM_lpage">1197</span>, <span class="refDoi"> DOI: 10.1592/phco.27.8.1189</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1592%2Fphco.27.8.1189" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=17655517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD2sXptlKqtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2007&pages=1189-1197&author=M.+Naritaauthor=B.+T.+Tsujiauthor=V.+L.+Yu&title=Linezolid-associated+peripheral+and+optic+neuropathy%2C+lactic+acidosis%2C+and+serotonin+syndrome&doi=10.1592%2Fphco.27.8.1189"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome</span></div><div class="casAuthors">Narita, Masashi; Tsuji, Brian T.; Yu, Victor L.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacotherapy</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1189-1197</span>CODEN:
                <span class="NLM_cas:coden">PHPYDQ</span>;
        ISSN:<span class="NLM_cas:issn">0277-0008</span>.
    
            (<span class="NLM_cas:orgname">Pharmacotherapy Publications</span>)
        </div><div class="casAbstract">A review.  Linezolid is an oxazolidinone antibacterial agent indicated for serious gram-pos. infections.  Only minor adverse effects were seen in phase III trials.  However, more serious adverse effects were reported after com. release, including cases of lactic acidosis, peripheral and optic neuropathy, and serotonin syndrome.  Peripheral and optic neuropathy was usually seen after several months of linezolid therapy (median 5 mo), lactic acidosis after several weeks (median 6 wks), and serotonin syndrome after several days (median 4 days).  Death occurred in two of seven reported cases of lactic acidosis, and three of 15 reported cases of serotonin syndrome.  Improvement or complete recovery occurred in all cases of optic neuropathy, whereas complete recovery failed to occur in any patient with peripheral neuropathy.  Linezolid should be discontinued immediately in patients experiencing these adverse effects.  Patients receiving linezolid for more than 28 days should be monitored for signs of peripheral and optic neuropathy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMHoqDj-lHIrVg90H21EOLACvtfcHk0ljDNpLIfxE1_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXptlKqtLc%253D&md5=ec758ac912569c37316e8fbb6e722081</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1592%2Fphco.27.8.1189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1592%252Fphco.27.8.1189%26sid%3Dliteratum%253Aachs%26aulast%3DNarita%26aufirst%3DM.%26aulast%3DTsuji%26aufirst%3DB.%2BT.%26aulast%3DYu%26aufirst%3DV.%2BL.%26atitle%3DLinezolid-associated%2520peripheral%2520and%2520optic%2520neuropathy%252C%2520lactic%2520acidosis%252C%2520and%2520serotonin%2520syndrome%26jtitle%3DPharmacotherapy%26date%3D2007%26volume%3D27%26spage%3D1189%26epage%3D1197%26doi%3D10.1592%2Fphco.27.8.1189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bressler, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmer, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmore, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somani, J.</span></span> <span> </span><span class="NLM_article-title">Peripheral neuropathy associated with prolonged use of linezolid</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">528</span>– <span class="NLM_lpage">531</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(04)01109-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2FS1473-3099%2804%2901109-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=15288827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A280%3ADC%252BD2czosFymsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=528-531&author=A.+M.+Bresslerauthor=S.+M.+Zimmerauthor=J.+L.+Gilmoreauthor=J.+Somani&title=Peripheral+neuropathy+associated+with+prolonged+use+of+linezolid&doi=10.1016%2FS1473-3099%2804%2901109-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Peripheral neuropathy associated with prolonged use of linezolid</span></div><div class="casAuthors">Bressler Adam M; Zimmer Shanta M; Gilmore Jane L; Somani Jyoti</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Infectious diseases</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">528-31</span>
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    </div><div class="casAbstract">We present a case of a woman who developed severe, painful peripheral neuropathy while receiving linezolid therapy for 6 months.  Nerve conduction studies indicated a sensory-motor axonal neuropathy.  Extensive assessment did not show alternative explanations for her neuropathy.  At the time of death 1 month after discontinuing linezolid, the neuropathy had not resolved.  A review of published material shows a growing body of evidence that long-term use of linezolid may be associated with severe peripheral and optic neuropathy. 21 cases have been reported.  In most cases, optic neuropathies resolved after stopping linezolid but peripheral neuropathies did not.  The duration of therapy rather than indication for treatment seems to be the most important factor.  The mechanism of toxicity is unknown but certain pharmacological properties of linezolid that may play a part are proposed.  This report highlights the importance of post-approval surveillance and reporting of serious adverse drug effects, and potential consequences of off-label use of pharmaceuticals.  It further demonstrates the critical role clinicians have in communicating awareness of emerging drug toxicities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSghVp0dJe6Wq2q3xNe7a7QfW6udTcc2eba1iiqggvzibntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2czosFymsg%253D%253D&md5=817a165b02499e886a00eb4ebdd8e397</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2804%2901109-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252804%252901109-0%26sid%3Dliteratum%253Aachs%26aulast%3DBressler%26aufirst%3DA.%2BM.%26aulast%3DZimmer%26aufirst%3DS.%2BM.%26aulast%3DGilmore%26aufirst%3DJ.%2BL.%26aulast%3DSomani%26aufirst%3DJ.%26atitle%3DPeripheral%2520neuropathy%2520associated%2520with%2520prolonged%2520use%2520of%2520linezolid%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2004%26volume%3D4%26spage%3D528%26epage%3D531%26doi%3D10.1016%2FS1473-3099%2804%2901109-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chao, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, S. T.</span></span> <span> </span><span class="NLM_article-title">Painful neuropathy with skin denervation after prolonged use of linezolid</span>. <i>J. Neurol., Neurosurg. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">99</span>, <span class="refDoi"> DOI: 10.1136/jnnp.2007.127910</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1136%2Fjnnp.2007.127910" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=17766431" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A280%3ADC%252BD2sjktFejuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2008&pages=97-99&author=C.+C.+Chaoauthor=H.+Y.+Sunauthor=Y.+C.+Changauthor=S.+T.+Hsieh&title=Painful+neuropathy+with+skin+denervation+after+prolonged+use+of+linezolid&doi=10.1136%2Fjnnp.2007.127910"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Painful neuropathy with skin denervation after prolonged use of linezolid</span></div><div class="casAuthors">Chao C-C; Sun H-Y; Chang Y-C; Hsieh S-T</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neurology, neurosurgery, and psychiatry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">97-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The prolonged use of linezolid, a new antibiotic against drug-resistant gram-positive pathogens, might cause painful neuropathy.  This finding raises the possibility that small-diameter sensory nerves in the skin, which are responsible for transmitting nociceptive information, might be affected.  We report a 53-year-old female who developed pure small-fibre painful neuropathy (visual analogue scale, VAS = 82 on 0-100 scale) with marked skin denervation in the leg (epidermal nerve density, END = 2.32 fibres/mm, norm <5.88 fibres/mm) and significant elevation of the warm threshold in the foot (40.0 degrees C, norm <39.4 degrees C) after the use of linezolid for 6 months.  Eight months after the discontinuation of linezolid, the skin became fully reinnervated (END = 9.04 fibres/mm), with disappearance of neuropathic pain (VAS = 0) and normalisation of the warm threshold (36.3 degrees C).  Nerve conduction studies for large-diameter motor and sensory nerves were normal.  This report documents a pure small-fibre sensory neuropathy after prolonged use of linezolid, and the relationship between skin innervation and corresponding neuropathic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRhZW7yFMdLk2gRQsDqrjW_fW6udTcc2eba1iiqggvzibntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2sjktFejuw%253D%253D&md5=5c258b2200b97330f4279c3eab3632a9</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1136%2Fjnnp.2007.127910&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fjnnp.2007.127910%26sid%3Dliteratum%253Aachs%26aulast%3DChao%26aufirst%3DC.%2BC.%26aulast%3DSun%26aufirst%3DH.%2BY.%26aulast%3DChang%26aufirst%3DY.%2BC.%26aulast%3DHsieh%26aufirst%3DS.%2BT.%26atitle%3DPainful%2520neuropathy%2520with%2520skin%2520denervation%2520after%2520prolonged%2520use%2520of%2520linezolid%26jtitle%3DJ.%2520Neurol.%252C%2520Neurosurg.%2520Psychiatry%26date%3D2008%26volume%3D79%26spage%3D97%26epage%3D99%26doi%3D10.1136%2Fjnnp.2007.127910" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stover, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tasneen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyagi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosset, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuermberger, E.</span></span> <span> </span><span class="NLM_article-title">Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">1314</span>– <span class="NLM_lpage">1319</span>, <span class="refDoi"> DOI: 10.1128/AAC.01182-08</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.01182-08" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=19075058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksFWksrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2009&pages=1314-1319&author=K.+N.+Williamsauthor=C.+K.+Stoverauthor=T.+Zhuauthor=R.+Tasneenauthor=S.+Tyagiauthor=J.+H.+Grossetauthor=E.+Nuermberger&title=Promising+antituberculosis+activity+of+the+oxazolidinone+PNU-100480+relative+to+that+of+linezolid+in+a+murine+model&doi=10.1128%2FAAC.01182-08"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model</span></div><div class="casAuthors">Williams, K. N.; Stover, C. K.; Zhu, T.; Tasneen, R.; Tyagi, S.; Grosset, J. H.; Nuermberger, E.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1314-1319</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Oxazolidinone antibiotics have activity against Mycobacterium tuberculosis.  Linezolid, the only marked oxazolidinone, has been used off-label in combination regimens to treat multidrug-resistant tuberculosis, but its precise contribution to the efficacy of such combinations is unclear.  Another oxazolidinone, PNU-100480, has been demonstrated to have more potent activity in vitro and in a murine model of tuberculosis.  In this study, we compared the pharmacokinetics and the antituberculosis activities of these two oxazolidinones over a range of doses and found that linezolid has limited activity at clin. relevant doses in the murine model compared to that of PNU-100480, which has potent bactericidal activity, even at lower drug exposures.  These findings were unexpected, given the similar in vitro activities of PNU-100480, its major metabolites, and linezolid.  Moreover, the incorporation of PNU-100480 dramatically improved the bactericidal activities of regimens contg. current first-line antituberculosis drugs and moxifloxacin.  For example, the addn. of PNU-100480 (100 mg/kg of body wt./day) to the std. daily regimen of rifampin (rifampicin), isoniazid, and pyrazinamide resulted in an addnl. 2.0-log10-unit redn. in lung CFU counts during the first 2 mo of treatment.  The combination of PNU-100480, moxifloxacin, and pyrazinamide, which does not contain either rifampin or isoniazid, was also more active than rifampin, isoniazid, and pyrazinamide.  These results suggest that PNU-100480 may have the potential to significantly shorten the duration of therapy for drug-susceptible as well as multidrug-resistant tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEbv65dLLnFLVg90H21EOLACvtfcHk0ljDNpLIfxE1_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksFWksrw%253D&md5=0b62de54c87cdf023e93851d44c9b28d</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1128%2FAAC.01182-08&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01182-08%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DK.%2BN.%26aulast%3DStover%26aufirst%3DC.%2BK.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DTasneen%26aufirst%3DR.%26aulast%3DTyagi%26aufirst%3DS.%26aulast%3DGrosset%26aufirst%3DJ.%2BH.%26aulast%3DNuermberger%26aufirst%3DE.%26atitle%3DPromising%2520antituberculosis%2520activity%2520of%2520the%2520oxazolidinone%2520PNU-100480%2520relative%2520to%2520that%2520of%2520linezolid%2520in%2520a%2520murine%2520model%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2009%26volume%3D53%26spage%3D1314%26epage%3D1319%26doi%3D10.1128%2FAAC.01182-08" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alffenaar, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Laan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simons, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Werf, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Kasteele, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Neeling, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Soolingen, D.</span></span> <span> </span><span class="NLM_article-title">Susceptibility of clinical mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1287</span>– <span class="NLM_lpage">1289</span>, <span class="refDoi"> DOI: 10.1128/AAC.01297-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.01297-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=21199931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktlamu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2011&pages=1287-1289&author=J.+W.+Alffenaarauthor=T.+van+der+Laanauthor=S.+Simonsauthor=T.+S.+van+der%0AWerfauthor=P.+J.+van+de+Kasteeleauthor=H.+de+Neelingauthor=D.+van+Soolingen&title=Susceptibility+of+clinical+mycobacterium+tuberculosis+isolates+to+a+potentially+less+toxic+derivate+of+linezolid%2C+PNU-100480&doi=10.1128%2FAAC.01297-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480</span></div><div class="casAuthors">Alffenaar, J. W. C.; van der Laan, T.; Simons, S.; van der Werf, T. S.; van de Kasteele, P. J.; de Neeling, H.; van Soolingen, D.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1287-1289</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Susceptibility of clin. Mycobacterium tuberculosis isolates to PNU-100480 and linezolid was evaluated by the MGIT 960 system.  The isolates had various susceptibilities to isoniazid (INH), rifampin, ethambutol, and streptomycin.  The mean MIC for PNU-100480 was 3.2 times lower than that for linezolid.  Therefore, PNU-100480 is a promising candidate to be developed further as an adjunct in the treatment of multidrug- and extensively drug-resistant tuberculosis (MDR/XDR-TB).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDIzcdMTy7drVg90H21EOLACvtfcHk0lhb02_jYWwb7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktlamu7o%253D&md5=74b1a71f925f5dc4fb9b97e79b19f8f7</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1128%2FAAC.01297-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01297-10%26sid%3Dliteratum%253Aachs%26aulast%3DAlffenaar%26aufirst%3DJ.%2BW.%26aulast%3Dvan%2Bder%2BLaan%26aufirst%3DT.%26aulast%3DSimons%26aufirst%3DS.%26aulast%3Dvan%2Bder%2BWerf%26aufirst%3DT.%2BS.%26aulast%3Dvan%2Bde%2BKasteele%26aufirst%3DP.%2BJ.%26aulast%3Dde%2BNeeling%26aufirst%3DH.%26aulast%3Dvan%2BSoolingen%26aufirst%3DD.%26atitle%3DSusceptibility%2520of%2520clinical%2520mycobacterium%2520tuberculosis%2520isolates%2520to%2520a%2520potentially%2520less%2520toxic%2520derivate%2520of%2520linezolid%252C%2520PNU-100480%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2011%26volume%3D55%26spage%3D1287%26epage%3D1289%26doi%3D10.1128%2FAAC.01297-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brickner, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stover, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogden, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tasneen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyagi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosset, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuermberger, E. L.</span></span> <span> </span><span class="NLM_article-title">Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>180</i></span>,  <span class="NLM_fpage">371</span>– <span class="NLM_lpage">376</span>, <span class="refDoi"> DOI: 10.1164/rccm.200904-0611OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1164%2Frccm.200904-0611OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=19520903" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFWrt73L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=180&publication_year=2009&pages=371-376&author=K.+N.+Williamsauthor=S.+J.+Bricknerauthor=C.+K.+Stoverauthor=T.+Zhuauthor=A.+Ogdenauthor=R.+Tasneenauthor=S.+Tyagiauthor=J.+H.+Grossetauthor=E.+L.+Nuermberger&title=Addition+of+PNU-100480+to+first-line+drugs+shortens+the+time+needed+to+cure+murine+tuberculosis&doi=10.1164%2Frccm.200904-0611OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis</span></div><div class="casAuthors">Williams, Kathy N.; Brickner, Steven J.; Stover, Charles K.; Zhu, Tong; Ogden, Adam; Tasneen, Rokeya; Tyagi, Sandeep; Grosset, Jacques H.; Nuermberger, Eric L.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">180</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">371-376</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">We recently reported strong bactericidal activity of the oxazolidinone PNU-100480 and its ability to increase the initial bactericidal effect of various combinations of first-line tuberculosis drugs and moxifloxacin in a murine model.  To investigate whether the addn. of PNU-100480 to the std. first-line regimen of rifampin, isoniazid, and pyrazinamide could shorten the duration of treatment necessary to prevent relapse after treatment discontinuation.  Following aerosol infection with Mycobacterium tuberculosis H37Rv and a 13-day incubation period, control mice were treated with the first-line regimen while test mice received the same regimen with PNU-100480 or linezolid added for the first 2 or 4 mo.  Efficacy was assessed on the basis of quant. cultures of lung homogenates performed monthly during treatment and 3 mo after completion of 3, 4, 5, or 6 mo of treatment to det. the relapse rate.  After 2 mo of treatment, mice receiving PNU-100480 in addn. to the first-line regimen had lung CFU counts two orders of magnitude lower than control mice receiving the first-line regimen alone.  Relapse rates after 4 mo of treatment were 90, 35, and 5% when PNU-100480 was added to the first-line regimen for 0, 2, and 4 mo, resp.  When the total treatment duration was 3 mo, relapse rates were 85 and 35 to 45% when mice received PNU-100480 for 2 and 3 mo, resp.; all control mice remained culture pos. at the time of treatment completion with 17 to 72 CFU per lung.  Addn. of linezolid to the first-line regimen had an antagonistic effect resulting in higher CFU counts and failure to render mice culture-neg. in 4 mo of treatment.  Together with previous findings, these results confirm that PNU-100480, which is now in Phase I clin. testing, has sterilizing activity in the murine model and suggest that it may be capable of shortening treatment duration for drug-susceptible as well as drug-resistant tuberculosis in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnFWkF1J81fbVg90H21EOLACvtfcHk0lhb02_jYWwb7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFWrt73L&md5=c4f5928eaf02b292e40d8b724ade1897</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1164%2Frccm.200904-0611OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200904-0611OC%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DK.%2BN.%26aulast%3DBrickner%26aufirst%3DS.%2BJ.%26aulast%3DStover%26aufirst%3DC.%2BK.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DOgden%26aufirst%3DA.%26aulast%3DTasneen%26aufirst%3DR.%26aulast%3DTyagi%26aufirst%3DS.%26aulast%3DGrosset%26aufirst%3DJ.%2BH.%26aulast%3DNuermberger%26aufirst%3DE.%2BL.%26atitle%3DAddition%2520of%2520PNU-100480%2520to%2520first-line%2520drugs%2520shortens%2520the%2520time%2520needed%2520to%2520cure%2520murine%2520tuberculosis%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2009%26volume%3D180%26spage%3D371%26epage%3D376%26doi%3D10.1164%2Frccm.200904-0611OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solapure, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deepthi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subbulakshmi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramya, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balganesh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melnick, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sambandamurthy, V. K.</span></span> <span> </span><span class="NLM_article-title">Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">495</span>– <span class="NLM_lpage">502</span>, <span class="refDoi"> DOI: 10.1128/AAC.01903-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.01903-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=24189255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFChsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=495-502&author=V.+Balasubramanianauthor=S.+Solapureauthor=H.+Iyerauthor=A.+Ghoshauthor=S.+Sharmaauthor=P.+Kaurauthor=R.+Deepthiauthor=V.+Subbulakshmiauthor=V.+Ramyaauthor=V.+Ramachandranauthor=M.+Balganeshauthor=L.+Wrightauthor=D.+Melnickauthor=S.+L.+Butlerauthor=V.+K.+Sambandamurthy&title=Bactericidal+activity+and+mechanism+of+action+of+AZD5847%2C+a+novel+oxazolidinone+for+treatment+of+tuberculosis&doi=10.1128%2FAAC.01903-13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis</span></div><div class="casAuthors">Balasubramanian, V.; Solapure, S.; Iyer, H.; Ghosh, A.; Sharma, S.; Kaur, P.; Deepthi, R.; Subbulakshmi, V.; Ramya, V.; Ramachandran, V.; Balganesh, M.; Wright, L.; Melnick, D.; Butler, S. L.; Sambandamurthy, V. K.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">495-502, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Treatment of tuberculosis (TB) is impaired by the long duration and complexity of therapy and the rising incidence of drug resistance.  There is an urgent need for new agents with improved efficacy, safety, and compatibility with combination chemotherapies.  Oxazolidinones offer a potential new class of TB drugs, and linezolid-the only currently approved oxazolidinone-has proven highly effective against extensively drug-resistant (XDR) TB in exptl. trials.  However, widespread use of linezolid is prohibited by its significant toxicities.  AZD5847, a novel oxazolidinone, demonstrates improved in vitro bactericidal activity against both extracellular and intracellular M. tuberculosis compared to that of linezolid.  Killing kinetics in broth media and in macrophages indicate that the rate and extent of kill obtained with AZD5847 are superior to those obtained with linezolid.  Moreover, the efficacy of AZD5847 was additive when tested along with a variety of conventional TB agents, indicating that AZD5847 may function well in combination therapies.  AZD5847 appears to function similarly to linezolid through impairment of the mycobacterial 50S ribosomal subunit.  Future studies should be undertaken to further characterize the pharmacodynamics and pharmacokinetics of AZD5847 in both in vitro and animal models as well is in human clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcnhn96nzN0bVg90H21EOLACvtfcHk0lhb02_jYWwb7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFChsr8%253D&md5=9a55e83a915b1677ccb1189192d850f8</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1128%2FAAC.01903-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01903-13%26sid%3Dliteratum%253Aachs%26aulast%3DBalasubramanian%26aufirst%3DV.%26aulast%3DSolapure%26aufirst%3DS.%26aulast%3DIyer%26aufirst%3DH.%26aulast%3DGhosh%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DKaur%26aufirst%3DP.%26aulast%3DDeepthi%26aufirst%3DR.%26aulast%3DSubbulakshmi%26aufirst%3DV.%26aulast%3DRamya%26aufirst%3DV.%26aulast%3DRamachandran%26aufirst%3DV.%26aulast%3DBalganesh%26aufirst%3DM.%26aulast%3DWright%26aufirst%3DL.%26aulast%3DMelnick%26aufirst%3DD.%26aulast%3DButler%26aufirst%3DS.%2BL.%26aulast%3DSambandamurthy%26aufirst%3DV.%2BK.%26atitle%3DBactericidal%2520activity%2520and%2520mechanism%2520of%2520action%2520of%2520AZD5847%252C%2520a%2520novel%2520oxazolidinone%2520for%2520treatment%2520of%2520tuberculosis%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26spage%3D495%26epage%3D502%26doi%3D10.1128%2FAAC.01903-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jadhavar, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaja, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhameliya, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakraborti, A. K.</span></span> <span> </span><span class="NLM_article-title">Oxazolidinones as anti-tubercular agents: Discovery, development and future perspectives</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">4379</span>– <span class="NLM_lpage">4397</span>, <span class="refDoi"> DOI: 10.2174/0929867323666151106125759</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.2174%2F0929867323666151106125759" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=26549430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVOmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=4379-4397&author=P.+S.+Jadhavarauthor=M.+D.+Vajaauthor=T.+M.+Dhameliyaauthor=A.+K.+Chakraborti&title=Oxazolidinones+as+anti-tubercular+agents%3A+Discovery%2C+development+and+future+perspectives&doi=10.2174%2F0929867323666151106125759"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Oxazolidinones as Anti-tubercular Agents: Discovery, Development and Future Perspectives</span></div><div class="casAuthors">Jadhavar, Pradeep S.; Vaja, Maulikkumar D.; Dhameliya, Tejas M.; Chakraborti, Asit K.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">4379-4397</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">TB drug development pipeline represents varied structural classes of mols.  Oxazolidinones represent synthetic anti-bacterial agents with unique mechanism of action having wide spectrum of activity, oral bioavailability and well established SAR.  They act by inhibiting translation at the initiation phase of protein synthesis.  Linezolid was the first oxazolidinone to reach the market in the year 2000 for the treatment of methicillin-resistant staphylococcal and vancomycin-resistant enterococcal infections.  Oxazolidinones have shown very good anti-mycobacterial activities.  Several oxazolidinones are currently in development for their possible use in TB therapy.  Oxazolidinones are classified on the basis of C-ring modifications.  DuP-721 was the first oxazolidinone having good anti-TB activity.  Linezolid, sutezolid and AZD5847 are in clin. development.  Several other C-ring modifications have shown promising results.  The usefulness of these oxazolidinones in the drug resistant TB is already established.  Toxicity, esp. myelosuppression, has been an important limiting factor for their development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqe0zxDblkvjLVg90H21EOLACvtfcHk0lj3CYWQbSKjbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVOmtw%253D%253D&md5=82f05591b2efaa98e30416bcecfc5749</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.2174%2F0929867323666151106125759&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867323666151106125759%26sid%3Dliteratum%253Aachs%26aulast%3DJadhavar%26aufirst%3DP.%2BS.%26aulast%3DVaja%26aufirst%3DM.%2BD.%26aulast%3DDhameliya%26aufirst%3DT.%2BM.%26aulast%3DChakraborti%26aufirst%3DA.%2BK.%26atitle%3DOxazolidinones%2520as%2520anti-tubercular%2520agents%253A%2520Discovery%252C%2520development%2520and%2520future%2520perspectives%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2015%26volume%3D22%26spage%3D4379%26epage%3D4397%26doi%3D10.2174%2F0929867323666151106125759" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du Bois, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Brakel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chheng, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peloquin, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alsultan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiel, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debanne, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boom, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diacon, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. L.</span></span> <span> </span><span class="NLM_article-title">Early bactericidal activity of AZD5847 in patients with pulmonary tuberculosis</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">6591</span>– <span class="NLM_lpage">6599</span>, <span class="refDoi"> DOI: 10.1128/AAC.01163-16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.01163-16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=27550361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitlSqtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2016&pages=6591-6599&author=J.+J.+Furinauthor=J.+Du+Boisauthor=E.+van+Brakelauthor=P.+Chhengauthor=A.+Venterauthor=C.+A.+Peloquinauthor=A.+Alsultanauthor=B.+A.+Thielauthor=S.+M.+Debanneauthor=W.+H.+Boomauthor=A.+H.+Diaconauthor=J.+L.+Johnson&title=Early+bactericidal+activity+of+AZD5847+in+patients+with+pulmonary+tuberculosis&doi=10.1128%2FAAC.01163-16"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Early bactericidal activity of AZD5847 in patients with pulmonary tuberculosis</span></div><div class="casAuthors">Furin, Jennifer J.; Du Bois, Jeannine; van Brakel, Elana; Chheng, Phalkun; Venter, Amour; Peloquin, Charles A.; Alsultan, Abdullah; Thiel, Bonnie A.; Debanne, Sara M.; Henry, Boom W.; Diacon, Andreas H.; Johnson, John L.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">6591-6599</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">AZD5847 is an oxazolidinone antibiotic with in vitro activity against Mycobacterium tuberculosis.  The objective of this study was to evaluate the antimycobacterial activity, safety, and pharmacokinetics of AZD5847 in patients with pulmonary tuberculosis.  Groups of 15 treatment-naive, sputum smear-pos. adults with pulmonary tuberculosis were randomly assigned to receive AZD5847 at one of four doses (500 mg once daily, 500 mg twice daily, 1,200 mg once daily, and 800 mg twice daily) or daily std. chemotherapy.  The primary efficacy endpoint was the mean daily rate of change in the log10 no. of CFU of M. tuberculosis per mL of sputum, expressed as the change in log10 no. of CFU per mL of sputum per day.  The mean 14-day activity of the combination of isoniazid, rifampin, ethambutol, and pyrazinamide (-0.163 log10 CFU/mL sputum/day; 95% confidence interval [CI],-0.193,-0.133 log10 CFU/mL sputum/day) was consistent with that found in previous studies.  AZD5847 at 500 mg twice daily significantly decreased the no. of CFU on solid medium (-0.039; 95% CI,-0.069,-0.009; P-0.0048).  No bactericidal activity was detected at doses of AZD5847 of 500 mg once daily (mean early bactericidal activity [EBA], 0.02 [95% CI,-0.01, 0.05]), 1,200 mg once daily (mean EBA, 0.02 [95% CI,-0.01, 0.05]), and 800 mg twice daily (mean EBA, 0.02 [95% CI, -0.01, 0.05]).  AZD5847 at doses of both 500 mg and 800 mg twice daily also showed an increase in the time to a pos. culture in MGIT liq. culture medium.  Two serious adverse events (grade 4 thrombocytopenia and grade 4 hyperbilirubinemia) occurred in patients receiving AZD5847 at higher doses.  AZD5847 dosed twice daily kills tubercle bacilli in the sputum of patients with pulmonary tuberculosis and has modest early bactericidal activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFmVDMI5oXW7Vg90H21EOLACvtfcHk0lj3CYWQbSKjbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitlSqtrk%253D&md5=cea62e375ddc80ad7ba61c1d560c378c</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1128%2FAAC.01163-16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01163-16%26sid%3Dliteratum%253Aachs%26aulast%3DFurin%26aufirst%3DJ.%2BJ.%26aulast%3DDu%2BBois%26aufirst%3DJ.%26aulast%3Dvan%2BBrakel%26aufirst%3DE.%26aulast%3DChheng%26aufirst%3DP.%26aulast%3DVenter%26aufirst%3DA.%26aulast%3DPeloquin%26aufirst%3DC.%2BA.%26aulast%3DAlsultan%26aufirst%3DA.%26aulast%3DThiel%26aufirst%3DB.%2BA.%26aulast%3DDebanne%26aufirst%3DS.%2BM.%26aulast%3DBoom%26aufirst%3DW.%2BH.%26aulast%3DDiacon%26aufirst%3DA.%2BH.%26aulast%3DJohnson%26aufirst%3DJ.%2BL.%26atitle%3DEarly%2520bactericidal%2520activity%2520of%2520AZD5847%2520in%2520patients%2520with%2520pulmonary%2520tuberculosis%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2016%26volume%3D60%26spage%3D6591%26epage%3D6599%26doi%3D10.1128%2FAAC.01163-16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Protopopova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crooks, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slayden, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terrot, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.,  3rd.</span></span> <span> </span><span class="NLM_article-title">Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates</span>. <i>J. Comb. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">172</span>– <span class="NLM_lpage">187</span>, <span class="refDoi"> DOI: 10.1021/cc020071p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cc020071p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkvFKguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2003&pages=172-187&author=R.+E.+Leeauthor=M.+Protopopovaauthor=E.+Crooksauthor=R.+A.+Slaydenauthor=M.+Terrotauthor=C.+E.+Barry&title=Combinatorial+lead+optimization+of+%5B1%2C2%5D-diamines+based+on+ethambutol+as+potential+antituberculosis+preclinical+candidates&doi=10.1021%2Fcc020071p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Combinatorial Lead Optimization of [1,2]-Diamines Based on Ethambutol as Potential Antituberculosis Preclinical Candidates</span></div><div class="casAuthors">Lee, Richard E.; Protopopova, Marina; Crooks, Emma; Slayden, Richard A.; Terrot, Marianne; Barry, Clifton E., III</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Combinatorial Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">172-187</span>CODEN:
                <span class="NLM_cas:coden">JCCHFF</span>;
        ISSN:<span class="NLM_cas:issn">1520-4766</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Despite relatively modest potency, ethambutol (EMB, (S,S)-[N,N-di-2-amino-1-butanol]ethylenediamine) is a mainstay of contemporary chemotherapy for the treatment of tuberculosis.  We have developed a solid-phase synthesis of 1,2-diamine analogs of EMB using a novel acylation-redn. sequence that is compatible with high-throughput 96-well format chem.  Using this procedure, we have synthesized 63,238 diamine analogs in pools of 10 that are suitable for testing.  MIC and a target-based reporter assay were used to direct deconvolution of 2796 individual compds. from these mixts., and the 69 most potent mols. were resynthesized in milligram quantities for hit confirmation.  Purifn. of these individual active diamine analogs allowed the identification of 26 compds. with activity equal to or greater than EMB.  Amines which occurred most frequently in active compds. included many with large hydrophobic moieties, suggesting that optimization was perhaps selecting for the isoprenoid binding site of the arabinosyltransferase target of EMB.  N-Geranyl-N'-(2-adamantyl)ethane-1,2-diamine, the most active of these diamines, displayed a 14-35-fold improvement in activity in vitro against Mycobacterium tuberculosis, as compared to EMB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7ViZZ_FOEcrVg90H21EOLACvtfcHk0lj3CYWQbSKjbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkvFKguw%253D%253D&md5=3005c111ca5aa61044f016dcfafc6d09</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1021%2Fcc020071p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcc020071p%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DR.%2BE.%26aulast%3DProtopopova%26aufirst%3DM.%26aulast%3DCrooks%26aufirst%3DE.%26aulast%3DSlayden%26aufirst%3DR.%2BA.%26aulast%3DTerrot%26aufirst%3DM.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26atitle%3DCombinatorial%2520lead%2520optimization%2520of%2520%255B1%252C2%255D-diamines%2520based%2520on%2520ethambutol%2520as%2520potential%2520antituberculosis%2520preclinical%2520candidates%26jtitle%3DJ.%2520Comb.%2520Chem.%26date%3D2003%26volume%3D5%26spage%3D172%26epage%3D187%26doi%3D10.1021%2Fcc020071p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Protopopova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanrahan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikonenko, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samala, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gearhart, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einck, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacy, C. A.</span></span> <span> </span><span class="NLM_article-title">Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">968</span>– <span class="NLM_lpage">974</span>, <span class="refDoi"> DOI: 10.1093/jac/dki319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1093%2Fjac%2Fdki319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=16172107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFCjtLjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2005&pages=968-974&author=M.+Protopopovaauthor=C.+Hanrahanauthor=B.+Nikonenkoauthor=R.+Samalaauthor=P.+Chenauthor=J.+Gearhartauthor=L.+Einckauthor=C.+A.+Nacy&title=Identification+of+a+new+antitubercular+drug+candidate%2C+SQ109%2C+from+a+combinatorial+library+of+1%2C2-ethylenediamines&doi=10.1093%2Fjac%2Fdki319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines</span></div><div class="casAuthors">Protopopova, Marina; Hanrahan, Colleen; Nikonenko, Boris; Samala, Rowena; Chen, Ping; Gearhart, Jackie; Einck, Leo; Nacy, Carol A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">968-974</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Objectives: The aim of this study was to identify a candidate drug for clin. development from a previously synthesized combinatorial library based on the 1,2-ethylenediamine structure of ethambutol.  Methods: Sixty-nine of the most potent hits against Mycobacterium tuberculosis from the original studies were subjected to a sequential set of tests in vitro and in vivo-detn. of MIC for M. tuberculosis H37Rv, cytotoxicity, intracellular antimycobacterial activity, permeability evaluation and in vivo efficacy testing.  Results: Twenty-seven compds. with MICs of ≤15.6 μM were tested on Vero cells to det. in vitro cytotoxicity (IC50) and to establish a selectivity index (SI) (SI = IC50/MIC).  Ten compds. with acceptable SI were tested for activity against intracellular bacteria; all were equiv. (within 1%) or superior to ethambutol and several demonstrated bactericidal activity.  Five of the most potent compds. were tested for in vivo efficacy in a murine model of chronic tuberculosis infection.  Conclusion: Compd. SQ109 with an MIC of 0.7-1.56 μM (H37Rv, Erdman and drug-resistant strains of M. tuberculosis), an SI of 16.7 and 99% inhibition activity against intracellular bacteria, demonstrated potency in vivo and limited toxicity in vitro and in vivo, and was selected for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqvmYc-WY3LrVg90H21EOLACvtfcHk0lhtRjHRA36h1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFCjtLjI&md5=2f3d82748de8a565112541b2aa4e5437</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdki319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdki319%26sid%3Dliteratum%253Aachs%26aulast%3DProtopopova%26aufirst%3DM.%26aulast%3DHanrahan%26aufirst%3DC.%26aulast%3DNikonenko%26aufirst%3DB.%26aulast%3DSamala%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DGearhart%26aufirst%3DJ.%26aulast%3DEinck%26aufirst%3DL.%26aulast%3DNacy%26aufirst%3DC.%2BA.%26atitle%3DIdentification%2520of%2520a%2520new%2520antitubercular%2520drug%2520candidate%252C%2520SQ109%252C%2520from%2520a%2520combinatorial%2520library%2520of%25201%252C2-ethylenediamines%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2005%26volume%3D56%26spage%3D968%26epage%3D974%26doi%3D10.1093%2Fjac%2Fdki319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gearhart, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Protopopova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einck, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacy, C. A.</span></span> <span> </span><span class="NLM_article-title">Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">332</span>– <span class="NLM_lpage">337</span>, <span class="refDoi"> DOI: 10.1093/jac/dkl227</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1093%2Fjac%2Fdkl227" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=16751637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD28Xotl2lsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2006&pages=332-337&author=P.+Chenauthor=J.+Gearhartauthor=M.+Protopopovaauthor=L.+Einckauthor=C.+A.+Nacy&title=Synergistic+interactions+of+SQ109%2C+a+new+ethylene+diamine%2C+with+front-line+antitubercular+drugs+in+vitro&doi=10.1093%2Fjac%2Fdkl227"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro</span></div><div class="casAuthors">Chen, Ping; Gearhart, Jackie; Protopopova, Marina; Einck, Leo; Nacy, Carol A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">332-337</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The purpose of this study was to det. interactions of SQ109, a new asym. diamine tuberculosis (TB) drug candidate, with existing antitubercular drugs in vitro and assess its potential to improve combination drug activities against Mycobacterium tuberculosis.  2 -Drug combinations at various concns. below their MICs were tested for growth inhibition of M. tuberculosis using the BACTEC 460 system in vitro.  Drug interactions were evaluated based on the quotient values that were derived numerically from the growth indexes of cultures treated with a single antibiotic or combination treatment with two antibiotics.  SQ109 at 0.5 of its MIC demonstrated strong Synergistic activity with 0.5 MIC isoniazid and as low as 0.1 MIC rifampicin in inhibition of M. tuberculosis growth.  Additive effects were obsd. between SQ109 and streptomycin, but neither synergy nor additive effects were obsd. with the combination of SQ109 with ethambutol or pyrazinamide.  The synergy between SQ109 and rifampicin was also demonstrated using rifampicin-resistant (RIFR) M. tuberculosis strains; SQ109 lowered the MIC of rifampicin for these drug-resistant strains.  SQ109 interacts synergistically with isoniazid and rifampicin, 2 of the most important front-line TB drugs.  This finding supports efforts to further evaluate new combination therapies contg. SQ109 in exptl. animal models of TB that emulate future clin. trial studies in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOvxKYKzx877Vg90H21EOLACvtfcHk0lhtRjHRA36h1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xotl2lsbw%253D&md5=d1f33ab9a1bd5636e683a07a773cf784</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdkl227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdkl227%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DP.%26aulast%3DGearhart%26aufirst%3DJ.%26aulast%3DProtopopova%26aufirst%3DM.%26aulast%3DEinck%26aufirst%3DL.%26aulast%3DNacy%26aufirst%3DC.%2BA.%26atitle%3DSynergistic%2520interactions%2520of%2520SQ109%252C%2520a%2520new%2520ethylene%2520diamine%252C%2520with%2520front-line%2520antitubercular%2520drugs%2520in%2520vitro%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2006%26volume%3D58%26spage%3D332%26epage%3D337%26doi%3D10.1093%2Fjac%2Fdkl227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noker, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coward, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorman, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Protopopova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomaszewski, J. E.</span></span> <span> </span><span class="NLM_article-title">Interspecies pharmacokinetics and in vitro metabolism of SQ109</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>147</i></span>,  <span class="NLM_fpage">476</span>– <span class="NLM_lpage">485</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0706650</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1038%2Fsj.bjp.0706650" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=16432511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD28XitVCmt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=2006&pages=476-485&author=L.+Jiaauthor=P.+E.+Nokerauthor=L.+Cowardauthor=G.+S.+Gormanauthor=M.+Protopopovaauthor=J.+E.+Tomaszewski&title=Interspecies+pharmacokinetics+and+in+vitro+metabolism+of+SQ109&doi=10.1038%2Fsj.bjp.0706650"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Interspecies pharmacokinetics and in vitro metabolism of SQ109</span></div><div class="casAuthors">Jia, Lee; Noker, Patricia E.; Coward, Lori; Gorman, Gregory S.; Protopopova, Marina; Tomaszewski, Joseph E.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">147</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">476-485</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">This study aimed at characterizing the interspecies absorption, distribution, metab. and elimination (ADME) profile of N-geranyl-N'-(2-adamantyl)ethane-1,2-diamine (SQ109), a new diamine-based antitubercular drug.  Single doses of SQ109 were administered ( i.v. and p.o.) to rodents and dogs and blood samples were analyzed by liq. chromatog. tandem mass spectrometry (LC/MS/MS).  Based on i.v. equiv. body surface area dose, the terminal half-life (t1/2) of SQ109 in dogs was longer than that in rodents, reflected by a larger vol. of distribution (Vss) and a higher clearance rate of SQ109 in dogs, compared to that in rodents.  The oral bioavailability of SQ109 in dogs, rats and mice were 2.4 - 5, 12 and 3.8%, resp.  After oral administration of [14C]SQ109 to rats, the highest level of radioactivity was in the liver, followed by the lung, spleen and kidney.  Tissue-to-blood ratios of [14C]SQ109 were greater than 1.  Fecal elimination of [14C]SQ109 accounted for 22.2% of the total dose of [14C]SQ109, while urinary excretion accounted for only 5.6%.  The binding of [14C]SQ109 (0.1 - 2.5 μg ml-1) to plasma proteins varied from 6 to 23% depending on the species (human, mouse, rat and dog).  SQ109 was metabolized by rat, mouse, dog and human liver microsomes, resulting in 22.8, 48.4 , 50.8 or 58.3%, resp. , of SQ109 remaining after a 10-min incubation at 37 °C.  The predominant metabolites in the human liver microsomes gave intense ion signals at 195, 347 and 363m/z, suggesting the oxidn., epoxidn. and N-dealkylation of SQ109.  P 450 reaction phenotyping using recombinant cDNA-expressed human CYPs in conjunction with specific CYP inhibitors indicated that CYP2D6 and CYP2C19 were the predominant CYPs involved in SQ109 metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqFPcT80iIfrVg90H21EOLACvtfcHk0lhtRjHRA36h1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XitVCmt78%253D&md5=5a519038ee0c5f0c7b68d0cd90fe8f76</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0706650&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0706650%26sid%3Dliteratum%253Aachs%26aulast%3DJia%26aufirst%3DL.%26aulast%3DNoker%26aufirst%3DP.%2BE.%26aulast%3DCoward%26aufirst%3DL.%26aulast%3DGorman%26aufirst%3DG.%2BS.%26aulast%3DProtopopova%26aufirst%3DM.%26aulast%3DTomaszewski%26aufirst%3DJ.%2BE.%26atitle%3DInterspecies%2520pharmacokinetics%2520and%2520in%2520vitro%2520metabolism%2520of%2520SQ109%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2006%26volume%3D147%26spage%3D476%26epage%3D485%26doi%3D10.1038%2Fsj.bjp.0706650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tahlan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kastrinsky, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arora, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alland, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boshoff, H. I.</span></span> <span> </span><span class="NLM_article-title">SQ109 targets mmpl3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of mycobacterium tuberculosis</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">1797</span>– <span class="NLM_lpage">1809</span>, <span class="refDoi"> DOI: 10.1128/AAC.05708-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.05708-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=22252828" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38XltV2ru7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=1797-1809&author=K.+Tahlanauthor=R.+Wilsonauthor=D.+B.+Kastrinskyauthor=K.+Aroraauthor=V.+Nairauthor=E.+Fischerauthor=S.+W.+Barnesauthor=J.+R.+Walkerauthor=D.+Allandauthor=C.+E.+Barryauthor=H.+I.+Boshoff&title=SQ109+targets+mmpl3%2C+a+membrane+transporter+of+trehalose+monomycolate+involved+in+mycolic+acid+donation+to+the+cell+wall+core+of+mycobacterium+tuberculosis&doi=10.1128%2FAAC.05708-11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis</span></div><div class="casAuthors">Tahlan, Kapil; Wilson, Regina; Kastrinsky, David B.; Arora, Kriti; Nair, Vinod; Fischer, Elizabeth; Barnes, S. Whitney; Walker, John R.; Alland, David; Barry, Clifton E., III; Boshoff, Helena I.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1797-1809</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">SQ109, a 1,2-diamine related to ethambutol, is currently in clin. trials for the treatment of tuberculosis, but its mode of action remains unclear.  Here, we demonstrate that SQ109 disrupts cell wall assembly, as evidenced by macromol. incorporation assays and ultrastructural analyses.  SQ109 interferes with the assembly of mycolic acids into the cell wall core of Mycobacterium tuberculosis, as bacilli exposed to SQ109 show immediate inhibition of trehalose dimycolate (TDM) prodn. and fail to attach mycolates to the cell wall arabinogalactan.  These effects were not due to inhibition of mycolate synthesis, since total mycolate levels were unaffected, but instead resulted in the accumulation of trehalose monomycolate (TMM), the precursor of TDM and cell wall mycolates.  In vitro assays using purified enzymes showed that this was not due to inhibition of the secreted Ag85 mycolyltransferases.  We were unable to achieve spontaneous generation of SQ109-resistant mutants; however, analogs of this compd. that resulted in similar shutdown of TDM synthesis with concomitant TMM accumulation were used to spontaneously generate resistant mutants that were also cross-resistant to SQ109.  Whole-genome sequencing of these mutants showed that these all had mutations in the essential mmpL3 gene, which encodes a transmembrane transporter.  Our results suggest that MmpL3 is the target of SQ109 and that MmpL3 is a transporter of mycobacterial TMM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpupM7fIKB8uLVg90H21EOLACvtfcHk0lghvuLnPyDllw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XltV2ru7k%253D&md5=6309318d9e4d2f0c75a9fed20b8108ea</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1128%2FAAC.05708-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.05708-11%26sid%3Dliteratum%253Aachs%26aulast%3DTahlan%26aufirst%3DK.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DKastrinsky%26aufirst%3DD.%2BB.%26aulast%3DArora%26aufirst%3DK.%26aulast%3DNair%26aufirst%3DV.%26aulast%3DFischer%26aufirst%3DE.%26aulast%3DBarnes%26aufirst%3DS.%2BW.%26aulast%3DWalker%26aufirst%3DJ.%2BR.%26aulast%3DAlland%26aufirst%3DD.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26aulast%3DBoshoff%26aufirst%3DH.%2BI.%26atitle%3DSQ109%2520targets%2520mmpl3%252C%2520a%2520membrane%2520transporter%2520of%2520trehalose%2520monomycolate%2520involved%2520in%2520mycolic%2520acid%2520donation%2520to%2520the%2520cell%2520wall%2520core%2520of%2520mycobacterium%2520tuberculosis%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D1797%26epage%3D1809%26doi%3D10.1128%2FAAC.05708-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grzegorzewicz, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gundi, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherman, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">North, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruppo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Born, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korduláková, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavadi, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenaerts, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeil, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, M.</span></span> <span> </span><span class="NLM_article-title">Inhibition of mycolic acid transport across the mycobacterium tuberculosis plasma membrane</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">334</span>– <span class="NLM_lpage">341</span>, <span class="refDoi"> DOI: 10.1038/nchembio.794</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1038%2Fnchembio.794" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=22344175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38XisVKktrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=334-341&author=A.+E.+Grzegorzewiczauthor=H.+Phamauthor=V.+A.+Gundiauthor=M.+S.+Schermanauthor=E.+J.+Northauthor=T.+Hessauthor=V.+Jonesauthor=V.+Gruppoauthor=S.+E.+Bornauthor=J.+Kordul%C3%A1kov%C3%A1author=S.+S.+Chavadiauthor=C.+Morisseauauthor=A.+J.+Lenaertsauthor=R.+E.+Leeauthor=M.+R.+McNeilauthor=M.+Jackson&title=Inhibition+of+mycolic+acid+transport+across+the+mycobacterium+tuberculosis+plasma+membrane&doi=10.1038%2Fnchembio.794"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane</span></div><div class="casAuthors">Grzegorzewicz, Anna E.; Pham, Ha; Gundi, Vijay A. K. B.; Scherman, Michael S.; North, Elton J.; Hess, Tamara; Jones, Victoria; Gruppo, Veronica; Born, Sarah E. M.; Kordulakova, Jana; Chavadi, Sivagami Sundaram; Morisseau, Christophe; Lenaerts, Anne J.; Lee, Richard E.; McNeil, Michael R.; Jackson, Mary</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">334-341</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">New chemotherapeutics active against multidrug-resistant Mycobacterium tuberculosis are urgently needed.  We report on the identification of an adamantyl urea compd. that shows potent bactericidal activity against M. tuberculosis and a unique mode of action, namely the abolition of the translocation of mycolic acids from the cytoplasm, where they are synthesized to the periplasmic side of the plasma membrane and are in turn transferred onto cell wall arabinogalactan or used in the formation of virulence-assocd., outer membrane, trehalose-contg. glycolipids.  Whole-genome sequencing of spontaneous-resistant mutants of M. tuberculosis selected in vitro followed by genetic validation expts. revealed that our prototype inhibitor targets the inner membrane transporter MmpL3.  Conditional gene expression of mmpL3 in mycobacteria and anal. of inhibitor-treated cells validate MmpL3 as essential for mycobacterial growth and support the involvement of this transporter in the translocation of trehalose monomycolate across the plasma membrane.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow3tM24PWRw7Vg90H21EOLACvtfcHk0lghvuLnPyDllw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XisVKktrg%253D&md5=0068aca13a9d9f342705035d0cb2c677</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.794&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.794%26sid%3Dliteratum%253Aachs%26aulast%3DGrzegorzewicz%26aufirst%3DA.%2BE.%26aulast%3DPham%26aufirst%3DH.%26aulast%3DGundi%26aufirst%3DV.%2BA.%26aulast%3DScherman%26aufirst%3DM.%2BS.%26aulast%3DNorth%26aufirst%3DE.%2BJ.%26aulast%3DHess%26aufirst%3DT.%26aulast%3DJones%26aufirst%3DV.%26aulast%3DGruppo%26aufirst%3DV.%26aulast%3DBorn%26aufirst%3DS.%2BE.%26aulast%3DKordul%25C3%25A1kov%25C3%25A1%26aufirst%3DJ.%26aulast%3DChavadi%26aufirst%3DS.%2BS.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DLenaerts%26aufirst%3DA.%2BJ.%26aulast%3DLee%26aufirst%3DR.%2BE.%26aulast%3DMcNeil%26aufirst%3DM.%2BR.%26aulast%3DJackson%26aufirst%3DM.%26atitle%3DInhibition%2520of%2520mycolic%2520acid%2520transport%2520across%2520the%2520mycobacterium%2520tuberculosis%2520plasma%2520membrane%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2012%26volume%3D8%26spage%3D334%26epage%3D341%26doi%3D10.1038%2Fnchembio.794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nikonenko, B. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Protopopova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samala, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einck, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacy, C. A.</span></span> <span> </span><span class="NLM_article-title">Drug therapy of experimental tuberculosis (tb): Improved outcome by combining SQ109, a new diamine antibiotic, with existing tb drugs</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">1563</span>– <span class="NLM_lpage">1565</span>, <span class="refDoi"> DOI: 10.1128/AAC.01326-06</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.01326-06" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=17242141" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD2sXktlOisr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2007&pages=1563-1565&author=B.+V.+Nikonenkoauthor=M.+Protopopovaauthor=R.+Samalaauthor=L.+Einckauthor=C.+A.+Nacy&title=Drug+therapy+of+experimental+tuberculosis+%28tb%29%3A+Improved+outcome+by+combining+SQ109%2C+a+new+diamine+antibiotic%2C+with+existing+tb+drugs&doi=10.1128%2FAAC.01326-06"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs</span></div><div class="casAuthors">Nikonenko, Boris V.; Protopopova, Marina; Samala, Rowena; Einck, Leo; Nacy, Carol A.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1563-1565</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Substitution of the new diamine antibiotic SQ109 for ethambutol in a mouse model of chronic tuberculosis (TB) improved efficacy of combination drug therapy with first-line TB drugs rifampin and isoniazid, with or without pyrazinamide: at 8 wk, lung bacteria were 1.5 log10 lower in SQ109-contg. regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrywULJFY6Xv7Vg90H21EOLACvtfcHk0lghvuLnPyDllw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXktlOisr4%253D&md5=179cfc6a3256417b542fd64decba25c3</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1128%2FAAC.01326-06&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01326-06%26sid%3Dliteratum%253Aachs%26aulast%3DNikonenko%26aufirst%3DB.%2BV.%26aulast%3DProtopopova%26aufirst%3DM.%26aulast%3DSamala%26aufirst%3DR.%26aulast%3DEinck%26aufirst%3DL.%26aulast%3DNacy%26aufirst%3DC.%2BA.%26atitle%3DDrug%2520therapy%2520of%2520experimental%2520tuberculosis%2520%2528tb%2529%253A%2520Improved%2520outcome%2520by%2520combining%2520SQ109%252C%2520a%2520new%2520diamine%2520antibiotic%252C%2520with%2520existing%2520tb%2520drugs%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2007%26volume%3D51%26spage%3D1563%26epage%3D1565%26doi%3D10.1128%2FAAC.01326-06" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulati, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crick, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cynamon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Docampo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">No, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oldfield, E.</span></span> <span> </span><span class="NLM_article-title">Oxa, thia, heterocycle, and carborane analogues of SQ109: Bacterial and protozoal cell growth inhibitors</span>. <i>ACS Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1021/acsinfecdis.5b00026</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsinfecdis.5b00026" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsFGnt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2015&pages=215-221&author=K.+Liauthor=Y.+Wangauthor=G.+Yangauthor=S.+Byunauthor=G.+Raoauthor=C.+Shoenauthor=H.+Yangauthor=A.+Gulatiauthor=D.+C.+Crickauthor=M.+Cynamonauthor=G.+Huangauthor=R.+Docampoauthor=J.+H.+Noauthor=E.+Oldfield&title=Oxa%2C+thia%2C+heterocycle%2C+and+carborane+analogues+of+SQ109%3A+Bacterial+and+protozoal+cell+growth+inhibitors&doi=10.1021%2Facsinfecdis.5b00026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Oxa, Thia, Heterocycle, and Carborane Analogues of SQ109: Bacterial and Protozoal Cell Growth Inhibitors</span></div><div class="casAuthors">Li, Kai; Wang, Yang; Yang, Gyongseon; Byun, Soo Young; Rao, Guodong; Shoen, Carolyn; Yang, Hongliang; Gulati, Anmol; Crick, Dean C.; Cynamon, Michael; Huang, Guozhong; Docampo, Roberto; No, Joo Hwan; Oldfield, Eric</div><div class="citationInfo"><span class="NLM_cas:title">ACS Infectious Diseases</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">215-221</span>CODEN:
                <span class="NLM_cas:coden">AIDCBC</span>;
        ISSN:<span class="NLM_cas:issn">2373-8227</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors synthesized a library of 48 analogs of the Mycobacterium tuberculosis cell growth inhibitor SQ109 in which the ethylenediamine linker was replaced by oxa, thia, or heterocyclic species, and in some cases, the adamantyl group was replaced by a 1,2-carborane or the N-geranyl group by another hydrophobic species.  Compds. were tested against M. tuberculosis (H37Rv and/or Erdman), Mycobacterium smegmatis, Bacillus subtilis, Escherichia coli, Saccharomyces cerevisiae, Trypanosoma brucei, and two human cell lines (human embryonic kidney, HEK293T, and the hepatocellular carcinoma, HepG2).  The most potent activity was found against T. brucei, the causative agent of human African trypanosomiasis, and involved targeting of the mitochondrial membrane potential with 15 SQ109 analogs being more active than was SQ109 in cell growth inhibition, having IC50 values as low as 12 nM (5.5 ng/mL) and a selectivity index of ∼300.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwRJduvLZTO7Vg90H21EOLACvtfcHk0ljImxn2iIdZQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsFGnt7c%253D&md5=d83c90f63177cca1aa54564738288074</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1021%2Facsinfecdis.5b00026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsinfecdis.5b00026%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DByun%26aufirst%3DS.%26aulast%3DRao%26aufirst%3DG.%26aulast%3DShoen%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DGulati%26aufirst%3DA.%26aulast%3DCrick%26aufirst%3DD.%2BC.%26aulast%3DCynamon%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DG.%26aulast%3DDocampo%26aufirst%3DR.%26aulast%3DNo%26aufirst%3DJ.%2BH.%26aulast%3DOldfield%26aufirst%3DE.%26atitle%3DOxa%252C%2520thia%252C%2520heterocycle%252C%2520and%2520carborane%2520analogues%2520of%2520SQ109%253A%2520Bacterial%2520and%2520protozoal%2520cell%2520growth%2520inhibitors%26jtitle%3DACS%2520Infect.%2520Dis.%26date%3D2015%26volume%3D1%26spage%3D215%26epage%3D221%26doi%3D10.1021%2Facsinfecdis.5b00026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bogatcheva, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanrahan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gearhart, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacksteder, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einck, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Protopopova, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of dipiperidines as new antitubercular agents</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">201</span>– <span class="NLM_lpage">205</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.10.135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmcl.2009.10.135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=19917527" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsF2jsb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=201-205&author=E.+Bogatchevaauthor=C.+Hanrahanauthor=P.+Chenauthor=J.+Gearhartauthor=K.+Sackstederauthor=L.+Einckauthor=C.+Nacyauthor=M.+Protopopova&title=Discovery+of+dipiperidines+as+new+antitubercular+agents&doi=10.1016%2Fj.bmcl.2009.10.135"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of dipiperidines as new antitubercular agents</span></div><div class="casAuthors">Bogatcheva, Elena; Hanrahan, Colleen; Chen, Ping; Gearhart, Jacqueline; Sacksteder, Katherine; Einck, Leo; Nacy, Carol; Protopopova, Marina</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">201-205</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">As part of our ongoing research effort to develop new therapeutics for treatment of tuberculosis (TB), we synthesized a combinatorial library of 10,358 compds. on solid support using a pool-and-split technique and tested the resulting compds. for activity against Mycobacterium tuberculosis.  Structure-activity relation (SAR) evaluation identified new compds. with antitubercular activity, including a novel hit series that is structurally unrelated to any existing antitubercular drugs, dipiperidines.  Dipiperidine representatives exhibited MIC values as low as 7.8 μM, the ability to induce promoter Rv0341 activated in response to cell wall biosynthesis inhibition, relatively low nonspecific cellular toxicity in the range of 30-162 μM, and log P values less than 4.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5KpxUHeC5irVg90H21EOLACvtfcHk0ljImxn2iIdZQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsF2jsb7M&md5=522927712851104a42a254391b322b2e</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.10.135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.10.135%26sid%3Dliteratum%253Aachs%26aulast%3DBogatcheva%26aufirst%3DE.%26aulast%3DHanrahan%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DGearhart%26aufirst%3DJ.%26aulast%3DSacksteder%26aufirst%3DK.%26aulast%3DEinck%26aufirst%3DL.%26aulast%3DNacy%26aufirst%3DC.%26aulast%3DProtopopova%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520dipiperidines%2520as%2520new%2520antitubercular%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D201%26epage%3D205%26doi%3D10.1016%2Fj.bmcl.2009.10.135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bogatcheva, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanrahan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikonenko, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de los Santos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einck, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Protopopova, M.</span></span> <span> </span><span class="NLM_article-title">Identification of SQ609 as a lead compound from a library of dipiperidines</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">5353</span>– <span class="NLM_lpage">5357</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.07.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmcl.2011.07.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=21807506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVKis73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=5353-5357&author=E.+Bogatchevaauthor=C.+Hanrahanauthor=B.+Nikonenkoauthor=G.+de+los+Santosauthor=V.+Reddyauthor=P.+Chenauthor=F.+Barbosaauthor=L.+Einckauthor=C.+Nacyauthor=M.+Protopopova&title=Identification+of+SQ609+as+a+lead+compound+from+a+library+of+dipiperidines&doi=10.1016%2Fj.bmcl.2011.07.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of SQ609 as a lead compound from a library of dipiperidines</span></div><div class="casAuthors">Bogatcheva, Elena; Hanrahan, Colleen; Nikonenko, Boris; de los Santos, Gladys; Reddy, Venkata; Chen, Ping; Barbosa, Francis; Einck, Leo; Nacy, Carol; Protopopova, Marina</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5353-5357</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">It was recently reported that compds. created around a dipiperidine scaffold demonstrated activity against Mycobacterium tuberculosis (Mtb).  To optimize the dipiperidine compd. series and to select a lead compd. to advance into preclin. studies, the structure-activity relationship (SAR) of the proprietary libraries was evaluated.  The (piperidin-4-ylmethyl)piperidine scaffold was an essential structural element required for antibacterial activity.  Based on SAR, a focused library of 313 new dipiperidines was synthesized to delineate addnl. structural features responsible for antitubercular activity.  Thirty new active compds. with MIC 10-20 μg/mL on Mtb were identified, but none was better than the original hits of this series, SQ609 (I), SQ614 (II), and SQ615 (III).  In Mtb-infected macrophages in vitro, SQ609 and SQ614 inhibited more than 90% of intracellular bacterial growth at 4 μg/mL; SQ615 was toxic to these cells.  In mice infected with Mtb, wt. loss was completely prevented by SQ609, but not SQ614, and SQ609 had a prolonged therapeutic effect, extended by 10-15 days, after cessation of therapy.  Based on in vitro and in vivo antitubercular activity, SQ609 was identified as the best-in-class dipiperidine compd. in the series.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDFxFAeNYceLVg90H21EOLACvtfcHk0ljImxn2iIdZQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVKis73M&md5=45b7703f67717ea6710e731d8e2c4a00</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.07.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.07.015%26sid%3Dliteratum%253Aachs%26aulast%3DBogatcheva%26aufirst%3DE.%26aulast%3DHanrahan%26aufirst%3DC.%26aulast%3DNikonenko%26aufirst%3DB.%26aulast%3Dde%2Blos%2BSantos%26aufirst%3DG.%26aulast%3DReddy%26aufirst%3DV.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DBarbosa%26aufirst%3DF.%26aulast%3DEinck%26aufirst%3DL.%26aulast%3DNacy%26aufirst%3DC.%26aulast%3DProtopopova%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520SQ609%2520as%2520a%2520lead%2520compound%2520from%2520a%2520library%2520of%2520dipiperidines%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D5353%26epage%3D5357%26doi%3D10.1016%2Fj.bmcl.2011.07.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bermudez, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolonoski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aralar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inderlied, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, L. S.</span></span> <span> </span><span class="NLM_article-title">Thiosemicarbazole (thiacetazone-like) compound with activity against mycobacterium avium in mice</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">2685</span>– <span class="NLM_lpage">2687</span>, <span class="refDoi"> DOI: 10.1128/AAC.47.8.2685-2687.2003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.47.8.2685-2687.2003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=12878542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlvFClsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2003&pages=2685-2687&author=L.+E.+Bermudezauthor=R.+Reynoldsauthor=P.+Kolonoskiauthor=P.+Aralarauthor=C.+B.+Inderliedauthor=L.+S.+Young&title=Thiosemicarbazole+%28thiacetazone-like%29+compound+with+activity+against+mycobacterium+avium+in+mice&doi=10.1128%2FAAC.47.8.2685-2687.2003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Thiosemicarbazole (thiacetazone-like) compound with activity against Mycobacterium avium in mice</span></div><div class="casAuthors">Bermudez, Luiz E.; Reynolds, Robert; Kolonoski, Peter; Aralar, Pricilla; Inderlied, Clark B.; Young, Lowell S.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2685-2687</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">In vitro screening of thiacetazone derivs. indicated that two derivs., SRI-286 and SRI-224, inhibited a panel of 25 Mycobacterium avium complex (MAC) isolates at concns. of 2 μg/mL or lower.  In mice, SRI-224 and thiacetazone had no significant activity against the MAC in livers and spleens, but treatment with SRI-286 resulted in significant redn. of bacterial loads in livers and spleens.  A combination of SRI-286 and moxifloxacin was significantly more active than single drug regimens in liver and spleen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwNxAxx5hlPLVg90H21EOLACvtfcHk0ljBOGFLoVa0HQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlvFClsLY%253D&md5=3c525cccb019b2d8d5246de1630934d2</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1128%2FAAC.47.8.2685-2687.2003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.47.8.2685-2687.2003%26sid%3Dliteratum%253Aachs%26aulast%3DBermudez%26aufirst%3DL.%2BE.%26aulast%3DReynolds%26aufirst%3DR.%26aulast%3DKolonoski%26aufirst%3DP.%26aulast%3DAralar%26aufirst%3DP.%26aulast%3DInderlied%26aufirst%3DC.%2BB.%26aulast%3DYoung%26aufirst%3DL.%2BS.%26atitle%3DThiosemicarbazole%2520%2528thiacetazone-like%2529%2520compound%2520with%2520activity%2520against%2520mycobacterium%2520avium%2520in%2520mice%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2003%26volume%3D47%26spage%3D2685%26epage%3D2687%26doi%3D10.1128%2FAAC.47.8.2685-2687.2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alahari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trivelli, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guérardel, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dover, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besra, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacchettini, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coxon, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, L.</span></span> <span> </span><span class="NLM_article-title">Thiacetazone, an antitubercular drug that inhibits cyclopropanation of cell wall mycolic acids in mycobacteria</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">e1343</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0001343</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1371%2Fjournal.pone.0001343" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=18094751" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=e1343&author=A.+Alahariauthor=X.+Trivelliauthor=Y.+Gu%C3%A9rardelauthor=L.+G.+Doverauthor=G.+S.+Besraauthor=J.+C.+Sacchettiniauthor=R.+C.+Reynoldsauthor=G.+D.+Coxonauthor=L.+Kremer&title=Thiacetazone%2C+an+antitubercular+drug+that+inhibits+cyclopropanation+of+cell+wall+mycolic+acids+in+mycobacteria&doi=10.1371%2Fjournal.pone.0001343"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0001343&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0001343%26sid%3Dliteratum%253Aachs%26aulast%3DAlahari%26aufirst%3DA.%26aulast%3DTrivelli%26aufirst%3DX.%26aulast%3DGu%25C3%25A9rardel%26aufirst%3DY.%26aulast%3DDover%26aufirst%3DL.%2BG.%26aulast%3DBesra%26aufirst%3DG.%2BS.%26aulast%3DSacchettini%26aufirst%3DJ.%2BC.%26aulast%3DReynolds%26aufirst%3DR.%2BC.%26aulast%3DCoxon%26aufirst%3DG.%2BD.%26aulast%3DKremer%26aufirst%3DL.%26atitle%3DThiacetazone%252C%2520an%2520antitubercular%2520drug%2520that%2520inhibits%2520cyclopropanation%2520of%2520cell%2520wall%2520mycolic%2520acids%2520in%2520mycobacteria%26jtitle%3DPLoS%2520One%26date%3D2007%26volume%3D2%26spage%3De1343%26doi%3D10.1371%2Fjournal.pone.0001343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naidu, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasarao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agnieszka, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ewa, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandra Sekhar, K. V.</span></span> <span> </span><span class="NLM_article-title">Seeking potent anti-tubercular agents: Design, synthesis, anti-tubercular activity and docking study of various ((triazoles/indole)-piperazin-1-yl/1,4-diazepan-1-yl)benzo[d]isoxazole derivatives</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2245</span>– <span class="NLM_lpage">2250</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.03.059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmcl.2016.03.059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=27020525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28XkvVyms7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=2245-2250&author=K.+M.+Naiduauthor=S.+Srinivasaraoauthor=N.+Agnieszkaauthor=A.+K.+Ewaauthor=M.+M.+Kumarauthor=K.+V.+Chandra+Sekhar&title=Seeking+potent+anti-tubercular+agents%3A+Design%2C+synthesis%2C+anti-tubercular+activity+and+docking+study+of+various+%28%28triazoles%2Findole%29-piperazin-1-yl%2F1%2C4-diazepan-1-yl%29benzo%5Bd%5Disoxazole+derivatives&doi=10.1016%2Fj.bmcl.2016.03.059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Seeking potent anti-tubercular agents: Design, synthesis, anti-tubercular activity and docking study of various ((triazoles/indole)-piperazin-1-yl/1,4-diazepan-1-yl)benzo[d]isoxazole derivatives</span></div><div class="casAuthors">Naidu, Kalaga Mahalakshmi; Srinivasarao, Singireddi; Agnieszka, Napiorkowska; Ewa, Augustynowicz-Kopec; Kumar, Muthyala Murali Krishna; Chandra Sekhar, Kondapalli Venkata Gowri</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2245-2250</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of thirty eight novel 3-(4-((substituted-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl/1,4-diazepan-1-yl)benzo[d]isoxazole and 1-(4-(benzo[d]isoxazol-3-yl)piperazin-1-yl/1,4-diazepan-1-yl)-2-(1H-indol-3-yl)substituted-1-one analogs were synthesized, characterized using various anal. techniques and evaluated for in vitro anti-tubercular activity against Mycobacterium tuberculosis H37Rv strain and two 'wild' strains Spec. 210 and Spec. 192.  The titled compds. exhibited min. inhibitory concn. (MIC) ranging from 6.16 to >200 μM.  Among the tested compds., 7i, 7y and 7z exhibited moderate activity (MIC = 24.03-29.19 μM) and 7j exhibited very good anti-tubercular activity (MIC = 6.16 μM).  Furthermore, 7i, 7j, 7y and 7z were found to be non-toxic against mouse macrophage cell lines when screened for toxicity.  All the synthesized compds. were docked to pantothenate synthetase enzyme site to know deferent binding interactions with the receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj6-cY7qwzobVg90H21EOLACvtfcHk0ljBOGFLoVa0HQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XkvVyms7Y%253D&md5=13c9b8f771a5f406159a3cbe35dd932a</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.03.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.03.059%26sid%3Dliteratum%253Aachs%26aulast%3DNaidu%26aufirst%3DK.%2BM.%26aulast%3DSrinivasarao%26aufirst%3DS.%26aulast%3DAgnieszka%26aufirst%3DN.%26aulast%3DEwa%26aufirst%3DA.%2BK.%26aulast%3DKumar%26aufirst%3DM.%2BM.%26aulast%3DChandra%2BSekhar%26aufirst%3DK.%2BV.%26atitle%3DSeeking%2520potent%2520anti-tubercular%2520agents%253A%2520Design%252C%2520synthesis%252C%2520anti-tubercular%2520activity%2520and%2520docking%2520study%2520of%2520various%2520%2528%2528triazoles%252Findole%2529-piperazin-1-yl%252F1%252C4-diazepan-1-yl%2529benzo%255Bd%255Disoxazole%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D2245%26epage%3D2250%26doi%3D10.1016%2Fj.bmcl.2016.03.059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchard, J. S.</span></span> <span> </span><span class="NLM_article-title">Steady-state and pre-steady-state kinetic analysis of mycobacterium tuberculosis pantothenate synthetase</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">12904</span>– <span class="NLM_lpage">12912</span>, <span class="refDoi"> DOI: 10.1021/bi011522+</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi011522%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnt12qurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2001&pages=12904-12912&author=R.+Zhengauthor=J.+S.+Blanchard&title=Steady-state+and+pre-steady-state+kinetic+analysis+of+mycobacterium+tuberculosis+pantothenate+synthetase&doi=10.1021%2Fbi011522%2B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Steady-State and Pre-Steady-State Kinetic Analysis of Mycobacterium tuberculosis Pantothenate Synthetase</span></div><div class="casAuthors">Zheng, Renjian; Blanchard, John S.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">12904-12912</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pantothenate synthetase (EC 6.3.2.1), encoded by the panC gene, catalyzes the essential ATP-dependent condensation of D-pantoate and β-alanine to form pantothenate in bacteria, yeast and plants.  Pantothenate synthetase from Mycobacterium tuberculosis was expressed in E. coli, purified to homogeneity, and found to be a homodimer with a subunit mol. mass of 33 kDa.  Initial velocity, product, and dead-end inhibition studies showed the kinetic mechanism of pantothenate synthetase to be Bi Uni Uni Bi Ping Pong, with ATP binding followed by D-pantoate binding, release of PPi, binding of β-alanine, followed by the release of pantothenate and AMP.  Michaelis consts. were 0.13, 0.8, and 2.6 mM for D-pantoate, β-alanine, and ATP, resp., and the turnover no., kcat, was 3.4 s-1.  The formation of pantoyl adenylate, suggested as a key intermediate by the kinetic mechanism, was confirmed by 31P NMR spectroscopy of [18O]AMP produced from 18O transfer using [carboxyl-18O]pantoate.  Single-turnover reactions for the formation of pyrophosphate and pantothenate were detd. using rapid quench techniques, and indicated that the two half-reactions occurred with max. rates of 1.3 ± 0.3 and 2.6 ± 0.3 s-1, resp., consistent with pantoyl adenylate being a kinetically competent intermediate in the pantothenate synthetase reaction.  These data also suggest that both half-reactions are partially rate-limiting.  Reverse isotope exchange of [14C]-β-alanine into pantothenate in the presence of AMP was obsd., indicating the reversible formation of the pantoyl adenylate intermediate from products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6V5kK1UYOOrVg90H21EOLACvtfcHk0lgFHcr6EDjqTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnt12qurw%253D&md5=caae3b38e8ab3c2a6ae1ac0b265a749e</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1021%2Fbi011522%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi011522%252B%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DR.%26aulast%3DBlanchard%26aufirst%3DJ.%2BS.%26atitle%3DSteady-state%2520and%2520pre-steady-state%2520kinetic%2520analysis%2520of%2520mycobacterium%2520tuberculosis%2520pantothenate%2520synthetase%26jtitle%3DBiochemistry%26date%3D2001%26volume%3D40%26spage%3D12904%26epage%3D12912%26doi%3D10.1021%2Fbi011522%2B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karabanovich, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zemanová, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smutný, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Székely, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Šarkan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Centárová, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pávková, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Čonka, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Němeček, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolaříková, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vejsová, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vávrová, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klimešová, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hrabálek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pávek, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikušová, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roh, J.</span></span> <span> </span><span class="NLM_article-title">Development of 3,5-dinitrobenzylsulfanyl-1,3,4-oxadiazoles and thiadiazoles as selective antitubercular agents active against replicating and nonreplicating mycobacterium tuberculosis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2362</span>– <span class="NLM_lpage">2380</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00608</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00608" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjs1yqt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2362-2380&author=G.+Karabanovichauthor=J.+Zemanov%C3%A1author=T.+Smutn%C3%BDauthor=R.+Sz%C3%A9kelyauthor=M.+%C5%A0arkanauthor=I.+Cent%C3%A1rov%C3%A1author=A.+Vocatauthor=I.+P%C3%A1vkov%C3%A1author=P.+%C4%8Conkaauthor=J.+N%C4%9Bme%C4%8Dekauthor=J.+Stola%C5%99%C3%ADkov%C3%A1author=M.+Vejsov%C3%A1author=K.+V%C3%A1vrov%C3%A1author=V.+Klime%C5%A1ov%C3%A1author=A.+Hrab%C3%A1lekauthor=P.+P%C3%A1vekauthor=S.+T.+Coleauthor=K.+Miku%C5%A1ov%C3%A1author=J.+Roh&title=Development+of+3%2C5-dinitrobenzylsulfanyl-1%2C3%2C4-oxadiazoles+and+thiadiazoles+as+selective+antitubercular+agents+active+against+replicating+and+nonreplicating+mycobacterium+tuberculosis&doi=10.1021%2Facs.jmedchem.5b00608"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-oxadiazoles and Thiadiazoles as Selective Antitubercular Agents Active Against Replicating and Nonreplicating Mycobacterium tuberculosis</span></div><div class="casAuthors">Karabanovich, Galina; Zemanova, Julia; Smutny, Tomas; Szekely, Rita; Sarkan, Michal; Centarova, Ivana; Vocat, Anthony; Pavkova, Ivona; Conka, Patrik; Nemecek, Jan; Stolarikova, Jirina; Vejsova, Marcela; Vavrova, Katerina; Klimesova, Vera; Hrabalek, Alexandr; Pavek, Petr; Cole, Stewart T.; Mikusova, Katarina; Roh, Jaroslav</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2362-2380</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein, we report the discovery and structure-activity relationships of 5-substituted-2-[(3,5-dinitrobenzyl)sulfanyl]-1,3,4-oxadiazoles and 1,3,4-thiadiazoles as a new class of antituberculosis agents.  The majority of these compds. exhibited outstanding in vitro activity against Mycobacterium tuberculosis CNCTC My 331/88 and six multidrug-resistant clin. isolated strains of M. tuberculosis, with min. inhibitory concn. values as low as 0.03 μM (0.011-0.026 μg/mL).  The investigated compds. had a highly selective antimycobacterial effect because they showed no activity against the other bacteria or fungi tested in this study.  Furthermore, the investigated compds. exhibited low in vitro toxicities in four proliferating mammalian cell lines and in isolated primary human hepatocytes.  Several in vitro genotoxicity assays indicated that the selected compds. have no mutagenic activity.  The oxadiazole and thiadiazole derivs. with the most favorable activity/toxicity profiles also showed potency comparable to that of rifampicin against the nonreplicating streptomycin-starved M. tuberculosis 18b-Lux strain, and therefore, these derivs., are of particular interest.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgBb0Hpi3vOrVg90H21EOLACvtfcHk0lgFHcr6EDjqTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjs1yqt7Y%253D&md5=788b65627cfd13854c699c08ae7aa756</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00608&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00608%26sid%3Dliteratum%253Aachs%26aulast%3DKarabanovich%26aufirst%3DG.%26aulast%3DZemanov%25C3%25A1%26aufirst%3DJ.%26aulast%3DSmutn%25C3%25BD%26aufirst%3DT.%26aulast%3DSz%25C3%25A9kely%26aufirst%3DR.%26aulast%3D%25C5%25A0arkan%26aufirst%3DM.%26aulast%3DCent%25C3%25A1rov%25C3%25A1%26aufirst%3DI.%26aulast%3DVocat%26aufirst%3DA.%26aulast%3DP%25C3%25A1vkov%25C3%25A1%26aufirst%3DI.%26aulast%3D%25C4%258Conka%26aufirst%3DP.%26aulast%3DN%25C4%259Bme%25C4%258Dek%26aufirst%3DJ.%26aulast%3DStola%25C5%2599%25C3%25ADkov%25C3%25A1%26aufirst%3DJ.%26aulast%3DVejsov%25C3%25A1%26aufirst%3DM.%26aulast%3DV%25C3%25A1vrov%25C3%25A1%26aufirst%3DK.%26aulast%3DKlime%25C5%25A1ov%25C3%25A1%26aufirst%3DV.%26aulast%3DHrab%25C3%25A1lek%26aufirst%3DA.%26aulast%3DP%25C3%25A1vek%26aufirst%3DP.%26aulast%3DCole%26aufirst%3DS.%2BT.%26aulast%3DMiku%25C5%25A1ov%25C3%25A1%26aufirst%3DK.%26aulast%3DRoh%26aufirst%3DJ.%26atitle%3DDevelopment%2520of%25203%252C5-dinitrobenzylsulfanyl-1%252C3%252C4-oxadiazoles%2520and%2520thiadiazoles%2520as%2520selective%2520antitubercular%2520agents%2520active%2520against%2520replicating%2520and%2520nonreplicating%2520mycobacterium%2520tuberculosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D2362%26epage%3D2380%26doi%3D10.1021%2Facs.jmedchem.5b00608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carette, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blondiaux, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willery, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lecat-Guillet, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lens, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wohlkönig, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wintjens, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soror, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frénois, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dirié, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villeret, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">England, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippens, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deprez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willand, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baulard, A. R.</span></span> <span> </span><span class="NLM_article-title">Structural activation of the transcriptional repressor EthR from mycobacterium tuberculosis by single amino acid change mimicking natural and synthetic ligands</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">3018</span>– <span class="NLM_lpage">3030</span>, <span class="refDoi"> DOI: 10.1093/nar/gkr1113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1093%2Fnar%2Fgkr1113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=22156370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38Xls1SntbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=3018-3030&author=X.+Caretteauthor=N.+Blondiauxauthor=E.+Willeryauthor=S.+Hoosauthor=N.+Lecat-Guilletauthor=Z.+Lensauthor=A.+Wohlk%C3%B6nigauthor=R.+Wintjensauthor=S.+H.+Sororauthor=F.+Fr%C3%A9noisauthor=B.+Diri%C3%A9author=V.+Villeretauthor=P.+Englandauthor=G.+Lippensauthor=B.+Deprezauthor=C.+Lochtauthor=N.+Willandauthor=A.+R.+Baulard&title=Structural+activation+of+the+transcriptional+repressor+EthR+from+mycobacterium+tuberculosis+by+single+amino+acid+change+mimicking+natural+and+synthetic+ligands&doi=10.1093%2Fnar%2Fgkr1113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Structural activation of the transcriptional repressor EthR from Mycobacterium tuberculosis by single amino acid change mimicking natural and synthetic ligands</span></div><div class="casAuthors">Carette, Xavier; Blondiaux, Nicolas; Willery, Eve; Hoos, Sylviane; Lecat-Guillet, Nathalie; Lens, Zoe; Wohlkoenig, Alexandre; Wintjens, Rene; Soror, Sameh H.; Frenois, Frederic; Dirie, Bertrand; Villeret, Vincent; England, Patrick; Lippens, Guy; Deprez, Benoit; Locht, Camille; Willand, Nicolas; Baulard, Alain R.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3018-3030</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Ethionamide is an antituberculous drug for the treatment of multidrug-resistant Mycobacterium tuberculosis.  This antibiotic requires activation by the monooxygenase EthA to exert its activity.  Prodn. of EthA is controlled by the transcriptional repressor EthR, a member of the TetR family.  The sensitivity of M. tuberculosis to ethionamide can be artificially enhanced using synthetic ligands of EthR that allosterically inactivate its DNA-binding activity.  Comparison of several structures of EthR co-crystd. with various ligands suggested that the structural reorganization of EthR resulting in its inactivation is controlled by a limited portion of the ligand-binding-pocket.  In silico simulation predicted that mutation G106W may mimic ligands.  X-ray crystallog. of variant G106W indeed revealed a protein structurally similar to ligand-bound EthR.  Surface plasmon resonance expts. established that this variant is unable to bind DNA, while thermal shift studies demonstrated that mutation G106W stabilizes EthR as strongly as ligands.  Proton NMR of the Me regions showed a lesser contribution of exchange broadening upon ligand binding, and the same quenched dynamics was obsd. in apo-variant G106W.  Altogether, we here show that the area surrounding Gly106 constitutes the mol. switch involved in the conformational reorganization of EthR.  These results also shed light on the mechanistic of ligand-induced allosterism controlling the DNA binding properties of TetR family repressors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphQGML1UonJLVg90H21EOLACvtfcHk0lgFHcr6EDjqTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xls1SntbY%253D&md5=f13df06708193401f2ab1168023456a8</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkr1113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkr1113%26sid%3Dliteratum%253Aachs%26aulast%3DCarette%26aufirst%3DX.%26aulast%3DBlondiaux%26aufirst%3DN.%26aulast%3DWillery%26aufirst%3DE.%26aulast%3DHoos%26aufirst%3DS.%26aulast%3DLecat-Guillet%26aufirst%3DN.%26aulast%3DLens%26aufirst%3DZ.%26aulast%3DWohlk%25C3%25B6nig%26aufirst%3DA.%26aulast%3DWintjens%26aufirst%3DR.%26aulast%3DSoror%26aufirst%3DS.%2BH.%26aulast%3DFr%25C3%25A9nois%26aufirst%3DF.%26aulast%3DDiri%25C3%25A9%26aufirst%3DB.%26aulast%3DVilleret%26aufirst%3DV.%26aulast%3DEngland%26aufirst%3DP.%26aulast%3DLippens%26aufirst%3DG.%26aulast%3DDeprez%26aufirst%3DB.%26aulast%3DLocht%26aufirst%3DC.%26aulast%3DWilland%26aufirst%3DN.%26aulast%3DBaulard%26aufirst%3DA.%2BR.%26atitle%3DStructural%2520activation%2520of%2520the%2520transcriptional%2520repressor%2520EthR%2520from%2520mycobacterium%2520tuberculosis%2520by%2520single%2520amino%2520acid%2520change%2520mimicking%2520natural%2520and%2520synthetic%2520ligands%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2012%26volume%3D40%26spage%3D3018%26epage%3D3030%26doi%3D10.1093%2Fnar%2Fgkr1113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Willand, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dirie, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carette, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bifani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singhal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desroses, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroux, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willery, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathys, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deprez-Poulain, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delcroix, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frenois, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aumercier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villeret, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deprez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baulard, A. R.</span></span> <span> </span><span class="NLM_article-title">Synthetic EthR inhibitors boost antituberculous activity of ethionamide</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">537</span>– <span class="NLM_lpage">544</span>, <span class="refDoi"> DOI: 10.1038/nm.1950</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1038%2Fnm.1950" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=19412174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltlSrsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=537-544&author=N.+Willandauthor=B.+Dirieauthor=X.+Caretteauthor=P.+Bifaniauthor=A.+Singhalauthor=M.+Desrosesauthor=F.+Lerouxauthor=E.+Willeryauthor=V.+Mathysauthor=R.+Deprez-Poulainauthor=G.+Delcroixauthor=F.+Frenoisauthor=M.+Aumercierauthor=C.+Lochtauthor=V.+Villeretauthor=B.+Deprezauthor=A.+R.+Baulard&title=Synthetic+EthR+inhibitors+boost+antituberculous+activity+of+ethionamide&doi=10.1038%2Fnm.1950"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic EthR inhibitors boost antituberculous activity of ethionamide</span></div><div class="casAuthors">Willand, Nicolas; Dirie, Bertrand; Carette, Xavier; Bifani, Pablo; Singhal, Amit; Desroses, Matthieu; Leroux, Florence; Willery, Eve; Mathys, Vanessa; Deprez-Poulain, Rebecca; Delcroix, Guy; Frenois, Frederic; Aumercier, Marc; Locht, Camille; Villeret, Vincent; Deprez, Benoit; Baulard, Alain R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">537-544</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The side effects assocd. with tuberculosis therapy bring with them the risk of noncompliance and subsequent drug resistance.  Increasing the therapeutic index of antituberculosis drugs should thus improve treatment effectiveness.  Several antituberculosis compds. require in situ metabolic activation to become inhibitory.  Various thiocarbamide-contg. drugs, including ethionamide, are activated by the mycobacterial monooxygenase EthA, the prodn. of which is controlled by the transcriptional repressor EthR.  Here we identify drug-like inhibitors of EthR that boost the bioactivation of ethionamide.  Compds. designed and screened for their capacity to inhibit EthR-DNA interaction were co-crystd. with EthR.  We exploited the three-dimensional structures of the complexes for the synthesis of improved analogs that boosted the ethionamide potency in culture more than tenfold.  In Mycobacterium tuberculosis-infected mice, one of these analogs, BDM31343, enabled a substantially reduced dose of ethionamide to lessen the mycobacterial load as efficiently as the conventional higher-dose treatment.  This provides proof of concept that inhibiting EthR improves the therapeutic index of thiocarbamide derivs., which should prompt reconsideration of their use as first-line drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgknfO8azsTrVg90H21EOLACvtfcHk0lhET3jESwDmIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltlSrsLk%253D&md5=a119c8e00d9cd41bfa34c2e056e4a1ad</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1038%2Fnm.1950&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.1950%26sid%3Dliteratum%253Aachs%26aulast%3DWilland%26aufirst%3DN.%26aulast%3DDirie%26aufirst%3DB.%26aulast%3DCarette%26aufirst%3DX.%26aulast%3DBifani%26aufirst%3DP.%26aulast%3DSinghal%26aufirst%3DA.%26aulast%3DDesroses%26aufirst%3DM.%26aulast%3DLeroux%26aufirst%3DF.%26aulast%3DWillery%26aufirst%3DE.%26aulast%3DMathys%26aufirst%3DV.%26aulast%3DDeprez-Poulain%26aufirst%3DR.%26aulast%3DDelcroix%26aufirst%3DG.%26aulast%3DFrenois%26aufirst%3DF.%26aulast%3DAumercier%26aufirst%3DM.%26aulast%3DLocht%26aufirst%3DC.%26aulast%3DVilleret%26aufirst%3DV.%26aulast%3DDeprez%26aufirst%3DB.%26aulast%3DBaulard%26aufirst%3DA.%2BR.%26atitle%3DSynthetic%2520EthR%2520inhibitors%2520boost%2520antituberculous%2520activity%2520of%2520ethionamide%26jtitle%3DNat.%2520Med.%26date%3D2009%26volume%3D15%26spage%3D537%26epage%3D544%26doi%3D10.1038%2Fnm.1950" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karabanovich, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Němeček, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valášková, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carazo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konečná, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolaříková, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hrabálek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavliš, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pávek, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vávrová, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klimešová, V.</span></span> <span> </span><span class="NLM_article-title">S-substituted 3,5-dinitrophenyl 1,3,4-oxadiazole-2-thiols and tetrazole-5-thiols as highly efficient antitubercular agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">369</span>– <span class="NLM_lpage">383</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.11.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.ejmech.2016.11.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=27907875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFKjsb3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2017&pages=369-383&author=G.+Karabanovichauthor=J.+N%C4%9Bme%C4%8Dekauthor=L.+Val%C3%A1%C5%A1kov%C3%A1author=A.+Carazoauthor=K.+Kone%C4%8Dn%C3%A1author=J.+Stola%C5%99%C3%ADkov%C3%A1author=A.+Hrab%C3%A1lekauthor=O.+Pavli%C5%A1author=P.+P%C3%A1vekauthor=K.+V%C3%A1vrov%C3%A1author=J.+Rohauthor=V.+Klime%C5%A1ov%C3%A1&title=S-substituted+3%2C5-dinitrophenyl+1%2C3%2C4-oxadiazole-2-thiols+and+tetrazole-5-thiols+as+highly+efficient+antitubercular+agents&doi=10.1016%2Fj.ejmech.2016.11.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">S-substituted 3,5-dinitrophenyl 1,3,4-oxadiazole-2-thiols and tetrazole-5-thiols as highly efficient antitubercular agents</span></div><div class="casAuthors">Karabanovich, Galina; Nemecek, Jan; Valaskova, Lenka; Carazo, Alejandro; Konecna, Klara; Stolarikova, Jirina; Hrabalek, Alexandr; Pavlis, Oto; Pavek, Petr; Vavrova, Katerina; Roh, Jaroslav; Klimesova, Vera</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">369-383</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Two new classes of antitubercular agents, namely 5-alkylsulfanyl-1-(3,5-dinitrophenyl)-1H-tetrazoles and 2-alkylsulfanyl-5-(3,5-dinitrophenyl)-1,3,4-oxadiazoles, and their structure-activity relationships are described.  These compds. possessed excellent activity against Mycobacterium tuberculosis, including the clin. isolated multidrug (MDR) and extensively drug-resistant (XDR) strains, with no cross resistance with first or second-line anti-TB drugs.  The min. inhibitory concn. (MIC) values of the most promising compds. reached 0.03 μM.  Furthermore, these compds. had a highly selective antimycobacterial effect because they were completely inactive against 4 gram pos. and 4 gram neg. bacteria and eight fungal strains and had low in vitro toxicity for four mammalian cell lines, including hepatic cell lines HepG2 and HuH7.  Although the structure-activity relationship study showed that the presence of two nitro groups is highly beneficial for antimycobacterial activity, the analogs with a trifluoromethyl group instead of one of the nitro groups maintained a high antimycobacterial activity, which indicates the possibility for further structural optimization of this class of antitubercular agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1nJC9MkunPLVg90H21EOLACvtfcHk0lhET3jESwDmIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFKjsb3I&md5=6d432e1f8b9bbaaab823de2cb053f1cd</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.11.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.11.041%26sid%3Dliteratum%253Aachs%26aulast%3DKarabanovich%26aufirst%3DG.%26aulast%3DN%25C4%259Bme%25C4%258Dek%26aufirst%3DJ.%26aulast%3DVal%25C3%25A1%25C5%25A1kov%25C3%25A1%26aufirst%3DL.%26aulast%3DCarazo%26aufirst%3DA.%26aulast%3DKone%25C4%258Dn%25C3%25A1%26aufirst%3DK.%26aulast%3DStola%25C5%2599%25C3%25ADkov%25C3%25A1%26aufirst%3DJ.%26aulast%3DHrab%25C3%25A1lek%26aufirst%3DA.%26aulast%3DPavli%25C5%25A1%26aufirst%3DO.%26aulast%3DP%25C3%25A1vek%26aufirst%3DP.%26aulast%3DV%25C3%25A1vrov%25C3%25A1%26aufirst%3DK.%26aulast%3DRoh%26aufirst%3DJ.%26aulast%3DKlime%25C5%25A1ov%25C3%25A1%26aufirst%3DV.%26atitle%3DS-substituted%25203%252C5-dinitrophenyl%25201%252C3%252C4-oxadiazole-2-thiols%2520and%2520tetrazole-5-thiols%2520as%2520highly%2520efficient%2520antitubercular%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D126%26spage%3D369%26epage%3D383%26doi%3D10.1016%2Fj.ejmech.2016.11.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bellale, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VB, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambady, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravishankar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiteaker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morayya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guptha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raichurkar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awasthy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Achar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vachaspati, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandodkar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterji, M.</span></span> <span> </span><span class="NLM_article-title">Diarylthiazole: An antimycobacterial scaffold potentially targeting PrrB-PrrA two-component system</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">6572</span>– <span class="NLM_lpage">6582</span>, <span class="refDoi"> DOI: 10.1021/jm500833f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500833f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVKnsLbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=6572-6582&author=E.+Bellaleauthor=M.+Naikauthor=V.+VBauthor=A.+Ambadyauthor=A.+Narayanauthor=S.+Ravishankarauthor=V.+Ramachandranauthor=P.+Kaurauthor=R.+McLaughlinauthor=J.+Whiteakerauthor=S.+Morayyaauthor=S.+Gupthaauthor=S.+Sharmaauthor=A.+Raichurkarauthor=D.+Awasthyauthor=V.+Acharauthor=P.+Vachaspatiauthor=B.+Bandodkarauthor=M.+Pandaauthor=M.+Chatterji&title=Diarylthiazole%3A+An+antimycobacterial+scaffold+potentially+targeting+PrrB-PrrA+two-component+system&doi=10.1021%2Fjm500833f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Diarylthiazole: an antimycobacterial scaffold potentially targeting PrrB-PrrA two-component system</span></div><div class="casAuthors">Bellale, Eknath; Naik, Maruti; Varun, V. B.; Ambady, Anisha; Narayan, Ashwini; Ravishankar, Sudha; Ramachandran, Vasanthi; Kaur, Parvinder; McLaughlin, Robert; Whiteaker, James; Morayya, Sapna; Guptha, Supreeth; Sharma, Sreevalli; Raichurkar, Anandkumar; Awasthy, Disha; Achar, Vijayshree; Vachaspati, Prakash; Bandodkar, Balachandra; Panda, Manoranjan; Chatterji, Monalisa</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6572-6582</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Diarylthiazole (DAT), a hit from diversity screening, was found to have potent antimycobacterial activity against Mycobacterium tuberculosis (Mtb).  In a systematic medicinal chem. exploration, the authors demonstrated chem. opportunities to optimize the potency and physicochem. properties.  The effort led to more than 10 compds. with submicromolar MICs and desirable physicochem. properties.  The potent antimycobacterial activity, in conjunction with low mol. wt., made the series an attractive lead (antibacterial ligand efficiency (ALE) >0.4).  The series exhibited excellent bactericidal activity and was active against drug-sensitive and resistant Mtb.  Mutational anal. showed that mutations in prrB impart resistance to DAT compds. but not to ref. drugs tested.  The sensor kinase PrrB belongs to the PrrBA two component system and is potentially the target for DAT.  PrrBA is a conserved, essential regulatory mechanism in Mtb and has been shown to have a role in virulence and metabolic adaptation to stress.  Hence, DATs provide an opportunity to understand a completely new target system for antimycobacterial drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_40E8zTrM7bVg90H21EOLACvtfcHk0ljARTPERjBlQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVKnsLbF&md5=f60841419f946e5f6b471a01d04256db</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1021%2Fjm500833f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500833f%26sid%3Dliteratum%253Aachs%26aulast%3DBellale%26aufirst%3DE.%26aulast%3DNaik%26aufirst%3DM.%26aulast%3DVB%26aufirst%3DV.%26aulast%3DAmbady%26aufirst%3DA.%26aulast%3DNarayan%26aufirst%3DA.%26aulast%3DRavishankar%26aufirst%3DS.%26aulast%3DRamachandran%26aufirst%3DV.%26aulast%3DKaur%26aufirst%3DP.%26aulast%3DMcLaughlin%26aufirst%3DR.%26aulast%3DWhiteaker%26aufirst%3DJ.%26aulast%3DMorayya%26aufirst%3DS.%26aulast%3DGuptha%26aufirst%3DS.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DRaichurkar%26aufirst%3DA.%26aulast%3DAwasthy%26aufirst%3DD.%26aulast%3DAchar%26aufirst%3DV.%26aulast%3DVachaspati%26aufirst%3DP.%26aulast%3DBandodkar%26aufirst%3DB.%26aulast%3DPanda%26aufirst%3DM.%26aulast%3DChatterji%26aufirst%3DM.%26atitle%3DDiarylthiazole%253A%2520An%2520antimycobacterial%2520scaffold%2520potentially%2520targeting%2520PrrB-PrrA%2520two-component%2520system%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D6572%26epage%3D6582%26doi%3D10.1021%2Fjm500833f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haydel, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malhotra, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelison, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark-Curtiss, J. E.</span></span> <span> </span><span class="NLM_article-title">The prrab two-component system is essential for mycobacterium tuberculosis viability and is induced under nitrogen-limiting conditions</span>. <i>J. Bacteriol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>194</i></span>,  <span class="NLM_fpage">354</span>– <span class="NLM_lpage">361</span>, <span class="refDoi"> DOI: 10.1128/JB.06258-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FJB.06258-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=22081401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsFWgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=194&publication_year=2012&pages=354-361&author=S.+E.+Haydelauthor=V.+Malhotraauthor=G.+L.+Cornelisonauthor=J.+E.+Clark-Curtiss&title=The+prrab+two-component+system+is+essential+for+mycobacterium+tuberculosis+viability+and+is+induced+under+nitrogen-limiting+conditions&doi=10.1128%2FJB.06258-11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">The prrAB two-component system is essential for Mycobacterium tuberculosis viability and is induced under nitrogen-limiting conditions</span></div><div class="casAuthors">Haydel, Shelley E.; Malhotra, Vandana; Cornelison, Garrett L.; Clark-Curtiss, Josephine E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Bacteriology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">194</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">354-361</span>CODEN:
                <span class="NLM_cas:coden">JOBAAY</span>;
        ISSN:<span class="NLM_cas:issn">0021-9193</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The Mycobacterium tuberculosis prrA-prrB (Rv0903c-Rv0902c) two-component regulatory system is expressed during intracellular growth in human macrophages and is required for early intracellular multiplication in murine macrophages, suggesting its importance in establishing infection.  To better understand the function of the prrA-prrB two-component system, the authors defined the transcriptional characteristics of the prrA and prrB genes during exponential and stationary growth and upon exposure to different environmental stresses and attempted to generate a prrA-prrB deletion mutant.  The prrA and prrB genes constitute an operon and are cotranscribed during logarithmic growth, with transcriptional levels decreasing in stationary phase and during hypoxia.  Despite the transcriptional differences, PrrA protein levels remained relatively stable throughout growth and in hypoxia.  Under conditions of nitrogen limitation, prrAB transcription was induced, while acidic pH stress and carbon starvation did not significantly alter transcript levels.  Deletion of the prrAB operon on the chromosome of M. tuberculosis H37Rv occurred only in the presence of an episomal copy of the prrAB genes, indicating that this two-component system is essential for viability.  Characterization of the prrAB locus in M. tuberculosis Mt21D3, a previously described prrA transposon mutant, revealed that this strain is not a true prrA knockout mutant.  Rather, Tn5367 transposon insertion into the prrA promoter only decreased prrA and prrB transcription and PrrA levels in Mt21D3 compared to those in the parental Mt103 clin. strain.  These data provide the first report describing the essentiality of the M. tuberculosis prrAB two-component system and reveal insights into its potential role in mycobacterial growth and metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCTv3wSydiJbVg90H21EOLACvtfcHk0ljARTPERjBlQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsFWgsQ%253D%253D&md5=18128c76baa288230bbb3afc247b1f84</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1128%2FJB.06258-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJB.06258-11%26sid%3Dliteratum%253Aachs%26aulast%3DHaydel%26aufirst%3DS.%2BE.%26aulast%3DMalhotra%26aufirst%3DV.%26aulast%3DCornelison%26aufirst%3DG.%2BL.%26aulast%3DClark-Curtiss%26aufirst%3DJ.%2BE.%26atitle%3DThe%2520prrab%2520two-component%2520system%2520is%2520essential%2520for%2520mycobacterium%2520tuberculosis%2520viability%2520and%2520is%2520induced%2520under%2520nitrogen-limiting%2520conditions%26jtitle%3DJ.%2520Bacteriol.%26date%3D2012%26volume%3D194%26spage%3D354%26epage%3D361%26doi%3D10.1128%2FJB.06258-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ewann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pethe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mielcarek, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ensergueix, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gicquel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Supply, P.</span></span> <span> </span><span class="NLM_article-title">Transient requirement of the prra-prrb two-component system for early intracellular multiplication of mycobacterium tuberculosis</span>. <i>Infect. Immun.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">2256</span>– <span class="NLM_lpage">2263</span>, <span class="refDoi"> DOI: 10.1128/IAI.70.5.2256-2263.2002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FIAI.70.5.2256-2263.2002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=11953357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD38XjtFKgtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2002&pages=2256-2263&author=F.+Ewannauthor=M.+Jacksonauthor=K.+Petheauthor=A.+Cooperauthor=N.+Mielcarekauthor=D.+Ensergueixauthor=B.+Gicquelauthor=C.+Lochtauthor=P.+Supply&title=Transient+requirement+of+the+prra-prrb+two-component+system+for+early+intracellular+multiplication+of+mycobacterium+tuberculosis&doi=10.1128%2FIAI.70.5.2256-2263.2002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Transient requirement of the PrrA-PrrB two-component system for early intracellular multiplication of Mycobacterium tuberculosis</span></div><div class="casAuthors">Ewann, Fanny; Jackson, Mary; Pethe, Kevin; Cooper, Andrea; Mielcarek, Nathalie; Ensergueix, Danielle; Gicquel, Brigitte; Locht, Camille; Supply, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Infection and Immunity</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2256-2263</span>CODEN:
                <span class="NLM_cas:coden">INFIBR</span>;
        ISSN:<span class="NLM_cas:issn">0019-9567</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Adaptive regulation of gene expression in response to environmental changes is a general property of bacterial pathogens.  By screening an ordered transposon mutagenesis library of Mycobacterium tuberculosis, we have identified three mutants contg. a transposon in the coding sequence or in the 5' regions of genes coding for two-component signal transduction systems (trcS, regX3, prrA).  The intracellular multiplication capacity of the three mutants was investigated in mouse bone marrow-derived macrophages.  Only the prrA mutant showed a defect in intracellular growth during the early phase of infection, and this defect was fully reverted when the mutant was complemented with prrA-prrB wild-type copies.  The mutant phenotype was transient, as after 1 wk this strain recovered full growth capacity to reach levels similar to that of the wild type at day 9.  Moreover, a transient induction of prrA promoter activity was obsd. during the initial phase of macrophage infection, as shown by a prrA promoter-gfp fusion in M. bovis BCG infecting the mouse macrophages.  The concordant transience of the prrA mutant phenotype and prrA promoter activity indicates that the PrrA-PrrB two-component system is involved in the environmental adaptation of M. tuberculosis, specifically in an early phase of the intracellular growth, and that, similar to other facultative intracellular parasites, M. tuberculosis can use genes temporarily required at different stages in the course of macrophage infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLGtYTsJ114LVg90H21EOLACvtfcHk0ljARTPERjBlQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjtFKgtLk%253D&md5=70536176046716cfde10afbce8e77f46</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1128%2FIAI.70.5.2256-2263.2002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FIAI.70.5.2256-2263.2002%26sid%3Dliteratum%253Aachs%26aulast%3DEwann%26aufirst%3DF.%26aulast%3DJackson%26aufirst%3DM.%26aulast%3DPethe%26aufirst%3DK.%26aulast%3DCooper%26aufirst%3DA.%26aulast%3DMielcarek%26aufirst%3DN.%26aulast%3DEnsergueix%26aufirst%3DD.%26aulast%3DGicquel%26aufirst%3DB.%26aulast%3DLocht%26aufirst%3DC.%26aulast%3DSupply%26aufirst%3DP.%26atitle%3DTransient%2520requirement%2520of%2520the%2520prra-prrb%2520two-component%2520system%2520for%2520early%2520intracellular%2520multiplication%2520of%2520mycobacterium%2520tuberculosis%26jtitle%3DInfect.%2520Immun.%26date%3D2002%26volume%3D70%26spage%3D2256%26epage%3D2263%26doi%3D10.1128%2FIAI.70.5.2256-2263.2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pieroni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franzblau, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costantino, G.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and investigation on the structure-activity relationships of n-substituted 2-aminothiazole derivatives as antitubercular agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">26</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.ejmech.2013.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=24333612" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1ylt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2014&pages=26-34&author=M.+Pieroniauthor=B.+Wanauthor=S.+Choauthor=S.+G.+Franzblauauthor=G.+Costantino&title=Design%2C+synthesis+and+investigation+on+the+structure-activity+relationships+of+n-substituted+2-aminothiazole+derivatives+as+antitubercular+agents&doi=10.1016%2Fj.ejmech.2013.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents</span></div><div class="casAuthors">Pieroni, Marco; Wan, Baojie; Cho, Sanghyun; Franzblau, Scott G.; Costantino, Gabriele</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">26-34</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Tuberculosis (TB) is one of the deadliest infectious diseases of all times, and its recent resurgence is a supreme matter of concern.  Co-infection with HIV and, in particular, the continuous isolation of new resistant strains, makes the discovery of novel anti-TB agents a strategic priority.  The research of novel agents should be driven by the accessibility of the synthetic procedure and, in particular, by the lack of cross-resistance with the drugs already marketed.  Moreover, in order to shorten the duration of the therapy, and therefore decrease the rate of resistance, these mols. should be active also against the nonreplicating persistent form (NRP-TB) of the infection.  The availability of an inhouse small library of compds. prompted us to investigate their anti-TB activity.  Two compds., embodying a 2-aminothiazole scaffold, were found to possess a certain inhibitory activity toward Mycobacterium tuberculosis H37Rv, and therefore a medicinal chem. campaign was initiated in order to increase the activity of the hit compds. and, esp., construct a plausible body of structure-activity relationships.  The potency of the hit compd. was successfully improved, and, much more importantly, some of the mols. synthesized were found to be active toward the persistent phenotype, and, also, toward a panel of resistant strains.  These findings encourage further investigations around this interesting antitubercular chemotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpcmctR8lRNrVg90H21EOLACvtfcHk0ljFJMgcMGwXiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1ylt70%253D&md5=254a604abcde3a94c6cc406ac56a29b8</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DPieroni%26aufirst%3DM.%26aulast%3DWan%26aufirst%3DB.%26aulast%3DCho%26aufirst%3DS.%26aulast%3DFranzblau%26aufirst%3DS.%2BG.%26aulast%3DCostantino%26aufirst%3DG.%26atitle%3DDesign%252C%2520synthesis%2520and%2520investigation%2520on%2520the%2520structure-activity%2520relationships%2520of%2520n-substituted%25202-aminothiazole%2520derivatives%2520as%2520antitubercular%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D72%26spage%3D26%26epage%3D34%26doi%3D10.1016%2Fj.ejmech.2013.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Landge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullick, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagalapur, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neres, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subbulakshmi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murugan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fellows, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humnabadkar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahadevaswamy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vachaspati, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudrapatna, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awasthy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sambandamurthy, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pojer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balganesh, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugarkar, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandodkar, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, V.</span></span> <span> </span><span class="NLM_article-title">Discovery of benzothiazoles as antimycobacterial agents: Synthesis, structure-activity relationships and binding studies with mycobacterium tuberculosis decaprenylphosphoryl-β-d-ribose 2′-oxidase</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">7694</span>– <span class="NLM_lpage">7710</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2015.11.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmc.2015.11.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=26643218" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFerur3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=7694-7710&author=S.+Landgeauthor=A.+B.+Mullickauthor=K.+Nagalapurauthor=J.+Neresauthor=V.+Subbulakshmiauthor=K.+Muruganauthor=A.+Ghoshauthor=C.+Sadlerauthor=M.+D.+Fellowsauthor=V.+Humnabadkarauthor=J.+Mahadevaswamyauthor=P.+Vachaspatiauthor=S.+Sharmaauthor=P.+Kaurauthor=M.+Mallyaauthor=S.+Rudrapatnaauthor=D.+Awasthyauthor=V.+K.+Sambandamurthyauthor=F.+Pojerauthor=S.+T.+Coleauthor=T.+S.+Balganeshauthor=B.+G.+Ugarkarauthor=V.+Balasubramanianauthor=B.+S.+Bandodkarauthor=M.+Pandaauthor=V.+Ramachandran&title=Discovery+of+benzothiazoles+as+antimycobacterial+agents%3A+Synthesis%2C+structure-activity+relationships+and+binding+studies+with+mycobacterium+tuberculosis+decaprenylphosphoryl-%CE%B2-d-ribose+2%E2%80%B2-oxidase&doi=10.1016%2Fj.bmc.2015.11.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of benzothiazoles as antimycobacterial agents: Synthesis, structure-activity relationships and binding studies with Mycobacterium tuberculosis decaprenylphosphoryl-β-D-ribose 2'-oxidase</span></div><div class="casAuthors">Landge, Sudhir; Mullick, Amrita B.; Nagalapur, Kavitha; Neres, Joao; Subbulakshmi, Venkita; Murugan, Kannan; Ghosh, Anirban; Sadler, Claire; Fellows, Mick D.; Humnabadkar, Vaishali; Mahadevaswamy, Jyothi; Vachaspati, Prakash; Sharma, Sreevalli; Kaur, Parvinder; Mallya, Meenakshi; Rudrapatna, Suresh; Awasthy, Disha; Sambandamurthy, Vasan K.; Pojer, Florence; Cole, Stewart T.; Balganesh, Tanjore S.; Ugarkar, Bheemarao G.; Balasubramanian, V.; Bandodkar, Balachandra S.; Panda, Manoranjan; Ramachandran, Vasanthi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7694-7710</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We report the discovery of benzothiazoles, a novel anti-mycobacterial series, identified from a whole cell based screening campaign.  Benzothiazoles exert their bactericidal activity against Mycobacterium tuberculosis (Mtb) through potent inhibition of decaprenylphosphoryl-β-D-ribose 2'-oxidase (DprE1), the key enzyme involved in arabinogalactan synthesis.  Specific target linkage and mode of binding were established using co-crystn. and protein mass spectrometry studies.  Most importantly, the current study provides insights on the utilization of systematic medicinal chem. approaches to mitigate safety liabilities while improving potency during progression from an initial genotoxic hit, the benzothiazole N-oxides (BTOs) to the lead-like AMES neg., crowded benzothiazoles (cBTs).  These findings offer opportunities for development of safe clin. candidates against tuberculosis.  The design strategy adopted could find potential application in discovery of safe drugs in other therapy areas too.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS7rEts75x7bVg90H21EOLACvtfcHk0ljFJMgcMGwXiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFerur3E&md5=cea6212afa6aee18530c45717f98b5c6</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.11.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.11.017%26sid%3Dliteratum%253Aachs%26aulast%3DLandge%26aufirst%3DS.%26aulast%3DMullick%26aufirst%3DA.%2BB.%26aulast%3DNagalapur%26aufirst%3DK.%26aulast%3DNeres%26aufirst%3DJ.%26aulast%3DSubbulakshmi%26aufirst%3DV.%26aulast%3DMurugan%26aufirst%3DK.%26aulast%3DGhosh%26aufirst%3DA.%26aulast%3DSadler%26aufirst%3DC.%26aulast%3DFellows%26aufirst%3DM.%2BD.%26aulast%3DHumnabadkar%26aufirst%3DV.%26aulast%3DMahadevaswamy%26aufirst%3DJ.%26aulast%3DVachaspati%26aufirst%3DP.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DKaur%26aufirst%3DP.%26aulast%3DMallya%26aufirst%3DM.%26aulast%3DRudrapatna%26aufirst%3DS.%26aulast%3DAwasthy%26aufirst%3DD.%26aulast%3DSambandamurthy%26aufirst%3DV.%2BK.%26aulast%3DPojer%26aufirst%3DF.%26aulast%3DCole%26aufirst%3DS.%2BT.%26aulast%3DBalganesh%26aufirst%3DT.%2BS.%26aulast%3DUgarkar%26aufirst%3DB.%2BG.%26aulast%3DBalasubramanian%26aufirst%3DV.%26aulast%3DBandodkar%26aufirst%3DB.%2BS.%26aulast%3DPanda%26aufirst%3DM.%26aulast%3DRamachandran%26aufirst%3DV.%26atitle%3DDiscovery%2520of%2520benzothiazoles%2520as%2520antimycobacterial%2520agents%253A%2520Synthesis%252C%2520structure-activity%2520relationships%2520and%2520binding%2520studies%2520with%2520mycobacterium%2520tuberculosis%2520decaprenylphosphoryl-%25CE%25B2-d-ribose%25202%25E2%2580%25B2-oxidase%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D7694%26epage%3D7710%26doi%3D10.1016%2Fj.bmc.2015.11.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mahajan, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhawale, S. C.</span></span> <span> </span><span class="NLM_article-title">Linked pyridinyl-thiadiazoles: Design and synthesis as potential candidate for treatment of xdr and mdr tuberculosis</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">243</span>– <span class="NLM_lpage">248</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.07.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.ejmech.2015.07.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=26280920" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlCitr%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2015&pages=243-248&author=N.+S.+Mahajanauthor=S.+C.+Dhawale&title=Linked+pyridinyl-thiadiazoles%3A+Design+and+synthesis+as+potential+candidate+for+treatment+of+xdr+and+mdr+tuberculosis&doi=10.1016%2Fj.ejmech.2015.07.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Linked pyridinyl-thiadiazoles: Design and synthesis as potential candidate for treatment of XDR and MDR tuberculosis</span></div><div class="casAuthors">Mahajan, Niranjan S.; Dhawale, S. C.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">243-248</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Design and synthesis of linked pyridinyl-thiadiazoles I (Ar = C6H5, CH2C6H5, 2-ClC6H4, etc.) and II which are specifically potent against several strains and isolates of TB is reported.  The hit compd. II (Ar = 4-ClC6H4) has also proved to be active against almost 25 clin. isolates comparable to marketed anti-TB agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGor7M-8k2TOCbVg90H21EOLACvtfcHk0ljFJMgcMGwXiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlCitr%252FI&md5=b1ad7c926e1aec3d88066a306f56cfa1</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.07.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.07.039%26sid%3Dliteratum%253Aachs%26aulast%3DMahajan%26aufirst%3DN.%2BS.%26aulast%3DDhawale%26aufirst%3DS.%2BC.%26atitle%3DLinked%2520pyridinyl-thiadiazoles%253A%2520Design%2520and%2520synthesis%2520as%2520potential%2520candidate%2520for%2520treatment%2520of%2520xdr%2520and%2520mdr%2520tuberculosis%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D102%26spage%3D243%26epage%3D248%26doi%3D10.1016%2Fj.ejmech.2015.07.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoener zu
Bentrup, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKinney, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacchettini, J. C.</span></span> <span> </span><span class="NLM_article-title">Structure of isocitrate lyase, a persistence factor of mycobacterium tuberculosis</span>. <i>Nat. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">663</span>– <span class="NLM_lpage">668</span>, <span class="refDoi"> DOI: 10.1038/77964</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1038%2F77964" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10932251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD3cXls1yqtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2000&pages=663-668&author=V.+Sharmaauthor=S.+Sharmaauthor=K.+Hoener+zu%0ABentrupauthor=J.+D.+McKinneyauthor=D.+G.+Russellauthor=W.+R.+Jacobsauthor=J.+C.+Sacchettini&title=Structure+of+isocitrate+lyase%2C+a+persistence+factor+of+mycobacterium+tuberculosis&doi=10.1038%2F77964"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of isocitrate lyase, a persistence factor of Mycobacterium tuberculosis</span></div><div class="casAuthors">Sharma, Vivek; Sharma, Sujata; Hoener zu Bentrup, Kerstin; McKinney, John D.; Russell, David G.; Jacobs, William R., Jr.; Sacchettini, James C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural Biology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">663-668</span>CODEN:
                <span class="NLM_cas:coden">NSBIEW</span>;
        ISSN:<span class="NLM_cas:issn">1072-8368</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">Isocitrate lyase (I) plays a pivotal role in the persistence of M. tuberculosis in mice by sustaining intracellular infection in inflammatory macrophages.  I allows net C gain by diverting acetyl-CoA from β-oxidn. of fatty acids into the glyoxylate shunt pathway.  Given its potential as a drug target against persistent infections, the authors solved its structure without ligands and in complex with 2 inhibitors, 3-bromopyruvate and 3-nitropropionate.  Covalent modification of an active site residue, Cys-191, by the inhibitor, 3-bromopyruvate, trapped the enzyme in a catalytic conformation with the active site completely inaccessible to solvent.  The structure of a C191S mutant of the enzyme with the inhibitor, 3-nitropropionate, provided further insight into the reaction mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9eCFXK4I3NrVg90H21EOLACvtfcHk0lh3xboGFpOWYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXls1yqtbg%253D&md5=9404e0c254b3247bcb2b3e0b4ca573fe</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1038%2F77964&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F77964%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DV.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DHoener%2Bzu%2BBentrup%26aufirst%3DK.%26aulast%3DMcKinney%26aufirst%3DJ.%2BD.%26aulast%3DRussell%26aufirst%3DD.%2BG.%26aulast%3DJacobs%26aufirst%3DW.%2BR.%26aulast%3DSacchettini%26aufirst%3DJ.%2BC.%26atitle%3DStructure%2520of%2520isocitrate%2520lyase%252C%2520a%2520persistence%2520factor%2520of%2520mycobacterium%2520tuberculosis%26jtitle%3DNat.%2520Struct.%2520Biol.%26date%3D2000%26volume%3D7%26spage%3D663%26epage%3D668%26doi%3D10.1038%2F77964" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Sullivan, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangadharam, P. R.</span></span> <span> </span><span class="NLM_article-title">Antimycobacterial activities of riminophenazines</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">615</span>– <span class="NLM_lpage">623</span>, <span class="refDoi"> DOI: 10.1093/jac/43.5.615</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1093%2Fjac%2F43.5.615" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10382882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADyaK1MXjsV2is7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=1999&pages=615-623&author=V.+M.+Reddyauthor=J.+F.+O%E2%80%99Sullivanauthor=P.+R.+Gangadharam&title=Antimycobacterial+activities+of+riminophenazines&doi=10.1093%2Fjac%2F43.5.615"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Antimycobacterial activities of riminophenazines</span></div><div class="casAuthors">Reddy, Venkata M.; O'Sullivan, John F.; Gangadharam, Pattisapu R. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">615-623</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review with 73 refs.  Riminophenazines were specifically developed as drugs active against Mycobacterium tuberculosis but extensive research over several decades has shown that these compds. are also active against many other mycobacterial infections, particularly those caused by Mycobacterium leprae and the Mycobacterium avium complex (MAC).  Clofazimine, the lead compd. in this series, is included in the regimens that are approved by the WHO for the treatment of leprosy and has contributed significantly to the control of that disease, particularly that caused by dapsone-resistant bacteria.  Despite early problems, clofazimine has shown clin. efficacy in tuberculosis, in particular that caused by multiple drug resistant strains.  Clofazimine does not induce resistance and also inhibits emergence of resistance to isoniazid in M. tuberculosis.  The efficacy of clofazimine against MAC is more varied and the availability of better drugs has limited its use.  Newer riminophenazines, such as B746 and B4157, not only showed increased anti-mycobacterial activity but also produced less skin pigmentation, which is the main drawback of this group of compds.  The most important virtues of riminophenazines, such as intracellular accumulation in mononuclear phagocytic cells, anti-inflammatory activity, a low incidence of drug resistance and slow metabolic elimination, make them attractive candidates for the treatment of mycobacterial infections.  It is essential, however, to investigate the newer analogs clin., while continuing the pursuit of alternate candidates that demonstrate higher anti-mycobacterial activity and lower rates of skin pigmentation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-TqcKj2elQ7Vg90H21EOLACvtfcHk0lh3xboGFpOWYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjsV2is7o%253D&md5=518c8ddbd4d717a3f8eb6da3e40245af</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1093%2Fjac%2F43.5.615&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252F43.5.615%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DV.%2BM.%26aulast%3DO%25E2%2580%2599Sullivan%26aufirst%3DJ.%2BF.%26aulast%3DGangadharam%26aufirst%3DP.%2BR.%26atitle%3DAntimycobacterial%2520activities%2520of%2520riminophenazines%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D1999%26volume%3D43%26spage%3D615%26epage%3D623%26doi%3D10.1093%2Fjac%2F43.5.615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arbiser, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moschella, S. L.</span></span> <span> </span><span class="NLM_article-title">Clofazimine: A review of its medical uses and mechanisms of action</span>. <i>J. Am. Acad. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">241</span>– <span class="NLM_lpage">247</span>, <span class="refDoi"> DOI: 10.1016/0190-9622(95)90134-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2F0190-9622%2895%2990134-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=7829710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A280%3ADyaK2M7jtVOrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1995&pages=241-247&author=J.+L.+Arbiserauthor=S.+L.+Moschella&title=Clofazimine%3A+A+review+of+its+medical+uses+and+mechanisms+of+action&doi=10.1016%2F0190-9622%2895%2990134-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Clofazimine: a review of its medical uses and mechanisms of action</span></div><div class="casAuthors">Arbiser J L; Moschella S L</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Academy of Dermatology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">2 Pt 1</span>),
    <span class="NLM_cas:pages">241-7</span>
        ISSN:<span class="NLM_cas:issn">0190-9622</span>.
    </div><div class="casAbstract">Clofazimine has been in clinical use for almost 40 years, but little is known of its mechanism of action.  The primary indication for clofazimine is multibacillary leprosy, but it is useful in several infectious and noninfectious diseases, such as typical myocobacterial infections, rhinoscleroma, pyoderma gangrenosum, necrobiosis lipoidica, severe acne, pustular psoriasis, and discoid lupus erythematosus.  Postulated mechanisms of action include intercalation of clofazimine with bacterial DNA and increasing levels of cellular phospholipase A2.  Clinical experience, possible mechanisms of action, and side effects of clofazimine are summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ_D4nBnsIGjHtlzo9xastyfW6udTcc2eZtd9lrNFFOibntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2M7jtVOrsA%253D%253D&md5=797e62c41ab2db6eb93b4979c5ee0919</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1016%2F0190-9622%2895%2990134-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0190-9622%252895%252990134-5%26sid%3Dliteratum%253Aachs%26aulast%3DArbiser%26aufirst%3DJ.%2BL.%26aulast%3DMoschella%26aufirst%3DS.%2BL.%26atitle%3DClofazimine%253A%2520A%2520review%2520of%2520its%2520medical%2520uses%2520and%2520mechanisms%2520of%2520action%26jtitle%3DJ.%2520Am.%2520Acad.%2520Dermatol.%26date%3D1995%26volume%3D32%26spage%3D241%26epage%3D247%26doi%3D10.1016%2F0190-9622%2895%2990134-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marley, G. M.</span></span> <span> </span><span class="NLM_article-title">The mode of action of clofazimine DNA binding studies</span>. <i>Int. J. Lepr. Other Mycobact. Dis.</i> <span class="NLM_year" style="font-weight: bold;">1976</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">134</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=945233" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A280%3ADyaE283ht1ertg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=1976&pages=133-134&author=N.+E.+Morrisonauthor=G.+M.+Marley&title=The+mode+of+action+of+clofazimine+DNA+binding+studies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">The mode of action of clofazimine DNA binding studies</span></div><div class="casAuthors">Morrison N E; Marley G M</div><div class="citationInfo"><span class="NLM_cas:title">International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association</span>
        (<span class="NLM_cas:date">1976</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">133-4</span>
        ISSN:<span class="NLM_cas:issn">0148-916X</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRqUJxcgluj_4NpW7w2tapOfW6udTcc2eZtd9lrNFFOibntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE283ht1ertg%253D%253D&md5=a697238eb114b18e1666c95658376694</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMorrison%26aufirst%3DN.%2BE.%26aulast%3DMarley%26aufirst%3DG.%2BM.%26atitle%3DThe%2520mode%2520of%2520action%2520of%2520clofazimine%2520DNA%2520binding%2520studies%26jtitle%3DInt.%2520J.%2520Lepr.%2520Other%2520Mycobact.%2520Dis.%26date%3D1976%26volume%3D44%26spage%3D133%26epage%3D134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nair, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okello, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangu, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gund, M. G.</span></span> <span> </span><span class="NLM_article-title">A novel molecule with notable activity against multi-drug resistant tuberculosis</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1269</span>– <span class="NLM_lpage">1273</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.01.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmcl.2015.01.050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=25677656" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslSnurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=1269-1273&author=V.+Nairauthor=M.+O.+Okelloauthor=N.+K.+Manguauthor=B.+I.+Seoauthor=M.+G.+Gund&title=A+novel+molecule+with+notable+activity+against+multi-drug+resistant+tuberculosis&doi=10.1016%2Fj.bmcl.2015.01.050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">A novel molecule with notable activity against multi-drug resistant tuberculosis</span></div><div class="casAuthors">Nair, Vasu; Okello, Maurice O.; Mangu, Naveen K.; Seo, Byung I.; Gund, Machhindra G.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1269-1273</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Multi-drug resistant tuberculosis (MDR-TB) is emerging as a serious global health problem, which has been elevated through co-infection involving HIV and MDR-Mtb.  The discovery of new compds. with anti-MDR TB efficacy and favorable metab. profiles is an important scientific challenge.  Using computational biol. and ligand docking data, we have conceived a multifunctional mol., 2, as a potential anti-MDR TB agent.  This compd. was produced through a multi-step synthesis.  It exhibited significant in vitro activity against MDR-TB (MIC 1.56 μg/mL) and its half-life (t1/2) in human liver microsomes was 14.4 h.  The metabolic profiles of compd. 2 with respect to human cytochrome P 450 (CYP) and uridine 5'-diphospho-glucuronosyltransferase (UGT) isoenzymes were favorable.  Compd. 2 also had relatively low in vitro cytotoxicity in uninfected macrophages.  It displayed synergistic behavior against MDR-TB in combination with PA-824.  Interestingly, compd. 2 also displayed in vitro anti-HIV activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEX8rZ7_17v7Vg90H21EOLACvtfcHk0ljgQOA9o5FocA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslSnurY%253D&md5=de6e679bf3e1e668ff33b61d459922db</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.01.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.01.050%26sid%3Dliteratum%253Aachs%26aulast%3DNair%26aufirst%3DV.%26aulast%3DOkello%26aufirst%3DM.%2BO.%26aulast%3DMangu%26aufirst%3DN.%2BK.%26aulast%3DSeo%26aufirst%3DB.%2BI.%26aulast%3DGund%26aufirst%3DM.%2BG.%26atitle%3DA%2520novel%2520molecule%2520with%2520notable%2520activity%2520against%2520multi-drug%2520resistant%2520tuberculosis%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D1269%26epage%3D1273%26doi%3D10.1016%2Fj.bmcl.2015.01.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van der Westhuyzen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winks, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyle, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gessner, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soares de Melo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Kock, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njoroge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunschwig, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirgel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Helden, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seldon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moosa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arista, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manjunatha, U. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Street, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chibale, K.</span></span> <span> </span><span class="NLM_article-title">Pyrrolo[3,4-c]pyridine-1,3(2h)-diones: A novel antimycobacterial class targeting mycobacterial respiration</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">9371</span>– <span class="NLM_lpage">9381</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01542</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01542" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslykurbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=9371-9381&author=R.+van+der+Westhuyzenauthor=S.+Winksauthor=C.+R.+Wilsonauthor=G.+A.+Boyleauthor=R.+K.+Gessnerauthor=C.+Soares+de+Meloauthor=D.+Taylorauthor=C.+de+Kockauthor=M.+Njorogeauthor=C.+Brunschwigauthor=N.+Lawrenceauthor=S.+P.+Raoauthor=F.+Sirgelauthor=P.+van+Heldenauthor=R.+Seldonauthor=A.+Moosaauthor=D.+F.+Warnerauthor=L.+Aristaauthor=U.+H.+Manjunathaauthor=P.+W.+Smithauthor=L.+J.+Streetauthor=K.+Chibale&title=Pyrrolo%5B3%2C4-c%5Dpyridine-1%2C3%282h%29-diones%3A+A+novel+antimycobacterial+class+targeting+mycobacterial+respiration&doi=10.1021%2Facs.jmedchem.5b01542"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrrolo[3,4-c]pyridine-1,3(2H)-diones: A Novel Antimycobacterial Class Targeting Mycobacterial Respiration</span></div><div class="casAuthors">van der Westhuyzen, Renier; Winks, Susan; Wilson, Colin R.; Boyle, Grant A.; Gessner, Richard K.; Soares de Melo, Candice; Taylor, Dale; de Kock, Carmen; Njoroge, Mathew; Brunschwig, Christel; Lawrence, Nina; Rao, Srinivasa P. S.; Sirgel, Frederick; van Helden, Paul; Seldon, Ronnett; Moosa, Atica; Warner, Digby F.; Arista, Luca; Manjunatha, Ujjini H.; Smith, Paul W.; Street, Leslie J.; Chibale, Kelly</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9371-9381</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">High-throughput screening of a library of small polar mols. against Mycobacterium tuberculosis led to the identification of a phthalimide-contg. ester hit compd. I, which was optimized for metabolic stability by replacing the ester moiety with a Me oxadiazole bioisostere.  A route utilizing polymer-supported reagents was designed and executed to explore structure-activity relationships with respect to the N-benzyl substituent, leading to compds. with nanomolar activity.  The front runner compd. II from these studies was well tolerated in mice.  A M. tuberculosis cytochrome bd oxidase deletion mutant (ΔcydKO) was hyper-susceptible to compds. from this series, and a strain carrying a single point mutation in qcrB, the gene encoding a subunit of the menaquinol cytochrome c oxidoreductase, was resistant to compds. in this series.  In combination, these observations indicate that this novel class of antimycobacterial compds. inhibits the cytochrome bc1 complex, a validated drug target in M. tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3Us_9IMcDi7Vg90H21EOLACvtfcHk0lj1PKmGxMfqRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslykurbO&md5=f4f32ca20ad5a8095be6bbf8dac5830a</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01542%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2Bder%2BWesthuyzen%26aufirst%3DR.%26aulast%3DWinks%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DC.%2BR.%26aulast%3DBoyle%26aufirst%3DG.%2BA.%26aulast%3DGessner%26aufirst%3DR.%2BK.%26aulast%3DSoares%2Bde%2BMelo%26aufirst%3DC.%26aulast%3DTaylor%26aufirst%3DD.%26aulast%3Dde%2BKock%26aufirst%3DC.%26aulast%3DNjoroge%26aufirst%3DM.%26aulast%3DBrunschwig%26aufirst%3DC.%26aulast%3DLawrence%26aufirst%3DN.%26aulast%3DRao%26aufirst%3DS.%2BP.%26aulast%3DSirgel%26aufirst%3DF.%26aulast%3Dvan%2BHelden%26aufirst%3DP.%26aulast%3DSeldon%26aufirst%3DR.%26aulast%3DMoosa%26aufirst%3DA.%26aulast%3DWarner%26aufirst%3DD.%2BF.%26aulast%3DArista%26aufirst%3DL.%26aulast%3DManjunatha%26aufirst%3DU.%2BH.%26aulast%3DSmith%26aufirst%3DP.%2BW.%26aulast%3DStreet%26aufirst%3DL.%2BJ.%26aulast%3DChibale%26aufirst%3DK.%26atitle%3DPyrrolo%255B3%252C4-c%255Dpyridine-1%252C3%25282h%2529-diones%253A%2520A%2520novel%2520antimycobacterial%2520class%2520targeting%2520mycobacterial%2520respiration%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D9371%26epage%3D9381%26doi%3D10.1021%2Facs.jmedchem.5b01542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pissinate, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villela, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues-Junior, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giacobbo, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grams, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbadi, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trindade, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roesler Nery, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonan, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Back, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campos, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basso, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machado, P.</span></span> <span> </span><span class="NLM_article-title">2-(quinolin-4-yloxy)acetamides are active against drug-susceptible and drug-resistant mycobacterium tuberculosis strains</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">239</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00324</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00324" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28Xmslersg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=235-239&author=K.+Pissinateauthor=A.+D.+Villelaauthor=V.+Rodrigues-Juniorauthor=B.+C.+Giacobboauthor=E.+S.+Gramsauthor=B.+L.+Abbadiauthor=R.+V.+Trindadeauthor=L.+Roesler+Neryauthor=C.+D.+Bonanauthor=D.+F.+Backauthor=M.+M.+Camposauthor=L.+A.+Bassoauthor=D.+S.+Santosauthor=P.+Machado&title=2-%28quinolin-4-yloxy%29acetamides+are+active+against+drug-susceptible+and+drug-resistant+mycobacterium+tuberculosis+strains&doi=10.1021%2Facsmedchemlett.5b00324"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">2-(Quinolin-4-yloxy)acetamides Are Active against Drug-Susceptible and Drug-Resistant Mycobacterium tuberculosis Strains</span></div><div class="casAuthors">Pissinate, Kenia; Villela, Anne Drumond; Rodrigues-Junior, Valnes; Giacobbo, Bruno Couto; Grams, Estevao Silveira; Abbadi, Bruno Lopes; Trindade, Rogerio Valim; Roesler Nery, Laura; Bonan, Carla Denise; Back, Davi Fernando; Campos, Maria Martha; Basso, Luiz Augusto; Santos, Diogenes Santiago; Machado, Pablo</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">235-239</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">2-(Quinolin-4-yloxy)acetamides have been described as potent in vitro inhibitors of Mycobacterium tuberculosis growth.  Herein, addnl. chem. modifications of lead compds. were carried out, yielding highly potent antitubercular agents I [R1 = H, MeO; R2 = Ph, Bn, 1-naphthyl, etc.] with min. inhibitory concn. (MIC) values as low as 0.05 μM.  Further, the synthesized compds. were active against drug-resistant strains and were devoid of apparent toxicity to Vero and HaCat cells (IC50s ≥ 20 μM).  In addn., the 2-(quinolin-4-yloxy)acetamides showed intracellular activity against the bacilli in infected macrophages with action similar to rifampin, low risk of drug-drug interactions, and no sign of cardiac toxicity in zebrafish (Danio rerio) at 1 and 5 μM.  Therefore, these data indicate that this class of compds. may furnish candidates for future development to, hopefully, provide drug alternatives for tuberculosis treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlDUeT5b7fVrVg90H21EOLACvtfcHk0lhUlqcxIrykxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xmslersg%253D%253D&md5=c2c4ff3de3ecc4fc49449b769707bfd7</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00324%26sid%3Dliteratum%253Aachs%26aulast%3DPissinate%26aufirst%3DK.%26aulast%3DVillela%26aufirst%3DA.%2BD.%26aulast%3DRodrigues-Junior%26aufirst%3DV.%26aulast%3DGiacobbo%26aufirst%3DB.%2BC.%26aulast%3DGrams%26aufirst%3DE.%2BS.%26aulast%3DAbbadi%26aufirst%3DB.%2BL.%26aulast%3DTrindade%26aufirst%3DR.%2BV.%26aulast%3DRoesler%2BNery%26aufirst%3DL.%26aulast%3DBonan%26aufirst%3DC.%2BD.%26aulast%3DBack%26aufirst%3DD.%2BF.%26aulast%3DCampos%26aufirst%3DM.%2BM.%26aulast%3DBasso%26aufirst%3DL.%2BA.%26aulast%3DSantos%26aufirst%3DD.%2BS.%26aulast%3DMachado%26aufirst%3DP.%26atitle%3D2-%2528quinolin-4-yloxy%2529acetamides%2520are%2520active%2520against%2520drug-susceptible%2520and%2520drug-resistant%2520mycobacterium%2520tuberculosis%2520strains%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D235%26epage%3D239%26doi%3D10.1021%2Facsmedchemlett.5b00324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giacobbo, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pissinate, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues-Junior, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villela, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grams, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbadi, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subtil, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperotto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trindade, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Back, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campos, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basso, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machado, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, D. S.</span></span> <span> </span><span class="NLM_article-title">New insights into the sar and drug combination synergy of 2-(quinolin-4-yloxy)acetamides against mycobacterium tuberculosis</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">491</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.11.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.ejmech.2016.11.048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=27914363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFymu7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2017&pages=491-501&author=B.+C.+Giacobboauthor=K.+Pissinateauthor=V.+Rodrigues-Juniorauthor=A.+D.+Villelaauthor=E.+S.+Gramsauthor=B.+L.+Abbadiauthor=F.+T.+Subtilauthor=N.+Sperottoauthor=R.+V.+Trindadeauthor=D.+F.+Backauthor=M.+M.+Camposauthor=L.+A.+Bassoauthor=P.+Machadoauthor=D.+S.+Santos&title=New+insights+into+the+sar+and+drug+combination+synergy+of+2-%28quinolin-4-yloxy%29acetamides+against+mycobacterium+tuberculosis&doi=10.1016%2Fj.ejmech.2016.11.048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">New insights into the SAR and drug combination synergy of 2-(quinolin-4-yloxy)acetamides against Mycobacterium tuberculosis</span></div><div class="casAuthors">Giacobbo, Bruno Couto; Pissinate, Kenia; Rodrigues-Junior, Valnes; Villela, Anne Drumond; Grams, Estevao Silveira; Abbadi, Bruno Lopes; Subtil, Fernanda Teixeira; Sperotto, Nathalia; Trindade, Rogerio Valim; Back, Davi Fernando; Campos, Maria Martha; Basso, Luiz Augusto; Machado, Pablo; Santos, Diogenes Santiago</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">491-501</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">2-(Quinolin-4-yloxy)acetamides have been described as potent and selective in vitro inhibitors of Mycobacterium tuberculosis (Mtb) growth.  Herein, a new series of optimized compds. were found to demonstrate highly potent antitubercular activity, with min. inhibitory concn. (MIC) values against drug-susceptible and drug-resistant Mycobacterium tuberculosis strains in the submicromolar range.  Furthermore, the most active compds. had no apparent toxicity to mammalian cells, and they showed intracellular activities similar to those of isoniazid and rifampin in a macrophage model of Mtb infection.  Use of the checkerboard method to investigate the assocn. profiles of lead compds. with first- and second-line antituberculosis drugs showed that 2-(quinolin-4-yloxy)acetamides have a synergistic effect with rifampin.  Ultimately, the good permeability, moderate rates of metab. and low risk of drug-drug interactions displayed by some of the synthesized compds. indicate that 2-(quinolin-4-yloxy)acetamides may yield candidates to use in the development of novel alternative therapeutics for tuberculosis treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQ1LRu8KJr37Vg90H21EOLACvtfcHk0lhUlqcxIrykxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFymu7rL&md5=fd8b8186ded825b2158940a08959da6a</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.11.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.11.048%26sid%3Dliteratum%253Aachs%26aulast%3DGiacobbo%26aufirst%3DB.%2BC.%26aulast%3DPissinate%26aufirst%3DK.%26aulast%3DRodrigues-Junior%26aufirst%3DV.%26aulast%3DVillela%26aufirst%3DA.%2BD.%26aulast%3DGrams%26aufirst%3DE.%2BS.%26aulast%3DAbbadi%26aufirst%3DB.%2BL.%26aulast%3DSubtil%26aufirst%3DF.%2BT.%26aulast%3DSperotto%26aufirst%3DN.%26aulast%3DTrindade%26aufirst%3DR.%2BV.%26aulast%3DBack%26aufirst%3DD.%2BF.%26aulast%3DCampos%26aufirst%3DM.%2BM.%26aulast%3DBasso%26aufirst%3DL.%2BA.%26aulast%3DMachado%26aufirst%3DP.%26aulast%3DSantos%26aufirst%3DD.%2BS.%26atitle%3DNew%2520insights%2520into%2520the%2520sar%2520and%2520drug%2520combination%2520synergy%2520of%25202-%2528quinolin-4-yloxy%2529acetamides%2520against%2520mycobacterium%2520tuberculosis%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D126%26spage%3D491%26epage%3D501%26doi%3D10.1016%2Fj.ejmech.2016.11.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Phummarin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boshoff, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiles, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copp, B. R.</span></span> <span> </span><span class="NLM_article-title">Sar and identification of 2-(quinolin-4-yloxy)acetamides as Mycobacterium tuberculosis cytochrome bc1 inhibitors</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">2122</span>– <span class="NLM_lpage">2127</span>, <span class="refDoi"> DOI: 10.1039/C6MD00236F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1039%2FC6MD00236F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=28337336" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlyks7zM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=2122-2127&author=N.+Phummarinauthor=H.+I.+Boshoffauthor=P.+S.+Tsangauthor=J.+Daltonauthor=S.+Wilesauthor=C.+E.+Barryauthor=B.+R.+Copp&title=Sar+and+identification+of+2-%28quinolin-4-yloxy%29acetamides+as+Mycobacterium+tuberculosis+cytochrome+bc1+inhibitors&doi=10.1039%2FC6MD00236F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">SAR and identification of 2-(quinolin-4-yloxy)acetamides as Mycobacterium tuberculosis cytochrome bc1 inhibitors</span></div><div class="casAuthors">Phummarin, Narisa; Boshoff, Helena I.; Tsang, Patricia S.; Dalton, James; Wiles, Siouxsie; Barry 3rd, Clifton E.; Copp, Brent R.</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2122-2127</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A previous phenotypic screen by GSK identified 2-(quinolin-4-yloxy)acetamides as potent growth inhibitors of Mycobacterium tuberculosis (Mtb).  We report the results of a preliminary structure-activity relationship (SAR) study of the compd. class which has yielded more potent inhibitors.  An Mtb cytochrome bd oxidase deletion mutant (cydKO) was found to be hypersensitive to most members of the compd. library, while strains carrying single-nucleotide polymorphisms of the qcrB gene, which encodes a subunit of the menaquinol cytochrome c oxidoreductase (bc1) complex, were resistant to the library.  These results identify that the 2-(quinolin-4-yloxy)acetamide class of Mtb growth inhibitors can be added to the growing no. of scaffolds that target the M. tuberculosis bc1 complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5mJG3TCn8TLVg90H21EOLACvtfcHk0lhUlqcxIrykxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlyks7zM&md5=410c379517a035079e01dafd2bbcf744</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1039%2FC6MD00236F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6MD00236F%26sid%3Dliteratum%253Aachs%26aulast%3DPhummarin%26aufirst%3DN.%26aulast%3DBoshoff%26aufirst%3DH.%2BI.%26aulast%3DTsang%26aufirst%3DP.%2BS.%26aulast%3DDalton%26aufirst%3DJ.%26aulast%3DWiles%26aufirst%3DS.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26aulast%3DCopp%26aufirst%3DB.%2BR.%26atitle%3DSar%2520and%2520identification%2520of%25202-%2528quinolin-4-yloxy%2529acetamides%2520as%2520Mycobacterium%2520tuberculosis%2520cytochrome%2520bc1%2520inhibitors%26jtitle%3DMedChemComm%26date%3D2016%26volume%3D7%26spage%3D2122%26epage%3D2127%26doi%3D10.1039%2FC6MD00236F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humnabadkar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tantry, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guptha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panduga, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manjrekar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jena, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koushik, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shanbhag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jatheendranath, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manjunatha, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorai, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bathula, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudrapatna, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Achar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambady, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegde, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahadevaswamy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sambandamurthy, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awasthy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravishankar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madhavapeddi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prabhakar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saralaya, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterji, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiteaker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarelli, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riccardi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasca, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binda, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neres, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Signorino-Gelo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKinney, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shandil, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tommasi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosagrahara, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavanagh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinesh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghorpade, S. R.</span></span> <span> </span><span class="NLM_article-title">4-aminoquinolone piperidine amides: Noncovalent inhibitors of DprE1 with long residence time and potent antimycobacterial activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5419</span>– <span class="NLM_lpage">5434</span>, <span class="refDoi"> DOI: 10.1021/jm5005978</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5005978" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2cXos1Wqt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5419-5434&author=M.+Naikauthor=V.+Humnabadkarauthor=S.+J.+Tantryauthor=M.+Pandaauthor=A.+Narayanauthor=S.+Gupthaauthor=V.+Pandugaauthor=P.+Manjrekarauthor=L.+K.+Jenaauthor=K.+Koushikauthor=G.+Shanbhagauthor=S.+Jatheendranathauthor=M.+R.+Manjunathaauthor=G.+Goraiauthor=C.+Bathulaauthor=S.+Rudrapatnaauthor=V.+Acharauthor=S.+Sharmaauthor=A.+Ambadyauthor=N.+Hegdeauthor=J.+Mahadevaswamyauthor=P.+Kaurauthor=V.+K.+Sambandamurthyauthor=D.+Awasthyauthor=C.+Narayanauthor=S.+Ravishankarauthor=P.+Madhavapeddiauthor=J.+Reddyauthor=K.+Prabhakarauthor=R.+Saralayaauthor=M.+Chatterjiauthor=J.+Whiteakerauthor=B.+McLaughlinauthor=L.+R.+Chiarelliauthor=G.+Riccardiauthor=M.+R.+Pascaauthor=C.+Bindaauthor=J.+Neresauthor=N.+Dharauthor=F.+Signorino-Geloauthor=J.+D.+McKinneyauthor=V.+Ramachandranauthor=R.+Shandilauthor=R.+Tommasiauthor=P.+S.+Iyerauthor=S.+Narayananauthor=V.+Hosagraharaauthor=S.+Kavanaghauthor=N.+Dineshauthor=S.+R.+Ghorpade&title=4-aminoquinolone+piperidine+amides%3A+Noncovalent+inhibitors+of+DprE1+with+long+residence+time+and+potent+antimycobacterial+activity&doi=10.1021%2Fjm5005978"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">4-Aminoquinolone Piperidine Amides: Noncovalent Inhibitors of DprE1 with Long Residence Time and Potent Antimycobacterial Activity</span></div><div class="casAuthors">Naik, Maruti; Humnabadkar, Vaishali; Tantry, Subramanyam J.; Panda, Manoranjan; Narayan, Ashwini; Guptha, Supreeth; Panduga, Vijender; Manjrekar, Praveena; Jena, Lalit kumar; Koushik, Krishna; Shanbhag, Gajanan; Jatheendranath, Sandesh; Manjunatha, M. R.; Gorai, Gopinath; Bathula, Chandramohan; Rudrapatna, Suresh; Achar, Vijayashree; Sharma, Sreevalli; Ambady, Anisha; Hegde, Naina; Mahadevaswamy, Jyothi; Kaur, Parvinder; Sambandamurthy, Vasan K.; Awasthy, Disha; Narayan, Chandan; Ravishankar, Sudha; Madhavapeddi, Prashanti; Reddy, Jitendar; Prabhakar, K. R.; Saralaya, Ramanatha; Chatterji, Monalisa; Whiteaker, James; McLaughlin, Bob; Chiarelli, Laurent R.; Riccardi, Giovanna; Pasca, Maria Rosalia; Binda, Claudia; Neres, Joao; Dhar, Neeraj; Signorino-Gelo, Francois; McKinney, John D.; Ramachandran, Vasanthi; Shandil, Radha; Tommasi, Ruben; Iyer, Pravin S.; Narayanan, Shridhar; Hosagrahara, Vinayak; Kavanagh, Stefan; Dinesh, Neela; Ghorpade, Sandeep R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5419-5434</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">4-Aminoquinolone piperidine amides (AQs) were identified as a novel scaffold starting from a whole cell screen, with potent cidality on Mycobacterium tuberculosis (Mtb).  Evaluation of the min. inhibitory concns., followed by whole genome sequencing of mutants raised against AQs, identified decaprenylphosphoryl-β-D-ribose 2'-epimerase (DprE1) as the primary target responsible for the antitubercular activity.  Mass spectrometry and enzyme kinetic studies indicated that AQs are noncovalent, reversible inhibitors of DprE1 with slow on rates and long residence times of ∼100 min on the enzyme.  In general, AQs have excellent leadlike properties and good in vitro secondary pharmacol. profile.  Although the scaffold started off as a single active compd. with moderate potency from the whole cell screen, structure-activity relationship optimization of the scaffold led to compds. with potent DprE1 inhibition (IC50 < 10 nM) along with potent cellular activity (MIC = 60 nM) against Mtb.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo427Eycvs4I7Vg90H21EOLACvtfcHk0ljA1R_9UKGZlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXos1Wqt7g%253D&md5=05e9a7f75679397a124088023762fe20</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1021%2Fjm5005978&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5005978%26sid%3Dliteratum%253Aachs%26aulast%3DNaik%26aufirst%3DM.%26aulast%3DHumnabadkar%26aufirst%3DV.%26aulast%3DTantry%26aufirst%3DS.%2BJ.%26aulast%3DPanda%26aufirst%3DM.%26aulast%3DNarayan%26aufirst%3DA.%26aulast%3DGuptha%26aufirst%3DS.%26aulast%3DPanduga%26aufirst%3DV.%26aulast%3DManjrekar%26aufirst%3DP.%26aulast%3DJena%26aufirst%3DL.%2BK.%26aulast%3DKoushik%26aufirst%3DK.%26aulast%3DShanbhag%26aufirst%3DG.%26aulast%3DJatheendranath%26aufirst%3DS.%26aulast%3DManjunatha%26aufirst%3DM.%2BR.%26aulast%3DGorai%26aufirst%3DG.%26aulast%3DBathula%26aufirst%3DC.%26aulast%3DRudrapatna%26aufirst%3DS.%26aulast%3DAchar%26aufirst%3DV.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DAmbady%26aufirst%3DA.%26aulast%3DHegde%26aufirst%3DN.%26aulast%3DMahadevaswamy%26aufirst%3DJ.%26aulast%3DKaur%26aufirst%3DP.%26aulast%3DSambandamurthy%26aufirst%3DV.%2BK.%26aulast%3DAwasthy%26aufirst%3DD.%26aulast%3DNarayan%26aufirst%3DC.%26aulast%3DRavishankar%26aufirst%3DS.%26aulast%3DMadhavapeddi%26aufirst%3DP.%26aulast%3DReddy%26aufirst%3DJ.%26aulast%3DPrabhakar%26aufirst%3DK.%26aulast%3DSaralaya%26aufirst%3DR.%26aulast%3DChatterji%26aufirst%3DM.%26aulast%3DWhiteaker%26aufirst%3DJ.%26aulast%3DMcLaughlin%26aufirst%3DB.%26aulast%3DChiarelli%26aufirst%3DL.%2BR.%26aulast%3DRiccardi%26aufirst%3DG.%26aulast%3DPasca%26aufirst%3DM.%2BR.%26aulast%3DBinda%26aufirst%3DC.%26aulast%3DNeres%26aufirst%3DJ.%26aulast%3DDhar%26aufirst%3DN.%26aulast%3DSignorino-Gelo%26aufirst%3DF.%26aulast%3DMcKinney%26aufirst%3DJ.%2BD.%26aulast%3DRamachandran%26aufirst%3DV.%26aulast%3DShandil%26aufirst%3DR.%26aulast%3DTommasi%26aufirst%3DR.%26aulast%3DIyer%26aufirst%3DP.%2BS.%26aulast%3DNarayanan%26aufirst%3DS.%26aulast%3DHosagrahara%26aufirst%3DV.%26aulast%3DKavanagh%26aufirst%3DS.%26aulast%3DDinesh%26aufirst%3DN.%26aulast%3DGhorpade%26aufirst%3DS.%2BR.%26atitle%3D4-aminoquinolone%2520piperidine%2520amides%253A%2520Noncovalent%2520inhibitors%2520of%2520DprE1%2520with%2520long%2520residence%2520time%2520and%2520potent%2520antimycobacterial%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5419%26epage%3D5434%26doi%3D10.1021%2Fjm5005978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Read, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braendvang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miranda, P. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gundersen, L. L.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of pyrimidine analogs of antimycobacterial purines</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">3885</span>– <span class="NLM_lpage">3897</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2010.04.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmc.2010.04.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=20488716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmslOis78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=3885-3897&author=M.+L.+Readauthor=M.+Braendvangauthor=P.+O.+Mirandaauthor=L.+L.+Gundersen&title=Synthesis+and+biological+evaluation+of+pyrimidine+analogs+of+antimycobacterial+purines&doi=10.1016%2Fj.bmc.2010.04.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of pyrimidine analogs of antimycobacterial purines</span></div><div class="casAuthors">Read, Matthew L.; Braendvang, Morten; Miranda, Pedro O.; Gundersen, Lise-Lotte</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3885-3897</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Pyrimidine analogs of antimycobacterial 6-aryl-9-benzylpurines have been synthesized and screened for antibacterial activity against Mycobacterium tuberculosis H37Rv in vitro.  Several active compds. were identified and the best results were obsd. for 5-formamidopyrimidines.  These compds. generally displayed IC90 values ≤1 μg/mL, and they exhibited low toxicity towards mammalian cells.  Imidazolylpyrimidines, which may be regarded as fleximer analogs of the parent purines, were also synthesized and one of them was found to be quite a potent inhibitor of M. tuberculosis (IC90 14 μg/mL).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUBD9DkOvZB7Vg90H21EOLACvtfcHk0ljA1R_9UKGZlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmslOis78%253D&md5=4307a02795503c2fac647e3af9d5e282</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.04.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.04.035%26sid%3Dliteratum%253Aachs%26aulast%3DRead%26aufirst%3DM.%2BL.%26aulast%3DBraendvang%26aufirst%3DM.%26aulast%3DMiranda%26aufirst%3DP.%2BO.%26aulast%3DGundersen%26aufirst%3DL.%2BL.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520pyrimidine%2520analogs%2520of%2520antimycobacterial%2520purines%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26spage%3D3885%26epage%3D3897%26doi%3D10.1016%2Fj.bmc.2010.04.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anand, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiwari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripathi, R. P.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of small libraries of triazolylmethoxy chalcones, flavanones and 2-aminopyrimidines as inhibitors of mycobacterial FAS-II and PknG</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">5150</span>– <span class="NLM_lpage">5163</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2012.07.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmc.2012.07.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=22854194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFahsbjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=5150-5163&author=N.+Anandauthor=P.+Singhauthor=A.+Sharmaauthor=S.+Tiwariauthor=V.+Singhauthor=D.+K.+Singhauthor=K.+K.+Srivastavaauthor=B.+N.+Singhauthor=R.+P.+Tripathi&title=Synthesis+and+evaluation+of+small+libraries+of+triazolylmethoxy+chalcones%2C+flavanones+and+2-aminopyrimidines+as+inhibitors+of+mycobacterial+FAS-II+and+PknG&doi=10.1016%2Fj.bmc.2012.07.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of small libraries of triazolylmethoxy chalcones, flavanones and 2-aminopyrimidines as inhibitors of mycobacterial FAS-II and PknG</span></div><div class="casAuthors">Anand, Namrata; Singh, Priyanka; Sharma, Anindra; Tiwari, Sameer; Singh, Vandana; Singh, Diwakar K.; Srivastava, Kishore K.; Singh, B. N.; Tripathi, Rama Pati</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5150-5163</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A synthetic strategy to access small libraries of triazolylmethoxy chalcones 4{1-20}, triazolylmethoxy flavanones 5{1-10} and triazolylmethoxy aminopyrimidines 6{1-17} from a common substrate 4-propargyloxy-2-hydroxy acetophenone using a set of different reactions has been developed.  The chalcones and flavanones were screened against mycobacterial FAS-II pathway using a recombinant mycobacterial strain, against which the most potent compd. showed ∼88% inhibition in bacterial growth and substantially induction of reporter gene activity at 100 μM concn.  The triazolylmethoxy aminopyrimdines were screened against PknG of Mycobacterium tuberculosis displaying moderate to good activity (23-53% inhibition at 100 μM), comparable to the action of a std. inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqF9nK00acPJLVg90H21EOLACvtfcHk0lgGua86vOHKZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFahsbjP&md5=b90ed351639bfc9768a7ea39507b798c</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2012.07.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2012.07.009%26sid%3Dliteratum%253Aachs%26aulast%3DAnand%26aufirst%3DN.%26aulast%3DSingh%26aufirst%3DP.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DTiwari%26aufirst%3DS.%26aulast%3DSingh%26aufirst%3DV.%26aulast%3DSingh%26aufirst%3DD.%2BK.%26aulast%3DSrivastava%26aufirst%3DK.%2BK.%26aulast%3DSingh%26aufirst%3DB.%2BN.%26aulast%3DTripathi%26aufirst%3DR.%2BP.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520small%2520libraries%2520of%2520triazolylmethoxy%2520chalcones%252C%2520flavanones%2520and%25202-aminopyrimidines%2520as%2520inhibitors%2520of%2520mycobacterial%2520FAS-II%2520and%2520PknG%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26spage%3D5150%26epage%3D5163%26doi%3D10.1016%2Fj.bmc.2012.07.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shirude, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy Choudhury, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kedari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandodkar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugarkar, B. G.</span></span> <span> </span><span class="NLM_article-title">Quinolinyl pyrimidines: Potent inhibitors of NDH-2 as a novel class of anti-TB agents</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">736</span>– <span class="NLM_lpage">740</span>, <span class="refDoi"> DOI: 10.1021/ml300134b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300134b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFOru7jN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=736-740&author=P.+S.+Shirudeauthor=B.+Paulauthor=N.+Roy+Choudhuryauthor=C.+Kedariauthor=B.+Bandodkarauthor=B.+G.+Ugarkar&title=Quinolinyl+pyrimidines%3A+Potent+inhibitors+of+NDH-2+as+a+novel+class+of+anti-TB+agents&doi=10.1021%2Fml300134b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Quinolinyl Pyrimidines: Potent Inhibitors of NDH-2 as a Novel Class of Anti-TB Agents</span></div><div class="casAuthors">Shirude, Pravin S.; Paul, Beena; Roy Choudhury, Nilanjana; Kedari, Chaitanya; Bandodkar, Balachandra; Ugarkar, Bheemarao G.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">736-740</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">NDH-2 is an essential respiratory enzyme in Mycobacterium tuberculosis (Mtb), which plays an important role in the physiol. of Mtb.  Herein, we present a target-based effort to identify a new structural class of inhibitors for NDH-2.  High-throughput screening of the AstraZeneca corporate collection resulted in the identification of quinolinyl pyrimidines as the most promising class of NDH-2 inhibitors.  Structure-activity relationship studies showed improved enzyme inhibition (IC50) against the NDH-2 target, which in turn translated into cellular activity against Mtb.  Thus, the compds. in this class show a good correlation between enzyme inhibition and cellular potency.  Furthermore, early ADME profiling of the best compds. showed promising results and highlighted the quinolinyl pyrimidine class as a potential lead for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOthIF3YZ5u7Vg90H21EOLACvtfcHk0lgGua86vOHKZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFOru7jN&md5=2401035993ef19c97289a272e3744950</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1021%2Fml300134b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300134b%26sid%3Dliteratum%253Aachs%26aulast%3DShirude%26aufirst%3DP.%2BS.%26aulast%3DPaul%26aufirst%3DB.%26aulast%3DRoy%2BChoudhury%26aufirst%3DN.%26aulast%3DKedari%26aufirst%3DC.%26aulast%3DBandodkar%26aufirst%3DB.%26aulast%3DUgarkar%26aufirst%3DB.%2BG.%26atitle%3DQuinolinyl%2520pyrimidines%253A%2520Potent%2520inhibitors%2520of%2520NDH-2%2520as%2520a%2520novel%2520class%2520of%2520anti-TB%2520agents%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D736%26epage%3D740%26doi%3D10.1021%2Fml300134b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahimian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aneja, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schechter, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, C. P.</span></span> <span> </span><span class="NLM_article-title">Mycobacterium tuberculosis type ii nadh-menaquinone oxidoreductase catalyzes electron transfer through a two-site ping-pong mechanism and has two quinone-binding sites</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">1179</span>– <span class="NLM_lpage">1190</span>, <span class="refDoi"> DOI: 10.1021/bi4013897</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi4013897" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVKksbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=1179-1190&author=T.+Yanoauthor=M.+Rahimianauthor=K.+K.+Anejaauthor=N.+M.+Schechterauthor=H.+Rubinauthor=C.+P.+Scott&title=Mycobacterium+tuberculosis+type+ii+nadh-menaquinone+oxidoreductase+catalyzes+electron+transfer+through+a+two-site+ping-pong+mechanism+and+has+two+quinone-binding+sites&doi=10.1021%2Fbi4013897"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Mycobacterium tuberculosis Type II NADH-Menaquinone Oxidoreductase Catalyzes Electron Transfer through a Two-Site Ping-Pong Mechanism and Has Two Quinone-Binding Sites</span></div><div class="casAuthors">Yano, Takahiro; Rahimian, Maryam; Aneja, Kawalpreet K.; Schechter, Norman M.; Rubin, Harvey; Scott, Charles P.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1179-1190</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Type II NADH-quinone oxidoreductase (NDH-2) catalyzes the transfer of electrons from NADH to the quinone pool and plays an essential role in the oxidative phosphorylation system of Mycobacterium tuberculosis (Mtb).  The absence of NDH-2 in the mammalian mitochondrial electron transport chain makes this enzyme an attractive target for antibiotic development.  To fully establish the kinetic properties of this enzyme, we studied the interaction of Mtb NDH-2 with substrates, NADH, and various quinone analogs and their products in both membrane and sol. environments.  These studies, and comparative analyses of the kinetics with thio-NAD+ and quinone electron acceptors, provided evidence that Mtb NDH-2 catalyzes the transfer electrons from NADH to quinone substrates by a nonclassical, two-site ping-pong kinetic mechanism whereby substrate quinones bind to a site that is distinct from the NADH-binding site.  Furthermore, the effects of quinols on Mtb NDH-2 catalytic activity demonstrate the presence of two binding sites for quinone ligands, one favoring the reduced form and the other favoring the oxidized form.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOs650KrNmKbVg90H21EOLACvtfcHk0lgGua86vOHKZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVKksbw%253D&md5=e6ae608c43551063701d028bbfcfd81c</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1021%2Fbi4013897&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi4013897%26sid%3Dliteratum%253Aachs%26aulast%3DYano%26aufirst%3DT.%26aulast%3DRahimian%26aufirst%3DM.%26aulast%3DAneja%26aufirst%3DK.%2BK.%26aulast%3DSchechter%26aufirst%3DN.%2BM.%26aulast%3DRubin%26aufirst%3DH.%26aulast%3DScott%26aufirst%3DC.%2BP.%26atitle%3DMycobacterium%2520tuberculosis%2520type%2520ii%2520nadh-menaquinone%2520oxidoreductase%2520catalyzes%2520electron%2520transfer%2520through%2520a%2520two-site%2520ping-pong%2520mechanism%2520and%2520has%2520two%2520quinone-binding%2520sites%26jtitle%3DBiochemistry%26date%3D2014%26volume%3D53%26spage%3D1179%26epage%3D1190%26doi%3D10.1021%2Fbi4013897" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kravchenko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verbitskiy, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medvinskiy, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusinov, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charushin, V. N.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antituberculosis activity of novel 5-styryl-4-(hetero)aryl-pyrimidines via combination of the pd-catalyzed suzuki cross-coupling and s(n)(h) reactions</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3118</span>– <span class="NLM_lpage">3120</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.05.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmcl.2014.05.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=24856062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2cXovVaisr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=3118-3120&author=M.+A.+Kravchenkoauthor=E.+V.+Verbitskiyauthor=I.+D.+Medvinskiyauthor=G.+L.+Rusinovauthor=V.+N.+Charushin&title=Synthesis+and+antituberculosis+activity+of+novel+5-styryl-4-%28hetero%29aryl-pyrimidines+via+combination+of+the+pd-catalyzed+suzuki+cross-coupling+and+s%28n%29%28h%29+reactions&doi=10.1016%2Fj.bmcl.2014.05.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antituberculosis activity of novel 5-styryl-4-(hetero)aryl-pyrimidines via combination of the Pd-catalyzed Suzuki cross-coupling and SHN reactions</span></div><div class="casAuthors">Kravchenko, Marionella A.; Verbitskiy, Egor V.; Medvinskiy, Igor D.; Rusinov, Gennady L.; Charushin, Valery N.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3118-3120</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Combination of the Suzuki cross-coupling and nucleophilic arom. substitution of hydrogen (SHN) reactions proved to be a convenient method for the synthesis of 5-styryl-4-(hetero)aryl substituted pyrimidines from com. available 5-bromopyrimidine.  All intermediate 5-bromo-4-(hetero)aryl substituted pyrimidines and also the targeted 5-styryl-4-(hetero)arylpyrimidines are active in micromolar concns. in vitro against Mycobacterium tuberculosis H37Rv, avium, terrae, and multi-drug-resistant strain isolated from tuberculosis patients in Ural region (Russia).  Some of these compds. possess a low toxicity and have a bacteriostatic effect, comparable and even higher with that of first-line antituberculosis drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU-7N2OvsfF7Vg90H21EOLACvtfcHk0lgGua86vOHKZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXovVaisr8%253D&md5=41fe9db251cdf861b373360d7195aa91</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.05.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.05.006%26sid%3Dliteratum%253Aachs%26aulast%3DKravchenko%26aufirst%3DM.%2BA.%26aulast%3DVerbitskiy%26aufirst%3DE.%2BV.%26aulast%3DMedvinskiy%26aufirst%3DI.%2BD.%26aulast%3DRusinov%26aufirst%3DG.%2BL.%26aulast%3DCharushin%26aufirst%3DV.%2BN.%26atitle%3DSynthesis%2520and%2520antituberculosis%2520activity%2520of%2520novel%25205-styryl-4-%2528hetero%2529aryl-pyrimidines%2520via%2520combination%2520of%2520the%2520pd-catalyzed%2520suzuki%2520cross-coupling%2520and%2520s%2528n%2529%2528h%2529%2520reactions%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D3118%26epage%3D3120%26doi%3D10.1016%2Fj.bmcl.2014.05.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verbitskiy, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baskakova, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kravchenko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skornyakov, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusinov, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chupakhin, O. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charushin, V. N.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of antitubercular activity of fluorinated 5-aryl-4-(hetero)aryl substituted pyrimidines</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3771</span>– <span class="NLM_lpage">3780</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.06.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmc.2016.06.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=27338658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVKgtLbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=3771-3780&author=E.+V.+Verbitskiyauthor=S.+A.+Baskakovaauthor=M.+A.+Kravchenkoauthor=S.+N.+Skornyakovauthor=G.+L.+Rusinovauthor=O.+N.+Chupakhinauthor=V.+N.+Charushin&title=Synthesis+and+evaluation+of+antitubercular+activity+of+fluorinated+5-aryl-4-%28hetero%29aryl+substituted+pyrimidines&doi=10.1016%2Fj.bmc.2016.06.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of antitubercular activity of fluorinated 5-aryl-4-(hetero)aryl substituted pyrimidines</span></div><div class="casAuthors">Verbitskiy, Egor V.; Baskakova, Svetlana A.; Kravchenko, Marionella A.; Skornyakov, Sergey N.; Rusinov, Gennady L.; Chupakhin, Oleg N.; Charushin, Valery N.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3771-3780</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Various 5-(fluoroaryl)-4-(hetero)aryl substituted pyrimidines have been synthesized based on the Suzuki cross-coupling and nucleophilic arom. substitution of hydrogen (SHN) reactions starting from com. available 5-bromopyrimidine and their antitubercular activity against Mycobacterium tuberculosis H37Rv has been explored.  The outcome of the study disclose that, some of the compds. have showed promising activity in micromolar concn. against Mycobacterium tuberculosis H37Rv, Mycobacterium avium, Mycobacterium terrae, and multidrug-resistant strains isolated from tuberculosis patients in Ural region (Russia).  The data concerning the 'structure-activity' relationship for fluorinated compds. have been discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfpux_5rKg37Vg90H21EOLACvtfcHk0lii0toe9cBvog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVKgtLbI&md5=8a5f1624b27c64aa994a95efe36432cd</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.06.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.06.020%26sid%3Dliteratum%253Aachs%26aulast%3DVerbitskiy%26aufirst%3DE.%2BV.%26aulast%3DBaskakova%26aufirst%3DS.%2BA.%26aulast%3DKravchenko%26aufirst%3DM.%2BA.%26aulast%3DSkornyakov%26aufirst%3DS.%2BN.%26aulast%3DRusinov%26aufirst%3DG.%2BL.%26aulast%3DChupakhin%26aufirst%3DO.%2BN.%26aulast%3DCharushin%26aufirst%3DV.%2BN.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520antitubercular%2520activity%2520of%2520fluorinated%25205-aryl-4-%2528hetero%2529aryl%2520substituted%2520pyrimidines%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D3771%26epage%3D3780%26doi%3D10.1016%2Fj.bmc.2016.06.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verbitskiy, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheprakova, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slepukhin, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kravchenko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skornyakov, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusinov, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chupakhin, O. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charushin, V. N.</span></span> <span> </span><span class="NLM_article-title">Synthesis, and structure-activity relationship for c(4) and/or c(5) thienyl substituted pyrimidines, as a new family of antimycobacterial compounds</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">234</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.05.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.ejmech.2015.05.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=25982331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotlKiu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2015&pages=225-234&author=E.+V.+Verbitskiyauthor=E.+M.+Cheprakovaauthor=P.+A.+Slepukhinauthor=M.+A.+Kravchenkoauthor=S.+N.+Skornyakovauthor=G.+L.+Rusinovauthor=O.+N.+Chupakhinauthor=V.+N.+Charushin&title=Synthesis%2C+and+structure-activity+relationship+for+c%284%29+and%2For+c%285%29+thienyl+substituted+pyrimidines%2C+as+a+new+family+of+antimycobacterial+compounds&doi=10.1016%2Fj.ejmech.2015.05.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, and structure-activity relationship for C(4) and/or C(5) thienyl substituted pyrimidines, as a new family of antimycobacterial compounds</span></div><div class="casAuthors">Verbitskiy, Egor V.; Cheprakova, Ekaterina M.; Slepukhin, Pavel A.; Kravchenko, Marionella A.; Skornyakov, Sergey N.; Rusinov, Gennady L.; Chupakhin, Oleg N.; Charushin, Valery N.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">225-234</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Combination of the Suzuki cross-coupling and nucleophilic arom. substitution of hydrogen (SHN) reactions proved to be a convenient method for the synthesis of C(4) and/or C(5) mono(thienyl) and di(thienyl) substituted pyrimidines from com. available 5-bromopyrimidine.  All new pyrimidines are active in micromolar concns. in vitro against H37Rv, avium, terrae, rifampicin and isoniazid-resistance strains of Mycobacterium tuberculosis.  The data for acute in vivo toxicity in mice were obtained for these compds. which appear to be promising antitubercular agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5qpeVACSF4rVg90H21EOLACvtfcHk0lii0toe9cBvog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotlKiu7o%253D&md5=c33a2aa5045fbff635a1da6e35e3e6ab</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.05.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.05.007%26sid%3Dliteratum%253Aachs%26aulast%3DVerbitskiy%26aufirst%3DE.%2BV.%26aulast%3DCheprakova%26aufirst%3DE.%2BM.%26aulast%3DSlepukhin%26aufirst%3DP.%2BA.%26aulast%3DKravchenko%26aufirst%3DM.%2BA.%26aulast%3DSkornyakov%26aufirst%3DS.%2BN.%26aulast%3DRusinov%26aufirst%3DG.%2BL.%26aulast%3DChupakhin%26aufirst%3DO.%2BN.%26aulast%3DCharushin%26aufirst%3DV.%2BN.%26atitle%3DSynthesis%252C%2520and%2520structure-activity%2520relationship%2520for%2520c%25284%2529%2520and%252For%2520c%25285%2529%2520thienyl%2520substituted%2520pyrimidines%252C%2520as%2520a%2520new%2520family%2520of%2520antimycobacterial%2520compounds%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D97%26spage%3D225%26epage%3D234%26doi%3D10.1016%2Fj.ejmech.2015.05.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yadlapalli, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chourasia, O. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vemuri, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sritharan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perali, R. S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and in vitro anticancer and antitubercular activity of diarylpyrazole ligated dihydropyrimidines possessing lipophilic carbamoyl group</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">2708</span>– <span class="NLM_lpage">2711</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.02.101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmcl.2012.02.101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=22437116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38XktFyjtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=2708-2711&author=R.+K.+Yadlapalliauthor=O.+P.+Chourasiaauthor=K.+Vemuriauthor=M.+Sritharanauthor=R.+S.+Perali&title=Synthesis+and+in+vitro+anticancer+and+antitubercular+activity+of+diarylpyrazole+ligated+dihydropyrimidines+possessing+lipophilic+carbamoyl+group&doi=10.1016%2Fj.bmcl.2012.02.101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and in vitro anticancer and antitubercular activity of diarylpyrazole ligated dihydropyrimidines possessing lipophilic carbamoyl group</span></div><div class="casAuthors">Yadlapalli, Rama Krishna; Chourasia, O. P.; Vemuri, Kiranmayi; Sritharan, Manjula; Perali, Ramu Sridhar</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2708-2711</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of dihydropyrimidine derivs., e. g. I and II, were synthesized by utilizing Biginelli reaction and evaluated for their in vitro anticancer activity against MCF-7 human breast cancer (HBC) cell line using sulforhodamine B (SRB) assay and antitubercular activity against Mycobacterium tuberculosis (MTB) H37Rv using Microplate Alamar Blue Assay (MABA).  I and II were exhibited 70.6% and 63.7% of HBC cell growth inhibition at 10 μM concn.  Interestingly, I was also found to be the most potent in the series against MTB H37Rv with MIC value of 0.125 μg/mL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGql0XildxmgRrVg90H21EOLACvtfcHk0lii0toe9cBvog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktFyjtL0%253D&md5=ff946cbc719252c03d23d20edf064cf7</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.02.101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.02.101%26sid%3Dliteratum%253Aachs%26aulast%3DYadlapalli%26aufirst%3DR.%2BK.%26aulast%3DChourasia%26aufirst%3DO.%2BP.%26aulast%3DVemuri%26aufirst%3DK.%26aulast%3DSritharan%26aufirst%3DM.%26aulast%3DPerali%26aufirst%3DR.%2BS.%26atitle%3DSynthesis%2520and%2520in%2520vitro%2520anticancer%2520and%2520antitubercular%2520activity%2520of%2520diarylpyrazole%2520ligated%2520dihydropyrimidines%2520possessing%2520lipophilic%2520carbamoyl%2520group%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D2708%26epage%3D2711%26doi%3D10.1016%2Fj.bmcl.2012.02.101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yokokawa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manjunatha, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakshminarayana, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kounde, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thayalan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanjundappa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravindran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gee, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dix, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pethe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glynne, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bifani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiricek, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of tetrahydropyrazolopyrimidine carboxamide derivatives as potent and orally active antitubercular agents</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">451</span>– <span class="NLM_lpage">455</span>, <span class="refDoi"> DOI: 10.1021/ml400071a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml400071a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltVCltb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=451-455&author=F.+Yokokawaauthor=G.+Wangauthor=W.+L.+Chanauthor=S.+H.+Angauthor=J.+Wongauthor=I.+Maauthor=S.+P.+Raoauthor=U.+Manjunathaauthor=S.+B.+Lakshminarayanaauthor=M.+Herveauthor=C.+Koundeauthor=B.+H.+Tanauthor=P.+Thayalanauthor=S.+H.+Ngauthor=M.+Nanjundappaauthor=S.+Ravindranauthor=P.+Geeauthor=M.+Tanauthor=L.+Weiauthor=A.+Gohauthor=P.+Y.+Chenauthor=K.+S.+Leeauthor=C.+Zhongauthor=T.+Wagnerauthor=I.+Dixauthor=A.+K.+Chatterjeeauthor=K.+Petheauthor=K.+Kuhenauthor=R.+Glynneauthor=P.+Smithauthor=P.+Bifaniauthor=J.+Jiricek&title=Discovery+of+tetrahydropyrazolopyrimidine+carboxamide+derivatives+as+potent+and+orally+active+antitubercular+agents&doi=10.1021%2Fml400071a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Tetrahydropyrazolopyrimidine Carboxamide Derivatives As Potent and Orally Active Antitubercular Agents</span></div><div class="casAuthors">Yokokawa, Fumiaki; Wang, Gang; Chan, Wai Ling; Ang, Shi Hua; Wong, Josephine; Ma, Ida; Rao, Srinivasa P. S.; Manjunatha, Ujjini; Lakshminarayana, Suresh B.; Herve, Maxime; Kounde, Cyrille; Tan, Bee Huat; Thayalan, Pamela; Dick, Thomas; Ng, Seow Hwee; Nanjundappa, Mahesh; Ravindran, Sindhu; Gee, Peck; Tan, Maria; Wei, Liu; Goh, Anne; Chen, Pei-Yu; Lee, Kok Sin; Zhong, Chen; Wagner, Trixie; Dix, Ina; Chatterjee, Arnab K.; Pethe, Kevin; Kuhen, Kelli; Glynne, Richard; Smith, Paul; Bifani, Pablo; Jiricek, Jan</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">451-455</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nonracemic (aryl)(fluoroalkyl)tetrahydropyrazolo[1,5-a]pyrimidinecarboxamides I [R = 4-MeC6H4, 5-Me-2-pyridinyl, 5-methyl-2-furyl, 4-(4-morpholinyl)C6H4, 4-(MeOCH2CH2O)C6H4, 4-(3-oxetanyloxy)C6H4; R1 = F3C, F2HC; R2 = 4-FC6H4CH2, 6-MeO-3-pyridinylmethyl, 5-F-2-pyridinylmethyl] were prepd. stereoselectively as potential antitubercular agents; their inhibition of Mycobacterium tuberculosis (Mtb), their aq. solubilities, their plasma protein binding, and their lipophilicities were detd.  I were prepd. from aryl Me ketones, Et trifluoro- or difluoroacetate, and Et 3-amino-4-pyrazolecarboxylate; resoln. of the intermediate cis-aryl(fluoroalkyl)tetrahydropyrazolopyrimidinecarboxylic acids by supercrit. fluid chromatog. followed by amidation or aryl modifications yielded the desired products.  While I inhibited Mtb with MIC of 0.13-52.2 μM, ent-I did not inhibit Mtb (MIC > 20 μM).  In particular, I (R = 4-MeC6H4; R1 = F3C; R2 = 4-FC6H4CH2) showed a promising in vivo DMPK profile in mouse and exhibited potent in vivo activity in a mouse antitubercular efficacy model, achieving a redn. of 3.5 log CFU of Mtb after oral administration to infected mice once a day at 100 mg/kg for 28 days.  I (R = 4-MeC6H4; R1 = F3C; R2 = 4-FC6H4CH2) is a potential candidate for inclusion in combination therapies for both drug-sensitive and drug-resistant TB.  The structure of a nonracemic (methylpyridinyl)(trifluoromethyl)tetrahydropyrazolopyrimidinecarboxylic acid intermediate and its abs. configuration were detd. by X-ray crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUOfiTtIIr5LVg90H21EOLACvtfcHk0lhe431hB8Mfnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltVCltb0%253D&md5=d4a33e9a3fc688dacdb3aa2e8c1c7465</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1021%2Fml400071a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400071a%26sid%3Dliteratum%253Aachs%26aulast%3DYokokawa%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DChan%26aufirst%3DW.%2BL.%26aulast%3DAng%26aufirst%3DS.%2BH.%26aulast%3DWong%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DI.%26aulast%3DRao%26aufirst%3DS.%2BP.%26aulast%3DManjunatha%26aufirst%3DU.%26aulast%3DLakshminarayana%26aufirst%3DS.%2BB.%26aulast%3DHerve%26aufirst%3DM.%26aulast%3DKounde%26aufirst%3DC.%26aulast%3DTan%26aufirst%3DB.%2BH.%26aulast%3DThayalan%26aufirst%3DP.%26aulast%3DNg%26aufirst%3DS.%2BH.%26aulast%3DNanjundappa%26aufirst%3DM.%26aulast%3DRavindran%26aufirst%3DS.%26aulast%3DGee%26aufirst%3DP.%26aulast%3DTan%26aufirst%3DM.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DGoh%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DP.%2BY.%26aulast%3DLee%26aufirst%3DK.%2BS.%26aulast%3DZhong%26aufirst%3DC.%26aulast%3DWagner%26aufirst%3DT.%26aulast%3DDix%26aufirst%3DI.%26aulast%3DChatterjee%26aufirst%3DA.%2BK.%26aulast%3DPethe%26aufirst%3DK.%26aulast%3DKuhen%26aufirst%3DK.%26aulast%3DGlynne%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DBifani%26aufirst%3DP.%26aulast%3DJiricek%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520tetrahydropyrazolopyrimidine%2520carboxamide%2520derivatives%2520as%2520potent%2520and%2520orally%2520active%2520antitubercular%2520agents%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D451%26epage%3D455%26doi%3D10.1021%2Fml400071a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shirude, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shandil, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosagrahara, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hameed, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinde, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bathula, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humnabadkar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panduga, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambady, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegde, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiteaker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madhavapeddi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guptha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awasthy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahadevaswamy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vishwas, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahuja, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prabhakar, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bharath, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kale, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramaiah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choudhury, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sambandamurthy, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solapure, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterji, M.</span></span> <span> </span><span class="NLM_article-title">Azaindoles: Noncovalent dpre1 inhibitors from scaffold morphing efforts, kill mycobacterium tuberculosis and are efficacious in vivo</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">9701</span>– <span class="NLM_lpage">9708</span>, <span class="refDoi"> DOI: 10.1021/jm401382v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401382v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslCku7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=9701-9708&author=P.+S.+Shirudeauthor=R.+Shandilauthor=C.+Sadlerauthor=M.+Naikauthor=V.+Hosagraharaauthor=S.+Hameedauthor=V.+Shindeauthor=C.+Bathulaauthor=V.+Humnabadkarauthor=N.+Kumarauthor=J.+Reddyauthor=V.+Pandugaauthor=S.+Sharmaauthor=A.+Ambadyauthor=N.+Hegdeauthor=J.+Whiteakerauthor=R.+E.+McLaughlinauthor=H.+Gardnerauthor=P.+Madhavapeddiauthor=V.+Ramachandranauthor=P.+Kaurauthor=A.+Narayanauthor=S.+Gupthaauthor=D.+Awasthyauthor=C.+Narayanauthor=J.+Mahadevaswamyauthor=K.+G.+Vishwasauthor=V.+Ahujaauthor=A.+Srivastavaauthor=K.+R.+Prabhakarauthor=S.+Bharathauthor=R.+Kaleauthor=M.+Ramaiahauthor=N.+R.+Choudhuryauthor=V.+K.+Sambandamurthyauthor=S.+Solapureauthor=P.+S.+Iyerauthor=S.+Narayananauthor=M.+Chatterji&title=Azaindoles%3A+Noncovalent+dpre1+inhibitors+from+scaffold+morphing+efforts%2C+kill+mycobacterium+tuberculosis+and+are+efficacious+in+vivo&doi=10.1021%2Fjm401382v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Azaindoles: Noncovalent DprE1 Inhibitors from Scaffold Morphing Efforts, Kill Mycobacterium tuberculosis and Are Efficacious in Vivo</span></div><div class="casAuthors">Shirude, Pravin S.; Shandil, Radha; Sadler, Claire; Naik, Maruti; Hosagrahara, Vinayak; Hameed, Shahul; Shinde, Vikas; Bathula, Chandramohan; Humnabadkar, Vaishali; Kumar, Naveen; Reddy, Jitendar; Panduga, Vijender; Sharma, Sreevalli; Ambady, Anisha; Hegde, Naina; Whiteaker, James; McLaughlin, Robert E.; Gardner, Humphrey; Madhavapeddi, Prashanti; Ramachandran, Vasanthi; Kaur, Parvinder; Narayan, Ashwini; Guptha, Supreeth; Awasthy, Disha; Narayan, Chandan; Mahadevaswamy, Jyothi; Vishwas, K. G.; Ahuja, Vijaykamal; Srivastava, Abhishek; Prabhakar, K. R.; Bharath, Sowmya; Kale, Ramesh; Ramaiah, Manjunatha; Choudhury, Nilanjana Roy; Sambandamurthy, Vasan K.; Solapure, Suresh; Iyer, Pravin S.; Narayanan, Shridhar; Chatterji, Monalisa</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9701-9708</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report 1,4-azaindoles as a new inhibitor class that kills Mycobacterium tuberculosis in vitro and demonstrates efficacy in mouse tuberculosis models.  The series emerged from scaffold morphing efforts and was demonstrated to noncovalently inhibit decaprenylphosphoryl-β-d-ribose2'-epimerase (DprE1).  With "drug-like" properties and no expectation of pre-existing resistance in the clinic, this chem. class has the potential to be developed as a therapy for drug-sensitive and drug-resistant tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqskQvJK4M2yrVg90H21EOLACvtfcHk0lhe431hB8Mfnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslCku7fM&md5=eba42d1952b164f66fd0ca620aaa4f19</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1021%2Fjm401382v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401382v%26sid%3Dliteratum%253Aachs%26aulast%3DShirude%26aufirst%3DP.%2BS.%26aulast%3DShandil%26aufirst%3DR.%26aulast%3DSadler%26aufirst%3DC.%26aulast%3DNaik%26aufirst%3DM.%26aulast%3DHosagrahara%26aufirst%3DV.%26aulast%3DHameed%26aufirst%3DS.%26aulast%3DShinde%26aufirst%3DV.%26aulast%3DBathula%26aufirst%3DC.%26aulast%3DHumnabadkar%26aufirst%3DV.%26aulast%3DKumar%26aufirst%3DN.%26aulast%3DReddy%26aufirst%3DJ.%26aulast%3DPanduga%26aufirst%3DV.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DAmbady%26aufirst%3DA.%26aulast%3DHegde%26aufirst%3DN.%26aulast%3DWhiteaker%26aufirst%3DJ.%26aulast%3DMcLaughlin%26aufirst%3DR.%2BE.%26aulast%3DGardner%26aufirst%3DH.%26aulast%3DMadhavapeddi%26aufirst%3DP.%26aulast%3DRamachandran%26aufirst%3DV.%26aulast%3DKaur%26aufirst%3DP.%26aulast%3DNarayan%26aufirst%3DA.%26aulast%3DGuptha%26aufirst%3DS.%26aulast%3DAwasthy%26aufirst%3DD.%26aulast%3DNarayan%26aufirst%3DC.%26aulast%3DMahadevaswamy%26aufirst%3DJ.%26aulast%3DVishwas%26aufirst%3DK.%2BG.%26aulast%3DAhuja%26aufirst%3DV.%26aulast%3DSrivastava%26aufirst%3DA.%26aulast%3DPrabhakar%26aufirst%3DK.%2BR.%26aulast%3DBharath%26aufirst%3DS.%26aulast%3DKale%26aufirst%3DR.%26aulast%3DRamaiah%26aufirst%3DM.%26aulast%3DChoudhury%26aufirst%3DN.%2BR.%26aulast%3DSambandamurthy%26aufirst%3DV.%2BK.%26aulast%3DSolapure%26aufirst%3DS.%26aulast%3DIyer%26aufirst%3DP.%2BS.%26aulast%3DNarayanan%26aufirst%3DS.%26aulast%3DChatterji%26aufirst%3DM.%26atitle%3DAzaindoles%253A%2520Noncovalent%2520dpre1%2520inhibitors%2520from%2520scaffold%2520morphing%2520efforts%252C%2520kill%2520mycobacterium%2520tuberculosis%2520and%2520are%2520efficacious%2520in%2520vivo%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D9701%26epage%3D9708%26doi%3D10.1021%2Fjm401382v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Velezheva, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivanov, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kornienko, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyubimov, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazarian, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikonenko, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majorov, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apt, A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antituberculosis activity of indole-pyridine derived hydrazides, hydrazide-hydrazones, and thiosemicarbazones</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">978</span>– <span class="NLM_lpage">985</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.12.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmcl.2015.12.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=26725953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVyqsLzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=978-985&author=V.+Velezhevaauthor=P.+Brennanauthor=P.+Ivanovauthor=A.+Kornienkoauthor=S.+Lyubimovauthor=K.+Kazarianauthor=B.+Nikonenkoauthor=K.+Majorovauthor=A.+Apt&title=Synthesis+and+antituberculosis+activity+of+indole-pyridine+derived+hydrazides%2C+hydrazide-hydrazones%2C+and+thiosemicarbazones&doi=10.1016%2Fj.bmcl.2015.12.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antituberculosis activity of indole-pyridine derived hydrazides, hydrazide-hydrazones, and thiosemicarbazones</span></div><div class="casAuthors">Velezheva, Valeriya; Brennan, Patrick; Ivanov, Pavel; Kornienko, Albert; Lyubimov, Sergey; Kazarian, Konstantin; Nikonenko, Boris; Majorov, Konstantin; Apt, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">978-985</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We describe the design, synthesis, and in vitro antimycobacterial activity of a series of novel simple hybrid hydrazides and hydrazide-hydrazones combining indole and pyridine nuclei.  The compds. are derivs. of 1-acetylindoxyl or substituted indole-3-carboxaldehydes tethered via a hydrazine group by simple C-N or double C:N bonds with 3- and 4-pyridines, 1-oxide 3- and 4-pyridine carbohydrazides.  The most active of the 15 compds. showed MICs values against an INH-sensitive strain of Mycobacterium tuberculosis H37Rv equal to that of INH (0.05-2 μg/mL).  Five compds. demonstrated appreciable activity against the INH-resistant M. tuberculosis CN-40 clin. isolate (MICs: 2-5 μg/mL), providing justification for further in vivo studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4xva4vDfrFbVg90H21EOLACvtfcHk0ljSXjXk5uQPYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVyqsLzF&md5=d4136529aa96fcaa078e16496e1e1d79</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.12.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.12.049%26sid%3Dliteratum%253Aachs%26aulast%3DVelezheva%26aufirst%3DV.%26aulast%3DBrennan%26aufirst%3DP.%26aulast%3DIvanov%26aufirst%3DP.%26aulast%3DKornienko%26aufirst%3DA.%26aulast%3DLyubimov%26aufirst%3DS.%26aulast%3DKazarian%26aufirst%3DK.%26aulast%3DNikonenko%26aufirst%3DB.%26aulast%3DMajorov%26aufirst%3DK.%26aulast%3DApt%26aufirst%3DA.%26atitle%3DSynthesis%2520and%2520antituberculosis%2520activity%2520of%2520indole-pyridine%2520derived%2520hydrazides%252C%2520hydrazide-hydrazones%252C%2520and%2520thiosemicarbazones%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D978%26epage%3D985%26doi%3D10.1016%2Fj.bmcl.2015.12.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baig, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, I. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. G.</span></span> <span> </span><span class="NLM_article-title">Synthesis, crystal structure and biological evaluation of substituted quinazolinone benzoates as novel antituberculosis agents targeting acetohydroxyacid synthase</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">298</span>– <span class="NLM_lpage">305</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.03.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.ejmech.2015.03.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=25771108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktVCkt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2015&pages=298-305&author=W.+Luauthor=I.+A.+Baigauthor=H.+J.+Sunauthor=C.+J.+Cuiauthor=R.+Guoauthor=I.+P.+Jungauthor=D.+Wangauthor=M.+Dongauthor=M.+Y.+Yoonauthor=J.+G.+Wang&title=Synthesis%2C+crystal+structure+and+biological+evaluation+of+substituted+quinazolinone+benzoates+as+novel+antituberculosis+agents+targeting+acetohydroxyacid+synthase&doi=10.1016%2Fj.ejmech.2015.03.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, crystal structure and biological evaluation of substituted quinazolinone benzoates as novel antituberculosis agents targeting acetohydroxyacid synthase</span></div><div class="casAuthors">Lu, Wei; Baig, Irshad Ahmed; Sun, Hui-Jie; Cui, Chang-Jun; Guo, Rui; Jung, In-Pil; Wang, Di; Dong, Mei; Yoon, Moon-Young; Wang, Jian-Guo</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">298-305</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Acetohydroxyacid synthase (AHAS) catalyzes the first essential biosynthetic step of branched-chain amino acids and is a biol. safe target against Mycobacterium tuberculosis (MTB).  In our previous research, we used virtual screening to identify some novel AHAS inhibitors as potent antituberculosis agents.  In this study, we synthesized twenty-four addnl. quinazolinone benzoates and explored their antitubercular activity.  Five of these compds. displayed significant MTB-AHAS inhibition and their IC50 values were detd. to be in the range of 6.50 μM-12.08 μM.  Importantly, these compds. also exhibited strong in vitro activity (MICs in the range of 2.5-10 mg/L) and intracellular activity against clin. isolated extensively drug-resistant strains of M. tuberculosis.  Taken together, these results indicated that the quinazolinone benzoate compds. should be regarded as promising lead compds. for the development of potent antituberculosis drugs with a novel mode of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9JXKcaR2i4LVg90H21EOLACvtfcHk0ljSXjXk5uQPYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktVCkt7s%253D&md5=12cc55409c9563e88fd3fcdbfbb3ab04</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.03.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.03.014%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DW.%26aulast%3DBaig%26aufirst%3DI.%2BA.%26aulast%3DSun%26aufirst%3DH.%2BJ.%26aulast%3DCui%26aufirst%3DC.%2BJ.%26aulast%3DGuo%26aufirst%3DR.%26aulast%3DJung%26aufirst%3DI.%2BP.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DDong%26aufirst%3DM.%26aulast%3DYoon%26aufirst%3DM.%2BY.%26aulast%3DWang%26aufirst%3DJ.%2BG.%26atitle%3DSynthesis%252C%2520crystal%2520structure%2520and%2520biological%2520evaluation%2520of%2520substituted%2520quinazolinone%2520benzoates%2520as%2520novel%2520antituberculosis%2520agents%2520targeting%2520acetohydroxyacid%2520synthase%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D94%26spage%3D298%26epage%3D305%26doi%3D10.1016%2Fj.ejmech.2015.03.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ranjith Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perumal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menéndez, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yogeeswari, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sriram, D.</span></span> <span> </span><span class="NLM_article-title">Antimycobacterial activity of novel 1,2,4-oxadiazole-pyranopyridine/chromene hybrids generated by chemoselective 1,3-dipolar cycloadditions of nitrile oxides</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">3444</span>– <span class="NLM_lpage">3450</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2011.04.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmc.2011.04.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=21592801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A280%3ADC%252BC3MrkslCmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=3444-3450&author=R.+Ranjith+Kumarauthor=S.+Perumalauthor=J.+C.+Men%C3%A9ndezauthor=P.+Yogeeswariauthor=D.+Sriram&title=Antimycobacterial+activity+of+novel+1%2C2%2C4-oxadiazole-pyranopyridine%2Fchromene+hybrids+generated+by+chemoselective+1%2C3-dipolar+cycloadditions+of+nitrile+oxides&doi=10.1016%2Fj.bmc.2011.04.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Antimycobacterial activity of novel 1,2,4-oxadiazole-pyranopyridine/chromene hybrids generated by chemoselective 1,3-dipolar cycloadditions of nitrile oxides</span></div><div class="casAuthors">Ranjith Kumar Raju; Perumal Subbu; Menendez J Carlos; Yogeeswari Perumal; Sriram Dharmarajan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & medicinal chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3444-50</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The 1,3-dipolar cycloaddition of nitrile oxides generated in situ from benzohydroximinoyl chloride and triethylamine to 2-aminopyranopyridine-3-carbonitriles and 2-aminochromene-3-carbonitriles occurred chemoselectively furnishing novel 1,2,4-oxadiazole-pyranopyridine/chromene hybrid heterocycles in moderate yields.  In vitro screening of these compounds against Mycobacterium tuberculosis H37Rv (MTB) disclosed that the 1,2,4-oxadiazole-pyranopyridine hybrids display enhanced activity relative to the 1,2,4-oxadiazole-chromene hybrids.  Among the compounds screened, 3-[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]-4-(2,4-dichlorophenyl)-8-[(E)-(2,4-dichlorophenyl)-methylidene]-6-methyl-5,6,7,8-tetrahydro-4H-pyrano[3,2-c]pyridin-2-amine (MIC: 0.31 μM) is 1.2, 15.2 and 24.6 times more active than standard antitubercular drugs, viz. isoniazid, ciprofloxacin and ethambutol, respectively.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSzDQQlg0ZtX0EksK8CslK8fW6udTcc2earnOF8uWRltrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MrkslCmug%253D%253D&md5=b94ad72e4fa28425aaab4cf2069cfdde</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2011.04.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2011.04.033%26sid%3Dliteratum%253Aachs%26aulast%3DRanjith%2BKumar%26aufirst%3DR.%26aulast%3DPerumal%26aufirst%3DS.%26aulast%3DMen%25C3%25A9ndez%26aufirst%3DJ.%2BC.%26aulast%3DYogeeswari%26aufirst%3DP.%26aulast%3DSriram%26aufirst%3DD.%26atitle%3DAntimycobacterial%2520activity%2520of%2520novel%25201%252C2%252C4-oxadiazole-pyranopyridine%252Fchromene%2520hybrids%2520generated%2520by%2520chemoselective%25201%252C3-dipolar%2520cycloadditions%2520of%2520nitrile%2520oxides%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2011%26volume%3D19%26spage%3D3444%26epage%3D3450%26doi%3D10.1016%2Fj.bmc.2011.04.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Almansour, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suresh Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arumugam, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sriram, D.</span></span> <span> </span><span class="NLM_article-title">A solvent free, four-component synthesis and 1,3-dipolar cycloaddition of 4(h)-pyrans with nitrile oxides: Synthesis and discovery of antimycobacterial activity of enantiomerically pure 1,2,4-oxadiazoles</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">416</span>– <span class="NLM_lpage">423</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2012.04.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.ejmech.2012.04.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=22575534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38XnvVygt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2012&pages=416-423&author=A.+I.+Almansourauthor=R.+Suresh+Kumarauthor=N.+Arumugamauthor=D.+Sriram&title=A+solvent+free%2C+four-component+synthesis+and+1%2C3-dipolar+cycloaddition+of+4%28h%29-pyrans+with+nitrile+oxides%3A+Synthesis+and+discovery+of+antimycobacterial+activity+of+enantiomerically+pure+1%2C2%2C4-oxadiazoles&doi=10.1016%2Fj.ejmech.2012.04.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">A solvent free, four-component synthesis and 1,3-dipolar cycloaddition of 4(H)-pyrans with nitrile oxides: Synthesis and discovery of antimycobacterial activity of enantiomerically pure 1,2,4-oxadiazoles</span></div><div class="casAuthors">Almansour, Abdulrahman I.; Suresh Kumar, Raju; Arumugam, Natarajan; Sriram, Dharmarajan</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">416-423</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Four-component reactions of (R)-1-(1-phenylethyl)tetrahydro-4(1H)-pyridinone, arom. aldehydes (2 equiv) and malononitrile in a 1:2:1 molar ratio in the presence of solid sodium ethoxide under solvent free conditions afforded an inseparable mixt. of two diastereomeric 4(H)-pyrans I (R = Ph, 4-Me-C6H4, 2-Cl-C6H4, 2,4-Cl2-C6H3, 1-naphthyl) in near quant. yields.  These compds. upon 1,3-dipolar cycloaddn. with nitrile oxides derived from N-hydroxyarylimidoyl chlorides furnished two enantiomerically pure 1,2,4-oxadiazoles in moderate yields, which were screened for in vitro activity against Mycobacterium tuberculosis H37Rv (MTB) and multi-drug resistant M. tuberculosis (MDR-TB).  Among the compds. screened, compd. II (ring stereo unassigned) was found to be the most active in vitro with a MIC value of 0.07 and 0.14 μM against MTB and MDR-TB resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHXsJkDg5Y7rVg90H21EOLACvtfcHk0liKxkKiW62Rzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnvVygt7c%253D&md5=f6df114c9cc69b304457e5fcb0c56c82</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2012.04.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2012.04.021%26sid%3Dliteratum%253Aachs%26aulast%3DAlmansour%26aufirst%3DA.%2BI.%26aulast%3DSuresh%2BKumar%26aufirst%3DR.%26aulast%3DArumugam%26aufirst%3DN.%26aulast%3DSriram%26aufirst%3DD.%26atitle%3DA%2520solvent%2520free%252C%2520four-component%2520synthesis%2520and%25201%252C3-dipolar%2520cycloaddition%2520of%25204%2528h%2529-pyrans%2520with%2520nitrile%2520oxides%253A%2520Synthesis%2520and%2520discovery%2520of%2520antimycobacterial%2520activity%2520of%2520enantiomerically%2520pure%25201%252C2%252C4-oxadiazoles%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2012%26volume%3D53%26spage%3D416%26epage%3D423%26doi%3D10.1016%2Fj.ejmech.2012.04.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sriram, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yogeeswari, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinakaran, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadhwal, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel antitubercular 2,10-dihydro-4ah-chromeno[3,2-c]pyridin-3-yl derivatives</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">120</span>– <span class="NLM_lpage">123</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2009.09.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.ejmech.2009.09.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=19942326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsF2ju7%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2010&pages=120-123&author=D.+Sriramauthor=P.+Yogeeswariauthor=M.+Dinakaranauthor=D.+Banerjeeauthor=P.+Bhatauthor=S.+Gadhwal&title=Discovery+of+novel+antitubercular+2%2C10-dihydro-4ah-chromeno%5B3%2C2-c%5Dpyridin-3-yl+derivatives&doi=10.1016%2Fj.ejmech.2009.09.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel antitubercular 2,10-dihydro-4aH-chromeno[3,2-c]pyridin-3-yl derivatives</span></div><div class="casAuthors">Sriram, Dharmarajan; Yogeeswari, Perumal; Dinakaran, Murugesan; Banerjee, Debjani; Bhat, Pritesh; Gadhwal, Sunil</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">120-123</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Twenty two novel 2,10-dihydro-4aH-chromeno[3,2-c]pyridin-3-yl derivs. were synthesized by reacting 3-formyl chromone, (sub)-2-amino pyridines, and N1-(prop-2-ynyl)arylamides in the presence of indium triflate.  The compds. were evaluated for their preliminary in-vitro and in-vivo activity against Mycobacterium tuberculosis H37Rv (MTB) and multi-drug resistant M. tuberculosis (MDR-TB).  Among them I was found to be the most active compd. in-vitro with MIC's of 0.22 and 0.07 μg/mL against MTB and MDR-TB resp.  In the in-vivo animal model I decreased the bacterial load in lung and spleen tissues with 1.11 and 2.94-log10 protections resp. at 25 mg/kg body wt. dose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWVPZwaPvoHLVg90H21EOLACvtfcHk0liKxkKiW62Rzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsF2ju7%252FO&md5=3d92b6be4c3db800d3303866eadea522</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2009.09.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2009.09.033%26sid%3Dliteratum%253Aachs%26aulast%3DSriram%26aufirst%3DD.%26aulast%3DYogeeswari%26aufirst%3DP.%26aulast%3DDinakaran%26aufirst%3DM.%26aulast%3DBanerjee%26aufirst%3DD.%26aulast%3DBhat%26aufirst%3DP.%26aulast%3DGadhwal%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520novel%2520antitubercular%25202%252C10-dihydro-4ah-chromeno%255B3%252C2-c%255Dpyridin-3-yl%2520derivatives%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2010%26volume%3D45%26spage%3D120%26epage%3D123%26doi%3D10.1016%2Fj.ejmech.2009.09.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jeyachandran, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramesh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sriram, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senthilkumar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yogeeswari, P.</span></span> <span> </span><span class="NLM_article-title">Synthesis and in vitro antitubercular activity of 4-aryl/alkylsulfonylmethylcoumarins as inhibitors of mycobacterium tuberculosis</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">4807</span>– <span class="NLM_lpage">4809</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.05.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmcl.2012.05.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=22726933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38XovFWku7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=4807-4809&author=M.+Jeyachandranauthor=P.+Rameshauthor=D.+Sriramauthor=P.+Senthilkumarauthor=P.+Yogeeswari&title=Synthesis+and+in+vitro+antitubercular+activity+of+4-aryl%2Falkylsulfonylmethylcoumarins+as+inhibitors+of+mycobacterium+tuberculosis&doi=10.1016%2Fj.bmcl.2012.05.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and in vitro antitubercular activity of 4-aryl/alkylsulfonylmethylcoumarins as inhibitors of Mycobacterium tuberculosis</span></div><div class="casAuthors">Jeyachandran, Malaichamy; Ramesh, Penugonda; Sriram, Dharmarajan; Senthilkumar, Palaniappan; Yogeeswari, Perumal</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4807-4809</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of 4-aryl/alkylsulfonylmethylcoumarins have been synthesized and screened for in vitro antitubercular activity against Mycobacterium tuberculosis H37Rv (MTB).  Four of the compds. showed MIC in the range of 0.78-3.13 μg/mL proving their potential activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgY51oiqEvk7Vg90H21EOLACvtfcHk0liKxkKiW62Rzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovFWku7w%253D&md5=34d3ce448161608ca7e95cda4d9917fd</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.05.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.05.054%26sid%3Dliteratum%253Aachs%26aulast%3DJeyachandran%26aufirst%3DM.%26aulast%3DRamesh%26aufirst%3DP.%26aulast%3DSriram%26aufirst%3DD.%26aulast%3DSenthilkumar%26aufirst%3DP.%26aulast%3DYogeeswari%26aufirst%3DP.%26atitle%3DSynthesis%2520and%2520in%2520vitro%2520antitubercular%2520activity%2520of%25204-aryl%252Falkylsulfonylmethylcoumarins%2520as%2520inhibitors%2520of%2520mycobacterium%2520tuberculosis%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D4807%26epage%3D4809%26doi%3D10.1016%2Fj.bmcl.2012.05.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palomba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briguglio, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corona, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piras, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jabes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guglierame, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molicotti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanetti, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and anti-mycobacterial activities of triazoloquinolones</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">320</span>– <span class="NLM_lpage">326</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2010.11.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.ejmech.2010.11.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=21145625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A280%3ADC%252BC3M%252Fls1SrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2011&pages=320-326&author=A.+Cartaauthor=M.+Palombaauthor=I.+Briguglioauthor=P.+Coronaauthor=S.+Pirasauthor=D.+Jabesauthor=P.+Guglierameauthor=P.+Molicottiauthor=S.+Zanetti&title=Synthesis+and+anti-mycobacterial+activities+of+triazoloquinolones&doi=10.1016%2Fj.ejmech.2010.11.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and anti-mycobacterial activities of triazoloquinolones</span></div><div class="casAuthors">Carta Antonio; Palomba Michele; Briguglio Irene; Corona Paola; Piras Sandra; Jabes Daniela; Guglierame Paola; Molicotti Paola; Zanetti Stefania</div><div class="citationInfo"><span class="NLM_cas:title">European journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">320-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">A number of quinolone derivatives have been reported to possess anti-mycobacterial activity.  Generally.  Mycobacterium tuberculosis isolates expressing resistance to both isoniazid and rifampin are susceptible to fluoroquinolones.  Benzotriazole is a hetero-bicyclic aromatic ring endowed with interesting chemical and biological properties and pharmacological activities.  In a preliminary study we have recently reported the activity of triazolo[4,5-h]quinolone-carboxylic acids, a new class of benzotriazole derivatives active against multi-drug resistant M. tuberculosis (MDR-Mtb).  In this study we confirm that this novel class of quinolones is endowed with a selective anti-mycobacterial activity, coupled with absence of cytotoxicity.  The SAR analysis of the new derivatives in comparison with the previous series shows that the methyl group is the most effective substituent in both N-3 and N-9 positions of the ring system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRGpSfNoQPp8UH3Rlp_k91zfW6udTcc2eaE4FANiHQQerntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M%252Fls1SrsA%253D%253D&md5=e2024c716bcfa9bd773a36f73fbd1d66</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2010.11.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2010.11.020%26sid%3Dliteratum%253Aachs%26aulast%3DCarta%26aufirst%3DA.%26aulast%3DPalomba%26aufirst%3DM.%26aulast%3DBriguglio%26aufirst%3DI.%26aulast%3DCorona%26aufirst%3DP.%26aulast%3DPiras%26aufirst%3DS.%26aulast%3DJabes%26aufirst%3DD.%26aulast%3DGuglierame%26aufirst%3DP.%26aulast%3DMolicotti%26aufirst%3DP.%26aulast%3DZanetti%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520anti-mycobacterial%2520activities%2520of%2520triazoloquinolones%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2011%26volume%3D46%26spage%3D320%26epage%3D326%26doi%3D10.1016%2Fj.ejmech.2010.11.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Makarov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neres, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartkoorn, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryabova, O. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazakova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huszar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolly, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conroy, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikusova, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S. T.</span></span> <span> </span><span class="NLM_article-title">The 8-pyrrole-benzothiazinones are noncovalent inhibitors of DprE1 from mycobacterium tuberculosis</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">4446</span>– <span class="NLM_lpage">4452</span>, <span class="refDoi"> DOI: 10.1128/AAC.00778-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.00778-15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=25987616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1KntLzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=4446-4452&author=V.+Makarovauthor=J.+Neresauthor=R.+C.+Hartkoornauthor=O.+B.+Ryabovaauthor=E.+Kazakovaauthor=M.+Sarkanauthor=S.+Huszarauthor=J.+Pitonauthor=G.+S.+Kollyauthor=A.+Vocatauthor=T.+M.+Conroyauthor=K.+Mikusovaauthor=S.+T.+Cole&title=The+8-pyrrole-benzothiazinones+are+noncovalent+inhibitors+of+DprE1+from+mycobacterium+tuberculosis&doi=10.1128%2FAAC.00778-15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">The 8-pyrrole-benzothiazinones are noncovalent inhibitors of DprE1 from Mycobacterium tuberculosis</span></div><div class="casAuthors">Makarov, Vadim; Neres, Joao; Hartkoorn, Ruben C.; Ryabova, Olga B.; Kazakova, Elena; Sarkan, Michal; Huszar, Stanislav; Piton, Jeremie; Kolly, Gaelle S.; Vocat, Anthony; Conroy, Trent M.; Mikusova, Katarina; Cole, Stewart T.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4446-4452</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">8-Nitro-benzothiazinones (BTZs), such as BTZ043 and PBTZ169, inhibit decaprenylphosphoryl-β-d-ribose 2'-oxidase (DprE1) and display nanomolar bactericidal activity against Mycobacterium tuberculosis in vitro.  Structure-activity relationship (SAR) studies revealed the 8-nitro group of the BTZ scaffold to be crucial for the mechanism of action, which involves formation of a semimercaptal bond with Cys387 in the active site of DprE1.  To date, substitution of the 8-nitro group has led to extensive loss of antimycobacterial activity.  Here, we report the synthesis and characterization of the pyrrole-benzothiazinones PyrBTZ01 and PyrBTZ02, non-nitro-benzothiazinones that retain significant antimycobacterial activity, with MICs of 0.16 μg/mL against M. tuberculosis.  These compds. inhibit DprE1 with 50% inhibitory concn. (IC50) values of <8 μM and present favorable in vitro absorption-distribution-metab.-excretion/toxicity (ADME/T) and in vivo pharmacokinetic profiles.  The most promising compd., PyrBTZ01, did not show efficacy in a mouse model of acute tuberculosis, suggesting that BTZ-mediated killing through DprE1 inhibition requires a combination of both covalent bond formation and compd. potency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCkI5dkX3OC7Vg90H21EOLACvtfcHk0lhAgNRBO41Cyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1KntLzN&md5=135807fc4818119172942c09971147fd</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1128%2FAAC.00778-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00778-15%26sid%3Dliteratum%253Aachs%26aulast%3DMakarov%26aufirst%3DV.%26aulast%3DNeres%26aufirst%3DJ.%26aulast%3DHartkoorn%26aufirst%3DR.%2BC.%26aulast%3DRyabova%26aufirst%3DO.%2BB.%26aulast%3DKazakova%26aufirst%3DE.%26aulast%3DSarkan%26aufirst%3DM.%26aulast%3DHuszar%26aufirst%3DS.%26aulast%3DPiton%26aufirst%3DJ.%26aulast%3DKolly%26aufirst%3DG.%2BS.%26aulast%3DVocat%26aufirst%3DA.%26aulast%3DConroy%26aufirst%3DT.%2BM.%26aulast%3DMikusova%26aufirst%3DK.%26aulast%3DCole%26aufirst%3DS.%2BT.%26atitle%3DThe%25208-pyrrole-benzothiazinones%2520are%2520noncovalent%2520inhibitors%2520of%2520DprE1%2520from%2520mycobacterium%2520tuberculosis%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26spage%3D4446%26epage%3D4452%26doi%3D10.1128%2FAAC.00778-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">182</a></strong><div class="NLM_citation" id="cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lechartier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartkoorn, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S. T.</span></span> <span> </span><span class="NLM_article-title">In vitro combination studies of benzothiazinone lead compound BTZ043 against mycobacterium tuberculosis</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">5790</span>– <span class="NLM_lpage">5793</span>, <span class="refDoi"> DOI: 10.1128/AAC.01476-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.01476-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=22926573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsF2iurnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=5790-5793&author=B.+Lechartierauthor=R.+C.+Hartkoornauthor=S.+T.+Cole&title=In+vitro+combination+studies+of+benzothiazinone+lead+compound+BTZ043+against+mycobacterium+tuberculosis&doi=10.1128%2FAAC.01476-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis</span></div><div class="casAuthors">Lechartier, Benoit; Hartkoorn, Ruben C.; Cole, Stewart T.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5790-5793</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Benzothiazinones (BTZ) are a new class of drug candidates to combat tuberculosis that inhibit decaprenyl-phosphoribose epimerase (DprE1), an essential enzyme involved in arabinan biosynthesis.  Using the checkerboard method and cell viability assays, the authors have studied the interaction profiles of BTZ043, the current lead compd., with several antituberculosis drugs or drug candidates against Mycobacterium tuberculosis strain H37Rv, namely, rifampin, isoniazid, ethambutol, TMC207, PA-824, moxifloxacin, meropenem with or without clavulanate, and SQ-109.  No antagonism was found between BTZ043 and the tested compds., and most of the interactions were purely additive.  Data from two different approaches clearly indicate that BTZ043 acts synergistically with TMC207, with a fractional inhibitory concn. index of 0.5.  TMC207 at a quarter of the MIC (20 ng/mL) used in combination with BTZ043 (1/4 MIC, 0.375 ng/mL) had a stronger bactericidal effect on M. tuberculosis than TMC207 alone at a concn. of 80 ng/mL.  This synergy was not obsd. when the combination was tested on a BTZ-resistant M. tuberculosis mutant, suggesting that DprE1 inhibition is the basis for the interaction.  This finding excludes the possibility of synergy occurring through an off-target mechanism.  We therefore hypothesize that sub-MICs of BTZ043 weaken the bacterial cell wall and allow improved penetration of TMC207 to its target.  Synergy between two new antimycobacterial compds., such as TMC207 and BTZ043, with novel targets, offers an attractive foundation for a new tuberculosis regimen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQb9Jz2Uer_rVg90H21EOLACvtfcHk0lhAgNRBO41Cyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsF2iurnJ&md5=51a7a69ecdfd6828fb8a7eb214902812</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1128%2FAAC.01476-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01476-12%26sid%3Dliteratum%253Aachs%26aulast%3DLechartier%26aufirst%3DB.%26aulast%3DHartkoorn%26aufirst%3DR.%2BC.%26aulast%3DCole%26aufirst%3DS.%2BT.%26atitle%3DIn%2520vitro%2520combination%2520studies%2520of%2520benzothiazinone%2520lead%2520compound%2520BTZ043%2520against%2520mycobacterium%2520tuberculosis%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D5790%26epage%3D5793%26doi%3D10.1128%2FAAC.01476-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref183"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref183'); return false;" data-citation="" class="refNumLink">183</a></strong><div class="NLM_citation" id="cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karoli, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuegg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Möllmann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, M. A.</span></span> <span> </span><span class="NLM_article-title">Identification of antitubercular benzothiazinone compounds by ligand-based design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">7940</span>– <span class="NLM_lpage">7944</span>, <span class="refDoi"> DOI: 10.1021/jm3008882</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3008882" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Ghu73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7940-7944&author=T.+Karoliauthor=B.+Beckerauthor=J.+Zueggauthor=U.+M%C3%B6llmannauthor=S.+Ramuauthor=J.+X.+Huangauthor=M.+A.+Cooper&title=Identification+of+antitubercular+benzothiazinone+compounds+by+ligand-based+design&doi=10.1021%2Fjm3008882"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Antitubercular Benzothiazinone Compounds by Ligand-Based Design</span></div><div class="casAuthors">Karoli, Tomislav; Becker, Bernd; Zuegg, Johannes; Mollmann, Ute; Ramu, Soumya; Huang, Johnny X.; Cooper, Matthew A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7940-7944</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">1,3-Benzothiazin-4-ones (BTZs) are a novel class of TB drug candidates with potent activity against M. tuberculosis.  An in silico ligand-based model based on structure-activity data from 170 BTZ compds. was used to design a new series.  Compds. were tested against a panel of mycobacterial strains and were profiled for cytotoxicity, stability, and antiproliferative effects.  Several of the compds. showed improved activity against MDR-TB while retaining low toxicity with higher microsomal, metabolic, and plasma stability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo55OwRcL9-ebVg90H21EOLACvtfcHk0liWY-Xh9WgwgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Ghu73K&md5=8f9d6a494927943613d7cfc78b97a188</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1021%2Fjm3008882&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3008882%26sid%3Dliteratum%253Aachs%26aulast%3DKaroli%26aufirst%3DT.%26aulast%3DBecker%26aufirst%3DB.%26aulast%3DZuegg%26aufirst%3DJ.%26aulast%3DM%25C3%25B6llmann%26aufirst%3DU.%26aulast%3DRamu%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DJ.%2BX.%26aulast%3DCooper%26aufirst%3DM.%2BA.%26atitle%3DIdentification%2520of%2520antitubercular%2520benzothiazinone%2520compounds%2520by%2520ligand-based%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7940%26epage%3D7944%26doi%3D10.1021%2Fjm3008882" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref184"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref184'); return false;" data-citation="" class="refNumLink">184</a></strong><div class="NLM_citation" id="cit184"><span> <i>Macozinone
(MCZ, PBTZ-169)</i>; <span class="NLM_publisher-name">The Working
Group for New TB Drugs</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">2018</span>; <a href="https://www.newtbdrugs.org/pipeline/compound/macozinone-mcz-pbtz-169" class="extLink">https://www.newtbdrugs.org/pipeline/compound/macozinone-mcz-pbtz-169</a> (accessed 2020-03-03).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Macozinone%0A%28MCZ%2C+PBTZ-169%29%3B+The+Working%0AGroup+for+New+TB+Drugs%3A+New+York%2C+2018%3B+https%3A%2F%2Fwww.newtbdrugs.org%2Fpipeline%2Fcompound%2Fmacozinone-mcz-pbtz-169+%28accessed+2020-03-03%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26jtitle%3DMacozinone%250A%2528MCZ%252C%2520PBTZ-169%2529%26pub%3DThe%2520Working%250AGroup%2520for%2520New%2520TB%2520Drugs%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref185"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref185'); return false;" data-citation="" class="refNumLink">185</a></strong><div class="NLM_citation" id="cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Almansour, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ismail, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choon, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellappan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elumalai, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandian, S.</span></span> <span> </span><span class="NLM_article-title">A regio- and stereoselective 1,3-dipolar cycloaddition for the synthesis of new-fangled dispiropyrrolothiazoles as antimycobacterial agents</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">7418</span>– <span class="NLM_lpage">7421</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.10.059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmcl.2012.10.059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=23122863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Wjs7%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=7418-7421&author=A.+I.+Almansourauthor=S.+Aliauthor=M.+A.+Aliauthor=R.+Ismailauthor=T.+S.+Choonauthor=V.+Sellappanauthor=K.+K.+Elumalaiauthor=S.+Pandian&title=A+regio-+and+stereoselective+1%2C3-dipolar+cycloaddition+for+the+synthesis+of+new-fangled+dispiropyrrolothiazoles+as+antimycobacterial+agents&doi=10.1016%2Fj.bmcl.2012.10.059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">A regio- and stereoselective 1,3-dipolar cycloaddition for the synthesis of new-fangled dispiropyrrolothiazoles as antimycobacterial agents</span></div><div class="casAuthors">Almansour, Abdulrahman I.; Ali, Sadath; Ali, Mohamed Ashraf; Ismail, Rusli; Choon, Tan Soo; Sellappan, Velmurugan; Elumalai, Karthi keyan; Pandian, Suresh</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7418-7421</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of dispiropyrrolothiazoles compds. were synthesized using 1,3-dipolar cycloaddn. and were screened for antimycobacterial activity against Mycobacterium tuberculosis H37Rv and INH resistant M. tuberculosis strains.  Two of them were showing good activity with MIC of less than 1 μM.  Compd. I (R = pyridyl) was found to be the most active with MIC of 0.210 and 8.312 μM resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5XqIAqogTjLVg90H21EOLACvtfcHk0liWY-Xh9WgwgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Wjs7%252FO&md5=f2c6fef32d4d65ce38f5604b042ab220</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.10.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.10.059%26sid%3Dliteratum%253Aachs%26aulast%3DAlmansour%26aufirst%3DA.%2BI.%26aulast%3DAli%26aufirst%3DS.%26aulast%3DAli%26aufirst%3DM.%2BA.%26aulast%3DIsmail%26aufirst%3DR.%26aulast%3DChoon%26aufirst%3DT.%2BS.%26aulast%3DSellappan%26aufirst%3DV.%26aulast%3DElumalai%26aufirst%3DK.%2BK.%26aulast%3DPandian%26aufirst%3DS.%26atitle%3DA%2520regio-%2520and%2520stereoselective%25201%252C3-dipolar%2520cycloaddition%2520for%2520the%2520synthesis%2520of%2520new-fangled%2520dispiropyrrolothiazoles%2520as%2520antimycobacterial%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D7418%26epage%3D7421%26doi%3D10.1016%2Fj.bmcl.2012.10.059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref186"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref186'); return false;" data-citation="" class="refNumLink">186</a></strong><div class="NLM_citation" id="cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karthikeyan, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bala, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raja, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perumal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yogeeswari, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sriram, D.</span></span> <span> </span><span class="NLM_article-title">A highly atom economic, chemo-, regio- and stereoselective synthesis and evaluation of spiro-pyrrolothiazoles as antitubercular agents</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">350</span>– <span class="NLM_lpage">353</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.10.107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmcl.2009.10.107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=19900810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsF2jsb3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=350-353&author=S.+V.+Karthikeyanauthor=B.+D.+Balaauthor=V.+P.+Rajaauthor=S.+Perumalauthor=P.+Yogeeswariauthor=D.+Sriram&title=A+highly+atom+economic%2C+chemo-%2C+regio-+and+stereoselective+synthesis+and+evaluation+of+spiro-pyrrolothiazoles+as+antitubercular+agents&doi=10.1016%2Fj.bmcl.2009.10.107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">A highly atom economic, chemo-, regio- and stereoselective synthesis and evaluation of spiro-pyrrolothiazoles as antitubercular agents</span></div><div class="casAuthors">Karthikeyan, Subramanian Vedhanarayanan; Bala, Balasubramanian Devi; Raja, Velanganni Paul Alex; Perumal, Subbu; Yogeeswari, Perumal; Sriram, Dharmarajan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">350-353</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The 1,3-dipolar cycloaddn. of azomethine ylides, derived from substituted isatins and 1,3-thiazolidine-4-carboxylic acid, to a series of 1-methyl-3,5-bis[(E)-arylmethylidene]-tetrahydro-4(1H)-pyridinones I (R = Ph, 4-FC6H4, 2-MeOC6H4, 2,4-Cl2C6H3, 2-thienyl, etc.) afforded novel spiro-pyrrolothiazoles II (X = H, Cl, O2N) chemo-, regio- and stereoselectively in excellent yields.  These compds. were screened for their in vitro activity against Mycobacterium tuberculosis H37Rv (MTB) and multi-drug resistant M. tuberculosis (MDR-TB) using agar diln. method.  Among the synthesized compds., I (R = 2,4-Cl2C6H3; X = O2N) was found to be the most active with a min. inhibitory concn. (MIC) of 0.6 μM against MTB and MDR-TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqkj6yCeaqqbVg90H21EOLACvtfcHk0liWY-Xh9WgwgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsF2jsb3F&md5=302cb2c22b03cb71f30408a6584d0ef6</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.10.107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.10.107%26sid%3Dliteratum%253Aachs%26aulast%3DKarthikeyan%26aufirst%3DS.%2BV.%26aulast%3DBala%26aufirst%3DB.%2BD.%26aulast%3DRaja%26aufirst%3DV.%2BP.%26aulast%3DPerumal%26aufirst%3DS.%26aulast%3DYogeeswari%26aufirst%3DP.%26aulast%3DSriram%26aufirst%3DD.%26atitle%3DA%2520highly%2520atom%2520economic%252C%2520chemo-%252C%2520regio-%2520and%2520stereoselective%2520synthesis%2520and%2520evaluation%2520of%2520spiro-pyrrolothiazoles%2520as%2520antitubercular%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D350%26epage%3D353%26doi%3D10.1016%2Fj.bmcl.2009.10.107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref187"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref187'); return false;" data-citation="" class="refNumLink">187</a></strong><div class="NLM_citation" id="cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, D. Q.</span></span> <span> </span><span class="NLM_article-title">Synthesis, structure-activity relationship and in vitro anti-mycobacterial evaluation of 13-n-octylberberine derivatives</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">158</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2012.03.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.ejmech.2012.03.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=22503208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtlSlu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=151-158&author=Y.+X.+Liuauthor=C.+L.+Xiaoauthor=Y.+X.+Wangauthor=Y.+H.+Liauthor=Y.+H.+Yangauthor=Y.+B.+Liauthor=C.+W.+Biauthor=L.+M.+Gaoauthor=J.+D.+Jiangauthor=D.+Q.+Song&title=Synthesis%2C+structure-activity+relationship+and+in+vitro+anti-mycobacterial+evaluation+of+13-n-octylberberine+derivatives&doi=10.1016%2Fj.ejmech.2012.03.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, structure-activity relationship and in vitro anti-mycobacterial evaluation of 13-n-octylberberine derivatives</span></div><div class="casAuthors">Liu, Yan-Xin; Xiao, Chun-Ling; Wang, Yan-Xiang; Li, Ying-Hong; Yang, Yan-Hui; Li, Yang-Biao; Bi, Chong-Wen; Gao, Li-Mei; Jiang, Jian-Dong; Song, Dan-Qing</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">151-158</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Twenty-eight new 13-n-octylberberine derivs. I (R1 = OMe, OH, OCH2Ph, etc., R2R3 = OCH2O; R1 = OMe, R2 = OH, OMe, OCH2Ph, etc., R3 = OH, O-n-Pr, O-n-Bu, etc.; R1 = OMe, R2 = R3 = OH; R1 = R2 = R3 = OH; R1 = OEt, OCH2Ph, O-n-Pr, O-n-Bu, R2 = OH, OEt, OCH2Ph, R3 = OEt, O-n-Pr, O-n-Bu, OCH2Ph) were synthesized and evaluated for their activities against drug-susceptible Mycobacterium tuberculosis (M. tuberculosis) strain H37Rv.  Among these compds., compd. I (R1 = R2 = R3 = OEt) (II) was the most effective anti-tubercular agent with a MIC value of 0.125 μg/mL.  Importantly, compd. II exhibited a more potent effect against rifampicin (RIF)- and isoniazid (INH)-resistant M. tuberculosis strains than both RIF and INH, suggesting a new mechanism of action.  Therefore, II has been selected as a drug candidate for further investigation, or as a chem. probe for identifying the protein target and studying tuberculosis biol.  We consider 13-n-octylberberine analogs to be a promising novel class of antituberculars against multi-drug-resistant (MDR) strains of M. tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocfJRw7pCmy7Vg90H21EOLACvtfcHk0lhwqYugrShG6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtlSlu7w%253D&md5=0e00abe606d8ba77f4838f66f72e3879</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2012.03.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2012.03.012%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%2BX.%26aulast%3DXiao%26aufirst%3DC.%2BL.%26aulast%3DWang%26aufirst%3DY.%2BX.%26aulast%3DLi%26aufirst%3DY.%2BH.%26aulast%3DYang%26aufirst%3DY.%2BH.%26aulast%3DLi%26aufirst%3DY.%2BB.%26aulast%3DBi%26aufirst%3DC.%2BW.%26aulast%3DGao%26aufirst%3DL.%2BM.%26aulast%3DJiang%26aufirst%3DJ.%2BD.%26aulast%3DSong%26aufirst%3DD.%2BQ.%26atitle%3DSynthesis%252C%2520structure-activity%2520relationship%2520and%2520in%2520vitro%2520anti-mycobacterial%2520evaluation%2520of%252013-n-octylberberine%2520derivatives%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2012%26volume%3D52%26spage%3D151%26epage%3D158%26doi%3D10.1016%2Fj.ejmech.2012.03.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref188"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref188'); return false;" data-citation="" class="refNumLink">188</a></strong><div class="NLM_citation" id="cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keffer, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huecas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammill, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wipf, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreu, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bewley, C. A.</span></span> <span> </span><span class="NLM_article-title">Chrysophaentins are competitive inhibitors of FtsZ and inhibit z-ring formation in live bacteria</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">5673</span>– <span class="NLM_lpage">5678</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.07.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmc.2013.07.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=23932448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1elur7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=5673-5678&author=J.+L.+Kefferauthor=S.+Huecasauthor=J.+T.+Hammillauthor=P.+Wipfauthor=J.+M.+Andreuauthor=C.+A.+Bewley&title=Chrysophaentins+are+competitive+inhibitors+of+FtsZ+and+inhibit+z-ring+formation+in+live+bacteria&doi=10.1016%2Fj.bmc.2013.07.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Chrysophaentins are competitive inhibitors of FtsZ and inhibit Z-ring formation in live bacteria</span></div><div class="casAuthors">Keffer, Jessica L.; Huecas, Sonia; Hammill, Jared T.; Wipf, Peter; Andreu, Jose M.; Bewley, Carole A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5673-5678</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The bacterial cell division protein FtsZ polymerizes in a GTP-dependent manner to form a Z-ring that marks the plane of division.  As a validated antimicrobial target, considerable efforts have been devoted to identify small mol. FtsZ inhibitors.  The authors recently discovered the chrysophaentins, a novel suite of marine natural products that inhibit FtsZ activity in vitro.  These natural products along with a synthetic hemi-chrysophaentin exhibit strong antimicrobial activity toward a broad spectrum of Gram-pos. pathogens.  To define the mechanisms of FtsZ inhibition and det. their in vivo effects in live bacteria, the authors used GTPase assays and fluorescence anisotropy to show that hemi-chrysophaentin competitively inhibits FtsZ activity.  Furthermore, they developed a model system using a permeable Escherichia coli strain, envA1, together with an inducible FtsZ-yellow fluorescent protein construct to show by fluorescence microscopy that both chrysophaentin A and hemi-chrysophaentin disrupt Z-rings in live bacteria.  The authors tested the E. coli system further by reproducing phenotypes obsd. for zantrins Z1 and Z3, and demonstrate that the alkaloid berberine, a reported FtsZ inhibitor, exhibits auto-fluorescence, making it incompatible with systems that employ GFP or YFP tagged FtsZ.  These studies describe unique examples of nonnucleotide, competitive FtsZ inhibitors that disrupt FtsZ in vivo, together with a model system that should be useful for in vivo testing of FtsZ inhibitor leads that have been identified through in vitro screens but are unable to penetrate the Gram-neg. outer membrane.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlTOsVKDet67Vg90H21EOLACvtfcHk0lhwqYugrShG6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1elur7K&md5=a9716bf8cd08d90092613473456db1ac</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.07.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.07.033%26sid%3Dliteratum%253Aachs%26aulast%3DKeffer%26aufirst%3DJ.%2BL.%26aulast%3DHuecas%26aufirst%3DS.%26aulast%3DHammill%26aufirst%3DJ.%2BT.%26aulast%3DWipf%26aufirst%3DP.%26aulast%3DAndreu%26aufirst%3DJ.%2BM.%26aulast%3DBewley%26aufirst%3DC.%2BA.%26atitle%3DChrysophaentins%2520are%2520competitive%2520inhibitors%2520of%2520FtsZ%2520and%2520inhibit%2520z-ring%2520formation%2520in%2520live%2520bacteria%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D5673%26epage%3D5678%26doi%3D10.1016%2Fj.bmc.2013.07.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref189"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref189'); return false;" data-citation="" class="refNumLink">189</a></strong><div class="NLM_citation" id="cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hotoda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furukawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daigo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murayama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muramatsu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyakoshi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takatsu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inukai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakuta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuoka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Utsui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohya, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antimycobacterial activity of capuramycin analogues. Part 1: Substitution of the azepan-2-one moiety of capuramycin</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">2829</span>– <span class="NLM_lpage">2832</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(03)00596-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2FS0960-894X%2803%2900596-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=14611838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmvFajtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=2829-2832&author=H.+Hotodaauthor=M.+Furukawaauthor=M.+Daigoauthor=K.+Murayamaauthor=M.+Kanekoauthor=Y.+Muramatsuauthor=M.+M.+Ishiiauthor=S.+Miyakoshiauthor=T.+Takatsuauthor=M.+Inukaiauthor=M.+Kakutaauthor=T.+Abeauthor=T.+Harasakiauthor=T.+Fukuokaauthor=Y.+Utsuiauthor=S.+Ohya&title=Synthesis+and+antimycobacterial+activity+of+capuramycin+analogues.+Part+1%3A+Substitution+of+the+azepan-2-one+moiety+of+capuramycin&doi=10.1016%2FS0960-894X%2803%2900596-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antimycobacterial activity of capuramycin analogs. Part 1: Substitution of the azepan-2-one moiety of capuramycin</span></div><div class="casAuthors">Hotoda, Hitoshi; Furukawa, Miyuki; Daigo, Makiko; Murayama, Kazuhiro; Kaneko, Masakatsu; Muramatsu, Yasunori; Ishii, Michiko Miyazawa; Miyakoshi, Shun-ichi; Takatsu, Toshio; Inukai, Masatoshi; Kakuta, Masayo; Abe, Tomomi; Harasaki, Tamako; Fukuoka, Takashi; Utsui, Yukio; Ohya, Satoshi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2829-2832</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Capuramycin analogs, e.g. I, with a variety of substituents in place of the azepan-2-one moiety were synthesized from A-500359E and were tested for their translocase I inhibitory activity and in vitro antimycobacterial activity.  Phenyl-type moieties were found to be effective substituents for capuramycin analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDe1IJkAmDh7Vg90H21EOLACvtfcHk0lhwqYugrShG6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmvFajtb0%253D&md5=439f894b257ccceffb84ca0cb39b675b</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2803%2900596-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252803%252900596-1%26sid%3Dliteratum%253Aachs%26aulast%3DHotoda%26aufirst%3DH.%26aulast%3DFurukawa%26aufirst%3DM.%26aulast%3DDaigo%26aufirst%3DM.%26aulast%3DMurayama%26aufirst%3DK.%26aulast%3DKaneko%26aufirst%3DM.%26aulast%3DMuramatsu%26aufirst%3DY.%26aulast%3DIshii%26aufirst%3DM.%2BM.%26aulast%3DMiyakoshi%26aufirst%3DS.%26aulast%3DTakatsu%26aufirst%3DT.%26aulast%3DInukai%26aufirst%3DM.%26aulast%3DKakuta%26aufirst%3DM.%26aulast%3DAbe%26aufirst%3DT.%26aulast%3DHarasaki%26aufirst%3DT.%26aulast%3DFukuoka%26aufirst%3DT.%26aulast%3DUtsui%26aufirst%3DY.%26aulast%3DOhya%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520antimycobacterial%2520activity%2520of%2520capuramycin%2520analogues.%2520Part%25201%253A%2520Substitution%2520of%2520the%2520azepan-2-one%2520moiety%2520of%2520capuramycin%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26spage%3D2829%26epage%3D2832%26doi%3D10.1016%2FS0960-894X%2803%2900596-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref190"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref190'); return false;" data-citation="" class="refNumLink">190</a></strong><div class="NLM_citation" id="cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bugg, T. D.</span></span> <span> </span><span class="NLM_article-title">Recent advances in antimicrobial nucleoside antibiotics targeting cell wall biosynthesis</span>. <i>Nat. Prod. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">252</span>– <span class="NLM_lpage">273</span>, <span class="refDoi"> DOI: 10.1039/b202149h</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1039%2Fb202149h" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=12735700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjslCqtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2003&pages=252-273&author=K.+Kimuraauthor=T.+D.+Bugg&title=Recent+advances+in+antimicrobial+nucleoside+antibiotics+targeting+cell+wall+biosynthesis&doi=10.1039%2Fb202149h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in antimicrobial nucleoside antibiotics targeting cell wall biosynthesis</span></div><div class="casAuthors">Kimura, Ken-Ichi; Bugg, Timothy D. H.</div><div class="citationInfo"><span class="NLM_cas:title">Natural Product Reports</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">252-273</span>CODEN:
                <span class="NLM_cas:coden">NPRRDF</span>;
        ISSN:<span class="NLM_cas:issn">0265-0568</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  The biosynthesis of peptidoglycan is essential for all bacteria and has no counterpart in eukaryotic cells.  It is one of the prime targets for antibiotic chemotherapy, esp. phospho-MurNAc-pentapeptide translocase (translocase I) is a fascinating target in which there is no com. antibiotic.  In this review we will describe three nucleoside translocase I inhibitors, mureidomycin, tunicamycin and liposidomycin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrksNstyeT_iLVg90H21EOLACvtfcHk0lg6bSr4xdH9qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjslCqtr4%253D&md5=8c6823d378a4754c368a6179b5bfa057</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1039%2Fb202149h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb202149h%26sid%3Dliteratum%253Aachs%26aulast%3DKimura%26aufirst%3DK.%26aulast%3DBugg%26aufirst%3DT.%2BD.%26atitle%3DRecent%2520advances%2520in%2520antimicrobial%2520nucleoside%2520antibiotics%2520targeting%2520cell%2520wall%2520biosynthesis%26jtitle%3DNat.%2520Prod.%2520Rep.%26date%3D2003%26volume%3D20%26spage%3D252%26epage%3D273%26doi%3D10.1039%2Fb202149h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref191"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref191'); return false;" data-citation="" class="refNumLink">191</a></strong><div class="NLM_citation" id="cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bugg, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lloyd, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roper, D. I.</span></span> <span> </span><span class="NLM_article-title">Phospho-MurNAc-pentapeptide translocase (MraY) as a target for antibacterial agents and antibacterial proteins</span>. <i>Infect. Disord.: Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">106</span>, <span class="refDoi"> DOI: 10.2174/187152606784112128</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.2174%2F187152606784112128" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=16789873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD28XmtFers7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=85-106&author=T.+D.+Buggauthor=A.+J.+Lloydauthor=D.+I.+Roper&title=Phospho-MurNAc-pentapeptide+translocase+%28MraY%29+as+a+target+for+antibacterial+agents+and+antibacterial+proteins&doi=10.2174%2F187152606784112128"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Phospho-MurNAc-pentapeptide translocase (MraY) as a target for antibacterial agents and antibacterial proteins</span></div><div class="casAuthors">Bugg, Timothy D. H.; Lloyd, Adrian J.; Roper, David I.</div><div class="citationInfo"><span class="NLM_cas:title">Infectious Disorders: Drug Targets</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">85-106</span>CODEN:
                <span class="NLM_cas:coden">IDDTAD</span>;
        ISSN:<span class="NLM_cas:issn">1871-5265</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Phospho-MurNAc-pentapeptide translocase (MraY, translocase I) catalyzes the first step of the lipid-linked cycle of reactions of bacterial peptidoglycan biosynthesis.  MraY is the target for five families of nucleoside antibacterial natural products: the tunicamycins, the mureidomycins (also pacidamycins, napsamycins), the liposidomycins, the muraymycins, and the capuramycins.  Recent structure-activity studies on these families have led to the identification of active pharmacophores, and insight into their mechanisms of action.  This step of peptidoglycan biosynthesis is also the target for the bacteriolytic E protein from bacteriophage .vphi.X174, and for cyclic peptides of the amphomycin family which complex the undecaprenyl phosphate cosubstrate.  The mechanisms of enzyme inhibition by these agents are discussed, and the state of knowledge regarding the transmembrane structure, active site, and catalytic mechanism of MraY.  The availability of high throughput assays and prospects of MraY as an antibacterial target are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoA2V6DpkrljrVg90H21EOLACvtfcHk0lg6bSr4xdH9qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmtFers7Y%253D&md5=b209c55dbd91c009a292e861eebecf44</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.2174%2F187152606784112128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152606784112128%26sid%3Dliteratum%253Aachs%26aulast%3DBugg%26aufirst%3DT.%2BD.%26aulast%3DLloyd%26aufirst%3DA.%2BJ.%26aulast%3DRoper%26aufirst%3DD.%2BI.%26atitle%3DPhospho-MurNAc-pentapeptide%2520translocase%2520%2528MraY%2529%2520as%2520a%2520target%2520for%2520antibacterial%2520agents%2520and%2520antibacterial%2520proteins%26jtitle%3DInfect.%2520Disord.%253A%2520Drug%2520Targets%26date%3D2006%26volume%3D6%26spage%3D85%26epage%3D106%26doi%3D10.2174%2F187152606784112128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref192"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref192'); return false;" data-citation="" class="refNumLink">192</a></strong><div class="NLM_citation" id="cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nikonenko, B. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Protopopova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogatcheva, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einck, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacy, C. A.</span></span> <span> </span><span class="NLM_article-title">Activity of SQ641, a capuramycin analog, in a murine model of tuberculosis</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">3138</span>– <span class="NLM_lpage">3139</span>, <span class="refDoi"> DOI: 10.1128/AAC.00366-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.00366-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=19414567" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotlajsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2009&pages=3138-3139&author=B.+V.+Nikonenkoauthor=V.+M.+Reddyauthor=M.+Protopopovaauthor=E.+Bogatchevaauthor=L.+Einckauthor=C.+A.+Nacy&title=Activity+of+SQ641%2C+a+capuramycin+analog%2C+in+a+murine+model+of+tuberculosis&doi=10.1128%2FAAC.00366-09"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of SQ641, a capuramycin analog, in a murine model of tuberculosis</span></div><div class="casAuthors">Nikonenko, Boris V.; Reddy, Venkata M.; Protopopova, Marina; Bogatcheva, Elena; Einck, Leo; Nacy, Carol A.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3138-3139</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">New delivery vehicles and routes of delivery were developed for the capuramycin analog SQ641.  While this compd. has remarkable in vitro potency against Mycobacterium tuberculosis, it has low soly. in water and poor intracellular activity.  We demonstrate here that SQ641 dissolved in the water-sol. vitamin E analog α-tocopheryl polyethylene glycol 1000 succinate (TPGS) or incorporated into TPGS-micelles has significant activity in a mouse model of tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpktljK0aIDd7Vg90H21EOLACvtfcHk0lg6bSr4xdH9qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotlajsb8%253D&md5=4b4f1a87b152b163e1d68e185e710102</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1128%2FAAC.00366-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00366-09%26sid%3Dliteratum%253Aachs%26aulast%3DNikonenko%26aufirst%3DB.%2BV.%26aulast%3DReddy%26aufirst%3DV.%2BM.%26aulast%3DProtopopova%26aufirst%3DM.%26aulast%3DBogatcheva%26aufirst%3DE.%26aulast%3DEinck%26aufirst%3DL.%26aulast%3DNacy%26aufirst%3DC.%2BA.%26atitle%3DActivity%2520of%2520SQ641%252C%2520a%2520capuramycin%2520analog%252C%2520in%2520a%2520murine%2520model%2520of%2520tuberculosis%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2009%26volume%3D53%26spage%3D3138%26epage%3D3139%26doi%3D10.1128%2FAAC.00366-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref193"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref193'); return false;" data-citation="" class="refNumLink">193</a></strong><div class="NLM_citation" id="cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koga, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuoka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hotoda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakuta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muramatsu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoshi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirota, T.</span></span> <span> </span><span class="NLM_article-title">Activity of capuramycin analogues against mycobacterium tuberculosis, mycobacterium avium and mycobacterium intracellulare in vitro and in vivo</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">755</span>– <span class="NLM_lpage">760</span>, <span class="refDoi"> DOI: 10.1093/jac/dkh417</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1093%2Fjac%2Fdkh417" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=15347635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD2cXotVyqtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2004&pages=755-760&author=T.+Kogaauthor=T.+Fukuokaauthor=N.+Doiauthor=T.+Harasakiauthor=H.+Inoueauthor=H.+Hotodaauthor=M.+Kakutaauthor=Y.+Muramatsuauthor=N.+Yamamuraauthor=M.+Hoshiauthor=T.+Hirota&title=Activity+of+capuramycin+analogues+against+mycobacterium+tuberculosis%2C+mycobacterium+avium+and+mycobacterium+intracellulare+in+vitro+and+in+vivo&doi=10.1093%2Fjac%2Fdkh417"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of capuramycin analogues against Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium intracellulare in vitro and in vivo</span></div><div class="casAuthors">Koga, Tetsufumi; Fukuoka, Takashi; Doi, Norio; Harasaki, Tamako; Inoue, Harumi; Hotoda, Hitoshi; Kakuta, Masayo; Muramatsu, Yasunori; Yamamura, Naotoshi; Hoshi, Misa; Hirota, Takashi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">755-760</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The antimycobacterial activities of RS-112997, RS-124922 and RS-118641, three capuramycin analogs that inhibit phospho-N-acetylmuramyl-pentapeptide translocase, were tested against clin. isolates of Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium intracellulare.  MICs were detd. by the broth microdilution method using a modified Middlebrook 7H9 broth.  RS-118641 was the most potent compd. overall.  The MIC50/90 (mg/L) results for RS-118641 were: M. tuberculosis, 1/2; multidrug-resistant (MDR) M. tuberculosis, 0.5/2; M. avium, 4/8; and M. intracellulare, 0.06/0.5.  No statistically significant differences in MIC distributions were obsd. between non-MDR and MDR M. tuberculosis for any of the capuramycin analogs tested.  In order to evaluate the therapeutic efficacy of RS-112997 and RS-124922 in a murine lung model of tuberculosis, both compds. were administered intranasally at 0.1 or 1 mg/mouse/day for 12 days.  The mycobacterial load in the lungs was significantly lower in all treatment groups than in the untreated controls.  Addnl. expts. were performed to evaluate the therapeutic efficacy of the three compds. against the M. intracellulare infection in mice.  All compds. were administered intranasally at 0.1 mg/mouse/day for 21 days.  The mycobacterial load in the lungs was significantly lower in all treatment groups than in the untreated controls.  These results suggest that capuramycin analogs exhibit strong antimycobacterial potential and should be considered for further evaluation in the treatment of M. tuberculosis and M. avium-M. intracellulare complex infections in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLQOhSGpvmQLVg90H21EOLACvtfcHk0lg6bSr4xdH9qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXotVyqtr4%253D&md5=98c345da115351f07989711c1dc4bbad</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdkh417&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdkh417%26sid%3Dliteratum%253Aachs%26aulast%3DKoga%26aufirst%3DT.%26aulast%3DFukuoka%26aufirst%3DT.%26aulast%3DDoi%26aufirst%3DN.%26aulast%3DHarasaki%26aufirst%3DT.%26aulast%3DInoue%26aufirst%3DH.%26aulast%3DHotoda%26aufirst%3DH.%26aulast%3DKakuta%26aufirst%3DM.%26aulast%3DMuramatsu%26aufirst%3DY.%26aulast%3DYamamura%26aufirst%3DN.%26aulast%3DHoshi%26aufirst%3DM.%26aulast%3DHirota%26aufirst%3DT.%26atitle%3DActivity%2520of%2520capuramycin%2520analogues%2520against%2520mycobacterium%2520tuberculosis%252C%2520mycobacterium%2520avium%2520and%2520mycobacterium%2520intracellulare%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2004%26volume%3D54%26spage%3D755%26epage%3D760%26doi%3D10.1093%2Fjac%2Fdkh417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref194"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref194'); return false;" data-citation="" class="refNumLink">194</a></strong><div class="NLM_citation" id="cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takemoto, Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis of cpzen-45: Construction of the 1,4-diazepin-2-one core by the cu-catalyzed intramolecular amidation of a vinyl iodide</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2300</span>– <span class="NLM_lpage">2303</span>, <span class="refDoi"> DOI: 10.1021/acs.orglett.6b00943</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.orglett.6b00943" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28Xmt1CnsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=2300-2303&author=H.+Nakamuraauthor=T.+Yoshidaauthor=C.+Tsukanoauthor=Y.+Takemoto&title=Synthesis+of+cpzen-45%3A+Construction+of+the+1%2C4-diazepin-2-one+core+by+the+cu-catalyzed+intramolecular+amidation+of+a+vinyl+iodide&doi=10.1021%2Facs.orglett.6b00943"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of CPZEN-45: Construction of the 1,4-Diazepin-2-one Core by the Cu-Catalyzed Intramolecular Amidation of a Vinyl Iodide</span></div><div class="casAuthors">Nakamura, Hugh; Yoshida, Takuma; Tsukano, Chihiro; Takemoto, Yoshiji</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2300-2303</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">CPZEN-45 was developed as an antibiotic against Mycobacterium tuberculosis by the chem. modification of caprazamycins.  CPZEN-45 has been synthesized in this study by the Cu-catalyzed intramol. amidation of a complex vinyl iodide precursor bearing uridine and sugar moieties with a secondary amide, allowing for the construction of its 1,4-diazepin-2-one core.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVMQEnbnn3ObVg90H21EOLACvtfcHk0ligPVaCBwRT2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xmt1CnsLc%253D&md5=f49acee02582b3b047d2c2cf90958ed1</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1021%2Facs.orglett.6b00943&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.orglett.6b00943%26sid%3Dliteratum%253Aachs%26aulast%3DNakamura%26aufirst%3DH.%26aulast%3DYoshida%26aufirst%3DT.%26aulast%3DTsukano%26aufirst%3DC.%26aulast%3DTakemoto%26aufirst%3DY.%26atitle%3DSynthesis%2520of%2520cpzen-45%253A%2520Construction%2520of%2520the%25201%252C4-diazepin-2-one%2520core%2520by%2520the%2520cu-catalyzed%2520intramolecular%2520amidation%2520of%2520a%2520vinyl%2520iodide%26jtitle%3DOrg.%2520Lett.%26date%3D2016%26volume%3D18%26spage%3D2300%26epage%3D2303%26doi%3D10.1021%2Facs.orglett.6b00943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref195"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref195'); return false;" data-citation="" class="refNumLink">195</a></strong><div class="NLM_citation" id="cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Igarashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shitara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naganawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyake, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akamatsu, Y.</span></span> <span> </span><span class="NLM_article-title">Caprazamycins, novel lipo-nucleoside antibiotics, from streptomyces sp. Ii. Structure elucidation of caprazamycins</span>. <i>J. Antibiot.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">327</span>– <span class="NLM_lpage">337</span>, <span class="refDoi"> DOI: 10.1038/ja.2005.41</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1038%2Fja.2005.41" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=16060385" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltVamt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2005&pages=327-337&author=M.+Igarashiauthor=Y.+Takahashiauthor=T.+Shitaraauthor=H.+Nakamuraauthor=H.+Naganawaauthor=T.+Miyakeauthor=Y.+Akamatsu&title=Caprazamycins%2C+novel+lipo-nucleoside+antibiotics%2C+from+streptomyces+sp.+Ii.+Structure+elucidation+of+caprazamycins&doi=10.1038%2Fja.2005.41"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Caprazamycins, novel lipo-nucleoside antibiotics, from Streptomyces sp.: II. Structure elucidation of caprazamycins</span></div><div class="casAuthors">Igarashi, Masayuki; Takahashi, Yoshiaki; Shitara, Tetsuo; Nakamura, Hikaru; Naganawa, Hiroshi; Miyake, Toshiaki; Akamatsu, Yuzuru</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antibiotics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">327-337</span>CODEN:
                <span class="NLM_cas:coden">JANTAJ</span>;
        ISSN:<span class="NLM_cas:issn">0021-8820</span>.
    
            (<span class="NLM_cas:orgname">Japan Antibiotics Research Association</span>)
        </div><div class="casAbstract">Novel antibiotics, active against acid-fast bacteria, caprazamycins, were previously isolated from the culture broth of Streptomyces sp. MK730-62F2.  The planar structures of the compds. were detd. by 2D NMR spectroscopic study.  Furthermore, the abs. configuration of caprazamycin B (I) was established by NMR spectroscopy, X-ray crystallog. of its degrdn. products and total synthesis of the 5-amino-5-deoxy-D-ribose moiety.  In the course of degrdn. studies of I under alk. and acidic conditions, the two core components, caprazene II (RR1 = bond) and caprazol II (R = H, R1 = OH), resp., were obtained in high yield.  Structurally, caprazamycins belong to a family of lipouridyl antibiotics, which have been shown to be specific inhibitors of a bacterial translocase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXta4i1PjqorVg90H21EOLACvtfcHk0ligPVaCBwRT2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltVamt78%253D&md5=97c79ad8f40ba48af9eec7a8392a0100</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1038%2Fja.2005.41&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fja.2005.41%26sid%3Dliteratum%253Aachs%26aulast%3DIgarashi%26aufirst%3DM.%26aulast%3DTakahashi%26aufirst%3DY.%26aulast%3DShitara%26aufirst%3DT.%26aulast%3DNakamura%26aufirst%3DH.%26aulast%3DNaganawa%26aufirst%3DH.%26aulast%3DMiyake%26aufirst%3DT.%26aulast%3DAkamatsu%26aufirst%3DY.%26atitle%3DCaprazamycins%252C%2520novel%2520lipo-nucleoside%2520antibiotics%252C%2520from%2520streptomyces%2520sp.%2520Ii.%2520Structure%2520elucidation%2520of%2520caprazamycins%26jtitle%3DJ.%2520Antibiot.%26date%3D2005%26volume%3D58%26spage%3D327%26epage%3D337%26doi%3D10.1038%2Fja.2005.41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref196"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref196'); return false;" data-citation="" class="refNumLink">196</a></strong><div class="NLM_citation" id="cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Igarashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naganawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamada, M.</span></span> <span> </span><span class="NLM_article-title">Caprazamycin b, a novel anti-tuberculosis antibiotic, from streptomyces sp</span>. <i>J. Antibiot.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">580</span>– <span class="NLM_lpage">583</span>, <span class="refDoi"> DOI: 10.7164/antibiotics.56.580</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.7164%2Fantibiotics.56.580" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=12931868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A280%3ADC%252BD3szpsVGksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2003&pages=580-583&author=M.+Igarashiauthor=N.+Nakagawaauthor=N.+Doiauthor=S.+Hattoriauthor=H.+Naganawaauthor=M.+Hamada&title=Caprazamycin+b%2C+a+novel+anti-tuberculosis+antibiotic%2C+from+streptomyces+sp&doi=10.7164%2Fantibiotics.56.580"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">Caprazamycin B, a novel anti-tuberculosis antibiotic, from Streptomyces sp</span></div><div class="casAuthors">Igarashi Masayuki; Nakagawa Naoko; Doi Norio; Hattori Seiko; Naganawa Hiroshi; Hamada Masa</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of antibiotics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">580-3</span>
        ISSN:<span class="NLM_cas:issn">0021-8820</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRQqbR9zAbdZ0NoizSOkG_FfW6udTcc2ebWN6Ip8qTMtrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3szpsVGksA%253D%253D&md5=be8d104d75f0a868b0af25735daf7e27</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.7164%2Fantibiotics.56.580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7164%252Fantibiotics.56.580%26sid%3Dliteratum%253Aachs%26aulast%3DIgarashi%26aufirst%3DM.%26aulast%3DNakagawa%26aufirst%3DN.%26aulast%3DDoi%26aufirst%3DN.%26aulast%3DHattori%26aufirst%3DS.%26aulast%3DNaganawa%26aufirst%3DH.%26aulast%3DHamada%26aufirst%3DM.%26atitle%3DCaprazamycin%2520b%252C%2520a%2520novel%2520anti-tuberculosis%2520antibiotic%252C%2520from%2520streptomyces%2520sp%26jtitle%3DJ.%2520Antibiot.%26date%3D2003%26volume%3D56%26spage%3D580%26epage%3D583%26doi%3D10.7164%2Fantibiotics.56.580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref197"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref197'); return false;" data-citation="" class="refNumLink">197</a></strong><div class="NLM_citation" id="cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishizaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Igarashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pujari, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crick, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomoto, A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of the first step in synthesis of the mycobacterial cell wall core, catalyzed by the glcnac-1-phosphate transferase weca, by the novel caprazamycin derivative cpzen-45</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>288</i></span>,  <span class="NLM_fpage">30309</span>– <span class="NLM_lpage">30319</span>, <span class="refDoi"> DOI: 10.1074/jbc.M113.492173</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1074%2Fjbc.M113.492173" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=23986448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Cru7%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=30309-30319&author=Y.+Ishizakiauthor=C.+Hayashiauthor=K.+Inoueauthor=M.+Igarashiauthor=Y.+Takahashiauthor=V.+Pujariauthor=D.+C.+Crickauthor=P.+J.+Brennanauthor=A.+Nomoto&title=Inhibition+of+the+first+step+in+synthesis+of+the+mycobacterial+cell+wall+core%2C+catalyzed+by+the+glcnac-1-phosphate+transferase+weca%2C+by+the+novel+caprazamycin+derivative+cpzen-45&doi=10.1074%2Fjbc.M113.492173"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of the First Step in Synthesis of the Mycobacterial Cell Wall Core, Catalyzed by the GlcNAc-1-phosphate Transferase WecA, by the Novel Caprazamycin Derivative CPZEN-45</span></div><div class="casAuthors">Ishizaki, Yoshimasa; Hayashi, Chigusa; Inoue, Kunio; Igarashi, Masayuki; Takahashi, Yoshiaki; Pujari, Venugopal; Crick, Dean C.; Brennan, Patrick J.; Nomoto, Akio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">30309-30319</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Because tuberculosis is one of the most prevalent and serious infections, countermeasures against it are urgently required.  We isolated the antitubercular agents caprazamycins from the culture of an actinomycete strain and created CPZEN-45 as the most promising deriv. of the caprazamycins.  Herein, we describe the mode of action of CPZEN-45 first against Bacillus subtilis.  Unlike the caprazamycins, CPZEN-45 strongly inhibited incorporation of radiolabeled glycerol into growing cultures and showed antibacterial activity against caprazamycin-resistant strains, including a strain overexpressing translocase-I (MraY, involved in the biosynthesis of peptidoglycan), the target of the caprazamycins.  By contrast, CPZEN-45 was not effective against a strain overexpressing undecaprenyl-phosphate-GlcNAc-1-phosphate transferase (TagO, involved in the biosynthesis of teichoic acid), and a mutation was found in the tagO gene of the spontaneous CPZEN-45-resistant strain.  This suggested that the primary target of CPZEN-45 in B. subtilis is TagO, which is a different target from that of the parent caprazamycins.  This suggestion was confirmed by evaluation of the activities of these enzymes.  Finally, we showed that CPZEN-45 was effective against WecA (Rv1302, also called Rfe) of Mycobacterium tuberculosis, the ortholog of TagO and involved in the biosynthesis of the mycolylarabinogalactan of the cell wall of M. tuberculosis.  The outlook for WecA as a promising target for the development of antituberculous drugs as a countermeasure of drug resistant tuberculosis is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNqoYWKso1VbVg90H21EOLACvtfcHk0ljgw4j4h7v-lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Cru7%252FO&md5=055f38e51b810e9001d63ec42a25d20c</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M113.492173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M113.492173%26sid%3Dliteratum%253Aachs%26aulast%3DIshizaki%26aufirst%3DY.%26aulast%3DHayashi%26aufirst%3DC.%26aulast%3DInoue%26aufirst%3DK.%26aulast%3DIgarashi%26aufirst%3DM.%26aulast%3DTakahashi%26aufirst%3DY.%26aulast%3DPujari%26aufirst%3DV.%26aulast%3DCrick%26aufirst%3DD.%2BC.%26aulast%3DBrennan%26aufirst%3DP.%2BJ.%26aulast%3DNomoto%26aufirst%3DA.%26atitle%3DInhibition%2520of%2520the%2520first%2520step%2520in%2520synthesis%2520of%2520the%2520mycobacterial%2520cell%2520wall%2520core%252C%2520catalyzed%2520by%2520the%2520glcnac-1-phosphate%2520transferase%2520weca%252C%2520by%2520the%2520novel%2520caprazamycin%2520derivative%2520cpzen-45%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26spage%3D30309%26epage%3D30319%26doi%3D10.1074%2Fjbc.M113.492173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref198"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref198'); return false;" data-citation="" class="refNumLink">198</a></strong><div class="NLM_citation" id="cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Horlacher, O. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartkoorn, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmann, K. H.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antimycobacterial activity of 2,1′-dihydropyridomycins</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">264</span>– <span class="NLM_lpage">268</span>, <span class="refDoi"> DOI: 10.1021/ml300385q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300385q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVCqsLvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=264-268&author=O.+P.+Horlacherauthor=R.+C.+Hartkoornauthor=S.+T.+Coleauthor=K.+H.+Altmann&title=Synthesis+and+antimycobacterial+activity+of+2%2C1%E2%80%B2-dihydropyridomycins&doi=10.1021%2Fml300385q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Antimycobacterial Activity of 2,1'-Dihydropyridomycins</span></div><div class="casAuthors">Horlacher, Oliver P.; Hartkoorn, Ruben C.; Cole, Stewart T.; Altmann, Karl-Heinz</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">264-268</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dihydropyridomycins 2 and 3 (II, 2R and 2S, resp.), which lack the characteristic enol ester moiety of the potent antimycobacterial natural product pyridomycin 1 (I), have been prepd. from L-Thr, R- and S-hydroxy isovaleric acid, and 3-pyridinecarboxaldehyde.  The 2R isomer 2 shows only 4-fold lower anti-Mtb activity than 1, indicating that the enol ester moiety in the natural product is not crit. for its biol. activity.  This finding establishes 2 as a potent and more practical lead for anti-TB drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5Dm4UKBOKirVg90H21EOLACvtfcHk0ljgw4j4h7v-lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVCqsLvF&md5=2b81e23c2b644a1c23cc9c17feb68f30</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1021%2Fml300385q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300385q%26sid%3Dliteratum%253Aachs%26aulast%3DHorlacher%26aufirst%3DO.%2BP.%26aulast%3DHartkoorn%26aufirst%3DR.%2BC.%26aulast%3DCole%26aufirst%3DS.%2BT.%26aulast%3DAltmann%26aufirst%3DK.%2BH.%26atitle%3DSynthesis%2520and%2520antimycobacterial%2520activity%2520of%25202%252C1%25E2%2580%25B2-dihydropyridomycins%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D264%26epage%3D268%26doi%3D10.1021%2Fml300385q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref199"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref199'); return false;" data-citation="" class="refNumLink">199</a></strong><div class="NLM_citation" id="cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hartkoorn, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pojer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingell, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neres, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horlacher, O. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmann, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S. T.</span></span> <span> </span><span class="NLM_article-title">Pyridomycin bridges the NADH- and substrate-binding pockets of the enoyl reductase InhA</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">96</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1405</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1038%2Fnchembio.1405" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=24292073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVGru7jF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=96-98&author=R.+C.+Hartkoornauthor=F.+Pojerauthor=J.+A.+Readauthor=H.+Gingellauthor=J.+Neresauthor=O.+P.+Horlacherauthor=K.+H.+Altmannauthor=S.+T.+Cole&title=Pyridomycin+bridges+the+NADH-+and+substrate-binding+pockets+of+the+enoyl+reductase+InhA&doi=10.1038%2Fnchembio.1405"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">Pyridomycin bridges the NADH- and substrate-binding pockets of the enoyl reductase InhA</span></div><div class="casAuthors">Hartkoorn, Ruben C.; Pojer, Florence; Read, Jon A.; Gingell, Helen; Neres, Joao; Horlacher, Oliver P.; Altmann, Karl-Heinz; Cole, Stewart T.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">96-98</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Pyridomycin, a natural product with potent antituberculosis activity, inhibits a major drug target, enoyl-ACP reductase InhA.  Here, the authors unveil the co-crystal structure and unique ability of pyridomycin to block both the NADH cofactor- and lipid substrate-binding pockets of InhA.  This is to the authors' knowledge a 1st-of-a-kind binding mode that discloses a new means of InhA inhibition.  Proof-of-principle studies showed how structure-assisted drug design could improve the activity of new pyridomycin derivs., OH 139 and OH 141.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNDXuoCfd497Vg90H21EOLACvtfcHk0ljgw4j4h7v-lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVGru7jF&md5=14631b559d1d19a6fc3b06e7211a2cc8</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1405&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1405%26sid%3Dliteratum%253Aachs%26aulast%3DHartkoorn%26aufirst%3DR.%2BC.%26aulast%3DPojer%26aufirst%3DF.%26aulast%3DRead%26aufirst%3DJ.%2BA.%26aulast%3DGingell%26aufirst%3DH.%26aulast%3DNeres%26aufirst%3DJ.%26aulast%3DHorlacher%26aufirst%3DO.%2BP.%26aulast%3DAltmann%26aufirst%3DK.%2BH.%26aulast%3DCole%26aufirst%3DS.%2BT.%26atitle%3DPyridomycin%2520bridges%2520the%2520NADH-%2520and%2520substrate-binding%2520pockets%2520of%2520the%2520enoyl%2520reductase%2520InhA%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2014%26volume%3D10%26spage%3D96%26epage%3D98%26doi%3D10.1038%2Fnchembio.1405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref200"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref200'); return false;" data-citation="" class="refNumLink">200</a></strong><div class="NLM_citation" id="cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfeiffer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmann, K. H.</span></span> <span> </span><span class="NLM_article-title">Recent developments in natural product-based drug discovery for tuberculosis</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">585</span>– <span class="NLM_lpage">591</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2016.11.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.drudis.2016.11.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=27890820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFOju73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=585-591&author=M.+Dongauthor=B.+Pfeifferauthor=K.+H.+Altmann&title=Recent+developments+in+natural+product-based+drug+discovery+for+tuberculosis&doi=10.1016%2Fj.drudis.2016.11.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">Recent developments in natural product-based drug discovery for tuberculosis</span></div><div class="casAuthors">Dong, Maryline; Pfeiffer, Bernhard; Altmann, Karl-Heinz</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">585-591</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Natural products (NPs) have been at the origin of several established drugs against tuberculosis (TB).  Although the current clin. TB pipeline does not feature any candidates derived from new NP scaffolds, numerous novel NPs or NP analogs have been discovered in the recent past with promising activity against Mycobacterium tuberculosis (Mtb).  This includes newly discovered structures as well as known NP classes that had not been previously recognized to be active against Mtb.  These compds. could help to replenish the dry clin. TB pipeline and, thus, contribute to improvements in the treatment of a devastating disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAXhHq_lFpAbVg90H21EOLACvtfcHk0liwo_uYKwd3MQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFOju73P&md5=62b390128a26c7083f919cc7377321ee</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2016.11.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2016.11.015%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DM.%26aulast%3DPfeiffer%26aufirst%3DB.%26aulast%3DAltmann%26aufirst%3DK.%2BH.%26atitle%3DRecent%2520developments%2520in%2520natural%2520product-based%2520drug%2520discovery%2520for%2520tuberculosis%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2017%26volume%3D22%26spage%3D585%26epage%3D591%26doi%3D10.1016%2Fj.drudis.2016.11.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref201"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref201'); return false;" data-citation="" class="refNumLink">201</a></strong><div class="NLM_citation" id="cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruhn, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janusic, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherbakov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherman, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boshoff, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rakesh</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waidyarachchi, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brewer, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gracia, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meibohm, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenaerts, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ainsa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottger, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. E.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationships of spectinamide antituberculosis agents: A dissection of ribosomal inhibition and native efflux avoidance contributions</span>. <i>ACS Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">72</span>– <span class="NLM_lpage">88</span>, <span class="refDoi"> DOI: 10.1021/acsinfecdis.6b00158</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsinfecdis.6b00158" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1elsb%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=72-88&author=J.+Liuauthor=D.+F.+Bruhnauthor=R.+B.+Leeauthor=Z.+Zhengauthor=T.+Janusicauthor=D.+Scherbakovauthor=M.+S.+Schermanauthor=H.+I.+Boshoffauthor=S.+Dasauthor=+Rakeshauthor=S.+L.+Waidyarachchiauthor=T.+A.+Brewerauthor=B.+Graciaauthor=L.+Yangauthor=J.+Bollingerauthor=G.+T.+Robertsonauthor=B.+Meibohmauthor=A.+J.+Lenaertsauthor=J.+Ainsaauthor=E.+C.+Bottgerauthor=R.+E.+Lee&title=Structure-activity+relationships+of+spectinamide+antituberculosis+agents%3A+A+dissection+of+ribosomal+inhibition+and+native+efflux+avoidance+contributions&doi=10.1021%2Facsinfecdis.6b00158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationships of Spectinamide Antituberculosis Agents: A Dissection of Ribosomal Inhibition and Native Efflux Avoidance Contributions</span></div><div class="casAuthors">Liu, Jiuyu; Bruhn, David F.; Lee, Robin B.; Zheng, Zhong; Janusic, Tanja; Scherbakov, Dimitri; Scherman, Michael S.; Boshoff, Helena I.; Das, Sourav; Rakesh; Waidyarachchi, Samanthi L.; Brewer, Tiffany A.; Gracia, Begona; Yang, Lei; Bollinger, John; Robertson, Gregory T.; Meibohm, Bernd; Lenaerts, Anne J.; Ainsa, Jose; Bottger, Erik C.; Lee, Richard E.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Infectious Diseases</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">72-88</span>CODEN:
                <span class="NLM_cas:coden">AIDCBC</span>;
        ISSN:<span class="NLM_cas:issn">2373-8227</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Spectinamides are a novel class of antitubercular agents with the potential to treat drug resistant tuberculosis infections.  Their antitubercular activity is derived from both ribosomal affinity and their ability to overcome intrinsic efflux mediated by the Mycobacterium tuberculosis Rv1258c efflux pump.  In this study the authors explore the structure activity relationships through anal. of 50 targeted spectinamides.  Compds. are evaluated for ribosomal translational inhibition, MIC activity in Rv1258c efflux pump deficient and wild type tuberculosis strains, and efficacy in an acute model of tuberculosis infection.  The results of this study show a narrow structure-activity relationship, consistent with a tight ribosome binding pocket and strict structural requirements to overcome native efflux.  Rationalization of ribosomal inhibition data using mol. dynamics simulations showed stable complex formation for halogenated spectinamides consistent with long post antibiotic effects obsd.  The lead spectinamides identified in this study demonstrated potent MIC activity against MDR and XDR tuberculosis, and had desirable antitubercular class specific features of low protein binding, low microsomal metab., no cytotoxicity, and produced significant redns. in bacterial burdens in the lungs of mice infected with M. tuberculosis.  The structure activity relationships detailed here emphasize the need to examine efflux-mediated resistance in the design of antituberculosis drugs and demonstrate that it is possible to overcoming intrinsic efflux with synthetic modification.  The ability to understand the structure requirements for this class has produced a variety of new substituted spectinamides, which may provide useful alternative candidates and promote the further development of this class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqTwY0RzYi_rVg90H21EOLACvtfcHk0liwo_uYKwd3MQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1elsb%252FM&md5=1a2135c281fac45be7665e047b4cdbf6</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1021%2Facsinfecdis.6b00158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsinfecdis.6b00158%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DBruhn%26aufirst%3DD.%2BF.%26aulast%3DLee%26aufirst%3DR.%2BB.%26aulast%3DZheng%26aufirst%3DZ.%26aulast%3DJanusic%26aufirst%3DT.%26aulast%3DScherbakov%26aufirst%3DD.%26aulast%3DScherman%26aufirst%3DM.%2BS.%26aulast%3DBoshoff%26aufirst%3DH.%2BI.%26aulast%3DDas%26aufirst%3DS.%26aulast%3DRakesh%26aulast%3DWaidyarachchi%26aufirst%3DS.%2BL.%26aulast%3DBrewer%26aufirst%3DT.%2BA.%26aulast%3DGracia%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DBollinger%26aufirst%3DJ.%26aulast%3DRobertson%26aufirst%3DG.%2BT.%26aulast%3DMeibohm%26aufirst%3DB.%26aulast%3DLenaerts%26aufirst%3DA.%2BJ.%26aulast%3DAinsa%26aufirst%3DJ.%26aulast%3DBottger%26aufirst%3DE.%2BC.%26aulast%3DLee%26aufirst%3DR.%2BE.%26atitle%3DStructure-activity%2520relationships%2520of%2520spectinamide%2520antituberculosis%2520agents%253A%2520A%2520dissection%2520of%2520ribosomal%2520inhibition%2520and%2520native%2520efflux%2520avoidance%2520contributions%26jtitle%3DACS%2520Infect.%2520Dis.%26date%3D2017%26volume%3D3%26spage%3D72%26epage%3D88%26doi%3D10.1021%2Facsinfecdis.6b00158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref202"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref202'); return false;" data-citation="" class="refNumLink">202</a></strong><div class="NLM_citation" id="cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vaddady, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trivedi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madhura, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meibohm, B.</span></span> <span> </span><span class="NLM_article-title">Dynamic time-kill curve characterization of spectinamide antibiotics 1445 and 1599 for the treatment of tuberculosis</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">233</span>– <span class="NLM_lpage">239</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2018.11.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.ejps.2018.11.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=30419293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFyqsLvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2019&pages=233-239&author=P.+K.+Vaddadyauthor=A.+Trivediauthor=C.+Rathiauthor=D.+B.+Madhuraauthor=J.+Liuauthor=R.+E.+Leeauthor=B.+Meibohm&title=Dynamic+time-kill+curve+characterization+of+spectinamide+antibiotics+1445+and+1599+for+the+treatment+of+tuberculosis&doi=10.1016%2Fj.ejps.2018.11.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">Dynamic time-kill curve characterization of spectinamide antibiotics 1445 and 1599 for the treatment of tuberculosis</span></div><div class="casAuthors">Vaddady, Pavan K.; Trivedi, Ashit; Rathi, Chetan; Madhura, Dora B.; Liu, Jiuyu; Lee, Richard E.; Meibohm, Bernd</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">233-239</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Spectinamides are a novel class of antibiotics under development for the treatment of MDR- and XDR-tuberculosis, with 1599 and 1445 as early lead candidates within this group.  In order to evaluate and differentiate the pharmacol. properties of these compds. and assist in candidate selection and design of optimal dosing regimens in animal models of Mtb infection, time kill curve assessments were performed in a previously established in vitro PK/PD model system.  The performed studies and subsequent pharmacometric anal. indicate that the anti-mycobacterial activity of 1599 exhibits concn.-dependent killing whereas 1445 shows time-dependent killing.  These findings are supported by the fact that the PKPD index that best describes bacterial killing is T > MIC for 1445, but fCmax/AUC for 1599.  The differential killing behavior among the lead candidates can be rationalized by the differences in post-antibiotic effect: 15.7 h for 1445 compared the 133 h for 1599.  Overall, the PK/PD based anal. of the in vitro pharmacol. killing profile of spectinamides 1599 and 1445 on mycobacteria provided valuable insights that contributed to lead candidate selection and preclin. development of these compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBROcUEjXuqrVg90H21EOLACvtfcHk0liwo_uYKwd3MQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFyqsLvI&md5=d511407a2b788007ccb09ee9d902024c</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2018.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2018.11.006%26sid%3Dliteratum%253Aachs%26aulast%3DVaddady%26aufirst%3DP.%2BK.%26aulast%3DTrivedi%26aufirst%3DA.%26aulast%3DRathi%26aufirst%3DC.%26aulast%3DMadhura%26aufirst%3DD.%2BB.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DR.%2BE.%26aulast%3DMeibohm%26aufirst%3DB.%26atitle%3DDynamic%2520time-kill%2520curve%2520characterization%2520of%2520spectinamide%2520antibiotics%25201445%2520and%25201599%2520for%2520the%2520treatment%2520of%2520tuberculosis%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2019%26volume%3D127%26spage%3D233%26epage%3D239%26doi%3D10.1016%2Fj.ejps.2018.11.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref203"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref203'); return false;" data-citation="" class="refNumLink">203</a></strong><div class="NLM_citation" id="cit203"><span> <i>Spectinamide 1810</i>; <span class="NLM_publisher-name">The Working Group
for
New TB Drugs</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">2017</span>; <a href="http://www.newtbdrugs.org/pipeline/compound/spectinamide-1810" class="extLink">http://www.newtbdrugs.org/pipeline/compound/spectinamide-1810</a> (accessed 2020-03-03).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Spectinamide+1810%3B+The+Working+Group%0Afor%0ANew+TB+Drugs%3A+New+York%2C+2017%3B+http%3A%2F%2Fwww.newtbdrugs.org%2Fpipeline%2Fcompound%2Fspectinamide-1810+%28accessed+2020-03-03%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26jtitle%3DSpectinamide%25201810%26pub%3DThe%2520Working%2520Group%250Afor%250ANew%2520TB%2520Drugs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref204"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref204'); return false;" data-citation="" class="refNumLink">204</a></strong><div class="NLM_citation" id="cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tripathi, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripathi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiwari, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bala, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, B. S.</span></span> <span> </span><span class="NLM_article-title">Synthesis of glycosylated beta-amino acids as new class of antitubercular agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">773</span>– <span class="NLM_lpage">781</span>, <span class="refDoi"> DOI: 10.1016/S0223-5234(02)01398-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2FS0223-5234%2802%2901398-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=12350294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD38Xntlanu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2002&pages=773-781&author=R.+P.+Tripathiauthor=R.+Tripathiauthor=V.+K.+Tiwariauthor=L.+Balaauthor=S.+Sinhaauthor=A.+Srivastavaauthor=R.+Srivastavaauthor=B.+S.+Srivastava&title=Synthesis+of+glycosylated+beta-amino+acids+as+new+class+of+antitubercular+agents&doi=10.1016%2FS0223-5234%2802%2901398-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of glycosylated β-amino acids as new class of antitubercular agents</span></div><div class="casAuthors">Tripathi, R. P.; Tripathi, R.; Tiwari, V. K.; Bala, Laxmi; Sinha, S.; Srivastava, A.; Srivastava, R.; Srivastava, B. S.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">773-781</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Editions Scientifiques et Medicales Elsevier</span>)
        </div><div class="casAbstract">A series of glycosylated β-amino acids was prepd. and evaluated against Mycobacterium tuberculosis, M. avium, M. fortuitum and M. smegmatis.  The compds. were designed to mimic the enzyme D-alanine racemase and glycosyl transferase involved in the biosynthesis of essential cell wall peptidoglycan and arabinogalactan.  Though most of the compds. exhibited little activity, however, I (R = n-hexadecyl) showed significant activity against all the strains in cell culture and activity was confirmed by Bactec method.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkpRvlGJPxNbVg90H21EOLACvtfcHk0ljA2lw4GlIWsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xntlanu78%253D&md5=ab365aa3656c3d53f21d14d84e367266</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1016%2FS0223-5234%2802%2901398-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0223-5234%252802%252901398-3%26sid%3Dliteratum%253Aachs%26aulast%3DTripathi%26aufirst%3DR.%2BP.%26aulast%3DTripathi%26aufirst%3DR.%26aulast%3DTiwari%26aufirst%3DV.%2BK.%26aulast%3DBala%26aufirst%3DL.%26aulast%3DSinha%26aufirst%3DS.%26aulast%3DSrivastava%26aufirst%3DA.%26aulast%3DSrivastava%26aufirst%3DR.%26aulast%3DSrivastava%26aufirst%3DB.%2BS.%26atitle%3DSynthesis%2520of%2520glycosylated%2520beta-amino%2520acids%2520as%2520new%2520class%2520of%2520antitubercular%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2002%26volume%3D37%26spage%3D773%26epage%3D781%26doi%3D10.1016%2FS0223-5234%2802%2901398-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref205"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref205'); return false;" data-citation="" class="refNumLink">205</a></strong><div class="NLM_citation" id="cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mugunthan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramakrishna, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sriram, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yogeeswari, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravindranathan Kartha, K. P.</span></span> <span> </span><span class="NLM_article-title">Synthesis and screening of galactose-linked nitroimidazoles and triazoles against mycobacterium tuberculosis</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">4725</span>– <span class="NLM_lpage">4732</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2011.05.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.ejmech.2011.05.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=21664731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtV2rtbjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2011&pages=4725-4732&author=G.+Mugunthanauthor=K.+Ramakrishnaauthor=D.+Sriramauthor=P.+Yogeeswariauthor=K.+P.+Ravindranathan+Kartha&title=Synthesis+and+screening+of+galactose-linked+nitroimidazoles+and+triazoles+against+mycobacterium+tuberculosis&doi=10.1016%2Fj.ejmech.2011.05.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and screening of galactose-linked nitroimidazoles and triazoles against Mycobacterium tuberculosis</span></div><div class="casAuthors">Mugunthan, G.; Ramakrishna, Kuppala; Sriram, Dharmarajan; Yogeeswari, Perumal; Ravindranathan Kartha, K. P.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4725-4732</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of galactose-linked nitroimidazoles/triazoles, e.g. I, were synthesized and screened against Mycobacterium tuberculosis H37Rv.  Preliminary results were promising with MIC values in the range 1.56-12.5 μg/mL.  Most importantly they are active under aerobic condition under which metronidazole is inactive.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorDlLgW_VPj7Vg90H21EOLACvtfcHk0ljA2lw4GlIWsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtV2rtbjF&md5=fe3db5f6585793c42bde11415e175148</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2011.05.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2011.05.045%26sid%3Dliteratum%253Aachs%26aulast%3DMugunthan%26aufirst%3DG.%26aulast%3DRamakrishna%26aufirst%3DK.%26aulast%3DSriram%26aufirst%3DD.%26aulast%3DYogeeswari%26aufirst%3DP.%26aulast%3DRavindranathan%2BKartha%26aufirst%3DK.%2BP.%26atitle%3DSynthesis%2520and%2520screening%2520of%2520galactose-linked%2520nitroimidazoles%2520and%2520triazoles%2520against%2520mycobacterium%2520tuberculosis%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2011%26volume%3D46%26spage%3D4725%26epage%3D4732%26doi%3D10.1016%2Fj.ejmech.2011.05.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref206"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref206'); return false;" data-citation="" class="refNumLink">206</a></strong><div class="NLM_citation" id="cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rane, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutte, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahu, N. U.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of novel 1,3,4-oxadiazole derivatives of marine bromopyrrole alkaloids as antimicrobial agent</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">6429</span>– <span class="NLM_lpage">6432</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.08.061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmcl.2012.08.061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=22967765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlaktbfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=6429-6432&author=R.+A.+Raneauthor=S.+D.+Gutteauthor=N.+U.+Sahu&title=Synthesis+and+evaluation+of+novel+1%2C3%2C4-oxadiazole+derivatives+of+marine+bromopyrrole+alkaloids+as+antimicrobial+agent&doi=10.1016%2Fj.bmcl.2012.08.061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of novel 1,3,4-oxadiazole derivatives of marine bromopyrrole alkaloids as antimicrobial agent</span></div><div class="casAuthors">Rane, Rajesh A.; Gutte, Shweta D.; Sahu, Niteshkumar U.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6429-6432</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In an attempt to identify new potential lead as antimicrobial agent, twenty hybrids of marine bromopyrrole alkaloids with 1,3,4-oxadiazole were designed based on mol. hybridization technique and synthesized.  Synthesized mols. were evaluated for their antibacterial, antifungal and antitubercular activities.  Four hybrids exhibited equiv. antibacterial activity (MIC of 1.56 μg/mL) compared with std. drug ciprofloxacin against Staphylococcus aureus and Escherichia coli.  Equal antifungal activity (MIC of 1.56 μg/mL) was shown by of three hybrids compared with std. Amphotericin-B.  The inhibition of Mycobacterium tuberculosis at concns. as low as 1.6 and 1.5 μg/mL by compds. I and II resp. indicates that these compds. can act as leads for development of newer anti-TB compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfhUpIl_IIi7Vg90H21EOLACvtfcHk0ljA2lw4GlIWsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlaktbfL&md5=0ce610d511f23150ab2b4b6d8b0be347</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.08.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.08.061%26sid%3Dliteratum%253Aachs%26aulast%3DRane%26aufirst%3DR.%2BA.%26aulast%3DGutte%26aufirst%3DS.%2BD.%26aulast%3DSahu%26aufirst%3DN.%2BU.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520novel%25201%252C3%252C4-oxadiazole%2520derivatives%2520of%2520marine%2520bromopyrrole%2520alkaloids%2520as%2520antimicrobial%2520agent%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D6429%26epage%3D6432%26doi%3D10.1016%2Fj.bmcl.2012.08.061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref207"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref207'); return false;" data-citation="" class="refNumLink">207</a></strong><div class="NLM_citation" id="cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tangallapally, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rakesh</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budha, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenaerts, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meibohm, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. E.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel isoxazolines as anti-tuberculosis agents</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">6638</span>– <span class="NLM_lpage">6642</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2007.09.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmcl.2007.09.048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=17937983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1OqsLnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=6638-6642&author=R.+P.+Tangallapallyauthor=D.+Sunauthor=+Rakeshauthor=N.+Budhaauthor=R.+E.+Leeauthor=A.+J.+Lenaertsauthor=B.+Meibohmauthor=R.+E.+Lee&title=Discovery+of+novel+isoxazolines+as+anti-tuberculosis+agents&doi=10.1016%2Fj.bmcl.2007.09.048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel isoxazolines as anti-tuberculosis agents</span></div><div class="casAuthors">Tangallapally, Rajendra P.; Sun, Dianqing; Rakesh; Budha, Nageshwar; Lee, Robin E. B.; Lenaerts, Anne J. M.; Meibohm, Bernd; Lee, Richard E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6638-6642</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Nitrofuranyl isoxazolines with increased proteolytic stability over nitrofuranyl amides were designed and synthesized leading to discovery of several compds. with potent in vitro anti-tuberculosis activity.  However, their in vivo activity was limited by high protein binding and poor distribution.  Consequently, a series of non-nitrofuran contg. isoxazolines were prepd. to det. if the core had residual anti-tuberculosis activity.  This led to the discovery of novel isoxazoline I as anti-tuberculosis agent with a MIC90 value of 1.56 μg/mL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPddyy5vhJerVg90H21EOLACvtfcHk0ljBZYtAhPGF7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1OqsLnP&md5=af6169ae8bcb3143c1d83924d42d6618</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.09.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.09.048%26sid%3Dliteratum%253Aachs%26aulast%3DTangallapally%26aufirst%3DR.%2BP.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DRakesh%26aulast%3DBudha%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DR.%2BE.%26aulast%3DLenaerts%26aufirst%3DA.%2BJ.%26aulast%3DMeibohm%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DR.%2BE.%26atitle%3DDiscovery%2520of%2520novel%2520isoxazolines%2520as%2520anti-tuberculosis%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D6638%26epage%3D6642%26doi%3D10.1016%2Fj.bmcl.2007.09.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref208"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref208'); return false;" data-citation="" class="refNumLink">208</a></strong><div class="NLM_citation" id="cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Si, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of the disubstituted oxazole analogues as a novel class anti-tuberculotic agents against mdr- and xdr-mtb</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">5178</span>– <span class="NLM_lpage">5181</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.09.072</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmcl.2015.09.072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=26459210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1Gksb%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=5178-5181&author=D.+Liauthor=N.+Gaoauthor=N.+Zhuauthor=Y.+Linauthor=Y.+Liauthor=M.+Chenauthor=X.+Youauthor=Y.+Luauthor=K.+Wanauthor=J.+D.+Jiangauthor=W.+Jiangauthor=S.+Si&title=Discovery+of+the+disubstituted+oxazole+analogues+as+a+novel+class+anti-tuberculotic+agents+against+mdr-+and+xdr-mtb&doi=10.1016%2Fj.bmcl.2015.09.072"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the disubstituted oxazole analogues as a novel class anti-tuberculotic agents against MDR- and XDR-MTB</span></div><div class="casAuthors">Li, Dongsheng; Gao, Nana; Zhu, Ningyu; Lin, Yuan; Li, Yan; Chen, Minghua; You, Xuefu; Lu, Yu; Wan, Kanglin; Jiang, Jian-Dong; Jiang, Wei; Si, Shuyi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5178-5181</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Aryl-piperidinyl-substituted oxazoles, thiazoles and isoxazoles I [1a-y; R1 = ClC6H4, FC6H4, Ph, MeOC6H4, CF3C6H4, 3-pyridyl, 2-furyl; R2, R3 = H, OMe; R2-R3 = OCH2CH2O, (CH2)4] were prepd. by heterocyclization of aldehydes, thioamides and alkynes with amino acid derivs., Friedel-Crafts acylation of disubstituted benzenes 1-R2-2-R3C6H4 with 4-piperidinoyl chloride and coupling of the aroylpiperidines with chloromethyl azoles; the compds. 1a-y were evaluated for their in vitro anti-TB activity vs. replicating, multi- and extensive drug resistant strains of Mycobacterium tuberculosis (MTB).  A high-throughput screening effort on 45,000 compds. resulted in the discovery of a disubstituted oxazole as a new structural class inhibitor of MTB.  In order to improve the activity and investigate the SAR of this scaffold, a series of disubstituted azole analogs have been designed and synthesized.  Almost all the compds. showed potent anti-TB activity with MIC of 1-64 mg/L.  The test of broad spectrum panel revealed that this series are specific to MTB.  The cytotoxicity assessment indicated that the compds. were not cytotoxic against HEK 293 cells.  The compds. could have a novel mechanism to anti-MTB as they can inhibit drug sensitive and drug resistant Mtb.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7VWyZg-WlSLVg90H21EOLACvtfcHk0ljBZYtAhPGF7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1Gksb%252FP&md5=1ad3a7711a9334e7112f46f681fb48ac</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.09.072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.09.072%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DGao%26aufirst%3DN.%26aulast%3DZhu%26aufirst%3DN.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DYou%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DWan%26aufirst%3DK.%26aulast%3DJiang%26aufirst%3DJ.%2BD.%26aulast%3DJiang%26aufirst%3DW.%26aulast%3DSi%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520the%2520disubstituted%2520oxazole%2520analogues%2520as%2520a%2520novel%2520class%2520anti-tuberculotic%2520agents%2520against%2520mdr-%2520and%2520xdr-mtb%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D5178%26epage%3D5181%26doi%3D10.1016%2Fj.bmcl.2015.09.072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref209"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref209'); return false;" data-citation="" class="refNumLink">209</a></strong><div class="NLM_citation" id="cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pedgaonkar, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridevi, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeankumar, V. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saxena, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devi, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renuka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yogeeswari, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sriram, D.</span></span> <span> </span><span class="NLM_article-title">Development of benzo[d]oxazol-2(3h)-ones derivatives as novel inhibitors of mycobacterium tuberculosis inha</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">6134</span>– <span class="NLM_lpage">6145</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2014.08.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmc.2014.08.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=25282650" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsV2ktLvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=6134-6145&author=G.+S.+Pedgaonkarauthor=J.+P.+Srideviauthor=V.+U.+Jeankumarauthor=S.+Saxenaauthor=P.+B.+Deviauthor=J.+Renukaauthor=P.+Yogeeswariauthor=D.+Sriram&title=Development+of+benzo%5Bd%5Doxazol-2%283h%29-ones+derivatives+as+novel+inhibitors+of+mycobacterium+tuberculosis+inha&doi=10.1016%2Fj.bmc.2014.08.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">Development of benzo[d]oxazol-2(3H)-ones derivatives as novel inhibitors of Mycobacterium tuberculosis InhA</span></div><div class="casAuthors">Pedgaonkar, Ganesh S.; Sridevi, Jonnalagadda Padma; Jeankumar, Variam Ullas; Saxena, Shalini; Devi, Parthiban Brindha; Renuka, Janupally; Yogeeswari, Perumal; Sriram, Dharmarajan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6134-6145</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of twenty seven substituted 2-(2-oxobenzo[d]oxazol-3(2H)-yl)acetamide derivs. was designed based on an earlier reported Mycobacterium tuberculosis (MTB) enoyl-acyl carrier protein reductase (InhA) lead.  Compds. were evaluated for MTB InhA inhibition study, in vitro activity against drug-sensitive and -resistant MTB strains, and cytotoxicity against RAW 264.7 cell line.  Among the compds. tested, 2-(6-nitro-2-oxobenzo[d]oxazol-3(2H)-yl)-N-(5-nitrothiazol-2-yl)acetamide (30) was found to be the most promising compd. with IC50 of 5.12 ± 0.44 μM against MTB InhA, inhibited drug sensitive MTB with MIC 17.11 μM and was non-cytotoxic at 100 μM.  The interaction with protein and enhancement of protein stability in complex with compd. 30 was further confirmed biophys. by differential scanning fluorimetry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcmAyJGQ1tu7Vg90H21EOLACvtfcHk0ljBZYtAhPGF7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsV2ktLvI&md5=add4a5d09dabefec6801f624c4f6bdec</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.08.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.08.031%26sid%3Dliteratum%253Aachs%26aulast%3DPedgaonkar%26aufirst%3DG.%2BS.%26aulast%3DSridevi%26aufirst%3DJ.%2BP.%26aulast%3DJeankumar%26aufirst%3DV.%2BU.%26aulast%3DSaxena%26aufirst%3DS.%26aulast%3DDevi%26aufirst%3DP.%2BB.%26aulast%3DRenuka%26aufirst%3DJ.%26aulast%3DYogeeswari%26aufirst%3DP.%26aulast%3DSriram%26aufirst%3DD.%26atitle%3DDevelopment%2520of%2520benzo%255Bd%255Doxazol-2%25283h%2529-ones%2520derivatives%2520as%2520novel%2520inhibitors%2520of%2520mycobacterium%2520tuberculosis%2520inha%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D6134%26epage%3D6145%26doi%3D10.1016%2Fj.bmc.2014.08.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref210"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref210'); return false;" data-citation="" class="refNumLink">210</a></strong><div class="NLM_citation" id="cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Costa, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boechat, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rangel, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Silva, F. e. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Souza, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Junior, I. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lourenço, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardell, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, V. F.</span></span> <span> </span><span class="NLM_article-title">Synthesis, tuberculosis inhibitory activity, and sar study of n-substituted-phenyl-1,2,3-triazole derivatives</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">8644</span>– <span class="NLM_lpage">8653</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2006.08.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmc.2006.08.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=16949290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFOjt7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=8644-8653&author=M.+S.+Costaauthor=N.+Boechatauthor=E.+A.+Rangelauthor=F.+e.+C.+da+Silvaauthor=A.+M.+de+Souzaauthor=C.+R.+Rodriguesauthor=H.+C.+Castroauthor=I.+N.+Juniorauthor=M.+C.+Louren%C3%A7oauthor=S.+M.+Wardellauthor=V.+F.+Ferreira&title=Synthesis%2C+tuberculosis+inhibitory+activity%2C+and+sar+study+of+n-substituted-phenyl-1%2C2%2C3-triazole+derivatives&doi=10.1016%2Fj.bmc.2006.08.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit210R"><div class="casContent"><span class="casTitleNuber">210</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, tuberculosis inhibitory activity, and SAR study of N-substituted-phenyl-1,2,3-triazole derivatives</span></div><div class="casAuthors">Costa, Marilia S.; Boechat, Nubia; Rangel, Erica A.; da Silva, Fernando de C.; de Souza, Alessandra M. T.; Rodrigues, Carlos R.; Castro, Helena C.; Junior, Ivan N.; Lourenco, Maria Cristina S.; Wardell, Solange M. S. V.; Ferreira, Vitor F.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8644-8653</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The aim of this work was to describe the synthesis, the in vitro anti-Mycobacterium tuberculosis profile, and the structure-activity relationship (SAR) study of new N-substituted-phenyl-1,2,3-triazole-4-carbaldehydes (3a-l).  The reactions of arom. amine hydrochlorides with diazomalonaldehyde (1) produced several N-substituted-phenyl-1,2,3-triazole-4-carbaldehydes (3a-l) in moderate-to-good yields.  In order to investigate the influence of the difluoromethylene group on the anti-Mycobacterium activity of these compds., fluorination of triazoles with DAST converted the corresponding carbaldehyde compds. into new difluoromethyl derivs. (4a-l) in excellent yield.  Characterization of all compds. was achieved by spectroscopic means and X-ray crystallog. for 1-(4-methylphenyl)-1,2,3-triazole-4-carbaldehyde, 3k (I).  Compds. (3a-l) and (4a-l) have been screened for the inhibitory activity against Mycobacterium tuberculosis H37Rv strain (ATCC 27294) and all of them were able to inhibit the growth of the bacterium.  Interestingly, 3a (3,5-dichlorophenyl deriv.) and 3k exhibited the best inhibition with MIC values of 2.5 μg/mL, similar to pharmaceuticals currently used in the treatment of tuberculosis.  Our SAR study indicated the importance of the hydrogen bond acceptor subunit (3a-l), the position in the arom. ring, the planarity of triazole and Ph rings in these compds., and a correlation between the uniform HOMO coeff. distribution and the anti-tubercular activity.  The significant activity of 3a and 3k pointed them as promising lead mols. for further synthetic and biol. exploration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6Pk97tdiQt7Vg90H21EOLACvtfcHk0ljBZYtAhPGF7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFOjt7jJ&md5=e78a1882b6d9fbd8d8c0965541d77250</span></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2006.08.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2006.08.019%26sid%3Dliteratum%253Aachs%26aulast%3DCosta%26aufirst%3DM.%2BS.%26aulast%3DBoechat%26aufirst%3DN.%26aulast%3DRangel%26aufirst%3DE.%2BA.%26aulast%3Dda%2BSilva%26aufirst%3DF.%2Be.%2BC.%26aulast%3Dde%2BSouza%26aufirst%3DA.%2BM.%26aulast%3DRodrigues%26aufirst%3DC.%2BR.%26aulast%3DCastro%26aufirst%3DH.%2BC.%26aulast%3DJunior%26aufirst%3DI.%2BN.%26aulast%3DLouren%25C3%25A7o%26aufirst%3DM.%2BC.%26aulast%3DWardell%26aufirst%3DS.%2BM.%26aulast%3DFerreira%26aufirst%3DV.%2BF.%26atitle%3DSynthesis%252C%2520tuberculosis%2520inhibitory%2520activity%252C%2520and%2520sar%2520study%2520of%2520n-substituted-phenyl-1%252C2%252C3-triazole%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2006%26volume%3D14%26spage%3D8644%26epage%3D8653%26doi%3D10.1016%2Fj.bmc.2006.08.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref211"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref211'); return false;" data-citation="" class="refNumLink">211</a></strong><div class="NLM_citation" id="cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menendez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chollet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasca, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lherbet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baltas, M.</span></span> <span> </span><span class="NLM_article-title">Chemical synthesis and biological evaluation of triazole derivatives as inhibitors of InhA and antituberculosis agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">275</span>– <span class="NLM_lpage">283</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2012.03.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.ejmech.2012.03.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=22483635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtlSksrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=275-283&author=C.+Menendezauthor=A.+Cholletauthor=F.+Rodriguezauthor=C.+Inardauthor=M.+R.+Pascaauthor=C.+Lherbetauthor=M.+Baltas&title=Chemical+synthesis+and+biological+evaluation+of+triazole+derivatives+as+inhibitors+of+InhA+and+antituberculosis+agents&doi=10.1016%2Fj.ejmech.2012.03.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit211R"><div class="casContent"><span class="casTitleNuber">211</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical synthesis and biological evaluation of triazole derivatives as inhibitors of InhA and antituberculosis agents</span></div><div class="casAuthors">Menendez, Christophe; Chollet, Aurelien; Rodriguez, Frederic; Inard, Cyril; Pasca, Maria Rosalia; Lherbet, Christian; Baltas, Michel</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">275-283</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of triazoles have been prepd. and evaluated as inhibitors of InhA as well as inhibitors of Mycobacterium tuberculosis H37Rv.  Several of these new compds. possess a good activity against InhA, particularly compds. I (n = 7, 8) for which mol. docking has been performed.  Concerning their activities against M. tuberculosis H37RV strain, two of the compds. were found to be good inhibitors with MIC values of 0.50 and 0.25 μg/mL, resp.  Particularly, compd. II presenting the best MIC value of all compds. tested (0.6 μM) is totally inactive against InhA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCsRCTAFSUw7Vg90H21EOLACvtfcHk0lhIRaMqOrm7_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtlSksrg%253D&md5=cfd7a7cdeda150492a33a612561237d5</span></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2012.03.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2012.03.029%26sid%3Dliteratum%253Aachs%26aulast%3DMenendez%26aufirst%3DC.%26aulast%3DChollet%26aufirst%3DA.%26aulast%3DRodriguez%26aufirst%3DF.%26aulast%3DInard%26aufirst%3DC.%26aulast%3DPasca%26aufirst%3DM.%2BR.%26aulast%3DLherbet%26aufirst%3DC.%26aulast%3DBaltas%26aufirst%3DM.%26atitle%3DChemical%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520triazole%2520derivatives%2520as%2520inhibitors%2520of%2520InhA%2520and%2520antituberculosis%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2012%26volume%3D52%26spage%3D275%26epage%3D283%26doi%3D10.1016%2Fj.ejmech.2012.03.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref212"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref212'); return false;" data-citation="" class="refNumLink">212</a></strong><div class="NLM_citation" id="cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adhikari, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chowdhury, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sumesh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pal, N. K.</span></span> <span> </span><span class="NLM_article-title">New quinolin-4-yl-1,2,3-triazoles carrying amides, sulphonamides and amidopiperazines as potential antitubercular agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">2503</span>– <span class="NLM_lpage">2512</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2011.03.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.ejmech.2011.03.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=21489660" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsVCnurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2011&pages=2503-2512&author=K.+D.+Thomasauthor=A.+V.+Adhikariauthor=I.+H.+Chowdhuryauthor=E.+Sumeshauthor=N.+K.+Pal&title=New+quinolin-4-yl-1%2C2%2C3-triazoles+carrying+amides%2C+sulphonamides+and+amidopiperazines+as+potential+antitubercular+agents&doi=10.1016%2Fj.ejmech.2011.03.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit212R"><div class="casContent"><span class="casTitleNuber">212</span><div class="casTitle"><span class="NLM_cas:atitle">New quinolin-4-yl-1,2,3-triazoles carrying amides, sulfonamides and amidopiperazines as potential antitubercular agents</span></div><div class="casAuthors">Thomas, K. D.; Adhikari, Airody Vasudeva; Chowdhury, Imran H.; Sumesh, E.; Pal, Nishith K.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2503-2512</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Three new series of quinolin-4-yl-1,2,3-triazoles carrying amide, sulfonamide and acylpiperazine substituents were synthesized through multi-step reactions.  The required intermediate, [1-(6-methoxy-2-methylquinolin-4-yl)-1H-1,2,3-triazol-4-yl]methanol (I) was prepd. by treating 4-azido-6-methoxy-2-methylquinoline with propargyl alc.  Three different series of compds. were synthesized from this intermediate.  All the newly synthesized compds. were characterized by spectral and elemental analyses.  The structure of I was confirmed by X-ray crystallog. study.  Further, the title compds. were evaluated for their in vitro anti-bacterial activity against five different bacterial strains and antimycobacterial activity against Mycobacterium tuberculosis H37Rv, Mycobacterium smegmatis (ATCC 19420) and Mycobacterium fortuitum (ATCC 19542).  Some were found to be active against Mycobacterium tuberculosis H37Rv strain and could be lead mols. of interest.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoA6r2oH8dFlrVg90H21EOLACvtfcHk0lhIRaMqOrm7_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsVCnurs%253D&md5=f0612143761844db0a77a6a7973f282f</span></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2011.03.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2011.03.039%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DK.%2BD.%26aulast%3DAdhikari%26aufirst%3DA.%2BV.%26aulast%3DChowdhury%26aufirst%3DI.%2BH.%26aulast%3DSumesh%26aufirst%3DE.%26aulast%3DPal%26aufirst%3DN.%2BK.%26atitle%3DNew%2520quinolin-4-yl-1%252C2%252C3-triazoles%2520carrying%2520amides%252C%2520sulphonamides%2520and%2520amidopiperazines%2520as%2520potential%2520antitubercular%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2011%26volume%3D46%26spage%3D2503%26epage%3D2512%26doi%3D10.1016%2Fj.ejmech.2011.03.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref213"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref213'); return false;" data-citation="" class="refNumLink">213</a></strong><div class="NLM_citation" id="cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menendez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribeiro, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zara, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frongia, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lobjois, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saffon, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasca, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lherbet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baltas, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of α-ketotriazoles and α,β-diketotriazoles as inhibitors of mycobacterium tuberculosis</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">167</span>– <span class="NLM_lpage">173</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.06.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.ejmech.2013.06.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=24016834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslaqs7%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2013&pages=167-173&author=C.+Menendezauthor=F.+Rodriguezauthor=A.+L.+Ribeiroauthor=F.+Zaraauthor=C.+Frongiaauthor=V.+Lobjoisauthor=N.+Saffonauthor=M.+R.+Pascaauthor=C.+Lherbetauthor=M.+Baltas&title=Synthesis+and+evaluation+of+%CE%B1-ketotriazoles+and+%CE%B1%2C%CE%B2-diketotriazoles+as+inhibitors+of+mycobacterium+tuberculosis&doi=10.1016%2Fj.ejmech.2013.06.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit213R"><div class="casContent"><span class="casTitleNuber">213</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of α-ketotriazoles and α,β-diketotriazoles as inhibitors of Mycobacterium tuberculosis</span></div><div class="casAuthors">Menendez, Christophe; Rodriguez, Frederic; de Jesus Lopes Ribeiro, Ana Luisa; Zara, Francesca; Frongia, Celine; Lobjois, Valerie; Saffon, Nathalie; Pasca, Maria Rosalia; Lherbet, Christian; Baltas, Michel</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">167-173</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Two series of α-ketotriazole and α,β-diketotriazole derivs. were synthesized and evaluated for antitubercular and cytotoxic activities.  Among them, two α,β-diketotriazole compds., I and II, exhibited good activities (min. inhibitory concn. = 7.6 μM and 6.9 μM, resp.) on Mycobacterium tuberculosis and multi-drug resistant M. tuberculosis strains and presented no cytotoxicity (IC50 > 50 μM) on colorectal cancer HCT116 and normal fibroblast GM637H cell lines.  These two compds. represent promising leads for further optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTS3A-2Fk-TbVg90H21EOLACvtfcHk0lhIRaMqOrm7_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslaqs7%252FO&md5=c2954a4fdf7aac3d12dfec9337248a44</span></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.06.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.06.042%26sid%3Dliteratum%253Aachs%26aulast%3DMenendez%26aufirst%3DC.%26aulast%3DRodriguez%26aufirst%3DF.%26aulast%3DRibeiro%26aufirst%3DA.%2BL.%26aulast%3DZara%26aufirst%3DF.%26aulast%3DFrongia%26aufirst%3DC.%26aulast%3DLobjois%26aufirst%3DV.%26aulast%3DSaffon%26aufirst%3DN.%26aulast%3DPasca%26aufirst%3DM.%2BR.%26aulast%3DLherbet%26aufirst%3DC.%26aulast%3DBaltas%26aufirst%3DM.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520%25CE%25B1-ketotriazoles%2520and%2520%25CE%25B1%252C%25CE%25B2-diketotriazoles%2520as%2520inhibitors%2520of%2520mycobacterium%2520tuberculosis%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D69%26spage%3D167%26epage%3D173%26doi%3D10.1016%2Fj.ejmech.2013.06.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref214"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref214'); return false;" data-citation="" class="refNumLink">214</a></strong><div class="NLM_citation" id="cit214"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awasthi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanardi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruzsicska, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knudson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonge, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slayden, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ojima, I.</span></span> <span> </span><span class="NLM_article-title">Novel trisubstituted benzimidazoles, targeting Mtb FtsZ, as a new class of antitubercular agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">374</span>– <span class="NLM_lpage">381</span>, <span class="refDoi"> DOI: 10.1021/jm1012006</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1012006" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFShtbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=374-381&author=K.+Kumarauthor=D.+Awasthiauthor=S.+Y.+Leeauthor=I.+Zanardiauthor=B.+Ruzsicskaauthor=S.+Knudsonauthor=P.+J.+Tongeauthor=R.+A.+Slaydenauthor=I.+Ojima&title=Novel+trisubstituted+benzimidazoles%2C+targeting+Mtb+FtsZ%2C+as+a+new+class+of+antitubercular+agents&doi=10.1021%2Fjm1012006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit214R"><div class="casContent"><span class="casTitleNuber">214</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Trisubstituted Benzimidazoles, Targeting Mtb FtsZ, as a New Class of Antitubercular Agents</span></div><div class="casAuthors">Kumar, Kunal; Awasthi, Divya; Lee, Seung-Yub; Zanardi, Ilaria; Ruzsicska, Bela; Knudson, Susan; Tonge, Peter J.; Slayden, Richard A.; Ojima, Iwao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">374-381</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Libraries of novel trisubstituted benzimidazoles were created through rational drug design.  A good no. of these benzimidazoles exhibited promising MIC values in the range of 0.5-6 μg/mL (2-15 μM) for their antibacterial activity against Mtb H37Rv strain.  Moreover, five of the lead compds. also exhibited excellent activity against clin. Mtb strains with different drug-resistance profiles.  All lead compds. did not show appreciable cytotoxicity (IC50 > 200 μM) against Vero cells, which inhibited Mtb FtsZ assembly in a dose dependent manner.  The two lead compds. unexpectedly showed enhancement of the GTPase activity of Mtb FtsZ.  The result strongly suggests that the increased GTPase activity destabilizes FtsZ assembly, leading to efficient inhibition of FtsZ polymn. and filament formation.  The TEM and SEM analyses of Mtb FtsZ and Mtb cells, resp., treated with a lead compd. strongly suggest that lead benzimidazoles have a novel mechanism of action on the inhibition of Mtb FtsZ assembly and Z-ring formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzXUSeMbGak7Vg90H21EOLACvtfcHk0liWeX7PDbCt3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFShtbzI&md5=80d27b16ed467b925daedf927576c5eb</span></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=10.1021%2Fjm1012006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1012006%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DK.%26aulast%3DAwasthi%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DS.%2BY.%26aulast%3DZanardi%26aufirst%3DI.%26aulast%3DRuzsicska%26aufirst%3DB.%26aulast%3DKnudson%26aufirst%3DS.%26aulast%3DTonge%26aufirst%3DP.%2BJ.%26aulast%3DSlayden%26aufirst%3DR.%2BA.%26aulast%3DOjima%26aufirst%3DI.%26atitle%3DNovel%2520trisubstituted%2520benzimidazoles%252C%2520targeting%2520Mtb%2520FtsZ%252C%2520as%2520a%2520new%2520class%2520of%2520antitubercular%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D374%26epage%3D381%26doi%3D10.1021%2Fjm1012006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref215"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref215'); return false;" data-citation="" class="refNumLink">215</a></strong><div class="NLM_citation" id="cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haranahalli, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ojima, I.</span></span> <span> </span><span class="NLM_article-title">Recent advances in the discovery and development of antibacterial agents targeting the cell-division protein ftsz</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">6354</span>– <span class="NLM_lpage">6369</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.05.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmc.2016.05.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=27189886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28XnvFOgu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=6354-6369&author=K.+Haranahalliauthor=S.+Tongauthor=I.+Ojima&title=Recent+advances+in+the+discovery+and+development+of+antibacterial+agents+targeting+the+cell-division+protein+ftsz&doi=10.1016%2Fj.bmc.2016.05.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit215R"><div class="casContent"><span class="casTitleNuber">215</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the discovery and development of antibacterial agents targeting the cell-division protein FtsZ</span></div><div class="casAuthors">Haranahalli, Krupanandan; Tong, Simon; Ojima, Iwao</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6354-6369</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  With the emergence of multidrug-resistant bacterial strains, there is a dire need for new drug targets for antibacterial drug discovery and development.  Filamentous temp. sensitive protein Z (FtsZ), is a GTP-dependent prokaryotic cell division protein, sharing less than 10% sequence identity with the eukaryotic cell division protein, tubulin.  FtsZ forms a dynamic Z-ring in the middle of the cell, leading to septation and subsequent cell division.  Inhibition of the Z-ring blocks cell division, thus making FtsZ a highly attractive target.  Various groups have been working on natural products and synthetic small mols. as inhibitors of FtsZ.  This review summarizes the recent advances in the development of FtsZ inhibitors, focusing on those in the last 5 years, but also includes significant findings in previous years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR-yPw_2hjULVg90H21EOLACvtfcHk0liWeX7PDbCt3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnvFOgu7s%253D&md5=80cf039e06bfc61c35e24939ac4379e3</span></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.05.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.05.003%26sid%3Dliteratum%253Aachs%26aulast%3DHaranahalli%26aufirst%3DK.%26aulast%3DTong%26aufirst%3DS.%26aulast%3DOjima%26aufirst%3DI.%26atitle%3DRecent%2520advances%2520in%2520the%2520discovery%2520and%2520development%2520of%2520antibacterial%2520agents%2520targeting%2520the%2520cell-division%2520protein%2520ftsz%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D6354%26epage%3D6369%26doi%3D10.1016%2Fj.bmc.2016.05.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref216"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref216'); return false;" data-citation="" class="refNumLink">216</a></strong><div class="NLM_citation" id="cit216"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knudson, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awasthi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carreau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goullieux, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagrange, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vermet, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ojima, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slayden, R. A.</span></span> <span> </span><span class="NLM_article-title">Cell division inhibitors with efficacy equivalent to isoniazid in the acute murine mycobacterium tuberculosis infection model</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">3070</span>– <span class="NLM_lpage">3073</span>, <span class="refDoi"> DOI: 10.1093/jac/dkv226</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1093%2Fjac%2Fdkv226" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=26245639" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28XjsFyisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2015&pages=3070-3073&author=S.+E.+Knudsonauthor=D.+Awasthiauthor=K.+Kumarauthor=A.+Carreauauthor=L.+Goullieuxauthor=S.+Lagrangeauthor=H.+Vermetauthor=I.+Ojimaauthor=R.+A.+Slayden&title=Cell+division+inhibitors+with+efficacy+equivalent+to+isoniazid+in+the+acute+murine+mycobacterium+tuberculosis+infection+model&doi=10.1093%2Fjac%2Fdkv226"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit216R"><div class="casContent"><span class="casTitleNuber">216</span><div class="casTitle"><span class="NLM_cas:atitle">Cell division inhibitors with efficacy equivalent to isoniazid in the acute murine Mycobacterium tuberculosis infection model</span></div><div class="casAuthors">Knudson, Susan E.; Awasthi, Divya; Kumar, Kunal; Carreau, Alexandra; Goullieux, Laurent; Lagrange, Sophie; Vermet, Helene; Ojima, Iwao; Slayden, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3070-3073</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Objectives: The increasing no. of clin. strains resistant to one or more of the front-line TB drugs complicates the management of this disease.  To develop next-generation benzimidazole-based FtsZ inhibitors with improved efficacy, we employed iterative optimization strategies based on whole bacteria potency, bactericidal activity, plasma and metabolic stability and in vivo efficacy studies.  Methods: Candidate benzimidazoles were evaluated for potency against Mycobacterium tuberculosis H37Rv and select clin. strains, toxicity against Vero cells and compd. stability in plasma and liver microsomes.  The efficacy of lead compds. was assessed in the acute murine M. tuberculosis infection model via i.p. and oral routes.  Results: MICs of SB-P17G-A33, SB-P17G-A38 and SB-P17G-A42 for M. tuberculosis H37Rv and select clin. strains were 0.18-0.39 mg/L.  SB-P17G-A38 and SB-P17G-A42 delivered at 50 mg/kg twice daily i.p. or orally demonstrated efficacy in reducing the bacterial load by 5.7-6.3 log10 cfu in the lungs and 3.9-5.0 log10 cfu in the spleen.  SB-P17G-A33 delivered at 50 mg/kg twice daily i.p. or orally also reduced the bacterial load by 1.7-2.1 log10 cfu in the lungs and 2.5-3.4 log10 cfu in the spleen.  Conclusions: Next-generation benzimidazoles with excellent potency and efficacy against M. tuberculosis have been developed.  This is the first report on benzimidazole-based FtsZ inhibitors showing an equiv. level of efficacy to isoniazid in an acute murine M. tuberculosis infection model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoauLxKmFVvD7Vg90H21EOLACvtfcHk0liWeX7PDbCt3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjsFyisbc%253D&md5=2538e3c9540b94e7769f26363812b77a</span></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdkv226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdkv226%26sid%3Dliteratum%253Aachs%26aulast%3DKnudson%26aufirst%3DS.%2BE.%26aulast%3DAwasthi%26aufirst%3DD.%26aulast%3DKumar%26aufirst%3DK.%26aulast%3DCarreau%26aufirst%3DA.%26aulast%3DGoullieux%26aufirst%3DL.%26aulast%3DLagrange%26aufirst%3DS.%26aulast%3DVermet%26aufirst%3DH.%26aulast%3DOjima%26aufirst%3DI.%26aulast%3DSlayden%26aufirst%3DR.%2BA.%26atitle%3DCell%2520division%2520inhibitors%2520with%2520efficacy%2520equivalent%2520to%2520isoniazid%2520in%2520the%2520acute%2520murine%2520mycobacterium%2520tuberculosis%2520infection%2520model%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2015%26volume%3D70%26spage%3D3070%26epage%3D3073%26doi%3D10.1093%2Fjac%2Fdkv226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref217"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref217'); return false;" data-citation="" class="refNumLink">217</a></strong><div class="NLM_citation" id="cit217"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahamad, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Islam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwivedi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan, M. I.</span></span> <span> </span><span class="NLM_article-title">2/3D-QSAR, molecular docking and md simulation studies of ftsz protein targeting benzimidazoles derivatives</span>. <i>Comput. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">398</span>– <span class="NLM_lpage">413</span>, <span class="refDoi"> DOI: 10.1016/j.compbiolchem.2018.12.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.compbiolchem.2018.12.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=30602415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC1MXosFan" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2019&pages=398-413&author=S.+Ahamadauthor=A.+Islamauthor=F.+Ahmadauthor=N.+Dwivediauthor=M.+I.+Hassan&title=2%2F3D-QSAR%2C+molecular+docking+and+md+simulation+studies+of+ftsz+protein+targeting+benzimidazoles+derivatives&doi=10.1016%2Fj.compbiolchem.2018.12.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit217R"><div class="casContent"><span class="casTitleNuber">217</span><div class="casTitle"><span class="NLM_cas:atitle">2/3D-QSAR, molecular docking and MD simulation studies of FtsZ protein targeting benzimidazoles derivatives</span></div><div class="casAuthors">Ahamad, Shahzaib; Islam, Asimul; Ahmad, Faizan; Dwivedi, Neeraj; Hassan, Md. Imtaiyaz</div><div class="citationInfo"><span class="NLM_cas:title">Computational Biology and Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">398-413</span>CODEN:
                <span class="NLM_cas:coden">CBCOCH</span>;
        ISSN:<span class="NLM_cas:issn">1476-9271</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The development of multi-drug and extensively-drug resistant strains of Mycobacterium tuberculosis (Mtb) have encouraged to develop new anti-TB agents with a unique mechanism of action.  FtsZ, an essential protein of bacterial cytokinesis, has emerged as a validated target for antibacterial therapy.  This study describes the utility of benzimidazoles (BI) derivs. as potential FtsZ inhibitors.  Through 2/3D QSAR (MLR) mol. modeling, new BI-inhibitors with improved activity have been designed.  Statistically significant models from 2D-QSAR (r2 = 0.90, q2 = 85 and pred_r2 = 0.60) indicated that the descriptors such as SaaOcount, -ve Potential Surface Area, and SdsCHE-index modulate the activity of a mol.  Similarly, 3D-QSAR (r2 = 0.78, q2 = 0.69 and pred_r2 = 0.59) results indicated both electrostatic and steric descriptors play a pivotal role.  These indications prompted us to design 223 new BI-derivs., out of which three BI-derivs. (D-83, D-116 and D-223) have shown some promising results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmJiySGVqLMbVg90H21EOLACvtfcHk0ljdXphhYBa3Kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXosFan&md5=c4ccd6f4785bf0367bba015fcb5acf4e</span></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=10.1016%2Fj.compbiolchem.2018.12.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.compbiolchem.2018.12.017%26sid%3Dliteratum%253Aachs%26aulast%3DAhamad%26aufirst%3DS.%26aulast%3DIslam%26aufirst%3DA.%26aulast%3DAhmad%26aufirst%3DF.%26aulast%3DDwivedi%26aufirst%3DN.%26aulast%3DHassan%26aufirst%3DM.%2BI.%26atitle%3D2%252F3D-QSAR%252C%2520molecular%2520docking%2520and%2520md%2520simulation%2520studies%2520of%2520ftsz%2520protein%2520targeting%2520benzimidazoles%2520derivatives%26jtitle%3DComput.%2520Biol.%2520Chem.%26date%3D2019%26volume%3D78%26spage%3D398%26epage%3D413%26doi%3D10.1016%2Fj.compbiolchem.2018.12.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref218"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref218'); return false;" data-citation="" class="refNumLink">218</a></strong><div class="NLM_citation" id="cit218"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gobis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foks, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bojanowski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augustynowicz-Kopeć, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Napiórkowska, A.</span></span> <span> </span><span class="NLM_article-title">Synthesis of novel 3-cyclohexylpropanoic acid-derived nitrogen heterocyclic compounds and their evaluation for tuberculostatic activity</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">137</span>– <span class="NLM_lpage">144</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2011.11.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmc.2011.11.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=22153872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38XitlCksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=137-144&author=K.+Gobisauthor=H.+Foksauthor=K.+Bojanowskiauthor=E.+Augustynowicz-Kope%C4%87author=A.+Napi%C3%B3rkowska&title=Synthesis+of+novel+3-cyclohexylpropanoic+acid-derived+nitrogen+heterocyclic+compounds+and+their+evaluation+for+tuberculostatic+activity&doi=10.1016%2Fj.bmc.2011.11.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit218R"><div class="casContent"><span class="casTitleNuber">218</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of novel 3-cyclohexylpropanoic acid-derived nitrogen heterocyclic compounds and their evaluation for tuberculostatic activity</span></div><div class="casAuthors">Gobis, Katarzyna; Foks, Henryk; Bojanowski, Krzysztof; Augustynowicz-Kopec, Ewa; Napiorkowska, Agnieszka</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">137-144</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of novel 3-cyclohexylpropanoic acid derivs. and 3-cyclohexylpropanoic acid-derived nitrogen heterocyclic compds. have been synthesized and evaluated for tuberculostatic activity.  Four compds. bearing benzimidazole or benzimidazole-like systems showed the most potent tuberculostatic activity against Mycobacterium tuberculosis strains with MIC values ranging from 1.5 to 12.5 μg/mL.  More importantly, 6-chloro-2-(2-cyclohexylethyl)-4-nitro-1H-benzo[d]imidazole and 2-(2-cyclohexylethyl)-1H-imidazo[4,5-b]phenazine appeared selective for M. tuberculosis as compared with eukaryotic cells (human fibroblasts), and other antimicrobial strains.  These compds. may thus represent a novel, selective class of antitubercular agents.  Addnl., compd. 6-chloro-2-(2-cyclohexylethyl)-4-nitro-1H-benzo[d]imidazole stimulated type I collagen output by fibroblasts, in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPWNS6IqtYarVg90H21EOLACvtfcHk0ljdXphhYBa3Kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitlCksQ%253D%253D&md5=be6da92216f031a4a8afd0f5b8c9f1b2</span></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2011.11.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2011.11.020%26sid%3Dliteratum%253Aachs%26aulast%3DGobis%26aufirst%3DK.%26aulast%3DFoks%26aufirst%3DH.%26aulast%3DBojanowski%26aufirst%3DK.%26aulast%3DAugustynowicz-Kope%25C4%2587%26aufirst%3DE.%26aulast%3DNapi%25C3%25B3rkowska%26aufirst%3DA.%26atitle%3DSynthesis%2520of%2520novel%25203-cyclohexylpropanoic%2520acid-derived%2520nitrogen%2520heterocyclic%2520compounds%2520and%2520their%2520evaluation%2520for%2520tuberculostatic%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26spage%3D137%26epage%3D144%26doi%3D10.1016%2Fj.bmc.2011.11.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref219"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref219'); return false;" data-citation="" class="refNumLink">219</a></strong><div class="NLM_citation" id="cit219"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abrahams, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghidelli-Disse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rullas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rebollo-Lopez, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurcha, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendoza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez-Navarro, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Martinez, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shillings, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argyrou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casanueva, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loman, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moynihan, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lelievre, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selenski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Axtman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bantscheff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo-Barturen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izquierdo, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cammack, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barros, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besra, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, R. H.</span></span> <span> </span><span class="NLM_article-title">Identification of KasA as the cellular target of an anti-tubercular scaffold</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">12581</span>, <span class="refDoi"> DOI: 10.1038/ncomms12581</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1038%2Fncomms12581" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=27581223" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVOru7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=12581&author=K.+A.+Abrahamsauthor=C.+W.+Chungauthor=S.+Ghidelli-Disseauthor=J.+Rullasauthor=M.+J.+Rebollo-Lopezauthor=S.+S.+Gurchaauthor=J.+A.+Coxauthor=A.+Mendozaauthor=E.+Jimenez-Navarroauthor=M.+S.+Martinez-Martinezauthor=M.+Neuauthor=A.+Shillingsauthor=P.+Homesauthor=A.+Argyrouauthor=R.+Casanuevaauthor=N.+J.+Lomanauthor=P.+J.+Moynihanauthor=J.+Lelievreauthor=C.+Selenskiauthor=M.+Axtmanauthor=L.+Kremerauthor=M.+Bantscheffauthor=I.+Angulo-Barturenauthor=M.+C.+Izquierdoauthor=N.+C.+Cammackauthor=G.+Drewesauthor=L.+Ballellauthor=D.+Barrosauthor=G.+S.+Besraauthor=R.+H.+Bates&title=Identification+of+KasA+as+the+cellular+target+of+an+anti-tubercular+scaffold&doi=10.1038%2Fncomms12581"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit219R"><div class="casContent"><span class="casTitleNuber">219</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of KasA as the cellular target of an anti-tubercular scaffold</span></div><div class="casAuthors">Abrahams, Katherine A.; Chung, Chun-wa; Ghidelli-Disse, Sonja; Rullas, Joaquin; Rebollo-Lopez, Maria Jose; Gurcha, Sudagar S.; Cox, Jonathan A. G.; Mendoza, Alfonso; Jimenez-Navarro, Elena; Martinez-Martinez, Maria Santos; Neu, Margarete; Shillings, Anthony; Homes, Paul; Argyrou, Argyrides; Casanueva, Ruth; Loman, Nicholas J.; Moynihan, Patrick J.; Lelievre, Joel; Selenski, Carolyn; Axtman, Matthew; Kremer, Laurent; Bantscheff, Marcus; Angulo-Barturen, Inigo; Izquierdo, Monica Cacho; Cammack, Nicholas C.; Drewes, Gerard; Ballell, Lluis; Barros, David; Besra, Gurdyal S.; Bates, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">12581</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Phenotypic screens for bactericidal compds. are starting to yield promising hits against tuberculosis.  In this regard, whole-genome sequencing of spontaneous resistant mutants generated against an indazole sulfonamide (GSK3011724A) identifies several specific single-nucleotide polymorphisms in the essential Mycobacterium tuberculosis β-ketoacyl synthase (kas) A gene.  Here, this genomic-based target assignment is confirmed by biochem. assays, chem. proteomics and structural resoln. of a KasA-GSK3011724A complex by X-ray crystallog.  Finally, M. tuberculosis GSK3011724A-resistant mutants increase the in vitro min. inhibitory concn. and the in vivo 99% ED in mice, establishing in vitro and in vivo target engagement.  Surprisingly, the lack of target engagement of the related β-ketoacyl synthases (FabH and KasB) suggests a different mode of inhibition when compared with other Kas inhibitors of fatty acid biosynthesis in bacteria.  These results clearly identify KasA as the biol. target of GSK3011724A and validate this enzyme for further drug discovery efforts against tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGockW3Zu8ZMEbVg90H21EOLACvtfcHk0ljdXphhYBa3Kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVOru7%252FI&md5=a1206008e181383854e026f36ad27489</span></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=10.1038%2Fncomms12581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms12581%26sid%3Dliteratum%253Aachs%26aulast%3DAbrahams%26aufirst%3DK.%2BA.%26aulast%3DChung%26aufirst%3DC.%2BW.%26aulast%3DGhidelli-Disse%26aufirst%3DS.%26aulast%3DRullas%26aufirst%3DJ.%26aulast%3DRebollo-Lopez%26aufirst%3DM.%2BJ.%26aulast%3DGurcha%26aufirst%3DS.%2BS.%26aulast%3DCox%26aufirst%3DJ.%2BA.%26aulast%3DMendoza%26aufirst%3DA.%26aulast%3DJimenez-Navarro%26aufirst%3DE.%26aulast%3DMartinez-Martinez%26aufirst%3DM.%2BS.%26aulast%3DNeu%26aufirst%3DM.%26aulast%3DShillings%26aufirst%3DA.%26aulast%3DHomes%26aufirst%3DP.%26aulast%3DArgyrou%26aufirst%3DA.%26aulast%3DCasanueva%26aufirst%3DR.%26aulast%3DLoman%26aufirst%3DN.%2BJ.%26aulast%3DMoynihan%26aufirst%3DP.%2BJ.%26aulast%3DLelievre%26aufirst%3DJ.%26aulast%3DSelenski%26aufirst%3DC.%26aulast%3DAxtman%26aufirst%3DM.%26aulast%3DKremer%26aufirst%3DL.%26aulast%3DBantscheff%26aufirst%3DM.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26aulast%3DIzquierdo%26aufirst%3DM.%2BC.%26aulast%3DCammack%26aufirst%3DN.%2BC.%26aulast%3DDrewes%26aufirst%3DG.%26aulast%3DBallell%26aufirst%3DL.%26aulast%3DBarros%26aufirst%3DD.%26aulast%3DBesra%26aufirst%3DG.%2BS.%26aulast%3DBates%26aufirst%3DR.%2BH.%26atitle%3DIdentification%2520of%2520KasA%2520as%2520the%2520cellular%2520target%2520of%2520an%2520anti-tubercular%2520scaffold%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26spage%3D12581%26doi%3D10.1038%2Fncomms12581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref220"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref220'); return false;" data-citation="" class="refNumLink">220</a></strong><div class="NLM_citation" id="cit220"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capodagli, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awasthi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shrestha, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maharaja, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukheja, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoyama, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho Liang, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarathy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasic, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perryman, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singleton, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soteropoulos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agnihotri, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salgame, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhee, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connell, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dartois, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neiditch, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freundlich, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alland, D.</span></span> <span> </span><span class="NLM_article-title">Synergistic lethality of a binary inhibitor of mycobacterium tuberculosis KasA</span>. <i>mBio</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">e02101-17</span>, <span class="refDoi"> DOI: 10.1128/mBio.02101-17</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FmBio.02101-17" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=30563908" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=e02101-17&author=P.+Kumarauthor=G.+C.+Capodagliauthor=D.+Awasthiauthor=R.+Shresthaauthor=K.+Maharajaauthor=P.+Sukhejaauthor=S.+G.+Liauthor=D.+Inoyamaauthor=M.+Zimmermanauthor=H.+P.+Ho+Liangauthor=J.+Sarathyauthor=M.+Minaauthor=G.+Rasicauthor=R.+Russoauthor=A.+L.+Perrymanauthor=T.+Richmannauthor=A.+Guptaauthor=E.+Singletonauthor=S.+Vermaauthor=S.+Husainauthor=P.+Soteropoulosauthor=Z.+Wangauthor=R.+Morrisauthor=G.+Porterauthor=G.+Agnihotriauthor=P.+Salgameauthor=S.+Ekinsauthor=K.+Y.+Rheeauthor=N.+Connellauthor=V.+Dartoisauthor=M.+B.+Neiditchauthor=J.+S.+Freundlichauthor=D.+Alland&title=Synergistic+lethality+of+a+binary+inhibitor+of+mycobacterium+tuberculosis+KasA&doi=10.1128%2FmBio.02101-17"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=10.1128%2FmBio.02101-17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FmBio.02101-17%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DP.%26aulast%3DCapodagli%26aufirst%3DG.%2BC.%26aulast%3DAwasthi%26aufirst%3DD.%26aulast%3DShrestha%26aufirst%3DR.%26aulast%3DMaharaja%26aufirst%3DK.%26aulast%3DSukheja%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DS.%2BG.%26aulast%3DInoyama%26aufirst%3DD.%26aulast%3DZimmerman%26aufirst%3DM.%26aulast%3DHo%2BLiang%26aufirst%3DH.%2BP.%26aulast%3DSarathy%26aufirst%3DJ.%26aulast%3DMina%26aufirst%3DM.%26aulast%3DRasic%26aufirst%3DG.%26aulast%3DRusso%26aufirst%3DR.%26aulast%3DPerryman%26aufirst%3DA.%2BL.%26aulast%3DRichmann%26aufirst%3DT.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DSingleton%26aufirst%3DE.%26aulast%3DVerma%26aufirst%3DS.%26aulast%3DHusain%26aufirst%3DS.%26aulast%3DSoteropoulos%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DMorris%26aufirst%3DR.%26aulast%3DPorter%26aufirst%3DG.%26aulast%3DAgnihotri%26aufirst%3DG.%26aulast%3DSalgame%26aufirst%3DP.%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DRhee%26aufirst%3DK.%2BY.%26aulast%3DConnell%26aufirst%3DN.%26aulast%3DDartois%26aufirst%3DV.%26aulast%3DNeiditch%26aufirst%3DM.%2BB.%26aulast%3DFreundlich%26aufirst%3DJ.%2BS.%26aulast%3DAlland%26aufirst%3DD.%26atitle%3DSynergistic%2520lethality%2520of%2520a%2520binary%2520inhibitor%2520of%2520mycobacterium%2520tuberculosis%2520KasA%26jtitle%3DmBio%26date%3D2018%26volume%3D9%26spage%3De02101-17%26doi%3D10.1128%2FmBio.02101-17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref221"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref221'); return false;" data-citation="" class="refNumLink">221</a></strong><div class="NLM_citation" id="cit221"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koumba Yoya, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Constant, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedos-Belval, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duran, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saffon, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daffé, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baltas, M.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of new cinnamic derivatives as antituberculosis agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1449</span>– <span class="NLM_lpage">1461</span>, <span class="refDoi"> DOI: 10.1021/jm101510d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101510d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvVWjurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1449-1461&author=P.+Deauthor=G.+Koumba+Yoyaauthor=P.+Constantauthor=F.+Bedos-Belvalauthor=H.+Duranauthor=N.+Saffonauthor=M.+Daff%C3%A9author=M.+Baltas&title=Design%2C+synthesis%2C+and+biological+evaluation+of+new+cinnamic+derivatives+as+antituberculosis+agents&doi=10.1021%2Fjm101510d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit221R"><div class="casContent"><span class="casTitleNuber">221</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of New Cinnamic Derivatives as Antituberculosis Agents</span></div><div class="casAuthors">De, Prithwiraj; Yoya, Georges Koumba; Constant, Patricia; Bedos-Belval, Florence; Duran, Hubert; Saffon, Nathalie; Daffe, Mamadou; Baltas, Michel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1449-1461</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tuberculosis, HIV coinfection with TB, emergence of multidrug-resistant TB, and extensively drug-resistant TB are the major causes of death from infectious diseases worldwide.  Because no new drug has been introduced in the last several decades, new classes of mols. as anti-TB drugs are urgently needed.  The synthesis and structure-activity relationships of a series of thioester, amide, hydrazide, and triazolophthalazine derivs. of 4-alkoxy cinnamic acid is reported in this paper.  Many compds. exhibited submicromolar min. inhibitory concns. against Mycobacterium tuberculosis strain (H37Rv).  Interestingly I, a 4-isopentenyloxycinnamyl triazolophthalazine deriv., was found to be 100-1800 times more active than isoniazid (INH) when tested for its ability to inhibit the growth of INH-resistant M. tuberculosis strains.  The results also revealed that I does not interfere with mycolic acid biosynthesis, thereby pointing to a different mode of action and representing an attractive lead compd. for the development of new anti-TB agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-D7wTlOp1o7Vg90H21EOLACvtfcHk0lgePEy15s3RVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvVWjurk%253D&md5=bcfc4d9dbd809e5e0fde4527cfeafa74</span></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=10.1021%2Fjm101510d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101510d%26sid%3Dliteratum%253Aachs%26aulast%3DDe%26aufirst%3DP.%26aulast%3DKoumba%2BYoya%26aufirst%3DG.%26aulast%3DConstant%26aufirst%3DP.%26aulast%3DBedos-Belval%26aufirst%3DF.%26aulast%3DDuran%26aufirst%3DH.%26aulast%3DSaffon%26aufirst%3DN.%26aulast%3DDaff%25C3%25A9%26aufirst%3DM.%26aulast%3DBaltas%26aufirst%3DM.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520new%2520cinnamic%2520derivatives%2520as%2520antituberculosis%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1449%26epage%3D1461%26doi%3D10.1021%2Fjm101510d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref222"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref222'); return false;" data-citation="" class="refNumLink">222</a></strong><div class="NLM_citation" id="cit222"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tawari, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bairwa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajan, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degani, M. S.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of 4-(5-nitrofuran-2-yl)prop-2-en-1-one derivatives as potent antitubercular agents</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">6175</span>– <span class="NLM_lpage">6178</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.08.127</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmcl.2010.08.127" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=20850299" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1KrsbrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=6175-6178&author=N.+R.+Tawariauthor=R.+Bairwaauthor=M.+K.+Rayauthor=M.+G.+Rajanauthor=M.+S.+Degani&title=Design%2C+synthesis%2C+and+biological+evaluation+of+4-%285-nitrofuran-2-yl%29prop-2-en-1-one+derivatives+as+potent+antitubercular+agents&doi=10.1016%2Fj.bmcl.2010.08.127"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit222R"><div class="casContent"><span class="casTitleNuber">222</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and biological evaluation of 4-(5-nitrofuran-2-yl)prop-2-en-1-one derivatives as potent antitubercular agents</span></div><div class="casAuthors">Tawari, Nilesh R.; Bairwa, Ranjeet; Ray, M. K.; Rajan, M. G. R.; Degani, Mariam S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6175-6178</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Based on stereoelectronic feature anal. using d. functional theory (DFT) at B3LYP/3-21*G level, a series of 4-(5-nitrofuran-2-yl)prop-2-en-1-one derivs. with low LUMO energies (< -0.10 eV); concd. over the nitro group, furan moiety and α,β-unsatd. carbonyl bridge were envisaged as potential antitubercular agents.  The target compds. were prepd. by condensation of 5-nitro-2-furaldehyde with various ketones under acidic condition.  The compds. were evaluated for antitubercular activity against Mycobacterium tuberculosis H37Rv and their cytotoxicity in VERO cell line.  Several synthesized compds. showed good antitubercular activity of < 5 μM along with low cytotoxicity.  In particular, compd. ((E)-3-(5-nitrofuran-2-yl)-1-(4-(piperidin-1-yl)phenyl)prop-2-en-1-one) (3v) was found to be very potent (MIC = 0.19 μM) with good selectivity index (MIC90/CC50 = >1800).  Thus, this study shows the potential of stereoelectronic property anal. in developing improved nitroaroms. as antitubercular agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUACoKUiWq4bVg90H21EOLACvtfcHk0lgePEy15s3RVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1KrsbrF&md5=a30bbf961b4161b7f38347170bcf6edd</span></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.08.127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.08.127%26sid%3Dliteratum%253Aachs%26aulast%3DTawari%26aufirst%3DN.%2BR.%26aulast%3DBairwa%26aufirst%3DR.%26aulast%3DRay%26aufirst%3DM.%2BK.%26aulast%3DRajan%26aufirst%3DM.%2BG.%26aulast%3DDegani%26aufirst%3DM.%2BS.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%25204-%25285-nitrofuran-2-yl%2529prop-2-en-1-one%2520derivatives%2520as%2520potent%2520antitubercular%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D6175%26epage%3D6178%26doi%3D10.1016%2Fj.bmcl.2010.08.127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref223"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref223'); return false;" data-citation="" class="refNumLink">223</a></strong><div class="NLM_citation" id="cit223"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Limaye, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumbhar, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natu, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paradkar, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honmore, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gample, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkar, D.</span></span> <span> </span><span class="NLM_article-title">One pot solvent free synthesis and in vitro antitubercular screening of 3-aracylphthalides against mycobacterium tuberculosis</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">711</span>– <span class="NLM_lpage">714</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.11.097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmcl.2012.11.097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=23265877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVyhs7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=711-714&author=R.+A.+Limayeauthor=V.+B.+Kumbharauthor=A.+D.+Natuauthor=M.+V.+Paradkarauthor=V.+S.+Honmoreauthor=R.+R.+Chauhanauthor=S.+P.+Gampleauthor=D.+Sarkar&title=One+pot+solvent+free+synthesis+and+in+vitro+antitubercular+screening+of+3-aracylphthalides+against+mycobacterium+tuberculosis&doi=10.1016%2Fj.bmcl.2012.11.097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit223R"><div class="casContent"><span class="casTitleNuber">223</span><div class="casTitle"><span class="NLM_cas:atitle">One-pot solvent-free synthesis and in vitro antitubercular screening of 3-Aracylphthalides against Mycobacterium tuberculosis</span></div><div class="casAuthors">Limaye, Rohan A.; Kumbhar, Virendra B.; Natu, Arun D.; Paradkar, Madhusudan V.; Honmore, Varsha S.; Chauhan, Rubia R.; Gample, Suwarna P.; Sarkar, Dhiman</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">711-714</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">One-pot synthesis of 3-aracylphthalides, e.g., I (R = H, Me, MeO, OH, NO2, Br, Cl), was accomplished in good yield by reacting 2-carboxy benzaldehyde with various arom. Me ketones in presence of methane sulfonic acid.  Various phthalides thus obtained were characterized with spectral techniques.  These phthalides were subjected to in vitro antitubercular screening against Mycobacterium tuberculosis H37Ra (MTB) by using XRMA protocol.  Among the phthalides screened, four exhibited half maximal inhibitory concn. (IC50) in the range of 0.81-1.24 μg/mL thereby providing potential lead compds. for future drug discovery studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmZvBdzxB6kLVg90H21EOLACvtfcHk0lgkNcuY5Rk6iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVyhs7bN&md5=69fa6dcc350c13b30d7eeeca9dfe2d8e</span></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.11.097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.11.097%26sid%3Dliteratum%253Aachs%26aulast%3DLimaye%26aufirst%3DR.%2BA.%26aulast%3DKumbhar%26aufirst%3DV.%2BB.%26aulast%3DNatu%26aufirst%3DA.%2BD.%26aulast%3DParadkar%26aufirst%3DM.%2BV.%26aulast%3DHonmore%26aufirst%3DV.%2BS.%26aulast%3DChauhan%26aufirst%3DR.%2BR.%26aulast%3DGample%26aufirst%3DS.%2BP.%26aulast%3DSarkar%26aufirst%3DD.%26atitle%3DOne%2520pot%2520solvent%2520free%2520synthesis%2520and%2520in%2520vitro%2520antitubercular%2520screening%2520of%25203-aracylphthalides%2520against%2520mycobacterium%2520tuberculosis%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D711%26epage%3D714%26doi%3D10.1016%2Fj.bmcl.2012.11.097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref224"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref224'); return false;" data-citation="" class="refNumLink">224</a></strong><div class="NLM_citation" id="cit224"><span> <i>GSK 3036656</i>; <span class="NLM_publisher-name">The Working Group for
New TB
Drugs</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">2019</span>; <a href="https://www.newtbdrugs.org/pipeline/compound/gsk-070-gsk-3036656" class="extLink">https://www.newtbdrugs.org/pipeline/compound/gsk-070-gsk-3036656</a> (accessed 2020-03-03).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+GSK+3036656%3B+The+Working+Group+for%0ANew+TB%0ADrugs%3A+New+York%2C+2019%3B+https%3A%2F%2Fwww.newtbdrugs.org%2Fpipeline%2Fcompound%2Fgsk-070-gsk-3036656+%28accessed+2020-03-03%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26jtitle%3DGSK%25203036656%26pub%3DThe%2520Working%2520Group%2520for%250ANew%2520TB%250ADrugs%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref225"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref225'); return false;" data-citation="" class="refNumLink">225</a></strong><div class="NLM_citation" id="cit225"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casey, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parish, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunin, B. A.</span></span> <span> </span><span class="NLM_article-title">Bayesian models for screening and TB mobile for target inference with mycobacterium tuberculosis</span>. <i>Tuberculosis (Oxford, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">162</span>– <span class="NLM_lpage">169</span>, <span class="refDoi"> DOI: 10.1016/j.tube.2013.12.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.tube.2013.12.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=24440548" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisFSmsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2014&pages=162-169&author=S.+Ekinsauthor=A.+C.+Caseyauthor=D.+Robertsauthor=T.+Parishauthor=B.+A.+Bunin&title=Bayesian+models+for+screening+and+TB+mobile+for+target+inference+with+mycobacterium+tuberculosis&doi=10.1016%2Fj.tube.2013.12.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit225R"><div class="casContent"><span class="casTitleNuber">225</span><div class="casTitle"><span class="NLM_cas:atitle">Bayesian models for screening and TB Mobile for target inference with Mycobacterium tuberculosis</span></div><div class="casAuthors">Ekins, Sean; Casey, Allen C.; Roberts, David; Parish, Tanya; Bunin, Barry A.</div><div class="citationInfo"><span class="NLM_cas:title">Tuberculosis (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">162-169</span>CODEN:
                <span class="NLM_cas:coden">TUBECU</span>;
        ISSN:<span class="NLM_cas:issn">1472-9792</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The search for compds. active against Mycobacterium tuberculosis is reliant upon high-throughput screening (HTS) in whole cells.  We have used Bayesian machine learning models which can predict anti-tubercular activity to filter an internal library of over 150,000 compds. prior to in vitro testing.  We used this to select and test 48 compds. in vitro; 11 were active with MIC values ranging from 0.4 μM to 10.2 μM, giving a high hit rate of 22.9%.  Among the hits, we identified several compds. belonging to the same series including five quinolones (including ciprofloxacin), three mols. with long aliph. linkers and three singletons.  This approach represents a rapid method to prioritize compds. for testing that can be used alongside medicinal chem. insight and other filters to identify active mols.  Such models can significantly increase the hit rate of HTS, above the usual 1% or lower rates seen.  In addn., the potential targets for the 11 mols. were predicted using TB Mobile and clustering alongside a set of over 740 mols. with known M. tuberculosis target annotations.  These predictions may serve as a mechanism for prioritizing compds. for further optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyNxo3fnyZxLVg90H21EOLACvtfcHk0lgkNcuY5Rk6iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisFSmsbk%253D&md5=1d80c6fa0949708d7ef9edc93e88e18b</span></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=10.1016%2Fj.tube.2013.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tube.2013.12.001%26sid%3Dliteratum%253Aachs%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DCasey%26aufirst%3DA.%2BC.%26aulast%3DRoberts%26aufirst%3DD.%26aulast%3DParish%26aufirst%3DT.%26aulast%3DBunin%26aufirst%3DB.%2BA.%26atitle%3DBayesian%2520models%2520for%2520screening%2520and%2520TB%2520mobile%2520for%2520target%2520inference%2520with%2520mycobacterium%2520tuberculosis%26jtitle%3DTuberculosis%2520%2528Oxford%252C%2520U.%2520K.%2529%26date%3D2014%26volume%3D94%26spage%3D162%26epage%3D169%26doi%3D10.1016%2Fj.tube.2013.12.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref226"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref226'); return false;" data-citation="" class="refNumLink">226</a></strong><div class="NLM_citation" id="cit226"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pottorf, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freundlich, J. S.</span></span> <span> </span><span class="NLM_article-title">Looking back to the future: Predicting in vivo efficacy of small molecules versus mycobacterium tuberculosis</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1070</span>– <span class="NLM_lpage">1082</span>, <span class="refDoi"> DOI: 10.1021/ci500077v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci500077v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkslamu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2014&pages=1070-1082&author=S.+Ekinsauthor=R.+Pottorfauthor=R.+C.+Reynoldsauthor=A.+J.+Williamsauthor=A.+M.+Clarkauthor=J.+S.+Freundlich&title=Looking+back+to+the+future%3A+Predicting+in+vivo+efficacy+of+small+molecules+versus+mycobacterium+tuberculosis&doi=10.1021%2Fci500077v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit226R"><div class="casContent"><span class="casTitleNuber">226</span><div class="casTitle"><span class="NLM_cas:atitle">Looking Back to the Future: Predicting in Vivo Efficacy of Small Molecules versus Mycobacterium tuberculosis</span></div><div class="casAuthors">Ekins, Sean; Pottorf, Richard; Reynolds, Robert C.; Williams, Antony J.; Clark, Alex M.; Freundlich, Joel S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1070-1082</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Selecting and translating in vitro leads for a disease into mols. with in vivo activity in an animal model of the disease is a challenge that takes considerable time and money.  As an example, recent years have seen whole-cell phenotypic screens of millions of compds. yielding over 1500 inhibitors of Mycobacterium tuberculosis (Mtb).  These must be prioritized for testing in the mouse in vivo assay for Mtb infection, a validated model utilized to select compds. for further testing.  The authors demonstrate learning from in vivo active and inactive compds. using machine learning classification models (Bayesian, support vector machines, and recursive partitioning) consisting of 773 compds.  The Bayesian model predicted 8 out of 11 addnl. in vivo actives not included in the model as an external test set.  Curation of 70 years of Mtb data can therefore provide statistically robust computational models to focus resources on in vivo active small mol. antituberculars.  This highlights a cost-effective predictor for in vivo testing elsewhere in other diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotUoWucn-1OrVg90H21EOLACvtfcHk0lgkNcuY5Rk6iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkslamu7Y%253D&md5=e5e27ddb07601604b0c9c2cde9dd313d</span></div><a href="/servlet/linkout?suffix=cit226&amp;dbid=16384&amp;doi=10.1021%2Fci500077v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci500077v%26sid%3Dliteratum%253Aachs%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DPottorf%26aufirst%3DR.%26aulast%3DReynolds%26aufirst%3DR.%2BC.%26aulast%3DWilliams%26aufirst%3DA.%2BJ.%26aulast%3DClark%26aufirst%3DA.%2BM.%26aulast%3DFreundlich%26aufirst%3DJ.%2BS.%26atitle%3DLooking%2520back%2520to%2520the%2520future%253A%2520Predicting%2520in%2520vivo%2520efficacy%2520of%2520small%2520molecules%2520versus%2520mycobacterium%2520tuberculosis%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2014%26volume%3D54%26spage%3D1070%26epage%3D1082%26doi%3D10.1021%2Fci500077v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref227"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref227'); return false;" data-citation="" class="refNumLink">227</a></strong><div class="NLM_citation" id="cit227"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipinski, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradford, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dole, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spektor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blondeau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goncharoff, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunin, B.</span></span> <span> </span><span class="NLM_article-title">Analysis and hit filtering of a very large library of compounds screened against mycobacterium tuberculosis</span>. <i>Mol. BioSyst.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">2316</span>– <span class="NLM_lpage">2324</span>, <span class="refDoi"> DOI: 10.1039/C0MB00104J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1039%2FC0MB00104J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=20835433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1KqtL7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=2316-2324&author=S.+Ekinsauthor=T.+Kanekoauthor=C.+A.+Lipinskiauthor=J.+Bradfordauthor=K.+Doleauthor=A.+Spektorauthor=K.+Gregoryauthor=D.+Blondeauauthor=S.+Ernstauthor=J.+Yangauthor=N.+Goncharoffauthor=M.+Hohmanauthor=B.+Bunin&title=Analysis+and+hit+filtering+of+a+very+large+library+of+compounds+screened+against+mycobacterium+tuberculosis&doi=10.1039%2FC0MB00104J"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit227R"><div class="casContent"><span class="casTitleNuber">227</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis and hit filtering of a very large library of compounds screened against Mycobacterium tuberculosis</span></div><div class="casAuthors">Ekins, Sean; Kaneko, Takushi; Lipinski, Christopher A.; Bradford, Justin; Dole, Krishna; Spektor, Anna; Gregory, Kellan; Blondeau, David; Ernst, Sylvia; Yang, Jeremy; Goncharoff, Nicko; Hohman, Moses M.; Bunin, Barry A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular BioSystems</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2316-2324</span>CODEN:
                <span class="NLM_cas:coden">MBOIBW</span>;
        ISSN:<span class="NLM_cas:issn">1742-206X</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">There is an urgent need for new drugs against tuberculosis which annually claims 1.7-1.8 million lives.  One approach to identify potential leads is to screen in vitro small mols. against Mycobacterium tuberculosis (Mtb).  Until recently there was no central repository to collect information on compds. screened.  Consequently, it has been difficult to analyze mol. properties of compds. that inhibit the growth of Mtb in vitro.  We have collected data from publically available sources on over 300 000 small mols. deposited in the Collaborative Drug Discovery TB Database.  A cheminformatics anal. on these compds. indicates that inhibitors of the growth of Mtb have statistically higher mean logP, rule of 5 alerts, while also having lower HBD count, atom count and lower PSA (ChemAxon descriptors), compared to compds. that are classed as inactive.  Addnl., Bayesian models for selecting Mtb active compds. were evaluated with over 100 000 compds. and, they demonstrated 10 fold enrichment over random for the top ranked 600 compds.  This represents a promising approach for finding compds. active against Mtb in whole cells screened under the same in vitro conditions.  Various sets of Mtb hit mols. were also examd. by various filtering rules used widely in the pharmaceutical industry to identify compds. with potentially reactive moieties.  We found differences between the no. of compds. flagged by these rules in Mtb datasets, malaria hits, FDA approved drugs and antibiotics.  Combining these approaches may enable selection of compds. with increased probability of inhibition of whole cell Mtb activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSaytzWyG0H7Vg90H21EOLACvtfcHk0lj6qUAoSRvt1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1KqtL7L&md5=66783a6e7ae22ad9b0022d94d6a77cea</span></div><a href="/servlet/linkout?suffix=cit227&amp;dbid=16384&amp;doi=10.1039%2FC0MB00104J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC0MB00104J%26sid%3Dliteratum%253Aachs%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DKaneko%26aufirst%3DT.%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26aulast%3DBradford%26aufirst%3DJ.%26aulast%3DDole%26aufirst%3DK.%26aulast%3DSpektor%26aufirst%3DA.%26aulast%3DGregory%26aufirst%3DK.%26aulast%3DBlondeau%26aufirst%3DD.%26aulast%3DErnst%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DGoncharoff%26aufirst%3DN.%26aulast%3DHohman%26aufirst%3DM.%26aulast%3DBunin%26aufirst%3DB.%26atitle%3DAnalysis%2520and%2520hit%2520filtering%2520of%2520a%2520very%2520large%2520library%2520of%2520compounds%2520screened%2520against%2520mycobacterium%2520tuberculosis%26jtitle%3DMol.%2520BioSyst.%26date%3D2010%26volume%3D6%26spage%3D2316%26epage%3D2324%26doi%3D10.1039%2FC0MB00104J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref228"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref228'); return false;" data-citation="" class="refNumLink">228</a></strong><div class="NLM_citation" id="cit228"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Landrum, G.</span></span> <i>RDkit Documentation</i>, <span class="NLM_edition">Release 2017.09.1</span>; <span class="NLM_publisher-name">Zenodo</span>, <span class="NLM_year">2016</span>; <span class="refDoi"> DOI: 10.5281/zenodo.60510</span>  (accessed 2020-03-03).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=G.+Landrum&title=RDkit+Documentation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit228&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26aulast%3DLandrum%26aufirst%3DG.%26jtitle%3DRDkit%2520Documentation%26pub%3DZenodo%26date%3D2016%26doi%3D10.5281%2Fzenodo.60510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref229"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref229'); return false;" data-citation="" class="refNumLink">229</a></strong><div class="NLM_citation" id="cit229"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McKinney, W.</span></span> <i>Pandas—Powerful Python Data Analysis Toolkit</i>; <span class="NLM_publisher-name">Pandas</span>, <span class="NLM_year">2020</span>; <a href="https://pandas.pydata.org/pandas-docs/stable/" class="extLink">https://pandas.pydata.org/pandas-docs/stable/</a> (accessed 2020-03-03).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=W.+McKinney&title=Pandas%E2%80%94Powerful+Python+Data+Analysis+Toolkit"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit229&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26aulast%3DMcKinney%26aufirst%3DW.%26jtitle%3DPandas%25E2%2580%2594Powerful%2520Python%2520Data%2520Analysis%2520Toolkit%26pub%3DPandas%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref230"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref230'); return false;" data-citation="" class="refNumLink">230</a></strong><div class="NLM_citation" id="cit230"><span> <i>NumPy Reference</i>, <span class="NLM_edition">release 1.11</span>; <span class="NLM_publisher-name">SciPy</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+NumPy+Reference%2C+release+1.11%3B+SciPy%2C+2016."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit230&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DNumPy%2520Reference%26pub%3DSciPy%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref231"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref231'); return false;" data-citation="" class="refNumLink">231</a></strong><div class="NLM_citation" id="cit231"><span> <i>Jupyter Notebook
Tutorial: The Definitive Guide</i>; <span class="NLM_publisher-name">DataCamp</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Jupyter+Notebook%0ATutorial%3A+The+Definitive+Guide%3B+DataCamp%2C+2019."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit231&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DJupyter%2520Notebook%250ATutorial%253A%2520The%2520Definitive%2520Guide%26pub%3DDataCamp%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref232"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref232'); return false;" data-citation="" class="refNumLink">232</a></strong><div class="NLM_citation" id="cit232"><span> <i>Scikit-learn
User Guide</i>, <span class="NLM_edition">release 0.22.2</span>; <span class="NLM_publisher-name">Scikit-learn Developers</span>, <span class="NLM_year">2020</span>; <a href="https://scikit-learn.org/stable/_downloads/scikit-learn-docs.pdf" class="extLink">https://scikit-learn.org/stable/_downloads/scikit-learn-docs.pdf</a> (accessed 2020-03-03).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Scikit-learn%0AUser+Guide%2C+release+0.22.2%3B+Scikit-learn+Developers%2C+2020%3B+https%3A%2F%2Fscikit-learn.org%2Fstable%2F_downloads%2Fscikit-learn-docs.pdf+%28accessed+2020-03-03%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit232&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DScikit-learn%250AUser%2520Guide%26pub%3DScikit-learn%2520Developers%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref233"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref233'); return false;" data-citation="" class="refNumLink">233</a></strong><div class="NLM_citation" id="cit233"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lane, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zorn, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korotcov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tkachenko, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perryman, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freundlich, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span> <span> </span><span class="NLM_article-title">Comparing and validating machine learning models for mycobacterium tuberculosis drug discovery</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">4346</span>– <span class="NLM_lpage">4360</span>, <span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.8b00083</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.8b00083" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnvV2lt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=4346-4360&author=T.+Laneauthor=D.+P.+Russoauthor=K.+M.+Zornauthor=A.+M.+Clarkauthor=A.+Korotcovauthor=V.+Tkachenkoauthor=R.+C.+Reynoldsauthor=A.+L.+Perrymanauthor=J.+S.+Freundlichauthor=S.+Ekins&title=Comparing+and+validating+machine+learning+models+for+mycobacterium+tuberculosis+drug+discovery&doi=10.1021%2Facs.molpharmaceut.8b00083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit233R"><div class="casContent"><span class="casTitleNuber">233</span><div class="casTitle"><span class="NLM_cas:atitle">Comparing and validating machine learning models for Mycobacterium tuberculosis drug discovery</span></div><div class="casAuthors">Lane, Thomas; Russo, Daniel P.; Zorn, Kimberley M.; Clark, Alex M.; Korotcov, Alexandru; Tkachenko, Valery; Reynolds, Robert C.; Perryman, Alexander L.; Freundlich, Joel S.; Ekins, Sean</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4346-4360</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tuberculosis is a global health dilemma.  In 2016, the WHO reported 10.4 million incidences and 1.7 million deaths.  The need to develop new treatments for those infected with Mycobacterium tuberculosis (Mtb) has led to many large-scale phenotypic screens and many thousands of new active compds. identified in vitro.  However, with limited funding, efforts to discover new active mols. against Mtb needs to be more efficient.  Several computational machine learning approaches have been shown to have good enrichment and hit rates.  We have curated small mol. Mtb data and developed new models with a total of 18,886 mols. with activity cutoffs of 10 μM, 1 μM, and 100 nM.  These data sets were used to evaluate different machine learning methods (including deep learning) and metrics and to generate predictions for addnl. mols. published in 2017.  One Mtb model, a combined in vitro and in vivo data Bayesian model at a 100 nM activity yielded the following metrics for 5-fold cross validation: accuracy = 0.88, precision = 0.22, recall = 0.91, specificity = 0.88, kappa = 0.31, and MCC = 0.41.  We have also curated an evaluation set (n = 153 compds.) published in 2017, and when used to test our model, it showed the comparable statistics (accuracy = 0.83, precision = 0.27, recall = 1.00, specificity = 0.81, kappa = 0.36, and MCC = 0.47).  We have also compared these models with addnl. machine learning algorithms showing Bayesian machine learning models constructed with literature Mtb data generated by different labs. generally were equiv. to or outperformed deep neural networks with external test sets.  Finally, we have also compared our training and test sets to show they were suitably diverse and different in order to represent useful evaluation sets.  Such Mtb machine learning models could help prioritize compds. for testing in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJzwbptdi_BrVg90H21EOLACvtfcHk0lj6qUAoSRvt1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnvV2lt70%253D&md5=9f856a1ccc13467380f6517534c1203a</span></div><a href="/servlet/linkout?suffix=cit233&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.8b00083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.8b00083%26sid%3Dliteratum%253Aachs%26aulast%3DLane%26aufirst%3DT.%26aulast%3DRusso%26aufirst%3DD.%2BP.%26aulast%3DZorn%26aufirst%3DK.%2BM.%26aulast%3DClark%26aufirst%3DA.%2BM.%26aulast%3DKorotcov%26aufirst%3DA.%26aulast%3DTkachenko%26aufirst%3DV.%26aulast%3DReynolds%26aufirst%3DR.%2BC.%26aulast%3DPerryman%26aufirst%3DA.%2BL.%26aulast%3DFreundlich%26aufirst%3DJ.%2BS.%26aulast%3DEkins%26aufirst%3DS.%26atitle%3DComparing%2520and%2520validating%2520machine%2520learning%2520models%2520for%2520mycobacterium%2520tuberculosis%2520drug%2520discovery%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2018%26volume%3D15%26spage%3D4346%26epage%3D4360%26doi%3D10.1021%2Facs.molpharmaceut.8b00083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref234"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref234'); return false;" data-citation="" class="refNumLink">234</a></strong><div class="NLM_citation" id="cit234"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, J.</span>; <span class="NLM_string-name">Dale, D.</span>; <span class="NLM_string-name">Firing, E.</span>; <span class="NLM_string-name">Droettboom, M.</span></span> <i>Matplotlib</i>, <span class="NLM_edition">release 2.2.2</span>; <span class="NLM_publisher-name">Matplotlib Development Team</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=J.+Hunter&author=D.+Dale&author=E.+Firing&author=M.+Droettboom&title=Matplotlib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit234&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26aulast%3DHunter%26aufirst%3DJ.%26jtitle%3DMatplotlib%26pub%3DMatplotlib%2520Development%2520Team%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref235"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref235'); return false;" data-citation="" class="refNumLink">235</a></strong><div class="NLM_citation" id="cit235"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prathipati, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, T. H.</span></span> <span> </span><span class="NLM_article-title">Global bayesian models for the prioritization of antitubercular agents</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">2362</span>– <span class="NLM_lpage">2370</span>, <span class="refDoi"> DOI: 10.1021/ci800143n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci800143n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlygs7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2008&pages=2362-2370&author=P.+Prathipatiauthor=N.+L.+Maauthor=T.+H.+Keller&title=Global+bayesian+models+for+the+prioritization+of+antitubercular+agents&doi=10.1021%2Fci800143n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit235R"><div class="casContent"><span class="casTitleNuber">235</span><div class="casTitle"><span class="NLM_cas:atitle">Global Bayesian Models for the Prioritization of Antitubercular Agents</span></div><div class="casAuthors">Prathipati, Philip; Ma, Ngai Ling; Keller, Thomas H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2362-2370</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To aid the creation of novel antituberculosis (antiTB) compds., Bayesian models were derived and validated on a data set of 3779 compds. which have been measured for min. inhibitory concn. (MIC) in the Mycobacterium tuberculosis H37Rv strain.  The model development and validation involved exploring six different training sets and 15 fingerprint types which resulted in a total of 90 models, with active compds. defined as those with MIC < 5 μM.  The best model was derived using Extended Class Fingerprints of max. diam. 12 (ECFP_12) and a few global descriptors on a training set derived using Functional Class Fingerprints of max. diam. 4 (FCFP_4).  This model demonstrated very good discriminant ability in general, with excellent discriminant statistics for the training set (total accuracy: 0.968; pos. recall: 0.967) and a good predictive ability for the test set (total accuracy: 0.869; pos. recall: 0.789).  The good predictive ability was maintained when the model was applied to a well-sepd. test set of 2880 compds. derived from a com. database (total accuracy: 0.73; pos. recall: 0.72).  The model revealed several conserved substructures present in the active and inactive compds. which are believed to have incremental and detrimental effects on the MIC, resp.  Strategies for enhancing the repertoire of antiTB compds. with the model, including virtual screening of large databases and combinatorial library design, are proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodFNgYRk32ErVg90H21EOLACvtfcHk0li9JIcD-1jWOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlygs7vI&md5=25c23c61ea8412f5da04010d39daf323</span></div><a href="/servlet/linkout?suffix=cit235&amp;dbid=16384&amp;doi=10.1021%2Fci800143n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci800143n%26sid%3Dliteratum%253Aachs%26aulast%3DPrathipati%26aufirst%3DP.%26aulast%3DMa%26aufirst%3DN.%2BL.%26aulast%3DKeller%26aufirst%3DT.%2BH.%26atitle%3DGlobal%2520bayesian%2520models%2520for%2520the%2520prioritization%2520of%2520antitubercular%2520agents%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2008%26volume%3D48%26spage%3D2362%26epage%3D2370%26doi%3D10.1021%2Fci800143n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref236"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref236'); return false;" data-citation="" class="refNumLink">236</a></strong><div class="NLM_citation" id="cit236"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradford, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dole, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spektor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blondeau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunin, B.</span></span> <span> </span><span class="NLM_article-title">A collaborative database and computational models for tuberculosis drug discovery</span>. <i>Mol. BioSyst.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">840</span>– <span class="NLM_lpage">851</span>, <span class="refDoi"> DOI: 10.1039/b917766c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1039%2Fb917766c" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=20567770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvVSrtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=840-851&author=S.+Ekinsauthor=J.+Bradfordauthor=K.+Doleauthor=A.+Spektorauthor=K.+Gregoryauthor=D.+Blondeauauthor=M.+Hohmanauthor=B.+Bunin&title=A+collaborative+database+and+computational+models+for+tuberculosis+drug+discovery&doi=10.1039%2Fb917766c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit236R"><div class="casContent"><span class="casTitleNuber">236</span><div class="casTitle"><span class="NLM_cas:atitle">A collaborative database and computational models for tuberculosis drug discovery</span></div><div class="casAuthors">Ekins, Sean; Bradford, Justin; Dole, Krishna; Spektor, Anna; Gregory, Kellan; Blondeau, David; Hohman, Moses; Bunin, Barry A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular BioSystems</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">840-851</span>CODEN:
                <span class="NLM_cas:coden">MBOIBW</span>;
        ISSN:<span class="NLM_cas:issn">1742-206X</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The search for mols. with activity against Mycobacterium tuberculosis (Mtb) is employing many approaches in parallel including high throughput screening and computational methods.  We have developed a database (CDD TB) to capture public and private Mtb data while enabling data mining and collaborations with other researchers.  We have used the public data along with several cheminformatics approaches to produce models that describe active and inactive compds.  We have compared these datasets to those for known FDA approved drugs and between Mtb active and inactive compds.  The distribution of polar surface area and pKa of active compds. was found to be a statistically significant determinant of activity against Mtb.  Hydrophobicity was not always statistically significant. Bayesian classification models for 220463 mols. were generated and tested with external mols., and enabled the discrimination of active or inactive substructures from other datasets in the CDD TB.  Computational pharmacophores based on known Mtb drugs were able to map to and retrieve a small subset of some of the Mtb datasets, including a high percentage of Mtb actives.  The combination of the database, dataset anal., Bayesian and pharmacophore models provides new insights into mol. properties and features that are determinants of activity in whole cells.  This study provides novel insights into the key 1D mol. descriptors, 2D chem. substructures and 3D pharmacophores which can be used to mine the chem. space, prioritizing those mols. with a higher probability of activity against Mtb.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgfg8SbojRpLVg90H21EOLACvtfcHk0li9JIcD-1jWOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvVSrtrg%253D&md5=5bab2de79f0bb02dc9f3b24563776b16</span></div><a href="/servlet/linkout?suffix=cit236&amp;dbid=16384&amp;doi=10.1039%2Fb917766c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb917766c%26sid%3Dliteratum%253Aachs%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DBradford%26aufirst%3DJ.%26aulast%3DDole%26aufirst%3DK.%26aulast%3DSpektor%26aufirst%3DA.%26aulast%3DGregory%26aufirst%3DK.%26aulast%3DBlondeau%26aufirst%3DD.%26aulast%3DHohman%26aufirst%3DM.%26aulast%3DBunin%26aufirst%3DB.%26atitle%3DA%2520collaborative%2520database%2520and%2520computational%2520models%2520for%2520tuberculosis%2520drug%2520discovery%26jtitle%3DMol.%2520BioSyst.%26date%3D2010%26volume%3D6%26spage%3D840%26epage%3D851%26doi%3D10.1039%2Fb917766c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref237"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref237'); return false;" data-citation="" class="refNumLink">237</a></strong><div class="NLM_citation" id="cit237"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gamo, F.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanz, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vidal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Cozar, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavandera, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderwall, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, D. V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peishoff, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardon, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Bustos, J. F.</span></span> <span> </span><span class="NLM_article-title">Thousands of chemical starting points for antimalarial lead identification</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>465</i></span>,  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">310</span>, <span class="refDoi"> DOI: 10.1038/nature09107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1038%2Fnature09107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=20485427" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmt1Ois7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=465&publication_year=2010&pages=305-310&author=F.-J.+Gamoauthor=L.+M.+Sanzauthor=J.+Vidalauthor=C.+de+Cozarauthor=E.+Alvarezauthor=J.-L.+Lavanderaauthor=D.+E.+Vanderwallauthor=D.+V.+S.+Greenauthor=V.+Kumarauthor=S.+Hasanauthor=J.+R.+Brownauthor=C.+E.+Peishoffauthor=L.+R.+Cardonauthor=J.+F.+Garcia-Bustos&title=Thousands+of+chemical+starting+points+for+antimalarial+lead+identification&doi=10.1038%2Fnature09107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit237R"><div class="casContent"><span class="casTitleNuber">237</span><div class="casTitle"><span class="NLM_cas:atitle">Thousands of chemical starting points for antimalarial lead identification</span></div><div class="casAuthors">Gamo, Francisco-Javier; Sanz, Laura M.; Vidal, Jaume; de Cozar, Cristina; Alvarez, Emilio; Lavandera, Jose-Luis; Vanderwall, Dana E.; Green, Darren V. S.; Kumar, Vinod; Hasan, Samiul; Brown, James R.; Peishoff, Catherine E.; Cardon, Lon R.; Garcia-Bustos, Jose F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">465</span>
        (<span class="NLM_cas:issue">7296</span>),
    <span class="NLM_cas:pages">305-310</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Malaria is a devastating infection caused by protozoa of the genus Plasmodium.  Drug resistance is widespread, no new chem. class of antimalarials has been introduced into clin. practice since 1996 and there is a recent rise of parasite strains with reduced sensitivity to the newest drugs.  We screened nearly 2 million compds. in GlaxoSmithKline's chem. library for inhibitors of P. falciparum, of which 13,533 were confirmed to inhibit parasite growth by at least 80% at 2 μM concn.  More than 8,000 also showed potent activity against the multidrug resistant strain Dd2.  Most (82%) compds. originate from internal company projects and are new to the malaria community.  Analyses using historic assay data suggest several novel mechanisms of antimalarial action, such as inhibition of protein kinases and host-pathogen interaction related targets.  Chem. structures and assocd. data are hereby made public to encourage addnl. drug lead identification efforts and further research into this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHijpWK_kBF7Vg90H21EOLACvtfcHk0li9JIcD-1jWOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmt1Ois7k%253D&md5=a1fd8c0b89a5650ecba31f5456928b42</span></div><a href="/servlet/linkout?suffix=cit237&amp;dbid=16384&amp;doi=10.1038%2Fnature09107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09107%26sid%3Dliteratum%253Aachs%26aulast%3DGamo%26aufirst%3DF.-J.%26aulast%3DSanz%26aufirst%3DL.%2BM.%26aulast%3DVidal%26aufirst%3DJ.%26aulast%3Dde%2BCozar%26aufirst%3DC.%26aulast%3DAlvarez%26aufirst%3DE.%26aulast%3DLavandera%26aufirst%3DJ.-L.%26aulast%3DVanderwall%26aufirst%3DD.%2BE.%26aulast%3DGreen%26aufirst%3DD.%2BV.%2BS.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DHasan%26aufirst%3DS.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3DPeishoff%26aufirst%3DC.%2BE.%26aulast%3DCardon%26aufirst%3DL.%2BR.%26aulast%3DGarcia-Bustos%26aufirst%3DJ.%2BF.%26atitle%3DThousands%2520of%2520chemical%2520starting%2520points%2520for%2520antimalarial%2520lead%2520identification%26jtitle%3DNature%26date%3D2010%26volume%3D465%26spage%3D305%26epage%3D310%26doi%3D10.1038%2Fnature09107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref238"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref238'); return false;" data-citation="" class="refNumLink">238</a></strong><div class="NLM_citation" id="cit238"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koo, M.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekonomidis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talaue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paget, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolhiser, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenaerts, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunin, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connell, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freundlich, J. S.</span></span> <span> </span><span class="NLM_article-title">Bayesian models leveraging bioactivity and cytotoxicity information for drug discovery</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">370</span>– <span class="NLM_lpage">378</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2013.01.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.chembiol.2013.01.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=23521795" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksFOgt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=370-378&author=S.+Ekinsauthor=R.+Reynoldsauthor=H.+Kimauthor=M.-S.+Kooauthor=M.+Ekonomidisauthor=M.+Talaueauthor=S.+D.+Pagetauthor=L.+K.+Woolhiserauthor=A.+J.+Lenaertsauthor=B.+A.+Buninauthor=N.+Connellauthor=J.+S.+Freundlich&title=Bayesian+models+leveraging+bioactivity+and+cytotoxicity+information+for+drug+discovery&doi=10.1016%2Fj.chembiol.2013.01.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit238R"><div class="casContent"><span class="casTitleNuber">238</span><div class="casTitle"><span class="NLM_cas:atitle">Bayesian Models Leveraging Bioactivity and Cytotoxicity Information for Drug Discovery</span></div><div class="casAuthors">Ekins, Sean; Reynolds, Robert C.; Kim, Hiyun; Koo, Mi-Sun; Ekonomidis, Marilyn; Talaue, Meliza; Paget, Steve D.; Woolhiser, Lisa K.; Lenaerts, Anne J.; Bunin, Barry A.; Connell, Nancy; Freundlich, Joel S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">370-378</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Identification of unique leads represents a significant challenge in drug discovery.  This hurdle is magnified in neglected diseases such as tuberculosis.  We have leveraged public high-throughput screening (HTS) data to exptl. validate a virtual screening approach employing Bayesian models built with bioactivity information (single-event model) as well as bioactivity and cytotoxicity information (dual-event model).  We virtually screened a com. library and exptl. confirmed actives with hit rates exceeding typical HTS results by one to two orders of magnitude.  This initial dual-event Bayesian model identified compds. with antitubercular whole-cell activity and low mammalian cell cytotoxicity from a published set of antimalarials.  The most potent hit exhibits the in vitro activity and in vitro/in vivo safety profile of a drug lead.  These Bayesian models offer significant economies in time and cost to drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHn7pP5TWKSbVg90H21EOLACvtfcHk0ljrfYGemOjCRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksFOgt7g%253D&md5=4b64d1c0fa67896b9d61c7f2fd606542</span></div><a href="/servlet/linkout?suffix=cit238&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2013.01.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2013.01.011%26sid%3Dliteratum%253Aachs%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DReynolds%26aufirst%3DR.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DKoo%26aufirst%3DM.-S.%26aulast%3DEkonomidis%26aufirst%3DM.%26aulast%3DTalaue%26aufirst%3DM.%26aulast%3DPaget%26aufirst%3DS.%2BD.%26aulast%3DWoolhiser%26aufirst%3DL.%2BK.%26aulast%3DLenaerts%26aufirst%3DA.%2BJ.%26aulast%3DBunin%26aufirst%3DB.%2BA.%26aulast%3DConnell%26aufirst%3DN.%26aulast%3DFreundlich%26aufirst%3DJ.%2BS.%26atitle%3DBayesian%2520models%2520leveraging%2520bioactivity%2520and%2520cytotoxicity%2520information%2520for%2520drug%2520discovery%26jtitle%3DChem.%2520Biol.%26date%3D2013%26volume%3D20%26spage%3D370%26epage%3D378%26doi%3D10.1016%2Fj.chembiol.2013.01.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref239"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref239'); return false;" data-citation="" class="refNumLink">239</a></strong><div class="NLM_citation" id="cit239"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franzblau, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freundlich, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunin, B. A.</span></span> <span> </span><span class="NLM_article-title">Enhancing hit identification in mycobacterium tuberculosis drug discovery using validated dual-event bayesian models</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">e63240</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0063240</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1371%2Fjournal.pone.0063240" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=23667592" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnvVCjsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=e63240&author=S.+Ekinsauthor=R.+C.+Reynoldsauthor=S.+G.+Franzblauauthor=B.+Wanauthor=J.+S.+Freundlichauthor=B.+A.+Bunin&title=Enhancing+hit+identification+in+mycobacterium+tuberculosis+drug+discovery+using+validated+dual-event+bayesian+models&doi=10.1371%2Fjournal.pone.0063240"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit239R"><div class="casContent"><span class="casTitleNuber">239</span><div class="casTitle"><span class="NLM_cas:atitle">Enhancing hit identification in Mycobacterium tuberculosis drug discovery using validated dual-event Bayesian models</span></div><div class="casAuthors">Ekins, Sean; Reynolds, Robert C.; Franzblau, Scott G.; Wan, Baojie; Freundlich, Joel S.; Bunin, Barry A.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">e63240</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">High-throughput screening (HTS) in whole cells is widely pursued to find compds. active against Mycobacterium tuberculosis (Mtb) for further development towards new tuberculosis (TB) drugs.  Hit rates from these screens, usually conducted at 10 to 25 μM concns., typically range from less than 1% to the low single digits.  New approaches to increase the efficiency of hit identification are urgently needed to learn from past screening data.  The pharmaceutical industry has for many years taken advantage of computational approaches to optimize compd. libraries for in vitro testing, a practice not fully embraced by academic labs. in the search for new TB drugs.  Adapting these proven approaches, we have recently built and validated Bayesian machine learning models for predicting compds. with activity against Mtb based on publicly available large-scale HTS data from the Tuberculosis Antimicrobial Acquisition Coordinating Facility.  We now demonstrate the largest prospective validation to date in which we computationally screened 82,403 mols. with these Bayesian models, assayed a total of 550 mols. in vitro, and identified 124 actives against Mtb.  Individual hit rates for the different datasets varied from 15-28 %.  We have identified several FDA approved and late stage clin. candidate kinase inhibitors with activity against Mtb which may represent starting points for further optimization.  The computational models developed herein and the com. available mols. derived from them are now available to any group pursuing Mtb drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPsobk7KkZ47Vg90H21EOLACvtfcHk0ljrfYGemOjCRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnvVCjsrg%253D&md5=df3b672dc3d0e3aca976952fa5dcbf20</span></div><a href="/servlet/linkout?suffix=cit239&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0063240&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0063240%26sid%3Dliteratum%253Aachs%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DReynolds%26aufirst%3DR.%2BC.%26aulast%3DFranzblau%26aufirst%3DS.%2BG.%26aulast%3DWan%26aufirst%3DB.%26aulast%3DFreundlich%26aufirst%3DJ.%2BS.%26aulast%3DBunin%26aufirst%3DB.%2BA.%26atitle%3DEnhancing%2520hit%2520identification%2520in%2520mycobacterium%2520tuberculosis%2520drug%2520discovery%2520using%2520validated%2520dual-event%2520bayesian%2520models%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26spage%3De63240%26doi%3D10.1371%2Fjournal.pone.0063240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref240"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref240'); return false;" data-citation="" class="refNumLink">240</a></strong><div class="NLM_citation" id="cit240"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casey, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parish, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunin, B. A.</span></span> <span> </span><span class="NLM_article-title">Bayesian models for screening and tb mobile for target inference with mycobacterium tuberculosis</span>. <i>Tuberculosis (Oxford, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">162</span>– <span class="NLM_lpage">169</span>, <span class="refDoi"> DOI: 10.1016/j.tube.2013.12.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.tube.2013.12.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=24440548" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisFSmsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2014&pages=162-169&author=S.+Ekinsauthor=A.+C.+Caseyauthor=D.+Robertsauthor=T.+Parishauthor=B.+A.+Bunin&title=Bayesian+models+for+screening+and+tb+mobile+for+target+inference+with+mycobacterium+tuberculosis&doi=10.1016%2Fj.tube.2013.12.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit240R"><div class="casContent"><span class="casTitleNuber">240</span><div class="casTitle"><span class="NLM_cas:atitle">Bayesian models for screening and TB Mobile for target inference with Mycobacterium tuberculosis</span></div><div class="casAuthors">Ekins, Sean; Casey, Allen C.; Roberts, David; Parish, Tanya; Bunin, Barry A.</div><div class="citationInfo"><span class="NLM_cas:title">Tuberculosis (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">162-169</span>CODEN:
                <span class="NLM_cas:coden">TUBECU</span>;
        ISSN:<span class="NLM_cas:issn">1472-9792</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The search for compds. active against Mycobacterium tuberculosis is reliant upon high-throughput screening (HTS) in whole cells.  We have used Bayesian machine learning models which can predict anti-tubercular activity to filter an internal library of over 150,000 compds. prior to in vitro testing.  We used this to select and test 48 compds. in vitro; 11 were active with MIC values ranging from 0.4 μM to 10.2 μM, giving a high hit rate of 22.9%.  Among the hits, we identified several compds. belonging to the same series including five quinolones (including ciprofloxacin), three mols. with long aliph. linkers and three singletons.  This approach represents a rapid method to prioritize compds. for testing that can be used alongside medicinal chem. insight and other filters to identify active mols.  Such models can significantly increase the hit rate of HTS, above the usual 1% or lower rates seen.  In addn., the potential targets for the 11 mols. were predicted using TB Mobile and clustering alongside a set of over 740 mols. with known M. tuberculosis target annotations.  These predictions may serve as a mechanism for prioritizing compds. for further optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyNxo3fnyZxLVg90H21EOLACvtfcHk0ljrfYGemOjCRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisFSmsbk%253D&md5=1d80c6fa0949708d7ef9edc93e88e18b</span></div><a href="/servlet/linkout?suffix=cit240&amp;dbid=16384&amp;doi=10.1016%2Fj.tube.2013.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tube.2013.12.001%26sid%3Dliteratum%253Aachs%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DCasey%26aufirst%3DA.%2BC.%26aulast%3DRoberts%26aufirst%3DD.%26aulast%3DParish%26aufirst%3DT.%26aulast%3DBunin%26aufirst%3DB.%2BA.%26atitle%3DBayesian%2520models%2520for%2520screening%2520and%2520tb%2520mobile%2520for%2520target%2520inference%2520with%2520mycobacterium%2520tuberculosis%26jtitle%3DTuberculosis%2520%2528Oxford%252C%2520U.%2520K.%2529%26date%3D2014%26volume%3D94%26spage%3D162%26epage%3D169%26doi%3D10.1016%2Fj.tube.2013.12.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref241"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref241'); return false;" data-citation="" class="refNumLink">241</a></strong><div class="NLM_citation" id="cit241"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freundlich, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, R. C.</span></span> <span> </span><span class="NLM_article-title">Fusing dual-event datasets for mycobacterium tuberculosis machine learning models and their evaluation</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">3054</span>– <span class="NLM_lpage">3063</span>, <span class="refDoi"> DOI: 10.1021/ci400480s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci400480s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Cgt7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2013&pages=3054-3063&author=S.+Ekinsauthor=J.+S.+Freundlichauthor=R.+C.+Reynolds&title=Fusing+dual-event+datasets+for+mycobacterium+tuberculosis+machine+learning+models+and+their+evaluation&doi=10.1021%2Fci400480s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit241R"><div class="casContent"><span class="casTitleNuber">241</span><div class="casTitle"><span class="NLM_cas:atitle">Fusing Dual-Event Data Sets for Mycobacterium tuberculosis Machine Learning Models and Their Evaluation</span></div><div class="casAuthors">Ekins, Sean; Freundlich, Joel S.; Reynolds, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3054-3063</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The search for new tuberculosis treatments continues as we need to find mols. that can act more quickly, be accommodated in multidrug regimens, and overcome ever increasing levels of drug resistance.  Multiple large scale phenotypic high-throughput screens against Mycobacterium tuberculosis (Mtb) have generated dose response data, enabling the generation of machine learning models.  These models also incorporated cytotoxicity data and were recently validated with a large external data set.  A cheminformatics data-fusion approach followed by Bayesian machine learning, Support Vector Machine, or Recursive Partitioning model development (based on publicly available Mtb screening data) was used to compare individual data sets and subsequent combined models.  A set of 1924 com. available mols. with promising antitubercular activity (and lack of relative cytotoxicity to Vero cells) were used to evaluate the predictive nature of the models.  We demonstrate that combining three data sets incorporating antitubercular and cytotoxicity data in Vero cells from our previous screens results in external validation receiver operator curve (ROC) of 0.83 (Bayesian or RP Forest).  Models that do not have the highest 5-fold cross-validation ROC scores can outperform other models in a test set dependent manner.  We demonstrate with predictions for a recently published set of Mtb leads from GlaxoSmithKline that no single machine learning model may be enough to identify compds. of interest.  Data set fusion represents a further useful strategy for machine learning construction as illustrated with Mtb.  Coverage of chem. and Mtb target spaces may also be limiting factors for the whole-cell screening data generated to date.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFnkjFPKUH4bVg90H21EOLACvtfcHk0liGEhPSS83t0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Cgt7bM&md5=2fa69551b36bea68056631cca1aff2d5</span></div><a href="/servlet/linkout?suffix=cit241&amp;dbid=16384&amp;doi=10.1021%2Fci400480s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci400480s%26sid%3Dliteratum%253Aachs%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DFreundlich%26aufirst%3DJ.%2BS.%26aulast%3DReynolds%26aufirst%3DR.%2BC.%26atitle%3DFusing%2520dual-event%2520datasets%2520for%2520mycobacterium%2520tuberculosis%2520machine%2520learning%2520models%2520and%2520their%2520evaluation%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2013%26volume%3D53%26spage%3D3054%26epage%3D3063%26doi%3D10.1021%2Fci400480s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref242"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref242'); return false;" data-citation="" class="refNumLink">242</a></strong><div class="NLM_citation" id="cit242"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freundlich, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobrath, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucile
White, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, R. C.</span></span> <span> </span><span class="NLM_article-title">Combining computational methods for hit to lead optimization in mycobacterium tuberculosis drug discovery</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">414</span>– <span class="NLM_lpage">435</span>, <span class="refDoi"> DOI: 10.1007/s11095-013-1172-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1007%2Fs11095-013-1172-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=24132686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1eisbfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2014&pages=414-435&author=S.+Ekinsauthor=J.+S.+Freundlichauthor=J.+V.+Hobrathauthor=E.+Lucile%0AWhiteauthor=R.+C.+Reynolds&title=Combining+computational+methods+for+hit+to+lead+optimization+in+mycobacterium+tuberculosis+drug+discovery&doi=10.1007%2Fs11095-013-1172-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit242R"><div class="casContent"><span class="casTitleNuber">242</span><div class="casTitle"><span class="NLM_cas:atitle">Combining Computational Methods for Hit to Lead Optimization in Mycobacterium Tuberculosis Drug Discovery</span></div><div class="casAuthors">Ekins, Sean; Freundlich, Joel S.; Hobrath, Judith V.; Lucile White, E.; Reynolds, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">414-435</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Tuberculosis treatments need to be shorter and overcome drug resistance.  Our previous large scale phenotypic high-throughput screening against Mycobacterium tuberculosis (Mtb) has identified 737 active compds. and thousands that are inactive.  We have used this data for building computational models as an approach to minimize the no. of compds. tested.  Methods: A cheminformatics clustering approach followed by Bayesian machine learning models (based on publicly available Mtb screening data) was used to illustrate that application of these models for screening set selections can enrich the hit rate.  Results: In order to explore chem. diversity around active cluster scaffolds of the dose-response hits obtained from our previous Mtb screens a set of 1924 com. available mols. have been selected and evaluated for antitubercular activity and cytotoxicity using Vero, THP-1 and HepG2 cell lines with 4.3%, 4.2% and 2.7% hit rates, resp.  We demonstrate that models incorporating antitubercular and cytotoxicity data in Vero cells can significantly enrich the selection of non-toxic actives compared to random selection.  Across all cell lines, the Mol. Libraries Small Mol. Repository (MLSMR) and cytotoxicity model identified ∼10% of the hits in the top 1% screened (>10 fold enrichment).  We also showed that seven out of nine Mtb active compds. from different academic published studies and eight out of eleven Mtb active compds. from a pharmaceutical screen (GSK) would have been identified by these Bayesian models.  Conclusion: Combining clustering and Bayesian models represents a useful strategy for compd. prioritization and hit-to lead optimization of antitubercular agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNLW4jI87eobVg90H21EOLACvtfcHk0liGEhPSS83t0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1eisbfP&md5=3c093021c9af0e506a656d381ac1eb1a</span></div><a href="/servlet/linkout?suffix=cit242&amp;dbid=16384&amp;doi=10.1007%2Fs11095-013-1172-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-013-1172-7%26sid%3Dliteratum%253Aachs%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DFreundlich%26aufirst%3DJ.%2BS.%26aulast%3DHobrath%26aufirst%3DJ.%2BV.%26aulast%3DLucile%2BWhite%26aufirst%3DE.%26aulast%3DReynolds%26aufirst%3DR.%2BC.%26atitle%3DCombining%2520computational%2520methods%2520for%2520hit%2520to%2520lead%2520optimization%2520in%2520mycobacterium%2520tuberculosis%2520drug%2520discovery%26jtitle%3DPharm.%2520Res.%26date%3D2014%26volume%3D31%26spage%3D414%26epage%3D435%26doi%3D10.1007%2Fs11095-013-1172-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref243"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref243'); return false;" data-citation="" class="refNumLink">243</a></strong><div class="NLM_citation" id="cit243"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freundlich, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, R. C.</span></span> <span> </span><span class="NLM_article-title">Are bigger data sets better for machine learning? Fusing single-point and dual-event dose response data for mycobacterium tuberculosis</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">2157</span>– <span class="NLM_lpage">2165</span>, <span class="refDoi"> DOI: 10.1021/ci500264r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci500264r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVCqsrjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2014&pages=2157-2165&author=S.+Ekinsauthor=J.+S.+Freundlichauthor=R.+C.+Reynolds&title=Are+bigger+data+sets+better+for+machine+learning%3F+Fusing+single-point+and+dual-event+dose+response+data+for+mycobacterium+tuberculosis&doi=10.1021%2Fci500264r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit243R"><div class="casContent"><span class="casTitleNuber">243</span><div class="casTitle"><span class="NLM_cas:atitle">Are Bigger Data Sets Better for Machine Learning? Fusing Single-Point and Dual-Event Dose Response Data for Mycobacterium tuberculosis</span></div><div class="casAuthors">Ekins, Sean; Freundlich, Joel S.; Reynolds, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2157-2165</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tuberculosis is a major, neglected disease for which the quest to find new treatments continues.  There is an abundance of data from large phenotypic screens in the public domain against Mycobacterium tuberculosis (Mtb).  Since machine learning methods can learn from past data, we were interested in addressing whether more data builds better models.  We now describe using Bayesian machine learning to assess whether we can improve our models by combining the large quantities of single-point data with the much smaller (higher quality) dual-event data sets, which use both dose-response data for both whole-cell antitubercular activity and Vero cell cytotoxicity.  We have evaluated 12 models ranging from different single-point, dual-event dose-response, single-point and dual-event dose-response as well as combined data sets for three distinct data sets from the same lab.  We used a fourth data set of active and inactive compds. from the same group as well as a smaller set of 177 active compds. from GlaxoSmithKline as test sets.  Our data suggest combining single-point with dual-event dose-response data does not diminish the internal or external predictive ability of the models based on the receiver operator curve (ROC) for these models (internal ROC range 0.83-0.91, external ROC range 0.62-0.83) compared to the orders of magnitude smaller dual-event models (internal ROC range 0.6-0.83 and external ROC 0.54-0.83).  In conclusion, models developed with 1200-5000 compds. appear to be as predictive as those generated with 25 000-350 000 mols.  Our results have implications for justifying further high-throughput screening vs. focused testing based on model predictions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCpZoV4MWmQbVg90H21EOLACvtfcHk0liGEhPSS83t0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVCqsrjK&md5=03392e131134b01309207831e8289e0e</span></div><a href="/servlet/linkout?suffix=cit243&amp;dbid=16384&amp;doi=10.1021%2Fci500264r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci500264r%26sid%3Dliteratum%253Aachs%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DFreundlich%26aufirst%3DJ.%2BS.%26aulast%3DReynolds%26aufirst%3DR.%2BC.%26atitle%3DAre%2520bigger%2520data%2520sets%2520better%2520for%2520machine%2520learning%253F%2520Fusing%2520single-point%2520and%2520dual-event%2520dose%2520response%2520data%2520for%2520mycobacterium%2520tuberculosis%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2014%26volume%3D54%26spage%3D2157%26epage%3D2165%26doi%3D10.1021%2Fci500264r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref244"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref244'); return false;" data-citation="" class="refNumLink">244</a></strong><div class="NLM_citation" id="cit244"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pottorf, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freundlich, J. S.</span></span> <span> </span><span class="NLM_article-title">Looking back to the future: Predicting in vivo efficacy of small molecules versus mycobacterium tuberculosis</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1070</span>– <span class="NLM_lpage">1082</span>, <span class="refDoi"> DOI: 10.1021/ci500077v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci500077v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkslamu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2014&pages=1070-1082&author=S.+Ekinsauthor=R.+Pottorfauthor=R.+C.+Reynoldsauthor=A.+J.+Williamsauthor=A.+M.+Clarkauthor=J.+S.+Freundlich&title=Looking+back+to+the+future%3A+Predicting+in+vivo+efficacy+of+small+molecules+versus+mycobacterium+tuberculosis&doi=10.1021%2Fci500077v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit244R"><div class="casContent"><span class="casTitleNuber">244</span><div class="casTitle"><span class="NLM_cas:atitle">Looking Back to the Future: Predicting in Vivo Efficacy of Small Molecules versus Mycobacterium tuberculosis</span></div><div class="casAuthors">Ekins, Sean; Pottorf, Richard; Reynolds, Robert C.; Williams, Antony J.; Clark, Alex M.; Freundlich, Joel S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1070-1082</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Selecting and translating in vitro leads for a disease into mols. with in vivo activity in an animal model of the disease is a challenge that takes considerable time and money.  As an example, recent years have seen whole-cell phenotypic screens of millions of compds. yielding over 1500 inhibitors of Mycobacterium tuberculosis (Mtb).  These must be prioritized for testing in the mouse in vivo assay for Mtb infection, a validated model utilized to select compds. for further testing.  The authors demonstrate learning from in vivo active and inactive compds. using machine learning classification models (Bayesian, support vector machines, and recursive partitioning) consisting of 773 compds.  The Bayesian model predicted 8 out of 11 addnl. in vivo actives not included in the model as an external test set.  Curation of 70 years of Mtb data can therefore provide statistically robust computational models to focus resources on in vivo active small mol. antituberculars.  This highlights a cost-effective predictor for in vivo testing elsewhere in other diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotUoWucn-1OrVg90H21EOLACvtfcHk0ljOabG-KE_wtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkslamu7Y%253D&md5=e5e27ddb07601604b0c9c2cde9dd313d</span></div><a href="/servlet/linkout?suffix=cit244&amp;dbid=16384&amp;doi=10.1021%2Fci500077v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci500077v%26sid%3Dliteratum%253Aachs%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DPottorf%26aufirst%3DR.%26aulast%3DReynolds%26aufirst%3DR.%2BC.%26aulast%3DWilliams%26aufirst%3DA.%2BJ.%26aulast%3DClark%26aufirst%3DA.%2BM.%26aulast%3DFreundlich%26aufirst%3DJ.%2BS.%26atitle%3DLooking%2520back%2520to%2520the%2520future%253A%2520Predicting%2520in%2520vivo%2520efficacy%2520of%2520small%2520molecules%2520versus%2520mycobacterium%2520tuberculosis%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2014%26volume%3D54%26spage%3D1070%26epage%3D1082%26doi%3D10.1021%2Fci500077v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref245"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref245'); return false;" data-citation="" class="refNumLink">245</a></strong><div class="NLM_citation" id="cit245"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perryman, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freundlich, J. S.</span></span> <span> </span><span class="NLM_article-title">Machine learning model analysis and data visualization with small molecules tested in a mouse model of mycobacterium tuberculosis infection (2014–2015)</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1332</span>– <span class="NLM_lpage">1343</span>, <span class="refDoi"> DOI: 10.1021/acs.jcim.6b00004</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.6b00004" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVCjtrvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2016&pages=1332-1343&issue=7&author=S.+Ekinsauthor=A.+L.+Perrymanauthor=A.+M.+Clarkauthor=R.+C.+Reynoldsauthor=J.+S.+Freundlich&title=Machine+learning+model+analysis+and+data+visualization+with+small+molecules+tested+in+a+mouse+model+of+mycobacterium+tuberculosis+infection+%282014%E2%80%932015%29&doi=10.1021%2Facs.jcim.6b00004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit245R"><div class="casContent"><span class="casTitleNuber">245</span><div class="casTitle"><span class="NLM_cas:atitle">Machine Learning Model Analysis and Data Visualization with Small Molecules Tested in a Mouse Model of Mycobacterium tuberculosis Infection (2014-2015)</span></div><div class="casAuthors">Ekins, Sean; Perryman, Alexander L.; Clark, Alex M.; Reynolds, Robert C.; Freundlich, Joel S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1332-1343</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The renewed urgency to develop new treatments for Mycobacterium tuberculosis (Mtb) infection resulted in large-scale phenotypic screening and thousands of new active compds. in vitro.  The next challenge is to identify candidates to pursue in a mouse in vivo efficacy model as a step to predicting clin. efficacy.  The authors previously analyzed over 70 years of this mouse in vivo efficacy data, which the authors used to generate and validate machine learning models.  Curation of 60 addnl. small mols. with in vivo data published in 2014 and 2015 was undertaken to further test these models.  This represents a much larger test set than for the previous models.  Several computational approaches have now been applied to analyze these mols. and compare their mol. properties beyond those attempted previously.  The authors' previous machine learning models have been updated, and a novel aspect has been added as mouse liver microsomal half-life (MLM t1/2) and in vitro-based Mtb models incorporating cytotoxicity data that were used to predict in vivo activity for comparison.  The authors' best Mtbin vivo models possess fivefold ROC values > 0.7, sensitivity > 80%, and concordance > 60%, while the best specificity value is >40%.  Use of an MLM t1/2 Bayesian model affords comparable results for scoring the 60 compds. tested.  Combining MLM stability and in vitro Mtb models in a novel consensus workflow in the best cases has a pos. predicted value (hit rate) > 77%.  The authors' results indicate that Bayesian models constructed with literature in vivoMtb data generated by different labs. in various mouse models can have predictive value and may be used alongside MLM t1/2 and in vitro-based Mtb models to assist in selecting antitubercular compds. with desirable in vivo efficacy.  Consensus models of any kind can be used to predict in vivo activity for Mtb.  In addn., the authors describe a new clustering method for data visualization and apply this to the in vivo training and test data, ultimately making the method accessible in a mobile app.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlyzvE6JX4JrVg90H21EOLACvtfcHk0ljOabG-KE_wtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVCjtrvI&md5=2aad186e524cd42aefb9cf7992f0bdfe</span></div><a href="/servlet/linkout?suffix=cit245&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.6b00004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.6b00004%26sid%3Dliteratum%253Aachs%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DPerryman%26aufirst%3DA.%2BL.%26aulast%3DClark%26aufirst%3DA.%2BM.%26aulast%3DReynolds%26aufirst%3DR.%2BC.%26aulast%3DFreundlich%26aufirst%3DJ.%2BS.%26atitle%3DMachine%2520learning%2520model%2520analysis%2520and%2520data%2520visualization%2520with%2520small%2520molecules%2520tested%2520in%2520a%2520mouse%2520model%2520of%2520mycobacterium%2520tuberculosis%2520infection%2520%25282014%25E2%2580%25932015%2529%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2016%26volume%3D56%26issue%3D7%26spage%3D1332%26epage%3D1343%26doi%3D10.1021%2Facs.jcim.6b00004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref246"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref246'); return false;" data-citation="" class="refNumLink">246</a></strong><div class="NLM_citation" id="cit246"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ballell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez-Gomez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez-Ruiz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barroso, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanco, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crespo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escribano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huss, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos-Villarejo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Plaza, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendoza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rebollo-Lopez, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remuinan-Blanco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavandera, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Herran, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamo-Benito, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Bustos, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barros, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cammack, N.</span></span> <span> </span><span class="NLM_article-title">Fueling open-source drug discovery: 177 small-molecule leads against tuberculosis</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">313</span>– <span class="NLM_lpage">321</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201200428</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1002%2Fcmdc.201200428" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=23307663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3sXls1Omug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=313-321&author=L.+Ballellauthor=R.+H.+Batesauthor=R.+J.+Youngauthor=D.+Alvarez-Gomezauthor=E.+Alvarez-Ruizauthor=V.+Barrosoauthor=D.+Blancoauthor=B.+Crespoauthor=J.+Escribanoauthor=R.+Gonzalezauthor=S.+Lozanoauthor=S.+Hussauthor=A.+Santos-Villarejoauthor=J.+J.+Martin-Plazaauthor=A.+Mendozaauthor=M.+J.+Rebollo-Lopezauthor=M.+Remuinan-Blancoauthor=J.+L.+Lavanderaauthor=E.+Perez-Herranauthor=F.+J.+Gamo-Benitoauthor=J.+F.+Garcia-Bustosauthor=D.+Barrosauthor=J.+P.+Castroauthor=N.+Cammack&title=Fueling+open-source+drug+discovery%3A+177+small-molecule+leads+against+tuberculosis&doi=10.1002%2Fcmdc.201200428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit246R"><div class="casContent"><span class="casTitleNuber">246</span><div class="casTitle"><span class="NLM_cas:atitle">Fueling Open-Source Drug Discovery: 177 Small-Molecule Leads against Tuberculosis</span></div><div class="casAuthors">Ballell, Lluis; Bates, Robert H.; Young, Rob J.; Alvarez-Gomez, Daniel; Alvarez-Ruiz, Emilio; Barroso, Vanessa; Blanco, Delia; Crespo, Benigno; Escribano, Jaime; Gonzalez, Ruben; Lozano, Sonia; Huss, Sophie; Santos-Villarejo, Angel; Martin-Plaza, Jose Julio; Mendoza, Alfonso; Rebollo-Lopez, Maria Jose; Remuinan-Blanco, Modesto; Lavandera, Jose Luis; Perez-Herran, Esther; Gamo-Benito, Francisco Javier; Garcia-Bustos, Jose Francisco; Barros, David; Castro, Julia P.; Cammack, Nicholas</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">313-321</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">With the aim of fuelling open-source, translational, early-stage drug discovery activities, the results of the recently completed antimycobacterial phenotypic screening campaign against Mycobacterium bovis BCG with hit confirmation in M. tuberculosis H37Rv were made publicly accessible.  A set of 177 potent non-cytotoxic H37Rv hits was identified and will be made available to maximize the potential impact of the compds. toward a chem. genetics/proteomics exercise, while at the same time providing a plethora of potential starting points for new synthetic lead-generation activities.  Two addnl. drug-discovery-relevant datasets are included: (a) a drug-like property anal. reflecting the latest lead-like guidelines and (b) an early lead-generation package of the most promising hits within the clusters identified.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUJ2sVPWfPALVg90H21EOLACvtfcHk0ljOabG-KE_wtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXls1Omug%253D%253D&md5=32c975dbe183849358c701ca697681d3</span></div><a href="/servlet/linkout?suffix=cit246&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201200428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201200428%26sid%3Dliteratum%253Aachs%26aulast%3DBallell%26aufirst%3DL.%26aulast%3DBates%26aufirst%3DR.%2BH.%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26aulast%3DAlvarez-Gomez%26aufirst%3DD.%26aulast%3DAlvarez-Ruiz%26aufirst%3DE.%26aulast%3DBarroso%26aufirst%3DV.%26aulast%3DBlanco%26aufirst%3DD.%26aulast%3DCrespo%26aufirst%3DB.%26aulast%3DEscribano%26aufirst%3DJ.%26aulast%3DGonzalez%26aufirst%3DR.%26aulast%3DLozano%26aufirst%3DS.%26aulast%3DHuss%26aufirst%3DS.%26aulast%3DSantos-Villarejo%26aufirst%3DA.%26aulast%3DMartin-Plaza%26aufirst%3DJ.%2BJ.%26aulast%3DMendoza%26aufirst%3DA.%26aulast%3DRebollo-Lopez%26aufirst%3DM.%2BJ.%26aulast%3DRemuinan-Blanco%26aufirst%3DM.%26aulast%3DLavandera%26aufirst%3DJ.%2BL.%26aulast%3DPerez-Herran%26aufirst%3DE.%26aulast%3DGamo-Benito%26aufirst%3DF.%2BJ.%26aulast%3DGarcia-Bustos%26aufirst%3DJ.%2BF.%26aulast%3DBarros%26aufirst%3DD.%26aulast%3DCastro%26aufirst%3DJ.%2BP.%26aulast%3DCammack%26aufirst%3DN.%26atitle%3DFueling%2520open-source%2520drug%2520discovery%253A%2520177%2520small-molecule%2520leads%2520against%2520tuberculosis%26jtitle%3DChemMedChem%26date%3D2013%26volume%3D8%26spage%3D313%26epage%3D321%26doi%3D10.1002%2Fcmdc.201200428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref247"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref247'); return false;" data-citation="" class="refNumLink">247</a></strong><div class="NLM_citation" id="cit247"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mikusova, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span> <span> </span><span class="NLM_article-title">Learning from the past for tb drug discovery in the future</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">534</span>– <span class="NLM_lpage">545</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2016.09.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.drudis.2016.09.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=27717850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A280%3ADC%252BC2svnsVWmtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=534-545&author=K.+Mikusovaauthor=S.+Ekins&title=Learning+from+the+past+for+tb+drug+discovery+in+the+future&doi=10.1016%2Fj.drudis.2016.09.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit247R"><div class="casContent"><span class="casTitleNuber">247</span><div class="casTitle"><span class="NLM_cas:atitle">Learning from the past for TB drug discovery in the future</span></div><div class="casAuthors">Mikusova Katarina; Ekins Sean</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">534-545</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Tuberculosis drug discovery has shifted in recent years from a primarily target-based approach to one that uses phenotypic high-throughput screens.  As examples of this, through our EU-funded FP7 collaborations, New Medicines for Tuberculosis was target-based and our more-recent More Medicines for Tuberculosis project predominantly used phenotypic screening.  From these projects we have examples of success (DprE1) and failure (PimA) going from drug to target and from target to drug, respectively.  It is clear that we still have much to learn about the drug targets and the complex effects of the drugs on Mycobacterium tuberculosis.  We propose a more integrated approach that learns from earlier drug discovery efforts that could help to move drug discovery forward.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTiiBeAayc7NTToTC3aBaesfW6udTcc2eYbSezaeNU-67ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svnsVWmtA%253D%253D&md5=8f169df66fbdee538f899b2619bba19e</span></div><a href="/servlet/linkout?suffix=cit247&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2016.09.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2016.09.025%26sid%3Dliteratum%253Aachs%26aulast%3DMikusova%26aufirst%3DK.%26aulast%3DEkins%26aufirst%3DS.%26atitle%3DLearning%2520from%2520the%2520past%2520for%2520tb%2520drug%2520discovery%2520in%2520the%2520future%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2017%26volume%3D22%26spage%3D534%26epage%3D545%26doi%3D10.1016%2Fj.drudis.2016.09.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref248"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref248'); return false;" data-citation="" class="refNumLink">248</a></strong><div class="NLM_citation" id="cit248"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paolino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brindisi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campiani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nannicini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giuliani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anzini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamponi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giorgi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sbardella, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferraris, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coletta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palucci, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minerva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delogu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pepponi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goletti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cappelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brogi, S.</span></span> <span> </span><span class="NLM_article-title">Development of potent inhibitors of the mycobacterium tuberculosis virulence factor Zmp1 and evaluation of their effect on mycobacterial survival inside macrophages</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">422</span>– <span class="NLM_lpage">430</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201700759</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1002%2Fcmdc.201700759" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=29334428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC1cXislSitrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=422-430&author=M.+Paolinoauthor=M.+Brindisiauthor=A.+Valloneauthor=S.+Butiniauthor=G.+Campianiauthor=C.+Nanniciniauthor=G.+Giulianiauthor=M.+Anziniauthor=S.+Lamponiauthor=G.+Giorgiauthor=D.+Sbardellaauthor=D.+M.+Ferrarisauthor=S.+Mariniauthor=M.+Colettaauthor=I.+Palucciauthor=M.+Minervaauthor=G.+Deloguauthor=I.+Pepponiauthor=D.+Golettiauthor=A.+Cappelliauthor=S.+Gemmaauthor=S.+Brogi&title=Development+of+potent+inhibitors+of+the+mycobacterium+tuberculosis+virulence+factor+Zmp1+and+evaluation+of+their+effect+on+mycobacterial+survival+inside+macrophages&doi=10.1002%2Fcmdc.201700759"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit248R"><div class="casContent"><span class="casTitleNuber">248</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Potent Inhibitors of the Mycobacterium tuberculosis Virulence Factor Zmp1 and Evaluation of Their Effect on Mycobacterial Survival inside Macrophages</span></div><div class="casAuthors">Paolino, Marco; Brindisi, Margherita; Vallone, Alessandra; Butini, Stefania; Campiani, Giuseppe; Nannicini, Chiara; Giuliani, Germano; Anzini, Maurizio; Lamponi, Stefania; Giorgi, Gianluca; Sbardella, Diego; Ferraris, Davide M.; Marini, Stefano; Coletta, Massimo; Palucci, Ivana; Minerva, Mariachiara; Delogu, Giovanni; Pepponi, Ilaria; Goletti, Delia; Cappelli, Andrea; Gemma, Sandra; Brogi, Simone</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">422-430</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The enzyme Zmp1 is a zinc-contg. peptidase that plays a crit. role in the pathogenicity of Mycobacterium tuberculosis.  Herein we describe the identification of a small set of Zmp1 inhibitors based on a novel 8-hydroxyquinoline-2-hydroxamate scaffold.  Among the synthesized compds., N-(benzyloxy)-8-hydroxyquinoline-2-carboxamide (1 c) was found to be the most potent Zmp1 inhibitor known to date, and its binding mode was analyzed both by kinetics studies and mol. modeling, identifying crit. interactions of 1 c with the zinc ion and residues in the active site.  The effect of 1 c on intracellular Mycobacterium survival was assayed in J774 murine macrophages infected with M. tuberculosis H37Rv or M. bovis BCG and human monocyte-derived macrophages infected with M. tuberculosis H37Rv.  Cytotoxicity and genotoxicity were also assessed.  Overall, inhibitor 1 c displays interesting in vitro antitubercular properties worthy of further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobhb30Gw07ybVg90H21EOLACvtfcHk0ljO8XyZ2QPIhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXislSitrs%253D&md5=2ef6d0413567cf7395e9affeddc5ba74</span></div><a href="/servlet/linkout?suffix=cit248&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201700759&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201700759%26sid%3Dliteratum%253Aachs%26aulast%3DPaolino%26aufirst%3DM.%26aulast%3DBrindisi%26aufirst%3DM.%26aulast%3DVallone%26aufirst%3DA.%26aulast%3DButini%26aufirst%3DS.%26aulast%3DCampiani%26aufirst%3DG.%26aulast%3DNannicini%26aufirst%3DC.%26aulast%3DGiuliani%26aufirst%3DG.%26aulast%3DAnzini%26aufirst%3DM.%26aulast%3DLamponi%26aufirst%3DS.%26aulast%3DGiorgi%26aufirst%3DG.%26aulast%3DSbardella%26aufirst%3DD.%26aulast%3DFerraris%26aufirst%3DD.%2BM.%26aulast%3DMarini%26aufirst%3DS.%26aulast%3DColetta%26aufirst%3DM.%26aulast%3DPalucci%26aufirst%3DI.%26aulast%3DMinerva%26aufirst%3DM.%26aulast%3DDelogu%26aufirst%3DG.%26aulast%3DPepponi%26aufirst%3DI.%26aulast%3DGoletti%26aufirst%3DD.%26aulast%3DCappelli%26aufirst%3DA.%26aulast%3DGemma%26aufirst%3DS.%26aulast%3DBrogi%26aufirst%3DS.%26atitle%3DDevelopment%2520of%2520potent%2520inhibitors%2520of%2520the%2520mycobacterium%2520tuberculosis%2520virulence%2520factor%2520Zmp1%2520and%2520evaluation%2520of%2520their%2520effect%2520on%2520mycobacterial%2520survival%2520inside%2520macrophages%26jtitle%3DChemMedChem%26date%3D2018%26volume%3D13%26spage%3D422%26epage%3D430%26doi%3D10.1002%2Fcmdc.201700759" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref249"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref249'); return false;" data-citation="" class="refNumLink">249</a></strong><div class="NLM_citation" id="cit249"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span> <span> </span><span class="NLM_article-title">Docking- and pharmacophore-based virtual screening for the identification of novel mycobacterium tuberculosis protein tyrosine phosphatase b (MptpB) inhibitor with a thiobarbiturate scaffold</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">229</span>– <span class="NLM_lpage">239</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2018.12.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bioorg.2018.12.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=30641319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVSguro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2019&pages=229-239&author=D.+Zhangauthor=Y.+Linauthor=X.+Chenauthor=W.+Zhaoauthor=D.+Chenauthor=M.+Gaoauthor=Q.+Wangauthor=B.+Wangauthor=H.+Huangauthor=Y.+Luauthor=Y.+Lu&title=Docking-+and+pharmacophore-based+virtual+screening+for+the+identification+of+novel+mycobacterium+tuberculosis+protein+tyrosine+phosphatase+b+%28MptpB%29+inhibitor+with+a+thiobarbiturate+scaffold&doi=10.1016%2Fj.bioorg.2018.12.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit249R"><div class="casContent"><span class="casTitleNuber">249</span><div class="casTitle"><span class="NLM_cas:atitle">Docking- and pharmacophore-based virtual screening for the identification of novel Mycobacterium tuberculosis protein tyrosine phosphatase B (MptpB) inhibitor with a thiobarbiturate scaffold</span></div><div class="casAuthors">Zhang, Dongfeng; Lin, Yun; Chen, Xi; Zhao, Wenting; Chen, Dongni; Gao, Meng; Wang, Qinglin; Wang, Bin; Huang, Haihong; Lu, Yongjun; Lu, Yu</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">229-239</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Mycobacterium tuberculosis (Mtb) protein tyrosine phosphatase B (MptpB) is an important virulence factor for Mtb that contributes to survival of the bacteria in macrophages.  The absence of a human ortholog makes MptpB an attractive target for new therapeutics to treat tuberculosis.  MptpB inhibitors could be an effective treatment to overcome emerging TB drug resistance.  Adopting a structure-based virtual screening strategy, the authors successfully identified thiobarbiturate-based drug-like MptpB inhibitor I with an IC50 of 22.4 μM, and as a noncompetitive inhibitor with a Ki of 24.7 μM.  Importantly, not only did it exhibit moderate cell membrane permeability, compd. I also displayed potent inhibition of intracellular TB growth in the macrophage, making it an excellent lead compd. for anti-TB drug discovery.  To the best of the knowledge, this novel thiobarbiturate is the first class of MptpB inhibitor reported so far that leveraged docking- and pharmacophore-based virtual screening approaches.  The results of preliminary structure-activity relationship demonstrated that compd. I identified herein was not a singleton and may inspire the design of novel selective and drug-like MptpB inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5A9nxRk4RjbVg90H21EOLACvtfcHk0ljO8XyZ2QPIhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVSguro%253D&md5=24c3541ab0573f07ee1cf87048b7335d</span></div><a href="/servlet/linkout?suffix=cit249&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2018.12.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2018.12.038%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DY.%26atitle%3DDocking-%2520and%2520pharmacophore-based%2520virtual%2520screening%2520for%2520the%2520identification%2520of%2520novel%2520mycobacterium%2520tuberculosis%2520protein%2520tyrosine%2520phosphatase%2520b%2520%2528MptpB%2529%2520inhibitor%2520with%2520a%2520thiobarbiturate%2520scaffold%26jtitle%3DBioorg.%2520Chem.%26date%3D2019%26volume%3D85%26spage%3D229%26epage%3D239%26doi%3D10.1016%2Fj.bioorg.2018.12.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref250"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref250'); return false;" data-citation="" class="refNumLink">250</a></strong><div class="NLM_citation" id="cit250"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bruhn, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherman, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherbakov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meibohm, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottger, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenaerts, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. E.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo evaluation of synergism between anti-tubercular spectinamides and non-classical tuberculosis antibiotics</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">13985</span>, <span class="refDoi"> DOI: 10.1038/srep13985</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1038%2Fsrep13985" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=26365087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFeisr3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=13985&author=D.+F.+Bruhnauthor=M.+S.+Schermanauthor=J.+Liuauthor=D.+Scherbakovauthor=B.+Meibohmauthor=E.+C.+Bottgerauthor=A.+J.+Lenaertsauthor=R.+E.+Lee&title=In+vitro+and+in+vivo+evaluation+of+synergism+between+anti-tubercular+spectinamides+and+non-classical+tuberculosis+antibiotics&doi=10.1038%2Fsrep13985"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit250R"><div class="casContent"><span class="casTitleNuber">250</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo Evaluation of Synergism between Anti-Tubercular Spectinamides and Non-Classical Tuberculosis Antibiotics</span></div><div class="casAuthors">Bruhn, David F.; Scherman, Michael S.; Liu, Jiuyu; Scherbakov, Dimitri; Meibohm, Bernd; Bottger, Erik C.; Lenaerts, Anne J.; Lee, Richard E.</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">13985</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Spectinamides are new semi-synthetic spectinomycin derivs. with potent anti-tubercular activity.  The reported synergism of the precursor spectinomycin with other antibiotics prompted us to examine whether spectinamides sensitize M. tuberculosis to other antibiotics not traditionally used in the treatment of tuberculosis to potentially expand therapeutic options for MDR/XDR Tuberculosis.  Whole cell synergy checkerboard screens were performed using the lab. strain M. tuberculosis H37Rv, lead spectinamide 1599, and a broad panel of 27 antibiotics.  In vitro, 1599 synergized with 11 drugs from 6 antibiotic classes.  The obsd. synergy was tested against clin. isolates confirming synergy with Clarithromycin, Doxycycline and Clindamycin, combinations of which were taken forward for in vivo efficacy detn.  Co-administration of 1599 and clarithromycin provided addnl. bacterial killing in a mouse model of acute tuberculosis infection, but not in a chronic infection model.  Further studies indicated that mismatched drug exposure profiles likely permitted induction of phenotypic clarithromycin resistance and subsequent loss of synergism.  These studies highlight the importance of validating in vitro synergism and the challenge of matching drug exposures to obtain a synergistic outcome in vivo.  Results from this study indicate that a 1599 clarithromycin combination is potentially viable, providing the drug exposures can be carefully monitored.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpetBnraFJKorVg90H21EOLACvtfcHk0ljdPpM5uBFh4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFeisr3K&md5=0e52e96c259b96668a3737575c037539</span></div><a href="/servlet/linkout?suffix=cit250&amp;dbid=16384&amp;doi=10.1038%2Fsrep13985&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep13985%26sid%3Dliteratum%253Aachs%26aulast%3DBruhn%26aufirst%3DD.%2BF.%26aulast%3DScherman%26aufirst%3DM.%2BS.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DScherbakov%26aufirst%3DD.%26aulast%3DMeibohm%26aufirst%3DB.%26aulast%3DBottger%26aufirst%3DE.%2BC.%26aulast%3DLenaerts%26aufirst%3DA.%2BJ.%26aulast%3DLee%26aufirst%3DR.%2BE.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520evaluation%2520of%2520synergism%2520between%2520anti-tubercular%2520spectinamides%2520and%2520non-classical%2520tuberculosis%2520antibiotics%26jtitle%3DSci.%2520Rep.%26date%3D2015%26volume%3D5%26spage%3D13985%26doi%3D10.1038%2Fsrep13985" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref251"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref251'); return false;" data-citation="" class="refNumLink">251</a></strong><div class="NLM_citation" id="cit251"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.,  3rd.</span></span> <span> </span><span class="NLM_article-title">Tb drug development: Immunology at the table</span>. <i>Immunol Rev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>264</i></span>,  <span class="NLM_fpage">308</span>– <span class="NLM_lpage">318</span>, <span class="refDoi"> DOI: 10.1111/imr.12275</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1111%2Fimr.12275" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=25703568" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtVyhtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=264&publication_year=2015&pages=308-318&author=C.+Nathanauthor=C.+E.+Barry&title=Tb+drug+development%3A+Immunology+at+the+table&doi=10.1111%2Fimr.12275"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit251R"><div class="casContent"><span class="casTitleNuber">251</span><div class="casTitle"><span class="NLM_cas:atitle">TB drug development: immunology at the table</span></div><div class="casAuthors">Nathan, Carl; Barry, Clifton E., III</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">264</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">308-318</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">1600-065X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Our understanding of the host-pathogen relationship in tuberculosis (TB) can help guide drug discovery in at least two ways.  First, the recognition that host immunopathol. affects lesional TB drug distribution means that pharmacokinetic evaluation of drug candidates needs to move beyond measurements of drug levels in blood, whole lungs, or alveolar epithelial lining fluid to include measurements in specific types of lesions.  Second, by restricting the replication of M. tuberculosis (Mtb) subpopulations in latent TB infection and in active disease, the host immune response puts Mtb into a state assocd. with phenotypic tolerance to TB drugs selected for their activity against replicating Mtb.  This has spurred a major effort to conduct high throughput screens in vitro for compds. that can kill Mtb when it is replicating slowly if at all.  Each condition used in vitro to slow Mtb's replication and thereby model the phenotypically drug-tolerant state has advantages and disadvantages.  Lead candidates emerging from such in vitro studies face daunting challenges in the design of proof-of-concept studies in animal models.  Moreover, some non-replicating subpopulations of Mtb fail to resume replication when plated on agar, although their viability is demonstrable by other means.  There is as yet no widely replicated assay in which to screen compds. for their ability to kill this 'viable but non-culturable' subpopulation.  Despite these hurdles, drugs that can kill slowly replicating or non-replicating Mtb may offer our best hope for treatment-shortening combination chemotherapy of TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTpj2qurNoHLVg90H21EOLACvtfcHk0ljdPpM5uBFh4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtVyhtL4%253D&md5=ee37d408eb9725a9ae32c65fc6a0872f</span></div><a href="/servlet/linkout?suffix=cit251&amp;dbid=16384&amp;doi=10.1111%2Fimr.12275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fimr.12275%26sid%3Dliteratum%253Aachs%26aulast%3DNathan%26aufirst%3DC.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26atitle%3DTb%2520drug%2520development%253A%2520Immunology%2520at%2520the%2520table%26jtitle%3DImmunol%2520Rev.%26date%3D2015%26volume%3D264%26spage%3D308%26epage%3D318%26doi%3D10.1111%2Fimr.12275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref252"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref252'); return false;" data-citation="" class="refNumLink">252</a></strong><div class="NLM_citation" id="cit252"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tornheim, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dooley, K. E.</span></span> <span> </span><span class="NLM_article-title">Challenges of TB and HIV co-treatment: Updates and insights</span>. <i>Curr. Opin. HIV AIDS</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">486</span>– <span class="NLM_lpage">491</span>, <span class="refDoi"> DOI: 10.1097/COH.0000000000000495</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1097%2FCOH.0000000000000495" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=30080683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVChtrfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=486-491&author=J.+A.+Tornheimauthor=K.+E.+Dooley&title=Challenges+of+TB+and+HIV+co-treatment%3A+Updates+and+insights&doi=10.1097%2FCOH.0000000000000495"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit252R"><div class="casContent"><span class="casTitleNuber">252</span><div class="casTitle"><span class="NLM_cas:atitle">Challenges of TB and HIV co-treatment: updates and insights</span></div><div class="casAuthors">Tornheim, Jeffrey A.; Dooley, Kelly E.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in HIV & AIDS</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">486-491</span>CODEN:
                <span class="NLM_cas:coden">COHABM</span>;
        ISSN:<span class="NLM_cas:issn">1746-630X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  In the past few years, tuberculosis (TB) has overtaken HIV as the infectious disease with the highest global mortality.  Successful management of this syndemic will require improved diagnostic tests, shorter preventive therapies, and more effective treatments, particularly in light of drug-resistant TB.  Results from several major studies have been published or presented recently, including the development of a more sensitive rapid, mol. assay for TB; several new symptom-based screening tools; use of a 1-mo regimen for TB prevention; the results of early vs. delayed TB preventive therapy for pregnant women; newer drugs and regimens for multidrug-resistant tuberculosis; and pharmacokinetic, safety, and efficacy studies of new HIV drugs in combination with TB treatment.  We reviewed each of these topic areas and summarize relevant findings for the management of TB and HIV co-infection.  Moving forward, as new treatment regimes for HIV or TB are developed, consideration of the HIV-TB co-infected patient must figure prominently, both when detg. the diagnostic tests employed and to assess properly the drug-drug and drug-disease interactions that influence dosing, safety, and response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5qhlyoAll9LVg90H21EOLACvtfcHk0ljdPpM5uBFh4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVChtrfI&md5=6c9f3dc0d35aefe298f6cb8d0efa0668</span></div><a href="/servlet/linkout?suffix=cit252&amp;dbid=16384&amp;doi=10.1097%2FCOH.0000000000000495&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCOH.0000000000000495%26sid%3Dliteratum%253Aachs%26aulast%3DTornheim%26aufirst%3DJ.%2BA.%26aulast%3DDooley%26aufirst%3DK.%2BE.%26atitle%3DChallenges%2520of%2520TB%2520and%2520HIV%2520co-treatment%253A%2520Updates%2520and%2520insights%26jtitle%3DCurr.%2520Opin.%2520HIV%2520AIDS%26date%3D2018%26volume%3D13%26spage%3D486%26epage%3D491%26doi%3D10.1097%2FCOH.0000000000000495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref253"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref253'); return false;" data-citation="" class="refNumLink">253</a></strong><div class="NLM_citation" id="cit253"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sadiq, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khajuria, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tandon, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahajan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J. B.</span></span> <span> </span><span class="NLM_article-title">Adverse drug reaction profile in patients on anti-tubercular treatment alone and in combination with highly active antiretroviral therapy</span>. <i>J. Clin. Diagn. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">FC01</span>, <span class="refDoi"> DOI: 10.7860/JCDR/2015/13452.6652</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.7860%2FJCDR%2F2015%2F13452.6652" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=26557538" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=FC01&author=S.+Sadiqauthor=V.+Khajuriaauthor=V.+R.+Tandonauthor=A.+Mahajanauthor=J.+B.+Singh&title=Adverse+drug+reaction+profile+in+patients+on+anti-tubercular+treatment+alone+and+in+combination+with+highly+active+antiretroviral+therapy&doi=10.7860%2FJCDR%2F2015%2F13452.6652"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit253&amp;dbid=16384&amp;doi=10.7860%2FJCDR%2F2015%2F13452.6652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7860%252FJCDR%252F2015%252F13452.6652%26sid%3Dliteratum%253Aachs%26aulast%3DSadiq%26aufirst%3DS.%26aulast%3DKhajuria%26aufirst%3DV.%26aulast%3DTandon%26aufirst%3DV.%2BR.%26aulast%3DMahajan%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DJ.%2BB.%26atitle%3DAdverse%2520drug%2520reaction%2520profile%2520in%2520patients%2520on%2520anti-tubercular%2520treatment%2520alone%2520and%2520in%2520combination%2520with%2520highly%2520active%2520antiretroviral%2520therapy%26jtitle%3DJ.%2520Clin.%2520Diagn.%2520Res.%26date%3D2015%26volume%3D9%26spage%3DFC01%26doi%3D10.7860%2FJCDR%2F2015%2F13452.6652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref254"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref254'); return false;" data-citation="" class="refNumLink">254</a></strong><div class="NLM_citation" id="cit254"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Braunstein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickey, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span> <span> </span><span class="NLM_article-title">Why wait? The case for treating tuberculosis with inhaled drugs</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">166</span>, <span class="refDoi"> DOI: 10.1007/s11095-019-2704-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1007%2Fs11095-019-2704-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=31650321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVaqu7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2019&pages=166&author=M.+Braunsteinauthor=A.+J.+Hickeyauthor=S.+Ekins&title=Why+wait%3F+The+case+for+treating+tuberculosis+with+inhaled+drugs&doi=10.1007%2Fs11095-019-2704-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit254R"><div class="casContent"><span class="casTitleNuber">254</span><div class="casTitle"><span class="NLM_cas:atitle">Why Wait? The Case for Treating Tuberculosis with Inhaled Drugs</span></div><div class="casAuthors">Braunstein, Miriam; Hickey, Anthony J.; Ekins, Sean</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">166</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The discovery of drugs to treat tuberculosis (TB) was a major medical milestone in the twentieth century.  However, from the outset, drug resistance was obsd.  Currently, of the 10 million people that exhibit TB symptoms each year, 450,000 have multidrug or extensively drug resistant (MDR or XDR) TB.  While greater understanding of the host and pathogen (Mycobacterium tuberculosis, Mtb) coupled with scientific ingenuity will lead to new drugs and vaccines, in the meantime 4000 people die daily from TB.  Thus, efforts to improve existing TB drugs should also be prioritized.  Improved efficacy and decreased dose and assocd. toxicity of existing drugs would translate to greater compliance, life expectancy and quality of life of Mtb infected individuals.  One potential strategy to improve existing drugs is to deliver them by inhalation as aerosols to the lung, the primary site of Mtb infection.  Inhaled drugs are used for other pulmonary diseases, but they have yet to be utilized for TB.  Inhaled therapies for TB represent an untapped opportunity that the pharmaceutical, clin. and regulatory communities should consider.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQ1pBwQn6GtbVg90H21EOLACvtfcHk0lgDCNhoSA3njg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVaqu7zN&md5=ac0fe28cdb08df83d092455a8c1903de</span></div><a href="/servlet/linkout?suffix=cit254&amp;dbid=16384&amp;doi=10.1007%2Fs11095-019-2704-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-019-2704-6%26sid%3Dliteratum%253Aachs%26aulast%3DBraunstein%26aufirst%3DM.%26aulast%3DHickey%26aufirst%3DA.%2BJ.%26aulast%3DEkins%26aufirst%3DS.%26atitle%3DWhy%2520wait%253F%2520The%2520case%2520for%2520treating%2520tuberculosis%2520with%2520inhaled%2520drugs%26jtitle%3DPharm.%2520Res.%26date%3D2019%26volume%3D36%26spage%3D166%26doi%3D10.1007%2Fs11095-019-2704-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182'],'ref183':['cit183'],'ref184':['cit184'],'ref185':['cit185'],'ref186':['cit186'],'ref187':['cit187'],'ref188':['cit188'],'ref189':['cit189'],'ref190':['cit190'],'ref191':['cit191'],'ref192':['cit192'],'ref193':['cit193'],'ref194':['cit194'],'ref195':['cit195'],'ref196':['cit196'],'ref197':['cit197'],'ref198':['cit198'],'ref199':['cit199'],'ref200':['cit200'],'ref201':['cit201'],'ref202':['cit202'],'ref203':['cit203'],'ref204':['cit204'],'ref205':['cit205'],'ref206':['cit206'],'ref207':['cit207'],'ref208':['cit208'],'ref209':['cit209'],'ref210':['cit210'],'ref211':['cit211'],'ref212':['cit212'],'ref213':['cit213'],'ref214':['cit214'],'ref215':['cit215'],'ref216':['cit216'],'ref217':['cit217'],'ref218':['cit218'],'ref219':['cit219'],'ref220':['cit220'],'ref221':['cit221'],'ref222':['cit222'],'ref223':['cit223'],'ref224':['cit224'],'ref225':['cit225'],'ref226':['cit226'],'ref227':['cit227'],'ref228':['cit228'],'ref229':['cit229'],'ref230':['cit230'],'ref231':['cit231'],'ref232':['cit232'],'ref233':['cit233'],'ref234':['cit234'],'ref235':['cit235'],'ref236':['cit236'],'ref237':['cit237'],'ref238':['cit238'],'ref239':['cit239'],'ref240':['cit240'],'ref241':['cit241'],'ref242':['cit242'],'ref243':['cit243'],'ref244':['cit244'],'ref245':['cit245'],'ref246':['cit246'],'ref247':['cit247'],'ref248':['cit248'],'ref249':['cit249'],'ref250':['cit250'],'ref251':['cit251'],'ref252':['cit252'],'ref253':['cit253'],'ref254':['cit254']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 6 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Ana C. Puhl, Thomas R. Lane, Patricia A. Vignaux, Kimberley M. Zorn, Glenn C. Capodagli, Matthew B. Neiditch, Joel S. Freundlich, <span class="NLM_string-name hlFld-ContribAuthor">Sean Ekins</span>. </span><span class="cited-content_cbyCitation_article-title">Computational Approaches to Identify Molecules Binding to Mycobacterium tuberculosis KasA. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2020,</strong> <em>5 </em>
                                    (46)
                                     , 29935-29942. <a href="https://doi.org/10.1021/acsomega.0c04271" title="DOI URL">https://doi.org/10.1021/acsomega.0c04271</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.0c04271&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.0c04271%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DComputational%252BApproaches%252Bto%252BIdentify%252BMolecules%252BBinding%252Bto%252BMycobacterium%252Btuberculosis%252BKasA%26aulast%3DPuhl%26aufirst%3DAna%2BC.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D01092020%26date%3D07102020%26date%3D15112020%26volume%3D5%26issue%3D46%26spage%3D29935%26epage%3D29942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Parvinder  Kaur</span>, <span class="hlFld-ContribAuthor ">Vijay  Potluri</span>, <span class="hlFld-ContribAuthor ">Vijay Kamal  Ahuja</span>, <span class="hlFld-ContribAuthor ">C.N.  Naveenkumar</span>, <span class="hlFld-ContribAuthor ">Ramya Vadageri  Krishnamurthy</span>, <span class="hlFld-ContribAuthor ">Shruthi Thimmalapura  Gangadharaiah</span>, <span class="hlFld-ContribAuthor ">Prasad  Shivarudraiah</span>, <span class="hlFld-ContribAuthor ">Sumesh  Eswaran</span>, <span class="hlFld-ContribAuthor ">Christy Rosaline  Nirmal</span>, <span class="hlFld-ContribAuthor ">Balasubramanian  Mahizhaveni</span>, <span class="hlFld-ContribAuthor ">Azger  Dusthackeer</span>, <span class="hlFld-ContribAuthor ">Rajesh  Mondal</span>, <span class="hlFld-ContribAuthor ">Sarah M.  Batt</span>, <span class="hlFld-ContribAuthor ">Emily J.  Richardson</span>, <span class="hlFld-ContribAuthor ">Nicholas J.  Loman</span>, <span class="hlFld-ContribAuthor ">Gurdyal Singh  Besra</span>, <span class="hlFld-ContribAuthor ">Radha Krishan  Shandil</span>, <span class="hlFld-ContribAuthor ">Shridhar  Narayanan</span>. </span><span class="cited-content_cbyCitation_article-title">A multi-targeting pre-clinical candidate against drug-resistant tuberculosis. </span><span class="cited-content_cbyCitation_journal-name">Tuberculosis</span><span> <strong>2021,</strong> <em>129 </em>, 102104. <a href="https://doi.org/10.1016/j.tube.2021.102104" title="DOI URL">https://doi.org/10.1016/j.tube.2021.102104</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tube.2021.102104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tube.2021.102104%26sid%3Dliteratum%253Aachs%26jtitle%3DTuberculosis%26atitle%3DA%252Bmulti-targeting%252Bpre-clinical%252Bcandidate%252Bagainst%252Bdrug-resistant%252Btuberculosis%26aulast%3DKaur%26aufirst%3DParvinder%26date%3D2021%26volume%3D129%26spage%3D102104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vien Q. T.  Ho</span>, <span class="hlFld-ContribAuthor ">Theo  Verboom</span>, <span class="hlFld-ContribAuthor ">Mark K.  Rong</span>, <span class="hlFld-ContribAuthor ">Eva  Habjan</span>, <span class="hlFld-ContribAuthor ">Wilbert  Bitter</span>, <span class="hlFld-ContribAuthor ">Alexander  Speer</span>. </span><span class="cited-content_cbyCitation_article-title">Heterologous Expression of
              ethA
              and
              katG
              in Mycobacterium marinum Enables the Rapid Identification of New Prodrugs Active against Mycobacterium tuberculosis. </span><span class="cited-content_cbyCitation_journal-name">Antimicrobial Agents and Chemotherapy</span><span> <strong>2021,</strong> <em>65 </em>
                                    (4)
                                     <a href="https://doi.org/10.1128/AAC.01445-20" title="DOI URL">https://doi.org/10.1128/AAC.01445-20</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1128/AAC.01445-20&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1128%2FAAC.01445-20%26sid%3Dliteratum%253Aachs%26jtitle%3DAntimicrobial%2520Agents%2520and%2520Chemotherapy%26atitle%3DHeterologous%252BExpression%252Bof%252BethA%252Band%252BkatG%252Bin%252BMycobacterium%252Bmarinum%252BEnables%252Bthe%252BRapid%252BIdentification%252Bof%252BNew%252BProdrugs%252BActive%252Bagainst%252BMycobacterium%252Btuberculosis%26aulast%3DHo%26aufirst%3DVien%2BQ.%2BT.%26date%3D2021%26volume%3D65%26issue%3D4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Egor V.  Verbitskiy</span>, <span class="hlFld-ContribAuthor ">Svetlana A.  Baskakova</span>, <span class="hlFld-ContribAuthor ">Danila V.  Belyaev</span>, <span class="hlFld-ContribAuthor ">Diana V.  Vakhrusheva</span>, <span class="hlFld-ContribAuthor ">Natalya I.  Eremeeva</span>, <span class="hlFld-ContribAuthor ">Gennady L.  Rusinov</span>, <span class="hlFld-ContribAuthor ">Valery N.  Charushin</span>. </span><span class="cited-content_cbyCitation_article-title">Renaissance of 4-(5-nitrofuran-2-yl)-5-arylamino substituted pyrimidines: microwave-assisted synthesis and antitubercular activity. </span><span class="cited-content_cbyCitation_journal-name">Mendeleev Communications</span><span> <strong>2021,</strong> <em>31 </em>
                                    (2)
                                     , 210-212. <a href="https://doi.org/10.1016/j.mencom.2021.03.021" title="DOI URL">https://doi.org/10.1016/j.mencom.2021.03.021</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.mencom.2021.03.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.mencom.2021.03.021%26sid%3Dliteratum%253Aachs%26jtitle%3DMendeleev%2520Communications%26atitle%3DRenaissance%252Bof%252B4-%2525285-nitrofuran-2-yl%252529-5-arylamino%252Bsubstituted%252Bpyrimidines%25253A%252Bmicrowave-assisted%252Bsynthesis%252Band%252Bantitubercular%252Bactivity%26aulast%3DVerbitskiy%26aufirst%3DEgor%2BV.%26date%3D2021%26volume%3D31%26issue%3D2%26spage%3D210%26epage%3D212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elizabeth  Fullam</span>, <span class="hlFld-ContribAuthor ">Robert J.  Young</span>. </span><span class="cited-content_cbyCitation_article-title">Physicochemical properties and
              Mycobacterium tuberculosis
              transporters: keys to efficacious antitubercular drugs?. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2021,</strong> <em>12 </em>
                                    (1)
                                     , 43-56. <a href="https://doi.org/10.1039/D0MD00265H" title="DOI URL">https://doi.org/10.1039/D0MD00265H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0MD00265H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0MD00265H%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DPhysicochemical%252Bproperties%252Band%252BMycobacterium%252Btuberculosis%252Btransporters%25253A%252Bkeys%252Bto%252Befficacious%252Bantitubercular%252Bdrugs%25253F%26aulast%3DFullam%26aufirst%3DElizabeth%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D1%26spage%3D43%26epage%3D56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sergey  Bukhdruker</span>, <span class="hlFld-ContribAuthor ">Tatsiana  Varaksa</span>, <span class="hlFld-ContribAuthor ">Irina  Grabovec</span>, <span class="hlFld-ContribAuthor ">Egor  Marin</span>, <span class="hlFld-ContribAuthor ">Polina  Shabunya</span>, <span class="hlFld-ContribAuthor ">Maria  Kadukova</span>, <span class="hlFld-ContribAuthor ">Sergei  Grudinin</span>, <span class="hlFld-ContribAuthor ">Anton  Kavaleuski</span>, <span class="hlFld-ContribAuthor ">Anastasiia  Gusach</span>, <span class="hlFld-ContribAuthor ">Andrei  Gilep</span>, <span class="hlFld-ContribAuthor ">Valentin  Borshchevskiy</span>, <span class="hlFld-ContribAuthor ">Natallia  Strushkevich</span>. </span><span class="cited-content_cbyCitation_article-title">Hydroxylation of Antitubercular Drug Candidate, SQ109, by Mycobacterial Cytochrome P450. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (20)
                                     , 7683. <a href="https://doi.org/10.3390/ijms21207683" title="DOI URL">https://doi.org/10.3390/ijms21207683</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21207683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21207683%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DHydroxylation%252Bof%252BAntitubercular%252BDrug%252BCandidate%25252C%252BSQ109%25252C%252Bby%252BMycobacterial%252BCytochrome%252BP450%26aulast%3DBukhdruker%26aufirst%3DSergey%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D20%26spage%3D7683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/medium/jm9b02075_0006.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/large/jm9b02075_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02075&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/medium/jm9b02075_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/large/jm9b02075_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Current TB drug pipeline.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> * denotes new chemical class. Molecules in phase 3 have all been FDA (bedaquiline and pretomanid) or EU (delamanid) approved but are also components of ongoing trials. Image courtesy of Dr. Barbara Laughon (NIAID) <a href="http://www.newtbdrugs.org" class="extLink">www.newtbdrugs.org</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/large/jm9b02075_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02075&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/medium/jm9b02075_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/large/jm9b02075_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Data visualization of <i>Mtb</i> approved drugs and <i>Mtb</i> lead compounds in this review. (A) The PCA generated with eight descriptors showed that <i>Mtb</i> approved drugs are overlapped with the 118 <i>Mtb</i> leads data set, with the three components of PCA representing 82.8% of the variance (<i>x</i> = 41.7%, <i>y</i> = 28.5%, <i>z</i> = 12.6%). Molecule numbers represent those outside the main cluster with structures shown (see also Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.9b02075/suppl_file/jm9b02075_si_001.pdf" class="ext-link">Table S3</a>). (B) Chemical network visualization containing compounds from <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> (green) and <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Tables <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">12</a> (red). This was generated using the same eight descriptors, with unsupervised hierarchical clustering using the Euclidean distance method, Wards linkage. Numbering corresponds to molecules in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>–<a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">12</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/large/jm9b02075_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02075&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/medium/jm9b02075_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/large/jm9b02075_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Principal component analysis of compounds in this review (blue) alongside a curated set of <i>Mtb</i> actives<a onclick="showRef(event, 'ref228'); return false;" href="javascript:void(0);" class="ref ref228">(228)</a> (red, MIC < 10 μM threshold). The PCA generated with eight descriptors showed that <i>Mtb</i> actives are overlapped with the 118 <i>Mtb</i> compound data set, with the three components of PCA representing 85.78% of the variance (<i>x</i> = 55.82%, <i>y</i> = 18.65%, <i>z</i> = 11.31%). Lead molecule <b>114</b> is clearly outside of the main cluster of TB actives (for structure, see Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.9b02075/suppl_file/jm9b02075_si_001.pdf" class="ext-link">Table S3</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/large/jm9b02075_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02075&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/medium/jm9b02075_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/large/jm9b02075_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Principal component analysis of 118 lead compounds in this review (blue) alongside a curated set of <i>Mtb</i> actives<a onclick="showRef(event, 'ref228'); return false;" href="javascript:void(0);" class="ref ref228">(228)</a> (red, MIC < 10 μM threshold), approved drugs (green), and Microsource spectrum (yellow), and we then generated a PCA fitted with eight descriptors of the merged frame including all four data sets. The three components explained a variation of 89.57% (<i>x</i> = 52.89%, <i>y</i> = 24.39%, <i>z</i> = 12.29%). A majority of the four data sets were found overlapped in the same PCA space.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/large/jm9b02075_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02075&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/medium/jm9b02075_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/large/jm9b02075_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Circular dendrogram obtained from the hierarchical clustering of the 118 lead compounds for <i>Mtb</i> using eight descriptors, Ward linkage, and Euclidian distance. Compound nodes and names are colored according to their MolLogP.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.9b02075/20200903/images/large/jm9b02075_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02075&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i28">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04372" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04372" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 254 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span> <i>Accelerating Discovery</i>; <span class="NLM_publisher-name">The Working Group
for New TB Drugs</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">2016</span>; <a href="http://www.newtbdrugs.org" class="extLink">www.newtbdrugs.org</a> (accessed 2020-03-03).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Accelerating+Discovery%3B+The+Working+Group%0Afor+New+TB+Drugs%3A+New+York%2C+2016%3B+www.newtbdrugs.org+%28accessed+2020-03-03%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26jtitle%3DAccelerating%2520Discovery%26pub%3DThe%2520Working%2520Group%250Afor%2520New%2520TB%2520Drugs%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Low, M.</span></span> <i>The Tuberculosis Treatment Pipeline: A Breakthrough Year For The Treatment Of XDR-TB</i>; <span class="NLM_publisher-name">Treatment Action Group</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">2017</span>;<a href="https://www.treatmentactiongroup.org/resources/pipeline-report/2017-pipeline-report/the-tuberculosis-treatment-pipeline-a-breakthrough-year-for-the-treatment-of-xdr-tb/" class="extLink">https://www.treatmentactiongroup.org/resources/pipeline-report/2017-pipeline-report/the-tuberculosis-treatment-pipeline-a-breakthrough-year-for-the-treatment-of-xdr-tb/</a> (accessed 2020-03-03).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=M.+Low&title=The+Tuberculosis+Treatment+Pipeline%3A+A+Breakthrough+Year+For+The+Treatment+Of+XDR-TB"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3DLow%26aufirst%3DM.%26jtitle%3DThe%2520Tuberculosis%2520Treatment%2520Pipeline%253A%2520A%2520Breakthrough%2520Year%2520For%2520The%2520Treatment%2520Of%2520XDR-TB%26pub%3DTreatment%2520Action%2520Group%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span> <i>Global Tuberculosis Report
2019</i>; <span class="NLM_publisher-name">World Health
Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2019</span>; <a href="https://www.who.int/tb/publications/global_report/en/" class="extLink">https://www.who.int/tb/publications/global_report/en/</a> (accessed 2020-03-03).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Global+Tuberculosis+Report%0A2019%3B+World+Health%0AOrganization%3A+Geneva%2C+2019%3B+https%3A%2F%2Fwww.who.int%2Ftb%2Fpublications%2Fglobal_report%2Fen%2F+%28accessed+2020-03-03%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26jtitle%3DGlobal%2520Tuberculosis%2520Report%250A2019%26pub%3DWorld%2520Health%250AOrganization%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jakab, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acosta, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kluge, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dara, M.</span></span> <span> </span><span class="NLM_article-title">Consolidated action plan to prevent and combat multidrug- and extensively drug-resistant tuberculosis in the WHO european region 2011–2015: Cost-effectiveness analysis</span>. <i>Tuberculosis (Oxford, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">S212</span>– <span class="NLM_lpage">S216</span>, <span class="refDoi"> DOI: 10.1016/j.tube.2015.02.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.tube.2015.02.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=25829287" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2015&pages=S212-S216&author=Z.+Jakabauthor=C.+D.+Acostaauthor=H.+H.+Klugeauthor=M.+Dara&title=Consolidated+action+plan+to+prevent+and+combat+multidrug-+and+extensively+drug-resistant+tuberculosis+in+the+WHO+european+region+2011%E2%80%932015%3A+Cost-effectiveness+analysis&doi=10.1016%2Fj.tube.2015.02.027"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.tube.2015.02.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tube.2015.02.027%26sid%3Dliteratum%253Aachs%26aulast%3DJakab%26aufirst%3DZ.%26aulast%3DAcosta%26aufirst%3DC.%2BD.%26aulast%3DKluge%26aufirst%3DH.%2BH.%26aulast%3DDara%26aufirst%3DM.%26atitle%3DConsolidated%2520action%2520plan%2520to%2520prevent%2520and%2520combat%2520multidrug-%2520and%2520extensively%2520drug-resistant%2520tuberculosis%2520in%2520the%2520WHO%2520european%2520region%25202011%25E2%2580%25932015%253A%2520Cost-effectiveness%2520analysis%26jtitle%3DTuberculosis%2520%2528Oxford%252C%2520U.%2520K.%2529%26date%3D2015%26volume%3D95%26spage%3DS212%26epage%3DS216%26doi%3D10.1016%2Fj.tube.2015.02.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mikusova, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span> <span> </span><span class="NLM_article-title">Learning from the past for tb drug discovery in the future</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">534</span>– <span class="NLM_lpage">545</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2016.09.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.drudis.2016.09.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=27717850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A280%3ADC%252BC2svnsVWmtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=534-545&author=K.+Mikusovaauthor=S.+Ekins&title=Learning+from+the+past+for+tb+drug+discovery+in+the+future&doi=10.1016%2Fj.drudis.2016.09.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Learning from the past for TB drug discovery in the future</span></div><div class="casAuthors">Mikusova Katarina; Ekins Sean</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">534-545</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Tuberculosis drug discovery has shifted in recent years from a primarily target-based approach to one that uses phenotypic high-throughput screens.  As examples of this, through our EU-funded FP7 collaborations, New Medicines for Tuberculosis was target-based and our more-recent More Medicines for Tuberculosis project predominantly used phenotypic screening.  From these projects we have examples of success (DprE1) and failure (PimA) going from drug to target and from target to drug, respectively.  It is clear that we still have much to learn about the drug targets and the complex effects of the drugs on Mycobacterium tuberculosis.  We propose a more integrated approach that learns from earlier drug discovery efforts that could help to move drug discovery forward.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTiiBeAayc7NTToTC3aBaesfW6udTcc2eZ7ZGXGSsNAKbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svnsVWmtA%253D%253D&md5=8f169df66fbdee538f899b2619bba19e</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2016.09.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2016.09.025%26sid%3Dliteratum%253Aachs%26aulast%3DMikusova%26aufirst%3DK.%26aulast%3DEkins%26aufirst%3DS.%26atitle%3DLearning%2520from%2520the%2520past%2520for%2520tb%2520drug%2520discovery%2520in%2520the%2520future%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2017%26volume%3D22%26spage%3D534%26epage%3D545%26doi%3D10.1016%2Fj.drudis.2016.09.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S. T.</span></span> <span> </span><span class="NLM_article-title">Tuberculosis drug discovery needs public-private consortia</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">477</span>– <span class="NLM_lpage">478</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2016.09.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.drudis.2016.09.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=27717851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A280%3ADC%252BC2svnsVWmtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=477-478&author=S.+T.+Cole&title=Tuberculosis+drug+discovery+needs+public-private+consortia&doi=10.1016%2Fj.drudis.2016.09.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Tuberculosis drug discovery needs public-private consortia</span></div><div class="casAuthors">Cole Stewart T</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">477-478</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTiiBeAayc7NSsZ1x6zOs0vfW6udTcc2eZ7ZGXGSsNAKbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svnsVWmtQ%253D%253D&md5=c4c07dfadbe8e89b8cbfaf6e1fa2b6f3</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2016.09.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2016.09.026%26sid%3Dliteratum%253Aachs%26aulast%3DCole%26aufirst%3DS.%2BT.%26atitle%3DTuberculosis%2520drug%2520discovery%2520needs%2520public-private%2520consortia%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2017%26volume%3D22%26spage%3D477%26epage%3D478%26doi%3D10.1016%2Fj.drudis.2016.09.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conradie, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diacon, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngubane, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howell, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everitt, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crook, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendel, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egizi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreira, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timm, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHugh, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wills, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bateson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Niekerk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olugbosi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spigelman, M.</span></span> <span> </span><span class="NLM_article-title">Treatment of highly drug-resistant pulmonary tuberculosis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>382</i></span>,  <span class="NLM_fpage">893</span>– <span class="NLM_lpage">902</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1901814</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1056%2FNEJMoa1901814" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=32130813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkvVKrsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=382&publication_year=2020&pages=893-902&author=F.+Conradieauthor=A.+H.+Diaconauthor=N.+Ngubaneauthor=P.+Howellauthor=D.+Everittauthor=A.+M.+Crookauthor=C.+M.+Mendelauthor=E.+Egiziauthor=J.+Moreiraauthor=J.+Timmauthor=T.+D.+McHughauthor=G.+H.+Willsauthor=A.+Batesonauthor=R.+Huntauthor=C.+Van+Niekerkauthor=M.+Liauthor=M.+Olugbosiauthor=M.+Spigelman&title=Treatment+of+highly+drug-resistant+pulmonary+tuberculosis&doi=10.1056%2FNEJMoa1901814"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of highly drug-resistant pulmonary tuberculosis</span></div><div class="casAuthors">Conradie, Francesca; Diacon, Andreas H.; Ngubane, Nosipho; Howell, Pauline; Everitt, Daniel; Crook, Angela M.; Mendel, Carl M.; Egizi, Erica; Moreira, Joanna; Timm, Juliano; McHugh, Timothy D.; Wills, Genevieve H.; Bateson, Anna; Hunt, Robert; Van Niekerk, Christo; Li, Mengchun; Olugbosi, Morounfolu; Spigelman, Melvin</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">382</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">893-902</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Patients with highly drug-resistant forms of tuberculosis have limited treatment options and historically have had poor outcomes. methods In an open-label, single-group study in which follow-up is ongoing at three South African sites, we investigated treatment with three oral drugs - bedaquiline, pretomanid, and linezolid - that have bactericidal activity against tuberculosis and to which there is little preexisting resistance.  We evaluated the safety and efficacy of the drug combination for 26 wk in patients with extensively drug-resistant tuberculosis and patients with multidrug-resistant tuberculosis that was not responsive to treatment or for which a second-line regimen had been discontinued because of side effects.  The primary end point was the incidence of an unfavorable outcome, defined as treatment failure (bacteriol. or clin.) or relapse during follow-up, which continued until 6 mo after the end of treatment.  Patients were classified as having a favorable outcome at 6 mo if they had resoln. of clin. disease, a neg. culture status, and had not already been classified as having had an unfavorable outcome.  Other efficacy end points and safety were also evaluated. results A total of 109 patients were enrolled in the study and were included in the evaluation of efficacy and safety end points.  At 6 mo after the end of treatment in the intention-to-treat anal., 11 patients (10%) had an unfavorable outcome and 98 patients (90%; 95% confidence interval, 83 to 95) had a favorable outcome.  The 11 unfavorable outcomes were 7 deaths (6 during treatment and 1 from an unknown cause during follow-up), 1 withdrawal of consent during treatment, 2 relapses during follow-up, and 1 loss to follow-up.  The expected linezolid toxic effects of peripheral neuropathy (occurring in 81% of patients) and myelosuppression (48%), although common, were manageable, often leading to dose redns. or interruptions in treatment with linezolid. conclusions The combination of bedaquiline, pretomanid, and linezolid led to a favorable outcome at 6 mo after the end of therapy in a high percentage of patients with highly drug-resistant forms of tuberculosis; some assocd. toxic effects were obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoagq93PXO5qrVg90H21EOLACvtfcHk0lg4oHsSK6P3TA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkvVKrsb0%253D&md5=e7210ad01d84d5c99708cdd124a29145</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1901814&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1901814%26sid%3Dliteratum%253Aachs%26aulast%3DConradie%26aufirst%3DF.%26aulast%3DDiacon%26aufirst%3DA.%2BH.%26aulast%3DNgubane%26aufirst%3DN.%26aulast%3DHowell%26aufirst%3DP.%26aulast%3DEveritt%26aufirst%3DD.%26aulast%3DCrook%26aufirst%3DA.%2BM.%26aulast%3DMendel%26aufirst%3DC.%2BM.%26aulast%3DEgizi%26aufirst%3DE.%26aulast%3DMoreira%26aufirst%3DJ.%26aulast%3DTimm%26aufirst%3DJ.%26aulast%3DMcHugh%26aufirst%3DT.%2BD.%26aulast%3DWills%26aufirst%3DG.%2BH.%26aulast%3DBateson%26aufirst%3DA.%26aulast%3DHunt%26aufirst%3DR.%26aulast%3DVan%2BNiekerk%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DOlugbosi%26aufirst%3DM.%26aulast%3DSpigelman%26aufirst%3DM.%26atitle%3DTreatment%2520of%2520highly%2520drug-resistant%2520pulmonary%2520tuberculosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2020%26volume%3D382%26spage%3D893%26epage%3D902%26doi%3D10.1056%2FNEJMoa1901814" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thwaites, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nahid, P.</span></span> <span> </span><span class="NLM_article-title">Triumph and tragedy of 21st century tuberculosis drug development</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>382</i></span>,  <span class="NLM_fpage">959</span>– <span class="NLM_lpage">960</span>, <span class="refDoi"> DOI: 10.1056/NEJMe2000860</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1056%2FNEJMe2000860" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=32130819" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A280%3ADC%252BB387ptlajuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=382&publication_year=2020&pages=959-960&author=G.+Thwaitesauthor=P.+Nahid&title=Triumph+and+tragedy+of+21st+century+tuberculosis+drug+development&doi=10.1056%2FNEJMe2000860"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Triumph and Tragedy of 21st Century Tuberculosis Drug Development</span></div><div class="casAuthors">Thwaites Guy; Nahid Payam</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">382</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">959-960</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTkHxyU3n4vkQpJitSxOdIlfW6udTcc2eZGlixU2BbqUrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB387ptlajuw%253D%253D&md5=1742bbff59536529629c904aa6c56887</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2FNEJMe2000860&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMe2000860%26sid%3Dliteratum%253Aachs%26aulast%3DThwaites%26aufirst%3DG.%26aulast%3DNahid%26aufirst%3DP.%26atitle%3DTriumph%2520and%2520tragedy%2520of%252021st%2520century%2520tuberculosis%2520drug%2520development%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2020%26volume%3D382%26spage%3D959%26epage%3D960%26doi%3D10.1056%2FNEJMe2000860" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vilcheze, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, W. R.,  Jr.</span></span> <span> </span><span class="NLM_article-title">The mechanism of isoniazid killing: Clarity through the scope of genetics</span>. <i>Annu. Rev. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">35</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1146/annurev.micro.61.111606.122346</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1146%2Fannurev.micro.61.111606.122346" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=18035606" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlartrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2007&pages=35-50&author=C.+Vilchezeauthor=W.+R.+Jacobs&title=The+mechanism+of+isoniazid+killing%3A+Clarity+through+the+scope+of+genetics&doi=10.1146%2Fannurev.micro.61.111606.122346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The mechanism of isoniazid killing: clarity through the scope of genetics</span></div><div class="casAuthors">Vilcheze, Catherine; Jacobs, William R., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Microbiology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">35-50</span>CODEN:
                <span class="NLM_cas:coden">ARMIAZ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4227</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Isoniazid (INH) is one of the most efficient drugs for the treatment of Mycobacterium tuberculosis infections.  Despite its rather simple chem. structure, the mechanism by which INH kills M. tuberculosis is complex.  A full understanding of the mechanisms of action of INH required the development of genetic tools in M. tuberculosis.  Herein, we discuss the different hypotheses that have been used to describe INH action against M. tuberculosis over the past 50 years in terms of the pregenetic and genetic era.  We also review the different mechanisms of INH resistance and propose what we think is the means by which INH kills M. tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdq3WkgwRRL7Vg90H21EOLACvtfcHk0lg4oHsSK6P3TA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlartrbI&md5=c4857e9173ad388225afbec9688585d7</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1146%2Fannurev.micro.61.111606.122346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.micro.61.111606.122346%26sid%3Dliteratum%253Aachs%26aulast%3DVilcheze%26aufirst%3DC.%26aulast%3DJacobs%26aufirst%3DW.%2BR.%26atitle%3DThe%2520mechanism%2520of%2520isoniazid%2520killing%253A%2520Clarity%2520through%2520the%2520scope%2520of%2520genetics%26jtitle%3DAnnu.%2520Rev.%2520Microbiol.%26date%3D2007%26volume%3D61%26spage%3D35%26epage%3D50%26doi%3D10.1146%2Fannurev.micro.61.111606.122346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scorpio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">662</span>– <span class="NLM_lpage">667</span>, <span class="refDoi"> DOI: 10.1038/nm0696-662</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1038%2Fnm0696-662" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=8640557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADyaK28XjsVSjtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1996&pages=662-667&author=A.+Scorpioauthor=Y.+Zhang&title=Mutations+in+pncA%2C+a+gene+encoding+pyrazinamidase%2Fnicotinamidase%2C+cause+resistance+to+the+antituberculous+drug+pyrazinamide+in+tubercle+bacillus&doi=10.1038%2Fnm0696-662"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus</span></div><div class="casAuthors">Scorpio, Angelo; Zhang, Ying</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">662-667</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Co.</span>)
        </div><div class="casAbstract">Naturally pyrazinamide (PZA)-resistant Mycobacterium bovis and acquired PZA-resistant M. tuberculosis strains lose pyrazinamidase (PZase).  To investigate the mol. mechanism of PZA resistance, we have cloned the gene (pncA) encoding M. tuberculosis PZase.  Mutations in pncA were identified in both types of PZA-resistant strains, and transformation of these strains with a functional pncA gene restored PZase activity and PZA susceptibility.  These findings, besides providing the basis for understanding how PZA works, should have implications for rapid detection of PZA-resistant clin. isolates of M. tuberculosis and also for rapid differentiation of M. bovis from M. tuberculosis strains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVdd4sFkh_b7Vg90H21EOLACvtfcHk0lg4oHsSK6P3TA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XjsVSjtbo%253D&md5=8b494b8294bc17e131105a8736fb5a3e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnm0696-662&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm0696-662%26sid%3Dliteratum%253Aachs%26aulast%3DScorpio%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DMutations%2520in%2520pncA%252C%2520a%2520gene%2520encoding%2520pyrazinamidase%252Fnicotinamidase%252C%2520cause%2520resistance%2520to%2520the%2520antituberculous%2520drug%2520pyrazinamide%2520in%2520tubercle%2520bacillus%26jtitle%3DNat.%2520Med.%26date%3D1996%26volume%3D2%26spage%3D662%26epage%3D667%26doi%3D10.1038%2Fnm0696-662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heifets, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flory, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindholm-Levy, P. J.</span></span> <span> </span><span class="NLM_article-title">Does pyrazinoic acid as an active moiety of pyrazinamide have specific activity against mycobacterium tuberculosis?</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">1252</span>– <span class="NLM_lpage">1254</span>, <span class="refDoi"> DOI: 10.1128/AAC.33.8.1252</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.33.8.1252" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=2508544" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADyaL1MXlslSqt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1989&pages=1252-1254&author=L.+B.+Heifetsauthor=M.+A.+Floryauthor=P.+J.+Lindholm-Levy&title=Does+pyrazinoic+acid+as+an+active+moiety+of+pyrazinamide+have+specific+activity+against+mycobacterium+tuberculosis%3F&doi=10.1128%2FAAC.33.8.1252"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Does pyrazinoic acid as an active moiety of pyrazinamide have specific activity against Mycobacterium tuberculosis?</span></div><div class="casAuthors">Heifets, Leonid B.; Flory, Marcella A.; Lindholm-Levy, Pamela J.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1252-4</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    </div><div class="casAbstract">The commonly accepted hypothesis explaining the mechanism of action of pyrazinamide (PZA) is based on the assumption that PZA-susceptible M. tuberculosis strains produce pyrazinamidase, which hydrolyzes PZA to the antibacterial moiety pyrazinoic acid (POA).  It is not clear whether POA has specific antimicrobial activity or whether the inhibition of growth caused by POA is due to its ability to lower the pH of the environment below the limits of tolerance of M. tuberculosis growth.  It was confirmed in this study that POA, depending on the concn., lowered the pH of 7H12 broth (pH 6.0) to values from 5.8 at 120.0 μg/mL to 4.6 at 960.0 μg/mL.  Therefore, the inhibitory effects of different concns. of POA were examd. in broth in which the final pH was adjusted to 5.6 by adding appropriate amts. of H3PO4 or K2HPO4.  Under these conditions, a clear concn.-response correlation was found, proving that POA does have specific antimicrobial activity.  The MIC of POA at pH 5.6 was 240-480 μg/mL, 8-16-fold higher than the MIC of PZA under the same conditions and much higher than the concns. achievable in humans.  This suggests that the action of POA in an acid environment is a combined effect of its specific activity and its ability to lower the pH below the limits of tolerance of the target organism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8rLsiPiAcarVg90H21EOLACvtfcHk0ljv1Ljp1-uUgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXlslSqt7g%253D&md5=8afd8fd6e18033e254d29e107b9b109b</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1128%2FAAC.33.8.1252&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.33.8.1252%26sid%3Dliteratum%253Aachs%26aulast%3DHeifets%26aufirst%3DL.%2BB.%26aulast%3DFlory%26aufirst%3DM.%2BA.%26aulast%3DLindholm-Levy%26aufirst%3DP.%2BJ.%26atitle%3DDoes%2520pyrazinoic%2520acid%2520as%2520an%2520active%2520moiety%2520of%2520pyrazinamide%2520have%2520specific%2520activity%2520against%2520mycobacterium%2520tuberculosis%253F%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1989%26volume%3D33%26spage%3D1252%26epage%3D1254%26doi%3D10.1128%2FAAC.33.8.1252" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Botha, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirgel, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkin, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Wal, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donald, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchison, D. A.</span></span> <span> </span><span class="NLM_article-title">Early bactericidal activity of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosis</span>. <i>S Afr. Med. J.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">158</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=8619142" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A280%3ADyaK287nvFGmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=1996&pages=155-158&author=F.+J.+Bothaauthor=F.+A.+Sirgelauthor=D.+P.+Parkinauthor=B.+W.+van+de+Walauthor=P.+R.+Donaldauthor=D.+A.+Mitchison&title=Early+bactericidal+activity+of+ethambutol%2C+pyrazinamide+and+the+fixed+combination+of+isoniazid%2C+rifampicin+and+pyrazinamide+%28Rifater%29+in+patients+with+pulmonary+tuberculosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Early bactericidal activity of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosis</span></div><div class="casAuthors">Botha F J; Sirgel F A; Parkin D P; van de Wal B W; Donald P R; Mitchison D A</div><div class="citationInfo"><span class="NLM_cas:title">South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">155-8</span>
        ISSN:<span class="NLM_cas:issn">0256-9574</span>.
    </div><div class="casAbstract">The early bactericidal activity (EBA) of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater: Mer National) was evaluated in patients with pulmonary tuberculosis who were sputum-positive on microscopy for acid-fast bacilli.  Twenty-eight patients (mean age 33 years and weight 51 kg on average; range 40-59 kg) were studied.  The fall in viable counts of Mycobacterium tuberculosis in sputum collections during the 2 days following the start of treatment was estimated from counts of colony-forming units (CFUs) of M. tuberculosis per ml of sputum cultured on selective 7H10 agar medium.  The EBA for ethambutol determined in 9 patients was 0.245 +/- 0.046, log10 CFU/ml sputum/day, that for pyrazinamide was 0.003 +/- 0.014 log10 CFU/ml sputum/day and that for Rifater 0.558 +/- 0.054 log10 CFU/ml sputum/day.  The results obtained are similar to those reported in a previous study of the first 2 days of treatment, but in smaller numbers of patients, and confirm the moderate EBA of ethambutol while pyrazinamide is again shown to have very little EBA.  Rifater has a marked EBA which may be due mainly to the action of isoniazid.  This methodology may be valuable in the rapid evaluation of the bactericidal activity of new antituberculosis agents and the comparison of different dose sizes of agents of the same class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTJ0XHzfjbvacve_zCu79I8fW6udTcc2eaz5r8N29gCe7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK287nvFGmsw%253D%253D&md5=dcd8bcb0199ab8a1e98dddcfad447894</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBotha%26aufirst%3DF.%2BJ.%26aulast%3DSirgel%26aufirst%3DF.%2BA.%26aulast%3DParkin%26aufirst%3DD.%2BP.%26aulast%3Dvan%2Bde%2BWal%26aufirst%3DB.%2BW.%26aulast%3DDonald%26aufirst%3DP.%2BR.%26aulast%3DMitchison%26aufirst%3DD.%2BA.%26atitle%3DEarly%2520bactericidal%2520activity%2520of%2520ethambutol%252C%2520pyrazinamide%2520and%2520the%2520fixed%2520combination%2520of%2520isoniazid%252C%2520rifampicin%2520and%2520pyrazinamide%2520%2528Rifater%2529%2520in%2520patients%2520with%2520pulmonary%2520tuberculosis%26jtitle%3DS%2520Afr.%2520Med.%2520J.%26date%3D1996%26volume%3D86%26spage%3D155%26epage%3D158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nusrath
Unissa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanna, L. E.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanisms of action, resistance, detection to the first-line anti tuberculosis drugs: Rifampicin and pyrazinamide in the post whole genome sequencing era</span>. <i>Tuberculosis (Oxford, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">96</span>– <span class="NLM_lpage">107</span>, <span class="refDoi"> DOI: 10.1016/j.tube.2017.04.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.tube.2017.04.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=28610794" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnsV2ltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2017&pages=96-107&author=A.+Nusrath%0AUnissaauthor=L.+E.+Hanna&title=Molecular+mechanisms+of+action%2C+resistance%2C+detection+to+the+first-line+anti+tuberculosis+drugs%3A+Rifampicin+and+pyrazinamide+in+the+post+whole+genome+sequencing+era&doi=10.1016%2Fj.tube.2017.04.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms of action, resistance, detection to the first-line anti tuberculosis drugs: Rifampicin and pyrazinamide in the post whole genome sequencing era</span></div><div class="casAuthors">Nusrath Unissa, Ameeruddin; Hanna, Luke Elizabeth</div><div class="citationInfo"><span class="NLM_cas:title">Tuberculosis (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">96-107</span>CODEN:
                <span class="NLM_cas:coden">TUBECU</span>;
        ISSN:<span class="NLM_cas:issn">1472-9792</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Recent studies in addn. to studies based on whole genome sequencing (WGS) of clin. isolates of Mycobacterium tuberculosis (MTB) from diverse geog. regions have provided useful insights into the mechanisms of drug resistance.  Of importance, are some of the findings pertaining to mechanisms of resistance to two of the first-line anti-tuberculosis (TB) drugs, namely, rifampicin (RIF) and pyrazinamide (PZA).  For example, the implication of mutations in rpoA and rpoC genes that act as compensatory mutations for those in the rpoB gene with respect to RIF resistance is noteworthy.  Similarly, in the case of PZA resistance, the role of rpsA and panD genes has recently been noted.  This highlights the evolving knowledge of resistance to these drugs.  The present article provides a detailed account of the mol. mechanisms of resistance against two sterilizing first line anti-TB drugs (RIF and PZA) as well as an overview of sequence-based methods for detection of resistance to the drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFC90MranjGrVg90H21EOLACvtfcHk0ljv1Ljp1-uUgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnsV2ltro%253D&md5=199d1cb67c061ade94bf1377781f3ed6</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.tube.2017.04.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tube.2017.04.008%26sid%3Dliteratum%253Aachs%26aulast%3DNusrath%2BUnissa%26aufirst%3DA.%26aulast%3DHanna%26aufirst%3DL.%2BE.%26atitle%3DMolecular%2520mechanisms%2520of%2520action%252C%2520resistance%252C%2520detection%2520to%2520the%2520first-line%2520anti%2520tuberculosis%2520drugs%253A%2520Rifampicin%2520and%2520pyrazinamide%2520in%2520the%2520post%2520whole%2520genome%2520sequencing%2520era%26jtitle%3DTuberculosis%2520%2528Oxford%252C%2520U.%2520K.%2529%26date%3D2017%26volume%3D105%26spage%3D96%26epage%3D107%26doi%3D10.1016%2Fj.tube.2017.04.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhasselt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillemont, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gohlmann, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neefs, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Gestel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timmerman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Chaffoy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huitric, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cambau, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truffot-Pernot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lounis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarlier, V.</span></span> <span> </span><span class="NLM_article-title">A diarylquinoline drug active on the ATP synthase of mycobacterium tuberculosis</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>307</i></span>,  <span class="NLM_fpage">223</span>– <span class="NLM_lpage">227</span>, <span class="refDoi"> DOI: 10.1126/science.1106753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1126%2Fscience.1106753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=15591164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD2MXisVKkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=307&publication_year=2005&pages=223-227&author=K.+Andriesauthor=P.+Verhasseltauthor=J.+Guillemontauthor=H.+W.+Gohlmannauthor=J.+M.+Neefsauthor=H.+Winklerauthor=J.+Van+Gestelauthor=P.+Timmermanauthor=M.+Zhuauthor=E.+Leeauthor=P.+Williamsauthor=D.+de+Chaffoyauthor=E.+Huitricauthor=S.+Hoffnerauthor=E.+Cambauauthor=C.+Truffot-Pernotauthor=N.+Lounisauthor=V.+Jarlier&title=A+diarylquinoline+drug+active+on+the+ATP+synthase+of+mycobacterium+tuberculosis&doi=10.1126%2Fscience.1106753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis</span></div><div class="casAuthors">Andries, Koen; Verhasselt, Peter; Guillemont, Jerome; Goehlmann, Hinrich W. H.; Neefs, Jean-Marc; Winkler, Hans; Van Gestel, Jef; Timmerman, Philip; Zhu, Min; Lee, Ennis; Williams, Peter; de Chaffoy, Didier; Huitric, Emma; Hoffner, Sven; Cambau, Emmanuelle; Truffot-Pernot, Chantal; Lounis, Nacer; Jarlier, Vincent</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">307</span>
        (<span class="NLM_cas:issue">5707</span>),
    <span class="NLM_cas:pages">223-227</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The incidence of tuberculosis has been increasing substantially on a worldwide basis over the past decade, but no tuberculosis-specific drugs have been discovered in 40 years.  We identified a diarylquinoline, R207910, that potently inhibits both drug-sensitive and drug-resistant Mycobacterium tuberculosis in vitro (min. inhibitory concn. 0.06 μg/mL).  In mice, R207910 exceeded the bactericidal activities of isoniazid and rifampin by at least 1 log unit.  Substitution of drugs included in the World Health Organization's first-line tuberculosis treatment regimen (rifampin, isoniazid, and pyrazinamide) with R207910 accelerated bactericidal activity, leading to complete culture conversion after 2 mo of treatment in some combinations.  A single dose of R207910 inhibited mycobacterial growth for 1 wk.  Plasma levels assocd. with efficacy in mice were well tolerated in healthy human volunteers.  Mutants selected in vitro suggest that the drug targets the proton pump of ATP (ATP) synthase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9LY7RSAIXUrVg90H21EOLACvtfcHk0liLe6yGD293Uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXisVKkug%253D%253D&md5=099b643f173bb77e70cf1aa6e9871ffe</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1126%2Fscience.1106753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1106753%26sid%3Dliteratum%253Aachs%26aulast%3DAndries%26aufirst%3DK.%26aulast%3DVerhasselt%26aufirst%3DP.%26aulast%3DGuillemont%26aufirst%3DJ.%26aulast%3DGohlmann%26aufirst%3DH.%2BW.%26aulast%3DNeefs%26aufirst%3DJ.%2BM.%26aulast%3DWinkler%26aufirst%3DH.%26aulast%3DVan%2BGestel%26aufirst%3DJ.%26aulast%3DTimmerman%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DE.%26aulast%3DWilliams%26aufirst%3DP.%26aulast%3Dde%2BChaffoy%26aufirst%3DD.%26aulast%3DHuitric%26aufirst%3DE.%26aulast%3DHoffner%26aufirst%3DS.%26aulast%3DCambau%26aufirst%3DE.%26aulast%3DTruffot-Pernot%26aufirst%3DC.%26aulast%3DLounis%26aufirst%3DN.%26aulast%3DJarlier%26aufirst%3DV.%26atitle%3DA%2520diarylquinoline%2520drug%2520active%2520on%2520the%2520ATP%2520synthase%2520of%2520mycobacterium%2520tuberculosis%26jtitle%3DScience%26date%3D2005%26volume%3D307%26spage%3D223%26epage%3D227%26doi%3D10.1126%2Fscience.1106753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diacon, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pym, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grobusch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patientia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rustomjee, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page-Shipp, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pistorius, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krause, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogoshi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Churchyard, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palomino, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Marez, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Heeswijk, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lounis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyvisch, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verbeeck, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parys, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Beule, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mc Neeley, D. F.</span></span> <span> </span><span class="NLM_article-title">The diarylquinoline TMC207 for multidrug-resistant tuberculosis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>360</i></span>,  <span class="NLM_fpage">2397</span>– <span class="NLM_lpage">2405</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa0808427</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1056%2FNEJMoa0808427" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=19494215" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntVKqsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=360&publication_year=2009&pages=2397-2405&author=A.+H.+Diaconauthor=A.+Pymauthor=M.+Grobuschauthor=R.+Patientiaauthor=R.+Rustomjeeauthor=L.+Page-Shippauthor=C.+Pistoriusauthor=R.+Krauseauthor=M.+Bogoshiauthor=G.+Churchyardauthor=A.+Venterauthor=J.+Allenauthor=J.+C.+Palominoauthor=T.+De+Marezauthor=R.+P.+van+Heeswijkauthor=N.+Lounisauthor=P.+Meyvischauthor=J.+Verbeeckauthor=W.+Parysauthor=K.+de+Beuleauthor=K.+Andriesauthor=D.+F.+Mc+Neeley&title=The+diarylquinoline+TMC207+for+multidrug-resistant+tuberculosis&doi=10.1056%2FNEJMoa0808427"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The diarylquinoline TMC207 for multidrug-resistant tuberculosis</span></div><div class="casAuthors">Diacon, Andreas H.; Pym, Alexander; Grobusch, Martin; Patientia, Ramonde; Rustomjee, Roxana; Page-Shipp, Liesl; Pistorius, Christoffel; Krause, Rene; Bogoshi, Mampedi; Churchyard, Gavin; Venter, Amour; Allen, Jenny; Palomino, Juan Carlos; De Marez, Tine; van Heeswijk, Rolf P. G.; Lounis, Nacer; Meyvisch, Paul; Verbeeck, Johan; Parys, Wim; de Beule, Karel; Andries, Koen; McNeeley, David F.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">360</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2397-2405</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND; The diarylquinoline TMC207 offers a new mechanism of antituberculosis action by inhibiting mycobacterial ATP synthase.  TMC207 potently inhibits drug-sensitive and drug-resistant Mycobacterium tuberculosis in vitro and shows bactericidal activity in patients who have drug-susceptible pulmonary tuberculosis.  METHODS: In the first stage of a two-stage, phase 2, randomized, controlled trial, we randomly assigned 47 patients who had newly diagnosed multidrug-resistant pulmonary tuberculosis to receive either TMC207 (400 mg daily for 2 wk, followed by 200 mg three times a week for 6 wk) (23 patients) or placebo (24 patients) in combination with a std. five-drug, second-line antituberculosis regimen.  The primary efficacy end point was the conversion of sputum cultures, in liq. broth, from pos. to neg.  RESULTS: The addn. of TMC207 to std. therapy for multidrug-resistant tuberculosis reduced the time to conversion to a neg. sputum culture, as compared with placebo (hazard ratio, 11.8; 95% confidence interval, 2.3 to 61.3; P = 0.003 by Cox regression anal.) and increased the proportion of patients with conversion of sputum culture (48% vs. 9%).  The mean log10 count of colony-forming units in the sputum declined more rapidly in the TMC207 group than in the placebo group.  No significant differences in av. plasma TMC207 concns. were noted between patients with and those without culture conversion.  Most adverse events were mild to moderate, and only nausea occurred significantly more frequently among patients in the TMC207 group than among patients in the placebo group (26% vs. 4%, P = 0.04).  CONCLUSIONS: The clin. activity of TMC207 validates ATP synthase as a viable target for the treatment of tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra39rie2VZP7Vg90H21EOLACvtfcHk0liLe6yGD293Uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntVKqsrs%253D&md5=76bdbf7f0263a168e58532addaf90a0a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0808427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0808427%26sid%3Dliteratum%253Aachs%26aulast%3DDiacon%26aufirst%3DA.%2BH.%26aulast%3DPym%26aufirst%3DA.%26aulast%3DGrobusch%26aufirst%3DM.%26aulast%3DPatientia%26aufirst%3DR.%26aulast%3DRustomjee%26aufirst%3DR.%26aulast%3DPage-Shipp%26aufirst%3DL.%26aulast%3DPistorius%26aufirst%3DC.%26aulast%3DKrause%26aufirst%3DR.%26aulast%3DBogoshi%26aufirst%3DM.%26aulast%3DChurchyard%26aufirst%3DG.%26aulast%3DVenter%26aufirst%3DA.%26aulast%3DAllen%26aufirst%3DJ.%26aulast%3DPalomino%26aufirst%3DJ.%2BC.%26aulast%3DDe%2BMarez%26aufirst%3DT.%26aulast%3Dvan%2BHeeswijk%26aufirst%3DR.%2BP.%26aulast%3DLounis%26aufirst%3DN.%26aulast%3DMeyvisch%26aufirst%3DP.%26aulast%3DVerbeeck%26aufirst%3DJ.%26aulast%3DParys%26aufirst%3DW.%26aulast%3Dde%2BBeule%26aufirst%3DK.%26aulast%3DAndries%26aufirst%3DK.%26aulast%3DMc%2BNeeley%26aufirst%3DD.%2BF.%26atitle%3DThe%2520diarylquinoline%2520TMC207%2520for%2520multidrug-resistant%2520tuberculosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D360%26spage%3D2397%26epage%3D2405%26doi%3D10.1056%2FNEJMoa0808427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dendouga, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vergauwen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molenberghs, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vranckx, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willebrords, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ristic, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lill, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorange, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillemont, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bald, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span> <span> </span><span class="NLM_article-title">Diarylquinolines target subunit c of mycobacterial ATP synthase</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">324</span>, <span class="refDoi"> DOI: 10.1038/nchembio884</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1038%2Fnchembio884" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=17496888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltlOjurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=323-324&author=A.+Koulauthor=N.+Dendougaauthor=K.+Vergauwenauthor=B.+Molenberghsauthor=L.+Vranckxauthor=R.+Willebrordsauthor=Z.+Risticauthor=H.+Lillauthor=I.+Dorangeauthor=J.+Guillemontauthor=D.+Baldauthor=K.+Andries&title=Diarylquinolines+target+subunit+c+of+mycobacterial+ATP+synthase&doi=10.1038%2Fnchembio884"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Diarylquinolines target subunit c of mycobacterial ATP synthase</span></div><div class="casAuthors">Koul, Anil; Dendouga, Najoua; Vergauwen, Karen; Molenberghs, Brenda; Vranckx, Luc; Willebrords, Rudy; Ristic, Zorica; Lill, Holger; Dorange, Ismet; Guillemont, Jerome; Bald, Dirk; Andries, Koen</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">323-324</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The diarylquinoline R207910 (TMC207) is a promising candidate in clin. development for the treatment of tuberculosis.  Though R207910-resistant mycobacteria bear mutations in ATP synthase, the compd.'s precise target is not known.  Here we establish by genetic, biochem. and binding assays that the oligomeric subunit c (AtpE) of ATP synthase is the target of R207910.  Thus targeting energy metab. is a new, promising approach for antibacterial drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoo57k1zZdTLVg90H21EOLACvtfcHk0lgnDiYVWWBT0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltlOjurc%253D&md5=f9ba04042bef448f5910cea0e89715f0</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fnchembio884&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio884%26sid%3Dliteratum%253Aachs%26aulast%3DKoul%26aufirst%3DA.%26aulast%3DDendouga%26aufirst%3DN.%26aulast%3DVergauwen%26aufirst%3DK.%26aulast%3DMolenberghs%26aufirst%3DB.%26aulast%3DVranckx%26aufirst%3DL.%26aulast%3DWillebrords%26aufirst%3DR.%26aulast%3DRistic%26aufirst%3DZ.%26aulast%3DLill%26aufirst%3DH.%26aulast%3DDorange%26aufirst%3DI.%26aulast%3DGuillemont%26aufirst%3DJ.%26aulast%3DBald%26aufirst%3DD.%26aulast%3DAndries%26aufirst%3DK.%26atitle%3DDiarylquinolines%2520target%2520subunit%2520c%2520of%2520mycobacterial%2520ATP%2520synthase%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2007%26volume%3D3%26spage%3D323%26epage%3D324%26doi%3D10.1038%2Fnchembio884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vranckx, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dendouga, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balemans, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van den
Wyngaert, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vergauwen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Göhlmann, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willebrords, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poncelet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillemont, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bald, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span> <span> </span><span class="NLM_article-title">Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">25273</span>– <span class="NLM_lpage">25280</span>, <span class="refDoi"> DOI: 10.1074/jbc.M803899200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1074%2Fjbc.M803899200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=18625705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVyisLrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=25273-25280&author=A.+Koulauthor=L.+Vranckxauthor=N.+Dendougaauthor=W.+Balemansauthor=I.+Van+den%0AWyngaertauthor=K.+Vergauwenauthor=H.+W.+G%C3%B6hlmannauthor=R.+Willebrordsauthor=A.+Ponceletauthor=J.+Guillemontauthor=D.+Baldauthor=K.+Andries&title=Diarylquinolines+are+bactericidal+for+dormant+mycobacteria+as+a+result+of+disturbed+ATP+homeostasis&doi=10.1074%2Fjbc.M803899200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Diarylquinolines Are Bactericidal for Dormant Mycobacteria as a Result of Disturbed ATP Homeostasis</span></div><div class="casAuthors">Koul, Anil; Vranckx, Luc; Dendouga, Najoua; Balemans, Wendy; Van den Wyngaert, Ilse; Vergauwen, Karen; Goehlmann, Hinrich W. H.; Willebrords, Rudy; Poncelet, Alain; Guillemont, Jerome; Bald, Dirk; Andries, Koen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">25273-25280</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">An estd. one-third of the world population is latently infected with Mycobacterium tuberculosis.  These nonreplicating, dormant bacilli are tolerant to conventional antituberculosis drugs, such as isoniazid.  We recently identified diarylquinoline R207910 (also called TMC207) as an inhibitor of ATP synthase with a remarkable activity against replicating mycobacteria.  In the present study, we show that R207910 kills dormant bacilli as effectively as aerobically grown bacilli with the same target specificity.  Despite a transcriptional down-regulation of the ATP synthase operon and significantly lower cellular ATP levels, we show that dormant mycobacteria do possess residual ATP synthase enzymic activity.  This activity is blocked by nanomolar concns. of R207910, thereby further reducing ATP levels and causing a pronounced bactericidal effect.  We conclude that this residual ATP synthase activity is indispensable for the survival of dormant mycobacteria, making it a promising drug target to tackle dormant infections.  The unique dual bactericidal activity of diarylquinolines on dormant as well as replicating bacterial subpopulations distinguishes them entirely from the current anti-tuberculosis drugs and underlines the potential of R207910 to shorten tuberculosis treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRevC8Pav5B7Vg90H21EOLACvtfcHk0lgnDiYVWWBT0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVyisLrP&md5=a7aab9f2cfbab62e204f7a91e78f32ec</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M803899200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M803899200%26sid%3Dliteratum%253Aachs%26aulast%3DKoul%26aufirst%3DA.%26aulast%3DVranckx%26aufirst%3DL.%26aulast%3DDendouga%26aufirst%3DN.%26aulast%3DBalemans%26aufirst%3DW.%26aulast%3DVan%2Bden%2BWyngaert%26aufirst%3DI.%26aulast%3DVergauwen%26aufirst%3DK.%26aulast%3DG%25C3%25B6hlmann%26aufirst%3DH.%2BW.%26aulast%3DWillebrords%26aufirst%3DR.%26aulast%3DPoncelet%26aufirst%3DA.%26aulast%3DGuillemont%26aufirst%3DJ.%26aulast%3DBald%26aufirst%3DD.%26aulast%3DAndries%26aufirst%3DK.%26atitle%3DDiarylquinolines%2520are%2520bactericidal%2520for%2520dormant%2520mycobacteria%2520as%2520a%2520result%2520of%2520disturbed%2520ATP%2520homeostasis%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26spage%3D25273%26epage%3D25280%26doi%3D10.1074%2Fjbc.M803899200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haagsma, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdillahi-Ibrahim, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krab, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vergauwen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillemont, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lill, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bald, D.</span></span> <span> </span><span class="NLM_article-title">Selectivity of TMC207 towards mycobacterial atp synthase compared with that towards the eukaryotic homologue</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">1290</span>– <span class="NLM_lpage">1292</span>, <span class="refDoi"> DOI: 10.1128/AAC.01393-08</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.01393-08" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=19075053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivF2ksbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2009&pages=1290-1292&author=A.+C.+Haagsmaauthor=R.+Abdillahi-Ibrahimauthor=M.+J.+Wagnerauthor=K.+Krabauthor=K.+Vergauwenauthor=J.+Guillemontauthor=K.+Andriesauthor=H.+Lillauthor=A.+Koulauthor=D.+Bald&title=Selectivity+of+TMC207+towards+mycobacterial+atp+synthase+compared+with+that+towards+the+eukaryotic+homologue&doi=10.1128%2FAAC.01393-08"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue</span></div><div class="casAuthors">Haagsma, Anna C.; Abdillahi-Ibrahim, Rooda; Wagner, Marijke J.; Krab, Klaas; Vergauwen, Karen; Guillemont, Jerome; Andries, Koen; Lill, Holger; Koul, Anil; Bald, Dirk</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1290-1292</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The diarylquinoline TMC207 kills Mycobacterium tuberculosis by specifically inhibiting ATP synthase.  We show here that human mitochondrial ATP synthase (50% inhibitory concn. [IC50] of >200 μM) displayed more than 20,000-fold lower sensitivity for TMC207 compared to that of mycobacterial ATP synthase (IC50 of 10 nM).  Also, oxygen consumption in mouse liver and bovine heart mitochondria showed very low sensitivity for TMC207.  These results suggest that TMC207 may not elicit ATP synthesis-related toxicity in mammalian cells.  ATP synthase, although highly conserved between prokaryotes and eukaryotes, may still qualify as an attractive antibiotic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQm0byrOhERLVg90H21EOLACvtfcHk0lgnDiYVWWBT0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivF2ksbs%253D&md5=531b56f5d74d1bb6d0f217b209cdd4be</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1128%2FAAC.01393-08&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01393-08%26sid%3Dliteratum%253Aachs%26aulast%3DHaagsma%26aufirst%3DA.%2BC.%26aulast%3DAbdillahi-Ibrahim%26aufirst%3DR.%26aulast%3DWagner%26aufirst%3DM.%2BJ.%26aulast%3DKrab%26aufirst%3DK.%26aulast%3DVergauwen%26aufirst%3DK.%26aulast%3DGuillemont%26aufirst%3DJ.%26aulast%3DAndries%26aufirst%3DK.%26aulast%3DLill%26aufirst%3DH.%26aulast%3DKoul%26aufirst%3DA.%26aulast%3DBald%26aufirst%3DD.%26atitle%3DSelectivity%2520of%2520TMC207%2520towards%2520mycobacterial%2520atp%2520synthase%2520compared%2520with%2520that%2520towards%2520the%2520eukaryotic%2520homologue%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2009%26volume%3D53%26spage%3D1290%26epage%3D1292%26doi%3D10.1128%2FAAC.01393-08" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Jonge, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koymans, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillemont, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span> <span> </span><span class="NLM_article-title">A computational model of the inhibition of mycobacterium tuberculosis ATPase by a new drug candidate r207910</span>. <i>Proteins: Struct., Funct., Genet.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">971</span>– <span class="NLM_lpage">980</span>, <span class="refDoi"> DOI: 10.1002/prot.21376</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1002%2Fprot.21376" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=17387738" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlsFSjsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=971-980&author=M.+R.+de%0AJongeauthor=L.+H.+Koymansauthor=J.+E.+Guillemontauthor=A.+Koulauthor=K.+Andries&title=A+computational+model+of+the+inhibition+of+mycobacterium+tuberculosis+ATPase+by+a+new+drug+candidate+r207910&doi=10.1002%2Fprot.21376"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910</span></div><div class="casAuthors">de Jonge, Marc R.; Koymans, Luc H. M.; Guillemont, Jerome E. G.; Koul, Anil; Andries, Koen</div><div class="citationInfo"><span class="NLM_cas:title">Proteins: Structure, Function, and Bioinformatics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">971-980</span>CODEN:
                <span class="NLM_cas:coden">PSFBAF</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Diarylquinolines (DARQs) are a new class of potent inhibitors of the ATPase of Mycobacterium tuberculosis.  We have created a homol. model of a binding site for this class of compds. located on the contact area of the a-subunit (gene atpB) and c-subunits (gene atpE) of Mycobacterium tuberculosis ATPase.  The binding pocket that was identified from the anal. of the homol. model is formed by 4 helixes of three c-subunits and 2 helixes of the a-subunit.  The lead compd. of the DARQ series, R207910, was docked into the pocket using a simulated annealing, multiple conformer, docking algorithm.  Different stereoisomers were treated sep.  The best docking pose for each stereoisomer was optimized by mol. dynamics simulation on the 5300 atoms of the binding region and ligand.  The interaction energies in the computed complexes enable us to rank the different stereoisomers in order of interaction strength with the ATPase binding pockets.  We propose that the activity of R207910 against Mycobacterium tuberculosis is based on interference of the compd. with the escapement geometry of the proton transfer chain.  Upon binding the compd. mimicks the conserved Arg-186 residue of the a-subunit and interacts in its place with the conserved acidic residue Glu-61 of the c-subunit.  This mode of action is corroborated by the good agreement between the computed interaction energies and the obsd. pattern of stereo-specificity in the model of the binding region.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroZmmKsrCXZ7Vg90H21EOLACvtfcHk0lgyntzsV_7U3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlsFSjsr8%253D&md5=7cfb48ec3eab0070e90cf8a0c1c6037e</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fprot.21376&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprot.21376%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BJonge%26aufirst%3DM.%2BR.%26aulast%3DKoymans%26aufirst%3DL.%2BH.%26aulast%3DGuillemont%26aufirst%3DJ.%2BE.%26aulast%3DKoul%26aufirst%3DA.%26aulast%3DAndries%26aufirst%3DK.%26atitle%3DA%2520computational%2520model%2520of%2520the%2520inhibition%2520of%2520mycobacterium%2520tuberculosis%2520ATPase%2520by%2520a%2520new%2520drug%2520candidate%2520r207910%26jtitle%3DProteins%253A%2520Struct.%252C%2520Funct.%252C%2520Genet.%26date%3D2007%26volume%3D67%26spage%3D971%26epage%3D980%26doi%3D10.1002%2Fprot.21376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smyej, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jonghe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Looszova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mannens, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhaeghe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thijssen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starckx, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lampo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouan, M. C.</span></span> <span> </span><span class="NLM_article-title">Dose- and time-dependency of the toxicity and pharmacokinetic profiles of bedaquiline and its n-desmethyl metabolite in dogs</span>. <i>Toxicol. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">663</span>– <span class="NLM_lpage">675</span>, <span class="refDoi"> DOI: 10.1177/0192623317723085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1177%2F0192623317723085" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=28789609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC1cXks1Cltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2017&pages=663-675&author=I.+Smyejauthor=S.+De+Jongheauthor=A.+Looszovaauthor=G.+Mannensauthor=T.+Verhaegheauthor=S.+Thijssenauthor=S.+Starckxauthor=A.+Lampoauthor=M.+C.+Rouan&title=Dose-+and+time-dependency+of+the+toxicity+and+pharmacokinetic+profiles+of+bedaquiline+and+its+n-desmethyl+metabolite+in+dogs&doi=10.1177%2F0192623317723085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Dose- and time-dependency of the toxicity and pharmacokinetic profiles of bedaquiline and its n-desmethyl metabolite in dogs</span></div><div class="casAuthors">Smyej, Ilham; De Jonghe, Sandra; Looszova, Adriana; Mannens, Geert; Verhaeghe, Tom; Thijssen, Sandy; Starckx, Sofie; Lampo, Ann; Rouan, Marie-Claude</div><div class="citationInfo"><span class="NLM_cas:title">Toxicologic Pathology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">663-675</span>CODEN:
                <span class="NLM_cas:coden">TOPADD</span>;
        ISSN:<span class="NLM_cas:issn">0192-6233</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Bedaquiline (BDQ) is an antibiotic to treat pulmonary multidrug-resistant tuberculosis (MDR-TB).  Studies up to 39 wk were conducted orally in dogs to assess the toxicity and pharmacokinetics of BDQ and its N-desmethyl metabolite (D-BDQ).  Phospholipidosis (PLD) seen in the monocytic phagocytic system was considered an adaptive change.  Skeletal muscle, heart, stomach, liver, and pancreas toxicities with D-BDQ as the main contributor were assocd. with a less-than-dose-proportional increase in plasma exposure and an overproportional tissue uptake of BDQ and D-BDQ at high-dose levels.  Tissue concns. of BDQ and D-BDQ slowly decreased after lowering the dose, contributing to the recovery of the pathol. findings.  Treatment was better tolerated at mid-dose levels, characterized by a dose-proportional increase in plasma and tissue exposures.  Treatment at a low dose, reaching exposures approximating therapeutic exposures, was without adverse effects and not assocd. with PLD.  There was no evidence of delayed toxicities after treatment cessation.  Intermittent dosing was better tolerated at high doses.  Since MDR-TB patients are dosed within the linear plasma exposure range and plasma levels of BDQ and D-BDQ are similar or lower than in dogs, PLD and adverse findings related to tissue accumulation that occurred at high doses in dogs are unlikely to occur in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGol3098AxhKMbVg90H21EOLACvtfcHk0lgyntzsV_7U3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXks1Cltw%253D%253D&md5=b69d2fad7b039dcf223463da324a9ce8</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1177%2F0192623317723085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0192623317723085%26sid%3Dliteratum%253Aachs%26aulast%3DSmyej%26aufirst%3DI.%26aulast%3DDe%2BJonghe%26aufirst%3DS.%26aulast%3DLooszova%26aufirst%3DA.%26aulast%3DMannens%26aufirst%3DG.%26aulast%3DVerhaeghe%26aufirst%3DT.%26aulast%3DThijssen%26aufirst%3DS.%26aulast%3DStarckx%26aufirst%3DS.%26aulast%3DLampo%26aufirst%3DA.%26aulast%3DRouan%26aufirst%3DM.%2BC.%26atitle%3DDose-%2520and%2520time-dependency%2520of%2520the%2520toxicity%2520and%2520pharmacokinetic%2520profiles%2520of%2520bedaquiline%2520and%2520its%2520n-desmethyl%2520metabolite%2520in%2520dogs%26jtitle%3DToxicol.%2520Pathol.%26date%3D2017%26volume%3D45%26spage%3D663%26epage%3D675%26doi%3D10.1177%2F0192623317723085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tong, A. S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherland, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, S. K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillemont, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motte, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van den Broeck, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franzblau, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upton, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denny, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conole, D.</span></span> <span> </span><span class="NLM_article-title">6-cyano analogues of bedaquiline as less lipophilic and potentially safer diarylquinolines for tuberculosis</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1019</span>– <span class="NLM_lpage">1024</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00196</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00196" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFCis7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1019-1024&author=A.+S.+T.+Tongauthor=P.+J.+Choiauthor=A.+Blaserauthor=H.+S.+Sutherlandauthor=S.+K.+Y.+Tsangauthor=J.+Guillemontauthor=M.+Motteauthor=C.+B.+Cooperauthor=K.+Andriesauthor=W.+Van+den+Broeckauthor=S.+G.+Franzblauauthor=A.+M.+Uptonauthor=W.+A.+Dennyauthor=B.+D.+Palmerauthor=D.+Conole&title=6-cyano+analogues+of+bedaquiline+as+less+lipophilic+and+potentially+safer+diarylquinolines+for+tuberculosis&doi=10.1021%2Facsmedchemlett.7b00196"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">6-Cyano Analogues of Bedaquiline as Less Lipophilic and Potentially Safer Diarylquinolines for Tuberculosis</span></div><div class="casAuthors">Tong, Amy S. T.; Choi, Peter J.; Blaser, Adrian; Sutherland, Hamish S.; Tsang, Sophia K. Y.; Guillemont, Jerome; Motte, Magali; Cooper, Christopher B.; Andries, Koen; Van den Broeck, Walter; Franzblau, Scott G.; Upton, Anna M.; Denny, William A.; Palmer, Brian D.; Conole, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1019-1024</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bedaquiline (1) is a new drug for tuberculosis and the first of the diarylquinoline class.  It demonstrates excellent efficacy against TB but induces phospholipidosis at high doses, has a long terminal elimination half-life (due to its high lipophilicity), and exhibits potent hERG channel inhibition, resulting in clin. QTc interval prolongation.  A no. of structural ring A analogs of bedaquiline have been prepd. and evaluated for their anti-M.tb activity (MIC90), with a view to their possible application as less lipophilic second generation compds.  It was previously obsd. that a range of 6-substituted analogs of 1 demonstrated a pos. correlation between potency (MIC90) toward M.tb and drug lipophilicity.  Contrary to this trend, we discovered, by virtue of a clogP/M.tb score, that a 6-cyano (CN) substituent provides a substantial redn. in lipophilicity with only modest effects on MIC values, suggesting this substituent as a useful tool in the search for effective and safer analogs of 1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh633c0HlHiLVg90H21EOLACvtfcHk0lgyntzsV_7U3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFCis7vN&md5=f7314475257a0b3a8bfe89cc0095b0ea</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00196%26sid%3Dliteratum%253Aachs%26aulast%3DTong%26aufirst%3DA.%2BS.%2BT.%26aulast%3DChoi%26aufirst%3DP.%2BJ.%26aulast%3DBlaser%26aufirst%3DA.%26aulast%3DSutherland%26aufirst%3DH.%2BS.%26aulast%3DTsang%26aufirst%3DS.%2BK.%2BY.%26aulast%3DGuillemont%26aufirst%3DJ.%26aulast%3DMotte%26aufirst%3DM.%26aulast%3DCooper%26aufirst%3DC.%2BB.%26aulast%3DAndries%26aufirst%3DK.%26aulast%3DVan%2Bden%2BBroeck%26aufirst%3DW.%26aulast%3DFranzblau%26aufirst%3DS.%2BG.%26aulast%3DUpton%26aufirst%3DA.%2BM.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DPalmer%26aufirst%3DB.%2BD.%26aulast%3DConole%26aufirst%3DD.%26atitle%3D6-cyano%2520analogues%2520of%2520bedaquiline%2520as%2520less%2520lipophilic%2520and%2520potentially%2520safer%2520diarylquinolines%2520for%2520tuberculosis%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D1019%26epage%3D1024%26doi%3D10.1021%2Facsmedchemlett.7b00196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guglielmetti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Du, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jachym, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caumes, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veziris, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metivier, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrejak, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brossier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chadelat, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dautzenberg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarlier, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raskine, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivoire, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veziris, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appere, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assouline, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borie, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boukari, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caseris, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caumes, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douadi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumoulin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duval, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faucher, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallien, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Grusse, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meynard, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naccache, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philippe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richaud, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saad, H.</span></span> <span> </span><span class="NLM_article-title">Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: Interim analysis of a french cohort</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">188</span>– <span class="NLM_lpage">194</span>, <span class="refDoi"> DOI: 10.1093/cid/ciu786</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1093%2Fcid%2Fciu786" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=25320286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFWlsb%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2015&pages=188-194&author=L.+Guglielmettiauthor=D.+Le+Duauthor=M.+Jachymauthor=B.+Henryauthor=D.+Martinauthor=E.+Caumesauthor=N.+Vezirisauthor=N.+Metivierauthor=J.+Robertauthor=C.+Andrejakauthor=C.+Bernardauthor=F.+Brossierauthor=K.+Chadelatauthor=B.+Dautzenbergauthor=V.+Jarlierauthor=L.+Raskineauthor=B.+Rivoireauthor=N.+Vezirisauthor=C.+Appereauthor=P.+Assoulineauthor=R.+Borieauthor=L.+Boukariauthor=M.+Caserisauthor=E.+Caumesauthor=Y.+Douadiauthor=J.+Dumoulinauthor=C.+Duvalauthor=J.+F.+Faucherauthor=S.+Gallienauthor=C.+Godetauthor=J.+Le+Grusseauthor=A.+Lopesauthor=J.+L.+Meynardauthor=J.+M.+Naccacheauthor=B.+Philippeauthor=C.+Richaudauthor=H.+Saad&title=Compassionate+use+of+bedaquiline+for+the+treatment+of+multidrug-resistant+and+extensively+drug-resistant+tuberculosis%3A+Interim+analysis+of+a+french+cohort&doi=10.1093%2Fcid%2Fciu786"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a french cohort</span></div><div class="casAuthors">Guglielmetti, Lorenzo; Le Du, Damien; Jachym, Mathilde; Henry, Benoit; Martin, Diane; Caumes, Eric; Veziris, Nicolas; Metivier, Nathalie; Robert, Jerome</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Infectious Diseases</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">188-194</span>CODEN:
                <span class="NLM_cas:coden">CIDIEL</span>;
        ISSN:<span class="NLM_cas:issn">1058-4838</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background.  Bedaquiline is a new antibiotic that was approved for the treatment of multidrug-resistant (MDR) tuberculosis.  We aimed to evaluate the short-term microbiol. efficacy and the tolerability profile of bedaquiline.  Methods.  We performed a retrospective cohort study among patients with MDR tuberculosis receiving bedaquiline for compassionate use between Jan. 2010 and July 2013 and evaluated at 6 mo of bedaquiline treatment.  Results.  A total of 35 patients with MDR tuberculosis were included in the study.  Nineteen (54%) had extensively drug-resistant (XDR) tuberculosis, and 14 (40%) had isolates resistant to fluoroquinolones (Fqs) or second-line injectables.  Bedaquiline was assocd. with a median of 4 (range, 2-5) other drugs, including linezolid in 33 (94%) cases.  At 6 mo of bedaquiline treatment, culture conversion was achieved in 28 of 29 (97%) cases with culture-pos. pulmonary tuberculosis at bedaquiline initiation.  Median time to culture conversion was 85 days (range, 8-235 days).  Variables independently assocd. with culture conversion were treatment with a Fq (P = .01), absence of lung cavities (P < .001), and absence of hepatitis C virus infection (P = .001).  A total of 7 patients (20%) experienced a ≥60-ms increase in QT interval, leading to bedaquiline discontinuation in 2 (6%) cases.  Severe liver enzyme elevation occurred in 2 patients (6%).  During the study period, 1 death (3%) occurred and was reported as unrelated to tuberculosis or antituberculosis treatment.  Conclusions.  The use of bedaquiline combined with other active drugs has the potential to achieve high culture conversion rates in complicated MDR and XDR tuberculosis cases, with a reassuring safety profile at 6 mo of treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqO-sBVN1eNCrVg90H21EOLACvtfcHk0lhJCadbNFQH4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFWlsb%252FM&md5=a058d6dae325811594f9090c064b07dd</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1093%2Fcid%2Fciu786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcid%252Fciu786%26sid%3Dliteratum%253Aachs%26aulast%3DGuglielmetti%26aufirst%3DL.%26aulast%3DLe%2BDu%26aufirst%3DD.%26aulast%3DJachym%26aufirst%3DM.%26aulast%3DHenry%26aufirst%3DB.%26aulast%3DMartin%26aufirst%3DD.%26aulast%3DCaumes%26aufirst%3DE.%26aulast%3DVeziris%26aufirst%3DN.%26aulast%3DMetivier%26aufirst%3DN.%26aulast%3DRobert%26aufirst%3DJ.%26aulast%3DAndrejak%26aufirst%3DC.%26aulast%3DBernard%26aufirst%3DC.%26aulast%3DBrossier%26aufirst%3DF.%26aulast%3DChadelat%26aufirst%3DK.%26aulast%3DDautzenberg%26aufirst%3DB.%26aulast%3DJarlier%26aufirst%3DV.%26aulast%3DRaskine%26aufirst%3DL.%26aulast%3DRivoire%26aufirst%3DB.%26aulast%3DVeziris%26aufirst%3DN.%26aulast%3DAppere%26aufirst%3DC.%26aulast%3DAssouline%26aufirst%3DP.%26aulast%3DBorie%26aufirst%3DR.%26aulast%3DBoukari%26aufirst%3DL.%26aulast%3DCaseris%26aufirst%3DM.%26aulast%3DCaumes%26aufirst%3DE.%26aulast%3DDouadi%26aufirst%3DY.%26aulast%3DDumoulin%26aufirst%3DJ.%26aulast%3DDuval%26aufirst%3DC.%26aulast%3DFaucher%26aufirst%3DJ.%2BF.%26aulast%3DGallien%26aufirst%3DS.%26aulast%3DGodet%26aufirst%3DC.%26aulast%3DLe%2BGrusse%26aufirst%3DJ.%26aulast%3DLopes%26aufirst%3DA.%26aulast%3DMeynard%26aufirst%3DJ.%2BL.%26aulast%3DNaccache%26aufirst%3DJ.%2BM.%26aulast%3DPhilippe%26aufirst%3DB.%26aulast%3DRichaud%26aufirst%3DC.%26aulast%3DSaad%26aufirst%3DH.%26atitle%3DCompassionate%2520use%2520of%2520bedaquiline%2520for%2520the%2520treatment%2520of%2520multidrug-resistant%2520and%2520extensively%2520drug-resistant%2520tuberculosis%253A%2520Interim%2520analysis%2520of%2520a%2520french%2520cohort%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2015%26volume%3D60%26spage%3D188%26epage%3D194%26doi%3D10.1093%2Fcid%2Fciu786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Esposito, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianchini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasi, F.</span></span> <span> </span><span class="NLM_article-title">Bedaquiline and delamanid in tuberculosis</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">2319</span>– <span class="NLM_lpage">2330</span>, <span class="refDoi"> DOI: 10.1517/14656566.2015.1080240</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1517%2F14656566.2015.1080240" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=26293803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A280%3ADC%252BC287kvVCqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=2319-2330&author=S.+Espositoauthor=S.+Bianchiniauthor=F.+Blasi&title=Bedaquiline+and+delamanid+in+tuberculosis&doi=10.1517%2F14656566.2015.1080240"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Bedaquiline and delamanid in tuberculosis</span></div><div class="casAuthors">Esposito Susanna; Bianchini Sonia; Blasi Francesco</div><div class="citationInfo"><span class="NLM_cas:title">Expert opinion on pharmacotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2319-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  In recent years, a pressing need to develop new, effective and safe drugs against tuberculosis (TB) has continued.  Poor adherence to a long therapeutic regimen against TB, intermittent drug use, errors in medical prescriptions, low quality of old TB drugs and ineffective TB control have led to the emergence of resistant TB.  AREAS COVERED:  Two new drugs have gained importance and seem promising against resistant TB: bedaquiline and delamanid.  This review summarizes the main characteristics of these two drugs and their role in TB management.  EXPERT OPINION:  Bedaquiline and delamanid appear to be promising new anti-TB drugs.  Due to a mechanism of action that is different from that of other available drugs, their efficacy has appeared optimal in cases of adults with resistant pulmonary TB.  Although their pharmacokinetic and pharmacodynamic profiles seem optimal, potential cardiologic side effects such as QT-interval prolongation have been associated with their use.  However, specific studies performed in the pediatric population are needed to confirm these results.  This seems particularly important considering the long duration of TB treatment required for resistant TB as well as the potential interactions with other drugs included in anti-TB regimens or administered for an underlying comorbidity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQx4lkJjTc-RUNoizSOkG_FfW6udTcc2eYr5uikPD1nVrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287kvVCqsA%253D%253D&md5=b0eed12fa6bc0ebfaf1b54e392faa662</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1517%2F14656566.2015.1080240&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2015.1080240%26sid%3Dliteratum%253Aachs%26aulast%3DEsposito%26aufirst%3DS.%26aulast%3DBianchini%26aufirst%3DS.%26aulast%3DBlasi%26aufirst%3DF.%26atitle%3DBedaquiline%2520and%2520delamanid%2520in%2520tuberculosis%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2015%26volume%3D16%26spage%3D2319%26epage%3D2330%26doi%3D10.1517%2F14656566.2015.1080240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stover, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warrener, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VanDevanter, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arain, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langhorne, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towell, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMurray, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreiswirth, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, W. R.</span></span> <span> </span><span class="NLM_article-title">A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>405</i></span>,  <span class="NLM_fpage">962</span>– <span class="NLM_lpage">966</span>, <span class="refDoi"> DOI: 10.1038/35016103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1038%2F35016103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10879539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD3cXks1Wksb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=405&publication_year=2000&pages=962-966&author=C.+K.+Stoverauthor=P.+Warrenerauthor=D.+R.+VanDevanterauthor=D.+R.+Shermanauthor=T.+M.+Arainauthor=M.+H.+Langhorneauthor=S.+W.+Andersonauthor=J.+A.+Towellauthor=Y.+Yuanauthor=D.+N.+McMurrayauthor=B.+N.+Kreiswirthauthor=C.+E.+Barryauthor=W.+R.+Baker&title=A+small-molecule+nitroimidazopyran+drug+candidate+for+the+treatment+of+tuberculosis&doi=10.1038%2F35016103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis</span></div><div class="casAuthors">Stover, C. Kendall; Warrener, Paul; VanDevanter, Donald R.; Sherman, David R.; Arain, Taraq M.; Langhorne, Michael H.; Anderson, Scott W.; Towell, J. Andrew; Yuan, Ying; McMurray, David N.; Krelswirth, Barry N.; Barry, Clifton E.; Baker, William R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">405</span>
        (<span class="NLM_cas:issue">6789</span>),
    <span class="NLM_cas:pages">962-966</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Mycobacterium tuberculosis, which causes tuberculosis, is the greatest single infectious cause of mortality worldwide, killing roughly; two million people annually.  Ests. indicate that one-third of the world population is infected with latent M. tuberculosis.  The synergy between tuberculosis and the AIDS epidemic, and the surge of multidrug-resistant clin. isolates of M. tuberculosis have reaffirmed tuberculosis as a primary public health threat.  However, new antitubercular drugs with new mechanisms of action have not been developed in over thirty years.  Here we report a series of compds. contg. a nitroimidazopyran nucleus that possess antitubercular activity.  After activation by a mechanism dependent on M. tuberculosis F420 cofactor, nitroimidazopyrans inhibited the synthesis of protein and cell wall lipid.  In contrast to current antitubercular drugs, nitroimidazopyrans exhibited bactericidal activity against both replicating and static M. tuberculosis.  Lead compd. PA-824 showed potent bactericidal activity against multidrug-resistant M. tuberculosis and promising oral activity in animal infection models.  We conclude that nitroimidazopyrans offer the practical qualities of a small mol. with the potential for the treatment of tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrw41eD4TtVwbVg90H21EOLACvtfcHk0lhJCadbNFQH4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXks1Wksb0%253D&md5=f5f6e2935928da72e328bddd4995515f</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2F35016103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35016103%26sid%3Dliteratum%253Aachs%26aulast%3DStover%26aufirst%3DC.%2BK.%26aulast%3DWarrener%26aufirst%3DP.%26aulast%3DVanDevanter%26aufirst%3DD.%2BR.%26aulast%3DSherman%26aufirst%3DD.%2BR.%26aulast%3DArain%26aufirst%3DT.%2BM.%26aulast%3DLanghorne%26aufirst%3DM.%2BH.%26aulast%3DAnderson%26aufirst%3DS.%2BW.%26aulast%3DTowell%26aufirst%3DJ.%2BA.%26aulast%3DYuan%26aufirst%3DY.%26aulast%3DMcMurray%26aufirst%3DD.%2BN.%26aulast%3DKreiswirth%26aufirst%3DB.%2BN.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26aulast%3DBaker%26aufirst%3DW.%2BR.%26atitle%3DA%2520small-molecule%2520nitroimidazopyran%2520drug%2520candidate%2520for%2520the%2520treatment%2520of%2520tuberculosis%26jtitle%3DNature%26date%3D2000%26volume%3D405%26spage%3D962%26epage%3D966%26doi%3D10.1038%2F35016103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span> <i>FDA
Approves New Treatment for Highly Drug-Resistant Forms of Tuberculosis</i>; <span class="NLM_publisher-name">TB Alliance</span>: <span class="NLM_publisher-loc">New
York</span>, <span class="NLM_year">2019</span>; <a href="https://www.tballiance.org/news/fda-approves-new-treatment-highly-drug-resistant-forms-tuberculosis" class="extLink">https://www.tballiance.org/news/fda-approves-new-treatment-highly-drug-resistant-forms-tuberculosis</a> (accessed Mar 3, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+FDA%0AApproves+New+Treatment+for+Highly+Drug-Resistant+Forms+of+Tuberculosis%3B+TB+Alliance%3A+New%0AYork%2C+2019%3B+https%3A%2F%2Fwww.tballiance.org%2Fnews%2Ffda-approves-new-treatment-highly-drug-resistant-forms-tuberculosis+%28accessed+Mar+3%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26jtitle%3DFDA%250AApproves%2520New%2520Treatment%2520for%2520Highly%2520Drug-Resistant%2520Forms%2520of%2520Tuberculosis%26pub%3DTB%2520Alliance%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zumla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nahid, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S. T.</span></span> <span> </span><span class="NLM_article-title">Advances in the development of new tuberculosis drugs and treatment regimens</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">388</span>– <span class="NLM_lpage">404</span>, <span class="refDoi"> DOI: 10.1038/nrd4001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1038%2Fnrd4001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=23629506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3sXms1Kmsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=388-404&author=A.+Zumlaauthor=P.+Nahidauthor=S.+T.+Cole&title=Advances+in+the+development+of+new+tuberculosis+drugs+and+treatment+regimens&doi=10.1038%2Fnrd4001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in the development of new tuberculosis drugs and treatment regimens</span></div><div class="casAuthors">Zumla, Alimuddin; Nahid, Payam; Cole, Stewart T.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">388-404</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the introduction 40 years ago of the inexpensive and effective four-drug (isoniazid, rifampicin, pyrazinamide and ethambutol) treatment regimen, tuberculosis (TB) continues to cause considerable morbidity and mortality worldwide.  For the first time since the 1960s, new and novel drugs and regimens for all forms of TB are emerging.  Such regimens are likely to utilize both repurposed drugs and new chem. entities, and several of these regimens are now progressing through clin. trials.  This article covers current concepts and recent advances in TB drug discovery and development, including an update of ongoing TB treatment trials, newer clin. trial designs, TB biomarkers and adjunct host-directed therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrs_a1A-oQwcrVg90H21EOLACvtfcHk0lgY0fI-OBxH8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXms1Kmsrk%253D&md5=fbf12f867a19ffff4d7fb74a98699682</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnrd4001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4001%26sid%3Dliteratum%253Aachs%26aulast%3DZumla%26aufirst%3DA.%26aulast%3DNahid%26aufirst%3DP.%26aulast%3DCole%26aufirst%3DS.%2BT.%26atitle%3DAdvances%2520in%2520the%2520development%2520of%2520new%2520tuberculosis%2520drugs%2520and%2520treatment%2520regimens%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D388%26epage%3D404%26doi%3D10.1038%2Fnrd4001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klopper, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gey van Pittius, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streicher, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirgel, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chabula-Nxiweni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoosain, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coetzee, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David van Helden, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Victor, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trollip, A. P.</span></span> <span> </span><span class="NLM_article-title">Emergence and spread of extensively and totally drug-resistant tuberculosis, South Africa</span>. <i>Emerging Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">449</span>– <span class="NLM_lpage">455</span>, <span class="refDoi"> DOI: 10.3201/eid1903.120246</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.3201%2Feid1903.120246" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=23622714" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A280%3ADC%252BC3srptFWmtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=449-455&author=M.+Klopperauthor=R.+M.+Warrenauthor=C.+Hayesauthor=N.+C.+Gey+van+Pittiusauthor=E.+M.+Streicherauthor=B.+M%C3%BCllerauthor=F.+A.+Sirgelauthor=M.+Chabula-Nxiweniauthor=E.+Hoosainauthor=G.+Coetzeeauthor=P.+David+van+Heldenauthor=T.+C.+Victorauthor=A.+P.+Trollip&title=Emergence+and+spread+of+extensively+and+totally+drug-resistant+tuberculosis%2C+South+Africa&doi=10.3201%2Feid1903.120246"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Emergence and spread of extensively and totally drug-resistant tuberculosis, South Africa</span></div><div class="casAuthors">Klopper Marisa; Warren Robin Mark; Hayes Cindy; Gey van Pittius Nicolaas Claudius; Streicher Elizabeth Maria; Muller Borna; Sirgel Frederick Adriaan; Chabula-Nxiweni Mamisa; Hoosain Ebrahim; Coetzee Gerrit; David van Helden Paul; Victor Thomas Calldo; Trollip Andre Phillip</div><div class="citationInfo"><span class="NLM_cas:title">Emerging infectious diseases</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">449-55</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Factors driving the increase in drug-resistant tuberculosis (TB) in the Eastern Cape Province, South Africa, are not understood.  A convenience sample of 309 drug-susceptible and 342 multidrug-resistant (MDR) TB isolates, collected July 2008-July 2009, were characterized by spoligotyping, DNA fingerprinting, insertion site mapping, and targeted DNA sequencing.  Analysis of molecular-based data showed diverse genetic backgrounds among drug-sensitive and MDR TB sensu stricto isolates in contrast to restricted genetic backgrounds among pre-extensively drug-resistant (pre-XDR) TB and XDR TB isolates.  Second-line drug resistance was significantly associated with the atypical Beijing genotype.  DNA fingerprinting and sequencing demonstrated that the pre-XDR and XDR atypical Beijing isolates evolved from a common progenitor; 85% and 92%, respectively, were clustered, indicating transmission.  Ninety-three percent of atypical XDR Beijing isolates had mutations that confer resistance to 10 anti-TB drugs, and some isolates also were resistant to para-aminosalicylic acid.  These findings suggest the emergence of totally drug-resistant TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQqLENfnM1xFLesJRIHUP1ofW6udTcc2ebZj0vi5N9sB7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3srptFWmtA%253D%253D&md5=92a85b3511db35661a99506c53ba5655</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.3201%2Feid1903.120246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3201%252Feid1903.120246%26sid%3Dliteratum%253Aachs%26aulast%3DKlopper%26aufirst%3DM.%26aulast%3DWarren%26aufirst%3DR.%2BM.%26aulast%3DHayes%26aufirst%3DC.%26aulast%3DGey%2Bvan%2BPittius%26aufirst%3DN.%2BC.%26aulast%3DStreicher%26aufirst%3DE.%2BM.%26aulast%3DM%25C3%25BCller%26aufirst%3DB.%26aulast%3DSirgel%26aufirst%3DF.%2BA.%26aulast%3DChabula-Nxiweni%26aufirst%3DM.%26aulast%3DHoosain%26aufirst%3DE.%26aulast%3DCoetzee%26aufirst%3DG.%26aulast%3DDavid%2Bvan%2BHelden%26aufirst%3DP.%26aulast%3DVictor%26aufirst%3DT.%2BC.%26aulast%3DTrollip%26aufirst%3DA.%2BP.%26atitle%3DEmergence%2520and%2520spread%2520of%2520extensively%2520and%2520totally%2520drug-resistant%2520tuberculosis%252C%2520South%2520Africa%26jtitle%3DEmerging%2520Infect.%2520Dis.%26date%3D2013%26volume%3D19%26spage%3D449%26epage%3D455%26doi%3D10.3201%2Feid1903.120246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Slomski, A.</span></span> <span> </span><span class="NLM_article-title">South Africa warns of emergence of ″totally″ drug-resistant tuberculosis</span>. <i>JAMA</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>309</i></span>,  <span class="NLM_fpage">1097</span>– <span class="NLM_lpage">1098</span>, <span class="refDoi"> DOI: 10.1001/jama.2013.1802</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1001%2Fjama.2013.1802" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=23512035" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltlOrtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=309&publication_year=2013&pages=1097-1098&author=A.+Slomski&title=South+Africa+warns+of+emergence+of+%E2%80%B3totally%E2%80%B3+drug-resistant+tuberculosis&doi=10.1001%2Fjama.2013.1802"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">South Africa warns of emergence of "totally' drug-resistant tuberculosis</span></div><div class="casAuthors">Slomski, Anita</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">309</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1097-1098</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">0098-7484</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyHpNQHGBVBLVg90H21EOLACvtfcHk0lgY0fI-OBxH8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltlOrtrk%253D&md5=5519cd62d449bfd52e9ac0c2f385bf35</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1001%2Fjama.2013.1802&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2013.1802%26sid%3Dliteratum%253Aachs%26aulast%3DSlomski%26aufirst%3DA.%26atitle%3DSouth%2520Africa%2520warns%2520of%2520emergence%2520of%2520%25E2%2580%25B3totally%25E2%2580%25B3%2520drug-resistant%2520tuberculosis%26jtitle%3DJAMA%26date%3D2013%26volume%3D309%26spage%3D1097%26epage%3D1098%26doi%3D10.1001%2Fjama.2013.1802" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span> <i>Latent Tuberculosis
Infection; Updated and Consolidated Guidelines
for Programmatic Management</i>; <span class="NLM_publisher-name">World Health
Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2018</span>; <a href="http://apps.who.int/iris/bitstream/10665/260233/1/9789241550239-eng.pdf" class="extLink">apps.who.int/iris/bitstream/10665/260233/1/9789241550239-eng.pdf</a> (accessed 2020-03-03).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Latent+Tuberculosis%0AInfection%3B+Updated+and+Consolidated+Guidelines%0Afor+Programmatic+Management%3B+World+Health%0AOrganization%3A+Geneva%2C+2018%3B+apps.who.int%2Firis%2Fbitstream%2F10665%2F260233%2F1%2F9789241550239-eng.pdf+%28accessed+2020-03-03%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26jtitle%3DLatent%2520Tuberculosis%250AInfection%253B%2520Updated%2520and%2520Consolidated%2520Guidelines%250Afor%2520Programmatic%2520Management%26pub%3DWorld%2520Health%250AOrganization%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yew, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barer, M. R.</span></span> <span> </span><span class="NLM_article-title">Targeting persisters for tuberculosis control</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">2223</span>– <span class="NLM_lpage">2230</span>, <span class="refDoi"> DOI: 10.1128/AAC.06288-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.06288-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=22391538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsVKktbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=2223-2230&author=Y.+Zhangauthor=W.+W.+Yewauthor=M.+R.+Barer&title=Targeting+persisters+for+tuberculosis+control&doi=10.1128%2FAAC.06288-11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting persisters for tuberculosis control</span></div><div class="casAuthors">Zhang, Ying; Yew, Wing Wai; Barer, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2223-2230</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">A review.  Mycobacterial persisters, the survivors from antibiotic exposure, necessitate the lengthy treatment of tuberculosis (TB) and pose a significant challenge for our control of the disease.  We suggest that persisters in TB are heterogeneous in nature and comprise various proportions of the population depending on the circumstances; the mechanisms of their formation are complex and may be related to those required for persistence in chronic infection.  Results from recent studies implicate multiple pathways for persister formation, including energy prodn., the stringent response, global regulators, the trans-translation pathway, proteasomal protein degrdn., toxin-antitoxin modules, and transporter or efflux mechanisms.  A combination of specifically persister-targeted approaches, such as catching them when active and susceptible either by stimulating them to "wake up" or by intermittent drug dosing, the development of new drugs, the use of appropriate drug combinations, and combined chemotherapy and immunotherapy, may be needed for more effective elimination of persisters and better treatment of TB.  Variations in levels of persister formation and in host genetics can play a role in the outcome of clin. treatment, and thus, these may entail personalized treatment regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9GlERNHgMUrVg90H21EOLACvtfcHk0ljRGKVbMZ8YCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsVKktbc%253D&md5=5711a4cb75fab28f2781c27349b6ae7d</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1128%2FAAC.06288-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.06288-11%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DYew%26aufirst%3DW.%2BW.%26aulast%3DBarer%26aufirst%3DM.%2BR.%26atitle%3DTargeting%2520persisters%2520for%2520tuberculosis%2520control%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D2223%26epage%3D2230%26doi%3D10.1128%2FAAC.06288-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iacobino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piccaro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannoni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustazzolu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fattorini, L.</span></span> <span> </span><span class="NLM_article-title">Fighting tuberculosis by drugs targeting nonreplicating mycobacterium tuberculosis bacilli</span>. <i>Int. J. Mycobacteriol</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.4103/ijmy.ijmy_85_17</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.4103%2Fijmy.ijmy_85_17" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=28776518" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A280%3ADC%252BC1cfksVaitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2017&pages=213-221&author=A.+Iacobinoauthor=G.+Piccaroauthor=F.+Giannoniauthor=A.+Mustazzoluauthor=L.+Fattorini&title=Fighting+tuberculosis+by+drugs+targeting+nonreplicating+mycobacterium+tuberculosis+bacilli&doi=10.4103%2Fijmy.ijmy_85_17"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Fighting tuberculosis by drugs targeting nonreplicating Mycobacterium tuberculosis bacilli</span></div><div class="casAuthors">Iacobino Angelo; Giannoni Federico; Mustazzolu Alessandro; Fattorini Lanfranco; Piccaro Giovanni</div><div class="citationInfo"><span class="NLM_cas:title">International journal of mycobacteriology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">213-221</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Current tuberculosis (TB) treatment requires 6 months of combination therapy with isoniazid (INH), rifampin (RIF), pyrazinamide (PZA), and ethambutol for active TB and 9 months of INH or 3 months of rifapentine (RFP) + INH for latent TB.  The lungs of patients with active and latent TB contain heterogeneous mixtures of cellular and caseous granulomas harboring Mycobacterium tuberculosis bacilli ranging from actively replicating (AR) to nonreplicating (NR), phenotypically drug-resistant stages.  Several in vitro models to obtain NR cells were reported, including exposure to hypoxia, nutrient starvation, acid + nitric oxide, and stationary phase.  Overall, these models showed that RIF, RFP, PA-824 (PA), metronidazole (MZ), bedaquiline (BQ), and fluoroquinolones were the most active drugs against NR M. tuberculosis.  In hypoxia at pH 5.8, some combinations killed AR plus NR cells, as shown by lack of regrowth in liquid media, whereas in hypoxia at pH 7.3 (the pH of the caseum), only RIF and RFP efficiently killed NR bacilli while several other drugs showed little effect.  In conventional mouse models, combinations containing RFP, BQ, PA, PZA, moxifloxacin, sutezolid, linezolid, and clofazimine sterilized animals in ≤2 months, as shown by lack of viable bacilli in lung homogenates after 3 months without therapy.  Drugs were less effective in C3HeB/FeJ mice forming caseous granulomas.  Overall, in vitro observations and in vivo studies suggest that the search for new TB drugs could be addressed to low lipophilic molecules (e.g., new rpoB inhibitors with clogP < 3) killing NR M. tuberculosis in hypoxia at neutral pH and reaching high rates of unbound drug in the caseum.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS463w1DslAViM8MEzWGjS9fW6udTcc2eb_6beqXY36T7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cfksVaitg%253D%253D&md5=4f58e1e755973f7fb52c90b1fa13840f</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.4103%2Fijmy.ijmy_85_17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252Fijmy.ijmy_85_17%26sid%3Dliteratum%253Aachs%26aulast%3DIacobino%26aufirst%3DA.%26aulast%3DPiccaro%26aufirst%3DG.%26aulast%3DGiannoni%26aufirst%3DF.%26aulast%3DMustazzolu%26aufirst%3DA.%26aulast%3DFattorini%26aufirst%3DL.%26atitle%3DFighting%2520tuberculosis%2520by%2520drugs%2520targeting%2520nonreplicating%2520mycobacterium%2520tuberculosis%2520bacilli%26jtitle%3DInt.%2520J.%2520Mycobacteriol%26date%3D2017%26volume%3D6%26spage%3D213%26epage%3D221%26doi%3D10.4103%2Fijmy.ijmy_85_17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span> <i>Global Tuberculosis
Report 2017</i>; <span class="NLM_publisher-name">World Health
Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2017</span>; <a href="https://www.who.int/tb/publications/global_report/gtbr2017_main_text.pdf" class="extLink">https://www.who.int/tb/publications/global_report/gtbr2017_main_text.pdf</a> (accessed 2020-03-03).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Global+Tuberculosis%0AReport+2017%3B+World+Health%0AOrganization%3A+Geneva%2C+2017%3B+https%3A%2F%2Fwww.who.int%2Ftb%2Fpublications%2Fglobal_report%2Fgtbr2017_main_text.pdf+%28accessed+2020-03-03%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26jtitle%3DGlobal%2520Tuberculosis%250AReport%25202017%26pub%3DWorld%2520Health%250AOrganization%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span> <i>Global Ministerial Conference
On Ending TB In The Sustainable Development
Era</i>; <span class="NLM_publisher-name">World Health Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2017</span>; <a href="http://www.who.int/mediacentre/events/2017/ministerial-conference-tb/en/" class="extLink">http://www.who.int/mediacentre/events/2017/ministerial-conference-tb/en/</a> (accessed Mar 3, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Global+Ministerial+Conference%0AOn+Ending+TB+In+The+Sustainable+Development%0AEra%3B+World+Health+Organization%3A+Geneva%2C+2017%3B+http%3A%2F%2Fwww.who.int%2Fmediacentre%2Fevents%2F2017%2Fministerial-conference-tb%2Fen%2F+%28accessed+Mar+3%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26jtitle%3DGlobal%2520Ministerial%2520Conference%250AOn%2520Ending%2520TB%2520In%2520The%2520Sustainable%2520Development%250AEra%26pub%3DWorld%2520Health%2520Organization%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dooley, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nahid, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoelscher, M.</span></span> <span> </span><span class="NLM_article-title">Challenges in the clinical assessment of novel tuberculosis drugs</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">116</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1016/j.addr.2016.01.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.addr.2016.01.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=26827911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFSksbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2016&pages=116-122&author=K.+E.+Dooleyauthor=P.+P.+Phillipsauthor=P.+Nahidauthor=M.+Hoelscher&title=Challenges+in+the+clinical+assessment+of+novel+tuberculosis+drugs&doi=10.1016%2Fj.addr.2016.01.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Challenges in the clinical assessment of novel tuberculosis drugs</span></div><div class="casAuthors">Dooley, Kelly E.; Phillips, Patrick P. J.; Nahid, Payam; Hoelscher, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">116-122</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">To tackle the global TB epidemic effectively, novel treatment strategies are critically needed to shorten the duration of TB therapy and treat drug-resistant TB.  Drug development for TB, stymied for decades, has enjoyed a renaissance over the past several years.  However, the development of new TB regimens is hindered by the limitations in our understanding and use of preclin. models; the paucity of accurate, early surrogate markers of cure, and challenges in untangling the individual contributions of drugs to multidrug regimens in a complex, multi-compartment disease.  Lack of profit motive, advocacy, and imagination has contributed mightily to the dearth of drugs we have on the shelf to treat this ancient disease.  Areas that will speed the development of new regimens for TB include novel murine and in vitro pharmacodynamics models, clin. endpoints that are not culture-based, innovative clin. trial designs, and an infusion of much-needed funding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryOQVd0wsQeLVg90H21EOLACvtfcHk0ljRGKVbMZ8YCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFSksbo%253D&md5=8e0c6922ed115b64df7723c386556e87</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2016.01.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2016.01.014%26sid%3Dliteratum%253Aachs%26aulast%3DDooley%26aufirst%3DK.%2BE.%26aulast%3DPhillips%26aufirst%3DP.%2BP.%26aulast%3DNahid%26aufirst%3DP.%26aulast%3DHoelscher%26aufirst%3DM.%26atitle%3DChallenges%2520in%2520the%2520clinical%2520assessment%2520of%2520novel%2520tuberculosis%2520drugs%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2016%26volume%3D102%26spage%3D116%26epage%3D122%26doi%3D10.1016%2Fj.addr.2016.01.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manjunatha, U. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. W.</span></span> <span> </span><span class="NLM_article-title">Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">5087</span>– <span class="NLM_lpage">5097</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2014.12.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmc.2014.12.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=25577708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltVamtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=5087-5097&author=U.+H.+Manjunathaauthor=P.+W.+Smith&title=Perspective%3A+Challenges+and+opportunities+in+TB+drug+discovery+from+phenotypic+screening&doi=10.1016%2Fj.bmc.2014.12.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening</span></div><div class="casAuthors">Manjunatha, Ujjini H.; Smith, Paul W.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5087-5097</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Tuberculosis poses a major global health problem and multi-drug resistant strains are increasingly prevalent.  Hence there is an urgent need to discover new TB drugs.  Cell based phenotypic screening represents a powerful approach to identify anti-mycobacterial compds. and elucidate novel targets.  Three high throughput phenotypic screens were performed at NITD against mycobacterium.  Hits were identified and chem. series selected for optimization.  This produced compds. with good in vitro anti-mycobacterial activity and pharmacokinetic properties.  Some compds. displayed oral activity in mouse efficacy models of TB.  Herein, the authors review the TB discovery efforts at NITD and share experiences in optimization of phenotypic hits, describing challenges encountered and lessons learned.  The authors also offer perspectives to facilitate future selection and advancement of phenotypic hits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGbroyRLtEcrVg90H21EOLACvtfcHk0lj7oQNSc65qZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltVamtg%253D%253D&md5=8d03c078275a58fa6629eaa9f36a5073</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.12.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.12.031%26sid%3Dliteratum%253Aachs%26aulast%3DManjunatha%26aufirst%3DU.%2BH.%26aulast%3DSmith%26aufirst%3DP.%2BW.%26atitle%3DPerspective%253A%2520Challenges%2520and%2520opportunities%2520in%2520TB%2520drug%2520discovery%2520from%2520phenotypic%2520screening%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D5087%26epage%3D5097%26doi%3D10.1016%2Fj.bmc.2014.12.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behr, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowdy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dheda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Divangahi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehme, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginsberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaminathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spigelman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getahun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menzies, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raviglione, M.</span></span> <span> </span><span class="NLM_article-title">Tuberculosis</span>. <i>Nat. Rev. Dis. Primers</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">16076</span>, <span class="refDoi"> DOI: 10.1038/nrdp.2016.76</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1038%2Fnrdp.2016.76" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=27784885" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A280%3ADC%252BC2sngtVCgsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2016&pages=16076&author=M.+Paiauthor=M.+A.+Behrauthor=D.+Dowdyauthor=K.+Dhedaauthor=M.+Divangahiauthor=C.+C.+Boehmeauthor=A.+Ginsbergauthor=S.+Swaminathanauthor=M.+Spigelmanauthor=H.+Getahunauthor=D.+Menziesauthor=M.+Raviglione&title=Tuberculosis&doi=10.1038%2Fnrdp.2016.76"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Tuberculosis</span></div><div class="casAuthors">Pai Madhukar; Behr Marcel A; Divangahi Maziar; Menzies Dick; Pai Madhukar; Dowdy David; Dheda Keertan; Boehme Catharina C; Ginsberg Ann; Swaminathan Soumya; Spigelman Melvin; Getahun Haileyesus; Raviglione Mario</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Disease primers</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">16076</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Tuberculosis (TB) is an airborne infectious disease caused by organisms of the Mycobacterium tuberculosis complex.  Although primarily a pulmonary pathogen, M. tuberculosis can cause disease in almost any part of the body.  Infection with M. tuberculosis can evolve from containment in the host, in which the bacteria are isolated within granulomas (latent TB infection), to a contagious state, in which the patient will show symptoms that can include cough, fever, night sweats and weight loss.  Only active pulmonary TB is contagious.  In many low-income and middle-income countries, TB continues to be a major cause of morbidity and mortality, and drug-resistant TB is a major concern in many settings.  Although several new TB diagnostics have been developed, including rapid molecular tests, there is a need for simpler point-of-care tests.  Treatment usually requires a prolonged course of multiple antimicrobials, stimulating efforts to develop shorter drug regimens.  Although the Bacillus Calmette-Guerin (BCG) vaccine is used worldwide, mainly to prevent life-threatening TB in infants and young children, it has been ineffective in controlling the global TB epidemic.  Thus, efforts are underway to develop newer vaccines with improved efficacy.  New tools as well as improved programme implementation and financing are necessary to end the global TB epidemic by 2035.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRkhlsQg_ocTUPI-fCgwosgfW6udTcc2eZzJUi9v9QMfbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sngtVCgsw%253D%253D&md5=b2170e953514895635d3d13d8deefa24</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fnrdp.2016.76&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrdp.2016.76%26sid%3Dliteratum%253Aachs%26aulast%3DPai%26aufirst%3DM.%26aulast%3DBehr%26aufirst%3DM.%2BA.%26aulast%3DDowdy%26aufirst%3DD.%26aulast%3DDheda%26aufirst%3DK.%26aulast%3DDivangahi%26aufirst%3DM.%26aulast%3DBoehme%26aufirst%3DC.%2BC.%26aulast%3DGinsberg%26aufirst%3DA.%26aulast%3DSwaminathan%26aufirst%3DS.%26aulast%3DSpigelman%26aufirst%3DM.%26aulast%3DGetahun%26aufirst%3DH.%26aulast%3DMenzies%26aufirst%3DD.%26aulast%3DRaviglione%26aufirst%3DM.%26atitle%3DTuberculosis%26jtitle%3DNat.%2520Rev.%2520Dis.%2520Primers%26date%3D2016%26volume%3D2%26spage%3D16076%26doi%3D10.1038%2Fnrdp.2016.76" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wallis, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeurer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mwaba, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakaya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rustomjee, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Migliori, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Churchyard, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaminathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoelscher, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zumla, A.</span></span> <span> </span><span class="NLM_article-title">Tuberculosis--advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">e34</span>– <span class="NLM_lpage">46</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(16)00070-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2FS1473-3099%2816%2900070-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=27036358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28Xksl2htbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=e34-46&author=R.+S.+Wallisauthor=M.+Maeurerauthor=P.+Mwabaauthor=J.+Chakayaauthor=R.+Rustomjeeauthor=G.+B.+Miglioriauthor=B.+Maraisauthor=M.+Schitoauthor=G.+Churchyardauthor=S.+Swaminathanauthor=M.+Hoelscherauthor=A.+Zumla&title=Tuberculosis%2D%2Dadvances+in+development+of+new+drugs%2C+treatment+regimens%2C+host-directed+therapies%2C+and+biomarkers&doi=10.1016%2FS1473-3099%2816%2900070-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Tuberculosis-advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers</span></div><div class="casAuthors">Wallis, Robert S.; Maeurer, Markus; Mwaba, Peter; Chakaya, Jeremiah; Rustomjee, Roxana; Migliori, Giovanni Battista; Marais, Ben; Schito, Marco; Churchyard, Gavin; Swaminathan, Soumya; Hoelscher, Michael; Zumla, Alimuddin</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e34-e46</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Tuberculosis is the leading infectious cause of death worldwide, with 9·6 million cases and 1·5 million deaths reported in 2014.  WHO ests. 480 000 cases of these were multidrug resistant (MDR).  Less than half of patients who entered into treatment for MDR tuberculosis successfully completed that treatment, mainly due to high mortality and loss to follow-up.  These in turn illustrate weaknesses in current treatment regimens and national tuberculosis programs, coupled with operational treatment challenges.  In this Review we provide an update on recent developments in the tuberculosis drug-development pipeline (including new and repurposed antimicrobials and host-directed drugs) as they are applied to new regimens to shorten and improve outcomes of tuberculosis treatment.  Several new or repurposed antimicrobial drugs are in advanced trial stages for MDR tuberculosis, and two new antimicrobial drug candidates are in early-stage trials.  Several trials to reduce the duration of therapy in MDR and drug-susceptible tuberculosis are ongoing.  A wide range of candidate host-directed therapies are being developed to accelerate eradication of infection, prevent new drug resistance, and prevent permanent lung injury.  As these drugs have been approved for other clin. indications, they are now ready for repurposing for tuberculosis in phase 2 clin. trials.  We assess risks assocd. with evaluation of new treatment regimens, and highlight opportunities to advance tuberculosis research generally through regulatory innovation in MDR tuberculosis.  Progress in tuberculosis-specific biomarkers (including culture conversion, PET and CT imaging, and gene expression profiles) can support this innovation.  Several global initiatives now provide unique opportunities to tackle the tuberculosis epidemic through collaborative partnerships between high-income countries and middle-income and low-income countries for clin. trials training and research, allowing funders to coordinate several national and regional programs for greatest overall effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqW7RYOzuq_erVg90H21EOLACvtfcHk0lj7oQNSc65qZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xksl2htbk%253D&md5=601317865b3b3f4581e5b30c7a923c7f</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2816%2900070-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252816%252900070-0%26sid%3Dliteratum%253Aachs%26aulast%3DWallis%26aufirst%3DR.%2BS.%26aulast%3DMaeurer%26aufirst%3DM.%26aulast%3DMwaba%26aufirst%3DP.%26aulast%3DChakaya%26aufirst%3DJ.%26aulast%3DRustomjee%26aufirst%3DR.%26aulast%3DMigliori%26aufirst%3DG.%2BB.%26aulast%3DMarais%26aufirst%3DB.%26aulast%3DSchito%26aufirst%3DM.%26aulast%3DChurchyard%26aufirst%3DG.%26aulast%3DSwaminathan%26aufirst%3DS.%26aulast%3DHoelscher%26aufirst%3DM.%26aulast%3DZumla%26aufirst%3DA.%26atitle%3DTuberculosis--advances%2520in%2520development%2520of%2520new%2520drugs%252C%2520treatment%2520regimens%252C%2520host-directed%2520therapies%252C%2520and%2520biomarkers%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2016%26volume%3D16%26spage%3De34%26epage%3D46%26doi%3D10.1016%2FS1473-3099%2816%2900070-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bloemberg, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stucki, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trauner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borrell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latshang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coscolla, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hömke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulthess, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagneux, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Böttger, E. C.</span></span> <span> </span><span class="NLM_article-title">Acquired resistance to bedaquiline and delamanid in therapy for tuberculosis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>373</i></span>,  <span class="NLM_fpage">1986</span>– <span class="NLM_lpage">1988</span>, <span class="refDoi"> DOI: 10.1056/NEJMc1505196</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1056%2FNEJMc1505196" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=26559594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A280%3ADC%252BC28vhsFShsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=1986-1988&author=G.+V.+Bloembergauthor=P.+M.+Kellerauthor=D.+Stuckiauthor=A.+Traunerauthor=S.+Borrellauthor=T.+Latshangauthor=M.+Coscollaauthor=T.+Rotheauthor=R.+H%C3%B6mkeauthor=C.+Ritterauthor=J.+Feldmannauthor=B.+Schulthessauthor=S.+Gagneuxauthor=E.+C.+B%C3%B6ttger&title=Acquired+resistance+to+bedaquiline+and+delamanid+in+therapy+for+tuberculosis&doi=10.1056%2FNEJMc1505196"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis</span></div><div class="casAuthors">Bloemberg Guido V; Keller Peter M; Stucki David; Stuckia David; Trauner Andrej; Borrell Sonia; Latshang Tsogyal; Coscolla Mireia; Rothe Thomas; Homke Rico; Ritter Claudia; Feldmann Julia; Schulthess Bettina; Gagneux Sebastien; Bottger Erik C</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1986-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Treatment of multidrug-resistant Mycobacterium tuberculosis is a challenge.  This letter describes the emergence of resistance to new therapies, bedaquiline and delamanid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTLIDv4u6-jfsuCWE5mhx1RfW6udTcc2eaaGJ6-h8hf9Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28vhsFShsQ%253D%253D&md5=24a5c9caaa21e592d780445e59bda863</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1056%2FNEJMc1505196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMc1505196%26sid%3Dliteratum%253Aachs%26aulast%3DBloemberg%26aufirst%3DG.%2BV.%26aulast%3DKeller%26aufirst%3DP.%2BM.%26aulast%3DStucki%26aufirst%3DD.%26aulast%3DTrauner%26aufirst%3DA.%26aulast%3DBorrell%26aufirst%3DS.%26aulast%3DLatshang%26aufirst%3DT.%26aulast%3DCoscolla%26aufirst%3DM.%26aulast%3DRothe%26aufirst%3DT.%26aulast%3DH%25C3%25B6mke%26aufirst%3DR.%26aulast%3DRitter%26aufirst%3DC.%26aulast%3DFeldmann%26aufirst%3DJ.%26aulast%3DSchulthess%26aufirst%3DB.%26aulast%3DGagneux%26aufirst%3DS.%26aulast%3DB%25C3%25B6ttger%26aufirst%3DE.%2BC.%26atitle%3DAcquired%2520resistance%2520to%2520bedaquiline%2520and%2520delamanid%2520in%2520therapy%2520for%2520tuberculosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26spage%3D1986%26epage%3D1988%26doi%3D10.1056%2FNEJMc1505196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Segala, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sougakoff, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nevejans-Chauffour, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarlier, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrella, S.</span></span> <span> </span><span class="NLM_article-title">New mutations in the mycobacterial atp synthase: New insights into the binding of the diarylquinoline TMC207 to the atp synthase c-ring structure</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">2326</span>– <span class="NLM_lpage">2334</span>, <span class="refDoi"> DOI: 10.1128/AAC.06154-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.06154-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=22354303" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsVKku7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=2326-2334&author=E.+Segalaauthor=W.+Sougakoffauthor=A.+Nevejans-Chauffourauthor=V.+Jarlierauthor=S.+Petrella&title=New+mutations+in+the+mycobacterial+atp+synthase%3A+New+insights+into+the+binding+of+the+diarylquinoline+TMC207+to+the+atp+synthase+c-ring+structure&doi=10.1128%2FAAC.06154-11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">New mutations in the mycobacterial ATP synthase: new insights into the binding of the diarylquinoline TMC207 to the ATP synthase C-ring structure</span></div><div class="casAuthors">Segala, Elena; Sougakoff, Wladimir; Nevejans-Chauffour, Aurelie; Jarlier, Vincent; Petrella, Stephanie</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2326-2334</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">TMC207 is a new antituberculous drug belonging to the diarylquinoline class which very efficiently inhibits the ATP synthase of mycobacteria such as Mycobacterium tuberculosis, one of the most important pathogens in the world.  In order to map the amino acid residues involved in the binding of the drug, we have selected in vitro TMC207-resistant mutants from M. tuberculosis and diverse atypical mycobacteria.  Six distinct mutations, Asp28→Gly, Asp28→Ala, Leu59→Val, Glu61→Asp, Ala63→Pro, and Ile66→Met, have been identified in the subunit c forming a C ring in the ATP synthase.  They were studied by evaluating the levels of resistance that they confer in the selected clones and by using an isogenic complementation system in Mycobacterium smegmatis.  The rates of increase of TMC207 MIC values (8- to 133-fold) were interpreted by constructing by homol. modeling a structure of the mycobacterial C ring which was used for docking simulations with TMC207.  Our results suggest that the residues found to be mutated in the resistant clones, together with a tyrosine specifically conserved at position 64 in mycobacteria, define a cleft located between two adjacent c subunits in the C ring.  This cleft, which encompasses the proton-binding site (Glu61), is well fitted to bind TMC207 at the level of the bromoquinoline moiety, with the drug being anchored by several ionic, hydrogen, and halogen bonds with residues Glu61, Tyr64, and Asp28, resp.  These data shed light on the mol. interactions allowing TMC207 to bind specifically and efficiently at the level of the proton-binding site of the mycobacterial C ring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQYj2k1m5D_7Vg90H21EOLACvtfcHk0ljMD1HKVg7_xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsVKku7o%253D&md5=0496b56930586279c2896a3ba375535f</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1128%2FAAC.06154-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.06154-11%26sid%3Dliteratum%253Aachs%26aulast%3DSegala%26aufirst%3DE.%26aulast%3DSougakoff%26aufirst%3DW.%26aulast%3DNevejans-Chauffour%26aufirst%3DA.%26aulast%3DJarlier%26aufirst%3DV.%26aulast%3DPetrella%26aufirst%3DS.%26atitle%3DNew%2520mutations%2520in%2520the%2520mycobacterial%2520atp%2520synthase%253A%2520New%2520insights%2520into%2520the%2520binding%2520of%2520the%2520diarylquinoline%2520TMC207%2520to%2520the%2520atp%2520synthase%2520c-ring%2520structure%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D2326%26epage%3D2334%26doi%3D10.1128%2FAAC.06154-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yew, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Mycobacterium tuberculosis mutations associated with reduced susceptibility to linezolid</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2542</span>– <span class="NLM_lpage">2544</span>, <span class="refDoi"> DOI: 10.1128/AAC.02941-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.02941-15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=26810645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1egtrvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2016&pages=2542-2544&author=S.+Zhangauthor=J.+Chenauthor=P.+Cuiauthor=W.+Shiauthor=X.+Shiauthor=H.+Niuauthor=D.+Chanauthor=W.+W.+Yewauthor=W.+Zhangauthor=Y.+Zhang&title=Mycobacterium+tuberculosis+mutations+associated+with+reduced+susceptibility+to+linezolid&doi=10.1128%2FAAC.02941-15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Mycobacterium tuberculosis mutations associated with reduced susceptibility to linezolid</span></div><div class="casAuthors">Zhang, Shuo; Chen, Jiazhen; Cui, Peng; Shi, Wanliang; Shi, Xiaohong; Niu, Hongxia; Chan, Denise; Yew, Wing Wai; Zhang, Wenhong; Zhang, Ying</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2542-2544</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Linezolid (LZD) has become increasingly important for the treatment of multidrug-resistant tuberculosis (MDR-TB), but its mechanisms of resistance are not well characterized.  We isolated 32 mutants of Mycobacterium tuberculosis with reduced susceptibility to LZD, which was accounted for by rrl and rplC mutations in almost equal proportions, causing lower and higher MICs, resp.  Our findings provide useful information for the rapid detection of LZD resistance for improved treatment of MDR-TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNlEoDGkb4t7Vg90H21EOLACvtfcHk0ljMD1HKVg7_xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1egtrvI&md5=c9c5155d3af6086adb2d915a7a15f993</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1128%2FAAC.02941-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02941-15%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DCui%26aufirst%3DP.%26aulast%3DShi%26aufirst%3DW.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DNiu%26aufirst%3DH.%26aulast%3DChan%26aufirst%3DD.%26aulast%3DYew%26aufirst%3DW.%2BW.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DMycobacterium%2520tuberculosis%2520mutations%2520associated%2520with%2520reduced%2520susceptibility%2520to%2520linezolid%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2016%26volume%3D60%26spage%3D2542%26epage%3D2544%26doi%3D10.1128%2FAAC.02941-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mukherjee, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boshoff, H.</span></span> <span> </span><span class="NLM_article-title">Nitroimidazoles for the treatment of TB: Past, present and future</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1427</span>– <span class="NLM_lpage">1454</span>, <span class="refDoi"> DOI: 10.4155/fmc.11.90</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.4155%2Ffmc.11.90" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=21879846" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFSktr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=1427-1454&author=T.+Mukherjeeauthor=H.+Boshoff&title=Nitroimidazoles+for+the+treatment+of+TB%3A+Past%2C+present+and+future&doi=10.4155%2Ffmc.11.90"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Nitroimidazoles for the treatment of TB: past, present and future</span></div><div class="casAuthors">Mukherjee, Tathagata; Boshoff, Helena</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1427-1454</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Tuberculosis remains a leading cause of death resulting from an infectious agent, and the spread of multi- and extensively drug-resistant strains of Mycobacterium tuberculosis poses a threat to management of global health.  New drugs that effectively shorten the duration of treatment and are active against drug-resistant strains of this pathogen are urgently required to develop effective chemotherapies to combat this disease.  Two nitroimidazoles, PA-824 and OPC-67683, are currently in Phase II clin. trials for the treatment of TB and the outcome of these may det. the future directions of drug development for anti-tubercular nitroimidazoles.  In this review we summarize the development of these nitroimidazoles and alternative analogs in these series that may offer attractive alternatives to PA-824 and OPC-67683 for further development in the drug-discovery pipeline.  Lastly, the potential pitfalls in the development of nitroimidazoles as drugs for TB are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8GQsibDorcLVg90H21EOLACvtfcHk0ljtu2L6MjVPhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFSktr%252FN&md5=44739c4906d7b9e1ffeaa76f65acb16c</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.4155%2Ffmc.11.90&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.11.90%26sid%3Dliteratum%253Aachs%26aulast%3DMukherjee%26aufirst%3DT.%26aulast%3DBoshoff%26aufirst%3DH.%26atitle%3DNitroimidazoles%2520for%2520the%2520treatment%2520of%2520TB%253A%2520Past%252C%2520present%2520and%2520future%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2011%26volume%3D3%26spage%3D1427%26epage%3D1454%26doi%3D10.4155%2Ffmc.11.90" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherland, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kmentova, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franzblau, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denny, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A. M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure-activity relationships for extended side chain analogues of the antitubercular drug (6s)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5h-imidazo[2,1-b][1, 3]oxazine (pa-824)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">3036</span>– <span class="NLM_lpage">3059</span>, <span class="refDoi"> DOI: 10.1021/jm501608q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501608q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksVOrtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3036-3059&author=B.+D.+Palmerauthor=H.+S.+Sutherlandauthor=A.+Blaserauthor=I.+Kmentovaauthor=S.+G.+Franzblauauthor=B.+Wanauthor=Y.+Wangauthor=Z.+Maauthor=W.+A.+Dennyauthor=A.+M.+Thompson&title=Synthesis+and+structure-activity+relationships+for+extended+side+chain+analogues+of+the+antitubercular+drug+%286s%29-2-nitro-6-%7B%5B4-%28trifluoromethoxy%29benzyl%5Doxy%7D-6%2C7-dihydro-5h-imidazo%5B2%2C1-b%5D%5B1%2C+3%5Doxazine+%28pa-824%29&doi=10.1021%2Fjm501608q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Structure-Activity Relationships for Extended Side Chain Analogues of the Antitubercular Drug (6S)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)</span></div><div class="casAuthors">Palmer, Brian D.; Sutherland, Hamish S.; Blaser, Adrian; Kmentova, Iveta; Franzblau, Scott G.; Wan, Baojie; Wang, Yuehong; Ma, Zhenkun; Denny, William A.; Thompson, Andrew M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3036-3059</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel extended side chain nitroimidazooxazine analogs featuring diverse linker groups between two aryl rings, e.g., I, were studied as a potential strategy to improve soly. and oral activity against chronic infection by Mycobacterium tuberculosis.  Both lipophilic and highly polar functionalities (e.g., carboxamide, alkylamine, piperazine, piperidine, but not sulfonamide) were well tolerated in vitro, and the hydrophilic linkers provided some soly. improvements, particularly in combination with pyridine rings.  Most of the 18 compds. further assessed showed high microsomal stabilities, although in the acute infection mouse model, just one stilbene (6-fold) and two pyridine-contg. acetylene derivs. (5-fold and >933-fold) gave in vivo efficacies notably superior to the clin. stage compd. pretomanid (PA-824).  The most efficacious analog, I, also displayed outstanding in vivo activity in the stringent chronic model (up to 24-fold better than the drug delamanid and 4-fold greater than our previous best phenylpyridine candidate), with favorable pharmacokinetics, including good oral bioavailability in the rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRBPDGOUW_AbVg90H21EOLACvtfcHk0ljtu2L6MjVPhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksVOrtrY%253D&md5=2ce7144ac56b5ec156d83a09d4d6af90</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fjm501608q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501608q%26sid%3Dliteratum%253Aachs%26aulast%3DPalmer%26aufirst%3DB.%2BD.%26aulast%3DSutherland%26aufirst%3DH.%2BS.%26aulast%3DBlaser%26aufirst%3DA.%26aulast%3DKmentova%26aufirst%3DI.%26aulast%3DFranzblau%26aufirst%3DS.%2BG.%26aulast%3DWan%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DZ.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DThompson%26aufirst%3DA.%2BM.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationships%2520for%2520extended%2520side%2520chain%2520analogues%2520of%2520the%2520antitubercular%2520drug%2520%25286s%2529-2-nitro-6-%257B%255B4-%2528trifluoromethoxy%2529benzyl%255Doxy%257D-6%252C7-dihydro-5h-imidazo%255B2%252C1-b%255D%255B1%252C%25203%255Doxazine%2520%2528pa-824%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D3036%26epage%3D3059%26doi%3D10.1021%2Fjm501608q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stinson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurepina, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujiwara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawasaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timm, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shashkina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreiswirth, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geiter, L.</span></span> <span> </span><span class="NLM_article-title">MIC of delamanid (OPC-67683) against mycobacterium tuberculosis clinical isolates and a proposed critical concentration</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">3316</span>– <span class="NLM_lpage">3322</span>, <span class="refDoi"> DOI: 10.1128/AAC.03014-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.03014-15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=26976868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1entrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2016&pages=3316-3322&author=K.+Stinsonauthor=N.+Kurepinaauthor=A.+Venterauthor=M.+Fujiwaraauthor=M.+Kawasakiauthor=J.+Timmauthor=E.+Shashkinaauthor=B.+N.+Kreiswirthauthor=Y.+Liuauthor=M.+Matsumotoauthor=L.+Geiter&title=MIC+of+delamanid+%28OPC-67683%29+against+mycobacterium+tuberculosis+clinical+isolates+and+a+proposed+critical+concentration&doi=10.1128%2FAAC.03014-15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">MIC of delamanid (OPC-67683) against Mycobacterium tuberculosis clinical isolates and a proposed critical concentration</span></div><div class="casAuthors">Stinson, Kelly; Kurepina, Natalia; Venter, Amour; Fujiwara, Mamoru; Kawasaki, Masanori; Timm, Juliano; Shashkina, Elena; Kreiswirth, Barry N.; Liu, Yongge; Matsumoto, Makoto; Geiter, Lawrence</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3316-3322</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The increasing global burden of multidrug-resistant tuberculosis (MDR-TB) requires reliable drug susceptibility testing that accurately characterizes susceptibility and resistance of pathogenic bacteria to effectively treat patients with this deadly disease.  Delamanid is an anti-TB agent first approved in the European Union in 2014 for the treatment of pulmonary MDR-TB in adults.  Using the agar proportion method, delamanid MIC was detd. for 460 isolates: 316 from patients enrolled in a phase 2 global clin. trial, 76 from two phase 2 early bactericidal activity trials conducted in South Africa, and 68 isolates obtained outside clin. trials (45 from Japanese patients and 23 from South African patients).  With the exception of two isolates, MICs ranged from 0.001 to 0.05 μg/mL, resulting in an MIC50 of 0.004 μg/mL and an MIC90 of 0.012 μg/mL.  Various degrees of resistance to other anti-TB drugs did not affect the distribution of MICs, nor did origin of isolates from regions/countries other than South Africa.  A crit. concn./breakpoint of 0.2 μg/mL can be used to define susceptible and resistant isolates based on the distribution of MICs and available pharmacokinetic data.  Thus, clin. isolates from delamanid-naive patients with tuberculosis have a very low MIC for delamanid and baseline resistance is rare, demonstrating the potential potency of delamanid and supporting its use in an optimized background treatment regimen for MDR-TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGot2O44cdNSm7Vg90H21EOLACvtfcHk0ljtu2L6MjVPhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1entrrL&md5=9a69303ff8d63f8aa0e73c8dd5f068cb</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1128%2FAAC.03014-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.03014-15%26sid%3Dliteratum%253Aachs%26aulast%3DStinson%26aufirst%3DK.%26aulast%3DKurepina%26aufirst%3DN.%26aulast%3DVenter%26aufirst%3DA.%26aulast%3DFujiwara%26aufirst%3DM.%26aulast%3DKawasaki%26aufirst%3DM.%26aulast%3DTimm%26aufirst%3DJ.%26aulast%3DShashkina%26aufirst%3DE.%26aulast%3DKreiswirth%26aufirst%3DB.%2BN.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DMatsumoto%26aufirst%3DM.%26aulast%3DGeiter%26aufirst%3DL.%26atitle%3DMIC%2520of%2520delamanid%2520%2528OPC-67683%2529%2520against%2520mycobacterium%2520tuberculosis%2520clinical%2520isolates%2520and%2520a%2520proposed%2520critical%2520concentration%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2016%26volume%3D60%26spage%3D3316%26epage%3D3322%26doi%3D10.1128%2FAAC.03014-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lenaerts, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruppo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marietta, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driscoll, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tompkins, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, I. M.</span></span> <span> </span><span class="NLM_article-title">Preclinical testing of the nitroimidazopyran PA-824 for activity against mycobacterium tuberculosis in a series of in vitro and in vivo models</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">2294</span>– <span class="NLM_lpage">2301</span>, <span class="refDoi"> DOI: 10.1128/AAC.49.6.2294-2301.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.49.6.2294-2301.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=15917524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkvFCgsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2005&pages=2294-2301&author=A.+J.+Lenaertsauthor=V.+Gruppoauthor=K.+S.+Mariettaauthor=C.+M.+Johnsonauthor=D.+K.+Driscollauthor=N.+M.+Tompkinsauthor=J.+D.+Roseauthor=R.+C.+Reynoldsauthor=I.+M.+Orme&title=Preclinical+testing+of+the+nitroimidazopyran+PA-824+for+activity+against+mycobacterium+tuberculosis+in+a+series+of+in+vitro+and+in+vivo+models&doi=10.1128%2FAAC.49.6.2294-2301.2005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models</span></div><div class="casAuthors">Lenaerts, Anne J.; Gruppo, Veronica; Marietta, Karen S.; Johnson, Christine M.; Driscoll, Diane K.; Tompkins, Nicholas M.; Rose, Jerry D.; Reynolds, Robert C.; Orme, Ian M.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2294-2301</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">This study extends earlier reports regarding the in vitro and in vivo efficacies of the nitroimidazopyran PA-824 against M. tuberculosis.  PA-824 was tested in vitro against a broad panel of multidrug-resistant clin. isolates and was found to be highly active against all isolates (MIC <1 μg/mL).  The activity of PA-824 against M. tuberculosis was also assessed grown under conditions of O2 depletion.  PA-824 showed significant activity at 2, 10, and 50 μg/mL, similar to that of metronidazole, in a dose-dependent manner.  In a short-course mouse infection model, the efficacy of PA-824 at 50, 100, and 300 mg/kg of body wt. formulated in methylcellulose or cyclodextrin/lecithin after 9 oral treatments was compared with those of isoniazid, rifampin, and moxifloxacin.  PA-824 at 100 mg/kg in cyclodextrin/lecithin was as active as moxifloxacin at 100 mg/kg and isoniazid at 25 mg/kg and was slightly more active than rifampin at 20 mg/kg.  Long-term treatment with PA-824 at 100 mg/kg in cyclodextrin/lecithin reduced the bacterial load below 500 CFU in the lungs and spleen.  No significant differences in activity between PA-824 and the other single drug treatments tested (isoniazid at 25 mg/kg, rifampin at 10 mg/kg, gatifloxacin at 100 mg/kg, and moxifloxacin at 100 mg/kg) could be obsd.  In summary, its good activity in in vivo models, as well as its activity against multidrug-resistant M. tuberculosis and against M. tuberculosis isolates in a potentially latent state, makes PA-824 an attractive drug candidate for the therapy of tuberculosis.  These data indicate that there is significant potential for effective oral delivery of PA-824 for the treatment of tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm0IFHIxA0KrVg90H21EOLACvtfcHk0li4GPRuVp5tVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkvFCgsrw%253D&md5=69ac4231bc1270bee6203ee69e955e26</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1128%2FAAC.49.6.2294-2301.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.49.6.2294-2301.2005%26sid%3Dliteratum%253Aachs%26aulast%3DLenaerts%26aufirst%3DA.%2BJ.%26aulast%3DGruppo%26aufirst%3DV.%26aulast%3DMarietta%26aufirst%3DK.%2BS.%26aulast%3DJohnson%26aufirst%3DC.%2BM.%26aulast%3DDriscoll%26aufirst%3DD.%2BK.%26aulast%3DTompkins%26aufirst%3DN.%2BM.%26aulast%3DRose%26aufirst%3DJ.%2BD.%26aulast%3DReynolds%26aufirst%3DR.%2BC.%26aulast%3DOrme%26aufirst%3DI.%2BM.%26atitle%3DPreclinical%2520testing%2520of%2520the%2520nitroimidazopyran%2520PA-824%2520for%2520activity%2520against%2520mycobacterium%2520tuberculosis%2520in%2520a%2520series%2520of%2520in%2520vitro%2520and%2520in%2520vivo%2520models%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2005%26volume%3D49%26spage%3D2294%26epage%3D2301%26doi%3D10.1128%2FAAC.49.6.2294-2301.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashizume, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomishige, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawasaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsubouchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimokawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komatsu, M.</span></span> <span> </span><span class="NLM_article-title">OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice</span>. <i>PLoS Med.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">e466</span>, <span class="refDoi"> DOI: 10.1371/journal.pmed.0030466</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1371%2Fjournal.pmed.0030466" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=17132069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A280%3ADC%252BD28npsFKgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2006&pages=e466&author=M.+Matsumotoauthor=H.+Hashizumeauthor=T.+Tomishigeauthor=M.+Kawasakiauthor=H.+Tsubouchiauthor=H.+Sasakiauthor=Y.+Shimokawaauthor=M.+Komatsu&title=OPC-67683%2C+a+nitro-dihydro-imidazooxazole+derivative+with+promising+action+against+tuberculosis+in+vitro+and+in+mice&doi=10.1371%2Fjournal.pmed.0030466"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice</span></div><div class="casAuthors">Matsumoto Makoto; Hashizume Hiroyuki; Tomishige Tatsuo; Kawasaki Masanori; Tsubouchi Hidetsugu; Sasaki Hirofumi; Shimokawa Yoshihiko; Komatsu Makoto</div><div class="citationInfo"><span class="NLM_cas:title">PLoS medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e466</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Tuberculosis (TB) is still a leading cause of death worldwide.  Almost a third of the world's population is infected with TB bacilli, and each year approximately 8 million people develop active TB and 2 million die as a result.  Today's TB treatment, which dates back to the 1970s, is long and burdensome, requiring at least 6 mo of multidrug chemotherapy.  The situation is further compounded by the emergence of multidrug-resistant TB (MDR-TB) and by the infection's lethal synergy with HIV/AIDS.  Global health and philanthropic organizations are now pleading for new drug interventions that can address these unmet needs in TB treatment.  METHODS AND FINDINGS:  Here we report OPC-67683, a nitro-dihydro-imidazooxazole derivative that was screened to help combat the unmet needs in TB treatment.  The compound is a mycolic acid biosynthesis inhibitor found to be free of mutagenicity and to possess highly potent activity against TB, including MDR-TB, as shown by its exceptionally low minimum inhibitory concentration (MIC) range of 0.006-0.024 microg/ml in vitro and highly effective therapeutic activity at low doses in vivo.  Additionally, the results of the post-antibiotic effect of OPC-67683 on intracellular Mycobacterium tuberculosis showed the agent to be highly and dose-dependently active also against intracellular M. tuberculosis H37Rv after a 4-h pulsed exposure, and this activity at a concentration of 0.1 microg/ml was similar to that of the first-line drug rifampicin (RFP) at a concentration of 3 microg/ml.  The combination of OPC-67683 with RFP and pyrazinamide (PZA) exhibited a remarkably quicker eradication (by at least 2 mo) of viable TB bacilli in the lung in comparison with the standard regimen consisting of RFP, isoniazid (INH), ethambutol (EB), and PZA.  Furthermore, OPC-67683 was not affected by nor did it affect the activity of liver microsome enzymes, suggesting the possibility for OPC-67683 to be used in combination with drugs, including anti-retrovirals, that induce or are metabolized by cytochrome P450 enzymes.  CONCLUSIONS:  We concluded that based on these properties OPC-67683 has the potential to be used as a TB drug to help combat the unmet needs in TB treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRSF0z_BNLNYeRS7coPn-RtfW6udTcc2ebU9V5_9y9z6rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28npsFKgug%253D%253D&md5=8a80560cc653b1c76ff4d47430317d18</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pmed.0030466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pmed.0030466%26sid%3Dliteratum%253Aachs%26aulast%3DMatsumoto%26aufirst%3DM.%26aulast%3DHashizume%26aufirst%3DH.%26aulast%3DTomishige%26aufirst%3DT.%26aulast%3DKawasaki%26aufirst%3DM.%26aulast%3DTsubouchi%26aufirst%3DH.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DShimokawa%26aufirst%3DY.%26aulast%3DKomatsu%26aufirst%3DM.%26atitle%3DOPC-67683%252C%2520a%2520nitro-dihydro-imidazooxazole%2520derivative%2520with%2520promising%2520action%2520against%2520tuberculosis%2520in%2520vitro%2520and%2520in%2520mice%26jtitle%3DPLoS%2520Med.%26date%3D2006%26volume%3D3%26spage%3De466%26doi%3D10.1371%2Fjournal.pmed.0030466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diacon, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanekom, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narunsky, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hittel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geiter, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paccaly, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donald, P. R.</span></span> <span> </span><span class="NLM_article-title">Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients</span>. <i>Int. J. Tuberc Lung Dis</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">949</span>– <span class="NLM_lpage">954</span>, <span class="refDoi"> DOI: 10.5588/ijtld.10.0616</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.5588%2Fijtld.10.0616" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=21682970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A280%3ADC%252BC3Mnhs1KisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2011&pages=949-954&author=A.+H.+Diaconauthor=R.+Dawsonauthor=M.+Hanekomauthor=K.+Narunskyauthor=A.+Venterauthor=N.+Hittelauthor=L.+J.+Geiterauthor=C.+D.+Wellsauthor=A.+J.+Paccalyauthor=P.+R.+Donald&title=Early+bactericidal+activity+of+delamanid+%28OPC-67683%29+in+smear-positive+pulmonary+tuberculosis+patients&doi=10.5588%2Fijtld.10.0616"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients</span></div><div class="casAuthors">Diacon A H; Dawson R; Hanekom M; Narunsky K; Venter A; Hittel N; Geiter L J; Wells C D; Paccaly A J; Donald P R</div><div class="citationInfo"><span class="NLM_cas:title">The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">949-54</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Delamanid (OPC-67683) is a novel mycolic acid biosynthesis inhibitor active against Mycobacterium tuberculosis at a low minimum inhibitory concentration.  METHODS:  Forty-eight patients with smear-positive tuberculosis (63% male; 54.7 ± 9.9 kg; 30.7 ± 10.8 years) were randomly assigned to receive delamanid 100, 200, 300 or 400 mg daily for 14 days.  Colony forming units (cfu) of M. tuberculosis were counted on agar plates from overnight sputum collections to calculate early bactericidal activity (EBA), defined as fall in log(10) cfu/ml sputum/day.  RESULTS:  The EBA of delamanid was monophasic and not significantly different between dosages; however, more patients receiving 200 mg (70%) and 300 mg (80%) experienced a response of ≥0.9 log(10) cfu/ml sputum decline over 14 days than those receiving 100 mg (45%) and 400 mg (27%).  The average EBA of all dosages combined (0.040 ± 0.056 log(10) cfu/ml sputum/day) was significant from day 2 onward.  Delamanid exposure was less than dosage-proportional, reaching a plateau at 300 mg, likely due to dose-limited absorption.  Moderate but significant correlation was found between C(max) and EBA, indicating exposure dependence.  Delamanid was well tolerated without significant toxicity.  CONCLUSIONS:  Delamanid at all dosages was safe, well tolerated and demonstrated significant exposure-dependent EBA over 14 days, supporting further investigation of its pharmacokinetics and anti-tuberculosis activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRTDc03ThD2G0h5eUSa2oe_fW6udTcc2ebU9V5_9y9z6rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3Mnhs1KisQ%253D%253D&md5=63848ed5b6c4f8c5f089a0e257efc02b</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.5588%2Fijtld.10.0616&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5588%252Fijtld.10.0616%26sid%3Dliteratum%253Aachs%26aulast%3DDiacon%26aufirst%3DA.%2BH.%26aulast%3DDawson%26aufirst%3DR.%26aulast%3DHanekom%26aufirst%3DM.%26aulast%3DNarunsky%26aufirst%3DK.%26aulast%3DVenter%26aufirst%3DA.%26aulast%3DHittel%26aufirst%3DN.%26aulast%3DGeiter%26aufirst%3DL.%2BJ.%26aulast%3DWells%26aufirst%3DC.%2BD.%26aulast%3DPaccaly%26aufirst%3DA.%2BJ.%26aulast%3DDonald%26aufirst%3DP.%2BR.%26atitle%3DEarly%2520bactericidal%2520activity%2520of%2520delamanid%2520%2528OPC-67683%2529%2520in%2520smear-positive%2520pulmonary%2520tuberculosis%2520patients%26jtitle%3DInt.%2520J.%2520Tuberc%2520Lung%2520Dis%26date%3D2011%26volume%3D15%26spage%3D949%26epage%3D954%26doi%3D10.5588%2Fijtld.10.0616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gler, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skripconoka, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Garavito, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabrera-Rivero, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vargas-Vasquez, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shim, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, G. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danilovits, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogata, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurve, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tupasi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koh, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seaworth, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geiter, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C. D.</span></span> <span> </span><span class="NLM_article-title">Delamanid for multidrug-resistant pulmonary tuberculosis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>366</i></span>,  <span class="NLM_fpage">2151</span>– <span class="NLM_lpage">2160</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1112433</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1056%2FNEJMoa1112433" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=22670901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38XovVSisr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=2151-2160&author=M.+T.+Glerauthor=V.+Skripconokaauthor=E.+Sanchez-Garavitoauthor=H.+Xiaoauthor=J.+L.+Cabrera-Riveroauthor=D.+E.+Vargas-Vasquezauthor=M.+Gaoauthor=M.+Awadauthor=S.+K.+Parkauthor=T.+S.+Shimauthor=G.+Y.+Suhauthor=M.+Danilovitsauthor=H.+Ogataauthor=A.+Kurveauthor=J.+Changauthor=K.+Suzukiauthor=T.+Tupasiauthor=W.+J.+Kohauthor=B.+Seaworthauthor=L.+J.+Geiterauthor=C.+D.+Wells&title=Delamanid+for+multidrug-resistant+pulmonary+tuberculosis&doi=10.1056%2FNEJMoa1112433"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Delamanid for multidrug-resistant pulmonary tuberculosis</span></div><div class="casAuthors">Gler, Maria Tarcela; Skripconoka, Vija; Sanchez-Garavito, Epifanio; Xiao, Heping; Cabrera-Rivero, Jose L.; Vargas-Vasquez, Dante E.; Gao, Mengqiu; Awad, Mohamed; Park, Seung-Kyu; Shim, Tae Sun; Suh, Gee Young; Danilovits, Manfred; Ogata, Hideo; Kurve, Anu; Chang, Joon; Suzuki, Katsuhiro; Tupasi, Thelma; Koh, Won-Jung; Seaworth, Barbara; Geiter, Lawrence J.; Wells, Charles D.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2151-2160</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Delamanid (OPC-67683), a nitro-dihydro-imidazooxazole deriv., is a new antituberculosis medication that inhibits mycolic acid synthesis and has shown potent in vitro and in vivo activity against drug-resistant strains of Mycobacterium tuberculosis.  In this randomized, placebo-controlled, multinational clin. trial, we assigned 481 patients (nearly all of whom were neg. for the human immunodeficiency virus) with pulmonary multidrug-resistant tuberculosis to receive delamanid, at a dose of 100 mg twice daily (161 patients) or 200 mg twice daily (160 patients), or placebo (160 patients) for 2 mo in combination with a background drug regimen developed according to World Health Organization guidelines.  Sputum cultures were as- sessed weekly with the use of both liq. broth and solid medium; sputum-culture conversion was defined as a series of 5 or more consecutive cultures that were neg. for growth of M. tuberculosis.  The primary efficacy end point was the proportion of patients with sputum-culture conversion in liq. broth medium at 2 mo.  Among patients who received a background drug regimen plus 100 mg of delamanid twice daily, 45.40/% had sputum-culture conversion in liq. broth at 2 mo, as compared with 29.6% of patients who received a background drug regimen plus placebo (P = 0.008).  Likewise, as compared with the placebo group, the group that received the background drug regimen plus 200 mg of delamanid twice daily had a higher proportion of patients with sputum-culture conversion (41.9%, P = 0.04).  The findings were similar with assessment of sputum-culture conversion in solid medium.  Most adverse events were mild to moderate in severity and were evenly distributed across groups.  Although no clin. events due to QT prolongation on electrocardiog. were obsd., QT prolongation was reported significantly more frequently in the groups that received delamanid.  Delamanid was assocd. with an increase in sputum-culture conversion at 2 mo among patients with multidrug-resistant tuberculosis.  This finding suggests that delamanid could enhance treatment options for multidrug-resistant tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaZFfjOeFeQ7Vg90H21EOLACvtfcHk0lgrHXCynwqhyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovVSisr4%253D&md5=5a2edf0b004340d589d1bf047430f9bb</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1112433&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1112433%26sid%3Dliteratum%253Aachs%26aulast%3DGler%26aufirst%3DM.%2BT.%26aulast%3DSkripconoka%26aufirst%3DV.%26aulast%3DSanchez-Garavito%26aufirst%3DE.%26aulast%3DXiao%26aufirst%3DH.%26aulast%3DCabrera-Rivero%26aufirst%3DJ.%2BL.%26aulast%3DVargas-Vasquez%26aufirst%3DD.%2BE.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DAwad%26aufirst%3DM.%26aulast%3DPark%26aufirst%3DS.%2BK.%26aulast%3DShim%26aufirst%3DT.%2BS.%26aulast%3DSuh%26aufirst%3DG.%2BY.%26aulast%3DDanilovits%26aufirst%3DM.%26aulast%3DOgata%26aufirst%3DH.%26aulast%3DKurve%26aufirst%3DA.%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DSuzuki%26aufirst%3DK.%26aulast%3DTupasi%26aufirst%3DT.%26aulast%3DKoh%26aufirst%3DW.%2BJ.%26aulast%3DSeaworth%26aufirst%3DB.%26aulast%3DGeiter%26aufirst%3DL.%2BJ.%26aulast%3DWells%26aufirst%3DC.%2BD.%26atitle%3DDelamanid%2520for%2520multidrug-resistant%2520pulmonary%2520tuberculosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26spage%3D2151%26epage%3D2160%26doi%3D10.1056%2FNEJMoa1112433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skripconoka, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danilovits, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pehme, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skenders, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kummik, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirule, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leimane, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurve, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levina, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geiter, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manissero, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C. D.</span></span> <span> </span><span class="NLM_article-title">Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">1393</span>– <span class="NLM_lpage">1400</span>, <span class="refDoi"> DOI: 10.1183/09031936.00125812</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1183%2F09031936.00125812" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=23018916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A280%3ADC%252BC3s%252Fgsl2ltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2013&pages=1393-1400&author=V.+Skripconokaauthor=M.+Danilovitsauthor=L.+Pehmeauthor=T.+Tomsonauthor=G.+Skendersauthor=T.+Kummikauthor=A.+Ciruleauthor=V.+Leimaneauthor=A.+Kurveauthor=K.+Levinaauthor=L.+J.+Geiterauthor=D.+Manisseroauthor=C.+D.+Wells&title=Delamanid+improves+outcomes+and+reduces+mortality+in+multidrug-resistant+tuberculosis&doi=10.1183%2F09031936.00125812"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis</span></div><div class="casAuthors">Skripconoka Vija; Danilovits Manfred; Pehme Lea; Tomson Tarmo; Skenders Girts; Kummik Tiina; Cirule Andra; Leimane Vaira; Kurve Anu; Levina Klavdia; Geiter Lawrence J; Manissero Davide; Wells Charles D</div><div class="citationInfo"><span class="NLM_cas:title">The European respiratory journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1393-400</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Multidrug-resistant and extensively drug-resistant tuberculosis (TB) are associated with worse treatment outcomes for patients, including higher mortality, than for drug-sensitive tuberculosis.  Delamanid (OPC-67683) is a novel anti-TB medication with demonstrated activity against multidrug-resistant disease.  Patients who participated in the previously reported randomised, placebo-controlled trial of delamanid and the subsequent open-label extension trial were eligible to participate in a 24-month observational study designed to capture treatment outcomes.  Treatment outcomes, as assessed by clinicians and defined by the World Health Organization, were categorised as favourable and unfavourable.  Delamanid treatment groups were combined for analysis, based on their duration of treatment.  In total, for 421 (87.5%) out of 481 patients from the original randomised controlled trial, consent was granted for follow-up assessments.  Favourable outcomes were observed in 143 (74.5%) out of 192 patients who received delamanid for ≥6 months, compared to 126 (55%) out of 229 patients who received delamanid for ≤2 months.  Mortality was reduced to 1.0% among those receiving long-term delamanid versus short-term/no delamanid (8.3%; p<0.001).  Treatment benefit was also seen among patients with extensively drug-resistant TB.  This analysis suggests that treatment with delamanid for 6 months in combination with an optimised background regimen can improve outcomes and reduce mortality among patients with both multidrug-resistant and extensively drug-resistant TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ2JcitGJjjkMNIRw0GKUoEfW6udTcc2eZ_Ro-1BAPWG7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s%252Fgsl2ltw%253D%253D&md5=63c616aef7dfd5858d274fe1a74ab290</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1183%2F09031936.00125812&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00125812%26sid%3Dliteratum%253Aachs%26aulast%3DSkripconoka%26aufirst%3DV.%26aulast%3DDanilovits%26aufirst%3DM.%26aulast%3DPehme%26aufirst%3DL.%26aulast%3DTomson%26aufirst%3DT.%26aulast%3DSkenders%26aufirst%3DG.%26aulast%3DKummik%26aufirst%3DT.%26aulast%3DCirule%26aufirst%3DA.%26aulast%3DLeimane%26aufirst%3DV.%26aulast%3DKurve%26aufirst%3DA.%26aulast%3DLevina%26aufirst%3DK.%26aulast%3DGeiter%26aufirst%3DL.%2BJ.%26aulast%3DManissero%26aufirst%3DD.%26aulast%3DWells%26aufirst%3DC.%2BD.%26atitle%3DDelamanid%2520improves%2520outcomes%2520and%2520reduces%2520mortality%2520in%2520multidrug-resistant%2520tuberculosis%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2013%26volume%3D41%26spage%3D1393%26epage%3D1400%26doi%3D10.1183%2F09031936.00125812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ginsberg, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurenzi, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouse, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitney, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spigelman, M. K.</span></span> <span> </span><span class="NLM_article-title">Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">3720</span>– <span class="NLM_lpage">3725</span>, <span class="refDoi"> DOI: 10.1128/AAC.00106-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.00106-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=19528280" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFCjsr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2009&pages=3720-3725&author=A.+M.+Ginsbergauthor=M.+W.+Laurenziauthor=D.+J.+Rouseauthor=K.+D.+Whitneyauthor=M.+K.+Spigelman&title=Safety%2C+tolerability%2C+and+pharmacokinetics+of+PA-824+in+healthy+subjects&doi=10.1128%2FAAC.00106-09"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects</span></div><div class="casAuthors">Ginsberg, Ann M.; Laurenzi, Martino W.; Rouse, Doris J.; Whitney, Karl D.; Spigelman, Melvin K.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3720-3725</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">PA-824 is a novel antibacterial agent that has shown in vitro activity against both drug-sensitive and drug-resistant Mycobacterium tuberculosis.  The compd.'s MIC is between 0.015 and 0.25 μg/mL for drug-sensitive strains and between 0.03 and 0.53 μg/mL for drug-resistant strains.  In addn., it is active against nonreplicating anaerobic Mycobacterium tuberculosis.  The safety, tolerability, and pharmacokinetics of PA-824 were evaluated in two escalating-dose clin. studies, one a single-dose study and the other a multiple-dose study (up to 7 days of daily dosing).  In 58 healthy subjects dosed with PA-824 in these studies, the drug candidate was well tolerated, with no significant or serious adverse events.  In both studies, following oral administration PA-824 reached maximal plasma levels in 4 to 5 h independently of the dose.  Maximal blood levels averaged approx. 3 μg/mL (1,500-mg dose) in the single-dose study and 3.8 μg/mL (600-mg dose) in the multiple-dose study.  Steady state was achieved after 5 to 6 days of daily dosing, with an accumulation ratio of approx. 2.  The elimination half-life averaged 16 to 20 h.  Overall, PA-824 was well tolerated following oral doses once daily for up to 7 days, and pharmacokinetic parameters were consistent with a once-a-day regimen.  The results of these studies, combined with the demonstrated activity of PA-824 against drug-sensitive and multidrug-resistant Mycobacterium tuberculosis, support the investigation of this novel compd. for the treatment of tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqOz72SCeRarVg90H21EOLACvtfcHk0lieaiwRggJAdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFCjsr7E&md5=b1a66b6df94526f21a3873747ad54487</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1128%2FAAC.00106-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00106-09%26sid%3Dliteratum%253Aachs%26aulast%3DGinsberg%26aufirst%3DA.%2BM.%26aulast%3DLaurenzi%26aufirst%3DM.%2BW.%26aulast%3DRouse%26aufirst%3DD.%2BJ.%26aulast%3DWhitney%26aufirst%3DK.%2BD.%26aulast%3DSpigelman%26aufirst%3DM.%2BK.%26atitle%3DSafety%252C%2520tolerability%252C%2520and%2520pharmacokinetics%2520of%2520PA-824%2520in%2520healthy%2520subjects%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2009%26volume%3D53%26spage%3D3720%26epage%3D3725%26doi%3D10.1128%2FAAC.00106-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ginsberg, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurenzi, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouse, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitney, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spigelman, M. K.</span></span> <span> </span><span class="NLM_article-title">Assessment of the effects of the nitroimidazo-oxazine PA-824 on renal function in healthy subjects</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">3726</span>– <span class="NLM_lpage">3733</span>, <span class="refDoi"> DOI: 10.1128/AAC.00112-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.00112-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=19528286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFCjsr7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2009&pages=3726-3733&author=A.+M.+Ginsbergauthor=M.+W.+Laurenziauthor=D.+J.+Rouseauthor=K.+D.+Whitneyauthor=M.+K.+Spigelman&title=Assessment+of+the+effects+of+the+nitroimidazo-oxazine+PA-824+on+renal+function+in+healthy+subjects&doi=10.1128%2FAAC.00112-09"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Assessment of the effects of the nitroimidazo-oxazine PA-824 on renal function in healthy subjects</span></div><div class="casAuthors">Ginsberg, Ann M.; Laurenzi, Martino W.; Rouse, Doris J.; Whitney, Karl D.; Spigelman, Mel K.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3726-3733</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The mechanism underlying a dose-dependent, reversible increase in serum creatinine (SC) caused by the administration of PA-824, a novel nitroimidazo-oxazine, was evaluated in 47 healthy male and female volunteers.  Subjects were administered either 800 or 1,000 mg PA-824 or matching placebo once daily for 8 days.  The following renal function parameters were detd. before and during dosing and after a 7-day washout: SC, glomerular filtration rate (GFR; measured as the iohexol clearance), effective renal plasma flow (ERPF; measured as the para-amino hippurate clearance), filtration fraction (FF), creatinine clearance (CrCl), extraglomerular creatinine excretion (EGCE; defined as CrCl minus GFR), blood urea nitrogen (BUN), and uric acid (UA) levels.  Eight days' administration of 800 or 1,000 mg PA-824 was assocd. with increased SC and a trend toward decreased CrCl and EGCE.  SC, CrCl, and EGCE values returned to normal/baseline within 1 wk's washout.  GFR, ERPF, FF, BUN, and UA values were similar across groups during treatment and washout.  The reversible increase in SC obsd. in this and earlier trials of PA-824, thus, did not appear to be the result of a pathol. effect on renal function (as measured by GFR, ERPF, FF, BUN, or UA).  Pharmacokinetic analyses confirmed that PA-824 exposures were similar to those in previous healthy-volunteer clin. studies.  That EGCE declined maximally when drug levels were highest suggests that PA-824 causes creatinine levels to rise by inhibiting renal tubular creatinine secretion.  Such an effect, considered clin. benign, has been described for several marketed drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGps3TtHUhGEmbVg90H21EOLACvtfcHk0lieaiwRggJAdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFCjsr7F&md5=810576f2b77f1ffe8e9235eee612fcac</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1128%2FAAC.00112-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00112-09%26sid%3Dliteratum%253Aachs%26aulast%3DGinsberg%26aufirst%3DA.%2BM.%26aulast%3DLaurenzi%26aufirst%3DM.%2BW.%26aulast%3DRouse%26aufirst%3DD.%2BJ.%26aulast%3DWhitney%26aufirst%3DK.%2BD.%26aulast%3DSpigelman%26aufirst%3DM.%2BK.%26atitle%3DAssessment%2520of%2520the%2520effects%2520of%2520the%2520nitroimidazo-oxazine%2520PA-824%2520on%2520renal%2520function%2520in%2520healthy%2520subjects%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2009%26volume%3D53%26spage%3D3726%26epage%3D3733%26doi%3D10.1128%2FAAC.00112-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diacon, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanekom, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narunsky, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maritz, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donald, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Niekerk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitney, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouse, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurenzi, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginsberg, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spigelman, M. K.</span></span> <span> </span><span class="NLM_article-title">Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">3402</span>– <span class="NLM_lpage">3407</span>, <span class="refDoi"> DOI: 10.1128/AAC.01354-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.01354-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=20498324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVOmsL%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2010&pages=3402-3407&author=A.+H.+Diaconauthor=R.+Dawsonauthor=M.+Hanekomauthor=K.+Narunskyauthor=S.+J.+Maritzauthor=A.+Venterauthor=P.+R.+Donaldauthor=C.+van+Niekerkauthor=K.+Whitneyauthor=D.+J.+Rouseauthor=M.+W.+Laurenziauthor=A.+M.+Ginsbergauthor=M.+K.+Spigelman&title=Early+bactericidal+activity+and+pharmacokinetics+of+PA-824+in+smear-positive+tuberculosis+patients&doi=10.1128%2FAAC.01354-09"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients</span></div><div class="casAuthors">Diacon, Andreas H.; Dawson, Rodney; Hanekom, Madeleine; Narunsky, Kim; Maritz, Stefan J.; Venter, Amour; Donald, Peter R.; van Niekerk, Christo; Whitney, Karl; Rouse, Doris J.; Laurenzi, Martino W.; Ginsberg, Ann M.; Spigelman, Melvin K.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3402-3407</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">PA-824 is a novel nitroimidazo-oxazine being evaluated for its potential to improve tuberculosis (TB) therapy.  This randomized study evaluated safety, tolerability, pharmacokinetics, and extended early bactericidal activity of PA-824 in drug-sensitive, sputum smear-pos., adult pulmonary tuberculosis patients.  Fifteen patients per cohort received 1 of 4 doses of oral PA-824: 200, 600, 1,000, or 1,200 mg per day for 14 days.  Eight subjects received once daily std. antituberculosis treatment as pos. control.  The primary efficacy endpoint was the mean rate of change in log CFU of Mycobacterium tuberculosis in sputum incubated on agar plates from serial overnight sputum collections, expressed as log10 CFU/day/mL (± std. deviation [SD]).  The drug demonstrated increases that were dose linear but less than dose proportional in serum concns. in doses from 200 to 1,000 mg daily.  Dosing of 1,200 mg gave no addnl. exposure compared to 1,000 mg daily.  The mean daily CFU fall under std. treatment was 0.148 (±0.055), consistent with that found in previous studies.  The mean daily fall under PA-824 was 0.098 (±0.072) and was equiv. for all four dosages.  PA-824 appeared safe and well tolerated; the incidence of adverse events potentially related to PA-824 appeared dose related.  We conclude that PA-824 demonstrated bactericidal activity over the dose range of 200 to 1,200 mg daily over 14 days.  Because max. efficacy was unexpectedly achieved at the lowest dosage tested, the activity of lower dosages should now be explored.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBHw5siQAbFbVg90H21EOLACvtfcHk0lieaiwRggJAdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVOmsL%252FM&md5=63a362b7dccb7ad7b5a7177ab81aecc6</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1128%2FAAC.01354-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01354-09%26sid%3Dliteratum%253Aachs%26aulast%3DDiacon%26aufirst%3DA.%2BH.%26aulast%3DDawson%26aufirst%3DR.%26aulast%3DHanekom%26aufirst%3DM.%26aulast%3DNarunsky%26aufirst%3DK.%26aulast%3DMaritz%26aufirst%3DS.%2BJ.%26aulast%3DVenter%26aufirst%3DA.%26aulast%3DDonald%26aufirst%3DP.%2BR.%26aulast%3Dvan%2BNiekerk%26aufirst%3DC.%26aulast%3DWhitney%26aufirst%3DK.%26aulast%3DRouse%26aufirst%3DD.%2BJ.%26aulast%3DLaurenzi%26aufirst%3DM.%2BW.%26aulast%3DGinsberg%26aufirst%3DA.%2BM.%26aulast%3DSpigelman%26aufirst%3DM.%2BK.%26atitle%3DEarly%2520bactericidal%2520activity%2520and%2520pharmacokinetics%2520of%2520PA-824%2520in%2520smear-positive%2520tuberculosis%2520patients%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2010%26volume%3D54%26spage%3D3402%26epage%3D3407%26doi%3D10.1128%2FAAC.01354-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diacon, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">du Bois, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narunsky, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donald, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Niekerk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erondu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginsberg, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spigelman, M. K.</span></span> <span> </span><span class="NLM_article-title">Phase ii dose-ranging trial of the early bactericidal activity of PA-824</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">3027</span>– <span class="NLM_lpage">3031</span>, <span class="refDoi"> DOI: 10.1128/AAC.06125-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.06125-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=22430968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38XnslWrtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=3027-3031&author=A.+H.+Diaconauthor=R.+Dawsonauthor=J.+du+Boisauthor=K.+Narunskyauthor=A.+Venterauthor=P.+R.+Donaldauthor=C.+van+Niekerkauthor=N.+Eronduauthor=A.+M.+Ginsbergauthor=P.+Beckerauthor=M.+K.+Spigelman&title=Phase+ii+dose-ranging+trial+of+the+early+bactericidal+activity+of+PA-824&doi=10.1128%2FAAC.06125-11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II dose-ranging trial of the early bactericidal activity of PA-824</span></div><div class="casAuthors">Diacon, Andreas H.; Dawson, Rodney; du Bois, Jeannine; Narunsky, Kim; Venter, Amour; Donald, Peter R.; van Niekerk, Christo; Erondu, Ngozi; Ginsberg, Ann M.; Becker, Piet; Spigelman, Melvin K.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3027-3031</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">PA-824 is a novel nitroimidazo-oxazine under evaluation as an antituberculosis agent.  A dose-ranging randomized study was conducted to evaluate the safety, tolerability, pharmacokinetics, and early bactericidal activity of PA-824 in drug-sensitive, sputum smear-pos. adult pulmonary-tuberculosis patients to find the lowest dose giving optimal bactericidal activity (EBA).  Fifteen patients per cohort received oral PA-824 in doses of 50 mg, 100 mg, 150 mg, or 200 mg per kg body wt. per day for 14 days.  Eight subjects received once-daily std. antituberculosis treatment with isoniazid, rifampin, pyrazinamide, and ethambutol (HRZE) as a pos. control.  The primary efficacy endpoint was the mean rate of decline in log CFU of Mycobacterium tuberculosis in sputum incubated on agar plates from serial overnight sputum collections, expressed as log10 CFU/day/mL sputum (± std. deviation).  The mean 14-day EBA of HRZE was consistent with previous studies (0.177 ± 0.042), and that of PA-824 at 50 mg, 100 mg, 150 mg, and 200 mg was 0.063 ± 0.058, 0.091 ± 0.073, 0.078 ± 0.074, and 0.112 ± 0.070, resp.  Although the study was not powered for testing the difference between arms, there was a trend toward significance, indicating a lower EBA at the 50-mg dose.  Serum PA-824 levels were approx. dose proportional with respect to the area under the time-concn. curve.  All doses were safe and well tolerated with no dose-limiting adverse events or clin. significant QTc changes.  A dose of 100 mg to 200 mg PA-824 daily appears to be safe and efficacious and will be further evaluated as a component of novel antituberculosis regimens for drug-sensitive and drug-resistant tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVNhRHi7F0urVg90H21EOLACvtfcHk0lgfff_OFqlErg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnslWrtrk%253D&md5=5ab64eb6bc8d02e4e7b1bb6d9d112920</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1128%2FAAC.06125-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.06125-11%26sid%3Dliteratum%253Aachs%26aulast%3DDiacon%26aufirst%3DA.%2BH.%26aulast%3DDawson%26aufirst%3DR.%26aulast%3Ddu%2BBois%26aufirst%3DJ.%26aulast%3DNarunsky%26aufirst%3DK.%26aulast%3DVenter%26aufirst%3DA.%26aulast%3DDonald%26aufirst%3DP.%2BR.%26aulast%3Dvan%2BNiekerk%26aufirst%3DC.%26aulast%3DErondu%26aufirst%3DN.%26aulast%3DGinsberg%26aufirst%3DA.%2BM.%26aulast%3DBecker%26aufirst%3DP.%26aulast%3DSpigelman%26aufirst%3DM.%2BK.%26atitle%3DPhase%2520ii%2520dose-ranging%2520trial%2520of%2520the%2520early%2520bactericidal%2520activity%2520of%2520PA-824%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D3027%26epage%3D3031%26doi%3D10.1128%2FAAC.06125-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diacon, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Groote-Bidlingmaier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symons, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donald, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Niekerk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everitt, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendel, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spigelman, M. K.</span></span> <span> </span><span class="NLM_article-title">14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: A randomised trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>380</i></span>,  <span class="NLM_fpage">986</span>– <span class="NLM_lpage">993</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(12)61080-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2FS0140-6736%2812%2961080-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=22828481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVykt7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2012&pages=986-993&author=A.+H.+Diaconauthor=R.+Dawsonauthor=F.+von+Groote-Bidlingmaierauthor=G.+Symonsauthor=A.+Venterauthor=P.+R.+Donaldauthor=C.+van+Niekerkauthor=D.+Everittauthor=H.+Winterauthor=P.+Beckerauthor=C.+M.+Mendelauthor=M.+K.+Spigelman&title=14-day+bactericidal+activity+of+PA-824%2C+bedaquiline%2C+pyrazinamide%2C+and+moxifloxacin+combinations%3A+A+randomised+trial&doi=10.1016%2FS0140-6736%2812%2961080-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial</span></div><div class="casAuthors">Diacon, Andreas H.; Dawson, Rodney; von Groote-Bidlingmaier, Florian; Symons, Gregory; Venter, Amour; Donald, Peter R.; van Niekerk, Christo; Everitt, Daniel; Winter, Helen; Becker, Piet; Mendel, Carl M.; Spigelman, Melvin K.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">380</span>
        (<span class="NLM_cas:issue">9846</span>),
    <span class="NLM_cas:pages">986-993</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">New drugs, but also shorter, better-tolerated regimens are needed to tackle the high global burden of tuberculosis complicated by drug resistance and retroviral disease.  We investigated new multiple-agent combinations over the first 14 days of treatment to assess their suitability for future development.In this prospective, randomised, early bactericidal activity (EBA) study, treatment-naive, drug-susceptible patients with uncomplicated pulmonary tuberculosis were admitted to hospitals in Cape Town, South Africa, between Oct 7, 2010, and Aug 19, 2011.  Patients were randomised centrally by computer-generated randomisation sequence to receive bedaquiline, bedaquiline-pyrazinamide, PA-824-pyrazinamide, bedaquiline-PA-824, PA-824-moxifloxacin-pyrazinamide, or unmasked std. antituberculosis treatment as pos. control.  The primary outcome was the 14-day EBA assessed in a central lab. from the daily fall in colony forming units (CFU) of M tuberculosis per mL of sputum in daily overnight sputum collections.  Bilinear regression curves were fitted for each group sep. and groups compared with ANOVA for ranks, followed by pair-wise comparisons adjusted for multiplicity.  Clin. staff were partially masked but lab. personnel were fully masked.  This study is registered, NCT01215851.The mean 14-day EBA of PA-824-moxifloxacin-pyrazinamide (n=13; 0·233 [SD 0·128]) was significantly higher than that of bedaquiline (14; 0·061 [0·068]), bedaquiline-pyrazinamide (15; 0·131 [0·102]), bedaquiline-PA-824 (14; 0·114 [0·050]), but not PA-824-pyrazinamide (14; 0·154 [0·040]), and comparable with that of std. treatment (ten; 0·140 [0·094]).  Treatments were well tolerated and appeared safe.  One patient on PA-824-moxifloxacin-pyrazinamide was withdrawn because of cor. QT interval changes exceeding criteria prespecified in the protocol.PA-824-moxifloxacin-pyrazinamide is potentially suitable for treating drug-sensitive and multidrug-resistant tuberculosis.  Multiagent EBA studies can contribute to reducing the time needed to develop new antituberculosis regimens.The Global Alliance for TB Drug Development (TB Alliance).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq84xfW4g0r6LVg90H21EOLACvtfcHk0lgfff_OFqlErg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVykt7bM&md5=4b387bb7346fff813e692518e073619c</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2812%2961080-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252812%252961080-0%26sid%3Dliteratum%253Aachs%26aulast%3DDiacon%26aufirst%3DA.%2BH.%26aulast%3DDawson%26aufirst%3DR.%26aulast%3Dvon%2BGroote-Bidlingmaier%26aufirst%3DF.%26aulast%3DSymons%26aufirst%3DG.%26aulast%3DVenter%26aufirst%3DA.%26aulast%3DDonald%26aufirst%3DP.%2BR.%26aulast%3Dvan%2BNiekerk%26aufirst%3DC.%26aulast%3DEveritt%26aufirst%3DD.%26aulast%3DWinter%26aufirst%3DH.%26aulast%3DBecker%26aufirst%3DP.%26aulast%3DMendel%26aufirst%3DC.%2BM.%26aulast%3DSpigelman%26aufirst%3DM.%2BK.%26atitle%3D14-day%2520bactericidal%2520activity%2520of%2520PA-824%252C%2520bedaquiline%252C%2520pyrazinamide%252C%2520and%2520moxifloxacin%2520combinations%253A%2520A%2520randomised%2520trial%26jtitle%3DLancet%26date%3D2012%26volume%3D380%26spage%3D986%26epage%3D993%26doi%3D10.1016%2FS0140-6736%2812%2961080-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winter, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egizi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erondu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginsberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouse, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Severynse-Stevens, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everitt, D.</span></span> <span> </span><span class="NLM_article-title">Evaluation of pharmacokinetic interaction between PA-824 and midazolam in healthy adult subjects</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3699</span>– <span class="NLM_lpage">3703</span>, <span class="refDoi"> DOI: 10.1128/AAC.02632-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.02632-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=23689718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Wgtb3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2013&pages=3699-3703&author=H.+Winterauthor=E.+Egiziauthor=N.+Eronduauthor=A.+Ginsbergauthor=D.+J.+Rouseauthor=D.+Severynse-Stevensauthor=E.+Pauliauthor=D.+Everitt&title=Evaluation+of+pharmacokinetic+interaction+between+PA-824+and+midazolam+in+healthy+adult+subjects&doi=10.1128%2FAAC.02632-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of pharmacokinetic interaction between PA-824 and midazolam in healthy adult subjects</span></div><div class="casAuthors">Winter, Helen; Egizi, Erica; Erondu, Ngozi; Ginsberg, Ann; Rouse, Doris J.; Severynse-Stevens, Diana; Pauli, Elliott; Everitt, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3699-3703</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">This study assessed the safety, tolerability, and pharmacokinetic interaction between PA-824, a novel antitubercular nitroimidazo-oxazine, and midazolam, a CYP3A4 substrate, in 14 healthy adult male and female subjects.  The study followed up on observations in vitro that PA-824 caused weak and time-dependent inhibition of CYP3A4.  Subjects received a single oral dose of midazolam (2 mg), followed by a 2-day washout.  After the washout, all subjects received PA-824 (400 mg) once daily for 14 consecutive days.  On day 14, all subjects received the final PA-824 dose coadministered with a 2-mg oral dose of midazolam.  The pharmacokinetic endpoints AUC0-t, AUC0-∞, and Cmax for midazolam and 1-hydroxy midazolam were compared between midazolam administered alone vs. midazolam coadministered with PA-824.  Statistical anal. demonstrated that the mean midazolam values of Cmax, AUC0-t, and AUC0-∞ parameters were reduced by ca. 16, 15, and 15%, resp., when PA-824 was coadministered with midazolam.  The total exposure (AUC) of 1-hydroxy midazolam was 13 to 14% greater when coadministered with PA-824 compared to midazolam administered alone.  The Cmax of 1-hydroxy midazolam was similar between treatments.  Based on these results, PA-824 does not inhibit or induce CYP3A4 to a clin. meaningful extent and is not likely to markedly affect the pharmacokinetics of CYP3A4 metabolized drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYL4vjAgGRCrVg90H21EOLACvtfcHk0lgfff_OFqlErg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Wgtb3L&md5=596e43ace93fca069a3d53ac661ab352</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1128%2FAAC.02632-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02632-12%26sid%3Dliteratum%253Aachs%26aulast%3DWinter%26aufirst%3DH.%26aulast%3DEgizi%26aufirst%3DE.%26aulast%3DErondu%26aufirst%3DN.%26aulast%3DGinsberg%26aufirst%3DA.%26aulast%3DRouse%26aufirst%3DD.%2BJ.%26aulast%3DSeverynse-Stevens%26aufirst%3DD.%26aulast%3DPauli%26aufirst%3DE.%26aulast%3DEveritt%26aufirst%3DD.%26atitle%3DEvaluation%2520of%2520pharmacokinetic%2520interaction%2520between%2520PA-824%2520and%2520midazolam%2520in%2520healthy%2520adult%2520subjects%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2013%26volume%3D57%26spage%3D3699%26epage%3D3703%26doi%3D10.1128%2FAAC.02632-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winter, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginsberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egizi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erondu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitney, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everitt, D.</span></span> <span> </span><span class="NLM_article-title">Effect of a high-calorie, high-fat meal on the bioavailability and pharmacokinetics of PA-824 in healthy adult subjects</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5516</span>– <span class="NLM_lpage">5520</span>, <span class="refDoi"> DOI: 10.1128/AAC.00798-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.00798-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=23979737" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1KjtrfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2013&pages=5516-5520&author=H.+Winterauthor=A.+Ginsbergauthor=E.+Egiziauthor=N.+Eronduauthor=K.+Whitneyauthor=E.+Pauliauthor=D.+Everitt&title=Effect+of+a+high-calorie%2C+high-fat+meal+on+the+bioavailability+and+pharmacokinetics+of+PA-824+in+healthy+adult+subjects&doi=10.1128%2FAAC.00798-13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of a high-calorie, high-fat meal on the bioavailability and pharmacokinetics of PA-824 in healthy adult subjects</span></div><div class="casAuthors">Winter, Helen; Ginsberg, Ann; Egizi, Erica; Erondu, Ngozi; Whitney, Karl; Pauli, Elliott; Everitt, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5516-5520</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">PA-824 is a novel nitroimidazo-oxazine being developed as an antituberculosis agent.  Two randomized studies evaluated the pharmacokinetics and safety of a single oral dose of PA-824 administered to healthy adult subjects 30 min after a high-calorie, high-fat meal (fed state) vs. after a min. 10-h fast (fasted state).  A total of 48 subjects were dosed in the two studies in a randomized crossover design with PA-824 at dose levels of 50, 200, or 1,000 mg in the fed state or fasted state.  After the administration of PA-824, the geometric mean ratios of Cmax and AUC0-∞ revealed an increase in exposure with the addn. of a high-caloric, high-fat meal compared to the fasted state by 140 and 145% at 50 mg, 176 and 188% at 200 mg, and 450 and 473% at 50, 200, and 1,000 mg, resp.  The median Tmax in the fed state was 4 h for the 50-mg dose and 5 h for the 200- and 1,000-mg doses.  In the fasted state, the median Tmax was 4 h for the 50- and 200-mg doses and 6.5 h for the 1,000-mg dose.  All doses were well tolerated, and no serious adverse events occurred in either study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhzWCvarM6ELVg90H21EOLACvtfcHk0ljSk98plld6YA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1KjtrfI&md5=4c5a3b058505d5609c814b430f4d0a8c</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1128%2FAAC.00798-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00798-13%26sid%3Dliteratum%253Aachs%26aulast%3DWinter%26aufirst%3DH.%26aulast%3DGinsberg%26aufirst%3DA.%26aulast%3DEgizi%26aufirst%3DE.%26aulast%3DErondu%26aufirst%3DN.%26aulast%3DWhitney%26aufirst%3DK.%26aulast%3DPauli%26aufirst%3DE.%26aulast%3DEveritt%26aufirst%3DD.%26atitle%3DEffect%2520of%2520a%2520high-calorie%252C%2520high-fat%2520meal%2520on%2520the%2520bioavailability%2520and%2520pharmacokinetics%2520of%2520PA-824%2520in%2520healthy%2520adult%2520subjects%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2013%26volume%3D57%26spage%3D5516%26epage%3D5520%26doi%3D10.1128%2FAAC.00798-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diacon, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Groote-Bidlingmaier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symons, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donald, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Niekerk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everitt, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchings, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schall, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendel, C. M.</span></span> <span> </span><span class="NLM_article-title">Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>191</i></span>,  <span class="NLM_fpage">943</span>– <span class="NLM_lpage">953</span>, <span class="refDoi"> DOI: 10.1164/rccm.201410-1801OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1164%2Frccm.201410-1801OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=25622149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFOktLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2015&pages=943-953&author=A.+H.+Diaconauthor=R.+Dawsonauthor=F.+von+Groote-Bidlingmaierauthor=G.+Symonsauthor=A.+Venterauthor=P.+R.+Donaldauthor=C.+van+Niekerkauthor=D.+Everittauthor=J.+Hutchingsauthor=D.+A.+Burgerauthor=R.+Schallauthor=C.+M.+Mendel&title=Bactericidal+activity+of+pyrazinamide+and+clofazimine+alone+and+in+combinations+with+pretomanid+and+bedaquiline&doi=10.1164%2Frccm.201410-1801OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline</span></div><div class="casAuthors">Diacon, Andreas H.; Dawson, Rodney; von Groote-Bidlingmaier, Florian; Symons, Gregory; Venter, Amour; Donald, Peter R.; van Niekerk, Christo; Everitt, Daniel; Hutchings, Jane; Burger, Divan A.; Schall, Robert; Mendel, Carl M.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">943-953</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Rationale: New regimens to shorten tuberculosis treatment and manage patients with drug- resistan t tuberculosis who are infected with HIV are urgently needed.  Exptl. and clin. evidence suggests that the new drugs bedaquiline (B) and pretomanid (Pa), combined with an existing drug, pyTazinaraide (Z), and a repurposed drug, clolazirnine (C), may assist treatment shortening of drug-susceptible and drug-resistant tuberculosis.  Objectives: To evaluate the 14-day bactericidal activity ofC and Z in monotherapy and in combinations with Pa and B.  Methods: Groups of 15 treatment-naive, sputum smear-pos. patients with pulmonary tuberculosis were randomized to receive combinations of B with Z-C, Pa-Z, Pa-Z-C, a nd Pa-C, or C or Z alone, or std. combination treatment for 14 days.  The primary endpoint was the mean daily fait in log10 Mycobacterium tuberculosis CPU per mL sputum estd. by joint nonlinear mixed-effects Bayesian regression modeling.  Measurements and Main Results: Estd. activities were 0.167 (95% confidence interval [CI], 0.075-0.257) for B-Pa-Z, 0.151 (95% CI, 0.071-0.232) for std. treatment, 0.124 (95% CI, 0.035-0.214) for B-Z-C, 0.115 (95% CI, 0.039-0.189) for B-Pa-Z-C, and 0.076 (95% CI, 0.005-0.145) for B-Pa-C.  Z alone had modest activity (0.036; 95% CI, -0.026 to 0.099).  C had no activity alone (-0.017; 95% CI, -0.085 to 0.053) or in combinations.  Treatments were well tolerated and safe.  Conclusions: B-Pa-Z, including two novel agents without resistance in prevalent M. tuberculosis strains, is a potential new tuberculosis treatment regimen.  C had no measurable activity in the first 14 days of treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzeaBbihJunrVg90H21EOLACvtfcHk0ljSk98plld6YA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFOktLk%253D&md5=92e0ef0ffb5904edb462cbd0b15755b6</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1164%2Frccm.201410-1801OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201410-1801OC%26sid%3Dliteratum%253Aachs%26aulast%3DDiacon%26aufirst%3DA.%2BH.%26aulast%3DDawson%26aufirst%3DR.%26aulast%3Dvon%2BGroote-Bidlingmaier%26aufirst%3DF.%26aulast%3DSymons%26aufirst%3DG.%26aulast%3DVenter%26aufirst%3DA.%26aulast%3DDonald%26aufirst%3DP.%2BR.%26aulast%3Dvan%2BNiekerk%26aufirst%3DC.%26aulast%3DEveritt%26aufirst%3DD.%26aulast%3DHutchings%26aufirst%3DJ.%26aulast%3DBurger%26aufirst%3DD.%2BA.%26aulast%3DSchall%26aufirst%3DR.%26aulast%3DMendel%26aufirst%3DC.%2BM.%26atitle%3DBactericidal%2520activity%2520of%2520pyrazinamide%2520and%2520clofazimine%2520alone%2520and%2520in%2520combinations%2520with%2520pretomanid%2520and%2520bedaquiline%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2015%26volume%3D191%26spage%3D943%26epage%3D953%26doi%3D10.1164%2Frccm.201410-1801OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diacon, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everitt, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Niekerk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donald, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schall, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spigelman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conradie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenach, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ive, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page-Shipp, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Variava, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reither, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ntinginya, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pym, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Groote-Bidlingmaier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendel, C. M.</span></span> <span> </span><span class="NLM_article-title">Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: A phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>385</i></span>,  <span class="NLM_fpage">1738</span>– <span class="NLM_lpage">1747</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(14)62002-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2FS0140-6736%2814%2962002-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=25795076" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvVWgs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=385&publication_year=2015&pages=1738-1747&author=R.+Dawsonauthor=A.+H.+Diaconauthor=D.+Everittauthor=C.+van+Niekerkauthor=P.+R.+Donaldauthor=D.+A.+Burgerauthor=R.+Schallauthor=M.+Spigelmanauthor=A.+Conradieauthor=K.+Eisenachauthor=A.+Venterauthor=P.+Iveauthor=L.+Page-Shippauthor=E.+Variavaauthor=K.+Reitherauthor=N.+E.+Ntinginyaauthor=A.+Pymauthor=F.+von+Groote-Bidlingmaierauthor=C.+M.+Mendel&title=Efficiency+and+safety+of+the+combination+of+moxifloxacin%2C+pretomanid+%28PA-824%29%2C+and+pyrazinamide+during+the+first+8+weeks+of+antituberculosis+treatment%3A+A+phase+2b%2C+open-label%2C+partly+randomised+trial+in+patients+with+drug-susceptible+or+drug-resistant+pulmonary+tuberculosis&doi=10.1016%2FS0140-6736%2814%2962002-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis</span></div><div class="casAuthors">Dawson, Rodney; Diacon, Andreas H.; Everitt, Daniel; van Niekerk, Christo; Donald, Peter R.; Burger, Divan A.; Schall, Robert; Spigelman, Melvin; Conradie, Almari; Eisenach, Kathleen; Venter, Amour; Ive, Prudence; Page-Shipp, Liesl; Variava, Ebrahim; Reither, Klaus; Ntinginya, Nyanda E.; Pym, Alexander; von Groote-Bidlingmaier, Florian; Mendel, Carl M.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">385</span>
        (<span class="NLM_cas:issue">9979</span>),
    <span class="NLM_cas:pages">1738-1747</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">New antituberculosis regimens are urgently needed to shorten tuberculosis treatment.  Following on from favorable assessment in a 2 wk study, we investigated a novel regimen for efficacy and safety in drug-susceptible and multidrug-resistant (MDR) tuberculosis during the first 8 wk of treatment.  We did this phase 2b study of bactericidal activity-defined as the decrease in colony forming units (CFUs) of Mycobacterium tuberculosis in the sputum of patients with microscopy smear-pos. pulmonary tuberculosis-at eight sites in South Africa and Tanzania.  We enrolled treatment-naive patients with drug-susceptible, pulmonary tuberculosis, who were randomly assigned by computer-generated sequences to receive either 8 wk of moxifloxacin, 100 mg pretomanid (formerly known as PA-824), and pyrazinamide (MPa100Z regimen); moxifloxacin, 200 mg pretomanid, and pyrazinamide (MPa200Z regimen); or the current std. care for drug-susceptible pulmonary tuberculosis, isoniazid, rifampicin, PZA, and ethambutol (HRZE regimen).  A group of patients with MDR tuberculosis received MPa200Z (DRMPa200Z group).  The primary outcome was bactericidal activity measured by the mean daily rate of redn. in M tuberculosis CFUs per mL overnight sputum collected once a week, with joint Bayesian non-linear mixed-effects regression modeling.  We also assessed safety and tolerability by monitoring adverse events.  This study is registered with ClinicalTrials.gov, no. NCT01498419.  Between March 24, 2012, and July 26, 2013 we enrolled 207 patients and randomly assigned them to treatment groups; we assigned 60 patients to the MPa100Z regimen, 62 to the MPa200Z regimen, and 59 to the HRZE regimen.  We non-randomly assigned 26 patients with drug-resistant tuberculosis to the DRMPa200Z regimen.  In patients with drug-susceptible tuberculosis, the bactericidal activity of MPa200Z (n=54) on days 0-56 (0·155, 95% Bayesian credibility interval 0·133-0·178) was significantly greater than for HRZE (n=54, 0·112, 0·093-0·131).  DRMPa200Z (n=9) had bactericidal activity of 0·117 (0·070-0·174).  The bactericidal activity on days 7-14 was strongly assocd. with bactericidal activity on days 7-56.  Frequencies of adverse events were similar to std. treatment in all groups.  The most common adverse event was hyperuricemia in 59 (29%) patients (17 [28%] patients in MPa100Z group, 17 [27%] patients in MPa200Z group, 17 [29%] patients. in HRZE group, and 8 [31%] patients in DRMPa200Z group).  Other common adverse events were nausea in (14 [23%] patients in MPa100Z group, 8 [13%] patients in MPa200Z group, 7 [12%] patients in HRZE group, and 8 [31%] patients in DRMPa200Z group) and vomiting (7 [12%] patients in MPa100Z group, 7 [11%] patients in MPa200Z group, 7 [12%] patients in HRZE group, and 4 [15%] patients in DRMPa200Z group).  No on-treatment ECG occurrences of cor. QT interval more than 500 ms (an indicator of potential of ventricular tachyarrhythmia) were reported.  No phenotypic resistance developed to any of the drugs in the regimen.  The combination of moxifloxacin, pretomanid, and pyrazinamide, was safe, well tolerated, and showed superior bactericidal activity in drug-susceptible tuberculosis during 8 wk of treatment.  Results were consistent between drug-susceptible and MDR tuberculosis.  This new regimen is ready to enter phase 3 trials in patients with drug-susceptible tuberculosis and MDR-tuberculosis, with the goal of shortening and simplifying treatment.  Global Alliance for TB Drug Development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIrFs7Z3Zt97Vg90H21EOLACvtfcHk0lhr17vrTp39rQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvVWgs7g%253D&md5=5dc925f5677225aa3003069a3fb12c05</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2814%2962002-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252814%252962002-X%26sid%3Dliteratum%253Aachs%26aulast%3DDawson%26aufirst%3DR.%26aulast%3DDiacon%26aufirst%3DA.%2BH.%26aulast%3DEveritt%26aufirst%3DD.%26aulast%3Dvan%2BNiekerk%26aufirst%3DC.%26aulast%3DDonald%26aufirst%3DP.%2BR.%26aulast%3DBurger%26aufirst%3DD.%2BA.%26aulast%3DSchall%26aufirst%3DR.%26aulast%3DSpigelman%26aufirst%3DM.%26aulast%3DConradie%26aufirst%3DA.%26aulast%3DEisenach%26aufirst%3DK.%26aulast%3DVenter%26aufirst%3DA.%26aulast%3DIve%26aufirst%3DP.%26aulast%3DPage-Shipp%26aufirst%3DL.%26aulast%3DVariava%26aufirst%3DE.%26aulast%3DReither%26aufirst%3DK.%26aulast%3DNtinginya%26aufirst%3DN.%2BE.%26aulast%3DPym%26aufirst%3DA.%26aulast%3Dvon%2BGroote-Bidlingmaier%26aufirst%3DF.%26aulast%3DMendel%26aufirst%3DC.%2BM.%26atitle%3DEfficiency%2520and%2520safety%2520of%2520the%2520combination%2520of%2520moxifloxacin%252C%2520pretomanid%2520%2528PA-824%2529%252C%2520and%2520pyrazinamide%2520during%2520the%2520first%25208%2520weeks%2520of%2520antituberculosis%2520treatment%253A%2520A%2520phase%25202b%252C%2520open-label%252C%2520partly%2520randomised%2520trial%2520in%2520patients%2520with%2520drug-susceptible%2520or%2520drug-resistant%2520pulmonary%2520tuberculosis%26jtitle%3DLancet%26date%3D2015%26volume%3D385%26spage%3D1738%26epage%3D1747%26doi%3D10.1016%2FS0140-6736%2814%2962002-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ashtekar, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa-Perira, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagrajan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vishvanathan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatt, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rittel, W.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo activities of the nitroimidazole CGI 17341 against mycobacterium tuberculosis</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">183</span>– <span class="NLM_lpage">186</span>, <span class="refDoi"> DOI: 10.1128/AAC.37.2.183</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.37.2.183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=8452346" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADyaK3sXitV2hu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1993&pages=183-186&author=D.+R.+Ashtekarauthor=R.+Costa-Periraauthor=K.+Nagrajanauthor=N.+Vishvanathanauthor=A.+D.+Bhattauthor=W.+Rittel&title=In+vitro+and+in+vivo+activities+of+the+nitroimidazole+CGI+17341+against+mycobacterium+tuberculosis&doi=10.1128%2FAAC.37.2.183"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis</span></div><div class="casAuthors">Ashtekar, Dilip R.; Costa-Perira, Rabi; Nagrajan, K.; Vishvanathan, N.; Bhatt, Arun D.; Rittel, Werner</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">183-6</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    </div><div class="casAbstract">CGI 17341 (2-ethyl-5-nitro-2,3-dihydro[2-1b]imidazooxazole, I)) is a novel orally active representative of the 5-nitroimidazole series of antimicrobial agents.  At concns. of 0.1-0.3 μg/mL, I inhibited the drug-susceptible and multidrug-resistant strains of M. tuberculosis.  I had no cross-resistance with isoniazid, rifampin, streptomycin, or ethambutol.  While the in vitro activity of I against M. tuberculosis was comparable to those of isoniazid and rifampin, it was superior to those of streptomycin, ciprofloxacin, norfloxacin, and oxazolidinone DuP 721.  The MIC of I was not affected when the pH of the medium was decreased from 6.8 to 5.6, while 4-6-fold increases in the MICs of ciprofloxacin and isoniazid were obsd.  In mice infected with M. tuberculosis, the 50% ED for I was 7.7 mg/kg body wt. (95% confidence limits, 3.5 and 10.27) when administered on days 11 and 12 postinfection.  I gave a dose-dependent and significant increase in the survival time.  I is a promising and novel antituberculosis compd. with potent in vitro and in vivo activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowsgP8VyIuv7Vg90H21EOLACvtfcHk0lhr17vrTp39rQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXitV2hu7k%253D&md5=b0867ca5ab8169a4dcf8940b1c69a11e</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1128%2FAAC.37.2.183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.37.2.183%26sid%3Dliteratum%253Aachs%26aulast%3DAshtekar%26aufirst%3DD.%2BR.%26aulast%3DCosta-Perira%26aufirst%3DR.%26aulast%3DNagrajan%26aufirst%3DK.%26aulast%3DVishvanathan%26aufirst%3DN.%26aulast%3DBhatt%26aufirst%3DA.%2BD.%26aulast%3DRittel%26aufirst%3DW.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520activities%2520of%2520the%2520nitroimidazole%2520CGI%252017341%2520against%2520mycobacterium%2520tuberculosis%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1993%26volume%3D37%26spage%3D183%26epage%3D186%26doi%3D10.1128%2FAAC.37.2.183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manjunatha, U. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boshoff, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowd, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albert, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norton, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.,  3rd.</span></span> <span> </span><span class="NLM_article-title">Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in mycobacterium tuberculosis</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">431</span>– <span class="NLM_lpage">436</span>, <span class="refDoi"> DOI: 10.1073/pnas.0508392103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1073%2Fpnas.0508392103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=16387854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD28XpsVSltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=431-436&author=U.+H.+Manjunathaauthor=H.+Boshoffauthor=C.+S.+Dowdauthor=L.+Zhangauthor=T.+J.+Albertauthor=J.+E.+Nortonauthor=L.+Danielsauthor=T.+Dickauthor=S.+S.+Pangauthor=C.+E.+Barry&title=Identification+of+a+nitroimidazo-oxazine-specific+protein+involved+in+PA-824+resistance+in+mycobacterium+tuberculosis&doi=10.1073%2Fpnas.0508392103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis</span></div><div class="casAuthors">Manjunatha, Ujjini H.; Boshoff, Helena; Dowd, Cynthia S.; Zhang, Liang; Albert, Thomas J.; Norton, Jason E.; Daniels, Lacy; Dick, Thomas; Pang, Siew Siew; Barry, Clifton E., III</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">431-436</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">PA-824 is a promising new compd. for the treatment of tuberculosis that is currently undergoing human trials.  Like its progenitors metronidazole and CGI-17341, PA-824 is a prodrug of the nitroimidazole class, requiring bioreductive activation of an arom. nitro group to exert an antitubercular effect.  The authors have confirmed that resistance to PA-824 (a nitroimidazo-oxazine) and CGI-17341 (a nitroimidazo-oxazole) is most commonly mediated by loss of a specific glucose-6-phosphate dehydrogenase (FGD1) or its deazaflavin cofactor F420, which together provide electrons for the reductive activation of this class of mols.  Although FGD1 and F420 are necessary for sensitivity to these compds., they are not sufficient and require addnl. accessory proteins that directly interact with the nitroimidazole.  To understand more proximal events in the reductive activation of PA-824, the authors examd. mutants that were wild-type for both FGD1 and F420 and found that, although these mutants had acquired high-level resistance to PA-824 (and another nitroimidazo-oxazine), they retained sensitivity to CGI-17341 (and a related nitroimidazo-oxazole).  Microarray-based comparative genome sequencing of these mutants identified lesions in Rv3547, a conserved hypothetical protein with no known function.  Complementation with intact Rv3547 fully restored sensitivity to nitroimidazo-oxazines and restored the ability of Mtb to metabolize PA-824.  These results suggest that the sensitivity of Mtb to PA-824 and related compds. is mediated by a protein that is highly specific for subtle structural variations in these bicyclic nitroimidazoles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX0bL9yx6FB7Vg90H21EOLACvtfcHk0lhr17vrTp39rQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpsVSltQ%253D%253D&md5=66a247925f28a6d254c75a543bb52e74</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0508392103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0508392103%26sid%3Dliteratum%253Aachs%26aulast%3DManjunatha%26aufirst%3DU.%2BH.%26aulast%3DBoshoff%26aufirst%3DH.%26aulast%3DDowd%26aufirst%3DC.%2BS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DAlbert%26aufirst%3DT.%2BJ.%26aulast%3DNorton%26aufirst%3DJ.%2BE.%26aulast%3DDaniels%26aufirst%3DL.%26aulast%3DDick%26aufirst%3DT.%26aulast%3DPang%26aufirst%3DS.%2BS.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26atitle%3DIdentification%2520of%2520a%2520nitroimidazo-oxazine-specific%2520protein%2520involved%2520in%2520PA-824%2520resistance%2520in%2520mycobacterium%2520tuberculosis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26spage%3D431%26epage%3D436%26doi%3D10.1073%2Fpnas.0508392103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sha, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, H.</span></span> <span> </span><span class="NLM_article-title">Clinical benefit of delamanid (opc-67683) in the treatment of multidrug-resistant tuberculosis patients in china</span>. <i>Cell Biochem. Biophys.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">957</span>– <span class="NLM_lpage">963</span>, <span class="refDoi"> DOI: 10.1007/s12013-013-9589-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1007%2Fs12013-013-9589-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=23546935" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVKit7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2013&pages=957-963&author=Q.+Zhangauthor=Y.+Liuauthor=S.+Tangauthor=W.+Shaauthor=H.+Xiao&title=Clinical+benefit+of+delamanid+%28opc-67683%29+in+the+treatment+of+multidrug-resistant+tuberculosis+patients+in+china&doi=10.1007%2Fs12013-013-9589-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical Benefit of Delamanid (OPC-67683) in the Treatment of Multidrug-Resistant Tuberculosis Patients in China</span></div><div class="casAuthors">Zhang, Qing; Liu, Yidian; Tang, Shenjie; Sha, Wei; Xiao, Heping</div><div class="citationInfo"><span class="NLM_cas:title">Cell Biochemistry and Biophysics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">957-963</span>CODEN:
                <span class="NLM_cas:coden">CBBIFV</span>;
        ISSN:<span class="NLM_cas:issn">1085-9195</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The cure rates are much lower for multidrug-resistant (MDR) tuberculosis (TB) patients.  Delamanid (OPC-67683) has been evaluated in phase-II MDR-TB clin. trials.  Herein, we reviewed MDR-TB cases in which treatment regimens, with/without delamanid, were administered.  Thirty-eight patients were enrolled; 26 received delamanid-contg. regimens (treatment group) while 12 received placebo-contg. regimens (control group) for 56 days.  Data regarding clin./radio-microbiol. characteristics, drug tolerability, and treatment outcomes were collected.  We found that all patients had isolates resistant to a median of 5 (range 2-7) drugs; 24 (92.3 fx) patients in treatment group and 11 (91.7 fx) in control group had cavities.  Culture conversion was obtained in 32 pulmonary TB cases (median 74.5 days).  At data censure, 30/38 patients successfully completed therapy with documented neg. cultures for at least 18 mo before the end of treatment.  Two patients (5 consecutive neg. cultures) are still on treatment.  Six patients had poor outcome (3 failures/2 lost/1 death).  In 13 patients, adverse events were obsd. that included mental disorder, QT interval prolongation, and increased blood cortisol whereas only 3 patients stopped delamanid treatment because of adverse events.  It was, therefore, concluded that delamanid was well-tolerated, had low rates of discontinuation, and could be effective for treating MDR-TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDwcBx_s8v47Vg90H21EOLACvtfcHk0li2bbNkax-gvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVKit7fO&md5=06493fae373a1b1e53bffb57ce315243</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1007%2Fs12013-013-9589-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12013-013-9589-5%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DS.%26aulast%3DSha%26aufirst%3DW.%26aulast%3DXiao%26aufirst%3DH.%26atitle%3DClinical%2520benefit%2520of%2520delamanid%2520%2528opc-67683%2529%2520in%2520the%2520treatment%2520of%2520multidrug-resistant%2520tuberculosis%2520patients%2520in%2520china%26jtitle%3DCell%2520Biochem.%2520Biophys.%26date%3D2013%26volume%3D67%26spage%3D957%26epage%3D963%26doi%3D10.1007%2Fs12013-013-9589-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manjunatha, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boshoff, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niyomrattanakit, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ledwidge, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowd, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, I. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiricek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.</span></span> <span> </span><span class="NLM_article-title">PA-824 kills nonreplicating mycobacterium tuberculosis by intracellular no release</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>322</i></span>,  <span class="NLM_fpage">1392</span>– <span class="NLM_lpage">1395</span>, <span class="refDoi"> DOI: 10.1126/science.1164571</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1126%2Fscience.1164571" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=19039139" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVagt7jN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=322&publication_year=2008&pages=1392-1395&author=R.+Singhauthor=U.+Manjunathaauthor=H.+I.+Boshoffauthor=Y.+H.+Haauthor=P.+Niyomrattanakitauthor=R.+Ledwidgeauthor=C.+S.+Dowdauthor=I.+Y.+Leeauthor=P.+Kimauthor=L.+Zhangauthor=S.+Kangauthor=T.+H.+Kellerauthor=J.+Jiricekauthor=C.+E.+Barry&title=PA-824+kills+nonreplicating+mycobacterium+tuberculosis+by+intracellular+no+release&doi=10.1126%2Fscience.1164571"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO Release</span></div><div class="casAuthors">Singh, Ramandeep; Manjunatha, Ujjini; Boshoff, Helena I. M.; Ha, Young Hwan; Niyomrattanakit, Pornwaratt; Ledwidge, Richard; Dowd, Cynthia S.; Lee, Ill Young; Kim, Pilho; Zhang, Liang; Kang, Sunhee; Keller, Thomas H.; Jiricek, Jan; Barry, Clifton E., III</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">322</span>
        (<span class="NLM_cas:issue">5906</span>),
    <span class="NLM_cas:pages">1392-1395</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Bicyclic nitroimidazoles, including PA-824, are exciting candidates for the treatment of tuberculosis.  These prodrugs require intracellular activation for their biol. function.  We found that Rv3547 is a deazaflavin-dependent nitroreductase (Ddn) that converts PA-824 into three primary metabolites; the major one is the corresponding des-nitroimidazole (des-nitro).  When derivs. of PA-824 were used, the amt. of des-nitro metabolite formed was highly correlated with anaerobic killing of Mycobacterium tuberculosis (Mtb).  Des-nitro metabolite formation generated reactive nitrogen species, including nitric oxide (NO), which are the major effectors of the anaerobic activity of these compds.  Furthermore, NO scavengers protected the bacilli from the lethal effects of the drug.  Thus, these compds. may act as intracellular NO donors and could augment a killing mechanism intrinsic to the innate immune system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdOQ6XyUn59bVg90H21EOLACvtfcHk0li2bbNkax-gvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVagt7jN&md5=5d7d8715b5565938b3ffd9fd35a723da</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1126%2Fscience.1164571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1164571%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DManjunatha%26aufirst%3DU.%26aulast%3DBoshoff%26aufirst%3DH.%2BI.%26aulast%3DHa%26aufirst%3DY.%2BH.%26aulast%3DNiyomrattanakit%26aufirst%3DP.%26aulast%3DLedwidge%26aufirst%3DR.%26aulast%3DDowd%26aufirst%3DC.%2BS.%26aulast%3DLee%26aufirst%3DI.%2BY.%26aulast%3DKim%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DKang%26aufirst%3DS.%26aulast%3DKeller%26aufirst%3DT.%2BH.%26aulast%3DJiricek%26aufirst%3DJ.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26atitle%3DPA-824%2520kills%2520nonreplicating%2520mycobacterium%2520tuberculosis%2520by%2520intracellular%2520no%2520release%26jtitle%3DScience%26date%3D2008%26volume%3D322%26spage%3D1392%26epage%3D1395%26doi%3D10.1126%2Fscience.1164571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stover, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warrener, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VanDevanter, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arain, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langhorne, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towell, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMurray, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreiswirth, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, W. R.</span></span> <span> </span><span class="NLM_article-title">A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>405</i></span>,  <span class="NLM_fpage">962</span>– <span class="NLM_lpage">966</span>, <span class="refDoi"> DOI: 10.1038/35016103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1038%2F35016103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10879539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD3cXks1Wksb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=405&publication_year=2000&pages=962-966&author=C.+K.+Stoverauthor=P.+Warrenerauthor=D.+R.+VanDevanterauthor=D.+R.+Shermanauthor=T.+M.+Arainauthor=M.+H.+Langhorneauthor=S.+W.+Andersonauthor=J.+A.+Towellauthor=Y.+Yuanauthor=D.+N.+McMurrayauthor=B.+N.+Kreiswirthauthor=C.+E.+Barryauthor=W.+R.+Baker&title=A+small-molecule+nitroimidazopyran+drug+candidate+for+the+treatment+of+tuberculosis&doi=10.1038%2F35016103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis</span></div><div class="casAuthors">Stover, C. Kendall; Warrener, Paul; VanDevanter, Donald R.; Sherman, David R.; Arain, Taraq M.; Langhorne, Michael H.; Anderson, Scott W.; Towell, J. Andrew; Yuan, Ying; McMurray, David N.; Krelswirth, Barry N.; Barry, Clifton E.; Baker, William R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">405</span>
        (<span class="NLM_cas:issue">6789</span>),
    <span class="NLM_cas:pages">962-966</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Mycobacterium tuberculosis, which causes tuberculosis, is the greatest single infectious cause of mortality worldwide, killing roughly; two million people annually.  Ests. indicate that one-third of the world population is infected with latent M. tuberculosis.  The synergy between tuberculosis and the AIDS epidemic, and the surge of multidrug-resistant clin. isolates of M. tuberculosis have reaffirmed tuberculosis as a primary public health threat.  However, new antitubercular drugs with new mechanisms of action have not been developed in over thirty years.  Here we report a series of compds. contg. a nitroimidazopyran nucleus that possess antitubercular activity.  After activation by a mechanism dependent on M. tuberculosis F420 cofactor, nitroimidazopyrans inhibited the synthesis of protein and cell wall lipid.  In contrast to current antitubercular drugs, nitroimidazopyrans exhibited bactericidal activity against both replicating and static M. tuberculosis.  Lead compd. PA-824 showed potent bactericidal activity against multidrug-resistant M. tuberculosis and promising oral activity in animal infection models.  We conclude that nitroimidazopyrans offer the practical qualities of a small mol. with the potential for the treatment of tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrw41eD4TtVwbVg90H21EOLACvtfcHk0li2bbNkax-gvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXks1Wksb0%253D&md5=f5f6e2935928da72e328bddd4995515f</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1038%2F35016103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35016103%26sid%3Dliteratum%253Aachs%26aulast%3DStover%26aufirst%3DC.%2BK.%26aulast%3DWarrener%26aufirst%3DP.%26aulast%3DVanDevanter%26aufirst%3DD.%2BR.%26aulast%3DSherman%26aufirst%3DD.%2BR.%26aulast%3DArain%26aufirst%3DT.%2BM.%26aulast%3DLanghorne%26aufirst%3DM.%2BH.%26aulast%3DAnderson%26aufirst%3DS.%2BW.%26aulast%3DTowell%26aufirst%3DJ.%2BA.%26aulast%3DYuan%26aufirst%3DY.%26aulast%3DMcMurray%26aufirst%3DD.%2BN.%26aulast%3DKreiswirth%26aufirst%3DB.%2BN.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26aulast%3DBaker%26aufirst%3DW.%2BR.%26atitle%3DA%2520small-molecule%2520nitroimidazopyran%2520drug%2520candidate%2520for%2520the%2520treatment%2520of%2520tuberculosis%26jtitle%3DNature%26date%3D2000%26volume%3D405%26spage%3D962%26epage%3D966%26doi%3D10.1038%2F35016103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parikh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalwadi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aboti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, L.</span></span> <span> </span><span class="NLM_article-title">Inhaled microparticles of antitubercular antibiotic for in vitro and in vivo alveolar macrophage targeting and activation of phagocytosis</span>. <i>J. Antibiot.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">387</span>– <span class="NLM_lpage">394</span>, <span class="refDoi"> DOI: 10.1038/ja.2014.13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1038%2Fja.2014.13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=24569669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2cXos1artLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2014&pages=387-394&author=R.+Parikhauthor=S.+Dalwadiauthor=P.+Abotiauthor=L.+Patel&title=Inhaled+microparticles+of+antitubercular+antibiotic+for+in+vitro+and+in+vivo+alveolar+macrophage+targeting+and+activation+of+phagocytosis&doi=10.1038%2Fja.2014.13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Inhaled microparticles of antitubercular antibiotic for in vitro and in vivo alveolar macrophage targeting and activation of phagocytosis</span></div><div class="casAuthors">Parikh, Rajesh; Dalwadi, Sonali; Aboti, Pooja; Patel, Leena</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antibiotics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">387-394</span>CODEN:
                <span class="NLM_cas:coden">JANTAJ</span>;
        ISSN:<span class="NLM_cas:issn">0021-8820</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Tuberculosis (TB) is a chronic infectious disease with increasing incidence of drug resistance.  Oral treatment for TB and multidrug resistance-TB can have serious side effects.  The causative agent of TB, Mycobacterium tuberculosis, resides in alveolar macrophages (AMs).  Pulmonary administration of antitubercular (anti-TB) antibiotic can help in delivery of high concn. to AM.  The ability of AM to phagocytose can also be utilized to generate mycobactericidal nitric oxide (NO) to improve efficacy of anti-TB antibiotics.  The objective in this investigation was made to prep. isoniazid microparticles (IM) and polymeric microparticles of isoniazid (INH-PM) using poly-ε-caprolactone as polymer and to evaluate in vitro through cell culture techniques and in vivo through pulmonary administration of IM and INH-PM for uptake of isoniazid by AM.  The hepatotoxicity was detd. through serum glutamate oxaloacetate transferase (SGOT) and serum glutamate pyruvate transferase (SGPT) levels and histol. examn.  The results depicted that the significantly higher (P<0.05) concn. of isoniazid was found in AM with INH-PM in vitro and in vivo.  NO prodn. was also significantly higher but less than toxic level.  SGOT and SGPT levels, uptake of INH by liver and histol. examn. were indicative of no hepatotoxicity with INH-PM and IM.  Phagocytosis of IM and INH-PM leads to significantly higher drug level in AM as well as prodn. of significantly higher levels of NO without compromising the viability of cells.  The administration of IM and INH-PM as dry powder inhalation formulation may reduce the treatment time of TB and chances of drug-resistant TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq169CcUy19TbVg90H21EOLACvtfcHk0li2bbNkax-gvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXos1artLg%253D&md5=4ac9749042bbaa5f7dd484ed403a4c7a</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1038%2Fja.2014.13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fja.2014.13%26sid%3Dliteratum%253Aachs%26aulast%3DParikh%26aufirst%3DR.%26aulast%3DDalwadi%26aufirst%3DS.%26aulast%3DAboti%26aufirst%3DP.%26aulast%3DPatel%26aufirst%3DL.%26atitle%3DInhaled%2520microparticles%2520of%2520antitubercular%2520antibiotic%2520for%2520in%2520vitro%2520and%2520in%2520vivo%2520alveolar%2520macrophage%2520targeting%2520and%2520activation%2520of%2520phagocytosis%26jtitle%3DJ.%2520Antibiot.%26date%3D2014%26volume%3D67%26spage%3D387%26epage%3D394%26doi%3D10.1038%2Fja.2014.13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manjunatha, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boshoff, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.</span></span> <span> </span><span class="NLM_article-title">The mechanism of action of PA-824: Novel insights from transcriptional profiling</span>. <i>Commun. Integr. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">218</span>, <span class="refDoi"> DOI: 10.4161/cib.2.3.7926</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.4161%2Fcib.2.3.7926" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=19641733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1yru7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2009&pages=215-218&author=U.+Manjunathaauthor=H.+I.+Boshoffauthor=C.+E.+Barry&title=The+mechanism+of+action+of+PA-824%3A+Novel+insights+from+transcriptional+profiling&doi=10.4161%2Fcib.2.3.7926"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">The mechanism of action of PA-824: novel insights from transcriptional profiling</span></div><div class="casAuthors">Manjunatha, Ujjini; Boshoff, Helena I. M.; Barry, Clifton E., III</div><div class="citationInfo"><span class="NLM_cas:title">Communicative & Integrative Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">215-218</span>CODEN:
                <span class="NLM_cas:coden">CIBOBQ</span>;
        ISSN:<span class="NLM_cas:issn">1942-0889</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">The bicyclic nitroimidazole PA-824 is a pro-drug with a very complex mechanism of action active against both replicating and hypoxic, non-replicating Mycobacterium tuberculosis.  Microarray anal. of the mode of action of PA-824 showed a puzzling mixed effect both on genes responsive to both cell wall inhibition (like isoniazid) and respiratory poisoning (like cyanide).  The aerobic killing mechanism of this drug appears to involve inhibition of cell wall mycolic acid biosynthesis through an as yet unknown mol. mechanism.  However, the structure-activity relationships governing aerobic activity do not parallel the relationships detg. anaerobic activity.  Based on the metabolite profiling of PA-824 and various derivs. by Ddn-mediated activation, we have shown that PA-824 acts directly as an NO donor.  This respiratory poisoning through nitric oxide release seemed to be a crucial element of anaerobic activity by PA-824.  The effect of PA-824 on the respiratory complex under hypoxic non-replicating conditions was also manifested in a rapid drop in intracellular ATP levels, again similar to that obsd. by cyanide treatment.  Thus, transcriptional profiling provided valuable clues to elucidating the mol. mechanism of mycobacterial killing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRIjCfr9dB9bVg90H21EOLACvtfcHk0liej_MwgI0Wng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1yru7bF&md5=b7b25a9c2c9b39ff446571c9a2d6d297</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.4161%2Fcib.2.3.7926&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcib.2.3.7926%26sid%3Dliteratum%253Aachs%26aulast%3DManjunatha%26aufirst%3DU.%26aulast%3DBoshoff%26aufirst%3DH.%2BI.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26atitle%3DThe%2520mechanism%2520of%2520action%2520of%2520PA-824%253A%2520Novel%2520insights%2520from%2520transcriptional%2520profiling%26jtitle%3DCommun.%2520Integr.%2520Biol.%26date%3D2009%26volume%3D2%26spage%3D215%26epage%3D218%26doi%3D10.4161%2Fcib.2.3.7926" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baptista, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fazakerley, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mur, L. A. J.</span></span> <span> </span><span class="NLM_article-title">Untargeted metabolomics reveals a new mode of action of pretomanid (PA-824)</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">5084</span>, <span class="refDoi"> DOI: 10.1038/s41598-018-23110-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1038%2Fs41598-018-23110-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=29572459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A280%3ADC%252BC1MnksVelsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=5084&author=R.+Baptistaauthor=D.+M.+Fazakerleyauthor=M.+Beckmannauthor=L.+Baillieauthor=L.+A.+J.+Mur&title=Untargeted+metabolomics+reveals+a+new+mode+of+action+of+pretomanid+%28PA-824%29&doi=10.1038%2Fs41598-018-23110-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Untargeted metabolomics reveals a new mode of action of pretomanid (PA-824)</span></div><div class="casAuthors">Baptista Rafael; Fazakerley David M; Beckmann Manfred; Mur Luis A J; Baillie Les</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5084</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Pretomanid is a promising anti-tubercular drug currently at clinical phase III, but its mechanisms of action are currently unclear.  This study aimed to: (i) reveal the metabolome of Mycobacterium smegmatis under pretomanid treatment; (ii) compare major sources of metabolite variation in bacteria treated with pretomanid treatment and other antibiotics; and (iii) to target metabolites responsible for the killing activity of pretomanid in mycobacteria.  Untargeted high-resolution metabolite profiling was carried out using flow infusion electrospray ion high resolution mass spectrometry (FIE-HRMS) to identify and quantify metabolites.  The identification of key metabolites was independently confirmed by gas-chromatography time-of flight mass spectrometry (GC-tofMS) in comparison to standards.  Pretomanid treatments generated a unique distinctive metabolite profile when compared to ampicillin, ethambutol, ethionamide, isoniazid, kanamycin, linezolid, rifampicin and streptomycin.  Metabolites which differed significantly only with pretomanid treatment were identified and mapped on to bacterial metabolic pathways.  This targeted the pentose phosphate pathway with significant accumulation seen with fructose-6-phosphate, ribose-5-phosphate and glyceraldehyde-3-phosphate.  These effects were linked to the accumulation of a toxic metabolite methylglyoxal.  This compound showed significant antimicrobial activity (MIC 0.65 mM) against M. smegmatis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSTqMwunm4ScKNc3HjJRoFAfW6udTcc2ebpdbNb91mcRLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MnksVelsg%253D%253D&md5=15e388e024002bd8c2212767f7573fff</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1038%2Fs41598-018-23110-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-018-23110-1%26sid%3Dliteratum%253Aachs%26aulast%3DBaptista%26aufirst%3DR.%26aulast%3DFazakerley%26aufirst%3DD.%2BM.%26aulast%3DBeckmann%26aufirst%3DM.%26aulast%3DBaillie%26aufirst%3DL.%26aulast%3DMur%26aufirst%3DL.%2BA.%2BJ.%26atitle%3DUntargeted%2520metabolomics%2520reveals%2520a%2520new%2520mode%2520of%2520action%2520of%2520pretomanid%2520%2528PA-824%2529%26jtitle%3DSci.%2520Rep.%26date%3D2018%26volume%3D8%26spage%3D5084%26doi%3D10.1038%2Fs41598-018-23110-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoyama, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jadhav, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stratton, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilotta, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singleton, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paget, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pottorf, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davila-Pagan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kandasamy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grady, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soteropoulos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dartois, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connell, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freundlich, J. S.</span></span> <span> </span><span class="NLM_article-title">Antitubercular triazines: Optimization and intrabacterial metabolism</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">172</span>– <span class="NLM_lpage">185</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2019.10.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.chembiol.2019.10.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=31711854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFegsr3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2020&pages=172-185&issue=2&author=X.+Wangauthor=D.+Inoyamaauthor=R.+Russoauthor=S.+G.+Liauthor=R.+Jadhavauthor=T.+P.+Strattonauthor=N.+Mittalauthor=J.+A.+Bilottaauthor=E.+Singletonauthor=T.+Kimauthor=S.+D.+Pagetauthor=R.+S.+Pottorfauthor=Y.+M.+Ahnauthor=A.+Davila-Paganauthor=S.+Kandasamyauthor=C.+Gradyauthor=S.+Hussainauthor=P.+Soteropoulosauthor=M.+D.+Zimmermanauthor=H.+P.+Hoauthor=S.+Parkauthor=V.+Dartoisauthor=S.+Ekinsauthor=N.+Connellauthor=P.+Kumarauthor=J.+S.+Freundlich&title=Antitubercular+triazines%3A+Optimization+and+intrabacterial+metabolism&doi=10.1016%2Fj.chembiol.2019.10.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Antitubercular Triazines: Optimization and Intrabacterial Metabolism</span></div><div class="casAuthors">Wang, Xin; Inoyama, Daigo; Russo, Riccardo; Li, Shao-Gang; Jadhav, Ravindra; Stratton, Thomas P.; Mittal, Nisha; Bilotta, Joseph A.; Singleton, Eric; Kim, Thomas; Paget, Steve D.; Pottorf, Richard S.; Ahn, Yong-Mo; Davila-Pagan, Alejandro; Kandasamy, Srinivasan; Grady, Courtney; Hussain, Seema; Soteropoulos, Patricia; Zimmerman, Matthew D.; Ho, Hsin Pin; Park, Steven; Dartois, Veronique; Ekins, Sean; Connell, Nancy; Kumar, Pradeep; Freundlich, Joel S.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">172-185.e11</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The triazine antitubercular JSF-2019 was of interest due to its in vitro efficacy and the nitro group shared with the clin. relevant delamanid and pretomanid.  JSF-2019 undergoes activation requiring F420H2 and one or more nitroreductases in addn. to Ddn.  An intrabacterial drug metab. (IBDM) platform was leveraged to demonstrate the system kinetics, evidencing formation of NO· and a des-nitro metabolite.  Structure-activity relationship studies focused on improving the soly. and mouse pharmacokinetic profile of JSF-2019 and culminated in JSF-2513, relying on the key introduction of a morpholine.  Mechanistic studies with JSF-2019, JSF-2513, and other triazines stressed the significance of achieving potent in vitro efficacy via release of intrabacterial NO· along with inhibition of InhA and, more generally, the FAS-II pathway.  This study highlights the importance of probing IBDM and its potential to clarify mechanism of action, which in this case is a combination of NO· release and InhA inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoFhvEW0PwI7Vg90H21EOLACvtfcHk0liej_MwgI0Wng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFegsr3K&md5=e45fbb9c5c65a3bd3356df164508f921</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2019.10.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2019.10.010%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DInoyama%26aufirst%3DD.%26aulast%3DRusso%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DS.%2BG.%26aulast%3DJadhav%26aufirst%3DR.%26aulast%3DStratton%26aufirst%3DT.%2BP.%26aulast%3DMittal%26aufirst%3DN.%26aulast%3DBilotta%26aufirst%3DJ.%2BA.%26aulast%3DSingleton%26aufirst%3DE.%26aulast%3DKim%26aufirst%3DT.%26aulast%3DPaget%26aufirst%3DS.%2BD.%26aulast%3DPottorf%26aufirst%3DR.%2BS.%26aulast%3DAhn%26aufirst%3DY.%2BM.%26aulast%3DDavila-Pagan%26aufirst%3DA.%26aulast%3DKandasamy%26aufirst%3DS.%26aulast%3DGrady%26aufirst%3DC.%26aulast%3DHussain%26aufirst%3DS.%26aulast%3DSoteropoulos%26aufirst%3DP.%26aulast%3DZimmerman%26aufirst%3DM.%2BD.%26aulast%3DHo%26aufirst%3DH.%2BP.%26aulast%3DPark%26aufirst%3DS.%26aulast%3DDartois%26aufirst%3DV.%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DConnell%26aufirst%3DN.%26aulast%3DKumar%26aufirst%3DP.%26aulast%3DFreundlich%26aufirst%3DJ.%2BS.%26atitle%3DAntitubercular%2520triazines%253A%2520Optimization%2520and%2520intrabacterial%2520metabolism%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2020%26volume%3D27%26issue%3D2%26spage%3D172%26epage%3D185%26doi%3D10.1016%2Fj.chembiol.2019.10.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">e11.</p></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Swaminathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundaramurthi, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palaniappan, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, S.</span></span> <span> </span><span class="NLM_article-title">Recent developments in genomics, bioinformatics and drug discovery to combat emerging drug-resistant tuberculosis</span>. <i>Tuberculosis (Oxford, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">40</span>, <span class="refDoi"> DOI: 10.1016/j.tube.2016.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.tube.2016.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=27865394" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlGmtLjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2016&pages=31-40&author=S.+Swaminathanauthor=J.+C.+Sundaramurthiauthor=A.+N.+Palaniappanauthor=S.+Narayanan&title=Recent+developments+in+genomics%2C+bioinformatics+and+drug+discovery+to+combat+emerging+drug-resistant+tuberculosis&doi=10.1016%2Fj.tube.2016.08.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Recent developments in genomics, bioinformatics and drug discovery to combat emerging drug-resistant tuberculosis</span></div><div class="casAuthors">Swaminathan, Soumya; Sundaramurthi, Jagadish Chandrabose; Palaniappan, Alangudi Natarajan; Narayanan, Sujatha</div><div class="citationInfo"><span class="NLM_cas:title">Tuberculosis (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">31-40</span>CODEN:
                <span class="NLM_cas:coden">TUBECU</span>;
        ISSN:<span class="NLM_cas:issn">1472-9792</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Emergence of drug-resistant tuberculosis (DR-TB) is a big challenge in TB control.  The delay in diagnosis of DR-TB leads to its increased transmission, and therefore prevalence.  Recent developments in genomics have enabled whole genome sequencing (WGS) of Mycobacterium tuberculosis (M. tuberculosis) from 3-day-old liq. culture and directly from uncultured sputa, while new bioinformatics tools facilitate to det. DR mutations rapidly from the resulting sequences.  The present drug discovery and development pipeline is filled with candidate drugs which have shown efficacy against DR-TB.  Furthermore, some of the FDA-approved drugs are being evaluated for repurposing, and this approach appears promising as several drugs are reported to enhance efficacy of the std. TB drugs, reduce drug tolerance, or modulate the host immune response to control the growth of intracellular M. tuberculosis.  Recent developments in genomics and bioinformatics along with new drug discovery collectively have the potential to result in synergistic impact leading to the development of a rapid protocol to det. the drug resistance profile of the infecting strain so as to provide personalized medicine.  Hence, in this review, we discuss recent developments in WGS, bioinformatics and drug discovery to perceive how they would transform the management of tuberculosis in a timely manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm0xa2-N193rVg90H21EOLACvtfcHk0lhA_iawOO7iGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlGmtLjI&md5=c4c84cc2fce629c326acd946331be4f8</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2Fj.tube.2016.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tube.2016.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DSwaminathan%26aufirst%3DS.%26aulast%3DSundaramurthi%26aufirst%3DJ.%2BC.%26aulast%3DPalaniappan%26aufirst%3DA.%2BN.%26aulast%3DNarayanan%26aufirst%3DS.%26atitle%3DRecent%2520developments%2520in%2520genomics%252C%2520bioinformatics%2520and%2520drug%2520discovery%2520to%2520combat%2520emerging%2520drug-resistant%2520tuberculosis%26jtitle%3DTuberculosis%2520%2528Oxford%252C%2520U.%2520K.%2529%26date%3D2016%26volume%3D101%26spage%3D31%26epage%3D40%26doi%3D10.1016%2Fj.tube.2016.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Campanico, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreira, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopes, F.</span></span> <span> </span><span class="NLM_article-title">Drug discovery in tuberculosis. New drug targets and antimycobacterial agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>150</i></span>,  <span class="NLM_fpage">525</span>– <span class="NLM_lpage">545</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.03.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.ejmech.2018.03.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=29549838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkslaitbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2018&pages=525-545&author=A.+Campanicoauthor=R.+Moreiraauthor=F.+Lopes&title=Drug+discovery+in+tuberculosis.+New+drug+targets+and+antimycobacterial+agents&doi=10.1016%2Fj.ejmech.2018.03.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Drug discovery in tuberculosis. New drug targets and antimycobacterial agents</span></div><div class="casAuthors">Campanico, Andre; Moreira, Rui; Lopes, Francisca</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">525-545</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Tuberculosis (TB) remains a major health problem worldwide.  The infectious agent, Mycobacterium tuberculosis, has a unique ability to survive within the host, alternating between active and latent disease states, and escaping the immune system defenses.  The extended duration of anti-TB regimens and the increasing prevalence of multidrug- (MDR) and extensively drug-resistant (XDR) M. tuberculosis strains have created an urgent need for new antibiotics active against drug-resistant organisms and that can shorten std. therapy.  However, despite success in identifying active compds. through phenotypic screens, the conversion of hits into novel chem. series and ultimately into clin. candidates is hampered by the poor efficacy in eliminating M. tuberculosis within different host compartments, including macrophages, as well as a lack of knowledge about the specific target(s) inhibited and/or upregulated.  The current status of anti-TB lead generation has much improved over the last decade, as exemplified by the recent approval of bedaquiline and delamanid to treat MDR-TB and XDR-TB.  This review provides a crit. anal. on the strategies used to progress hit compds. into viable lead candidates, and how emerging targets may play a role in TB drug discovery in the near future.  Four new relevant targets are addressed: the enoyl-acyl carrier protein reductase, InhA; the transmembrane transport protein large, MmpL3; the decaprenylphospho-beta-D-ribofuranose 2-oxidase, DprE1; and the ubiquinol-cytochrome C reductase, QcrB.  Validated hit compds. for each target are presented and explored, and the medicinal chem. strategies to expand SAR around novel chemotypes analyzed.  In addn., very recent emerging targets are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUk-MoGG4LfbVg90H21EOLACvtfcHk0lhA_iawOO7iGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkslaitbc%253D&md5=57f1035f8081c62033438d9123ee0280</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.03.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.03.020%26sid%3Dliteratum%253Aachs%26aulast%3DCampanico%26aufirst%3DA.%26aulast%3DMoreira%26aufirst%3DR.%26aulast%3DLopes%26aufirst%3DF.%26atitle%3DDrug%2520discovery%2520in%2520tuberculosis.%2520New%2520drug%2520targets%2520and%2520antimycobacterial%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D150%26spage%3D525%26epage%3D545%26doi%3D10.1016%2Fj.ejmech.2018.03.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chiarelli, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esposito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orena, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasca, M. R.</span></span> <span> </span><span class="NLM_article-title">New and old hot drug targets in tuberculosis</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3813</span>– <span class="NLM_lpage">3846</span>, <span class="refDoi"> DOI: 10.2174/1389557516666160831164925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.2174%2F1389557516666160831164925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=27666933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVOhtbvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=3813-3846&author=L.+R.+Chiarelliauthor=G.+Moriauthor=M.+Espositoauthor=B.+S.+Orenaauthor=M.+R.+Pasca&title=New+and+old+hot+drug+targets+in+tuberculosis&doi=10.2174%2F1389557516666160831164925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">New and Old Hot Drug Targets in Tuberculosis</span></div><div class="casAuthors">Chiarelli, Laurent Roberto; Mori, Giorgia; Esposito, Marta; Orena, Beatrice Silvia; Pasca, Maria Rosalia</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">3813-3846</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Tuberculosis is an infectious disease caused by the bacillus Mycobacterium tuberculosis.  The World Health Organization publishes global tuberculosis reports annually in order to provide the latest information in the surveillance of drug resistance.  Given the alarming rise of resistance to antitubercular drugs worldwide, finding new cellular targets and developing new analogs or new compds. with greater potency against already known targets are both important aspects in fighting drug-sensitive and drug-resistant M. tuberculosis strains.  In this context, the introduction of the phenotypic screens as an efficient tool for the identification of active compds. for tuberculosis drug discovery has improved the possibility to find new effective targets.  With this review we describe the state of art of the currently well validated antitubercular drug targets as well as the advances in discovery of new ones.  The main targets will be discussed starting from the oldest such as the enoyl reductase InhA which is constantly repurposed with new inhibitors, through the well assessed targets like the gyrase, the ATP synthetase or the RNA polymerase, up to the hot promiscuous targets decaprenylphosphoryl-Dribose oxidase DprE1 and the mycolic acid transporter MmpL3, or the newly validated and promising targets like the CTP synthetase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvbtYX91i0i7Vg90H21EOLACvtfcHk0lhA_iawOO7iGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVOhtbvL&md5=f00c5400343d8a9945e1b26039fd95f1</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.2174%2F1389557516666160831164925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389557516666160831164925%26sid%3Dliteratum%253Aachs%26aulast%3DChiarelli%26aufirst%3DL.%2BR.%26aulast%3DMori%26aufirst%3DG.%26aulast%3DEsposito%26aufirst%3DM.%26aulast%3DOrena%26aufirst%3DB.%2BS.%26aulast%3DPasca%26aufirst%3DM.%2BR.%26atitle%3DNew%2520and%2520old%2520hot%2520drug%2520targets%2520in%2520tuberculosis%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2016%26volume%3D23%26spage%3D3813%26epage%3D3846%26doi%3D10.2174%2F1389557516666160831164925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mdluli, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upton, A.</span></span> <span> </span><span class="NLM_article-title">The tuberculosis drug discovery and development pipeline and emerging drug targets</span>. <i>Cold Spring Harbor Perspect. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">a021154</span>, <span class="refDoi"> DOI: 10.1101/cshperspect.a021154</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1101%2Fcshperspect.a021154" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=25635061" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=a021154&author=K.+Mdluliauthor=T.+Kanekoauthor=A.+Upton&title=The+tuberculosis+drug+discovery+and+development+pipeline+and+emerging+drug+targets&doi=10.1101%2Fcshperspect.a021154"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a021154&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a021154%26sid%3Dliteratum%253Aachs%26aulast%3DMdluli%26aufirst%3DK.%26aulast%3DKaneko%26aufirst%3DT.%26aulast%3DUpton%26aufirst%3DA.%26atitle%3DThe%2520tuberculosis%2520drug%2520discovery%2520and%2520development%2520pipeline%2520and%2520emerging%2520drug%2520targets%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspect.%2520Med.%26date%3D2015%26volume%3D5%26spage%3Da021154%26doi%3D10.1101%2Fcshperspect.a021154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Man Chin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dos Santos, J. L.</span></span> <span> </span><span class="NLM_article-title">Advances in drug discovery of new antitubercular multidrug-resistant compounds</span>. <i>Pharmaceuticals</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">51</span>, <span class="refDoi"> DOI: 10.3390/ph10020051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.3390%2Fph10020051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVGgtL3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2017&pages=51&author=G.+Fernandesauthor=C.+Man+Chinauthor=J.+L.+Dos+Santos&title=Advances+in+drug+discovery+of+new+antitubercular+multidrug-resistant+compounds&doi=10.3390%2Fph10020051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in drug discovery of new antitubercular multidrug-resistant compounds</span></div><div class="casAuthors">Fernandes, Guilherme Felipe dos Santos; Chin, Chung Man; Dos, Jean Leandro Santo</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceuticals</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">51/1-51/17</span>CODEN:
                <span class="NLM_cas:coden">PHARH2</span>;
        ISSN:<span class="NLM_cas:issn">1424-8247</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Tuberculosis (TB), a disease caused mainly by the Mycobacterium tuberculosis (Mtb), is according to the World Health Organization (WHO) the infectious disease responsible for the highest no. of deaths worldwide.  The increased no. of multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) strains, and the ineffectiveness of the current treatment against latent tuberculosis are challenges to be overcome in the coming years.  The scenario of drug discovery becomes alarming when it is considered that the no. of new drugs does not increase proportionally to the emergence of drug resistance.  In this review, we will demonstrate the current advances in antitubercular drug discovery, focusing on the research of compds. with potent antituberculosis activity against MDR-TB strains.  Herein, active compds. against MDR-TB with min. inhibitory concns. (MICs) less than 11 μM and low toxicity published in the last 4 years in the databases PubMed, Web of Science and Scopus will be presented and discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr42opO3TGqlbVg90H21EOLACvtfcHk0liZ7KapO6F42Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVGgtL3F&md5=396d4e24b26faa44e68f661e6706b2e6</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.3390%2Fph10020051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fph10020051%26sid%3Dliteratum%253Aachs%26aulast%3DFernandes%26aufirst%3DG.%26aulast%3DMan%2BChin%26aufirst%3DC.%26aulast%3DDos%2BSantos%26aufirst%3DJ.%2BL.%26atitle%3DAdvances%2520in%2520drug%2520discovery%2520of%2520new%2520antitubercular%2520multidrug-resistant%2520compounds%26jtitle%3DPharmaceuticals%26date%3D2017%26volume%3D10%26spage%3D51%26doi%3D10.3390%2Fph10020051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, R.</span></span> <span> </span><span class="NLM_article-title">New structural classes of antituberculosis agents</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">684</span>– <span class="NLM_lpage">740</span>, <span class="refDoi"> DOI: 10.1002/med.21454</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1002%2Fmed.21454" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=28598559" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A280%3ADC%252BC1cnmslWltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2018&pages=684-740&author=V.+Kumarauthor=S.+Patelauthor=R.+Jain&title=New+structural+classes+of+antituberculosis+agents&doi=10.1002%2Fmed.21454"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">New structural classes of antituberculosis agents</span></div><div class="casAuthors">Kumar Vajinder; Patel Sanjay; Jain Rahul; Kumar Vajinder</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal research reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">684-740</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Tuberculosis (TB), one of the deadliest diseases is shattering the health and socioeconomic status of the society.  The emergence of multidrug resistant (MDR) and extremely drug resistant (XDR) strains has provided unprecedented lethal character to TB.  The development of MDR and XDR strains of TB results in more deaths, longer duration of therapy, and appearance of the disease in the immunocompromised patients.  Because of the development of rapid resistance by Mycobacterium tuberculosis, researchers are confronted with serious challenges in combating TB.  For instance, the need for potency and specificity in therapeutic agents approaching clinics, and the increasing demand of low toxicity due to long duration of treatment.  Recently, it is proposed that such challenges could be addressed by a shift from contemporary or known classes of drugs to new scaffold-containing or entirely new structural classes of drugs that possibly act on the previously unknown targets, resulting in possibly less instances of resistance development.  The exploitation of advances made in the biology of TB in the last and present decades have created opportunities to discover a large number of new structural classes that specifically targets TB by molecular mechanism of action(s) unknown earlier.  We have earlier reviewed new structural classes of anti-TB agents up to year 2005.  This review covers literature reports of the subsequent 10 years on the discovery of new structural classes of synthetic anti-TB agents.  Due to the availability of large number of research reports, we have divided new compounds in 38 structural classes, 368 structures, and 307 references.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSeCgKMDdtGrekdrW1FkXG-fW6udTcc2eZHm8KqC7EZ0bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnmslWltg%253D%253D&md5=78d6b10f567bb66c82241ab993b160e4</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1002%2Fmed.21454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21454%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DJain%26aufirst%3DR.%26atitle%3DNew%2520structural%2520classes%2520of%2520antituberculosis%2520agents%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2018%26volume%3D38%26spage%3D684%26epage%3D740%26doi%3D10.1002%2Fmed.21454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">da
Silva, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campos, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribeiro, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Silva, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavan, F. R.</span></span> <span> </span><span class="NLM_article-title">New antimycobacterial agents in the pre-clinical phase or beyond: Recent advances in patent literature (2001–2016)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">269</span>– <span class="NLM_lpage">282</span>, <span class="refDoi"> DOI: 10.1080/13543776.2017.1253681</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1080%2F13543776.2017.1253681" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=27796146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVOjsLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=269-282&author=P.+B.+da%0ASilvaauthor=D.+L.+Camposauthor=C.+M.+Ribeiroauthor=I.+C.+da+Silvaauthor=F.+R.+Pavan&title=New+antimycobacterial+agents+in+the+pre-clinical+phase+or+beyond%3A+Recent+advances+in+patent+literature+%282001%E2%80%932016%29&doi=10.1080%2F13543776.2017.1253681"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">New antimycobacterial agents in the pre-clinical phase or beyond: recent advances in patent literature (2001-2016)</span></div><div class="casAuthors">da Silva, Patricia Bento; Campos, Debora Leite; Ribeiro, Camila Maringolo; da Silva, Isabel Cristiane; Pavan, Fernando Rogerio</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">269-282</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Introduction: Tuberculosis, an infectious disease, has caused more deaths worldwide than any other single infectious disease, killing more than 1.5 million people each year; equating to 4,100 deaths a day.  In the past 60 years, no new drugs have been added to the first line regimen, in spite of the fact that thousands of papers have been published on drugs against tuberculosis and hundreds of drugs have received patents as new potential products.  Thus, there is undoubtedly an urgent need for the deployment of new effective drugs against tuberculosis.  Areas covered: This review brings to the reader the opportunity to understand the chem. and biol. characteristics of all patented anti-tuberculosis drugs in North America, Europe, Japan, and Russia.  The 116 patents discussed here concern new mols. in the early or advanced phase of development in the last 16 years.  Expert opinion: Of all 116 patents, only one developed drug, bedaquiline, is used, and then, only in specific cases.  Another three drugs are in clin. studies.  However, many other compds., for which there are in vitro and in vivo studies, seem to fulfil the requisite criteria to be a new anti-tuberculosis agent.  However, why are they not in use.  Why were so many studies interrupted.  Why is there no more news for many of these drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1S72vxKotPLVg90H21EOLACvtfcHk0liZ7KapO6F42Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVOjsLjP&md5=b2360bfe2bcff758c005ef23c6905660</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1080%2F13543776.2017.1253681&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2017.1253681%26sid%3Dliteratum%253Aachs%26aulast%3Dda%2BSilva%26aufirst%3DP.%2BB.%26aulast%3DCampos%26aufirst%3DD.%2BL.%26aulast%3DRibeiro%26aufirst%3DC.%2BM.%26aulast%3Dda%2BSilva%26aufirst%3DI.%2BC.%26aulast%3DPavan%26aufirst%3DF.%2BR.%26atitle%3DNew%2520antimycobacterial%2520agents%2520in%2520the%2520pre-clinical%2520phase%2520or%2520beyond%253A%2520Recent%2520advances%2520in%2520patent%2520literature%2520%25282001%25E2%2580%25932016%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2017%26volume%3D27%26spage%3D269%26epage%3D282%26doi%3D10.1080%2F13543776.2017.1253681" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evangelopoulos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHugh, T. D.</span></span> <span> </span><span class="NLM_article-title">Improving the tuberculosis drug development pipeline</span>. <i>Chem. Biol. Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">951</span>– <span class="NLM_lpage">960</span>, <span class="refDoi"> DOI: 10.1111/cbdd.12549</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1111%2Fcbdd.12549" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=25772393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1CntL7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2015&pages=951-960&author=D.+Evangelopoulosauthor=T.+D.+McHugh&title=Improving+the+tuberculosis+drug+development+pipeline&doi=10.1111%2Fcbdd.12549"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Improving the Tuberculosis Drug Development Pipeline</span></div><div class="casAuthors">Evangelopoulos, Dimitrios; McHugh, Timothy D.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">951-960</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Mycobacterium tuberculosis is considered one of the most successful pathogens and multidrug-resistant tuberculosis, a disease that urgently requires new chem. entities to be developed for treatment.  There are currently several new mols. under clin. investigation in the tuberculosis (TB) drug development pipeline.  However, the complex lifestyle of M. tuberculosis within the host presents a barrier to the development of new drugs.  In this review, we highlight the reasons that make TB drug discovery and development challenging as well as providing solns., future directions and alternative approaches to new therapeutics for TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiYXL_L7EpMrVg90H21EOLACvtfcHk0ljOxzSGvXBkzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1CntL7L&md5=942bf372a15ce0c8d21f6b121552d892</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1111%2Fcbdd.12549&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcbdd.12549%26sid%3Dliteratum%253Aachs%26aulast%3DEvangelopoulos%26aufirst%3DD.%26aulast%3DMcHugh%26aufirst%3DT.%2BD.%26atitle%3DImproving%2520the%2520tuberculosis%2520drug%2520development%2520pipeline%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2015%26volume%3D86%26spage%3D951%26epage%3D960%26doi%3D10.1111%2Fcbdd.12549" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Libardo, M. D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boshoff, H. I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.,  III</span></span> <span> </span><span class="NLM_article-title">The present state of the tuberculosis drug development pipeline</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">81</span>– <span class="NLM_lpage">94</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2018.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.coph.2018.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=30144650" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2018&pages=81-94&author=M.+D.+J.+Libardoauthor=H.+I.+M.+Boshoffauthor=C.+E.+Barry&title=The+present+state+of+the+tuberculosis+drug+development+pipeline&doi=10.1016%2Fj.coph.2018.08.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2018.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2018.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DLibardo%26aufirst%3DM.%2BD.%2BJ.%26aulast%3DBoshoff%26aufirst%3DH.%2BI.%2BM.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26atitle%3DThe%2520present%2520state%2520of%2520the%2520tuberculosis%2520drug%2520development%2520pipeline%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2018%26volume%3D42%26spage%3D81%26epage%3D94%26doi%3D10.1016%2Fj.coph.2018.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trapero, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacitto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabbah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coyne, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizrahi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blundell, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ascher, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abell, C.</span></span> <span> </span><span class="NLM_article-title">Fragment-based approach to targeting inosine-5′-monophosphate dehydrogenase (IMPDH) from mycobacterium tuberculosis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2806</span>– <span class="NLM_lpage">2822</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01622</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01622" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltVGksb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2806-2822&author=A.+Traperoauthor=A.+Pacittoauthor=V.+Singhauthor=M.+Sabbahauthor=A.+G.+Coyneauthor=V.+Mizrahiauthor=T.+L.+Blundellauthor=D.+B.+Ascherauthor=C.+Abell&title=Fragment-based+approach+to+targeting+inosine-5%E2%80%B2-monophosphate+dehydrogenase+%28IMPDH%29+from+mycobacterium+tuberculosis&doi=10.1021%2Facs.jmedchem.7b01622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-Based Approach to Targeting Inosine-5'-monophosphate Dehydrogenase (IMPDH) from Mycobacterium tuberculosis</span></div><div class="casAuthors">Trapero, Ana; Pacitto, Angela; Singh, Vinayak; Sabbah, Mohamad; Coyne, Anthony G.; Mizrahi, Valerie; Blundell, Tom L.; Ascher, David B.; Abell, Chris</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2806-2822</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tuberculosis (TB) remains a major cause of mortality worldwide, and improved treatments are needed to combat emergence of drug resistance.  IMP dehydrogenase (IMPDH), a crucial enzyme required for de novo synthesis of guanine nucleotides, is an attractive TB drug target.  Herein, we describe the identification of potent IMPDH inhibitors using fragment-based screening and structure-based design techniques.  Screening of a fragment library for Mycobacterium thermoresistible (Mth) IMPDH ΔCBS inhibitors identified a low affinity phenylimidazole deriv.  X-ray crystallog. of the Mth IMPDH ΔCBS-IMP-inhibitor complex revealed that two mols. of the fragment were bound in the NAD binding pocket of IMPDH.  Linking the two mols. of the fragment afforded compds. with more than 1000-fold improvement in IMPDH affinity over the initial fragment hit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIloJxzRRl5bVg90H21EOLACvtfcHk0ljOxzSGvXBkzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltVGksb0%253D&md5=a0decf859d321144e41547dda2b38fbf</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01622%26sid%3Dliteratum%253Aachs%26aulast%3DTrapero%26aufirst%3DA.%26aulast%3DPacitto%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DV.%26aulast%3DSabbah%26aufirst%3DM.%26aulast%3DCoyne%26aufirst%3DA.%2BG.%26aulast%3DMizrahi%26aufirst%3DV.%26aulast%3DBlundell%26aufirst%3DT.%2BL.%26aulast%3DAscher%26aufirst%3DD.%2BB.%26aulast%3DAbell%26aufirst%3DC.%26atitle%3DFragment-based%2520approach%2520to%2520targeting%2520inosine-5%25E2%2580%25B2-monophosphate%2520dehydrogenase%2520%2528IMPDH%2529%2520from%2520mycobacterium%2520tuberculosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D2806%26epage%3D2822%26doi%3D10.1021%2Facs.jmedchem.7b01622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ananthan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faaleolea, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobrath, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwong, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laughon, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maddry, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasmussen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Secrist, J. A.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shindo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Showe, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosa, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suling, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, E. L.</span></span> <span> </span><span class="NLM_article-title">High-throughput screening for inhibitors of mycobacterium tuberculosis h37rv</span>. <i>Tuberculosis (Oxford, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">334</span>– <span class="NLM_lpage">353</span>, <span class="refDoi"> DOI: 10.1016/j.tube.2009.05.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.tube.2009.05.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=19758845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlaktbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2009&pages=334-353&author=S.+Ananthanauthor=E.+R.+Faaleoleaauthor=R.+C.+Goldmanauthor=J.+V.+Hobrathauthor=C.+D.+Kwongauthor=B.+E.+Laughonauthor=J.+A.+Maddryauthor=A.+Mehtaauthor=L.+Rasmussenauthor=R.+C.+Reynoldsauthor=J.+A.+Secristauthor=N.+Shindoauthor=D.+N.+Showeauthor=M.+I.+Sosaauthor=W.+J.+Sulingauthor=E.+L.+White&title=High-throughput+screening+for+inhibitors+of+mycobacterium+tuberculosis+h37rv&doi=10.1016%2Fj.tube.2009.05.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv</span></div><div class="casAuthors">Ananthan, Subramaniam; Faaleolea, Ellen R.; Goldman, Robert C.; Hobrath, Judith V.; Kwong, Cecil D.; Laughon, Barbara E.; Maddry, Joseph A.; Mehta, Alka; Rasmussen, Lynn; Reynolds, Robert C.; Secrist, John A., III; Shindo, Nice; Showe, Dustin N.; Sosa, Melinda I.; Suling, William J.; White, E. Lucile</div><div class="citationInfo"><span class="NLM_cas:title">Tuberculosis (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">334-353</span>CODEN:
                <span class="NLM_cas:coden">TUBECU</span>;
        ISSN:<span class="NLM_cas:issn">1472-9792</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">There is an urgent need for the discovery and development of new antitubercular agents that target new biochem. pathways and treat drug resistant forms of the disease.  One approach to addressing this need is through high-throughput screening of medicinally relevant libraries against the whole bacterium in order to discover a variety of new, active scaffolds that will stimulate new biol. research and drug discovery.  Through the Tuberculosis Antimicrobial Acquisition and Coordinating Facility (www.taacf.org), a large, medicinally relevant chem. library was screened against M. tuberculosis strain H37Rv.  The screening methods and a medicinal chem. anal. of the results are reported herein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqJYVfZDJLPrVg90H21EOLACvtfcHk0ljOxzSGvXBkzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlaktbs%253D&md5=709badc384ae51ed8c9d42e30d4e9653</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.tube.2009.05.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tube.2009.05.008%26sid%3Dliteratum%253Aachs%26aulast%3DAnanthan%26aufirst%3DS.%26aulast%3DFaaleolea%26aufirst%3DE.%2BR.%26aulast%3DGoldman%26aufirst%3DR.%2BC.%26aulast%3DHobrath%26aufirst%3DJ.%2BV.%26aulast%3DKwong%26aufirst%3DC.%2BD.%26aulast%3DLaughon%26aufirst%3DB.%2BE.%26aulast%3DMaddry%26aufirst%3DJ.%2BA.%26aulast%3DMehta%26aufirst%3DA.%26aulast%3DRasmussen%26aufirst%3DL.%26aulast%3DReynolds%26aufirst%3DR.%2BC.%26aulast%3DSecrist%26aufirst%3DJ.%2BA.%26aulast%3DShindo%26aufirst%3DN.%26aulast%3DShowe%26aufirst%3DD.%2BN.%26aulast%3DSosa%26aufirst%3DM.%2BI.%26aulast%3DSuling%26aufirst%3DW.%2BJ.%26aulast%3DWhite%26aufirst%3DE.%2BL.%26atitle%3DHigh-throughput%2520screening%2520for%2520inhibitors%2520of%2520mycobacterium%2520tuberculosis%2520h37rv%26jtitle%3DTuberculosis%2520%2528Oxford%252C%2520U.%2520K.%2529%26date%3D2009%26volume%3D89%26spage%3D334%26epage%3D353%26doi%3D10.1016%2Fj.tube.2009.05.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maddry, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ananthan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobrath, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwong, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maddox, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasmussen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Secrist, J. A.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosa, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span> <span> </span><span class="NLM_article-title">Antituberculosis activity of the molecular libraries screening center network library</span>. <i>Tuberculosis (Oxford, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">354</span>– <span class="NLM_lpage">363</span>, <span class="refDoi"> DOI: 10.1016/j.tube.2009.07.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.tube.2009.07.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=19783214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlaktbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2009&pages=354-363&author=J.+A.+Maddryauthor=S.+Ananthanauthor=R.+C.+Goldmanauthor=J.+V.+Hobrathauthor=C.+D.+Kwongauthor=C.+Maddoxauthor=L.+Rasmussenauthor=R.+C.+Reynoldsauthor=J.+A.+Secristauthor=M.+I.+Sosaauthor=E.+L.+Whiteauthor=W.+Zhang&title=Antituberculosis+activity+of+the+molecular+libraries+screening+center+network+library&doi=10.1016%2Fj.tube.2009.07.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Antituberculosis activity of the Molecular Libraries Screening Center Network library</span></div><div class="casAuthors">Maddry, Joseph A.; Ananthan, Subramaniam; Goldman, Robert C.; Hobrath, Judith V.; Kwong, Cecil D.; Maddox, Clinton; Rasmussen, Lynn; Reynolds, Robert C.; Secrist, John A., III; Sosa, Melinda I.; White, E. Lucile; Zhang, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Tuberculosis (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">354-363</span>CODEN:
                <span class="NLM_cas:coden">TUBECU</span>;
        ISSN:<span class="NLM_cas:issn">1472-9792</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">There is an urgent need for the discovery and development of new antitubercular agents that target novel biochem. pathways and treat drug-resistant forms of the disease.  One approach to addressing this need is through high-throughput screening of drug-like small mol. libraries against the whole bacterium in order to identify a variety of new, active scaffolds that will stimulate addnl. biol. research and drug discovery.  Through the Mol. Libraries Screening Center Network, the NIAID Tuberculosis Antimicrobial Acquisition and Coordinating Facility tested a 215,110-compd. library against Mycobacterium tuberculosis strain H37Rv.  A medicinal chem. survey of the results from the screening campaign is reported herein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH1oCyettJJLVg90H21EOLACvtfcHk0lj82R3JVzI_Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlaktbY%253D&md5=2b8d1ea9ef392231534d6eb020771da9</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1016%2Fj.tube.2009.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tube.2009.07.006%26sid%3Dliteratum%253Aachs%26aulast%3DMaddry%26aufirst%3DJ.%2BA.%26aulast%3DAnanthan%26aufirst%3DS.%26aulast%3DGoldman%26aufirst%3DR.%2BC.%26aulast%3DHobrath%26aufirst%3DJ.%2BV.%26aulast%3DKwong%26aufirst%3DC.%2BD.%26aulast%3DMaddox%26aufirst%3DC.%26aulast%3DRasmussen%26aufirst%3DL.%26aulast%3DReynolds%26aufirst%3DR.%2BC.%26aulast%3DSecrist%26aufirst%3DJ.%2BA.%26aulast%3DSosa%26aufirst%3DM.%2BI.%26aulast%3DWhite%26aufirst%3DE.%2BL.%26aulast%3DZhang%26aufirst%3DW.%26atitle%3DAntituberculosis%2520activity%2520of%2520the%2520molecular%2520libraries%2520screening%2520center%2520network%2520library%26jtitle%3DTuberculosis%2520%2528Oxford%252C%2520U.%2520K.%2529%26date%3D2009%26volume%3D89%26spage%3D354%26epage%3D363%26doi%3D10.1016%2Fj.tube.2009.07.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ananthan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faaleolea, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobrath, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwong, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maddox, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasmussen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosa, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thammasuvimol, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Secrist, J. A.,  3rd.</span></span> <span> </span><span class="NLM_article-title">High throughput screening of a library based on kinase inhibitor scaffolds against mycobacterium tuberculosis h37rv</span>. <i>Tuberculosis (Oxford, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">72</span>– <span class="NLM_lpage">83</span>, <span class="refDoi"> DOI: 10.1016/j.tube.2011.05.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.tube.2011.05.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=21708485" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVCjur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2012&pages=72-83&author=R.+C.+Reynoldsauthor=S.+Ananthanauthor=E.+Faaleoleaauthor=J.+V.+Hobrathauthor=C.+D.+Kwongauthor=C.+Maddoxauthor=L.+Rasmussenauthor=M.+I.+Sosaauthor=E.+Thammasuvimolauthor=E.+L.+Whiteauthor=W.+Zhangauthor=J.+A.+Secrist&title=High+throughput+screening+of+a+library+based+on+kinase+inhibitor+scaffolds+against+mycobacterium+tuberculosis+h37rv&doi=10.1016%2Fj.tube.2011.05.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">High throughput screening of a library based on kinase inhibitor scaffolds against Mycobacterium tuberculosis H37Rv</span></div><div class="casAuthors">Reynolds, Robert C.; Ananthan, Subramaniam; Faaleolea, Ellen; Hobrath, Judith V.; Kwong, Cecil D.; Maddox, Clinton; Rasmussen, Lynn; Sosa, Melinda I.; Thammasuvimol, Elizabeth; White, E. Lucile; Zhang, Wei; Secrist, John A., III</div><div class="citationInfo"><span class="NLM_cas:title">Tuberculosis (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">72-83</span>CODEN:
                <span class="NLM_cas:coden">TUBECU</span>;
        ISSN:<span class="NLM_cas:issn">1472-9792</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Summary: Kinase targets are being pursued in a variety of diseases beyond cancer, including immune and metabolic as well as viral, parasitic, fungal and bacterial.  In particular, there is a relatively recent interest in kinase and ATP-binding targets in Mycobacterium tuberculosis in order to identify inhibitors and potential drugs for essential proteins that are not targeted by current drug regimens.  Herein, we report the high throughput screening results for a targeted library of approx. 26,000 compds. that was designed based on current kinase inhibitor scaffolds and known kinase binding sites.  The phenotypic data presented herein may form the basis for selecting scaffolds/compds. for further enzymic screens against specific kinase or other ATP-binding targets in Mycobacterium tuberculosis based on the apparent activity against the whole bacteria in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMT3SfbMPvRLVg90H21EOLACvtfcHk0lj82R3JVzI_Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVCjur0%253D&md5=00aa700691dc03d427fd3d4851e605b7</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2Fj.tube.2011.05.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tube.2011.05.005%26sid%3Dliteratum%253Aachs%26aulast%3DReynolds%26aufirst%3DR.%2BC.%26aulast%3DAnanthan%26aufirst%3DS.%26aulast%3DFaaleolea%26aufirst%3DE.%26aulast%3DHobrath%26aufirst%3DJ.%2BV.%26aulast%3DKwong%26aufirst%3DC.%2BD.%26aulast%3DMaddox%26aufirst%3DC.%26aulast%3DRasmussen%26aufirst%3DL.%26aulast%3DSosa%26aufirst%3DM.%2BI.%26aulast%3DThammasuvimol%26aufirst%3DE.%26aulast%3DWhite%26aufirst%3DE.%2BL.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DSecrist%26aufirst%3DJ.%2BA.%26atitle%3DHigh%2520throughput%2520screening%2520of%2520a%2520library%2520based%2520on%2520kinase%2520inhibitor%2520scaffolds%2520against%2520mycobacterium%2520tuberculosis%2520h37rv%26jtitle%3DTuberculosis%2520%2528Oxford%252C%2520U.%2520K.%2529%26date%3D2012%26volume%3D92%26spage%3D72%26epage%3D83%26doi%3D10.1016%2Fj.tube.2011.05.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Makarov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lechartier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neres, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Sar, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raadsen, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartkoorn, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryabova, O. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decosterd, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widmer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buclin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bitter, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pojer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyson, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S. T.</span></span> <span> </span><span class="NLM_article-title">Towards a new combination therapy for tuberculosis with next generation benzothiazinones</span>. <i>EMBO Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">372</span>– <span class="NLM_lpage">383</span>, <span class="refDoi"> DOI: 10.1002/emmm.201303575</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1002%2Femmm.201303575" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=24500695" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjvVyjtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=372-383&author=V.+Makarovauthor=B.+Lechartierauthor=M.+Zhangauthor=J.+Neresauthor=A.+M.+van+der%0ASarauthor=S.+A.+Raadsenauthor=R.+C.+Hartkoornauthor=O.+B.+Ryabovaauthor=A.+Vocatauthor=L.+A.+Decosterdauthor=N.+Widmerauthor=T.+Buclinauthor=W.+Bitterauthor=K.+Andriesauthor=F.+Pojerauthor=P.+J.+Dysonauthor=S.+T.+Cole&title=Towards+a+new+combination+therapy+for+tuberculosis+with+next+generation+benzothiazinones&doi=10.1002%2Femmm.201303575"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Towards a new combination therapy for tuberculosis with next generation benzothiazinones</span></div><div class="casAuthors">Makarov, Vadim; Lechartier, Benoit; Zhang, Ming; Neres, Joao; van der Sar, Astrid M.; Raadsen, Susanne A.; Hartkoorn, Ruben C.; Ryabova, Olga B.; Vocat, Anthony; Decosterd, Laurent A.; Widmer, Nicolas; Buclin, Thierry; Bitter, Wilbert; Andries, Koen; Pojer, Florence; Dyson, Paul J.; Cole, Stewart T.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Molecular Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">372-383</span>CODEN:
                <span class="NLM_cas:coden">EMMMAM</span>;
        ISSN:<span class="NLM_cas:issn">1757-4684</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The benzothiazinone lead compd., BTZ043, kills Mycobacterium tuberculosis by inhibiting the essential flavo-enzyme DprE1, decaprenylphosphoryl-beta-D-ribose 2-epimerase.  Here, we synthesized a new series of piperazine-contg. benzothiazinones (PBTZ) and show that, like BTZ043, the preclin. candidate PBTZ169 binds covalently to DprE1.  The crystal structure of the DprE1-PBTZ169 complex reveals formation of a semimercaptal adduct with Cys387 in the active site and explains the irreversible inactivation of the enzyme.  Compared to BTZ043, PBTZ169 has improved potency, safety and efficacy in zebrafish and mouse models of tuberculosis (TB).  When combined with other TB drugs, PBTZ169 showed additive activity against M. tuberculosis in vitro except with bedaquiline (BDQ) where synergy was obsd.  A new regimen comprising PBTZ169, BDQ and pyrazinamide was found to be more efficacious than the std. three drug treatment in a murine model of chronic disease.  PBTZ169 is thus an attractive drug candidate to treat TB in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_BD_M46wCiLVg90H21EOLACvtfcHk0liG6szRQAO9QQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjvVyjtLw%253D&md5=5393e68ca6f35be17ae10a397b443907</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1002%2Femmm.201303575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Femmm.201303575%26sid%3Dliteratum%253Aachs%26aulast%3DMakarov%26aufirst%3DV.%26aulast%3DLechartier%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DNeres%26aufirst%3DJ.%26aulast%3Dvan%2Bder%2BSar%26aufirst%3DA.%2BM.%26aulast%3DRaadsen%26aufirst%3DS.%2BA.%26aulast%3DHartkoorn%26aufirst%3DR.%2BC.%26aulast%3DRyabova%26aufirst%3DO.%2BB.%26aulast%3DVocat%26aufirst%3DA.%26aulast%3DDecosterd%26aufirst%3DL.%2BA.%26aulast%3DWidmer%26aufirst%3DN.%26aulast%3DBuclin%26aufirst%3DT.%26aulast%3DBitter%26aufirst%3DW.%26aulast%3DAndries%26aufirst%3DK.%26aulast%3DPojer%26aufirst%3DF.%26aulast%3DDyson%26aufirst%3DP.%2BJ.%26aulast%3DCole%26aufirst%3DS.%2BT.%26atitle%3DTowards%2520a%2520new%2520combination%2520therapy%2520for%2520tuberculosis%2520with%2520next%2520generation%2520benzothiazinones%26jtitle%3DEMBO%2520Mol.%2520Med.%26date%3D2014%26volume%3D6%26spage%3D372%26epage%3D383%26doi%3D10.1002%2Femmm.201303575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Makarov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manina, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikusova, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mollmann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryabova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saint-Joanis, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasca, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buroni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucarelli, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rossi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belanova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bobovska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dianiskova, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kordulakova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sala, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fullam, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKinney, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christophe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waddell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butcher, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrethsen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenkrands, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brosch, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nandi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bharath, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaonkar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shandil, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balganesh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyagi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosset, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riccardi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S. T.</span></span> <span> </span><span class="NLM_article-title">Benzothiazinones kill mycobacterium tuberculosis by blocking arabinan synthesis</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>324</i></span>,  <span class="NLM_fpage">801</span>– <span class="NLM_lpage">804</span>, <span class="refDoi"> DOI: 10.1126/science.1171583</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1126%2Fscience.1171583" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=19299584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsVeksrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=324&publication_year=2009&pages=801-804&author=V.+Makarovauthor=G.+Maninaauthor=K.+Mikusovaauthor=U.+Mollmannauthor=O.+Ryabovaauthor=B.+Saint-Joanisauthor=N.+Dharauthor=M.+R.+Pascaauthor=S.+Buroniauthor=A.+P.+Lucarelliauthor=A.+Milanoauthor=E.+De+Rossiauthor=M.+Belanovaauthor=A.+Bobovskaauthor=P.+Dianiskovaauthor=J.+Kordulakovaauthor=C.+Salaauthor=E.+Fullamauthor=P.+Schneiderauthor=J.+D.+McKinneyauthor=P.+Brodinauthor=T.+Christopheauthor=S.+Waddellauthor=P.+Butcherauthor=J.+Albrethsenauthor=I.+Rosenkrandsauthor=R.+Broschauthor=V.+Nandiauthor=S.+Bharathauthor=S.+Gaonkarauthor=R.+K.+Shandilauthor=V.+Balasubramanianauthor=T.+Balganeshauthor=S.+Tyagiauthor=J.+Grossetauthor=G.+Riccardiauthor=S.+T.+Cole&title=Benzothiazinones+kill+mycobacterium+tuberculosis+by+blocking+arabinan+synthesis&doi=10.1126%2Fscience.1171583"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis</span></div><div class="casAuthors">Makarov, Vadim; Manina, Giulia; Mikusova, Katarina; Moellmann, Ute; Ryabova, Olga; Saint-Joanis, Brigitte; Dhar, Neeraj; Pasca, Maria Rosalia; Buroni, Silvia; Lucarelli, Anna Paola; Milano, Anna; De Rossi, Edda; Belanova, Martina; Bobovska, Adela; Dianiskova, Petronela; Kordulakova, Jana; Sala, Claudia; Fullam, Elizabeth; Schneider, Patricia; McKinney, John D.; Brodin, Priscille; Christophe, Thierry; Waddell, Simon; Butcher, Philip; Albrethsen, Jakob; Rosenkrands, Ida; Brosch, Roland; Nandi, Vrinda; Bharath, Sowmya; Gaonkar, Sheshagiri; Shandil, Radha K.; Balasubramanian, Venkataraman; Balganesh, Tanjore; Tyagi, Sandeep; Grosset, Jacques; Riccardi, Giovanna; Cole, Stewart T.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">324</span>
        (<span class="NLM_cas:issue">5928</span>),
    <span class="NLM_cas:pages">801-804</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">New drugs are required to counter the tuberculosis (TB) pandemic.  Here, we describe the synthesis and characterization of 1,3-benzothiazin-4-ones (BTZs), a new class of antimycobacterial agents that kill Mycobacterium tuberculosis in vitro, ex vivo, and in mouse models of TB.  Using genetics and biochem., we identified the enzyme decaprenylphosphoryl-β-D-ribose 2'-epimerase as a major BTZ target.  Inhibition of this enzymic activity abolishes the formation of decaprenylphosphoryl arabinose, a key precursor that is required for the synthesis of the cell-wall arabinans, thus provoking cell lysis and bacterial death.  The most advanced compd., BTZ043, is a candidate for inclusion in combination therapies for both drug-sensitive and extensively drug-resistant TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZiVvk0T_DOrVg90H21EOLACvtfcHk0liG6szRQAO9QQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsVeksrY%253D&md5=1d80f14ba88460ef5c8ea31793dbb592</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1126%2Fscience.1171583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1171583%26sid%3Dliteratum%253Aachs%26aulast%3DMakarov%26aufirst%3DV.%26aulast%3DManina%26aufirst%3DG.%26aulast%3DMikusova%26aufirst%3DK.%26aulast%3DMollmann%26aufirst%3DU.%26aulast%3DRyabova%26aufirst%3DO.%26aulast%3DSaint-Joanis%26aufirst%3DB.%26aulast%3DDhar%26aufirst%3DN.%26aulast%3DPasca%26aufirst%3DM.%2BR.%26aulast%3DBuroni%26aufirst%3DS.%26aulast%3DLucarelli%26aufirst%3DA.%2BP.%26aulast%3DMilano%26aufirst%3DA.%26aulast%3DDe%2BRossi%26aufirst%3DE.%26aulast%3DBelanova%26aufirst%3DM.%26aulast%3DBobovska%26aufirst%3DA.%26aulast%3DDianiskova%26aufirst%3DP.%26aulast%3DKordulakova%26aufirst%3DJ.%26aulast%3DSala%26aufirst%3DC.%26aulast%3DFullam%26aufirst%3DE.%26aulast%3DSchneider%26aufirst%3DP.%26aulast%3DMcKinney%26aufirst%3DJ.%2BD.%26aulast%3DBrodin%26aufirst%3DP.%26aulast%3DChristophe%26aufirst%3DT.%26aulast%3DWaddell%26aufirst%3DS.%26aulast%3DButcher%26aufirst%3DP.%26aulast%3DAlbrethsen%26aufirst%3DJ.%26aulast%3DRosenkrands%26aufirst%3DI.%26aulast%3DBrosch%26aufirst%3DR.%26aulast%3DNandi%26aufirst%3DV.%26aulast%3DBharath%26aufirst%3DS.%26aulast%3DGaonkar%26aufirst%3DS.%26aulast%3DShandil%26aufirst%3DR.%2BK.%26aulast%3DBalasubramanian%26aufirst%3DV.%26aulast%3DBalganesh%26aufirst%3DT.%26aulast%3DTyagi%26aufirst%3DS.%26aulast%3DGrosset%26aufirst%3DJ.%26aulast%3DRiccardi%26aufirst%3DG.%26aulast%3DCole%26aufirst%3DS.%2BT.%26atitle%3DBenzothiazinones%2520kill%2520mycobacterium%2520tuberculosis%2520by%2520blocking%2520arabinan%2520synthesis%26jtitle%3DScience%26date%3D2009%26volume%3D324%26spage%3D801%26epage%3D804%26doi%3D10.1126%2Fscience.1171583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freundlich, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talcott, C.</span></span> <span> </span><span class="NLM_article-title">Computational databases, pathway and cheminformatics tools for tuberculosis drug discovery</span>. <i>Trends Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">74</span>, <span class="refDoi"> DOI: 10.1016/j.tim.2010.10.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.tim.2010.10.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=21129975" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFyrtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=65-74&author=S.+Ekinsauthor=J.+S.+Freundlichauthor=I.+Choiauthor=M.+Sarkerauthor=C.+Talcott&title=Computational+databases%2C+pathway+and+cheminformatics+tools+for+tuberculosis+drug+discovery&doi=10.1016%2Fj.tim.2010.10.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Computational databases, pathway and cheminformatics tools for tuberculosis drug discovery</span></div><div class="casAuthors">Ekins, Sean; Freundlich, Joel S.; Choi, Inhee; Sarker, Malabika; Talcott, Carolyn</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Microbiology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">65-74</span>CODEN:
                <span class="NLM_cas:coden">TRMIEA</span>;
        ISSN:<span class="NLM_cas:issn">0966-842X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  We are witnessing the growing menace of both increasing cases of drug-sensitive and drug-resistant Mycobacterium tuberculosis strains and the challenge to produce the first new tuberculosis (TB) drug in well over 40 years.  The TB community, having invested in extensive high-throughput screening efforts, is faced with the question of how to optimally leverage these data to move from a hit to a lead to a clin. candidate and potentially, a new drug.  Complementing this approach, yet conducted on a much smaller scale, cheminformatic techniques have been leveraged and are examd. in this review.  We suggest that these computational approaches should be optimally integrated within a workflow with exptl. approaches to accelerate TB drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplSgfEUzeep7Vg90H21EOLACvtfcHk0liG6szRQAO9QQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFyrtrc%253D&md5=bc87f2b9ac1aced3dac949fda2acf5b9</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.tim.2010.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tim.2010.10.005%26sid%3Dliteratum%253Aachs%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DFreundlich%26aufirst%3DJ.%2BS.%26aulast%3DChoi%26aufirst%3DI.%26aulast%3DSarker%26aufirst%3DM.%26aulast%3DTalcott%26aufirst%3DC.%26atitle%3DComputational%2520databases%252C%2520pathway%2520and%2520cheminformatics%2520tools%2520for%2520tuberculosis%2520drug%2520discovery%26jtitle%3DTrends%2520Microbiol.%26date%3D2011%26volume%3D19%26spage%3D65%26epage%3D74%26doi%3D10.1016%2Fj.tim.2010.10.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipinski, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradford, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dole, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spektor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blondeau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goncharoff, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohman, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunin, B. A.</span></span> <span> </span><span class="NLM_article-title">Analysis and hit filtering of a very large library of compounds screened against mycobacterium tuberculosis</span>. <i>Mol. BioSyst.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">2316</span>– <span class="NLM_lpage">2324</span>, <span class="refDoi"> DOI: 10.1039/C0MB00104J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1039%2FC0MB00104J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=20835433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1KqtL7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=2316-2324&author=S.+Ekinsauthor=T.+Kanekoauthor=C.+A.+Lipinskiauthor=J.+Bradfordauthor=K.+Doleauthor=A.+Spektorauthor=K.+Gregoryauthor=D.+Blondeauauthor=S.+Ernstauthor=J.+Yangauthor=N.+Goncharoffauthor=M.+M.+Hohmanauthor=B.+A.+Bunin&title=Analysis+and+hit+filtering+of+a+very+large+library+of+compounds+screened+against+mycobacterium+tuberculosis&doi=10.1039%2FC0MB00104J"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis and hit filtering of a very large library of compounds screened against Mycobacterium tuberculosis</span></div><div class="casAuthors">Ekins, Sean; Kaneko, Takushi; Lipinski, Christopher A.; Bradford, Justin; Dole, Krishna; Spektor, Anna; Gregory, Kellan; Blondeau, David; Ernst, Sylvia; Yang, Jeremy; Goncharoff, Nicko; Hohman, Moses M.; Bunin, Barry A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular BioSystems</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2316-2324</span>CODEN:
                <span class="NLM_cas:coden">MBOIBW</span>;
        ISSN:<span class="NLM_cas:issn">1742-206X</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">There is an urgent need for new drugs against tuberculosis which annually claims 1.7-1.8 million lives.  One approach to identify potential leads is to screen in vitro small mols. against Mycobacterium tuberculosis (Mtb).  Until recently there was no central repository to collect information on compds. screened.  Consequently, it has been difficult to analyze mol. properties of compds. that inhibit the growth of Mtb in vitro.  We have collected data from publically available sources on over 300 000 small mols. deposited in the Collaborative Drug Discovery TB Database.  A cheminformatics anal. on these compds. indicates that inhibitors of the growth of Mtb have statistically higher mean logP, rule of 5 alerts, while also having lower HBD count, atom count and lower PSA (ChemAxon descriptors), compared to compds. that are classed as inactive.  Addnl., Bayesian models for selecting Mtb active compds. were evaluated with over 100 000 compds. and, they demonstrated 10 fold enrichment over random for the top ranked 600 compds.  This represents a promising approach for finding compds. active against Mtb in whole cells screened under the same in vitro conditions.  Various sets of Mtb hit mols. were also examd. by various filtering rules used widely in the pharmaceutical industry to identify compds. with potentially reactive moieties.  We found differences between the no. of compds. flagged by these rules in Mtb datasets, malaria hits, FDA approved drugs and antibiotics.  Combining these approaches may enable selection of compds. with increased probability of inhibition of whole cell Mtb activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSaytzWyG0H7Vg90H21EOLACvtfcHk0liIAc8Sz3hcXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1KqtL7L&md5=66783a6e7ae22ad9b0022d94d6a77cea</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1039%2FC0MB00104J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC0MB00104J%26sid%3Dliteratum%253Aachs%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DKaneko%26aufirst%3DT.%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26aulast%3DBradford%26aufirst%3DJ.%26aulast%3DDole%26aufirst%3DK.%26aulast%3DSpektor%26aufirst%3DA.%26aulast%3DGregory%26aufirst%3DK.%26aulast%3DBlondeau%26aufirst%3DD.%26aulast%3DErnst%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DGoncharoff%26aufirst%3DN.%26aulast%3DHohman%26aufirst%3DM.%2BM.%26aulast%3DBunin%26aufirst%3DB.%2BA.%26atitle%3DAnalysis%2520and%2520hit%2520filtering%2520of%2520a%2520very%2520large%2520library%2520of%2520compounds%2520screened%2520against%2520mycobacterium%2520tuberculosis%26jtitle%3DMol.%2520BioSyst.%26date%3D2010%26volume%3D6%26spage%3D2316%26epage%3D2324%26doi%3D10.1039%2FC0MB00104J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradford, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dole, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spektor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blondeau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunin, B. A.</span></span> <span> </span><span class="NLM_article-title">A collaborative database and computational models for tuberculosis drug discovery</span>. <i>Mol. BioSyst.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">840</span>– <span class="NLM_lpage">851</span>, <span class="refDoi"> DOI: 10.1039/b917766c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1039%2Fb917766c" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=20567770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvVSrtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=840-851&author=S.+Ekinsauthor=J.+Bradfordauthor=K.+Doleauthor=A.+Spektorauthor=K.+Gregoryauthor=D.+Blondeauauthor=M.+Hohmanauthor=B.+A.+Bunin&title=A+collaborative+database+and+computational+models+for+tuberculosis+drug+discovery&doi=10.1039%2Fb917766c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">A collaborative database and computational models for tuberculosis drug discovery</span></div><div class="casAuthors">Ekins, Sean; Bradford, Justin; Dole, Krishna; Spektor, Anna; Gregory, Kellan; Blondeau, David; Hohman, Moses; Bunin, Barry A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular BioSystems</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">840-851</span>CODEN:
                <span class="NLM_cas:coden">MBOIBW</span>;
        ISSN:<span class="NLM_cas:issn">1742-206X</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The search for mols. with activity against Mycobacterium tuberculosis (Mtb) is employing many approaches in parallel including high throughput screening and computational methods.  We have developed a database (CDD TB) to capture public and private Mtb data while enabling data mining and collaborations with other researchers.  We have used the public data along with several cheminformatics approaches to produce models that describe active and inactive compds.  We have compared these datasets to those for known FDA approved drugs and between Mtb active and inactive compds.  The distribution of polar surface area and pKa of active compds. was found to be a statistically significant determinant of activity against Mtb.  Hydrophobicity was not always statistically significant. Bayesian classification models for 220463 mols. were generated and tested with external mols., and enabled the discrimination of active or inactive substructures from other datasets in the CDD TB.  Computational pharmacophores based on known Mtb drugs were able to map to and retrieve a small subset of some of the Mtb datasets, including a high percentage of Mtb actives.  The combination of the database, dataset anal., Bayesian and pharmacophore models provides new insights into mol. properties and features that are determinants of activity in whole cells.  This study provides novel insights into the key 1D mol. descriptors, 2D chem. substructures and 3D pharmacophores which can be used to mine the chem. space, prioritizing those mols. with a higher probability of activity against Mtb.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgfg8SbojRpLVg90H21EOLACvtfcHk0liIAc8Sz3hcXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvVSrtrg%253D&md5=5bab2de79f0bb02dc9f3b24563776b16</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1039%2Fb917766c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb917766c%26sid%3Dliteratum%253Aachs%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DBradford%26aufirst%3DJ.%26aulast%3DDole%26aufirst%3DK.%26aulast%3DSpektor%26aufirst%3DA.%26aulast%3DGregory%26aufirst%3DK.%26aulast%3DBlondeau%26aufirst%3DD.%26aulast%3DHohman%26aufirst%3DM.%26aulast%3DBunin%26aufirst%3DB.%2BA.%26atitle%3DA%2520collaborative%2520database%2520and%2520computational%2520models%2520for%2520tuberculosis%2520drug%2520discovery%26jtitle%3DMol.%2520BioSyst.%26date%3D2010%26volume%3D6%26spage%3D840%26epage%3D851%26doi%3D10.1039%2Fb917766c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koo, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekonomidis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talaue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paget, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolhiser, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenaerts, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunin, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connell, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freundlich, J. S.</span></span> <span> </span><span class="NLM_article-title">Bayesian models leveraging bioactivity and cytotoxicity information for drug discovery</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">370</span>– <span class="NLM_lpage">378</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2013.01.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.chembiol.2013.01.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=23521795" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksFOgt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=370-378&author=S.+Ekinsauthor=R.+C.+Reynoldsauthor=H.+Kimauthor=M.+S.+Kooauthor=M.+Ekonomidisauthor=M.+Talaueauthor=S.+D.+Pagetauthor=L.+K.+Woolhiserauthor=A.+J.+Lenaertsauthor=B.+A.+Buninauthor=N.+Connellauthor=J.+S.+Freundlich&title=Bayesian+models+leveraging+bioactivity+and+cytotoxicity+information+for+drug+discovery&doi=10.1016%2Fj.chembiol.2013.01.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Bayesian Models Leveraging Bioactivity and Cytotoxicity Information for Drug Discovery</span></div><div class="casAuthors">Ekins, Sean; Reynolds, Robert C.; Kim, Hiyun; Koo, Mi-Sun; Ekonomidis, Marilyn; Talaue, Meliza; Paget, Steve D.; Woolhiser, Lisa K.; Lenaerts, Anne J.; Bunin, Barry A.; Connell, Nancy; Freundlich, Joel S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">370-378</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Identification of unique leads represents a significant challenge in drug discovery.  This hurdle is magnified in neglected diseases such as tuberculosis.  We have leveraged public high-throughput screening (HTS) data to exptl. validate a virtual screening approach employing Bayesian models built with bioactivity information (single-event model) as well as bioactivity and cytotoxicity information (dual-event model).  We virtually screened a com. library and exptl. confirmed actives with hit rates exceeding typical HTS results by one to two orders of magnitude.  This initial dual-event Bayesian model identified compds. with antitubercular whole-cell activity and low mammalian cell cytotoxicity from a published set of antimalarials.  The most potent hit exhibits the in vitro activity and in vitro/in vivo safety profile of a drug lead.  These Bayesian models offer significant economies in time and cost to drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHn7pP5TWKSbVg90H21EOLACvtfcHk0liIAc8Sz3hcXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksFOgt7g%253D&md5=4b64d1c0fa67896b9d61c7f2fd606542</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2013.01.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2013.01.011%26sid%3Dliteratum%253Aachs%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DReynolds%26aufirst%3DR.%2BC.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DKoo%26aufirst%3DM.%2BS.%26aulast%3DEkonomidis%26aufirst%3DM.%26aulast%3DTalaue%26aufirst%3DM.%26aulast%3DPaget%26aufirst%3DS.%2BD.%26aulast%3DWoolhiser%26aufirst%3DL.%2BK.%26aulast%3DLenaerts%26aufirst%3DA.%2BJ.%26aulast%3DBunin%26aufirst%3DB.%2BA.%26aulast%3DConnell%26aufirst%3DN.%26aulast%3DFreundlich%26aufirst%3DJ.%2BS.%26atitle%3DBayesian%2520models%2520leveraging%2520bioactivity%2520and%2520cytotoxicity%2520information%2520for%2520drug%2520discovery%26jtitle%3DChem.%2520Biol.%26date%3D2013%26volume%3D20%26spage%3D370%26epage%3D378%26doi%3D10.1016%2Fj.chembiol.2013.01.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mori, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarelli, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esposito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makarov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellinzoni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartkoorn, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degiacomi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boldrin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jesus Lopes Ribeiro, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marino, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Centarova, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svetlikova, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasko, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazakova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lepioshkin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barilone, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fondi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baulard, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikusova, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alzari, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manganelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Carvalho, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riccardi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasca, M. R.</span></span> <span> </span><span class="NLM_article-title">Thiophenecarboxamide derivatives activated by etha kill mycobacterium tuberculosis by inhibiting the CTP synthetase PyrG</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">917</span>– <span class="NLM_lpage">927</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2015.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.chembiol.2015.05.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=26097035" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtV2it7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=917-927&author=G.+Moriauthor=L.+R.+Chiarelliauthor=M.+Espositoauthor=V.+Makarovauthor=M.+Bellinzoniauthor=R.+C.+Hartkoornauthor=G.+Degiacomiauthor=F.+Boldrinauthor=S.+Ekinsauthor=A.+L.+de+Jesus+Lopes+Ribeiroauthor=L.+B.+Marinoauthor=I.+Centarovaauthor=Z.+Svetlikovaauthor=J.+Blaskoauthor=E.+Kazakovaauthor=A.+Lepioshkinauthor=N.+Bariloneauthor=G.+Zanoniauthor=A.+Portaauthor=M.+Fondiauthor=R.+Faniauthor=A.+R.+Baulardauthor=K.+Mikusovaauthor=P.+M.+Alzariauthor=R.+Manganelliauthor=L.+P.+de+Carvalhoauthor=G.+Riccardiauthor=S.+T.+Coleauthor=M.+R.+Pasca&title=Thiophenecarboxamide+derivatives+activated+by+etha+kill+mycobacterium+tuberculosis+by+inhibiting+the+CTP+synthetase+PyrG&doi=10.1016%2Fj.chembiol.2015.05.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Thiophenecarboxamide Derivatives Activated by EthA Kill Mycobacterium tuberculosis by Inhibiting the CTP Synthetase PyrG</span></div><div class="casAuthors">Mori, Giorgia; Chiarelli, Laurent R.; Esposito, Marta; Makarov, Vadim; Bellinzoni, Marco; Hartkoorn, Ruben C.; Degiacomi, Giulia; Boldrin, Francesca; Ekins, Sean; Ribeiro, Ana Luisa de Jesus Lopes; Marino, Leonardo B.; Centarova, Ivana; Svetlikova, Zuzana; Blasko, Jaroslav; Kazakova, Elena; Lepioshkin, Alexander; Barilone, Nathalie; Zanoni, Giuseppe; Porta, Alessio; Fondi, Marco; Fani, Renato; Baulard, Alain R.; Mikusova, Katarina; Alzari, Pedro M.; Manganelli, Riccardo; de Carvalho, Luiz Pedro S.; Riccardi, Giovanna; Cole, Stewart T.; Pasca, Maria Rosalia</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">917-927</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">To combat the emergence of drug-resistant strains of Mycobacterium tuberculosis, new antitubercular agents and novel drug targets are needed.  Phenotypic screening of a library of 594 hit compds. uncovered two leads that were active against M. tuberculosis in its replicating, non-replicating, and intracellular states: compds. 7947882 (5-methyl-N-(4-nitrophenyl)thiophene-2-carboxamide) and 7904688 (3-phenyl-N-[(4-piperidin-1-ylphenyl)carbamothioyl]propanamide).  Mutants resistant to both compds. harbored mutations in ethA (rv3854c), the gene encoding the monooxygenase EthA, and/or in pyrG (rv1699) coding for the CTP synthetase, PyrG.  Biochem. studies demonstrated that EthA is responsible for the activation of the compds., and by mass spectrometry the authors identified the active metabolite of 7947882, which directly inhibits PyrG activity.  Metabolomic studies revealed that pharmacol. inhibition of PyrG strongly perturbs DNA and RNA biosynthesis, and other metabolic processes requiring nucleotides.  Finally, the crystal structure of PyrG was solved, paving the way for rational drug design with this newly validated drug target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFEer4apXX9LVg90H21EOLACvtfcHk0lgrHnloZpA2ag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtV2it7jJ&md5=7d03e0254f93e8504dc0b3f4248ea54c</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2015.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2015.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DMori%26aufirst%3DG.%26aulast%3DChiarelli%26aufirst%3DL.%2BR.%26aulast%3DEsposito%26aufirst%3DM.%26aulast%3DMakarov%26aufirst%3DV.%26aulast%3DBellinzoni%26aufirst%3DM.%26aulast%3DHartkoorn%26aufirst%3DR.%2BC.%26aulast%3DDegiacomi%26aufirst%3DG.%26aulast%3DBoldrin%26aufirst%3DF.%26aulast%3DEkins%26aufirst%3DS.%26aulast%3Dde%2BJesus%2BLopes%2BRibeiro%26aufirst%3DA.%2BL.%26aulast%3DMarino%26aufirst%3DL.%2BB.%26aulast%3DCentarova%26aufirst%3DI.%26aulast%3DSvetlikova%26aufirst%3DZ.%26aulast%3DBlasko%26aufirst%3DJ.%26aulast%3DKazakova%26aufirst%3DE.%26aulast%3DLepioshkin%26aufirst%3DA.%26aulast%3DBarilone%26aufirst%3DN.%26aulast%3DZanoni%26aufirst%3DG.%26aulast%3DPorta%26aufirst%3DA.%26aulast%3DFondi%26aufirst%3DM.%26aulast%3DFani%26aufirst%3DR.%26aulast%3DBaulard%26aufirst%3DA.%2BR.%26aulast%3DMikusova%26aufirst%3DK.%26aulast%3DAlzari%26aufirst%3DP.%2BM.%26aulast%3DManganelli%26aufirst%3DR.%26aulast%3Dde%2BCarvalho%26aufirst%3DL.%2BP.%26aulast%3DRiccardi%26aufirst%3DG.%26aulast%3DCole%26aufirst%3DS.%2BT.%26aulast%3DPasca%26aufirst%3DM.%2BR.%26atitle%3DThiophenecarboxamide%2520derivatives%2520activated%2520by%2520etha%2520kill%2520mycobacterium%2520tuberculosis%2520by%2520inhibiting%2520the%2520CTP%2520synthetase%2520PyrG%26jtitle%3DChem.%2520Biol.%26date%3D2015%26volume%3D22%26spage%3D917%26epage%3D927%26doi%3D10.1016%2Fj.chembiol.2015.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madrid, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stratton, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talcott, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourbon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Travers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yadav, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freundlich, J. S.</span></span> <span> </span><span class="NLM_article-title">Combining metabolite-based pharmacophores with bayesian machine learning models for mycobacterium tuberculosis drug discovery</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">e0141076</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0141076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1371%2Fjournal.pone.0141076" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=26517557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFGqu7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=e0141076&author=S.+Ekinsauthor=P.+B.+Madridauthor=M.+Sarkerauthor=S.+G.+Liauthor=N.+Mittalauthor=P.+Kumarauthor=X.+Wangauthor=T.+P.+Strattonauthor=M.+Zimmermanauthor=C.+Talcottauthor=P.+Bourbonauthor=M.+Traversauthor=M.+Yadavauthor=J.+S.+Freundlich&title=Combining+metabolite-based+pharmacophores+with+bayesian+machine+learning+models+for+mycobacterium+tuberculosis+drug+discovery&doi=10.1371%2Fjournal.pone.0141076"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Combining metabolite-based pharmacophores with Bayesian machine Learning Models for Mycobacterium tuberculosis drug discovery</span></div><div class="casAuthors">Ekins, Sean; Madrid, Peter B.; Sarker, Malabika; Li, Shao-Gang; Mittal, Nisha; Kumar, Pradeep; Wang, Xin; Stratton, Thomas P.; Zimmerman, Matthew; Talcott, Carolyn; Bourbon, Pauline; Travers, Mike; Yadav, Maneesh; Freundlich, Joel S.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e0141076/1-e0141076/20</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Integrated computational approaches for Mycobacterium tuberculosis (Mtb) are useful to identify new mols. that could lead to future tuberculosis (TB) drugs.  Our approach uses information derived from the TBCyc pathway and genome database, the Collaborative Drug Discovery TB database combined with 3D pharmacophores and dual event Bayesian models of whole-cell activity and lack of cytotoxicity.  We have prioritized a large no. of mols. that may act as mimics of substrates and metabolites in the TB metabolome.  We computationally searched over 200,000 com. mols. using 66 pharmacophores based on substrates and metabolites from Mtb and further filtering with Bayesian models.  We ultimately tested 110 compds. in vitro that resulted in two compds. of interest, BAS 04912643 and BAS 00623753 (MIC of 2.5 and 5 μg/mL, resp.).  These mols. were used as a starting point for hit-to-lead optimization.  The most promising class proved to be the quinoxaline di-N-oxides, evidenced by transcriptional profiling to induce mRNA level perturbations most closely resembling known protonophores.  One of these, SRI58 exhibited an MIC = 1.25 μg/mL vs. Mtband a CC50 in Vero cells of >40 μg/mL, while featuring fair Caco-2 A-B permeability (2.3 × 10-6 cm/s), kinetic soly. (125 μMat pH 7.4 in PBS) and mouse metabolic stability (63.6% remaining after 1 h incubation with mouse liver microsomes).  Despite demonstration of how a combined bioinformatics/cheminformatics approach afforded a small mol. with promising in vitro profiles, we found that SRI58 did not exhibit quantifiable blood levels in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1Q4DnXCIy_LVg90H21EOLACvtfcHk0lgrHnloZpA2ag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFGqu7vN&md5=d19ba65818e14fc9fb1305664a827340</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0141076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0141076%26sid%3Dliteratum%253Aachs%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DMadrid%26aufirst%3DP.%2BB.%26aulast%3DSarker%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DS.%2BG.%26aulast%3DMittal%26aufirst%3DN.%26aulast%3DKumar%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DStratton%26aufirst%3DT.%2BP.%26aulast%3DZimmerman%26aufirst%3DM.%26aulast%3DTalcott%26aufirst%3DC.%26aulast%3DBourbon%26aufirst%3DP.%26aulast%3DTravers%26aufirst%3DM.%26aulast%3DYadav%26aufirst%3DM.%26aulast%3DFreundlich%26aufirst%3DJ.%2BS.%26atitle%3DCombining%2520metabolite-based%2520pharmacophores%2520with%2520bayesian%2520machine%2520learning%2520models%2520for%2520mycobacterium%2520tuberculosis%2520drug%2520discovery%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26spage%3De0141076%26doi%3D10.1371%2Fjournal.pone.0141076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merceron, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gracia, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quintana, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Risseeuw, M. D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hulpia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ainsa, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munier-Lehmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savvides, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Calenbergh, S.</span></span> <span> </span><span class="NLM_article-title">Structure guided lead generation toward nonchiral m. Tuberculosis thymidylate kinase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2753</span>– <span class="NLM_lpage">2775</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01570</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01570" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjvFWnsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2753-2775&author=L.+Songauthor=R.+Merceronauthor=B.+Graciaauthor=A.+L.+Quintanaauthor=M.+D.+P.+Risseeuwauthor=F.+Hulpiaauthor=P.+Cosauthor=J.+A.+Ainsaauthor=H.+Munier-Lehmannauthor=S.+N.+Savvidesauthor=S.+Van+Calenbergh&title=Structure+guided+lead+generation+toward+nonchiral+m.+Tuberculosis+thymidylate+kinase+inhibitors&doi=10.1021%2Facs.jmedchem.7b01570"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Structure Guided Lead Generation toward Nonchiral M. tuberculosis Thymidylate Kinase Inhibitors</span></div><div class="casAuthors">Song, Lijun; Merceron, Romain; Gracia, Begona; Quintana, Ainhoa Lucia; Risseeuw, Martijn D. P.; Hulpia, Fabian; Cos, Paul; Ainsa, Jose A.; Munier-Lehmann, Helene; Savvides, Savvas N.; Van Calenbergh, Serge</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2753-2775</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In recent years, thymidylate kinase (TMPK), an enzyme indispensable for bacterial DNA biosynthesis, has been pursued for the development of new antibacterial agents including against Mycobacterium tuberculosis, the causative agent for the widespread infectious disease tuberculosis (TB).  In response to a growing need for more effective anti-TB drugs, the authors have built upon the authors' previous efforts toward the exploration of novel and potent Mycobacterium tuberculosis TMPK (MtTMPK) inhibitors, and reported here the design of a novel series of non-nucleoside inhibitors of MtTMPK.  The inhibitors display hitherto unexplored interactions in the active site of MtTMPK, offering new insights into structure-activity relationships.  To investigate the discrepancy between enzyme inhibitory activity and the whole-cell activity, expts. with efflux pump inhibitors and efflux pump knockout mutants were performed.  The min. inhibitory concns. of particular inhibitors increased significantly when detd. for the efflux pump mmr knockout mutant, which partly explains the obsd. dissonance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4USuGJ25TnbVg90H21EOLACvtfcHk0lgvUPFK8It55g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjvFWnsr4%253D&md5=c4b195c0bb6969ad71abece65c82bd4a</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01570&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01570%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DL.%26aulast%3DMerceron%26aufirst%3DR.%26aulast%3DGracia%26aufirst%3DB.%26aulast%3DQuintana%26aufirst%3DA.%2BL.%26aulast%3DRisseeuw%26aufirst%3DM.%2BD.%2BP.%26aulast%3DHulpia%26aufirst%3DF.%26aulast%3DCos%26aufirst%3DP.%26aulast%3DAinsa%26aufirst%3DJ.%2BA.%26aulast%3DMunier-Lehmann%26aufirst%3DH.%26aulast%3DSavvides%26aufirst%3DS.%2BN.%26aulast%3DVan%2BCalenbergh%26aufirst%3DS.%26atitle%3DStructure%2520guided%2520lead%2520generation%2520toward%2520nonchiral%2520m.%2520Tuberculosis%2520thymidylate%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D2753%26epage%3D2775%26doi%3D10.1021%2Facs.jmedchem.7b01570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nyantakyi, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dartois, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gengenbacher, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Go, M. L.</span></span> <span> </span><span class="NLM_article-title">Indolyl azaspiroketal mannich bases are potent antimycobacterial agents with selective membrane permeabilizing effects and in vivo activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">5733</span>– <span class="NLM_lpage">5750</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00777</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00777" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFamtbrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5733-5750&author=S.+A.+Nyantakyiauthor=M.+Liauthor=P.+Gopalauthor=M.+Zimmermanauthor=V.+Dartoisauthor=M.+Gengenbacherauthor=T.+Dickauthor=M.+L.+Go&title=Indolyl+azaspiroketal+mannich+bases+are+potent+antimycobacterial+agents+with+selective+membrane+permeabilizing+effects+and+in+vivo+activity&doi=10.1021%2Facs.jmedchem.8b00777"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Indolyl Azaspiroketal Mannich Bases Are Potent Antimycobacterial Agents with Selective Membrane Permeabilizing Effects and in Vivo Activity</span></div><div class="casAuthors">Nyantakyi, Samuel Agyei; Li, Ming; Gopal, Pooja; Zimmerman, Matthew; Dartois, Veronique; Gengenbacher, Martin; Dick, Thomas; Go, Mei-Lin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5733-5750</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The inclusion of an azaspiroketal Mannich base in the membrane targeting antitubercular 6-methoxy-1-n-octyl-1H-indole scaffold resulted in analogs with improved selectivity and submicromolar activity against Mycobacterium tuberculosis H37Rv.  The potency enhancing properties of the spiro-ring fused motif was affirmed by SAR and validated in a mouse model of tuberculosis.  As expected for membrane inserting agents, the indolyl azaspiroketal Mannich bases perturbed phospholipid vesicles, permeabilized bacterial cells and induced the mycobacterial cell envelope stress reporter promoter piniBAC.  Surprisingly, their membrane disruptive effects did not appear to be assocd. with bacterial membrane depolarization.  This profile was not uniquely assocd. with azaspiroketal Mannich bases but was characteristic of indolyl Mannich bases as a class.  Whereas resistant mycobacteria could not be isolated for a less potent indolyl Mannich base, the more potent azaspiroketal analog displayed low spontaneous resistance mutation frequency of 10-8/CFU.  This may indicate involvement of an addnl. envelope-related target in its mechanism of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5WAc0tww1bLVg90H21EOLACvtfcHk0lgvUPFK8It55g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFamtbrL&md5=625be13274f01452304295afed077bf6</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00777&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00777%26sid%3Dliteratum%253Aachs%26aulast%3DNyantakyi%26aufirst%3DS.%2BA.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DGopal%26aufirst%3DP.%26aulast%3DZimmerman%26aufirst%3DM.%26aulast%3DDartois%26aufirst%3DV.%26aulast%3DGengenbacher%26aufirst%3DM.%26aulast%3DDick%26aufirst%3DT.%26aulast%3DGo%26aufirst%3DM.%2BL.%26atitle%3DIndolyl%2520azaspiroketal%2520mannich%2520bases%2520are%2520potent%2520antimycobacterial%2520agents%2520with%2520selective%2520membrane%2520permeabilizing%2520effects%2520and%2520in%2520vivo%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D5733%26epage%3D5750%26doi%3D10.1021%2Facs.jmedchem.8b00777" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cleghorn, L. A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Odingo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wescott, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korkegian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masquelin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez Moure, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huggett, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epemolu, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuccotto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scullion, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shishikura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rullas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guijarro, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hipskind, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parish, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyatt, P. G.</span></span> <span> </span><span class="NLM_article-title">Identification of morpholino thiophenes as novel mycobacterium tuberculosis inhibitors, targeting QcrB</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">6592</span>– <span class="NLM_lpage">6608</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00172</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00172" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Snu7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6592-6608&author=L.+A.+T.+Cleghornauthor=P.+C.+Rayauthor=J.+Odingoauthor=A.+Kumarauthor=H.+Wescottauthor=A.+Korkegianauthor=T.+Masquelinauthor=A.+Lopez+Moureauthor=C.+Wilsonauthor=S.+Davisauthor=M.+Huggettauthor=P.+Turnerauthor=A.+Smithauthor=O.+Epemoluauthor=F.+Zuccottoauthor=J.+Rileyauthor=P.+Scullionauthor=Y.+Shishikuraauthor=L.+Fergusonauthor=J.+Rullasauthor=L.+Guijarroauthor=K.+D.+Readauthor=S.+R.+Greenauthor=P.+Hipskindauthor=T.+Parishauthor=P.+G.+Wyatt&title=Identification+of+morpholino+thiophenes+as+novel+mycobacterium+tuberculosis+inhibitors%2C+targeting+QcrB&doi=10.1021%2Facs.jmedchem.8b00172"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Morpholino Thiophenes as Novel Mycobacterium tuberculosis Inhibitors, Targeting QcrB</span></div><div class="casAuthors">Cleghorn, Laura A. T.; Ray, Peter C.; Odingo, Joshua; Kumar, Anuradha; Wescott, Heather; Korkegian, Aaron; Masquelin, Thierry; Lopez Moure, Abraham; Wilson, Caroline; Davis, Susan; Huggett, Margaret; Turner, Penelope; Smith, Alasdair; Epemolu, Ola; Zuccotto, Fabio; Riley, Jennifer; Scullion, Paul; Shishikura, Yoko; Ferguson, Liam; Rullas, Joaquin; Guijarro, Laura; Read, Kevin D.; Green, Simon R.; Hipskind, Phil; Parish, Tanya; Wyatt, Paul G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6592-6608</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">With the emergence of multidrug-resistant strains of Mycobacterium tuberculosis there is a pressing need for new oral drugs with novel mechanisms of action.  Herein, we describe the identification of a novel morpholino-thiophenes (MOT) series following phenotypic screening of the Eli Lilly corporate library against M. tuberculosis strain H37Rv.  The design, synthesis, and structure-activity relationships of a range of analogs around the confirmed actives are described.  Optimized leads with potent whole cell activity against H37Rv, no cytotoxicity flags, and in vivo efficacy in an acute murine model of infection are described.  Mode-of-action studies suggest that the novel scaffold targets QcrB, a subunit of the menaquinol cytochrome c oxidoreductase, part of the bc1-aa3-type cytochrome c oxidase complex that is responsible for driving oxygen-dependent respiration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnvp7vi-tDWrVg90H21EOLACvtfcHk0lgvUPFK8It55g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Snu7vJ&md5=ded53f24ded8bce34881a03dc4034aa4</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00172&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00172%26sid%3Dliteratum%253Aachs%26aulast%3DCleghorn%26aufirst%3DL.%2BA.%2BT.%26aulast%3DRay%26aufirst%3DP.%2BC.%26aulast%3DOdingo%26aufirst%3DJ.%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DWescott%26aufirst%3DH.%26aulast%3DKorkegian%26aufirst%3DA.%26aulast%3DMasquelin%26aufirst%3DT.%26aulast%3DLopez%2BMoure%26aufirst%3DA.%26aulast%3DWilson%26aufirst%3DC.%26aulast%3DDavis%26aufirst%3DS.%26aulast%3DHuggett%26aufirst%3DM.%26aulast%3DTurner%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DEpemolu%26aufirst%3DO.%26aulast%3DZuccotto%26aufirst%3DF.%26aulast%3DRiley%26aufirst%3DJ.%26aulast%3DScullion%26aufirst%3DP.%26aulast%3DShishikura%26aufirst%3DY.%26aulast%3DFerguson%26aufirst%3DL.%26aulast%3DRullas%26aufirst%3DJ.%26aulast%3DGuijarro%26aufirst%3DL.%26aulast%3DRead%26aufirst%3DK.%2BD.%26aulast%3DGreen%26aufirst%3DS.%2BR.%26aulast%3DHipskind%26aufirst%3DP.%26aulast%3DParish%26aufirst%3DT.%26aulast%3DWyatt%26aufirst%3DP.%2BG.%26atitle%3DIdentification%2520of%2520morpholino%2520thiophenes%2520as%2520novel%2520mycobacterium%2520tuberculosis%2520inhibitors%252C%2520targeting%2520QcrB%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D6592%26epage%3D6608%26doi%3D10.1021%2Facs.jmedchem.8b00172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chacko, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boshoff, H. I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferraris, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gollapalli, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pepi, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joachimiak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizrahi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuny, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedstrom, L.</span></span> <span> </span><span class="NLM_article-title">Expanding benzoxazole-based inosine 5′-monophosphate dehydrogenase (IMPDH) inhibitor structure-activity as potential antituberculosis agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">4739</span>– <span class="NLM_lpage">4756</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01839</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01839" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpt12hsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4739-4756&author=S.+Chackoauthor=H.+I.+M.+Boshoffauthor=V.+Singhauthor=D.+M.+Ferrarisauthor=D.+R.+Gollapalliauthor=M.+Zhangauthor=A.+P.+Lawsonauthor=M.+J.+Pepiauthor=A.+Joachimiakauthor=M.+Rizziauthor=V.+Mizrahiauthor=G.+D.+Cunyauthor=L.+Hedstrom&title=Expanding+benzoxazole-based+inosine+5%E2%80%B2-monophosphate+dehydrogenase+%28IMPDH%29+inhibitor+structure-activity+as+potential+antituberculosis+agents&doi=10.1021%2Facs.jmedchem.7b01839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Expanding Benzoxazole-Based Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitor Structure-Activity As Potential Antituberculosis Agents</span></div><div class="casAuthors">Chacko, Shibin; Boshoff, Helena I. M.; Singh, Vinayak; Ferraris, Davide M.; Gollapalli, Deviprasad R.; Zhang, Minjia; Lawson, Ann P.; Pepi, Michael J.; Joachimiak, Andrzej; Rizzi, Menico; Mizrahi, Valerie; Cuny, Gregory D.; Hedstrom, Lizbeth</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4739-4756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">New drugs and mol. targets are urgently needed to address the emergence and spread of drug-resistant tuberculosis.  Mycobacterium tuberculosis (Mtb) IMP dehydrogenase 2 (MtbIMPDH2) is a promising yet controversial potential target.  The inhibition of MtbIMPDH2 blocks the biosynthesis of guanine nucleotides, but high concns. of guanine can potentially rescue the bacteria.  Herein we describe an expansion of the structure-activity relationship (SAR) for the benzoxazole series of MtbIMPDH2 inhibitors and demonstrate that min. inhibitory concns. (MIC) of ≤1 μM can be achieved.  The antibacterial activity of the most promising compd., 17b (Q151), is derived from the inhibition of MtbIMPDH2 as demonstrated by conditional knockdown and resistant strains.  Importantly, guanine does not change the MIC of 17b, alleviating the concern that guanine salvage can protect Mtb in vivo.  These findings suggest that MtbIMPDH2 is a vulnerable target for tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTo6ddjA2z7LVg90H21EOLACvtfcHk0lgW5zRxZBNM9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpt12hsrg%253D&md5=525dca6fb8eadbb47fcb42814797ab1e</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01839%26sid%3Dliteratum%253Aachs%26aulast%3DChacko%26aufirst%3DS.%26aulast%3DBoshoff%26aufirst%3DH.%2BI.%2BM.%26aulast%3DSingh%26aufirst%3DV.%26aulast%3DFerraris%26aufirst%3DD.%2BM.%26aulast%3DGollapalli%26aufirst%3DD.%2BR.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DLawson%26aufirst%3DA.%2BP.%26aulast%3DPepi%26aufirst%3DM.%2BJ.%26aulast%3DJoachimiak%26aufirst%3DA.%26aulast%3DRizzi%26aufirst%3DM.%26aulast%3DMizrahi%26aufirst%3DV.%26aulast%3DCuny%26aufirst%3DG.%2BD.%26aulast%3DHedstrom%26aufirst%3DL.%26atitle%3DExpanding%2520benzoxazole-based%2520inosine%25205%25E2%2580%25B2-monophosphate%2520dehydrogenase%2520%2528IMPDH%2529%2520inhibitor%2520structure-activity%2520as%2520potential%2520antituberculosis%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D4739%26epage%3D4756%26doi%3D10.1021%2Facs.jmedchem.7b01839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spain, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagalingam, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batten, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hortle, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oehlers, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murage, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orford, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crisologo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Triccas, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutledge, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Todd, M. H.</span></span> <span> </span><span class="NLM_article-title">Antitubercular bis-substituted cyclam derivatives: Structure-activity relationships and in vivo studies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">3595</span>– <span class="NLM_lpage">3608</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01569</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01569" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltFOlsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=3595-3608&author=M.+Spainauthor=J.+K.+Wongauthor=G.+Nagalingamauthor=J.+M.+Battenauthor=E.+Hortleauthor=S.+H.+Oehlersauthor=X.+F.+Jiangauthor=H.+E.+Murageauthor=J.+T.+Orfordauthor=P.+Crisologoauthor=J.+A.+Triccasauthor=P.+J.+Rutledgeauthor=M.+H.+Todd&title=Antitubercular+bis-substituted+cyclam+derivatives%3A+Structure-activity+relationships+and+in+vivo+studies&doi=10.1021%2Facs.jmedchem.7b01569"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Antitubercular Bis-Substituted Cyclam Derivatives: Structure-Activity Relationships and in Vivo Studies</span></div><div class="casAuthors">Spain, Malcolm; Wong, Joseph K.-H.; Nagalingam, Gayathri; Batten, James M.; Hortle, Elinor; Oehlers, Stefan H.; Jiang, Xiao Fan; Murage, Hasini E.; Orford, Jack T.; Crisologo, Patrick; Triccas, James A.; Rutledge, Peter J.; Todd, Matthew H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3595-3608</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors recently reported the discovery of nontoxic cyclam-derived compds. that are active against drug-resistant Mycobacterium tuberculosis.  In this paper the authors report exploration of the structure-activity relationship for this class of compds., identifying several simpler compds. with comparable activity.  The most promising compd. identified, possessing significantly improved water soly., displayed high levels of bacterial clearance in an in vivo zebrafish embryo model, suggesting this compd. series has promise for in vivo treatment of tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpooUdSuTJfE7Vg90H21EOLACvtfcHk0lgW5zRxZBNM9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltFOlsbk%253D&md5=2c717da9cf4db74818d3163da0f446bc</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01569%26sid%3Dliteratum%253Aachs%26aulast%3DSpain%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DJ.%2BK.%26aulast%3DNagalingam%26aufirst%3DG.%26aulast%3DBatten%26aufirst%3DJ.%2BM.%26aulast%3DHortle%26aufirst%3DE.%26aulast%3DOehlers%26aufirst%3DS.%2BH.%26aulast%3DJiang%26aufirst%3DX.%2BF.%26aulast%3DMurage%26aufirst%3DH.%2BE.%26aulast%3DOrford%26aufirst%3DJ.%2BT.%26aulast%3DCrisologo%26aufirst%3DP.%26aulast%3DTriccas%26aufirst%3DJ.%2BA.%26aulast%3DRutledge%26aufirst%3DP.%2BJ.%26aulast%3DTodd%26aufirst%3DM.%2BH.%26atitle%3DAntitubercular%2520bis-substituted%2520cyclam%2520derivatives%253A%2520Structure-activity%2520relationships%2520and%2520in%2520vivo%2520studies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D3595%26epage%3D3608%26doi%3D10.1021%2Facs.jmedchem.7b01569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Azzali, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machado, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaushik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacondio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flisi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabassi, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamichhane, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viveiros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costantino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieroni, M.</span></span> <span> </span><span class="NLM_article-title">Substituted n-phenyl-5-(2-(phenylamino)thiazol-4-yl)isoxazole-3-carboxamides are valuable antitubercular candidates that evade innate efflux machinery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">7108</span>– <span class="NLM_lpage">7122</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00793</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00793" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Cntb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=7108-7122&author=E.+Azzaliauthor=D.+Machadoauthor=A.+Kaushikauthor=F.+Vacondioauthor=S.+Flisiauthor=C.+S.+Cabassiauthor=G.+Lamichhaneauthor=M.+Viveirosauthor=G.+Costantinoauthor=M.+Pieroni&title=Substituted+n-phenyl-5-%282-%28phenylamino%29thiazol-4-yl%29isoxazole-3-carboxamides+are+valuable+antitubercular+candidates+that+evade+innate+efflux+machinery&doi=10.1021%2Facs.jmedchem.7b00793"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Substituted N-Phenyl-5-(2-(phenylamino)thiazol-4-yl)isoxazole-3-carboxamides Are Valuable Antitubercular Candidates that Evade Innate Efflux Machinery</span></div><div class="casAuthors">Azzali, Elisa; Machado, Diana; Kaushik, Amit; Vacondio, Federica; Flisi, Sara; Cabassi, Clotilde Silvia; Lamichhane, Gyanu; Viveiros, Miguel; Costantino, Gabriele; Pieroni, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7108-7122</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tuberculosis remains one of the deadliest infectious diseases in the world, and the increased no. of multidrug-resistant and extremely drug-resistant strains is a significant reason for concern.  This makes the discovery of novel antitubercular agents a cogent priority.  The authors have previously addressed this need by reporting a series of substituted 2-aminothiazoles capable to inhibit the growth of actively replicating, nonreplicating persistent, and resistant Mycobacterium tuberculosis strains.  Clues from the structure-activity relationships lining up the antitubercular activity were exploited for the rational design of improved analogs.  Two compds., namely N-phenyl-5-(2-(p-tolylamino)thiazol-4-yl)isoxazole-3-carboxamide I and N-(pyridin-2-yl)-5-(2-(p-tolylamino)thiazol-4-yl)isoxazole-3-carboxamide II,were found to show high inhibitory activity toward susceptible M. tuberculosis strains, with an MIC90 of 0.125-0.25 μg/mL (0.33-0.66 μM) and 0.06-0.125 μg/mL (0.16-0.32 μM), resp.  Moreover, they maintained good activity also toward resistant strains, and they were selective over other bacterial species and eukaryotic cells, metabolically stable, and apparently not susceptible to the action of efflux pumps.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyE_6sjwqBxLVg90H21EOLACvtfcHk0liri9HFB_XxjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Cntb7M&md5=afde65c4b74ba9f180dc8c8834d551dd</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00793&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00793%26sid%3Dliteratum%253Aachs%26aulast%3DAzzali%26aufirst%3DE.%26aulast%3DMachado%26aufirst%3DD.%26aulast%3DKaushik%26aufirst%3DA.%26aulast%3DVacondio%26aufirst%3DF.%26aulast%3DFlisi%26aufirst%3DS.%26aulast%3DCabassi%26aufirst%3DC.%2BS.%26aulast%3DLamichhane%26aufirst%3DG.%26aulast%3DViveiros%26aufirst%3DM.%26aulast%3DCostantino%26aufirst%3DG.%26aulast%3DPieroni%26aufirst%3DM.%26atitle%3DSubstituted%2520n-phenyl-5-%25282-%2528phenylamino%2529thiazol-4-yl%2529isoxazole-3-carboxamides%2520are%2520valuable%2520antitubercular%2520candidates%2520that%2520evade%2520innate%2520efflux%2520machinery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D7108%26epage%3D7122%26doi%3D10.1021%2Facs.jmedchem.7b00793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Machado, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azzali, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Couto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costantino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieroni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viveiros, M.</span></span> <span> </span><span class="NLM_article-title">Adjuvant therapies against tuberculosis: Discovery of a 2-aminothiazole targeting mycobacterium tuberculosis energetics</span>. <i>Future Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1383</span>– <span class="NLM_lpage">1402</span>, <span class="refDoi"> DOI: 10.2217/fmb-2018-0110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.2217%2Ffmb-2018-0110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=30259757" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVKgtLfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=1383-1402&author=D.+Machadoauthor=E.+Azzaliauthor=I.+Coutoauthor=G.+Costantinoauthor=M.+Pieroniauthor=M.+Viveiros&title=Adjuvant+therapies+against+tuberculosis%3A+Discovery+of+a+2-aminothiazole+targeting+mycobacterium+tuberculosis+energetics&doi=10.2217%2Ffmb-2018-0110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Adjuvant therapies against tuberculosis: discovery of a 2-aminothiazole targeting Mycobacterium tuberculosis energetics</span></div><div class="casAuthors">Machado, Diana; Azzali, Elisa; Couto, Isabel; Costantino, Gabriele; Pieroni, Marco; Viveiros, Miguel</div><div class="citationInfo"><span class="NLM_cas:title">Future Microbiology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1383-1402</span>CODEN:
                <span class="NLM_cas:coden">FMUIAR</span>;
        ISSN:<span class="NLM_cas:issn">1746-0913</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">To evaluate the activity of the 2-aminothiazole UPAR-174 following an unexplored approach: targeting Mycobacterium tuberculosis with lipophilic compds. that present antituberculosis and efflux inhibitory activity.  Antituberculosis activity was assessed against replicating, nonreplicating and intracellular bacilli.  Its capacity to inhibit active efflux was detd.  ATP quantification and membrane potential anal. were performed.  Intracellular activity was studied on human-monocyte-derived macrophages.  UPAR-174 is an efflux inhibitor active against replicating, nonreplicating and intracellular M. tuberculosis.  It dissipates the membrane potential and causes ATP depletion.  Targeting M. tuberculosis with lipophilic efflux inhibitors, exploring their dual activity - dissipation of the proton motive force and efflux inhibition - represents an attractive strategy to fight against drug-resistant tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDq9jEhaFSELVg90H21EOLACvtfcHk0liri9HFB_XxjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVKgtLfF&md5=d14603271d909853723bfc199eaabd56</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.2217%2Ffmb-2018-0110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffmb-2018-0110%26sid%3Dliteratum%253Aachs%26aulast%3DMachado%26aufirst%3DD.%26aulast%3DAzzali%26aufirst%3DE.%26aulast%3DCouto%26aufirst%3DI.%26aulast%3DCostantino%26aufirst%3DG.%26aulast%3DPieroni%26aufirst%3DM.%26aulast%3DViveiros%26aufirst%3DM.%26atitle%3DAdjuvant%2520therapies%2520against%2520tuberculosis%253A%2520Discovery%2520of%2520a%25202-aminothiazole%2520targeting%2520mycobacterium%2520tuberculosis%2520energetics%26jtitle%3DFuture%2520Microbiol.%26date%3D2018%26volume%3D13%26spage%3D1383%26epage%3D1402%26doi%3D10.2217%2Ffmb-2018-0110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gessner, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moosa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seldon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizrahi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soares de
Melo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simelane, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nchinda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abay, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njoroge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunschwig, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boshoff, H. I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirgel, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Helden, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghidelli-Disse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pflaumer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boesche, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rebollo-Lopez, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urones, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selenski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafuente-Monasterio, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Axtman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lelievre, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Street, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghorpade, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chibale, K.</span></span> <span> </span><span class="NLM_article-title">Novel antitubercular 6-dialkylaminopyrimidine carboxamides from phenotypic whole-cell high throughput screening of a softfocus library: Structure-activity relationship and target identification studies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">10118</span>– <span class="NLM_lpage">10134</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01347</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01347" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVWqtbjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=10118-10134&author=C.+R.+Wilsonauthor=R.+K.+Gessnerauthor=A.+Moosaauthor=R.+Seldonauthor=D.+F.+Warnerauthor=V.+Mizrahiauthor=C.+Soares+de%0AMeloauthor=S.+B.+Simelaneauthor=A.+Nchindaauthor=E.+Abayauthor=D.+Taylorauthor=M.+Njorogeauthor=C.+Brunschwigauthor=N.+Lawrenceauthor=H.+I.+M.+Boshoffauthor=C.+E.+Barryauthor=F.+A.+Sirgelauthor=P.+van+Heldenauthor=C.+J.+Harrisauthor=R.+Gordonauthor=S.+Ghidelli-Disseauthor=H.+Pflaumerauthor=M.+Boescheauthor=G.+Drewesauthor=O.+Sanzauthor=G.+Santosauthor=M.+J.+Rebollo-Lopezauthor=B.+Uronesauthor=C.+Selenskiauthor=M.+J.+Lafuente-Monasterioauthor=M.+Axtmanauthor=J.+Lelievreauthor=L.+Ballellauthor=R.+Muellerauthor=L.+J.+Streetauthor=S.+R.+Ghorpadeauthor=K.+Chibale&title=Novel+antitubercular+6-dialkylaminopyrimidine+carboxamides+from+phenotypic+whole-cell+high+throughput+screening+of+a+softfocus+library%3A+Structure-activity+relationship+and+target+identification+studies&doi=10.1021%2Facs.jmedchem.7b01347"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Antitubercular 6-Dialkylaminopyrimidine Carboxamides from Phenotypic Whole-Cell High Throughput Screening of a SoftFocus Library: Structure-Activity Relationship and Target Identification Studies</span></div><div class="casAuthors">Wilson, Colin R.; Gessner, Richard K.; Moosa, Atica; Seldon, Ronnett; Warner, Digby F.; Mizrahi, Valerie; Soares de Melo, Candice; Simelane, Sandile B.; Nchinda, Aloysius; Abay, Efrem; Taylor, Dale; Njoroge, Mathew; Brunschwig, Christel; Lawrence, Nina; Boshoff, Helena I. M.; Barry, Clifton E.; Sirgel, Frederick A.; van Helden, Paul; Harris, C. John; Gordon, Richard; Ghidelli-Disse, Sonja; Pflaumer, Hannah; Boesche, Markus; Drewes, Gerard; Sanz, Olalla; Santos, Gracia; Rebollo-Lopez, Maria Jose; Urones, Beatriz; Selenski, Carolyn; Lafuente-Monasterio, Maria Jose; Axtman, Matthew; Lelievre, Joel; Ballell, Lluis; Mueller, Rudolf; Street, Leslie J.; Ghorpade, Sandeep R.; Chibale, Kelly</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10118-10134</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A BioFocus DPI SoftFocus library of ∼35,000 compds. was screened against Mycobacterium tuberculosis (Mtb) to identify novel hits with antitubercular activity.  The hits were evaluated in biol. triage assays to exclude compds. suggested to function via frequently encountered promiscuous mechanisms of action including inhibition of the QcrB subunit of the cytochrome bc1 complex, disruption of cell-wall homeostasis, and DNA damage.  Among the hits that passed this screening cascade, a 6-dialkylaminopyrimidine carboxamide series was prioritized for hit to lead optimization.  Compds. from this series were active against clin. Mtb strains, while no cross-resistance to conventional antituberculosis drugs was obsd.  This suggested a novel mechanism of action, which was confirmed by chemoproteomic anal. leading to the identification of BCG_3193 and BCG_3827 as putative targets of the series with unknown function.  Initial structure-activity relationship studies have resulted in compds. with moderate to potent antitubercular activity and improved physicochem. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdBt_xcb2SIbVg90H21EOLACvtfcHk0liri9HFB_XxjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVWqtbjL&md5=364c9cd37481ad64be7ea86ea0c042e3</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01347&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01347%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DC.%2BR.%26aulast%3DGessner%26aufirst%3DR.%2BK.%26aulast%3DMoosa%26aufirst%3DA.%26aulast%3DSeldon%26aufirst%3DR.%26aulast%3DWarner%26aufirst%3DD.%2BF.%26aulast%3DMizrahi%26aufirst%3DV.%26aulast%3DSoares%2Bde%2BMelo%26aufirst%3DC.%26aulast%3DSimelane%26aufirst%3DS.%2BB.%26aulast%3DNchinda%26aufirst%3DA.%26aulast%3DAbay%26aufirst%3DE.%26aulast%3DTaylor%26aufirst%3DD.%26aulast%3DNjoroge%26aufirst%3DM.%26aulast%3DBrunschwig%26aufirst%3DC.%26aulast%3DLawrence%26aufirst%3DN.%26aulast%3DBoshoff%26aufirst%3DH.%2BI.%2BM.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26aulast%3DSirgel%26aufirst%3DF.%2BA.%26aulast%3Dvan%2BHelden%26aufirst%3DP.%26aulast%3DHarris%26aufirst%3DC.%2BJ.%26aulast%3DGordon%26aufirst%3DR.%26aulast%3DGhidelli-Disse%26aufirst%3DS.%26aulast%3DPflaumer%26aufirst%3DH.%26aulast%3DBoesche%26aufirst%3DM.%26aulast%3DDrewes%26aufirst%3DG.%26aulast%3DSanz%26aufirst%3DO.%26aulast%3DSantos%26aufirst%3DG.%26aulast%3DRebollo-Lopez%26aufirst%3DM.%2BJ.%26aulast%3DUrones%26aufirst%3DB.%26aulast%3DSelenski%26aufirst%3DC.%26aulast%3DLafuente-Monasterio%26aufirst%3DM.%2BJ.%26aulast%3DAxtman%26aufirst%3DM.%26aulast%3DLelievre%26aufirst%3DJ.%26aulast%3DBallell%26aufirst%3DL.%26aulast%3DMueller%26aufirst%3DR.%26aulast%3DStreet%26aufirst%3DL.%2BJ.%26aulast%3DGhorpade%26aufirst%3DS.%2BR.%26aulast%3DChibale%26aufirst%3DK.%26atitle%3DNovel%2520antitubercular%25206-dialkylaminopyrimidine%2520carboxamides%2520from%2520phenotypic%2520whole-cell%2520high%2520throughput%2520screening%2520of%2520a%2520softfocus%2520library%253A%2520Structure-activity%2520relationship%2520and%2520target%2520identification%2520studies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D10118%26epage%3D10134%26doi%3D10.1021%2Facs.jmedchem.7b01347" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dos
Santos Fernandes, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Souza, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno-Viguri, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santivanez-Veliz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paucar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Silanes, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chegaev, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guglielmo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazzarato, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fruttero, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Man Chin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Silva, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chorilli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solcia, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribeiro, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, C. S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marino, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosquesi, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Carvalho, L. P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Souza Costa, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franzblau, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavan, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dos Santos, J. L.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and characterization of N-oxide-containing heterocycles with in vivo sterilizing antitubercular activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">8647</span>– <span class="NLM_lpage">8660</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01332</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01332" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFyrtbzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=8647-8660&author=G.+F.+Dos%0ASantos+Fernandesauthor=P.+C.+de+Souzaauthor=E.+Moreno-Viguriauthor=M.+Santivanez-Velizauthor=R.+Paucarauthor=S.+Perez-Silanesauthor=K.+Chegaevauthor=S.+Guglielmoauthor=L.+Lazzaratoauthor=R.+Frutteroauthor=C.+Man+Chinauthor=P.+B.+da+Silvaauthor=M.+Chorilliauthor=M.+C.+Solciaauthor=C.+M.+Ribeiroauthor=C.+S.+P.+Silvaauthor=L.+B.+Marinoauthor=P.+L.+Bosquesiauthor=D.+M.+Huntauthor=L.+P.+S.+de+Carvalhoauthor=C.+A.+de+Souza+Costaauthor=S.+H.+Choauthor=Y.+Wangauthor=S.+G.+Franzblauauthor=F.+R.+Pavanauthor=J.+L.+Dos+Santos&title=Design%2C+synthesis%2C+and+characterization+of+N-oxide-containing+heterocycles+with+in+vivo+sterilizing+antitubercular+activity&doi=10.1021%2Facs.jmedchem.7b01332"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Characterization of N-Oxide-Containing Heterocycles with in Vivo Sterilizing Antitubercular Activity</span></div><div class="casAuthors">dos Santos Fernandes, Guilherme Felipe; de Souza, Paula Carolina; Moreno-Viguri, Elsa; Santivanez-Veliz, Mery; Paucar, Rocio; Perez-Silanes, Silvia; Chegaev, Konstantin; Guglielmo, Stefano; Lazzarato, Loretta; Fruttero, Roberta; Man Chin, Chung; da Silva, Patricia Bento; Chorilli, Marlus; Solcia, Mariana Cristina; Ribeiro, Camila Maringolo; Silva, Caio Sander Paiva; Marino, Leonardo Biancolino; Bosquesi, Priscila Longhin; Hunt, Debbie M.; de Carvalho, Luiz Pedro S.; de Souza Costa, Carlos Alberto; Cho, Sang Hyun; Wang, Yuehong; Franzblau, Scott Gary; Pavan, Fernando Rogerio; dos Santos, Jean Leandro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8647-8660</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tuberculosis, caused by Mycobacterium tuberculosis (Mtb), is the infectious disease responsible for the highest no. of deaths worldwide.  Herein, 22 new N-oxide-contg. heterocyclic compds. were synthesized followed by in vitro and in vivo evaluation of their antitubercular potential against Mtb.  (E)-6-((2-Isonicotinoylhydrazono)methyl)benzo[c][1,2,5]oxadiazole 1-oxide (8) is the most promising compd., with MIC90 values of 1.10 and 6.62 μM against active and nonreplicating Mtb, resp.  Addnl., the authors carried out in vivo expts. to confirm the safety and efficacy of compd. 8; the compd. is orally bioavailable and highly effective, leading to a redn. of Mtb to undetectable levels in a mouse model of infection.  Microarray-based initial studies on the mechanism of action suggest that compd. 8 blocks translation.  Altogether, these results indicate that benzofuroxan deriv. 8 is a promising lead compd. for the development of a novel chem. class of antitubercular drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnVx2fk-STtrVg90H21EOLACvtfcHk0lgwMKtFQJuWQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFyrtbzJ&md5=8a3cfe6b45fcb347a40123f8447c9a98</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01332%26sid%3Dliteratum%253Aachs%26aulast%3DDos%2BSantos%2BFernandes%26aufirst%3DG.%2BF.%26aulast%3Dde%2BSouza%26aufirst%3DP.%2BC.%26aulast%3DMoreno-Viguri%26aufirst%3DE.%26aulast%3DSantivanez-Veliz%26aufirst%3DM.%26aulast%3DPaucar%26aufirst%3DR.%26aulast%3DPerez-Silanes%26aufirst%3DS.%26aulast%3DChegaev%26aufirst%3DK.%26aulast%3DGuglielmo%26aufirst%3DS.%26aulast%3DLazzarato%26aufirst%3DL.%26aulast%3DFruttero%26aufirst%3DR.%26aulast%3DMan%2BChin%26aufirst%3DC.%26aulast%3Dda%2BSilva%26aufirst%3DP.%2BB.%26aulast%3DChorilli%26aufirst%3DM.%26aulast%3DSolcia%26aufirst%3DM.%2BC.%26aulast%3DRibeiro%26aufirst%3DC.%2BM.%26aulast%3DSilva%26aufirst%3DC.%2BS.%2BP.%26aulast%3DMarino%26aufirst%3DL.%2BB.%26aulast%3DBosquesi%26aufirst%3DP.%2BL.%26aulast%3DHunt%26aufirst%3DD.%2BM.%26aulast%3Dde%2BCarvalho%26aufirst%3DL.%2BP.%2BS.%26aulast%3Dde%2BSouza%2BCosta%26aufirst%3DC.%2BA.%26aulast%3DCho%26aufirst%3DS.%2BH.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DFranzblau%26aufirst%3DS.%2BG.%26aulast%3DPavan%26aufirst%3DF.%2BR.%26aulast%3DDos%2BSantos%26aufirst%3DJ.%2BL.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520characterization%2520of%2520N-oxide-containing%2520heterocycles%2520with%2520in%2520vivo%2520sterilizing%2520antitubercular%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D8647%26epage%3D8660%26doi%3D10.1021%2Facs.jmedchem.7b01332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rogacki, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitta, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balabon, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huss, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Roman, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argyrou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanco-Ruano, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cacho, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vande Velde, C. M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augustyns, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barros, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Veken, P.</span></span> <span> </span><span class="NLM_article-title">Identification and profiling of hydantoins-a novel class of potent antimycobacterial dpre1 inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">11221</span>– <span class="NLM_lpage">11249</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01356</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01356" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlylsLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=11221-11249&author=M.+K.+Rogackiauthor=E.+Pittaauthor=O.+Balabonauthor=S.+Hussauthor=E.+M.+Lopez-Romanauthor=A.+Argyrouauthor=D.+Blanco-Ruanoauthor=M.+Cachoauthor=C.+M.+L.+Vande+Veldeauthor=K.+Augustynsauthor=L.+Ballellauthor=D.+Barrosauthor=R.+H.+Batesauthor=F.+Cunninghamauthor=P.+Van+der+Veken&title=Identification+and+profiling+of+hydantoins-a+novel+class+of+potent+antimycobacterial+dpre1+inhibitors&doi=10.1021%2Facs.jmedchem.8b01356"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and Profiling of Hydantoins-A Novel Class of Potent Antimycobacterial DprE1 Inhibitors</span></div><div class="casAuthors">Rogacki, Maciej K.; Pitta, Eleni; Balabon, Olga; Huss, Sophie; Lopez-Roman, Eva Maria; Argyrou, Argyrides; Blanco-Ruano, Delia; Cacho, Monica; Vande Velde, Christophe M. L.; Augustyns, Koen; Ballell, Lluis; Barros, David; Bates, Robert H.; Cunningham, Fraser; Van der Veken, Pieter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">11221-11249</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tuberculosis is the leading cause of death worldwide from infectious diseases.  With the development of drug-resistant strains of Mycobacterium tuberculosis, there is an acute need for new medicines with novel modes of action.  Herein, we report the discovery and profiling of a novel hydantoin-based family of antimycobacterial inhibitors of the decaprenylphospho-β-D-ribofuranose 2-oxidase (DprE1).  In this study, we have prepd. a library of more than a 100 compds. and evaluated them for their biol. and physicochem. properties.  The series is characterized by high enzymic and whole-cell activity, low cytotoxicity, and a good overall physicochem. profile.  In addn., we show that the series acts via reversible inhibition of the DprE1 enzyme.  Overall, the novel compd. family forms an attractive base for progression to further stages of optimization and may provide a promising drug candidate in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMw2Vn8XKan7Vg90H21EOLACvtfcHk0lgwMKtFQJuWQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlylsLzE&md5=647fdfe146a1802016d7e38a8543e522</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01356&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01356%26sid%3Dliteratum%253Aachs%26aulast%3DRogacki%26aufirst%3DM.%2BK.%26aulast%3DPitta%26aufirst%3DE.%26aulast%3DBalabon%26aufirst%3DO.%26aulast%3DHuss%26aufirst%3DS.%26aulast%3DLopez-Roman%26aufirst%3DE.%2BM.%26aulast%3DArgyrou%26aufirst%3DA.%26aulast%3DBlanco-Ruano%26aufirst%3DD.%26aulast%3DCacho%26aufirst%3DM.%26aulast%3DVande%2BVelde%26aufirst%3DC.%2BM.%2BL.%26aulast%3DAugustyns%26aufirst%3DK.%26aulast%3DBallell%26aufirst%3DL.%26aulast%3DBarros%26aufirst%3DD.%26aulast%3DBates%26aufirst%3DR.%2BH.%26aulast%3DCunningham%26aufirst%3DF.%26aulast%3DVan%2Bder%2BVeken%26aufirst%3DP.%26atitle%3DIdentification%2520and%2520profiling%2520of%2520hydantoins-a%2520novel%2520class%2520of%2520potent%2520antimycobacterial%2520dpre1%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D11221%26epage%3D11249%26doi%3D10.1021%2Facs.jmedchem.8b01356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manson, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Earl, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunosewoyo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishai, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L. F.</span></span> <span> </span><span class="NLM_article-title">Identification of novel coumestan derivatives as polyketide synthase 13 inhibitors against mycobacterium tuberculosis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">791</span>– <span class="NLM_lpage">803</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01319</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01319" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotVyqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=791-803&author=W.+Zhangauthor=S.+Lunauthor=S.+H.+Wangauthor=X.+W.+Jiangauthor=F.+Yangauthor=J.+Tangauthor=A.+L.+Mansonauthor=A.+M.+Earlauthor=H.+Gunosewoyoauthor=W.+R.+Bishaiauthor=L.+F.+Yu&title=Identification+of+novel+coumestan+derivatives+as+polyketide+synthase+13+inhibitors+against+mycobacterium+tuberculosis&doi=10.1021%2Facs.jmedchem.7b01319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis</span></div><div class="casAuthors">Zhang, Wei; Lun, Shichun; Wang, Shu-Huan; Jiang, Xing-Wu; Yang, Fan; Tang, Jie; Manson, Abigail L.; Earl, Ashlee M.; Gunosewoyo, Hendra; Bishai, William R.; Yu, Li-Fang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">791-803</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of the mycolic acid pathway has proven a viable strategy in antitubercular drug discovery.  The AccA3/AccD4/FadD32/Pks13 complex of Mycobacterium tuberculosis constitutes an essential biosynthetic mechanism for mycolic acids.  Small mols. targeting the thioesterase domain of Pks13 have been reported, including a benzofuran-based compd. whose X-ray cocrystal structure has been very recently solved.  Its initial inactivity in a serum inhibition titrn. (SIT) assay led us to further probe other structurally related benzofurans with the aim to improve their potency and bioavailability.  Herein, we report our preliminary structure-activity relationship studies around this scaffold, highlighting a natural product-inspired cyclization strategy to form coumestans that are shown to be active in SIT.  Whole genome deep sequencing of the coumestan-resistant mutants confirmed a single nucleotide polymorphism in the pks13 gene responsible for the resistance phenotype, demonstrating the druggability of this target for the development of new antitubercular agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1LJWIdOrTvLVg90H21EOLACvtfcHk0ljzcXFY_uRiGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotVyqtw%253D%253D&md5=053f265d21ca7eff9f396c33907a1d75</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01319%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DLun%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DS.%2BH.%26aulast%3DJiang%26aufirst%3DX.%2BW.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DManson%26aufirst%3DA.%2BL.%26aulast%3DEarl%26aufirst%3DA.%2BM.%26aulast%3DGunosewoyo%26aufirst%3DH.%26aulast%3DBishai%26aufirst%3DW.%2BR.%26aulast%3DYu%26aufirst%3DL.%2BF.%26atitle%3DIdentification%2520of%2520novel%2520coumestan%2520derivatives%2520as%2520polyketide%2520synthase%252013%2520inhibitors%2520against%2520mycobacterium%2520tuberculosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D791%26epage%3D803%26doi%3D10.1021%2Facs.jmedchem.7b01319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunosewoyo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishai, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L. F.</span></span> <span> </span><span class="NLM_article-title">Identification of novel coumestan derivatives as polyketide synthase 13 inhibitors against mycobacterium tuberculosis. Part ii</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">3575</span>– <span class="NLM_lpage">3589</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00010</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00010" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC1MXltFeksL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=3575-3589&author=W.+Zhangauthor=S.+Lunauthor=L.+L.+Liuauthor=S.+Xiaoauthor=G.+Duanauthor=H.+Gunosewoyoauthor=F.+Yangauthor=J.+Tangauthor=W.+R.+Bishaiauthor=L.+F.+Yu&title=Identification+of+novel+coumestan+derivatives+as+polyketide+synthase+13+inhibitors+against+mycobacterium+tuberculosis.+Part+ii&doi=10.1021%2Facs.jmedchem.9b00010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of novel coumestan derivatives as polyketide synthase 13 inhibitors against Mycobacterium tuberculosis. part II</span></div><div class="casAuthors">Zhang, Wei; Lun, Shichun; Liu, Ling-Ling; Xiao, Shiqi; Duan, Guanfu; Gunosewoyo, Hendra; Yang, Fan; Tang, Jie; Bishai, William R.; Yu, Li-Fang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3575-3589</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Our group recently reported the identification of novel coumestan derivs. as Mycobacterium tuberculosis (Mtb) Pks13-thioesterase (TE) domain inhibitors, with mutations obsd. (D1644G and N1640K) in the generated coumestan-resistant Mtb colonies.  Herein, we report a further structure-activity relationships exploration exploiting the available Pks13-TE X-ray co-crystal structure that resulted in the discovery of extremely potent coumestan analogs 48(I) and 50(II).  These mols. possess excellent anti-tuberculosis activity against both the drug-susceptible (MIC = 0.0039 μg/mL) and drug-resistant Mtb strains (MIC = 0.0078 μg/mL).  Moreover, the excellent in vitro activity is translated to the in vivo mouse serum inhibitory titrn. assay, with administration of I at 100 mg/kg showing an 8-fold higher activity than that of isoniazid or TAM16 given at 10 or 100 mg/kg, resp.  Preliminary ADME-Tox data for the coumestans were promising and, coupled with the practicality of synthesis, warrant further in vivo efficacy assessments of the coumestan derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolhzlD7NMcz7Vg90H21EOLACvtfcHk0ljzcXFY_uRiGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXltFeksL0%253D&md5=30c5e50311e413573a0c861fc5c64cb3</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00010%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DLun%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DL.%2BL.%26aulast%3DXiao%26aufirst%3DS.%26aulast%3DDuan%26aufirst%3DG.%26aulast%3DGunosewoyo%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DBishai%26aufirst%3DW.%2BR.%26aulast%3DYu%26aufirst%3DL.%2BF.%26atitle%3DIdentification%2520of%2520novel%2520coumestan%2520derivatives%2520as%2520polyketide%2520synthase%252013%2520inhibitors%2520against%2520mycobacterium%2520tuberculosis.%2520Part%2520ii%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D3575%26epage%3D3589%26doi%3D10.1021%2Facs.jmedchem.9b00010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upton, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span> <span> </span><span class="NLM_article-title">Identification of less lipophilic riminophenazine derivatives for the treatment of drug-resistant tuberculosis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">8409</span>– <span class="NLM_lpage">8417</span>, <span class="refDoi"> DOI: 10.1021/jm300828h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300828h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1yrsbjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8409-8417&author=D.+Zhangauthor=Y.+Luauthor=K.+Liuauthor=B.+Liuauthor=J.+Wangauthor=G.+Zhangauthor=H.+Zhangauthor=Y.+Liuauthor=B.+Wangauthor=M.+Zhengauthor=L.+Fuauthor=Y.+Houauthor=N.+Gongauthor=Y.+Lvauthor=C.+Liauthor=C.+B.+Cooperauthor=A.+M.+Uptonauthor=D.+Yinauthor=Z.+Maauthor=H.+Huang&title=Identification+of+less+lipophilic+riminophenazine+derivatives+for+the+treatment+of+drug-resistant+tuberculosis&doi=10.1021%2Fjm300828h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Less Lipophilic Riminophenazine Derivatives for the Treatment of Drug-Resistant Tuberculosis</span></div><div class="casAuthors">Zhang, Dongfeng; Lu, Yu; Liu, Kai; Liu, Binna; Wang, Jingbin; Zhang, Gang; Zhang, Hao; Liu, Yang; Wang, Bin; Zheng, Meiqin; Fu, Lei; Hou, Yanyan; Gong, Ningbo; Lv, Yang; Li, Chun; Cooper, Christopher B.; Upton, Anna M.; Yin, Dali; Ma, Zhenkun; Huang, Haihong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8409-8417</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Clofazimine (CFZ), a member of the riminophenazine class, has been studied in clin. trials for the treatment of multidrug-resistant tuberculosis (MDR-TB).  CFZ has several side effects which can be attributed to its extremely high lipophilicity.  A series of novel riminophenazine analogs bearing a C-2 pyridyl substituent was designed and synthesized with the goal of maintaining potent activity against Mycobacterium tuberculosis (M. tuberculosis) while improving upon its safety profile by lowering the lipophilicity.  All compds. were evaluated for their in vitro activity and cytotoxicity.  The results demonstrated that many new compds. had potent activity against M. tuberculosis with MICs of less than 0.03 μg/mL and low cytotoxicity with IC50 values greater than 64 μg/mL.  Some compds. were tested for in vivo efficacy against MDR-TB in an exptl. mouse infection model.  Two compds. I [R = 2-OMe, 6-Me] demonstrated equiv. or better efficacy than CFZ in this model with significantly reduced skin discoloration potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFLZ4IRiNxTbVg90H21EOLACvtfcHk0ljzcXFY_uRiGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1yrsbjJ&md5=591d0b4655abf45726abfce56fb4b868</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1021%2Fjm300828h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300828h%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DFu%26aufirst%3DL.%26aulast%3DHou%26aufirst%3DY.%26aulast%3DGong%26aufirst%3DN.%26aulast%3DLv%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DCooper%26aufirst%3DC.%2BB.%26aulast%3DUpton%26aufirst%3DA.%2BM.%26aulast%3DYin%26aufirst%3DD.%26aulast%3DMa%26aufirst%3DZ.%26aulast%3DHuang%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520less%2520lipophilic%2520riminophenazine%2520derivatives%2520for%2520the%2520treatment%2520of%2520drug-resistant%2520tuberculosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8409%26epage%3D8417%26doi%3D10.1021%2Fjm300828h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guardia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baiget, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cacho, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortega-Guerra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nxumalo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khanye, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rullas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortega, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Herran, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraile-Gabaldon, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esquivias, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porras-De Francisco, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Encinas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivero, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miguel-Siles, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osende, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badiola, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutledge, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Todd, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remuinan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alemparte, C.</span></span> <span> </span><span class="NLM_article-title">Easy-to-synthesize spirocyclic compounds possess remarkable in vivo activity against mycobacterium tuberculosis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">11327</span>– <span class="NLM_lpage">11340</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01533</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01533" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1OqsLjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=11327-11340&author=A.+Guardiaauthor=J.+Baigetauthor=M.+Cachoauthor=A.+Perezauthor=M.+Ortega-Guerraauthor=W.+Nxumaloauthor=S.+D.+Khanyeauthor=J.+Rullasauthor=F.+Ortegaauthor=E.+Jimenezauthor=E.+Perez-Herranauthor=M.+T.+Fraile-Gabaldonauthor=J.+Esquiviasauthor=R.+Fernandezauthor=E.+Porras-De+Franciscoauthor=L.+Encinasauthor=M.+Alonsoauthor=I.+Giordanoauthor=C.+Riveroauthor=J.+Miguel-Silesauthor=J.+G.+Osendeauthor=K.+A.+Badiolaauthor=P.+J.+Rutledgeauthor=M.+H.+Toddauthor=M.+Remuinanauthor=C.+Alemparte&title=Easy-to-synthesize+spirocyclic+compounds+possess+remarkable+in+vivo+activity+against+mycobacterium+tuberculosis&doi=10.1021%2Facs.jmedchem.8b01533"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Easy-To-Synthesize Spirocyclic Compounds Possess Remarkable in Vivo Activity against Mycobacterium tuberculosis</span></div><div class="casAuthors">Guardia, Ana; Baiget, Jessica; Cacho, Monica; Perez, Arancha; Ortega-Guerra, Montserrat; Nxumalo, Winston; Khanye, Setshaba D.; Rullas, Joaquin; Ortega, Fatima; Jimenez, Elena; Perez-Herran, Esther; Fraile-Gabaldon, Maria Teresa; Esquivias, Jorge; Fernandez, Raquel; Porras-De Francisco, Esther; Encinas, Lourdes; Alonso, Marta; Giordano, Ilaria; Rivero, Cristina; Miguel-Siles, Juan; Osende, Javier G.; Badiola, Katrina A.; Rutledge, Peter J.; Todd, Matthew H.; Remuinan, Modesto; Alemparte, Carlos</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">11327-11340</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Society urgently needs new, effective medicines for the treatment of tuberculosis.  To kick-start the required hit-to-lead campaigns, the libraries of pharmaceutical companies have recently been evaluated for starting points.  The GlaxoSmithKline (GSK) library yielded many high-quality hits, and the assocd. data were placed in the public domain to stimulate engagement by the wider community.  One such series, the spiro compds., are described here.  The compds. were explored by a combination of traditional inhouse research and open source methods.  The series benefits from a particularly simple structure and a short assocd. synthetic chem. route.  Many members of the series displayed striking potency and low toxicity, and highly promising in vivo activity in a mouse model was confirmed with one of the analogs.  Ultimately the series was discontinued due to concerns over safety, but the assocd. data remain public domain, empowering others to resume the series if the perceived deficiencies can be overcome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmizcPsa-ok7Vg90H21EOLACvtfcHk0ljXk_tJLqm1Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1OqsLjJ&md5=ca3395ecd8dc725c5162f0965eee84db</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01533&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01533%26sid%3Dliteratum%253Aachs%26aulast%3DGuardia%26aufirst%3DA.%26aulast%3DBaiget%26aufirst%3DJ.%26aulast%3DCacho%26aufirst%3DM.%26aulast%3DPerez%26aufirst%3DA.%26aulast%3DOrtega-Guerra%26aufirst%3DM.%26aulast%3DNxumalo%26aufirst%3DW.%26aulast%3DKhanye%26aufirst%3DS.%2BD.%26aulast%3DRullas%26aufirst%3DJ.%26aulast%3DOrtega%26aufirst%3DF.%26aulast%3DJimenez%26aufirst%3DE.%26aulast%3DPerez-Herran%26aufirst%3DE.%26aulast%3DFraile-Gabaldon%26aufirst%3DM.%2BT.%26aulast%3DEsquivias%26aufirst%3DJ.%26aulast%3DFernandez%26aufirst%3DR.%26aulast%3DPorras-De%2BFrancisco%26aufirst%3DE.%26aulast%3DEncinas%26aufirst%3DL.%26aulast%3DAlonso%26aufirst%3DM.%26aulast%3DGiordano%26aufirst%3DI.%26aulast%3DRivero%26aufirst%3DC.%26aulast%3DMiguel-Siles%26aufirst%3DJ.%26aulast%3DOsende%26aufirst%3DJ.%2BG.%26aulast%3DBadiola%26aufirst%3DK.%2BA.%26aulast%3DRutledge%26aufirst%3DP.%2BJ.%26aulast%3DTodd%26aufirst%3DM.%2BH.%26aulast%3DRemuinan%26aufirst%3DM.%26aulast%3DAlemparte%26aufirst%3DC.%26atitle%3DEasy-to-synthesize%2520spirocyclic%2520compounds%2520possess%2520remarkable%2520in%2520vivo%2520activity%2520against%2520mycobacterium%2520tuberculosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D11327%26epage%3D11340%26doi%3D10.1021%2Facs.jmedchem.8b01533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taban, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elshihawy, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torun, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zucchini, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altuwairigi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngu, A. S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLean, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sood, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marino, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munro, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Carvalho, L. P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simons, C.</span></span> <span> </span><span class="NLM_article-title">Novel aryl substituted pyrazoles as small molecule inhibitors of cytochrome P450 CYP121a1: Synthesis and antimycobacterial evaluation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">10257</span>– <span class="NLM_lpage">10267</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01562</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01562" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvV2mtLzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=10257-10267&author=I.+M.+Tabanauthor=H.+Elshihawyauthor=B.+Torunauthor=B.+Zucchiniauthor=C.+J.+Williamsonauthor=D.+Altuwairigiauthor=A.+S.+T.+Nguauthor=K.+J.+McLeanauthor=C.+W.+Levyauthor=S.+Soodauthor=L.+B.+Marinoauthor=A.+W.+Munroauthor=L.+P.+S.+de+Carvalhoauthor=C.+Simons&title=Novel+aryl+substituted+pyrazoles+as+small+molecule+inhibitors+of+cytochrome+P450+CYP121a1%3A+Synthesis+and+antimycobacterial+evaluation&doi=10.1021%2Facs.jmedchem.7b01562"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Aryl Substituted Pyrazoles as Small Molecule Inhibitors of Cytochrome P450 CYP121A1: Synthesis and Antimycobacterial Evaluation</span></div><div class="casAuthors">Taban, Ismail M.; Elshihawy, Hosam E. A. E.; Torun, Beyza; Zucchini, Benedetta; Williamson, Clare J.; Altuwairigi, Dania; Ngu, Adeline S. T.; McLean, Kirsty J.; Levy, Colin W.; Sood, Sakshi; Marino, Leonardo B.; Munro, Andrew W.; de Carvalho, Luiz Pedro S.; Simons, Claire</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10257-10267</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Three series of biarylpyrazole, imidazole and triazoles are described, which vary in the linker between the biaryl pyrazole and imidazole/triazole group.  The imidazole and triazole series with the short -CH2- linker displayed promising antimycobacterial activity, with the imidazole-CH2- series showing low MIC values (6.25-25 μg/mL), which was also influenced by lipophilicity.  Extending the linker to -C(O)NH(CH2)2- resulted in a loss of antimycobacterial activity.  The binding affinity of the compds. with CYP121A1 was detd. by UV-visible optical titrns. with KD values of 2.63, 35.6, and 290 μM, resp., for the tightest binding compds. I, II, and III from their resp. series.  Both binding affinity assays and docking studies of the CYP121A1 inhibitors suggest type II indirect binding through interstitial water mols., with key binding residues Thr77, Val78, Val82, Val83, Met86, Ser237, Gln385, and Arg386, comparable with the binding interactions obsd. with fluconazole and the natural substrate dicyclotyrosine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNC8RyFfrTz7Vg90H21EOLACvtfcHk0ljXk_tJLqm1Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvV2mtLzF&md5=10b15551ca37506e6034c6d582ade219</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01562&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01562%26sid%3Dliteratum%253Aachs%26aulast%3DTaban%26aufirst%3DI.%2BM.%26aulast%3DElshihawy%26aufirst%3DH.%26aulast%3DTorun%26aufirst%3DB.%26aulast%3DZucchini%26aufirst%3DB.%26aulast%3DWilliamson%26aufirst%3DC.%2BJ.%26aulast%3DAltuwairigi%26aufirst%3DD.%26aulast%3DNgu%26aufirst%3DA.%2BS.%2BT.%26aulast%3DMcLean%26aufirst%3DK.%2BJ.%26aulast%3DLevy%26aufirst%3DC.%2BW.%26aulast%3DSood%26aufirst%3DS.%26aulast%3DMarino%26aufirst%3DL.%2BB.%26aulast%3DMunro%26aufirst%3DA.%2BW.%26aulast%3Dde%2BCarvalho%26aufirst%3DL.%2BP.%2BS.%26aulast%3DSimons%26aufirst%3DC.%26atitle%3DNovel%2520aryl%2520substituted%2520pyrazoles%2520as%2520small%2520molecule%2520inhibitors%2520of%2520cytochrome%2520P450%2520CYP121a1%253A%2520Synthesis%2520and%2520antimycobacterial%2520evaluation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D10257%26epage%3D10267%26doi%3D10.1021%2Facs.jmedchem.7b01562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelhart, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallach, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnappinger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arora, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manikkam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gac, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murgolo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodwin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutphin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiner, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Via, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boshoff, H. I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.,  3rd.</span></span> <span> </span><span class="NLM_article-title">Discovery and structure-activity-relationship study of n-alkyl-5-hydroxypyrimidinone carboxamides as novel antitubercular agents targeting decaprenylphosphoryl-beta-d-ribose 2′-oxidase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">9952</span>– <span class="NLM_lpage">9965</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00883</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00883" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvV2rsrfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9952-9965&author=S.+Ohauthor=Y.+Parkauthor=C.+A.+Engelhartauthor=J.+B.+Wallachauthor=D.+Schnappingerauthor=K.+Aroraauthor=M.+Manikkamauthor=B.+Gacauthor=H.+Wangauthor=N.+Murgoloauthor=D.+B.+Olsenauthor=M.+Goodwinauthor=M.+Sutphinauthor=D.+M.+Weinerauthor=L.+E.+Viaauthor=H.+I.+M.+Boshoffauthor=C.+E.+Barry&title=Discovery+and+structure-activity-relationship+study+of+n-alkyl-5-hydroxypyrimidinone+carboxamides+as+novel+antitubercular+agents+targeting+decaprenylphosphoryl-beta-d-ribose+2%E2%80%B2-oxidase&doi=10.1021%2Facs.jmedchem.8b00883"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Structure-Activity-Relationship Study of N-Alkyl-5-hydroxypyrimidinone Carboxamides as Novel Antitubercular Agents Targeting Decaprenylphosphoryl-β-D-ribose 2'-Oxidase</span></div><div class="casAuthors">Oh, Sangmi; Park, Yumi; Engelhart, Curtis A.; Wallach, Joshua B.; Schnappinger, Dirk; Arora, Kriti; Manikkam, Michelle; Gac, Brian; Wang, Hongwu; Murgolo, Nicholas; Olsen, David B.; Goodwin, Michael; Sutphin, Michelle; Weiner, Danielle M.; Via, Laura E.; Boshoff, Helena I. M.; Barry, Clifton E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9952-9965</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Magnesium plays an important role in infection with Mycobacterium tuberculosis (Mtb) as a signal of the extracellular environment, as a cofactor for many enzymes, and as a structural element in important macromols.  Raltegravir, an antiretroviral drug that inhibits HIV-1 integrase is known to derive its potency from selective sequestration of active-site magnesium ions in addn. to binding to a hydrophobic pocket.  In order to det. if essential Mtb-related phosphoryl transfers could be disrupted in a similar manner, a directed screen of known mols. with integrase inhibitor-like pharmacophores (N-alkyl-5-hydroxypyrimidinone carboxamides) was performed.  Initial hits afforded compds. with low-micromolar potency against Mtb, acceptable cytotoxicity and PK characteristics, and robust SAR.  Elucidation of the target of these compds. revealed that they lacked magnesium dependence and instead disappointingly inhibited a known promiscuous target in Mtb, decaprenylphosphoryl-β-D-ribose 2'-oxidase (DprE1, Rv3790).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOxHRHtAf2rbVg90H21EOLACvtfcHk0lij3ff6vLra_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvV2rsrfP&md5=5c8f50d73f857fcde7277ca80109fee9</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00883%26sid%3Dliteratum%253Aachs%26aulast%3DOh%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DY.%26aulast%3DEngelhart%26aufirst%3DC.%2BA.%26aulast%3DWallach%26aufirst%3DJ.%2BB.%26aulast%3DSchnappinger%26aufirst%3DD.%26aulast%3DArora%26aufirst%3DK.%26aulast%3DManikkam%26aufirst%3DM.%26aulast%3DGac%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DMurgolo%26aufirst%3DN.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DGoodwin%26aufirst%3DM.%26aulast%3DSutphin%26aufirst%3DM.%26aulast%3DWeiner%26aufirst%3DD.%2BM.%26aulast%3DVia%26aufirst%3DL.%2BE.%26aulast%3DBoshoff%26aufirst%3DH.%2BI.%2BM.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26atitle%3DDiscovery%2520and%2520structure-activity-relationship%2520study%2520of%2520n-alkyl-5-hydroxypyrimidinone%2520carboxamides%2520as%2520novel%2520antitubercular%2520agents%2520targeting%2520decaprenylphosphoryl-beta-d-ribose%25202%25E2%2580%25B2-oxidase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D9952%26epage%3D9965%26doi%3D10.1021%2Facs.jmedchem.8b00883" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vickers, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, A. P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakraborty, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurepina, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saville, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naranjo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pons, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnettger, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreiswith, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perlin, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavet, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabernero, L.</span></span> <span> </span><span class="NLM_article-title">Structure-based design of mptpb inhibitors that reduce multidrug-resistant mycobacterium tuberculosis survival and infection burden in vivo</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">8337</span>– <span class="NLM_lpage">8352</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00832</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00832" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1WitLfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=8337-8352&author=C.+F.+Vickersauthor=A.+P.+G.+Silvaauthor=A.+Chakrabortyauthor=P.+Fernandezauthor=N.+Kurepinaauthor=C.+Savilleauthor=Y.+Naranjoauthor=M.+Ponsauthor=L.+S.+Schnettgerauthor=M.+G.+Gutierrezauthor=S.+Parkauthor=B.+N.+Kreiswithauthor=D.+S.+Perlinauthor=E.+J.+Thomasauthor=J.+S.+Cavetauthor=L.+Tabernero&title=Structure-based+design+of+mptpb+inhibitors+that+reduce+multidrug-resistant+mycobacterium+tuberculosis+survival+and+infection+burden+in+vivo&doi=10.1021%2Facs.jmedchem.8b00832"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design of MptpB Inhibitors That Reduce Multidrug-Resistant Mycobacterium tuberculosis Survival and Infection Burden in Vivo</span></div><div class="casAuthors">Vickers, Clare F.; Silva, Ana P. G.; Chakraborty, Ajanta; Fernandez, Paulina; Kurepina, Natalia; Saville, Charis; Naranjo, Yandi; Pons, Miquel; Schnettger, Laura S.; Gutierrez, Maximiliano G.; Park, Steven; Kreiswith, Barry N.; Perlin, David S.; Thomas, Eric J.; Cavet, Jennifer S.; Tabernero, Lydia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8337-8352</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mycobacterium tuberculosis protein tyrosine-phosphatase B (MptpB) is a secreted virulence factor that subverts antimicrobial activity in the host.  The authors report the structure-based design of selective MptpB inhibitors that reduce survival of multidrug-resistant tuberculosis strains in macrophages and enhance killing efficacy by first-line antibiotics.  Monotherapy with an orally bioavailable MptpB inhibitor reduces infection burden in acute and chronic guinea pig models and improves the overall pathol.  The authors' findings provide a new paradigm for tuberculosis treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0GsTlmstuSLVg90H21EOLACvtfcHk0lij3ff6vLra_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1WitLfP&md5=4c3614b7cf3955301131cbf33f734546</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00832&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00832%26sid%3Dliteratum%253Aachs%26aulast%3DVickers%26aufirst%3DC.%2BF.%26aulast%3DSilva%26aufirst%3DA.%2BP.%2BG.%26aulast%3DChakraborty%26aufirst%3DA.%26aulast%3DFernandez%26aufirst%3DP.%26aulast%3DKurepina%26aufirst%3DN.%26aulast%3DSaville%26aufirst%3DC.%26aulast%3DNaranjo%26aufirst%3DY.%26aulast%3DPons%26aufirst%3DM.%26aulast%3DSchnettger%26aufirst%3DL.%2BS.%26aulast%3DGutierrez%26aufirst%3DM.%2BG.%26aulast%3DPark%26aufirst%3DS.%26aulast%3DKreiswith%26aufirst%3DB.%2BN.%26aulast%3DPerlin%26aufirst%3DD.%2BS.%26aulast%3DThomas%26aufirst%3DE.%2BJ.%26aulast%3DCavet%26aufirst%3DJ.%2BS.%26aulast%3DTabernero%26aufirst%3DL.%26atitle%3DStructure-based%2520design%2520of%2520mptpb%2520inhibitors%2520that%2520reduce%2520multidrug-resistant%2520mycobacterium%2520tuberculosis%2520survival%2520and%2520infection%2520burden%2520in%2520vivo%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D8337%26epage%3D8352%26doi%3D10.1021%2Facs.jmedchem.8b00832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lagorce, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperandio, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miteva, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villoutreix, B. O.</span></span> <span> </span><span class="NLM_article-title">FAF-drugs3: A web server for compound property calculation and chemical library design</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">W200</span>– <span class="NLM_lpage">207</span>, <span class="refDoi"> DOI: 10.1093/nar/gkv353</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1093%2Fnar%2Fgkv353" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=25883137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVymtLfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=W200-207&author=D.+Lagorceauthor=O.+Sperandioauthor=J.+B.+Baellauthor=M.+A.+Mitevaauthor=B.+O.+Villoutreix&title=FAF-drugs3%3A+A+web+server+for+compound+property+calculation+and+chemical+library+design&doi=10.1093%2Fnar%2Fgkv353"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">FAF-Drugs3: a web server for compound property calculation and chemical library design</span></div><div class="casAuthors">Lagorce, David; Sperandio, Olivier; Baell, Jonathan B.; Miteva, Maria A.; Villoutreix, Bruno O.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">W1</span>),
    <span class="NLM_cas:pages">W200-W207</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Drug attrition late in preclin. or clin. development is a serious economic problem in the field of drug discovery.  These problems can be linked, in part, to the quality of the compd. collections used during the hit generation stage and to the selection of compds. undergoing optimization.  Here, we present FAF-Drugs3, a web server that can be used for drug discovery and chem. biol. projects to help in prepg. compd. libraries and to assist decision-making during the hit selection/lead optimization phase.  Since it was first described in 2006, FAF-Drugs has been significantly modified.  The tool now applies an enhanced structure curation procedure, can filter or analyze mols. with user-defined or eight predefined physicochem. filters as well as with several simple ADMET (absorption, distribution, metab., excretion and toxicity) rules.  In addn., compds. can be filtered using an updated list of 154 hand-curated structural alerts while Pan Assay Interference compds. (PAINS) and other, generally unwanted groups are also investigated.  FAF-Drugs3 offers access to user-friendly html result pages and the possibility to download all computed data.  The server requires as input an SDF file of the compds.; it is open to all users and can be accessed without registration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxYZ-hCUhlmrVg90H21EOLACvtfcHk0lij3ff6vLra_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVymtLfM&md5=5cf8888c489b90f392117ab065986214</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkv353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkv353%26sid%3Dliteratum%253Aachs%26aulast%3DLagorce%26aufirst%3DD.%26aulast%3DSperandio%26aufirst%3DO.%26aulast%3DBaell%26aufirst%3DJ.%2BB.%26aulast%3DMiteva%26aufirst%3DM.%2BA.%26aulast%3DVilloutreix%26aufirst%3DB.%2BO.%26atitle%3DFAF-drugs3%253A%2520A%2520web%2520server%2520for%2520compound%2520property%2520calculation%2520and%2520chemical%2520library%2520design%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2015%26volume%3D43%26spage%3DW200%26epage%3D207%26doi%3D10.1093%2Fnar%2Fgkv353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ursu, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipinski, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sklar, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oprea, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bologa, C. G.</span></span> <span> </span><span class="NLM_article-title">Badapple: Promiscuity patterns from noisy evidence</span>. <i>J. Cheminf.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">29</span>, <span class="refDoi"> DOI: 10.1186/s13321-016-0137-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1186%2Fs13321-016-0137-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=29&author=J.+J.+Yangauthor=O.+Ursuauthor=C.+A.+Lipinskiauthor=L.+A.+Sklarauthor=T.+I.+Opreaauthor=C.+G.+Bologa&title=Badapple%3A+Promiscuity+patterns+from+noisy+evidence&doi=10.1186%2Fs13321-016-0137-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1186%2Fs13321-016-0137-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13321-016-0137-3%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.%2BJ.%26aulast%3DUrsu%26aufirst%3DO.%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26aulast%3DSklar%26aufirst%3DL.%2BA.%26aulast%3DOprea%26aufirst%3DT.%2BI.%26aulast%3DBologa%26aufirst%3DC.%2BG.%26atitle%3DBadapple%253A%2520Promiscuity%2520patterns%2520from%2520noisy%2520evidence%26jtitle%3DJ.%2520Cheminf.%26date%3D2016%26volume%3D8%26spage%3D29%26doi%3D10.1186%2Fs13321-016-0137-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deidda, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lampis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fioravanti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biava, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porretta, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanetti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pompei, R.</span></span> <span> </span><span class="NLM_article-title">Bactericidal activities of the pyrrole derivative BM212 against multidrug-resistant and intramacrophagic mycobacterium tuberculosis strains</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">3035</span>– <span class="NLM_lpage">3037</span>, <span class="refDoi"> DOI: 10.1128/AAC.42.11.3035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.42.11.3035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=9797251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADyaK1cXnt1ShtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1998&pages=3035-3037&author=D.+Deiddaauthor=G.+Lampisauthor=R.+Fioravantiauthor=M.+Biavaauthor=G.+C.+Porrettaauthor=S.+Zanettiauthor=R.+Pompei&title=Bactericidal+activities+of+the+pyrrole+derivative+BM212+against+multidrug-resistant+and+intramacrophagic+mycobacterium+tuberculosis+strains&doi=10.1128%2FAAC.42.11.3035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Bactericidal activities of the pyrrole derivative BM212 against multidrug-resistant and intramacrophagic Mycobacterium tuberculosis strains</span></div><div class="casAuthors">Deidda, Della; Lampis, Giorgio; Fioravanti, Rossella; Biava, Mariangela; Porretta, Giulio Cesare; Zanetti, Stefania; Pompei, Raffaello</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3035-3037</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The pyrrole deriv. BM212 (I) was shown to possess strong inhibitory activity against both Mycobacterium tuberculosis and some nontuberculosis mycobacteria.  I was inhibitory to drug-resistant mycobacteria and also exerted bactericidal activity against intracellular bacilli residing in the U937 human histiocytic lymphoma cell line.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8kBYE37EBcLVg90H21EOLACvtfcHk0liO-LCs4VJGfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnt1ShtLY%253D&md5=177ce62fe435889b34f4f90aea30dcec</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1128%2FAAC.42.11.3035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.42.11.3035%26sid%3Dliteratum%253Aachs%26aulast%3DDeidda%26aufirst%3DD.%26aulast%3DLampis%26aufirst%3DG.%26aulast%3DFioravanti%26aufirst%3DR.%26aulast%3DBiava%26aufirst%3DM.%26aulast%3DPorretta%26aufirst%3DG.%2BC.%26aulast%3DZanetti%26aufirst%3DS.%26aulast%3DPompei%26aufirst%3DR.%26atitle%3DBactericidal%2520activities%2520of%2520the%2520pyrrole%2520derivative%2520BM212%2520against%2520multidrug-resistant%2520and%2520intramacrophagic%2520mycobacterium%2520tuberculosis%2520strains%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1998%26volume%3D42%26spage%3D3035%26epage%3D3037%26doi%3D10.1128%2FAAC.42.11.3035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">La Rosa, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poce, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canseco, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buroni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasca, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biava, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raju, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porretta, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfonso, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battilocchio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javid, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorrentino, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ioerger, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacchettini, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Logu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rossi, E.</span></span> <span> </span><span class="NLM_article-title">Mmpl3 is the cellular target of the antitubercular pyrrole derivative BM212</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">324</span>– <span class="NLM_lpage">331</span>, <span class="refDoi"> DOI: 10.1128/AAC.05270-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.05270-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=22024828" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1Gqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=324-331&author=V.+La+Rosaauthor=G.+Poceauthor=J.+O.+Cansecoauthor=S.+Buroniauthor=M.+R.+Pascaauthor=M.+Biavaauthor=R.+M.+Rajuauthor=G.+C.+Porrettaauthor=S.+Alfonsoauthor=C.+Battilocchioauthor=B.+Javidauthor=F.+Sorrentinoauthor=T.+R.+Ioergerauthor=J.+C.+Sacchettiniauthor=F.+Manettiauthor=M.+Bottaauthor=A.+De+Loguauthor=E.+J.+Rubinauthor=E.+De+Rossi&title=Mmpl3+is+the+cellular+target+of+the+antitubercular+pyrrole+derivative+BM212&doi=10.1128%2FAAC.05270-11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212</span></div><div class="casAuthors">La Rosa, Valentina; Poce, Giovanna; Canseco, Julio Ortiz; Buroni, Silvia; Pasca, Maria Rosalia; Biava, Mariangela; Raju, Ravikiran M.; Porretta, Giulio Cesare; Alfonso, Salvatore; Battilocchio, Claudio; Javid, Babak; Sorrentino, Flavia; Ioerger, Thomas R.; Sacchettini, James C.; Manetti, Fabrizio; Botta, Maurizio; De Logu, Alessandro; Rubin, Eric J.; De Rossi, Edda</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">324-331</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The 1,5-diarylpyrrole deriv. BM212 was previously shown to be active against multidrug-resistant clin. isolates and Mycobacterium tuberculosis residing within macrophages as well as against Mycobacterium avium and other atypical mycobacteria.  To det. its mechanism of action, the cellular target was identified.  Spontaneous Mycobacterium smegmatis, Mycobacterium bovis BCG, and M. tuberculosis H37Rv mutants that were resistant to BM212 were isolated.  By the screening of genomic libraries and by whole-genome sequencing, it was found that all the characterized mutants showed mutations in the mmpL3 gene, allowing the conclusion that resistance to BM212 maps to the MmpL3 protein, a member of the MmpL (mycobacterial membrane protein, large) family.  Susceptibility was unaffected by the efflux pump inhibitors reserpine, carbonylcyanide m-chlorophenylhydrazone, and verapamil.  Uptake/efflux expts. with [14C]BM212 demonstrated that resistance is not driven by the efflux of BM212.  Together, these data strongly suggest that the MmpL3 protein is the cellular target of BM212.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBpqZddgKhTLVg90H21EOLACvtfcHk0liO-LCs4VJGfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1Gqtw%253D%253D&md5=f73b43cff2112c31ae27878eeb740d76</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1128%2FAAC.05270-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.05270-11%26sid%3Dliteratum%253Aachs%26aulast%3DLa%2BRosa%26aufirst%3DV.%26aulast%3DPoce%26aufirst%3DG.%26aulast%3DCanseco%26aufirst%3DJ.%2BO.%26aulast%3DBuroni%26aufirst%3DS.%26aulast%3DPasca%26aufirst%3DM.%2BR.%26aulast%3DBiava%26aufirst%3DM.%26aulast%3DRaju%26aufirst%3DR.%2BM.%26aulast%3DPorretta%26aufirst%3DG.%2BC.%26aulast%3DAlfonso%26aufirst%3DS.%26aulast%3DBattilocchio%26aufirst%3DC.%26aulast%3DJavid%26aufirst%3DB.%26aulast%3DSorrentino%26aufirst%3DF.%26aulast%3DIoerger%26aufirst%3DT.%2BR.%26aulast%3DSacchettini%26aufirst%3DJ.%2BC.%26aulast%3DManetti%26aufirst%3DF.%26aulast%3DBotta%26aufirst%3DM.%26aulast%3DDe%2BLogu%26aufirst%3DA.%26aulast%3DRubin%26aufirst%3DE.%2BJ.%26aulast%3DDe%2BRossi%26aufirst%3DE.%26atitle%3DMmpl3%2520is%2520the%2520cellular%2520target%2520of%2520the%2520antitubercular%2520pyrrole%2520derivative%2520BM212%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D324%26epage%3D331%26doi%3D10.1128%2FAAC.05270-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhakta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scalacci, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dasugari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evangelopoulos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHugh, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortazavi, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Twist, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petricci, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castagnolo, D.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of 1-((1,5-bis(4-chlorophenyl)-2-methyl-1h-pyrrol-3-yl)methyl)-4-methylpiperazine (bm212) and n-adamantan-2-yl-n′-((e)-3,7-dimethylocta-2,6-dienyl)ethane-1,2-diamine (SQ109) pyrrole hybrid derivatives: Discovery of potent antitubercular agents effective against multidrug-resistant mycobacteria</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2780</span>– <span class="NLM_lpage">2793</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00031</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00031" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28XjtVCisr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2780-2793&author=S.+Bhaktaauthor=N.+Scalacciauthor=A.+Maitraauthor=A.+K.+Brownauthor=S.+Dasugariauthor=D.+Evangelopoulosauthor=T.+D.+McHughauthor=P.+N.+Mortazaviauthor=A.+Twistauthor=E.+Petricciauthor=F.+Manettiauthor=D.+Castagnolo&title=Design+and+synthesis+of+1-%28%281%2C5-bis%284-chlorophenyl%29-2-methyl-1h-pyrrol-3-yl%29methyl%29-4-methylpiperazine+%28bm212%29+and+n-adamantan-2-yl-n%E2%80%B2-%28%28e%29-3%2C7-dimethylocta-2%2C6-dienyl%29ethane-1%2C2-diamine+%28SQ109%29+pyrrole+hybrid+derivatives%3A+Discovery+of+potent+antitubercular+agents+effective+against+multidrug-resistant+mycobacteria&doi=10.1021%2Facs.jmedchem.6b00031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of 1-((1,5-Bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-yl)methyl)-4-methylpiperazine (BM212) and N-Adamantan-2-yl-N'-((E)-3,7-dimethylocta-2,6-dienyl)ethane-1,2-diamine (SQ109) Pyrrole Hybrid Derivatives: Discovery of Potent Antitubercular Agents Effective against Multidrug-Resistant Mycobacteria</span></div><div class="casAuthors">Bhakta, Sanjib; Scalacci, Nicolo; Maitra, Arundhati; Brown, Alistair K.; Dasugari, Saiprasad; Evangelopoulos, Dimitrios; McHugh, Timothy D.; Mortazavi, Parisa N.; Twist, Alexander; Petricci, Elena; Manetti, Fabrizio; Castagnolo, Daniele</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2780-2793</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel pyrroles have been designed, synthesized, and evaluated against mycobacterial strains.  The pyrroles have originally been designed as hybrids of the antitubercular drugs BM212 and SQ109, which showed common chem. features with very similar topol. distribution.  A perfect superposition of the structures of BM212 and SQ109 revealed by computational studies suggested the introduction of bulky substituents at the terminal portion of the pyrrole C3 side chain and the removal of the C5 aryl moiety.  Five compds. showed high activity toward Mycobacterium tuberculosis, while I and II were highly active also against multidrug-resistant clin. isolates.  Compd. II showed low eukaryotic cell toxicity, turning out to be an excellent lead candidate for preclin. trials.  In addn., four compds. showed potent inhibition (comparable to that of verapamil) toward the whole-cell drug efflux pump activity of mycobacteria, thus turning out to be promising multidrug-resistance-reversing agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiHSHN7HZypLVg90H21EOLACvtfcHk0limBp22opHk3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjtVCisr4%253D&md5=75b64a2124cf35b56ea26b402ca993a7</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00031%26sid%3Dliteratum%253Aachs%26aulast%3DBhakta%26aufirst%3DS.%26aulast%3DScalacci%26aufirst%3DN.%26aulast%3DMaitra%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DA.%2BK.%26aulast%3DDasugari%26aufirst%3DS.%26aulast%3DEvangelopoulos%26aufirst%3DD.%26aulast%3DMcHugh%26aufirst%3DT.%2BD.%26aulast%3DMortazavi%26aufirst%3DP.%2BN.%26aulast%3DTwist%26aufirst%3DA.%26aulast%3DPetricci%26aufirst%3DE.%26aulast%3DManetti%26aufirst%3DF.%26aulast%3DCastagnolo%26aufirst%3DD.%26atitle%3DDesign%2520and%2520synthesis%2520of%25201-%2528%25281%252C5-bis%25284-chlorophenyl%2529-2-methyl-1h-pyrrol-3-yl%2529methyl%2529-4-methylpiperazine%2520%2528bm212%2529%2520and%2520n-adamantan-2-yl-n%25E2%2580%25B2-%2528%2528e%2529-3%252C7-dimethylocta-2%252C6-dienyl%2529ethane-1%252C2-diamine%2520%2528SQ109%2529%2520pyrrole%2520hybrid%2520derivatives%253A%2520Discovery%2520of%2520potent%2520antitubercular%2520agents%2520effective%2520against%2520multidrug-resistant%2520mycobacteria%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D2780%26epage%3D2793%26doi%3D10.1021%2Facs.jmedchem.6b00031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group">Anon</span> <span> </span><span class="NLM_article-title">Ll-3858</span>. <i>Tuberculosis (Oxford, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">126</span>, <span class="refDoi"> DOI: 10.1016/S1472-9792(08)70015-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2FS1472-9792%2808%2970015-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=18486049" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2008&pages=126&author=Anon&title=Ll-3858&doi=10.1016%2FS1472-9792%2808%2970015-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1016%2FS1472-9792%2808%2970015-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1472-9792%252808%252970015-5%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DLl-3858%26jtitle%3DTuberculosis%2520%2528Oxford%252C%2520U.%2520K.%2529%26date%3D2008%26volume%3D88%26spage%3D126%26doi%3D10.1016%2FS1472-9792%2808%2970015-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cardona, P.-J.</span></span> <i>Understanding Tuberculosis: New Approaches to Fighting Against Drug Resistance</i>; <span class="NLM_publisher-name">IntechOpen</span>: <span class="NLM_publisher-loc">London</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.5772%2F2477" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=P.-J.+Cardona&title=Understanding+Tuberculosis%3A+New+Approaches+to+Fighting+Against+Drug+Resistance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.5772%2F2477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.5772%252F2477%26sid%3Dliteratum%253Aachs%26aulast%3DCardona%26aufirst%3DP.-J.%26btitle%3DUnderstanding%2520Tuberculosis%253A%2520New%2520Approaches%2520to%2520Fighting%2520Against%2520Drug%2520Resistance%26pub%3DIntechOpen%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stec, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onajole, O. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merenbloom, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vistoli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishai, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Indole-2-carboxamide-based MmpL3 inhibitors show exceptional antitubercular activity in an animal model of tuberculosis infection</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">6232</span>– <span class="NLM_lpage">6247</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00415</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00415" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsVCltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=6232-6247&author=J.+Stecauthor=O.+K.+Onajoleauthor=S.+Lunauthor=H.+Guoauthor=B.+Merenbloomauthor=G.+Vistoliauthor=W.+R.+Bishaiauthor=A.+P.+Kozikowski&title=Indole-2-carboxamide-based+MmpL3+inhibitors+show+exceptional+antitubercular+activity+in+an+animal+model+of+tuberculosis+infection&doi=10.1021%2Facs.jmedchem.6b00415"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Indole-2-carboxamide-based MmpL3 Inhibitors Show Exceptional Antitubercular Activity in an Animal Model of Tuberculosis Infection</span></div><div class="casAuthors">Stec, Jozef; Onajole, Oluseye K.; Lun, Shichun; Guo, Haidan; Merenbloom, Benjamin; Vistoli, Giulio; Bishai, William R.; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6232-6247</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Our team had previously identified certain indolecarboxamides that represented a new chem. scaffold that showed promising anti-TB activity at both an in vitro and in vivo level.  Based on mutational anal. using bacteria found resistant to one of these indolecarboxamides, we identified the trehalose monomycolate transporter MmpL3 as the likely target of these compds.  In the present work, we now further elaborate on the SAR of these compds., which has led in turn to the identification of a new analog, 4,6-difluoro-N-((1R,2R,3R,5S)-2,6,6-trimethylbicyclo[3.1.1]heptan-3-yl)-1H-indole-2-carboxamide (26), that shows excellent activity against drug-sensitive (MIC = 0.012 μM; SI ≥ 16000), multidrug-resistant (MDR), and extensively drug-resistant (XDR) Mycobacterium tuberculosis strains, has superior ADMET properties, and shows excellent activity in the TB aerosol lung infection model.  Compd. 26 is also shown to work in synergy with rifampin.  Because of these properties, we believe that indolecarboxamide 26 is a possible candidate for advancement to human clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg0h9TR-VL5rVg90H21EOLACvtfcHk0limBp22opHk3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsVCltb8%253D&md5=f9e3d545a65f85deb3f97054dca77c1f</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00415%26sid%3Dliteratum%253Aachs%26aulast%3DStec%26aufirst%3DJ.%26aulast%3DOnajole%26aufirst%3DO.%2BK.%26aulast%3DLun%26aufirst%3DS.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DMerenbloom%26aufirst%3DB.%26aulast%3DVistoli%26aufirst%3DG.%26aulast%3DBishai%26aufirst%3DW.%2BR.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DIndole-2-carboxamide-based%2520MmpL3%2520inhibitors%2520show%2520exceptional%2520antitubercular%2520activity%2520in%2520an%2520animal%2520model%2520of%2520tuberculosis%2520infection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D6232%26epage%3D6247%26doi%3D10.1021%2Facs.jmedchem.6b00415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njire, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franzblauc, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of pyrazolo[1,5-a]pyridine-3-carboxamides as novel antitubercular agents</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">814</span>– <span class="NLM_lpage">818</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00176</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00176" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVansL3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=814-818&author=J.+Tangauthor=B.+Wangauthor=T.+Wuauthor=J.+Wanauthor=Z.+Tuauthor=M.+Njireauthor=B.+Wanauthor=S.+G.+Franzblaucauthor=T.+Zhangauthor=X.+Luauthor=K.+Ding&title=Design%2C+synthesis%2C+and+biological+evaluation+of+pyrazolo%5B1%2C5-a%5Dpyridine-3-carboxamides+as+novel+antitubercular+agents&doi=10.1021%2Facsmedchemlett.5b00176"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of Pyrazolo[1,5-a]pyridine-3-carboxamides as Novel Antitubercular Agents</span></div><div class="casAuthors">Tang, Jian; Wang, Bangxing; Wu, Tian; Wan, Junting; Tu, Zhengchao; Njire, Moses; Wan, Baojie; Franzblauc, Scott G.; Zhang, Tianyu; Lu, Xiaoyun; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">814-818</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pyrazolo[1,5-a]pyridine-3-carboxamides such as I (R = Me, MeO, H, Et, i-Pr, t-Bu, Cl, F3C) were prepd. as potential antituberculosis agents; their toxicities to Vero cells and their inhibition of drug-susceptible and drug-resistant Mycobacterium tuberculosis (Mtb) strains were detd.  The activities of selected compds. were detd. against a fluorescent reporter-contg. Mtb strain and against a drug-resistant Mtb strain in mice.  In particular, I (R = MeO) significantly reduced the bacterial burden in an autoluminescent H37Ra infected mouse model, suggesting it to be a potential lead compd. for future antitubercular drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQQpKb_Lf-TrVg90H21EOLACvtfcHk0ljHYdhExsMs1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVansL3O&md5=1064849b13a2674f43e162b503c3f851</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00176&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00176%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DWan%26aufirst%3DJ.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DNjire%26aufirst%3DM.%26aulast%3DWan%26aufirst%3DB.%26aulast%3DFranzblauc%26aufirst%3DS.%2BG.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520pyrazolo%255B1%252C5-a%255Dpyridine-3-carboxamides%2520as%2520novel%2520antitubercular%2520agents%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D814%26epage%3D818%26doi%3D10.1021%2Facsmedchemlett.5b00176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Panda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirude, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humnabadkar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagalapur, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guptha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahadevaswamy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambady, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegde, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudrapatna, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosagrahara, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sambandamurthy, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raichurkar, A.</span></span> <span> </span><span class="NLM_article-title">Discovery of pyrazolopyridones as a novel class of noncovalent DprE1 inhibitor with potent anti-mycobacterial activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4761</span>– <span class="NLM_lpage">4771</span>, <span class="refDoi"> DOI: 10.1021/jm5002937</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5002937" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnvVShtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4761-4771&author=M.+Pandaauthor=S.+Ramachandranauthor=V.+Ramachandranauthor=P.+S.+Shirudeauthor=V.+Humnabadkarauthor=K.+Nagalapurauthor=S.+Sharmaauthor=P.+Kaurauthor=S.+Gupthaauthor=A.+Narayanauthor=J.+Mahadevaswamyauthor=A.+Ambadyauthor=N.+Hegdeauthor=S.+S.+Rudrapatnaauthor=V.+P.+Hosagraharaauthor=V.+K.+Sambandamurthyauthor=A.+Raichurkar&title=Discovery+of+pyrazolopyridones+as+a+novel+class+of+noncovalent+DprE1+inhibitor+with+potent+anti-mycobacterial+activity&doi=10.1021%2Fjm5002937"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Pyrazolopyridones as a Novel Class of Noncovalent DprE1 Inhibitor with Potent Anti-Mycobacterial Activity</span></div><div class="casAuthors">Panda, Manoranjan; Ramachandran, Sreekanth; Ramachandran, Vasanthi; Shirude, Pravin S.; Humnabadkar, Vaishali; Nagalapur, Kavitha; Sharma, Sreevalli; Kaur, Parvinder; Guptha, Supreeth; Narayan, Ashwini; Mahadevaswamy, Jyothi; Ambady, Anisha; Hegde, Naina; Rudrapatna, Suresh S.; Hosagrahara, Vinayak P.; Sambandamurthy, Vasan K.; Raichurkar, Anandkumar</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4761-4771</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel pyrazolopyridone class of inhibitors was identified from whole cell screening against Mycobacterium tuberculosis (Mtb).  The series exhibits excellent bactericidality in vitro, resulting in a 4 log redn. in colony forming units following compd. exposure.  The significant modulation of min. inhibitory concn. (MIC) against a Mtb strain overexpressing the Rv3790 gene suggested the target of pyrazolopyridones to be decaprenylphosphoryl-β-D-ribose-2'-epimerase (DprE1).  Genetic mapping of resistance mutation coupled with potent enzyme inhibition activity confirmed the mol. target.  Detailed biochem. characterization revealed the series to be a noncovalent inhibitor of DprE1.  Docking studies at the active site suggest that the series can be further diversified to improve the physicochem. properties without compromising the antimycobacterial activity.  The pyrazolopyridone class of inhibitors offers an attractive non-nitro lead series targeting the essential and vulnerable DprE1 enzyme for the discovery of novel antimycobacterial agents to treat both drug susceptible and drug resistant strains of Mtb.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdYV8Pi2ynA7Vg90H21EOLACvtfcHk0ljHYdhExsMs1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnvVShtrw%253D&md5=dd3c1daf880d2f50d3187a0f9d1ab363</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1021%2Fjm5002937&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5002937%26sid%3Dliteratum%253Aachs%26aulast%3DPanda%26aufirst%3DM.%26aulast%3DRamachandran%26aufirst%3DS.%26aulast%3DRamachandran%26aufirst%3DV.%26aulast%3DShirude%26aufirst%3DP.%2BS.%26aulast%3DHumnabadkar%26aufirst%3DV.%26aulast%3DNagalapur%26aufirst%3DK.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DKaur%26aufirst%3DP.%26aulast%3DGuptha%26aufirst%3DS.%26aulast%3DNarayan%26aufirst%3DA.%26aulast%3DMahadevaswamy%26aufirst%3DJ.%26aulast%3DAmbady%26aufirst%3DA.%26aulast%3DHegde%26aufirst%3DN.%26aulast%3DRudrapatna%26aufirst%3DS.%2BS.%26aulast%3DHosagrahara%26aufirst%3DV.%2BP.%26aulast%3DSambandamurthy%26aufirst%3DV.%2BK.%26aulast%3DRaichurkar%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520pyrazolopyridones%2520as%2520a%2520novel%2520class%2520of%2520noncovalent%2520DprE1%2520inhibitor%2520with%2520potent%2520anti-mycobacterial%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4761%26epage%3D4771%26doi%3D10.1021%2Fjm5002937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Riccardi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasca, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarelli, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manina, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattevi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binda, C.</span></span> <span> </span><span class="NLM_article-title">The dpre1 enzyme, one of the most vulnerable targets of mycobacterium tuberculosis</span>. <i>Appl. Microbiol. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">8841</span>– <span class="NLM_lpage">8848</span>, <span class="refDoi"> DOI: 10.1007/s00253-013-5218-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1007%2Fs00253-013-5218-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=24037308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVCnurrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2013&pages=8841-8848&author=G.+Riccardiauthor=M.+R.+Pascaauthor=L.+R.+Chiarelliauthor=G.+Maninaauthor=A.+Matteviauthor=C.+Binda&title=The+dpre1+enzyme%2C+one+of+the+most+vulnerable+targets+of+mycobacterium+tuberculosis&doi=10.1007%2Fs00253-013-5218-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">The DprE1 enzyme, one of the most vulnerable targets of Mycobacterium tuberculosis</span></div><div class="casAuthors">Riccardi, Giovanna; Pasca, Maria Rosalia; Chiarelli, Laurent Roberto; Manina, Giulia; Mattevi, Andrea; Binda, Claudia</div><div class="citationInfo"><span class="NLM_cas:title">Applied Microbiology and Biotechnology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8841-8848</span>CODEN:
                <span class="NLM_cas:coden">AMBIDG</span>;
        ISSN:<span class="NLM_cas:issn">0175-7598</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  The re-emergence of tuberculosis (TB) in recent years led the World Health Organization (WHO) to launch the Stop TB Strategy program.  In addn. to repurposing existing drugs and exploring novel mol. combinations, an essential step to face the burden of TB will be to develop new drugs by identifying vulnerable bacterial targets.  Recent studies have focused on decaprenylphosphoryl-D-ribose oxidase (DprE1) of M. tuberculosis, an essential enzyme involved in cell wall metab., for which new promising mols. have proved efficacy as antitubercular agents.  Here, the authors summarize the state of the art concerning DprE1 in terms of structure, enzymic activity, and inhibitors.  This enzyme is emerging as one of the most vulnerable targets in M. tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA_XaR7fi41bVg90H21EOLACvtfcHk0ljHYdhExsMs1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVCnurrO&md5=a04f5e574bdf2c42a68fb9af89d7bd4b</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1007%2Fs00253-013-5218-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00253-013-5218-x%26sid%3Dliteratum%253Aachs%26aulast%3DRiccardi%26aufirst%3DG.%26aulast%3DPasca%26aufirst%3DM.%2BR.%26aulast%3DChiarelli%26aufirst%3DL.%2BR.%26aulast%3DManina%26aufirst%3DG.%26aulast%3DMattevi%26aufirst%3DA.%26aulast%3DBinda%26aufirst%3DC.%26atitle%3DThe%2520dpre1%2520enzyme%252C%2520one%2520of%2520the%2520most%2520vulnerable%2520targets%2520of%2520mycobacterium%2520tuberculosis%26jtitle%3DAppl.%2520Microbiol.%2520Biotechnol.%26date%3D2013%26volume%3D97%26spage%3D8841%26epage%3D8848%26doi%3D10.1007%2Fs00253-013-5218-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brecik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Centárová, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukherjee, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolly, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huszár, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bobovská, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilacsková, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mokošová, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svetlíková, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Šarkan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neres, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korduláková, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikušová, K.</span></span> <span> </span><span class="NLM_article-title">DprE1 is a vulnerable tuberculosis drug target due to its cell wall localization</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1631</span>– <span class="NLM_lpage">1636</span>, <span class="refDoi"> DOI: 10.1021/acschembio.5b00237</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.5b00237" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntVWns70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1631-1636&author=M.+Brecikauthor=I.+Cent%C3%A1rov%C3%A1author=R.+Mukherjeeauthor=G.+S.+Kollyauthor=S.+Husz%C3%A1rauthor=A.+Bobovsk%C3%A1author=E.+Kilacskov%C3%A1author=V.+Moko%C5%A1ov%C3%A1author=Z.+Svetl%C3%ADkov%C3%A1author=M.+%C5%A0arkanauthor=J.+Neresauthor=J.+Kordul%C3%A1kov%C3%A1author=S.+T.+Coleauthor=K.+Miku%C5%A1ov%C3%A1&title=DprE1+is+a+vulnerable+tuberculosis+drug+target+due+to+its+cell+wall+localization&doi=10.1021%2Facschembio.5b00237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">DprE1 Is a Vulnerable Tuberculosis Drug Target Due to Its Cell Wall Localization</span></div><div class="casAuthors">Brecik, Miroslav; Centarova, Ivana; Mukherjee, Raju; Kolly, Gaelle S.; Huszar, Stanislav; Bobovska, Adela; Kilacskova, Emoke; Mokosova, Veronika; Svetlikova, Zuzana; Sarkan, Michal; Neres, Joao; Kordulakova, Jana; Cole, Stewart T.; Mikusova, Katarina</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1631-1636</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The flavo-enzyme DprE1 catalyzes a key epimerization step in the decaprenyl-phosphoryl D-arabinose (DPA) pathway, which is essential for mycobacterial cell wall biogenesis and targeted by several new tuberculosis drug candidates.  Here, using differential radiolabeling with DPA precursors and high-resoln. fluorescence microscopy, we disclose the unexpected extracytoplasmic localization of DprE1 and periplasmic synthesis of DPA.  Collectively, this explains the vulnerability of DprE1 and the remarkable potency of the best inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2tTdrWjQmBrVg90H21EOLACvtfcHk0liBY62XFSCqCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntVWns70%253D&md5=bc1317378445d84300aca1615ef8d058</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1021%2Facschembio.5b00237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.5b00237%26sid%3Dliteratum%253Aachs%26aulast%3DBrecik%26aufirst%3DM.%26aulast%3DCent%25C3%25A1rov%25C3%25A1%26aufirst%3DI.%26aulast%3DMukherjee%26aufirst%3DR.%26aulast%3DKolly%26aufirst%3DG.%2BS.%26aulast%3DHusz%25C3%25A1r%26aufirst%3DS.%26aulast%3DBobovsk%25C3%25A1%26aufirst%3DA.%26aulast%3DKilacskov%25C3%25A1%26aufirst%3DE.%26aulast%3DMoko%25C5%25A1ov%25C3%25A1%26aufirst%3DV.%26aulast%3DSvetl%25C3%25ADkov%25C3%25A1%26aufirst%3DZ.%26aulast%3D%25C5%25A0arkan%26aufirst%3DM.%26aulast%3DNeres%26aufirst%3DJ.%26aulast%3DKordul%25C3%25A1kov%25C3%25A1%26aufirst%3DJ.%26aulast%3DCole%26aufirst%3DS.%2BT.%26aulast%3DMiku%25C5%25A1ov%25C3%25A1%26aufirst%3DK.%26atitle%3DDprE1%2520is%2520a%2520vulnerable%2520tuberculosis%2520drug%2520target%2520due%2520to%2520its%2520cell%2520wall%2520localization%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2015%26volume%3D10%26spage%3D1631%26epage%3D1636%26doi%3D10.1021%2Facschembio.5b00237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, X.</span></span> <span> </span><span class="NLM_article-title">Identification of n-(2-phenoxyethyl)imidazo[1,2-a]pyridine-3- carboxamides as new antituberculosis agents</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1130</span>– <span class="NLM_lpage">1133</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00330</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00330" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1CmtbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=1130-1133&author=Z.+Wuauthor=Y.+Luauthor=L.+Liauthor=R.+Zhaoauthor=B.+Wangauthor=K.+Lvauthor=M.+Liuauthor=X.+You&title=Identification+of+n-%282-phenoxyethyl%29imidazo%5B1%2C2-a%5Dpyridine-3-+carboxamides+as+new+antituberculosis+agents&doi=10.1021%2Facsmedchemlett.6b00330"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of N-(2-Phenoxyethyl)imidazo[1,2-a]pyridine-3-carboxamides as New Antituberculosis Agents</span></div><div class="casAuthors">Wu, Zhaoyang; Lu, Yu; Li, Linhu; Zhao, Rui; Wang, Bin; Lv, Kai; Liu, Mingliang; You, Xuefu</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1130-1133</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of imidazo[1,2-a]pyridine carboxamides (IPAs) bearing an N-(2-phenoxyethyl) moiety was designed and synthesized as new antitubercular agents.  Seven 2,6-di-Me IPAs demonstrated excellent in vitro activity (MIC: 0.025-0.054 μg/mL) against the drug susceptive H37Rv strain and two clin. isolated multidrug-resistant Mycobacterium tuberculosis strains.  Compd. I displayed acceptable safety and pharmacokinetic properties, opening a new direction for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDiXPMdtzWD7Vg90H21EOLACvtfcHk0liBY62XFSCqCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1CmtbvI&md5=f4f5d7f14c67d86e515289cc03dd50bf</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00330%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DLv%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DYou%26aufirst%3DX.%26atitle%3DIdentification%2520of%2520n-%25282-phenoxyethyl%2529imidazo%255B1%252C2-a%255Dpyridine-3-%2520carboxamides%2520as%2520new%2520antituberculosis%2520agents%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D1130%26epage%3D1133%26doi%3D10.1021%2Facsmedchemlett.6b00330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Post-Martens, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denkin, S.</span></span> <span> </span><span class="NLM_article-title">New drug candidates and therapeutic targets for tuberculosis therapy</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">27</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(05)03626-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2FS1359-6446%2805%2903626-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=16478687" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD28XhsFygsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2006&pages=21-27&author=Y.+Zhangauthor=K.+Post-Martensauthor=S.+Denkin&title=New+drug+candidates+and+therapeutic+targets+for+tuberculosis+therapy&doi=10.1016%2FS1359-6446%2805%2903626-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">New drug candidates and therapeutic targets for tuberculosis therapy</span></div><div class="casAuthors">Zhang, Ying; Post-Martens, Katrin; Denkin, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1 & 2</span>),
    <span class="NLM_cas:pages">21-27</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Despite advances in chemotherapy and the BCG (Bacillus Calmette-Guerin) vaccine, tuberculosis remains a significant infectious disease.  Although it can be cured, the therapy takes at least 6-9 mo, and the laborious and lengthy treatment brings with it dangers of noncompliance, significant toxicity and drug resistance.  The increasing emergence of drug resistance and the problem of mycobacterial persistence highlight the need to develop novel TB drugs that are active against drug resistant bacteria but, more importantly, kill persistent bacteria and shorten the length of treatment.  Recent new and exciting developments in tuberculosis drug discovery show good promise of a possible revolution in the chemotherapy of tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfStEdhpVTDLVg90H21EOLACvtfcHk0liBY62XFSCqCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhsFygsbc%253D&md5=0db52ffead572bcf52139af571749954</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2805%2903626-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252805%252903626-3%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DPost-Martens%26aufirst%3DK.%26aulast%3DDenkin%26aufirst%3DS.%26atitle%3DNew%2520drug%2520candidates%2520and%2520therapeutic%2520targets%2520for%2520tuberculosis%2520therapy%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2006%26volume%3D11%26spage%3D21%26epage%3D27%26doi%3D10.1016%2FS1359-6446%2805%2903626-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leach, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brickner, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noe, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, P. F.</span></span> <span> </span><span class="NLM_article-title">Linezolid, the first oxazolidinone antibacterial agent</span>. <i>Ann. N. Y. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>1222</i></span>,  <span class="NLM_fpage">49</span>– <span class="NLM_lpage">54</span>, <span class="refDoi"> DOI: 10.1111/j.1749-6632.2011.05962.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1111%2Fj.1749-6632.2011.05962.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=21434942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtVykurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1222&publication_year=2011&pages=49-54&author=K.+L.+Leachauthor=S.+J.+Bricknerauthor=M.+C.+Noeauthor=P.+F.+Miller&title=Linezolid%2C+the+first+oxazolidinone+antibacterial+agent&doi=10.1111%2Fj.1749-6632.2011.05962.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Linezolid, the first oxazolidinone antibacterial agent</span></div><div class="casAuthors">Leach, Karen L.; Brickner, Steven J.; Noe, Mark C.; Miller, Paul F.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the New York Academy of Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">1222</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">49-54</span>CODEN:
                <span class="NLM_cas:coden">ANYAA9</span>;
        ISSN:<span class="NLM_cas:issn">0077-8923</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Linezolid (Zyvox) is the first member of an entirely new class of antibiotics to reach the market in over 35 years; it was approved for use in 2000.  A member of the oxazolidinone class of antibiotics, linezolid is highly effective for the treatment of serious Gram-pos. infections and has activity that compares favorably with vancomycin for most clin. relevant pathogens.  Zyvox is approved for use against serious Gram-pos. infections, including those caused by Streptococcus pneumoniae, and the very challenging methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium organisms.  Zyvox inhibits bacterial protein synthesis by binding to 23S rRNA in the catalytic site of the 50S ribosome.  It can be administered both orally and i.v. and has good tissue distribution.  Recent results have demonstrated that oxazolidinone analogs related to linezolid are effective in treating pulmonary tuberculosis caused by resistant Mycobacterium tuberculosis in animal infection models and suggest addnl. new therapeutic applications for these antibiotics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwUe7BGP38ObVg90H21EOLACvtfcHk0lgB2L7X_7QHBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtVykurs%253D&md5=986e1ad5613495d3344b26f03489e4ab</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1111%2Fj.1749-6632.2011.05962.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1749-6632.2011.05962.x%26sid%3Dliteratum%253Aachs%26aulast%3DLeach%26aufirst%3DK.%2BL.%26aulast%3DBrickner%26aufirst%3DS.%2BJ.%26aulast%3DNoe%26aufirst%3DM.%2BC.%26aulast%3DMiller%26aufirst%3DP.%2BF.%26atitle%3DLinezolid%252C%2520the%2520first%2520oxazolidinone%2520antibacterial%2520agent%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D2011%26volume%3D1222%26spage%3D49%26epage%3D54%26doi%3D10.1111%2Fj.1749-6632.2011.05962.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Falagas, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siempos, I. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vardakas, K. Z.</span></span> <span> </span><span class="NLM_article-title">Linezolid versus glycopeptide or beta-lactam for treatment of gram-positive bacterial infections: Meta-analysis of randomised controlled trials</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">53</span>– <span class="NLM_lpage">66</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(07)70312-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2FS1473-3099%2807%2970312-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=18156089" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhs1ejtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=53-66&author=M.+E.+Falagasauthor=I.+I.+Siemposauthor=K.+Z.+Vardakas&title=Linezolid+versus+glycopeptide+or+beta-lactam+for+treatment+of+gram-positive+bacterial+infections%3A+Meta-analysis+of+randomised+controlled+trials&doi=10.1016%2FS1473-3099%2807%2970312-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Linezolid versus glycopeptide or β-lactam for treatment of Gram-positive bacterial infections: a meta-analysis of randomised controlled trials</span></div><div class="casAuthors">Falagas, Matthew E.; Siempos, Ilias I.; Vardakas, Konstantinos Z.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">53-66</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Linezolid has been approved for the treatment of patients with infections caused by Gram-pos. cocci that are resistant to traditionally used antibiotics, including glycopeptides.  This oxazolidinone antibiotic has been reported to have excellent pharmacokinetics and effectiveness.  We did a meta-anal. of randomised controlled trials (RCTs) to clarify whether linezolid is superior to glycopeptides or β-lactams for the treatment of Gram-pos. infections.  12 RCTs, involving 6093 patients, were included.  Overall, with respect to treatment success, linezolid was more effective than glycopeptides or β-lactams (odds ratio [OR] 1.41 [95% CI 1.11-1.81]).  Mortality was similar between the groups (OR 0.97 [0.79-1.19]).  Linezolid was more effective than comparators in patients with skin and soft-tissue infections (OR 1.67 [1.31-2.12]) and bacteremia (OR 2.07 [1.13-3.78]).  However, there was no difference in treatment success for patients with pneumonia (OR 1.03 [0.75-1.42]).  Treatment with linezolid was not assocd. with more adverse effects in general (OR 1.40 [0.95-2.06]); however, thrombocytopenia was recorded more commonly in patients receiving linezolid (OR 11.72 [3.66-37.57]).  Although linezolid is more effective than its comparators for the empirical treatment of selected patients, several points, such as the use of less potent antistaphylococcal β-lactams, the same all-cause mortality, and the higher probability of thrombocytopenia, should be taken into account and may limit the use of linezolid to specific patient populations or infections that are difficult to treat with other antibiotics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8g49kzGy9GrVg90H21EOLACvtfcHk0lgB2L7X_7QHBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhs1ejtb0%253D&md5=ccd6c273993bb91c9a50ea4b19064083</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2807%2970312-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252807%252970312-2%26sid%3Dliteratum%253Aachs%26aulast%3DFalagas%26aufirst%3DM.%2BE.%26aulast%3DSiempos%26aufirst%3DI.%2BI.%26aulast%3DVardakas%26aufirst%3DK.%2BZ.%26atitle%3DLinezolid%2520versus%2520glycopeptide%2520or%2520beta-lactam%2520for%2520treatment%2520of%2520gram-positive%2520bacterial%2520infections%253A%2520Meta-analysis%2520of%2520randomised%2520controlled%2520trials%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2008%26volume%3D8%26spage%3D53%26epage%3D66%26doi%3D10.1016%2FS1473-3099%2807%2970312-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Narita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuji, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, V. L.</span></span> <span> </span><span class="NLM_article-title">Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome</span>. <i>Pharmacotherapy</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1189</span>– <span class="NLM_lpage">1197</span>, <span class="refDoi"> DOI: 10.1592/phco.27.8.1189</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1592%2Fphco.27.8.1189" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=17655517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD2sXptlKqtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2007&pages=1189-1197&author=M.+Naritaauthor=B.+T.+Tsujiauthor=V.+L.+Yu&title=Linezolid-associated+peripheral+and+optic+neuropathy%2C+lactic+acidosis%2C+and+serotonin+syndrome&doi=10.1592%2Fphco.27.8.1189"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome</span></div><div class="casAuthors">Narita, Masashi; Tsuji, Brian T.; Yu, Victor L.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacotherapy</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1189-1197</span>CODEN:
                <span class="NLM_cas:coden">PHPYDQ</span>;
        ISSN:<span class="NLM_cas:issn">0277-0008</span>.
    
            (<span class="NLM_cas:orgname">Pharmacotherapy Publications</span>)
        </div><div class="casAbstract">A review.  Linezolid is an oxazolidinone antibacterial agent indicated for serious gram-pos. infections.  Only minor adverse effects were seen in phase III trials.  However, more serious adverse effects were reported after com. release, including cases of lactic acidosis, peripheral and optic neuropathy, and serotonin syndrome.  Peripheral and optic neuropathy was usually seen after several months of linezolid therapy (median 5 mo), lactic acidosis after several weeks (median 6 wks), and serotonin syndrome after several days (median 4 days).  Death occurred in two of seven reported cases of lactic acidosis, and three of 15 reported cases of serotonin syndrome.  Improvement or complete recovery occurred in all cases of optic neuropathy, whereas complete recovery failed to occur in any patient with peripheral neuropathy.  Linezolid should be discontinued immediately in patients experiencing these adverse effects.  Patients receiving linezolid for more than 28 days should be monitored for signs of peripheral and optic neuropathy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMHoqDj-lHIrVg90H21EOLACvtfcHk0lgB2L7X_7QHBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXptlKqtLc%253D&md5=ec758ac912569c37316e8fbb6e722081</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1592%2Fphco.27.8.1189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1592%252Fphco.27.8.1189%26sid%3Dliteratum%253Aachs%26aulast%3DNarita%26aufirst%3DM.%26aulast%3DTsuji%26aufirst%3DB.%2BT.%26aulast%3DYu%26aufirst%3DV.%2BL.%26atitle%3DLinezolid-associated%2520peripheral%2520and%2520optic%2520neuropathy%252C%2520lactic%2520acidosis%252C%2520and%2520serotonin%2520syndrome%26jtitle%3DPharmacotherapy%26date%3D2007%26volume%3D27%26spage%3D1189%26epage%3D1197%26doi%3D10.1592%2Fphco.27.8.1189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bressler, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmer, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmore, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somani, J.</span></span> <span> </span><span class="NLM_article-title">Peripheral neuropathy associated with prolonged use of linezolid</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">528</span>– <span class="NLM_lpage">531</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(04)01109-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2FS1473-3099%2804%2901109-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=15288827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A280%3ADC%252BD2czosFymsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=528-531&author=A.+M.+Bresslerauthor=S.+M.+Zimmerauthor=J.+L.+Gilmoreauthor=J.+Somani&title=Peripheral+neuropathy+associated+with+prolonged+use+of+linezolid&doi=10.1016%2FS1473-3099%2804%2901109-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Peripheral neuropathy associated with prolonged use of linezolid</span></div><div class="casAuthors">Bressler Adam M; Zimmer Shanta M; Gilmore Jane L; Somani Jyoti</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Infectious diseases</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">528-31</span>
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    </div><div class="casAbstract">We present a case of a woman who developed severe, painful peripheral neuropathy while receiving linezolid therapy for 6 months.  Nerve conduction studies indicated a sensory-motor axonal neuropathy.  Extensive assessment did not show alternative explanations for her neuropathy.  At the time of death 1 month after discontinuing linezolid, the neuropathy had not resolved.  A review of published material shows a growing body of evidence that long-term use of linezolid may be associated with severe peripheral and optic neuropathy. 21 cases have been reported.  In most cases, optic neuropathies resolved after stopping linezolid but peripheral neuropathies did not.  The duration of therapy rather than indication for treatment seems to be the most important factor.  The mechanism of toxicity is unknown but certain pharmacological properties of linezolid that may play a part are proposed.  This report highlights the importance of post-approval surveillance and reporting of serious adverse drug effects, and potential consequences of off-label use of pharmaceuticals.  It further demonstrates the critical role clinicians have in communicating awareness of emerging drug toxicities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSghVp0dJe6Wq2q3xNe7a7QfW6udTcc2ebcpAcLi23d_Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2czosFymsg%253D%253D&md5=817a165b02499e886a00eb4ebdd8e397</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2804%2901109-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252804%252901109-0%26sid%3Dliteratum%253Aachs%26aulast%3DBressler%26aufirst%3DA.%2BM.%26aulast%3DZimmer%26aufirst%3DS.%2BM.%26aulast%3DGilmore%26aufirst%3DJ.%2BL.%26aulast%3DSomani%26aufirst%3DJ.%26atitle%3DPeripheral%2520neuropathy%2520associated%2520with%2520prolonged%2520use%2520of%2520linezolid%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2004%26volume%3D4%26spage%3D528%26epage%3D531%26doi%3D10.1016%2FS1473-3099%2804%2901109-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chao, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, S. T.</span></span> <span> </span><span class="NLM_article-title">Painful neuropathy with skin denervation after prolonged use of linezolid</span>. <i>J. Neurol., Neurosurg. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">99</span>, <span class="refDoi"> DOI: 10.1136/jnnp.2007.127910</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1136%2Fjnnp.2007.127910" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=17766431" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A280%3ADC%252BD2sjktFejuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2008&pages=97-99&author=C.+C.+Chaoauthor=H.+Y.+Sunauthor=Y.+C.+Changauthor=S.+T.+Hsieh&title=Painful+neuropathy+with+skin+denervation+after+prolonged+use+of+linezolid&doi=10.1136%2Fjnnp.2007.127910"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Painful neuropathy with skin denervation after prolonged use of linezolid</span></div><div class="casAuthors">Chao C-C; Sun H-Y; Chang Y-C; Hsieh S-T</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neurology, neurosurgery, and psychiatry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">97-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The prolonged use of linezolid, a new antibiotic against drug-resistant gram-positive pathogens, might cause painful neuropathy.  This finding raises the possibility that small-diameter sensory nerves in the skin, which are responsible for transmitting nociceptive information, might be affected.  We report a 53-year-old female who developed pure small-fibre painful neuropathy (visual analogue scale, VAS = 82 on 0-100 scale) with marked skin denervation in the leg (epidermal nerve density, END = 2.32 fibres/mm, norm <5.88 fibres/mm) and significant elevation of the warm threshold in the foot (40.0 degrees C, norm <39.4 degrees C) after the use of linezolid for 6 months.  Eight months after the discontinuation of linezolid, the skin became fully reinnervated (END = 9.04 fibres/mm), with disappearance of neuropathic pain (VAS = 0) and normalisation of the warm threshold (36.3 degrees C).  Nerve conduction studies for large-diameter motor and sensory nerves were normal.  This report documents a pure small-fibre sensory neuropathy after prolonged use of linezolid, and the relationship between skin innervation and corresponding neuropathic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRhZW7yFMdLk2gRQsDqrjW_fW6udTcc2eYdB5H7g6jK7Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2sjktFejuw%253D%253D&md5=5c258b2200b97330f4279c3eab3632a9</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1136%2Fjnnp.2007.127910&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fjnnp.2007.127910%26sid%3Dliteratum%253Aachs%26aulast%3DChao%26aufirst%3DC.%2BC.%26aulast%3DSun%26aufirst%3DH.%2BY.%26aulast%3DChang%26aufirst%3DY.%2BC.%26aulast%3DHsieh%26aufirst%3DS.%2BT.%26atitle%3DPainful%2520neuropathy%2520with%2520skin%2520denervation%2520after%2520prolonged%2520use%2520of%2520linezolid%26jtitle%3DJ.%2520Neurol.%252C%2520Neurosurg.%2520Psychiatry%26date%3D2008%26volume%3D79%26spage%3D97%26epage%3D99%26doi%3D10.1136%2Fjnnp.2007.127910" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stover, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tasneen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyagi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosset, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuermberger, E.</span></span> <span> </span><span class="NLM_article-title">Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">1314</span>– <span class="NLM_lpage">1319</span>, <span class="refDoi"> DOI: 10.1128/AAC.01182-08</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.01182-08" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=19075058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksFWksrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2009&pages=1314-1319&author=K.+N.+Williamsauthor=C.+K.+Stoverauthor=T.+Zhuauthor=R.+Tasneenauthor=S.+Tyagiauthor=J.+H.+Grossetauthor=E.+Nuermberger&title=Promising+antituberculosis+activity+of+the+oxazolidinone+PNU-100480+relative+to+that+of+linezolid+in+a+murine+model&doi=10.1128%2FAAC.01182-08"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model</span></div><div class="casAuthors">Williams, K. N.; Stover, C. K.; Zhu, T.; Tasneen, R.; Tyagi, S.; Grosset, J. H.; Nuermberger, E.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1314-1319</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Oxazolidinone antibiotics have activity against Mycobacterium tuberculosis.  Linezolid, the only marked oxazolidinone, has been used off-label in combination regimens to treat multidrug-resistant tuberculosis, but its precise contribution to the efficacy of such combinations is unclear.  Another oxazolidinone, PNU-100480, has been demonstrated to have more potent activity in vitro and in a murine model of tuberculosis.  In this study, we compared the pharmacokinetics and the antituberculosis activities of these two oxazolidinones over a range of doses and found that linezolid has limited activity at clin. relevant doses in the murine model compared to that of PNU-100480, which has potent bactericidal activity, even at lower drug exposures.  These findings were unexpected, given the similar in vitro activities of PNU-100480, its major metabolites, and linezolid.  Moreover, the incorporation of PNU-100480 dramatically improved the bactericidal activities of regimens contg. current first-line antituberculosis drugs and moxifloxacin.  For example, the addn. of PNU-100480 (100 mg/kg of body wt./day) to the std. daily regimen of rifampin (rifampicin), isoniazid, and pyrazinamide resulted in an addnl. 2.0-log10-unit redn. in lung CFU counts during the first 2 mo of treatment.  The combination of PNU-100480, moxifloxacin, and pyrazinamide, which does not contain either rifampin or isoniazid, was also more active than rifampin, isoniazid, and pyrazinamide.  These results suggest that PNU-100480 may have the potential to significantly shorten the duration of therapy for drug-susceptible as well as multidrug-resistant tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEbv65dLLnFLVg90H21EOLACvtfcHk0lgzk-1GTvOSWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksFWksrw%253D&md5=0b62de54c87cdf023e93851d44c9b28d</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1128%2FAAC.01182-08&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01182-08%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DK.%2BN.%26aulast%3DStover%26aufirst%3DC.%2BK.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DTasneen%26aufirst%3DR.%26aulast%3DTyagi%26aufirst%3DS.%26aulast%3DGrosset%26aufirst%3DJ.%2BH.%26aulast%3DNuermberger%26aufirst%3DE.%26atitle%3DPromising%2520antituberculosis%2520activity%2520of%2520the%2520oxazolidinone%2520PNU-100480%2520relative%2520to%2520that%2520of%2520linezolid%2520in%2520a%2520murine%2520model%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2009%26volume%3D53%26spage%3D1314%26epage%3D1319%26doi%3D10.1128%2FAAC.01182-08" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alffenaar, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Laan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simons, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Werf, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Kasteele, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Neeling, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Soolingen, D.</span></span> <span> </span><span class="NLM_article-title">Susceptibility of clinical mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1287</span>– <span class="NLM_lpage">1289</span>, <span class="refDoi"> DOI: 10.1128/AAC.01297-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.01297-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=21199931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktlamu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2011&pages=1287-1289&author=J.+W.+Alffenaarauthor=T.+van+der+Laanauthor=S.+Simonsauthor=T.+S.+van+der%0AWerfauthor=P.+J.+van+de+Kasteeleauthor=H.+de+Neelingauthor=D.+van+Soolingen&title=Susceptibility+of+clinical+mycobacterium+tuberculosis+isolates+to+a+potentially+less+toxic+derivate+of+linezolid%2C+PNU-100480&doi=10.1128%2FAAC.01297-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480</span></div><div class="casAuthors">Alffenaar, J. W. C.; van der Laan, T.; Simons, S.; van der Werf, T. S.; van de Kasteele, P. J.; de Neeling, H.; van Soolingen, D.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1287-1289</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Susceptibility of clin. Mycobacterium tuberculosis isolates to PNU-100480 and linezolid was evaluated by the MGIT 960 system.  The isolates had various susceptibilities to isoniazid (INH), rifampin, ethambutol, and streptomycin.  The mean MIC for PNU-100480 was 3.2 times lower than that for linezolid.  Therefore, PNU-100480 is a promising candidate to be developed further as an adjunct in the treatment of multidrug- and extensively drug-resistant tuberculosis (MDR/XDR-TB).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDIzcdMTy7drVg90H21EOLACvtfcHk0lgzk-1GTvOSWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktlamu7o%253D&md5=74b1a71f925f5dc4fb9b97e79b19f8f7</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1128%2FAAC.01297-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01297-10%26sid%3Dliteratum%253Aachs%26aulast%3DAlffenaar%26aufirst%3DJ.%2BW.%26aulast%3Dvan%2Bder%2BLaan%26aufirst%3DT.%26aulast%3DSimons%26aufirst%3DS.%26aulast%3Dvan%2Bder%2BWerf%26aufirst%3DT.%2BS.%26aulast%3Dvan%2Bde%2BKasteele%26aufirst%3DP.%2BJ.%26aulast%3Dde%2BNeeling%26aufirst%3DH.%26aulast%3Dvan%2BSoolingen%26aufirst%3DD.%26atitle%3DSusceptibility%2520of%2520clinical%2520mycobacterium%2520tuberculosis%2520isolates%2520to%2520a%2520potentially%2520less%2520toxic%2520derivate%2520of%2520linezolid%252C%2520PNU-100480%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2011%26volume%3D55%26spage%3D1287%26epage%3D1289%26doi%3D10.1128%2FAAC.01297-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brickner, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stover, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogden, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tasneen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyagi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosset, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuermberger, E. L.</span></span> <span> </span><span class="NLM_article-title">Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>180</i></span>,  <span class="NLM_fpage">371</span>– <span class="NLM_lpage">376</span>, <span class="refDoi"> DOI: 10.1164/rccm.200904-0611OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1164%2Frccm.200904-0611OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=19520903" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFWrt73L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=180&publication_year=2009&pages=371-376&author=K.+N.+Williamsauthor=S.+J.+Bricknerauthor=C.+K.+Stoverauthor=T.+Zhuauthor=A.+Ogdenauthor=R.+Tasneenauthor=S.+Tyagiauthor=J.+H.+Grossetauthor=E.+L.+Nuermberger&title=Addition+of+PNU-100480+to+first-line+drugs+shortens+the+time+needed+to+cure+murine+tuberculosis&doi=10.1164%2Frccm.200904-0611OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis</span></div><div class="casAuthors">Williams, Kathy N.; Brickner, Steven J.; Stover, Charles K.; Zhu, Tong; Ogden, Adam; Tasneen, Rokeya; Tyagi, Sandeep; Grosset, Jacques H.; Nuermberger, Eric L.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">180</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">371-376</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">We recently reported strong bactericidal activity of the oxazolidinone PNU-100480 and its ability to increase the initial bactericidal effect of various combinations of first-line tuberculosis drugs and moxifloxacin in a murine model.  To investigate whether the addn. of PNU-100480 to the std. first-line regimen of rifampin, isoniazid, and pyrazinamide could shorten the duration of treatment necessary to prevent relapse after treatment discontinuation.  Following aerosol infection with Mycobacterium tuberculosis H37Rv and a 13-day incubation period, control mice were treated with the first-line regimen while test mice received the same regimen with PNU-100480 or linezolid added for the first 2 or 4 mo.  Efficacy was assessed on the basis of quant. cultures of lung homogenates performed monthly during treatment and 3 mo after completion of 3, 4, 5, or 6 mo of treatment to det. the relapse rate.  After 2 mo of treatment, mice receiving PNU-100480 in addn. to the first-line regimen had lung CFU counts two orders of magnitude lower than control mice receiving the first-line regimen alone.  Relapse rates after 4 mo of treatment were 90, 35, and 5% when PNU-100480 was added to the first-line regimen for 0, 2, and 4 mo, resp.  When the total treatment duration was 3 mo, relapse rates were 85 and 35 to 45% when mice received PNU-100480 for 2 and 3 mo, resp.; all control mice remained culture pos. at the time of treatment completion with 17 to 72 CFU per lung.  Addn. of linezolid to the first-line regimen had an antagonistic effect resulting in higher CFU counts and failure to render mice culture-neg. in 4 mo of treatment.  Together with previous findings, these results confirm that PNU-100480, which is now in Phase I clin. testing, has sterilizing activity in the murine model and suggest that it may be capable of shortening treatment duration for drug-susceptible as well as drug-resistant tuberculosis in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnFWkF1J81fbVg90H21EOLACvtfcHk0likWPOaW9wiUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFWrt73L&md5=c4f5928eaf02b292e40d8b724ade1897</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1164%2Frccm.200904-0611OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200904-0611OC%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DK.%2BN.%26aulast%3DBrickner%26aufirst%3DS.%2BJ.%26aulast%3DStover%26aufirst%3DC.%2BK.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DOgden%26aufirst%3DA.%26aulast%3DTasneen%26aufirst%3DR.%26aulast%3DTyagi%26aufirst%3DS.%26aulast%3DGrosset%26aufirst%3DJ.%2BH.%26aulast%3DNuermberger%26aufirst%3DE.%2BL.%26atitle%3DAddition%2520of%2520PNU-100480%2520to%2520first-line%2520drugs%2520shortens%2520the%2520time%2520needed%2520to%2520cure%2520murine%2520tuberculosis%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2009%26volume%3D180%26spage%3D371%26epage%3D376%26doi%3D10.1164%2Frccm.200904-0611OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solapure, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deepthi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subbulakshmi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramya, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balganesh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melnick, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sambandamurthy, V. K.</span></span> <span> </span><span class="NLM_article-title">Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">495</span>– <span class="NLM_lpage">502</span>, <span class="refDoi"> DOI: 10.1128/AAC.01903-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.01903-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=24189255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFChsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=495-502&author=V.+Balasubramanianauthor=S.+Solapureauthor=H.+Iyerauthor=A.+Ghoshauthor=S.+Sharmaauthor=P.+Kaurauthor=R.+Deepthiauthor=V.+Subbulakshmiauthor=V.+Ramyaauthor=V.+Ramachandranauthor=M.+Balganeshauthor=L.+Wrightauthor=D.+Melnickauthor=S.+L.+Butlerauthor=V.+K.+Sambandamurthy&title=Bactericidal+activity+and+mechanism+of+action+of+AZD5847%2C+a+novel+oxazolidinone+for+treatment+of+tuberculosis&doi=10.1128%2FAAC.01903-13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis</span></div><div class="casAuthors">Balasubramanian, V.; Solapure, S.; Iyer, H.; Ghosh, A.; Sharma, S.; Kaur, P.; Deepthi, R.; Subbulakshmi, V.; Ramya, V.; Ramachandran, V.; Balganesh, M.; Wright, L.; Melnick, D.; Butler, S. L.; Sambandamurthy, V. K.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">495-502, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Treatment of tuberculosis (TB) is impaired by the long duration and complexity of therapy and the rising incidence of drug resistance.  There is an urgent need for new agents with improved efficacy, safety, and compatibility with combination chemotherapies.  Oxazolidinones offer a potential new class of TB drugs, and linezolid-the only currently approved oxazolidinone-has proven highly effective against extensively drug-resistant (XDR) TB in exptl. trials.  However, widespread use of linezolid is prohibited by its significant toxicities.  AZD5847, a novel oxazolidinone, demonstrates improved in vitro bactericidal activity against both extracellular and intracellular M. tuberculosis compared to that of linezolid.  Killing kinetics in broth media and in macrophages indicate that the rate and extent of kill obtained with AZD5847 are superior to those obtained with linezolid.  Moreover, the efficacy of AZD5847 was additive when tested along with a variety of conventional TB agents, indicating that AZD5847 may function well in combination therapies.  AZD5847 appears to function similarly to linezolid through impairment of the mycobacterial 50S ribosomal subunit.  Future studies should be undertaken to further characterize the pharmacodynamics and pharmacokinetics of AZD5847 in both in vitro and animal models as well is in human clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcnhn96nzN0bVg90H21EOLACvtfcHk0likWPOaW9wiUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFChsr8%253D&md5=9a55e83a915b1677ccb1189192d850f8</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1128%2FAAC.01903-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01903-13%26sid%3Dliteratum%253Aachs%26aulast%3DBalasubramanian%26aufirst%3DV.%26aulast%3DSolapure%26aufirst%3DS.%26aulast%3DIyer%26aufirst%3DH.%26aulast%3DGhosh%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DKaur%26aufirst%3DP.%26aulast%3DDeepthi%26aufirst%3DR.%26aulast%3DSubbulakshmi%26aufirst%3DV.%26aulast%3DRamya%26aufirst%3DV.%26aulast%3DRamachandran%26aufirst%3DV.%26aulast%3DBalganesh%26aufirst%3DM.%26aulast%3DWright%26aufirst%3DL.%26aulast%3DMelnick%26aufirst%3DD.%26aulast%3DButler%26aufirst%3DS.%2BL.%26aulast%3DSambandamurthy%26aufirst%3DV.%2BK.%26atitle%3DBactericidal%2520activity%2520and%2520mechanism%2520of%2520action%2520of%2520AZD5847%252C%2520a%2520novel%2520oxazolidinone%2520for%2520treatment%2520of%2520tuberculosis%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26spage%3D495%26epage%3D502%26doi%3D10.1128%2FAAC.01903-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jadhavar, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaja, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhameliya, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakraborti, A. K.</span></span> <span> </span><span class="NLM_article-title">Oxazolidinones as anti-tubercular agents: Discovery, development and future perspectives</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">4379</span>– <span class="NLM_lpage">4397</span>, <span class="refDoi"> DOI: 10.2174/0929867323666151106125759</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.2174%2F0929867323666151106125759" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=26549430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVOmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=4379-4397&author=P.+S.+Jadhavarauthor=M.+D.+Vajaauthor=T.+M.+Dhameliyaauthor=A.+K.+Chakraborti&title=Oxazolidinones+as+anti-tubercular+agents%3A+Discovery%2C+development+and+future+perspectives&doi=10.2174%2F0929867323666151106125759"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Oxazolidinones as Anti-tubercular Agents: Discovery, Development and Future Perspectives</span></div><div class="casAuthors">Jadhavar, Pradeep S.; Vaja, Maulikkumar D.; Dhameliya, Tejas M.; Chakraborti, Asit K.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">4379-4397</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">TB drug development pipeline represents varied structural classes of mols.  Oxazolidinones represent synthetic anti-bacterial agents with unique mechanism of action having wide spectrum of activity, oral bioavailability and well established SAR.  They act by inhibiting translation at the initiation phase of protein synthesis.  Linezolid was the first oxazolidinone to reach the market in the year 2000 for the treatment of methicillin-resistant staphylococcal and vancomycin-resistant enterococcal infections.  Oxazolidinones have shown very good anti-mycobacterial activities.  Several oxazolidinones are currently in development for their possible use in TB therapy.  Oxazolidinones are classified on the basis of C-ring modifications.  DuP-721 was the first oxazolidinone having good anti-TB activity.  Linezolid, sutezolid and AZD5847 are in clin. development.  Several other C-ring modifications have shown promising results.  The usefulness of these oxazolidinones in the drug resistant TB is already established.  Toxicity, esp. myelosuppression, has been an important limiting factor for their development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqe0zxDblkvjLVg90H21EOLACvtfcHk0likWPOaW9wiUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVOmtw%253D%253D&md5=82f05591b2efaa98e30416bcecfc5749</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.2174%2F0929867323666151106125759&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867323666151106125759%26sid%3Dliteratum%253Aachs%26aulast%3DJadhavar%26aufirst%3DP.%2BS.%26aulast%3DVaja%26aufirst%3DM.%2BD.%26aulast%3DDhameliya%26aufirst%3DT.%2BM.%26aulast%3DChakraborti%26aufirst%3DA.%2BK.%26atitle%3DOxazolidinones%2520as%2520anti-tubercular%2520agents%253A%2520Discovery%252C%2520development%2520and%2520future%2520perspectives%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2015%26volume%3D22%26spage%3D4379%26epage%3D4397%26doi%3D10.2174%2F0929867323666151106125759" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du Bois, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Brakel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chheng, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peloquin, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alsultan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiel, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debanne, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boom, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diacon, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. L.</span></span> <span> </span><span class="NLM_article-title">Early bactericidal activity of AZD5847 in patients with pulmonary tuberculosis</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">6591</span>– <span class="NLM_lpage">6599</span>, <span class="refDoi"> DOI: 10.1128/AAC.01163-16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.01163-16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=27550361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitlSqtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2016&pages=6591-6599&author=J.+J.+Furinauthor=J.+Du+Boisauthor=E.+van+Brakelauthor=P.+Chhengauthor=A.+Venterauthor=C.+A.+Peloquinauthor=A.+Alsultanauthor=B.+A.+Thielauthor=S.+M.+Debanneauthor=W.+H.+Boomauthor=A.+H.+Diaconauthor=J.+L.+Johnson&title=Early+bactericidal+activity+of+AZD5847+in+patients+with+pulmonary+tuberculosis&doi=10.1128%2FAAC.01163-16"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Early bactericidal activity of AZD5847 in patients with pulmonary tuberculosis</span></div><div class="casAuthors">Furin, Jennifer J.; Du Bois, Jeannine; van Brakel, Elana; Chheng, Phalkun; Venter, Amour; Peloquin, Charles A.; Alsultan, Abdullah; Thiel, Bonnie A.; Debanne, Sara M.; Henry, Boom W.; Diacon, Andreas H.; Johnson, John L.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">6591-6599</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">AZD5847 is an oxazolidinone antibiotic with in vitro activity against Mycobacterium tuberculosis.  The objective of this study was to evaluate the antimycobacterial activity, safety, and pharmacokinetics of AZD5847 in patients with pulmonary tuberculosis.  Groups of 15 treatment-naive, sputum smear-pos. adults with pulmonary tuberculosis were randomly assigned to receive AZD5847 at one of four doses (500 mg once daily, 500 mg twice daily, 1,200 mg once daily, and 800 mg twice daily) or daily std. chemotherapy.  The primary efficacy endpoint was the mean daily rate of change in the log10 no. of CFU of M. tuberculosis per mL of sputum, expressed as the change in log10 no. of CFU per mL of sputum per day.  The mean 14-day activity of the combination of isoniazid, rifampin, ethambutol, and pyrazinamide (-0.163 log10 CFU/mL sputum/day; 95% confidence interval [CI],-0.193,-0.133 log10 CFU/mL sputum/day) was consistent with that found in previous studies.  AZD5847 at 500 mg twice daily significantly decreased the no. of CFU on solid medium (-0.039; 95% CI,-0.069,-0.009; P-0.0048).  No bactericidal activity was detected at doses of AZD5847 of 500 mg once daily (mean early bactericidal activity [EBA], 0.02 [95% CI,-0.01, 0.05]), 1,200 mg once daily (mean EBA, 0.02 [95% CI,-0.01, 0.05]), and 800 mg twice daily (mean EBA, 0.02 [95% CI, -0.01, 0.05]).  AZD5847 at doses of both 500 mg and 800 mg twice daily also showed an increase in the time to a pos. culture in MGIT liq. culture medium.  Two serious adverse events (grade 4 thrombocytopenia and grade 4 hyperbilirubinemia) occurred in patients receiving AZD5847 at higher doses.  AZD5847 dosed twice daily kills tubercle bacilli in the sputum of patients with pulmonary tuberculosis and has modest early bactericidal activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFmVDMI5oXW7Vg90H21EOLACvtfcHk0liS91_c4wGLgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitlSqtrk%253D&md5=cea62e375ddc80ad7ba61c1d560c378c</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1128%2FAAC.01163-16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01163-16%26sid%3Dliteratum%253Aachs%26aulast%3DFurin%26aufirst%3DJ.%2BJ.%26aulast%3DDu%2BBois%26aufirst%3DJ.%26aulast%3Dvan%2BBrakel%26aufirst%3DE.%26aulast%3DChheng%26aufirst%3DP.%26aulast%3DVenter%26aufirst%3DA.%26aulast%3DPeloquin%26aufirst%3DC.%2BA.%26aulast%3DAlsultan%26aufirst%3DA.%26aulast%3DThiel%26aufirst%3DB.%2BA.%26aulast%3DDebanne%26aufirst%3DS.%2BM.%26aulast%3DBoom%26aufirst%3DW.%2BH.%26aulast%3DDiacon%26aufirst%3DA.%2BH.%26aulast%3DJohnson%26aufirst%3DJ.%2BL.%26atitle%3DEarly%2520bactericidal%2520activity%2520of%2520AZD5847%2520in%2520patients%2520with%2520pulmonary%2520tuberculosis%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2016%26volume%3D60%26spage%3D6591%26epage%3D6599%26doi%3D10.1128%2FAAC.01163-16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Protopopova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crooks, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slayden, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terrot, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.,  3rd.</span></span> <span> </span><span class="NLM_article-title">Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates</span>. <i>J. Comb. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">172</span>– <span class="NLM_lpage">187</span>, <span class="refDoi"> DOI: 10.1021/cc020071p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cc020071p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkvFKguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2003&pages=172-187&author=R.+E.+Leeauthor=M.+Protopopovaauthor=E.+Crooksauthor=R.+A.+Slaydenauthor=M.+Terrotauthor=C.+E.+Barry&title=Combinatorial+lead+optimization+of+%5B1%2C2%5D-diamines+based+on+ethambutol+as+potential+antituberculosis+preclinical+candidates&doi=10.1021%2Fcc020071p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Combinatorial Lead Optimization of [1,2]-Diamines Based on Ethambutol as Potential Antituberculosis Preclinical Candidates</span></div><div class="casAuthors">Lee, Richard E.; Protopopova, Marina; Crooks, Emma; Slayden, Richard A.; Terrot, Marianne; Barry, Clifton E., III</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Combinatorial Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">172-187</span>CODEN:
                <span class="NLM_cas:coden">JCCHFF</span>;
        ISSN:<span class="NLM_cas:issn">1520-4766</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Despite relatively modest potency, ethambutol (EMB, (S,S)-[N,N-di-2-amino-1-butanol]ethylenediamine) is a mainstay of contemporary chemotherapy for the treatment of tuberculosis.  We have developed a solid-phase synthesis of 1,2-diamine analogs of EMB using a novel acylation-redn. sequence that is compatible with high-throughput 96-well format chem.  Using this procedure, we have synthesized 63,238 diamine analogs in pools of 10 that are suitable for testing.  MIC and a target-based reporter assay were used to direct deconvolution of 2796 individual compds. from these mixts., and the 69 most potent mols. were resynthesized in milligram quantities for hit confirmation.  Purifn. of these individual active diamine analogs allowed the identification of 26 compds. with activity equal to or greater than EMB.  Amines which occurred most frequently in active compds. included many with large hydrophobic moieties, suggesting that optimization was perhaps selecting for the isoprenoid binding site of the arabinosyltransferase target of EMB.  N-Geranyl-N'-(2-adamantyl)ethane-1,2-diamine, the most active of these diamines, displayed a 14-35-fold improvement in activity in vitro against Mycobacterium tuberculosis, as compared to EMB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7ViZZ_FOEcrVg90H21EOLACvtfcHk0liS91_c4wGLgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkvFKguw%253D%253D&md5=3005c111ca5aa61044f016dcfafc6d09</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1021%2Fcc020071p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcc020071p%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DR.%2BE.%26aulast%3DProtopopova%26aufirst%3DM.%26aulast%3DCrooks%26aufirst%3DE.%26aulast%3DSlayden%26aufirst%3DR.%2BA.%26aulast%3DTerrot%26aufirst%3DM.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26atitle%3DCombinatorial%2520lead%2520optimization%2520of%2520%255B1%252C2%255D-diamines%2520based%2520on%2520ethambutol%2520as%2520potential%2520antituberculosis%2520preclinical%2520candidates%26jtitle%3DJ.%2520Comb.%2520Chem.%26date%3D2003%26volume%3D5%26spage%3D172%26epage%3D187%26doi%3D10.1021%2Fcc020071p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Protopopova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanrahan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikonenko, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samala, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gearhart, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einck, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacy, C. A.</span></span> <span> </span><span class="NLM_article-title">Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">968</span>– <span class="NLM_lpage">974</span>, <span class="refDoi"> DOI: 10.1093/jac/dki319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1093%2Fjac%2Fdki319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=16172107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFCjtLjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2005&pages=968-974&author=M.+Protopopovaauthor=C.+Hanrahanauthor=B.+Nikonenkoauthor=R.+Samalaauthor=P.+Chenauthor=J.+Gearhartauthor=L.+Einckauthor=C.+A.+Nacy&title=Identification+of+a+new+antitubercular+drug+candidate%2C+SQ109%2C+from+a+combinatorial+library+of+1%2C2-ethylenediamines&doi=10.1093%2Fjac%2Fdki319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines</span></div><div class="casAuthors">Protopopova, Marina; Hanrahan, Colleen; Nikonenko, Boris; Samala, Rowena; Chen, Ping; Gearhart, Jackie; Einck, Leo; Nacy, Carol A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">968-974</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Objectives: The aim of this study was to identify a candidate drug for clin. development from a previously synthesized combinatorial library based on the 1,2-ethylenediamine structure of ethambutol.  Methods: Sixty-nine of the most potent hits against Mycobacterium tuberculosis from the original studies were subjected to a sequential set of tests in vitro and in vivo-detn. of MIC for M. tuberculosis H37Rv, cytotoxicity, intracellular antimycobacterial activity, permeability evaluation and in vivo efficacy testing.  Results: Twenty-seven compds. with MICs of ≤15.6 μM were tested on Vero cells to det. in vitro cytotoxicity (IC50) and to establish a selectivity index (SI) (SI = IC50/MIC).  Ten compds. with acceptable SI were tested for activity against intracellular bacteria; all were equiv. (within 1%) or superior to ethambutol and several demonstrated bactericidal activity.  Five of the most potent compds. were tested for in vivo efficacy in a murine model of chronic tuberculosis infection.  Conclusion: Compd. SQ109 with an MIC of 0.7-1.56 μM (H37Rv, Erdman and drug-resistant strains of M. tuberculosis), an SI of 16.7 and 99% inhibition activity against intracellular bacteria, demonstrated potency in vivo and limited toxicity in vitro and in vivo, and was selected for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqvmYc-WY3LrVg90H21EOLACvtfcHk0liS91_c4wGLgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFCjtLjI&md5=2f3d82748de8a565112541b2aa4e5437</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdki319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdki319%26sid%3Dliteratum%253Aachs%26aulast%3DProtopopova%26aufirst%3DM.%26aulast%3DHanrahan%26aufirst%3DC.%26aulast%3DNikonenko%26aufirst%3DB.%26aulast%3DSamala%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DGearhart%26aufirst%3DJ.%26aulast%3DEinck%26aufirst%3DL.%26aulast%3DNacy%26aufirst%3DC.%2BA.%26atitle%3DIdentification%2520of%2520a%2520new%2520antitubercular%2520drug%2520candidate%252C%2520SQ109%252C%2520from%2520a%2520combinatorial%2520library%2520of%25201%252C2-ethylenediamines%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2005%26volume%3D56%26spage%3D968%26epage%3D974%26doi%3D10.1093%2Fjac%2Fdki319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gearhart, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Protopopova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einck, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacy, C. A.</span></span> <span> </span><span class="NLM_article-title">Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">332</span>– <span class="NLM_lpage">337</span>, <span class="refDoi"> DOI: 10.1093/jac/dkl227</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1093%2Fjac%2Fdkl227" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=16751637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD28Xotl2lsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2006&pages=332-337&author=P.+Chenauthor=J.+Gearhartauthor=M.+Protopopovaauthor=L.+Einckauthor=C.+A.+Nacy&title=Synergistic+interactions+of+SQ109%2C+a+new+ethylene+diamine%2C+with+front-line+antitubercular+drugs+in+vitro&doi=10.1093%2Fjac%2Fdkl227"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro</span></div><div class="casAuthors">Chen, Ping; Gearhart, Jackie; Protopopova, Marina; Einck, Leo; Nacy, Carol A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">332-337</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The purpose of this study was to det. interactions of SQ109, a new asym. diamine tuberculosis (TB) drug candidate, with existing antitubercular drugs in vitro and assess its potential to improve combination drug activities against Mycobacterium tuberculosis.  2 -Drug combinations at various concns. below their MICs were tested for growth inhibition of M. tuberculosis using the BACTEC 460 system in vitro.  Drug interactions were evaluated based on the quotient values that were derived numerically from the growth indexes of cultures treated with a single antibiotic or combination treatment with two antibiotics.  SQ109 at 0.5 of its MIC demonstrated strong Synergistic activity with 0.5 MIC isoniazid and as low as 0.1 MIC rifampicin in inhibition of M. tuberculosis growth.  Additive effects were obsd. between SQ109 and streptomycin, but neither synergy nor additive effects were obsd. with the combination of SQ109 with ethambutol or pyrazinamide.  The synergy between SQ109 and rifampicin was also demonstrated using rifampicin-resistant (RIFR) M. tuberculosis strains; SQ109 lowered the MIC of rifampicin for these drug-resistant strains.  SQ109 interacts synergistically with isoniazid and rifampicin, 2 of the most important front-line TB drugs.  This finding supports efforts to further evaluate new combination therapies contg. SQ109 in exptl. animal models of TB that emulate future clin. trial studies in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOvxKYKzx877Vg90H21EOLACvtfcHk0ljqy3f1-1-JUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xotl2lsbw%253D&md5=d1f33ab9a1bd5636e683a07a773cf784</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdkl227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdkl227%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DP.%26aulast%3DGearhart%26aufirst%3DJ.%26aulast%3DProtopopova%26aufirst%3DM.%26aulast%3DEinck%26aufirst%3DL.%26aulast%3DNacy%26aufirst%3DC.%2BA.%26atitle%3DSynergistic%2520interactions%2520of%2520SQ109%252C%2520a%2520new%2520ethylene%2520diamine%252C%2520with%2520front-line%2520antitubercular%2520drugs%2520in%2520vitro%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2006%26volume%3D58%26spage%3D332%26epage%3D337%26doi%3D10.1093%2Fjac%2Fdkl227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noker, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coward, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorman, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Protopopova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomaszewski, J. E.</span></span> <span> </span><span class="NLM_article-title">Interspecies pharmacokinetics and in vitro metabolism of SQ109</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>147</i></span>,  <span class="NLM_fpage">476</span>– <span class="NLM_lpage">485</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0706650</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1038%2Fsj.bjp.0706650" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=16432511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD28XitVCmt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=2006&pages=476-485&author=L.+Jiaauthor=P.+E.+Nokerauthor=L.+Cowardauthor=G.+S.+Gormanauthor=M.+Protopopovaauthor=J.+E.+Tomaszewski&title=Interspecies+pharmacokinetics+and+in+vitro+metabolism+of+SQ109&doi=10.1038%2Fsj.bjp.0706650"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Interspecies pharmacokinetics and in vitro metabolism of SQ109</span></div><div class="casAuthors">Jia, Lee; Noker, Patricia E.; Coward, Lori; Gorman, Gregory S.; Protopopova, Marina; Tomaszewski, Joseph E.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">147</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">476-485</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">This study aimed at characterizing the interspecies absorption, distribution, metab. and elimination (ADME) profile of N-geranyl-N'-(2-adamantyl)ethane-1,2-diamine (SQ109), a new diamine-based antitubercular drug.  Single doses of SQ109 were administered ( i.v. and p.o.) to rodents and dogs and blood samples were analyzed by liq. chromatog. tandem mass spectrometry (LC/MS/MS).  Based on i.v. equiv. body surface area dose, the terminal half-life (t1/2) of SQ109 in dogs was longer than that in rodents, reflected by a larger vol. of distribution (Vss) and a higher clearance rate of SQ109 in dogs, compared to that in rodents.  The oral bioavailability of SQ109 in dogs, rats and mice were 2.4 - 5, 12 and 3.8%, resp.  After oral administration of [14C]SQ109 to rats, the highest level of radioactivity was in the liver, followed by the lung, spleen and kidney.  Tissue-to-blood ratios of [14C]SQ109 were greater than 1.  Fecal elimination of [14C]SQ109 accounted for 22.2% of the total dose of [14C]SQ109, while urinary excretion accounted for only 5.6%.  The binding of [14C]SQ109 (0.1 - 2.5 μg ml-1) to plasma proteins varied from 6 to 23% depending on the species (human, mouse, rat and dog).  SQ109 was metabolized by rat, mouse, dog and human liver microsomes, resulting in 22.8, 48.4 , 50.8 or 58.3%, resp. , of SQ109 remaining after a 10-min incubation at 37 °C.  The predominant metabolites in the human liver microsomes gave intense ion signals at 195, 347 and 363m/z, suggesting the oxidn., epoxidn. and N-dealkylation of SQ109.  P 450 reaction phenotyping using recombinant cDNA-expressed human CYPs in conjunction with specific CYP inhibitors indicated that CYP2D6 and CYP2C19 were the predominant CYPs involved in SQ109 metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqFPcT80iIfrVg90H21EOLACvtfcHk0ljqy3f1-1-JUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XitVCmt78%253D&md5=5a519038ee0c5f0c7b68d0cd90fe8f76</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0706650&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0706650%26sid%3Dliteratum%253Aachs%26aulast%3DJia%26aufirst%3DL.%26aulast%3DNoker%26aufirst%3DP.%2BE.%26aulast%3DCoward%26aufirst%3DL.%26aulast%3DGorman%26aufirst%3DG.%2BS.%26aulast%3DProtopopova%26aufirst%3DM.%26aulast%3DTomaszewski%26aufirst%3DJ.%2BE.%26atitle%3DInterspecies%2520pharmacokinetics%2520and%2520in%2520vitro%2520metabolism%2520of%2520SQ109%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2006%26volume%3D147%26spage%3D476%26epage%3D485%26doi%3D10.1038%2Fsj.bjp.0706650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tahlan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kastrinsky, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arora, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alland, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boshoff, H. I.</span></span> <span> </span><span class="NLM_article-title">SQ109 targets mmpl3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of mycobacterium tuberculosis</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">1797</span>– <span class="NLM_lpage">1809</span>, <span class="refDoi"> DOI: 10.1128/AAC.05708-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.05708-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=22252828" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38XltV2ru7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=1797-1809&author=K.+Tahlanauthor=R.+Wilsonauthor=D.+B.+Kastrinskyauthor=K.+Aroraauthor=V.+Nairauthor=E.+Fischerauthor=S.+W.+Barnesauthor=J.+R.+Walkerauthor=D.+Allandauthor=C.+E.+Barryauthor=H.+I.+Boshoff&title=SQ109+targets+mmpl3%2C+a+membrane+transporter+of+trehalose+monomycolate+involved+in+mycolic+acid+donation+to+the+cell+wall+core+of+mycobacterium+tuberculosis&doi=10.1128%2FAAC.05708-11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis</span></div><div class="casAuthors">Tahlan, Kapil; Wilson, Regina; Kastrinsky, David B.; Arora, Kriti; Nair, Vinod; Fischer, Elizabeth; Barnes, S. Whitney; Walker, John R.; Alland, David; Barry, Clifton E., III; Boshoff, Helena I.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1797-1809</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">SQ109, a 1,2-diamine related to ethambutol, is currently in clin. trials for the treatment of tuberculosis, but its mode of action remains unclear.  Here, we demonstrate that SQ109 disrupts cell wall assembly, as evidenced by macromol. incorporation assays and ultrastructural analyses.  SQ109 interferes with the assembly of mycolic acids into the cell wall core of Mycobacterium tuberculosis, as bacilli exposed to SQ109 show immediate inhibition of trehalose dimycolate (TDM) prodn. and fail to attach mycolates to the cell wall arabinogalactan.  These effects were not due to inhibition of mycolate synthesis, since total mycolate levels were unaffected, but instead resulted in the accumulation of trehalose monomycolate (TMM), the precursor of TDM and cell wall mycolates.  In vitro assays using purified enzymes showed that this was not due to inhibition of the secreted Ag85 mycolyltransferases.  We were unable to achieve spontaneous generation of SQ109-resistant mutants; however, analogs of this compd. that resulted in similar shutdown of TDM synthesis with concomitant TMM accumulation were used to spontaneously generate resistant mutants that were also cross-resistant to SQ109.  Whole-genome sequencing of these mutants showed that these all had mutations in the essential mmpL3 gene, which encodes a transmembrane transporter.  Our results suggest that MmpL3 is the target of SQ109 and that MmpL3 is a transporter of mycobacterial TMM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpupM7fIKB8uLVg90H21EOLACvtfcHk0ljqy3f1-1-JUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XltV2ru7k%253D&md5=6309318d9e4d2f0c75a9fed20b8108ea</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1128%2FAAC.05708-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.05708-11%26sid%3Dliteratum%253Aachs%26aulast%3DTahlan%26aufirst%3DK.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DKastrinsky%26aufirst%3DD.%2BB.%26aulast%3DArora%26aufirst%3DK.%26aulast%3DNair%26aufirst%3DV.%26aulast%3DFischer%26aufirst%3DE.%26aulast%3DBarnes%26aufirst%3DS.%2BW.%26aulast%3DWalker%26aufirst%3DJ.%2BR.%26aulast%3DAlland%26aufirst%3DD.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26aulast%3DBoshoff%26aufirst%3DH.%2BI.%26atitle%3DSQ109%2520targets%2520mmpl3%252C%2520a%2520membrane%2520transporter%2520of%2520trehalose%2520monomycolate%2520involved%2520in%2520mycolic%2520acid%2520donation%2520to%2520the%2520cell%2520wall%2520core%2520of%2520mycobacterium%2520tuberculosis%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D1797%26epage%3D1809%26doi%3D10.1128%2FAAC.05708-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grzegorzewicz, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gundi, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherman, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">North, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruppo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Born, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korduláková, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavadi, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenaerts, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeil, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, M.</span></span> <span> </span><span class="NLM_article-title">Inhibition of mycolic acid transport across the mycobacterium tuberculosis plasma membrane</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">334</span>– <span class="NLM_lpage">341</span>, <span class="refDoi"> DOI: 10.1038/nchembio.794</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1038%2Fnchembio.794" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=22344175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38XisVKktrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=334-341&author=A.+E.+Grzegorzewiczauthor=H.+Phamauthor=V.+A.+Gundiauthor=M.+S.+Schermanauthor=E.+J.+Northauthor=T.+Hessauthor=V.+Jonesauthor=V.+Gruppoauthor=S.+E.+Bornauthor=J.+Kordul%C3%A1kov%C3%A1author=S.+S.+Chavadiauthor=C.+Morisseauauthor=A.+J.+Lenaertsauthor=R.+E.+Leeauthor=M.+R.+McNeilauthor=M.+Jackson&title=Inhibition+of+mycolic+acid+transport+across+the+mycobacterium+tuberculosis+plasma+membrane&doi=10.1038%2Fnchembio.794"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane</span></div><div class="casAuthors">Grzegorzewicz, Anna E.; Pham, Ha; Gundi, Vijay A. K. B.; Scherman, Michael S.; North, Elton J.; Hess, Tamara; Jones, Victoria; Gruppo, Veronica; Born, Sarah E. M.; Kordulakova, Jana; Chavadi, Sivagami Sundaram; Morisseau, Christophe; Lenaerts, Anne J.; Lee, Richard E.; McNeil, Michael R.; Jackson, Mary</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">334-341</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">New chemotherapeutics active against multidrug-resistant Mycobacterium tuberculosis are urgently needed.  We report on the identification of an adamantyl urea compd. that shows potent bactericidal activity against M. tuberculosis and a unique mode of action, namely the abolition of the translocation of mycolic acids from the cytoplasm, where they are synthesized to the periplasmic side of the plasma membrane and are in turn transferred onto cell wall arabinogalactan or used in the formation of virulence-assocd., outer membrane, trehalose-contg. glycolipids.  Whole-genome sequencing of spontaneous-resistant mutants of M. tuberculosis selected in vitro followed by genetic validation expts. revealed that our prototype inhibitor targets the inner membrane transporter MmpL3.  Conditional gene expression of mmpL3 in mycobacteria and anal. of inhibitor-treated cells validate MmpL3 as essential for mycobacterial growth and support the involvement of this transporter in the translocation of trehalose monomycolate across the plasma membrane.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow3tM24PWRw7Vg90H21EOLACvtfcHk0liuePyD3Nk4ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XisVKktrg%253D&md5=0068aca13a9d9f342705035d0cb2c677</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.794&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.794%26sid%3Dliteratum%253Aachs%26aulast%3DGrzegorzewicz%26aufirst%3DA.%2BE.%26aulast%3DPham%26aufirst%3DH.%26aulast%3DGundi%26aufirst%3DV.%2BA.%26aulast%3DScherman%26aufirst%3DM.%2BS.%26aulast%3DNorth%26aufirst%3DE.%2BJ.%26aulast%3DHess%26aufirst%3DT.%26aulast%3DJones%26aufirst%3DV.%26aulast%3DGruppo%26aufirst%3DV.%26aulast%3DBorn%26aufirst%3DS.%2BE.%26aulast%3DKordul%25C3%25A1kov%25C3%25A1%26aufirst%3DJ.%26aulast%3DChavadi%26aufirst%3DS.%2BS.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DLenaerts%26aufirst%3DA.%2BJ.%26aulast%3DLee%26aufirst%3DR.%2BE.%26aulast%3DMcNeil%26aufirst%3DM.%2BR.%26aulast%3DJackson%26aufirst%3DM.%26atitle%3DInhibition%2520of%2520mycolic%2520acid%2520transport%2520across%2520the%2520mycobacterium%2520tuberculosis%2520plasma%2520membrane%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2012%26volume%3D8%26spage%3D334%26epage%3D341%26doi%3D10.1038%2Fnchembio.794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nikonenko, B. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Protopopova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samala, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einck, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacy, C. A.</span></span> <span> </span><span class="NLM_article-title">Drug therapy of experimental tuberculosis (tb): Improved outcome by combining SQ109, a new diamine antibiotic, with existing tb drugs</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">1563</span>– <span class="NLM_lpage">1565</span>, <span class="refDoi"> DOI: 10.1128/AAC.01326-06</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.01326-06" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=17242141" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD2sXktlOisr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2007&pages=1563-1565&author=B.+V.+Nikonenkoauthor=M.+Protopopovaauthor=R.+Samalaauthor=L.+Einckauthor=C.+A.+Nacy&title=Drug+therapy+of+experimental+tuberculosis+%28tb%29%3A+Improved+outcome+by+combining+SQ109%2C+a+new+diamine+antibiotic%2C+with+existing+tb+drugs&doi=10.1128%2FAAC.01326-06"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs</span></div><div class="casAuthors">Nikonenko, Boris V.; Protopopova, Marina; Samala, Rowena; Einck, Leo; Nacy, Carol A.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1563-1565</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Substitution of the new diamine antibiotic SQ109 for ethambutol in a mouse model of chronic tuberculosis (TB) improved efficacy of combination drug therapy with first-line TB drugs rifampin and isoniazid, with or without pyrazinamide: at 8 wk, lung bacteria were 1.5 log10 lower in SQ109-contg. regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrywULJFY6Xv7Vg90H21EOLACvtfcHk0liuePyD3Nk4ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXktlOisr4%253D&md5=179cfc6a3256417b542fd64decba25c3</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1128%2FAAC.01326-06&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01326-06%26sid%3Dliteratum%253Aachs%26aulast%3DNikonenko%26aufirst%3DB.%2BV.%26aulast%3DProtopopova%26aufirst%3DM.%26aulast%3DSamala%26aufirst%3DR.%26aulast%3DEinck%26aufirst%3DL.%26aulast%3DNacy%26aufirst%3DC.%2BA.%26atitle%3DDrug%2520therapy%2520of%2520experimental%2520tuberculosis%2520%2528tb%2529%253A%2520Improved%2520outcome%2520by%2520combining%2520SQ109%252C%2520a%2520new%2520diamine%2520antibiotic%252C%2520with%2520existing%2520tb%2520drugs%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2007%26volume%3D51%26spage%3D1563%26epage%3D1565%26doi%3D10.1128%2FAAC.01326-06" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulati, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crick, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cynamon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Docampo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">No, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oldfield, E.</span></span> <span> </span><span class="NLM_article-title">Oxa, thia, heterocycle, and carborane analogues of SQ109: Bacterial and protozoal cell growth inhibitors</span>. <i>ACS Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1021/acsinfecdis.5b00026</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsinfecdis.5b00026" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsFGnt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2015&pages=215-221&author=K.+Liauthor=Y.+Wangauthor=G.+Yangauthor=S.+Byunauthor=G.+Raoauthor=C.+Shoenauthor=H.+Yangauthor=A.+Gulatiauthor=D.+C.+Crickauthor=M.+Cynamonauthor=G.+Huangauthor=R.+Docampoauthor=J.+H.+Noauthor=E.+Oldfield&title=Oxa%2C+thia%2C+heterocycle%2C+and+carborane+analogues+of+SQ109%3A+Bacterial+and+protozoal+cell+growth+inhibitors&doi=10.1021%2Facsinfecdis.5b00026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Oxa, Thia, Heterocycle, and Carborane Analogues of SQ109: Bacterial and Protozoal Cell Growth Inhibitors</span></div><div class="casAuthors">Li, Kai; Wang, Yang; Yang, Gyongseon; Byun, Soo Young; Rao, Guodong; Shoen, Carolyn; Yang, Hongliang; Gulati, Anmol; Crick, Dean C.; Cynamon, Michael; Huang, Guozhong; Docampo, Roberto; No, Joo Hwan; Oldfield, Eric</div><div class="citationInfo"><span class="NLM_cas:title">ACS Infectious Diseases</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">215-221</span>CODEN:
                <span class="NLM_cas:coden">AIDCBC</span>;
        ISSN:<span class="NLM_cas:issn">2373-8227</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors synthesized a library of 48 analogs of the Mycobacterium tuberculosis cell growth inhibitor SQ109 in which the ethylenediamine linker was replaced by oxa, thia, or heterocyclic species, and in some cases, the adamantyl group was replaced by a 1,2-carborane or the N-geranyl group by another hydrophobic species.  Compds. were tested against M. tuberculosis (H37Rv and/or Erdman), Mycobacterium smegmatis, Bacillus subtilis, Escherichia coli, Saccharomyces cerevisiae, Trypanosoma brucei, and two human cell lines (human embryonic kidney, HEK293T, and the hepatocellular carcinoma, HepG2).  The most potent activity was found against T. brucei, the causative agent of human African trypanosomiasis, and involved targeting of the mitochondrial membrane potential with 15 SQ109 analogs being more active than was SQ109 in cell growth inhibition, having IC50 values as low as 12 nM (5.5 ng/mL) and a selectivity index of ∼300.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwRJduvLZTO7Vg90H21EOLACvtfcHk0liuePyD3Nk4ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsFGnt7c%253D&md5=d83c90f63177cca1aa54564738288074</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1021%2Facsinfecdis.5b00026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsinfecdis.5b00026%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DByun%26aufirst%3DS.%26aulast%3DRao%26aufirst%3DG.%26aulast%3DShoen%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DGulati%26aufirst%3DA.%26aulast%3DCrick%26aufirst%3DD.%2BC.%26aulast%3DCynamon%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DG.%26aulast%3DDocampo%26aufirst%3DR.%26aulast%3DNo%26aufirst%3DJ.%2BH.%26aulast%3DOldfield%26aufirst%3DE.%26atitle%3DOxa%252C%2520thia%252C%2520heterocycle%252C%2520and%2520carborane%2520analogues%2520of%2520SQ109%253A%2520Bacterial%2520and%2520protozoal%2520cell%2520growth%2520inhibitors%26jtitle%3DACS%2520Infect.%2520Dis.%26date%3D2015%26volume%3D1%26spage%3D215%26epage%3D221%26doi%3D10.1021%2Facsinfecdis.5b00026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bogatcheva, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanrahan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gearhart, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacksteder, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einck, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Protopopova, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of dipiperidines as new antitubercular agents</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">201</span>– <span class="NLM_lpage">205</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.10.135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmcl.2009.10.135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=19917527" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsF2jsb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=201-205&author=E.+Bogatchevaauthor=C.+Hanrahanauthor=P.+Chenauthor=J.+Gearhartauthor=K.+Sackstederauthor=L.+Einckauthor=C.+Nacyauthor=M.+Protopopova&title=Discovery+of+dipiperidines+as+new+antitubercular+agents&doi=10.1016%2Fj.bmcl.2009.10.135"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of dipiperidines as new antitubercular agents</span></div><div class="casAuthors">Bogatcheva, Elena; Hanrahan, Colleen; Chen, Ping; Gearhart, Jacqueline; Sacksteder, Katherine; Einck, Leo; Nacy, Carol; Protopopova, Marina</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">201-205</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">As part of our ongoing research effort to develop new therapeutics for treatment of tuberculosis (TB), we synthesized a combinatorial library of 10,358 compds. on solid support using a pool-and-split technique and tested the resulting compds. for activity against Mycobacterium tuberculosis.  Structure-activity relation (SAR) evaluation identified new compds. with antitubercular activity, including a novel hit series that is structurally unrelated to any existing antitubercular drugs, dipiperidines.  Dipiperidine representatives exhibited MIC values as low as 7.8 μM, the ability to induce promoter Rv0341 activated in response to cell wall biosynthesis inhibition, relatively low nonspecific cellular toxicity in the range of 30-162 μM, and log P values less than 4.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5KpxUHeC5irVg90H21EOLACvtfcHk0liXFWxcWQBzZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsF2jsb7M&md5=522927712851104a42a254391b322b2e</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.10.135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.10.135%26sid%3Dliteratum%253Aachs%26aulast%3DBogatcheva%26aufirst%3DE.%26aulast%3DHanrahan%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DGearhart%26aufirst%3DJ.%26aulast%3DSacksteder%26aufirst%3DK.%26aulast%3DEinck%26aufirst%3DL.%26aulast%3DNacy%26aufirst%3DC.%26aulast%3DProtopopova%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520dipiperidines%2520as%2520new%2520antitubercular%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D201%26epage%3D205%26doi%3D10.1016%2Fj.bmcl.2009.10.135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bogatcheva, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanrahan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikonenko, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de los Santos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einck, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Protopopova, M.</span></span> <span> </span><span class="NLM_article-title">Identification of SQ609 as a lead compound from a library of dipiperidines</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">5353</span>– <span class="NLM_lpage">5357</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.07.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmcl.2011.07.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=21807506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVKis73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=5353-5357&author=E.+Bogatchevaauthor=C.+Hanrahanauthor=B.+Nikonenkoauthor=G.+de+los+Santosauthor=V.+Reddyauthor=P.+Chenauthor=F.+Barbosaauthor=L.+Einckauthor=C.+Nacyauthor=M.+Protopopova&title=Identification+of+SQ609+as+a+lead+compound+from+a+library+of+dipiperidines&doi=10.1016%2Fj.bmcl.2011.07.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of SQ609 as a lead compound from a library of dipiperidines</span></div><div class="casAuthors">Bogatcheva, Elena; Hanrahan, Colleen; Nikonenko, Boris; de los Santos, Gladys; Reddy, Venkata; Chen, Ping; Barbosa, Francis; Einck, Leo; Nacy, Carol; Protopopova, Marina</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5353-5357</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">It was recently reported that compds. created around a dipiperidine scaffold demonstrated activity against Mycobacterium tuberculosis (Mtb).  To optimize the dipiperidine compd. series and to select a lead compd. to advance into preclin. studies, the structure-activity relationship (SAR) of the proprietary libraries was evaluated.  The (piperidin-4-ylmethyl)piperidine scaffold was an essential structural element required for antibacterial activity.  Based on SAR, a focused library of 313 new dipiperidines was synthesized to delineate addnl. structural features responsible for antitubercular activity.  Thirty new active compds. with MIC 10-20 μg/mL on Mtb were identified, but none was better than the original hits of this series, SQ609 (I), SQ614 (II), and SQ615 (III).  In Mtb-infected macrophages in vitro, SQ609 and SQ614 inhibited more than 90% of intracellular bacterial growth at 4 μg/mL; SQ615 was toxic to these cells.  In mice infected with Mtb, wt. loss was completely prevented by SQ609, but not SQ614, and SQ609 had a prolonged therapeutic effect, extended by 10-15 days, after cessation of therapy.  Based on in vitro and in vivo antitubercular activity, SQ609 was identified as the best-in-class dipiperidine compd. in the series.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDFxFAeNYceLVg90H21EOLACvtfcHk0liXFWxcWQBzZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVKis73M&md5=45b7703f67717ea6710e731d8e2c4a00</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.07.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.07.015%26sid%3Dliteratum%253Aachs%26aulast%3DBogatcheva%26aufirst%3DE.%26aulast%3DHanrahan%26aufirst%3DC.%26aulast%3DNikonenko%26aufirst%3DB.%26aulast%3Dde%2Blos%2BSantos%26aufirst%3DG.%26aulast%3DReddy%26aufirst%3DV.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DBarbosa%26aufirst%3DF.%26aulast%3DEinck%26aufirst%3DL.%26aulast%3DNacy%26aufirst%3DC.%26aulast%3DProtopopova%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520SQ609%2520as%2520a%2520lead%2520compound%2520from%2520a%2520library%2520of%2520dipiperidines%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D5353%26epage%3D5357%26doi%3D10.1016%2Fj.bmcl.2011.07.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bermudez, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolonoski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aralar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inderlied, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, L. S.</span></span> <span> </span><span class="NLM_article-title">Thiosemicarbazole (thiacetazone-like) compound with activity against mycobacterium avium in mice</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">2685</span>– <span class="NLM_lpage">2687</span>, <span class="refDoi"> DOI: 10.1128/AAC.47.8.2685-2687.2003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.47.8.2685-2687.2003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=12878542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlvFClsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2003&pages=2685-2687&author=L.+E.+Bermudezauthor=R.+Reynoldsauthor=P.+Kolonoskiauthor=P.+Aralarauthor=C.+B.+Inderliedauthor=L.+S.+Young&title=Thiosemicarbazole+%28thiacetazone-like%29+compound+with+activity+against+mycobacterium+avium+in+mice&doi=10.1128%2FAAC.47.8.2685-2687.2003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Thiosemicarbazole (thiacetazone-like) compound with activity against Mycobacterium avium in mice</span></div><div class="casAuthors">Bermudez, Luiz E.; Reynolds, Robert; Kolonoski, Peter; Aralar, Pricilla; Inderlied, Clark B.; Young, Lowell S.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2685-2687</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">In vitro screening of thiacetazone derivs. indicated that two derivs., SRI-286 and SRI-224, inhibited a panel of 25 Mycobacterium avium complex (MAC) isolates at concns. of 2 μg/mL or lower.  In mice, SRI-224 and thiacetazone had no significant activity against the MAC in livers and spleens, but treatment with SRI-286 resulted in significant redn. of bacterial loads in livers and spleens.  A combination of SRI-286 and moxifloxacin was significantly more active than single drug regimens in liver and spleen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwNxAxx5hlPLVg90H21EOLACvtfcHk0liXFWxcWQBzZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlvFClsLY%253D&md5=3c525cccb019b2d8d5246de1630934d2</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1128%2FAAC.47.8.2685-2687.2003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.47.8.2685-2687.2003%26sid%3Dliteratum%253Aachs%26aulast%3DBermudez%26aufirst%3DL.%2BE.%26aulast%3DReynolds%26aufirst%3DR.%26aulast%3DKolonoski%26aufirst%3DP.%26aulast%3DAralar%26aufirst%3DP.%26aulast%3DInderlied%26aufirst%3DC.%2BB.%26aulast%3DYoung%26aufirst%3DL.%2BS.%26atitle%3DThiosemicarbazole%2520%2528thiacetazone-like%2529%2520compound%2520with%2520activity%2520against%2520mycobacterium%2520avium%2520in%2520mice%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2003%26volume%3D47%26spage%3D2685%26epage%3D2687%26doi%3D10.1128%2FAAC.47.8.2685-2687.2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alahari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trivelli, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guérardel, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dover, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besra, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacchettini, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coxon, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, L.</span></span> <span> </span><span class="NLM_article-title">Thiacetazone, an antitubercular drug that inhibits cyclopropanation of cell wall mycolic acids in mycobacteria</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">e1343</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0001343</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1371%2Fjournal.pone.0001343" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=18094751" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=e1343&author=A.+Alahariauthor=X.+Trivelliauthor=Y.+Gu%C3%A9rardelauthor=L.+G.+Doverauthor=G.+S.+Besraauthor=J.+C.+Sacchettiniauthor=R.+C.+Reynoldsauthor=G.+D.+Coxonauthor=L.+Kremer&title=Thiacetazone%2C+an+antitubercular+drug+that+inhibits+cyclopropanation+of+cell+wall+mycolic+acids+in+mycobacteria&doi=10.1371%2Fjournal.pone.0001343"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0001343&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0001343%26sid%3Dliteratum%253Aachs%26aulast%3DAlahari%26aufirst%3DA.%26aulast%3DTrivelli%26aufirst%3DX.%26aulast%3DGu%25C3%25A9rardel%26aufirst%3DY.%26aulast%3DDover%26aufirst%3DL.%2BG.%26aulast%3DBesra%26aufirst%3DG.%2BS.%26aulast%3DSacchettini%26aufirst%3DJ.%2BC.%26aulast%3DReynolds%26aufirst%3DR.%2BC.%26aulast%3DCoxon%26aufirst%3DG.%2BD.%26aulast%3DKremer%26aufirst%3DL.%26atitle%3DThiacetazone%252C%2520an%2520antitubercular%2520drug%2520that%2520inhibits%2520cyclopropanation%2520of%2520cell%2520wall%2520mycolic%2520acids%2520in%2520mycobacteria%26jtitle%3DPLoS%2520One%26date%3D2007%26volume%3D2%26spage%3De1343%26doi%3D10.1371%2Fjournal.pone.0001343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naidu, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasarao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agnieszka, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ewa, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandra Sekhar, K. V.</span></span> <span> </span><span class="NLM_article-title">Seeking potent anti-tubercular agents: Design, synthesis, anti-tubercular activity and docking study of various ((triazoles/indole)-piperazin-1-yl/1,4-diazepan-1-yl)benzo[d]isoxazole derivatives</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2245</span>– <span class="NLM_lpage">2250</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.03.059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmcl.2016.03.059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=27020525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28XkvVyms7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=2245-2250&author=K.+M.+Naiduauthor=S.+Srinivasaraoauthor=N.+Agnieszkaauthor=A.+K.+Ewaauthor=M.+M.+Kumarauthor=K.+V.+Chandra+Sekhar&title=Seeking+potent+anti-tubercular+agents%3A+Design%2C+synthesis%2C+anti-tubercular+activity+and+docking+study+of+various+%28%28triazoles%2Findole%29-piperazin-1-yl%2F1%2C4-diazepan-1-yl%29benzo%5Bd%5Disoxazole+derivatives&doi=10.1016%2Fj.bmcl.2016.03.059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Seeking potent anti-tubercular agents: Design, synthesis, anti-tubercular activity and docking study of various ((triazoles/indole)-piperazin-1-yl/1,4-diazepan-1-yl)benzo[d]isoxazole derivatives</span></div><div class="casAuthors">Naidu, Kalaga Mahalakshmi; Srinivasarao, Singireddi; Agnieszka, Napiorkowska; Ewa, Augustynowicz-Kopec; Kumar, Muthyala Murali Krishna; Chandra Sekhar, Kondapalli Venkata Gowri</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2245-2250</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of thirty eight novel 3-(4-((substituted-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl/1,4-diazepan-1-yl)benzo[d]isoxazole and 1-(4-(benzo[d]isoxazol-3-yl)piperazin-1-yl/1,4-diazepan-1-yl)-2-(1H-indol-3-yl)substituted-1-one analogs were synthesized, characterized using various anal. techniques and evaluated for in vitro anti-tubercular activity against Mycobacterium tuberculosis H37Rv strain and two 'wild' strains Spec. 210 and Spec. 192.  The titled compds. exhibited min. inhibitory concn. (MIC) ranging from 6.16 to >200 μM.  Among the tested compds., 7i, 7y and 7z exhibited moderate activity (MIC = 24.03-29.19 μM) and 7j exhibited very good anti-tubercular activity (MIC = 6.16 μM).  Furthermore, 7i, 7j, 7y and 7z were found to be non-toxic against mouse macrophage cell lines when screened for toxicity.  All the synthesized compds. were docked to pantothenate synthetase enzyme site to know deferent binding interactions with the receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj6-cY7qwzobVg90H21EOLACvtfcHk0ljlb-vOXyXEYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XkvVyms7Y%253D&md5=13c9b8f771a5f406159a3cbe35dd932a</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.03.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.03.059%26sid%3Dliteratum%253Aachs%26aulast%3DNaidu%26aufirst%3DK.%2BM.%26aulast%3DSrinivasarao%26aufirst%3DS.%26aulast%3DAgnieszka%26aufirst%3DN.%26aulast%3DEwa%26aufirst%3DA.%2BK.%26aulast%3DKumar%26aufirst%3DM.%2BM.%26aulast%3DChandra%2BSekhar%26aufirst%3DK.%2BV.%26atitle%3DSeeking%2520potent%2520anti-tubercular%2520agents%253A%2520Design%252C%2520synthesis%252C%2520anti-tubercular%2520activity%2520and%2520docking%2520study%2520of%2520various%2520%2528%2528triazoles%252Findole%2529-piperazin-1-yl%252F1%252C4-diazepan-1-yl%2529benzo%255Bd%255Disoxazole%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D2245%26epage%3D2250%26doi%3D10.1016%2Fj.bmcl.2016.03.059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchard, J. S.</span></span> <span> </span><span class="NLM_article-title">Steady-state and pre-steady-state kinetic analysis of mycobacterium tuberculosis pantothenate synthetase</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">12904</span>– <span class="NLM_lpage">12912</span>, <span class="refDoi"> DOI: 10.1021/bi011522+</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi011522%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnt12qurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2001&pages=12904-12912&author=R.+Zhengauthor=J.+S.+Blanchard&title=Steady-state+and+pre-steady-state+kinetic+analysis+of+mycobacterium+tuberculosis+pantothenate+synthetase&doi=10.1021%2Fbi011522%2B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Steady-State and Pre-Steady-State Kinetic Analysis of Mycobacterium tuberculosis Pantothenate Synthetase</span></div><div class="casAuthors">Zheng, Renjian; Blanchard, John S.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">12904-12912</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pantothenate synthetase (EC 6.3.2.1), encoded by the panC gene, catalyzes the essential ATP-dependent condensation of D-pantoate and β-alanine to form pantothenate in bacteria, yeast and plants.  Pantothenate synthetase from Mycobacterium tuberculosis was expressed in E. coli, purified to homogeneity, and found to be a homodimer with a subunit mol. mass of 33 kDa.  Initial velocity, product, and dead-end inhibition studies showed the kinetic mechanism of pantothenate synthetase to be Bi Uni Uni Bi Ping Pong, with ATP binding followed by D-pantoate binding, release of PPi, binding of β-alanine, followed by the release of pantothenate and AMP.  Michaelis consts. were 0.13, 0.8, and 2.6 mM for D-pantoate, β-alanine, and ATP, resp., and the turnover no., kcat, was 3.4 s-1.  The formation of pantoyl adenylate, suggested as a key intermediate by the kinetic mechanism, was confirmed by 31P NMR spectroscopy of [18O]AMP produced from 18O transfer using [carboxyl-18O]pantoate.  Single-turnover reactions for the formation of pyrophosphate and pantothenate were detd. using rapid quench techniques, and indicated that the two half-reactions occurred with max. rates of 1.3 ± 0.3 and 2.6 ± 0.3 s-1, resp., consistent with pantoyl adenylate being a kinetically competent intermediate in the pantothenate synthetase reaction.  These data also suggest that both half-reactions are partially rate-limiting.  Reverse isotope exchange of [14C]-β-alanine into pantothenate in the presence of AMP was obsd., indicating the reversible formation of the pantoyl adenylate intermediate from products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6V5kK1UYOOrVg90H21EOLACvtfcHk0ljlb-vOXyXEYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnt12qurw%253D&md5=caae3b38e8ab3c2a6ae1ac0b265a749e</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1021%2Fbi011522%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi011522%252B%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DR.%26aulast%3DBlanchard%26aufirst%3DJ.%2BS.%26atitle%3DSteady-state%2520and%2520pre-steady-state%2520kinetic%2520analysis%2520of%2520mycobacterium%2520tuberculosis%2520pantothenate%2520synthetase%26jtitle%3DBiochemistry%26date%3D2001%26volume%3D40%26spage%3D12904%26epage%3D12912%26doi%3D10.1021%2Fbi011522%2B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karabanovich, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zemanová, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smutný, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Székely, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Šarkan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Centárová, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pávková, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Čonka, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Němeček, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolaříková, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vejsová, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vávrová, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klimešová, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hrabálek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pávek, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikušová, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roh, J.</span></span> <span> </span><span class="NLM_article-title">Development of 3,5-dinitrobenzylsulfanyl-1,3,4-oxadiazoles and thiadiazoles as selective antitubercular agents active against replicating and nonreplicating mycobacterium tuberculosis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2362</span>– <span class="NLM_lpage">2380</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00608</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00608" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjs1yqt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2362-2380&author=G.+Karabanovichauthor=J.+Zemanov%C3%A1author=T.+Smutn%C3%BDauthor=R.+Sz%C3%A9kelyauthor=M.+%C5%A0arkanauthor=I.+Cent%C3%A1rov%C3%A1author=A.+Vocatauthor=I.+P%C3%A1vkov%C3%A1author=P.+%C4%8Conkaauthor=J.+N%C4%9Bme%C4%8Dekauthor=J.+Stola%C5%99%C3%ADkov%C3%A1author=M.+Vejsov%C3%A1author=K.+V%C3%A1vrov%C3%A1author=V.+Klime%C5%A1ov%C3%A1author=A.+Hrab%C3%A1lekauthor=P.+P%C3%A1vekauthor=S.+T.+Coleauthor=K.+Miku%C5%A1ov%C3%A1author=J.+Roh&title=Development+of+3%2C5-dinitrobenzylsulfanyl-1%2C3%2C4-oxadiazoles+and+thiadiazoles+as+selective+antitubercular+agents+active+against+replicating+and+nonreplicating+mycobacterium+tuberculosis&doi=10.1021%2Facs.jmedchem.5b00608"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-oxadiazoles and Thiadiazoles as Selective Antitubercular Agents Active Against Replicating and Nonreplicating Mycobacterium tuberculosis</span></div><div class="casAuthors">Karabanovich, Galina; Zemanova, Julia; Smutny, Tomas; Szekely, Rita; Sarkan, Michal; Centarova, Ivana; Vocat, Anthony; Pavkova, Ivona; Conka, Patrik; Nemecek, Jan; Stolarikova, Jirina; Vejsova, Marcela; Vavrova, Katerina; Klimesova, Vera; Hrabalek, Alexandr; Pavek, Petr; Cole, Stewart T.; Mikusova, Katarina; Roh, Jaroslav</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2362-2380</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein, we report the discovery and structure-activity relationships of 5-substituted-2-[(3,5-dinitrobenzyl)sulfanyl]-1,3,4-oxadiazoles and 1,3,4-thiadiazoles as a new class of antituberculosis agents.  The majority of these compds. exhibited outstanding in vitro activity against Mycobacterium tuberculosis CNCTC My 331/88 and six multidrug-resistant clin. isolated strains of M. tuberculosis, with min. inhibitory concn. values as low as 0.03 μM (0.011-0.026 μg/mL).  The investigated compds. had a highly selective antimycobacterial effect because they showed no activity against the other bacteria or fungi tested in this study.  Furthermore, the investigated compds. exhibited low in vitro toxicities in four proliferating mammalian cell lines and in isolated primary human hepatocytes.  Several in vitro genotoxicity assays indicated that the selected compds. have no mutagenic activity.  The oxadiazole and thiadiazole derivs. with the most favorable activity/toxicity profiles also showed potency comparable to that of rifampicin against the nonreplicating streptomycin-starved M. tuberculosis 18b-Lux strain, and therefore, these derivs., are of particular interest.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgBb0Hpi3vOrVg90H21EOLACvtfcHk0lhdVeus0MA4iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjs1yqt7Y%253D&md5=788b65627cfd13854c699c08ae7aa756</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00608&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00608%26sid%3Dliteratum%253Aachs%26aulast%3DKarabanovich%26aufirst%3DG.%26aulast%3DZemanov%25C3%25A1%26aufirst%3DJ.%26aulast%3DSmutn%25C3%25BD%26aufirst%3DT.%26aulast%3DSz%25C3%25A9kely%26aufirst%3DR.%26aulast%3D%25C5%25A0arkan%26aufirst%3DM.%26aulast%3DCent%25C3%25A1rov%25C3%25A1%26aufirst%3DI.%26aulast%3DVocat%26aufirst%3DA.%26aulast%3DP%25C3%25A1vkov%25C3%25A1%26aufirst%3DI.%26aulast%3D%25C4%258Conka%26aufirst%3DP.%26aulast%3DN%25C4%259Bme%25C4%258Dek%26aufirst%3DJ.%26aulast%3DStola%25C5%2599%25C3%25ADkov%25C3%25A1%26aufirst%3DJ.%26aulast%3DVejsov%25C3%25A1%26aufirst%3DM.%26aulast%3DV%25C3%25A1vrov%25C3%25A1%26aufirst%3DK.%26aulast%3DKlime%25C5%25A1ov%25C3%25A1%26aufirst%3DV.%26aulast%3DHrab%25C3%25A1lek%26aufirst%3DA.%26aulast%3DP%25C3%25A1vek%26aufirst%3DP.%26aulast%3DCole%26aufirst%3DS.%2BT.%26aulast%3DMiku%25C5%25A1ov%25C3%25A1%26aufirst%3DK.%26aulast%3DRoh%26aufirst%3DJ.%26atitle%3DDevelopment%2520of%25203%252C5-dinitrobenzylsulfanyl-1%252C3%252C4-oxadiazoles%2520and%2520thiadiazoles%2520as%2520selective%2520antitubercular%2520agents%2520active%2520against%2520replicating%2520and%2520nonreplicating%2520mycobacterium%2520tuberculosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D2362%26epage%3D2380%26doi%3D10.1021%2Facs.jmedchem.5b00608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carette, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blondiaux, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willery, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lecat-Guillet, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lens, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wohlkönig, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wintjens, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soror, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frénois, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dirié, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villeret, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">England, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippens, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deprez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willand, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baulard, A. R.</span></span> <span> </span><span class="NLM_article-title">Structural activation of the transcriptional repressor EthR from mycobacterium tuberculosis by single amino acid change mimicking natural and synthetic ligands</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">3018</span>– <span class="NLM_lpage">3030</span>, <span class="refDoi"> DOI: 10.1093/nar/gkr1113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1093%2Fnar%2Fgkr1113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=22156370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38Xls1SntbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=3018-3030&author=X.+Caretteauthor=N.+Blondiauxauthor=E.+Willeryauthor=S.+Hoosauthor=N.+Lecat-Guilletauthor=Z.+Lensauthor=A.+Wohlk%C3%B6nigauthor=R.+Wintjensauthor=S.+H.+Sororauthor=F.+Fr%C3%A9noisauthor=B.+Diri%C3%A9author=V.+Villeretauthor=P.+Englandauthor=G.+Lippensauthor=B.+Deprezauthor=C.+Lochtauthor=N.+Willandauthor=A.+R.+Baulard&title=Structural+activation+of+the+transcriptional+repressor+EthR+from+mycobacterium+tuberculosis+by+single+amino+acid+change+mimicking+natural+and+synthetic+ligands&doi=10.1093%2Fnar%2Fgkr1113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Structural activation of the transcriptional repressor EthR from Mycobacterium tuberculosis by single amino acid change mimicking natural and synthetic ligands</span></div><div class="casAuthors">Carette, Xavier; Blondiaux, Nicolas; Willery, Eve; Hoos, Sylviane; Lecat-Guillet, Nathalie; Lens, Zoe; Wohlkoenig, Alexandre; Wintjens, Rene; Soror, Sameh H.; Frenois, Frederic; Dirie, Bertrand; Villeret, Vincent; England, Patrick; Lippens, Guy; Deprez, Benoit; Locht, Camille; Willand, Nicolas; Baulard, Alain R.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3018-3030</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Ethionamide is an antituberculous drug for the treatment of multidrug-resistant Mycobacterium tuberculosis.  This antibiotic requires activation by the monooxygenase EthA to exert its activity.  Prodn. of EthA is controlled by the transcriptional repressor EthR, a member of the TetR family.  The sensitivity of M. tuberculosis to ethionamide can be artificially enhanced using synthetic ligands of EthR that allosterically inactivate its DNA-binding activity.  Comparison of several structures of EthR co-crystd. with various ligands suggested that the structural reorganization of EthR resulting in its inactivation is controlled by a limited portion of the ligand-binding-pocket.  In silico simulation predicted that mutation G106W may mimic ligands.  X-ray crystallog. of variant G106W indeed revealed a protein structurally similar to ligand-bound EthR.  Surface plasmon resonance expts. established that this variant is unable to bind DNA, while thermal shift studies demonstrated that mutation G106W stabilizes EthR as strongly as ligands.  Proton NMR of the Me regions showed a lesser contribution of exchange broadening upon ligand binding, and the same quenched dynamics was obsd. in apo-variant G106W.  Altogether, we here show that the area surrounding Gly106 constitutes the mol. switch involved in the conformational reorganization of EthR.  These results also shed light on the mechanistic of ligand-induced allosterism controlling the DNA binding properties of TetR family repressors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphQGML1UonJLVg90H21EOLACvtfcHk0lhdVeus0MA4iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xls1SntbY%253D&md5=f13df06708193401f2ab1168023456a8</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkr1113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkr1113%26sid%3Dliteratum%253Aachs%26aulast%3DCarette%26aufirst%3DX.%26aulast%3DBlondiaux%26aufirst%3DN.%26aulast%3DWillery%26aufirst%3DE.%26aulast%3DHoos%26aufirst%3DS.%26aulast%3DLecat-Guillet%26aufirst%3DN.%26aulast%3DLens%26aufirst%3DZ.%26aulast%3DWohlk%25C3%25B6nig%26aufirst%3DA.%26aulast%3DWintjens%26aufirst%3DR.%26aulast%3DSoror%26aufirst%3DS.%2BH.%26aulast%3DFr%25C3%25A9nois%26aufirst%3DF.%26aulast%3DDiri%25C3%25A9%26aufirst%3DB.%26aulast%3DVilleret%26aufirst%3DV.%26aulast%3DEngland%26aufirst%3DP.%26aulast%3DLippens%26aufirst%3DG.%26aulast%3DDeprez%26aufirst%3DB.%26aulast%3DLocht%26aufirst%3DC.%26aulast%3DWilland%26aufirst%3DN.%26aulast%3DBaulard%26aufirst%3DA.%2BR.%26atitle%3DStructural%2520activation%2520of%2520the%2520transcriptional%2520repressor%2520EthR%2520from%2520mycobacterium%2520tuberculosis%2520by%2520single%2520amino%2520acid%2520change%2520mimicking%2520natural%2520and%2520synthetic%2520ligands%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2012%26volume%3D40%26spage%3D3018%26epage%3D3030%26doi%3D10.1093%2Fnar%2Fgkr1113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Willand, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dirie, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carette, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bifani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singhal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desroses, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroux, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willery, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathys, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deprez-Poulain, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delcroix, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frenois, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aumercier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villeret, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deprez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baulard, A. R.</span></span> <span> </span><span class="NLM_article-title">Synthetic EthR inhibitors boost antituberculous activity of ethionamide</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">537</span>– <span class="NLM_lpage">544</span>, <span class="refDoi"> DOI: 10.1038/nm.1950</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1038%2Fnm.1950" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=19412174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltlSrsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=537-544&author=N.+Willandauthor=B.+Dirieauthor=X.+Caretteauthor=P.+Bifaniauthor=A.+Singhalauthor=M.+Desrosesauthor=F.+Lerouxauthor=E.+Willeryauthor=V.+Mathysauthor=R.+Deprez-Poulainauthor=G.+Delcroixauthor=F.+Frenoisauthor=M.+Aumercierauthor=C.+Lochtauthor=V.+Villeretauthor=B.+Deprezauthor=A.+R.+Baulard&title=Synthetic+EthR+inhibitors+boost+antituberculous+activity+of+ethionamide&doi=10.1038%2Fnm.1950"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic EthR inhibitors boost antituberculous activity of ethionamide</span></div><div class="casAuthors">Willand, Nicolas; Dirie, Bertrand; Carette, Xavier; Bifani, Pablo; Singhal, Amit; Desroses, Matthieu; Leroux, Florence; Willery, Eve; Mathys, Vanessa; Deprez-Poulain, Rebecca; Delcroix, Guy; Frenois, Frederic; Aumercier, Marc; Locht, Camille; Villeret, Vincent; Deprez, Benoit; Baulard, Alain R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">537-544</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The side effects assocd. with tuberculosis therapy bring with them the risk of noncompliance and subsequent drug resistance.  Increasing the therapeutic index of antituberculosis drugs should thus improve treatment effectiveness.  Several antituberculosis compds. require in situ metabolic activation to become inhibitory.  Various thiocarbamide-contg. drugs, including ethionamide, are activated by the mycobacterial monooxygenase EthA, the prodn. of which is controlled by the transcriptional repressor EthR.  Here we identify drug-like inhibitors of EthR that boost the bioactivation of ethionamide.  Compds. designed and screened for their capacity to inhibit EthR-DNA interaction were co-crystd. with EthR.  We exploited the three-dimensional structures of the complexes for the synthesis of improved analogs that boosted the ethionamide potency in culture more than tenfold.  In Mycobacterium tuberculosis-infected mice, one of these analogs, BDM31343, enabled a substantially reduced dose of ethionamide to lessen the mycobacterial load as efficiently as the conventional higher-dose treatment.  This provides proof of concept that inhibiting EthR improves the therapeutic index of thiocarbamide derivs., which should prompt reconsideration of their use as first-line drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgknfO8azsTrVg90H21EOLACvtfcHk0lhdVeus0MA4iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltlSrsLk%253D&md5=a119c8e00d9cd41bfa34c2e056e4a1ad</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1038%2Fnm.1950&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.1950%26sid%3Dliteratum%253Aachs%26aulast%3DWilland%26aufirst%3DN.%26aulast%3DDirie%26aufirst%3DB.%26aulast%3DCarette%26aufirst%3DX.%26aulast%3DBifani%26aufirst%3DP.%26aulast%3DSinghal%26aufirst%3DA.%26aulast%3DDesroses%26aufirst%3DM.%26aulast%3DLeroux%26aufirst%3DF.%26aulast%3DWillery%26aufirst%3DE.%26aulast%3DMathys%26aufirst%3DV.%26aulast%3DDeprez-Poulain%26aufirst%3DR.%26aulast%3DDelcroix%26aufirst%3DG.%26aulast%3DFrenois%26aufirst%3DF.%26aulast%3DAumercier%26aufirst%3DM.%26aulast%3DLocht%26aufirst%3DC.%26aulast%3DVilleret%26aufirst%3DV.%26aulast%3DDeprez%26aufirst%3DB.%26aulast%3DBaulard%26aufirst%3DA.%2BR.%26atitle%3DSynthetic%2520EthR%2520inhibitors%2520boost%2520antituberculous%2520activity%2520of%2520ethionamide%26jtitle%3DNat.%2520Med.%26date%3D2009%26volume%3D15%26spage%3D537%26epage%3D544%26doi%3D10.1038%2Fnm.1950" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karabanovich, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Němeček, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valášková, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carazo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konečná, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolaříková, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hrabálek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavliš, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pávek, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vávrová, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klimešová, V.</span></span> <span> </span><span class="NLM_article-title">S-substituted 3,5-dinitrophenyl 1,3,4-oxadiazole-2-thiols and tetrazole-5-thiols as highly efficient antitubercular agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">369</span>– <span class="NLM_lpage">383</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.11.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.ejmech.2016.11.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=27907875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFKjsb3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2017&pages=369-383&author=G.+Karabanovichauthor=J.+N%C4%9Bme%C4%8Dekauthor=L.+Val%C3%A1%C5%A1kov%C3%A1author=A.+Carazoauthor=K.+Kone%C4%8Dn%C3%A1author=J.+Stola%C5%99%C3%ADkov%C3%A1author=A.+Hrab%C3%A1lekauthor=O.+Pavli%C5%A1author=P.+P%C3%A1vekauthor=K.+V%C3%A1vrov%C3%A1author=J.+Rohauthor=V.+Klime%C5%A1ov%C3%A1&title=S-substituted+3%2C5-dinitrophenyl+1%2C3%2C4-oxadiazole-2-thiols+and+tetrazole-5-thiols+as+highly+efficient+antitubercular+agents&doi=10.1016%2Fj.ejmech.2016.11.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">S-substituted 3,5-dinitrophenyl 1,3,4-oxadiazole-2-thiols and tetrazole-5-thiols as highly efficient antitubercular agents</span></div><div class="casAuthors">Karabanovich, Galina; Nemecek, Jan; Valaskova, Lenka; Carazo, Alejandro; Konecna, Klara; Stolarikova, Jirina; Hrabalek, Alexandr; Pavlis, Oto; Pavek, Petr; Vavrova, Katerina; Roh, Jaroslav; Klimesova, Vera</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">369-383</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Two new classes of antitubercular agents, namely 5-alkylsulfanyl-1-(3,5-dinitrophenyl)-1H-tetrazoles and 2-alkylsulfanyl-5-(3,5-dinitrophenyl)-1,3,4-oxadiazoles, and their structure-activity relationships are described.  These compds. possessed excellent activity against Mycobacterium tuberculosis, including the clin. isolated multidrug (MDR) and extensively drug-resistant (XDR) strains, with no cross resistance with first or second-line anti-TB drugs.  The min. inhibitory concn. (MIC) values of the most promising compds. reached 0.03 μM.  Furthermore, these compds. had a highly selective antimycobacterial effect because they were completely inactive against 4 gram pos. and 4 gram neg. bacteria and eight fungal strains and had low in vitro toxicity for four mammalian cell lines, including hepatic cell lines HepG2 and HuH7.  Although the structure-activity relationship study showed that the presence of two nitro groups is highly beneficial for antimycobacterial activity, the analogs with a trifluoromethyl group instead of one of the nitro groups maintained a high antimycobacterial activity, which indicates the possibility for further structural optimization of this class of antitubercular agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1nJC9MkunPLVg90H21EOLACvtfcHk0lgBN7tOQLqy_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFKjsb3I&md5=6d432e1f8b9bbaaab823de2cb053f1cd</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.11.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.11.041%26sid%3Dliteratum%253Aachs%26aulast%3DKarabanovich%26aufirst%3DG.%26aulast%3DN%25C4%259Bme%25C4%258Dek%26aufirst%3DJ.%26aulast%3DVal%25C3%25A1%25C5%25A1kov%25C3%25A1%26aufirst%3DL.%26aulast%3DCarazo%26aufirst%3DA.%26aulast%3DKone%25C4%258Dn%25C3%25A1%26aufirst%3DK.%26aulast%3DStola%25C5%2599%25C3%25ADkov%25C3%25A1%26aufirst%3DJ.%26aulast%3DHrab%25C3%25A1lek%26aufirst%3DA.%26aulast%3DPavli%25C5%25A1%26aufirst%3DO.%26aulast%3DP%25C3%25A1vek%26aufirst%3DP.%26aulast%3DV%25C3%25A1vrov%25C3%25A1%26aufirst%3DK.%26aulast%3DRoh%26aufirst%3DJ.%26aulast%3DKlime%25C5%25A1ov%25C3%25A1%26aufirst%3DV.%26atitle%3DS-substituted%25203%252C5-dinitrophenyl%25201%252C3%252C4-oxadiazole-2-thiols%2520and%2520tetrazole-5-thiols%2520as%2520highly%2520efficient%2520antitubercular%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D126%26spage%3D369%26epage%3D383%26doi%3D10.1016%2Fj.ejmech.2016.11.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bellale, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VB, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambady, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravishankar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiteaker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morayya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guptha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raichurkar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awasthy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Achar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vachaspati, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandodkar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterji, M.</span></span> <span> </span><span class="NLM_article-title">Diarylthiazole: An antimycobacterial scaffold potentially targeting PrrB-PrrA two-component system</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">6572</span>– <span class="NLM_lpage">6582</span>, <span class="refDoi"> DOI: 10.1021/jm500833f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500833f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVKnsLbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=6572-6582&author=E.+Bellaleauthor=M.+Naikauthor=V.+VBauthor=A.+Ambadyauthor=A.+Narayanauthor=S.+Ravishankarauthor=V.+Ramachandranauthor=P.+Kaurauthor=R.+McLaughlinauthor=J.+Whiteakerauthor=S.+Morayyaauthor=S.+Gupthaauthor=S.+Sharmaauthor=A.+Raichurkarauthor=D.+Awasthyauthor=V.+Acharauthor=P.+Vachaspatiauthor=B.+Bandodkarauthor=M.+Pandaauthor=M.+Chatterji&title=Diarylthiazole%3A+An+antimycobacterial+scaffold+potentially+targeting+PrrB-PrrA+two-component+system&doi=10.1021%2Fjm500833f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Diarylthiazole: an antimycobacterial scaffold potentially targeting PrrB-PrrA two-component system</span></div><div class="casAuthors">Bellale, Eknath; Naik, Maruti; Varun, V. B.; Ambady, Anisha; Narayan, Ashwini; Ravishankar, Sudha; Ramachandran, Vasanthi; Kaur, Parvinder; McLaughlin, Robert; Whiteaker, James; Morayya, Sapna; Guptha, Supreeth; Sharma, Sreevalli; Raichurkar, Anandkumar; Awasthy, Disha; Achar, Vijayshree; Vachaspati, Prakash; Bandodkar, Balachandra; Panda, Manoranjan; Chatterji, Monalisa</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6572-6582</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Diarylthiazole (DAT), a hit from diversity screening, was found to have potent antimycobacterial activity against Mycobacterium tuberculosis (Mtb).  In a systematic medicinal chem. exploration, the authors demonstrated chem. opportunities to optimize the potency and physicochem. properties.  The effort led to more than 10 compds. with submicromolar MICs and desirable physicochem. properties.  The potent antimycobacterial activity, in conjunction with low mol. wt., made the series an attractive lead (antibacterial ligand efficiency (ALE) >0.4).  The series exhibited excellent bactericidal activity and was active against drug-sensitive and resistant Mtb.  Mutational anal. showed that mutations in prrB impart resistance to DAT compds. but not to ref. drugs tested.  The sensor kinase PrrB belongs to the PrrBA two component system and is potentially the target for DAT.  PrrBA is a conserved, essential regulatory mechanism in Mtb and has been shown to have a role in virulence and metabolic adaptation to stress.  Hence, DATs provide an opportunity to understand a completely new target system for antimycobacterial drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_40E8zTrM7bVg90H21EOLACvtfcHk0lgBN7tOQLqy_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVKnsLbF&md5=f60841419f946e5f6b471a01d04256db</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1021%2Fjm500833f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500833f%26sid%3Dliteratum%253Aachs%26aulast%3DBellale%26aufirst%3DE.%26aulast%3DNaik%26aufirst%3DM.%26aulast%3DVB%26aufirst%3DV.%26aulast%3DAmbady%26aufirst%3DA.%26aulast%3DNarayan%26aufirst%3DA.%26aulast%3DRavishankar%26aufirst%3DS.%26aulast%3DRamachandran%26aufirst%3DV.%26aulast%3DKaur%26aufirst%3DP.%26aulast%3DMcLaughlin%26aufirst%3DR.%26aulast%3DWhiteaker%26aufirst%3DJ.%26aulast%3DMorayya%26aufirst%3DS.%26aulast%3DGuptha%26aufirst%3DS.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DRaichurkar%26aufirst%3DA.%26aulast%3DAwasthy%26aufirst%3DD.%26aulast%3DAchar%26aufirst%3DV.%26aulast%3DVachaspati%26aufirst%3DP.%26aulast%3DBandodkar%26aufirst%3DB.%26aulast%3DPanda%26aufirst%3DM.%26aulast%3DChatterji%26aufirst%3DM.%26atitle%3DDiarylthiazole%253A%2520An%2520antimycobacterial%2520scaffold%2520potentially%2520targeting%2520PrrB-PrrA%2520two-component%2520system%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D6572%26epage%3D6582%26doi%3D10.1021%2Fjm500833f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haydel, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malhotra, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelison, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark-Curtiss, J. E.</span></span> <span> </span><span class="NLM_article-title">The prrab two-component system is essential for mycobacterium tuberculosis viability and is induced under nitrogen-limiting conditions</span>. <i>J. Bacteriol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>194</i></span>,  <span class="NLM_fpage">354</span>– <span class="NLM_lpage">361</span>, <span class="refDoi"> DOI: 10.1128/JB.06258-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FJB.06258-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=22081401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsFWgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=194&publication_year=2012&pages=354-361&author=S.+E.+Haydelauthor=V.+Malhotraauthor=G.+L.+Cornelisonauthor=J.+E.+Clark-Curtiss&title=The+prrab+two-component+system+is+essential+for+mycobacterium+tuberculosis+viability+and+is+induced+under+nitrogen-limiting+conditions&doi=10.1128%2FJB.06258-11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">The prrAB two-component system is essential for Mycobacterium tuberculosis viability and is induced under nitrogen-limiting conditions</span></div><div class="casAuthors">Haydel, Shelley E.; Malhotra, Vandana; Cornelison, Garrett L.; Clark-Curtiss, Josephine E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Bacteriology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">194</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">354-361</span>CODEN:
                <span class="NLM_cas:coden">JOBAAY</span>;
        ISSN:<span class="NLM_cas:issn">0021-9193</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The Mycobacterium tuberculosis prrA-prrB (Rv0903c-Rv0902c) two-component regulatory system is expressed during intracellular growth in human macrophages and is required for early intracellular multiplication in murine macrophages, suggesting its importance in establishing infection.  To better understand the function of the prrA-prrB two-component system, the authors defined the transcriptional characteristics of the prrA and prrB genes during exponential and stationary growth and upon exposure to different environmental stresses and attempted to generate a prrA-prrB deletion mutant.  The prrA and prrB genes constitute an operon and are cotranscribed during logarithmic growth, with transcriptional levels decreasing in stationary phase and during hypoxia.  Despite the transcriptional differences, PrrA protein levels remained relatively stable throughout growth and in hypoxia.  Under conditions of nitrogen limitation, prrAB transcription was induced, while acidic pH stress and carbon starvation did not significantly alter transcript levels.  Deletion of the prrAB operon on the chromosome of M. tuberculosis H37Rv occurred only in the presence of an episomal copy of the prrAB genes, indicating that this two-component system is essential for viability.  Characterization of the prrAB locus in M. tuberculosis Mt21D3, a previously described prrA transposon mutant, revealed that this strain is not a true prrA knockout mutant.  Rather, Tn5367 transposon insertion into the prrA promoter only decreased prrA and prrB transcription and PrrA levels in Mt21D3 compared to those in the parental Mt103 clin. strain.  These data provide the first report describing the essentiality of the M. tuberculosis prrAB two-component system and reveal insights into its potential role in mycobacterial growth and metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCTv3wSydiJbVg90H21EOLACvtfcHk0ljWJFmFpIjalw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsFWgsQ%253D%253D&md5=18128c76baa288230bbb3afc247b1f84</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1128%2FJB.06258-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJB.06258-11%26sid%3Dliteratum%253Aachs%26aulast%3DHaydel%26aufirst%3DS.%2BE.%26aulast%3DMalhotra%26aufirst%3DV.%26aulast%3DCornelison%26aufirst%3DG.%2BL.%26aulast%3DClark-Curtiss%26aufirst%3DJ.%2BE.%26atitle%3DThe%2520prrab%2520two-component%2520system%2520is%2520essential%2520for%2520mycobacterium%2520tuberculosis%2520viability%2520and%2520is%2520induced%2520under%2520nitrogen-limiting%2520conditions%26jtitle%3DJ.%2520Bacteriol.%26date%3D2012%26volume%3D194%26spage%3D354%26epage%3D361%26doi%3D10.1128%2FJB.06258-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ewann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pethe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mielcarek, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ensergueix, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gicquel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Supply, P.</span></span> <span> </span><span class="NLM_article-title">Transient requirement of the prra-prrb two-component system for early intracellular multiplication of mycobacterium tuberculosis</span>. <i>Infect. Immun.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">2256</span>– <span class="NLM_lpage">2263</span>, <span class="refDoi"> DOI: 10.1128/IAI.70.5.2256-2263.2002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FIAI.70.5.2256-2263.2002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=11953357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD38XjtFKgtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2002&pages=2256-2263&author=F.+Ewannauthor=M.+Jacksonauthor=K.+Petheauthor=A.+Cooperauthor=N.+Mielcarekauthor=D.+Ensergueixauthor=B.+Gicquelauthor=C.+Lochtauthor=P.+Supply&title=Transient+requirement+of+the+prra-prrb+two-component+system+for+early+intracellular+multiplication+of+mycobacterium+tuberculosis&doi=10.1128%2FIAI.70.5.2256-2263.2002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Transient requirement of the PrrA-PrrB two-component system for early intracellular multiplication of Mycobacterium tuberculosis</span></div><div class="casAuthors">Ewann, Fanny; Jackson, Mary; Pethe, Kevin; Cooper, Andrea; Mielcarek, Nathalie; Ensergueix, Danielle; Gicquel, Brigitte; Locht, Camille; Supply, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Infection and Immunity</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2256-2263</span>CODEN:
                <span class="NLM_cas:coden">INFIBR</span>;
        ISSN:<span class="NLM_cas:issn">0019-9567</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Adaptive regulation of gene expression in response to environmental changes is a general property of bacterial pathogens.  By screening an ordered transposon mutagenesis library of Mycobacterium tuberculosis, we have identified three mutants contg. a transposon in the coding sequence or in the 5' regions of genes coding for two-component signal transduction systems (trcS, regX3, prrA).  The intracellular multiplication capacity of the three mutants was investigated in mouse bone marrow-derived macrophages.  Only the prrA mutant showed a defect in intracellular growth during the early phase of infection, and this defect was fully reverted when the mutant was complemented with prrA-prrB wild-type copies.  The mutant phenotype was transient, as after 1 wk this strain recovered full growth capacity to reach levels similar to that of the wild type at day 9.  Moreover, a transient induction of prrA promoter activity was obsd. during the initial phase of macrophage infection, as shown by a prrA promoter-gfp fusion in M. bovis BCG infecting the mouse macrophages.  The concordant transience of the prrA mutant phenotype and prrA promoter activity indicates that the PrrA-PrrB two-component system is involved in the environmental adaptation of M. tuberculosis, specifically in an early phase of the intracellular growth, and that, similar to other facultative intracellular parasites, M. tuberculosis can use genes temporarily required at different stages in the course of macrophage infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLGtYTsJ114LVg90H21EOLACvtfcHk0ljWJFmFpIjalw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjtFKgtLk%253D&md5=70536176046716cfde10afbce8e77f46</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1128%2FIAI.70.5.2256-2263.2002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FIAI.70.5.2256-2263.2002%26sid%3Dliteratum%253Aachs%26aulast%3DEwann%26aufirst%3DF.%26aulast%3DJackson%26aufirst%3DM.%26aulast%3DPethe%26aufirst%3DK.%26aulast%3DCooper%26aufirst%3DA.%26aulast%3DMielcarek%26aufirst%3DN.%26aulast%3DEnsergueix%26aufirst%3DD.%26aulast%3DGicquel%26aufirst%3DB.%26aulast%3DLocht%26aufirst%3DC.%26aulast%3DSupply%26aufirst%3DP.%26atitle%3DTransient%2520requirement%2520of%2520the%2520prra-prrb%2520two-component%2520system%2520for%2520early%2520intracellular%2520multiplication%2520of%2520mycobacterium%2520tuberculosis%26jtitle%3DInfect.%2520Immun.%26date%3D2002%26volume%3D70%26spage%3D2256%26epage%3D2263%26doi%3D10.1128%2FIAI.70.5.2256-2263.2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pieroni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franzblau, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costantino, G.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and investigation on the structure-activity relationships of n-substituted 2-aminothiazole derivatives as antitubercular agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">26</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.ejmech.2013.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=24333612" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1ylt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2014&pages=26-34&author=M.+Pieroniauthor=B.+Wanauthor=S.+Choauthor=S.+G.+Franzblauauthor=G.+Costantino&title=Design%2C+synthesis+and+investigation+on+the+structure-activity+relationships+of+n-substituted+2-aminothiazole+derivatives+as+antitubercular+agents&doi=10.1016%2Fj.ejmech.2013.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents</span></div><div class="casAuthors">Pieroni, Marco; Wan, Baojie; Cho, Sanghyun; Franzblau, Scott G.; Costantino, Gabriele</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">26-34</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Tuberculosis (TB) is one of the deadliest infectious diseases of all times, and its recent resurgence is a supreme matter of concern.  Co-infection with HIV and, in particular, the continuous isolation of new resistant strains, makes the discovery of novel anti-TB agents a strategic priority.  The research of novel agents should be driven by the accessibility of the synthetic procedure and, in particular, by the lack of cross-resistance with the drugs already marketed.  Moreover, in order to shorten the duration of the therapy, and therefore decrease the rate of resistance, these mols. should be active also against the nonreplicating persistent form (NRP-TB) of the infection.  The availability of an inhouse small library of compds. prompted us to investigate their anti-TB activity.  Two compds., embodying a 2-aminothiazole scaffold, were found to possess a certain inhibitory activity toward Mycobacterium tuberculosis H37Rv, and therefore a medicinal chem. campaign was initiated in order to increase the activity of the hit compds. and, esp., construct a plausible body of structure-activity relationships.  The potency of the hit compd. was successfully improved, and, much more importantly, some of the mols. synthesized were found to be active toward the persistent phenotype, and, also, toward a panel of resistant strains.  These findings encourage further investigations around this interesting antitubercular chemotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpcmctR8lRNrVg90H21EOLACvtfcHk0ljWJFmFpIjalw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1ylt70%253D&md5=254a604abcde3a94c6cc406ac56a29b8</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DPieroni%26aufirst%3DM.%26aulast%3DWan%26aufirst%3DB.%26aulast%3DCho%26aufirst%3DS.%26aulast%3DFranzblau%26aufirst%3DS.%2BG.%26aulast%3DCostantino%26aufirst%3DG.%26atitle%3DDesign%252C%2520synthesis%2520and%2520investigation%2520on%2520the%2520structure-activity%2520relationships%2520of%2520n-substituted%25202-aminothiazole%2520derivatives%2520as%2520antitubercular%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D72%26spage%3D26%26epage%3D34%26doi%3D10.1016%2Fj.ejmech.2013.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Landge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullick, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagalapur, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neres, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subbulakshmi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murugan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fellows, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humnabadkar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahadevaswamy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vachaspati, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudrapatna, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awasthy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sambandamurthy, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pojer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balganesh, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugarkar, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandodkar, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, V.</span></span> <span> </span><span class="NLM_article-title">Discovery of benzothiazoles as antimycobacterial agents: Synthesis, structure-activity relationships and binding studies with mycobacterium tuberculosis decaprenylphosphoryl-β-d-ribose 2′-oxidase</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">7694</span>– <span class="NLM_lpage">7710</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2015.11.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmc.2015.11.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=26643218" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFerur3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=7694-7710&author=S.+Landgeauthor=A.+B.+Mullickauthor=K.+Nagalapurauthor=J.+Neresauthor=V.+Subbulakshmiauthor=K.+Muruganauthor=A.+Ghoshauthor=C.+Sadlerauthor=M.+D.+Fellowsauthor=V.+Humnabadkarauthor=J.+Mahadevaswamyauthor=P.+Vachaspatiauthor=S.+Sharmaauthor=P.+Kaurauthor=M.+Mallyaauthor=S.+Rudrapatnaauthor=D.+Awasthyauthor=V.+K.+Sambandamurthyauthor=F.+Pojerauthor=S.+T.+Coleauthor=T.+S.+Balganeshauthor=B.+G.+Ugarkarauthor=V.+Balasubramanianauthor=B.+S.+Bandodkarauthor=M.+Pandaauthor=V.+Ramachandran&title=Discovery+of+benzothiazoles+as+antimycobacterial+agents%3A+Synthesis%2C+structure-activity+relationships+and+binding+studies+with+mycobacterium+tuberculosis+decaprenylphosphoryl-%CE%B2-d-ribose+2%E2%80%B2-oxidase&doi=10.1016%2Fj.bmc.2015.11.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of benzothiazoles as antimycobacterial agents: Synthesis, structure-activity relationships and binding studies with Mycobacterium tuberculosis decaprenylphosphoryl-β-D-ribose 2'-oxidase</span></div><div class="casAuthors">Landge, Sudhir; Mullick, Amrita B.; Nagalapur, Kavitha; Neres, Joao; Subbulakshmi, Venkita; Murugan, Kannan; Ghosh, Anirban; Sadler, Claire; Fellows, Mick D.; Humnabadkar, Vaishali; Mahadevaswamy, Jyothi; Vachaspati, Prakash; Sharma, Sreevalli; Kaur, Parvinder; Mallya, Meenakshi; Rudrapatna, Suresh; Awasthy, Disha; Sambandamurthy, Vasan K.; Pojer, Florence; Cole, Stewart T.; Balganesh, Tanjore S.; Ugarkar, Bheemarao G.; Balasubramanian, V.; Bandodkar, Balachandra S.; Panda, Manoranjan; Ramachandran, Vasanthi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7694-7710</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We report the discovery of benzothiazoles, a novel anti-mycobacterial series, identified from a whole cell based screening campaign.  Benzothiazoles exert their bactericidal activity against Mycobacterium tuberculosis (Mtb) through potent inhibition of decaprenylphosphoryl-β-D-ribose 2'-oxidase (DprE1), the key enzyme involved in arabinogalactan synthesis.  Specific target linkage and mode of binding were established using co-crystn. and protein mass spectrometry studies.  Most importantly, the current study provides insights on the utilization of systematic medicinal chem. approaches to mitigate safety liabilities while improving potency during progression from an initial genotoxic hit, the benzothiazole N-oxides (BTOs) to the lead-like AMES neg., crowded benzothiazoles (cBTs).  These findings offer opportunities for development of safe clin. candidates against tuberculosis.  The design strategy adopted could find potential application in discovery of safe drugs in other therapy areas too.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS7rEts75x7bVg90H21EOLACvtfcHk0linAJ-CPfZS8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFerur3E&md5=cea6212afa6aee18530c45717f98b5c6</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.11.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.11.017%26sid%3Dliteratum%253Aachs%26aulast%3DLandge%26aufirst%3DS.%26aulast%3DMullick%26aufirst%3DA.%2BB.%26aulast%3DNagalapur%26aufirst%3DK.%26aulast%3DNeres%26aufirst%3DJ.%26aulast%3DSubbulakshmi%26aufirst%3DV.%26aulast%3DMurugan%26aufirst%3DK.%26aulast%3DGhosh%26aufirst%3DA.%26aulast%3DSadler%26aufirst%3DC.%26aulast%3DFellows%26aufirst%3DM.%2BD.%26aulast%3DHumnabadkar%26aufirst%3DV.%26aulast%3DMahadevaswamy%26aufirst%3DJ.%26aulast%3DVachaspati%26aufirst%3DP.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DKaur%26aufirst%3DP.%26aulast%3DMallya%26aufirst%3DM.%26aulast%3DRudrapatna%26aufirst%3DS.%26aulast%3DAwasthy%26aufirst%3DD.%26aulast%3DSambandamurthy%26aufirst%3DV.%2BK.%26aulast%3DPojer%26aufirst%3DF.%26aulast%3DCole%26aufirst%3DS.%2BT.%26aulast%3DBalganesh%26aufirst%3DT.%2BS.%26aulast%3DUgarkar%26aufirst%3DB.%2BG.%26aulast%3DBalasubramanian%26aufirst%3DV.%26aulast%3DBandodkar%26aufirst%3DB.%2BS.%26aulast%3DPanda%26aufirst%3DM.%26aulast%3DRamachandran%26aufirst%3DV.%26atitle%3DDiscovery%2520of%2520benzothiazoles%2520as%2520antimycobacterial%2520agents%253A%2520Synthesis%252C%2520structure-activity%2520relationships%2520and%2520binding%2520studies%2520with%2520mycobacterium%2520tuberculosis%2520decaprenylphosphoryl-%25CE%25B2-d-ribose%25202%25E2%2580%25B2-oxidase%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D7694%26epage%3D7710%26doi%3D10.1016%2Fj.bmc.2015.11.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mahajan, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhawale, S. C.</span></span> <span> </span><span class="NLM_article-title">Linked pyridinyl-thiadiazoles: Design and synthesis as potential candidate for treatment of xdr and mdr tuberculosis</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">243</span>– <span class="NLM_lpage">248</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.07.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.ejmech.2015.07.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=26280920" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlCitr%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2015&pages=243-248&author=N.+S.+Mahajanauthor=S.+C.+Dhawale&title=Linked+pyridinyl-thiadiazoles%3A+Design+and+synthesis+as+potential+candidate+for+treatment+of+xdr+and+mdr+tuberculosis&doi=10.1016%2Fj.ejmech.2015.07.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Linked pyridinyl-thiadiazoles: Design and synthesis as potential candidate for treatment of XDR and MDR tuberculosis</span></div><div class="casAuthors">Mahajan, Niranjan S.; Dhawale, S. C.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">243-248</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Design and synthesis of linked pyridinyl-thiadiazoles I (Ar = C6H5, CH2C6H5, 2-ClC6H4, etc.) and II which are specifically potent against several strains and isolates of TB is reported.  The hit compd. II (Ar = 4-ClC6H4) has also proved to be active against almost 25 clin. isolates comparable to marketed anti-TB agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGor7M-8k2TOCbVg90H21EOLACvtfcHk0linAJ-CPfZS8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlCitr%252FI&md5=b1ad7c926e1aec3d88066a306f56cfa1</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.07.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.07.039%26sid%3Dliteratum%253Aachs%26aulast%3DMahajan%26aufirst%3DN.%2BS.%26aulast%3DDhawale%26aufirst%3DS.%2BC.%26atitle%3DLinked%2520pyridinyl-thiadiazoles%253A%2520Design%2520and%2520synthesis%2520as%2520potential%2520candidate%2520for%2520treatment%2520of%2520xdr%2520and%2520mdr%2520tuberculosis%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D102%26spage%3D243%26epage%3D248%26doi%3D10.1016%2Fj.ejmech.2015.07.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoener zu
Bentrup, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKinney, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacchettini, J. C.</span></span> <span> </span><span class="NLM_article-title">Structure of isocitrate lyase, a persistence factor of mycobacterium tuberculosis</span>. <i>Nat. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">663</span>– <span class="NLM_lpage">668</span>, <span class="refDoi"> DOI: 10.1038/77964</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1038%2F77964" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10932251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD3cXls1yqtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2000&pages=663-668&author=V.+Sharmaauthor=S.+Sharmaauthor=K.+Hoener+zu%0ABentrupauthor=J.+D.+McKinneyauthor=D.+G.+Russellauthor=W.+R.+Jacobsauthor=J.+C.+Sacchettini&title=Structure+of+isocitrate+lyase%2C+a+persistence+factor+of+mycobacterium+tuberculosis&doi=10.1038%2F77964"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of isocitrate lyase, a persistence factor of Mycobacterium tuberculosis</span></div><div class="casAuthors">Sharma, Vivek; Sharma, Sujata; Hoener zu Bentrup, Kerstin; McKinney, John D.; Russell, David G.; Jacobs, William R., Jr.; Sacchettini, James C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural Biology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">663-668</span>CODEN:
                <span class="NLM_cas:coden">NSBIEW</span>;
        ISSN:<span class="NLM_cas:issn">1072-8368</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">Isocitrate lyase (I) plays a pivotal role in the persistence of M. tuberculosis in mice by sustaining intracellular infection in inflammatory macrophages.  I allows net C gain by diverting acetyl-CoA from β-oxidn. of fatty acids into the glyoxylate shunt pathway.  Given its potential as a drug target against persistent infections, the authors solved its structure without ligands and in complex with 2 inhibitors, 3-bromopyruvate and 3-nitropropionate.  Covalent modification of an active site residue, Cys-191, by the inhibitor, 3-bromopyruvate, trapped the enzyme in a catalytic conformation with the active site completely inaccessible to solvent.  The structure of a C191S mutant of the enzyme with the inhibitor, 3-nitropropionate, provided further insight into the reaction mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9eCFXK4I3NrVg90H21EOLACvtfcHk0linAJ-CPfZS8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXls1yqtbg%253D&md5=9404e0c254b3247bcb2b3e0b4ca573fe</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1038%2F77964&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F77964%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DV.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DHoener%2Bzu%2BBentrup%26aufirst%3DK.%26aulast%3DMcKinney%26aufirst%3DJ.%2BD.%26aulast%3DRussell%26aufirst%3DD.%2BG.%26aulast%3DJacobs%26aufirst%3DW.%2BR.%26aulast%3DSacchettini%26aufirst%3DJ.%2BC.%26atitle%3DStructure%2520of%2520isocitrate%2520lyase%252C%2520a%2520persistence%2520factor%2520of%2520mycobacterium%2520tuberculosis%26jtitle%3DNat.%2520Struct.%2520Biol.%26date%3D2000%26volume%3D7%26spage%3D663%26epage%3D668%26doi%3D10.1038%2F77964" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Sullivan, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangadharam, P. R.</span></span> <span> </span><span class="NLM_article-title">Antimycobacterial activities of riminophenazines</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">615</span>– <span class="NLM_lpage">623</span>, <span class="refDoi"> DOI: 10.1093/jac/43.5.615</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1093%2Fjac%2F43.5.615" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10382882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADyaK1MXjsV2is7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=1999&pages=615-623&author=V.+M.+Reddyauthor=J.+F.+O%E2%80%99Sullivanauthor=P.+R.+Gangadharam&title=Antimycobacterial+activities+of+riminophenazines&doi=10.1093%2Fjac%2F43.5.615"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Antimycobacterial activities of riminophenazines</span></div><div class="casAuthors">Reddy, Venkata M.; O'Sullivan, John F.; Gangadharam, Pattisapu R. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">615-623</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review with 73 refs.  Riminophenazines were specifically developed as drugs active against Mycobacterium tuberculosis but extensive research over several decades has shown that these compds. are also active against many other mycobacterial infections, particularly those caused by Mycobacterium leprae and the Mycobacterium avium complex (MAC).  Clofazimine, the lead compd. in this series, is included in the regimens that are approved by the WHO for the treatment of leprosy and has contributed significantly to the control of that disease, particularly that caused by dapsone-resistant bacteria.  Despite early problems, clofazimine has shown clin. efficacy in tuberculosis, in particular that caused by multiple drug resistant strains.  Clofazimine does not induce resistance and also inhibits emergence of resistance to isoniazid in M. tuberculosis.  The efficacy of clofazimine against MAC is more varied and the availability of better drugs has limited its use.  Newer riminophenazines, such as B746 and B4157, not only showed increased anti-mycobacterial activity but also produced less skin pigmentation, which is the main drawback of this group of compds.  The most important virtues of riminophenazines, such as intracellular accumulation in mononuclear phagocytic cells, anti-inflammatory activity, a low incidence of drug resistance and slow metabolic elimination, make them attractive candidates for the treatment of mycobacterial infections.  It is essential, however, to investigate the newer analogs clin., while continuing the pursuit of alternate candidates that demonstrate higher anti-mycobacterial activity and lower rates of skin pigmentation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-TqcKj2elQ7Vg90H21EOLACvtfcHk0lii0N8MqOH1Yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjsV2is7o%253D&md5=518c8ddbd4d717a3f8eb6da3e40245af</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1093%2Fjac%2F43.5.615&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252F43.5.615%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DV.%2BM.%26aulast%3DO%25E2%2580%2599Sullivan%26aufirst%3DJ.%2BF.%26aulast%3DGangadharam%26aufirst%3DP.%2BR.%26atitle%3DAntimycobacterial%2520activities%2520of%2520riminophenazines%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D1999%26volume%3D43%26spage%3D615%26epage%3D623%26doi%3D10.1093%2Fjac%2F43.5.615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arbiser, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moschella, S. L.</span></span> <span> </span><span class="NLM_article-title">Clofazimine: A review of its medical uses and mechanisms of action</span>. <i>J. Am. Acad. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">241</span>– <span class="NLM_lpage">247</span>, <span class="refDoi"> DOI: 10.1016/0190-9622(95)90134-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2F0190-9622%2895%2990134-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=7829710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A280%3ADyaK2M7jtVOrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1995&pages=241-247&author=J.+L.+Arbiserauthor=S.+L.+Moschella&title=Clofazimine%3A+A+review+of+its+medical+uses+and+mechanisms+of+action&doi=10.1016%2F0190-9622%2895%2990134-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Clofazimine: a review of its medical uses and mechanisms of action</span></div><div class="casAuthors">Arbiser J L; Moschella S L</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Academy of Dermatology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">2 Pt 1</span>),
    <span class="NLM_cas:pages">241-7</span>
        ISSN:<span class="NLM_cas:issn">0190-9622</span>.
    </div><div class="casAbstract">Clofazimine has been in clinical use for almost 40 years, but little is known of its mechanism of action.  The primary indication for clofazimine is multibacillary leprosy, but it is useful in several infectious and noninfectious diseases, such as typical myocobacterial infections, rhinoscleroma, pyoderma gangrenosum, necrobiosis lipoidica, severe acne, pustular psoriasis, and discoid lupus erythematosus.  Postulated mechanisms of action include intercalation of clofazimine with bacterial DNA and increasing levels of cellular phospholipase A2.  Clinical experience, possible mechanisms of action, and side effects of clofazimine are summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ_D4nBnsIGjHtlzo9xastyfW6udTcc2ebNuTQmpWBlsLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2M7jtVOrsA%253D%253D&md5=797e62c41ab2db6eb93b4979c5ee0919</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1016%2F0190-9622%2895%2990134-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0190-9622%252895%252990134-5%26sid%3Dliteratum%253Aachs%26aulast%3DArbiser%26aufirst%3DJ.%2BL.%26aulast%3DMoschella%26aufirst%3DS.%2BL.%26atitle%3DClofazimine%253A%2520A%2520review%2520of%2520its%2520medical%2520uses%2520and%2520mechanisms%2520of%2520action%26jtitle%3DJ.%2520Am.%2520Acad.%2520Dermatol.%26date%3D1995%26volume%3D32%26spage%3D241%26epage%3D247%26doi%3D10.1016%2F0190-9622%2895%2990134-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marley, G. M.</span></span> <span> </span><span class="NLM_article-title">The mode of action of clofazimine DNA binding studies</span>. <i>Int. J. Lepr. Other Mycobact. Dis.</i> <span class="NLM_year" style="font-weight: bold;">1976</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">134</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=945233" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A280%3ADyaE283ht1ertg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=1976&pages=133-134&author=N.+E.+Morrisonauthor=G.+M.+Marley&title=The+mode+of+action+of+clofazimine+DNA+binding+studies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">The mode of action of clofazimine DNA binding studies</span></div><div class="casAuthors">Morrison N E; Marley G M</div><div class="citationInfo"><span class="NLM_cas:title">International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association</span>
        (<span class="NLM_cas:date">1976</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">133-4</span>
        ISSN:<span class="NLM_cas:issn">0148-916X</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRqUJxcgluj_4NpW7w2tapOfW6udTcc2ebNuTQmpWBlsLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE283ht1ertg%253D%253D&md5=a697238eb114b18e1666c95658376694</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMorrison%26aufirst%3DN.%2BE.%26aulast%3DMarley%26aufirst%3DG.%2BM.%26atitle%3DThe%2520mode%2520of%2520action%2520of%2520clofazimine%2520DNA%2520binding%2520studies%26jtitle%3DInt.%2520J.%2520Lepr.%2520Other%2520Mycobact.%2520Dis.%26date%3D1976%26volume%3D44%26spage%3D133%26epage%3D134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nair, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okello, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangu, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gund, M. G.</span></span> <span> </span><span class="NLM_article-title">A novel molecule with notable activity against multi-drug resistant tuberculosis</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1269</span>– <span class="NLM_lpage">1273</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.01.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmcl.2015.01.050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=25677656" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslSnurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=1269-1273&author=V.+Nairauthor=M.+O.+Okelloauthor=N.+K.+Manguauthor=B.+I.+Seoauthor=M.+G.+Gund&title=A+novel+molecule+with+notable+activity+against+multi-drug+resistant+tuberculosis&doi=10.1016%2Fj.bmcl.2015.01.050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">A novel molecule with notable activity against multi-drug resistant tuberculosis</span></div><div class="casAuthors">Nair, Vasu; Okello, Maurice O.; Mangu, Naveen K.; Seo, Byung I.; Gund, Machhindra G.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1269-1273</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Multi-drug resistant tuberculosis (MDR-TB) is emerging as a serious global health problem, which has been elevated through co-infection involving HIV and MDR-Mtb.  The discovery of new compds. with anti-MDR TB efficacy and favorable metab. profiles is an important scientific challenge.  Using computational biol. and ligand docking data, we have conceived a multifunctional mol., 2, as a potential anti-MDR TB agent.  This compd. was produced through a multi-step synthesis.  It exhibited significant in vitro activity against MDR-TB (MIC 1.56 μg/mL) and its half-life (t1/2) in human liver microsomes was 14.4 h.  The metabolic profiles of compd. 2 with respect to human cytochrome P 450 (CYP) and uridine 5'-diphospho-glucuronosyltransferase (UGT) isoenzymes were favorable.  Compd. 2 also had relatively low in vitro cytotoxicity in uninfected macrophages.  It displayed synergistic behavior against MDR-TB in combination with PA-824.  Interestingly, compd. 2 also displayed in vitro anti-HIV activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEX8rZ7_17v7Vg90H21EOLACvtfcHk0lgN3a1yFLWOww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslSnurY%253D&md5=de6e679bf3e1e668ff33b61d459922db</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.01.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.01.050%26sid%3Dliteratum%253Aachs%26aulast%3DNair%26aufirst%3DV.%26aulast%3DOkello%26aufirst%3DM.%2BO.%26aulast%3DMangu%26aufirst%3DN.%2BK.%26aulast%3DSeo%26aufirst%3DB.%2BI.%26aulast%3DGund%26aufirst%3DM.%2BG.%26atitle%3DA%2520novel%2520molecule%2520with%2520notable%2520activity%2520against%2520multi-drug%2520resistant%2520tuberculosis%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D1269%26epage%3D1273%26doi%3D10.1016%2Fj.bmcl.2015.01.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van der Westhuyzen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winks, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyle, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gessner, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soares de Melo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Kock, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njoroge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunschwig, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirgel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Helden, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seldon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moosa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arista, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manjunatha, U. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Street, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chibale, K.</span></span> <span> </span><span class="NLM_article-title">Pyrrolo[3,4-c]pyridine-1,3(2h)-diones: A novel antimycobacterial class targeting mycobacterial respiration</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">9371</span>– <span class="NLM_lpage">9381</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01542</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01542" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslykurbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=9371-9381&author=R.+van+der+Westhuyzenauthor=S.+Winksauthor=C.+R.+Wilsonauthor=G.+A.+Boyleauthor=R.+K.+Gessnerauthor=C.+Soares+de+Meloauthor=D.+Taylorauthor=C.+de+Kockauthor=M.+Njorogeauthor=C.+Brunschwigauthor=N.+Lawrenceauthor=S.+P.+Raoauthor=F.+Sirgelauthor=P.+van+Heldenauthor=R.+Seldonauthor=A.+Moosaauthor=D.+F.+Warnerauthor=L.+Aristaauthor=U.+H.+Manjunathaauthor=P.+W.+Smithauthor=L.+J.+Streetauthor=K.+Chibale&title=Pyrrolo%5B3%2C4-c%5Dpyridine-1%2C3%282h%29-diones%3A+A+novel+antimycobacterial+class+targeting+mycobacterial+respiration&doi=10.1021%2Facs.jmedchem.5b01542"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrrolo[3,4-c]pyridine-1,3(2H)-diones: A Novel Antimycobacterial Class Targeting Mycobacterial Respiration</span></div><div class="casAuthors">van der Westhuyzen, Renier; Winks, Susan; Wilson, Colin R.; Boyle, Grant A.; Gessner, Richard K.; Soares de Melo, Candice; Taylor, Dale; de Kock, Carmen; Njoroge, Mathew; Brunschwig, Christel; Lawrence, Nina; Rao, Srinivasa P. S.; Sirgel, Frederick; van Helden, Paul; Seldon, Ronnett; Moosa, Atica; Warner, Digby F.; Arista, Luca; Manjunatha, Ujjini H.; Smith, Paul W.; Street, Leslie J.; Chibale, Kelly</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9371-9381</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">High-throughput screening of a library of small polar mols. against Mycobacterium tuberculosis led to the identification of a phthalimide-contg. ester hit compd. I, which was optimized for metabolic stability by replacing the ester moiety with a Me oxadiazole bioisostere.  A route utilizing polymer-supported reagents was designed and executed to explore structure-activity relationships with respect to the N-benzyl substituent, leading to compds. with nanomolar activity.  The front runner compd. II from these studies was well tolerated in mice.  A M. tuberculosis cytochrome bd oxidase deletion mutant (ΔcydKO) was hyper-susceptible to compds. from this series, and a strain carrying a single point mutation in qcrB, the gene encoding a subunit of the menaquinol cytochrome c oxidoreductase, was resistant to compds. in this series.  In combination, these observations indicate that this novel class of antimycobacterial compds. inhibits the cytochrome bc1 complex, a validated drug target in M. tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3Us_9IMcDi7Vg90H21EOLACvtfcHk0lgN3a1yFLWOww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslykurbO&md5=f4f32ca20ad5a8095be6bbf8dac5830a</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01542%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2Bder%2BWesthuyzen%26aufirst%3DR.%26aulast%3DWinks%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DC.%2BR.%26aulast%3DBoyle%26aufirst%3DG.%2BA.%26aulast%3DGessner%26aufirst%3DR.%2BK.%26aulast%3DSoares%2Bde%2BMelo%26aufirst%3DC.%26aulast%3DTaylor%26aufirst%3DD.%26aulast%3Dde%2BKock%26aufirst%3DC.%26aulast%3DNjoroge%26aufirst%3DM.%26aulast%3DBrunschwig%26aufirst%3DC.%26aulast%3DLawrence%26aufirst%3DN.%26aulast%3DRao%26aufirst%3DS.%2BP.%26aulast%3DSirgel%26aufirst%3DF.%26aulast%3Dvan%2BHelden%26aufirst%3DP.%26aulast%3DSeldon%26aufirst%3DR.%26aulast%3DMoosa%26aufirst%3DA.%26aulast%3DWarner%26aufirst%3DD.%2BF.%26aulast%3DArista%26aufirst%3DL.%26aulast%3DManjunatha%26aufirst%3DU.%2BH.%26aulast%3DSmith%26aufirst%3DP.%2BW.%26aulast%3DStreet%26aufirst%3DL.%2BJ.%26aulast%3DChibale%26aufirst%3DK.%26atitle%3DPyrrolo%255B3%252C4-c%255Dpyridine-1%252C3%25282h%2529-diones%253A%2520A%2520novel%2520antimycobacterial%2520class%2520targeting%2520mycobacterial%2520respiration%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D9371%26epage%3D9381%26doi%3D10.1021%2Facs.jmedchem.5b01542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pissinate, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villela, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues-Junior, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giacobbo, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grams, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbadi, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trindade, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roesler Nery, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonan, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Back, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campos, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basso, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machado, P.</span></span> <span> </span><span class="NLM_article-title">2-(quinolin-4-yloxy)acetamides are active against drug-susceptible and drug-resistant mycobacterium tuberculosis strains</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">239</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00324</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00324" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28Xmslersg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=235-239&author=K.+Pissinateauthor=A.+D.+Villelaauthor=V.+Rodrigues-Juniorauthor=B.+C.+Giacobboauthor=E.+S.+Gramsauthor=B.+L.+Abbadiauthor=R.+V.+Trindadeauthor=L.+Roesler+Neryauthor=C.+D.+Bonanauthor=D.+F.+Backauthor=M.+M.+Camposauthor=L.+A.+Bassoauthor=D.+S.+Santosauthor=P.+Machado&title=2-%28quinolin-4-yloxy%29acetamides+are+active+against+drug-susceptible+and+drug-resistant+mycobacterium+tuberculosis+strains&doi=10.1021%2Facsmedchemlett.5b00324"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">2-(Quinolin-4-yloxy)acetamides Are Active against Drug-Susceptible and Drug-Resistant Mycobacterium tuberculosis Strains</span></div><div class="casAuthors">Pissinate, Kenia; Villela, Anne Drumond; Rodrigues-Junior, Valnes; Giacobbo, Bruno Couto; Grams, Estevao Silveira; Abbadi, Bruno Lopes; Trindade, Rogerio Valim; Roesler Nery, Laura; Bonan, Carla Denise; Back, Davi Fernando; Campos, Maria Martha; Basso, Luiz Augusto; Santos, Diogenes Santiago; Machado, Pablo</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">235-239</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">2-(Quinolin-4-yloxy)acetamides have been described as potent in vitro inhibitors of Mycobacterium tuberculosis growth.  Herein, addnl. chem. modifications of lead compds. were carried out, yielding highly potent antitubercular agents I [R1 = H, MeO; R2 = Ph, Bn, 1-naphthyl, etc.] with min. inhibitory concn. (MIC) values as low as 0.05 μM.  Further, the synthesized compds. were active against drug-resistant strains and were devoid of apparent toxicity to Vero and HaCat cells (IC50s ≥ 20 μM).  In addn., the 2-(quinolin-4-yloxy)acetamides showed intracellular activity against the bacilli in infected macrophages with action similar to rifampin, low risk of drug-drug interactions, and no sign of cardiac toxicity in zebrafish (Danio rerio) at 1 and 5 μM.  Therefore, these data indicate that this class of compds. may furnish candidates for future development to, hopefully, provide drug alternatives for tuberculosis treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlDUeT5b7fVrVg90H21EOLACvtfcHk0lgN3a1yFLWOww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xmslersg%253D%253D&md5=c2c4ff3de3ecc4fc49449b769707bfd7</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00324%26sid%3Dliteratum%253Aachs%26aulast%3DPissinate%26aufirst%3DK.%26aulast%3DVillela%26aufirst%3DA.%2BD.%26aulast%3DRodrigues-Junior%26aufirst%3DV.%26aulast%3DGiacobbo%26aufirst%3DB.%2BC.%26aulast%3DGrams%26aufirst%3DE.%2BS.%26aulast%3DAbbadi%26aufirst%3DB.%2BL.%26aulast%3DTrindade%26aufirst%3DR.%2BV.%26aulast%3DRoesler%2BNery%26aufirst%3DL.%26aulast%3DBonan%26aufirst%3DC.%2BD.%26aulast%3DBack%26aufirst%3DD.%2BF.%26aulast%3DCampos%26aufirst%3DM.%2BM.%26aulast%3DBasso%26aufirst%3DL.%2BA.%26aulast%3DSantos%26aufirst%3DD.%2BS.%26aulast%3DMachado%26aufirst%3DP.%26atitle%3D2-%2528quinolin-4-yloxy%2529acetamides%2520are%2520active%2520against%2520drug-susceptible%2520and%2520drug-resistant%2520mycobacterium%2520tuberculosis%2520strains%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D235%26epage%3D239%26doi%3D10.1021%2Facsmedchemlett.5b00324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giacobbo, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pissinate, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues-Junior, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villela, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grams, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbadi, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subtil, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperotto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trindade, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Back, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campos, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basso, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machado, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, D. S.</span></span> <span> </span><span class="NLM_article-title">New insights into the sar and drug combination synergy of 2-(quinolin-4-yloxy)acetamides against mycobacterium tuberculosis</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">491</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.11.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.ejmech.2016.11.048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=27914363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFymu7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2017&pages=491-501&author=B.+C.+Giacobboauthor=K.+Pissinateauthor=V.+Rodrigues-Juniorauthor=A.+D.+Villelaauthor=E.+S.+Gramsauthor=B.+L.+Abbadiauthor=F.+T.+Subtilauthor=N.+Sperottoauthor=R.+V.+Trindadeauthor=D.+F.+Backauthor=M.+M.+Camposauthor=L.+A.+Bassoauthor=P.+Machadoauthor=D.+S.+Santos&title=New+insights+into+the+sar+and+drug+combination+synergy+of+2-%28quinolin-4-yloxy%29acetamides+against+mycobacterium+tuberculosis&doi=10.1016%2Fj.ejmech.2016.11.048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">New insights into the SAR and drug combination synergy of 2-(quinolin-4-yloxy)acetamides against Mycobacterium tuberculosis</span></div><div class="casAuthors">Giacobbo, Bruno Couto; Pissinate, Kenia; Rodrigues-Junior, Valnes; Villela, Anne Drumond; Grams, Estevao Silveira; Abbadi, Bruno Lopes; Subtil, Fernanda Teixeira; Sperotto, Nathalia; Trindade, Rogerio Valim; Back, Davi Fernando; Campos, Maria Martha; Basso, Luiz Augusto; Machado, Pablo; Santos, Diogenes Santiago</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">491-501</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">2-(Quinolin-4-yloxy)acetamides have been described as potent and selective in vitro inhibitors of Mycobacterium tuberculosis (Mtb) growth.  Herein, a new series of optimized compds. were found to demonstrate highly potent antitubercular activity, with min. inhibitory concn. (MIC) values against drug-susceptible and drug-resistant Mycobacterium tuberculosis strains in the submicromolar range.  Furthermore, the most active compds. had no apparent toxicity to mammalian cells, and they showed intracellular activities similar to those of isoniazid and rifampin in a macrophage model of Mtb infection.  Use of the checkerboard method to investigate the assocn. profiles of lead compds. with first- and second-line antituberculosis drugs showed that 2-(quinolin-4-yloxy)acetamides have a synergistic effect with rifampin.  Ultimately, the good permeability, moderate rates of metab. and low risk of drug-drug interactions displayed by some of the synthesized compds. indicate that 2-(quinolin-4-yloxy)acetamides may yield candidates to use in the development of novel alternative therapeutics for tuberculosis treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQ1LRu8KJr37Vg90H21EOLACvtfcHk0liLBO2RaV-cWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFymu7rL&md5=fd8b8186ded825b2158940a08959da6a</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.11.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.11.048%26sid%3Dliteratum%253Aachs%26aulast%3DGiacobbo%26aufirst%3DB.%2BC.%26aulast%3DPissinate%26aufirst%3DK.%26aulast%3DRodrigues-Junior%26aufirst%3DV.%26aulast%3DVillela%26aufirst%3DA.%2BD.%26aulast%3DGrams%26aufirst%3DE.%2BS.%26aulast%3DAbbadi%26aufirst%3DB.%2BL.%26aulast%3DSubtil%26aufirst%3DF.%2BT.%26aulast%3DSperotto%26aufirst%3DN.%26aulast%3DTrindade%26aufirst%3DR.%2BV.%26aulast%3DBack%26aufirst%3DD.%2BF.%26aulast%3DCampos%26aufirst%3DM.%2BM.%26aulast%3DBasso%26aufirst%3DL.%2BA.%26aulast%3DMachado%26aufirst%3DP.%26aulast%3DSantos%26aufirst%3DD.%2BS.%26atitle%3DNew%2520insights%2520into%2520the%2520sar%2520and%2520drug%2520combination%2520synergy%2520of%25202-%2528quinolin-4-yloxy%2529acetamides%2520against%2520mycobacterium%2520tuberculosis%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D126%26spage%3D491%26epage%3D501%26doi%3D10.1016%2Fj.ejmech.2016.11.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Phummarin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boshoff, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiles, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copp, B. R.</span></span> <span> </span><span class="NLM_article-title">Sar and identification of 2-(quinolin-4-yloxy)acetamides as Mycobacterium tuberculosis cytochrome bc1 inhibitors</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">2122</span>– <span class="NLM_lpage">2127</span>, <span class="refDoi"> DOI: 10.1039/C6MD00236F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1039%2FC6MD00236F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=28337336" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlyks7zM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=2122-2127&author=N.+Phummarinauthor=H.+I.+Boshoffauthor=P.+S.+Tsangauthor=J.+Daltonauthor=S.+Wilesauthor=C.+E.+Barryauthor=B.+R.+Copp&title=Sar+and+identification+of+2-%28quinolin-4-yloxy%29acetamides+as+Mycobacterium+tuberculosis+cytochrome+bc1+inhibitors&doi=10.1039%2FC6MD00236F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">SAR and identification of 2-(quinolin-4-yloxy)acetamides as Mycobacterium tuberculosis cytochrome bc1 inhibitors</span></div><div class="casAuthors">Phummarin, Narisa; Boshoff, Helena I.; Tsang, Patricia S.; Dalton, James; Wiles, Siouxsie; Barry 3rd, Clifton E.; Copp, Brent R.</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2122-2127</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A previous phenotypic screen by GSK identified 2-(quinolin-4-yloxy)acetamides as potent growth inhibitors of Mycobacterium tuberculosis (Mtb).  We report the results of a preliminary structure-activity relationship (SAR) study of the compd. class which has yielded more potent inhibitors.  An Mtb cytochrome bd oxidase deletion mutant (cydKO) was found to be hypersensitive to most members of the compd. library, while strains carrying single-nucleotide polymorphisms of the qcrB gene, which encodes a subunit of the menaquinol cytochrome c oxidoreductase (bc1) complex, were resistant to the library.  These results identify that the 2-(quinolin-4-yloxy)acetamide class of Mtb growth inhibitors can be added to the growing no. of scaffolds that target the M. tuberculosis bc1 complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5mJG3TCn8TLVg90H21EOLACvtfcHk0liLBO2RaV-cWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlyks7zM&md5=410c379517a035079e01dafd2bbcf744</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1039%2FC6MD00236F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6MD00236F%26sid%3Dliteratum%253Aachs%26aulast%3DPhummarin%26aufirst%3DN.%26aulast%3DBoshoff%26aufirst%3DH.%2BI.%26aulast%3DTsang%26aufirst%3DP.%2BS.%26aulast%3DDalton%26aufirst%3DJ.%26aulast%3DWiles%26aufirst%3DS.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26aulast%3DCopp%26aufirst%3DB.%2BR.%26atitle%3DSar%2520and%2520identification%2520of%25202-%2528quinolin-4-yloxy%2529acetamides%2520as%2520Mycobacterium%2520tuberculosis%2520cytochrome%2520bc1%2520inhibitors%26jtitle%3DMedChemComm%26date%3D2016%26volume%3D7%26spage%3D2122%26epage%3D2127%26doi%3D10.1039%2FC6MD00236F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humnabadkar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tantry, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guptha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panduga, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manjrekar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jena, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koushik, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shanbhag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jatheendranath, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manjunatha, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorai, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bathula, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudrapatna, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Achar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambady, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegde, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahadevaswamy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sambandamurthy, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awasthy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravishankar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madhavapeddi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prabhakar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saralaya, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterji, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiteaker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarelli, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riccardi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasca, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binda, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neres, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Signorino-Gelo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKinney, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shandil, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tommasi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosagrahara, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavanagh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinesh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghorpade, S. R.</span></span> <span> </span><span class="NLM_article-title">4-aminoquinolone piperidine amides: Noncovalent inhibitors of DprE1 with long residence time and potent antimycobacterial activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5419</span>– <span class="NLM_lpage">5434</span>, <span class="refDoi"> DOI: 10.1021/jm5005978</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5005978" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2cXos1Wqt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5419-5434&author=M.+Naikauthor=V.+Humnabadkarauthor=S.+J.+Tantryauthor=M.+Pandaauthor=A.+Narayanauthor=S.+Gupthaauthor=V.+Pandugaauthor=P.+Manjrekarauthor=L.+K.+Jenaauthor=K.+Koushikauthor=G.+Shanbhagauthor=S.+Jatheendranathauthor=M.+R.+Manjunathaauthor=G.+Goraiauthor=C.+Bathulaauthor=S.+Rudrapatnaauthor=V.+Acharauthor=S.+Sharmaauthor=A.+Ambadyauthor=N.+Hegdeauthor=J.+Mahadevaswamyauthor=P.+Kaurauthor=V.+K.+Sambandamurthyauthor=D.+Awasthyauthor=C.+Narayanauthor=S.+Ravishankarauthor=P.+Madhavapeddiauthor=J.+Reddyauthor=K.+Prabhakarauthor=R.+Saralayaauthor=M.+Chatterjiauthor=J.+Whiteakerauthor=B.+McLaughlinauthor=L.+R.+Chiarelliauthor=G.+Riccardiauthor=M.+R.+Pascaauthor=C.+Bindaauthor=J.+Neresauthor=N.+Dharauthor=F.+Signorino-Geloauthor=J.+D.+McKinneyauthor=V.+Ramachandranauthor=R.+Shandilauthor=R.+Tommasiauthor=P.+S.+Iyerauthor=S.+Narayananauthor=V.+Hosagraharaauthor=S.+Kavanaghauthor=N.+Dineshauthor=S.+R.+Ghorpade&title=4-aminoquinolone+piperidine+amides%3A+Noncovalent+inhibitors+of+DprE1+with+long+residence+time+and+potent+antimycobacterial+activity&doi=10.1021%2Fjm5005978"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">4-Aminoquinolone Piperidine Amides: Noncovalent Inhibitors of DprE1 with Long Residence Time and Potent Antimycobacterial Activity</span></div><div class="casAuthors">Naik, Maruti; Humnabadkar, Vaishali; Tantry, Subramanyam J.; Panda, Manoranjan; Narayan, Ashwini; Guptha, Supreeth; Panduga, Vijender; Manjrekar, Praveena; Jena, Lalit kumar; Koushik, Krishna; Shanbhag, Gajanan; Jatheendranath, Sandesh; Manjunatha, M. R.; Gorai, Gopinath; Bathula, Chandramohan; Rudrapatna, Suresh; Achar, Vijayashree; Sharma, Sreevalli; Ambady, Anisha; Hegde, Naina; Mahadevaswamy, Jyothi; Kaur, Parvinder; Sambandamurthy, Vasan K.; Awasthy, Disha; Narayan, Chandan; Ravishankar, Sudha; Madhavapeddi, Prashanti; Reddy, Jitendar; Prabhakar, K. R.; Saralaya, Ramanatha; Chatterji, Monalisa; Whiteaker, James; McLaughlin, Bob; Chiarelli, Laurent R.; Riccardi, Giovanna; Pasca, Maria Rosalia; Binda, Claudia; Neres, Joao; Dhar, Neeraj; Signorino-Gelo, Francois; McKinney, John D.; Ramachandran, Vasanthi; Shandil, Radha; Tommasi, Ruben; Iyer, Pravin S.; Narayanan, Shridhar; Hosagrahara, Vinayak; Kavanagh, Stefan; Dinesh, Neela; Ghorpade, Sandeep R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5419-5434</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">4-Aminoquinolone piperidine amides (AQs) were identified as a novel scaffold starting from a whole cell screen, with potent cidality on Mycobacterium tuberculosis (Mtb).  Evaluation of the min. inhibitory concns., followed by whole genome sequencing of mutants raised against AQs, identified decaprenylphosphoryl-β-D-ribose 2'-epimerase (DprE1) as the primary target responsible for the antitubercular activity.  Mass spectrometry and enzyme kinetic studies indicated that AQs are noncovalent, reversible inhibitors of DprE1 with slow on rates and long residence times of ∼100 min on the enzyme.  In general, AQs have excellent leadlike properties and good in vitro secondary pharmacol. profile.  Although the scaffold started off as a single active compd. with moderate potency from the whole cell screen, structure-activity relationship optimization of the scaffold led to compds. with potent DprE1 inhibition (IC50 < 10 nM) along with potent cellular activity (MIC = 60 nM) against Mtb.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo427Eycvs4I7Vg90H21EOLACvtfcHk0ljfb5yxdvVK6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXos1Wqt7g%253D&md5=05e9a7f75679397a124088023762fe20</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1021%2Fjm5005978&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5005978%26sid%3Dliteratum%253Aachs%26aulast%3DNaik%26aufirst%3DM.%26aulast%3DHumnabadkar%26aufirst%3DV.%26aulast%3DTantry%26aufirst%3DS.%2BJ.%26aulast%3DPanda%26aufirst%3DM.%26aulast%3DNarayan%26aufirst%3DA.%26aulast%3DGuptha%26aufirst%3DS.%26aulast%3DPanduga%26aufirst%3DV.%26aulast%3DManjrekar%26aufirst%3DP.%26aulast%3DJena%26aufirst%3DL.%2BK.%26aulast%3DKoushik%26aufirst%3DK.%26aulast%3DShanbhag%26aufirst%3DG.%26aulast%3DJatheendranath%26aufirst%3DS.%26aulast%3DManjunatha%26aufirst%3DM.%2BR.%26aulast%3DGorai%26aufirst%3DG.%26aulast%3DBathula%26aufirst%3DC.%26aulast%3DRudrapatna%26aufirst%3DS.%26aulast%3DAchar%26aufirst%3DV.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DAmbady%26aufirst%3DA.%26aulast%3DHegde%26aufirst%3DN.%26aulast%3DMahadevaswamy%26aufirst%3DJ.%26aulast%3DKaur%26aufirst%3DP.%26aulast%3DSambandamurthy%26aufirst%3DV.%2BK.%26aulast%3DAwasthy%26aufirst%3DD.%26aulast%3DNarayan%26aufirst%3DC.%26aulast%3DRavishankar%26aufirst%3DS.%26aulast%3DMadhavapeddi%26aufirst%3DP.%26aulast%3DReddy%26aufirst%3DJ.%26aulast%3DPrabhakar%26aufirst%3DK.%26aulast%3DSaralaya%26aufirst%3DR.%26aulast%3DChatterji%26aufirst%3DM.%26aulast%3DWhiteaker%26aufirst%3DJ.%26aulast%3DMcLaughlin%26aufirst%3DB.%26aulast%3DChiarelli%26aufirst%3DL.%2BR.%26aulast%3DRiccardi%26aufirst%3DG.%26aulast%3DPasca%26aufirst%3DM.%2BR.%26aulast%3DBinda%26aufirst%3DC.%26aulast%3DNeres%26aufirst%3DJ.%26aulast%3DDhar%26aufirst%3DN.%26aulast%3DSignorino-Gelo%26aufirst%3DF.%26aulast%3DMcKinney%26aufirst%3DJ.%2BD.%26aulast%3DRamachandran%26aufirst%3DV.%26aulast%3DShandil%26aufirst%3DR.%26aulast%3DTommasi%26aufirst%3DR.%26aulast%3DIyer%26aufirst%3DP.%2BS.%26aulast%3DNarayanan%26aufirst%3DS.%26aulast%3DHosagrahara%26aufirst%3DV.%26aulast%3DKavanagh%26aufirst%3DS.%26aulast%3DDinesh%26aufirst%3DN.%26aulast%3DGhorpade%26aufirst%3DS.%2BR.%26atitle%3D4-aminoquinolone%2520piperidine%2520amides%253A%2520Noncovalent%2520inhibitors%2520of%2520DprE1%2520with%2520long%2520residence%2520time%2520and%2520potent%2520antimycobacterial%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5419%26epage%3D5434%26doi%3D10.1021%2Fjm5005978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Read, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braendvang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miranda, P. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gundersen, L. L.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of pyrimidine analogs of antimycobacterial purines</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">3885</span>– <span class="NLM_lpage">3897</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2010.04.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmc.2010.04.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=20488716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmslOis78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=3885-3897&author=M.+L.+Readauthor=M.+Braendvangauthor=P.+O.+Mirandaauthor=L.+L.+Gundersen&title=Synthesis+and+biological+evaluation+of+pyrimidine+analogs+of+antimycobacterial+purines&doi=10.1016%2Fj.bmc.2010.04.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of pyrimidine analogs of antimycobacterial purines</span></div><div class="casAuthors">Read, Matthew L.; Braendvang, Morten; Miranda, Pedro O.; Gundersen, Lise-Lotte</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3885-3897</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Pyrimidine analogs of antimycobacterial 6-aryl-9-benzylpurines have been synthesized and screened for antibacterial activity against Mycobacterium tuberculosis H37Rv in vitro.  Several active compds. were identified and the best results were obsd. for 5-formamidopyrimidines.  These compds. generally displayed IC90 values ≤1 μg/mL, and they exhibited low toxicity towards mammalian cells.  Imidazolylpyrimidines, which may be regarded as fleximer analogs of the parent purines, were also synthesized and one of them was found to be quite a potent inhibitor of M. tuberculosis (IC90 14 μg/mL).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUBD9DkOvZB7Vg90H21EOLACvtfcHk0ljfb5yxdvVK6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmslOis78%253D&md5=4307a02795503c2fac647e3af9d5e282</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.04.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.04.035%26sid%3Dliteratum%253Aachs%26aulast%3DRead%26aufirst%3DM.%2BL.%26aulast%3DBraendvang%26aufirst%3DM.%26aulast%3DMiranda%26aufirst%3DP.%2BO.%26aulast%3DGundersen%26aufirst%3DL.%2BL.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520pyrimidine%2520analogs%2520of%2520antimycobacterial%2520purines%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26spage%3D3885%26epage%3D3897%26doi%3D10.1016%2Fj.bmc.2010.04.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anand, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiwari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripathi, R. P.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of small libraries of triazolylmethoxy chalcones, flavanones and 2-aminopyrimidines as inhibitors of mycobacterial FAS-II and PknG</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">5150</span>– <span class="NLM_lpage">5163</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2012.07.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmc.2012.07.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=22854194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFahsbjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=5150-5163&author=N.+Anandauthor=P.+Singhauthor=A.+Sharmaauthor=S.+Tiwariauthor=V.+Singhauthor=D.+K.+Singhauthor=K.+K.+Srivastavaauthor=B.+N.+Singhauthor=R.+P.+Tripathi&title=Synthesis+and+evaluation+of+small+libraries+of+triazolylmethoxy+chalcones%2C+flavanones+and+2-aminopyrimidines+as+inhibitors+of+mycobacterial+FAS-II+and+PknG&doi=10.1016%2Fj.bmc.2012.07.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of small libraries of triazolylmethoxy chalcones, flavanones and 2-aminopyrimidines as inhibitors of mycobacterial FAS-II and PknG</span></div><div class="casAuthors">Anand, Namrata; Singh, Priyanka; Sharma, Anindra; Tiwari, Sameer; Singh, Vandana; Singh, Diwakar K.; Srivastava, Kishore K.; Singh, B. N.; Tripathi, Rama Pati</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5150-5163</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A synthetic strategy to access small libraries of triazolylmethoxy chalcones 4{1-20}, triazolylmethoxy flavanones 5{1-10} and triazolylmethoxy aminopyrimidines 6{1-17} from a common substrate 4-propargyloxy-2-hydroxy acetophenone using a set of different reactions has been developed.  The chalcones and flavanones were screened against mycobacterial FAS-II pathway using a recombinant mycobacterial strain, against which the most potent compd. showed ∼88% inhibition in bacterial growth and substantially induction of reporter gene activity at 100 μM concn.  The triazolylmethoxy aminopyrimdines were screened against PknG of Mycobacterium tuberculosis displaying moderate to good activity (23-53% inhibition at 100 μM), comparable to the action of a std. inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqF9nK00acPJLVg90H21EOLACvtfcHk0ljfb5yxdvVK6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFahsbjP&md5=b90ed351639bfc9768a7ea39507b798c</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2012.07.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2012.07.009%26sid%3Dliteratum%253Aachs%26aulast%3DAnand%26aufirst%3DN.%26aulast%3DSingh%26aufirst%3DP.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DTiwari%26aufirst%3DS.%26aulast%3DSingh%26aufirst%3DV.%26aulast%3DSingh%26aufirst%3DD.%2BK.%26aulast%3DSrivastava%26aufirst%3DK.%2BK.%26aulast%3DSingh%26aufirst%3DB.%2BN.%26aulast%3DTripathi%26aufirst%3DR.%2BP.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520small%2520libraries%2520of%2520triazolylmethoxy%2520chalcones%252C%2520flavanones%2520and%25202-aminopyrimidines%2520as%2520inhibitors%2520of%2520mycobacterial%2520FAS-II%2520and%2520PknG%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26spage%3D5150%26epage%3D5163%26doi%3D10.1016%2Fj.bmc.2012.07.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shirude, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy Choudhury, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kedari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandodkar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugarkar, B. G.</span></span> <span> </span><span class="NLM_article-title">Quinolinyl pyrimidines: Potent inhibitors of NDH-2 as a novel class of anti-TB agents</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">736</span>– <span class="NLM_lpage">740</span>, <span class="refDoi"> DOI: 10.1021/ml300134b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300134b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFOru7jN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=736-740&author=P.+S.+Shirudeauthor=B.+Paulauthor=N.+Roy+Choudhuryauthor=C.+Kedariauthor=B.+Bandodkarauthor=B.+G.+Ugarkar&title=Quinolinyl+pyrimidines%3A+Potent+inhibitors+of+NDH-2+as+a+novel+class+of+anti-TB+agents&doi=10.1021%2Fml300134b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Quinolinyl Pyrimidines: Potent Inhibitors of NDH-2 as a Novel Class of Anti-TB Agents</span></div><div class="casAuthors">Shirude, Pravin S.; Paul, Beena; Roy Choudhury, Nilanjana; Kedari, Chaitanya; Bandodkar, Balachandra; Ugarkar, Bheemarao G.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">736-740</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">NDH-2 is an essential respiratory enzyme in Mycobacterium tuberculosis (Mtb), which plays an important role in the physiol. of Mtb.  Herein, we present a target-based effort to identify a new structural class of inhibitors for NDH-2.  High-throughput screening of the AstraZeneca corporate collection resulted in the identification of quinolinyl pyrimidines as the most promising class of NDH-2 inhibitors.  Structure-activity relationship studies showed improved enzyme inhibition (IC50) against the NDH-2 target, which in turn translated into cellular activity against Mtb.  Thus, the compds. in this class show a good correlation between enzyme inhibition and cellular potency.  Furthermore, early ADME profiling of the best compds. showed promising results and highlighted the quinolinyl pyrimidine class as a potential lead for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOthIF3YZ5u7Vg90H21EOLACvtfcHk0lgszOQZFtLaHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFOru7jN&md5=2401035993ef19c97289a272e3744950</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1021%2Fml300134b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300134b%26sid%3Dliteratum%253Aachs%26aulast%3DShirude%26aufirst%3DP.%2BS.%26aulast%3DPaul%26aufirst%3DB.%26aulast%3DRoy%2BChoudhury%26aufirst%3DN.%26aulast%3DKedari%26aufirst%3DC.%26aulast%3DBandodkar%26aufirst%3DB.%26aulast%3DUgarkar%26aufirst%3DB.%2BG.%26atitle%3DQuinolinyl%2520pyrimidines%253A%2520Potent%2520inhibitors%2520of%2520NDH-2%2520as%2520a%2520novel%2520class%2520of%2520anti-TB%2520agents%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D736%26epage%3D740%26doi%3D10.1021%2Fml300134b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahimian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aneja, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schechter, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, C. P.</span></span> <span> </span><span class="NLM_article-title">Mycobacterium tuberculosis type ii nadh-menaquinone oxidoreductase catalyzes electron transfer through a two-site ping-pong mechanism and has two quinone-binding sites</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">1179</span>– <span class="NLM_lpage">1190</span>, <span class="refDoi"> DOI: 10.1021/bi4013897</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi4013897" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVKksbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=1179-1190&author=T.+Yanoauthor=M.+Rahimianauthor=K.+K.+Anejaauthor=N.+M.+Schechterauthor=H.+Rubinauthor=C.+P.+Scott&title=Mycobacterium+tuberculosis+type+ii+nadh-menaquinone+oxidoreductase+catalyzes+electron+transfer+through+a+two-site+ping-pong+mechanism+and+has+two+quinone-binding+sites&doi=10.1021%2Fbi4013897"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Mycobacterium tuberculosis Type II NADH-Menaquinone Oxidoreductase Catalyzes Electron Transfer through a Two-Site Ping-Pong Mechanism and Has Two Quinone-Binding Sites</span></div><div class="casAuthors">Yano, Takahiro; Rahimian, Maryam; Aneja, Kawalpreet K.; Schechter, Norman M.; Rubin, Harvey; Scott, Charles P.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1179-1190</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Type II NADH-quinone oxidoreductase (NDH-2) catalyzes the transfer of electrons from NADH to the quinone pool and plays an essential role in the oxidative phosphorylation system of Mycobacterium tuberculosis (Mtb).  The absence of NDH-2 in the mammalian mitochondrial electron transport chain makes this enzyme an attractive target for antibiotic development.  To fully establish the kinetic properties of this enzyme, we studied the interaction of Mtb NDH-2 with substrates, NADH, and various quinone analogs and their products in both membrane and sol. environments.  These studies, and comparative analyses of the kinetics with thio-NAD+ and quinone electron acceptors, provided evidence that Mtb NDH-2 catalyzes the transfer electrons from NADH to quinone substrates by a nonclassical, two-site ping-pong kinetic mechanism whereby substrate quinones bind to a site that is distinct from the NADH-binding site.  Furthermore, the effects of quinols on Mtb NDH-2 catalytic activity demonstrate the presence of two binding sites for quinone ligands, one favoring the reduced form and the other favoring the oxidized form.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOs650KrNmKbVg90H21EOLACvtfcHk0lgszOQZFtLaHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVKksbw%253D&md5=e6ae608c43551063701d028bbfcfd81c</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1021%2Fbi4013897&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi4013897%26sid%3Dliteratum%253Aachs%26aulast%3DYano%26aufirst%3DT.%26aulast%3DRahimian%26aufirst%3DM.%26aulast%3DAneja%26aufirst%3DK.%2BK.%26aulast%3DSchechter%26aufirst%3DN.%2BM.%26aulast%3DRubin%26aufirst%3DH.%26aulast%3DScott%26aufirst%3DC.%2BP.%26atitle%3DMycobacterium%2520tuberculosis%2520type%2520ii%2520nadh-menaquinone%2520oxidoreductase%2520catalyzes%2520electron%2520transfer%2520through%2520a%2520two-site%2520ping-pong%2520mechanism%2520and%2520has%2520two%2520quinone-binding%2520sites%26jtitle%3DBiochemistry%26date%3D2014%26volume%3D53%26spage%3D1179%26epage%3D1190%26doi%3D10.1021%2Fbi4013897" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kravchenko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verbitskiy, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medvinskiy, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusinov, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charushin, V. N.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antituberculosis activity of novel 5-styryl-4-(hetero)aryl-pyrimidines via combination of the pd-catalyzed suzuki cross-coupling and s(n)(h) reactions</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3118</span>– <span class="NLM_lpage">3120</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.05.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmcl.2014.05.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=24856062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2cXovVaisr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=3118-3120&author=M.+A.+Kravchenkoauthor=E.+V.+Verbitskiyauthor=I.+D.+Medvinskiyauthor=G.+L.+Rusinovauthor=V.+N.+Charushin&title=Synthesis+and+antituberculosis+activity+of+novel+5-styryl-4-%28hetero%29aryl-pyrimidines+via+combination+of+the+pd-catalyzed+suzuki+cross-coupling+and+s%28n%29%28h%29+reactions&doi=10.1016%2Fj.bmcl.2014.05.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antituberculosis activity of novel 5-styryl-4-(hetero)aryl-pyrimidines via combination of the Pd-catalyzed Suzuki cross-coupling and SHN reactions</span></div><div class="casAuthors">Kravchenko, Marionella A.; Verbitskiy, Egor V.; Medvinskiy, Igor D.; Rusinov, Gennady L.; Charushin, Valery N.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3118-3120</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Combination of the Suzuki cross-coupling and nucleophilic arom. substitution of hydrogen (SHN) reactions proved to be a convenient method for the synthesis of 5-styryl-4-(hetero)aryl substituted pyrimidines from com. available 5-bromopyrimidine.  All intermediate 5-bromo-4-(hetero)aryl substituted pyrimidines and also the targeted 5-styryl-4-(hetero)arylpyrimidines are active in micromolar concns. in vitro against Mycobacterium tuberculosis H37Rv, avium, terrae, and multi-drug-resistant strain isolated from tuberculosis patients in Ural region (Russia).  Some of these compds. possess a low toxicity and have a bacteriostatic effect, comparable and even higher with that of first-line antituberculosis drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU-7N2OvsfF7Vg90H21EOLACvtfcHk0lgszOQZFtLaHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXovVaisr8%253D&md5=41fe9db251cdf861b373360d7195aa91</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.05.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.05.006%26sid%3Dliteratum%253Aachs%26aulast%3DKravchenko%26aufirst%3DM.%2BA.%26aulast%3DVerbitskiy%26aufirst%3DE.%2BV.%26aulast%3DMedvinskiy%26aufirst%3DI.%2BD.%26aulast%3DRusinov%26aufirst%3DG.%2BL.%26aulast%3DCharushin%26aufirst%3DV.%2BN.%26atitle%3DSynthesis%2520and%2520antituberculosis%2520activity%2520of%2520novel%25205-styryl-4-%2528hetero%2529aryl-pyrimidines%2520via%2520combination%2520of%2520the%2520pd-catalyzed%2520suzuki%2520cross-coupling%2520and%2520s%2528n%2529%2528h%2529%2520reactions%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D3118%26epage%3D3120%26doi%3D10.1016%2Fj.bmcl.2014.05.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verbitskiy, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baskakova, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kravchenko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skornyakov, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusinov, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chupakhin, O. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charushin, V. N.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of antitubercular activity of fluorinated 5-aryl-4-(hetero)aryl substituted pyrimidines</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3771</span>– <span class="NLM_lpage">3780</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.06.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmc.2016.06.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=27338658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVKgtLbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=3771-3780&author=E.+V.+Verbitskiyauthor=S.+A.+Baskakovaauthor=M.+A.+Kravchenkoauthor=S.+N.+Skornyakovauthor=G.+L.+Rusinovauthor=O.+N.+Chupakhinauthor=V.+N.+Charushin&title=Synthesis+and+evaluation+of+antitubercular+activity+of+fluorinated+5-aryl-4-%28hetero%29aryl+substituted+pyrimidines&doi=10.1016%2Fj.bmc.2016.06.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of antitubercular activity of fluorinated 5-aryl-4-(hetero)aryl substituted pyrimidines</span></div><div class="casAuthors">Verbitskiy, Egor V.; Baskakova, Svetlana A.; Kravchenko, Marionella A.; Skornyakov, Sergey N.; Rusinov, Gennady L.; Chupakhin, Oleg N.; Charushin, Valery N.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3771-3780</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Various 5-(fluoroaryl)-4-(hetero)aryl substituted pyrimidines have been synthesized based on the Suzuki cross-coupling and nucleophilic arom. substitution of hydrogen (SHN) reactions starting from com. available 5-bromopyrimidine and their antitubercular activity against Mycobacterium tuberculosis H37Rv has been explored.  The outcome of the study disclose that, some of the compds. have showed promising activity in micromolar concn. against Mycobacterium tuberculosis H37Rv, Mycobacterium avium, Mycobacterium terrae, and multidrug-resistant strains isolated from tuberculosis patients in Ural region (Russia).  The data concerning the 'structure-activity' relationship for fluorinated compds. have been discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfpux_5rKg37Vg90H21EOLACvtfcHk0lhYI8Zcl1tqIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVKgtLbI&md5=8a5f1624b27c64aa994a95efe36432cd</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.06.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.06.020%26sid%3Dliteratum%253Aachs%26aulast%3DVerbitskiy%26aufirst%3DE.%2BV.%26aulast%3DBaskakova%26aufirst%3DS.%2BA.%26aulast%3DKravchenko%26aufirst%3DM.%2BA.%26aulast%3DSkornyakov%26aufirst%3DS.%2BN.%26aulast%3DRusinov%26aufirst%3DG.%2BL.%26aulast%3DChupakhin%26aufirst%3DO.%2BN.%26aulast%3DCharushin%26aufirst%3DV.%2BN.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520antitubercular%2520activity%2520of%2520fluorinated%25205-aryl-4-%2528hetero%2529aryl%2520substituted%2520pyrimidines%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D3771%26epage%3D3780%26doi%3D10.1016%2Fj.bmc.2016.06.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verbitskiy, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheprakova, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slepukhin, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kravchenko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skornyakov, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusinov, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chupakhin, O. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charushin, V. N.</span></span> <span> </span><span class="NLM_article-title">Synthesis, and structure-activity relationship for c(4) and/or c(5) thienyl substituted pyrimidines, as a new family of antimycobacterial compounds</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">234</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.05.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.ejmech.2015.05.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=25982331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotlKiu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2015&pages=225-234&author=E.+V.+Verbitskiyauthor=E.+M.+Cheprakovaauthor=P.+A.+Slepukhinauthor=M.+A.+Kravchenkoauthor=S.+N.+Skornyakovauthor=G.+L.+Rusinovauthor=O.+N.+Chupakhinauthor=V.+N.+Charushin&title=Synthesis%2C+and+structure-activity+relationship+for+c%284%29+and%2For+c%285%29+thienyl+substituted+pyrimidines%2C+as+a+new+family+of+antimycobacterial+compounds&doi=10.1016%2Fj.ejmech.2015.05.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, and structure-activity relationship for C(4) and/or C(5) thienyl substituted pyrimidines, as a new family of antimycobacterial compounds</span></div><div class="casAuthors">Verbitskiy, Egor V.; Cheprakova, Ekaterina M.; Slepukhin, Pavel A.; Kravchenko, Marionella A.; Skornyakov, Sergey N.; Rusinov, Gennady L.; Chupakhin, Oleg N.; Charushin, Valery N.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">225-234</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Combination of the Suzuki cross-coupling and nucleophilic arom. substitution of hydrogen (SHN) reactions proved to be a convenient method for the synthesis of C(4) and/or C(5) mono(thienyl) and di(thienyl) substituted pyrimidines from com. available 5-bromopyrimidine.  All new pyrimidines are active in micromolar concns. in vitro against H37Rv, avium, terrae, rifampicin and isoniazid-resistance strains of Mycobacterium tuberculosis.  The data for acute in vivo toxicity in mice were obtained for these compds. which appear to be promising antitubercular agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5qpeVACSF4rVg90H21EOLACvtfcHk0lhYI8Zcl1tqIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotlKiu7o%253D&md5=c33a2aa5045fbff635a1da6e35e3e6ab</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.05.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.05.007%26sid%3Dliteratum%253Aachs%26aulast%3DVerbitskiy%26aufirst%3DE.%2BV.%26aulast%3DCheprakova%26aufirst%3DE.%2BM.%26aulast%3DSlepukhin%26aufirst%3DP.%2BA.%26aulast%3DKravchenko%26aufirst%3DM.%2BA.%26aulast%3DSkornyakov%26aufirst%3DS.%2BN.%26aulast%3DRusinov%26aufirst%3DG.%2BL.%26aulast%3DChupakhin%26aufirst%3DO.%2BN.%26aulast%3DCharushin%26aufirst%3DV.%2BN.%26atitle%3DSynthesis%252C%2520and%2520structure-activity%2520relationship%2520for%2520c%25284%2529%2520and%252For%2520c%25285%2529%2520thienyl%2520substituted%2520pyrimidines%252C%2520as%2520a%2520new%2520family%2520of%2520antimycobacterial%2520compounds%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D97%26spage%3D225%26epage%3D234%26doi%3D10.1016%2Fj.ejmech.2015.05.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yadlapalli, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chourasia, O. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vemuri, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sritharan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perali, R. S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and in vitro anticancer and antitubercular activity of diarylpyrazole ligated dihydropyrimidines possessing lipophilic carbamoyl group</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">2708</span>– <span class="NLM_lpage">2711</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.02.101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmcl.2012.02.101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=22437116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38XktFyjtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=2708-2711&author=R.+K.+Yadlapalliauthor=O.+P.+Chourasiaauthor=K.+Vemuriauthor=M.+Sritharanauthor=R.+S.+Perali&title=Synthesis+and+in+vitro+anticancer+and+antitubercular+activity+of+diarylpyrazole+ligated+dihydropyrimidines+possessing+lipophilic+carbamoyl+group&doi=10.1016%2Fj.bmcl.2012.02.101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and in vitro anticancer and antitubercular activity of diarylpyrazole ligated dihydropyrimidines possessing lipophilic carbamoyl group</span></div><div class="casAuthors">Yadlapalli, Rama Krishna; Chourasia, O. P.; Vemuri, Kiranmayi; Sritharan, Manjula; Perali, Ramu Sridhar</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2708-2711</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of dihydropyrimidine derivs., e. g. I and II, were synthesized by utilizing Biginelli reaction and evaluated for their in vitro anticancer activity against MCF-7 human breast cancer (HBC) cell line using sulforhodamine B (SRB) assay and antitubercular activity against Mycobacterium tuberculosis (MTB) H37Rv using Microplate Alamar Blue Assay (MABA).  I and II were exhibited 70.6% and 63.7% of HBC cell growth inhibition at 10 μM concn.  Interestingly, I was also found to be the most potent in the series against MTB H37Rv with MIC value of 0.125 μg/mL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGql0XildxmgRrVg90H21EOLACvtfcHk0lhYI8Zcl1tqIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktFyjtL0%253D&md5=ff946cbc719252c03d23d20edf064cf7</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.02.101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.02.101%26sid%3Dliteratum%253Aachs%26aulast%3DYadlapalli%26aufirst%3DR.%2BK.%26aulast%3DChourasia%26aufirst%3DO.%2BP.%26aulast%3DVemuri%26aufirst%3DK.%26aulast%3DSritharan%26aufirst%3DM.%26aulast%3DPerali%26aufirst%3DR.%2BS.%26atitle%3DSynthesis%2520and%2520in%2520vitro%2520anticancer%2520and%2520antitubercular%2520activity%2520of%2520diarylpyrazole%2520ligated%2520dihydropyrimidines%2520possessing%2520lipophilic%2520carbamoyl%2520group%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D2708%26epage%3D2711%26doi%3D10.1016%2Fj.bmcl.2012.02.101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yokokawa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manjunatha, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakshminarayana, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kounde, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thayalan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanjundappa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravindran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gee, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dix, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pethe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glynne, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bifani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiricek, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of tetrahydropyrazolopyrimidine carboxamide derivatives as potent and orally active antitubercular agents</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">451</span>– <span class="NLM_lpage">455</span>, <span class="refDoi"> DOI: 10.1021/ml400071a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml400071a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltVCltb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=451-455&author=F.+Yokokawaauthor=G.+Wangauthor=W.+L.+Chanauthor=S.+H.+Angauthor=J.+Wongauthor=I.+Maauthor=S.+P.+Raoauthor=U.+Manjunathaauthor=S.+B.+Lakshminarayanaauthor=M.+Herveauthor=C.+Koundeauthor=B.+H.+Tanauthor=P.+Thayalanauthor=S.+H.+Ngauthor=M.+Nanjundappaauthor=S.+Ravindranauthor=P.+Geeauthor=M.+Tanauthor=L.+Weiauthor=A.+Gohauthor=P.+Y.+Chenauthor=K.+S.+Leeauthor=C.+Zhongauthor=T.+Wagnerauthor=I.+Dixauthor=A.+K.+Chatterjeeauthor=K.+Petheauthor=K.+Kuhenauthor=R.+Glynneauthor=P.+Smithauthor=P.+Bifaniauthor=J.+Jiricek&title=Discovery+of+tetrahydropyrazolopyrimidine+carboxamide+derivatives+as+potent+and+orally+active+antitubercular+agents&doi=10.1021%2Fml400071a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Tetrahydropyrazolopyrimidine Carboxamide Derivatives As Potent and Orally Active Antitubercular Agents</span></div><div class="casAuthors">Yokokawa, Fumiaki; Wang, Gang; Chan, Wai Ling; Ang, Shi Hua; Wong, Josephine; Ma, Ida; Rao, Srinivasa P. S.; Manjunatha, Ujjini; Lakshminarayana, Suresh B.; Herve, Maxime; Kounde, Cyrille; Tan, Bee Huat; Thayalan, Pamela; Dick, Thomas; Ng, Seow Hwee; Nanjundappa, Mahesh; Ravindran, Sindhu; Gee, Peck; Tan, Maria; Wei, Liu; Goh, Anne; Chen, Pei-Yu; Lee, Kok Sin; Zhong, Chen; Wagner, Trixie; Dix, Ina; Chatterjee, Arnab K.; Pethe, Kevin; Kuhen, Kelli; Glynne, Richard; Smith, Paul; Bifani, Pablo; Jiricek, Jan</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">451-455</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nonracemic (aryl)(fluoroalkyl)tetrahydropyrazolo[1,5-a]pyrimidinecarboxamides I [R = 4-MeC6H4, 5-Me-2-pyridinyl, 5-methyl-2-furyl, 4-(4-morpholinyl)C6H4, 4-(MeOCH2CH2O)C6H4, 4-(3-oxetanyloxy)C6H4; R1 = F3C, F2HC; R2 = 4-FC6H4CH2, 6-MeO-3-pyridinylmethyl, 5-F-2-pyridinylmethyl] were prepd. stereoselectively as potential antitubercular agents; their inhibition of Mycobacterium tuberculosis (Mtb), their aq. solubilities, their plasma protein binding, and their lipophilicities were detd.  I were prepd. from aryl Me ketones, Et trifluoro- or difluoroacetate, and Et 3-amino-4-pyrazolecarboxylate; resoln. of the intermediate cis-aryl(fluoroalkyl)tetrahydropyrazolopyrimidinecarboxylic acids by supercrit. fluid chromatog. followed by amidation or aryl modifications yielded the desired products.  While I inhibited Mtb with MIC of 0.13-52.2 μM, ent-I did not inhibit Mtb (MIC > 20 μM).  In particular, I (R = 4-MeC6H4; R1 = F3C; R2 = 4-FC6H4CH2) showed a promising in vivo DMPK profile in mouse and exhibited potent in vivo activity in a mouse antitubercular efficacy model, achieving a redn. of 3.5 log CFU of Mtb after oral administration to infected mice once a day at 100 mg/kg for 28 days.  I (R = 4-MeC6H4; R1 = F3C; R2 = 4-FC6H4CH2) is a potential candidate for inclusion in combination therapies for both drug-sensitive and drug-resistant TB.  The structure of a nonracemic (methylpyridinyl)(trifluoromethyl)tetrahydropyrazolopyrimidinecarboxylic acid intermediate and its abs. configuration were detd. by X-ray crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUOfiTtIIr5LVg90H21EOLACvtfcHk0ljacqB7a38-Hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltVCltb0%253D&md5=d4a33e9a3fc688dacdb3aa2e8c1c7465</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1021%2Fml400071a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400071a%26sid%3Dliteratum%253Aachs%26aulast%3DYokokawa%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DChan%26aufirst%3DW.%2BL.%26aulast%3DAng%26aufirst%3DS.%2BH.%26aulast%3DWong%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DI.%26aulast%3DRao%26aufirst%3DS.%2BP.%26aulast%3DManjunatha%26aufirst%3DU.%26aulast%3DLakshminarayana%26aufirst%3DS.%2BB.%26aulast%3DHerve%26aufirst%3DM.%26aulast%3DKounde%26aufirst%3DC.%26aulast%3DTan%26aufirst%3DB.%2BH.%26aulast%3DThayalan%26aufirst%3DP.%26aulast%3DNg%26aufirst%3DS.%2BH.%26aulast%3DNanjundappa%26aufirst%3DM.%26aulast%3DRavindran%26aufirst%3DS.%26aulast%3DGee%26aufirst%3DP.%26aulast%3DTan%26aufirst%3DM.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DGoh%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DP.%2BY.%26aulast%3DLee%26aufirst%3DK.%2BS.%26aulast%3DZhong%26aufirst%3DC.%26aulast%3DWagner%26aufirst%3DT.%26aulast%3DDix%26aufirst%3DI.%26aulast%3DChatterjee%26aufirst%3DA.%2BK.%26aulast%3DPethe%26aufirst%3DK.%26aulast%3DKuhen%26aufirst%3DK.%26aulast%3DGlynne%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DBifani%26aufirst%3DP.%26aulast%3DJiricek%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520tetrahydropyrazolopyrimidine%2520carboxamide%2520derivatives%2520as%2520potent%2520and%2520orally%2520active%2520antitubercular%2520agents%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D451%26epage%3D455%26doi%3D10.1021%2Fml400071a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shirude, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shandil, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosagrahara, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hameed, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinde, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bathula, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humnabadkar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panduga, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambady, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegde, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiteaker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madhavapeddi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guptha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awasthy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahadevaswamy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vishwas, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahuja, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prabhakar, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bharath, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kale, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramaiah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choudhury, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sambandamurthy, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solapure, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterji, M.</span></span> <span> </span><span class="NLM_article-title">Azaindoles: Noncovalent dpre1 inhibitors from scaffold morphing efforts, kill mycobacterium tuberculosis and are efficacious in vivo</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">9701</span>– <span class="NLM_lpage">9708</span>, <span class="refDoi"> DOI: 10.1021/jm401382v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401382v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslCku7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=9701-9708&author=P.+S.+Shirudeauthor=R.+Shandilauthor=C.+Sadlerauthor=M.+Naikauthor=V.+Hosagraharaauthor=S.+Hameedauthor=V.+Shindeauthor=C.+Bathulaauthor=V.+Humnabadkarauthor=N.+Kumarauthor=J.+Reddyauthor=V.+Pandugaauthor=S.+Sharmaauthor=A.+Ambadyauthor=N.+Hegdeauthor=J.+Whiteakerauthor=R.+E.+McLaughlinauthor=H.+Gardnerauthor=P.+Madhavapeddiauthor=V.+Ramachandranauthor=P.+Kaurauthor=A.+Narayanauthor=S.+Gupthaauthor=D.+Awasthyauthor=C.+Narayanauthor=J.+Mahadevaswamyauthor=K.+G.+Vishwasauthor=V.+Ahujaauthor=A.+Srivastavaauthor=K.+R.+Prabhakarauthor=S.+Bharathauthor=R.+Kaleauthor=M.+Ramaiahauthor=N.+R.+Choudhuryauthor=V.+K.+Sambandamurthyauthor=S.+Solapureauthor=P.+S.+Iyerauthor=S.+Narayananauthor=M.+Chatterji&title=Azaindoles%3A+Noncovalent+dpre1+inhibitors+from+scaffold+morphing+efforts%2C+kill+mycobacterium+tuberculosis+and+are+efficacious+in+vivo&doi=10.1021%2Fjm401382v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Azaindoles: Noncovalent DprE1 Inhibitors from Scaffold Morphing Efforts, Kill Mycobacterium tuberculosis and Are Efficacious in Vivo</span></div><div class="casAuthors">Shirude, Pravin S.; Shandil, Radha; Sadler, Claire; Naik, Maruti; Hosagrahara, Vinayak; Hameed, Shahul; Shinde, Vikas; Bathula, Chandramohan; Humnabadkar, Vaishali; Kumar, Naveen; Reddy, Jitendar; Panduga, Vijender; Sharma, Sreevalli; Ambady, Anisha; Hegde, Naina; Whiteaker, James; McLaughlin, Robert E.; Gardner, Humphrey; Madhavapeddi, Prashanti; Ramachandran, Vasanthi; Kaur, Parvinder; Narayan, Ashwini; Guptha, Supreeth; Awasthy, Disha; Narayan, Chandan; Mahadevaswamy, Jyothi; Vishwas, K. G.; Ahuja, Vijaykamal; Srivastava, Abhishek; Prabhakar, K. R.; Bharath, Sowmya; Kale, Ramesh; Ramaiah, Manjunatha; Choudhury, Nilanjana Roy; Sambandamurthy, Vasan K.; Solapure, Suresh; Iyer, Pravin S.; Narayanan, Shridhar; Chatterji, Monalisa</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9701-9708</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report 1,4-azaindoles as a new inhibitor class that kills Mycobacterium tuberculosis in vitro and demonstrates efficacy in mouse tuberculosis models.  The series emerged from scaffold morphing efforts and was demonstrated to noncovalently inhibit decaprenylphosphoryl-β-d-ribose2'-epimerase (DprE1).  With "drug-like" properties and no expectation of pre-existing resistance in the clinic, this chem. class has the potential to be developed as a therapy for drug-sensitive and drug-resistant tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqskQvJK4M2yrVg90H21EOLACvtfcHk0ljacqB7a38-Hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslCku7fM&md5=eba42d1952b164f66fd0ca620aaa4f19</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1021%2Fjm401382v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401382v%26sid%3Dliteratum%253Aachs%26aulast%3DShirude%26aufirst%3DP.%2BS.%26aulast%3DShandil%26aufirst%3DR.%26aulast%3DSadler%26aufirst%3DC.%26aulast%3DNaik%26aufirst%3DM.%26aulast%3DHosagrahara%26aufirst%3DV.%26aulast%3DHameed%26aufirst%3DS.%26aulast%3DShinde%26aufirst%3DV.%26aulast%3DBathula%26aufirst%3DC.%26aulast%3DHumnabadkar%26aufirst%3DV.%26aulast%3DKumar%26aufirst%3DN.%26aulast%3DReddy%26aufirst%3DJ.%26aulast%3DPanduga%26aufirst%3DV.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DAmbady%26aufirst%3DA.%26aulast%3DHegde%26aufirst%3DN.%26aulast%3DWhiteaker%26aufirst%3DJ.%26aulast%3DMcLaughlin%26aufirst%3DR.%2BE.%26aulast%3DGardner%26aufirst%3DH.%26aulast%3DMadhavapeddi%26aufirst%3DP.%26aulast%3DRamachandran%26aufirst%3DV.%26aulast%3DKaur%26aufirst%3DP.%26aulast%3DNarayan%26aufirst%3DA.%26aulast%3DGuptha%26aufirst%3DS.%26aulast%3DAwasthy%26aufirst%3DD.%26aulast%3DNarayan%26aufirst%3DC.%26aulast%3DMahadevaswamy%26aufirst%3DJ.%26aulast%3DVishwas%26aufirst%3DK.%2BG.%26aulast%3DAhuja%26aufirst%3DV.%26aulast%3DSrivastava%26aufirst%3DA.%26aulast%3DPrabhakar%26aufirst%3DK.%2BR.%26aulast%3DBharath%26aufirst%3DS.%26aulast%3DKale%26aufirst%3DR.%26aulast%3DRamaiah%26aufirst%3DM.%26aulast%3DChoudhury%26aufirst%3DN.%2BR.%26aulast%3DSambandamurthy%26aufirst%3DV.%2BK.%26aulast%3DSolapure%26aufirst%3DS.%26aulast%3DIyer%26aufirst%3DP.%2BS.%26aulast%3DNarayanan%26aufirst%3DS.%26aulast%3DChatterji%26aufirst%3DM.%26atitle%3DAzaindoles%253A%2520Noncovalent%2520dpre1%2520inhibitors%2520from%2520scaffold%2520morphing%2520efforts%252C%2520kill%2520mycobacterium%2520tuberculosis%2520and%2520are%2520efficacious%2520in%2520vivo%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D9701%26epage%3D9708%26doi%3D10.1021%2Fjm401382v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Velezheva, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivanov, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kornienko, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyubimov, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazarian, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikonenko, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majorov, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apt, A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antituberculosis activity of indole-pyridine derived hydrazides, hydrazide-hydrazones, and thiosemicarbazones</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">978</span>– <span class="NLM_lpage">985</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.12.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmcl.2015.12.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=26725953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVyqsLzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=978-985&author=V.+Velezhevaauthor=P.+Brennanauthor=P.+Ivanovauthor=A.+Kornienkoauthor=S.+Lyubimovauthor=K.+Kazarianauthor=B.+Nikonenkoauthor=K.+Majorovauthor=A.+Apt&title=Synthesis+and+antituberculosis+activity+of+indole-pyridine+derived+hydrazides%2C+hydrazide-hydrazones%2C+and+thiosemicarbazones&doi=10.1016%2Fj.bmcl.2015.12.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antituberculosis activity of indole-pyridine derived hydrazides, hydrazide-hydrazones, and thiosemicarbazones</span></div><div class="casAuthors">Velezheva, Valeriya; Brennan, Patrick; Ivanov, Pavel; Kornienko, Albert; Lyubimov, Sergey; Kazarian, Konstantin; Nikonenko, Boris; Majorov, Konstantin; Apt, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">978-985</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We describe the design, synthesis, and in vitro antimycobacterial activity of a series of novel simple hybrid hydrazides and hydrazide-hydrazones combining indole and pyridine nuclei.  The compds. are derivs. of 1-acetylindoxyl or substituted indole-3-carboxaldehydes tethered via a hydrazine group by simple C-N or double C:N bonds with 3- and 4-pyridines, 1-oxide 3- and 4-pyridine carbohydrazides.  The most active of the 15 compds. showed MICs values against an INH-sensitive strain of Mycobacterium tuberculosis H37Rv equal to that of INH (0.05-2 μg/mL).  Five compds. demonstrated appreciable activity against the INH-resistant M. tuberculosis CN-40 clin. isolate (MICs: 2-5 μg/mL), providing justification for further in vivo studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4xva4vDfrFbVg90H21EOLACvtfcHk0lg-m5PyyGOcZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVyqsLzF&md5=d4136529aa96fcaa078e16496e1e1d79</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.12.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.12.049%26sid%3Dliteratum%253Aachs%26aulast%3DVelezheva%26aufirst%3DV.%26aulast%3DBrennan%26aufirst%3DP.%26aulast%3DIvanov%26aufirst%3DP.%26aulast%3DKornienko%26aufirst%3DA.%26aulast%3DLyubimov%26aufirst%3DS.%26aulast%3DKazarian%26aufirst%3DK.%26aulast%3DNikonenko%26aufirst%3DB.%26aulast%3DMajorov%26aufirst%3DK.%26aulast%3DApt%26aufirst%3DA.%26atitle%3DSynthesis%2520and%2520antituberculosis%2520activity%2520of%2520indole-pyridine%2520derived%2520hydrazides%252C%2520hydrazide-hydrazones%252C%2520and%2520thiosemicarbazones%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D978%26epage%3D985%26doi%3D10.1016%2Fj.bmcl.2015.12.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baig, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, I. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. G.</span></span> <span> </span><span class="NLM_article-title">Synthesis, crystal structure and biological evaluation of substituted quinazolinone benzoates as novel antituberculosis agents targeting acetohydroxyacid synthase</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">298</span>– <span class="NLM_lpage">305</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.03.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.ejmech.2015.03.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=25771108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktVCkt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2015&pages=298-305&author=W.+Luauthor=I.+A.+Baigauthor=H.+J.+Sunauthor=C.+J.+Cuiauthor=R.+Guoauthor=I.+P.+Jungauthor=D.+Wangauthor=M.+Dongauthor=M.+Y.+Yoonauthor=J.+G.+Wang&title=Synthesis%2C+crystal+structure+and+biological+evaluation+of+substituted+quinazolinone+benzoates+as+novel+antituberculosis+agents+targeting+acetohydroxyacid+synthase&doi=10.1016%2Fj.ejmech.2015.03.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, crystal structure and biological evaluation of substituted quinazolinone benzoates as novel antituberculosis agents targeting acetohydroxyacid synthase</span></div><div class="casAuthors">Lu, Wei; Baig, Irshad Ahmed; Sun, Hui-Jie; Cui, Chang-Jun; Guo, Rui; Jung, In-Pil; Wang, Di; Dong, Mei; Yoon, Moon-Young; Wang, Jian-Guo</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">298-305</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Acetohydroxyacid synthase (AHAS) catalyzes the first essential biosynthetic step of branched-chain amino acids and is a biol. safe target against Mycobacterium tuberculosis (MTB).  In our previous research, we used virtual screening to identify some novel AHAS inhibitors as potent antituberculosis agents.  In this study, we synthesized twenty-four addnl. quinazolinone benzoates and explored their antitubercular activity.  Five of these compds. displayed significant MTB-AHAS inhibition and their IC50 values were detd. to be in the range of 6.50 μM-12.08 μM.  Importantly, these compds. also exhibited strong in vitro activity (MICs in the range of 2.5-10 mg/L) and intracellular activity against clin. isolated extensively drug-resistant strains of M. tuberculosis.  Taken together, these results indicated that the quinazolinone benzoate compds. should be regarded as promising lead compds. for the development of potent antituberculosis drugs with a novel mode of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9JXKcaR2i4LVg90H21EOLACvtfcHk0lg-m5PyyGOcZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktVCkt7s%253D&md5=12cc55409c9563e88fd3fcdbfbb3ab04</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.03.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.03.014%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DW.%26aulast%3DBaig%26aufirst%3DI.%2BA.%26aulast%3DSun%26aufirst%3DH.%2BJ.%26aulast%3DCui%26aufirst%3DC.%2BJ.%26aulast%3DGuo%26aufirst%3DR.%26aulast%3DJung%26aufirst%3DI.%2BP.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DDong%26aufirst%3DM.%26aulast%3DYoon%26aufirst%3DM.%2BY.%26aulast%3DWang%26aufirst%3DJ.%2BG.%26atitle%3DSynthesis%252C%2520crystal%2520structure%2520and%2520biological%2520evaluation%2520of%2520substituted%2520quinazolinone%2520benzoates%2520as%2520novel%2520antituberculosis%2520agents%2520targeting%2520acetohydroxyacid%2520synthase%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D94%26spage%3D298%26epage%3D305%26doi%3D10.1016%2Fj.ejmech.2015.03.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ranjith Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perumal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menéndez, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yogeeswari, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sriram, D.</span></span> <span> </span><span class="NLM_article-title">Antimycobacterial activity of novel 1,2,4-oxadiazole-pyranopyridine/chromene hybrids generated by chemoselective 1,3-dipolar cycloadditions of nitrile oxides</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">3444</span>– <span class="NLM_lpage">3450</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2011.04.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmc.2011.04.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=21592801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A280%3ADC%252BC3MrkslCmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=3444-3450&author=R.+Ranjith+Kumarauthor=S.+Perumalauthor=J.+C.+Men%C3%A9ndezauthor=P.+Yogeeswariauthor=D.+Sriram&title=Antimycobacterial+activity+of+novel+1%2C2%2C4-oxadiazole-pyranopyridine%2Fchromene+hybrids+generated+by+chemoselective+1%2C3-dipolar+cycloadditions+of+nitrile+oxides&doi=10.1016%2Fj.bmc.2011.04.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Antimycobacterial activity of novel 1,2,4-oxadiazole-pyranopyridine/chromene hybrids generated by chemoselective 1,3-dipolar cycloadditions of nitrile oxides</span></div><div class="casAuthors">Ranjith Kumar Raju; Perumal Subbu; Menendez J Carlos; Yogeeswari Perumal; Sriram Dharmarajan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & medicinal chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3444-50</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The 1,3-dipolar cycloaddition of nitrile oxides generated in situ from benzohydroximinoyl chloride and triethylamine to 2-aminopyranopyridine-3-carbonitriles and 2-aminochromene-3-carbonitriles occurred chemoselectively furnishing novel 1,2,4-oxadiazole-pyranopyridine/chromene hybrid heterocycles in moderate yields.  In vitro screening of these compounds against Mycobacterium tuberculosis H37Rv (MTB) disclosed that the 1,2,4-oxadiazole-pyranopyridine hybrids display enhanced activity relative to the 1,2,4-oxadiazole-chromene hybrids.  Among the compounds screened, 3-[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]-4-(2,4-dichlorophenyl)-8-[(E)-(2,4-dichlorophenyl)-methylidene]-6-methyl-5,6,7,8-tetrahydro-4H-pyrano[3,2-c]pyridin-2-amine (MIC: 0.31 μM) is 1.2, 15.2 and 24.6 times more active than standard antitubercular drugs, viz. isoniazid, ciprofloxacin and ethambutol, respectively.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSzDQQlg0ZtX0EksK8CslK8fW6udTcc2eaOFWQv01_0krntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MrkslCmug%253D%253D&md5=b94ad72e4fa28425aaab4cf2069cfdde</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2011.04.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2011.04.033%26sid%3Dliteratum%253Aachs%26aulast%3DRanjith%2BKumar%26aufirst%3DR.%26aulast%3DPerumal%26aufirst%3DS.%26aulast%3DMen%25C3%25A9ndez%26aufirst%3DJ.%2BC.%26aulast%3DYogeeswari%26aufirst%3DP.%26aulast%3DSriram%26aufirst%3DD.%26atitle%3DAntimycobacterial%2520activity%2520of%2520novel%25201%252C2%252C4-oxadiazole-pyranopyridine%252Fchromene%2520hybrids%2520generated%2520by%2520chemoselective%25201%252C3-dipolar%2520cycloadditions%2520of%2520nitrile%2520oxides%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2011%26volume%3D19%26spage%3D3444%26epage%3D3450%26doi%3D10.1016%2Fj.bmc.2011.04.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Almansour, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suresh Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arumugam, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sriram, D.</span></span> <span> </span><span class="NLM_article-title">A solvent free, four-component synthesis and 1,3-dipolar cycloaddition of 4(h)-pyrans with nitrile oxides: Synthesis and discovery of antimycobacterial activity of enantiomerically pure 1,2,4-oxadiazoles</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">416</span>– <span class="NLM_lpage">423</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2012.04.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.ejmech.2012.04.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=22575534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38XnvVygt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2012&pages=416-423&author=A.+I.+Almansourauthor=R.+Suresh+Kumarauthor=N.+Arumugamauthor=D.+Sriram&title=A+solvent+free%2C+four-component+synthesis+and+1%2C3-dipolar+cycloaddition+of+4%28h%29-pyrans+with+nitrile+oxides%3A+Synthesis+and+discovery+of+antimycobacterial+activity+of+enantiomerically+pure+1%2C2%2C4-oxadiazoles&doi=10.1016%2Fj.ejmech.2012.04.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">A solvent free, four-component synthesis and 1,3-dipolar cycloaddition of 4(H)-pyrans with nitrile oxides: Synthesis and discovery of antimycobacterial activity of enantiomerically pure 1,2,4-oxadiazoles</span></div><div class="casAuthors">Almansour, Abdulrahman I.; Suresh Kumar, Raju; Arumugam, Natarajan; Sriram, Dharmarajan</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">416-423</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Four-component reactions of (R)-1-(1-phenylethyl)tetrahydro-4(1H)-pyridinone, arom. aldehydes (2 equiv) and malononitrile in a 1:2:1 molar ratio in the presence of solid sodium ethoxide under solvent free conditions afforded an inseparable mixt. of two diastereomeric 4(H)-pyrans I (R = Ph, 4-Me-C6H4, 2-Cl-C6H4, 2,4-Cl2-C6H3, 1-naphthyl) in near quant. yields.  These compds. upon 1,3-dipolar cycloaddn. with nitrile oxides derived from N-hydroxyarylimidoyl chlorides furnished two enantiomerically pure 1,2,4-oxadiazoles in moderate yields, which were screened for in vitro activity against Mycobacterium tuberculosis H37Rv (MTB) and multi-drug resistant M. tuberculosis (MDR-TB).  Among the compds. screened, compd. II (ring stereo unassigned) was found to be the most active in vitro with a MIC value of 0.07 and 0.14 μM against MTB and MDR-TB resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHXsJkDg5Y7rVg90H21EOLACvtfcHk0li1vIC9kNXcLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnvVygt7c%253D&md5=f6df114c9cc69b304457e5fcb0c56c82</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2012.04.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2012.04.021%26sid%3Dliteratum%253Aachs%26aulast%3DAlmansour%26aufirst%3DA.%2BI.%26aulast%3DSuresh%2BKumar%26aufirst%3DR.%26aulast%3DArumugam%26aufirst%3DN.%26aulast%3DSriram%26aufirst%3DD.%26atitle%3DA%2520solvent%2520free%252C%2520four-component%2520synthesis%2520and%25201%252C3-dipolar%2520cycloaddition%2520of%25204%2528h%2529-pyrans%2520with%2520nitrile%2520oxides%253A%2520Synthesis%2520and%2520discovery%2520of%2520antimycobacterial%2520activity%2520of%2520enantiomerically%2520pure%25201%252C2%252C4-oxadiazoles%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2012%26volume%3D53%26spage%3D416%26epage%3D423%26doi%3D10.1016%2Fj.ejmech.2012.04.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sriram, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yogeeswari, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinakaran, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadhwal, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel antitubercular 2,10-dihydro-4ah-chromeno[3,2-c]pyridin-3-yl derivatives</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">120</span>– <span class="NLM_lpage">123</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2009.09.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.ejmech.2009.09.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=19942326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsF2ju7%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2010&pages=120-123&author=D.+Sriramauthor=P.+Yogeeswariauthor=M.+Dinakaranauthor=D.+Banerjeeauthor=P.+Bhatauthor=S.+Gadhwal&title=Discovery+of+novel+antitubercular+2%2C10-dihydro-4ah-chromeno%5B3%2C2-c%5Dpyridin-3-yl+derivatives&doi=10.1016%2Fj.ejmech.2009.09.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel antitubercular 2,10-dihydro-4aH-chromeno[3,2-c]pyridin-3-yl derivatives</span></div><div class="casAuthors">Sriram, Dharmarajan; Yogeeswari, Perumal; Dinakaran, Murugesan; Banerjee, Debjani; Bhat, Pritesh; Gadhwal, Sunil</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">120-123</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Twenty two novel 2,10-dihydro-4aH-chromeno[3,2-c]pyridin-3-yl derivs. were synthesized by reacting 3-formyl chromone, (sub)-2-amino pyridines, and N1-(prop-2-ynyl)arylamides in the presence of indium triflate.  The compds. were evaluated for their preliminary in-vitro and in-vivo activity against Mycobacterium tuberculosis H37Rv (MTB) and multi-drug resistant M. tuberculosis (MDR-TB).  Among them I was found to be the most active compd. in-vitro with MIC's of 0.22 and 0.07 μg/mL against MTB and MDR-TB resp.  In the in-vivo animal model I decreased the bacterial load in lung and spleen tissues with 1.11 and 2.94-log10 protections resp. at 25 mg/kg body wt. dose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWVPZwaPvoHLVg90H21EOLACvtfcHk0li1vIC9kNXcLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsF2ju7%252FO&md5=3d92b6be4c3db800d3303866eadea522</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2009.09.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2009.09.033%26sid%3Dliteratum%253Aachs%26aulast%3DSriram%26aufirst%3DD.%26aulast%3DYogeeswari%26aufirst%3DP.%26aulast%3DDinakaran%26aufirst%3DM.%26aulast%3DBanerjee%26aufirst%3DD.%26aulast%3DBhat%26aufirst%3DP.%26aulast%3DGadhwal%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520novel%2520antitubercular%25202%252C10-dihydro-4ah-chromeno%255B3%252C2-c%255Dpyridin-3-yl%2520derivatives%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2010%26volume%3D45%26spage%3D120%26epage%3D123%26doi%3D10.1016%2Fj.ejmech.2009.09.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jeyachandran, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramesh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sriram, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senthilkumar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yogeeswari, P.</span></span> <span> </span><span class="NLM_article-title">Synthesis and in vitro antitubercular activity of 4-aryl/alkylsulfonylmethylcoumarins as inhibitors of mycobacterium tuberculosis</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">4807</span>– <span class="NLM_lpage">4809</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.05.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmcl.2012.05.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=22726933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38XovFWku7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=4807-4809&author=M.+Jeyachandranauthor=P.+Rameshauthor=D.+Sriramauthor=P.+Senthilkumarauthor=P.+Yogeeswari&title=Synthesis+and+in+vitro+antitubercular+activity+of+4-aryl%2Falkylsulfonylmethylcoumarins+as+inhibitors+of+mycobacterium+tuberculosis&doi=10.1016%2Fj.bmcl.2012.05.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and in vitro antitubercular activity of 4-aryl/alkylsulfonylmethylcoumarins as inhibitors of Mycobacterium tuberculosis</span></div><div class="casAuthors">Jeyachandran, Malaichamy; Ramesh, Penugonda; Sriram, Dharmarajan; Senthilkumar, Palaniappan; Yogeeswari, Perumal</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4807-4809</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of 4-aryl/alkylsulfonylmethylcoumarins have been synthesized and screened for in vitro antitubercular activity against Mycobacterium tuberculosis H37Rv (MTB).  Four of the compds. showed MIC in the range of 0.78-3.13 μg/mL proving their potential activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgY51oiqEvk7Vg90H21EOLACvtfcHk0li1vIC9kNXcLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovFWku7w%253D&md5=34d3ce448161608ca7e95cda4d9917fd</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.05.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.05.054%26sid%3Dliteratum%253Aachs%26aulast%3DJeyachandran%26aufirst%3DM.%26aulast%3DRamesh%26aufirst%3DP.%26aulast%3DSriram%26aufirst%3DD.%26aulast%3DSenthilkumar%26aufirst%3DP.%26aulast%3DYogeeswari%26aufirst%3DP.%26atitle%3DSynthesis%2520and%2520in%2520vitro%2520antitubercular%2520activity%2520of%25204-aryl%252Falkylsulfonylmethylcoumarins%2520as%2520inhibitors%2520of%2520mycobacterium%2520tuberculosis%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D4807%26epage%3D4809%26doi%3D10.1016%2Fj.bmcl.2012.05.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palomba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briguglio, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corona, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piras, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jabes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guglierame, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molicotti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanetti, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and anti-mycobacterial activities of triazoloquinolones</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">320</span>– <span class="NLM_lpage">326</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2010.11.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.ejmech.2010.11.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=21145625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A280%3ADC%252BC3M%252Fls1SrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2011&pages=320-326&author=A.+Cartaauthor=M.+Palombaauthor=I.+Briguglioauthor=P.+Coronaauthor=S.+Pirasauthor=D.+Jabesauthor=P.+Guglierameauthor=P.+Molicottiauthor=S.+Zanetti&title=Synthesis+and+anti-mycobacterial+activities+of+triazoloquinolones&doi=10.1016%2Fj.ejmech.2010.11.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and anti-mycobacterial activities of triazoloquinolones</span></div><div class="casAuthors">Carta Antonio; Palomba Michele; Briguglio Irene; Corona Paola; Piras Sandra; Jabes Daniela; Guglierame Paola; Molicotti Paola; Zanetti Stefania</div><div class="citationInfo"><span class="NLM_cas:title">European journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">320-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">A number of quinolone derivatives have been reported to possess anti-mycobacterial activity.  Generally.  Mycobacterium tuberculosis isolates expressing resistance to both isoniazid and rifampin are susceptible to fluoroquinolones.  Benzotriazole is a hetero-bicyclic aromatic ring endowed with interesting chemical and biological properties and pharmacological activities.  In a preliminary study we have recently reported the activity of triazolo[4,5-h]quinolone-carboxylic acids, a new class of benzotriazole derivatives active against multi-drug resistant M. tuberculosis (MDR-Mtb).  In this study we confirm that this novel class of quinolones is endowed with a selective anti-mycobacterial activity, coupled with absence of cytotoxicity.  The SAR analysis of the new derivatives in comparison with the previous series shows that the methyl group is the most effective substituent in both N-3 and N-9 positions of the ring system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRGpSfNoQPp8UH3Rlp_k91zfW6udTcc2eZFUeLVaqtEDbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M%252Fls1SrsA%253D%253D&md5=e2024c716bcfa9bd773a36f73fbd1d66</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2010.11.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2010.11.020%26sid%3Dliteratum%253Aachs%26aulast%3DCarta%26aufirst%3DA.%26aulast%3DPalomba%26aufirst%3DM.%26aulast%3DBriguglio%26aufirst%3DI.%26aulast%3DCorona%26aufirst%3DP.%26aulast%3DPiras%26aufirst%3DS.%26aulast%3DJabes%26aufirst%3DD.%26aulast%3DGuglierame%26aufirst%3DP.%26aulast%3DMolicotti%26aufirst%3DP.%26aulast%3DZanetti%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520anti-mycobacterial%2520activities%2520of%2520triazoloquinolones%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2011%26volume%3D46%26spage%3D320%26epage%3D326%26doi%3D10.1016%2Fj.ejmech.2010.11.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Makarov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neres, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartkoorn, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryabova, O. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazakova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huszar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolly, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conroy, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikusova, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S. T.</span></span> <span> </span><span class="NLM_article-title">The 8-pyrrole-benzothiazinones are noncovalent inhibitors of DprE1 from mycobacterium tuberculosis</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">4446</span>– <span class="NLM_lpage">4452</span>, <span class="refDoi"> DOI: 10.1128/AAC.00778-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.00778-15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=25987616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1KntLzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=4446-4452&author=V.+Makarovauthor=J.+Neresauthor=R.+C.+Hartkoornauthor=O.+B.+Ryabovaauthor=E.+Kazakovaauthor=M.+Sarkanauthor=S.+Huszarauthor=J.+Pitonauthor=G.+S.+Kollyauthor=A.+Vocatauthor=T.+M.+Conroyauthor=K.+Mikusovaauthor=S.+T.+Cole&title=The+8-pyrrole-benzothiazinones+are+noncovalent+inhibitors+of+DprE1+from+mycobacterium+tuberculosis&doi=10.1128%2FAAC.00778-15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">The 8-pyrrole-benzothiazinones are noncovalent inhibitors of DprE1 from Mycobacterium tuberculosis</span></div><div class="casAuthors">Makarov, Vadim; Neres, Joao; Hartkoorn, Ruben C.; Ryabova, Olga B.; Kazakova, Elena; Sarkan, Michal; Huszar, Stanislav; Piton, Jeremie; Kolly, Gaelle S.; Vocat, Anthony; Conroy, Trent M.; Mikusova, Katarina; Cole, Stewart T.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4446-4452</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">8-Nitro-benzothiazinones (BTZs), such as BTZ043 and PBTZ169, inhibit decaprenylphosphoryl-β-d-ribose 2'-oxidase (DprE1) and display nanomolar bactericidal activity against Mycobacterium tuberculosis in vitro.  Structure-activity relationship (SAR) studies revealed the 8-nitro group of the BTZ scaffold to be crucial for the mechanism of action, which involves formation of a semimercaptal bond with Cys387 in the active site of DprE1.  To date, substitution of the 8-nitro group has led to extensive loss of antimycobacterial activity.  Here, we report the synthesis and characterization of the pyrrole-benzothiazinones PyrBTZ01 and PyrBTZ02, non-nitro-benzothiazinones that retain significant antimycobacterial activity, with MICs of 0.16 μg/mL against M. tuberculosis.  These compds. inhibit DprE1 with 50% inhibitory concn. (IC50) values of <8 μM and present favorable in vitro absorption-distribution-metab.-excretion/toxicity (ADME/T) and in vivo pharmacokinetic profiles.  The most promising compd., PyrBTZ01, did not show efficacy in a mouse model of acute tuberculosis, suggesting that BTZ-mediated killing through DprE1 inhibition requires a combination of both covalent bond formation and compd. potency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCkI5dkX3OC7Vg90H21EOLACvtfcHk0lgezPcjyW47aA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1KntLzN&md5=135807fc4818119172942c09971147fd</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1128%2FAAC.00778-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00778-15%26sid%3Dliteratum%253Aachs%26aulast%3DMakarov%26aufirst%3DV.%26aulast%3DNeres%26aufirst%3DJ.%26aulast%3DHartkoorn%26aufirst%3DR.%2BC.%26aulast%3DRyabova%26aufirst%3DO.%2BB.%26aulast%3DKazakova%26aufirst%3DE.%26aulast%3DSarkan%26aufirst%3DM.%26aulast%3DHuszar%26aufirst%3DS.%26aulast%3DPiton%26aufirst%3DJ.%26aulast%3DKolly%26aufirst%3DG.%2BS.%26aulast%3DVocat%26aufirst%3DA.%26aulast%3DConroy%26aufirst%3DT.%2BM.%26aulast%3DMikusova%26aufirst%3DK.%26aulast%3DCole%26aufirst%3DS.%2BT.%26atitle%3DThe%25208-pyrrole-benzothiazinones%2520are%2520noncovalent%2520inhibitors%2520of%2520DprE1%2520from%2520mycobacterium%2520tuberculosis%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26spage%3D4446%26epage%3D4452%26doi%3D10.1128%2FAAC.00778-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">182</a></strong><div class="NLM_citation" id="rightTab-cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lechartier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartkoorn, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S. T.</span></span> <span> </span><span class="NLM_article-title">In vitro combination studies of benzothiazinone lead compound BTZ043 against mycobacterium tuberculosis</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">5790</span>– <span class="NLM_lpage">5793</span>, <span class="refDoi"> DOI: 10.1128/AAC.01476-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.01476-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=22926573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsF2iurnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=5790-5793&author=B.+Lechartierauthor=R.+C.+Hartkoornauthor=S.+T.+Cole&title=In+vitro+combination+studies+of+benzothiazinone+lead+compound+BTZ043+against+mycobacterium+tuberculosis&doi=10.1128%2FAAC.01476-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis</span></div><div class="casAuthors">Lechartier, Benoit; Hartkoorn, Ruben C.; Cole, Stewart T.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5790-5793</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Benzothiazinones (BTZ) are a new class of drug candidates to combat tuberculosis that inhibit decaprenyl-phosphoribose epimerase (DprE1), an essential enzyme involved in arabinan biosynthesis.  Using the checkerboard method and cell viability assays, the authors have studied the interaction profiles of BTZ043, the current lead compd., with several antituberculosis drugs or drug candidates against Mycobacterium tuberculosis strain H37Rv, namely, rifampin, isoniazid, ethambutol, TMC207, PA-824, moxifloxacin, meropenem with or without clavulanate, and SQ-109.  No antagonism was found between BTZ043 and the tested compds., and most of the interactions were purely additive.  Data from two different approaches clearly indicate that BTZ043 acts synergistically with TMC207, with a fractional inhibitory concn. index of 0.5.  TMC207 at a quarter of the MIC (20 ng/mL) used in combination with BTZ043 (1/4 MIC, 0.375 ng/mL) had a stronger bactericidal effect on M. tuberculosis than TMC207 alone at a concn. of 80 ng/mL.  This synergy was not obsd. when the combination was tested on a BTZ-resistant M. tuberculosis mutant, suggesting that DprE1 inhibition is the basis for the interaction.  This finding excludes the possibility of synergy occurring through an off-target mechanism.  We therefore hypothesize that sub-MICs of BTZ043 weaken the bacterial cell wall and allow improved penetration of TMC207 to its target.  Synergy between two new antimycobacterial compds., such as TMC207 and BTZ043, with novel targets, offers an attractive foundation for a new tuberculosis regimen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQb9Jz2Uer_rVg90H21EOLACvtfcHk0lgezPcjyW47aA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsF2iurnJ&md5=51a7a69ecdfd6828fb8a7eb214902812</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1128%2FAAC.01476-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01476-12%26sid%3Dliteratum%253Aachs%26aulast%3DLechartier%26aufirst%3DB.%26aulast%3DHartkoorn%26aufirst%3DR.%2BC.%26aulast%3DCole%26aufirst%3DS.%2BT.%26atitle%3DIn%2520vitro%2520combination%2520studies%2520of%2520benzothiazinone%2520lead%2520compound%2520BTZ043%2520against%2520mycobacterium%2520tuberculosis%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D5790%26epage%3D5793%26doi%3D10.1128%2FAAC.01476-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref183"><div class="reference"><strong class="refLabel"><a href="#ref183" class="rightTabRefNumLink">183</a></strong><div class="NLM_citation" id="rightTab-cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karoli, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuegg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Möllmann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, M. A.</span></span> <span> </span><span class="NLM_article-title">Identification of antitubercular benzothiazinone compounds by ligand-based design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">7940</span>– <span class="NLM_lpage">7944</span>, <span class="refDoi"> DOI: 10.1021/jm3008882</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3008882" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Ghu73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7940-7944&author=T.+Karoliauthor=B.+Beckerauthor=J.+Zueggauthor=U.+M%C3%B6llmannauthor=S.+Ramuauthor=J.+X.+Huangauthor=M.+A.+Cooper&title=Identification+of+antitubercular+benzothiazinone+compounds+by+ligand-based+design&doi=10.1021%2Fjm3008882"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Antitubercular Benzothiazinone Compounds by Ligand-Based Design</span></div><div class="casAuthors">Karoli, Tomislav; Becker, Bernd; Zuegg, Johannes; Mollmann, Ute; Ramu, Soumya; Huang, Johnny X.; Cooper, Matthew A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7940-7944</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">1,3-Benzothiazin-4-ones (BTZs) are a novel class of TB drug candidates with potent activity against M. tuberculosis.  An in silico ligand-based model based on structure-activity data from 170 BTZ compds. was used to design a new series.  Compds. were tested against a panel of mycobacterial strains and were profiled for cytotoxicity, stability, and antiproliferative effects.  Several of the compds. showed improved activity against MDR-TB while retaining low toxicity with higher microsomal, metabolic, and plasma stability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo55OwRcL9-ebVg90H21EOLACvtfcHk0liO6es2W2zUIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Ghu73K&md5=8f9d6a494927943613d7cfc78b97a188</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1021%2Fjm3008882&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3008882%26sid%3Dliteratum%253Aachs%26aulast%3DKaroli%26aufirst%3DT.%26aulast%3DBecker%26aufirst%3DB.%26aulast%3DZuegg%26aufirst%3DJ.%26aulast%3DM%25C3%25B6llmann%26aufirst%3DU.%26aulast%3DRamu%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DJ.%2BX.%26aulast%3DCooper%26aufirst%3DM.%2BA.%26atitle%3DIdentification%2520of%2520antitubercular%2520benzothiazinone%2520compounds%2520by%2520ligand-based%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7940%26epage%3D7944%26doi%3D10.1021%2Fjm3008882" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref184"><div class="reference"><strong class="refLabel"><a href="#ref184" class="rightTabRefNumLink">184</a></strong><div class="NLM_citation" id="rightTab-cit184"><span> <i>Macozinone
(MCZ, PBTZ-169)</i>; <span class="NLM_publisher-name">The Working
Group for New TB Drugs</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">2018</span>; <a href="https://www.newtbdrugs.org/pipeline/compound/macozinone-mcz-pbtz-169" class="extLink">https://www.newtbdrugs.org/pipeline/compound/macozinone-mcz-pbtz-169</a> (accessed 2020-03-03).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Macozinone%0A%28MCZ%2C+PBTZ-169%29%3B+The+Working%0AGroup+for+New+TB+Drugs%3A+New+York%2C+2018%3B+https%3A%2F%2Fwww.newtbdrugs.org%2Fpipeline%2Fcompound%2Fmacozinone-mcz-pbtz-169+%28accessed+2020-03-03%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26jtitle%3DMacozinone%250A%2528MCZ%252C%2520PBTZ-169%2529%26pub%3DThe%2520Working%250AGroup%2520for%2520New%2520TB%2520Drugs%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref185"><div class="reference"><strong class="refLabel"><a href="#ref185" class="rightTabRefNumLink">185</a></strong><div class="NLM_citation" id="rightTab-cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Almansour, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ismail, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choon, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellappan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elumalai, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandian, S.</span></span> <span> </span><span class="NLM_article-title">A regio- and stereoselective 1,3-dipolar cycloaddition for the synthesis of new-fangled dispiropyrrolothiazoles as antimycobacterial agents</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">7418</span>– <span class="NLM_lpage">7421</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.10.059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmcl.2012.10.059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=23122863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Wjs7%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=7418-7421&author=A.+I.+Almansourauthor=S.+Aliauthor=M.+A.+Aliauthor=R.+Ismailauthor=T.+S.+Choonauthor=V.+Sellappanauthor=K.+K.+Elumalaiauthor=S.+Pandian&title=A+regio-+and+stereoselective+1%2C3-dipolar+cycloaddition+for+the+synthesis+of+new-fangled+dispiropyrrolothiazoles+as+antimycobacterial+agents&doi=10.1016%2Fj.bmcl.2012.10.059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">A regio- and stereoselective 1,3-dipolar cycloaddition for the synthesis of new-fangled dispiropyrrolothiazoles as antimycobacterial agents</span></div><div class="casAuthors">Almansour, Abdulrahman I.; Ali, Sadath; Ali, Mohamed Ashraf; Ismail, Rusli; Choon, Tan Soo; Sellappan, Velmurugan; Elumalai, Karthi keyan; Pandian, Suresh</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7418-7421</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of dispiropyrrolothiazoles compds. were synthesized using 1,3-dipolar cycloaddn. and were screened for antimycobacterial activity against Mycobacterium tuberculosis H37Rv and INH resistant M. tuberculosis strains.  Two of them were showing good activity with MIC of less than 1 μM.  Compd. I (R = pyridyl) was found to be the most active with MIC of 0.210 and 8.312 μM resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5XqIAqogTjLVg90H21EOLACvtfcHk0liO6es2W2zUIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Wjs7%252FO&md5=f2c6fef32d4d65ce38f5604b042ab220</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.10.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.10.059%26sid%3Dliteratum%253Aachs%26aulast%3DAlmansour%26aufirst%3DA.%2BI.%26aulast%3DAli%26aufirst%3DS.%26aulast%3DAli%26aufirst%3DM.%2BA.%26aulast%3DIsmail%26aufirst%3DR.%26aulast%3DChoon%26aufirst%3DT.%2BS.%26aulast%3DSellappan%26aufirst%3DV.%26aulast%3DElumalai%26aufirst%3DK.%2BK.%26aulast%3DPandian%26aufirst%3DS.%26atitle%3DA%2520regio-%2520and%2520stereoselective%25201%252C3-dipolar%2520cycloaddition%2520for%2520the%2520synthesis%2520of%2520new-fangled%2520dispiropyrrolothiazoles%2520as%2520antimycobacterial%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D7418%26epage%3D7421%26doi%3D10.1016%2Fj.bmcl.2012.10.059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref186"><div class="reference"><strong class="refLabel"><a href="#ref186" class="rightTabRefNumLink">186</a></strong><div class="NLM_citation" id="rightTab-cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karthikeyan, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bala, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raja, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perumal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yogeeswari, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sriram, D.</span></span> <span> </span><span class="NLM_article-title">A highly atom economic, chemo-, regio- and stereoselective synthesis and evaluation of spiro-pyrrolothiazoles as antitubercular agents</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">350</span>– <span class="NLM_lpage">353</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.10.107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmcl.2009.10.107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=19900810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsF2jsb3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=350-353&author=S.+V.+Karthikeyanauthor=B.+D.+Balaauthor=V.+P.+Rajaauthor=S.+Perumalauthor=P.+Yogeeswariauthor=D.+Sriram&title=A+highly+atom+economic%2C+chemo-%2C+regio-+and+stereoselective+synthesis+and+evaluation+of+spiro-pyrrolothiazoles+as+antitubercular+agents&doi=10.1016%2Fj.bmcl.2009.10.107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">A highly atom economic, chemo-, regio- and stereoselective synthesis and evaluation of spiro-pyrrolothiazoles as antitubercular agents</span></div><div class="casAuthors">Karthikeyan, Subramanian Vedhanarayanan; Bala, Balasubramanian Devi; Raja, Velanganni Paul Alex; Perumal, Subbu; Yogeeswari, Perumal; Sriram, Dharmarajan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">350-353</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The 1,3-dipolar cycloaddn. of azomethine ylides, derived from substituted isatins and 1,3-thiazolidine-4-carboxylic acid, to a series of 1-methyl-3,5-bis[(E)-arylmethylidene]-tetrahydro-4(1H)-pyridinones I (R = Ph, 4-FC6H4, 2-MeOC6H4, 2,4-Cl2C6H3, 2-thienyl, etc.) afforded novel spiro-pyrrolothiazoles II (X = H, Cl, O2N) chemo-, regio- and stereoselectively in excellent yields.  These compds. were screened for their in vitro activity against Mycobacterium tuberculosis H37Rv (MTB) and multi-drug resistant M. tuberculosis (MDR-TB) using agar diln. method.  Among the synthesized compds., I (R = 2,4-Cl2C6H3; X = O2N) was found to be the most active with a min. inhibitory concn. (MIC) of 0.6 μM against MTB and MDR-TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqkj6yCeaqqbVg90H21EOLACvtfcHk0liO6es2W2zUIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsF2jsb3F&md5=302cb2c22b03cb71f30408a6584d0ef6</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.10.107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.10.107%26sid%3Dliteratum%253Aachs%26aulast%3DKarthikeyan%26aufirst%3DS.%2BV.%26aulast%3DBala%26aufirst%3DB.%2BD.%26aulast%3DRaja%26aufirst%3DV.%2BP.%26aulast%3DPerumal%26aufirst%3DS.%26aulast%3DYogeeswari%26aufirst%3DP.%26aulast%3DSriram%26aufirst%3DD.%26atitle%3DA%2520highly%2520atom%2520economic%252C%2520chemo-%252C%2520regio-%2520and%2520stereoselective%2520synthesis%2520and%2520evaluation%2520of%2520spiro-pyrrolothiazoles%2520as%2520antitubercular%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D350%26epage%3D353%26doi%3D10.1016%2Fj.bmcl.2009.10.107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref187"><div class="reference"><strong class="refLabel"><a href="#ref187" class="rightTabRefNumLink">187</a></strong><div class="NLM_citation" id="rightTab-cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, D. Q.</span></span> <span> </span><span class="NLM_article-title">Synthesis, structure-activity relationship and in vitro anti-mycobacterial evaluation of 13-n-octylberberine derivatives</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">158</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2012.03.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.ejmech.2012.03.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=22503208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtlSlu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=151-158&author=Y.+X.+Liuauthor=C.+L.+Xiaoauthor=Y.+X.+Wangauthor=Y.+H.+Liauthor=Y.+H.+Yangauthor=Y.+B.+Liauthor=C.+W.+Biauthor=L.+M.+Gaoauthor=J.+D.+Jiangauthor=D.+Q.+Song&title=Synthesis%2C+structure-activity+relationship+and+in+vitro+anti-mycobacterial+evaluation+of+13-n-octylberberine+derivatives&doi=10.1016%2Fj.ejmech.2012.03.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, structure-activity relationship and in vitro anti-mycobacterial evaluation of 13-n-octylberberine derivatives</span></div><div class="casAuthors">Liu, Yan-Xin; Xiao, Chun-Ling; Wang, Yan-Xiang; Li, Ying-Hong; Yang, Yan-Hui; Li, Yang-Biao; Bi, Chong-Wen; Gao, Li-Mei; Jiang, Jian-Dong; Song, Dan-Qing</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">151-158</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Twenty-eight new 13-n-octylberberine derivs. I (R1 = OMe, OH, OCH2Ph, etc., R2R3 = OCH2O; R1 = OMe, R2 = OH, OMe, OCH2Ph, etc., R3 = OH, O-n-Pr, O-n-Bu, etc.; R1 = OMe, R2 = R3 = OH; R1 = R2 = R3 = OH; R1 = OEt, OCH2Ph, O-n-Pr, O-n-Bu, R2 = OH, OEt, OCH2Ph, R3 = OEt, O-n-Pr, O-n-Bu, OCH2Ph) were synthesized and evaluated for their activities against drug-susceptible Mycobacterium tuberculosis (M. tuberculosis) strain H37Rv.  Among these compds., compd. I (R1 = R2 = R3 = OEt) (II) was the most effective anti-tubercular agent with a MIC value of 0.125 μg/mL.  Importantly, compd. II exhibited a more potent effect against rifampicin (RIF)- and isoniazid (INH)-resistant M. tuberculosis strains than both RIF and INH, suggesting a new mechanism of action.  Therefore, II has been selected as a drug candidate for further investigation, or as a chem. probe for identifying the protein target and studying tuberculosis biol.  We consider 13-n-octylberberine analogs to be a promising novel class of antituberculars against multi-drug-resistant (MDR) strains of M. tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocfJRw7pCmy7Vg90H21EOLACvtfcHk0lh6eX5Vkaqdrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtlSlu7w%253D&md5=0e00abe606d8ba77f4838f66f72e3879</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2012.03.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2012.03.012%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%2BX.%26aulast%3DXiao%26aufirst%3DC.%2BL.%26aulast%3DWang%26aufirst%3DY.%2BX.%26aulast%3DLi%26aufirst%3DY.%2BH.%26aulast%3DYang%26aufirst%3DY.%2BH.%26aulast%3DLi%26aufirst%3DY.%2BB.%26aulast%3DBi%26aufirst%3DC.%2BW.%26aulast%3DGao%26aufirst%3DL.%2BM.%26aulast%3DJiang%26aufirst%3DJ.%2BD.%26aulast%3DSong%26aufirst%3DD.%2BQ.%26atitle%3DSynthesis%252C%2520structure-activity%2520relationship%2520and%2520in%2520vitro%2520anti-mycobacterial%2520evaluation%2520of%252013-n-octylberberine%2520derivatives%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2012%26volume%3D52%26spage%3D151%26epage%3D158%26doi%3D10.1016%2Fj.ejmech.2012.03.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref188"><div class="reference"><strong class="refLabel"><a href="#ref188" class="rightTabRefNumLink">188</a></strong><div class="NLM_citation" id="rightTab-cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keffer, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huecas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammill, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wipf, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreu, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bewley, C. A.</span></span> <span> </span><span class="NLM_article-title">Chrysophaentins are competitive inhibitors of FtsZ and inhibit z-ring formation in live bacteria</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">5673</span>– <span class="NLM_lpage">5678</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.07.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmc.2013.07.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=23932448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1elur7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=5673-5678&author=J.+L.+Kefferauthor=S.+Huecasauthor=J.+T.+Hammillauthor=P.+Wipfauthor=J.+M.+Andreuauthor=C.+A.+Bewley&title=Chrysophaentins+are+competitive+inhibitors+of+FtsZ+and+inhibit+z-ring+formation+in+live+bacteria&doi=10.1016%2Fj.bmc.2013.07.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Chrysophaentins are competitive inhibitors of FtsZ and inhibit Z-ring formation in live bacteria</span></div><div class="casAuthors">Keffer, Jessica L.; Huecas, Sonia; Hammill, Jared T.; Wipf, Peter; Andreu, Jose M.; Bewley, Carole A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5673-5678</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The bacterial cell division protein FtsZ polymerizes in a GTP-dependent manner to form a Z-ring that marks the plane of division.  As a validated antimicrobial target, considerable efforts have been devoted to identify small mol. FtsZ inhibitors.  The authors recently discovered the chrysophaentins, a novel suite of marine natural products that inhibit FtsZ activity in vitro.  These natural products along with a synthetic hemi-chrysophaentin exhibit strong antimicrobial activity toward a broad spectrum of Gram-pos. pathogens.  To define the mechanisms of FtsZ inhibition and det. their in vivo effects in live bacteria, the authors used GTPase assays and fluorescence anisotropy to show that hemi-chrysophaentin competitively inhibits FtsZ activity.  Furthermore, they developed a model system using a permeable Escherichia coli strain, envA1, together with an inducible FtsZ-yellow fluorescent protein construct to show by fluorescence microscopy that both chrysophaentin A and hemi-chrysophaentin disrupt Z-rings in live bacteria.  The authors tested the E. coli system further by reproducing phenotypes obsd. for zantrins Z1 and Z3, and demonstrate that the alkaloid berberine, a reported FtsZ inhibitor, exhibits auto-fluorescence, making it incompatible with systems that employ GFP or YFP tagged FtsZ.  These studies describe unique examples of nonnucleotide, competitive FtsZ inhibitors that disrupt FtsZ in vivo, together with a model system that should be useful for in vivo testing of FtsZ inhibitor leads that have been identified through in vitro screens but are unable to penetrate the Gram-neg. outer membrane.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlTOsVKDet67Vg90H21EOLACvtfcHk0lh6eX5Vkaqdrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1elur7K&md5=a9716bf8cd08d90092613473456db1ac</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.07.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.07.033%26sid%3Dliteratum%253Aachs%26aulast%3DKeffer%26aufirst%3DJ.%2BL.%26aulast%3DHuecas%26aufirst%3DS.%26aulast%3DHammill%26aufirst%3DJ.%2BT.%26aulast%3DWipf%26aufirst%3DP.%26aulast%3DAndreu%26aufirst%3DJ.%2BM.%26aulast%3DBewley%26aufirst%3DC.%2BA.%26atitle%3DChrysophaentins%2520are%2520competitive%2520inhibitors%2520of%2520FtsZ%2520and%2520inhibit%2520z-ring%2520formation%2520in%2520live%2520bacteria%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D5673%26epage%3D5678%26doi%3D10.1016%2Fj.bmc.2013.07.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref189"><div class="reference"><strong class="refLabel"><a href="#ref189" class="rightTabRefNumLink">189</a></strong><div class="NLM_citation" id="rightTab-cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hotoda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furukawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daigo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murayama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muramatsu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyakoshi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takatsu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inukai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakuta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuoka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Utsui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohya, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antimycobacterial activity of capuramycin analogues. Part 1: Substitution of the azepan-2-one moiety of capuramycin</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">2829</span>– <span class="NLM_lpage">2832</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(03)00596-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2FS0960-894X%2803%2900596-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=14611838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmvFajtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=2829-2832&author=H.+Hotodaauthor=M.+Furukawaauthor=M.+Daigoauthor=K.+Murayamaauthor=M.+Kanekoauthor=Y.+Muramatsuauthor=M.+M.+Ishiiauthor=S.+Miyakoshiauthor=T.+Takatsuauthor=M.+Inukaiauthor=M.+Kakutaauthor=T.+Abeauthor=T.+Harasakiauthor=T.+Fukuokaauthor=Y.+Utsuiauthor=S.+Ohya&title=Synthesis+and+antimycobacterial+activity+of+capuramycin+analogues.+Part+1%3A+Substitution+of+the+azepan-2-one+moiety+of+capuramycin&doi=10.1016%2FS0960-894X%2803%2900596-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antimycobacterial activity of capuramycin analogs. Part 1: Substitution of the azepan-2-one moiety of capuramycin</span></div><div class="casAuthors">Hotoda, Hitoshi; Furukawa, Miyuki; Daigo, Makiko; Murayama, Kazuhiro; Kaneko, Masakatsu; Muramatsu, Yasunori; Ishii, Michiko Miyazawa; Miyakoshi, Shun-ichi; Takatsu, Toshio; Inukai, Masatoshi; Kakuta, Masayo; Abe, Tomomi; Harasaki, Tamako; Fukuoka, Takashi; Utsui, Yukio; Ohya, Satoshi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2829-2832</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Capuramycin analogs, e.g. I, with a variety of substituents in place of the azepan-2-one moiety were synthesized from A-500359E and were tested for their translocase I inhibitory activity and in vitro antimycobacterial activity.  Phenyl-type moieties were found to be effective substituents for capuramycin analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDe1IJkAmDh7Vg90H21EOLACvtfcHk0lh6eX5Vkaqdrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmvFajtb0%253D&md5=439f894b257ccceffb84ca0cb39b675b</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2803%2900596-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252803%252900596-1%26sid%3Dliteratum%253Aachs%26aulast%3DHotoda%26aufirst%3DH.%26aulast%3DFurukawa%26aufirst%3DM.%26aulast%3DDaigo%26aufirst%3DM.%26aulast%3DMurayama%26aufirst%3DK.%26aulast%3DKaneko%26aufirst%3DM.%26aulast%3DMuramatsu%26aufirst%3DY.%26aulast%3DIshii%26aufirst%3DM.%2BM.%26aulast%3DMiyakoshi%26aufirst%3DS.%26aulast%3DTakatsu%26aufirst%3DT.%26aulast%3DInukai%26aufirst%3DM.%26aulast%3DKakuta%26aufirst%3DM.%26aulast%3DAbe%26aufirst%3DT.%26aulast%3DHarasaki%26aufirst%3DT.%26aulast%3DFukuoka%26aufirst%3DT.%26aulast%3DUtsui%26aufirst%3DY.%26aulast%3DOhya%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520antimycobacterial%2520activity%2520of%2520capuramycin%2520analogues.%2520Part%25201%253A%2520Substitution%2520of%2520the%2520azepan-2-one%2520moiety%2520of%2520capuramycin%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26spage%3D2829%26epage%3D2832%26doi%3D10.1016%2FS0960-894X%2803%2900596-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref190"><div class="reference"><strong class="refLabel"><a href="#ref190" class="rightTabRefNumLink">190</a></strong><div class="NLM_citation" id="rightTab-cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bugg, T. D.</span></span> <span> </span><span class="NLM_article-title">Recent advances in antimicrobial nucleoside antibiotics targeting cell wall biosynthesis</span>. <i>Nat. Prod. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">252</span>– <span class="NLM_lpage">273</span>, <span class="refDoi"> DOI: 10.1039/b202149h</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1039%2Fb202149h" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=12735700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjslCqtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2003&pages=252-273&author=K.+Kimuraauthor=T.+D.+Bugg&title=Recent+advances+in+antimicrobial+nucleoside+antibiotics+targeting+cell+wall+biosynthesis&doi=10.1039%2Fb202149h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in antimicrobial nucleoside antibiotics targeting cell wall biosynthesis</span></div><div class="casAuthors">Kimura, Ken-Ichi; Bugg, Timothy D. H.</div><div class="citationInfo"><span class="NLM_cas:title">Natural Product Reports</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">252-273</span>CODEN:
                <span class="NLM_cas:coden">NPRRDF</span>;
        ISSN:<span class="NLM_cas:issn">0265-0568</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  The biosynthesis of peptidoglycan is essential for all bacteria and has no counterpart in eukaryotic cells.  It is one of the prime targets for antibiotic chemotherapy, esp. phospho-MurNAc-pentapeptide translocase (translocase I) is a fascinating target in which there is no com. antibiotic.  In this review we will describe three nucleoside translocase I inhibitors, mureidomycin, tunicamycin and liposidomycin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrksNstyeT_iLVg90H21EOLACvtfcHk0lieXFFz3LrODw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjslCqtr4%253D&md5=8c6823d378a4754c368a6179b5bfa057</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1039%2Fb202149h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb202149h%26sid%3Dliteratum%253Aachs%26aulast%3DKimura%26aufirst%3DK.%26aulast%3DBugg%26aufirst%3DT.%2BD.%26atitle%3DRecent%2520advances%2520in%2520antimicrobial%2520nucleoside%2520antibiotics%2520targeting%2520cell%2520wall%2520biosynthesis%26jtitle%3DNat.%2520Prod.%2520Rep.%26date%3D2003%26volume%3D20%26spage%3D252%26epage%3D273%26doi%3D10.1039%2Fb202149h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref191"><div class="reference"><strong class="refLabel"><a href="#ref191" class="rightTabRefNumLink">191</a></strong><div class="NLM_citation" id="rightTab-cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bugg, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lloyd, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roper, D. I.</span></span> <span> </span><span class="NLM_article-title">Phospho-MurNAc-pentapeptide translocase (MraY) as a target for antibacterial agents and antibacterial proteins</span>. <i>Infect. Disord.: Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">106</span>, <span class="refDoi"> DOI: 10.2174/187152606784112128</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.2174%2F187152606784112128" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=16789873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD28XmtFers7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=85-106&author=T.+D.+Buggauthor=A.+J.+Lloydauthor=D.+I.+Roper&title=Phospho-MurNAc-pentapeptide+translocase+%28MraY%29+as+a+target+for+antibacterial+agents+and+antibacterial+proteins&doi=10.2174%2F187152606784112128"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Phospho-MurNAc-pentapeptide translocase (MraY) as a target for antibacterial agents and antibacterial proteins</span></div><div class="casAuthors">Bugg, Timothy D. H.; Lloyd, Adrian J.; Roper, David I.</div><div class="citationInfo"><span class="NLM_cas:title">Infectious Disorders: Drug Targets</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">85-106</span>CODEN:
                <span class="NLM_cas:coden">IDDTAD</span>;
        ISSN:<span class="NLM_cas:issn">1871-5265</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Phospho-MurNAc-pentapeptide translocase (MraY, translocase I) catalyzes the first step of the lipid-linked cycle of reactions of bacterial peptidoglycan biosynthesis.  MraY is the target for five families of nucleoside antibacterial natural products: the tunicamycins, the mureidomycins (also pacidamycins, napsamycins), the liposidomycins, the muraymycins, and the capuramycins.  Recent structure-activity studies on these families have led to the identification of active pharmacophores, and insight into their mechanisms of action.  This step of peptidoglycan biosynthesis is also the target for the bacteriolytic E protein from bacteriophage .vphi.X174, and for cyclic peptides of the amphomycin family which complex the undecaprenyl phosphate cosubstrate.  The mechanisms of enzyme inhibition by these agents are discussed, and the state of knowledge regarding the transmembrane structure, active site, and catalytic mechanism of MraY.  The availability of high throughput assays and prospects of MraY as an antibacterial target are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoA2V6DpkrljrVg90H21EOLACvtfcHk0lieXFFz3LrODw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmtFers7Y%253D&md5=b209c55dbd91c009a292e861eebecf44</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.2174%2F187152606784112128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152606784112128%26sid%3Dliteratum%253Aachs%26aulast%3DBugg%26aufirst%3DT.%2BD.%26aulast%3DLloyd%26aufirst%3DA.%2BJ.%26aulast%3DRoper%26aufirst%3DD.%2BI.%26atitle%3DPhospho-MurNAc-pentapeptide%2520translocase%2520%2528MraY%2529%2520as%2520a%2520target%2520for%2520antibacterial%2520agents%2520and%2520antibacterial%2520proteins%26jtitle%3DInfect.%2520Disord.%253A%2520Drug%2520Targets%26date%3D2006%26volume%3D6%26spage%3D85%26epage%3D106%26doi%3D10.2174%2F187152606784112128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref192"><div class="reference"><strong class="refLabel"><a href="#ref192" class="rightTabRefNumLink">192</a></strong><div class="NLM_citation" id="rightTab-cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nikonenko, B. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Protopopova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogatcheva, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einck, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacy, C. A.</span></span> <span> </span><span class="NLM_article-title">Activity of SQ641, a capuramycin analog, in a murine model of tuberculosis</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">3138</span>– <span class="NLM_lpage">3139</span>, <span class="refDoi"> DOI: 10.1128/AAC.00366-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FAAC.00366-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=19414567" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotlajsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2009&pages=3138-3139&author=B.+V.+Nikonenkoauthor=V.+M.+Reddyauthor=M.+Protopopovaauthor=E.+Bogatchevaauthor=L.+Einckauthor=C.+A.+Nacy&title=Activity+of+SQ641%2C+a+capuramycin+analog%2C+in+a+murine+model+of+tuberculosis&doi=10.1128%2FAAC.00366-09"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of SQ641, a capuramycin analog, in a murine model of tuberculosis</span></div><div class="casAuthors">Nikonenko, Boris V.; Reddy, Venkata M.; Protopopova, Marina; Bogatcheva, Elena; Einck, Leo; Nacy, Carol A.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3138-3139</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">New delivery vehicles and routes of delivery were developed for the capuramycin analog SQ641.  While this compd. has remarkable in vitro potency against Mycobacterium tuberculosis, it has low soly. in water and poor intracellular activity.  We demonstrate here that SQ641 dissolved in the water-sol. vitamin E analog α-tocopheryl polyethylene glycol 1000 succinate (TPGS) or incorporated into TPGS-micelles has significant activity in a mouse model of tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpktljK0aIDd7Vg90H21EOLACvtfcHk0lieXFFz3LrODw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotlajsb8%253D&md5=4b4f1a87b152b163e1d68e185e710102</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1128%2FAAC.00366-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00366-09%26sid%3Dliteratum%253Aachs%26aulast%3DNikonenko%26aufirst%3DB.%2BV.%26aulast%3DReddy%26aufirst%3DV.%2BM.%26aulast%3DProtopopova%26aufirst%3DM.%26aulast%3DBogatcheva%26aufirst%3DE.%26aulast%3DEinck%26aufirst%3DL.%26aulast%3DNacy%26aufirst%3DC.%2BA.%26atitle%3DActivity%2520of%2520SQ641%252C%2520a%2520capuramycin%2520analog%252C%2520in%2520a%2520murine%2520model%2520of%2520tuberculosis%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2009%26volume%3D53%26spage%3D3138%26epage%3D3139%26doi%3D10.1128%2FAAC.00366-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref193"><div class="reference"><strong class="refLabel"><a href="#ref193" class="rightTabRefNumLink">193</a></strong><div class="NLM_citation" id="rightTab-cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koga, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuoka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hotoda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakuta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muramatsu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoshi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirota, T.</span></span> <span> </span><span class="NLM_article-title">Activity of capuramycin analogues against mycobacterium tuberculosis, mycobacterium avium and mycobacterium intracellulare in vitro and in vivo</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">755</span>– <span class="NLM_lpage">760</span>, <span class="refDoi"> DOI: 10.1093/jac/dkh417</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1093%2Fjac%2Fdkh417" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=15347635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD2cXotVyqtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2004&pages=755-760&author=T.+Kogaauthor=T.+Fukuokaauthor=N.+Doiauthor=T.+Harasakiauthor=H.+Inoueauthor=H.+Hotodaauthor=M.+Kakutaauthor=Y.+Muramatsuauthor=N.+Yamamuraauthor=M.+Hoshiauthor=T.+Hirota&title=Activity+of+capuramycin+analogues+against+mycobacterium+tuberculosis%2C+mycobacterium+avium+and+mycobacterium+intracellulare+in+vitro+and+in+vivo&doi=10.1093%2Fjac%2Fdkh417"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of capuramycin analogues against Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium intracellulare in vitro and in vivo</span></div><div class="casAuthors">Koga, Tetsufumi; Fukuoka, Takashi; Doi, Norio; Harasaki, Tamako; Inoue, Harumi; Hotoda, Hitoshi; Kakuta, Masayo; Muramatsu, Yasunori; Yamamura, Naotoshi; Hoshi, Misa; Hirota, Takashi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">755-760</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The antimycobacterial activities of RS-112997, RS-124922 and RS-118641, three capuramycin analogs that inhibit phospho-N-acetylmuramyl-pentapeptide translocase, were tested against clin. isolates of Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium intracellulare.  MICs were detd. by the broth microdilution method using a modified Middlebrook 7H9 broth.  RS-118641 was the most potent compd. overall.  The MIC50/90 (mg/L) results for RS-118641 were: M. tuberculosis, 1/2; multidrug-resistant (MDR) M. tuberculosis, 0.5/2; M. avium, 4/8; and M. intracellulare, 0.06/0.5.  No statistically significant differences in MIC distributions were obsd. between non-MDR and MDR M. tuberculosis for any of the capuramycin analogs tested.  In order to evaluate the therapeutic efficacy of RS-112997 and RS-124922 in a murine lung model of tuberculosis, both compds. were administered intranasally at 0.1 or 1 mg/mouse/day for 12 days.  The mycobacterial load in the lungs was significantly lower in all treatment groups than in the untreated controls.  Addnl. expts. were performed to evaluate the therapeutic efficacy of the three compds. against the M. intracellulare infection in mice.  All compds. were administered intranasally at 0.1 mg/mouse/day for 21 days.  The mycobacterial load in the lungs was significantly lower in all treatment groups than in the untreated controls.  These results suggest that capuramycin analogs exhibit strong antimycobacterial potential and should be considered for further evaluation in the treatment of M. tuberculosis and M. avium-M. intracellulare complex infections in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLQOhSGpvmQLVg90H21EOLACvtfcHk0lhoKSPIDJJ3Ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXotVyqtr4%253D&md5=98c345da115351f07989711c1dc4bbad</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdkh417&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdkh417%26sid%3Dliteratum%253Aachs%26aulast%3DKoga%26aufirst%3DT.%26aulast%3DFukuoka%26aufirst%3DT.%26aulast%3DDoi%26aufirst%3DN.%26aulast%3DHarasaki%26aufirst%3DT.%26aulast%3DInoue%26aufirst%3DH.%26aulast%3DHotoda%26aufirst%3DH.%26aulast%3DKakuta%26aufirst%3DM.%26aulast%3DMuramatsu%26aufirst%3DY.%26aulast%3DYamamura%26aufirst%3DN.%26aulast%3DHoshi%26aufirst%3DM.%26aulast%3DHirota%26aufirst%3DT.%26atitle%3DActivity%2520of%2520capuramycin%2520analogues%2520against%2520mycobacterium%2520tuberculosis%252C%2520mycobacterium%2520avium%2520and%2520mycobacterium%2520intracellulare%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2004%26volume%3D54%26spage%3D755%26epage%3D760%26doi%3D10.1093%2Fjac%2Fdkh417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref194"><div class="reference"><strong class="refLabel"><a href="#ref194" class="rightTabRefNumLink">194</a></strong><div class="NLM_citation" id="rightTab-cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takemoto, Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis of cpzen-45: Construction of the 1,4-diazepin-2-one core by the cu-catalyzed intramolecular amidation of a vinyl iodide</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2300</span>– <span class="NLM_lpage">2303</span>, <span class="refDoi"> DOI: 10.1021/acs.orglett.6b00943</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.orglett.6b00943" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28Xmt1CnsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=2300-2303&author=H.+Nakamuraauthor=T.+Yoshidaauthor=C.+Tsukanoauthor=Y.+Takemoto&title=Synthesis+of+cpzen-45%3A+Construction+of+the+1%2C4-diazepin-2-one+core+by+the+cu-catalyzed+intramolecular+amidation+of+a+vinyl+iodide&doi=10.1021%2Facs.orglett.6b00943"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of CPZEN-45: Construction of the 1,4-Diazepin-2-one Core by the Cu-Catalyzed Intramolecular Amidation of a Vinyl Iodide</span></div><div class="casAuthors">Nakamura, Hugh; Yoshida, Takuma; Tsukano, Chihiro; Takemoto, Yoshiji</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2300-2303</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">CPZEN-45 was developed as an antibiotic against Mycobacterium tuberculosis by the chem. modification of caprazamycins.  CPZEN-45 has been synthesized in this study by the Cu-catalyzed intramol. amidation of a complex vinyl iodide precursor bearing uridine and sugar moieties with a secondary amide, allowing for the construction of its 1,4-diazepin-2-one core.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVMQEnbnn3ObVg90H21EOLACvtfcHk0lhoKSPIDJJ3Ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xmt1CnsLc%253D&md5=f49acee02582b3b047d2c2cf90958ed1</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1021%2Facs.orglett.6b00943&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.orglett.6b00943%26sid%3Dliteratum%253Aachs%26aulast%3DNakamura%26aufirst%3DH.%26aulast%3DYoshida%26aufirst%3DT.%26aulast%3DTsukano%26aufirst%3DC.%26aulast%3DTakemoto%26aufirst%3DY.%26atitle%3DSynthesis%2520of%2520cpzen-45%253A%2520Construction%2520of%2520the%25201%252C4-diazepin-2-one%2520core%2520by%2520the%2520cu-catalyzed%2520intramolecular%2520amidation%2520of%2520a%2520vinyl%2520iodide%26jtitle%3DOrg.%2520Lett.%26date%3D2016%26volume%3D18%26spage%3D2300%26epage%3D2303%26doi%3D10.1021%2Facs.orglett.6b00943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref195"><div class="reference"><strong class="refLabel"><a href="#ref195" class="rightTabRefNumLink">195</a></strong><div class="NLM_citation" id="rightTab-cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Igarashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shitara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naganawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyake, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akamatsu, Y.</span></span> <span> </span><span class="NLM_article-title">Caprazamycins, novel lipo-nucleoside antibiotics, from streptomyces sp. Ii. Structure elucidation of caprazamycins</span>. <i>J. Antibiot.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">327</span>– <span class="NLM_lpage">337</span>, <span class="refDoi"> DOI: 10.1038/ja.2005.41</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1038%2Fja.2005.41" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=16060385" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltVamt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2005&pages=327-337&author=M.+Igarashiauthor=Y.+Takahashiauthor=T.+Shitaraauthor=H.+Nakamuraauthor=H.+Naganawaauthor=T.+Miyakeauthor=Y.+Akamatsu&title=Caprazamycins%2C+novel+lipo-nucleoside+antibiotics%2C+from+streptomyces+sp.+Ii.+Structure+elucidation+of+caprazamycins&doi=10.1038%2Fja.2005.41"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Caprazamycins, novel lipo-nucleoside antibiotics, from Streptomyces sp.: II. Structure elucidation of caprazamycins</span></div><div class="casAuthors">Igarashi, Masayuki; Takahashi, Yoshiaki; Shitara, Tetsuo; Nakamura, Hikaru; Naganawa, Hiroshi; Miyake, Toshiaki; Akamatsu, Yuzuru</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antibiotics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">327-337</span>CODEN:
                <span class="NLM_cas:coden">JANTAJ</span>;
        ISSN:<span class="NLM_cas:issn">0021-8820</span>.
    
            (<span class="NLM_cas:orgname">Japan Antibiotics Research Association</span>)
        </div><div class="casAbstract">Novel antibiotics, active against acid-fast bacteria, caprazamycins, were previously isolated from the culture broth of Streptomyces sp. MK730-62F2.  The planar structures of the compds. were detd. by 2D NMR spectroscopic study.  Furthermore, the abs. configuration of caprazamycin B (I) was established by NMR spectroscopy, X-ray crystallog. of its degrdn. products and total synthesis of the 5-amino-5-deoxy-D-ribose moiety.  In the course of degrdn. studies of I under alk. and acidic conditions, the two core components, caprazene II (RR1 = bond) and caprazol II (R = H, R1 = OH), resp., were obtained in high yield.  Structurally, caprazamycins belong to a family of lipouridyl antibiotics, which have been shown to be specific inhibitors of a bacterial translocase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXta4i1PjqorVg90H21EOLACvtfcHk0lhoKSPIDJJ3Ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltVamt78%253D&md5=97c79ad8f40ba48af9eec7a8392a0100</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1038%2Fja.2005.41&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fja.2005.41%26sid%3Dliteratum%253Aachs%26aulast%3DIgarashi%26aufirst%3DM.%26aulast%3DTakahashi%26aufirst%3DY.%26aulast%3DShitara%26aufirst%3DT.%26aulast%3DNakamura%26aufirst%3DH.%26aulast%3DNaganawa%26aufirst%3DH.%26aulast%3DMiyake%26aufirst%3DT.%26aulast%3DAkamatsu%26aufirst%3DY.%26atitle%3DCaprazamycins%252C%2520novel%2520lipo-nucleoside%2520antibiotics%252C%2520from%2520streptomyces%2520sp.%2520Ii.%2520Structure%2520elucidation%2520of%2520caprazamycins%26jtitle%3DJ.%2520Antibiot.%26date%3D2005%26volume%3D58%26spage%3D327%26epage%3D337%26doi%3D10.1038%2Fja.2005.41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref196"><div class="reference"><strong class="refLabel"><a href="#ref196" class="rightTabRefNumLink">196</a></strong><div class="NLM_citation" id="rightTab-cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Igarashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naganawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamada, M.</span></span> <span> </span><span class="NLM_article-title">Caprazamycin b, a novel anti-tuberculosis antibiotic, from streptomyces sp</span>. <i>J. Antibiot.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">580</span>– <span class="NLM_lpage">583</span>, <span class="refDoi"> DOI: 10.7164/antibiotics.56.580</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.7164%2Fantibiotics.56.580" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=12931868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A280%3ADC%252BD3szpsVGksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2003&pages=580-583&author=M.+Igarashiauthor=N.+Nakagawaauthor=N.+Doiauthor=S.+Hattoriauthor=H.+Naganawaauthor=M.+Hamada&title=Caprazamycin+b%2C+a+novel+anti-tuberculosis+antibiotic%2C+from+streptomyces+sp&doi=10.7164%2Fantibiotics.56.580"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">Caprazamycin B, a novel anti-tuberculosis antibiotic, from Streptomyces sp</span></div><div class="casAuthors">Igarashi Masayuki; Nakagawa Naoko; Doi Norio; Hattori Seiko; Naganawa Hiroshi; Hamada Masa</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of antibiotics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">580-3</span>
        ISSN:<span class="NLM_cas:issn">0021-8820</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRQqbR9zAbdZ0NoizSOkG_FfW6udTcc2ebG4NsoxAwddrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3szpsVGksA%253D%253D&md5=be8d104d75f0a868b0af25735daf7e27</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.7164%2Fantibiotics.56.580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7164%252Fantibiotics.56.580%26sid%3Dliteratum%253Aachs%26aulast%3DIgarashi%26aufirst%3DM.%26aulast%3DNakagawa%26aufirst%3DN.%26aulast%3DDoi%26aufirst%3DN.%26aulast%3DHattori%26aufirst%3DS.%26aulast%3DNaganawa%26aufirst%3DH.%26aulast%3DHamada%26aufirst%3DM.%26atitle%3DCaprazamycin%2520b%252C%2520a%2520novel%2520anti-tuberculosis%2520antibiotic%252C%2520from%2520streptomyces%2520sp%26jtitle%3DJ.%2520Antibiot.%26date%3D2003%26volume%3D56%26spage%3D580%26epage%3D583%26doi%3D10.7164%2Fantibiotics.56.580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref197"><div class="reference"><strong class="refLabel"><a href="#ref197" class="rightTabRefNumLink">197</a></strong><div class="NLM_citation" id="rightTab-cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishizaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Igarashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pujari, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crick, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomoto, A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of the first step in synthesis of the mycobacterial cell wall core, catalyzed by the glcnac-1-phosphate transferase weca, by the novel caprazamycin derivative cpzen-45</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>288</i></span>,  <span class="NLM_fpage">30309</span>– <span class="NLM_lpage">30319</span>, <span class="refDoi"> DOI: 10.1074/jbc.M113.492173</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1074%2Fjbc.M113.492173" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=23986448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Cru7%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=30309-30319&author=Y.+Ishizakiauthor=C.+Hayashiauthor=K.+Inoueauthor=M.+Igarashiauthor=Y.+Takahashiauthor=V.+Pujariauthor=D.+C.+Crickauthor=P.+J.+Brennanauthor=A.+Nomoto&title=Inhibition+of+the+first+step+in+synthesis+of+the+mycobacterial+cell+wall+core%2C+catalyzed+by+the+glcnac-1-phosphate+transferase+weca%2C+by+the+novel+caprazamycin+derivative+cpzen-45&doi=10.1074%2Fjbc.M113.492173"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of the First Step in Synthesis of the Mycobacterial Cell Wall Core, Catalyzed by the GlcNAc-1-phosphate Transferase WecA, by the Novel Caprazamycin Derivative CPZEN-45</span></div><div class="casAuthors">Ishizaki, Yoshimasa; Hayashi, Chigusa; Inoue, Kunio; Igarashi, Masayuki; Takahashi, Yoshiaki; Pujari, Venugopal; Crick, Dean C.; Brennan, Patrick J.; Nomoto, Akio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">30309-30319</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Because tuberculosis is one of the most prevalent and serious infections, countermeasures against it are urgently required.  We isolated the antitubercular agents caprazamycins from the culture of an actinomycete strain and created CPZEN-45 as the most promising deriv. of the caprazamycins.  Herein, we describe the mode of action of CPZEN-45 first against Bacillus subtilis.  Unlike the caprazamycins, CPZEN-45 strongly inhibited incorporation of radiolabeled glycerol into growing cultures and showed antibacterial activity against caprazamycin-resistant strains, including a strain overexpressing translocase-I (MraY, involved in the biosynthesis of peptidoglycan), the target of the caprazamycins.  By contrast, CPZEN-45 was not effective against a strain overexpressing undecaprenyl-phosphate-GlcNAc-1-phosphate transferase (TagO, involved in the biosynthesis of teichoic acid), and a mutation was found in the tagO gene of the spontaneous CPZEN-45-resistant strain.  This suggested that the primary target of CPZEN-45 in B. subtilis is TagO, which is a different target from that of the parent caprazamycins.  This suggestion was confirmed by evaluation of the activities of these enzymes.  Finally, we showed that CPZEN-45 was effective against WecA (Rv1302, also called Rfe) of Mycobacterium tuberculosis, the ortholog of TagO and involved in the biosynthesis of the mycolylarabinogalactan of the cell wall of M. tuberculosis.  The outlook for WecA as a promising target for the development of antituberculous drugs as a countermeasure of drug resistant tuberculosis is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNqoYWKso1VbVg90H21EOLACvtfcHk0lg3uJ5f2PDuGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Cru7%252FO&md5=055f38e51b810e9001d63ec42a25d20c</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M113.492173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M113.492173%26sid%3Dliteratum%253Aachs%26aulast%3DIshizaki%26aufirst%3DY.%26aulast%3DHayashi%26aufirst%3DC.%26aulast%3DInoue%26aufirst%3DK.%26aulast%3DIgarashi%26aufirst%3DM.%26aulast%3DTakahashi%26aufirst%3DY.%26aulast%3DPujari%26aufirst%3DV.%26aulast%3DCrick%26aufirst%3DD.%2BC.%26aulast%3DBrennan%26aufirst%3DP.%2BJ.%26aulast%3DNomoto%26aufirst%3DA.%26atitle%3DInhibition%2520of%2520the%2520first%2520step%2520in%2520synthesis%2520of%2520the%2520mycobacterial%2520cell%2520wall%2520core%252C%2520catalyzed%2520by%2520the%2520glcnac-1-phosphate%2520transferase%2520weca%252C%2520by%2520the%2520novel%2520caprazamycin%2520derivative%2520cpzen-45%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26spage%3D30309%26epage%3D30319%26doi%3D10.1074%2Fjbc.M113.492173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref198"><div class="reference"><strong class="refLabel"><a href="#ref198" class="rightTabRefNumLink">198</a></strong><div class="NLM_citation" id="rightTab-cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Horlacher, O. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartkoorn, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmann, K. H.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antimycobacterial activity of 2,1′-dihydropyridomycins</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">264</span>– <span class="NLM_lpage">268</span>, <span class="refDoi"> DOI: 10.1021/ml300385q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300385q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVCqsLvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=264-268&author=O.+P.+Horlacherauthor=R.+C.+Hartkoornauthor=S.+T.+Coleauthor=K.+H.+Altmann&title=Synthesis+and+antimycobacterial+activity+of+2%2C1%E2%80%B2-dihydropyridomycins&doi=10.1021%2Fml300385q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Antimycobacterial Activity of 2,1'-Dihydropyridomycins</span></div><div class="casAuthors">Horlacher, Oliver P.; Hartkoorn, Ruben C.; Cole, Stewart T.; Altmann, Karl-Heinz</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">264-268</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dihydropyridomycins 2 and 3 (II, 2R and 2S, resp.), which lack the characteristic enol ester moiety of the potent antimycobacterial natural product pyridomycin 1 (I), have been prepd. from L-Thr, R- and S-hydroxy isovaleric acid, and 3-pyridinecarboxaldehyde.  The 2R isomer 2 shows only 4-fold lower anti-Mtb activity than 1, indicating that the enol ester moiety in the natural product is not crit. for its biol. activity.  This finding establishes 2 as a potent and more practical lead for anti-TB drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5Dm4UKBOKirVg90H21EOLACvtfcHk0lg3uJ5f2PDuGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVCqsLvF&md5=2b81e23c2b644a1c23cc9c17feb68f30</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1021%2Fml300385q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300385q%26sid%3Dliteratum%253Aachs%26aulast%3DHorlacher%26aufirst%3DO.%2BP.%26aulast%3DHartkoorn%26aufirst%3DR.%2BC.%26aulast%3DCole%26aufirst%3DS.%2BT.%26aulast%3DAltmann%26aufirst%3DK.%2BH.%26atitle%3DSynthesis%2520and%2520antimycobacterial%2520activity%2520of%25202%252C1%25E2%2580%25B2-dihydropyridomycins%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D264%26epage%3D268%26doi%3D10.1021%2Fml300385q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref199"><div class="reference"><strong class="refLabel"><a href="#ref199" class="rightTabRefNumLink">199</a></strong><div class="NLM_citation" id="rightTab-cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hartkoorn, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pojer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingell, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neres, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horlacher, O. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmann, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S. T.</span></span> <span> </span><span class="NLM_article-title">Pyridomycin bridges the NADH- and substrate-binding pockets of the enoyl reductase InhA</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">96</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1405</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1038%2Fnchembio.1405" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=24292073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVGru7jF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=96-98&author=R.+C.+Hartkoornauthor=F.+Pojerauthor=J.+A.+Readauthor=H.+Gingellauthor=J.+Neresauthor=O.+P.+Horlacherauthor=K.+H.+Altmannauthor=S.+T.+Cole&title=Pyridomycin+bridges+the+NADH-+and+substrate-binding+pockets+of+the+enoyl+reductase+InhA&doi=10.1038%2Fnchembio.1405"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">Pyridomycin bridges the NADH- and substrate-binding pockets of the enoyl reductase InhA</span></div><div class="casAuthors">Hartkoorn, Ruben C.; Pojer, Florence; Read, Jon A.; Gingell, Helen; Neres, Joao; Horlacher, Oliver P.; Altmann, Karl-Heinz; Cole, Stewart T.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">96-98</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Pyridomycin, a natural product with potent antituberculosis activity, inhibits a major drug target, enoyl-ACP reductase InhA.  Here, the authors unveil the co-crystal structure and unique ability of pyridomycin to block both the NADH cofactor- and lipid substrate-binding pockets of InhA.  This is to the authors' knowledge a 1st-of-a-kind binding mode that discloses a new means of InhA inhibition.  Proof-of-principle studies showed how structure-assisted drug design could improve the activity of new pyridomycin derivs., OH 139 and OH 141.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNDXuoCfd497Vg90H21EOLACvtfcHk0liq6ZS0G5Nm8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVGru7jF&md5=14631b559d1d19a6fc3b06e7211a2cc8</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1405&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1405%26sid%3Dliteratum%253Aachs%26aulast%3DHartkoorn%26aufirst%3DR.%2BC.%26aulast%3DPojer%26aufirst%3DF.%26aulast%3DRead%26aufirst%3DJ.%2BA.%26aulast%3DGingell%26aufirst%3DH.%26aulast%3DNeres%26aufirst%3DJ.%26aulast%3DHorlacher%26aufirst%3DO.%2BP.%26aulast%3DAltmann%26aufirst%3DK.%2BH.%26aulast%3DCole%26aufirst%3DS.%2BT.%26atitle%3DPyridomycin%2520bridges%2520the%2520NADH-%2520and%2520substrate-binding%2520pockets%2520of%2520the%2520enoyl%2520reductase%2520InhA%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2014%26volume%3D10%26spage%3D96%26epage%3D98%26doi%3D10.1038%2Fnchembio.1405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref200"><div class="reference"><strong class="refLabel"><a href="#ref200" class="rightTabRefNumLink">200</a></strong><div class="NLM_citation" id="rightTab-cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfeiffer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmann, K. H.</span></span> <span> </span><span class="NLM_article-title">Recent developments in natural product-based drug discovery for tuberculosis</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">585</span>– <span class="NLM_lpage">591</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2016.11.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.drudis.2016.11.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=27890820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFOju73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=585-591&author=M.+Dongauthor=B.+Pfeifferauthor=K.+H.+Altmann&title=Recent+developments+in+natural+product-based+drug+discovery+for+tuberculosis&doi=10.1016%2Fj.drudis.2016.11.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">Recent developments in natural product-based drug discovery for tuberculosis</span></div><div class="casAuthors">Dong, Maryline; Pfeiffer, Bernhard; Altmann, Karl-Heinz</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">585-591</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Natural products (NPs) have been at the origin of several established drugs against tuberculosis (TB).  Although the current clin. TB pipeline does not feature any candidates derived from new NP scaffolds, numerous novel NPs or NP analogs have been discovered in the recent past with promising activity against Mycobacterium tuberculosis (Mtb).  This includes newly discovered structures as well as known NP classes that had not been previously recognized to be active against Mtb.  These compds. could help to replenish the dry clin. TB pipeline and, thus, contribute to improvements in the treatment of a devastating disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAXhHq_lFpAbVg90H21EOLACvtfcHk0liq6ZS0G5Nm8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFOju73P&md5=62b390128a26c7083f919cc7377321ee</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2016.11.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2016.11.015%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DM.%26aulast%3DPfeiffer%26aufirst%3DB.%26aulast%3DAltmann%26aufirst%3DK.%2BH.%26atitle%3DRecent%2520developments%2520in%2520natural%2520product-based%2520drug%2520discovery%2520for%2520tuberculosis%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2017%26volume%3D22%26spage%3D585%26epage%3D591%26doi%3D10.1016%2Fj.drudis.2016.11.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref201"><div class="reference"><strong class="refLabel"><a href="#ref201" class="rightTabRefNumLink">201</a></strong><div class="NLM_citation" id="rightTab-cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruhn, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janusic, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherbakov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherman, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boshoff, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rakesh</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waidyarachchi, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brewer, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gracia, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meibohm, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenaerts, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ainsa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottger, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. E.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationships of spectinamide antituberculosis agents: A dissection of ribosomal inhibition and native efflux avoidance contributions</span>. <i>ACS Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">72</span>– <span class="NLM_lpage">88</span>, <span class="refDoi"> DOI: 10.1021/acsinfecdis.6b00158</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsinfecdis.6b00158" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1elsb%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=72-88&author=J.+Liuauthor=D.+F.+Bruhnauthor=R.+B.+Leeauthor=Z.+Zhengauthor=T.+Janusicauthor=D.+Scherbakovauthor=M.+S.+Schermanauthor=H.+I.+Boshoffauthor=S.+Dasauthor=+Rakeshauthor=S.+L.+Waidyarachchiauthor=T.+A.+Brewerauthor=B.+Graciaauthor=L.+Yangauthor=J.+Bollingerauthor=G.+T.+Robertsonauthor=B.+Meibohmauthor=A.+J.+Lenaertsauthor=J.+Ainsaauthor=E.+C.+Bottgerauthor=R.+E.+Lee&title=Structure-activity+relationships+of+spectinamide+antituberculosis+agents%3A+A+dissection+of+ribosomal+inhibition+and+native+efflux+avoidance+contributions&doi=10.1021%2Facsinfecdis.6b00158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationships of Spectinamide Antituberculosis Agents: A Dissection of Ribosomal Inhibition and Native Efflux Avoidance Contributions</span></div><div class="casAuthors">Liu, Jiuyu; Bruhn, David F.; Lee, Robin B.; Zheng, Zhong; Janusic, Tanja; Scherbakov, Dimitri; Scherman, Michael S.; Boshoff, Helena I.; Das, Sourav; Rakesh; Waidyarachchi, Samanthi L.; Brewer, Tiffany A.; Gracia, Begona; Yang, Lei; Bollinger, John; Robertson, Gregory T.; Meibohm, Bernd; Lenaerts, Anne J.; Ainsa, Jose; Bottger, Erik C.; Lee, Richard E.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Infectious Diseases</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">72-88</span>CODEN:
                <span class="NLM_cas:coden">AIDCBC</span>;
        ISSN:<span class="NLM_cas:issn">2373-8227</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Spectinamides are a novel class of antitubercular agents with the potential to treat drug resistant tuberculosis infections.  Their antitubercular activity is derived from both ribosomal affinity and their ability to overcome intrinsic efflux mediated by the Mycobacterium tuberculosis Rv1258c efflux pump.  In this study the authors explore the structure activity relationships through anal. of 50 targeted spectinamides.  Compds. are evaluated for ribosomal translational inhibition, MIC activity in Rv1258c efflux pump deficient and wild type tuberculosis strains, and efficacy in an acute model of tuberculosis infection.  The results of this study show a narrow structure-activity relationship, consistent with a tight ribosome binding pocket and strict structural requirements to overcome native efflux.  Rationalization of ribosomal inhibition data using mol. dynamics simulations showed stable complex formation for halogenated spectinamides consistent with long post antibiotic effects obsd.  The lead spectinamides identified in this study demonstrated potent MIC activity against MDR and XDR tuberculosis, and had desirable antitubercular class specific features of low protein binding, low microsomal metab., no cytotoxicity, and produced significant redns. in bacterial burdens in the lungs of mice infected with M. tuberculosis.  The structure activity relationships detailed here emphasize the need to examine efflux-mediated resistance in the design of antituberculosis drugs and demonstrate that it is possible to overcoming intrinsic efflux with synthetic modification.  The ability to understand the structure requirements for this class has produced a variety of new substituted spectinamides, which may provide useful alternative candidates and promote the further development of this class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqTwY0RzYi_rVg90H21EOLACvtfcHk0liq6ZS0G5Nm8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1elsb%252FM&md5=1a2135c281fac45be7665e047b4cdbf6</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1021%2Facsinfecdis.6b00158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsinfecdis.6b00158%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DBruhn%26aufirst%3DD.%2BF.%26aulast%3DLee%26aufirst%3DR.%2BB.%26aulast%3DZheng%26aufirst%3DZ.%26aulast%3DJanusic%26aufirst%3DT.%26aulast%3DScherbakov%26aufirst%3DD.%26aulast%3DScherman%26aufirst%3DM.%2BS.%26aulast%3DBoshoff%26aufirst%3DH.%2BI.%26aulast%3DDas%26aufirst%3DS.%26aulast%3DRakesh%26aulast%3DWaidyarachchi%26aufirst%3DS.%2BL.%26aulast%3DBrewer%26aufirst%3DT.%2BA.%26aulast%3DGracia%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DBollinger%26aufirst%3DJ.%26aulast%3DRobertson%26aufirst%3DG.%2BT.%26aulast%3DMeibohm%26aufirst%3DB.%26aulast%3DLenaerts%26aufirst%3DA.%2BJ.%26aulast%3DAinsa%26aufirst%3DJ.%26aulast%3DBottger%26aufirst%3DE.%2BC.%26aulast%3DLee%26aufirst%3DR.%2BE.%26atitle%3DStructure-activity%2520relationships%2520of%2520spectinamide%2520antituberculosis%2520agents%253A%2520A%2520dissection%2520of%2520ribosomal%2520inhibition%2520and%2520native%2520efflux%2520avoidance%2520contributions%26jtitle%3DACS%2520Infect.%2520Dis.%26date%3D2017%26volume%3D3%26spage%3D72%26epage%3D88%26doi%3D10.1021%2Facsinfecdis.6b00158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref202"><div class="reference"><strong class="refLabel"><a href="#ref202" class="rightTabRefNumLink">202</a></strong><div class="NLM_citation" id="rightTab-cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vaddady, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trivedi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madhura, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meibohm, B.</span></span> <span> </span><span class="NLM_article-title">Dynamic time-kill curve characterization of spectinamide antibiotics 1445 and 1599 for the treatment of tuberculosis</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">233</span>– <span class="NLM_lpage">239</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2018.11.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.ejps.2018.11.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=30419293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFyqsLvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2019&pages=233-239&author=P.+K.+Vaddadyauthor=A.+Trivediauthor=C.+Rathiauthor=D.+B.+Madhuraauthor=J.+Liuauthor=R.+E.+Leeauthor=B.+Meibohm&title=Dynamic+time-kill+curve+characterization+of+spectinamide+antibiotics+1445+and+1599+for+the+treatment+of+tuberculosis&doi=10.1016%2Fj.ejps.2018.11.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">Dynamic time-kill curve characterization of spectinamide antibiotics 1445 and 1599 for the treatment of tuberculosis</span></div><div class="casAuthors">Vaddady, Pavan K.; Trivedi, Ashit; Rathi, Chetan; Madhura, Dora B.; Liu, Jiuyu; Lee, Richard E.; Meibohm, Bernd</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">233-239</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Spectinamides are a novel class of antibiotics under development for the treatment of MDR- and XDR-tuberculosis, with 1599 and 1445 as early lead candidates within this group.  In order to evaluate and differentiate the pharmacol. properties of these compds. and assist in candidate selection and design of optimal dosing regimens in animal models of Mtb infection, time kill curve assessments were performed in a previously established in vitro PK/PD model system.  The performed studies and subsequent pharmacometric anal. indicate that the anti-mycobacterial activity of 1599 exhibits concn.-dependent killing whereas 1445 shows time-dependent killing.  These findings are supported by the fact that the PKPD index that best describes bacterial killing is T > MIC for 1445, but fCmax/AUC for 1599.  The differential killing behavior among the lead candidates can be rationalized by the differences in post-antibiotic effect: 15.7 h for 1445 compared the 133 h for 1599.  Overall, the PK/PD based anal. of the in vitro pharmacol. killing profile of spectinamides 1599 and 1445 on mycobacteria provided valuable insights that contributed to lead candidate selection and preclin. development of these compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBROcUEjXuqrVg90H21EOLACvtfcHk0lirIIRlmkTwVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFyqsLvI&md5=d511407a2b788007ccb09ee9d902024c</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2018.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2018.11.006%26sid%3Dliteratum%253Aachs%26aulast%3DVaddady%26aufirst%3DP.%2BK.%26aulast%3DTrivedi%26aufirst%3DA.%26aulast%3DRathi%26aufirst%3DC.%26aulast%3DMadhura%26aufirst%3DD.%2BB.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DR.%2BE.%26aulast%3DMeibohm%26aufirst%3DB.%26atitle%3DDynamic%2520time-kill%2520curve%2520characterization%2520of%2520spectinamide%2520antibiotics%25201445%2520and%25201599%2520for%2520the%2520treatment%2520of%2520tuberculosis%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2019%26volume%3D127%26spage%3D233%26epage%3D239%26doi%3D10.1016%2Fj.ejps.2018.11.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref203"><div class="reference"><strong class="refLabel"><a href="#ref203" class="rightTabRefNumLink">203</a></strong><div class="NLM_citation" id="rightTab-cit203"><span> <i>Spectinamide 1810</i>; <span class="NLM_publisher-name">The Working Group
for
New TB Drugs</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">2017</span>; <a href="http://www.newtbdrugs.org/pipeline/compound/spectinamide-1810" class="extLink">http://www.newtbdrugs.org/pipeline/compound/spectinamide-1810</a> (accessed 2020-03-03).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Spectinamide+1810%3B+The+Working+Group%0Afor%0ANew+TB+Drugs%3A+New+York%2C+2017%3B+http%3A%2F%2Fwww.newtbdrugs.org%2Fpipeline%2Fcompound%2Fspectinamide-1810+%28accessed+2020-03-03%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26jtitle%3DSpectinamide%25201810%26pub%3DThe%2520Working%2520Group%250Afor%250ANew%2520TB%2520Drugs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref204"><div class="reference"><strong class="refLabel"><a href="#ref204" class="rightTabRefNumLink">204</a></strong><div class="NLM_citation" id="rightTab-cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tripathi, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripathi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiwari, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bala, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, B. S.</span></span> <span> </span><span class="NLM_article-title">Synthesis of glycosylated beta-amino acids as new class of antitubercular agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">773</span>– <span class="NLM_lpage">781</span>, <span class="refDoi"> DOI: 10.1016/S0223-5234(02)01398-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2FS0223-5234%2802%2901398-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=12350294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD38Xntlanu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2002&pages=773-781&author=R.+P.+Tripathiauthor=R.+Tripathiauthor=V.+K.+Tiwariauthor=L.+Balaauthor=S.+Sinhaauthor=A.+Srivastavaauthor=R.+Srivastavaauthor=B.+S.+Srivastava&title=Synthesis+of+glycosylated+beta-amino+acids+as+new+class+of+antitubercular+agents&doi=10.1016%2FS0223-5234%2802%2901398-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of glycosylated β-amino acids as new class of antitubercular agents</span></div><div class="casAuthors">Tripathi, R. P.; Tripathi, R.; Tiwari, V. K.; Bala, Laxmi; Sinha, S.; Srivastava, A.; Srivastava, R.; Srivastava, B. S.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">773-781</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Editions Scientifiques et Medicales Elsevier</span>)
        </div><div class="casAbstract">A series of glycosylated β-amino acids was prepd. and evaluated against Mycobacterium tuberculosis, M. avium, M. fortuitum and M. smegmatis.  The compds. were designed to mimic the enzyme D-alanine racemase and glycosyl transferase involved in the biosynthesis of essential cell wall peptidoglycan and arabinogalactan.  Though most of the compds. exhibited little activity, however, I (R = n-hexadecyl) showed significant activity against all the strains in cell culture and activity was confirmed by Bactec method.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkpRvlGJPxNbVg90H21EOLACvtfcHk0lirIIRlmkTwVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xntlanu78%253D&md5=ab365aa3656c3d53f21d14d84e367266</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1016%2FS0223-5234%2802%2901398-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0223-5234%252802%252901398-3%26sid%3Dliteratum%253Aachs%26aulast%3DTripathi%26aufirst%3DR.%2BP.%26aulast%3DTripathi%26aufirst%3DR.%26aulast%3DTiwari%26aufirst%3DV.%2BK.%26aulast%3DBala%26aufirst%3DL.%26aulast%3DSinha%26aufirst%3DS.%26aulast%3DSrivastava%26aufirst%3DA.%26aulast%3DSrivastava%26aufirst%3DR.%26aulast%3DSrivastava%26aufirst%3DB.%2BS.%26atitle%3DSynthesis%2520of%2520glycosylated%2520beta-amino%2520acids%2520as%2520new%2520class%2520of%2520antitubercular%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2002%26volume%3D37%26spage%3D773%26epage%3D781%26doi%3D10.1016%2FS0223-5234%2802%2901398-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref205"><div class="reference"><strong class="refLabel"><a href="#ref205" class="rightTabRefNumLink">205</a></strong><div class="NLM_citation" id="rightTab-cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mugunthan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramakrishna, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sriram, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yogeeswari, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravindranathan Kartha, K. P.</span></span> <span> </span><span class="NLM_article-title">Synthesis and screening of galactose-linked nitroimidazoles and triazoles against mycobacterium tuberculosis</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">4725</span>– <span class="NLM_lpage">4732</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2011.05.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.ejmech.2011.05.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=21664731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtV2rtbjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2011&pages=4725-4732&author=G.+Mugunthanauthor=K.+Ramakrishnaauthor=D.+Sriramauthor=P.+Yogeeswariauthor=K.+P.+Ravindranathan+Kartha&title=Synthesis+and+screening+of+galactose-linked+nitroimidazoles+and+triazoles+against+mycobacterium+tuberculosis&doi=10.1016%2Fj.ejmech.2011.05.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and screening of galactose-linked nitroimidazoles and triazoles against Mycobacterium tuberculosis</span></div><div class="casAuthors">Mugunthan, G.; Ramakrishna, Kuppala; Sriram, Dharmarajan; Yogeeswari, Perumal; Ravindranathan Kartha, K. P.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4725-4732</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of galactose-linked nitroimidazoles/triazoles, e.g. I, were synthesized and screened against Mycobacterium tuberculosis H37Rv.  Preliminary results were promising with MIC values in the range 1.56-12.5 μg/mL.  Most importantly they are active under aerobic condition under which metronidazole is inactive.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorDlLgW_VPj7Vg90H21EOLACvtfcHk0lirIIRlmkTwVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtV2rtbjF&md5=fe3db5f6585793c42bde11415e175148</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2011.05.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2011.05.045%26sid%3Dliteratum%253Aachs%26aulast%3DMugunthan%26aufirst%3DG.%26aulast%3DRamakrishna%26aufirst%3DK.%26aulast%3DSriram%26aufirst%3DD.%26aulast%3DYogeeswari%26aufirst%3DP.%26aulast%3DRavindranathan%2BKartha%26aufirst%3DK.%2BP.%26atitle%3DSynthesis%2520and%2520screening%2520of%2520galactose-linked%2520nitroimidazoles%2520and%2520triazoles%2520against%2520mycobacterium%2520tuberculosis%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2011%26volume%3D46%26spage%3D4725%26epage%3D4732%26doi%3D10.1016%2Fj.ejmech.2011.05.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref206"><div class="reference"><strong class="refLabel"><a href="#ref206" class="rightTabRefNumLink">206</a></strong><div class="NLM_citation" id="rightTab-cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rane, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutte, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahu, N. U.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of novel 1,3,4-oxadiazole derivatives of marine bromopyrrole alkaloids as antimicrobial agent</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">6429</span>– <span class="NLM_lpage">6432</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.08.061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmcl.2012.08.061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=22967765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlaktbfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=6429-6432&author=R.+A.+Raneauthor=S.+D.+Gutteauthor=N.+U.+Sahu&title=Synthesis+and+evaluation+of+novel+1%2C3%2C4-oxadiazole+derivatives+of+marine+bromopyrrole+alkaloids+as+antimicrobial+agent&doi=10.1016%2Fj.bmcl.2012.08.061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of novel 1,3,4-oxadiazole derivatives of marine bromopyrrole alkaloids as antimicrobial agent</span></div><div class="casAuthors">Rane, Rajesh A.; Gutte, Shweta D.; Sahu, Niteshkumar U.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6429-6432</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In an attempt to identify new potential lead as antimicrobial agent, twenty hybrids of marine bromopyrrole alkaloids with 1,3,4-oxadiazole were designed based on mol. hybridization technique and synthesized.  Synthesized mols. were evaluated for their antibacterial, antifungal and antitubercular activities.  Four hybrids exhibited equiv. antibacterial activity (MIC of 1.56 μg/mL) compared with std. drug ciprofloxacin against Staphylococcus aureus and Escherichia coli.  Equal antifungal activity (MIC of 1.56 μg/mL) was shown by of three hybrids compared with std. Amphotericin-B.  The inhibition of Mycobacterium tuberculosis at concns. as low as 1.6 and 1.5 μg/mL by compds. I and II resp. indicates that these compds. can act as leads for development of newer anti-TB compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfhUpIl_IIi7Vg90H21EOLACvtfcHk0lhb3Ff6Xfhk1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlaktbfL&md5=0ce610d511f23150ab2b4b6d8b0be347</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.08.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.08.061%26sid%3Dliteratum%253Aachs%26aulast%3DRane%26aufirst%3DR.%2BA.%26aulast%3DGutte%26aufirst%3DS.%2BD.%26aulast%3DSahu%26aufirst%3DN.%2BU.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520novel%25201%252C3%252C4-oxadiazole%2520derivatives%2520of%2520marine%2520bromopyrrole%2520alkaloids%2520as%2520antimicrobial%2520agent%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D6429%26epage%3D6432%26doi%3D10.1016%2Fj.bmcl.2012.08.061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref207"><div class="reference"><strong class="refLabel"><a href="#ref207" class="rightTabRefNumLink">207</a></strong><div class="NLM_citation" id="rightTab-cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tangallapally, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rakesh</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budha, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenaerts, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meibohm, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. E.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel isoxazolines as anti-tuberculosis agents</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">6638</span>– <span class="NLM_lpage">6642</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2007.09.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmcl.2007.09.048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=17937983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1OqsLnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=6638-6642&author=R.+P.+Tangallapallyauthor=D.+Sunauthor=+Rakeshauthor=N.+Budhaauthor=R.+E.+Leeauthor=A.+J.+Lenaertsauthor=B.+Meibohmauthor=R.+E.+Lee&title=Discovery+of+novel+isoxazolines+as+anti-tuberculosis+agents&doi=10.1016%2Fj.bmcl.2007.09.048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel isoxazolines as anti-tuberculosis agents</span></div><div class="casAuthors">Tangallapally, Rajendra P.; Sun, Dianqing; Rakesh; Budha, Nageshwar; Lee, Robin E. B.; Lenaerts, Anne J. M.; Meibohm, Bernd; Lee, Richard E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6638-6642</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Nitrofuranyl isoxazolines with increased proteolytic stability over nitrofuranyl amides were designed and synthesized leading to discovery of several compds. with potent in vitro anti-tuberculosis activity.  However, their in vivo activity was limited by high protein binding and poor distribution.  Consequently, a series of non-nitrofuran contg. isoxazolines were prepd. to det. if the core had residual anti-tuberculosis activity.  This led to the discovery of novel isoxazoline I as anti-tuberculosis agent with a MIC90 value of 1.56 μg/mL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPddyy5vhJerVg90H21EOLACvtfcHk0lhb3Ff6Xfhk1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1OqsLnP&md5=af6169ae8bcb3143c1d83924d42d6618</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.09.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.09.048%26sid%3Dliteratum%253Aachs%26aulast%3DTangallapally%26aufirst%3DR.%2BP.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DRakesh%26aulast%3DBudha%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DR.%2BE.%26aulast%3DLenaerts%26aufirst%3DA.%2BJ.%26aulast%3DMeibohm%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DR.%2BE.%26atitle%3DDiscovery%2520of%2520novel%2520isoxazolines%2520as%2520anti-tuberculosis%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D6638%26epage%3D6642%26doi%3D10.1016%2Fj.bmcl.2007.09.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref208"><div class="reference"><strong class="refLabel"><a href="#ref208" class="rightTabRefNumLink">208</a></strong><div class="NLM_citation" id="rightTab-cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Si, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of the disubstituted oxazole analogues as a novel class anti-tuberculotic agents against mdr- and xdr-mtb</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">5178</span>– <span class="NLM_lpage">5181</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.09.072</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmcl.2015.09.072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=26459210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1Gksb%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=5178-5181&author=D.+Liauthor=N.+Gaoauthor=N.+Zhuauthor=Y.+Linauthor=Y.+Liauthor=M.+Chenauthor=X.+Youauthor=Y.+Luauthor=K.+Wanauthor=J.+D.+Jiangauthor=W.+Jiangauthor=S.+Si&title=Discovery+of+the+disubstituted+oxazole+analogues+as+a+novel+class+anti-tuberculotic+agents+against+mdr-+and+xdr-mtb&doi=10.1016%2Fj.bmcl.2015.09.072"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the disubstituted oxazole analogues as a novel class anti-tuberculotic agents against MDR- and XDR-MTB</span></div><div class="casAuthors">Li, Dongsheng; Gao, Nana; Zhu, Ningyu; Lin, Yuan; Li, Yan; Chen, Minghua; You, Xuefu; Lu, Yu; Wan, Kanglin; Jiang, Jian-Dong; Jiang, Wei; Si, Shuyi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5178-5181</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Aryl-piperidinyl-substituted oxazoles, thiazoles and isoxazoles I [1a-y; R1 = ClC6H4, FC6H4, Ph, MeOC6H4, CF3C6H4, 3-pyridyl, 2-furyl; R2, R3 = H, OMe; R2-R3 = OCH2CH2O, (CH2)4] were prepd. by heterocyclization of aldehydes, thioamides and alkynes with amino acid derivs., Friedel-Crafts acylation of disubstituted benzenes 1-R2-2-R3C6H4 with 4-piperidinoyl chloride and coupling of the aroylpiperidines with chloromethyl azoles; the compds. 1a-y were evaluated for their in vitro anti-TB activity vs. replicating, multi- and extensive drug resistant strains of Mycobacterium tuberculosis (MTB).  A high-throughput screening effort on 45,000 compds. resulted in the discovery of a disubstituted oxazole as a new structural class inhibitor of MTB.  In order to improve the activity and investigate the SAR of this scaffold, a series of disubstituted azole analogs have been designed and synthesized.  Almost all the compds. showed potent anti-TB activity with MIC of 1-64 mg/L.  The test of broad spectrum panel revealed that this series are specific to MTB.  The cytotoxicity assessment indicated that the compds. were not cytotoxic against HEK 293 cells.  The compds. could have a novel mechanism to anti-MTB as they can inhibit drug sensitive and drug resistant Mtb.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7VWyZg-WlSLVg90H21EOLACvtfcHk0lhb3Ff6Xfhk1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1Gksb%252FP&md5=1ad3a7711a9334e7112f46f681fb48ac</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.09.072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.09.072%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DGao%26aufirst%3DN.%26aulast%3DZhu%26aufirst%3DN.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DYou%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DWan%26aufirst%3DK.%26aulast%3DJiang%26aufirst%3DJ.%2BD.%26aulast%3DJiang%26aufirst%3DW.%26aulast%3DSi%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520the%2520disubstituted%2520oxazole%2520analogues%2520as%2520a%2520novel%2520class%2520anti-tuberculotic%2520agents%2520against%2520mdr-%2520and%2520xdr-mtb%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D5178%26epage%3D5181%26doi%3D10.1016%2Fj.bmcl.2015.09.072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref209"><div class="reference"><strong class="refLabel"><a href="#ref209" class="rightTabRefNumLink">209</a></strong><div class="NLM_citation" id="rightTab-cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pedgaonkar, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridevi, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeankumar, V. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saxena, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devi, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renuka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yogeeswari, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sriram, D.</span></span> <span> </span><span class="NLM_article-title">Development of benzo[d]oxazol-2(3h)-ones derivatives as novel inhibitors of mycobacterium tuberculosis inha</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">6134</span>– <span class="NLM_lpage">6145</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2014.08.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmc.2014.08.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=25282650" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsV2ktLvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=6134-6145&author=G.+S.+Pedgaonkarauthor=J.+P.+Srideviauthor=V.+U.+Jeankumarauthor=S.+Saxenaauthor=P.+B.+Deviauthor=J.+Renukaauthor=P.+Yogeeswariauthor=D.+Sriram&title=Development+of+benzo%5Bd%5Doxazol-2%283h%29-ones+derivatives+as+novel+inhibitors+of+mycobacterium+tuberculosis+inha&doi=10.1016%2Fj.bmc.2014.08.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">Development of benzo[d]oxazol-2(3H)-ones derivatives as novel inhibitors of Mycobacterium tuberculosis InhA</span></div><div class="casAuthors">Pedgaonkar, Ganesh S.; Sridevi, Jonnalagadda Padma; Jeankumar, Variam Ullas; Saxena, Shalini; Devi, Parthiban Brindha; Renuka, Janupally; Yogeeswari, Perumal; Sriram, Dharmarajan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6134-6145</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of twenty seven substituted 2-(2-oxobenzo[d]oxazol-3(2H)-yl)acetamide derivs. was designed based on an earlier reported Mycobacterium tuberculosis (MTB) enoyl-acyl carrier protein reductase (InhA) lead.  Compds. were evaluated for MTB InhA inhibition study, in vitro activity against drug-sensitive and -resistant MTB strains, and cytotoxicity against RAW 264.7 cell line.  Among the compds. tested, 2-(6-nitro-2-oxobenzo[d]oxazol-3(2H)-yl)-N-(5-nitrothiazol-2-yl)acetamide (30) was found to be the most promising compd. with IC50 of 5.12 ± 0.44 μM against MTB InhA, inhibited drug sensitive MTB with MIC 17.11 μM and was non-cytotoxic at 100 μM.  The interaction with protein and enhancement of protein stability in complex with compd. 30 was further confirmed biophys. by differential scanning fluorimetry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcmAyJGQ1tu7Vg90H21EOLACvtfcHk0lj1UH15-8qm6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsV2ktLvI&md5=add4a5d09dabefec6801f624c4f6bdec</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.08.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.08.031%26sid%3Dliteratum%253Aachs%26aulast%3DPedgaonkar%26aufirst%3DG.%2BS.%26aulast%3DSridevi%26aufirst%3DJ.%2BP.%26aulast%3DJeankumar%26aufirst%3DV.%2BU.%26aulast%3DSaxena%26aufirst%3DS.%26aulast%3DDevi%26aufirst%3DP.%2BB.%26aulast%3DRenuka%26aufirst%3DJ.%26aulast%3DYogeeswari%26aufirst%3DP.%26aulast%3DSriram%26aufirst%3DD.%26atitle%3DDevelopment%2520of%2520benzo%255Bd%255Doxazol-2%25283h%2529-ones%2520derivatives%2520as%2520novel%2520inhibitors%2520of%2520mycobacterium%2520tuberculosis%2520inha%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D6134%26epage%3D6145%26doi%3D10.1016%2Fj.bmc.2014.08.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref210"><div class="reference"><strong class="refLabel"><a href="#ref210" class="rightTabRefNumLink">210</a></strong><div class="NLM_citation" id="rightTab-cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Costa, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boechat, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rangel, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Silva, F. e. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Souza, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Junior, I. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lourenço, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardell, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, V. F.</span></span> <span> </span><span class="NLM_article-title">Synthesis, tuberculosis inhibitory activity, and sar study of n-substituted-phenyl-1,2,3-triazole derivatives</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">8644</span>– <span class="NLM_lpage">8653</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2006.08.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmc.2006.08.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=16949290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFOjt7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=8644-8653&author=M.+S.+Costaauthor=N.+Boechatauthor=E.+A.+Rangelauthor=F.+e.+C.+da+Silvaauthor=A.+M.+de+Souzaauthor=C.+R.+Rodriguesauthor=H.+C.+Castroauthor=I.+N.+Juniorauthor=M.+C.+Louren%C3%A7oauthor=S.+M.+Wardellauthor=V.+F.+Ferreira&title=Synthesis%2C+tuberculosis+inhibitory+activity%2C+and+sar+study+of+n-substituted-phenyl-1%2C2%2C3-triazole+derivatives&doi=10.1016%2Fj.bmc.2006.08.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit210R"><div class="casContent"><span class="casTitleNuber">210</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, tuberculosis inhibitory activity, and SAR study of N-substituted-phenyl-1,2,3-triazole derivatives</span></div><div class="casAuthors">Costa, Marilia S.; Boechat, Nubia; Rangel, Erica A.; da Silva, Fernando de C.; de Souza, Alessandra M. T.; Rodrigues, Carlos R.; Castro, Helena C.; Junior, Ivan N.; Lourenco, Maria Cristina S.; Wardell, Solange M. S. V.; Ferreira, Vitor F.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8644-8653</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The aim of this work was to describe the synthesis, the in vitro anti-Mycobacterium tuberculosis profile, and the structure-activity relationship (SAR) study of new N-substituted-phenyl-1,2,3-triazole-4-carbaldehydes (3a-l).  The reactions of arom. amine hydrochlorides with diazomalonaldehyde (1) produced several N-substituted-phenyl-1,2,3-triazole-4-carbaldehydes (3a-l) in moderate-to-good yields.  In order to investigate the influence of the difluoromethylene group on the anti-Mycobacterium activity of these compds., fluorination of triazoles with DAST converted the corresponding carbaldehyde compds. into new difluoromethyl derivs. (4a-l) in excellent yield.  Characterization of all compds. was achieved by spectroscopic means and X-ray crystallog. for 1-(4-methylphenyl)-1,2,3-triazole-4-carbaldehyde, 3k (I).  Compds. (3a-l) and (4a-l) have been screened for the inhibitory activity against Mycobacterium tuberculosis H37Rv strain (ATCC 27294) and all of them were able to inhibit the growth of the bacterium.  Interestingly, 3a (3,5-dichlorophenyl deriv.) and 3k exhibited the best inhibition with MIC values of 2.5 μg/mL, similar to pharmaceuticals currently used in the treatment of tuberculosis.  Our SAR study indicated the importance of the hydrogen bond acceptor subunit (3a-l), the position in the arom. ring, the planarity of triazole and Ph rings in these compds., and a correlation between the uniform HOMO coeff. distribution and the anti-tubercular activity.  The significant activity of 3a and 3k pointed them as promising lead mols. for further synthetic and biol. exploration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6Pk97tdiQt7Vg90H21EOLACvtfcHk0lj1UH15-8qm6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFOjt7jJ&md5=e78a1882b6d9fbd8d8c0965541d77250</span></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2006.08.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2006.08.019%26sid%3Dliteratum%253Aachs%26aulast%3DCosta%26aufirst%3DM.%2BS.%26aulast%3DBoechat%26aufirst%3DN.%26aulast%3DRangel%26aufirst%3DE.%2BA.%26aulast%3Dda%2BSilva%26aufirst%3DF.%2Be.%2BC.%26aulast%3Dde%2BSouza%26aufirst%3DA.%2BM.%26aulast%3DRodrigues%26aufirst%3DC.%2BR.%26aulast%3DCastro%26aufirst%3DH.%2BC.%26aulast%3DJunior%26aufirst%3DI.%2BN.%26aulast%3DLouren%25C3%25A7o%26aufirst%3DM.%2BC.%26aulast%3DWardell%26aufirst%3DS.%2BM.%26aulast%3DFerreira%26aufirst%3DV.%2BF.%26atitle%3DSynthesis%252C%2520tuberculosis%2520inhibitory%2520activity%252C%2520and%2520sar%2520study%2520of%2520n-substituted-phenyl-1%252C2%252C3-triazole%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2006%26volume%3D14%26spage%3D8644%26epage%3D8653%26doi%3D10.1016%2Fj.bmc.2006.08.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref211"><div class="reference"><strong class="refLabel"><a href="#ref211" class="rightTabRefNumLink">211</a></strong><div class="NLM_citation" id="rightTab-cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menendez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chollet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasca, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lherbet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baltas, M.</span></span> <span> </span><span class="NLM_article-title">Chemical synthesis and biological evaluation of triazole derivatives as inhibitors of InhA and antituberculosis agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">275</span>– <span class="NLM_lpage">283</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2012.03.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.ejmech.2012.03.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=22483635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtlSksrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=275-283&author=C.+Menendezauthor=A.+Cholletauthor=F.+Rodriguezauthor=C.+Inardauthor=M.+R.+Pascaauthor=C.+Lherbetauthor=M.+Baltas&title=Chemical+synthesis+and+biological+evaluation+of+triazole+derivatives+as+inhibitors+of+InhA+and+antituberculosis+agents&doi=10.1016%2Fj.ejmech.2012.03.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit211R"><div class="casContent"><span class="casTitleNuber">211</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical synthesis and biological evaluation of triazole derivatives as inhibitors of InhA and antituberculosis agents</span></div><div class="casAuthors">Menendez, Christophe; Chollet, Aurelien; Rodriguez, Frederic; Inard, Cyril; Pasca, Maria Rosalia; Lherbet, Christian; Baltas, Michel</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">275-283</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of triazoles have been prepd. and evaluated as inhibitors of InhA as well as inhibitors of Mycobacterium tuberculosis H37Rv.  Several of these new compds. possess a good activity against InhA, particularly compds. I (n = 7, 8) for which mol. docking has been performed.  Concerning their activities against M. tuberculosis H37RV strain, two of the compds. were found to be good inhibitors with MIC values of 0.50 and 0.25 μg/mL, resp.  Particularly, compd. II presenting the best MIC value of all compds. tested (0.6 μM) is totally inactive against InhA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCsRCTAFSUw7Vg90H21EOLACvtfcHk0lj1UH15-8qm6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtlSksrg%253D&md5=cfd7a7cdeda150492a33a612561237d5</span></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2012.03.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2012.03.029%26sid%3Dliteratum%253Aachs%26aulast%3DMenendez%26aufirst%3DC.%26aulast%3DChollet%26aufirst%3DA.%26aulast%3DRodriguez%26aufirst%3DF.%26aulast%3DInard%26aufirst%3DC.%26aulast%3DPasca%26aufirst%3DM.%2BR.%26aulast%3DLherbet%26aufirst%3DC.%26aulast%3DBaltas%26aufirst%3DM.%26atitle%3DChemical%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520triazole%2520derivatives%2520as%2520inhibitors%2520of%2520InhA%2520and%2520antituberculosis%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2012%26volume%3D52%26spage%3D275%26epage%3D283%26doi%3D10.1016%2Fj.ejmech.2012.03.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref212"><div class="reference"><strong class="refLabel"><a href="#ref212" class="rightTabRefNumLink">212</a></strong><div class="NLM_citation" id="rightTab-cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adhikari, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chowdhury, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sumesh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pal, N. K.</span></span> <span> </span><span class="NLM_article-title">New quinolin-4-yl-1,2,3-triazoles carrying amides, sulphonamides and amidopiperazines as potential antitubercular agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">2503</span>– <span class="NLM_lpage">2512</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2011.03.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.ejmech.2011.03.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=21489660" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsVCnurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2011&pages=2503-2512&author=K.+D.+Thomasauthor=A.+V.+Adhikariauthor=I.+H.+Chowdhuryauthor=E.+Sumeshauthor=N.+K.+Pal&title=New+quinolin-4-yl-1%2C2%2C3-triazoles+carrying+amides%2C+sulphonamides+and+amidopiperazines+as+potential+antitubercular+agents&doi=10.1016%2Fj.ejmech.2011.03.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit212R"><div class="casContent"><span class="casTitleNuber">212</span><div class="casTitle"><span class="NLM_cas:atitle">New quinolin-4-yl-1,2,3-triazoles carrying amides, sulfonamides and amidopiperazines as potential antitubercular agents</span></div><div class="casAuthors">Thomas, K. D.; Adhikari, Airody Vasudeva; Chowdhury, Imran H.; Sumesh, E.; Pal, Nishith K.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2503-2512</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Three new series of quinolin-4-yl-1,2,3-triazoles carrying amide, sulfonamide and acylpiperazine substituents were synthesized through multi-step reactions.  The required intermediate, [1-(6-methoxy-2-methylquinolin-4-yl)-1H-1,2,3-triazol-4-yl]methanol (I) was prepd. by treating 4-azido-6-methoxy-2-methylquinoline with propargyl alc.  Three different series of compds. were synthesized from this intermediate.  All the newly synthesized compds. were characterized by spectral and elemental analyses.  The structure of I was confirmed by X-ray crystallog. study.  Further, the title compds. were evaluated for their in vitro anti-bacterial activity against five different bacterial strains and antimycobacterial activity against Mycobacterium tuberculosis H37Rv, Mycobacterium smegmatis (ATCC 19420) and Mycobacterium fortuitum (ATCC 19542).  Some were found to be active against Mycobacterium tuberculosis H37Rv strain and could be lead mols. of interest.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoA6r2oH8dFlrVg90H21EOLACvtfcHk0lhyVHQzgFNdPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsVCnurs%253D&md5=f0612143761844db0a77a6a7973f282f</span></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2011.03.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2011.03.039%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DK.%2BD.%26aulast%3DAdhikari%26aufirst%3DA.%2BV.%26aulast%3DChowdhury%26aufirst%3DI.%2BH.%26aulast%3DSumesh%26aufirst%3DE.%26aulast%3DPal%26aufirst%3DN.%2BK.%26atitle%3DNew%2520quinolin-4-yl-1%252C2%252C3-triazoles%2520carrying%2520amides%252C%2520sulphonamides%2520and%2520amidopiperazines%2520as%2520potential%2520antitubercular%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2011%26volume%3D46%26spage%3D2503%26epage%3D2512%26doi%3D10.1016%2Fj.ejmech.2011.03.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref213"><div class="reference"><strong class="refLabel"><a href="#ref213" class="rightTabRefNumLink">213</a></strong><div class="NLM_citation" id="rightTab-cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menendez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribeiro, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zara, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frongia, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lobjois, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saffon, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasca, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lherbet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baltas, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of α-ketotriazoles and α,β-diketotriazoles as inhibitors of mycobacterium tuberculosis</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">167</span>– <span class="NLM_lpage">173</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.06.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.ejmech.2013.06.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=24016834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslaqs7%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2013&pages=167-173&author=C.+Menendezauthor=F.+Rodriguezauthor=A.+L.+Ribeiroauthor=F.+Zaraauthor=C.+Frongiaauthor=V.+Lobjoisauthor=N.+Saffonauthor=M.+R.+Pascaauthor=C.+Lherbetauthor=M.+Baltas&title=Synthesis+and+evaluation+of+%CE%B1-ketotriazoles+and+%CE%B1%2C%CE%B2-diketotriazoles+as+inhibitors+of+mycobacterium+tuberculosis&doi=10.1016%2Fj.ejmech.2013.06.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit213R"><div class="casContent"><span class="casTitleNuber">213</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of α-ketotriazoles and α,β-diketotriazoles as inhibitors of Mycobacterium tuberculosis</span></div><div class="casAuthors">Menendez, Christophe; Rodriguez, Frederic; de Jesus Lopes Ribeiro, Ana Luisa; Zara, Francesca; Frongia, Celine; Lobjois, Valerie; Saffon, Nathalie; Pasca, Maria Rosalia; Lherbet, Christian; Baltas, Michel</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">167-173</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Two series of α-ketotriazole and α,β-diketotriazole derivs. were synthesized and evaluated for antitubercular and cytotoxic activities.  Among them, two α,β-diketotriazole compds., I and II, exhibited good activities (min. inhibitory concn. = 7.6 μM and 6.9 μM, resp.) on Mycobacterium tuberculosis and multi-drug resistant M. tuberculosis strains and presented no cytotoxicity (IC50 > 50 μM) on colorectal cancer HCT116 and normal fibroblast GM637H cell lines.  These two compds. represent promising leads for further optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTS3A-2Fk-TbVg90H21EOLACvtfcHk0lhyVHQzgFNdPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslaqs7%252FO&md5=c2954a4fdf7aac3d12dfec9337248a44</span></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.06.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.06.042%26sid%3Dliteratum%253Aachs%26aulast%3DMenendez%26aufirst%3DC.%26aulast%3DRodriguez%26aufirst%3DF.%26aulast%3DRibeiro%26aufirst%3DA.%2BL.%26aulast%3DZara%26aufirst%3DF.%26aulast%3DFrongia%26aufirst%3DC.%26aulast%3DLobjois%26aufirst%3DV.%26aulast%3DSaffon%26aufirst%3DN.%26aulast%3DPasca%26aufirst%3DM.%2BR.%26aulast%3DLherbet%26aufirst%3DC.%26aulast%3DBaltas%26aufirst%3DM.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520%25CE%25B1-ketotriazoles%2520and%2520%25CE%25B1%252C%25CE%25B2-diketotriazoles%2520as%2520inhibitors%2520of%2520mycobacterium%2520tuberculosis%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D69%26spage%3D167%26epage%3D173%26doi%3D10.1016%2Fj.ejmech.2013.06.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref214"><div class="reference"><strong class="refLabel"><a href="#ref214" class="rightTabRefNumLink">214</a></strong><div class="NLM_citation" id="rightTab-cit214"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awasthi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanardi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruzsicska, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knudson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonge, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slayden, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ojima, I.</span></span> <span> </span><span class="NLM_article-title">Novel trisubstituted benzimidazoles, targeting Mtb FtsZ, as a new class of antitubercular agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">374</span>– <span class="NLM_lpage">381</span>, <span class="refDoi"> DOI: 10.1021/jm1012006</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1012006" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFShtbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=374-381&author=K.+Kumarauthor=D.+Awasthiauthor=S.+Y.+Leeauthor=I.+Zanardiauthor=B.+Ruzsicskaauthor=S.+Knudsonauthor=P.+J.+Tongeauthor=R.+A.+Slaydenauthor=I.+Ojima&title=Novel+trisubstituted+benzimidazoles%2C+targeting+Mtb+FtsZ%2C+as+a+new+class+of+antitubercular+agents&doi=10.1021%2Fjm1012006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit214R"><div class="casContent"><span class="casTitleNuber">214</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Trisubstituted Benzimidazoles, Targeting Mtb FtsZ, as a New Class of Antitubercular Agents</span></div><div class="casAuthors">Kumar, Kunal; Awasthi, Divya; Lee, Seung-Yub; Zanardi, Ilaria; Ruzsicska, Bela; Knudson, Susan; Tonge, Peter J.; Slayden, Richard A.; Ojima, Iwao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">374-381</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Libraries of novel trisubstituted benzimidazoles were created through rational drug design.  A good no. of these benzimidazoles exhibited promising MIC values in the range of 0.5-6 μg/mL (2-15 μM) for their antibacterial activity against Mtb H37Rv strain.  Moreover, five of the lead compds. also exhibited excellent activity against clin. Mtb strains with different drug-resistance profiles.  All lead compds. did not show appreciable cytotoxicity (IC50 > 200 μM) against Vero cells, which inhibited Mtb FtsZ assembly in a dose dependent manner.  The two lead compds. unexpectedly showed enhancement of the GTPase activity of Mtb FtsZ.  The result strongly suggests that the increased GTPase activity destabilizes FtsZ assembly, leading to efficient inhibition of FtsZ polymn. and filament formation.  The TEM and SEM analyses of Mtb FtsZ and Mtb cells, resp., treated with a lead compd. strongly suggest that lead benzimidazoles have a novel mechanism of action on the inhibition of Mtb FtsZ assembly and Z-ring formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzXUSeMbGak7Vg90H21EOLACvtfcHk0lhyVHQzgFNdPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFShtbzI&md5=80d27b16ed467b925daedf927576c5eb</span></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=10.1021%2Fjm1012006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1012006%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DK.%26aulast%3DAwasthi%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DS.%2BY.%26aulast%3DZanardi%26aufirst%3DI.%26aulast%3DRuzsicska%26aufirst%3DB.%26aulast%3DKnudson%26aufirst%3DS.%26aulast%3DTonge%26aufirst%3DP.%2BJ.%26aulast%3DSlayden%26aufirst%3DR.%2BA.%26aulast%3DOjima%26aufirst%3DI.%26atitle%3DNovel%2520trisubstituted%2520benzimidazoles%252C%2520targeting%2520Mtb%2520FtsZ%252C%2520as%2520a%2520new%2520class%2520of%2520antitubercular%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D374%26epage%3D381%26doi%3D10.1021%2Fjm1012006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref215"><div class="reference"><strong class="refLabel"><a href="#ref215" class="rightTabRefNumLink">215</a></strong><div class="NLM_citation" id="rightTab-cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haranahalli, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ojima, I.</span></span> <span> </span><span class="NLM_article-title">Recent advances in the discovery and development of antibacterial agents targeting the cell-division protein ftsz</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">6354</span>– <span class="NLM_lpage">6369</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.05.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmc.2016.05.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=27189886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28XnvFOgu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=6354-6369&author=K.+Haranahalliauthor=S.+Tongauthor=I.+Ojima&title=Recent+advances+in+the+discovery+and+development+of+antibacterial+agents+targeting+the+cell-division+protein+ftsz&doi=10.1016%2Fj.bmc.2016.05.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit215R"><div class="casContent"><span class="casTitleNuber">215</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the discovery and development of antibacterial agents targeting the cell-division protein FtsZ</span></div><div class="casAuthors">Haranahalli, Krupanandan; Tong, Simon; Ojima, Iwao</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6354-6369</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  With the emergence of multidrug-resistant bacterial strains, there is a dire need for new drug targets for antibacterial drug discovery and development.  Filamentous temp. sensitive protein Z (FtsZ), is a GTP-dependent prokaryotic cell division protein, sharing less than 10% sequence identity with the eukaryotic cell division protein, tubulin.  FtsZ forms a dynamic Z-ring in the middle of the cell, leading to septation and subsequent cell division.  Inhibition of the Z-ring blocks cell division, thus making FtsZ a highly attractive target.  Various groups have been working on natural products and synthetic small mols. as inhibitors of FtsZ.  This review summarizes the recent advances in the development of FtsZ inhibitors, focusing on those in the last 5 years, but also includes significant findings in previous years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR-yPw_2hjULVg90H21EOLACvtfcHk0lhVK4JQnJoKfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnvFOgu7s%253D&md5=80cf039e06bfc61c35e24939ac4379e3</span></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.05.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.05.003%26sid%3Dliteratum%253Aachs%26aulast%3DHaranahalli%26aufirst%3DK.%26aulast%3DTong%26aufirst%3DS.%26aulast%3DOjima%26aufirst%3DI.%26atitle%3DRecent%2520advances%2520in%2520the%2520discovery%2520and%2520development%2520of%2520antibacterial%2520agents%2520targeting%2520the%2520cell-division%2520protein%2520ftsz%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D6354%26epage%3D6369%26doi%3D10.1016%2Fj.bmc.2016.05.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref216"><div class="reference"><strong class="refLabel"><a href="#ref216" class="rightTabRefNumLink">216</a></strong><div class="NLM_citation" id="rightTab-cit216"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knudson, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awasthi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carreau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goullieux, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagrange, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vermet, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ojima, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slayden, R. A.</span></span> <span> </span><span class="NLM_article-title">Cell division inhibitors with efficacy equivalent to isoniazid in the acute murine mycobacterium tuberculosis infection model</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">3070</span>– <span class="NLM_lpage">3073</span>, <span class="refDoi"> DOI: 10.1093/jac/dkv226</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1093%2Fjac%2Fdkv226" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=26245639" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28XjsFyisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2015&pages=3070-3073&author=S.+E.+Knudsonauthor=D.+Awasthiauthor=K.+Kumarauthor=A.+Carreauauthor=L.+Goullieuxauthor=S.+Lagrangeauthor=H.+Vermetauthor=I.+Ojimaauthor=R.+A.+Slayden&title=Cell+division+inhibitors+with+efficacy+equivalent+to+isoniazid+in+the+acute+murine+mycobacterium+tuberculosis+infection+model&doi=10.1093%2Fjac%2Fdkv226"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit216R"><div class="casContent"><span class="casTitleNuber">216</span><div class="casTitle"><span class="NLM_cas:atitle">Cell division inhibitors with efficacy equivalent to isoniazid in the acute murine Mycobacterium tuberculosis infection model</span></div><div class="casAuthors">Knudson, Susan E.; Awasthi, Divya; Kumar, Kunal; Carreau, Alexandra; Goullieux, Laurent; Lagrange, Sophie; Vermet, Helene; Ojima, Iwao; Slayden, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3070-3073</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Objectives: The increasing no. of clin. strains resistant to one or more of the front-line TB drugs complicates the management of this disease.  To develop next-generation benzimidazole-based FtsZ inhibitors with improved efficacy, we employed iterative optimization strategies based on whole bacteria potency, bactericidal activity, plasma and metabolic stability and in vivo efficacy studies.  Methods: Candidate benzimidazoles were evaluated for potency against Mycobacterium tuberculosis H37Rv and select clin. strains, toxicity against Vero cells and compd. stability in plasma and liver microsomes.  The efficacy of lead compds. was assessed in the acute murine M. tuberculosis infection model via i.p. and oral routes.  Results: MICs of SB-P17G-A33, SB-P17G-A38 and SB-P17G-A42 for M. tuberculosis H37Rv and select clin. strains were 0.18-0.39 mg/L.  SB-P17G-A38 and SB-P17G-A42 delivered at 50 mg/kg twice daily i.p. or orally demonstrated efficacy in reducing the bacterial load by 5.7-6.3 log10 cfu in the lungs and 3.9-5.0 log10 cfu in the spleen.  SB-P17G-A33 delivered at 50 mg/kg twice daily i.p. or orally also reduced the bacterial load by 1.7-2.1 log10 cfu in the lungs and 2.5-3.4 log10 cfu in the spleen.  Conclusions: Next-generation benzimidazoles with excellent potency and efficacy against M. tuberculosis have been developed.  This is the first report on benzimidazole-based FtsZ inhibitors showing an equiv. level of efficacy to isoniazid in an acute murine M. tuberculosis infection model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoauLxKmFVvD7Vg90H21EOLACvtfcHk0lhVK4JQnJoKfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjsFyisbc%253D&md5=2538e3c9540b94e7769f26363812b77a</span></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdkv226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdkv226%26sid%3Dliteratum%253Aachs%26aulast%3DKnudson%26aufirst%3DS.%2BE.%26aulast%3DAwasthi%26aufirst%3DD.%26aulast%3DKumar%26aufirst%3DK.%26aulast%3DCarreau%26aufirst%3DA.%26aulast%3DGoullieux%26aufirst%3DL.%26aulast%3DLagrange%26aufirst%3DS.%26aulast%3DVermet%26aufirst%3DH.%26aulast%3DOjima%26aufirst%3DI.%26aulast%3DSlayden%26aufirst%3DR.%2BA.%26atitle%3DCell%2520division%2520inhibitors%2520with%2520efficacy%2520equivalent%2520to%2520isoniazid%2520in%2520the%2520acute%2520murine%2520mycobacterium%2520tuberculosis%2520infection%2520model%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2015%26volume%3D70%26spage%3D3070%26epage%3D3073%26doi%3D10.1093%2Fjac%2Fdkv226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref217"><div class="reference"><strong class="refLabel"><a href="#ref217" class="rightTabRefNumLink">217</a></strong><div class="NLM_citation" id="rightTab-cit217"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahamad, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Islam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwivedi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan, M. I.</span></span> <span> </span><span class="NLM_article-title">2/3D-QSAR, molecular docking and md simulation studies of ftsz protein targeting benzimidazoles derivatives</span>. <i>Comput. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">398</span>– <span class="NLM_lpage">413</span>, <span class="refDoi"> DOI: 10.1016/j.compbiolchem.2018.12.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.compbiolchem.2018.12.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=30602415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC1MXosFan" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2019&pages=398-413&author=S.+Ahamadauthor=A.+Islamauthor=F.+Ahmadauthor=N.+Dwivediauthor=M.+I.+Hassan&title=2%2F3D-QSAR%2C+molecular+docking+and+md+simulation+studies+of+ftsz+protein+targeting+benzimidazoles+derivatives&doi=10.1016%2Fj.compbiolchem.2018.12.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit217R"><div class="casContent"><span class="casTitleNuber">217</span><div class="casTitle"><span class="NLM_cas:atitle">2/3D-QSAR, molecular docking and MD simulation studies of FtsZ protein targeting benzimidazoles derivatives</span></div><div class="casAuthors">Ahamad, Shahzaib; Islam, Asimul; Ahmad, Faizan; Dwivedi, Neeraj; Hassan, Md. Imtaiyaz</div><div class="citationInfo"><span class="NLM_cas:title">Computational Biology and Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">398-413</span>CODEN:
                <span class="NLM_cas:coden">CBCOCH</span>;
        ISSN:<span class="NLM_cas:issn">1476-9271</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The development of multi-drug and extensively-drug resistant strains of Mycobacterium tuberculosis (Mtb) have encouraged to develop new anti-TB agents with a unique mechanism of action.  FtsZ, an essential protein of bacterial cytokinesis, has emerged as a validated target for antibacterial therapy.  This study describes the utility of benzimidazoles (BI) derivs. as potential FtsZ inhibitors.  Through 2/3D QSAR (MLR) mol. modeling, new BI-inhibitors with improved activity have been designed.  Statistically significant models from 2D-QSAR (r2 = 0.90, q2 = 85 and pred_r2 = 0.60) indicated that the descriptors such as SaaOcount, -ve Potential Surface Area, and SdsCHE-index modulate the activity of a mol.  Similarly, 3D-QSAR (r2 = 0.78, q2 = 0.69 and pred_r2 = 0.59) results indicated both electrostatic and steric descriptors play a pivotal role.  These indications prompted us to design 223 new BI-derivs., out of which three BI-derivs. (D-83, D-116 and D-223) have shown some promising results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmJiySGVqLMbVg90H21EOLACvtfcHk0lhVK4JQnJoKfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXosFan&md5=c4ccd6f4785bf0367bba015fcb5acf4e</span></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=10.1016%2Fj.compbiolchem.2018.12.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.compbiolchem.2018.12.017%26sid%3Dliteratum%253Aachs%26aulast%3DAhamad%26aufirst%3DS.%26aulast%3DIslam%26aufirst%3DA.%26aulast%3DAhmad%26aufirst%3DF.%26aulast%3DDwivedi%26aufirst%3DN.%26aulast%3DHassan%26aufirst%3DM.%2BI.%26atitle%3D2%252F3D-QSAR%252C%2520molecular%2520docking%2520and%2520md%2520simulation%2520studies%2520of%2520ftsz%2520protein%2520targeting%2520benzimidazoles%2520derivatives%26jtitle%3DComput.%2520Biol.%2520Chem.%26date%3D2019%26volume%3D78%26spage%3D398%26epage%3D413%26doi%3D10.1016%2Fj.compbiolchem.2018.12.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref218"><div class="reference"><strong class="refLabel"><a href="#ref218" class="rightTabRefNumLink">218</a></strong><div class="NLM_citation" id="rightTab-cit218"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gobis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foks, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bojanowski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augustynowicz-Kopeć, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Napiórkowska, A.</span></span> <span> </span><span class="NLM_article-title">Synthesis of novel 3-cyclohexylpropanoic acid-derived nitrogen heterocyclic compounds and their evaluation for tuberculostatic activity</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">137</span>– <span class="NLM_lpage">144</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2011.11.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmc.2011.11.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=22153872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38XitlCksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=137-144&author=K.+Gobisauthor=H.+Foksauthor=K.+Bojanowskiauthor=E.+Augustynowicz-Kope%C4%87author=A.+Napi%C3%B3rkowska&title=Synthesis+of+novel+3-cyclohexylpropanoic+acid-derived+nitrogen+heterocyclic+compounds+and+their+evaluation+for+tuberculostatic+activity&doi=10.1016%2Fj.bmc.2011.11.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit218R"><div class="casContent"><span class="casTitleNuber">218</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of novel 3-cyclohexylpropanoic acid-derived nitrogen heterocyclic compounds and their evaluation for tuberculostatic activity</span></div><div class="casAuthors">Gobis, Katarzyna; Foks, Henryk; Bojanowski, Krzysztof; Augustynowicz-Kopec, Ewa; Napiorkowska, Agnieszka</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">137-144</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of novel 3-cyclohexylpropanoic acid derivs. and 3-cyclohexylpropanoic acid-derived nitrogen heterocyclic compds. have been synthesized and evaluated for tuberculostatic activity.  Four compds. bearing benzimidazole or benzimidazole-like systems showed the most potent tuberculostatic activity against Mycobacterium tuberculosis strains with MIC values ranging from 1.5 to 12.5 μg/mL.  More importantly, 6-chloro-2-(2-cyclohexylethyl)-4-nitro-1H-benzo[d]imidazole and 2-(2-cyclohexylethyl)-1H-imidazo[4,5-b]phenazine appeared selective for M. tuberculosis as compared with eukaryotic cells (human fibroblasts), and other antimicrobial strains.  These compds. may thus represent a novel, selective class of antitubercular agents.  Addnl., compd. 6-chloro-2-(2-cyclohexylethyl)-4-nitro-1H-benzo[d]imidazole stimulated type I collagen output by fibroblasts, in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPWNS6IqtYarVg90H21EOLACvtfcHk0lg8BSh9XlQtzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitlCksQ%253D%253D&md5=be6da92216f031a4a8afd0f5b8c9f1b2</span></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2011.11.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2011.11.020%26sid%3Dliteratum%253Aachs%26aulast%3DGobis%26aufirst%3DK.%26aulast%3DFoks%26aufirst%3DH.%26aulast%3DBojanowski%26aufirst%3DK.%26aulast%3DAugustynowicz-Kope%25C4%2587%26aufirst%3DE.%26aulast%3DNapi%25C3%25B3rkowska%26aufirst%3DA.%26atitle%3DSynthesis%2520of%2520novel%25203-cyclohexylpropanoic%2520acid-derived%2520nitrogen%2520heterocyclic%2520compounds%2520and%2520their%2520evaluation%2520for%2520tuberculostatic%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26spage%3D137%26epage%3D144%26doi%3D10.1016%2Fj.bmc.2011.11.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref219"><div class="reference"><strong class="refLabel"><a href="#ref219" class="rightTabRefNumLink">219</a></strong><div class="NLM_citation" id="rightTab-cit219"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abrahams, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghidelli-Disse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rullas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rebollo-Lopez, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurcha, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendoza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez-Navarro, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Martinez, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shillings, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argyrou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casanueva, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loman, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moynihan, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lelievre, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selenski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Axtman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bantscheff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo-Barturen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izquierdo, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cammack, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barros, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besra, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, R. H.</span></span> <span> </span><span class="NLM_article-title">Identification of KasA as the cellular target of an anti-tubercular scaffold</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">12581</span>, <span class="refDoi"> DOI: 10.1038/ncomms12581</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1038%2Fncomms12581" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=27581223" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVOru7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=12581&author=K.+A.+Abrahamsauthor=C.+W.+Chungauthor=S.+Ghidelli-Disseauthor=J.+Rullasauthor=M.+J.+Rebollo-Lopezauthor=S.+S.+Gurchaauthor=J.+A.+Coxauthor=A.+Mendozaauthor=E.+Jimenez-Navarroauthor=M.+S.+Martinez-Martinezauthor=M.+Neuauthor=A.+Shillingsauthor=P.+Homesauthor=A.+Argyrouauthor=R.+Casanuevaauthor=N.+J.+Lomanauthor=P.+J.+Moynihanauthor=J.+Lelievreauthor=C.+Selenskiauthor=M.+Axtmanauthor=L.+Kremerauthor=M.+Bantscheffauthor=I.+Angulo-Barturenauthor=M.+C.+Izquierdoauthor=N.+C.+Cammackauthor=G.+Drewesauthor=L.+Ballellauthor=D.+Barrosauthor=G.+S.+Besraauthor=R.+H.+Bates&title=Identification+of+KasA+as+the+cellular+target+of+an+anti-tubercular+scaffold&doi=10.1038%2Fncomms12581"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit219R"><div class="casContent"><span class="casTitleNuber">219</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of KasA as the cellular target of an anti-tubercular scaffold</span></div><div class="casAuthors">Abrahams, Katherine A.; Chung, Chun-wa; Ghidelli-Disse, Sonja; Rullas, Joaquin; Rebollo-Lopez, Maria Jose; Gurcha, Sudagar S.; Cox, Jonathan A. G.; Mendoza, Alfonso; Jimenez-Navarro, Elena; Martinez-Martinez, Maria Santos; Neu, Margarete; Shillings, Anthony; Homes, Paul; Argyrou, Argyrides; Casanueva, Ruth; Loman, Nicholas J.; Moynihan, Patrick J.; Lelievre, Joel; Selenski, Carolyn; Axtman, Matthew; Kremer, Laurent; Bantscheff, Marcus; Angulo-Barturen, Inigo; Izquierdo, Monica Cacho; Cammack, Nicholas C.; Drewes, Gerard; Ballell, Lluis; Barros, David; Besra, Gurdyal S.; Bates, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">12581</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Phenotypic screens for bactericidal compds. are starting to yield promising hits against tuberculosis.  In this regard, whole-genome sequencing of spontaneous resistant mutants generated against an indazole sulfonamide (GSK3011724A) identifies several specific single-nucleotide polymorphisms in the essential Mycobacterium tuberculosis β-ketoacyl synthase (kas) A gene.  Here, this genomic-based target assignment is confirmed by biochem. assays, chem. proteomics and structural resoln. of a KasA-GSK3011724A complex by X-ray crystallog.  Finally, M. tuberculosis GSK3011724A-resistant mutants increase the in vitro min. inhibitory concn. and the in vivo 99% ED in mice, establishing in vitro and in vivo target engagement.  Surprisingly, the lack of target engagement of the related β-ketoacyl synthases (FabH and KasB) suggests a different mode of inhibition when compared with other Kas inhibitors of fatty acid biosynthesis in bacteria.  These results clearly identify KasA as the biol. target of GSK3011724A and validate this enzyme for further drug discovery efforts against tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGockW3Zu8ZMEbVg90H21EOLACvtfcHk0lg8BSh9XlQtzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVOru7%252FI&md5=a1206008e181383854e026f36ad27489</span></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=10.1038%2Fncomms12581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms12581%26sid%3Dliteratum%253Aachs%26aulast%3DAbrahams%26aufirst%3DK.%2BA.%26aulast%3DChung%26aufirst%3DC.%2BW.%26aulast%3DGhidelli-Disse%26aufirst%3DS.%26aulast%3DRullas%26aufirst%3DJ.%26aulast%3DRebollo-Lopez%26aufirst%3DM.%2BJ.%26aulast%3DGurcha%26aufirst%3DS.%2BS.%26aulast%3DCox%26aufirst%3DJ.%2BA.%26aulast%3DMendoza%26aufirst%3DA.%26aulast%3DJimenez-Navarro%26aufirst%3DE.%26aulast%3DMartinez-Martinez%26aufirst%3DM.%2BS.%26aulast%3DNeu%26aufirst%3DM.%26aulast%3DShillings%26aufirst%3DA.%26aulast%3DHomes%26aufirst%3DP.%26aulast%3DArgyrou%26aufirst%3DA.%26aulast%3DCasanueva%26aufirst%3DR.%26aulast%3DLoman%26aufirst%3DN.%2BJ.%26aulast%3DMoynihan%26aufirst%3DP.%2BJ.%26aulast%3DLelievre%26aufirst%3DJ.%26aulast%3DSelenski%26aufirst%3DC.%26aulast%3DAxtman%26aufirst%3DM.%26aulast%3DKremer%26aufirst%3DL.%26aulast%3DBantscheff%26aufirst%3DM.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26aulast%3DIzquierdo%26aufirst%3DM.%2BC.%26aulast%3DCammack%26aufirst%3DN.%2BC.%26aulast%3DDrewes%26aufirst%3DG.%26aulast%3DBallell%26aufirst%3DL.%26aulast%3DBarros%26aufirst%3DD.%26aulast%3DBesra%26aufirst%3DG.%2BS.%26aulast%3DBates%26aufirst%3DR.%2BH.%26atitle%3DIdentification%2520of%2520KasA%2520as%2520the%2520cellular%2520target%2520of%2520an%2520anti-tubercular%2520scaffold%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26spage%3D12581%26doi%3D10.1038%2Fncomms12581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref220"><div class="reference"><strong class="refLabel"><a href="#ref220" class="rightTabRefNumLink">220</a></strong><div class="NLM_citation" id="rightTab-cit220"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capodagli, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awasthi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shrestha, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maharaja, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukheja, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoyama, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho Liang, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarathy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasic, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perryman, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singleton, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soteropoulos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agnihotri, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salgame, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhee, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connell, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dartois, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neiditch, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freundlich, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alland, D.</span></span> <span> </span><span class="NLM_article-title">Synergistic lethality of a binary inhibitor of mycobacterium tuberculosis KasA</span>. <i>mBio</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">e02101-17</span>, <span class="refDoi"> DOI: 10.1128/mBio.02101-17</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1128%2FmBio.02101-17" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=30563908" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=e02101-17&author=P.+Kumarauthor=G.+C.+Capodagliauthor=D.+Awasthiauthor=R.+Shresthaauthor=K.+Maharajaauthor=P.+Sukhejaauthor=S.+G.+Liauthor=D.+Inoyamaauthor=M.+Zimmermanauthor=H.+P.+Ho+Liangauthor=J.+Sarathyauthor=M.+Minaauthor=G.+Rasicauthor=R.+Russoauthor=A.+L.+Perrymanauthor=T.+Richmannauthor=A.+Guptaauthor=E.+Singletonauthor=S.+Vermaauthor=S.+Husainauthor=P.+Soteropoulosauthor=Z.+Wangauthor=R.+Morrisauthor=G.+Porterauthor=G.+Agnihotriauthor=P.+Salgameauthor=S.+Ekinsauthor=K.+Y.+Rheeauthor=N.+Connellauthor=V.+Dartoisauthor=M.+B.+Neiditchauthor=J.+S.+Freundlichauthor=D.+Alland&title=Synergistic+lethality+of+a+binary+inhibitor+of+mycobacterium+tuberculosis+KasA&doi=10.1128%2FmBio.02101-17"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=10.1128%2FmBio.02101-17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FmBio.02101-17%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DP.%26aulast%3DCapodagli%26aufirst%3DG.%2BC.%26aulast%3DAwasthi%26aufirst%3DD.%26aulast%3DShrestha%26aufirst%3DR.%26aulast%3DMaharaja%26aufirst%3DK.%26aulast%3DSukheja%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DS.%2BG.%26aulast%3DInoyama%26aufirst%3DD.%26aulast%3DZimmerman%26aufirst%3DM.%26aulast%3DHo%2BLiang%26aufirst%3DH.%2BP.%26aulast%3DSarathy%26aufirst%3DJ.%26aulast%3DMina%26aufirst%3DM.%26aulast%3DRasic%26aufirst%3DG.%26aulast%3DRusso%26aufirst%3DR.%26aulast%3DPerryman%26aufirst%3DA.%2BL.%26aulast%3DRichmann%26aufirst%3DT.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DSingleton%26aufirst%3DE.%26aulast%3DVerma%26aufirst%3DS.%26aulast%3DHusain%26aufirst%3DS.%26aulast%3DSoteropoulos%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DMorris%26aufirst%3DR.%26aulast%3DPorter%26aufirst%3DG.%26aulast%3DAgnihotri%26aufirst%3DG.%26aulast%3DSalgame%26aufirst%3DP.%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DRhee%26aufirst%3DK.%2BY.%26aulast%3DConnell%26aufirst%3DN.%26aulast%3DDartois%26aufirst%3DV.%26aulast%3DNeiditch%26aufirst%3DM.%2BB.%26aulast%3DFreundlich%26aufirst%3DJ.%2BS.%26aulast%3DAlland%26aufirst%3DD.%26atitle%3DSynergistic%2520lethality%2520of%2520a%2520binary%2520inhibitor%2520of%2520mycobacterium%2520tuberculosis%2520KasA%26jtitle%3DmBio%26date%3D2018%26volume%3D9%26spage%3De02101-17%26doi%3D10.1128%2FmBio.02101-17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref221"><div class="reference"><strong class="refLabel"><a href="#ref221" class="rightTabRefNumLink">221</a></strong><div class="NLM_citation" id="rightTab-cit221"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koumba Yoya, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Constant, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedos-Belval, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duran, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saffon, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daffé, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baltas, M.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of new cinnamic derivatives as antituberculosis agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1449</span>– <span class="NLM_lpage">1461</span>, <span class="refDoi"> DOI: 10.1021/jm101510d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101510d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvVWjurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1449-1461&author=P.+Deauthor=G.+Koumba+Yoyaauthor=P.+Constantauthor=F.+Bedos-Belvalauthor=H.+Duranauthor=N.+Saffonauthor=M.+Daff%C3%A9author=M.+Baltas&title=Design%2C+synthesis%2C+and+biological+evaluation+of+new+cinnamic+derivatives+as+antituberculosis+agents&doi=10.1021%2Fjm101510d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit221R"><div class="casContent"><span class="casTitleNuber">221</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of New Cinnamic Derivatives as Antituberculosis Agents</span></div><div class="casAuthors">De, Prithwiraj; Yoya, Georges Koumba; Constant, Patricia; Bedos-Belval, Florence; Duran, Hubert; Saffon, Nathalie; Daffe, Mamadou; Baltas, Michel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1449-1461</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tuberculosis, HIV coinfection with TB, emergence of multidrug-resistant TB, and extensively drug-resistant TB are the major causes of death from infectious diseases worldwide.  Because no new drug has been introduced in the last several decades, new classes of mols. as anti-TB drugs are urgently needed.  The synthesis and structure-activity relationships of a series of thioester, amide, hydrazide, and triazolophthalazine derivs. of 4-alkoxy cinnamic acid is reported in this paper.  Many compds. exhibited submicromolar min. inhibitory concns. against Mycobacterium tuberculosis strain (H37Rv).  Interestingly I, a 4-isopentenyloxycinnamyl triazolophthalazine deriv., was found to be 100-1800 times more active than isoniazid (INH) when tested for its ability to inhibit the growth of INH-resistant M. tuberculosis strains.  The results also revealed that I does not interfere with mycolic acid biosynthesis, thereby pointing to a different mode of action and representing an attractive lead compd. for the development of new anti-TB agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-D7wTlOp1o7Vg90H21EOLACvtfcHk0lgnLl28B59qrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvVWjurk%253D&md5=bcfc4d9dbd809e5e0fde4527cfeafa74</span></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=10.1021%2Fjm101510d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101510d%26sid%3Dliteratum%253Aachs%26aulast%3DDe%26aufirst%3DP.%26aulast%3DKoumba%2BYoya%26aufirst%3DG.%26aulast%3DConstant%26aufirst%3DP.%26aulast%3DBedos-Belval%26aufirst%3DF.%26aulast%3DDuran%26aufirst%3DH.%26aulast%3DSaffon%26aufirst%3DN.%26aulast%3DDaff%25C3%25A9%26aufirst%3DM.%26aulast%3DBaltas%26aufirst%3DM.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520new%2520cinnamic%2520derivatives%2520as%2520antituberculosis%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1449%26epage%3D1461%26doi%3D10.1021%2Fjm101510d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref222"><div class="reference"><strong class="refLabel"><a href="#ref222" class="rightTabRefNumLink">222</a></strong><div class="NLM_citation" id="rightTab-cit222"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tawari, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bairwa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajan, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degani, M. S.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of 4-(5-nitrofuran-2-yl)prop-2-en-1-one derivatives as potent antitubercular agents</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">6175</span>– <span class="NLM_lpage">6178</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.08.127</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmcl.2010.08.127" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=20850299" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1KrsbrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=6175-6178&author=N.+R.+Tawariauthor=R.+Bairwaauthor=M.+K.+Rayauthor=M.+G.+Rajanauthor=M.+S.+Degani&title=Design%2C+synthesis%2C+and+biological+evaluation+of+4-%285-nitrofuran-2-yl%29prop-2-en-1-one+derivatives+as+potent+antitubercular+agents&doi=10.1016%2Fj.bmcl.2010.08.127"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit222R"><div class="casContent"><span class="casTitleNuber">222</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and biological evaluation of 4-(5-nitrofuran-2-yl)prop-2-en-1-one derivatives as potent antitubercular agents</span></div><div class="casAuthors">Tawari, Nilesh R.; Bairwa, Ranjeet; Ray, M. K.; Rajan, M. G. R.; Degani, Mariam S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6175-6178</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Based on stereoelectronic feature anal. using d. functional theory (DFT) at B3LYP/3-21*G level, a series of 4-(5-nitrofuran-2-yl)prop-2-en-1-one derivs. with low LUMO energies (< -0.10 eV); concd. over the nitro group, furan moiety and α,β-unsatd. carbonyl bridge were envisaged as potential antitubercular agents.  The target compds. were prepd. by condensation of 5-nitro-2-furaldehyde with various ketones under acidic condition.  The compds. were evaluated for antitubercular activity against Mycobacterium tuberculosis H37Rv and their cytotoxicity in VERO cell line.  Several synthesized compds. showed good antitubercular activity of < 5 μM along with low cytotoxicity.  In particular, compd. ((E)-3-(5-nitrofuran-2-yl)-1-(4-(piperidin-1-yl)phenyl)prop-2-en-1-one) (3v) was found to be very potent (MIC = 0.19 μM) with good selectivity index (MIC90/CC50 = >1800).  Thus, this study shows the potential of stereoelectronic property anal. in developing improved nitroaroms. as antitubercular agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUACoKUiWq4bVg90H21EOLACvtfcHk0lgnLl28B59qrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1KrsbrF&md5=a30bbf961b4161b7f38347170bcf6edd</span></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.08.127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.08.127%26sid%3Dliteratum%253Aachs%26aulast%3DTawari%26aufirst%3DN.%2BR.%26aulast%3DBairwa%26aufirst%3DR.%26aulast%3DRay%26aufirst%3DM.%2BK.%26aulast%3DRajan%26aufirst%3DM.%2BG.%26aulast%3DDegani%26aufirst%3DM.%2BS.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%25204-%25285-nitrofuran-2-yl%2529prop-2-en-1-one%2520derivatives%2520as%2520potent%2520antitubercular%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D6175%26epage%3D6178%26doi%3D10.1016%2Fj.bmcl.2010.08.127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref223"><div class="reference"><strong class="refLabel"><a href="#ref223" class="rightTabRefNumLink">223</a></strong><div class="NLM_citation" id="rightTab-cit223"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Limaye, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumbhar, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natu, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paradkar, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honmore, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gample, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkar, D.</span></span> <span> </span><span class="NLM_article-title">One pot solvent free synthesis and in vitro antitubercular screening of 3-aracylphthalides against mycobacterium tuberculosis</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">711</span>– <span class="NLM_lpage">714</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.11.097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bmcl.2012.11.097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=23265877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVyhs7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=711-714&author=R.+A.+Limayeauthor=V.+B.+Kumbharauthor=A.+D.+Natuauthor=M.+V.+Paradkarauthor=V.+S.+Honmoreauthor=R.+R.+Chauhanauthor=S.+P.+Gampleauthor=D.+Sarkar&title=One+pot+solvent+free+synthesis+and+in+vitro+antitubercular+screening+of+3-aracylphthalides+against+mycobacterium+tuberculosis&doi=10.1016%2Fj.bmcl.2012.11.097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit223R"><div class="casContent"><span class="casTitleNuber">223</span><div class="casTitle"><span class="NLM_cas:atitle">One-pot solvent-free synthesis and in vitro antitubercular screening of 3-Aracylphthalides against Mycobacterium tuberculosis</span></div><div class="casAuthors">Limaye, Rohan A.; Kumbhar, Virendra B.; Natu, Arun D.; Paradkar, Madhusudan V.; Honmore, Varsha S.; Chauhan, Rubia R.; Gample, Suwarna P.; Sarkar, Dhiman</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">711-714</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">One-pot synthesis of 3-aracylphthalides, e.g., I (R = H, Me, MeO, OH, NO2, Br, Cl), was accomplished in good yield by reacting 2-carboxy benzaldehyde with various arom. Me ketones in presence of methane sulfonic acid.  Various phthalides thus obtained were characterized with spectral techniques.  These phthalides were subjected to in vitro antitubercular screening against Mycobacterium tuberculosis H37Ra (MTB) by using XRMA protocol.  Among the phthalides screened, four exhibited half maximal inhibitory concn. (IC50) in the range of 0.81-1.24 μg/mL thereby providing potential lead compds. for future drug discovery studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmZvBdzxB6kLVg90H21EOLACvtfcHk0lgnLl28B59qrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVyhs7bN&md5=69fa6dcc350c13b30d7eeeca9dfe2d8e</span></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.11.097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.11.097%26sid%3Dliteratum%253Aachs%26aulast%3DLimaye%26aufirst%3DR.%2BA.%26aulast%3DKumbhar%26aufirst%3DV.%2BB.%26aulast%3DNatu%26aufirst%3DA.%2BD.%26aulast%3DParadkar%26aufirst%3DM.%2BV.%26aulast%3DHonmore%26aufirst%3DV.%2BS.%26aulast%3DChauhan%26aufirst%3DR.%2BR.%26aulast%3DGample%26aufirst%3DS.%2BP.%26aulast%3DSarkar%26aufirst%3DD.%26atitle%3DOne%2520pot%2520solvent%2520free%2520synthesis%2520and%2520in%2520vitro%2520antitubercular%2520screening%2520of%25203-aracylphthalides%2520against%2520mycobacterium%2520tuberculosis%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D711%26epage%3D714%26doi%3D10.1016%2Fj.bmcl.2012.11.097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref224"><div class="reference"><strong class="refLabel"><a href="#ref224" class="rightTabRefNumLink">224</a></strong><div class="NLM_citation" id="rightTab-cit224"><span> <i>GSK 3036656</i>; <span class="NLM_publisher-name">The Working Group for
New TB
Drugs</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">2019</span>; <a href="https://www.newtbdrugs.org/pipeline/compound/gsk-070-gsk-3036656" class="extLink">https://www.newtbdrugs.org/pipeline/compound/gsk-070-gsk-3036656</a> (accessed 2020-03-03).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+GSK+3036656%3B+The+Working+Group+for%0ANew+TB%0ADrugs%3A+New+York%2C+2019%3B+https%3A%2F%2Fwww.newtbdrugs.org%2Fpipeline%2Fcompound%2Fgsk-070-gsk-3036656+%28accessed+2020-03-03%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26jtitle%3DGSK%25203036656%26pub%3DThe%2520Working%2520Group%2520for%250ANew%2520TB%250ADrugs%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref225"><div class="reference"><strong class="refLabel"><a href="#ref225" class="rightTabRefNumLink">225</a></strong><div class="NLM_citation" id="rightTab-cit225"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casey, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parish, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunin, B. A.</span></span> <span> </span><span class="NLM_article-title">Bayesian models for screening and TB mobile for target inference with mycobacterium tuberculosis</span>. <i>Tuberculosis (Oxford, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">162</span>– <span class="NLM_lpage">169</span>, <span class="refDoi"> DOI: 10.1016/j.tube.2013.12.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.tube.2013.12.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=24440548" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisFSmsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2014&pages=162-169&author=S.+Ekinsauthor=A.+C.+Caseyauthor=D.+Robertsauthor=T.+Parishauthor=B.+A.+Bunin&title=Bayesian+models+for+screening+and+TB+mobile+for+target+inference+with+mycobacterium+tuberculosis&doi=10.1016%2Fj.tube.2013.12.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit225R"><div class="casContent"><span class="casTitleNuber">225</span><div class="casTitle"><span class="NLM_cas:atitle">Bayesian models for screening and TB Mobile for target inference with Mycobacterium tuberculosis</span></div><div class="casAuthors">Ekins, Sean; Casey, Allen C.; Roberts, David; Parish, Tanya; Bunin, Barry A.</div><div class="citationInfo"><span class="NLM_cas:title">Tuberculosis (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">162-169</span>CODEN:
                <span class="NLM_cas:coden">TUBECU</span>;
        ISSN:<span class="NLM_cas:issn">1472-9792</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The search for compds. active against Mycobacterium tuberculosis is reliant upon high-throughput screening (HTS) in whole cells.  We have used Bayesian machine learning models which can predict anti-tubercular activity to filter an internal library of over 150,000 compds. prior to in vitro testing.  We used this to select and test 48 compds. in vitro; 11 were active with MIC values ranging from 0.4 μM to 10.2 μM, giving a high hit rate of 22.9%.  Among the hits, we identified several compds. belonging to the same series including five quinolones (including ciprofloxacin), three mols. with long aliph. linkers and three singletons.  This approach represents a rapid method to prioritize compds. for testing that can be used alongside medicinal chem. insight and other filters to identify active mols.  Such models can significantly increase the hit rate of HTS, above the usual 1% or lower rates seen.  In addn., the potential targets for the 11 mols. were predicted using TB Mobile and clustering alongside a set of over 740 mols. with known M. tuberculosis target annotations.  These predictions may serve as a mechanism for prioritizing compds. for further optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyNxo3fnyZxLVg90H21EOLACvtfcHk0liX95Dwg76nVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisFSmsbk%253D&md5=1d80c6fa0949708d7ef9edc93e88e18b</span></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=10.1016%2Fj.tube.2013.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tube.2013.12.001%26sid%3Dliteratum%253Aachs%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DCasey%26aufirst%3DA.%2BC.%26aulast%3DRoberts%26aufirst%3DD.%26aulast%3DParish%26aufirst%3DT.%26aulast%3DBunin%26aufirst%3DB.%2BA.%26atitle%3DBayesian%2520models%2520for%2520screening%2520and%2520TB%2520mobile%2520for%2520target%2520inference%2520with%2520mycobacterium%2520tuberculosis%26jtitle%3DTuberculosis%2520%2528Oxford%252C%2520U.%2520K.%2529%26date%3D2014%26volume%3D94%26spage%3D162%26epage%3D169%26doi%3D10.1016%2Fj.tube.2013.12.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref226"><div class="reference"><strong class="refLabel"><a href="#ref226" class="rightTabRefNumLink">226</a></strong><div class="NLM_citation" id="rightTab-cit226"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pottorf, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freundlich, J. S.</span></span> <span> </span><span class="NLM_article-title">Looking back to the future: Predicting in vivo efficacy of small molecules versus mycobacterium tuberculosis</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1070</span>– <span class="NLM_lpage">1082</span>, <span class="refDoi"> DOI: 10.1021/ci500077v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci500077v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkslamu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2014&pages=1070-1082&author=S.+Ekinsauthor=R.+Pottorfauthor=R.+C.+Reynoldsauthor=A.+J.+Williamsauthor=A.+M.+Clarkauthor=J.+S.+Freundlich&title=Looking+back+to+the+future%3A+Predicting+in+vivo+efficacy+of+small+molecules+versus+mycobacterium+tuberculosis&doi=10.1021%2Fci500077v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit226R"><div class="casContent"><span class="casTitleNuber">226</span><div class="casTitle"><span class="NLM_cas:atitle">Looking Back to the Future: Predicting in Vivo Efficacy of Small Molecules versus Mycobacterium tuberculosis</span></div><div class="casAuthors">Ekins, Sean; Pottorf, Richard; Reynolds, Robert C.; Williams, Antony J.; Clark, Alex M.; Freundlich, Joel S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1070-1082</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Selecting and translating in vitro leads for a disease into mols. with in vivo activity in an animal model of the disease is a challenge that takes considerable time and money.  As an example, recent years have seen whole-cell phenotypic screens of millions of compds. yielding over 1500 inhibitors of Mycobacterium tuberculosis (Mtb).  These must be prioritized for testing in the mouse in vivo assay for Mtb infection, a validated model utilized to select compds. for further testing.  The authors demonstrate learning from in vivo active and inactive compds. using machine learning classification models (Bayesian, support vector machines, and recursive partitioning) consisting of 773 compds.  The Bayesian model predicted 8 out of 11 addnl. in vivo actives not included in the model as an external test set.  Curation of 70 years of Mtb data can therefore provide statistically robust computational models to focus resources on in vivo active small mol. antituberculars.  This highlights a cost-effective predictor for in vivo testing elsewhere in other diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotUoWucn-1OrVg90H21EOLACvtfcHk0liX95Dwg76nVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkslamu7Y%253D&md5=e5e27ddb07601604b0c9c2cde9dd313d</span></div><a href="/servlet/linkout?suffix=cit226&amp;dbid=16384&amp;doi=10.1021%2Fci500077v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci500077v%26sid%3Dliteratum%253Aachs%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DPottorf%26aufirst%3DR.%26aulast%3DReynolds%26aufirst%3DR.%2BC.%26aulast%3DWilliams%26aufirst%3DA.%2BJ.%26aulast%3DClark%26aufirst%3DA.%2BM.%26aulast%3DFreundlich%26aufirst%3DJ.%2BS.%26atitle%3DLooking%2520back%2520to%2520the%2520future%253A%2520Predicting%2520in%2520vivo%2520efficacy%2520of%2520small%2520molecules%2520versus%2520mycobacterium%2520tuberculosis%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2014%26volume%3D54%26spage%3D1070%26epage%3D1082%26doi%3D10.1021%2Fci500077v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref227"><div class="reference"><strong class="refLabel"><a href="#ref227" class="rightTabRefNumLink">227</a></strong><div class="NLM_citation" id="rightTab-cit227"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipinski, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradford, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dole, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spektor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blondeau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goncharoff, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunin, B.</span></span> <span> </span><span class="NLM_article-title">Analysis and hit filtering of a very large library of compounds screened against mycobacterium tuberculosis</span>. <i>Mol. BioSyst.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">2316</span>– <span class="NLM_lpage">2324</span>, <span class="refDoi"> DOI: 10.1039/C0MB00104J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1039%2FC0MB00104J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=20835433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1KqtL7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=2316-2324&author=S.+Ekinsauthor=T.+Kanekoauthor=C.+A.+Lipinskiauthor=J.+Bradfordauthor=K.+Doleauthor=A.+Spektorauthor=K.+Gregoryauthor=D.+Blondeauauthor=S.+Ernstauthor=J.+Yangauthor=N.+Goncharoffauthor=M.+Hohmanauthor=B.+Bunin&title=Analysis+and+hit+filtering+of+a+very+large+library+of+compounds+screened+against+mycobacterium+tuberculosis&doi=10.1039%2FC0MB00104J"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit227R"><div class="casContent"><span class="casTitleNuber">227</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis and hit filtering of a very large library of compounds screened against Mycobacterium tuberculosis</span></div><div class="casAuthors">Ekins, Sean; Kaneko, Takushi; Lipinski, Christopher A.; Bradford, Justin; Dole, Krishna; Spektor, Anna; Gregory, Kellan; Blondeau, David; Ernst, Sylvia; Yang, Jeremy; Goncharoff, Nicko; Hohman, Moses M.; Bunin, Barry A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular BioSystems</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2316-2324</span>CODEN:
                <span class="NLM_cas:coden">MBOIBW</span>;
        ISSN:<span class="NLM_cas:issn">1742-206X</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">There is an urgent need for new drugs against tuberculosis which annually claims 1.7-1.8 million lives.  One approach to identify potential leads is to screen in vitro small mols. against Mycobacterium tuberculosis (Mtb).  Until recently there was no central repository to collect information on compds. screened.  Consequently, it has been difficult to analyze mol. properties of compds. that inhibit the growth of Mtb in vitro.  We have collected data from publically available sources on over 300 000 small mols. deposited in the Collaborative Drug Discovery TB Database.  A cheminformatics anal. on these compds. indicates that inhibitors of the growth of Mtb have statistically higher mean logP, rule of 5 alerts, while also having lower HBD count, atom count and lower PSA (ChemAxon descriptors), compared to compds. that are classed as inactive.  Addnl., Bayesian models for selecting Mtb active compds. were evaluated with over 100 000 compds. and, they demonstrated 10 fold enrichment over random for the top ranked 600 compds.  This represents a promising approach for finding compds. active against Mtb in whole cells screened under the same in vitro conditions.  Various sets of Mtb hit mols. were also examd. by various filtering rules used widely in the pharmaceutical industry to identify compds. with potentially reactive moieties.  We found differences between the no. of compds. flagged by these rules in Mtb datasets, malaria hits, FDA approved drugs and antibiotics.  Combining these approaches may enable selection of compds. with increased probability of inhibition of whole cell Mtb activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSaytzWyG0H7Vg90H21EOLACvtfcHk0liX95Dwg76nVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1KqtL7L&md5=66783a6e7ae22ad9b0022d94d6a77cea</span></div><a href="/servlet/linkout?suffix=cit227&amp;dbid=16384&amp;doi=10.1039%2FC0MB00104J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC0MB00104J%26sid%3Dliteratum%253Aachs%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DKaneko%26aufirst%3DT.%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26aulast%3DBradford%26aufirst%3DJ.%26aulast%3DDole%26aufirst%3DK.%26aulast%3DSpektor%26aufirst%3DA.%26aulast%3DGregory%26aufirst%3DK.%26aulast%3DBlondeau%26aufirst%3DD.%26aulast%3DErnst%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DGoncharoff%26aufirst%3DN.%26aulast%3DHohman%26aufirst%3DM.%26aulast%3DBunin%26aufirst%3DB.%26atitle%3DAnalysis%2520and%2520hit%2520filtering%2520of%2520a%2520very%2520large%2520library%2520of%2520compounds%2520screened%2520against%2520mycobacterium%2520tuberculosis%26jtitle%3DMol.%2520BioSyst.%26date%3D2010%26volume%3D6%26spage%3D2316%26epage%3D2324%26doi%3D10.1039%2FC0MB00104J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref228"><div class="reference"><strong class="refLabel"><a href="#ref228" class="rightTabRefNumLink">228</a></strong><div class="NLM_citation" id="rightTab-cit228"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Landrum, G.</span></span> <i>RDkit Documentation</i>, <span class="NLM_edition">Release 2017.09.1</span>; <span class="NLM_publisher-name">Zenodo</span>, <span class="NLM_year">2016</span>; <span class="refDoi"> DOI: 10.5281/zenodo.60510</span>  (accessed 2020-03-03).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=G.+Landrum&title=RDkit+Documentation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit228&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26aulast%3DLandrum%26aufirst%3DG.%26jtitle%3DRDkit%2520Documentation%26pub%3DZenodo%26date%3D2016%26doi%3D10.5281%2Fzenodo.60510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref229"><div class="reference"><strong class="refLabel"><a href="#ref229" class="rightTabRefNumLink">229</a></strong><div class="NLM_citation" id="rightTab-cit229"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McKinney, W.</span></span> <i>Pandas—Powerful Python Data Analysis Toolkit</i>; <span class="NLM_publisher-name">Pandas</span>, <span class="NLM_year">2020</span>; <a href="https://pandas.pydata.org/pandas-docs/stable/" class="extLink">https://pandas.pydata.org/pandas-docs/stable/</a> (accessed 2020-03-03).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=W.+McKinney&title=Pandas%E2%80%94Powerful+Python+Data+Analysis+Toolkit"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit229&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26aulast%3DMcKinney%26aufirst%3DW.%26jtitle%3DPandas%25E2%2580%2594Powerful%2520Python%2520Data%2520Analysis%2520Toolkit%26pub%3DPandas%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref230"><div class="reference"><strong class="refLabel"><a href="#ref230" class="rightTabRefNumLink">230</a></strong><div class="NLM_citation" id="rightTab-cit230"><span> <i>NumPy Reference</i>, <span class="NLM_edition">release 1.11</span>; <span class="NLM_publisher-name">SciPy</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+NumPy+Reference%2C+release+1.11%3B+SciPy%2C+2016."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit230&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DNumPy%2520Reference%26pub%3DSciPy%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref231"><div class="reference"><strong class="refLabel"><a href="#ref231" class="rightTabRefNumLink">231</a></strong><div class="NLM_citation" id="rightTab-cit231"><span> <i>Jupyter Notebook
Tutorial: The Definitive Guide</i>; <span class="NLM_publisher-name">DataCamp</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Jupyter+Notebook%0ATutorial%3A+The+Definitive+Guide%3B+DataCamp%2C+2019."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit231&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DJupyter%2520Notebook%250ATutorial%253A%2520The%2520Definitive%2520Guide%26pub%3DDataCamp%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref232"><div class="reference"><strong class="refLabel"><a href="#ref232" class="rightTabRefNumLink">232</a></strong><div class="NLM_citation" id="rightTab-cit232"><span> <i>Scikit-learn
User Guide</i>, <span class="NLM_edition">release 0.22.2</span>; <span class="NLM_publisher-name">Scikit-learn Developers</span>, <span class="NLM_year">2020</span>; <a href="https://scikit-learn.org/stable/_downloads/scikit-learn-docs.pdf" class="extLink">https://scikit-learn.org/stable/_downloads/scikit-learn-docs.pdf</a> (accessed 2020-03-03).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Scikit-learn%0AUser+Guide%2C+release+0.22.2%3B+Scikit-learn+Developers%2C+2020%3B+https%3A%2F%2Fscikit-learn.org%2Fstable%2F_downloads%2Fscikit-learn-docs.pdf+%28accessed+2020-03-03%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit232&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DScikit-learn%250AUser%2520Guide%26pub%3DScikit-learn%2520Developers%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref233"><div class="reference"><strong class="refLabel"><a href="#ref233" class="rightTabRefNumLink">233</a></strong><div class="NLM_citation" id="rightTab-cit233"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lane, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zorn, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korotcov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tkachenko, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perryman, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freundlich, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span> <span> </span><span class="NLM_article-title">Comparing and validating machine learning models for mycobacterium tuberculosis drug discovery</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">4346</span>– <span class="NLM_lpage">4360</span>, <span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.8b00083</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.8b00083" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnvV2lt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=4346-4360&author=T.+Laneauthor=D.+P.+Russoauthor=K.+M.+Zornauthor=A.+M.+Clarkauthor=A.+Korotcovauthor=V.+Tkachenkoauthor=R.+C.+Reynoldsauthor=A.+L.+Perrymanauthor=J.+S.+Freundlichauthor=S.+Ekins&title=Comparing+and+validating+machine+learning+models+for+mycobacterium+tuberculosis+drug+discovery&doi=10.1021%2Facs.molpharmaceut.8b00083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit233R"><div class="casContent"><span class="casTitleNuber">233</span><div class="casTitle"><span class="NLM_cas:atitle">Comparing and validating machine learning models for Mycobacterium tuberculosis drug discovery</span></div><div class="casAuthors">Lane, Thomas; Russo, Daniel P.; Zorn, Kimberley M.; Clark, Alex M.; Korotcov, Alexandru; Tkachenko, Valery; Reynolds, Robert C.; Perryman, Alexander L.; Freundlich, Joel S.; Ekins, Sean</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4346-4360</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tuberculosis is a global health dilemma.  In 2016, the WHO reported 10.4 million incidences and 1.7 million deaths.  The need to develop new treatments for those infected with Mycobacterium tuberculosis (Mtb) has led to many large-scale phenotypic screens and many thousands of new active compds. identified in vitro.  However, with limited funding, efforts to discover new active mols. against Mtb needs to be more efficient.  Several computational machine learning approaches have been shown to have good enrichment and hit rates.  We have curated small mol. Mtb data and developed new models with a total of 18,886 mols. with activity cutoffs of 10 μM, 1 μM, and 100 nM.  These data sets were used to evaluate different machine learning methods (including deep learning) and metrics and to generate predictions for addnl. mols. published in 2017.  One Mtb model, a combined in vitro and in vivo data Bayesian model at a 100 nM activity yielded the following metrics for 5-fold cross validation: accuracy = 0.88, precision = 0.22, recall = 0.91, specificity = 0.88, kappa = 0.31, and MCC = 0.41.  We have also curated an evaluation set (n = 153 compds.) published in 2017, and when used to test our model, it showed the comparable statistics (accuracy = 0.83, precision = 0.27, recall = 1.00, specificity = 0.81, kappa = 0.36, and MCC = 0.47).  We have also compared these models with addnl. machine learning algorithms showing Bayesian machine learning models constructed with literature Mtb data generated by different labs. generally were equiv. to or outperformed deep neural networks with external test sets.  Finally, we have also compared our training and test sets to show they were suitably diverse and different in order to represent useful evaluation sets.  Such Mtb machine learning models could help prioritize compds. for testing in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJzwbptdi_BrVg90H21EOLACvtfcHk0lgmce8Tpzpp8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnvV2lt70%253D&md5=9f856a1ccc13467380f6517534c1203a</span></div><a href="/servlet/linkout?suffix=cit233&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.8b00083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.8b00083%26sid%3Dliteratum%253Aachs%26aulast%3DLane%26aufirst%3DT.%26aulast%3DRusso%26aufirst%3DD.%2BP.%26aulast%3DZorn%26aufirst%3DK.%2BM.%26aulast%3DClark%26aufirst%3DA.%2BM.%26aulast%3DKorotcov%26aufirst%3DA.%26aulast%3DTkachenko%26aufirst%3DV.%26aulast%3DReynolds%26aufirst%3DR.%2BC.%26aulast%3DPerryman%26aufirst%3DA.%2BL.%26aulast%3DFreundlich%26aufirst%3DJ.%2BS.%26aulast%3DEkins%26aufirst%3DS.%26atitle%3DComparing%2520and%2520validating%2520machine%2520learning%2520models%2520for%2520mycobacterium%2520tuberculosis%2520drug%2520discovery%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2018%26volume%3D15%26spage%3D4346%26epage%3D4360%26doi%3D10.1021%2Facs.molpharmaceut.8b00083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref234"><div class="reference"><strong class="refLabel"><a href="#ref234" class="rightTabRefNumLink">234</a></strong><div class="NLM_citation" id="rightTab-cit234"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, J.</span>; <span class="NLM_string-name">Dale, D.</span>; <span class="NLM_string-name">Firing, E.</span>; <span class="NLM_string-name">Droettboom, M.</span></span> <i>Matplotlib</i>, <span class="NLM_edition">release 2.2.2</span>; <span class="NLM_publisher-name">Matplotlib Development Team</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=J.+Hunter&author=D.+Dale&author=E.+Firing&author=M.+Droettboom&title=Matplotlib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit234&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26aulast%3DHunter%26aufirst%3DJ.%26jtitle%3DMatplotlib%26pub%3DMatplotlib%2520Development%2520Team%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref235"><div class="reference"><strong class="refLabel"><a href="#ref235" class="rightTabRefNumLink">235</a></strong><div class="NLM_citation" id="rightTab-cit235"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prathipati, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, T. H.</span></span> <span> </span><span class="NLM_article-title">Global bayesian models for the prioritization of antitubercular agents</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">2362</span>– <span class="NLM_lpage">2370</span>, <span class="refDoi"> DOI: 10.1021/ci800143n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci800143n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlygs7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2008&pages=2362-2370&author=P.+Prathipatiauthor=N.+L.+Maauthor=T.+H.+Keller&title=Global+bayesian+models+for+the+prioritization+of+antitubercular+agents&doi=10.1021%2Fci800143n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit235R"><div class="casContent"><span class="casTitleNuber">235</span><div class="casTitle"><span class="NLM_cas:atitle">Global Bayesian Models for the Prioritization of Antitubercular Agents</span></div><div class="casAuthors">Prathipati, Philip; Ma, Ngai Ling; Keller, Thomas H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2362-2370</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To aid the creation of novel antituberculosis (antiTB) compds., Bayesian models were derived and validated on a data set of 3779 compds. which have been measured for min. inhibitory concn. (MIC) in the Mycobacterium tuberculosis H37Rv strain.  The model development and validation involved exploring six different training sets and 15 fingerprint types which resulted in a total of 90 models, with active compds. defined as those with MIC < 5 μM.  The best model was derived using Extended Class Fingerprints of max. diam. 12 (ECFP_12) and a few global descriptors on a training set derived using Functional Class Fingerprints of max. diam. 4 (FCFP_4).  This model demonstrated very good discriminant ability in general, with excellent discriminant statistics for the training set (total accuracy: 0.968; pos. recall: 0.967) and a good predictive ability for the test set (total accuracy: 0.869; pos. recall: 0.789).  The good predictive ability was maintained when the model was applied to a well-sepd. test set of 2880 compds. derived from a com. database (total accuracy: 0.73; pos. recall: 0.72).  The model revealed several conserved substructures present in the active and inactive compds. which are believed to have incremental and detrimental effects on the MIC, resp.  Strategies for enhancing the repertoire of antiTB compds. with the model, including virtual screening of large databases and combinatorial library design, are proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodFNgYRk32ErVg90H21EOLACvtfcHk0lgmce8Tpzpp8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlygs7vI&md5=25c23c61ea8412f5da04010d39daf323</span></div><a href="/servlet/linkout?suffix=cit235&amp;dbid=16384&amp;doi=10.1021%2Fci800143n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci800143n%26sid%3Dliteratum%253Aachs%26aulast%3DPrathipati%26aufirst%3DP.%26aulast%3DMa%26aufirst%3DN.%2BL.%26aulast%3DKeller%26aufirst%3DT.%2BH.%26atitle%3DGlobal%2520bayesian%2520models%2520for%2520the%2520prioritization%2520of%2520antitubercular%2520agents%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2008%26volume%3D48%26spage%3D2362%26epage%3D2370%26doi%3D10.1021%2Fci800143n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref236"><div class="reference"><strong class="refLabel"><a href="#ref236" class="rightTabRefNumLink">236</a></strong><div class="NLM_citation" id="rightTab-cit236"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradford, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dole, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spektor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blondeau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunin, B.</span></span> <span> </span><span class="NLM_article-title">A collaborative database and computational models for tuberculosis drug discovery</span>. <i>Mol. BioSyst.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">840</span>– <span class="NLM_lpage">851</span>, <span class="refDoi"> DOI: 10.1039/b917766c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1039%2Fb917766c" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=20567770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvVSrtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=840-851&author=S.+Ekinsauthor=J.+Bradfordauthor=K.+Doleauthor=A.+Spektorauthor=K.+Gregoryauthor=D.+Blondeauauthor=M.+Hohmanauthor=B.+Bunin&title=A+collaborative+database+and+computational+models+for+tuberculosis+drug+discovery&doi=10.1039%2Fb917766c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit236R"><div class="casContent"><span class="casTitleNuber">236</span><div class="casTitle"><span class="NLM_cas:atitle">A collaborative database and computational models for tuberculosis drug discovery</span></div><div class="casAuthors">Ekins, Sean; Bradford, Justin; Dole, Krishna; Spektor, Anna; Gregory, Kellan; Blondeau, David; Hohman, Moses; Bunin, Barry A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular BioSystems</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">840-851</span>CODEN:
                <span class="NLM_cas:coden">MBOIBW</span>;
        ISSN:<span class="NLM_cas:issn">1742-206X</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The search for mols. with activity against Mycobacterium tuberculosis (Mtb) is employing many approaches in parallel including high throughput screening and computational methods.  We have developed a database (CDD TB) to capture public and private Mtb data while enabling data mining and collaborations with other researchers.  We have used the public data along with several cheminformatics approaches to produce models that describe active and inactive compds.  We have compared these datasets to those for known FDA approved drugs and between Mtb active and inactive compds.  The distribution of polar surface area and pKa of active compds. was found to be a statistically significant determinant of activity against Mtb.  Hydrophobicity was not always statistically significant. Bayesian classification models for 220463 mols. were generated and tested with external mols., and enabled the discrimination of active or inactive substructures from other datasets in the CDD TB.  Computational pharmacophores based on known Mtb drugs were able to map to and retrieve a small subset of some of the Mtb datasets, including a high percentage of Mtb actives.  The combination of the database, dataset anal., Bayesian and pharmacophore models provides new insights into mol. properties and features that are determinants of activity in whole cells.  This study provides novel insights into the key 1D mol. descriptors, 2D chem. substructures and 3D pharmacophores which can be used to mine the chem. space, prioritizing those mols. with a higher probability of activity against Mtb.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgfg8SbojRpLVg90H21EOLACvtfcHk0lgrGoI59kkjpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvVSrtrg%253D&md5=5bab2de79f0bb02dc9f3b24563776b16</span></div><a href="/servlet/linkout?suffix=cit236&amp;dbid=16384&amp;doi=10.1039%2Fb917766c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb917766c%26sid%3Dliteratum%253Aachs%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DBradford%26aufirst%3DJ.%26aulast%3DDole%26aufirst%3DK.%26aulast%3DSpektor%26aufirst%3DA.%26aulast%3DGregory%26aufirst%3DK.%26aulast%3DBlondeau%26aufirst%3DD.%26aulast%3DHohman%26aufirst%3DM.%26aulast%3DBunin%26aufirst%3DB.%26atitle%3DA%2520collaborative%2520database%2520and%2520computational%2520models%2520for%2520tuberculosis%2520drug%2520discovery%26jtitle%3DMol.%2520BioSyst.%26date%3D2010%26volume%3D6%26spage%3D840%26epage%3D851%26doi%3D10.1039%2Fb917766c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref237"><div class="reference"><strong class="refLabel"><a href="#ref237" class="rightTabRefNumLink">237</a></strong><div class="NLM_citation" id="rightTab-cit237"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gamo, F.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanz, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vidal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Cozar, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavandera, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderwall, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, D. V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peishoff, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardon, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Bustos, J. F.</span></span> <span> </span><span class="NLM_article-title">Thousands of chemical starting points for antimalarial lead identification</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>465</i></span>,  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">310</span>, <span class="refDoi"> DOI: 10.1038/nature09107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1038%2Fnature09107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=20485427" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmt1Ois7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=465&publication_year=2010&pages=305-310&author=F.-J.+Gamoauthor=L.+M.+Sanzauthor=J.+Vidalauthor=C.+de+Cozarauthor=E.+Alvarezauthor=J.-L.+Lavanderaauthor=D.+E.+Vanderwallauthor=D.+V.+S.+Greenauthor=V.+Kumarauthor=S.+Hasanauthor=J.+R.+Brownauthor=C.+E.+Peishoffauthor=L.+R.+Cardonauthor=J.+F.+Garcia-Bustos&title=Thousands+of+chemical+starting+points+for+antimalarial+lead+identification&doi=10.1038%2Fnature09107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit237R"><div class="casContent"><span class="casTitleNuber">237</span><div class="casTitle"><span class="NLM_cas:atitle">Thousands of chemical starting points for antimalarial lead identification</span></div><div class="casAuthors">Gamo, Francisco-Javier; Sanz, Laura M.; Vidal, Jaume; de Cozar, Cristina; Alvarez, Emilio; Lavandera, Jose-Luis; Vanderwall, Dana E.; Green, Darren V. S.; Kumar, Vinod; Hasan, Samiul; Brown, James R.; Peishoff, Catherine E.; Cardon, Lon R.; Garcia-Bustos, Jose F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">465</span>
        (<span class="NLM_cas:issue">7296</span>),
    <span class="NLM_cas:pages">305-310</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Malaria is a devastating infection caused by protozoa of the genus Plasmodium.  Drug resistance is widespread, no new chem. class of antimalarials has been introduced into clin. practice since 1996 and there is a recent rise of parasite strains with reduced sensitivity to the newest drugs.  We screened nearly 2 million compds. in GlaxoSmithKline's chem. library for inhibitors of P. falciparum, of which 13,533 were confirmed to inhibit parasite growth by at least 80% at 2 μM concn.  More than 8,000 also showed potent activity against the multidrug resistant strain Dd2.  Most (82%) compds. originate from internal company projects and are new to the malaria community.  Analyses using historic assay data suggest several novel mechanisms of antimalarial action, such as inhibition of protein kinases and host-pathogen interaction related targets.  Chem. structures and assocd. data are hereby made public to encourage addnl. drug lead identification efforts and further research into this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHijpWK_kBF7Vg90H21EOLACvtfcHk0lgrGoI59kkjpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmt1Ois7k%253D&md5=a1fd8c0b89a5650ecba31f5456928b42</span></div><a href="/servlet/linkout?suffix=cit237&amp;dbid=16384&amp;doi=10.1038%2Fnature09107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09107%26sid%3Dliteratum%253Aachs%26aulast%3DGamo%26aufirst%3DF.-J.%26aulast%3DSanz%26aufirst%3DL.%2BM.%26aulast%3DVidal%26aufirst%3DJ.%26aulast%3Dde%2BCozar%26aufirst%3DC.%26aulast%3DAlvarez%26aufirst%3DE.%26aulast%3DLavandera%26aufirst%3DJ.-L.%26aulast%3DVanderwall%26aufirst%3DD.%2BE.%26aulast%3DGreen%26aufirst%3DD.%2BV.%2BS.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DHasan%26aufirst%3DS.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3DPeishoff%26aufirst%3DC.%2BE.%26aulast%3DCardon%26aufirst%3DL.%2BR.%26aulast%3DGarcia-Bustos%26aufirst%3DJ.%2BF.%26atitle%3DThousands%2520of%2520chemical%2520starting%2520points%2520for%2520antimalarial%2520lead%2520identification%26jtitle%3DNature%26date%3D2010%26volume%3D465%26spage%3D305%26epage%3D310%26doi%3D10.1038%2Fnature09107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref238"><div class="reference"><strong class="refLabel"><a href="#ref238" class="rightTabRefNumLink">238</a></strong><div class="NLM_citation" id="rightTab-cit238"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koo, M.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekonomidis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talaue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paget, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolhiser, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenaerts, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunin, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connell, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freundlich, J. S.</span></span> <span> </span><span class="NLM_article-title">Bayesian models leveraging bioactivity and cytotoxicity information for drug discovery</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">370</span>– <span class="NLM_lpage">378</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2013.01.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.chembiol.2013.01.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=23521795" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksFOgt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=370-378&author=S.+Ekinsauthor=R.+Reynoldsauthor=H.+Kimauthor=M.-S.+Kooauthor=M.+Ekonomidisauthor=M.+Talaueauthor=S.+D.+Pagetauthor=L.+K.+Woolhiserauthor=A.+J.+Lenaertsauthor=B.+A.+Buninauthor=N.+Connellauthor=J.+S.+Freundlich&title=Bayesian+models+leveraging+bioactivity+and+cytotoxicity+information+for+drug+discovery&doi=10.1016%2Fj.chembiol.2013.01.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit238R"><div class="casContent"><span class="casTitleNuber">238</span><div class="casTitle"><span class="NLM_cas:atitle">Bayesian Models Leveraging Bioactivity and Cytotoxicity Information for Drug Discovery</span></div><div class="casAuthors">Ekins, Sean; Reynolds, Robert C.; Kim, Hiyun; Koo, Mi-Sun; Ekonomidis, Marilyn; Talaue, Meliza; Paget, Steve D.; Woolhiser, Lisa K.; Lenaerts, Anne J.; Bunin, Barry A.; Connell, Nancy; Freundlich, Joel S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">370-378</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Identification of unique leads represents a significant challenge in drug discovery.  This hurdle is magnified in neglected diseases such as tuberculosis.  We have leveraged public high-throughput screening (HTS) data to exptl. validate a virtual screening approach employing Bayesian models built with bioactivity information (single-event model) as well as bioactivity and cytotoxicity information (dual-event model).  We virtually screened a com. library and exptl. confirmed actives with hit rates exceeding typical HTS results by one to two orders of magnitude.  This initial dual-event Bayesian model identified compds. with antitubercular whole-cell activity and low mammalian cell cytotoxicity from a published set of antimalarials.  The most potent hit exhibits the in vitro activity and in vitro/in vivo safety profile of a drug lead.  These Bayesian models offer significant economies in time and cost to drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHn7pP5TWKSbVg90H21EOLACvtfcHk0lgrGoI59kkjpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksFOgt7g%253D&md5=4b64d1c0fa67896b9d61c7f2fd606542</span></div><a href="/servlet/linkout?suffix=cit238&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2013.01.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2013.01.011%26sid%3Dliteratum%253Aachs%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DReynolds%26aufirst%3DR.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DKoo%26aufirst%3DM.-S.%26aulast%3DEkonomidis%26aufirst%3DM.%26aulast%3DTalaue%26aufirst%3DM.%26aulast%3DPaget%26aufirst%3DS.%2BD.%26aulast%3DWoolhiser%26aufirst%3DL.%2BK.%26aulast%3DLenaerts%26aufirst%3DA.%2BJ.%26aulast%3DBunin%26aufirst%3DB.%2BA.%26aulast%3DConnell%26aufirst%3DN.%26aulast%3DFreundlich%26aufirst%3DJ.%2BS.%26atitle%3DBayesian%2520models%2520leveraging%2520bioactivity%2520and%2520cytotoxicity%2520information%2520for%2520drug%2520discovery%26jtitle%3DChem.%2520Biol.%26date%3D2013%26volume%3D20%26spage%3D370%26epage%3D378%26doi%3D10.1016%2Fj.chembiol.2013.01.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref239"><div class="reference"><strong class="refLabel"><a href="#ref239" class="rightTabRefNumLink">239</a></strong><div class="NLM_citation" id="rightTab-cit239"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franzblau, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freundlich, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunin, B. A.</span></span> <span> </span><span class="NLM_article-title">Enhancing hit identification in mycobacterium tuberculosis drug discovery using validated dual-event bayesian models</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">e63240</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0063240</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1371%2Fjournal.pone.0063240" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=23667592" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnvVCjsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=e63240&author=S.+Ekinsauthor=R.+C.+Reynoldsauthor=S.+G.+Franzblauauthor=B.+Wanauthor=J.+S.+Freundlichauthor=B.+A.+Bunin&title=Enhancing+hit+identification+in+mycobacterium+tuberculosis+drug+discovery+using+validated+dual-event+bayesian+models&doi=10.1371%2Fjournal.pone.0063240"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit239R"><div class="casContent"><span class="casTitleNuber">239</span><div class="casTitle"><span class="NLM_cas:atitle">Enhancing hit identification in Mycobacterium tuberculosis drug discovery using validated dual-event Bayesian models</span></div><div class="casAuthors">Ekins, Sean; Reynolds, Robert C.; Franzblau, Scott G.; Wan, Baojie; Freundlich, Joel S.; Bunin, Barry A.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">e63240</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">High-throughput screening (HTS) in whole cells is widely pursued to find compds. active against Mycobacterium tuberculosis (Mtb) for further development towards new tuberculosis (TB) drugs.  Hit rates from these screens, usually conducted at 10 to 25 μM concns., typically range from less than 1% to the low single digits.  New approaches to increase the efficiency of hit identification are urgently needed to learn from past screening data.  The pharmaceutical industry has for many years taken advantage of computational approaches to optimize compd. libraries for in vitro testing, a practice not fully embraced by academic labs. in the search for new TB drugs.  Adapting these proven approaches, we have recently built and validated Bayesian machine learning models for predicting compds. with activity against Mtb based on publicly available large-scale HTS data from the Tuberculosis Antimicrobial Acquisition Coordinating Facility.  We now demonstrate the largest prospective validation to date in which we computationally screened 82,403 mols. with these Bayesian models, assayed a total of 550 mols. in vitro, and identified 124 actives against Mtb.  Individual hit rates for the different datasets varied from 15-28 %.  We have identified several FDA approved and late stage clin. candidate kinase inhibitors with activity against Mtb which may represent starting points for further optimization.  The computational models developed herein and the com. available mols. derived from them are now available to any group pursuing Mtb drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPsobk7KkZ47Vg90H21EOLACvtfcHk0ljeBGJxAyN_cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnvVCjsrg%253D&md5=df3b672dc3d0e3aca976952fa5dcbf20</span></div><a href="/servlet/linkout?suffix=cit239&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0063240&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0063240%26sid%3Dliteratum%253Aachs%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DReynolds%26aufirst%3DR.%2BC.%26aulast%3DFranzblau%26aufirst%3DS.%2BG.%26aulast%3DWan%26aufirst%3DB.%26aulast%3DFreundlich%26aufirst%3DJ.%2BS.%26aulast%3DBunin%26aufirst%3DB.%2BA.%26atitle%3DEnhancing%2520hit%2520identification%2520in%2520mycobacterium%2520tuberculosis%2520drug%2520discovery%2520using%2520validated%2520dual-event%2520bayesian%2520models%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26spage%3De63240%26doi%3D10.1371%2Fjournal.pone.0063240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref240"><div class="reference"><strong class="refLabel"><a href="#ref240" class="rightTabRefNumLink">240</a></strong><div class="NLM_citation" id="rightTab-cit240"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casey, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parish, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunin, B. A.</span></span> <span> </span><span class="NLM_article-title">Bayesian models for screening and tb mobile for target inference with mycobacterium tuberculosis</span>. <i>Tuberculosis (Oxford, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">162</span>– <span class="NLM_lpage">169</span>, <span class="refDoi"> DOI: 10.1016/j.tube.2013.12.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.tube.2013.12.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=24440548" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisFSmsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2014&pages=162-169&author=S.+Ekinsauthor=A.+C.+Caseyauthor=D.+Robertsauthor=T.+Parishauthor=B.+A.+Bunin&title=Bayesian+models+for+screening+and+tb+mobile+for+target+inference+with+mycobacterium+tuberculosis&doi=10.1016%2Fj.tube.2013.12.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit240R"><div class="casContent"><span class="casTitleNuber">240</span><div class="casTitle"><span class="NLM_cas:atitle">Bayesian models for screening and TB Mobile for target inference with Mycobacterium tuberculosis</span></div><div class="casAuthors">Ekins, Sean; Casey, Allen C.; Roberts, David; Parish, Tanya; Bunin, Barry A.</div><div class="citationInfo"><span class="NLM_cas:title">Tuberculosis (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">162-169</span>CODEN:
                <span class="NLM_cas:coden">TUBECU</span>;
        ISSN:<span class="NLM_cas:issn">1472-9792</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The search for compds. active against Mycobacterium tuberculosis is reliant upon high-throughput screening (HTS) in whole cells.  We have used Bayesian machine learning models which can predict anti-tubercular activity to filter an internal library of over 150,000 compds. prior to in vitro testing.  We used this to select and test 48 compds. in vitro; 11 were active with MIC values ranging from 0.4 μM to 10.2 μM, giving a high hit rate of 22.9%.  Among the hits, we identified several compds. belonging to the same series including five quinolones (including ciprofloxacin), three mols. with long aliph. linkers and three singletons.  This approach represents a rapid method to prioritize compds. for testing that can be used alongside medicinal chem. insight and other filters to identify active mols.  Such models can significantly increase the hit rate of HTS, above the usual 1% or lower rates seen.  In addn., the potential targets for the 11 mols. were predicted using TB Mobile and clustering alongside a set of over 740 mols. with known M. tuberculosis target annotations.  These predictions may serve as a mechanism for prioritizing compds. for further optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyNxo3fnyZxLVg90H21EOLACvtfcHk0ljeBGJxAyN_cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisFSmsbk%253D&md5=1d80c6fa0949708d7ef9edc93e88e18b</span></div><a href="/servlet/linkout?suffix=cit240&amp;dbid=16384&amp;doi=10.1016%2Fj.tube.2013.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tube.2013.12.001%26sid%3Dliteratum%253Aachs%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DCasey%26aufirst%3DA.%2BC.%26aulast%3DRoberts%26aufirst%3DD.%26aulast%3DParish%26aufirst%3DT.%26aulast%3DBunin%26aufirst%3DB.%2BA.%26atitle%3DBayesian%2520models%2520for%2520screening%2520and%2520tb%2520mobile%2520for%2520target%2520inference%2520with%2520mycobacterium%2520tuberculosis%26jtitle%3DTuberculosis%2520%2528Oxford%252C%2520U.%2520K.%2529%26date%3D2014%26volume%3D94%26spage%3D162%26epage%3D169%26doi%3D10.1016%2Fj.tube.2013.12.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref241"><div class="reference"><strong class="refLabel"><a href="#ref241" class="rightTabRefNumLink">241</a></strong><div class="NLM_citation" id="rightTab-cit241"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freundlich, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, R. C.</span></span> <span> </span><span class="NLM_article-title">Fusing dual-event datasets for mycobacterium tuberculosis machine learning models and their evaluation</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">3054</span>– <span class="NLM_lpage">3063</span>, <span class="refDoi"> DOI: 10.1021/ci400480s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci400480s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Cgt7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2013&pages=3054-3063&author=S.+Ekinsauthor=J.+S.+Freundlichauthor=R.+C.+Reynolds&title=Fusing+dual-event+datasets+for+mycobacterium+tuberculosis+machine+learning+models+and+their+evaluation&doi=10.1021%2Fci400480s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit241R"><div class="casContent"><span class="casTitleNuber">241</span><div class="casTitle"><span class="NLM_cas:atitle">Fusing Dual-Event Data Sets for Mycobacterium tuberculosis Machine Learning Models and Their Evaluation</span></div><div class="casAuthors">Ekins, Sean; Freundlich, Joel S.; Reynolds, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3054-3063</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The search for new tuberculosis treatments continues as we need to find mols. that can act more quickly, be accommodated in multidrug regimens, and overcome ever increasing levels of drug resistance.  Multiple large scale phenotypic high-throughput screens against Mycobacterium tuberculosis (Mtb) have generated dose response data, enabling the generation of machine learning models.  These models also incorporated cytotoxicity data and were recently validated with a large external data set.  A cheminformatics data-fusion approach followed by Bayesian machine learning, Support Vector Machine, or Recursive Partitioning model development (based on publicly available Mtb screening data) was used to compare individual data sets and subsequent combined models.  A set of 1924 com. available mols. with promising antitubercular activity (and lack of relative cytotoxicity to Vero cells) were used to evaluate the predictive nature of the models.  We demonstrate that combining three data sets incorporating antitubercular and cytotoxicity data in Vero cells from our previous screens results in external validation receiver operator curve (ROC) of 0.83 (Bayesian or RP Forest).  Models that do not have the highest 5-fold cross-validation ROC scores can outperform other models in a test set dependent manner.  We demonstrate with predictions for a recently published set of Mtb leads from GlaxoSmithKline that no single machine learning model may be enough to identify compds. of interest.  Data set fusion represents a further useful strategy for machine learning construction as illustrated with Mtb.  Coverage of chem. and Mtb target spaces may also be limiting factors for the whole-cell screening data generated to date.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFnkjFPKUH4bVg90H21EOLACvtfcHk0ljeBGJxAyN_cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Cgt7bM&md5=2fa69551b36bea68056631cca1aff2d5</span></div><a href="/servlet/linkout?suffix=cit241&amp;dbid=16384&amp;doi=10.1021%2Fci400480s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci400480s%26sid%3Dliteratum%253Aachs%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DFreundlich%26aufirst%3DJ.%2BS.%26aulast%3DReynolds%26aufirst%3DR.%2BC.%26atitle%3DFusing%2520dual-event%2520datasets%2520for%2520mycobacterium%2520tuberculosis%2520machine%2520learning%2520models%2520and%2520their%2520evaluation%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2013%26volume%3D53%26spage%3D3054%26epage%3D3063%26doi%3D10.1021%2Fci400480s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref242"><div class="reference"><strong class="refLabel"><a href="#ref242" class="rightTabRefNumLink">242</a></strong><div class="NLM_citation" id="rightTab-cit242"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freundlich, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobrath, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucile
White, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, R. C.</span></span> <span> </span><span class="NLM_article-title">Combining computational methods for hit to lead optimization in mycobacterium tuberculosis drug discovery</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">414</span>– <span class="NLM_lpage">435</span>, <span class="refDoi"> DOI: 10.1007/s11095-013-1172-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1007%2Fs11095-013-1172-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=24132686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1eisbfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2014&pages=414-435&author=S.+Ekinsauthor=J.+S.+Freundlichauthor=J.+V.+Hobrathauthor=E.+Lucile%0AWhiteauthor=R.+C.+Reynolds&title=Combining+computational+methods+for+hit+to+lead+optimization+in+mycobacterium+tuberculosis+drug+discovery&doi=10.1007%2Fs11095-013-1172-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit242R"><div class="casContent"><span class="casTitleNuber">242</span><div class="casTitle"><span class="NLM_cas:atitle">Combining Computational Methods for Hit to Lead Optimization in Mycobacterium Tuberculosis Drug Discovery</span></div><div class="casAuthors">Ekins, Sean; Freundlich, Joel S.; Hobrath, Judith V.; Lucile White, E.; Reynolds, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">414-435</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Tuberculosis treatments need to be shorter and overcome drug resistance.  Our previous large scale phenotypic high-throughput screening against Mycobacterium tuberculosis (Mtb) has identified 737 active compds. and thousands that are inactive.  We have used this data for building computational models as an approach to minimize the no. of compds. tested.  Methods: A cheminformatics clustering approach followed by Bayesian machine learning models (based on publicly available Mtb screening data) was used to illustrate that application of these models for screening set selections can enrich the hit rate.  Results: In order to explore chem. diversity around active cluster scaffolds of the dose-response hits obtained from our previous Mtb screens a set of 1924 com. available mols. have been selected and evaluated for antitubercular activity and cytotoxicity using Vero, THP-1 and HepG2 cell lines with 4.3%, 4.2% and 2.7% hit rates, resp.  We demonstrate that models incorporating antitubercular and cytotoxicity data in Vero cells can significantly enrich the selection of non-toxic actives compared to random selection.  Across all cell lines, the Mol. Libraries Small Mol. Repository (MLSMR) and cytotoxicity model identified ∼10% of the hits in the top 1% screened (>10 fold enrichment).  We also showed that seven out of nine Mtb active compds. from different academic published studies and eight out of eleven Mtb active compds. from a pharmaceutical screen (GSK) would have been identified by these Bayesian models.  Conclusion: Combining clustering and Bayesian models represents a useful strategy for compd. prioritization and hit-to lead optimization of antitubercular agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNLW4jI87eobVg90H21EOLACvtfcHk0lhV-2S_rVpV5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1eisbfP&md5=3c093021c9af0e506a656d381ac1eb1a</span></div><a href="/servlet/linkout?suffix=cit242&amp;dbid=16384&amp;doi=10.1007%2Fs11095-013-1172-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-013-1172-7%26sid%3Dliteratum%253Aachs%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DFreundlich%26aufirst%3DJ.%2BS.%26aulast%3DHobrath%26aufirst%3DJ.%2BV.%26aulast%3DLucile%2BWhite%26aufirst%3DE.%26aulast%3DReynolds%26aufirst%3DR.%2BC.%26atitle%3DCombining%2520computational%2520methods%2520for%2520hit%2520to%2520lead%2520optimization%2520in%2520mycobacterium%2520tuberculosis%2520drug%2520discovery%26jtitle%3DPharm.%2520Res.%26date%3D2014%26volume%3D31%26spage%3D414%26epage%3D435%26doi%3D10.1007%2Fs11095-013-1172-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref243"><div class="reference"><strong class="refLabel"><a href="#ref243" class="rightTabRefNumLink">243</a></strong><div class="NLM_citation" id="rightTab-cit243"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freundlich, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, R. C.</span></span> <span> </span><span class="NLM_article-title">Are bigger data sets better for machine learning? Fusing single-point and dual-event dose response data for mycobacterium tuberculosis</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">2157</span>– <span class="NLM_lpage">2165</span>, <span class="refDoi"> DOI: 10.1021/ci500264r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci500264r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVCqsrjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2014&pages=2157-2165&author=S.+Ekinsauthor=J.+S.+Freundlichauthor=R.+C.+Reynolds&title=Are+bigger+data+sets+better+for+machine+learning%3F+Fusing+single-point+and+dual-event+dose+response+data+for+mycobacterium+tuberculosis&doi=10.1021%2Fci500264r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit243R"><div class="casContent"><span class="casTitleNuber">243</span><div class="casTitle"><span class="NLM_cas:atitle">Are Bigger Data Sets Better for Machine Learning? Fusing Single-Point and Dual-Event Dose Response Data for Mycobacterium tuberculosis</span></div><div class="casAuthors">Ekins, Sean; Freundlich, Joel S.; Reynolds, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2157-2165</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tuberculosis is a major, neglected disease for which the quest to find new treatments continues.  There is an abundance of data from large phenotypic screens in the public domain against Mycobacterium tuberculosis (Mtb).  Since machine learning methods can learn from past data, we were interested in addressing whether more data builds better models.  We now describe using Bayesian machine learning to assess whether we can improve our models by combining the large quantities of single-point data with the much smaller (higher quality) dual-event data sets, which use both dose-response data for both whole-cell antitubercular activity and Vero cell cytotoxicity.  We have evaluated 12 models ranging from different single-point, dual-event dose-response, single-point and dual-event dose-response as well as combined data sets for three distinct data sets from the same lab.  We used a fourth data set of active and inactive compds. from the same group as well as a smaller set of 177 active compds. from GlaxoSmithKline as test sets.  Our data suggest combining single-point with dual-event dose-response data does not diminish the internal or external predictive ability of the models based on the receiver operator curve (ROC) for these models (internal ROC range 0.83-0.91, external ROC range 0.62-0.83) compared to the orders of magnitude smaller dual-event models (internal ROC range 0.6-0.83 and external ROC 0.54-0.83).  In conclusion, models developed with 1200-5000 compds. appear to be as predictive as those generated with 25 000-350 000 mols.  Our results have implications for justifying further high-throughput screening vs. focused testing based on model predictions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCpZoV4MWmQbVg90H21EOLACvtfcHk0lhV-2S_rVpV5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVCqsrjK&md5=03392e131134b01309207831e8289e0e</span></div><a href="/servlet/linkout?suffix=cit243&amp;dbid=16384&amp;doi=10.1021%2Fci500264r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci500264r%26sid%3Dliteratum%253Aachs%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DFreundlich%26aufirst%3DJ.%2BS.%26aulast%3DReynolds%26aufirst%3DR.%2BC.%26atitle%3DAre%2520bigger%2520data%2520sets%2520better%2520for%2520machine%2520learning%253F%2520Fusing%2520single-point%2520and%2520dual-event%2520dose%2520response%2520data%2520for%2520mycobacterium%2520tuberculosis%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2014%26volume%3D54%26spage%3D2157%26epage%3D2165%26doi%3D10.1021%2Fci500264r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref244"><div class="reference"><strong class="refLabel"><a href="#ref244" class="rightTabRefNumLink">244</a></strong><div class="NLM_citation" id="rightTab-cit244"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pottorf, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freundlich, J. S.</span></span> <span> </span><span class="NLM_article-title">Looking back to the future: Predicting in vivo efficacy of small molecules versus mycobacterium tuberculosis</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1070</span>– <span class="NLM_lpage">1082</span>, <span class="refDoi"> DOI: 10.1021/ci500077v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci500077v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkslamu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2014&pages=1070-1082&author=S.+Ekinsauthor=R.+Pottorfauthor=R.+C.+Reynoldsauthor=A.+J.+Williamsauthor=A.+M.+Clarkauthor=J.+S.+Freundlich&title=Looking+back+to+the+future%3A+Predicting+in+vivo+efficacy+of+small+molecules+versus+mycobacterium+tuberculosis&doi=10.1021%2Fci500077v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit244R"><div class="casContent"><span class="casTitleNuber">244</span><div class="casTitle"><span class="NLM_cas:atitle">Looking Back to the Future: Predicting in Vivo Efficacy of Small Molecules versus Mycobacterium tuberculosis</span></div><div class="casAuthors">Ekins, Sean; Pottorf, Richard; Reynolds, Robert C.; Williams, Antony J.; Clark, Alex M.; Freundlich, Joel S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1070-1082</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Selecting and translating in vitro leads for a disease into mols. with in vivo activity in an animal model of the disease is a challenge that takes considerable time and money.  As an example, recent years have seen whole-cell phenotypic screens of millions of compds. yielding over 1500 inhibitors of Mycobacterium tuberculosis (Mtb).  These must be prioritized for testing in the mouse in vivo assay for Mtb infection, a validated model utilized to select compds. for further testing.  The authors demonstrate learning from in vivo active and inactive compds. using machine learning classification models (Bayesian, support vector machines, and recursive partitioning) consisting of 773 compds.  The Bayesian model predicted 8 out of 11 addnl. in vivo actives not included in the model as an external test set.  Curation of 70 years of Mtb data can therefore provide statistically robust computational models to focus resources on in vivo active small mol. antituberculars.  This highlights a cost-effective predictor for in vivo testing elsewhere in other diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotUoWucn-1OrVg90H21EOLACvtfcHk0lhV-2S_rVpV5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkslamu7Y%253D&md5=e5e27ddb07601604b0c9c2cde9dd313d</span></div><a href="/servlet/linkout?suffix=cit244&amp;dbid=16384&amp;doi=10.1021%2Fci500077v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci500077v%26sid%3Dliteratum%253Aachs%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DPottorf%26aufirst%3DR.%26aulast%3DReynolds%26aufirst%3DR.%2BC.%26aulast%3DWilliams%26aufirst%3DA.%2BJ.%26aulast%3DClark%26aufirst%3DA.%2BM.%26aulast%3DFreundlich%26aufirst%3DJ.%2BS.%26atitle%3DLooking%2520back%2520to%2520the%2520future%253A%2520Predicting%2520in%2520vivo%2520efficacy%2520of%2520small%2520molecules%2520versus%2520mycobacterium%2520tuberculosis%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2014%26volume%3D54%26spage%3D1070%26epage%3D1082%26doi%3D10.1021%2Fci500077v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref245"><div class="reference"><strong class="refLabel"><a href="#ref245" class="rightTabRefNumLink">245</a></strong><div class="NLM_citation" id="rightTab-cit245"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perryman, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freundlich, J. S.</span></span> <span> </span><span class="NLM_article-title">Machine learning model analysis and data visualization with small molecules tested in a mouse model of mycobacterium tuberculosis infection (2014–2015)</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1332</span>– <span class="NLM_lpage">1343</span>, <span class="refDoi"> DOI: 10.1021/acs.jcim.6b00004</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.6b00004" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVCjtrvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2016&pages=1332-1343&issue=7&author=S.+Ekinsauthor=A.+L.+Perrymanauthor=A.+M.+Clarkauthor=R.+C.+Reynoldsauthor=J.+S.+Freundlich&title=Machine+learning+model+analysis+and+data+visualization+with+small+molecules+tested+in+a+mouse+model+of+mycobacterium+tuberculosis+infection+%282014%E2%80%932015%29&doi=10.1021%2Facs.jcim.6b00004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit245R"><div class="casContent"><span class="casTitleNuber">245</span><div class="casTitle"><span class="NLM_cas:atitle">Machine Learning Model Analysis and Data Visualization with Small Molecules Tested in a Mouse Model of Mycobacterium tuberculosis Infection (2014-2015)</span></div><div class="casAuthors">Ekins, Sean; Perryman, Alexander L.; Clark, Alex M.; Reynolds, Robert C.; Freundlich, Joel S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1332-1343</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The renewed urgency to develop new treatments for Mycobacterium tuberculosis (Mtb) infection resulted in large-scale phenotypic screening and thousands of new active compds. in vitro.  The next challenge is to identify candidates to pursue in a mouse in vivo efficacy model as a step to predicting clin. efficacy.  The authors previously analyzed over 70 years of this mouse in vivo efficacy data, which the authors used to generate and validate machine learning models.  Curation of 60 addnl. small mols. with in vivo data published in 2014 and 2015 was undertaken to further test these models.  This represents a much larger test set than for the previous models.  Several computational approaches have now been applied to analyze these mols. and compare their mol. properties beyond those attempted previously.  The authors' previous machine learning models have been updated, and a novel aspect has been added as mouse liver microsomal half-life (MLM t1/2) and in vitro-based Mtb models incorporating cytotoxicity data that were used to predict in vivo activity for comparison.  The authors' best Mtbin vivo models possess fivefold ROC values > 0.7, sensitivity > 80%, and concordance > 60%, while the best specificity value is >40%.  Use of an MLM t1/2 Bayesian model affords comparable results for scoring the 60 compds. tested.  Combining MLM stability and in vitro Mtb models in a novel consensus workflow in the best cases has a pos. predicted value (hit rate) > 77%.  The authors' results indicate that Bayesian models constructed with literature in vivoMtb data generated by different labs. in various mouse models can have predictive value and may be used alongside MLM t1/2 and in vitro-based Mtb models to assist in selecting antitubercular compds. with desirable in vivo efficacy.  Consensus models of any kind can be used to predict in vivo activity for Mtb.  In addn., the authors describe a new clustering method for data visualization and apply this to the in vivo training and test data, ultimately making the method accessible in a mobile app.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlyzvE6JX4JrVg90H21EOLACvtfcHk0liaUOrvWQV3Hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVCjtrvI&md5=2aad186e524cd42aefb9cf7992f0bdfe</span></div><a href="/servlet/linkout?suffix=cit245&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.6b00004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.6b00004%26sid%3Dliteratum%253Aachs%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DPerryman%26aufirst%3DA.%2BL.%26aulast%3DClark%26aufirst%3DA.%2BM.%26aulast%3DReynolds%26aufirst%3DR.%2BC.%26aulast%3DFreundlich%26aufirst%3DJ.%2BS.%26atitle%3DMachine%2520learning%2520model%2520analysis%2520and%2520data%2520visualization%2520with%2520small%2520molecules%2520tested%2520in%2520a%2520mouse%2520model%2520of%2520mycobacterium%2520tuberculosis%2520infection%2520%25282014%25E2%2580%25932015%2529%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2016%26volume%3D56%26issue%3D7%26spage%3D1332%26epage%3D1343%26doi%3D10.1021%2Facs.jcim.6b00004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref246"><div class="reference"><strong class="refLabel"><a href="#ref246" class="rightTabRefNumLink">246</a></strong><div class="NLM_citation" id="rightTab-cit246"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ballell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez-Gomez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez-Ruiz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barroso, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanco, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crespo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escribano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huss, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos-Villarejo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Plaza, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendoza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rebollo-Lopez, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remuinan-Blanco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavandera, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Herran, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamo-Benito, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Bustos, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barros, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cammack, N.</span></span> <span> </span><span class="NLM_article-title">Fueling open-source drug discovery: 177 small-molecule leads against tuberculosis</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">313</span>– <span class="NLM_lpage">321</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201200428</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1002%2Fcmdc.201200428" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=23307663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC3sXls1Omug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=313-321&author=L.+Ballellauthor=R.+H.+Batesauthor=R.+J.+Youngauthor=D.+Alvarez-Gomezauthor=E.+Alvarez-Ruizauthor=V.+Barrosoauthor=D.+Blancoauthor=B.+Crespoauthor=J.+Escribanoauthor=R.+Gonzalezauthor=S.+Lozanoauthor=S.+Hussauthor=A.+Santos-Villarejoauthor=J.+J.+Martin-Plazaauthor=A.+Mendozaauthor=M.+J.+Rebollo-Lopezauthor=M.+Remuinan-Blancoauthor=J.+L.+Lavanderaauthor=E.+Perez-Herranauthor=F.+J.+Gamo-Benitoauthor=J.+F.+Garcia-Bustosauthor=D.+Barrosauthor=J.+P.+Castroauthor=N.+Cammack&title=Fueling+open-source+drug+discovery%3A+177+small-molecule+leads+against+tuberculosis&doi=10.1002%2Fcmdc.201200428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit246R"><div class="casContent"><span class="casTitleNuber">246</span><div class="casTitle"><span class="NLM_cas:atitle">Fueling Open-Source Drug Discovery: 177 Small-Molecule Leads against Tuberculosis</span></div><div class="casAuthors">Ballell, Lluis; Bates, Robert H.; Young, Rob J.; Alvarez-Gomez, Daniel; Alvarez-Ruiz, Emilio; Barroso, Vanessa; Blanco, Delia; Crespo, Benigno; Escribano, Jaime; Gonzalez, Ruben; Lozano, Sonia; Huss, Sophie; Santos-Villarejo, Angel; Martin-Plaza, Jose Julio; Mendoza, Alfonso; Rebollo-Lopez, Maria Jose; Remuinan-Blanco, Modesto; Lavandera, Jose Luis; Perez-Herran, Esther; Gamo-Benito, Francisco Javier; Garcia-Bustos, Jose Francisco; Barros, David; Castro, Julia P.; Cammack, Nicholas</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">313-321</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">With the aim of fuelling open-source, translational, early-stage drug discovery activities, the results of the recently completed antimycobacterial phenotypic screening campaign against Mycobacterium bovis BCG with hit confirmation in M. tuberculosis H37Rv were made publicly accessible.  A set of 177 potent non-cytotoxic H37Rv hits was identified and will be made available to maximize the potential impact of the compds. toward a chem. genetics/proteomics exercise, while at the same time providing a plethora of potential starting points for new synthetic lead-generation activities.  Two addnl. drug-discovery-relevant datasets are included: (a) a drug-like property anal. reflecting the latest lead-like guidelines and (b) an early lead-generation package of the most promising hits within the clusters identified.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUJ2sVPWfPALVg90H21EOLACvtfcHk0liaUOrvWQV3Hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXls1Omug%253D%253D&md5=32c975dbe183849358c701ca697681d3</span></div><a href="/servlet/linkout?suffix=cit246&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201200428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201200428%26sid%3Dliteratum%253Aachs%26aulast%3DBallell%26aufirst%3DL.%26aulast%3DBates%26aufirst%3DR.%2BH.%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26aulast%3DAlvarez-Gomez%26aufirst%3DD.%26aulast%3DAlvarez-Ruiz%26aufirst%3DE.%26aulast%3DBarroso%26aufirst%3DV.%26aulast%3DBlanco%26aufirst%3DD.%26aulast%3DCrespo%26aufirst%3DB.%26aulast%3DEscribano%26aufirst%3DJ.%26aulast%3DGonzalez%26aufirst%3DR.%26aulast%3DLozano%26aufirst%3DS.%26aulast%3DHuss%26aufirst%3DS.%26aulast%3DSantos-Villarejo%26aufirst%3DA.%26aulast%3DMartin-Plaza%26aufirst%3DJ.%2BJ.%26aulast%3DMendoza%26aufirst%3DA.%26aulast%3DRebollo-Lopez%26aufirst%3DM.%2BJ.%26aulast%3DRemuinan-Blanco%26aufirst%3DM.%26aulast%3DLavandera%26aufirst%3DJ.%2BL.%26aulast%3DPerez-Herran%26aufirst%3DE.%26aulast%3DGamo-Benito%26aufirst%3DF.%2BJ.%26aulast%3DGarcia-Bustos%26aufirst%3DJ.%2BF.%26aulast%3DBarros%26aufirst%3DD.%26aulast%3DCastro%26aufirst%3DJ.%2BP.%26aulast%3DCammack%26aufirst%3DN.%26atitle%3DFueling%2520open-source%2520drug%2520discovery%253A%2520177%2520small-molecule%2520leads%2520against%2520tuberculosis%26jtitle%3DChemMedChem%26date%3D2013%26volume%3D8%26spage%3D313%26epage%3D321%26doi%3D10.1002%2Fcmdc.201200428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref247"><div class="reference"><strong class="refLabel"><a href="#ref247" class="rightTabRefNumLink">247</a></strong><div class="NLM_citation" id="rightTab-cit247"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mikusova, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span> <span> </span><span class="NLM_article-title">Learning from the past for tb drug discovery in the future</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">534</span>– <span class="NLM_lpage">545</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2016.09.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.drudis.2016.09.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=27717850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A280%3ADC%252BC2svnsVWmtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=534-545&author=K.+Mikusovaauthor=S.+Ekins&title=Learning+from+the+past+for+tb+drug+discovery+in+the+future&doi=10.1016%2Fj.drudis.2016.09.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit247R"><div class="casContent"><span class="casTitleNuber">247</span><div class="casTitle"><span class="NLM_cas:atitle">Learning from the past for TB drug discovery in the future</span></div><div class="casAuthors">Mikusova Katarina; Ekins Sean</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">534-545</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Tuberculosis drug discovery has shifted in recent years from a primarily target-based approach to one that uses phenotypic high-throughput screens.  As examples of this, through our EU-funded FP7 collaborations, New Medicines for Tuberculosis was target-based and our more-recent More Medicines for Tuberculosis project predominantly used phenotypic screening.  From these projects we have examples of success (DprE1) and failure (PimA) going from drug to target and from target to drug, respectively.  It is clear that we still have much to learn about the drug targets and the complex effects of the drugs on Mycobacterium tuberculosis.  We propose a more integrated approach that learns from earlier drug discovery efforts that could help to move drug discovery forward.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTiiBeAayc7NTToTC3aBaesfW6udTcc2eauzlhgY8jAMbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svnsVWmtA%253D%253D&md5=8f169df66fbdee538f899b2619bba19e</span></div><a href="/servlet/linkout?suffix=cit247&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2016.09.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2016.09.025%26sid%3Dliteratum%253Aachs%26aulast%3DMikusova%26aufirst%3DK.%26aulast%3DEkins%26aufirst%3DS.%26atitle%3DLearning%2520from%2520the%2520past%2520for%2520tb%2520drug%2520discovery%2520in%2520the%2520future%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2017%26volume%3D22%26spage%3D534%26epage%3D545%26doi%3D10.1016%2Fj.drudis.2016.09.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref248"><div class="reference"><strong class="refLabel"><a href="#ref248" class="rightTabRefNumLink">248</a></strong><div class="NLM_citation" id="rightTab-cit248"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paolino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brindisi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campiani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nannicini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giuliani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anzini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamponi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giorgi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sbardella, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferraris, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coletta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palucci, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minerva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delogu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pepponi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goletti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cappelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brogi, S.</span></span> <span> </span><span class="NLM_article-title">Development of potent inhibitors of the mycobacterium tuberculosis virulence factor Zmp1 and evaluation of their effect on mycobacterial survival inside macrophages</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">422</span>– <span class="NLM_lpage">430</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201700759</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1002%2Fcmdc.201700759" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=29334428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC1cXislSitrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=422-430&author=M.+Paolinoauthor=M.+Brindisiauthor=A.+Valloneauthor=S.+Butiniauthor=G.+Campianiauthor=C.+Nanniciniauthor=G.+Giulianiauthor=M.+Anziniauthor=S.+Lamponiauthor=G.+Giorgiauthor=D.+Sbardellaauthor=D.+M.+Ferrarisauthor=S.+Mariniauthor=M.+Colettaauthor=I.+Palucciauthor=M.+Minervaauthor=G.+Deloguauthor=I.+Pepponiauthor=D.+Golettiauthor=A.+Cappelliauthor=S.+Gemmaauthor=S.+Brogi&title=Development+of+potent+inhibitors+of+the+mycobacterium+tuberculosis+virulence+factor+Zmp1+and+evaluation+of+their+effect+on+mycobacterial+survival+inside+macrophages&doi=10.1002%2Fcmdc.201700759"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit248R"><div class="casContent"><span class="casTitleNuber">248</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Potent Inhibitors of the Mycobacterium tuberculosis Virulence Factor Zmp1 and Evaluation of Their Effect on Mycobacterial Survival inside Macrophages</span></div><div class="casAuthors">Paolino, Marco; Brindisi, Margherita; Vallone, Alessandra; Butini, Stefania; Campiani, Giuseppe; Nannicini, Chiara; Giuliani, Germano; Anzini, Maurizio; Lamponi, Stefania; Giorgi, Gianluca; Sbardella, Diego; Ferraris, Davide M.; Marini, Stefano; Coletta, Massimo; Palucci, Ivana; Minerva, Mariachiara; Delogu, Giovanni; Pepponi, Ilaria; Goletti, Delia; Cappelli, Andrea; Gemma, Sandra; Brogi, Simone</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">422-430</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The enzyme Zmp1 is a zinc-contg. peptidase that plays a crit. role in the pathogenicity of Mycobacterium tuberculosis.  Herein we describe the identification of a small set of Zmp1 inhibitors based on a novel 8-hydroxyquinoline-2-hydroxamate scaffold.  Among the synthesized compds., N-(benzyloxy)-8-hydroxyquinoline-2-carboxamide (1 c) was found to be the most potent Zmp1 inhibitor known to date, and its binding mode was analyzed both by kinetics studies and mol. modeling, identifying crit. interactions of 1 c with the zinc ion and residues in the active site.  The effect of 1 c on intracellular Mycobacterium survival was assayed in J774 murine macrophages infected with M. tuberculosis H37Rv or M. bovis BCG and human monocyte-derived macrophages infected with M. tuberculosis H37Rv.  Cytotoxicity and genotoxicity were also assessed.  Overall, inhibitor 1 c displays interesting in vitro antitubercular properties worthy of further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobhb30Gw07ybVg90H21EOLACvtfcHk0lhP2iWcmP1uYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXislSitrs%253D&md5=2ef6d0413567cf7395e9affeddc5ba74</span></div><a href="/servlet/linkout?suffix=cit248&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201700759&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201700759%26sid%3Dliteratum%253Aachs%26aulast%3DPaolino%26aufirst%3DM.%26aulast%3DBrindisi%26aufirst%3DM.%26aulast%3DVallone%26aufirst%3DA.%26aulast%3DButini%26aufirst%3DS.%26aulast%3DCampiani%26aufirst%3DG.%26aulast%3DNannicini%26aufirst%3DC.%26aulast%3DGiuliani%26aufirst%3DG.%26aulast%3DAnzini%26aufirst%3DM.%26aulast%3DLamponi%26aufirst%3DS.%26aulast%3DGiorgi%26aufirst%3DG.%26aulast%3DSbardella%26aufirst%3DD.%26aulast%3DFerraris%26aufirst%3DD.%2BM.%26aulast%3DMarini%26aufirst%3DS.%26aulast%3DColetta%26aufirst%3DM.%26aulast%3DPalucci%26aufirst%3DI.%26aulast%3DMinerva%26aufirst%3DM.%26aulast%3DDelogu%26aufirst%3DG.%26aulast%3DPepponi%26aufirst%3DI.%26aulast%3DGoletti%26aufirst%3DD.%26aulast%3DCappelli%26aufirst%3DA.%26aulast%3DGemma%26aufirst%3DS.%26aulast%3DBrogi%26aufirst%3DS.%26atitle%3DDevelopment%2520of%2520potent%2520inhibitors%2520of%2520the%2520mycobacterium%2520tuberculosis%2520virulence%2520factor%2520Zmp1%2520and%2520evaluation%2520of%2520their%2520effect%2520on%2520mycobacterial%2520survival%2520inside%2520macrophages%26jtitle%3DChemMedChem%26date%3D2018%26volume%3D13%26spage%3D422%26epage%3D430%26doi%3D10.1002%2Fcmdc.201700759" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref249"><div class="reference"><strong class="refLabel"><a href="#ref249" class="rightTabRefNumLink">249</a></strong><div class="NLM_citation" id="rightTab-cit249"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span> <span> </span><span class="NLM_article-title">Docking- and pharmacophore-based virtual screening for the identification of novel mycobacterium tuberculosis protein tyrosine phosphatase b (MptpB) inhibitor with a thiobarbiturate scaffold</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">229</span>– <span class="NLM_lpage">239</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2018.12.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1016%2Fj.bioorg.2018.12.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=30641319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVSguro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2019&pages=229-239&author=D.+Zhangauthor=Y.+Linauthor=X.+Chenauthor=W.+Zhaoauthor=D.+Chenauthor=M.+Gaoauthor=Q.+Wangauthor=B.+Wangauthor=H.+Huangauthor=Y.+Luauthor=Y.+Lu&title=Docking-+and+pharmacophore-based+virtual+screening+for+the+identification+of+novel+mycobacterium+tuberculosis+protein+tyrosine+phosphatase+b+%28MptpB%29+inhibitor+with+a+thiobarbiturate+scaffold&doi=10.1016%2Fj.bioorg.2018.12.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit249R"><div class="casContent"><span class="casTitleNuber">249</span><div class="casTitle"><span class="NLM_cas:atitle">Docking- and pharmacophore-based virtual screening for the identification of novel Mycobacterium tuberculosis protein tyrosine phosphatase B (MptpB) inhibitor with a thiobarbiturate scaffold</span></div><div class="casAuthors">Zhang, Dongfeng; Lin, Yun; Chen, Xi; Zhao, Wenting; Chen, Dongni; Gao, Meng; Wang, Qinglin; Wang, Bin; Huang, Haihong; Lu, Yongjun; Lu, Yu</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">229-239</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Mycobacterium tuberculosis (Mtb) protein tyrosine phosphatase B (MptpB) is an important virulence factor for Mtb that contributes to survival of the bacteria in macrophages.  The absence of a human ortholog makes MptpB an attractive target for new therapeutics to treat tuberculosis.  MptpB inhibitors could be an effective treatment to overcome emerging TB drug resistance.  Adopting a structure-based virtual screening strategy, the authors successfully identified thiobarbiturate-based drug-like MptpB inhibitor I with an IC50 of 22.4 μM, and as a noncompetitive inhibitor with a Ki of 24.7 μM.  Importantly, not only did it exhibit moderate cell membrane permeability, compd. I also displayed potent inhibition of intracellular TB growth in the macrophage, making it an excellent lead compd. for anti-TB drug discovery.  To the best of the knowledge, this novel thiobarbiturate is the first class of MptpB inhibitor reported so far that leveraged docking- and pharmacophore-based virtual screening approaches.  The results of preliminary structure-activity relationship demonstrated that compd. I identified herein was not a singleton and may inspire the design of novel selective and drug-like MptpB inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5A9nxRk4RjbVg90H21EOLACvtfcHk0lhP2iWcmP1uYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVSguro%253D&md5=24c3541ab0573f07ee1cf87048b7335d</span></div><a href="/servlet/linkout?suffix=cit249&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2018.12.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2018.12.038%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DY.%26atitle%3DDocking-%2520and%2520pharmacophore-based%2520virtual%2520screening%2520for%2520the%2520identification%2520of%2520novel%2520mycobacterium%2520tuberculosis%2520protein%2520tyrosine%2520phosphatase%2520b%2520%2528MptpB%2529%2520inhibitor%2520with%2520a%2520thiobarbiturate%2520scaffold%26jtitle%3DBioorg.%2520Chem.%26date%3D2019%26volume%3D85%26spage%3D229%26epage%3D239%26doi%3D10.1016%2Fj.bioorg.2018.12.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref250"><div class="reference"><strong class="refLabel"><a href="#ref250" class="rightTabRefNumLink">250</a></strong><div class="NLM_citation" id="rightTab-cit250"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bruhn, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherman, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherbakov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meibohm, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottger, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenaerts, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. E.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo evaluation of synergism between anti-tubercular spectinamides and non-classical tuberculosis antibiotics</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">13985</span>, <span class="refDoi"> DOI: 10.1038/srep13985</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1038%2Fsrep13985" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=26365087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFeisr3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=13985&author=D.+F.+Bruhnauthor=M.+S.+Schermanauthor=J.+Liuauthor=D.+Scherbakovauthor=B.+Meibohmauthor=E.+C.+Bottgerauthor=A.+J.+Lenaertsauthor=R.+E.+Lee&title=In+vitro+and+in+vivo+evaluation+of+synergism+between+anti-tubercular+spectinamides+and+non-classical+tuberculosis+antibiotics&doi=10.1038%2Fsrep13985"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit250R"><div class="casContent"><span class="casTitleNuber">250</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo Evaluation of Synergism between Anti-Tubercular Spectinamides and Non-Classical Tuberculosis Antibiotics</span></div><div class="casAuthors">Bruhn, David F.; Scherman, Michael S.; Liu, Jiuyu; Scherbakov, Dimitri; Meibohm, Bernd; Bottger, Erik C.; Lenaerts, Anne J.; Lee, Richard E.</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">13985</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Spectinamides are new semi-synthetic spectinomycin derivs. with potent anti-tubercular activity.  The reported synergism of the precursor spectinomycin with other antibiotics prompted us to examine whether spectinamides sensitize M. tuberculosis to other antibiotics not traditionally used in the treatment of tuberculosis to potentially expand therapeutic options for MDR/XDR Tuberculosis.  Whole cell synergy checkerboard screens were performed using the lab. strain M. tuberculosis H37Rv, lead spectinamide 1599, and a broad panel of 27 antibiotics.  In vitro, 1599 synergized with 11 drugs from 6 antibiotic classes.  The obsd. synergy was tested against clin. isolates confirming synergy with Clarithromycin, Doxycycline and Clindamycin, combinations of which were taken forward for in vivo efficacy detn.  Co-administration of 1599 and clarithromycin provided addnl. bacterial killing in a mouse model of acute tuberculosis infection, but not in a chronic infection model.  Further studies indicated that mismatched drug exposure profiles likely permitted induction of phenotypic clarithromycin resistance and subsequent loss of synergism.  These studies highlight the importance of validating in vitro synergism and the challenge of matching drug exposures to obtain a synergistic outcome in vivo.  Results from this study indicate that a 1599 clarithromycin combination is potentially viable, providing the drug exposures can be carefully monitored.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpetBnraFJKorVg90H21EOLACvtfcHk0lhTyuGO85cwdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFeisr3K&md5=0e52e96c259b96668a3737575c037539</span></div><a href="/servlet/linkout?suffix=cit250&amp;dbid=16384&amp;doi=10.1038%2Fsrep13985&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep13985%26sid%3Dliteratum%253Aachs%26aulast%3DBruhn%26aufirst%3DD.%2BF.%26aulast%3DScherman%26aufirst%3DM.%2BS.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DScherbakov%26aufirst%3DD.%26aulast%3DMeibohm%26aufirst%3DB.%26aulast%3DBottger%26aufirst%3DE.%2BC.%26aulast%3DLenaerts%26aufirst%3DA.%2BJ.%26aulast%3DLee%26aufirst%3DR.%2BE.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520evaluation%2520of%2520synergism%2520between%2520anti-tubercular%2520spectinamides%2520and%2520non-classical%2520tuberculosis%2520antibiotics%26jtitle%3DSci.%2520Rep.%26date%3D2015%26volume%3D5%26spage%3D13985%26doi%3D10.1038%2Fsrep13985" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref251"><div class="reference"><strong class="refLabel"><a href="#ref251" class="rightTabRefNumLink">251</a></strong><div class="NLM_citation" id="rightTab-cit251"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.,  3rd.</span></span> <span> </span><span class="NLM_article-title">Tb drug development: Immunology at the table</span>. <i>Immunol Rev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>264</i></span>,  <span class="NLM_fpage">308</span>– <span class="NLM_lpage">318</span>, <span class="refDoi"> DOI: 10.1111/imr.12275</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1111%2Fimr.12275" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=25703568" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtVyhtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=264&publication_year=2015&pages=308-318&author=C.+Nathanauthor=C.+E.+Barry&title=Tb+drug+development%3A+Immunology+at+the+table&doi=10.1111%2Fimr.12275"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit251R"><div class="casContent"><span class="casTitleNuber">251</span><div class="casTitle"><span class="NLM_cas:atitle">TB drug development: immunology at the table</span></div><div class="casAuthors">Nathan, Carl; Barry, Clifton E., III</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">264</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">308-318</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">1600-065X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Our understanding of the host-pathogen relationship in tuberculosis (TB) can help guide drug discovery in at least two ways.  First, the recognition that host immunopathol. affects lesional TB drug distribution means that pharmacokinetic evaluation of drug candidates needs to move beyond measurements of drug levels in blood, whole lungs, or alveolar epithelial lining fluid to include measurements in specific types of lesions.  Second, by restricting the replication of M. tuberculosis (Mtb) subpopulations in latent TB infection and in active disease, the host immune response puts Mtb into a state assocd. with phenotypic tolerance to TB drugs selected for their activity against replicating Mtb.  This has spurred a major effort to conduct high throughput screens in vitro for compds. that can kill Mtb when it is replicating slowly if at all.  Each condition used in vitro to slow Mtb's replication and thereby model the phenotypically drug-tolerant state has advantages and disadvantages.  Lead candidates emerging from such in vitro studies face daunting challenges in the design of proof-of-concept studies in animal models.  Moreover, some non-replicating subpopulations of Mtb fail to resume replication when plated on agar, although their viability is demonstrable by other means.  There is as yet no widely replicated assay in which to screen compds. for their ability to kill this 'viable but non-culturable' subpopulation.  Despite these hurdles, drugs that can kill slowly replicating or non-replicating Mtb may offer our best hope for treatment-shortening combination chemotherapy of TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTpj2qurNoHLVg90H21EOLACvtfcHk0lhTyuGO85cwdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtVyhtL4%253D&md5=ee37d408eb9725a9ae32c65fc6a0872f</span></div><a href="/servlet/linkout?suffix=cit251&amp;dbid=16384&amp;doi=10.1111%2Fimr.12275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fimr.12275%26sid%3Dliteratum%253Aachs%26aulast%3DNathan%26aufirst%3DC.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26atitle%3DTb%2520drug%2520development%253A%2520Immunology%2520at%2520the%2520table%26jtitle%3DImmunol%2520Rev.%26date%3D2015%26volume%3D264%26spage%3D308%26epage%3D318%26doi%3D10.1111%2Fimr.12275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref252"><div class="reference"><strong class="refLabel"><a href="#ref252" class="rightTabRefNumLink">252</a></strong><div class="NLM_citation" id="rightTab-cit252"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tornheim, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dooley, K. E.</span></span> <span> </span><span class="NLM_article-title">Challenges of TB and HIV co-treatment: Updates and insights</span>. <i>Curr. Opin. HIV AIDS</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">486</span>– <span class="NLM_lpage">491</span>, <span class="refDoi"> DOI: 10.1097/COH.0000000000000495</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1097%2FCOH.0000000000000495" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=30080683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVChtrfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=486-491&author=J.+A.+Tornheimauthor=K.+E.+Dooley&title=Challenges+of+TB+and+HIV+co-treatment%3A+Updates+and+insights&doi=10.1097%2FCOH.0000000000000495"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit252R"><div class="casContent"><span class="casTitleNuber">252</span><div class="casTitle"><span class="NLM_cas:atitle">Challenges of TB and HIV co-treatment: updates and insights</span></div><div class="casAuthors">Tornheim, Jeffrey A.; Dooley, Kelly E.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in HIV & AIDS</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">486-491</span>CODEN:
                <span class="NLM_cas:coden">COHABM</span>;
        ISSN:<span class="NLM_cas:issn">1746-630X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  In the past few years, tuberculosis (TB) has overtaken HIV as the infectious disease with the highest global mortality.  Successful management of this syndemic will require improved diagnostic tests, shorter preventive therapies, and more effective treatments, particularly in light of drug-resistant TB.  Results from several major studies have been published or presented recently, including the development of a more sensitive rapid, mol. assay for TB; several new symptom-based screening tools; use of a 1-mo regimen for TB prevention; the results of early vs. delayed TB preventive therapy for pregnant women; newer drugs and regimens for multidrug-resistant tuberculosis; and pharmacokinetic, safety, and efficacy studies of new HIV drugs in combination with TB treatment.  We reviewed each of these topic areas and summarize relevant findings for the management of TB and HIV co-infection.  Moving forward, as new treatment regimes for HIV or TB are developed, consideration of the HIV-TB co-infected patient must figure prominently, both when detg. the diagnostic tests employed and to assess properly the drug-drug and drug-disease interactions that influence dosing, safety, and response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5qhlyoAll9LVg90H21EOLACvtfcHk0lhTyuGO85cwdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVChtrfI&md5=6c9f3dc0d35aefe298f6cb8d0efa0668</span></div><a href="/servlet/linkout?suffix=cit252&amp;dbid=16384&amp;doi=10.1097%2FCOH.0000000000000495&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCOH.0000000000000495%26sid%3Dliteratum%253Aachs%26aulast%3DTornheim%26aufirst%3DJ.%2BA.%26aulast%3DDooley%26aufirst%3DK.%2BE.%26atitle%3DChallenges%2520of%2520TB%2520and%2520HIV%2520co-treatment%253A%2520Updates%2520and%2520insights%26jtitle%3DCurr.%2520Opin.%2520HIV%2520AIDS%26date%3D2018%26volume%3D13%26spage%3D486%26epage%3D491%26doi%3D10.1097%2FCOH.0000000000000495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref253"><div class="reference"><strong class="refLabel"><a href="#ref253" class="rightTabRefNumLink">253</a></strong><div class="NLM_citation" id="rightTab-cit253"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sadiq, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khajuria, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tandon, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahajan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J. B.</span></span> <span> </span><span class="NLM_article-title">Adverse drug reaction profile in patients on anti-tubercular treatment alone and in combination with highly active antiretroviral therapy</span>. <i>J. Clin. Diagn. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">FC01</span>, <span class="refDoi"> DOI: 10.7860/JCDR/2015/13452.6652</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.7860%2FJCDR%2F2015%2F13452.6652" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=26557538" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=FC01&author=S.+Sadiqauthor=V.+Khajuriaauthor=V.+R.+Tandonauthor=A.+Mahajanauthor=J.+B.+Singh&title=Adverse+drug+reaction+profile+in+patients+on+anti-tubercular+treatment+alone+and+in+combination+with+highly+active+antiretroviral+therapy&doi=10.7860%2FJCDR%2F2015%2F13452.6652"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit253&amp;dbid=16384&amp;doi=10.7860%2FJCDR%2F2015%2F13452.6652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7860%252FJCDR%252F2015%252F13452.6652%26sid%3Dliteratum%253Aachs%26aulast%3DSadiq%26aufirst%3DS.%26aulast%3DKhajuria%26aufirst%3DV.%26aulast%3DTandon%26aufirst%3DV.%2BR.%26aulast%3DMahajan%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DJ.%2BB.%26atitle%3DAdverse%2520drug%2520reaction%2520profile%2520in%2520patients%2520on%2520anti-tubercular%2520treatment%2520alone%2520and%2520in%2520combination%2520with%2520highly%2520active%2520antiretroviral%2520therapy%26jtitle%3DJ.%2520Clin.%2520Diagn.%2520Res.%26date%3D2015%26volume%3D9%26spage%3DFC01%26doi%3D10.7860%2FJCDR%2F2015%2F13452.6652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref254"><div class="reference"><strong class="refLabel"><a href="#ref254" class="rightTabRefNumLink">254</a></strong><div class="NLM_citation" id="rightTab-cit254"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Braunstein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickey, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span> <span> </span><span class="NLM_article-title">Why wait? The case for treating tuberculosis with inhaled drugs</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">166</span>, <span class="refDoi"> DOI: 10.1007/s11095-019-2704-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=10.1007%2Fs11095-019-2704-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=31650321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVaqu7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2019&pages=166&author=M.+Braunsteinauthor=A.+J.+Hickeyauthor=S.+Ekins&title=Why+wait%3F+The+case+for+treating+tuberculosis+with+inhaled+drugs&doi=10.1007%2Fs11095-019-2704-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit254R"><div class="casContent"><span class="casTitleNuber">254</span><div class="casTitle"><span class="NLM_cas:atitle">Why Wait? The Case for Treating Tuberculosis with Inhaled Drugs</span></div><div class="casAuthors">Braunstein, Miriam; Hickey, Anthony J.; Ekins, Sean</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">166</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The discovery of drugs to treat tuberculosis (TB) was a major medical milestone in the twentieth century.  However, from the outset, drug resistance was obsd.  Currently, of the 10 million people that exhibit TB symptoms each year, 450,000 have multidrug or extensively drug resistant (MDR or XDR) TB.  While greater understanding of the host and pathogen (Mycobacterium tuberculosis, Mtb) coupled with scientific ingenuity will lead to new drugs and vaccines, in the meantime 4000 people die daily from TB.  Thus, efforts to improve existing TB drugs should also be prioritized.  Improved efficacy and decreased dose and assocd. toxicity of existing drugs would translate to greater compliance, life expectancy and quality of life of Mtb infected individuals.  One potential strategy to improve existing drugs is to deliver them by inhalation as aerosols to the lung, the primary site of Mtb infection.  Inhaled drugs are used for other pulmonary diseases, but they have yet to be utilized for TB.  Inhaled therapies for TB represent an untapped opportunity that the pharmaceutical, clin. and regulatory communities should consider.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQ1pBwQn6GtbVg90H21EOLACvtfcHk0lga_g-vmNZSqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVaqu7zN&md5=ac0fe28cdb08df83d092455a8c1903de</span></div><a href="/servlet/linkout?suffix=cit254&amp;dbid=16384&amp;doi=10.1007%2Fs11095-019-2704-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-019-2704-6%26sid%3Dliteratum%253Aachs%26aulast%3DBraunstein%26aufirst%3DM.%26aulast%3DHickey%26aufirst%3DA.%2BJ.%26aulast%3DEkins%26aufirst%3DS.%26atitle%3DWhy%2520wait%253F%2520The%2520case%2520for%2520treating%2520tuberculosis%2520with%2520inhaled%2520drugs%26jtitle%3DPharm.%2520Res.%26date%3D2019%26volume%3D36%26spage%3D166%26doi%3D10.1007%2Fs11095-019-2704-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i20"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b02075">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_64118"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.9b02075?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b02075</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Molecular properties <a class="ref showTableEvent internalNav" href="#tbl1">Table <a class="ref showTableEvent internalNav" href="#tbl1">1</a></a> and <a class="ref showTableEvent internalNav" href="#tbl3">Tables <a class="ref showTableEvent internalNav" href="#tbl3">3</a></a>–<a class="ref showTableEvent internalNav" href="#tbl12">12</a> compounds; bold highlights represent molecules that appear as outliers on <a id="rightTab-" class=" internalNav" href="#fig2">Figures <a id="rightTab-" class=" internalNav" href="#fig2">2</a></a> or <a id="rightTab-" class=" internalNav" href="#fig3">3</a>; outlier molecules from <a id="rightTab-" class=" internalNav" href="#fig2">Figures <a id="rightTab-" class=" internalNav" href="#fig2">2</a></a> and <a id="rightTab-" class=" internalNav" href="#fig3">3</a> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b02075/suppl_file/jm9b02075_si_001.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b02075/suppl_file/jm9b02075_si_001.pdf">jm9b02075_si_001.pdf (103.95 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b02075&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b02075%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-17%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b02075" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                10MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799aed71c4b1243","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
